{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "a9b7093c-94bd-4080-8923-3456723a7ca6",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.document_loaders import PyMuPDFLoader"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "898db0bd-70e7-447d-9ce2-7878362fdc21",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "'Gastrointestinal and Liver Disease.pdf'   text-extraction-and-chunking.ipynb\n"
     ]
    }
   ],
   "source": [
    "ls"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "6fa3e872-9620-4c0e-a317-c7338fdf9bc1",
   "metadata": {},
   "outputs": [],
   "source": [
    "loader = PyMuPDFLoader('Gastrointestinal and Liver Disease.pdf', extract_images= True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "c7161e68-9a7b-4c25-9b7e-915af1a830a8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<langchain_community.document_loaders.pdf.PyMuPDFLoader at 0x7ff4aab61960>"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "loader"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "a5ad9987-10a3-4233-980e-240815e2df09",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Document(metadata={'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 0, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}, page_content='806\\nPeptic Ulcer Disease\\nFrancis K.L. Chan, James Y.W. Lau\\n53\\nAn ulcer in the GI tract can be defined as a 5 mm or larger break in \\nthe lining of the mucosa, with appreciable depth at endoscopy or \\nwith histologic evidence of submucosal extension. An erosion is a \\nbreak less than 5 mm. The distinction between an ulcer and an ero\\xad\\nsion is somewhat arbitrary. The term PUD is used to include ulcer\\xad\\nations and erosions in the stomach and duodenum from a number \\nof causes. These lesions are called “peptic” because the enzyme \\npepsin, proteolytic at an acidic pH (see Chapter 51), plays a major \\nrole in causing the mucosal breaks, regardless of the inciting agent.\\nDecades of research focused on the role of gastric acid \\nsecretion and the effects of stress, personality type, and \\ngenetics in the pathogenesis of PUD. The discovery of the \\nhistamine-2 (H2) receptor and development of H2RAs,1 and \\nsubsequently PPIs, led to major changes in the management \\nof PUD. The discovery of Hp and its role in PUD (see Chap\\xad\\nter 52) transformed PUD from a chronic, recurrent disease \\nto a curable one.2 Hp infection remains an important cause \\nof PUD in the world. In developed countries, frequent use of \\nNSAIDs, including low-dose aspirin for cardiovascular indi\\xad\\ncations, has emerged as a leading cause of PUD, especially \\namong the aging population.\\nEPIDEMIOLOGY\\nThe epidemiology of PUD has undergone remarkable changes \\nin the past 2 centuries. The risk of developing PUD, and dying \\nfrom PUD, increased in successive cohorts born between 1840 and \\n1890, and then declined thereafter.3 There was a peak in the inci\\xad\\ndence of GU in the first half of the 19th century and a subsequent \\npeak in the incidence of DU in the second half of the 19th century. \\nSonnenberg proposed a birth-cohort effect to explain the peaks in \\nthe incidence of, and mortality from, peptic ulcers. Hp infection \\nacquired during childhood or adolescence became manifested as \\npeptic diseases in later years. As Hp infection gradually declined in \\nthe population over time, the prevalence of infection also gradually \\nshifted from a younger toward older age groups. The incidence of \\nDU and GU has declined in parallel with the decline in the preva\\xad\\nlence of Hp infection, likely a result of improved sanitary condi\\xad\\ntions and a safer food and water supply.\\nBased on physicians’ diagnoses, the annual incidence of PUD \\nranges from 0.14% to 0.19% in developed countries. Based on \\nhospital diagnoses, the incidence is lower: 0.03% to 0.17%. The \\nprevalence of PUD ranges from 0.12% to 4.7% for physician-\\ndiagnosed, and from 0.1% to 2.6% for hospital-diagnosed case \\nseries.4 There is a wide geographic variation in the prevalence \\nof PUD. In an endoscopic series involving 1022 volunteers from \\nShanghai, China (average age, 48 years), the prevalence of PUD \\nwas 17.2%, of whom 93% were infected with Hp.5\\nThe most frequent complication from PUD is bleeding; the \\nreported annual incidence of bleeding among populations varies \\nfrom 19 to 57 per 100,000 individuals (≈0.02% to 0.06%). Peptic \\nulcer perforation (PULP), less frequent than bleeding, has reported \\nincidences of 4 to 14 per 100,000 individuals (0.004% to 0.014%).6 \\nAlong with a decline in uncomplicated PUD cases, there is a similar \\ndecline in incidence of ulcer complications in recent years. Laine and \\ncolleagues7 used a national inpatient database to calculate the annual \\nincidence of, and mortality from, GI complications during 2001 to \\n2009. During this time period, the incidence of peptic ulcer bleeding \\nfell from 48.7 to 32.1 per 100,000. Over the same period, the age- \\nand sex-adjusted case fatality rates from UGI bleeding decreased \\nfrom 3.8% to 2.7%. In 2009, the case fatality rate for UGI bleeding \\n(2.45%) was considerably lower than for UGI perforation (10.7%). \\nIn a nationwide population-based cohort study of 403,567 Taiwan\\xad\\nese patients, hospitalizations for complicated peptic ulcers decreased \\nsignificantly over a 10 year period8; thus the annual incidence of hos\\xad\\npitalizations for bleeding DU or for perforated DU fell from 108 to \\n40 and from 9.8 to 5.8 per 100,000, respectively. A similar decline \\nwas evident for bleeding and perforated GUs (from 117 to 61 and \\nfrom 11 to 6 per 100,000, respectively).\\u200a\\nETIOLOGY AND PATHOGENESIS\\nThe principal risk factors of PUD are Hp infection and NSAID \\nuse (Fig. 53.1) and as will be discussed, many patients with PUD \\nhave both of these risk factors. On the other hand, PUD patients \\nmay have neither of these risk factors (Hp-negative, NSAID-\\nnegative ulcers); some of these latter patients will have another \\ncause of ulcer such as gastrinoma (ZES; see Chapter 34), whereas \\nothers will have ulcers that are idiopathic.\\nCHAPTER OUTLINE\\nEPIDEMIOLOGY\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�806\\nETIOLOGY AND PATHOGENESIS\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�806\\nHp Infection\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�807\\nUse of Aspirin and Other NSAIDs\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�807\\nOther Causes of Ulcers and Idiopathic Ulcers\\x08.�.�.�.�.�.�.�.�.�808\\nCLINICAL FEATURES AND DIAGNOSIS\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�808\\nMEDICAL THERAPY OF ACTIVE PEPTIC ULCER \\nDISEASE\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�810\\nPharmaceutical Agents\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�810\\nHp-associated Ulcers \\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�811\\nNSAID Ulcers\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�812\\nOther Causes of Ulcers and Idiopathic Ulcers\\x08.�.�.�.�.�.�.�.�.�812\\nREFRACTORY ULCERS\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�812\\nPREVENTION OF ULCER DISEASE\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�812\\nAntacids\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�812\\nH2RAs\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�813\\nMisoprostol\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�813\\nPPIs \\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�813\\nCOX-2 Inhibitors (In Place of NSAIDs)\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�813\\nAssessing Risk and Choice of Agent(s)\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�814\\nCOMPLICATIONS AND THEIR TREATMENT \\x08.�.�.�.�.�.�.�.�.�.�.�815\\nBleeding\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�815\\nPerforation \\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�817\\nObstruction\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�818\\nSTRESS ULCERS\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�819\\nDownloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, \\n2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.\\n')"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "docs = loader.load()\n",
    "docs[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "c7acc091-73ee-4f4f-a3da-5454d5d4fa31",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "272"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "id": "72a5be26-6bd2-4994-8320-148103bf43bf",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Japan. In addition, the rate of H. pylori infection with\\nprimary resistance to levoﬂoxacin is high in Japan. The\\neradication rate of triple therapy with PPI/VPZ, amox-\\nicillin, and metronidazole is still high [4], and does not\\ndiffer between the two regimens [29–31].\\nThird-line eradication therapy\\nCQ-7\\nWhat regimen should we select for third-line H. pylori\\neradication therapy?\\n•\\nTriple therapy with PPI, sitaﬂoxacin, and metronida-\\nzole or PPI, sitaﬂoxacin, and amoxicillin is suggested\\n(not covered by the Japanese insurance system).\\nRecommendation: weak, 100% agreed, evidence level\\nB.\\nComment: Three Japanese RCTs of third-line therapies\\nshowed that the eradication rates were 70.0–90.9%\\n[32–34]. The eradication rate of triple therapy with PPI,\\nsitaﬂoxacin,\\nand\\nmetronidazole\\nwas\\n70.0–88.9%\\n[32–34], and that of PPI, sitaﬂoxacin, and amoxicillin\\nwas 72.4–90.9% [33, 34]. Because these eradication\\nrates were not high enough, these regimens are not\\nrecommended, but suggested.\\nUlcer recurrence after H. pylori eradication\\nCQ-8\\nIs maintenance treatment necessary for the recurrence of\\npeptic ulcer after successful H. pylori eradication?\\n•\\nWhen the cause of peptic ulcer recurrence is unclear,\\nlong-term maintenance treatment with PPIs or H2RAs\\nis suggested.\\nRecommendation: weak, 100% agreed, evidence level\\nD.\\nComment: There are currently no published RCTs or\\nMAs. Causes of the recurrence of peptic ulcers after\\nsuccessful H. pylori eradication include using LDA and\\nNSAIDs, reinfection with H. pylori, and smoking\\nhabits. To prevent peptic ulcer recurrence, the exclu-\\nsion of these factors is necessary. Idiopathic peptic\\nulcers are thought to be one of unknown causes of\\npeptic ulcers after successful H. pylori eradication;\\ntherefore, long-term maintenance treatment with PPIs\\nor H2RAs is suggested, when the cause of peptic ulcer\\nrecurrence is unclear.\\nNon-eradication therapy\\nInitial therapy.\\nGastric ulcer\\nCQ-9\\nWhat is the ﬁrst-line drug for the initial non-eradication\\ntreatment of gastric ulcers?\\n•\\nEither PPIs or P-CAB is recommended.\\nRecommendation: strong, 100% agreed, evidence level\\nA.\\n•\\nIf PPIs and P-CAB cannot be prescribed, H2RAs are\\nrecommended.\\nRecommendation: strong, 100% agreed, evidence level\\nB.\\n•\\nIf PPIs and P-CAB cannot be prescribed, pirenzepine,\\nsucralfate, and misoprostol are suggested.\\nRecommendation: weak, 100% agreed, evidence level\\nB.\\n•\\nIf the above drugs cannot be prescribed, gastric\\nmucosa-protecting agents (excluding sucralfate and\\nmisoprostol) are suggested.\\nRecommendation: weak, 100% agreed, evidence level\\nB.\\nComment: We recommend either PPIs or P-CAB due to\\ntheir demonstrated ulcer healing rate of PPIs being\\nsigniﬁcantly higher than that of H2RAs [35–38].\\nFig. 3 Forest plots of eradication rates of second-line therapy\\nbetween proton pump inhibitor/amoxicillin/metronidazole (PAM)\\ntherapy\\nand\\nproton\\npump\\ninhibitor/amoxicillin/clarithromycin\\n(PAC) therapy in the randomized control trials in Japan. In meta-\\nanalysis, the eradication rates of PAM therapy are signiﬁcantly higher\\nthan that of PAC therapy (odds ratio 0.14; 95% CI 0.08–0.24)\\nJ Gastroenterol (2021) 56:303–322\\n307\\n123\\nPAM\\nPAC\\nOddsRatio\\nOddsRatio\\nStudyorSubgroup\\nEvents\\nTotal\\nEvents\\nTotal\\nWeight\\nM-H,Fixed,95%CI\\nYear\\nM-H,Fixed,95%CI\\nNishizawa2015\\n6\\n64\\n16\\n60\\n17.6%\\n0.28[0.10,0.79]\\n2015\\nAdachi2017\\n6\\n72\\n20\\n68\\n22.2%\\n0.22[0.08,0.58]\\n2017\\nMabe2018\\n6\\n169\\n48\\n137\\n60.2%\\n0.07[0.03, 0.17]\\n2018\\nTotal (95% CI)\\n305\\n265\\n100.0%\\n0.14[0.08,0.24]\\nTotalevents\\n18\\n84\\nHeterogeneity:Chi²=5.17,df=2 (P =0.08);1²=61%\\n0.01\\n0.1\\n1\\n10\\n100\\nTestforoveralleffect:Z=7.18(P<0.00001)\\nFavours[PAM]\\nFavours[PAC]'"
      ]
     },
     "execution_count": 110,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "docs[151].page_content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "id": "8366c6f5-b130-4a01-ab9d-a8d50b54f130",
   "metadata": {},
   "outputs": [],
   "source": [
    "# docs[0].metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "id": "c5f2d28b-eac8-4ccd-8d7d-af56b582dfc4",
   "metadata": {},
   "outputs": [],
   "source": [
    "# print(docs[1].page_content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e1c7d016-575f-47d2-a1e9-3af34a572bfe",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "id": "3f30f9a6-d5a1-41d9-bb34-9deedbc5f4a7",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_text_splitters import RecursiveCharacterTextSplitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "id": "e5498a8f-27fa-4a55-9ee8-62270d3a41b0",
   "metadata": {},
   "outputs": [],
   "source": [
    "text_splitter = RecursiveCharacterTextSplitter(\n",
    "    # Set a really small chunk size, just to show.\n",
    "    separators=['\\n'],\n",
    "    chunk_size=2024,\n",
    "    chunk_overlap=204,\n",
    "    length_function=len,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "id": "964b4e75-7480-4374-8596-a13e5c3b6149",
   "metadata": {},
   "outputs": [],
   "source": [
    "data = text_splitter.split_documents(docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "id": "35b68628-d149-49ca-a32f-045a3af3e8c2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1004"
      ]
     },
     "execution_count": 114,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "id": "a00bfc81-c067-493c-9c64-6855aef79b96",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'and sex-adjusted case fatality rates from UGI bleeding decreased \\nfrom 3.8% to 2.7%. In 2009, the case fatality rate for UGI bleeding \\n(2.45%) was considerably lower than for UGI perforation (10.7%). \\nIn a nationwide population-based cohort study of 403,567 Taiwan\\xad\\nese patients, hospitalizations for complicated peptic ulcers decreased \\nsignificantly over a 10 year period8; thus the annual incidence of hos\\xad\\npitalizations for bleeding DU or for perforated DU fell from 108 to \\n40 and from 9.8 to 5.8 per 100,000, respectively. A similar decline \\nwas evident for bleeding and perforated GUs (from 117 to 61 and \\nfrom 11 to 6 per 100,000, respectively).\\u200a\\nETIOLOGY AND PATHOGENESIS\\nThe principal risk factors of PUD are Hp infection and NSAID \\nuse (Fig. 53.1) and as will be discussed, many patients with PUD \\nhave both of these risk factors. On the other hand, PUD patients \\nmay have neither of these risk factors (Hp-negative, NSAID-\\nnegative ulcers); some of these latter patients will have another \\ncause of ulcer such as gastrinoma (ZES; see Chapter 34), whereas \\nothers will have ulcers that are idiopathic.\\nCHAPTER OUTLINE\\nEPIDEMIOLOGY\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�806\\nETIOLOGY AND PATHOGENESIS\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�806\\nHp Infection\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�807\\nUse of Aspirin and Other NSAIDs\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�807\\nOther Causes of Ulcers and Idiopathic Ulcers\\x08.�.�.�.�.�.�.�.�.�808\\nCLINICAL FEATURES AND DIAGNOSIS\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�808\\nMEDICAL THERAPY OF ACTIVE PEPTIC ULCER \\nDISEASE\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�810\\nPharmaceutical Agents\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�810\\nHp-associated Ulcers \\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�811\\nNSAID Ulcers\\x08.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�812\\nOther Causes of Ulcers and Idiopathic Ulcers\\x08.�.�.�.�.�.�.�.�.�812'"
      ]
     },
     "execution_count": 117,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data[2].page_content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 171,
   "id": "3090d5e3-bb55-40c2-94ec-c5a11d31d90b",
   "metadata": {},
   "outputs": [],
   "source": [
    "def remove_ws(d):\n",
    "    text = d.page_content.replace('Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.', '')\n",
    "    d.page_content = text\n",
    "    return d"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 172,
   "id": "8f1780ae-b12e-40f7-a5a7-592de9e23d16",
   "metadata": {},
   "outputs": [],
   "source": [
    "# import re\n",
    "data = [remove_ws(d) for d in data]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 179,
   "id": "b0c98617-ae5d-4335-8d9b-52138d4c21fd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'updated meta-analysis showed similar findings.22 Among patients who are about to start NSAID therapy, eradication of Hp reduces the subsequent risk of ulcer development.23,24 A systematic review has shown that testing for (and eradication of) Hp lowers the risk of peptic ulcers among NSAID users;25 however, eradication of Hp infection alone is insufficient to prevent peptic ulcer bleeding in NSAID users at high ulcer risk.26,27There is also evidence that Hp infection increases the risk of PUD in patients receiving low-dose aspirin. Among Hp-infected patients with recent ulcer bleeding who continued to take low-dose aspirin, successful eradication of Hp infection resulted in a very low risk of recurrent ulcer bleeding, similar to that seen with aspirin/omeprazole co-therapy.26 This low risk of ulcer rebleed\\xading after eradication of Hp was not seen in patients with bleeding ulcers who continued to take NSAIDs. In a long-term prospec\\xadtive cohort study,28 Hp-infected low-dose aspirin users (≤160 mg/day) with bleeding ulcers who resumed their aspirin had a low risk of recurrent ulcer bleeding after eradication of Hp, a risk that was not significantly different from the risk in new aspirin users with no history of ulcer disease (<1 bleed per 100 patient-years). In contrast, aspirin users with bleeding ulcers but without None knownNone knownZES, otherZES, otherNSAIDuseNSAIDuseHpinfectionHpinfectionDuodenalGastricFig. 53.1\\u2002 Pie charts depicting conditions associated with PUD. The percentages shown are rough approximations based on studies from Western countries. The relative contributions of Hp infection and NSAID use to peptic ulcer vary considerably among different populations and, within populations, vary with age and socioeconomic status. Also, the separation depicted in this figure is somewhat artificial because NSAID use and Hp infection often coexist.'"
      ]
     },
     "execution_count": 179,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data[7].page_content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 181,
   "id": "9145b42a-61be-45bd-9dbf-5f257956d347",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "list"
      ]
     },
     "execution_count": 181,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 182,
   "id": "063f63f7-d40f-4a8c-857c-3befdb8bc6ca",
   "metadata": {},
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "Object of type Document is not JSON serializable",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[182], line 4\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[38;5;28;01mimport\u001b[39;00m \u001b[38;5;21;01mjson\u001b[39;00m\n\u001b[1;32m      3\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m \u001b[38;5;28mopen\u001b[39m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mextracted_data_acm.json\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mw\u001b[39m\u001b[38;5;124m\"\u001b[39m) \u001b[38;5;28;01mas\u001b[39;00m json_file:\n\u001b[0;32m----> 4\u001b[0m     \u001b[43mjson\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mdump\u001b[49m\u001b[43m(\u001b[49m\u001b[43mdata\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mjson_file\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/miniconda3/envs/acm/lib/python3.10/json/__init__.py:179\u001b[0m, in \u001b[0;36mdump\u001b[0;34m(obj, fp, skipkeys, ensure_ascii, check_circular, allow_nan, cls, indent, separators, default, sort_keys, **kw)\u001b[0m\n\u001b[1;32m    173\u001b[0m     iterable \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mcls\u001b[39m(skipkeys\u001b[38;5;241m=\u001b[39mskipkeys, ensure_ascii\u001b[38;5;241m=\u001b[39mensure_ascii,\n\u001b[1;32m    174\u001b[0m         check_circular\u001b[38;5;241m=\u001b[39mcheck_circular, allow_nan\u001b[38;5;241m=\u001b[39mallow_nan, indent\u001b[38;5;241m=\u001b[39mindent,\n\u001b[1;32m    175\u001b[0m         separators\u001b[38;5;241m=\u001b[39mseparators,\n\u001b[1;32m    176\u001b[0m         default\u001b[38;5;241m=\u001b[39mdefault, sort_keys\u001b[38;5;241m=\u001b[39msort_keys, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkw)\u001b[38;5;241m.\u001b[39miterencode(obj)\n\u001b[1;32m    177\u001b[0m \u001b[38;5;66;03m# could accelerate with writelines in some versions of Python, at\u001b[39;00m\n\u001b[1;32m    178\u001b[0m \u001b[38;5;66;03m# a debuggability cost\u001b[39;00m\n\u001b[0;32m--> 179\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m chunk \u001b[38;5;129;01min\u001b[39;00m iterable:\n\u001b[1;32m    180\u001b[0m     fp\u001b[38;5;241m.\u001b[39mwrite(chunk)\n",
      "File \u001b[0;32m~/miniconda3/envs/acm/lib/python3.10/json/encoder.py:429\u001b[0m, in \u001b[0;36m_make_iterencode.<locals>._iterencode\u001b[0;34m(o, _current_indent_level)\u001b[0m\n\u001b[1;32m    427\u001b[0m     \u001b[38;5;28;01myield\u001b[39;00m _floatstr(o)\n\u001b[1;32m    428\u001b[0m \u001b[38;5;28;01melif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(o, (\u001b[38;5;28mlist\u001b[39m, \u001b[38;5;28mtuple\u001b[39m)):\n\u001b[0;32m--> 429\u001b[0m     \u001b[38;5;28;01myield from\u001b[39;00m _iterencode_list(o, _current_indent_level)\n\u001b[1;32m    430\u001b[0m \u001b[38;5;28;01melif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(o, \u001b[38;5;28mdict\u001b[39m):\n\u001b[1;32m    431\u001b[0m     \u001b[38;5;28;01myield from\u001b[39;00m _iterencode_dict(o, _current_indent_level)\n",
      "File \u001b[0;32m~/miniconda3/envs/acm/lib/python3.10/json/encoder.py:325\u001b[0m, in \u001b[0;36m_make_iterencode.<locals>._iterencode_list\u001b[0;34m(lst, _current_indent_level)\u001b[0m\n\u001b[1;32m    323\u001b[0m         \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m    324\u001b[0m             chunks \u001b[38;5;241m=\u001b[39m _iterencode(value, _current_indent_level)\n\u001b[0;32m--> 325\u001b[0m         \u001b[38;5;28;01myield from\u001b[39;00m chunks\n\u001b[1;32m    326\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m newline_indent \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m    327\u001b[0m     _current_indent_level \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m=\u001b[39m \u001b[38;5;241m1\u001b[39m\n",
      "File \u001b[0;32m~/miniconda3/envs/acm/lib/python3.10/json/encoder.py:438\u001b[0m, in \u001b[0;36m_make_iterencode.<locals>._iterencode\u001b[0;34m(o, _current_indent_level)\u001b[0m\n\u001b[1;32m    436\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mCircular reference detected\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m    437\u001b[0m     markers[markerid] \u001b[38;5;241m=\u001b[39m o\n\u001b[0;32m--> 438\u001b[0m o \u001b[38;5;241m=\u001b[39m \u001b[43m_default\u001b[49m\u001b[43m(\u001b[49m\u001b[43mo\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    439\u001b[0m \u001b[38;5;28;01myield from\u001b[39;00m _iterencode(o, _current_indent_level)\n\u001b[1;32m    440\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m markers \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n",
      "File \u001b[0;32m~/miniconda3/envs/acm/lib/python3.10/json/encoder.py:179\u001b[0m, in \u001b[0;36mJSONEncoder.default\u001b[0;34m(self, o)\u001b[0m\n\u001b[1;32m    160\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mdefault\u001b[39m(\u001b[38;5;28mself\u001b[39m, o):\n\u001b[1;32m    161\u001b[0m \u001b[38;5;250m    \u001b[39m\u001b[38;5;124;03m\"\"\"Implement this method in a subclass such that it returns\u001b[39;00m\n\u001b[1;32m    162\u001b[0m \u001b[38;5;124;03m    a serializable object for ``o``, or calls the base implementation\u001b[39;00m\n\u001b[1;32m    163\u001b[0m \u001b[38;5;124;03m    (to raise a ``TypeError``).\u001b[39;00m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    177\u001b[0m \n\u001b[1;32m    178\u001b[0m \u001b[38;5;124;03m    \"\"\"\u001b[39;00m\n\u001b[0;32m--> 179\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mTypeError\u001b[39;00m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mObject of type \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mo\u001b[38;5;241m.\u001b[39m\u001b[38;5;18m__class__\u001b[39m\u001b[38;5;241m.\u001b[39m\u001b[38;5;18m__name__\u001b[39m\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m \u001b[39m\u001b[38;5;124m'\u001b[39m\n\u001b[1;32m    180\u001b[0m                     \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mis not JSON serializable\u001b[39m\u001b[38;5;124m'\u001b[39m)\n",
      "\u001b[0;31mTypeError\u001b[0m: Object of type Document is not JSON serializable"
     ]
    }
   ],
   "source": [
    "import json\n",
    "\n",
    "with open(\"extracted_data_acm.json\", \"w\") as json_file:\n",
    "    json.dump(data, json_file)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 193,
   "id": "8788f574-cba1-4e7e-b270-00505f11b5af",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "# Assuming Document class has 'metadata' and 'page_content' attributes\n",
    "# Define a function to convert the Document object into a dictionary\n",
    "def document_to_dict(doc):\n",
    "    return {\n",
    "        'metadata': doc.metadata,   # assuming doc.metadata is already a dictionary\n",
    "        'page_content': doc.page_content  # assuming doc.page_content is a string\n",
    "    }\n",
    "\n",
    "# Function to save list of Document objects to JSON\n",
    "def save_documents_to_json(document_list, filename='documents.json'):\n",
    "    # Convert the list of Document objects to a list of dictionaries\n",
    "    document_dicts = [document_to_dict(doc) for doc in document_list]\n",
    "    \n",
    "    # Write the list of dictionaries to a JSON file\n",
    "    with open(filename, 'w') as f:\n",
    "        json.dump(document_dicts, f, indent=4)\n",
    "\n",
    "# Example usage with your data list\n",
    "# Assuming 'data' is a list of Document objects\n",
    "save_documents_to_json(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 192,
   "id": "522e38d1-2447-44f4-9c86-6e726c623450",
   "metadata": {},
   "outputs": [],
   "source": [
    "# data[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "8e9cb830-c790-46ea-b241-114e5f947f25",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 0, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "806Peptic Ulcer DiseaseFrancis K.L. Chan, James Y.W. Lau53An ulcer in the GI tract can be defined as\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 0, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "the incidence of, and mortality from, peptic ulcers. Hp infection acquired during childhood or adole\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 0, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and sex-adjusted case fatality rates from UGI bleeding decreased from 3.8% to 2.7%. In 2009, the cas\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 0, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "NSAID Ulcers.................................812Other Causes of Ulcers and Idiopathic Ulcers........\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 1, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER 53  Peptic Ulcer Disease80753Hp InfectionThe prevalence of Hp infection varies widely among \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 1, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tion13 and predisposes to GU formation. In these individuals, it is proposed that weakened mucosal d\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 1, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "isoforms COX-1 and COX-2 are responsible for the synthesis of prostaglandins. COX-1 is expressed in \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 1, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "updated meta-analysis showed similar findings.22 Among patients who are about to start NSAID therapy\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 1, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "within populations, vary with age and socioeconomic status. Also, the separation depicted in this fi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 2, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PART VI  Stomach and Duodenum808Hp infection (past or present) were at high risk of recurrent ulcer \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 2, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "peptic ulcers. Rarer causes of peptic ulcers include eosinophilic gastroenteritis, viral infections \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 2, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "cific than radiologic studies, such as UGI series with barium. Nevertheless, endoscopy is expensive \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 3, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER 53  Peptic Ulcer Disease80953Dyspeptic upper abdominal symptoms consisting of pain or dis­co\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 3, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "patients and found a slight benefit at 12 months of prompt EGD on dyspeptic symptoms over test-and-t\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 4, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PART VI  Stomach and Duodenum810According to a joint ACG/Canadian Association of Gastro­enterology g\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 4, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "moderate- to- high Hp prevalence, the test-and-treat strategy is preferred. The Maastricht Consensus\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 4, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tory drugs in the management of gastrinoma (ZES) is discussed in Chapter 34.H2RasH2RAs are competiti\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 4, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "can occasionally cause gynecomastia and impotence.51Both cimetidine and ranitidine bind to the hepat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 4, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "proton pumps that are actively secreting acid. With meal stimu­lation, 60% to 70% of the proton pump\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 5, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER 53  Peptic Ulcer Disease81153PPIs, by raising the gastric pH, can affect the absorption of a\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 5, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of PPIs. To date, PPI use has been implicated in many condi­tions, including osteoporosis, hypomagne\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 5, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "little (<5%) of sucralfate is absorbed owing to its poor solubility, and the drug is excreted via th\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 5, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "FDA for the prevention of NSAID-induced PUD.70 The drug not only enhances mucosal defense mechanisms\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 5, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "cation following antibiotic therapy is not recommended routinely in patients with uncomplicated DUs.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 6, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PART VI  Stomach and Duodenum812NSAID UlcersH2RAsConventional doses of H2RAs are more effective in h\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 6, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "have shown that misoprostol is effective for the healing of small bowel ulcers and erosions in patie\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 6, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "(see Chapter 52). • Is the patient still taking an NSAID? NSAID use may be sur­reptitious. A careful\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 6, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "regimens. An “endoscopic ulcer” has been arbitrarily defined as a circumscribed mucosal defect havin\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 7, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER 53  Peptic Ulcer Disease81353in the prevention of NSAID-induced ulcers. Antacids may mask dy\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 7, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "this trial experienced GI upset, thereby limiting its clinical use. Even though endoscopic studies h\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 7, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "abilities of remaining ulcer free were 91%, 95%, and 93% for pantoprazole 20 mg, pantoprazole 40 mg,\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 7, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "as well as fewer withdrawals caused by GI symptoms94; however, the sparing effect of COX-2 inhibitor\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 8, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PART VI  Stomach and Duodenum814Despite the improved gastric safety profile of COX-2 inhibi­tors, th\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 8, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "but also nonselective NSAIDs, with the exception of full-dose naproxen (1000 mg/day), increase cardi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 8, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "than with ibuprofen; however, the proportion of patients con­tinued on concomitant low-dose aspirin \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 8, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "in these patients, not only because of the high risk of ulcer com­plications but also owing to the s\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 8, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "†High CV risk denotes the requirement for prophylactic low-dose aspirin for primary or secondary pre\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 9, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER 53  Peptic Ulcer Disease81553the American Heart Association guidelines. Because the potentia\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 9, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "as well as management implications. Variceal hemorrhage carries a higher death rate than ulcer bleed\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 9, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "hepatic failure.110 The GBS has been the most widely validated score and correlates with clinical ou\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 9, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "concluded that clot removal followed by endoscopic treatment of the vessel underneath lowers the ris\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 9, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "epinephrine allows a clear view of the bleeding vessel and should then be combined with application \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 10, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PART VI  Stomach and Duodenum816bleeding (RR 0.57, 0.43 to 0.76), emergency surgery (RR 0.68, 0.5 to\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 10, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "either through-the-scope hemo-clips or thermal-coagulation with or without pre-injection of epinephr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 10, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of PPI (OR 0.53; 95% CI, 0.31 to 0.91).Spurting (Ia)A visible vessel IIaFlat pigmentation IIcOozing \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 11, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER 53  Peptic Ulcer Disease81753The optimal PPI dose to use and the routine of PPI admin­istrat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 11, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "while there was an increase in the use of endoscopic treatment (12.9% to 22.2%).128 In an UK Nationa\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 11, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tive ulcer surgery, 4 re-bled and none died.132 In a trial conducted by the French Association of Su\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 11, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "is often attempted before surgery. A recent RCT that compared added embolization to standard treatme\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 12, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PART VI  Stomach and Duodenum818surgery within 6 hours, mortality was 17% in 117 hospitals with stri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 12, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "medical illnesses, and perforation longer than 12 hours as impor­tant adverse prognostic factors. Th\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 12, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "forations (>10 mm) suggest sizable ulcerations and should also be managed by laparotomy; often, gast\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 12, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Hp eradication to closure alone in patients with perforated DU showed that the pooled incidence of u\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 12, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "is, therefore, deferred until after an adequate trial of conserva­tive management. Other factors tha\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 13, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER 53  Peptic Ulcer Disease81953through-the-scope balloon is then passed over the guidewire, an\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 13, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "patients, only 1.5% developed clinically important bleeding. Respiratory failure (OR 15.6) and coagu\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 13, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Fig. 53.6  A through-the-scope dila­tion of an obstructed pylorus caused by an ulcer. The procedure \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 14, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "819.e1REFERENCES 1. Black J, Duncan W, Durant D. Definition and antagonism of hista­mine H2 receptor\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 14, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "11. Sanchez-Delgado J, Gene E, Suarez D, et al. Has H pylori prevalence in bleeding peptic ulcer bee\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 14, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "sin on blood coagulation and platelet aggregation. A possible con­tributor prolonged gastroduodenal \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 14, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "29. Pecha RE, Prindiville T, Pecha BS, et al. Association of cocaine and methamphetamine use with gi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 14, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "2003;98:2409–14. 39. Gisbert JP, Calvet X. Helicobacter pylori “test-and-treat” strategy for managem\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 15, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "References819.e2 49. Richter JM, Colditz GA, Huse DM, et al. Cimetidine and adverse reactions: a met\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 15, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "2010;363:1909–17. 60. O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacody­namic effect and clin\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 15, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "69. Walt RP. Misoprostol for the treatment of peptic ulcer and antiin­flammatory-drug-induced gastro\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 15, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Group. Arch Intern Med 2000;160:1455–61. 77. Goldstein JL, Johanson JF, Hawkey CJ, et al. Clinical t\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 15, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "per gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology 201\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 16, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "References 819.e353 93. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazol\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 16, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "lecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastroi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 16, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "need for treatment for upper gastrointestinal haemorrhage. Lancet 2000;356:1318–21.111. Stanley AJ, \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 16, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tion versus epinephrine injection and a second endoscopic meth­od in high risk bleeding ulcers. Coch\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 16, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "2012;99:1672–80.130. Elmunzer BJ, Young SD, Inadomi JM, et  al. Systematic review of the predictors \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 17, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "References819.e4135. Kyaw M, Tse Y, Ang D, et al. Embolization versus surgery for pep­tic ulcer blee\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 17, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "cobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation rand\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 17, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "155. Krag M, Marker S, Perner A, Wetterslev J, Wise MP,Schefold JC et al. Pantoprazole in patients a\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 18, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Harrison's Principles of Internal Medicine, 21eChapter 324: Peptic Ulcer Disease and Related Disord\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 18, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "gastric gland area and contain mucous and endocrine cells. The 75% of gastric glands are found withi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 18, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "kidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 18, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "aggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinne\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 18, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "MCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatme\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 19, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "FIGURE 324­1Diagrammatic representation of the oxyntic gastric gland. (Reproduced with permission fr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 19, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "MitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasp\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 19, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utili\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 19, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "DCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acut\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 19, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "mucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntesti\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 20, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "FIGURE 324­2Gastric parietal cell undergoing transformation after secretagogue­mediated stimulation.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 20, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "factor. (Republished with permission of John Wiley and Son’s Inc, from Bioregulation and Its Disorde\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 20, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCI\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 20, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactors\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 20, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 21, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Components involved in providing gastroduodenal mucosal defense and repair. CCK, cholecystokinin; CR\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 21, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "injured microvascular bed occurs. Both FGF and vascular endothelial growth factor (VEGF) are importa\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 21, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of tissues, including the stomach, platelets, kidneys, and endothelial cells. This isoform is expres\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 21, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpn\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 21, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "is maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sul\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 21, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: N\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 22, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "epithelial cell restitution. Prostaglandins are derived from esterified arachidonic acid, which is f\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 22, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "NO is important in the maintenance of gastric mucosal integrity. The key enzyme NO synthase is const\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 22, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "microorganism homeostasis will play a role in aspects of certain disorders such as PUD, gastritis, a\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 22, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "inflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrity\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 22, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "mucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 22, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)H\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 22, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "H.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pyl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 23, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Physiology of Gastric SecretionHCl and pepsinogen are the two principal gastric secretory products c\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 23, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "production by both direct (parietal cell) and indirect mechanisms (decreased histamine release from \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 23, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "pathways explains the potentiation of acid secretion that occurs when histamine and gastrin or acety\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 23, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle©2024 McGraw Hill. All Rights\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 23, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "BSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Har\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 23, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Copyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNe\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 23, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kas\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 24, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "The enzyme H+,K+­ATPase is responsible for generating the large concentration of H+. It is a membran\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 24, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "acid environment within the stomach leads to cleavage of the inactive precursor to pepsin and provid\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 24, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "since then. The death rates, need for surgery, and physician visits have decreased by >50% over the \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 24, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Yonsei University Medical LibraryAccess Provided by:Downloaded 2024­5­29 3:6 A  Your IP is 116.89.17\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 24, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allright\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 24, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "EnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 24, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "FUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatosta\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 25, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "DUODENAL ULCERSDUs occur most often in the first portion of the duodenum (>95%), with ~90% located w\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 25, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "may also play a role in this process (see below).GASTRIC ULCERSAs in DUs, the majority of GUs can be\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 25, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "circumstances does not appear to invade cells. It is strategically designed to live within the aggre\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 25, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "the organism with distinct pathogenic features.EpidemiologyThe prevalence of H. pylori varies throug\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 25, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrights\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 25, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "vessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison P\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 25, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 26, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Cag A activates a series of cellular events important in cell growth and cytokine production. H. pyl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 26, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "calculated through mathematical models that improved sanitation during the latter half of the ninete\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 26, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "The particular end result of H. pylori infection (gastritis, PUD, gastric MALT lymphoma, gastric can\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 26, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Community-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidney\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 26, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "oxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocy\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 26, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMC\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 27, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "FIGURE 324­6Outline of the bacterial and host factors important in determining H. pylori–induced gas\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 27, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "contribute to epithelial cell injury (see below). H. pylori makes proteases and phospholipases that \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 27, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "species and enhanced epithelial cell turnover and (2) apoptosis related to interaction with T cells \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 27, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Yonsei University Medical LibraryAccess Provided by:Downloaded 2024­5­29 3:6 A  Your IP is 116.89.17\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 27, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allright\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 27, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "EnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 27, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "FUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatosta\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 28, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "remains unknown. H. pylori also appears to regulate NO formation via different mechanisms that in tu\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 28, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "in gastric acid secretion after long­term infection may be due to the bacterium’s ability to inhibit\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 28, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Yonsei University Medical LibraryAccess Provided by:Downloaded 2024­5­29 3:6 A  Your IP is 116.89.17\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 28, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allright\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 28, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "EnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 28, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "FUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatosta\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 29, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "8).FIGURE 324­8Natural history of H. pylori infection. MALT, mucosal­associated lymphoid tissue. (Fr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 29, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "important to identify patients who are at increased risk for morbidity and mortality related to NSAI\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 29, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "angiotensinogen (AGT), and an organic ion transporting polypeptide (SLCO1B1), but these findings nee\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 29, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCI\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 29, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactors\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 29, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 30, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Prostaglandins play a critical role in maintaining gastroduodenal mucosal integrity and repair. It t\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 30, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Pharmacol 180:114147, 2020.)Injury to the mucosa also occurs as a result of the topical use of NSAID\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 30, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "perforation. The mechanism responsible for increased ulcer diathesis in smokers is unknown. Theories\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 30, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Page 13 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2Arachido\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 30, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Gastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsP\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 30, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,S\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 30, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-pred\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 31, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "decreased proximal duodenal bicarbonate production, increased risk for H. pylori infection, and ciga\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 31, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "advanced age, (2) chronic pulmonary disease, (3) chronic renal failure, (4) cirrhosis, (5) nephrolit\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 31, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginfla\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 31, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Adrenal corticosteroidsPepsinH'HCIpH20MucusHCOS2PH7.0MucusH'Unstirred layerofmucus and bicarbonate2）\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 31, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACA\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 31, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Antral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimu\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 32, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Abbreviations: Hp, H. pylori; NSAIDs, nonsteroidal anti­inflammatory drugs.Multiple factors play a r\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 32, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Ga\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 32, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "MucusH'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,gene\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 32, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACA\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 32, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Antral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimu\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 33, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Abbreviations: Hp, H. pylori; NSAIDs, nonsteroidal anti­inflammatory drugs. Idiopathic hypersecretor\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 33, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "chemical receptors in the duodenum, enhanced duodenal sensitivity to bile acids and pepsin, and alte\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 33, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "mortality in PUD­related bleeding is due to nonbleeding causes such as multiorgan failure (24%), pul\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 33, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointest\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 33, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "mucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 33, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)H\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 33, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "H.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pyl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 34, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "mortality of >20%. Acute abdominal pain, tachycardia, and abdominal rigidity compose the classic tri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 34, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Differential DiagnosisThe list of GI and non­GI disorders that can mimic ulceration of the stomach o\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 34, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "<45 years of age, before embarking on a diagnostic evaluation (Chap. 45).Barium studies of the proxi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 34, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrights\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 34, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Alkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismuc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 34, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 35, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "must be followed by endoscopy and biopsy.FIGURE 324­10Barium study demonstrating (A) a benign duoden\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 35, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Yonsei University Medical LibraryAccess Provided by:Downloaded 2024­5­29 3:6 A  Your IP is 116.89.17\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 35, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allright\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 35, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "EnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 35, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "FUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatosta\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 36, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Abbreviation: PPIs, proton pump inhibitors.Although the methods for diagnosing H. pylori are outline\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 36, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "important in the pathogenesis of PUD, eradication of H. pylori and therapy/prevention of NSAID­induc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 36, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Muc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 36, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "maintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynerg\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 36, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "triple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadruple\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 37, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Abbreviation: hs, at bedtime (hora somni).TREATMENT OF PEPTIC ULCER DISEASEBefore the discovery of H\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 37, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "(e.g., Maalox, Mylanta) have a combination of both aluminum and magnesium hydroxide in order to avoi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 37, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsres\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 37, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "sensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersform\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 37, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLev\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 38, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "symptomatic relief of dyspepsia. The most commonly used agents are mixtures of aluminum hydroxide an\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 38, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of cimetidine’s ability to inhibit cytochrome P450, careful monitoring of drugs such as warfarin, ph\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 38, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "aimed at improving treatment of gastroesophageal reflux disease (GERD). These are the most potent ac\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 38, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "inhibited by >95% after 1 week of therapy. The half­life of PPIs is ~18 h; thus, it can take between\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 38, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • AccessibilityPage\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 38, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo, J. Larry Jameson:Harrison's Principles of Intemal Medicine,21eHormonal regulationGastrin,\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 38, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Copyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNe\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 38, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kas\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 39, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "maximized if they are administered before a meal (except for the immediate­release formulation of om\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 39, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "overall clinical significance of this observation is not definitely established. Caution should be t\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 39, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Diarrhea is also associated with PPI use, which in some cases has been associated with the developme\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 39, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "interaction on mortality is not clearly established. The mechanism involves the competition of the P\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 39, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "consistently eliminated, thus making it difficult to establish a definitive association between PPIs\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 39, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "kidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 39, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "aggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinne\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 39, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "MCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatme\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 40, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "therapy. Although high­dose H2 blockers have been considered an option, these do not appear to be as\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 40, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Development of novel acid inhibitory agents continues in an attempt to primarily address the need fo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 40, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "prostaglandin synthesis, stimulating mucus and bicarbonate secretion, and enhancing mucosal defense \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 40, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrights\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 40, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Alkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismuc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 40, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 41, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "pgy,g,gpyg,constipation being most common (2–3%). It should be avoided in patients with chronic rena\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 41, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "toxicity and the development of potent antisecretory agents, these are rarely, if ever, used today. \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 41, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "to H. pylori eradication. The Maastricht IV/Florence Consensus Report recommends a test­and­treat ap\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 41, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "quartz, or cement; and/or work in quarries); and H. pylori–positive patients with a fear of gastric \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 41, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBon\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 41, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "prostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal fr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 41, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)H\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 41, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "H.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pyl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 42, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "quartz, or cement; and/or work in quarries); and H. pylori–positive patients with a fear of gastric \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 42, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Addition of acid suppression assists in providing early symptom relief and enhances bacterial eradic\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 42, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpn\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 42, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "is maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sul\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 42, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: N\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 43, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "aSeveral PPI, clarithromycin, and amoxicillin combinations have achieved FDA approval. The regimen o\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 43, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "twice per day for 14 days, whereas Helidac constituents are taken four times per day with an antisec\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 43, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "the United States, with resistance to amoxicillin being <1% and resistance to both metronidazole and\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 43, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "C.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitial\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 43, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Muscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelia\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 43, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: Y\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 44, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "gygtetracycline and rifabutin (see below) is reported to be <2% in the United States. In light of th\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 44, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "compliant patient, then culture and sensitivity of the organism should be considered. One challenge \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 44, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBon\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 44, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "prostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal fr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 44, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)H\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 44, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "H.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pyl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 45, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "aPPI, bismuth, tetracycline, and metronidazole prescribed separately is not an FDA­approved treatmen\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 45, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "14NoAmoxicillin (1 g tid or 750 mg qid)tid or qidIn view of the observation that 15–25% of patients \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 45, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • AccessibilityPage\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 45, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo, J. Larry Jameson:Harrison's Principles of Intemal Medicine,21eHormonal regulationGastrin,\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 45, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Copyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNe\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 45, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kas\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 46, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Abbreviations: COX­2, isoenzyme of cyclooxygenase; NSAID, nonsteroidal anti­inflammatory drug; PPI, \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 46, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "abdominal discomfort/pain, resulting in enhanced tolerability of H. pylori therapies. Additional stu\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 46, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "approach to primary prevention has included avoiding the agent, using the lowest possible dose of th\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 46, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Yonsei University Medical LibraryAccess Provided by:Downloaded 2024­5­29 3:6 A  Your IP is 116.89.17\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 46, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allright\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 46, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "EnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 46, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "FUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatosta\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 47, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Abbreviations: CV, cardiovascular; GI, gastrointestinal; NSAID, nonsteroidal anti­inflammatory drug;\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 47, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "high­risk patients. For example, concomitant use of warfarin and a COX­2 inhibitor was associated wi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 47, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "long­term traditional NSAID therapy should also be considered for H. pylori testing and treatment if\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 47, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Guide to NSAID TherapyNO/LOW NSAID GI RISKNSAID GI RISKNo CV risk (noaspirin)Traditional NSAIDCoxib \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 47, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsrati\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 47, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNe\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 47, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*Recom\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 48, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Abbreviations: CV, cardiovascular; GI, gastrointestinal; NSAID, nonsteroidal anti­inflammatory drug;\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 48, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "4–6 weeks. H. pylori eradication should be documented 4 weeks after completing antibiotics. The test\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 48, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Yonsei University Medical LibraryAccess Provided by:Downloaded 2024­5­29 3:6 A  Your IP is 116.89.17\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 48, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "kidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 48, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "aggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinne\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 48, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "MCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatme\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 49, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "frail should be treated with long­term acid suppression, thus making documentation of H. pylori erad\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 49, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "higher dose is also effective in maintaining remission. Surgical intervention may be a consideration\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 49, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "abdominal pain with peritoneal signs and evidence of pneumoperitoneum on abdominal imaging is the cl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 49, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "drainage (by pyloroplasty, gastroduodenostomy, or gastrojejunostomy), (2) highly selective vagotomy \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 49, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      ">40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasiv\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 50, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Surgical treatment was originally designed to decrease gastric acid secretion. Operations most commo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 50, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "acid output, acid secretion recovers over time. By the end of the first postoperative year, basal an\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 50, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Page 33 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kaspe\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 51, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "reconstruction.FIGURE 324­15Schematic representation of Billroth I and II procedures.Of these proced\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 51, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "indicated in fragile patients with a high GU. Ulcer recurrence approaches 30% with this procedure.Su\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 52, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "p)ggpp,gy,pp y,gy (gp),yindicated in fragile patients with a high GU. Ulcer recurrence approaches 30\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 52, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "question of incomplete vagotomy or retained gastric antrum should be explored. For the latter, fasti\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 52, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and bloating that occur 20–60 min after meals. Pain is often followed by nausea and vomiting of bile\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 52, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "symptoms often improve with time, but a severe protracted picture can occur in up to 1% of patients.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 53, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "plasma volume contraction and acute intestinal distention. Release of vasoactive GI hormones (vasoac\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 53, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "acting agent. In addition, patient weight gain and quality of life appear to be superior with the lo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 53, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "vomiting improves, but early satiety and bloating may persist in up to 50% of patients.Maldigestion \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 53, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "in men after gastric surgery as in a control population. It may take years before x­ray findings dem\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 54, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Malabsorption of vitamin D and calcium resulting in osteoporosis and osteomalacia is common after pa\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 54, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "RELATED CONDITIONSZOLLINGER­ELLISON SYNDROMESevere peptic ulcer diathesis secondary to gastric acid \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 54, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "increased parietal cell mass. The increased gastric acid output leads to peptic ulcer diathesis, ero\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 54, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Yonsei University Medical LibraryAccess Provided by:Downloaded 2024­5­29 3:6 A  Your IP is 116.89.17\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 55, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "heart, liver, and lymph nodes. More than 60% of tumors are considered malignant, with up to 30–50% o\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 55, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "from marked volume overload to the small bowel, pancreatic enzyme inactivation by acid, and damage o\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 55, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "patients with MEN 1 is the higher incidence of gastric carcinoid tumor development (as compared to p\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 55, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "clinical scenarios that should arouse suspicion regarding this diagnosis is shown in Table 324­8. Fa\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 55, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Anti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBT\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 56, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "pgggg ggpassay are usually <150 pg/mL. A normal fasting gastrin, on two separate occasions, especial\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 56, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "retained gastric antrum; G­cell hyperplasia; gastric outlet obstruction; renal insufficiency; massiv\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 56, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "the presence of hypergastrinemia is considered pathognomonic of ZES, but up to 12% of patients with \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 56, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • AccessibilityPage\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 57, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Abbreviations: CT, computed tomography; EUS, endoscopic ultrasonography; MRI, magnetic resonance ima\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 57, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Tumor LocalizationOnce the biochemical diagnosis of gastrinoma has been confirmed (if possible), the\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 57, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "SENSITIVITY, %STUDYPRIMARY GASTRINOMAMETASTATIC GASTRINOMAUltrasound21–2814CT scan55–70>85Selective \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 58, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Abbreviations: CT, computed tomography; EUS, endoscopic ultrasonography; MRI, magnetic resonance ima\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 58, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "before surgery. Selective arterial secretin injection may be a useful adjuvant for localizing tumors\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 58, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "high as 33% with 10­year disease­free intervals as high as 95% in sporadic gastrinoma patients under\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 59, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "starting PPIs and increasing the dose accordingly are paramount. Although the somatostatin analogue \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 59, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "clearly defined. Laparoscopic surgical interventions may provide attractive approaches in the future\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 59, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "radiofrequency ablation or cryoablation of liver lesions and use of agents that block the VEGF recep\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 59, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "failure requiring mechanical ventilation and underlying coagulopathy are risk factors for bleeding, \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 59, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • AccessibilityPage\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 60, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "normal protective barriers of the stomach, systemic release of cytokines, poor GI motility, and oxid\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 60, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "better approach would be a total gastrectomy, which has an exceedingly high mortality rate in this s\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 60, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "gross inspection of the gastric mucosa is poor. Therefore, there is no typical clinical manifestatio\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 61, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "D.  SarcoidosisE.  Isolated granulomatous gastritisF.  Russell body gastritisThe correlation between\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 61, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chronic GastritisChronic gastritis is identified histologically by an inflammatory cell infiltrate c\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 61, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "blood vessels.Gastric glands may undergo morphologic transformation in chronic gastritis. Intestinal\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 61, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Parietal cell antibodies and atrophic gastritis are observed in family members of patients with pern\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 62, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "pylori infection can lead to a similar distribution of gastritis. The characteristics of an autoimmu\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 62, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Gastric acid plays an important role in feedback inhibition of gastrin release from G cells. Achlorh\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 62, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Multifocal atrophic gastritis, gastric atrophy with subsequent metaplasia, has been observed in chro\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 62, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "pain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHbloc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 63, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Multifocal atrophic gastritis, gastric atrophy with subsequent metaplasia, has been observed in chro\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 63, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "TREATMENT OF CHRONIC GASTRITISTreatment in chronic gastritis is aimed at the sequelae and not the un\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 63, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "These prominent antral folds can lead to outlet obstruction. Patients can present with epigastric di\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 63, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "later in the course of therapy. The diagnosis is made by the histologic findings on gastric mucosal \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 64, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Immune checkpoint inhibitor–induced enterocolitis and gastritis are recognized sequelae of these onc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 64, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "The overexpression of TGF­α in turn results in overstimulation of the epidermal growth factor recept\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 64, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "yields varying results. Ulcers should be treated with a standard approach. The discovery that MD is \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 64, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Yonsei University Medical LibraryAccess Provided by:Downloaded 2024­5­29 3:6 A  Your IP is 116.89.17\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 65, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ygpy,Engevik  AC  et al: The physiology of the gastric parietal cell. Physiol Rev 100:573, 2019.  [P\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 65, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "25943389] Melcarne  L  et al: Management of NSAID­associated peptic ulcer disease. Expert Rev Gastro\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 65, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Page 48 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kaspe\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 66, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      ",Sugano  K  et al: Kyoto global consensus report on Helicobacter pylori gastritis. Gut 64:1353, 2015\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 67, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER  141 ACID PEPTIC DISEASE886cobblestone appearance, termed nodular gastritis (a lesion found \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 67, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "intestinal tract, two thirds occur in the stomach.141 ACID PEPTIC DISEASEERNST J. KUIPERS AND MARTIN\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 68, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER  141 ACID PEPTIC DISEASE887EPIDEMIOLOGYThe worldwide prevalence of gastritis reflects the pr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 68, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "related to nonsteroidal anti-inflammatory drugs (NSAIDs) in older persons.In Western countries, duod\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 68, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "the presence of the s1m1 genotype; a high level of cytokine induction, owing to the presence of gene\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 68, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "NSAIDs and ulcer disease and the risk for recurrence of ulcers with their continued use, patients wi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 68, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "association with polyposis syndromes, especially familial adenomatous polyposis and, to a much lesse\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 69, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER  141 ACID PEPTIC DISEASE888characterized by irregular longitudinal shapes. Ulcers in the duo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 69, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "affecting the mesenteric veins, may cause gastric ulcer disease. Systemic amyloidosis (Chapter 194) \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 69, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ORIGINCONDITIONFREQUENCY*DIAGNOSTIC TESTFINDINGSMicrobesHelicobacter pyloriVery commonHelicobacter p\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 69, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Mesenteric vascular occlusionCommonAngiographyVascular diseasePolycythemia veraRareBlood countsPolyc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 70, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER  141 ACID PEPTIC DISEASE889hypergastrinemic hyperacidity syndromes are the retained gastric \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 70, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "for gastroduodenal mucosal perfusion are not widely available, but a tech­nique for directly measuri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 70, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "rent ulcers, often located at the anastomosis or within the jejunum immedi­ately opposite the anasto\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 70, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tocytosis (Chapter 263) is characterized by a proliferation of mast cells in the bone marrow, skin, \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 70, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "thies may rarely develop intramural hematoma of the gastrointestinal tract. Depending on the locatio\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 71, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER  141 ACID PEPTIC DISEASE890a silent ulcer may be recognized only when it presents abruptly w\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 71, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tomatic intervals. During periods of remission, patients may feel well and may be able to eat even h\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 71, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "141-2). Because of the high prevalence and the often spontaneous improve­ment of dyspeptic symptoms,\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 71, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and to assess for H. pylori (see Fig. 141-3); and performing therapeutic interventions.In rare cases\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 71, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Stool antigen testCarbon-13 urea breath testSerum antibodiesUlcer Associated with Nonsteroidal Anti-\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 72, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER  141 ACID PEPTIC DISEASE891Etiologic DiagnosisDiagnosis also must focus on establishing the \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 72, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "low. Serology is not helpful to verify whether H. pylori has been eradicated with antibiotics becaus\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 72, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of ulcer disease and are diagnosed by special tests (see Table 141-3). Zollinger-Ellison syndrome sh\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 72, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of gastric pH less than 2. To skip the cumbersome gastric analysis, a gastric pH determination showi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 72, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "radiograph, angiography, ileocolonoscopy, and abdominal CT.Differential DiagnosisThe differential di\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 72, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "appropriate H. pylori eradication drugs (see later) and observed for 4 to 6 weeks. If the patient is\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 73, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER  141 ACID PEPTIC DISEASE892TABLE 141-4 OVERVIEW OF ANTIBIOTICS USED FOR HELICOBACTER PYLORI \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 73, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "owing to re-infection or in the presence of another ulcerogenic factor, par­ticularly NSAID use.Dise\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 73, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "suppressive therapy can be withdrawn if there are no additional risk factors for ulcer disease, such\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 73, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "than triple therapy. 4  Nevertheless, 7-day treatment may be acceptable in regions where local studi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 73, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "patients with dyspeptic symptoms, but there is no specific way to prevent H. pylori–associated ulcer\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 74, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER  141 ACID PEPTIC DISEASE893pump inhibitors (at a dose equivalent to omeprazole 20 mg once da\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 74, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "is as effective as a proton pump inhibitor for the prevention of recurrent ulcers. 6  In H. pylori–n\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 74, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "importance in determining the need for transfusion and subsequent manage­ment (Table 141-5). Initial\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 74, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "patients with an admission score ≤2 but is required in more than 40% of patients with a score ≥6.TAB\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 74, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "adherent clot is found, an attempt should be made to remove it by water flushing or snaring to allow\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 75, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CHAPTER  141 ACID PEPTIC DISEASE894for transfusion or the occurrence of rebleeding or death. For pat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 75, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "patients who recover after a peptic ulcer hemorrhage is similar to the treat­ment of patients with u\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 75, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "begins by correcting hemodynamic, fluid, and electrolyte imbalances. Naso­gastric suction is helpful\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 75, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Cameron’s ulcers are treated by potent acid suppression therapy (e.g., omeprazole 20 mg twice daily)\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 76, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "This step facilitates an accurate diagnosis. Nasogastric suction may need to be maintained for sever\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 76, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;3\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 76, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "15. Sung JJ, Lau YW, Ching JYL, et al. Continuation of low-dose aspirin in peptic ulcer bleeding: a \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 77, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "219Upper GI TractCHAPTER 32Peptic ulcerC. J. Hawkey and John C. AthertonNottingham Digestive Disease\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 77, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "causes. Tests for H. pylori have a low but measurable false negative rate and NSAIDs purchased direc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 77, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ESSENTIALS OF TREATMENT  AND PROGNOSIS• Successful H. pylori eradication results in permanent ulcer \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 78, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Upper GI TractPart 2:  Diseases of the Gut and Liver220pylori remains common, the prevalence of pept\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 78, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PathogenesisIt is a truism that mucosal integrity represents a balance between aggressive and protec\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 78, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "cause, and one possibility is the widespread adoption of smoking – an important co-factor for duoden\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 79, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 32:  Peptic ulcer221Upper GI TractFigure 32.3  Recent trends in ulcer epidemiology. Top: Dea\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 79, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "virulence factor is the vacuolating cytotoxin, VacA. H. pylori strains producing more active forms a\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 80, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Upper GI TractPart 2:  Diseases of the Gut and Liver222hypergastrinemia [30]. Gastrin stimulates the\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 80, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Duodenal ulcerationDuodenal ulcers occur against a background of H. pylori colo-nization with a pred\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 80, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "70Low doseMediumHighHawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 81, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 32:  Peptic ulcer223Upper GI Tractunderstood. The mucosa is normally anesthetic, but contain\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 81, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "in Chapters 50 and 116 respectively.Pathogenesis of symptomsPain is the hallmark symptom of peptic u\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 82, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Upper GI TractPart 2:  Diseases of the Gut and Liver224Empiric management of dyspepsiaIn patients wi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 82, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "sies should also be taken for microbiologic culture and antibiotic sensitivity testing, if this serv\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 82, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Because ulcers naturally form and heal, pain is classically epi-sodic, typically with clusters of pa\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 82, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "usually upper gastrointestinal endoscopy. Because dyspeptic symptoms are so common, most healthcare \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 83, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 32:  Peptic ulcer225Upper GI Tractraised serum tryptase, and expression of CD2 and CD25 in c\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 83, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "therapy where amoxicillin 1 g twice a day is added to the above regimen (giving three effective drug\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 83, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "This should be suspected where Zollinger-Ellison syndrome is associated with hyperparathyroidism (se\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 84, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Upper GI TractPart 2:  Diseases of the Gut and Liver226lumiracoxib. The VIGOR and CLASS studies of r\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 84, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "H. pylori -positive NSAID or aspirin associated ulcersNSAIDsThis is a controversial area. The eviden\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 84, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Figure 32.8  Ulcer relapse following H. pylori eradication. There is a marked reduction in relapse r\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 85, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 32:  Peptic ulcer227Upper GI Tractmyocardial infarction (as is the case for aspirin plus NSA\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 85, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "inhibitor.AspirinIt is possible that H. pylori eradication may be sufficiently effective to protect \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 85, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "0NaproxenRofecoxibCumulative incidence (%)Study day0246810120901802703604201.41.01.20.80.60.40.20Non\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 86, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Upper GI TractPart 2:  Diseases of the Gut and Liver228variation. Many perforated ulcers are H. pylo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 86, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "stantially to reduce the readmission rate for ulcer complica-tions over 6 months [54–58].MortalityIn\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 87, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 32:  Peptic ulcer229Upper GI Tractor treatment with acid suppression can restore gastric emp\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 87, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tions. They can be managed with acid-suppressing drugs.  The role of H. pylori in this situation is \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 87, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Gastric outlet obstructionEpidemiologyGastric outlet obstruction by peptic ulcers is relatively unco\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 88, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Upper GI TractPart 2:  Diseases of the Gut and Liver230ProphylaxisTreatment with H2 receptor antagon\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 88, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tive therapy.• Patients given H. pylori treatment should be told of the importance of close complian\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 88, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "A need for ventilation because of respiratory failure is the most important risk factor, increasing \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 89, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 32:  Peptic ulcer231Upper GI Tractfor the first time in our evolutionary history have any di\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 89, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "2006;101(5):945–953.11.  Cai S, Garcia Rodriguez LA, Masso-Gonzalez EL, Hernandez-Diaz S. Uncomplica\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 89, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "www.digestive.niddk.nih.gov/ddiseases/pubs/hpylori/ www.digestive.niddk.nih.gov/ddiseases/pubs/nsaid\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 89, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "aim of primary prevention of peptic ulcers and gastric cancer?• H. pylori has co-evolved with humans\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 90, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Upper GI TractPart 2:  Diseases of the Gut and Liver232selective COX-2 inhibitors (NASA1 – SPACE1). \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 90, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "45.  Silverstein F, Simon L, Faich G. Reporting of 6-month vs 12-month data in a clinical trial of c\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 90, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized contro\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 90, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "phisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol. \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 91, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 32:  Peptic ulcer233Upper GI Tract64.  MacDonald TM,Wei L. Effect of ibuprofen on cardioprot\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 91, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "74.  Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointesti\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 91, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "J Med. 2001;344:967–973.56.  Chan FK, Hung LC, Suen BY et al. Celecoxib versus diclof­enac and omepr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 91, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "2001;345:1809–1817.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 92, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "234Upper GI TractCHAPTER 33GastritisRichard H. Lash and Robert M. GentaCaris Diagnostics/Miraca; Uni\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 92, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "signs or symptoms. A subset of patients may have symptoms due to gastritis, but no independent tests\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 92, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "countries and populations with a high incidence of gastric adenocarcinoma– Carcinoma and lymphoma ma\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 93, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 33:  Gastritis235Upper GI TractCauses, risk factors, disease associationsHumans are the only\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 93, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "FungiParasitesGastritis with or without ulcer/granuloma and identifiable organisms/viral cytopathic \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 94, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Part 2: Diseases of the Gut and Liver236Upper GI Tractbeen suspected of an association with particul\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 94, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "sia. Atrophic pangastritis is the predominant phenotype in subjects from less industrialized areas o\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 94, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "mucosal levels of interleukin-8 and marked neutrophil infiltrationIncrease risk of a symptomatic out\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 95, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 33:  Gastritis237Upper GI Tractorganisms have a characteristic tight spiral morphology and a\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 95, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ring cell) gastric cancer of the stomach, which accounts for 50% or more of all gastric cancers in s\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 95, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "stain, which can also identify organisms after treatment with proton pump inhibitors and antibiotics\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 96, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Part 2: Diseases of the Gut and Liver238Upper GI TractTable 33.3  Invasive and non-invasive tests fo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 96, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and specificity (85%−90%)InexpensiveUseful for initial diagnosisSpecificity may be “population-speci\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 97, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 33:  Gastritis239Upper GI Tract14 days has a reported efficacy between 75% and 95% in patien\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 97, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "within the United States before it can be recommended as a first-line therapy;” the European Maastri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 97, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "• a history of documented peptic ulcer• gastric MALT lymphoma.Testing of asymptomatic subjects and p\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 97, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "that antibiotic, increasing in most countries, exceeds 15–20%. Although there has been debate on the\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 98, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Part 2: Diseases of the Gut and Liver240Upper GI TractESSENTIAL FACTS ABOUT AUTOIMMUNE  GASTRITIS• C\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 98, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "carcinoid tumours. Such tumours are often multiple, are  associated with various levels of backgroun\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 98, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "haplotypes (HLA-B8 and -DR3) in patients with corpus-restricted atrophic gastritis and its associati\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 99, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 33:  Gastritis241Upper GI TractThe atrophic gastritis is characterized histologically by chr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 99, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Table 33.4.Lymphocytic gastritisThis is a distinctive type of pangastritis characterized by the pres\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 99, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "nicious anemia, are mostly sessile, small, and multiple. Most are hyperplastic, but up to 10% may co\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 100, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Part 2: Diseases of the Gut and Liver242Upper GI TractTable 33.4  Infectious gastritides caused by a\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 100, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "gastritis featured endoscopic descriptions of large gastric folds with nodules and erosions, clinica\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 101, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 33:  Gastritis243Upper GI TractPrimary gastric tuberculosis has been reported mostly from de\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 101, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "an ulcer crater. Rare entities causing gastric granuloma include immune-mediated vasculitis syndrome\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 101, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "chronic gastritis, in which (exclusive of focal lymphoepithelial lesions) few intraepithelial lympho\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 102, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Part 2: Diseases of the Gut and Liver244Upper GI TractESSENTIAL FACTS ABOUT REACTIVE  GASTROPATHY• A\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 102, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "factors (older age, female sex, and previous episodes), there is no way prospectively to identify NS\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 102, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "or chemical gastropathy, even in settings other than those of NSAID ingestion.Figure 33.6  Reactive \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 103, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 33:  Gastritis245Upper GI Tractnized and better understood. The three classic types of hyper\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 103, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "minemia as a consequence of the chronic protein loss. Child-hood Ménétrier’s disease is due to gastr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 103, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "vessels in biopsies with formalin fixation, and also reflects the fact that the primary and most str\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 103, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 104, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Part 2: Diseases of the Gut and Liver246Upper GI Tract  9.  Yamaoka Y, Kato M, Asaka M. Geographic d\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 104, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "21.  Marshall B. Sequential therapy for Helicobacter pylori: a worth-while effort for your patients.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 104, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "TreatmentA monoclonal antibody against the TGF receptor may hold some promise as a therapeutic agent\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 104, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "4.  Stolte M, Kroher G, Meining A, et al. A comparison of Helico­bacter pylori and H. heilmannii gas\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 105, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Chapter 33:  Gastritis247Upper GI Tract35.  Genta RM. Differential diagnosis of reactive gastropathy\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 106, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Gastrointestinal bleeding is a medical emergency and represents the most common cause of hospitaliza\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 106, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "those who develop bleeding in the community setting4,5.EpidemiologyThe most common cause of NVUGIB i\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 106, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "medical emergency, and mortality is in the range ~1–5%. After resuscitation and initial assessment, \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 107, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Important developments in medicine in the past 20 years have affected the incidence and outcomes of \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 107, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "to ~25–35 per 100,000 people in the early 2000s16–19. However, data are difficult to compare between\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 107, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PUB events were related to H. pylori infection, 18.7% to gastrotoxic drug use, 19.8% to both factors\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 107, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Madrid, Spain.3Gedyt Endoscopy Center, Buenos Aires, Argentina.4Division of Gastroenterology and Far\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 108, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "was threefold higher in Mexico, twofold higher in Argentina and Chile and only slightly higher in Ta\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 108, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "cause, exposure of the underlying blood vessels to the action of acid and pepsin further erodes the \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 108, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "denal bulb, which may be colonized by H. pylori and favour ulcer formation3,40.NSAID and LDA use. St\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 108, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "12 hours after admission once haemodynamic stability has been achieved to ascertain the cause of hae\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 109, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "constant, with acidic NSAIDs being the most potent. Consequently, use of acidic NSAIDs (including as\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 109, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ured using ­prothrombin and partial ­thromboplastin times)44 (FIG. 3).Pepsin, a proteolytic enzyme t\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 109, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "context, the antiplatelet effect would be similar to that of anticoagulants such as vitamin K antago\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 109, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1994–2009New Zealand2001–2010Figure 1 | The decline in incidence of NVUGIB over time. Percentage dec\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 110, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Mallory–Weiss syndrome. In Mallory–Weiss syn­drome, mucosal disruption and laceration result from se\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 110, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "plasia of the stomach may have a similar pathogenetic profile as Dieulafoy lesions. Intermittent sub\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 110, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "induce a break in the mucosa by acting both locally and systemically, whereas Helicobacter pylori da\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 111, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "whereas platelet and clotting dysfunction, platelet–­vessel interaction and haemodynamic instability\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 111, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "more risk factors have increased risk. A history of previ­ous ulcers puts any patient ­receiving NSA\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 111, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "lism or activation of drugs taken concomitantly. How different PPIs interact with different CYPs mig\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 111, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "At pH 6.8, platelet aggregation is negatively affected, and at pH 5.9, it is completely abolished. A\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 112, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Histological analysis and/or culture of biopsy speci­mens may also provide false-negative results76.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 112, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "rectal examination than with patient-reported history of melena or the presence of blood clots in th\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 112, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "• Altered  microperfusion• Systemic  inﬂammatory  statusGastric cancerGenetic predisposition• COX in\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 113, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Each patient presenting with NVUGIB should have pre-endoscopic risk stratification. Among the differ\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 113, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "patient presentation)85–87. Nevertheless, controversy per­sists because very early endoscopy reveals\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 113, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "concluding that there was a bene­ficial effect of com­bining therapeutic endoscopy with intra­venous\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 113, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "inhibitors) with LDA, thienopyridine antiplatelet agents (for example, clopidogrel), warfarin, novel\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 114, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "signals on ulcer bases using a Doppler probe in patients with Forrest type Ia bleeding are high (100\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 114, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and results in a twofold to fivefold increase in mortality5. However, current evidence-based guideli\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 114, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "sensitive to low oxygen-carrying capacity, but overtrans­fusion should be avoided as it can be assoc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 114, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "selective serotonin reuptake inhibitor.Nature Reviews | Disease PrimersTreatments  No drug useCOX2 i\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 115, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "erythromycin 30–120 minutes before endoscopy, ­especially in those with severe and ongoing bleeding,\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 115, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "capacity to include the whole lesion and induce pres­sure, and are good options for salvage or rescu\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 115, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Admission Rockall score for NVUGIB (pre-endoscopy)This scoring system (0–7 points) aims to predict t\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 115, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "system alongside endoscopic stigmata (absence of stigmata or dark spots on ulcers, blood in the uppe\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 116, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of evidence and scarcity of comparative data. Bleeding associated with Mallory–Weiss tears is ­usual\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 116, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "gastric pH to >6 is based on studies that demonstrated that acidity affects platelet aggregation and\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 116, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "versus 64.8 ± 4.2% (mean ± standard error) for oral PPI), although intravenous PPI increased pH to >\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 117, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Patients with PUB have an unacceptably high rate of recurrent bleeding. In an RCT of patients with H\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 117, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Recurrent bleedingIn patients with clinical evidence of re-bleeding, repeat upper endoscopy should b\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 117, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "variceal ligation•Over-the-scope clip (OTSC system; OVESCO Endoscopy AG, Tübingen, Germany): a large\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 118, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "angiographic embolization than surgery, but no signifi­cant difference in mortality or need for addi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 118, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "is often stopped and resumed after 3–5 days in those at high risk of recurrent NVUGIB to avoid the p\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 118, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "plasma (FFP)151. Vitamin K should be injected slowly to minimize severe (anaphylactic or anaphy­lact\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 119, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "is not recommended (high cost and 11% thromboembo­lism risk)160. FIGURE 8 summarizes commonly accept\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 119, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of reversal agents, which could be used in the case of life-threatening gastrointestinal bleeding, b\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 119, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "prevention of cardiovascular events, it should be discontinued in patients with a history of peptic \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 120, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "assessed as normal in 93.4% at the start of the intended procedure (1.6 hours after idarucizumab adm\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 120, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "is still a matter of debate, war­farin should be restarted 7–14 days following NVUGIB on the basis o\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 120, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "• INR <1.5: recheck in 6 hours, then daily• INR >1.5: seek advice and consider PCC reinfusionNo haem\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 121, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "admission for NVUGIB, patients have reported levels of general and physical fatigue to be considerab\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 121, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "HRQOL generally follows an upward trajectory in the weeks and months following hospital discharge fo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 121, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ManagementFrom a pathogenetic point of view and in addition to the appropriate endoscopic management\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 121, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "vary depending on the reagents used. Approximately 20% of patients who take dabigatran have a normal\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 122, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Patients on antiplatelet or anticoagulation agentsThe clearest changes are the progressive decline i\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 122, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "has declined over time owing to a parallel decrease in the number of events, mortality linked to the\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 122, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Rhythm Association167,176,180.Nature Reviews | Disease PrimersUndergo measures to control mild bleed\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 122, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "incidence, etiology and outcomes in a population-based setting. Scand. J. Gastroenterol. 48, 439–447\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 122, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Am. J. Gastroenterol. 100, 1685–1693 (2005).18. Ahsberg, K., Ye, W., Lu, Y., Zheng, Z. & Staël von H\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 123, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "20. Sonnenberg, A. Time trends of ulcer mortality in non-European countries. Am. J. Gastroenterol. 1\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 123, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroe\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 123, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "to stimulation of somatostatin and inhibition of histamine secretion. Am. J. Physiol. Gastrointest. \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 123, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "peptic ulcer bleeding. Aliment. Pharmacol. Ther. 21, 677–686 (2005).49. Halvorsen, S. et al. Managem\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 123, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "characteristics of angiodysplasia presenting as upper gastrointestinal bleeding. Kor. J. Intern. Med\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 123, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose asp\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 123, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "75. Malfertheiner, P. et al. Management of Helicobacter pylori infection-the Maastricht V/Florence C\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 124, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "83. Hearnshaw, S. A. et al. Use of endoscopy for management of acute upper gastrointestinal bleeding\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 124, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "93. Lau, J. Y. et al. Stigmata of hemorrhage in bleeding peptic ulcers: an interobserver agreement s\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 124, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "102.El Ouali, S. et al. Is routine second-look endoscopy effective after endoscopic hemostasis in ac\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 124, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of meta-analyses. Gastrointest. Endosc. 69, 786–799 (2009).110. Sung, J. J., Tsoi, K. K., Lai, L. H.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 124, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "upper gastrointestinal bleeding: a multicenter study (the “GRAPHE” registry). Endoscopy 48, 1084–109\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 124, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "mucosal damage: review of drug therapy. J. Clin. Gastroenterol. 12 (Suppl. 2), S35–S40 (1990).129.Pe\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 124, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated ga\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 125, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "144.Sung, J. J. et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomiz\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 125, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Pract\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 125, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "13, 86–99 (2015).161.Witt, D. M., Clark, N. P., Kaatz, S., Schnurr, T. & Ansell, J. E. Guidance for \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 125, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "170.Wang, X. et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. A\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 125, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Thromb. Haemost. 117, 238–245 (2017).180.Chatterjee, P. & Weitz, J. I. Assessment and management of \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 125, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "(CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 125, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "study. Aliment. Pharmacol. Ther. 39, 176–187 (2014).197.De Franceschi, L., Iolascon, A., Taher, A. &\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 126, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "205.Chan, F. K. et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients star\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 126, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxa\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 126, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "prevention (R.H.H., A.L., A.R. and M.F.); Management (J.J.Y.S., I.M.G., J.M.S. and J.-M.D.); Quality\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 127, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1062  |  wileyonlinelibrary.com/journal/aptAliment Pharmacol Ther. 2024;59:1062–1081.© 2024 John Wil\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 127, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "meta-­analysis with random effects methods and odds ratios with 95% confidence intervals.Results: Pr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 128, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  1063SHUNG and LAINEreversed.1 Furthermore, despite increasing co-­morbidities and anti-­thromboti\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 128, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "take-­home points are collated in a table, separated by different phases of care. (Table 1) We provi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 128, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Glasgow-­Blatchford Score (GBS) of 0–1 are candidates for discharge from the emergency department wi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 128, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "2.2.1 | GuidelinesThere are no recommendations across the U.S., European or inter-national guideline\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 129, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1064  |    SHUNG and LAINETA B LE 1 Summary of take-­home points by pre-­endoscopic, endoscopic and \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 129, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "modalities.OTSCs are suggested as a treatment option for recurrent bleeding after conventional endos\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 129, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "is common. Treatment with TC-­325 haemostatic powder spray may hold promise, but therapy for the und\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 129, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "for End-­Stage Liver Disease; OTSC, over-­the-­scope-­clips; PPI, proton pump inhibitor therapy; TIP\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 130, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  1065SHUNG and LAINEpractice.5,6,8 The Asia-­Pacific guidelines do not recommend use of risk score\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 130, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "cardiovascular disease, they suggest red blood cell transfusion at a haemoglobin threshold of <8 g/d\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 131, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1066  |    SHUNG and LAINEcardiovascular disease.8 U.S. guidelines also noted that it is reasonable \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 131, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "with pre-­existing cardiovascular disease because trials in this population used a restrictive thres\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 131, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Continuous infusion ortherapyintermittent intravenous orI high-dose PPl for 3 daysoralTwice-daily or\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 132, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  1067SHUNG and LAINEFI G U R E 3 Endoscopic management and post-­endoscopic management for patient\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 132, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "RecurrentBleeding?Repeat endoscopyRepeat endoscopyDefinitive or palliative ttherapyI (e.g.Repeat end\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 133, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1068  |    SHUNG and LAINE2.3.3 | Take-­home pointTransfuse at a threshold of haemoglobin <7 g/dL un\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 133, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "U.S. guidelines did not provide a recommendation for or against pre-­endoscopic PPI therapy.5 Europe\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 133, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "choose to give pre-­endoscopic PPIs, despite the fact that they do not improve clinical outcomes.2.6\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 134, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  1069SHUNG and LAINEand constant infusion tranexamic versus placebo. No suggestion of a benefit in\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 134, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "quinolones or cephalosporins.43 In patients with advanced cirrhosis, a randomised trial found that i\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 134, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "guidance recommend that patients with suspected acute variceal bleeding should undergo endoscopy wit\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 135, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1070  |    SHUNG and LAINEof earlier endoscopy: further bleeding 10.9 versus 7.8%; mortality 8.9 ver\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 135, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and international guidelines.5,6,8 For patients with an adherent clot re-sistant to vigorous irrigat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 135, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "3.3.2 | Best available evidenceRandomised controlled trials support each of the endoscopic thera-pie\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 136, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  1071SHUNG and LAINEabsolute ethanol injection and clips are all appropriate endoscopic haemostati\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 136, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ment for patients with actively bleeding ulcers. European, interna-tional and Asia-­Pacific guidelin\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 136, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "balloon tamponade.20,42Best available evidenceIn patients with severe refractory variceal bleeding, \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 137, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1072  |    SHUNG and LAINE3.6.2 | Best available evidenceA recent meta-­analysis of 10 randomised tr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 137, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Baveno VII suggests endoscopic therapy with tissue adhesives for bleeding from IGV and GOV-­2,20 whi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 137, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "does not divert blood from the portal system as TIPS does. A ran-domised trial showed BRTO increased\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 137, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "(N = 24)82,83 more rebleeding occurred with ligation than with butyl-­cyanoacrylate in IGV (OR: 15.9\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 138, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  1073SHUNG and LAINEconsidered for GOV1 bleeding because of fewer adverse events. TIPS and BRTO ar\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 138, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "p < 0.001), including gastric ulcers, in the cyanoacrylate group.923.8.3 | Take-­home pointFurther e\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 138, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "guidelines stating evidence is inadequate to recommend a specific modality.95,963.10.2 | Best availa\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 139, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1074  |    SHUNG and LAINE1/9 with endoscopic therapy and 3/8 controls – none of the fur-ther bleedi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 139, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "17%.103–105 Small randomised comparisons of clips versus ligation reveal excellent results for both \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 139, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ing from the malignant lesion): all 28 patients in the TC-­325 group re-ceived therapy and had haemo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 140, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  1075SHUNG and LAINEtherapy for the underlying malignancy, if possible, is most important to preve\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 140, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "aggregating these trials may be questionable due to differences in refeeding regimens and population\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 140, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "U.S. and international guidelines recommend that after this ini-tial 3-­day period, twice-­daily PPI\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 141, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1076  |    SHUNG and LAINE4.3 | Treatment of recurrent ulcer bleeding4.3.1 | GuidelinesInternational\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 141, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "embolisation. Nevertheless, patients and providers who place greater value on avoiding further bleed\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 141, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "second trial included Child-­Pugh Class B patients with and without active bleeding, and subgroup an\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 141, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Pugh class B or C with score <14) after initial endoscopic ligation and vasoactive medical therapy, \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 142, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  1077SHUNG and LAINE4.5 | Treatment of recurrent variceal bleeding4.5.1 | GuidelinesIf further ble\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 142, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ACKNOWLEDGEMENTSWe acknowledge the assistance of Alyssa Grimshaw, medical librar-ian at Yale, in cra\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 142, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Gastroenterol. 2021;116(5):899–917.6. Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F, et  a\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 142, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "2011;74(6):1215–24. 14. Laursen SB, Oakland K, Laine L, Bieber V, Marmo R, Redondo-­Cerezo E, et al.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 143, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1078  |    SHUNG and LAINE 15. Marmo R, Soncini M, Bucci C, Occhipinti V, Pellegrini L, Zullo A. Der\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 143, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "versus liberal transfusion strategy in upper gastrointestinal bleeding: a randomized controlled tria\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 143, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "death and thromboembolic events in patients with acute gastroin-testinal bleeding (HALT-­IT): an int\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 143, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "2018;6(1):46–54. 38. Bagnenko SF, Verbitskiĭ VG. Antifibrinolitic therapy for the treat-ment of mass\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 143, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tion of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the Europea\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 144, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  1079SHUNG and LAINE 49. Huaringa-­Marcelo J, Huaman MR, Brañez-­Condorena A, Villacorta-­Landeo P\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 144, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "variceal bleeding: a systematic review with meta-­analysis. Eur J Gastroenterol Hepatol. 2021;33(1S \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 144, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tial treatment in patients with bleeding from a nonvariceal upper gastrointestinal cause. Ann Intern\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 144, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. He\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 144, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "79. Lee EW, Eghtesad B, Garcia-­Tsao G, Haskal ZJ, Hernandez-­Gea V, Jalaeian H, et al. AASLD practi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 145, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1080  |    SHUNG and LAINE 81. Tantau M, Crisan D, Popa D, Vesa S, Tantau A. Band ligation vs. N-­Bu\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 145, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Gastroenterol. 2010;31(4):279–84. 88. Robles-­Medranda C, Oleas R, Valero M, Puga-­Tejada M, Baqueri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 145, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tasia: a systematic review and meta-­analysis of randomized con-trolled trials. Clin Endosc. 2021;54\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 145, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "prognostic value of endoscopy in patients with upper gastrointes-tinal hemorrhage. Gastroenterology.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 145, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "nant bleeding: a randomized controlled trial. Endosc Int Open. 2022;10(10):E1350–E1357.111. Cheng HC\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 146, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  1081SHUNG and LAINE113. Tarasconi A, Baiocchi GL, Pattonieri V, Perrone G, Abongwa HK, Molfino S,\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 146, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "2022;10(8):874–87.120. Zhang H, Zhang H, Li H, Zhang H, Zheng D, Sun CM, et al. TIPS versus endoscop\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 147, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "REVIEWEvidence-based clinical practice guidelines for peptic ulcer disease2020Tomoari Kamada1,2 • Ki\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 147, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "hemorrhagic ulcer history. In patients with a history ofulcers receiving NSAID therapy, PPIs with or\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 147, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Okayama 700-8505, Japan2Guidelines Committee for Creating and Evaluating the‘‘Evidence-Based Clinica\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 148, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "antithrombotic drugs and the treatment of ischemic duo-denal ulcers have been added as a CQ and FRQ,\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 148, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "therefore, expected to be superior to that of proton pumpinhibitors (PPIs). Recent reports have show\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 148, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "(PT-INR) or to change warfarin to heparin.Recommendation: weak, 100% agreed, evidence levelD.•In pat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 149, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CQ-2Is interventional radiology (IVR) effective in patientsundergoing refractory endoscopic treatmen\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 149, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "re-bleeding, surgical intervention, and overall durationof hospital stay with no signiﬁcant differen\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 149, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "receiving warfarin with concomitant antiplatelet drugsor NSAIDs (45% reduction (hazard ratio 0.55; 9\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 150, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "compared with that of PPIs, VPZ is recommended as aﬁrst-line therapy.Recommendation: strong, 100% ag\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 150, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "eradication therapy?•Triple therapy with PPI/VPZ, amoxicillin, and metron-idazole is recommended.Rec\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 150, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "3298032170.1%0.30[0.19,0.48]2016Maruyama2017372216919.6%0.10 [0.03, 0.35]2017Sue 2018755125110.3%0.4\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 151, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Japan. In addition, the rate of H. pylori infection withprimary resistance to levoﬂoxacin is high in\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 151, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "recurrence is unclear.Non-eradication therapyInitial therapy.Gastric ulcerCQ-9What is the ﬁrst-line \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 152, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "P-CAB gained popularity in recent years due to theirhigh ulcer healing rate for gastric ulcers compa\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 152, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "MA in this guideline indicated that the healing rate ofpeptic ulcers over 8 weeks was higher in PPI \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 153, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "H2RAs or PG analogs for peptic ulcers and furtherbleeding; therefore, PPIs are suggested as a ﬁrst-l\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 153, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "NSAIDs and antithrombotic drugs or glucocorticoids orbisphosphonates,whoareelderly,orhaveseverecompl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 154, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "A.Comment: The incidence rate of peptic ulcers inWestern countries is signiﬁcantly lower in patients\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 154, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1999Simon 199917423291379.3%0.19 [0.11, 0.33] 1999Laine 1999173644016710.4%0.19 [0.11, 0.33] 1999Haw\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 155, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "NSAIDs. Using COX-2 selective inhibitors had a lowerrisk of developing serious ulcer complications.A\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 155, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "LDA-induced ulcerTreatmentCQ-18How should LDA-related peptic ulcers be treated?•Concomitant use of P\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 155, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "independently conduct an MA. We found no signiﬁcantdifference (RR 0.26; 95% CI 0.04–1.81, P = 0.17) \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 156, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Recommendation: strong, 100% agreed, evidence levelA.(PPI and VPZ are not covered by Japanese insura\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 156, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "with ulcer complications related to the long-term use ofLDA, treatment with lansoprazole in addition\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 156, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "2443.8%0.20 [0.01, 4.05]2011Yano20120651653.4%0.33 [0.01, 8.03]2012Ng 201231631214822.3%0.23 [0.07,0\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 157, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "with concomitant use of rabeprazole showed no differ-ence in the incidence of recurrent upper GI ulc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 157, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "LDA-related peptic ulcers without a history of ulcers.Recommendation: strong, 82% agreed, evidence l\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 157, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "arthritis patients taking LDA, the risk of GI events waslower with celecoxib than with naproxen or i\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 158, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CQ-25Is PPI recommended for the prevention of recurrence ofpeptic ulcers with NSAID treatment in pat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 158, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "without preventive treatment was 42.3%, higher thanthat of the H. pylori ulcer group (11.2%). Furthe\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 158, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "for preventing carcinogenesis. We should be cautiousabout the recovery of acid secretion after eradi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 159, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "regarding eradication therapy were found, but not forPPI or H2RA treatment. Several reports were ina\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 159, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "remains unclear. From the viewpoint of mucosalprotection, misoprostol is suggested. In the case ofac\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 159, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "mended and PPIs are suggested for ulcer prevention.However, PPIs are recommended for elderly patient\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 160, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "therapy is recommended. Finally, for patients receivingcombinations of LDA and NSAID therapy, CXB wi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 160, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "continuingofNSAIDsulcertherapytherapyInitial therapy1)PPIorP-CABEradicationEradication2)HRAsuccessfa\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 161, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "authors received support (commercial/academic cooperation): Aji-nomoto Pharmaceuticals Co., Ltd., As\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 161, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "OVPZ(CQ13)(CQ14)(CQ15)(CQ 17)(CQ16):recommendation,：suggestion)ConcomitantuseConcomitantuseof NSAIDs\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 162, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "AppendixMembers of the Guidelines Committee who created andevaluated the JSGE ‘‘Evidence-based clini\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 162, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "moto (First Department of Internal Medicine, Faculty ofMedicine, University of Yamanashi).SR collabo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 162, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "anticoagulants. Dig Endosc. 2018;30:433–40.4. Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 163, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "7. Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-doseaspirin-associated ulcer recurrence: \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 163, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "disease. N Engl J Med. 2010;363:1909–17.17. Ren YH, Zhao M, Chen YD, et al. Omeprazole affects clopi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 163, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "metronidazole in ﬁrst-line Helicobacter pylori triple eradicationtherapy based on resistance to anti\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 163, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Japan. J Gastroenterol Hepatol. 2014;29:487–93.34. Mori H, Suzuki H, Matsuzaki J, et al. Efﬁcacy of \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 164, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "42. Agrawal NM, Campbell DR, Safdi MA, NSAID-AssociatedGastric Ulcer Study Group, et al. Superiority\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 164, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tant drugs for the prevention and treatment of peptic ulcer dis-ease and its complications: a meta-a\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 164, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "randomizeddouble-blindcomparison.Lancet.1999;354:2106–11.58. Laine L, Harper S, Simon T, et al. A ra\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 164, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "adults using acetylsalicylic acid: systematic review and meta-analysis. Open Med. 2012;6:e109–17.66.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 164, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "74. Tunggal P, Ng FH, Lam KF, et al. Effect of esomeprazole versusfamotidine on platelet inhibition \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 165, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "75. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent uppergastrointestinal bleeding in patien\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 165, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and famotidine against gastroduodenal mucosal damage inpatients taking low-dose aspirin. J Gastroent\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 165, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "studies of selective and nonselective inhibitors of cyclooxyge-nase 2. JAMA. 2006;296:1633–44.91. La\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 165, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "disease.EurJGastroenterolHepatol.1997;9:371–4.100. Lee YT, Sung JJ, Choi CL, et al. Ulcer recurrence\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 166, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "109. Julka RN, Aduli F, Lamps LW, et al. Ischemic duodenal ulcer,an unusual presentation of sickle c\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 167, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "www.thelancet.com   Vol 390   August 5, 2017613SeminarPeptic ulcer diseaseAngel Lanas, Francis K L C\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 167, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "half of the 20th century have changed this perception.EpidemiologyLifetime prevalence of peptic ulce\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 167, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "in mortality from gastric ulcers and duodenal ulcers has also been recorded, and showed a birth-coho\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 167, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "50009, Spainalanas@unizar.es Search strategy and selection criteriaWe searched MEDLINE and Embase (f\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 168, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Seminar614www.thelancet.com   Vol 390   August 5, 2017Pathogenic mechanisms and risk factorsH pylori\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 168, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "vacA s2/m2 strains with low cytokine response and host interaction, which could have clinical conseq\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 168, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "aldosterone antagonists, or anticoagulants substantially increase the risk of upper gastrointestinal\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 168, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "incidence, in part by influencing health risk behaviours, and had similar effects on the disease rel\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 169, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Seminarwww.thelancet.com   Vol 390   August 5, 2017615that inhibit parietal cell secretion,49 or dir\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 169, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "mechanism. Reduced mucosal prostaglandin values are associated with low mucus and bicarbonate secret\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 169, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "idiopathic peptic ulcers are largely unknown. An imbalance between mucosal defensive mechanisms and \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 169, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "detection of H pylori infection with histology or rapid urease tests is essential to the subsequent \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 170, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Seminar616www.thelancet.com   Vol 390   August 5, 2017ManagementPrevention of ulcer recurrence is th\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 170, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "the duration of triple therapy from 7 days to a maximum of 14 days.40,68−73 The recommended standard\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 170, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "areas with low (<10%) quinolone resistance.40,67,68,81 However, a rapid increase in primary quinolon\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 170, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Standard dose of PPI every 12 h1000 mg amoxicillin every 12 h500 mg levofloxacin every 24 h240 mg bi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 171, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Seminarwww.thelancet.com   Vol 390   August 5, 2017617(PPI, rifabutin, and amoxicillin) for 10 days \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 171, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Whether PPI is better than an H₂ receptor antagonist for aspirin users has yielded conflicting resul\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 171, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PPI plus amoxicillin pluslevoﬂoxacin with orwithout bismuth (14 days)PPI plus amoxicillin plusclarit\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 172, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Seminar618www.thelancet.com   Vol 390   August 5, 2017complications. These strategies include co-the\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 172, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "a non-selective NSAID (relative risk 0·72, 95% CI 0·62–0·95). A similar conclusion has been reached \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 172, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "setting. Serological tests could be useful to detect false-negative H pylori infection. After exclus\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 172, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "High cardiovascular risk¶Naproxen; add PPI if patient is taking aspirinNo NSAIDs; naproxen plus PPI;\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 173, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Seminarwww.thelancet.com   Vol 390   August 5, 2017619has been associated with reduced mortality.106\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 173, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "identifies low-risk patients suitable for early hospital discharge. Endoscopic treatment is indicate\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 173, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "treatment and surgery. A Glasgow-Blatchford score of zero reliably predicts early discharge without \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 174, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Seminar620www.thelancet.com   Vol 390   August 5, 2017high-risk stigmata. Unlike Asian populations, \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 174, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "gastrointestinal bleeding resulting from coagulopathy can be treated with vitamin K, fresh frozen pl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 174, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Antiplatelet agent forsecondary preventionAnticoagulants*Endoscopytreatmentsuccessful• Withhold anti\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 175, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Seminarwww.thelancet.com   Vol 390   August 5, 2017621US Food and Drug Administration (FDA) for reve\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 175, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "NSAID-associated, and aspirin-associated peptic ulcer disease has uncovered idiopathic disease. The \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 175, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "the mortality associated with such bleeding, because comorbidities are now the major cause of death \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 175, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Gastroenterology 2007; 132: 2320−27.6Sonnenberg A. Time trends of ulcer mortality in non-European co\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 176, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Seminar622www.thelancet.com   Vol 390   August 5, 201713Huang JQ, Sridhar S, Hunt RH. Role of Helico\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 176, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "23 García-González MA, Lanas A, Savelkoul PH, et al. Association of interleukin 1 gene family polymo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 176, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "inflammatory and antiplatelet drug use in Asia: a multidisciplinary working party report. Clin Gastr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 176, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am J Gastr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 176, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine s\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 177, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Seminarwww.thelancet.com   Vol 390   August 5, 201762357Wallace JL. Nonsteroidal anti-inflammatory d\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 177, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Report. Gut 2017; 66: 6–30.69 Graham DY, Laine L. The Toronto Helicobacter pylori consensus in conte\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 177, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "79Hsu PI, Kao SS, Wu DC, et al. A randomized controlled study comparing reverse hybrid therapy and s\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 177, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind,\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 177, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Aliment Pharmacol Ther 2016; 43: 1262−75.96 Rostom A, Muir K, Dube C, Lanas A, Jolicoeur E, Tugwell \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 178, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Seminar624www.thelancet.com   Vol 390   August 5, 2017102 Lanas AI, Remacha B, Esteva F, Sáinz R. Ri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 178, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Gastrointest Endosc 2010; 72: 1138–45.112 Cook DJ, Guyatt GH, Salena BJ, Laine LA. Endoscopic therap\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 178, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 179, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Acute upper gastrointestinalbleeding in over 16s:managementClinical guidelinePublished: 13 June 2012\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 180, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "YYour responsibilityour responsibilityThe recommendations in this guideline represent the view of NI\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 181, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ContentsContentsIntroduction .......................................................................\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 181, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1.7 Primary prophylaxis for acutely ill patients in critical care...................................\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 182, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "This guideline is the basis of QS38.IntroductionIntroductionAcute upper gastrointestinal bleeding is\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 183, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "PPatient-centred careatient-centred careThis guideline offers best practice advice on the care of ad\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 184, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "KKeey priorities for implementationy priorities for implementationThe following recommendations have\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 185, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Management of variceal bleedingManagement of variceal bleedingOffer prophylactic antibiotic therapy \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 186, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "11GuidanceGuidanceThe following guidance is based on the best available evidence. The full guideline\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 187, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and actively bleeding.1.2.6Treat patients who are taking warfarin and whose upper gastrointestinalbl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 188, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1.4.4Offer proton pump inhibitors to patients with non-variceal uppergastrointestinal bleeding and s\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 189, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1.5.6Offer TIPS if bleeding from gastric varices is not controlled by endoscopicinjection of N-butyl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 189, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and following discharge. This should include:giving verbal information that is recorded in medical r\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 190, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "different members of clinical teams providing consistent informationproviding written information wh\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 191, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Update informationUpdate informationAugust 2016August 2016: A footnote was added to recommendation 1\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 192, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Aliment Pharmacol Ther. 2020;52:789–797.﻿  |  789wileyonlinelibrary.com/journal/apt Received: 11 Mar\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 192, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "This study was funded in full by HK inno.N Corp., Seoul, Korea.SummaryBackground: Tegoprazan is a no\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 193, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "790  |    CHO et al.1 | INTRODUCTIONProton pump inhibitors (PPIs) are used widely for the treatment \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 193, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "eradication in South Korea from July 2018. Tegoprazan showed rapid response from the time of initial\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 193, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of CJ-12420 in Patients with Gastric Ulcer).2.2 | Study populationPatients who met all of the follow\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 193, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "authorised personnel only. A double-dummy method, using match-ing tegoprazan 50 mg, tegoprazan 100 m\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 194, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  791CHO et al.At the start of the screening period, patient demographics and other baseline charac\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 194, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "b.i.d + amoxicillin 1 g b.i.d + clarithromycin 500 mg b.i.d for 7 days) after last follow-up. H. pyl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 194, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "at 0.025 (one-sided). A power of >90% was assumed for detecting non-inferiority as shown by the diff\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 194, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "with healed GUs and GI symptoms were analysed by calculating frequencies, point estimates and two-si\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 195, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "792  |    CHO et al.in a 1:1:1 ratio to one of the three treatment arms: tegoprazan 50 mg, tegopraza\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 195, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "These findings were supported by the secondary analyses in the FAS. In the FAS analysis, the cumulat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 195, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Drop outWithdrawal of subjectsn=3Withdrawalofsubjectsn=2Withdrawalofsubjectsn=3Inclusion/exclusion v\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 196, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  793CHO et al.3.3 | Safety analysisSafety analysis was performed in 304 patients who received ≥1 d\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 196, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "but these returned to their baseline levels after completion of the treat-ment period. No significan\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 196, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "73 (85.88)Multiple14 (15.91)20 (21.51)12 (14.12)Current ulcer; size3-5 mm23 (20.54)27 (21.95)29 (26.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 197, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "794  |    CHO et al.4 and 8 weeks. The increase in serum gastrin concentration, and safety profiles \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 197, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "87 (90.63)91 (91.92)83 (89.25)Difference from lansoprazole with 95% CId (−7.20, 9.96)c (−5.60, 10.95\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 198, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  795CHO et al.66.55% of tegoprazan 100 mg in healthy males. Because two doses of tegoprazan showed\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 198, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "But changes of serum gastrin levels were comparable among tego-prazan and lansoprazole groups in thi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 199, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "796  |    CHO et al.of tegoprazan compared with lansoprazole. In conclusion, we have shown that tego\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 199, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "5. Oshima T, Miwa H. Potent potassium-competitive acid block-ers: a new era for the treatment of aci\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 199, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "prazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 199, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 200, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "|  797CHO et al.Goyang, Korea. Dae Hwan Kang: Pusan National University Yangsan Hospital, Pusan Nati\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 200, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "University College of Medicines, Gwangju, Korea. Jae Gyu Kim: Chung-Ang University College of Medici\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 201, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "The new england  journal of medicinen engl j med 382;14  nejm.org  April 2, 20201299established in 1\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 201, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "endoscopy group and in 20 (7.8%) in the early-endoscopy group (difference, 3.1 percentage points; 95\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 202, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 382;14  nejm.org  April 2, 20201300The new engl and jour nal of medicineAcute upper gas\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 202, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "3012 patients, a threshold score of 7 or higher was shown to provide the most accurate predic-tion o\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 202, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "for the fidelity of the trial to the protocol, avail-able with the full text of this article at NEJM\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 203, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 382;14  nejm.org  April 2, 20201301Endoscopy for Upper Gastrointestinal Bleedingenrollm\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 203, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "in the early-endoscopy group whose gastroen-terologic consultation took place between mid-night and \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 203, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "inhibitor was continued for 72 hours. We de-fined further bleeding as a composite of persis-tent ble\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 204, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 382;14  nejm.org  April 2, 20201302The new engl and jour nal of medicinein 30-day morta\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 204, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Glasgow–Blatchford score of 12 or higher, and 516 were enrolled in the trial and underwent randomiza\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 204, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "hours, respectively. Therefore, the mean time from presentation to endoscopy was 9.9±6.1 hours in th\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 205, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 382;14  nejm.org  April 2, 20201303Endoscopy for Upper Gastrointestinal BleedingThe dif\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 205, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "25 (9.7)19 (7.4)Other findings on endoscopy — no. (%)§72 (27.9)75 (29.1)No abnormality detected — no\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 206, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 382;14  nejm.org  April 2, 20201304The new engl and jour nal of medicineFurther Bleedin\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 206, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "2.5±1.716.8±6.8Time from presentation to endoscopy — hr‡9.9±6.124.7±9.0Distribution of time from gas\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 207, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 382;14  nejm.org  April 2, 20201305Endoscopy for Upper Gastrointestinal Bleedingwere fo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 207, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and 3 of 44 (6.8%) of those who underwent en-doscopy between 6 and 12 hours after random-ization die\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 207, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "202530Cumulative Probability1.000.800.900.700.600.400.300.100.500.200.00051015202530Days since Rando\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 208, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 382;14  nejm.org  April 2, 20201306The new engl and jour nal of medicineulcers that wer\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 208, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "total no. with varices20/2517/190.89 (0.70–1.15)Endoscopic treatment for other conditions — no. of  \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 209, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 382;14  nejm.org  April 2, 20201307Endoscopy for Upper Gastrointestinal Bleedingour ear\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 209, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "used the Glasgow–Blatchford score as a measure of risk; the score has been shown to correlate with m\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 209, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Antibe Therapeutics, lecture fees from Eisai, EA Pharma, Pfizer Upjohn Korea, and Fuji Film, and gra\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 209, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "rhage. Gastrointest Endosc 2001;​53:​6-13.8. Adamopoulos AB, Baibas NM, Efsta-thiou SP, et al. Diffe\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 210, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 382;14  nejm.org  April 2, 20201308Endoscopy for Upper Gastrointestinal Bleedingbleedin\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 210, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Muckadell OB. Relationship between tim-ing of endoscopy and mortality in patients with peptic ulcer \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 210, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Methodology for randomized trials of pa-tients with nonvariceal upper gastrointes-tinal bleeding: re\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 211, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Indications for the Use of Proton Pump Inhibitorsfor Stress Ulcer Prophylaxis and Peptic UlcerBleedi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 211, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "kidney injury, chronic kidney disease, and hypomagnesemia. Proton pump inhibitors are overused in th\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 211, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "setting should be a priority. With the intention of pro-moting value-based quality improvement, in t\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 212, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "use of proton pump inhibitors for stress ulcer prophy-laxis and peptic ulcer bleeding.EVIDENCE AND G\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 212, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "way, Switzerland, and the United Kingdom.9 This multicen-ter, parallel-group, blinded, randomized co\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 212, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "renal replacement therapy, established liver disease, andelevated scores of organ failure.Prior stud\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 212, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "setting and then are often inappropri-ately continued after hospital dis-charge. Clinicians require \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 213, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "standard of care) practice of administering proton pumpinhibitors to patients before endoscopy. Ther\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 213, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "excellent bioavailability ranging from 70%-90% andshould be as efﬁcacious as those administered intr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 213, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "gastrointestinal bleeding (hematemesis or melena) followedby oral or intravenous proton pump inhibit\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 213, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "pitalization and at the time of discharge from the hospital.Such interventions focus on appropriate \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 214, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "development of clinical guidelines, and pharmacist-ledinterventions.32-37COMPLICATIONS OF LONG-TERM \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 214, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "observational studies, Kwok et al5 found that the risk ofdeveloping a C. difﬁcile infection was incr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 214, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "another large cohort study.41 The mechanism by which pro-ton pump inhibitor use leads to chronic kid\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 214, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Proton pump inhibitors linked to hypomagnesemia: a systematicreview and meta-analysis of observation\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 215, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "10. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHPCommission on Therapeutics and appr\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 215, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ing peptic ulcer. Am J Med 2001;111(4):280–4.21. Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 215, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Pharmacol Ther 2005;21(10):1203–9. https://doi.org/10.1111/j.1365-2036.2005.02454.x.30. Pham CQ, Reg\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 215, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "to reducing the overutilization of stress ulcer prophylaxis in adultmedical and surgical intensive c\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 216, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "CLINICAL PRACTICE UPDATEAGA Clinical Practice Update on Endoscopic Therapies for Non-Variceal Upper \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 216, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and preparation for upper endoscopy. After stabilization, patientswith NVUGIB should undergo endosco\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 216, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "NVUGIB, the etiology of bleeding (peptic ulcer disease, unknownsource, post surgical); patient facto\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 216, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "endoscopicsubmucosal dissection;MHF,monopolar hemostatic forceps; NVUGIB, non-variceal upper gastroi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 217, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "related issues, including age, comorbid conditions, prior sur-gery, history of gastrointestinal blee\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 217, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "neurologists,andhematologists when appropriate to provide advice, includinguse of reversal agents, s\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 217, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Endoscopic diagnosis0, 2Stigmata of recent hemorrhageand/or presence of blood onendoscopy0, 2AIMS-65\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 218, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "erythromycin or metoclopramide may be given intravenously toselected patients before upper endoscopy\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 218, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "hours for elective cases.22,23 A common decision is decidingwhether or not to wait until the next mo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 218, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "NVUGIB, active hematemesis, or suspected retained gastriccontentsshouldundergoendotrachealintubation\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 218, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Plan forsedation·Resuscitation·Unstable vital signs·Need for ETT for airwayprotectionorgeneral·IV fl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 219, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "repeated after allowing time for gastric emptying to completethe examination of the stomach, with th\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 219, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "denum, lesser curvature of the stomach) and certain ulcercharacteristics (eg ﬁbrosis, large ulcerati\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 219, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "signiﬁcantly decreased rate of rebleeding within 30 days ofendoscopic hemostasis in patients randomi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 219, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "rigid ﬁbrotic base. Unlike certain thermal probes units, whichapply a ﬁxed current for a deﬁned time\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 220, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "generator settings to a forced coagulation mode (availableon several commercially available electros\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 220, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "rent peptic ulcer bleeding.4 There are also nonrandomizeddata suggesting that over-the-scope clips m\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 220, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "contact with moisture, the endoscopic powder aggregates,creating a mechanical barrier upon the mucos\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 220, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "limiting subsequent mucosal assessment. Subsequent washingat the lesion site is not recommended, as \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 221, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Diffuse tumor bleeding is a challenging clinical problemthat is often not responsive to conventional\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 221, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "because the latter may interfere with completing the resec-tion. For post-sphincterotomy bleeding, b\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 221, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "not successfulSpray hemostatic powderto improve local controlSpray hemostatic powderas a second-line\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 222, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "given to closing sites, when amenable, in patients who requireimmediate resumption of AT medications\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 222, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "for a high-risk lesion; or if thermal or mechanical therapy aloneor in combination was performed but\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 222, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "withmultiplecomorbidities,oftenreceiving anticoagulants, or with severe coagulopathies(such as seen \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 222, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "mechanical therapies are not successful at achieving hemo-stasis, sprayed hemostatic powder is a val\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 223, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "4. Schmidt A, Golder S, Goetz M, et al. Over-the-scopeclips are more effective than standard endosco\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 223, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "cians. Ann Intern Med 2013;159:770–779.13. Villanueva C, Colomo A, Bosch A. Transfusion for acuteupp\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 223, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "study in healthy male volunteers. Aliment PharmacolTher 2003;18:151–155.22. Kumar NL, Cohen AJ, Nayo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 223, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "31. Vergara M, Bennett C, Calvet X, et al. Epinephrine in-jectionversusepinephrineinjectionand aseco\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 224, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "evaluation of the BICAP and Gold probes. Gastroenter-ology 1991;100:107–112.35. Laine L, Long GL, Ba\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 224, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "endoscopic treatment with OTSC in patients with high-risk non-variceal upper gastrointestinal bleedi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 224, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "acute gastrointestinal bleeding undergoing endoscopictreatment with Hemospray. Dig Endosc 2020;32:96\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 224, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "800708, Charlottesville, Virginia 22908. e-mail: ayw7d@virginia.edu; fax: 434-244-7590.Acknowledgmen\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 225, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "For personal use only 1 of 13summarizing evidence for risk assessment, resuscitation, blood transfus\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 225, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "globin values than patients with hematemesis, probably because presentation is more likely to be del\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 225, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "non-variceal bleeding (for example, injection, thermal probes, or clips for lesions with active blee\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 226, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 2 of 13Overall quality of evidenceNumerous randomized c\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 226, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "managed in outpatient settings in Europe.Sources and selection criteriaWe searched PubMed, Medline, \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 226, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "an altered mental status or lack of gag reflex).No RCTs have assessed fluid resuscitation in upper g\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 226, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "therapy; endoscopic therapy may also be used for ulcers with adherent clots•Injection therapy (eg, e\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 227, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 3 of 13kidney injury (odds ratio 0.91, 0.84 to 0.99) an\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 227, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "(0.68, 0.47 to 0.98) with a transfusion hemoglobin thresh­old of 70 g/L versus 90 g/L.25 A subsequen\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 227, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      ")DYRUVUHVWULFWLYH)DYRUVOLEHUDO0RUWDOLW\\)DYRUVUHVWULFWLYH)DYRUVOLEHUDO%ODLU-DLUDWK9LOODQXHYD7RWDOO 3 \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 228, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 4 of 13outcome.3 6 This enables patients predicted to b\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 228, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "sion and be offered outpatient endoscopy.4 28Subsequently two large international comparative studie\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 228, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "agents.45 However, observational studies have failed to identify clinical benefit, and a cohort stud\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 229, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 5 of 13to fresh frozen plasma because of the smaller vo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 229, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "parallel decreases in procoagulant and anticoagulant factors.54 The prothrombin time measures procoa\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 229, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "0.93) but has no effect on patient outcomes, including rebleeding, need for surgery, or mortality (1\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 229, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "(HALT-IT) will finish recruitment shortly and the results should help clarify the role of TXA in upp\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 230, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 6 of 13PPIs should not be given concurrently to patient\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 230, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "phy is used in patients who are not candidates for endos­copy. However, these investigations are mos\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 230, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of 12 601 Danish patients with upper gastrointestinal bleeding secondary to peptic ulcers. This stud\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 231, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 7 of 13of sclerosants such as absolute ethanol, thermal\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 231, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "RCTs, but results of individual trials were very heteroge­neous.80 This has led to guideline recomme\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 231, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "scopic therapy showed that high dose PPIs, usually given as an intravenous bolus of 80 mg followed b\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 231, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "on day 3. When he was discharged from hospital a week later he was still taking oral PPIs twice dail\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 232, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 8 of 13meta-analysis of 13 studies found that a bolus f\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 232, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "events (hazard ratio 0.99, 0.68 to 1.44).97 The US Food and Drug Administration recommends avoiding \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 232, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Several studies suggest a survival benefit from continuing or reintroducing antithrombotic drugs aft\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 232, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "or earlier depending on the clinical situation.5No randomized studies are available to guide clinici\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 233, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 9 of 13Data on the timing of the reintroduction of DOAC\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 233, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "h) or over-the-scope clips (OTSC) as a rescue modality is suggested, in parallel with ongoing resusc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 233, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "available (although they are not approved in the US). An RCT of 28 patients compared these stents wi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 233, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "guide to endoscopic therapy. A recent dual center RCT of 148 patients with severe non-variceal upper\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 234, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 10 of 13intestinal bleeding (non-variceal and variceal)\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 234, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "scopic management. Technical improvements and more widely available services for interventional radi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 234, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Consider within 12 h if high risk features (eg, hemodynamic instability, bloody emesis in hospital)A\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 234, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "h) if hemodynamic instability, after resuscitation and stabilizationAfter endoscopic hemostasis is a\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 235, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 11 of 13Thanks to Deepak Vishwanath for help with the r\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 235, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "2018;67:1757-68. 10.1136/gutjnl-2018-316276.  pmid:29691276.7Tripathi D, Stanley AJ, Hayes PC, et al\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 235, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Wuerth BA, Rockey DC. Changing epidemiology of upper gastrointestinal hemorrhage in the last decade:\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 235, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Cochrane Database Syst Rev 2016;10:CD002042.pmid:27731885.22Carson JL, Guyatt G, Heddle NM, et al. C\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 235, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "gut.38.3.316  pmid:8675081.30 Saeed ZA, Winchester CB, Michaletz PA, Woods KL, Graham DY. A scoring \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 235, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Blatchford score is the most accurate assessment of patients with upper gastrointestinal hemorrhage.\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 236, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 12 of 1341Dunne PDJ, Laursen SB, Laine L, et al. Previo\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 236, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "treatment. Gut 1994;35:464-6. 10.1136/gut.35.4.464  pmid:8174982.49Wolf AT, Wasan SK, Saltzman JR. I\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 236, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "bleeding. Cochrane Database Syst Rev 2010;7:CD005415.pmid:20614440.57Hwang JH, Fisher DA, Ben-Menach\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 236, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "5  pmid:7564670.64 Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin a\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 236, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "acute lower gastrointestinal bleeding. Am J Gastroenterol 2016;111:459-74. 10.1038/ajg.2016.41.  pmi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 236, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 1999;50:755-61. 10.1016/S0016-\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 237, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 13 of 1385Enestvedt BK, Gralnek IM, Mattek N, Lieberman\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 237, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and ectopic varices. World J Gastroenterol 2012;18:5912-7. 10.3748/wjg.v18.i41.5912  pmid:23139607.9\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 237, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ligation. Lancet 1995;346:1666-9. 10.1016/S0140-6736(95)92840-5  pmid:8551824.101 García-Pagán JC, C\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 237, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "10.1001/archinternmed.2012.4261  pmid:22987143.108 Gage BF, Waterman AD, Shannon W, Boechler M, Rich\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 237, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "surgery in treatment of major nonvariceal upper gastrointestinal bleeding. Clin Exp Gastroenterol 20\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 237, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "10.1177/1756283X15572587  pmid:26082803.123 Kwek BEA, Ang TL, Ong PLJ, et al. TC-325 versus the conv\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 238, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 14 of 13 on 29 May 2024 at Yonsei University (Medical L\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 239, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "STATE OF THE ART REVIEWFor personal use only 15 of 13 on 29 May 2024 at Yonsei University (Medical L\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 240, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "The new engl and jour nal of medicinen engl j med 374;24  nejm.org  June 16, 20162367Clinical Practi\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 240, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of nonsteroidal antiinflammatory drugs (NSAIDs), occur in the stomach or duo-denum and are the most \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 241, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 374;24  nejm.org  June 16, 20162368The new engl and jour nal of medicine2368bleeding in\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 241, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "are a poor initial indicator of the severity of up-per gastrointestinal bleeding. Because patients b\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 241, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "•In patients with upper gastrointestinal bleeding, tachycardia (heart rate, ≥100 beats per minute), \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 242, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 374;24  nejm.org  June 16, 20162369Clinical Practicebleeding soon after presentation di\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 242, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "surgery, length of hospitalization, and mortal-ity.8,11,16,17,19,20Most patients with a low clinical\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 242, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "bleeding, 313 (14%) had a score of 0 (positive predictive value, 99.0%), 562 (24%) had a score of 0 \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 243, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 374;24  nejm.org  June 16, 20162370The new engl and jour nal of medicineoccurs in appro\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 243, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "doscopic therapy also may be used for vascular ectasias, Dieulafoy’s lesions, neoplasms, and activel\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 244, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 374;24 nejm.org June 16, 20162371Clinical Practicehas been recommended because some obs\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 244, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "have rebleeding in the coming weeks does not justify hospitalization for more than 3 days in patient\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 245, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 374;24  nejm.org  June 16, 20162372The new engl and jour nal of medicineA trial compare\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 245, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "those who received maintenance antisecretory therapy.34Eradication of H. pylori should be confirmed \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 245, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "vascular death is 1745.40 The risk of recurrent upper gastrointestinal bleeding probably out-weighs \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 246, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 374;24  nejm.org  June 16, 20162373Clinical Practiceused for secondary prevention43,44;\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 246, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "are not known: bismuth-containing quadruple therapy and concomitant (non–bismuth-containing quadrupl\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 246, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "long termDiscontinue aspirinpermanently inmost patientsThe New England Journal of MedicineDownloaded\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 247, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 374;24  nejm.org  June 16, 20162374The new engl and jour nal of medicineHowever, treatm\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 247, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "for enteric infections), and it is not known whether they are causal.48-50 In patients with a prior \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 247, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "scribe therapy for H. pylori infection for 2 weeks, followed by 2 to 4 weeks of a proton-pump in-hib\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 248, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 374;24  nejm.org  June 16, 20162375Clinical PracticeReferences1. Peery AF, Crockett SD,\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 248, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "al. Performance of new thresholds of the Glasgow Blatchford score in managing patients with upper ga\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 248, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "analysis. Med Care 1998;​36:​462-74.20.Wysocki JD, Srivastav S, Winstead NS. A nationwide analysis o\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 248, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a sys-tematic review an\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 248, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Celecoxib versus diclofenac and omepra-zole in reducing the risk of recurrent ulcer bleeding in pati\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 249, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "n engl j med 374;24  nejm.org  June 16, 20162376Clinical Practicenejm clinical practice centerExplor\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 249, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "46.Lai KC, Lam SK, Chu KM, et al. Lanso-prazole for the prevention of recurrences of ulcer complicat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 250, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Management of Nonvariceal Upper Gastrointestinal Bleeding:Guideline Recommendations From the Interna\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 250, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "patients at very low risk for rebleeding, who may not requirehospitalization. In patients without ca\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 250, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "including those from our group (in 2003, with an up-date in 2010) (3, 4), the American College of Ga\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 251, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Sources, Literature Searches, and SystematicReviewsSources included the evidentiary base of previous\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 251, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ment Appendix 2, available at Annals.org).Assessment of the Quality of EvidenceThe methodologists (F\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 251, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "After reviewing the evidence proﬁles, the participantsanonymously voted on their degree of agreement\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 251, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "would be designated as strong with the phrase “werecommend.”Consensus was not reached on 4 PICO ques\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 252, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "decision-making process. Recommendations are basedon evidence from the literature and consensus disc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 252, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Preendoscopy ManagementStatement A1For patients with acute UGIB and hemodynamic in-stability, resusc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 252, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "pared with crystalloids and because colloids are moreexpensive, the consensus group agreed that rout\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 252, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "dynamic compromise.Statement A2aFor patients with acute UGIB, we suggest using aGlasgow Blatchford s\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 253, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Table 1. Summary of Consensus Recommendations for the Management of UGIB*A. Resuscitation, risk asse\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 253, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 80%; uncer\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 253, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "B6. The role of endoscopic therapy for ulcers with adherent clots is controversial. Endoscopic thera\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 253, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "6b1 in Supplement Appendix 2)B12. Routine second-look endoscopy is not recommended.‡B13. A second at\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 254, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "No Recommendation AFor patients with acute UGIB, the consensus groupcould not make a recommendation \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 254, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "D4. Where available, percutaneous embolization can be considered as an alternative to surgery for pa\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 254, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 85%; uncer\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 254, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "GRADE: no recommendation, very low-quality evidence. Vote on PICO question: yes, 24%; uncertain/neut\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 255, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "department patients with UGIB who were predicted tobe at very low risk for undesirable outcomes (GBS\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 255, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "vironment, access to hospital or ambulance services,access to out-of-hours endoscopy, and reimbursem\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 255, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "UGIB (33).In the systematic review of 5 randomized con-trolled trials in patients with UGIB (n = 196\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 255, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ably the least expensive.Only 3 randomized trials provided mortality data inthe UGIB-speciﬁc review,\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 256, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "ability of units, hemodilution factors, and degree of he-modynamic stability. In addition, some pati\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 256, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "imprecision (very small sample size).Reanalysis of the overall data from the meta-analysis of 11 tri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 256, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "group did not recommend a speciﬁc cutoff, stating thata cutoff would depend on other factors, includ\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 256, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "bleeding (OR, 0.7 [CI, 0.3 to 1.8]), thromboembolicevents (OR, 0.5 [CI, 0.1 to 2.1]), or endoscopy-r\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 257, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "embolism but not rebleeding, whereas anticoagulantinterruption did not affect the risk for either ou\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 257, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "doscopic hemostatic therapy was not addressed.Other guidelines recommend administration of vi-tamin \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 257, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "care (52). The QoE was downgraded for serious risk ofbias, indirectness, and very serious imprecisio\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 257, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tients with acute UGIB (4). This recommendation wasbased on data suggesting that early endoscopy al-\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 258, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "more high-risk endoscopic stigmata that would haveresolved spontaneously (52, 53), which may offset \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 258, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "hours) may increase mortality risk, whereas early en-doscopy between 6 and 24 hours may reduce morta\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 258, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "(GRADE:strongrecommendation,low-qualityevidence)Statement B10bFor patients with acutely bleeding ulc\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 258, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "not mortality (RR, 2.15 [CI, 0.59 to 7.78]) (68, 71).Discussion.Endoscopic hemostatic therapy hasbee\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 259, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "sensus group agreed with the prior statements that en-doscopic therapy is indicated in patients with\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 259, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "with TC-325 monotherapy versus a conventional com-bination endoscopic technique (epinephrine injecti\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 259, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tional therapy alone or TC-325 alone in most patientpopulations with nonvariceal UGIB (77). TC-325 f\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 259, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "low-risk lesions (ﬂat spot) were considered indirect, be-cause these lesions are not routinely subje\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 260, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Discussion. More studies are needed to determinewhether DEP would be useful to guide endoscopictreat\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 260, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Two Cochrane reviews on PPIs inUGIB were updated for this guideline (81, 82). The ﬁrst(81), which in\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 260, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "the studies. Overall, no consistent signal of a differencewas found between PPI therapy and placebo \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 260, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "* Boldface signiﬁes statistically signiﬁcant results.Management of Upper Gastrointestinal BleedingCL\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 261, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "but not mortality compared with no PPI therapy, a ma-jority of the consensus group did not vote to r\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 261, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "once daily) through 14 days, followed by once daily.(GRADE: conditional recommendation, very low-qua\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 261, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "done. All 5 trials were conducted in Hong Kong. A his-tory of H pylori infection and eradication tre\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 261, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "randomized trials (n = 4805) comparing PPI versus noPPI therapy in patients receiving prophylactic D\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 262, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "no effects on mortality (n = 3 studies; RR, 1.02 [CI, 0.68to 1.54]) or myocardial infarction risk (n\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 262, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "tients who require single- or dual-antiplatelet therapyfor a duration consistent with the ongoing ne\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 262, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "fection, and Clostridium difﬁcile infection (105–109). Ananalysis of factors, such as consistency, s\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 262, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "moclips (115, 116). In addition, the use of DEP to guidehemostasis has been studied further (117). A\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 263, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "literature search was not performed and the GRADEapproach was not applied.APPLICABILITY AND IMPLEMEN\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 263, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Hospital, Dijon, France (R.L., M.B.); University of Sa˜o Paulo, Sa˜oPaulo, Brazil (F.M.); George Was\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 263, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "group thanks Dr. Waleed Alhazzani (McMaster University) forparticipation in the development of PICO \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 263, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Boehringer Ingelheim, Janssen, Pﬁzer, Bayer, Bristol-MyersSquibb, Sanoﬁ, and Daiichi Sankyo outside \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 264, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Corresponding Author: Alan N. Barkun, MD, Division of Gas-troenterology, McGill University and the M\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 264, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "[PMID: 22624808] doi:10.1016/j.gie.2012.02.0337. National Institute for Health and Care Excellence. \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 264, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "15. Schu¨nemann HJ, Mustafa R, Brozek J, et al; GRADE WorkingGroup. GRADE Guidelines: 16. GRADE evid\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 264, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and the Pragmatic Critical Care Research Group. Balanced crystal-loids versus saline in critically i\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 264, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "gency department patients with upper gastrointestinal bleeding: asystematic review. Acad Emerg Med. \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 265, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "per gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2015;13:115-21.e2. [PMID: 25058843] doi:1\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 265, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "of randomised trials with meta-analysis and trial sequential analysis.BMJ. 2015;350:h1354. [PMID: 25\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 265, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circu\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 265, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1999;50:755-61. [PMID: 10570332]53. Bjorkman DJ, Zaman A, Fennerty MB, et al. Urgent vs. electiveend\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 265, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "intestinal bleeding. Can J Gastroenterol. 2007;21:425-9. [PMID:17637943]61. Tai CM, Huang SP, Wang H\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 266, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "controlled trials. Clin Gastroenterol Hepatol. 2009;7:33-47; quiz 1-2.[PMID: 18986845] doi:10.1016/j\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 266, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "72. Kwek BEA, Ang TL, Ong PLJ, et al. TC-325 versus the conven-tional combined technique for endosco\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 266, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "[PMID: 28167214] doi:10.1053/j.gastro.2017.01.04280. Chen VK, Wong RC. Endoscopic Doppler ultrasound\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 266, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "-2013-30653188. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention ofrecurrences of ulce\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 266, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "N Engl J Med. 2010;363:1909-17. [PMID: 20925534] doi:10.1056/NEJMoa100796496. Wei P, Zhang YG, Ling \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 267, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "98. Wu H, Jing Q, Wang J, et al. Pantoprazole for the prevention ofgastrointestinal bleeding in high\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 267, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "and anticoagulants. Am J Gastroenterol. 2007;102:507-15. [PMID:17338735]105. Islam MM, Poly TN, Walt\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 267, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "gators. Pantoprazole to prevent gastroduodenal events in patientsreceiving rivaroxaban and/or aspiri\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 268, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Current Author Addresses: Dr. Barkun: Division of Gastroen-terology, McGill University and the McGil\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 268, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "University Hospital, London, Ontario N6A 4V2, Canada.Dr. Jensen: Ronald Reagan UCLA Medical Center, \n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 268, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Jairath, J. Lau, G.Y.H. Lip, R. Loffroy, F. Maluf-Filho, A.C.Meltzer, J.R. Saltzman, M. Bardou.Draft\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 269, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Appendix Table 1. Pooled Sensitivity and Speciﬁcity of Pre-endoscopic Scoring Systems to Identify Pa\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 269, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "1 SR and MA, 5 RCTs (33)64/765 (8.5)117/877 (13.5)0.58 (0.40 to 0.84)−56 (−80 to −21)Surgical or rad\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 270, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Appendix Table 3. Summary of Adjusted Results From Studies Assessing Timing of Endoscopy in Patients\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 270, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "upper gastrointestinal bleeding.* Boldface signiﬁes statistically signiﬁcant results.† Not all patie\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 271, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "Appendix Table 4. Areas of Future ResearchA. Resuscitation, risk assessment, and preendoscopy manage\n",
      "{'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 271, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}\n",
      "C. Pharmacologic managementEfﬁcacy and safety of various PPI regimens (including timing, dose, anddu\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "\n",
    "# Assuming you have a Document class\n",
    "class Document:\n",
    "    def __init__(self, metadata, page_content):\n",
    "        self.metadata = metadata\n",
    "        self.page_content = page_content\n",
    "\n",
    "    def __repr__(self):\n",
    "        # Customize the representation to match the output format you want\n",
    "        return f\"Document(metadata={self.metadata}, page_content={self.page_content})\"\n",
    "\n",
    "# Function to read the JSON file and load it as a list of Document objects\n",
    "def load_documents_from_json(filename='documents.json'):\n",
    "    with open(filename, 'r') as f:\n",
    "        document_dicts = json.load(f)\n",
    "    \n",
    "    # Convert each dictionary back into a Document object\n",
    "    document_list = [Document(d['metadata'], d['page_content']) for d in document_dicts]\n",
    "    return document_list\n",
    "\n",
    "# Example usage\n",
    "loaded_data = load_documents_from_json()\n",
    "\n",
    "# Now you can access the loaded Document objects\n",
    "for doc in loaded_data:\n",
    "    print(doc.metadata)\n",
    "    print(doc.page_content[:100])  # Print first 100 characters of page content\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "434301f1-6a6a-466e-9c15-17b42e235103",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Assuming loaded_data is a list of Document objects\n",
    "\n",
    "page_contents = []\n",
    "\n",
    "for doc in loaded_data:\n",
    "    # Append only the page_content attribute from each Document object\n",
    "    page_contents.append(doc.page_content)\n",
    "\n",
    "# Now page_contents contains only the content of each document without metadata\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "0cd6c3eb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Document(metadata={'source': 'Gastrointestinal and Liver Disease.pdf', 'file_path': 'Gastrointestinal and Liver Disease.pdf', 'page': 0, 'total_pages': 272, 'format': 'PDF 1.7', 'title': 'Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group', 'author': 'Alan N.\\xa0Barkun, Majid\\xa0Almadi, Ernst J.\\xa0Kuipers, Loren\\xa0Laine, Joseph\\xa0Sung, Frances\\xa0Tse, Grigorios I.\\xa0Leontiadis, Neena S.\\xa0Abraham, Xavier\\xa0Calvet, Francis K.L.\\xa0Chan, James\\xa0Douketis, Robert\\xa0Enns, Ian M.\\xa0Gralnek, Vipul\\xa0Jairath, Dennis\\xa0Jensen, James\\xa0Lau, Gregory Y.H.\\xa0Lip, Romaric\\xa0Loffroy, Fauze\\xa0Maluf-Filho, Andrew C.\\xa0Meltzer, Nageshwar\\xa0Reddy, John R.\\xa0Saltzman, John K.\\xa0Marshall, and Marc\\xa0Bardou', 'subject': 'Ann Intern Med 2019.171:805-822', 'keywords': '', 'creator': 'XPP', 'producer': 'Adobe LiveCycle PDF Generator; modified using iText 4.2.0 by 1T3XT', 'creationDate': '13th September 2020', 'modDate': 'D:20240611221533Z', 'trapped': ''}, page_content=806Peptic Ulcer DiseaseFrancis K.L. Chan, James Y.W. Lau53An ulcer in the GI tract can be defined as a 5 mm or larger break in the lining of the mucosa, with appreciable depth at endoscopy or with histologic evidence of submucosal extension. An erosion is a break less than 5 mm. The distinction between an ulcer and an ero­sion is somewhat arbitrary. The term PUD is used to include ulcer­ations and erosions in the stomach and duodenum from a number of causes. These lesions are called “peptic” because the enzyme pepsin, proteolytic at an acidic pH (see Chapter 51), plays a major role in causing the mucosal breaks, regardless of the inciting agent.Decades of research focused on the role of gastric acid secretion and the effects of stress, personality type, and genetics in the pathogenesis of PUD. The discovery of the histamine-2 (H2) receptor and development of H2RAs,1 and subsequently PPIs, led to major changes in the management of PUD. The discovery of Hp and its role in PUD (see Chap­ter 52) transformed PUD from a chronic, recurrent disease to a curable one.2 Hp infection remains an important cause of PUD in the world. In developed countries, frequent use of NSAIDs, including low-dose aspirin for cardiovascular indi­cations, has emerged as a leading cause of PUD, especially among the aging population.EPIDEMIOLOGYThe epidemiology of PUD has undergone remarkable changes in the past 2 centuries. The risk of developing PUD, and dying from PUD, increased in successive cohorts born between 1840 and 1890, and then declined thereafter.3 There was a peak in the inci­dence of GU in the first half of the 19th century and a subsequent peak in the incidence of DU in the second half of the 19th century. Sonnenberg proposed a birth-cohort effect to explain the peaks in the incidence of, and mortality from, peptic ulcers. Hp infection acquired during childhood or adolescence became manifested as peptic diseases in later years. As Hp infection gradually declined in)"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "loaded_data[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5e2b3382",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Assuming loaded_data is a list of Document objects\n",
    "# Each document has 'metadata' and 'page_content' as attributes\n",
    "\n",
    "page_contents = []\n",
    "\n",
    "for doc in loaded_data:\n",
    "    # Check if the document has the 'page_content' attribute\n",
    "    if hasattr(doc, 'page_content'):\n",
    "        page_contents.append(doc.page_content)\n",
    "    else:\n",
    "        print(f\"Warning: 'page_content' attribute not found in document: {doc}\")\n",
    "\n",
    "# Now page_contents contains only the content of each document without metadata\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "b60e9dd8-36fe-43a5-b7a8-9681172bbfe9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['806Peptic Ulcer DiseaseFrancis K.L. Chan, James Y.W. Lau53An ulcer in the GI tract can be defined as a 5 mm or larger break in the lining of the mucosa, with appreciable depth at endoscopy or with histologic evidence of submucosal extension. An erosion is a break less than 5 mm. The distinction between an ulcer and an ero\\xadsion is somewhat arbitrary. The term PUD is used to include ulcer\\xadations and erosions in the stomach and duodenum from a number of causes. These lesions are called “peptic” because the enzyme pepsin, proteolytic at an acidic pH (see Chapter 51), plays a major role in causing the mucosal breaks, regardless of the inciting agent.Decades of research focused on the role of gastric acid secretion and the effects of stress, personality type, and genetics in the pathogenesis of PUD. The discovery of the histamine-2 (H2) receptor and development of H2RAs,1 and subsequently PPIs, led to major changes in the management of PUD. The discovery of Hp and its role in PUD (see Chap\\xadter 52) transformed PUD from a chronic, recurrent disease to a curable one.2 Hp infection remains an important cause of PUD in the world. In developed countries, frequent use of NSAIDs, including low-dose aspirin for cardiovascular indi\\xadcations, has emerged as a leading cause of PUD, especially among the aging population.EPIDEMIOLOGYThe epidemiology of PUD has undergone remarkable changes in the past 2 centuries. The risk of developing PUD, and dying from PUD, increased in successive cohorts born between 1840 and 1890, and then declined thereafter.3 There was a peak in the inci\\xaddence of GU in the first half of the 19th century and a subsequent peak in the incidence of DU in the second half of the 19th century. Sonnenberg proposed a birth-cohort effect to explain the peaks in the incidence of, and mortality from, peptic ulcers. Hp infection acquired during childhood or adolescence became manifested as peptic diseases in later years. As Hp infection gradually declined in',\n",
       " 'the incidence of, and mortality from, peptic ulcers. Hp infection acquired during childhood or adolescence became manifested as peptic diseases in later years. As Hp infection gradually declined in the population over time, the prevalence of infection also gradually shifted from a younger toward older age groups. The incidence of DU and GU has declined in parallel with the decline in the preva\\xadlence of Hp infection, likely a result of improved sanitary condi\\xadtions and a safer food and water supply.Based on physicians’ diagnoses, the annual incidence of PUD ranges from 0.14% to 0.19% in developed countries. Based on hospital diagnoses, the incidence is lower: 0.03% to 0.17%. The prevalence of PUD ranges from 0.12% to 4.7% for physician-diagnosed, and from 0.1% to 2.6% for hospital-diagnosed case series.4 There is a wide geographic variation in the prevalence of PUD. In an endoscopic series involving 1022 volunteers from Shanghai, China (average age, 48 years), the prevalence of PUD was 17.2%, of whom 93% were infected with Hp.5The most frequent complication from PUD is bleeding; the reported annual incidence of bleeding among populations varies from 19 to 57 per 100,000 individuals (≈0.02% to 0.06%). Peptic ulcer perforation (PULP), less frequent than bleeding, has reported incidences of 4 to 14 per 100,000 individuals (0.004% to 0.014%).6 Along with a decline in uncomplicated PUD cases, there is a similar decline in incidence of ulcer complications in recent years. Laine and colleagues7 used a national inpatient database to calculate the annual incidence of, and mortality from, GI complications during 2001 to 2009. During this time period, the incidence of peptic ulcer bleeding fell from 48.7 to 32.1 per 100,000. Over the same period, the age- and sex-adjusted case fatality rates from UGI bleeding decreased from 3.8% to 2.7%. In 2009, the case fatality rate for UGI bleeding (2.45%) was considerably lower than for UGI perforation (10.7%).',\n",
       " 'and sex-adjusted case fatality rates from UGI bleeding decreased from 3.8% to 2.7%. In 2009, the case fatality rate for UGI bleeding (2.45%) was considerably lower than for UGI perforation (10.7%). In a nationwide population-based cohort study of 403,567 Taiwan\\xadese patients, hospitalizations for complicated peptic ulcers decreased significantly over a 10 year period8; thus the annual incidence of hos\\xadpitalizations for bleeding DU or for perforated DU fell from 108 to 40 and from 9.8 to 5.8 per 100,000, respectively. A similar decline was evident for bleeding and perforated GUs (from 117 to 61 and from 11 to 6 per 100,000, respectively).\\u200aETIOLOGY AND PATHOGENESISThe principal risk factors of PUD are Hp infection and NSAID use (Fig. 53.1) and as will be discussed, many patients with PUD have both of these risk factors. On the other hand, PUD patients may have neither of these risk factors (Hp-negative, NSAID-negative ulcers); some of these latter patients will have another cause of ulcer such as gastrinoma (ZES; see Chapter 34), whereas others will have ulcers that are idiopathic.CHAPTER OUTLINEEPIDEMIOLOGY................................806ETIOLOGY AND PATHOGENESIS....................806Hp Infection..................................807Use of Aspirin and Other NSAIDs..................807Other Causes of Ulcers and Idiopathic Ulcers.........808CLINICAL FEATURES AND DIAGNOSIS...............808MEDICAL THERAPY OF ACTIVE PEPTIC ULCER DISEASE......................................810Pharmaceutical Agents.........................810Hp-associated Ulcers ..........................811NSAID Ulcers.................................812Other Causes of Ulcers and Idiopathic Ulcers.........812',\n",
       " 'NSAID Ulcers.................................812Other Causes of Ulcers and Idiopathic Ulcers.........812REFRACTORY ULCERS...........................812PREVENTION OF ULCER DISEASE..................812Antacids....................................812H2RAs......................................813Misoprostol..................................813PPIs .......................................813COX-2 Inhibitors (In Place of NSAIDs)...............813Assessing Risk and Choice of Agent(s)..............814COMPLICATIONS AND THEIR TREATMENT ...........815Bleeding....................................815Perforation ..................................817Obstruction..................................818STRESS ULCERS...............................819',\n",
       " 'CHAPTER 53\\u2003 Peptic Ulcer Disease80753Hp InfectionThe prevalence of Hp infection varies widely among countries in the world (see Chapter 52). In series reported between 2009 and 2011, the prevalence of infection ranged from 7% to 87%, depending on the methods of diagnosis and the population that was sampled. The lowest prevalence was observed in the USA and European countries (7% to 33%).9 Those reported from Japan and China ranged from 56% to 72%. In general, the rate of Hp infection is declining. Feinstein and colleagues studied hos\\xadpital discharge records for PUD in the USA between 1998 and 2005.10 In parallel with a decline in annual hospitalization rates for PUD, from 71.1 to 56.5 per 100,000, there was a decrease in hospitalization due to Hp-related disease, from 35.9 to 19.2 per 100,000. The prevalence of Hp infection in patients with bleed\\xading ulcers remains high. Sanchez-Delgado and colleagues com\\xadpiled 71 studies containing 8496 patients with bleeding peptic ulcers and found an Hp infection rate of 72%. The use of an Hp diagnostic test after the index bleed was associated with high Hp prevalence.11As discussed in Chapters 51 and 52, Hp causes an antrum-predominant gastritis in 10% to 20% of infected patients, which results in high gastric acid secretion and an increased risk of DU. The increased acid output from the stomach results in increased acid load to the duodenum that can result in gastric metaplasia in the duodenal bulb.12 Some believe that the metaplastic epithe\\xadlium then becomes infected with Hp from the stomach, resulting in focal “duodenitis” (technically, gastritis), sometimes followed by erosion and ulcer formation.Most patients with Hp infection have a pan-gastritis involving both the antral and fundic mucosa that lowers gastric acid secre\\xadtion13 and predisposes to GU formation. In these individuals, it is proposed that weakened mucosal defense mechanisms (see Chapter 51), rather than high acid secretion, are what predisposes',\n",
       " 'tion13 and predisposes to GU formation. In these individuals, it is proposed that weakened mucosal defense mechanisms (see Chapter 51), rather than high acid secretion, are what predisposes to gastric ulceration. The role of Hp’s genes and their protein products in the pathogenesis of PUD is discussed in Chapter 52.\\u200aUse of Aspirin and Other NSAIDsAspirin is increasingly used on a regular basis for the prevention of cardiovascular events, either alone or in combination with a platelet adenosine diphosphate inhibitor such as clopidogrel (dual antiplatelet therapy). NSAIDs are used on a regular basis by approximately 11% of the U.S. population. Regular use of NSAIDs increases the odds of GI bleeding up to 5- to 6-fold.14 Serious ulcer-related complications often leading to hospitaliza\\xadtion occur in 1% to 4% of NSAID users.15 NSAID users who also take aspirin are at an especially high risk for complications. In a population-based study from Denmark, the odds ratio for GI bleeding in people taking low-dose aspirin alone was 2.6, and this ratio increased to 5.6 in patients who were also taking an NSAID.16 In a national study of mortality associated with a hos\\xadpital admission for adverse GI events related to NSAID use in Spain, the death rate attributed to NSAID/aspirin use was 15.3 per 100,000 population compared to 2.5 per 100,000 of the gen\\xaderal population.17The gastric and duodenal mucosa have several defense mechanisms protecting them from digestion by acid and pep\\xadsin (see Chapter 51). NSAIDs cause mucosal damage through disruption of mucus phospholipids, cell membranes and by uncoupling mitochondrial oxidative phosphorylation, but most evidence suggests that NSAIDs damage the gastric and duode\\xadnal mucosa by suppression of prostaglandin synthesis.18 COX isoforms COX-1 and COX-2 are responsible for the synthesis of prostaglandins. COX-1 is expressed in the stomach and helps maintain the integrity of gastric epithelium and the mucous',\n",
       " 'isoforms COX-1 and COX-2 are responsible for the synthesis of prostaglandins. COX-1 is expressed in the stomach and helps maintain the integrity of gastric epithelium and the mucous barrier. COX-2 is not expressed in the healthy stomach but is rapidly expressed in response to the cytokines generated by inflammatory processes. Conventional NSAIDs such as ibu\\xadprofen inhibit the COX-1 and the COX-2 isoenzymes more or less equally. COX-1 inhibition reduces prostaglandin syn\\xadthesis, which leads to a reduction in mucosal defense. Animal experiments have found that neutrophil adherence to the gastric microcirculation plays a critical role in initiating NSAID injury. Neutrophil adherence liberates oxygen-free radicals, releases proteases, and obstructs capillary blood flow. Inhibition of neu\\xadtrophil adherence has been shown to reduce NSAID-induced damage. In addition, 2 gaseous mediators, nitric oxide (NO) and hydrogen sulfide (H2S), contribute to maintaining the gas\\xadtric mucosal barrier. NO and H2S increase mucosal blood flow, stimulate mucus secretion, and inhibit neutrophil adherence.19 NO-releasing and H2S-releasing derivatives of NSAIDs have been shown to protect against gastric damage when compared to the parent drugs. Gastric acid plays a secondary but impor\\xadtant role by turning superficial mucosal lesions into deeper injury, interfering with platelet aggregation, and impairing ulcer healing.20Hp infection appears to influence the risk of PUD in patients receiving NSAIDs. A meta-analysis showed that Hp infection raised the risk of peptic ulcer bleeding more than 6-fold in patients receiving long-term NSAIDs, whereas Hp alone and NSAID use alone raised the risk by 1.79-fold and 4.85-fold, respectively.21 An updated meta-analysis showed similar findings.22 Among patients who are about to start NSAID therapy, eradication of Hp reduces the subsequent risk of ulcer development.23,24 A systematic review',\n",
       " 'updated meta-analysis showed similar findings.22 Among patients who are about to start NSAID therapy, eradication of Hp reduces the subsequent risk of ulcer development.23,24 A systematic review has shown that testing for (and eradication of) Hp lowers the risk of peptic ulcers among NSAID users;25 however, eradication of Hp infection alone is insufficient to prevent peptic ulcer bleeding in NSAID users at high ulcer risk.26,27There is also evidence that Hp infection increases the risk of PUD in patients receiving low-dose aspirin. Among Hp-infected patients with recent ulcer bleeding who continued to take low-dose aspirin, successful eradication of Hp infection resulted in a very low risk of recurrent ulcer bleeding, similar to that seen with aspirin/omeprazole co-therapy.26 This low risk of ulcer rebleed\\xading after eradication of Hp was not seen in patients with bleeding ulcers who continued to take NSAIDs. In a long-term prospec\\xadtive cohort study,28 Hp-infected low-dose aspirin users (≤160 mg/day) with bleeding ulcers who resumed their aspirin had a low risk of recurrent ulcer bleeding after eradication of Hp, a risk that was not significantly different from the risk in new aspirin users with no history of ulcer disease (<1 bleed per 100 patient-years). In contrast, aspirin users with bleeding ulcers but without None knownNone knownZES, otherZES, otherNSAIDuseNSAIDuseHpinfectionHpinfectionDuodenalGastricFig. 53.1\\u2002 Pie charts depicting conditions associated with PUD. The percentages shown are rough approximations based on studies from Western countries. The relative contributions of Hp infection and NSAID use to peptic ulcer vary considerably among different populations and, within populations, vary with age and socioeconomic status. Also, the separation depicted in this figure is somewhat artificial because NSAID use and Hp infection often coexist.',\n",
       " 'within populations, vary with age and socioeconomic status. Also, the separation depicted in this figure is somewhat artificial because NSAID use and Hp infection often coexist.',\n",
       " 'PART VI\\u2003 Stomach and Duodenum808Hp infection (past or present) were at high risk of recurrent ulcer bleeding with continued enteric-coated aspirin treatment (>5 bleeds per 100 patient-years).\\u200aOther Causes of Ulcers and Idiopathic UlcersDeep ulcers and perforations of the stomach and duodenum have been described in cocaine and methamphetamine users, presum\\xadably due to mucosal ischemia.29 Bisphosphonate therapy has also been associated with gastroduodenal ulceration,30 although esophageal injury with bisphosphonates is clinically more of a concern. There is little, if any, risk for PUD in patients taking glucocorticoids.31 In combination with NSAIDs, however, gluco\\xadcorticoids increase the risk of PUD above the risk with NSAIDs alone.32 There is also a weak association between use of selective serotonin reuptake inhibitor antidepressants and PUD, especially in those with concurrent NSAID use.Smoking, stress, type A personality, and excessive alcohol use are some of the risk factors implicated for PUD. Although these factors can contribute to PUD, none has emerged as a sole cause of the disease. Hp infection is a confounder that was not addressed in earlier studies.An uncommon cause of PUD is gastrinoma (ZES) (see Chapter 34).33 Systemic mastocytosis (see Chapter 37) is another uncommon condition in which multiple ulcers may occur in the stomach or duodenum.34 Secretion of histamine by the mast cells is thought to result in the excessive stimula\\xadtion of acid production through the histamine receptor. Asso\\xadciations between PUD and α1-antitrypsin deficiency, chronic obstructive lung disease, and chronic kidney disease have been described. Several other diseases (e.g., gastric cancer, gastric lymphoma, Crohn disease) can cause ulcers that can mimic peptic ulcers. Rarer causes of peptic ulcers include eosinophilic gastroenteritis, viral infections (e.g., cytomegalovirus), Behcet disease in immunocompromised patients, Helicobacter heilmannii',\n",
       " 'peptic ulcers. Rarer causes of peptic ulcers include eosinophilic gastroenteritis, viral infections (e.g., cytomegalovirus), Behcet disease in immunocompromised patients, Helicobacter heilmannii infection, and ulcers in a Meckel diverticulum with heterotopic gastric mucosa.With a global decline in the prevalence of Hp infection, the proportion of patients with idiopathic ulcers has been increasing. Studies in North America have shown that more than 10% of peptic ulcers are not associated with Hp infection or the use of NSAIDs. Whether the incidence of idiopathic ulcers is increasing or not is controversial. It has been argued that only the relative propor\\xadtion, but not the true incidence, of idiopathic ulcers has increased as a result of a falling incidence of Hp ulcers. However, there are prospective data showing that the absolute incidence of idiopathic bleeding ulcers has increased by 4-fold. Importantly, patients with a history of idiopathic bleeding ulcers have a 4-fold increased risk of recurrent ulcer bleeding and more than 2-fold increase in mor\\xadtality compared to patients with history of Hp ulcers.35\\u200aCLINICAL FEATURES AND DIAGNOSISThe predominant symptom of patients with uncomplicated PUD is epigastric pain. Pain is typically associated with hunger, occurs at night, and is often relieved by food and antacids. Often patients complain of dyspeptic symptoms such as a bloated sensation and fullness. Some patients complain of heartburn that may or may not be accompanied by erosive esophagitis. Chronic NSAID users, typically older adult patients, can present with ulcer bleed\\xading or perforation without prior ulcer symptoms.EGD is the procedure of choice for diagnosis of uncompli\\xadcated PUD (Fig. 53.2A and B). EGD is more sensitive and spe\\xadcific than radiologic studies, such as UGI series with barium. Nevertheless, endoscopy is expensive and has the potential for complications (see Chapter 42). Therefore, the decision to per\\xad',\n",
       " 'cific than radiologic studies, such as UGI series with barium. Nevertheless, endoscopy is expensive and has the potential for complications (see Chapter 42). Therefore, the decision to per\\xadform endoscopy in a patient suspected of having PUD is based on a number of factors. As discussed later in this chapter and in Chapter 20, patients presenting with acute GI bleeding need endoscopic evaluation to allow an accurate diagnosis and for the administration of endoscopic therapy. Furthermore, patients with epigastric pain suggestive of PUD but also with “alarm” features such as weight loss or recurrent vomiting may prompt concern for gastric malignancy as well as require EGD (Box 53.1). If a DU or GU is found during EGD, gastric mucosal biopsies should be obtained for a rapid urease test to diagnose Hp infection (see Chapter 52). Biopsies should also be taken from the edges of GUs because of risk of gastric cancer. Cus\\xadtomarily, if the GU biopsies are benign, EGD is repeated 8 weeks later to confirm healing of the GU, because up to 4% of apparently benign GUs at initial endoscopy are subsequently found to be malignant.36,37BAFig. 53.2\\u2002 A, Endoscopic view of a clean-based antral GU in a patient taking an NSAID. Tests for infection with Hp were negative. B, Endoscopic view of a DU in a patient with a positive rapid urease test for Hp. There was no history of NSAID use.0..',\n",
       " 'CHAPTER 53\\u2003 Peptic Ulcer Disease80953Dyspeptic upper abdominal symptoms consisting of pain or dis\\xadcomfort in the upper abdomen are common in clinical practice, accounting for 2% to 5% of visits to family practitioners (see Chap\\xadter 14).38 Owing to the high cost and impracticality of subjecting all dyspeptic individuals to prompt endoscopy, 2 other nonendoscopic strategies (besides UGI series, with its inherent lower sensitivity and specificity for PUD) have been proposed as an initial step in the management of suspected PUD (Fig. 53.3). The strategies are (1) “test-and-treat,” based on a noninvasive diagnosis of Hp infection and subsequent eradication therapy when Hp is detected, and (2) empirical antisecretory therapy, usually with a PPI.Gisbert and Calvet39 reviewed the literature and concluded that the Hp test-and-treat strategy will cure most cases of PUD and prevent most cases of gastroduodenal disease. A small pro\\xadportion of patients with Hp-related functional dyspepsia would also improve in their symptoms. The test-and-treat strategy has been compared with endoscopy-directed diagnosis in 8 random\\xadized controlled trials (RCTs). These trials differed in how Hp was diagnosed, and the upper age cutoff varied from 45 to 55 years. In some studies, serology was used for diagnosis of infection, which is less specific than 13C urea breath testing (see Chapter 52). The background Hp prevalence in the study populations ranged from 23% to 53%. After a 12-month follow-up, the prevalence of dys\\xadpeptic symptoms was similar in the 2 groups. In 7 of the 8 trials, cost data were reported, and the test-and-treat strategy was less expensive because of the many endoscopies avoided. Ford and colleagues performed a meta-analysis of 5 RCTs involving 1924 patients and found a slight benefit at 12 months of prompt EGD on dyspeptic symptoms over test-and-treat (risk ratio, 0.95; 95% confidence index [CI], 0.92 to 0.99), possibly because a normal',\n",
       " 'patients and found a slight benefit at 12 months of prompt EGD on dyspeptic symptoms over test-and-treat (risk ratio, 0.95; 95% confidence index [CI], 0.92 to 0.99), possibly because a normal EGD may have had a reassuring effect in some patients.40BOX 53.1\\u2002 Alarm Features in Patients With UGI Symptoms*Age older than 55 years with new-onset dyspepsiaFamily history of UGI cancerGI bleeding, acute or chronic, including unexplained iron deficiencyJaundiceLeft supraclavicular lymphadenopathy (Virchow node)Palpable abdominal massPersistent vomitingProgressive dysphagiaUnintended weight loss\\u2003 \\u2003*These features should prompt EGD and often other testing to establish a definitive diagnosis (see Chapter 14).OrganicpathologyNormalManage accordingto relevant guidelineManage according toChapter 14EndoscopyAdult dyspepsia patient≥ 60 years of age< 60 years of ageHptest and treatHperadicationPPINoResponseNoResponseResponseResponseResponseResponsePositiveNegativeNo responseTCAor prokineticConsiderpsychotherapySuccessFig. 53.3\\u2002 ACG and Canadian Association of Gastroenterology (CAG) guideline algorithm for the management of undiagnosed PUD. This is also the current management approach for patients with suspected PUD. TCA, tricyclic antidepressant. (Adapted from Moayyedi P, Lacy BE, Andrews CN, et\\xa0al. ACG and CAG clinical guide\\xadline: management of dyspepsia. Am J Gastroenterol 2017; 112:988-1013.)',\n",
       " 'PART VI\\u2003 Stomach and Duodenum810According to a joint ACG/Canadian Association of Gastro\\xadenterology guidelines, it was recommended that patients with uninvestigated dyspepsia who are below 60 years of age should have a noninvasive test H and treatment if positive. Those with a negative test or do not respond to this approach should receive a trial of PPI therapy. Tricyclic antidepressants or prokinetic therapies can be tried if they are not responsive to PPI therapy. The incidence of UGI malignancies including gastric cancer rises with age and, thus, current nonendoscopic management strategies are generally reserved for younger patients with upper abdominal symptoms. The age after which prompt EGD should become routine is debated and, to a substantial degree, depends on the epidemiology of UGI cancer in the population under consideration. In Western populations, UGI cancer is uncom\\xadmon in young individuals, and therefore an age cutoff of 50 or 55 years is often used. Patients older than age 60 presenting with new-onset upper abdominal symptoms suggestive of PUD should therefore be referred for EGD. In Asia and Eastern Europe, where the incidence of gastric cancer is substantially higher than in Western nations, a younger age cutoff may be reasonable.The Joint ACG/Canadian Association of Gastroenterology guidelines on dyspepsia in 2017 recommended that patients with uninvestigated dyspepsia who are less than 60 years of age should have a noninvasive Hp test and treatment if positive.39,41 Those with a negative Hp test or who do not respond to this approach should receive a trial of a PPI therapy. Tricyclic antidepressants or prokinetic therapies can be tried if the patients are not respon\\xadsive to PPI therapy (see Chapter 14 and Fig. 53.3). In areas of moderate- to- high Hp prevalence, the test-and-treat strategy is preferred. The Maastricht Consensus Conference Report in 2017 recommended a test-and-treat strategy for uninvestigated',\n",
       " 'moderate- to- high Hp prevalence, the test-and-treat strategy is preferred. The Maastricht Consensus Conference Report in 2017 recommended a test-and-treat strategy for uninvestigated dyspepsia. This approach is subject to regional Hp prevalence and cost-benefit considerations.40,42 The test-and-treat strategy is, however, not applicable to patients with alarm symptoms or to older patients. The ability of alarm features (see Box 53.1) to accurately predict malignancy (as opposed to PUD or nonul\\xadcer dyspepsia) has, however, been questioned in a review of 15 studies.43 The sensitivity of alarm symptoms in the diagnosis of malignancy varied from 0% to 83% across studies.\\u200aMEDICAL THERAPY OF ACTIVE PEPTIC ULCER DISEASESeveral pharmaceutical agents are available to attempt to heal active DUs and GUs.Pharmaceutical AgentsAntacidsAntacids neutralize gastric acid but their ability to heal ulcers is poor. Most physicians do not use antacids as primary therapy to heal ulcers but instead recommend their use to relieve dyspeptic symptoms. The most common adverse effect of magnesium-con\\xadtaining antacids is diarrhea. In contrast, aluminum- and calcium-containing antacids may cause constipation. All antacids must be used with caution, if at all, in patients who have chronic kidney disease, in whom magnesium-containing agents can cause hyper\\xadmagnesemia, calcium-containing antacids hypercalcemia, and aluminum-containing antacid neurotoxicity.44\\u200aAntisecretory AgentsAntisecretory therapy is not routinely required for patients with uncomplicated Hp ulcers in whom ulcers heal after successful eradication of Hp even without antisecretory therapy; however, antisecretory drugs play an important role in the management of patients with PUD not associated with Hp. The role of antisecre\\xadtory drugs in the management of gastrinoma (ZES) is discussed in Chapter 34.H2RasH2RAs are competitive inhibitors of histamine-stimulated acid',\n",
       " 'tory drugs in the management of gastrinoma (ZES) is discussed in Chapter 34.H2RasH2RAs are competitive inhibitors of histamine-stimulated acid secretion (see Chapter 51) and markedly suppress basal and meal-stimulated acid secretion.45 When administered in the evening, H2RAs are effective in suppressing nocturnal acid output.46 H2RAs are well absorbed after oral dosing, and their absorption is not affected by food. Peak blood levels are achieved within 1 to 3 hours after an oral dose. H2RAs cross the blood-brain barrier and the placenta.47,48 After oral administration, several H2RAs (cimetidine, ranitidine, and famotidine) undergo first-pass hepatic metabolism, which reduces their bioavailability by 35% to 60%. In contrast, the H2RA nizatidine does not undergo first-pass metabolism, and its bioavailability approaches 100% with oral dosing. H2RAs are eliminated by a combination of renal excre\\xadtion and hepatic metabolism. Dose reductions are recommended when the creatinine clearance is below 50 mL/min. Dialysis does not remove substantial amounts of H2RAs; thus, dose adjust\\xadments are not necessary for dialysis patients. Dose reductions are generally not required for patients with hepatic failure unless it is accompanied by chronic kidney disease. Tolerance to the anti\\xadsecretory effects of H2RAs develops quickly and frequently,49 although the mechanism for tolerance is not clear.H2RAs are safe and well tolerated. One meta-analysis of ran\\xaddomized clinical trials concluded that the overall rate of adverse effects reported for H2RAs did not differ significantly from pla\\xadcebo treatment.50 Nevertheless, a number of untoward effects have been described, primarily in anecdotal reports and uncon\\xadtrolled series. Cimetidine has weak antiandrogenic activity that can occasionally cause gynecomastia and impotence.51Both cimetidine and ranitidine bind to the hepatic cytochrome P-450 (CYP) mixed-function oxidase system. This binding',\n",
       " 'can occasionally cause gynecomastia and impotence.51Both cimetidine and ranitidine bind to the hepatic cytochrome P-450 (CYP) mixed-function oxidase system. This binding can inhibit the elimination of other drugs that are metabolized through the same system, including warfarin, theophylline, phe\\xadnytoin, lidocaine, and quinidine.52 In contrast, famotidine and nizatidine have no significant avidity for the CYP system.\\u200aPPIs.PPIs decrease gastric acid secretion through inhibition of H+, K+-ATPase, the proton pump of the parietal cell (see Chapter 51). These agents are prodrugs that must be activated by acid to inhibit the H+, K+-ATPase. Interestingly, prodrug PPIs are also acid-labile compounds that must be protected from degradation by gastric acid after oral administration by enteric coating or an antacid.53 Absorption of the enteric-coated PPIs may be erratic, and peak serum concentrations are not achieved until 2 to 5 hours after oral administration. Although the plasma half-life of PPIs is short (≈2 hours), the duration of acid inhibition is long as a result of covalent binding of the active metabolite of the prodrug to the H+, K+-ATPase. PPIs undergo significant hepatic metabolism, but dose adjustments are not required in patients with significant renal or hepatic impairment. There is genetic polymorphism in CYP2C19, one of the isoenzymes involved in PPI metabolism. Approximately 25% of Asians and 3% of white persons have deficient CYP2C19 activity. This polymorphism leads to sub\\xadstantially higher plasma levels of omeprazole, lansoprazole, and pantoprazole, but not rabeprazole.36,37,54PPIs, as a result of their requirement for concentration and activation in acidic compartments, bind predominantly to those proton pumps that are actively secreting acid. With meal stimu\\xadlation, 60% to 70% of the proton pumps actively secrete acid; thus, PPIs are most effective if they are administered immediately',\n",
       " 'proton pumps that are actively secreting acid. With meal stimu\\xadlation, 60% to 70% of the proton pumps actively secrete acid; thus, PPIs are most effective if they are administered immediately before meals. For once-daily dosing, it is recommended that PPIs be taken immediately before breakfast.55 Unlike H2RAs, toler\\xadance to the antisecretory effects of PPI therapy has not been seen.',\n",
       " 'CHAPTER 53\\u2003 Peptic Ulcer Disease81153PPIs, by raising the gastric pH, can affect the absorption of a number of drugs. However, this pH effect rarely has clinically important effects, except when the PPIs are given with keto\\xadconazole or digoxin.55-57 Ketoconazole requires gastric acid for absorption, and this antifungal drug may not be absorbed effec\\xadtively if PPIs have also been prescribed. If a patient requires both a PPI and antifungal therapy, it is recommended that an agent other than ketoconazole be chosen. Conversely, an elevated gastric pH facilitates absorption of digoxin, resulting in higher plasma digoxin levels. For patients treated concomitantly with PPIs and digoxin, clinicians should consider monitoring plasma digoxin levels.Because PPIs are metabolized by the CYP system, they have the potential to alter the metabolism of other drugs that are elim\\xadinated by CYP enzymes. The potential interaction between PPIs and clopidogrel has drawn widespread attention. Clopidogrel, a nonaspirin antiplatelet prodrug, is activated by hepatic CYP2C19 and other CYPs to its active metabolite. PPIs reduce the anti\\xadplatelet effect of clopidogrel through competitive inhibition of CYP2C19. Meta-analysis of observational studies reported a sig\\xadnificant increase in major adverse cardiovascular events includ\\xading cardiovascular deaths among patients receiving concomitant PPIs and clopidogrel.58,59 However, an association between PPI and clopidogrel use has not been confirmed by prospective stud\\xadies and a large-scale RCT.60,61 Despite the inconsistent findings, regulatory authorities in the USA and Europe have issued warn\\xadings against the use of certain PPIs in patients receiving concomi\\xadtant clopidogrel.There are other concerns about the safety of long-term use of PPIs. To date, PPI use has been implicated in many condi\\xadtions, including osteoporosis, hypomagnesaemia, gastric cancer, enteric infections, interstitial nephritis, pneumonia, dementia,',\n",
       " 'of PPIs. To date, PPI use has been implicated in many condi\\xadtions, including osteoporosis, hypomagnesaemia, gastric cancer, enteric infections, interstitial nephritis, pneumonia, dementia, and NSAID-enteropathy. Currently, there is no definite evidence to suggest that these conditions are attributable to PPI use.62 It is possible that a new evidence will emerge to indicate a causal relationship. In the meantime, long-term use of PPI without a strong indication should be discouraged.\\u200aPotassium-Competitive Acid BlockerPotassium-competitive acid blocker (P-CAB) therapy com\\xadpetes with potassium to inhibit H+, K+-ATPase in parietal cells at the final stage of the acid secretory pathway (see Chapter 51).63 Unlike PPIs, a P-CAB is acid stable and does not require an acidic environment for activation (i.e., a pro\\xaddrug is not required). To date, vonoprazan is the only P-CAB commercially available in Japan and some other countries. Vonoprazan exerts a near-maximum inhibitory effect from the first dose and its effect lasts for 24 hours.63 In 2 phase 3 RCTs, vonoprazan (20 mg once daily) was not inferior to lansoprazole (30 mg once daily) for the healing of GUs and DUs. RCTs.64,65 Two other randomized trials showed that vonoprazan (10 and 20 mg) was as effective as lansoprazole (15 mg) in preventing ulcer recurrence associated with long-term use of NSAIDs and low-dose aspirin.66\\u200aMucosal Protective AgentsSucralfate is a complex aluminum salt of sulfated sucrose. When exposed to gastric acid, the sulfate anions can bind electrostatically to positively charged proteins in damaged tissue.67,68 Sucralfate (1g 4 times daily) is equally effective to H2RAs in healing DUs and is approved by the FDA in the USA for this indication. Very little (<5%) of sucralfate is absorbed owing to its poor solubility, and the drug is excreted via the enteral route. Because of its lack of systemic absorption, sucralfate appears to have no systemic',\n",
       " 'little (<5%) of sucralfate is absorbed owing to its poor solubility, and the drug is excreted via the enteral route. Because of its lack of systemic absorption, sucralfate appears to have no systemic toxicity. The effect on the accumulation of aluminum in the body has not been adequately studied in patients with chronic kidney disease treated with sucralfate, and sucralfate is best avoided in this population. Important drug interactions appear to be rare and can be avoided if sucralfate is administered at a time separate from other medications.Colloidal bismuth preparations, such as colloidal bismuth subcitrate and bismuth subsalicylate (e.g., Pepto-Bismol), have modest efficacy in healing peptic ulcers, but the mechanism is unclear.69 The bismuth salts form complexes with mucus that appear to coat ulcer craters. Bismuth-induced increased muco\\xadsal prostaglandin synthesis and bicarbonate secretion have also been proposed. Bismuth salts have antimicrobial activity against Hp, and bismuth has been approved in the USA by the FDA for use, in combination with other agents, for the treatment of Hp infection (see Chapter 52). Bismuth is largely unabsorbed and excreted in the feces. Colonic bacteria convert bismuth salts to bismuth sulfide, which turns the stools black. Trace amounts of bismuth are absorbed in the UGI tract, with the bismuth then slowly excreted in the urine for 3 months or longer. Short-term, standard-dose therapy with bismuth appears to carry little risk of toxicity; however, there is the potential for bismuth encepha\\xadlopathy with neuropsychiatric symptoms if the agent is given for extended periods in high dosage, especially in patients with chronic kidney disease.Misoprostol is a prostaglandin E1 analog approved by the FDA for the prevention of NSAID-induced PUD.70 The drug not only enhances mucosal defense mechanisms but also inhibits gastric acid secretion through inhibition of histamine-stimulated',\n",
       " \"FDA for the prevention of NSAID-induced PUD.70 The drug not only enhances mucosal defense mechanisms but also inhibits gastric acid secretion through inhibition of histamine-stimulated cyclic 3',5'-cyclic adenosine monophosphate (AMP) produc\\xadtion.71 Well absorbed after oral administration, the plasma miso\\xadprostol concentration peaks after approximately 30 minutes, with a serum half-life of approximately 1.5 hours. The drug has no effect on hepatic CYP450. Misoprostol metabolites are excreted in the urine, but dose reductions are unnecessary in patients with chronic kidney disease. Dose-related diarrhea is the most common adverse effect, occurring in up to 30% of patients and limiting the usefulness of misoprostol. Diarrhea is related to prostaglandin-induced increases in intestinal electrolyte and water secretion and/or acceleration of intestinal transit time. Administration of misoprostol with food may reduce diarrhea. Misoprostol also stimulates uterine smooth muscle and is there\\xadfore contraindicated in women who may be pregnant.\\u200aHp-associated UlcersTreatment of Hp infection is discussed in detail in Chapter 51. It is well established that curing Hp infection not only heals pep\\xadtic ulcers but also prevents ulcer relapses and complications.72-75 Because Hp infection accounts for 80% to 90% of DU cases, test\\xading for the infection in patients with DU is mandatory. If the diagnosis of DU is made endoscopically, gastric biopsy specimens should be taken to detect Hp infection. There is good evidence that a 10- to 14-day course of Hp eradication therapy is suffi\\xadcient to heal DUs such that additional antisecretory therapy is not usually required. Follow-up endoscopic examination in order to document healing and perform testing to document Hp eradi\\xadcation following antibiotic therapy is not recommended routinely in patients with uncomplicated DUs. However, noninvasive tests such as the urea breath test can be used to confirm Hp eradi\\xad\",\n",
       " 'cation following antibiotic therapy is not recommended routinely in patients with uncomplicated DUs. However, noninvasive tests such as the urea breath test can be used to confirm Hp eradi\\xadcation. Whether antisecretory therapy is required after a 7- to 14-day course of Hp eradication therapy in patients with GU is somewhat controversial. One week of antibacterial therapy without acid suppression effectively heals Hp-related GUs.72 In a meta-analysis of GU healing trials, treatment with Hp eradi\\xadcation therapy produced similar outcomes to treatment with an ulcer-healing drug;73 however, in patients with large or compli\\xadcated GUs, additional antisecretory therapy can facilitate ulcer healing. Follow-up endoscopy is recommended in patients with large or complicated GUs to document healing, exclude malig\\xadnancy, and confirm successful Hp eradication.\\u200a',\n",
       " 'PART VI\\u2003 Stomach and Duodenum812NSAID UlcersH2RAsConventional doses of H2RAs are more effective in healing NSAID-related DUs than GUs. There are limited data on the efficacy of H2RAs in healing peptic ulcers if patients continue to receive NSAIDs. Therefore, H2RAs are not preferred agents in patients with ulcers who require uninterrupted NSAID therapy.\\u200aPPIsCurrent evidence76-78 indicates that PPIs are superior to stan\\xaddard-dose H2RAs in healing NSAID-induced peptic ulcers. In a randomized comparison of esomeprazole (20 or 40 mg/day) and ranitidine (150 mg twice daily) in ulcer patients who continued to take NSAIDs, ulcer healing at 8 weeks occurred in 85% and 86% of patients given esomeprazole and in 76% of those given raniti\\xaddine.78 In another study of patients with NSAID-associated GUs who continued to use NSAIDs, ulcer healing at 8 weeks occurred in 69% and 73% of patients given lansoprazole (15 or 30 mg/day) but in only 53% of those given ranitidine (150 mg twice daily).77\\u200aMisoprostolIn ulcer patients who continued their NSAID, misoprostol healed the ulcers in 67% of patients at 8 weeks, compared with only 26% of patients treated with placebo.79 However, misoprostol is not as effective as PPI therapy in healing NSAID-associated ulcers. One randomized trial compared full-dose misoprostol (200 μg 4 times daily) with omeprazole (20 or 40 mg daily) in DU or GU patients who continued NSAID treatment.80 After 8 weeks, DUs had healed in 89% of patients receiving either dose of omeprazole and in 77% of those receiving misoprostol. Similarly, GUs had healed in 87% of those receiving 20 mg of omeprazole, 80% of those receiving 40 mg of omeprazole, and 73% of those receiv\\xading misoprostol. Although misoprostol is seldom used for treat\\xadment or prevention of peptic ulcer nowadays, 2 randomized trials have shown that misoprostol is effective for the healing of small bowel ulcers and erosions in patients with obscure bleeding taking NSAIDs and low-dose aspirin.81,82',\n",
       " 'have shown that misoprostol is effective for the healing of small bowel ulcers and erosions in patients with obscure bleeding taking NSAIDs and low-dose aspirin.81,82Other Causes of Ulcers and Idiopathic UlcersWhen the cause of a peptic ulcer can be identified as other than Hp or NSAID use (e.g., gastrinoma), the underlying disorder should be treated (see Chapter 34).The treatment of idiopathic, non-Hp, non-NSAID ulcers relies on acid antisecretory therapy, usually a PPI, which is often given long term (maintenance therapy), much as antisecretory therapy is used long term to prevent NSAID-induced ulcers in moderate- and high-risk patients (see later).\\u200aREFRACTORY ULCERSMost peptic ulcers heal within 8 weeks of initiation of antisecre\\xadtory therapy. Nevertheless, in a small but considerable minor\\xadity of patients, the ulcers persist despite conventional treatment. Such ulcers can be considered refractory. There is no standardized definition for refractory peptic ulcer, making comparisons among studies difficult. In some patients with refractory ulcers, symptoms of ulcer disease persist and may be severe. In others, the refrac\\xadtory ulcer becomes asymptomatic and is only detected at endoscopy (e.g., at the 8-week follow-up endoscopy to assess healing of a GU).For the patient whose ulcer does not heal despite a trial of conventional therapy, the clinician should ask the following ques\\xadtions:\\u2003 \\u2003 • Has the patient complied with the prescribed treatment? • Is the ulcer penetrating the pancreas, liver, or other organ? • Is there Hp infection? If antibiotic therapy had already been prescribed, the patient should be tested to confirm that the infection has indeed been eradicated. If no attempt had been made to diagnose and treat Hp infection, it should be made now. False-negative test results for Hp should be considered (see Chapter 52). • Is the patient still taking an NSAID? NSAID use may be sur\\xadreptitious. A careful history regarding the use of over-the-',\n",
       " '(see Chapter 52). • Is the patient still taking an NSAID? NSAID use may be sur\\xadreptitious. A careful history regarding the use of over-the-counter NSAIDs (including low-dose aspirin) should be ob\\xadtained, and NSAIDs should be stopped if possible. • Does the patient smoke cigarettes? If so, he or she should be counseled strongly to discontinue cigarettes. • Has the duration of ulcer treatment been adequate? Large ul\\xadcers require a longer duration of therapy than small ulcers to heal. A large ulcer (e.g., >2 cm) probably should not be con\\xadsidered refractory until it has persisted beyond 12 weeks of antisecretory therapy. • Is there evidence of a hyper-secretory condition? A family his\\xadtory of gastrinoma or MEN type I or a personal history of chronic diarrhea, hypercalcemia caused by hyperparathyroid\\xadism, or ulcers involving the postbulbar duodenum or proximal jejunum suggest a diagnosis of ZES (see Chapter 34). • Finally, is the ulcer indeed peptic? Primary or metastatic neo\\xadplasms, infections (e.g., cytomegalovirus), cocaine use, eosino\\xadphilic gastroenteritis, and Crohn disease can cause ulcerations of the stomach and duodenum that can mimic peptic ulcers. These disorders should be considered and excluded appropriately.\\u2003 \\u2003Treatment options for truly refractory peptic ulcers include a more prolonged course of antisecretory therapy, often at dou\\xadble the prior PPI dose. Although uncommon nowadays, elective ulcer surgery may be necessary to attempt to heal a symptomatic refractory or penetrating ulcer. Surgical options are discussed later in this chapter.\\u200aPREVENTION OF ULCER DISEASEMost studies of ulcer prophylaxis have used endoscopy endpoints (rather than clinical endpoints) to assess the effectiveness of various regimens. An “endoscopic ulcer” has been arbitrarily defined as a circumscribed mucosal defect having a diameter of 5 mm or more with a perceivable depth.83 However, many studies have loosened',\n",
       " 'regimens. An “endoscopic ulcer” has been arbitrarily defined as a circumscribed mucosal defect having a diameter of 5 mm or more with a perceivable depth.83 However, many studies have loosened this criterion to include flat mucosal breaks with a diameter of 3 mm or more as ulcers. The distinction between small ulcers and erosions is arbitrary and is prone to interobserver bias. The clini\\xadcal relevance of these minor endoscopic lesions is uncertain. It is assumed that endoscopic findings roughly correlate with clinical outcomes in subjects at low-to-average risk for ulcer complications. It is unclear if results of endoscopic studies can be generalized to high-risk patients. Because there are few prospective outcome tri\\xadals to evaluate the true clinical efficacy of ulcer prophylactic agents, clinical judgment relies on data largely using endoscopic endpoints.Hp ulcers do not require ulcer prophylaxis if the organism can be eradicated from the stomach (see earlier and Chapter 52). Most use of ulcer prophylaxis regimens is, therefore, related to preven\\xadtion of NSAID ulcers in patients at moderate-to-high ulcer risk. The risk factors for NSAID-induced ulcers are listed in Table 53.1. Pharmaceutical agents that may reduce the development of NSAID-induced ulcers are discussed later. Ulcer prophylaxis is also frequently used in patients with idiopathic ulcers. Among the agents listed, only the antisecretory agents are commonly used in the prevention of idiopathic ulcers.AntacidsMany clinicians prescribe antacids as co-therapy for patients tak\\xading NSAIDs, both to relieve dyspeptic symptoms and to (hope\\xadfully) prevent ulcers; however, antacids have no proved efficacy ',\n",
       " 'CHAPTER 53\\u2003 Peptic Ulcer Disease81353in the prevention of NSAID-induced ulcers. Antacids may mask dyspeptic symptoms, thereby creating a false sense of ulcer protection and increasing the risk of silent ulcer complications with prolonged NSAID therapy. Co-prescription of antacids in patients taking NSAIDs who are at risk for ulcer should be dis\\xadcouraged.\\u200aH2RAsUsing standard doses of H2RAs is not effective in preventing NSAID-induced GUs,84,85 and, as already mentioned, may be harmful. A systematic review85 of randomized trials in NSAID users concluded that using twice the standard daily dose of H2RA significantly reduces the risk of endoscopic NSAID-induced DUs and GUs. However, whether high-dose H2RAs prevent NSAID-induced ulcer complications is unknown. In contrast, H2RAs appear to be more effective for prevention of ulcers asso\\xadciated with low-dose aspirin than with NSAIDs. In a 12 month, multi-center randomized trial of low-dose aspirin users at risk for recurrent ulcer bleeding, there was no significant difference in the incidence rates of recurrent bleeding between patients receiv\\xading a PPI and patients receiving an H2RA.89\\u200aMisoprostolThe efficacy of misoprostol in preventing NSAID-induced ulcers has been assessed in RCTs.86,87 A systematic review of these tri\\xadals indicated that all doses of misoprostol studied (400 to 800 μg/day) reduce the risk of NSAID-induced endoscopic ulcers.85 However, only full-dose misoprostol (800 μg/day) reduces ulcer complications.86 In a randomized double-blind trial in patients with rheumatoid arthritis who received NSAIDs, misoprostol (200 μg 4 times daily) lowered the rate of GI complications by 40% (from 0.95% in the placebo group to 0.57% in the misoprostol group). However, up to 30% of misoprostol-treated patients in this trial experienced GI upset, thereby limiting its clinical use. Even though endoscopic studies had suggested that lower doses of misoprostol, such as 200 μg 2 or 3 times daily, can prevent NSAID-',\n",
       " 'this trial experienced GI upset, thereby limiting its clinical use. Even though endoscopic studies had suggested that lower doses of misoprostol, such as 200 μg 2 or 3 times daily, can prevent NSAID-induced ulcers with fewer adverse effects than the full dose,86 such low doses of misoprostol fail to prevent ulcer complications.88\\u200aPPIsPPIs significantly reduce the risk of endoscopic duodenal and GUs.85 The efficacy of PPIs has been compared with that of H2RAs and with misoprostol in patients who received NSAIDs. Two 6-month studies compared omeprazole 20 mg once daily with either standard-dose ranitidine (150 mg twice daily) and half-dose misoprostol (200 μg twice daily).76,80 Omeprazole was more effec\\xadtive than standard-dose ranitidine and comparable with half-dose misoprostol in preventing endoscopic ulcers. The superiority of omeprazole over ranitidine in preventing NSAID-related ulcer was due to a greater reduction in endoscopic DUs. A posthoc analysis revealed that most of the added protection attributable to omepra\\xadzole over ranitidine occurred among those with Hp infection. Another endoscopic study compared high-dose misoprostol (200 μg 4 times daily) with 2 doses of lansoprazole (15 and 30 mg daily) for the prevention of ulcers in long-term NSAID users without Hp infection and with a history of GU.88 Misoprostol was more effective than either dose of lansoprazole in preventing GU, but there was no practical advantage of misoprostol over lansoprazole because of the high withdrawal rate in the misoprostol group. In a head-to-head endoscopic ulcer prevention study comparing 2 doses of pantoprazole with 20 mg/day of omeprazole in patients with rheumatoid arthritis receiving NSAIDs, the 6-month prob\\xadabilities of remaining ulcer free were 91%, 95%, and 93% for pantoprazole 20 mg, pantoprazole 40 mg, and omeprazole 20 mg, respectively.89Two identical multicenter randomized clinical trials compared',\n",
       " 'abilities of remaining ulcer free were 91%, 95%, and 93% for pantoprazole 20 mg, pantoprazole 40 mg, and omeprazole 20 mg, respectively.89Two identical multicenter randomized clinical trials compared esomeprazole (20 or 40 mg) with placebo in the prevention of ulcers in patients taking NSAIDs or COX-2 inhibitors over a 6 month period. Patients in both studies were Hp negative, older than age 60, and had a history of GU or DU. Overall, the rates of ulcers were 17.0%, 5.2%, and 4.6% in the groups receiving placebo, esomeprazole 20 mg, and esomeprazole 40 mg, respectively.90Whether PPIs can reduce the risk of NSAID-associated peptic ulcer bleeding is largely based on observational studies and 1 ran\\xaddomized trial in high-risk patients. A large-scale, case-control study found that PPI therapy was associated with a significant reduction in risk of UGI bleeding among chronic NSAID users (relative risk, 0.13; 95% CI, 0.09 to 0.19).91 The randomized trial compared long-term (6 months) omeprazole therapy to 1 week of Hp eradi\\xadcation therapy for the prevention of recurrent ulcer bleeding in Hp-infected patients with a recent history of NSAID-related ulcer bleeding who continued to use naproxen.92 Recurrent ulcer bleed\\xading occurred in 18.8% of patients undergoing eradication therapy compared with only 4.4% of patients receiving omeprazole.\\u200aCOX-2 Inhibitors (In Place of NSAIDs)COX-2 inhibitors offer the hope of minimizing GI toxicity of NSAIDs while preserving their therapeutic effects.93-97 In a sys\\xadtematic review of randomized trials, when compared with nonse\\xadlective NSAIDs the COX-2 inhibitors led to significantly fewer gastroduodenal ulcers (relative risk, 0.26; 95% CI, 0.23 to 0.30) and ulcer complications (relative risk, 0.39; 95% CI, 0.31 to 0.5), as well as fewer withdrawals caused by GI symptoms94; however, the sparing effect of COX-2 inhibitors on ulcer development is negated by concomitant use of low-dose aspirin.59',\n",
       " 'as well as fewer withdrawals caused by GI symptoms94; however, the sparing effect of COX-2 inhibitors on ulcer development is negated by concomitant use of low-dose aspirin.59Current evidence indicates that COX-2 inhibitors are as effec\\xadtive as a combination of nonselective NSAIDs combined with a PPI in patients at risk for ulcers. In a randomized comparison of the NSAID diclofenac plus omeprazole versus celecoxib for secondary prevention of ulcer bleeding in patients who either were Hp negative or had undergone Hp eradication,95 a similar proportion of patients had recurrent bleeding in 6 months (6.4% in the diclofenac/omeprazole group and 4.9% of patients in the celecoxib group). Although the 2 treatments were comparable in terms of the incidence of ulcer bleeding, a subsequent follow-up endoscopic study showed that 20% to 25% of patients receiv\\xading either treatment developed recurrent endoscopic ulcers at 6 months. These findings suggest that neither treatment can elimi\\xadnate the risk of recurrent bleeding in very high-risk patients. In a 13-month, double-blind randomized trial comparing celecoxib alone with celecoxib/esomeprazole in patients with a history of NSAID-associated ulcer bleeding, 8.9% of the celecoxib-alone group had recurrent ulcer bleeding compared with none of the combined therapy group (P = 0.0004).96TABLE 53.1\\u2002 Risk Factors for NSAID Ulcers*Risk factorRisk ratioHistory of complicated ulcer13.5Use of multiple NSAIDs (including aspirin, COX-2 inhibitors)9Use of high doses of NSAIDs7Use of an anticoagulant6.4History of an uncomplicated ulcer6.1Age >70 years5.6Hp infection3.5Use of a glucocorticoid2.2\\u2003 \\u2003*Not all NSAIDs pose the same risk.\\u2003 \\u2003',\n",
       " 'PART VI\\u2003 Stomach and Duodenum814Despite the improved gastric safety profile of COX-2 inhibi\\xadtors, the cardiovascular risk associated with this new class of NSAIDs has been a subject of much concern. In the VIGOR study,97 the incidence of acute myocardial events, although low, was 4 times higher among patients receiving rofecoxib than among patients receiving naproxen. Whether this observed dif\\xadference in myocardial infarction rates was related to an anti\\xadplatelet property of naproxen or to a pro-thrombotic effect of rofecoxib was debated. Further data regarding the cardiovascu\\xadlar hazards of COX-2 inhibitors were derived from 2 long-term studies of colon polyp prevention, using either rofecoxib (the Adenomatous Polyp Prevention on Vioxx [APPROVE] study)98 and celecoxib (the Adenoma Prevention with Celecoxib [APC] study).99 In APPROVE, interim data at 18 months indicated that patients who had received 25 mg rofecoxib a day had twice the risk of serious cardiovascular events compared with patients who received placebo. In 2004, rofecoxib was voluntarily withdrawn from worldwide markets in light of this unexpected finding. In the APC study, interim data at 33 months showed that serious cardiovascular events were significantly more frequent with cele\\xadcoxib at the high dose of 400 mg twice a day (hazard ratio, 1.9; 95% CI, 1 to 3.3). The MEDAL program was a pre-specified pooled analysis of cardiothrombotic events from 3 trials in which patients with osteoarthritis or rheumatoid arthritis were ran\\xaddomly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily). After an average treatment of 18 months, rates of cardiothrombotic events were similar between the 2 treatment groups.100Current evidence suggests that not only COX-2 inhibitors but also nonselective NSAIDs, with the exception of full-dose naproxen (1000 mg/day), increase cardiothrombotic risk. In a meta-analysis of randomized trials of COX-2 inhibitors (data',\n",
       " 'but also nonselective NSAIDs, with the exception of full-dose naproxen (1000 mg/day), increase cardiothrombotic risk. In a meta-analysis of randomized trials of COX-2 inhibitors (data mostly derived from rofecoxib and celecoxib), all COX-2 inhibi\\xadtors increased the cardiothrombotic risk compared with placebo (risk ratio, 1.42; 95% CI, 1.13 to 1.78). This was largely attribut\\xadable to an increased risk of myocardial infarction, with little dif\\xadference in other vascular outcomes. A dose-dependent increase in cardiothrombotic events was observed with celecoxib. Impor\\xadtantly, there was no significant difference in cardiothrombotic risk between COX-2 inhibitors and nonselective NSAIDs, with naproxen (500 mg twice daily) the only exception. In a meta-anal\\xadysis of observational studies, high-dose rofecoxib (≥25 mg a day), diclofenac, and indomethacin were associated with an increase in cardiothrombotic events, whereas celecoxib did not significantly increase the cardiothrombotic risk, although an increased risk could not be excluded with doses greater than 200 mg/day.101 In a large-scale, randomized, noninferiority trial of celecoxib versus naproxen and ibuprofen in patients with arthritis (mostly osteo\\xadarthritis) and with increased cardiovascular risk,102 more than 24,000 patients were recruited with a mean treatment duration of 20 months and a mean follow-up period of 34 months. Celecoxib (on average approximately 200 mg/day) was found to be nonin\\xadferior to ibuprofen (approximately 2000 mg/day) or naproxen (approximately 850 mg/day) with regard to cardiovascular safety. Patients treated with celecoxib had a significantly lower risk of adverse GI events than with naproxen or ibuprofen. The risk of adverse renal events was also significantly lower with celecoxib than with ibuprofen; however, the proportion of patients con\\xadtinued on concomitant low-dose aspirin during the study period was unclear and very few patients had a history of GI bleed\\xad',\n",
       " 'than with ibuprofen; however, the proportion of patients con\\xadtinued on concomitant low-dose aspirin during the study period was unclear and very few patients had a history of GI bleed\\xading. It is, therefore, unclear whether the advantage of celecoxib over naproxen or ibuprofen can be extrapolated to patients on concomitant aspirin with high risk of GI bleeding. In another 18-month randomized trial of patients at high risk of both cardio\\xadvascular and GI adverse events who required concomitant low-dose aspirin and an NSAID, celecoxib plus a PPI was found to be superior to naproxen plus a PPI in reducing the risk of recurrent ulcer bleeding.103, 108\\u200aAssessing Risk and Choice of Agent(s)Safe prescription of NSAIDs should be based on assessment of an individual patient’s GI and cardiovascular risks. In patients with low cardiovascular risk, the therapeutic approach can be stratified according to their levels of GI risk as follows (Table 53.2):\\u2003 \\u2003 • Low ulcer risk: no risk factors. Patients without risk factors (see Table 53.1) are at very low risk of ulcer complications with NSAID use (≈1% per year). Rational use of NSAIDs, including avoidance of high doses of NSAIDs and use of a less ulcerogenic NSAID (e.g., ibuprofen, diclofenac) at the lowest effective dose is a cost-effective approach. • Moderate ulcer risk: 1 or 2 risk factors. These patients should receive combination therapy with an antiulcer agent (a PPI or misoprostol) and an NSAID. Alternatively, substitution with celecoxib alone is as effective as the combination therapy men\\xadtioned earlier.\\u2003 \\u2003High ulcer risk: 3 or more risk factors, history of ulcer compli\\xadcations, or concomitant use of low-dose aspirin, glucocorticoids, or anticoagulant therapy. In general, NSAIDs should be avoided in these patients, not only because of the high risk of ulcer com\\xadplications but also owing to the serious consequences of ulcer complications in the presence of comorbidities. Glucocorticoid',\n",
       " 'in these patients, not only because of the high risk of ulcer com\\xadplications but also owing to the serious consequences of ulcer complications in the presence of comorbidities. Glucocorticoid therapy (without NSAID) can be considered if short-term anti-inflammatory therapy is required for acute, self-limiting arthritis (e.g., gout), because glucocorticoids alone do not increase the risk of ulcer. If regular anti-inflammatory therapy is required for chronic arthritis, the combination of celecoxib and a PPI offers the best GI protection.Defining patients with high cardiovascular risk remains arbi\\xadtrary. The American Heart Association recommends that aspirin should be considered in all apparently healthy men and women whose 10-year risk for a cardiovascular event is 10% or above.104 We consider patients with arthritis to have significant cardiovas\\xadcular risk if they are already on aspirin for secondary prophylaxis or if they require aspirin for primary prophylaxis according to TABLE 53.2\\u2002 Recommendations for Reducing the Risk of NSAID Ulcers as a Function of GI and Cardiovascular RiskGI Risk*LowModerateHighLow CV riskNSAID at the lowest effective doseNSAID plus a PPI, or celecoxib aloneCelecoxib plus a PPIHigh CV risk†Naproxen or celecoxib, plus a PPINaproxen or celecoxib, plus a PPICelecoxib plus a PPI if simple analgesics failed\\u2003 \\u2003*Low GI risk denotes no risk factors (see Table 53.1); moderate GI risk denotes 1 or 2 risk factors; high GI risk denotes ≥3 risk factors, prior complicated ulcer, or concomitant use of low-dose aspirin or anticoagulants. All patients with a history of ulcer who require NSAIDs should be tested for Hp, and if infection is present, eradication therapy should be given (see Chapter 52).†High CV risk denotes the requirement for prophylactic low-dose aspirin for primary or secondary prevention of serious CV events.CV, cardiovascular.',\n",
       " '†High CV risk denotes the requirement for prophylactic low-dose aspirin for primary or secondary prevention of serious CV events.CV, cardiovascular.\\u2003 \\u2003',\n",
       " 'CHAPTER 53\\u2003 Peptic Ulcer Disease81553the American Heart Association guidelines. Because the potential cardiovascular hazards of COX-2 inhibitors and most nonselec\\xadtive NSAIDs, patients with high cardiovascular risk should avoid using these drugs, if possible. Ibuprofen can attenuate the cardio\\xadprotective effect of aspirin, possibly through competitive bind\\xading to platelet COX-1, and concomitant use of ibuprofen and low-dose aspirin, therefore, should be avoided. If an NSAID is deemed necessary in patients at high cardiovascular risk, current evidence suggests that either celecoxib at moderate dose (200 mg/day) or naproxen can be considered. One major drawback of con\\xadcomitant use of NSAIDs such as naproxen and low-dose aspirin is that the combination will markedly increase the risk of ulcer complications; thus, combination of celecoxib and low-dose aspi\\xadrin may be the best available option for patients with high GI and high cardiovascular risk who require NSAIDs for long term.Because Hp infection increases the risk of ulcer complications in NSAID users, patients with a history of PUD who require NSAIDs for long term should be tested for Hp and, if present, the infection should be eradicated.\\u200aCOMPLICATIONS AND THEIR TREATMENTBleedingAcute UGI bleeding, the most common complication of PUD, is discussed in detail in Chapter 20. PUD remains the leading cause of acute UGI bleeding.105 Consensus groups have recommended a multidisciplinary approach to the care of patients presenting with UGI bleeding.106 Patients with acute UGI bleeding should be assessed promptly on presentation. Volume resuscitation should take priority and precede endoscopy. Features of liver disease should call attention to the possibility of bleeding from esophago-gastric varices rather than an ulcer. This distinction has prognostic as well as management implications. Variceal hemorrhage carries a higher death rate than ulcer bleeding. The possibility of variceal',\n",
       " 'as well as management implications. Variceal hemorrhage carries a higher death rate than ulcer bleeding. The possibility of variceal hemorrhage calls for specific measures prior to endoscopy, such as the use of vasoactive drugs (e.g., octreotide) and antibiotics (e.g., cefotaxime) as prophylaxis against infective complications such as spontaneous bacterial peritonitis (see Chapters 92 and 93).Endoscopic TherapyEarly endoscopy is generally defined as EGD performed within 24 hours of the patient’s admission. In patients with signs of active UGI bleeding, urgent endoscopy establishes a diagnosis and offers a possible intervention. RCTs demonstrated that early endoscopy in patients at low risk for rebleeding allowed early hospital discharge, reduced resource utilization, and facilitated management as outpatients.107-109 Meta-analysis of 18 clinical tri\\xadals that compared endoscopic therapy to pharmacotherapy alone showed that endoscopic therapy was superior with regard to the rates of further bleeding (odds ratio [OR] 0.35; 95% CI, 0.27 to 0.46), surgery (OR 0.57; 95% CI, 0.41 to 0.81), and, importantly, mortality (OR 0.57; 95% CI, 0.37 to 0.89).110An International Consensus group104 recommended the use of a prognostic score to guide patient management. The Rock\\xadall scoring system is a composite score using pre- and posten\\xaddoscopy clinical parameters to predict mortality. The score was derived from data gathered from the first National UK Audit.109 The Glasgow Blatchford score (GBS), on the other hand, uses only clinical parameters to predict the need for intervention and is calculated from patient’s Hgb level and blood urea concentra\\xadtion, pulse and systolic blood pressure on admission, the presence or absence of melena or syncope, as well as evidence of cardiac or hepatic failure.110 The GBS has been the most widely validated score and correlates with clinical outcomes.In a multicentre prospective study111 of 3012 patients,',\n",
       " 'hepatic failure.110 The GBS has been the most widely validated score and correlates with clinical outcomes.In a multicentre prospective study111 of 3012 patients, the GBS score was the best of the 4 at predicting the need for intervention or death with an area under the receiver operat\\xading curve (AUROC) of 0.86. A GBS score of 1 appears to be the threshold for outpatient management. The GBS score, however, does not define a cutoff value above which urgent endoscopy becomes mandatory. A significant proportion of patients at low-to-median scores require endoscopic treatment.At the time of EGD, endoscopic stigmata of bleeding in a ulcer not only pinpoint PUD as the source of bleeding but are themselves prognostic for patient outcomes (see Chapter 20). The commonly used nomenclature is a version modified from Forrest and Finlayson’s112 original description. Laine and Jen\\xadsen113 summarized rates of further bleeding, surgery, and mor\\xadtality associated with stigmata of bleeding in prospective trials without endoscopic therapy.\\u2003 \\u2003 • Type I: Active bleeding:Ia: Spurting hemorrhage (Fig. 53.4)Ib: Oozing hemorrhage (see Fig. 53.4) • Type II: Stigmata of recent hemorrhage:IIa: Nonbleeding visible vessel (see Fig. 53.4)IIb: Adherent clot (see Fig. 53.4)IIc: Flat pigmentation (see Fig. 53.4) • Type III: Clean-base ulcers\\u2003 \\u2003Actively bleeding ulcers and ulcers with nonbleeding visible vessels (“protuberant discoloration” or a “sentinel clot”) warrant endoscopic therapy (see Chapter 20).Endoscopic therapy of ulcers with “adherent clots” had been controversial. The definition of adherent clot varies with the vigor in endoscopic washing. Two randomized controlled stud\\xadies114,115 and a meta-analysis116 compared medical therapy to endoscopic treatment in ulcer patients with “adherent clots” and concluded that clot removal followed by endoscopic treatment of the vessel underneath lowers the risk of recurrent bleeding from 30% to 5%.',\n",
       " 'concluded that clot removal followed by endoscopic treatment of the vessel underneath lowers the risk of recurrent bleeding from 30% to 5%.The term sentinel clot, is often used synonymously with visible vessel.117 It represents a fibrin clot, which plugs the rent in an eroded artery. As the ulcer begins to heal, the clot resolves leav\\xading a flat pigmentation to the ulcer base, which eventually disap\\xadpears from the ulcer floor. This evolution of a bleeding vessel usually takes less than 72 hours. Ulcers with a flat pigmentation or a clean base do not warrant endoscopic therapy.Recently, a group from UCLA reported their experience with the use of an endoscopic Doppler probe to interrogate the ulcer base. In a prospective cohort of 163 patients with bleeding ulcers and varying endoscopic stigmata or recent hemorrhage, Doppler signals were found in ulcers with minor stigmata (adherent clots, 68.4%, and flat pigmentations, 40.5%).118 In a subsequent RCT of 148 patients with bleed\\xading peptic ulcers, Jensen and associates119 compared Doppler endoscopic probe–guided hemostasis to standard endoscopic hemostasis. The 30 day re-bleeding rate was lower with the use of a Doppler probe to guide the treatment endpoint (11.1% vs. 26.3%, P =.02).Endoscopic therapeutic modalities are discussed in more detail in Chapter 20, and the methods used are discussed briefly here.\\u200aInjection MethodsEndoscopic injection of diluted epinephrine into a bleeding pep\\xadtic ulcer works by volume tamponade and local vasoconstriction. The technique is easy to learn and is not damaging to tissues. Diluted epinephrine, however, does not induce vessel thrombo\\xadsis. Recurrent bleeding after injection with diluted epinephrine alone occurs in 20% to 30% of patients. Injection with diluted epinephrine allows a clear view of the bleeding vessel and should then be combined with application of either thermal-coagulation or clips. In a meta-analysis,120 addition of a second modality after',\n",
       " 'epinephrine allows a clear view of the bleeding vessel and should then be combined with application of either thermal-coagulation or clips. In a meta-analysis,120 addition of a second modality after epinephrine injection significantly reduced the rate of recurrent ',\n",
       " 'PART VI\\u2003 Stomach and Duodenum816bleeding (RR 0.57, 0.43 to 0.76), emergency surgery (RR 0.68, 0.5 to 0.93), and mortality (RR 0.64, 0.39 to 1.06). Improved outcomes seem to be more evident in ulcers with active bleeding (Forrest type I ulcers). Injection with diluted epinephrine alone should no longer be considered an adequate treatment. A second treatment to induce arterial thrombosis should be added.\\u200aThermal MethodsThermal methods include contact and noncontact methods. Contact thermal methods are more often used. Commonly used contact thermal probes are the heater probe and bipolar probes. The term coaptive thermal-coagulation emphasizes the need for firm mechanical compression of the vessel. Cessation of blood flow by compression reduces the “heat-sink” effect when heat energy is generated, welding the arterial lumen. The main noncontact method is argon plasma coagulation (see Chapter 20).\\u200aMechanical MethodsThe mechanical method of hemoclipping is widely used. Tangential applications of clips in treating bleeding posterior duodenal bulbar or lesser curvature ulcers with the endoscope in a retroflexed position can be technically difficult. In meta-analy\\xadses comparing endoscopic treatment modalities, hemoclips was superior to injection alone in rate of hemostasis and comparable to thermal coagulation.108,121Recently, a multicenter RCT compared the use of over-the-scope-clips (OTSC) to standard through-the-scope clips and thermal methods in 66 patients with refractory bleeding ulcers.122 The use of OTSC was associated with a reduced rate of further bleeding (15.2% vs. 57.6%). OTSC are made of shape memory nitinol of up to 13 mm in diameter capable of strong tissue com\\xadpression over a wider area. The current standard is the use of either through-the-scope hemo-clips or thermal-coagulation with or without pre-injection of epinephrine. OTSC appears to be a useful rescue when other modalities fail.\\u200aAntisecretory Therapy',\n",
       " 'either through-the-scope hemo-clips or thermal-coagulation with or without pre-injection of epinephrine. OTSC appears to be a useful rescue when other modalities fail.\\u200aAntisecretory TherapyThe rationale for antisecretory therapy in bleeding PUD is based on the fact that both pepsin activity and platelet aggregation are pH dependent. An ulcer stops bleeding when a fibrin or plate\\xadlet plug blocks the rent in a bleeding artery. When gastric pH exceeds 4, pepsin is inactivated, preventing enzymatic digestion of blood clots. A gastric pH of 6 or greater is critical for clot stability and hemostasis. Labenz and associates123 studied gastric pH in patients with GU or DU who were receiving either a high dose of omeprazole (IV bolus 80 mg, followed by 8 mg/hr) or a high dose of ranitidine (IV bolus 50 mg, followed by 0.25 mg/kg/hr). The gastric pH exceeded 6 with omeprazole 99.9% of the time, but less than 50% of the time in patients receiving ranitidine (46% of the time in GU patients and 20% of the time in DU patients). The PUB study was an international multicenter study that enrolled 764 patients with ulcer bleeding. It evaluated use of high-dose esomeprazole after endoscopic hemostasis in bleeding peptic ulcers. The PPI reduced the rate of recurrent bleeding over 30 days from 11.6% to 6.4%. In addition, fewer patients given the PPI needed further endoscopic therapy, blood transfusion, and surgery.124A Cochrane Systematic Review of randomized trials that compared PPI use to placebo or a H2RA concluded that the use of PPI therapy significantly reduces rates of recurrent bleeding and surgery but not overall mortality.125 In a subgroup analysis among patients with active bleeding or with a nonbleeding visible vessel, a significant reduction in mortality was observed with use of PPI (OR 0.53; 95% CI, 0.31 to 0.91).Spurting (Ia)A visible vessel IIaFlat pigmentation IIcOozing (Ib)An adherent clot (IIb)Clean base (III)',\n",
       " 'of PPI (OR 0.53; 95% CI, 0.31 to 0.91).Spurting (Ia)A visible vessel IIaFlat pigmentation IIcOozing (Ib)An adherent clot (IIb)Clean base (III)Fig. 53.4\\u2002 Endoscopic appearances of bleeding peptic ulcers using the Forrest classification.139',\n",
       " 'CHAPTER 53\\u2003 Peptic Ulcer Disease81753The optimal PPI dose to use and the routine of PPI admin\\xadistration continue to be controversial. A meta-analysis of RCTs that compared low- to high-dose PPI use after endoscopic hemo\\xadstasis consisted of trials that included bleeding ulcers with minor stigmata of bleeding and clean-based ulcers.126 The majority of studies were underpowered to declare equivalence between low- and high-dose PPI. An international consensus group has contin\\xadued to endorse the use of a high-dose PPI, especially in high-risk patients.104Pre-emptive use of an IV PPI infusion prior to endoscopy was studied in a large-scale randomized study.127 Patients with overt signs of UGI bleeding were randomized to receive either a high-dose PPI infusion or placebo. Most (60%) of the patients in this cohort were found at EGD to be bleeding from a peptic ulcer. The study demonstrated that early PPI infusion down-staged endoscopic bleeding stigmata in patients with peptic ulcers and thereby reduced the need for endoscopic therapy; thus, there were fewer ulcers with active bleeding or with major stigmata of recent hemorrhage observed during the following morning’s EGD in the PPI group. PPI infusion starts ulcer healing, and significantly more clean-based ulcers are seen the next day. The study has cost-saving implications, with less endoscopic therapy required with the preemptive use of an IV PPI. In patients await\\xading endoscopy, it is reasonable to start PPI therapy.\\u200aSurgical TherapyEffective endoscopic intervention and improved pharmacother\\xadapy have greatly reduced the need for emergency ulcer surgery. In the USA, the incidence of surgery to control ulcer bleeding has continued to decline (from 13.1% in 1993 to 9.7% in 2006), while there was an increase in the use of endoscopic treatment (12.9% to 22.2%).128 In an UK National Audit in 2006, only 2.3% of 4478 patients who presented with UGI bleeding required sur\\xad',\n",
       " 'while there was an increase in the use of endoscopic treatment (12.9% to 22.2%).128 In an UK National Audit in 2006, only 2.3% of 4478 patients who presented with UGI bleeding required sur\\xadgery. Mortality after surgery was 29%.129 Surgery is indicated in patients with bleeding not controlled during endoscopy or with further bleeding refractory to endoscopic therapy. Independent predictors to recurrent bleeding after endoscopic hemostatic ther\\xadapy include hemodynamic instability, comorbid illnesses, active bleeding at endoscopy, large ulcer size, posterior DU, or lesser curvature ulcer.130 Often, an attempt at further endoscopic control is indicated. A RCT that compared endoscopic re-treatment to surgery suggested that the former can secure bleeding in 75% of cases and is associated with less procedure-related morbidities.131The type of emergency operation to be performed for ulcer bleeding is controversial. Some surgeons maintain that oversew\\xading of ulcers alone, combined with acid-suppression therapy, is safer than “definitive” surgery using either gastrectomy or vagot\\xadomy. Hp eradication and PPIs have provided incentives for sur\\xadgeons to perform the minimum operation.Two RCTs that compared minimal with definitive surgery were published before the era of endoscopic hemostasis and PPI infusion.132,133 A UK multicenter study compared minimal sur\\xadgery (oversewing the vessel or ulcer excision alone plus IV H2RA therapy) with a definitive ulcer operation (vagotomy and pylo\\xadroplasty or partial gastrectomy) in patients with bleeding GUs or DUs. The trial was aborted because of the high rate of fatal recurrent bleeding in those assigned to minimal surgery (7 in 62 patients, with 6 deaths). Of the 67 patients who received defini\\xadtive ulcer surgery, 4 re-bled and none died.132 In a trial conducted by the French Association of Surgical Research, patients with DU were randomized to receive oversewing plus vagotomy and',\n",
       " 'tive ulcer surgery, 4 re-bled and none died.132 In a trial conducted by the French Association of Surgical Research, patients with DU were randomized to receive oversewing plus vagotomy and drainage or partial gastrectomy.133 After oversewing and vagot\\xadomy, recurrent bleeding occurred in 10 of 60 patients (17%); conversion to a Billroth II gastrectomy was required in 6 of the 10 patients with recurrent bleeding. In the group of 60 patients assigned to undergo partial gastrectomy, only 2 (3%) had re-bleeding, and both recovered with conservative treatment. With an intention-to-treat analysis, no differences in overall mortality rates or duodenal leak rates were seen. These 2 RCTs suggest that simple oversewing with or without vagotomy is associated with a higher rate of recurrent bleeding. Exclusion of an ulcer or, in the case of GUs, ulcer excision is important in preventing recurrent bleeding. In a review of data from the American Col\\xadlege Surgeons National Surgical Quality Improvement Program, 30 day mortality was higher in patients who underwent a simple oversewing or ulcer excision (106/498, 21.3%) when compared to that after vagotomy with resection or drainage (39/283, 13.8%). There was obvious bias in this retrospective analysis.134\\u200aAngiographic TherapyAngiographic embolization of bleeding arteries is a nonoperative alternative to surgery in patients with bleeding peptic ulcer. In a pooled analysis of 6 retrospective studies comparing angiography and surgery, a higher re-bleeding rate was observed after angio\\xadgraphic treatment (51/178, or 29% vs. 36/241, or 15%; RR 1.82; 95% CI, 1.20 to 2.67).135 Mortality was not significantly different (17% vs. 23%). When radiology skills are available, angiography is often attempted before surgery. A recent RCT that compared added embolization to standard treatment after endoscopic hemo\\xadstasis did not confirm a mortality benefit of prophylactic emboliza\\xad',\n",
       " 'is often attempted before surgery. A recent RCT that compared added embolization to standard treatment after endoscopic hemo\\xadstasis did not confirm a mortality benefit of prophylactic emboliza\\xadtion.136 In a per protocol analysis, rate of further bleeding was lower after added embolization (6/96, or 6.2% vs. 14/123, or 11.4%). In a subgroup analysis of ulcers of 15 mm or more in size, embolization reduced bleeding from 23.1% to 4.5%. The authors suggested that for larger ulcers with significant bleeding, angiographic emboliza\\xadtion should be considered after endoscopic hemostasis.\\u200aPerforationPerforation of a GU or DU (Fig. 53.5) is a surgical emergency that may be the initial manifestation of PUD, especially in patients using NSAIDs. Ulcer perforation is associated with a mortality approaching 30%. Older adults with significant comor\\xadbid illnesses and a delay in performing surgery have the worst prognosis. The clinical presentation is one of peritonitis but clinical signs can be obscured in older and immunocompromised patients (see Chapter 39).Medical TherapyIt has been suggested that a standardized peri-operative man\\xadagement protocol can improve outcomes. In a Danish multi\\xadcenter study (n = 2619),137 the PULP trial group showed that with aggressive and specific treatment of sepsis and, importantly, Fig. 53.5\\u2002 Laparoscopic view of a perforated DU (arrow) with fibrinous exudate on the adjacent peritoneum.',\n",
       " 'PART VI\\u2003 Stomach and Duodenum818surgery within 6 hours, mortality was 17% in 117 hospitals with strict management protocols and was 27% in 512 hospitals without protocols. Other measures include goal-directed fluid therapy, general respiratory and circulatory support, intravenous broad-spectrum antibiotics, and insertion of a double-barreled NG tube, and a urinary catheter. An intravenous PPI is given routinely after surgery.Nonoperative management of ulcer perforation should sel\\xaddom be practiced. It involves NG suctioning, parenteral antibi\\xadotics, and IV fluids. In a RCT, Crofts and associates138 assigned patients with the presumptive diagnosis of perforated peptic ulcers to either conservative treatment or prompt surgery. Over\\xadall morbidity and mortality rates (5%) were low and similar in the medical and surgical groups. Of the 40 patients assigned to con\\xadservative treatment, 11 showed no improvement within 12 hours and underwent operation. Three of these 11 patients were found to have perforated carcinomas (2 gastric and 1 sigmoid colon). Findings of the study highlight common objections to the use of non-operative management: uncertainty of the site of perforation, the possibility of a perforated GI tumor, and atrophic momentum making spontaneous sealing unlikely. Older adults tolerate sepsis poorly. Any delay in definitive treatment leads to poor outcomes.\\u200aSurgical TherapyPerforated gastroduodenal ulcer carries a high mortality rate. In a review of surgery for perforated ulcers between 2011 and 2013 in Denmark, the 90-day mortality was 25.5% among 726 patients. Re-operation was required in 124 patients (17.1%), approxi\\xadmately one third of them caused by persistent leaks.139Boey and associates140 identified preoperative shock, major medical illnesses, and perforation longer than 12 hours as impor\\xadtant adverse prognostic factors. The PULP score was recently developed from a cohort of 2668 patients who received surgery in',\n",
       " 'medical illnesses, and perforation longer than 12 hours as impor\\xadtant adverse prognostic factors. The PULP score was recently developed from a cohort of 2668 patients who received surgery in 11 hospitals across Denmark. Variables included were age greater than 65 years, active malignant disease or acquired immunodefi\\xadciency, cirrhosis, glucocorticoid use, perforation more than 24 hours, shock, raised serum creatinine level, and American Soci\\xadety of Anesthesiologists (ASA) score greater than 1. The PULP score was accurate in predicting mortality from ulcer perforation (AUROC of 0.83).141 The score, however, has not been validated in centers outside Denmark.The controversies in the operative management of perfo\\xadrated peptic ulcers have revolved around the choice between laparoscopic and open repair and the need for a definitive ulcer operation after closure of the perforation (and which definitive operation to perform). Treatment also differs for duodenal and gastric perforations. Simple closure of a perforated duodenal or a juxta-pyloric ulcer with the use of an omental patch is widely practiced.Meta-analyses of 3 RCTs (2 from Hong Kong and the Dutch LAMA Study) that compared laparoscopic to open surgical treat\\xadment of perforated peptic ulcers tends to favor laparoscopic repair with respect to rates of abdominal septic complications (OR 0.66; 95% CI, 0.3 to 1.47), and pulmonary complications (OR 0.43; 95% CI, 0.17 to 1.12)142; thus, laparoscopic repair should, at the least, be considered not inferior to open repair. There may, how\\xadever, have been selection bias in these RCTs. Poor risk patients (those with delayed presentations, shock, and with significant comorbidities) may be better suited for a laparotomy. Large per\\xadforations (>10 mm) suggest sizable ulcerations and should also be managed by laparotomy; often, gastric resections are required in such patients.GU accounts for approximately 20% of perforated peptic',\n",
       " 'forations (>10 mm) suggest sizable ulcerations and should also be managed by laparotomy; often, gastric resections are required in such patients.GU accounts for approximately 20% of perforated peptic ulcers. Epidemiologic data suggest a rising proportion of GUs among perforated ulcers, especially in older adult patients who use NSAIDs. Patients with perforated GUs are more likely to be older and to have significant comorbid illnesses, making their prognosis less favorable. As with perforated DUs, there has been a debate regarding the choice of surgery for perforated GUs. Simple closure should be offered to small perforations at the prepyloric area. The optimal treatment of an angular notch GU along the lesser curvature should entail an antrectomy and lesser curve ulcer excision, followed by either a Billroth type I or II reconstruction. The role of vagotomy is unclear. The advocates for primary resection in perforated GUs argue that mortality rates after gastrectomy are not increased and that the rate of post\\xadoperative ulcer-related complications is reduced. The arguments for primary resection also include the possibility that the ulcer is malignant. Malignancy is seen in approximately 6% of perforated GUs.143 In a retrospective series comprising 287 perforated GUs, death occurred in 21.5% of patients who underwent patch closure alone and in 24.3% of those who underwent gastric resections.144In Hp-associated ulcers, Hp eradication reduces the relapse of ulceration after patch repair. In a RCT from Hong Kong, 99 patients after patch repairs for perforated ulcers, were assigned to Hp eradication or a course of PPI. At 1 year, there were fewer relapses in those given Hp eradication (4.8% vs. 38.1%).145 A meta-analysis of 5 RCTs that compared simple closure plus Hp eradication to closure alone in patients with perforated DU showed that the pooled incidence of ulcer relapse in the year after Hp eradication was 5.2% compared to 35.2% in those without',\n",
       " 'Hp eradication to closure alone in patients with perforated DU showed that the pooled incidence of ulcer relapse in the year after Hp eradication was 5.2% compared to 35.2% in those without eradication. These data support the use of simple closure in the majority of perforated DUs.146\\u200aObstructionGastric outlet obstruction is now an infrequent complication of PUD. Its clinical manifestations—nausea and postprandial vom\\xaditing, abdominal fullness, pain, and early satiety—are discussed in Chapters 15 and 50, as is the diagnostic approach to patients presenting with possible gastric outlet obstruction. Gastric out\\xadlet obstruction should alert clinicians to possible malignancy (see Chapter 54).Medical TherapyPatients with obstructing peptic ulcers are often volume depleted. The loss of fluid, hydrogen ions, and chloride ions in the vomitus leads to hypochloremic, hypokalemic metabolic alkalosis. The patient should be volume resuscitated with normal saline fol\\xadlowed by potassium replacement once urine output is adequate. In severely malnourished patients, parenteral nutrition should be considered. Decompression of the stomach by a large-bore NG tube relieves vomiting, helps to monitor fluid loss, and allows the stomach to regain its tone. A high-volume, non–bile-stained aspi\\xadrate can help distinguish gastric outlet obstruction from a high small bowel obstruction. Use of an IV PPI reduces gastric acid output, making fluid and electrolyte management easier. PPI therapy also initiates ulcer healing, ameliorates inflammatory edema, and assists in resolving obstruction. Approximately half of patients respond to this management. Improvement is especially noticeable in patients with active ulceration and edema. Surgery is, therefore, deferred until after an adequate trial of conserva\\xadtive management. Other factors that may influence the decision to proceed to surgery are chronicity, a history of previous ulcer',\n",
       " 'is, therefore, deferred until after an adequate trial of conserva\\xadtive management. Other factors that may influence the decision to proceed to surgery are chronicity, a history of previous ulcer complication, and the patient’s age and general medical condi\\xadtion. Furthermore, many authorities argue for initial endoscopic dilation before surgery.\\u200aEndoscopic TherapyEndoscopic balloon dilation has been used successfully in patients with gastric outlet obstruction from PUD (Fig. 53.6).147-149 During endoscopic examination, the stenosis is traversed by means of a biliary-type guidewire with a flexible tip. A low-compliance ',\n",
       " 'CHAPTER 53\\u2003 Peptic Ulcer Disease81953through-the-scope balloon is then passed over the guidewire, and dilation can be seen through the endoscope. The use of a balloon is preferred because its inflation produces a uniform radial force, which has a theoretical advantage over the longitudinal shearing force associated with the use of conventional dilators. The pro\\xadcedure is typically performed with fluoroscopic guidance. A regi\\xadmen of gradual dilation over 2 or 3 sessions seems sensible. The targeted diameter is unclear; many authorities recommend dila\\xadtion to 15 mm, which is often associated with relief of symptoms. The presence of gastric atony also contributes to symptoms. The risk of perforation increases with the size of balloon. Endoscopic series reported immediate relief of obstruction in 78% to 100% of cases. In a small series of Hp-infected patients, balloon dilation followed by Hp eradication led to sustained symptom relief.150\\u200aSurgical TherapyA variety of operations have been described for obstructing DUs, pyloric channel ulcers, and pre-pyloric ulcers. They include vagotomy with either a drainage procedure (gastrojejunostomy or pyloroplasty) or an antrectomy. In the unusual event of an obstructing prepyloric GU, an antrectomy followed by a Billroth type I gastroduodenostomy is the procedure of choice.\\u200aSTRESS ULCERSStress-related gastric and duodenal mucosal injury (stress ulcers) is an illness of the critically ill who are typically cared for in an ICU. The etiology of stress ulceration is probably related to mucosal ischemia and splanchnic hypo-perfusion from shock or low cardiac output. Fortunately, only a small proportion of patients with stress-related mucosal lesions have clinically overt GI bleeding. In a cohort study151 of 2252 ICU patients, only 1.5% developed clinically important bleeding. Respiratory failure (OR 15.6) and coagulopathy (OR 4.3) were independent predictive factors for bleeding stress ulcers. In',\n",
       " 'patients, only 1.5% developed clinically important bleeding. Respiratory failure (OR 15.6) and coagulopathy (OR 4.3) were independent predictive factors for bleeding stress ulcers. In 2015, a prospective study152 of 1034 patients admitted to ICUs was published; clinically important GI bleeding occurred in 2.6% of patients. Those with 3 or more comorbid illnesses, liver disease, receiving renal replacement therapy, and with a high organ failure score were at risk. Patients in the ICU with traumatic brain injuries and burns also belong to a high-risk group of developing GI bleeding. Across different studies, there appears to be different candidate predictors for bleeding. The use of enteral nutrients buffers acid and protects against bleeding.PPI, H2RA and sucralfate are drugs used for stress ulcer prophylaxis. In a network meta-analysis of 57 RCTs (n = 7293), Alhazzani and associates153 showed that PPIs were more effec\\xadtive for preventing clinically important bleeding than H2RA (OR 0.38), sucralfate (OR 0.30), or placebo (OR 0.24). PPIs, how\\xadever, increased the risk of nosocomial pneumonia compared with H2RA (OR 1.27), sucralfate (OR 1.65), and placebo (OR 1.52). There is concern that acid suppression predisposes patients to nosocomial infection probably linked to gut dysbiosis.154 A Euro\\xadpean multicenter study randomized 3298 ICU patients to receive 40 mg of intravenous PPI or placebo and found that deaths by 90 days were similar between groups (31.1% vs. 30.4%). The rate of composite adverse events (gastrointestinal bleeding, Clostrid\\xadium difficile infection, pneumonia, or myocardial ischemia) were comparable (21.9 vs. 22.6%). There were fewer clinically impor\\xadtant bleeding events in the PPI group (2.5 vs. 4.2%).155Full references for this chapter can be found onwww.expertconsult.com.Fig. 53.6\\u2002 A through-the-scope dila\\xadtion of an obstructed pylorus caused by an ulcer. The procedure was per\\xadformed under fluoroscopic guidance.',\n",
       " 'Fig. 53.6\\u2002 A through-the-scope dila\\xadtion of an obstructed pylorus caused by an ulcer. The procedure was per\\xadformed under fluoroscopic guidance. A dual-channel endoscope with a 3.7 mm therapeutic channel was used. A, The stricture was first traversed with a biliary-type guidewire (arrow\\xadhead). A through-the-scope balloon was passed over the guidewire across the stricture. B, A waist, representing the stricture (arrow), was observed and was nearly abolished on balloon inflation (C).ABC',\n",
       " '819.e1REFERENCES 1. Black J, Duncan W, Durant D. Definition and antagonism of hista\\xadmine H2 receptors. Nature 1972;236:365–90. 2. Marshall B, Warren J. Unidentified curved bacilli in the stomachs of patients with gastritis and peptic ulcer. Lancet 1984;1:1311–5. 3. Sonnenberg A. Causes underlying the birth-cohort phenomenon of peptic ulcer: analysis of mortality data 1911-2000, England and Wales. Int J Epidemiol 2006;35:1090–7. 4. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009;29:938–46. 5. Li Z, Zou D, Ma X, et\\xa0al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol 2010;105:2570–7. 6. Lau JY, Sung J, Hill C, et\\xa0al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk fac\\xadtors and mortality. Digestion 2011;84:102–13. 7. Laine L, Yang H, Chang SC, et\\xa0al. Trends for incidence of hospital\\xadization and death due to GI complications in the United States from 2001-2009. Am J Gastroenterol 2012;107:1190–5. 8. Wu CY, Wu CH, Wu MS, et\\xa0al. A nationwide population-based cohort study shows reduced hospitalization for peptic ulcer disease associated with H. pylori eradication and proton pump inhibitor use. Clin Gastroenterol Hepatol 2009;7:427–31. 9. Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin N Am 2011;21:613–35. 10. Feinstein LB, Holman RC, Yorita Christensen KL, et\\xa0al. Trends in hospitalizations for peptic ulcer disease, United States, 1998-2005. Emerg Infect Dis 2010;16:1410–8. 11. Sanchez-Delgado J, Gene E, Suarez D, et\\xa0al. Has H pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol 2011;106:398–405.',\n",
       " '11. Sanchez-Delgado J, Gene E, Suarez D, et\\xa0al. Has H pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol 2011;106:398–405. 12. Olbe L, Hamlet A, Dalenback J, et\\xa0al. A mechanism by which Helico\\xadbacter pylori infection of the antrum contributes to the development of duodenal ulcer. Gastroenterology 1996;110:1386–94. 13. El-Omar EM. Mechanisms of increased acid secretion after eradica\\xadtion of Helicobacter pylori infection. Gut 2006;55:144–6. 14. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gas\\xadtrointestinal complications among users of acetaminophen and non\\xadsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570–6. 15. Wilcox C, Allison J, Benzuly K, et\\xa0al. Consensus development con\\xadference on the use of nonsteroidal anti-inflammatory agents, includ\\xading cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroen\\xadterol Hepatol 2006;4:1082–9. 16. Sørensen HT, Mellemkjaer L, Blot WJ, et\\xa0al. Risk of upper gas\\xadtrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000;95:2218–24. 17. Lanas A, Perez-Aisa MA, Feu F, et\\xa0al. A nationwide study of mortal\\xadity associated with hospital admission due to severe gastrointesti\\xadnal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005;100:1685–93. 18. Bjarnason I, Scarpignato C, Holmgren E, et\\xa0al. Mechanisms of dam\\xadage to the gastrointestinal tract from nonsteroidal anti-inflammato\\xadry drugs. Gastroenterology 2018;154:500–14. 19. Fiorucci S, Distrutti E, Santucci L. NSAIDs, Coxinbs CINOD and H2S-releasing NSAIDs: what lies beyond the horizon? Dig Liver Dis 2007;39:1043–51. 20. Green Jr FW, Kaplan MM, Curtis LE, et\\xa0al. Effect of acid and pep\\xadsin on blood coagulation and platelet aggregation. A possible con\\xadtributor prolonged gastroduodenal mucosal hemorrhage. Gastroen\\xadterology 1978;74:38–43.',\n",
       " 'sin on blood coagulation and platelet aggregation. A possible con\\xadtributor prolonged gastroduodenal mucosal hemorrhage. Gastroen\\xadterology 1978;74:38–43. 21. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14–22. 22. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411–8. 23. Chan FK, Sung JY, Chung SC, et\\xa0al. Randomised trial of eradication of Helicobacter pylori before starting non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975–9. 24. Chan FK, To KF, Wu JC, et\\xa0al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9–13. 25. Leontiadis GI, Sreedharan A, Dorward S, et\\xa0al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007;11:1–164. 26. Chan FK, Chung SC, Suen BY, et\\xa0al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infec\\xadtion who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967–73. 27. Hawkey CJ, Tulassay Z, Szczepanski L, et\\xa0 al. Randomised con\\xadtrolled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs. HELP NSAIDs study. Lancet 1998;352:1016–21. 28. Chan FK, Ching JY, Suen BY, et\\xa0al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose as\\xadpirin users. Gastroenterology 2013;144:528–35. 29. Pecha RE, Prindiville T, Pecha BS, et\\xa0al. Association of cocaine and methamphetamine use with giant gastroduodenal ulcers. Am J Gas\\xadtroenterol 1996;91:2523–7.',\n",
       " '29. Pecha RE, Prindiville T, Pecha BS, et\\xa0al. Association of cocaine and methamphetamine use with giant gastroduodenal ulcers. Am J Gas\\xadtroenterol 1996;91:2523–7. 30. Lanza FL, Hunt RH, Thomson AB, et\\xa0al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendro\\xadnate in postmenopausal women. Gastroenterology 2000;119:631–8. 31. Conn H, Blitzer B. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976;294:473–9. 32. Piper J, Ray W, Daugherty J, Griffin M. Corticosteroid use and peptic ulcer disease: role of non-steroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735–40. 33. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neo\\xadplasia type I and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004;83:43–83. 34. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000;14:579–623. 35. Wong GL, Wong VW, Chan Y, et\\xa0al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009;137:525–31. 36. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of in\\xadhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on hu\\xadman cytochrome P450 activities. Drug Metab Dispos 2004;32:821–7. 37. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and pro\\xadton pump inhibitors. Basic Clin Pharmacol Toxicol 2004;95:2–8. 38. Majumdar SR, Soumerai SB, Farraye FA, et\\xa0al. Chronic acid-related disorders are common and underinvestigated. Am J Gastroenterol 2003;98:2409–14. 39. Gisbert JP, Calvet X. Helicobacter pylori “test-and-treat” strategy for management of dyspepsia: a comprehensive review. Clin Transl Gastroenterol 2013;4:e32.',\n",
       " '2003;98:2409–14. 39. Gisbert JP, Calvet X. Helicobacter pylori “test-and-treat” strategy for management of dyspepsia: a comprehensive review. Clin Transl Gastroenterol 2013;4:e32. 40. Ford AC, Qume M, Moayyedi P, et\\xa0al. Helicobacter pylori test and treat or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005;128:1838–44. 41. Moayyedi PM, Lacy BE, Andrews CN, et\\xa0 al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol 2017;112:988–1013. 42. Malfertheiner P, Megraud F, O’Morain CA, et\\xa0al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus re\\xadport. European Helicobacter and Microbiota study group and con\\xadsensus panel. Gut 2017;66:6–30. 43. Canga 3rd C, Vakil N. Upper GI malignancy, uncomplicated dys\\xadpepsia, and the age threshold for early endoscopy. Am J Gastroen\\xadterol 2002;97:600–3. 44. Feldman M, Burton ME. Histamine2-receptor antagonists: standard therapy for acid-peptic diseases. N Engl J Med 1990;323:1672–80. 45. Patel N, Ward U, Rogers MJ, Primrose JN. Night-time or morning dosing with H2-receptor antagonists: studies on acid inhibition in normal subjects. Aliment Pharmacol Ther 1992;6:381–7. 46. Michaletz-Onody PA. Peptic ulcer disease in pregnancy. Gastroen\\xadterol Clin North Am 1992;21:817–26. 47. Cantu TG, Korek JS. Central nervous system reactions to hista\\xadmine2-receptor blockers. Ann Intern Med 1991;114:1027–34. 48. Wilder-Smith CH, Ernst T, Genonni M, et\\xa0al. Tolerance to oral H2-receptor antagonists. Dig Dis Sci 1990;8:976–83.',\n",
       " 'References819.e2 49. Richter JM, Colditz GA, Huse DM, et\\xa0al. Cimetidine and adverse reactions: a meta-analysis of randomized clinical trials of short-term therapy. Am J Med 1989;87:278–84. 50. Garcia Rodriguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other anti-ulcer drugs. BMJ 1994;308:503–6. 51. Hansten PD. Drug interactions with anti-secretory agents. Aliment Pharmacol Ther 1991;5:121–8. 52. Robinson M, Horn J. Clinical pharmacology of proton pump in\\xadhibitors: what the practising physician needs to know. Drugs 2003;63:2739–54. 53. Zhang L, Mei Q, Li QS, et\\xa0al. The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. J Clin Pharm Ther 2010;35:713–22. 54. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000;118:S9–31. 55. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 2012;72:437–45. 56. Lew EA. Pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther 1999;13:11–6. 57. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump in\\xadhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010;31:810–23. 58. Focks JJ, Brouwer MA, van Oijen MG, et\\xa0al. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome—a systematic review. Heart 2013;99:520–7. 59. Bhatt DL, Cryer BL, Contant CF, et\\xa0 al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909–17. 60. O’Donoghue ML, Braunwald E, Antman EM, et\\xa0al. Pharmacody\\xadnamic effect and clinical efficacy of clopidogrel and prasugrel with',\n",
       " '2010;363:1909–17. 60. O’Donoghue ML, Braunwald E, Antman EM, et\\xa0al. Pharmacody\\xadnamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989–97. 61. Targownik L. Discontinuing long-term PPI therapy: WHY, with whom, and how? Am J Gastroenterol 2018;113:519–28. 62. Hori Y, Imanishi A, Matsukawa J, et\\xa0 al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-compet\\xaditive acid blocker for the treatment of acid-related diseases. J Phar\\xadmacol Exp Ther 2010;335:231–8. 63. Sakurai Y, Mori Y, Okamoto H, et\\xa0al. Acid-inhibitory effects of vo\\xadnoprazan 20 mg compared with esomeprazole 20 mg or rabepra\\xadzole 10 mg in healthy adult male subjects—a randomised open-label cross-over study. Aliment Pharmacol Ther 2015;42:719–30. 64. Miwa H, Uedo N, Watari J, et\\xa0al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers—results from two phase 3, non-inferiority ran\\xaddomised controlled trials. Aliment Pharmacol Ther 2017;45:240–52. 65. Kawai T, Oda K, Funao N, et\\xa0al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 2018;67:1033–41. 66. Mizokami Y, Oda K, Funao N, et\\xa0al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lanso\\xadprazole-controlled non-inferiority and single-blind extension study. Gut 2018;67:1042–51. 67. McCarthy DM. Sucralfate. N Engl J Med 1991;325:1017–25. 68. Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988;36:132–57. 69. Walt RP. Misoprostol for the treatment of peptic ulcer and antiin\\xadflammatory-drug-induced gastroduodenal ulceration. N Engl J Med 1992;327:1575–80.',\n",
       " '69. Walt RP. Misoprostol for the treatment of peptic ulcer and antiin\\xadflammatory-drug-induced gastroduodenal ulceration. N Engl J Med 1992;327:1575–80. 70. Chen MC, Amirian DA, Toomey M, et\\xa0al. Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine tri\\xadphosphate-binding protein of adenylate cyclase. Gastroenterology 1988;94:1121–9. 71. Sung JJ, Chung SC, Ling TK, et\\xa0 al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995;332:139–42. 72. Ford AC, Delaney BC, Forman D, et\\xa0al. Eradication therapy in He\\xadlicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833–55. 73. Malfertheiner P, Kirchner T, Kist M, et\\xa0al. Helicobacter pylori eradi\\xadcation and gastric ulcer healing—comparison of three pantoprazole-based triple therapies. BYK Advanced Gastric Ulcer Study Group. Aliment Pharmacol Ther 2003;17:1125–35. 74. Higuchi K, Fujiwara Y, Tominaga K, et\\xa0al. Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment Pharmacol Ther 2003;17:111–7. 75. Yeomans ND, Tulassay Z, Juhasz L, et\\xa0al. A comparison of omepra\\xadzole with ranitidine for ulcers associated with non-steroidal an\\xadtiinflammatory drugs. Acid Suppression Trial: ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRO\\xadNAUT) study group. N Engl J Med 1998;338:719–26. 76. Agrawal NM, Campbell DR, Safdi MA, et\\xa0al. Superiority of lanso\\xadprazole versus ranitidine in healing nonsteroidal antiinflammatory drug-associated gastric ulcers: results of a double-blind, random\\xadized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000;160:1455–61. 77. Goldstein JL, Johanson JF, Hawkey CJ, et\\xa0al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID',\n",
       " 'Group. Arch Intern Med 2000;160:1455–61. 77. Goldstein JL, Johanson JF, Hawkey CJ, et\\xa0al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy—a randomized study comparing ranitidine with esomepra\\xadzole. Aliment Pharmacol Ther 2007;26:1101–11. 78. Roth S, Agrawal N, Mahowald M, et\\xa0al. Misoprostol heals gastrodu\\xadodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 1989;149:775–9. 79. Hawkey CJ, Karrasch JA, Szezepanski L, et\\xa0al. Omeprazole com\\xadpared with misoprostol for ulcers associated with non-steroidal an\\xadtiinflammatory drugs: omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727–34. 80. Kyaw MH, Otani K, Ching JYL, et\\xa0al. Misoprostol heals small bow\\xadel ulcers in aspirin users with small bowel bleeding. Gastroenterol\\xadogy 2018;S0016–5085(18)34698–5. 81. Taha AS, McCloskey C, McSkimming P, McConnachie A. Miso\\xadprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MAS\\xadTERS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2018;3:469–76. 82. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of nonsteroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991;32:252–5. 83. Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999;26:18–24. 84. Rostom A, Wells G, Tugwell P, et\\xa0al. Prevention of NSAID-in\\xadduced gastroduodenal ulcers (Cochrane review). Cochrane Data\\xadbase Syst Rev 2000;4:CD002296. 85. Chan FK, Kyaw M, Tanigawa T, et\\xa0al. Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of up\\xadper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology 2017;152:105–10. 86. Chan FK, Sung JJ, Ching JY, et\\xa0al. Randomized trial of low-dose',\n",
       " 'per gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology 2017;152:105–10. 86. Chan FK, Sung JJ, Ching JY, et\\xa0al. Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2001;15:19–24. 87. Graham DY, Agrawal NM, Campbell DR, et\\xa0al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002;62:169–75. 88. Regula J, Butruk E, Dekkers CP, et\\xa0al. Prevention of NSAID-as\\xadsociated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 2006;101:1747–55. 89. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et\\xa0al. Effect of antise\\xadcretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007;102:507–15. 90. Chan FK, To KF, Wu JC, et\\xa0al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. Lancet 2002;359:9–13. 91. Chan FK, Hung LC, Suen BY, et\\xa0al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104–10. 92. Rostom A, Muir K, Dube C, et\\xa0al. Gastrointestinal safety of cyclo\\xadoxygenase-2 inhibitors: a Cochrane collaboration systematic review. Clin Gastroenterol Hepatol 2007;5:818–28.',\n",
       " 'References 819.e353 93. Chan FK, Hung LC, Suen BY, et\\xa0al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a random\\xadized double-blind trial. Gastroenterology 2004;127:1038–43. 94. Chan FK, Wong VW, Suen BY, et\\xa0al. Combination of a cyclo-ox\\xadygenase-2 inhibitor and a proton pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind randomized trial. Lancet 2007;369:1621–6. 95. Bombardier C, Laine L, Reicin A, et\\xa0 al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000;343:1520–8. 96. Bresalier RS, Sandler RS, Quan H, et\\xa0al. Cardiovascular events as\\xadsociated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092–102. 97. 1SD, McMurray JJV, Pfeffer MA, et\\xa0al. For the Adenoma Preven\\xadtion with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–80. 98. Cannon CP, Curtis SP, FitzGerald GA, et\\xa0al. Cardiovascular out\\xadcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Di\\xadclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771–81. 99. McGettigan P, Henry D. Cardiovascular risk and inhibition of cy\\xadclooxygenase: a systematic review of the observational studies of se\\xadlective and nonselective inhibitors of cyclooxygenase 2. J Am Med Assoc 2006;296:1633–44.100. Nissen SE, Yeomans ND, Solomon DH, et\\xa0al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016;375(26):2519–29.101. Chan FKL, Ching JYL, Tse YK, et\\xa0al. Gastrointestinal safety of ce\\xadlecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an',\n",
       " 'lecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet 2017;389:2375–82.102. Pearson TA, Blair SN, Daniels SR, et\\xa0al. AHA scientific statement: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update, 71-0226. Circulation 2002;106:388–91.103. Hearnshaw SA, Logan RF, Lowe D, et\\xa0al. Acute upper gastroin\\xadtestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011;60:1327–35.104. Barkun A, Bardou M, Kuipers EJ, et\\xa0 al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101–13.105. Lin HJ, Wang K, Perng CL, et\\xa0al. Early or delayed endoscopy for patients with peptic ulcer bleeding: a prospective randomized con\\xadtrolled trial. J Clin Gastroenterol 1996;22:267–71.106. Lee JG, Turnipseed S, Romano PS, et\\xa0al. Endoscopy-based triage significantly reduces hospitalization rates and costs of treating up\\xadper GI bleeding: a randomized controlled trial. Gastrointest Endosc 1999;50:755–61.107. Cipolletta L, Bianco MA, Rotondano G, et\\xa0al. Outpatient manage\\xadment for low-risk nonvariceal upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 2002;55:1–5.108. Barkun A, Martel M, Toubouti Y, Rahme E, Bardou M. Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk le\\xadsions: a series of meta-analyses. Gastrointest Endosc 2009;69:786–99.109. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:316–21.110. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper gastrointestinal haemorrhage. Lancet 2000;356:1318–21.111. Stanley AJ, Laine L, Dalton HR, Ngu JH, Schultz M, Abazi R, et\\xa0al.',\n",
       " 'need for treatment for upper gastrointestinal haemorrhage. Lancet 2000;356:1318–21.111. Stanley AJ, Laine L, Dalton HR, Ngu JH, Schultz M, Abazi R, et\\xa0al. Comparison of risk scoring systems for patients presenting with up\\xadper gastrointestinal bleeding: international multicentre prospective study. BMJ 2017;356:6432.112. Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointes\\xadtinal bleeding. Lancet 1974;2:394–7.113. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012;107:345–60.114. Jensen DM, Kovacs TO, Jutabha R, et\\xa0al. Randomized trial of medi\\xadcal or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology 2002;123:407–13. 115.115. Bleau BL, Gostout CJ, Shearman KE, et\\xa0 al. Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy. Gastrointest Endosc 2002;56:1–6.116. Kahi CJ, Jensen DM, Sung JJ, et\\xa0al. Endoscopic therapy versus med\\xadical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Gastroenterology 2005;129:855–62.117. Johnston JH. The sentinel clot and invisible vessel: pathologic anat\\xadomy of bleeding peptic ulcer. Gastrointest Endosc 1984;30:313–5.118. Jensen DM, Ohning GV, Kovacs TOG, et\\xa0al. Doppler endoscopic probe as a guide to risk stratification an definitive hemostasis of pep\\xadtic ulcer bleeding. Gastrontest Endosc 2016;83:129–36.119. Jensen DM, Kovacs TOG, Ohning GV, et\\xa0al. Doppler endoscopic probe monitoring of blood flow improves risk stratification and outcomes of patients with severe nonvariceal upper gastrointestinal hemorrhage. Gastroenterology 2017;152:1310–8.120. Vergara M, Bennett C, Calvet X, Gisbert JP. Epinephrine injec\\xadtion versus epinephrine injection and a second endoscopic meth\\xadod in high risk bleeding ulcers. Cochrane Database Syst Rev 2014;(10):CD005584.',\n",
       " 'tion versus epinephrine injection and a second endoscopic meth\\xadod in high risk bleeding ulcers. Cochrane Database Syst Rev 2014;(10):CD005584.121. Sung JJ, Tsoi KK, Lai LH, et\\xa0al. Endoscopic clipping versus injec\\xadtion and thermocoagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta-analysis. Gut 2007;56:1364–73.122. Schmidt A, Golder S, Goetz M, et\\xa0 al. Over-the-scope clips are more effective than standard endoscopic therapy for patients with recurrent bleeding of peptic ulcers. Gastroenterology 2018;05:037. [Epub ahead of print].123. Labenz J, Peitz U, Leusing C, et\\xa0al. Efficacy of primed infusions with high-dose ranitidine and omeprazole to maintain high intra\\xadgastric pH in patients with peptic ulcer bleeding: a prospective ran\\xaddomised controlled study. Gut 1997;40:36–41.124. Sung JJY, Barkum A, Kuipers EJ, et\\xa0al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding. Ann Int Med 2009;150:455–64.125. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006;25:CD902094.126. Neumann I, Letelier LM, Rada G, et\\xa0al. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2013;60:CD007999.127. Lau JY, Leung WK, Wu JC, et\\xa0 al. Omeprazole before endos\\xadcopy in patients with gastrointestinal bleeding. N Engl J Med 2007;356:1631–40.128. Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hos\\xadpitalizations for peptic ulcer disease in the united states, 1993 to 2006. Ann Surg 2010;251:51–8.129. Jairath V, Kahan BC, Logan RF, et\\xa0al. National audit of the use of surgery and radiological embolization after failed endoscopic he\\xadmostasis for non-variceal upper gastrointestinal bleeding. Br J Surg 2012;99:1672–80.130. Elmunzer BJ, Young SD, Inadomi JM, et\\xa0 al. Systematic review of the predictors of recurrent hemorrhage after endoscopic he\\xad',\n",
       " '2012;99:1672–80.130. Elmunzer BJ, Young SD, Inadomi JM, et\\xa0 al. Systematic review of the predictors of recurrent hemorrhage after endoscopic he\\xadmostatic therapy for bleeding peptic ulcer. Am J Gastroenterol 2008;103:2625–32.131. Lau JY, Sung JJY, Lam YH, et\\xa0al. Endoscopic re-treatment com\\xadpared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999;340:751–6.132. Poxon VA, Keighley MRB, Dykes PW, et\\xa0al. Comparison of mini\\xadmal and conventional surgery in patients with bleeding ulcer: A mul\\xadticentre trial. Br J Surg 1991;78:1344–5.133. Millat B, Hay JM, Valleur P, et\\xa0al. Emergency surgical treatment for bleeding duodenal ulcer: oversewing plus vagotomy versus gas\\xadtric resection, a controlled randomized trial french associations for surgical research. World J Surg 1993;17:568–74.134. Schroder VT, Pappas T, Vaslef S, et\\xa0al. Vagotomy/Drainage is su\\xadperior to local oversew in patients who require emergency surgery for bleeding peptic ulcers. Ann Surg 2014;259:1111–8.',\n",
       " 'References819.e4135. Kyaw M, Tse Y, Ang D, et\\xa0al. Embolization versus surgery for pep\\xadtic ulcer bleeding after failed endoscopic hemostasis: a meta-analy\\xadsis. Endosc Int Open 2014;02:6–14.136. Lau JY, Pittayanon R, Wong KT, Pinjaroen N, Chiu PWY, Rerknimitr R, et\\xa0al. Prophylactic angiographic embolisation after endoscopic control of bleeding to high-risk peptic ulcers: a random\\xadized controlled trial. Gut 2018;0:1–8.137. Moller MH, Adamsen S, Thomsen RW, Moller AM. Peptic Ulcer Perforation (PULP) trial group Multicentre trial of a perioperative protocol to reduce mortality in patients with peptic ulcer perfora\\xadtions. Br J Surg 2011;98:802–10.138. Crofts TJ, Park KGM, Steele RJC, et\\xa0 al. A randomized trial of nonoperative treatment for perforated peptic ulcer. N Engl J Med 1989;320:970–3.139. Wilhelmsen M, Moller MH, Rosenstock S. Surgical complications after open and laparoscopic surgery for perforated peptic ulcer in a nationwide cohort. Br J Surg 2015;102:382–7.140. Boey J, Choi SKY, Alagaratnam TT, Poon A. Risk stratification in perforated duodenal ulcers: a prospective validation of predictive factors. Ann Surg 1987;205:22.141. Moller MH, Engebjerg MC, Adamsen S, et\\xa0 al. The Peptic Ul\\xadcer Perforation (PULP) score: a predictor of mortality following peptic ulcer perforation a cohort study. Acta Anaesthesiol Scand 2012;56:655–62.142. Sanabria A, Villegas MI, Morales Uribe CH. Laparoscopic repair for perforated peptic ulcer disease. Cochrane Database Syst Rev 2013;28:CD004778.143. McGee GS, Sawyers JL. Perforated gastric ulcers: a plea for man\\xadagement by primary gastric resection. Arch Surg 1987;122:555–61.144. Lanng C, Hansen CP, Christensen A, et\\xa0al. Perforated gastric ulcer. Br J Surg 1988;75:758–9.145. Ng EK, Lam YH, Sung JJ, Yung MY, et\\xa0al. Eradication of Heli\\xadcobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation randomized controlled trial. Ann Surg 2000;231:153–8.',\n",
       " 'cobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation randomized controlled trial. Ann Surg 2000;231:153–8.146. Tomtitchong P, Siribumrungwong B, Vilaichone RK, et\\xa0 al. Sys\\xadtemic review and meta-analysis: helicobacter pylori eradication ther\\xadapy after simple closure of perforated duodenal ulcer. Helicobacter 2012;17:148–52.147. Lau JY, Chung SC, Sung JY, et\\xa0al. Through-the-scope balloon di\\xadlation for pyloric stenosis: long term results. Gastrointest Endosc 1996;43:98–101.148. Griffin SM, Chung SC, Leung JW, Li AK. Peptic pyloric stenosis treated by endoscopic balloon dilatation. Br J Surg 1989;76:1147–8.149. Craig PI, Gillespie PE. Through the endoscope balloon dilatation of benign gastric outlet obstruction. BMJ 1988;297:396.150. Lam YH, Lau JY, Fung TM, et\\xa0al. Endoscopic balloon dilation for benign gastric outlet obstruction with or without Helicobacter pylori infection. Gastrointest Endosc 2004;60:229–33.151. Cook DJ, Fuller HD, Guyatt GH, et\\xa0al. Risk factors for gastrointes\\xadtinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994;330:377–81.152. Krag M, Perner A, Wetterslev J, et\\xa0al. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med 2015;41:833–45.153. Alhazzani W, Alshamsi F, Belley-Cote E, et\\xa0al. Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials. Intensive Care Med 2018;44:1–11.154. Cook D, Guyatt G. Prophylaxis against upper gastrointestinal bleeding in hospitalized patients. N Engl J Med 2018;378:2506–16.155. Krag M, Marker S, Perner A, Wetterslev J, Wise MP,Schefold JC et al. Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU. N Engl J Med 2018;379:2199–208.',\n",
       " '155. Krag M, Marker S, Perner A, Wetterslev J, Wise MP,Schefold JC et al. Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU. N Engl J Med 2018;379:2199–208.',\n",
       " \"Harrison's\\xa0Principles\\xa0of\\xa0Internal\\xa0Medicine,\\xa021e\\ue92fChapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0DisordersJohn\\xa0Del\\xa0VallePEPTIC\\xa0ULCER\\xa0DISEASEA\\xa0peptic\\xa0ulcer\\xa0is\\xa0defined\\xa0as\\xa0disruption\\xa0of\\xa0the\\xa0mucosal\\xa0integrity\\xa0of\\xa0the\\xa0stomach\\xa0and/or\\xa0duodenum\\xa0leading\\xa0to\\xa0a\\xa0local\\xa0defect\\xa0or\\xa0excavation\\xa0due\\xa0to\\xa0activeinflammation.\\xa0Although\\xa0burning\\xa0epigastric\\xa0pain\\xa0exacerbated\\xa0by\\xa0fasting\\xa0and\\xa0improved\\xa0with\\xa0meals\\xa0is\\xa0a\\xa0symptom\\xa0complex\\xa0associated\\xa0with\\xa0peptic\\xa0ulcerdisease\\xa0(PUD),\\xa0it\\xa0is\\xa0now\\xa0clear\\xa0that\\xa0>90%\\xa0patients\\xa0with\\xa0this\\xa0symptom\\xa0complex\\xa0(dyspepsia)\\xa0do\\xa0not\\xa0have\\xa0ulcers\\xa0and\\xa0that\\xa0the\\xa0majority\\xa0of\\xa0patients\\xa0with\\xa0pepticulcers\\xa0may\\xa0be\\xa0asymptomatic.\\xa0Ulcers\\xa0occur\\xa0within\\xa0the\\xa0stomach\\xa0and/or\\xa0duodenum\\xa0and\\xa0are\\xa0often\\xa0chronic\\xa0in\\xa0nature.\\xa0Acid\\xa0peptic\\xa0disorders\\xa0are\\xa0verycommon\\xa0in\\xa0the\\xa0United\\xa0States,\\xa0with\\xa04\\xa0million\\xa0individuals\\xa0(new\\xa0cases\\xa0and\\xa0recurrences)\\xa0affected\\xa0per\\xa0year.\\xa0Lifetime\\xa0overall\\xa0prevalence\\xa0of\\xa0PUD\\xa0in\\xa0the\\xa0UnitedStates\\xa0is\\xa0~8.4%\\xa0with\\xa0a\\xa0slightly\\xa0higher\\xa0prevalence\\xa0in\\xa0men.\\xa0PUD\\xa0significantly\\xa0affects\\xa0quality\\xa0of\\xa0life\\xa0by\\xa0impairing\\xa0overall\\xa0patient\\xa0well\\xadbeing\\xa0and\\xa0contributingsubstantially\\xa0to\\xa0work\\xa0absenteeism.\\xa0Moreover,\\xa0an\\xa0estimated\\xa015,000\\xa0deaths\\xa0per\\xa0year\\xa0occur\\xa0as\\xa0a\\xa0consequence\\xa0of\\xa0complicated\\xa0PUD.\\xa0The\\xa0financial\\xa0impact\\xa0ofthese\\xa0common\\xa0disorders\\xa0has\\xa0been\\xa0substantial,\\xa0with\\xa0an\\xa0estimated\\xa0burden\\xa0on\\xa0direct\\xa0and\\xa0indirect\\xa0health\\xa0care\\xa0costs\\xa0of\\xa0~$6\\xa0billion\\xa0per\\xa0year\\xa0in\\xa0the\\xa0UnitedStates,\\xa0with\\xa0$3\\xa0billion\\xa0spent\\xa0on\\xa0hospitalizations,\\xa0$2\\xa0billion\\xa0on\\xa0physician\\xa0office\\xa0visits,\\xa0and\\xa0$1\\xa0billion\\xa0in\\xa0decreased\\xa0productivity\\xa0and\\xa0days\\xa0lost\\xa0from\\xa0work.GASTRIC\\xa0PHYSIOLOGYGastric\\xa0AnatomyThe\\xa0gastric\\xa0epithelial\\xa0lining\\xa0consists\\xa0of\\xa0rugae\\xa0that\\xa0contain\\xa0microscopic\\xa0gastric\\xa0pits,\\xa0each\\xa0branching\\xa0into\\xa0four\\xa0or\\xa0five\\xa0gastric\\xa0glands\\xa0made\\xa0up\\xa0of\\xa0highlyspecialized\\xa0epithelial\\xa0cells.\\xa0The\\xa0makeup\\xa0of\\xa0gastric\\xa0glands\\xa0varies\\xa0with\\xa0their\\xa0anatomic\\xa0location.\\xa0Glands\\xa0within\\xa0the\\xa0gastric\\xa0cardia\\xa0comprise\\xa0<5%\\xa0of\\xa0thegastric\\xa0gland\\xa0area\\xa0and\\xa0contain\\xa0mucous\\xa0and\\xa0endocrine\\xa0cells.\\xa0The\\xa075%\\xa0of\\xa0gastric\\xa0glands\\xa0are\\xa0found\\xa0within\\xa0the\\xa0oxyntic\\xa0mucosa\\xa0and\\xa0contain\\xa0mucous\\xa0neck,\",\n",
       " \"gastric\\xa0gland\\xa0area\\xa0and\\xa0contain\\xa0mucous\\xa0and\\xa0endocrine\\xa0cells.\\xa0The\\xa075%\\xa0of\\xa0gastric\\xa0glands\\xa0are\\xa0found\\xa0within\\xa0the\\xa0oxyntic\\xa0mucosa\\xa0and\\xa0contain\\xa0mucous\\xa0neck,parietal,\\xa0chief,\\xa0endocrine,\\xa0enterochromaffin,\\xa0and\\xa0enterochromaffin\\xadlike\\xa0(ECL)\\xa0cells\\xa0(Fig.\\xa0324\\xad1).\\xa0Highly\\xa0specialized\\xa0tuft\\xa0cells\\xa0are\\xa0located\\xa0in\\xa0the\\xa0neckregion\\xa0of\\xa0the\\xa0gastric\\xa0gland.\\xa0These\\xa0specialized\\xa0cells\\xa0are\\xa0thought\\xa0to\\xa0sample\\xa0luminal\\xa0contents,\\xa0which\\xa0in\\xa0turn\\xa0may\\xa0be\\xa0important\\xa0in\\xa0regulating\\xa0gastric\\xa0acidsecretion.\\xa0Pyloric\\xa0glands\\xa0contain\\xa0mucous\\xa0and\\xa0endocrine\\xa0cells\\xa0(including\\xa0gastrin\\xa0cells)\\xa0and\\xa0are\\xa0found\\xa0in\\xa0the\\xa0antrum.FIGURE\\xa0324\\xad1Diagrammatic\\xa0representation\\xa0of\\xa0the\\xa0oxyntic\\xa0gastric\\xa0gland. (Reproduced\\xa0with\\xa0permission\\xa0from\\xa0S\\xa0Ito,\\xa0RJ\\xa0Winchester:\\xa0The\\xa0Fine\\xa0Structure\\xa0of\\xa0theGastric\\xa0Mucosa\\xa0in\\xa0the\\xa0Bat.\\xa0J\\xa0Cell\\xa0Biol\\xa016:541,\\xa01963.)Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 1 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21e\",\n",
       " 'kidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison\\'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)',\n",
       " \"aggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycin\",\n",
       " \"MCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " \"FIGURE\\xa0324\\xad1Diagrammatic\\xa0representation\\xa0of\\xa0the\\xa0oxyntic\\xa0gastric\\xa0gland. (Reproduced\\xa0with\\xa0permission\\xa0from\\xa0S\\xa0Ito,\\xa0RJ\\xa0Winchester:\\xa0The\\xa0Fine\\xa0Structure\\xa0of\\xa0theGastric\\xa0Mucosa\\xa0in\\xa0the\\xa0Bat.\\xa0J\\xa0Cell\\xa0Biol\\xa016:541,\\xa01963.)The\\xa0parietal\\xa0cell,\\xa0also\\xa0known\\xa0as\\xa0the\\xa0oxyntic\\xa0cell,\\xa0is\\xa0usually\\xa0found\\xa0in\\xa0the\\xa0neck\\xa0or\\xa0isthmus\\xa0or\\xa0in\\xa0the\\xa0oxyntic\\xa0gland.\\xa0The\\xa0resting,\\xa0or\\xa0unstimulated,\\xa0parietalcell\\xa0has\\xa0prominent\\xa0cytoplasmic\\xa0tubulovesicles\\xa0and\\xa0intracellular\\xa0canaliculi\\xa0containing\\xa0short\\xa0microvilli\\xa0along\\xa0its\\xa0apical\\xa0surface\\xa0(Fig.\\xa0324\\xad2).\\xa0H+,K+\\xadadenosine\\xa0triphosphatase\\xa0(ATPase)\\xa0is\\xa0expressed\\xa0in\\xa0the\\xa0tubulovesicle\\xa0membrane;\\xa0upon\\xa0cell\\xa0stimulation,\\xa0this\\xa0membrane,\\xa0along\\xa0with\\xa0apical\\xa0membranes,transforms\\xa0into\\xa0a\\xa0dense\\xa0network\\xa0of\\xa0apical\\xa0intracellular\\xa0canaliculi\\xa0containing\\xa0long\\xa0microvilli.\\xa0Acid\\xa0secretion,\\xa0a\\xa0process\\xa0requiring\\xa0high\\xa0energy,\\xa0occurs\\xa0atthe\\xa0apical\\xa0canalicular\\xa0surface.\\xa0Numerous\\xa0mitochondria\\xa0(30–40%\\xa0of\\xa0total\\xa0cell\\xa0volume)\\xa0generate\\xa0the\\xa0energy\\xa0required\\xa0for\\xa0secretion.FIGURE\\xa0324\\xad2Gastric\\xa0parietal\\xa0cell\\xa0undergoing\\xa0transformation\\xa0after\\xa0secretagogue\\xadmediated\\xa0stimulation.\\xa0cAMP,\\xa0cyclic\\xa0adenosine\\xa0monophosphate.\\xa0(Reproducedwith\\xa0permission\\xa0from\\xa0SJ\\xa0Hersey,\\xa0G\\xa0Sachs:\\xa0Gastric\\xa0acid\\xa0secretion.\\xa0Am\\xa0Physiol\\xa0Soc\\xa075:155,\\xa01995.)Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 2 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21e\",\n",
       " 'MitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison\\'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillaries',\n",
       " '4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,',\n",
       " \"DCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedage\",\n",
       " \"mucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'FIGURE\\xa0324\\xad2Gastric\\xa0parietal\\xa0cell\\xa0undergoing\\xa0transformation\\xa0after\\xa0secretagogue\\xadmediated\\xa0stimulation.\\xa0cAMP,\\xa0cyclic\\xa0adenosine\\xa0monophosphate.\\xa0(Reproducedwith\\xa0permission\\xa0from\\xa0SJ\\xa0Hersey,\\xa0G\\xa0Sachs:\\xa0Gastric\\xa0acid\\xa0secretion.\\xa0Am\\xa0Physiol\\xa0Soc\\xa075:155,\\xa01995.)Gastroduodenal\\xa0Mucosal\\xa0DefenseThe\\xa0gastric\\xa0epithelium\\xa0is\\xa0under\\xa0constant\\xa0assault\\xa0by\\xa0a\\xa0series\\xa0of\\xa0endogenous\\xa0noxious\\xa0factors,\\xa0including\\xa0hydrochloric\\xa0acid\\xa0(HCl),\\xa0pepsinogen/pepsin,\\xa0andbile\\xa0salts.\\xa0In\\xa0addition,\\xa0a\\xa0steady\\xa0flow\\xa0of\\xa0exogenous\\xa0substances\\xa0such\\xa0as\\xa0medications,\\xa0alcohol,\\xa0and\\xa0bacteria\\xa0encounter\\xa0the\\xa0gastric\\xa0mucosa.\\xa0A\\xa0highlyintricate\\xa0biologic\\xa0system\\xa0is\\xa0in\\xa0place\\xa0to\\xa0provide\\xa0defense\\xa0from\\xa0mucosal\\xa0injury\\xa0and\\xa0to\\xa0repair\\xa0any\\xa0injury\\xa0that\\xa0may\\xa0occur.The\\xa0mucosal\\xa0defense\\xa0system\\xa0can\\xa0be\\xa0envisioned\\xa0as\\xa0a\\xa0three\\xadlevel\\xa0barrier,\\xa0composed\\xa0of\\xa0preepithelial,\\xa0epithelial,\\xa0and\\xa0subepithelial\\xa0elements\\xa0(Fig.\\xa0324\\xad3).The\\xa0first\\xa0line\\xa0of\\xa0defense\\xa0is\\xa0a\\xa0mucus\\xadbicarbonate\\xadphospholipid\\xa0layer,\\xa0which\\xa0serves\\xa0as\\xa0a\\xa0physicochemical\\xa0barrier\\xa0to\\xa0multiple\\xa0molecules,\\xa0includinghydrogen\\xa0ions.\\xa0Mucus\\xa0is\\xa0secreted\\xa0in\\xa0a\\xa0regulated\\xa0fashion\\xa0by\\xa0gastroduodenal\\xa0surface\\xa0epithelial\\xa0cells.\\xa0It\\xa0consists\\xa0primarily\\xa0of\\xa0water\\xa0(95%)\\xa0and\\xa0a\\xa0mixture\\xa0ofphospholipids\\xa0and\\xa0glycoproteins\\xa0(mucin).\\xa0The\\xa0mucous\\xa0gel\\xa0functions\\xa0as\\xa0a\\xa0nonstirred\\xa0water\\xa0layer\\xa0impeding\\xa0diffusion\\xa0of\\xa0ions\\xa0and\\xa0molecules\\xa0such\\xa0aspepsin.\\xa0Bicarbonate,\\xa0secreted\\xa0in\\xa0a\\xa0regulated\\xa0manner\\xa0by\\xa0surface\\xa0epithelial\\xa0cells\\xa0of\\xa0the\\xa0gastroduodenal\\xa0mucosa\\xa0into\\xa0the\\xa0mucous\\xa0gel,\\xa0forms\\xa0a\\xa0pH\\xa0gradientranging\\xa0from\\xa01\\xa0to\\xa02\\xa0at\\xa0the\\xa0gastric\\xa0luminal\\xa0surface\\xa0and\\xa0reaching\\xa06–7\\xa0along\\xa0the\\xa0epithelial\\xa0cell\\xa0surface.FIGURE\\xa0324\\xad3Components\\xa0involved\\xa0in\\xa0providing\\xa0gastroduodenal\\xa0mucosal\\xa0defense\\xa0and\\xa0repair.\\xa0CCK,\\xa0cholecystokinin;\\xa0CRF,\\xa0corticotropin\\xadreleasing\\xa0factor;EGF,\\xa0epidermal\\xa0growth\\xa0factor;\\xa0HCl,\\xa0hydrochloride;\\xa0IGF,\\xa0insulin\\xadlike\\xa0growth\\xa0factor;\\xa0TGFα,\\xa0transforming\\xa0growth\\xa0factor\\xa0α;\\xa0TRF,\\xa0thyrotropin\\xa0releasingfactor.\\xa0(Republished\\xa0with\\xa0permission\\xa0of\\xa0John\\xa0Wiley\\xa0and\\xa0Son’s\\xa0Inc,\\xa0from\\xa0Bioregulation\\xa0and\\xa0Its\\xa0Disorders\\xa0in\\xa0the\\xa0Gastrointestinal\\xa0Tract,\\xa0T\\xa0Yoshikawa,\\xa0T',\n",
       " \"factor.\\xa0(Republished\\xa0with\\xa0permission\\xa0of\\xa0John\\xa0Wiley\\xa0and\\xa0Son’s\\xa0Inc,\\xa0from\\xa0Bioregulation\\xa0and\\xa0Its\\xa0Disorders\\xa0in\\xa0the\\xa0Gastrointestinal\\xa0Tract,\\xa0T\\xa0Yoshikawa,\\xa0TArakawa\\xa0[eds]:\\xa01998;\\xa0permission\\xa0conveyed\\xa0through\\xa0Copyright\\xa0Clearance\\xa0Center,\\xa0Inc.)Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 3 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamine\",\n",
       " 'CopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorins',\n",
       " \"Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculus\",\n",
       " \"Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'Components\\xa0involved\\xa0in\\xa0providing\\xa0gastroduodenal\\xa0mucosal\\xa0defense\\xa0and\\xa0repair.\\xa0CCK,\\xa0cholecystokinin;\\xa0CRF,\\xa0corticotropin\\xadreleasing\\xa0factor;EGF,\\xa0epidermal\\xa0growth\\xa0factor;\\xa0HCl,\\xa0hydrochloride;\\xa0IGF,\\xa0insulin\\xadlike\\xa0growth\\xa0factor;\\xa0TGFα,\\xa0transforming\\xa0growth\\xa0factor\\xa0α;\\xa0TRF,\\xa0thyrotropin\\xa0releasingfactor.\\xa0(Republished\\xa0with\\xa0permission\\xa0of\\xa0John\\xa0Wiley\\xa0and\\xa0Son’s\\xa0Inc,\\xa0from\\xa0Bioregulation\\xa0and\\xa0Its\\xa0Disorders\\xa0in\\xa0the\\xa0Gastrointestinal\\xa0Tract,\\xa0T\\xa0Yoshikawa,\\xa0TArakawa\\xa0[eds]:\\xa01998;\\xa0permission\\xa0conveyed\\xa0through\\xa0Copyright\\xa0Clearance\\xa0Center,\\xa0Inc.)Surface\\xa0epithelial\\xa0cells\\xa0provide\\xa0the\\xa0next\\xa0line\\xa0of\\xa0defense\\xa0through\\xa0several\\xa0factors,\\xa0including\\xa0mucus\\xa0production,\\xa0epithelial\\xa0cell\\xa0ionic\\xa0transporters\\xa0thatmaintain\\xa0intracellular\\xa0pH\\xa0and\\xa0bicarbonate\\xa0production,\\xa0and\\xa0intracellular\\xa0tight\\xa0junctions.\\xa0Surface\\xa0epithelial\\xa0cells\\xa0generate\\xa0heat\\xa0shock\\xa0proteins\\xa0thatprevent\\xa0protein\\xa0denaturation\\xa0and\\xa0protect\\xa0cells\\xa0from\\xa0certain\\xa0factors\\xa0such\\xa0as\\xa0increased\\xa0temperature,\\xa0cytotoxic\\xa0agents,\\xa0or\\xa0oxidative\\xa0stress.\\xa0Epithelial\\xa0cellsalso\\xa0generate\\xa0trefoil\\xa0factor\\xa0family\\xa0peptides\\xa0and\\xa0cathelicidins,\\xa0which\\xa0also\\xa0play\\xa0a\\xa0role\\xa0in\\xa0surface\\xa0cell\\xa0protection\\xa0and\\xa0regeneration.\\xa0If\\xa0the\\xa0preepithelialbarrier\\xa0is\\xa0breached,\\xa0gastric\\xa0epithelial\\xa0cells\\xa0bordering\\xa0a\\xa0site\\xa0of\\xa0injury\\xa0can\\xa0migrate\\xa0to\\xa0restore\\xa0a\\xa0damaged\\xa0region\\xa0(restitution).\\xa0This\\xa0process\\xa0occursindependent\\xa0of\\xa0cell\\xa0division\\xa0and\\xa0requires\\xa0uninterrupted\\xa0blood\\xa0flow\\xa0and\\xa0an\\xa0alkaline\\xa0pH\\xa0in\\xa0the\\xa0surrounding\\xa0environment.\\xa0Several\\xa0growth\\xa0factors,including\\xa0epidermal\\xa0growth\\xa0factor\\xa0(EGF),\\xa0transforming\\xa0growth\\xa0factor\\xa0(TGF)\\xa0α,\\xa0and\\xa0basic\\xa0fibroblast\\xa0growth\\xa0factor\\xa0(FGF),\\xa0modulate\\xa0the\\xa0process\\xa0ofrestitution.\\xa0Larger\\xa0defects\\xa0that\\xa0are\\xa0not\\xa0effectively\\xa0repaired\\xa0by\\xa0restitution\\xa0require\\xa0cell\\xa0proliferation.\\xa0Epithelial\\xa0cell\\xa0regeneration\\xa0is\\xa0regulated\\xa0byprostaglandins\\xa0and\\xa0growth\\xa0factors\\xa0such\\xa0as\\xa0EGF\\xa0and\\xa0TGF\\xadα.\\xa0In\\xa0tandem\\xa0with\\xa0epithelial\\xa0cell\\xa0renewal,\\xa0formation\\xa0of\\xa0new\\xa0vessels\\xa0(angiogenesis)\\xa0within\\xa0theinjured\\xa0microvascular\\xa0bed\\xa0occurs.\\xa0Both\\xa0FGF\\xa0and\\xa0vascular\\xa0endothelial\\xa0growth\\xa0factor\\xa0(VEGF)\\xa0are\\xa0important\\xa0in\\xa0regulating\\xa0angiogenesis\\xa0in\\xa0the\\xa0gastric',\n",
       " 'injured\\xa0microvascular\\xa0bed\\xa0occurs.\\xa0Both\\xa0FGF\\xa0and\\xa0vascular\\xa0endothelial\\xa0growth\\xa0factor\\xa0(VEGF)\\xa0are\\xa0important\\xa0in\\xa0regulating\\xa0angiogenesis\\xa0in\\xa0the\\xa0gastricmucosa.\\xa0In\\xa0addition,\\xa0the\\xa0gastric\\xa0peptide\\xa0gastrin\\xa0(see\\xa0below)\\xa0has\\xa0been\\xa0recently\\xa0found\\xa0to\\xa0stimulate\\xa0cell\\xa0proliferation,\\xa0migration,\\xa0invasion,\\xa0angiogenesis,and\\xa0autophagy.\\xa0Finally,\\xa0gastric\\xa0parietal\\xa0cells\\xa0(see\\xa0below)\\xa0express\\xa0sonic\\xa0hedgehog,\\xa0a\\xa0family\\xa0of\\xa0proteins\\xa0important\\xa0in\\xa0regulating\\xa0cell\\xa0lineage\\xa0in\\xa0multipleorgans.\\xa0This\\xa0latter\\xa0finding\\xa0suggests\\xa0that\\xa0parietal\\xa0cells\\xa0may\\xa0also\\xa0have\\xa0the\\xa0ability\\xa0to\\xa0regulate\\xa0gastric\\xa0stem\\xa0cells.An\\xa0elaborate\\xa0microvascular\\xa0system\\xa0within\\xa0the\\xa0gastric\\xa0submucosal\\xa0layer\\xa0is\\xa0the\\xa0key\\xa0component\\xa0of\\xa0the\\xa0subepithelial\\xa0defense/repair\\xa0system,\\xa0providingHCO3−,\\xa0which\\xa0neutralizes\\xa0the\\xa0acid\\xa0generated\\xa0by\\xa0the\\xa0parietal\\xa0cell.\\xa0Moreover,\\xa0this\\xa0microcirculatory\\xa0bed\\xa0provides\\xa0an\\xa0adequate\\xa0supply\\xa0of\\xa0micronutrientsand\\xa0oxygen\\xa0while\\xa0removing\\xa0toxic\\xa0metabolic\\xa0by\\xadproducts.\\xa0Several\\xa0locally\\xa0produced\\xa0factors\\xa0including\\xa0nitric\\xa0oxide\\xa0(NO)\\xa0(see\\xa0below),\\xa0hydrogen\\xa0sulfide,\\xa0andprostacyclin\\xa0contribute\\xa0to\\xa0the\\xa0vascular\\xa0protective\\xa0pathway\\xa0through\\xa0vasodilation\\xa0of\\xa0the\\xa0microcirculation.Prostaglandins\\xa0play\\xa0a\\xa0central\\xa0role\\xa0in\\xa0gastric\\xa0epithelial\\xa0defense/repair\\xa0(Fig.\\xa0324\\xad4).\\xa0The\\xa0gastric\\xa0mucosa\\xa0contains\\xa0abundant\\xa0levels\\xa0of\\xa0prostaglandins\\xa0thatregulate\\xa0the\\xa0release\\xa0of\\xa0mucosal\\xa0bicarbonate\\xa0and\\xa0mucus,\\xa0inhibit\\xa0parietal\\xa0cell\\xa0secretion,\\xa0and\\xa0are\\xa0important\\xa0in\\xa0maintaining\\xa0mucosal\\xa0blood\\xa0flow\\xa0andepithelial\\xa0cell\\xa0restitution.\\xa0Prostaglandins\\xa0are\\xa0derived\\xa0from\\xa0esterified\\xa0arachidonic\\xa0acid,\\xa0which\\xa0is\\xa0formed\\xa0from\\xa0phospholipids\\xa0(cell\\xa0membrane)\\xa0by\\xa0theaction\\xa0of\\xa0phospholipase\\xa0A2.\\xa0A\\xa0key\\xa0enzyme\\xa0that\\xa0controls\\xa0the\\xa0rate\\xadlimiting\\xa0step\\xa0in\\xa0prostaglandin\\xa0synthesis\\xa0is\\xa0cyclooxygenase\\xa0(COX),\\xa0which\\xa0is\\xa0present\\xa0intwo\\xa0isoforms\\xa0(COX\\xad1,\\xa0COX\\xad2),\\xa0each\\xa0having\\xa0distinct\\xa0characteristics\\xa0regarding\\xa0structure,\\xa0tissue\\xa0distribution,\\xa0and\\xa0expression.\\xa0COX\\xad1\\xa0is\\xa0expressed\\xa0in\\xa0a\\xa0hostof\\xa0tissues,\\xa0including\\xa0the\\xa0stomach,\\xa0platelets,\\xa0kidneys,\\xa0and\\xa0endothelial\\xa0cells.\\xa0This\\xa0isoform\\xa0is\\xa0expressed\\xa0in\\xa0a\\xa0constitutive\\xa0manner\\xa0and\\xa0plays\\xa0an\\xa0important',\n",
       " \"of\\xa0tissues,\\xa0including\\xa0the\\xa0stomach,\\xa0platelets,\\xa0kidneys,\\xa0and\\xa0endothelial\\xa0cells.\\xa0This\\xa0isoform\\xa0is\\xa0expressed\\xa0in\\xa0a\\xa0constitutive\\xa0manner\\xa0and\\xa0plays\\xa0an\\xa0importantrole\\xa0in\\xa0maintaining\\xa0the\\xa0integrity\\xa0of\\xa0renal\\xa0function,\\xa0platelet\\xa0aggregation,\\xa0and\\xa0gastrointestinal\\xa0(GI)\\xa0mucosal\\xa0integrity.\\xa0In\\xa0contrast,\\xa0the\\xa0expression\\xa0of\\xa0COX\\xad2is\\xa0inducible\\xa0by\\xa0inflammatory\\xa0stimuli,\\xa0and\\xa0it\\xa0is\\xa0expressed\\xa0in\\xa0macrophages,\\xa0leukocytes,\\xa0fibroblasts,\\xa0and\\xa0synovial\\xa0cells.\\xa0The\\xa0beneficial\\xa0effects\\xa0ofnonsteroidal\\xa0anti\\xadinflammatory\\xa0drugs\\xa0(NSAIDs)\\xa0on\\xa0tissue\\xa0inflammation\\xa0are\\xa0due\\xa0to\\xa0inhibition\\xa0of\\xa0COX\\xad2;\\xa0the\\xa0toxicity\\xa0of\\xa0these\\xa0drugs\\xa0(e.g.,\\xa0GI\\xa0mucosalulceration\\xa0and\\xa0renal\\xa0dysfunction)\\xa0is\\xa0related\\xa0to\\xa0inhibition\\xa0of\\xa0the\\xa0COX\\xad1\\xa0isoform.\\xa0The\\xa0highly\\xa0COX\\xad2–selective\\xa0NSAIDs\\xa0have\\xa0the\\xa0potential\\xa0to\\xa0provide\\xa0thebeneficial\\xa0effect\\xa0of\\xa0decreasing\\xa0tissue\\xa0inflammation\\xa0while\\xa0minimizing\\xa0toxicity\\xa0in\\xa0the\\xa0GI\\xa0tract.\\xa0Selective\\xa0COX\\xad2\\xa0inhibitors\\xa0have\\xa0had\\xa0adverse\\xa0effects\\xa0on\\xa0thecardiovascular\\xa0(CV)\\xa0system,\\xa0leading\\xa0to\\xa0increased\\xa0risk\\xa0of\\xa0myocardial\\xa0infarction.\\xa0Therefore,\\xa0the\\xa0U.S.\\xa0Food\\xa0and\\xa0Drug\\xa0Administration\\xa0(FDA)\\xa0has\\xa0removedYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 4 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritis\",\n",
       " 'CopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison\\'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregation',\n",
       " \"is maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:No\",\n",
       " \"1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'epithelial\\xa0cell\\xa0restitution.\\xa0Prostaglandins\\xa0are\\xa0derived\\xa0from\\xa0esterified\\xa0arachidonic\\xa0acid,\\xa0which\\xa0is\\xa0formed\\xa0from\\xa0phospholipids\\xa0(cell\\xa0membrane)\\xa0by\\xa0theaction\\xa0of\\xa0phospholipase\\xa0A2.\\xa0A\\xa0key\\xa0enzyme\\xa0that\\xa0controls\\xa0the\\xa0rate\\xadlimiting\\xa0step\\xa0in\\xa0prostaglandin\\xa0synthesis\\xa0is\\xa0cyclooxygenase\\xa0(COX),\\xa0which\\xa0is\\xa0present\\xa0intwo\\xa0isoforms\\xa0(COX\\xad1,\\xa0COX\\xad2),\\xa0each\\xa0having\\xa0distinct\\xa0characteristics\\xa0regarding\\xa0structure,\\xa0tissue\\xa0distribution,\\xa0and\\xa0expression.\\xa0COX\\xad1\\xa0is\\xa0expressed\\xa0in\\xa0a\\xa0hostof\\xa0tissues,\\xa0including\\xa0the\\xa0stomach,\\xa0platelets,\\xa0kidneys,\\xa0and\\xa0endothelial\\xa0cells.\\xa0This\\xa0isoform\\xa0is\\xa0expressed\\xa0in\\xa0a\\xa0constitutive\\xa0manner\\xa0and\\xa0plays\\xa0an\\xa0importantrole\\xa0in\\xa0maintaining\\xa0the\\xa0integrity\\xa0of\\xa0renal\\xa0function,\\xa0platelet\\xa0aggregation,\\xa0and\\xa0gastrointestinal\\xa0(GI)\\xa0mucosal\\xa0integrity.\\xa0In\\xa0contrast,\\xa0the\\xa0expression\\xa0of\\xa0COX\\xad2is\\xa0inducible\\xa0by\\xa0inflammatory\\xa0stimuli,\\xa0and\\xa0it\\xa0is\\xa0expressed\\xa0in\\xa0macrophages,\\xa0leukocytes,\\xa0fibroblasts,\\xa0and\\xa0synovial\\xa0cells.\\xa0The\\xa0beneficial\\xa0effects\\xa0ofnonsteroidal\\xa0anti\\xadinflammatory\\xa0drugs\\xa0(NSAIDs)\\xa0on\\xa0tissue\\xa0inflammation\\xa0are\\xa0due\\xa0to\\xa0inhibition\\xa0of\\xa0COX\\xad2;\\xa0the\\xa0toxicity\\xa0of\\xa0these\\xa0drugs\\xa0(e.g.,\\xa0GI\\xa0mucosalulceration\\xa0and\\xa0renal\\xa0dysfunction)\\xa0is\\xa0related\\xa0to\\xa0inhibition\\xa0of\\xa0the\\xa0COX\\xad1\\xa0isoform.\\xa0The\\xa0highly\\xa0COX\\xad2–selective\\xa0NSAIDs\\xa0have\\xa0the\\xa0potential\\xa0to\\xa0provide\\xa0thebeneficial\\xa0effect\\xa0of\\xa0decreasing\\xa0tissue\\xa0inflammation\\xa0while\\xa0minimizing\\xa0toxicity\\xa0in\\xa0the\\xa0GI\\xa0tract.\\xa0Selective\\xa0COX\\xad2\\xa0inhibitors\\xa0have\\xa0had\\xa0adverse\\xa0effects\\xa0on\\xa0thecardiovascular\\xa0(CV)\\xa0system,\\xa0leading\\xa0to\\xa0increased\\xa0risk\\xa0of\\xa0myocardial\\xa0infarction.\\xa0Therefore,\\xa0the\\xa0U.S.\\xa0Food\\xa0and\\xa0Drug\\xa0Administration\\xa0(FDA)\\xa0has\\xa0removedtwo\\xa0of\\xa0these\\xa0agents\\xa0(valdecoxib\\xa0and\\xa0rofecoxib)\\xa0from\\xa0the\\xa0market\\xa0(see\\xa0below).FIGURE\\xa0324\\xad4Schematic\\xa0representation\\xa0of\\xa0the\\xa0steps\\xa0involved\\xa0in\\xa0synthesis\\xa0of\\xa0prostaglandin\\xa0E2\\xa0(PGE2)\\xa0and\\xa0prostacyclin\\xa0(PGI2).\\xa0Characteristics\\xa0anddistribution\\xa0of\\xa0the\\xa0cyclooxygenase\\xa0(COX)\\xa0enzymes\\xa01\\xa0and\\xa02\\xa0are\\xa0also\\xa0shown.\\xa0TXA2,\\xa0thromboxane\\xa0A2.NO\\xa0is\\xa0important\\xa0in\\xa0the\\xa0maintenance\\xa0of\\xa0gastric\\xa0mucosal\\xa0integrity.\\xa0The\\xa0key\\xa0enzyme\\xa0NO\\xa0synthase\\xa0is\\xa0constitutively\\xa0expressed\\xa0in\\xa0the\\xa0mucosa\\xa0and',\n",
       " 'NO\\xa0is\\xa0important\\xa0in\\xa0the\\xa0maintenance\\xa0of\\xa0gastric\\xa0mucosal\\xa0integrity.\\xa0The\\xa0key\\xa0enzyme\\xa0NO\\xa0synthase\\xa0is\\xa0constitutively\\xa0expressed\\xa0in\\xa0the\\xa0mucosa\\xa0andcontributes\\xa0to\\xa0cytoprotection\\xa0by\\xa0stimulating\\xa0gastric\\xa0mucus,\\xa0increasing\\xa0mucosal\\xa0blood\\xa0flow,\\xa0and\\xa0maintaining\\xa0epithelial\\xa0cell\\xa0barrier\\xa0function.\\xa0The\\xa0centralnervous\\xa0system\\xa0(CNS)\\xa0and\\xa0hormonal\\xa0factors\\xa0also\\xa0play\\xa0a\\xa0role\\xa0in\\xa0regulating\\xa0mucosal\\xa0defense\\xa0through\\xa0multiple\\xa0pathways\\xa0(Fig.\\xa0324\\xad3).Since\\xa0the\\xa0discovery\\xa0of\\xa0Helicobacter\\xa0pylori\\xa0and\\xa0its\\xa0impact\\xa0on\\xa0gastric\\xa0pathology,\\xa0it\\xa0has\\xa0become\\xa0clear\\xa0that\\xa0the\\xa0stomach\\xa0has\\xa0an\\xa0elaborate\\xa0and\\xa0complexinherent\\xa0immunologic\\xa0system\\xa0in\\xa0place.\\xa0Although\\xa0a\\xa0detailed\\xa0description\\xa0of\\xa0the\\xa0gastric\\xa0immune\\xa0system\\xa0is\\xa0beyond\\xa0the\\xa0scope\\xa0of\\xa0this\\xa0chapter,\\xa0severalfeatures\\xa0are\\xa0worth\\xa0highlighting.\\xa0The\\xa0gastric\\xa0immune\\xa0response\\xa0to\\xa0certain\\xa0pathogens\\xa0such\\xa0as\\xa0H.\\xa0pylori\\xa0(see\\xa0below)\\xa0involves\\xa0extensive\\xa0interplay\\xa0betweeninnate\\xa0(dendritic\\xa0cells,\\xa0epithelial\\xa0cells,\\xa0neutrophils,\\xa0and\\xa0macrophages)\\xa0and\\xa0adaptive\\xa0(B\\xa0and\\xa0T\\xa0cells)\\xa0components.\\xa0Helper\\xa0T\\xa0cells\\xa0(TH\\xa0and\\xa0TH\\xa0regulatorycells)\\xa0have\\xa0been\\xa0extensively\\xa0studied\\xa0and\\xa0appear\\xa0to\\xa0play\\xa0an\\xa0important\\xa0role\\xa0in\\xa0a\\xa0broad\\xa0array\\xa0of\\xa0gastric\\xa0physiology\\xa0extending\\xa0from\\xa0gastric\\xa0secretion\\xa0toepithelial\\xa0cell\\xa0turnover\\xa0via\\xa0production\\xa0of\\xa0a\\xa0number\\xa0of\\xa0cytokines.The\\xa0discovery\\xa0of\\xa0H.\\xa0pylori\\xa0has\\xa0also\\xa0led\\xa0to\\xa0the\\xa0understanding\\xa0that\\xa0the\\xa0stomach,\\xa0once\\xa0thought\\xa0to\\xa0be\\xa0devoid\\xa0of\\xa0microorganisms\\xa0due\\xa0to\\xa0its\\xa0highly\\xa0adverseenvironment\\xa0(acid\\xa0and\\xa0pepsin),\\xa0can\\xa0serve\\xa0as\\xa0host\\xa0for\\xa0bacterial\\xa0communities\\xa0consisting\\xa0of\\xa0hundreds\\xa0of\\xa0phylotypes,\\xa0otherwise\\xa0known\\xa0as\\xa0its\\xa0microbiota.The\\xa0conceptual\\xa0framework\\xa0of\\xa0the\\xa0microbiome\\xa0has\\xa0been\\xa0receiving\\xa0extensive\\xa0attention\\xa0in\\xa0light\\xa0of\\xa0its\\xa0importance\\xa0in\\xa0human\\xa0health\\xa0and\\xa0disease.\\xa0Theoverall\\xa0relevance\\xa0of\\xa0the\\xa0gastric\\xa0microbiome\\xa0and\\xa0its\\xa0impact\\xa0on\\xa0gastric\\xa0pathology\\xa0remain\\xa0to\\xa0be\\xa0established,\\xa0but\\xa0it\\xa0is\\xa0likely\\xa0that\\xa0alteration\\xa0ofmicroorganism\\xa0homeostasis\\xa0will\\xa0play\\xa0a\\xa0role\\xa0in\\xa0aspects\\xa0of\\xa0certain\\xa0disorders\\xa0such\\xa0as\\xa0PUD,\\xa0gastritis,\\xa0and\\xa0gastric\\xa0cancer.Physiology\\xa0of\\xa0Gastric\\xa0Secretion',\n",
       " 'microorganism\\xa0homeostasis\\xa0will\\xa0play\\xa0a\\xa0role\\xa0in\\xa0aspects\\xa0of\\xa0certain\\xa0disorders\\xa0such\\xa0as\\xa0PUD,\\xa0gastritis,\\xa0and\\xa0gastric\\xa0cancer.Physiology\\xa0of\\xa0Gastric\\xa0SecretionHCl\\xa0and\\xa0pepsinogen\\xa0are\\xa0the\\xa0two\\xa0principal\\xa0gastric\\xa0secretory\\xa0products\\xa0capable\\xa0of\\xa0inducing\\xa0mucosal\\xa0injury.\\xa0Gastric\\xa0acid\\xa0and\\xa0pepsinogen\\xa0play\\xa0aphysiologic\\xa0role\\xa0in\\xa0protein\\xa0digestion;\\xa0absorption\\xa0of\\xa0iron,\\xa0calcium,\\xa0magnesium,\\xa0and\\xa0vitamin\\xa0B12;\\xa0and\\xa0killing\\xa0ingested\\xa0bacteria.\\xa0Acid\\xa0secretion\\xa0should\\xa0beviewed\\xa0as\\xa0occurring\\xa0under\\xa0basal\\xa0and\\xa0stimulated\\xa0conditions.\\xa0Basal\\xa0acid\\xa0production\\xa0occurs\\xa0in\\xa0a\\xa0circadian\\xa0pattern,\\xa0with\\xa0the\\xa0highest\\xa0levels\\xa0occurringduring\\xa0the\\xa0night\\xa0and\\xa0lowest\\xa0levels\\xa0during\\xa0the\\xa0morning\\xa0hours.\\xa0Cholinergic\\xa0input\\xa0via\\xa0the\\xa0vagus\\xa0nerve\\xa0and\\xa0histaminergic\\xa0input\\xa0from\\xa0local\\xa0gastric\\xa0sourcesare\\xa0the\\xa0principal\\xa0contributors\\xa0to\\xa0basal\\xa0acid\\xa0secretion.\\xa0Stimulated\\xa0gastric\\xa0acid\\xa0secretion\\xa0occurs\\xa0primarily\\xa0in\\xa0three\\xa0phases\\xa0based\\xa0on\\xa0the\\xa0site\\xa0where\\xa0thesignal\\xa0originates\\xa0(cephalic,\\xa0gastric,\\xa0and\\xa0intestinal).\\xa0Sight,\\xa0smell,\\xa0and\\xa0taste\\xa0of\\xa0food\\xa0are\\xa0the\\xa0components\\xa0of\\xa0the\\xa0cephalic\\xa0phase,\\xa0which\\xa0stimulates\\xa0gastricsecretion\\xa0via\\xa0the\\xa0vagus\\xa0nerve.\\xa0The\\xa0gastric\\xa0phase\\xa0is\\xa0activated\\xa0once\\xa0food\\xa0enters\\xa0the\\xa0stomach.\\xa0This\\xa0component\\xa0of\\xa0secretion\\xa0is\\xa0driven\\xa0by\\xa0nutrients\\xa0(aminoacids and amines) that directly (via peptone and amino acid receptors) and indirectly (via stimulation of intramural gastrin releasing peptide neurons)Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 5 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?',\n",
       " \"inflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison's Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH'HCIpH20MucusHCOS2PH7.0MucusH'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosal\",\n",
       " 'mucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)Acid',\n",
       " \"CopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproduction\",\n",
       " \"H.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'Physiology\\xa0of\\xa0Gastric\\xa0SecretionHCl\\xa0and\\xa0pepsinogen\\xa0are\\xa0the\\xa0two\\xa0principal\\xa0gastric\\xa0secretory\\xa0products\\xa0capable\\xa0of\\xa0inducing\\xa0mucosal\\xa0injury.\\xa0Gastric\\xa0acid\\xa0and\\xa0pepsinogen\\xa0play\\xa0aphysiologic\\xa0role\\xa0in\\xa0protein\\xa0digestion;\\xa0absorption\\xa0of\\xa0iron,\\xa0calcium,\\xa0magnesium,\\xa0and\\xa0vitamin\\xa0B12;\\xa0and\\xa0killing\\xa0ingested\\xa0bacteria.\\xa0Acid\\xa0secretion\\xa0should\\xa0beviewed\\xa0as\\xa0occurring\\xa0under\\xa0basal\\xa0and\\xa0stimulated\\xa0conditions.\\xa0Basal\\xa0acid\\xa0production\\xa0occurs\\xa0in\\xa0a\\xa0circadian\\xa0pattern,\\xa0with\\xa0the\\xa0highest\\xa0levels\\xa0occurringduring\\xa0the\\xa0night\\xa0and\\xa0lowest\\xa0levels\\xa0during\\xa0the\\xa0morning\\xa0hours.\\xa0Cholinergic\\xa0input\\xa0via\\xa0the\\xa0vagus\\xa0nerve\\xa0and\\xa0histaminergic\\xa0input\\xa0from\\xa0local\\xa0gastric\\xa0sourcesare\\xa0the\\xa0principal\\xa0contributors\\xa0to\\xa0basal\\xa0acid\\xa0secretion.\\xa0Stimulated\\xa0gastric\\xa0acid\\xa0secretion\\xa0occurs\\xa0primarily\\xa0in\\xa0three\\xa0phases\\xa0based\\xa0on\\xa0the\\xa0site\\xa0where\\xa0thesignal\\xa0originates\\xa0(cephalic,\\xa0gastric,\\xa0and\\xa0intestinal).\\xa0Sight,\\xa0smell,\\xa0and\\xa0taste\\xa0of\\xa0food\\xa0are\\xa0the\\xa0components\\xa0of\\xa0the\\xa0cephalic\\xa0phase,\\xa0which\\xa0stimulates\\xa0gastricsecretion\\xa0via\\xa0the\\xa0vagus\\xa0nerve.\\xa0The\\xa0gastric\\xa0phase\\xa0is\\xa0activated\\xa0once\\xa0food\\xa0enters\\xa0the\\xa0stomach.\\xa0This\\xa0component\\xa0of\\xa0secretion\\xa0is\\xa0driven\\xa0by\\xa0nutrients\\xa0(aminoacids\\xa0and\\xa0amines)\\xa0that\\xa0directly\\xa0(via\\xa0peptone\\xa0and\\xa0amino\\xa0acid\\xa0receptors)\\xa0and\\xa0indirectly\\xa0(via\\xa0stimulation\\xa0of\\xa0intramural\\xa0gastrin\\xadreleasing\\xa0peptide\\xa0neurons)stimulate\\xa0the\\xa0G\\xa0cell\\xa0to\\xa0release\\xa0gastrin,\\xa0which\\xa0in\\xa0turn\\xa0activates\\xa0the\\xa0parietal\\xa0cell\\xa0via\\xa0direct\\xa0and\\xa0indirect\\xa0mechanisms.\\xa0Distention\\xa0of\\xa0the\\xa0stomach\\xa0wall\\xa0alsoleads\\xa0to\\xa0gastrin\\xa0release\\xa0and\\xa0acid\\xa0production.\\xa0The\\xa0last\\xa0phase\\xa0of\\xa0gastric\\xa0acid\\xa0secretion\\xa0is\\xa0initiated\\xa0as\\xa0food\\xa0enters\\xa0the\\xa0intestine\\xa0and\\xa0is\\xa0mediated\\xa0by\\xa0luminaldistention\\xa0and\\xa0nutrient\\xa0assimilation.\\xa0A\\xa0series\\xa0of\\xa0pathways\\xa0that\\xa0inhibit\\xa0gastric\\xa0acid\\xa0production\\xa0are\\xa0also\\xa0set\\xa0into\\xa0motion\\xa0during\\xa0these\\xa0phases.\\xa0The\\xa0GIhormone\\xa0somatostatin\\xa0is\\xa0released\\xa0from\\xa0endocrine\\xa0cells\\xa0found\\xa0in\\xa0the\\xa0gastric\\xa0mucosa\\xa0(D\\xa0cells)\\xa0in\\xa0response\\xa0to\\xa0HCl.\\xa0Somatostatin\\xa0can\\xa0inhibit\\xa0acidproduction\\xa0by\\xa0both\\xa0direct\\xa0(parietal\\xa0cell)\\xa0and\\xa0indirect\\xa0mechanisms\\xa0(decreased\\xa0histamine\\xa0release\\xa0from\\xa0ECL\\xa0cells,\\xa0ghrelin\\xa0release\\xa0from\\xa0Gr\\xa0cells\\xa0and\\xa0gastrin',\n",
       " 'production\\xa0by\\xa0both\\xa0direct\\xa0(parietal\\xa0cell)\\xa0and\\xa0indirect\\xa0mechanisms\\xa0(decreased\\xa0histamine\\xa0release\\xa0from\\xa0ECL\\xa0cells,\\xa0ghrelin\\xa0release\\xa0from\\xa0Gr\\xa0cells\\xa0and\\xa0gastrinrelease\\xa0from\\xa0G\\xa0cells).\\xa0Additional\\xa0neural\\xa0(central\\xa0and\\xa0peripheral)\\xa0and\\xa0humoral\\xa0(amylin,\\xa0atrial\\xa0natriuretic\\xa0peptide\\xa0[ANP],\\xa0cholecystokinin,\\xa0ghrelin,interleukin\\xa011\\xa0[IL\\xad11],\\xa0obestatin,\\xa0secretin,\\xa0and\\xa0serotonin)\\xa0factors\\xa0play\\xa0a\\xa0role\\xa0in\\xa0counterbalancing\\xa0acid\\xa0secretion.\\xa0Under\\xa0physiologic\\xa0circumstances,\\xa0thesephases\\xa0occur\\xa0simultaneously.\\xa0Ghrelin,\\xa0the\\xa0appetite\\xadregulating\\xa0hormone\\xa0expressed\\xa0in\\xa0Gr\\xa0cells\\xa0in\\xa0the\\xa0stomach,\\xa0and\\xa0its\\xa0related\\xa0peptide\\xa0motilin\\xa0(releasedfrom\\xa0the\\xa0duodenum)\\xa0may\\xa0increase\\xa0gastric\\xa0acid\\xa0secretion\\xa0through\\xa0stimulation\\xa0of\\xa0histamine\\xa0release\\xa0from\\xa0ECL\\xa0cells,\\xa0but\\xa0this\\xa0remains\\xa0to\\xa0be\\xa0confirmed.The\\xa0acid\\xadsecreting\\xa0parietal\\xa0cell\\xa0is\\xa0located\\xa0in\\xa0the\\xa0oxyntic\\xa0gland,\\xa0adjacent\\xa0to\\xa0other\\xa0cellular\\xa0elements\\xa0(ECL\\xa0cell,\\xa0D\\xa0cell)\\xa0important\\xa0in\\xa0the\\xa0gastric\\xa0secretoryprocess\\xa0(Fig.\\xa0324\\xad5).\\xa0This\\xa0unique\\xa0cell\\xa0also\\xa0secretes\\xa0intrinsic\\xa0factor\\xa0(IF)\\xa0and\\xa0IL\\xad11.\\xa0The\\xa0parietal\\xa0cell\\xa0expresses\\xa0receptors\\xa0for\\xa0several\\xa0stimulants\\xa0of\\xa0acidsecretion,\\xa0including\\xa0histamine\\xa0(H2),\\xa0gastrin\\xa0(cholecystokinin\\xa02/gastrin\\xa0receptor),\\xa0and\\xa0acetylcholine\\xa0(muscarinic,\\xa0M3).\\xa0Binding\\xa0of\\xa0histamine\\xa0to\\xa0the\\xa0H2receptor\\xa0leads\\xa0to\\xa0activation\\xa0of\\xa0adenylate\\xa0cyclase\\xa0and\\xa0the\\xa0phosphoinositol\\xa0pathways,\\xa0in\\xa0turn\\xa0resulting\\xa0in\\xa0an\\xa0increase\\xa0in\\xa0cyclic\\xa0adenosinemonophosphate\\xa0(AMP)\\xa0and\\xa0intracellular\\xa0calcium,\\xa0respectively.\\xa0Activation\\xa0of\\xa0the\\xa0gastrin\\xa0and\\xa0muscarinic\\xa0receptors\\xa0results\\xa0in\\xa0activation\\xa0of\\xa0the\\xa0proteinkinase\\xa0C/phosphoinositide\\xa0signaling\\xa0pathway.\\xa0Each\\xa0of\\xa0these\\xa0signaling\\xa0pathways\\xa0in\\xa0turn\\xa0regulates\\xa0a\\xa0series\\xa0of\\xa0downstream\\xa0kinase\\xa0cascades\\xa0that\\xa0controlthe\\xa0acid\\xadsecreting\\xa0pump,\\xa0H+,K+\\xadATPase.\\xa0The\\xa0discovery\\xa0that\\xa0different\\xa0ligands\\xa0and\\xa0their\\xa0corresponding\\xa0receptors\\xa0lead\\xa0to\\xa0activation\\xa0of\\xa0different\\xa0signalingpathways\\xa0explains\\xa0the\\xa0potentiation\\xa0of\\xa0acid\\xa0secretion\\xa0that\\xa0occurs\\xa0when\\xa0histamine\\xa0and\\xa0gastrin\\xa0or\\xa0acetylcholine\\xa0are\\xa0combined.\\xa0More\\xa0importantly,\\xa0this',\n",
       " 'pathways\\xa0explains\\xa0the\\xa0potentiation\\xa0of\\xa0acid\\xa0secretion\\xa0that\\xa0occurs\\xa0when\\xa0histamine\\xa0and\\xa0gastrin\\xa0or\\xa0acetylcholine\\xa0are\\xa0combined.\\xa0More\\xa0importantly,\\xa0thisobservation\\xa0explains\\xa0why\\xa0blocking\\xa0one\\xa0receptor\\xa0type\\xa0(H2)\\xa0decreases\\xa0acid\\xa0secretion\\xa0stimulated\\xa0by\\xa0agents\\xa0that\\xa0activate\\xa0a\\xa0different\\xa0pathway\\xa0(gastrin,acetylcholine).\\xa0Parietal\\xa0cells\\xa0also\\xa0express\\xa0receptors\\xa0for\\xa0ligands\\xa0that\\xa0inhibit\\xa0acid\\xa0production\\xa0(glucagon\\xadlike\\xa0peptide\\xad1,\\xa0prostaglandins,\\xa0somatostatin,EGF,\\xa0neurotensin,\\xa0and\\xa0urocortin).\\xa0Histamine\\xa0also\\xa0stimulates\\xa0gastric\\xa0acid\\xa0secretion\\xa0indirectly\\xa0by\\xa0activating\\xa0the\\xa0histamine\\xa0H3\\xa0receptor\\xa0on\\xa0D\\xa0cells,\\xa0whichinhibits\\xa0somatostatin\\xa0release.FIGURE\\xa0324\\xad5Regulation\\xa0of\\xa0gastric\\xa0acid\\xa0secretion\\xa0at\\xa0the\\xa0cellular\\xa0level.\\xa0ACh,\\xa0acetylcholine;\\xa0ANP,\\xa0atrial\\xa0natriuretic\\xa0peptide;\\xa0CGRP,\\xa0calcitonin\\xa0gene\\xadrelatedpeptide;\\xa0EC,\\xa0enterochromaffin;\\xa0ECL,\\xa0enterochromaffin\\xadlike;\\xa0GRP,\\xa0gastrin\\xadreleasing\\xa0peptide;\\xa0PACAP,\\xa0pituitary\\xa0adenylate\\xadcyclase\\xa0activating\\xa0peptide;\\xa0SST,somatostatin;\\xa0VIP,\\xa0vasoactive\\xa0intestinal\\xa0peptide.The\\xa0enzyme\\xa0H+,K+\\xadATPase\\xa0is\\xa0responsible\\xa0for\\xa0generating\\xa0the\\xa0large\\xa0concentration\\xa0of\\xa0H+.\\xa0It\\xa0is\\xa0a\\xa0membrane\\xadbound\\xa0protein\\xa0that\\xa0consists\\xa0of\\xa0two\\xa0subunits,\\xa0αand\\xa0β.\\xa0The\\xa0active\\xa0catalytic\\xa0site\\xa0is\\xa0found\\xa0within\\xa0the\\xa0α\\xa0subunit;\\xa0the\\xa0function\\xa0of\\xa0the\\xa0β\\xa0subunit\\xa0is\\xa0unclear.\\xa0This\\xa0enzyme\\xa0uses\\xa0the\\xa0chemical\\xa0energy\\xa0ofadenosine\\xa0triphosphate\\xa0(ATP)\\xa0to\\xa0transfer\\xa0H+\\xa0ions\\xa0from\\xa0parietal\\xa0cell\\xa0cytoplasm\\xa0to\\xa0the\\xa0secretory\\xa0canaliculi\\xa0in\\xa0exchange\\xa0for\\xa0K+.\\xa0The\\xa0H+,K+\\xadATPase\\xa0is\\xa0locatedwithin\\xa0the\\xa0secretory\\xa0canaliculus\\xa0and\\xa0in\\xa0nonsecretory\\xa0cytoplasmic\\xa0tubulovesicles.\\xa0The\\xa0tubulovesicles\\xa0are\\xa0impermeable\\xa0to\\xa0K+,\\xa0which\\xa0leads\\xa0to\\xa0an\\xa0inactivepump\\xa0in\\xa0this\\xa0location.\\xa0The\\xa0distribution\\xa0of\\xa0pumps\\xa0between\\xa0the\\xa0nonsecretory\\xa0vesicles\\xa0and\\xa0the\\xa0secretory\\xa0canaliculus\\xa0varies\\xa0according\\xa0to\\xa0parietal\\xa0cell()(Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0Accessibility',\n",
       " \"Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 6 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison's Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatonin\",\n",
       " 'BSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecell',\n",
       " \"Copyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21e\",\n",
       " \"+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'The\\xa0enzyme\\xa0H+,K+\\xadATPase\\xa0is\\xa0responsible\\xa0for\\xa0generating\\xa0the\\xa0large\\xa0concentration\\xa0of\\xa0H+.\\xa0It\\xa0is\\xa0a\\xa0membrane\\xadbound\\xa0protein\\xa0that\\xa0consists\\xa0of\\xa0two\\xa0subunits,\\xa0αand\\xa0β.\\xa0The\\xa0active\\xa0catalytic\\xa0site\\xa0is\\xa0found\\xa0within\\xa0the\\xa0α\\xa0subunit;\\xa0the\\xa0function\\xa0of\\xa0the\\xa0β\\xa0subunit\\xa0is\\xa0unclear.\\xa0This\\xa0enzyme\\xa0uses\\xa0the\\xa0chemical\\xa0energy\\xa0ofadenosine\\xa0triphosphate\\xa0(ATP)\\xa0to\\xa0transfer\\xa0H+\\xa0ions\\xa0from\\xa0parietal\\xa0cell\\xa0cytoplasm\\xa0to\\xa0the\\xa0secretory\\xa0canaliculi\\xa0in\\xa0exchange\\xa0for\\xa0K+.\\xa0The\\xa0H+,K+\\xadATPase\\xa0is\\xa0locatedwithin\\xa0the\\xa0secretory\\xa0canaliculus\\xa0and\\xa0in\\xa0nonsecretory\\xa0cytoplasmic\\xa0tubulovesicles.\\xa0The\\xa0tubulovesicles\\xa0are\\xa0impermeable\\xa0to\\xa0K+,\\xa0which\\xa0leads\\xa0to\\xa0an\\xa0inactivepump\\xa0in\\xa0this\\xa0location.\\xa0The\\xa0distribution\\xa0of\\xa0pumps\\xa0between\\xa0the\\xa0nonsecretory\\xa0vesicles\\xa0and\\xa0the\\xa0secretory\\xa0canaliculus\\xa0varies\\xa0according\\xa0to\\xa0parietal\\xa0cellactivity\\xa0(Fig.\\xa0324\\xad2).\\xa0Proton\\xa0pumps\\xa0are\\xa0recycled\\xa0back\\xa0to\\xa0the\\xa0inactive\\xa0state\\xa0in\\xa0cytoplasmic\\xa0vesicles\\xa0once\\xa0parietal\\xa0cell\\xa0activation\\xa0ceases.\\xa0Ezrin\\xa0(an\\xa0actinbinding\\xa0protein),\\xa0actin,\\xa0myosin,\\xa0soluble\\xa0N\\xadethylmaleimide\\xadsensitive\\xa0factor\\xa0attachment\\xa0protein\\xa0receptors\\xa0(SNAREs),\\xa0small\\xa0G\\xa0proteins\\xa0of\\xa0the\\xa0Rab\\xa0family,and\\xa0secretory\\xa0carrier\\xa0membrane\\xa0proteins\\xa0(SCAMPS)\\xa0are\\xa0postulated\\xa0to\\xa0participate\\xa0in\\xa0parietal\\xa0cell\\xa0membrane\\xa0translocation.\\xa0In\\xa0addition,\\xa0acid\\xa0secretionrequires\\xa0a\\xa0number\\xa0of\\xa0apical\\xa0and\\xa0basolateral\\xa0parietal\\xa0cell\\xa0membrane\\xa0chloride\\xa0and\\xa0potassium\\xa0channels.\\xa0Parietal\\xa0cells\\xa0also\\xa0express\\xa0members\\xa0of\\xa0the\\xa0sonichedgehog\\xa0(Shh)\\xa0family\\xa0proteins,\\xa0which\\xa0play\\xa0an\\xa0important\\xa0role\\xa0in\\xa0regulating\\xa0cell\\xa0types\\xa0in\\xa0multiple\\xa0organs.\\xa0This\\xa0family\\xa0of\\xa0proteins\\xa0may\\xa0also\\xa0regulate\\xa0celldifferentiation\\xa0as\\xa0well\\xa0as\\xa0restitution\\xa0of\\xa0mucosal\\xa0defense\\xa0in\\xa0the\\xa0gastric\\xa0epithelium.The\\xa0chief\\xa0cell,\\xa0found\\xa0primarily\\xa0in\\xa0the\\xa0gastric\\xa0fundus,\\xa0synthesizes\\xa0and\\xa0secretes\\xa0pepsinogen,\\xa0the\\xa0inactive\\xa0precursor\\xa0of\\xa0the\\xa0proteolytic\\xa0enzyme\\xa0pepsin.\\xa0Theacid\\xa0environment\\xa0within\\xa0the\\xa0stomach\\xa0leads\\xa0to\\xa0cleavage\\xa0of\\xa0the\\xa0inactive\\xa0precursor\\xa0to\\xa0pepsin\\xa0and\\xa0provides\\xa0the\\xa0low\\xa0pH\\xa0(<2)\\xa0required\\xa0for\\xa0pepsin\\xa0activity.',\n",
       " 'acid\\xa0environment\\xa0within\\xa0the\\xa0stomach\\xa0leads\\xa0to\\xa0cleavage\\xa0of\\xa0the\\xa0inactive\\xa0precursor\\xa0to\\xa0pepsin\\xa0and\\xa0provides\\xa0the\\xa0low\\xa0pH\\xa0(<2)\\xa0required\\xa0for\\xa0pepsin\\xa0activity.Pepsin\\xa0activity\\xa0is\\xa0significantly\\xa0diminished\\xa0at\\xa0a\\xa0pH\\xa0of\\xa04\\xa0and\\xa0irreversibly\\xa0inactivated\\xa0and\\xa0denatured\\xa0at\\xa0a\\xa0pH\\xa0of\\xa0≥7.\\xa0Many\\xa0of\\xa0the\\xa0secretagogues\\xa0that\\xa0stimulateacid\\xa0secretion\\xa0also\\xa0stimulate\\xa0pepsinogen\\xa0release.\\xa0The\\xa0precise\\xa0role\\xa0of\\xa0pepsin\\xa0in\\xa0the\\xa0pathogenesis\\xa0of\\xa0PUD\\xa0remains\\xa0to\\xa0be\\xa0established.PATHOPHYSIOLOGIC\\xa0BASIS\\xa0OF\\xa0PUDPUD\\xa0encompasses\\xa0both\\xa0gastric\\xa0ulcers\\xa0(GUs)\\xa0and\\xa0duodenal\\xa0ulcers\\xa0(DUs).\\xa0Ulcers\\xa0are\\xa0defined\\xa0as\\xa0breaks\\xa0in\\xa0the\\xa0mucosal\\xa0surface\\xa0>5\\xa0mm\\xa0in\\xa0size,\\xa0with\\xa0depthto\\xa0the\\xa0submucosa.\\xa0DUs\\xa0and\\xa0GUs\\xa0share\\xa0many\\xa0common\\xa0features\\xa0in\\xa0terms\\xa0of\\xa0pathogenesis,\\xa0diagnosis,\\xa0and\\xa0treatment,\\xa0but\\xa0several\\xa0factors\\xa0distinguish\\xa0themfrom\\xa0one\\xa0another.\\xa0H.\\xa0pylori\\xa0and\\xa0NSAIDs\\xa0are\\xa0the\\xa0most\\xa0common\\xa0risk\\xa0factors\\xa0for\\xa0PUD,\\xa0with\\xa0estimated\\xa0odds\\xa0ratios\\xa0in\\xa0the\\xa0United\\xa0States\\xa0of\\xa03.7\\xa0and\\xa03.3,respectively.\\xa0Additional\\xa0risk\\xa0factors\\xa0(odds\\xa0ratio)\\xa0include\\xa0chronic\\xa0obstructive\\xa0lung\\xa0disease\\xa0(2.34),\\xa0chronic\\xa0renal\\xa0insufficiency\\xa0(2.29),\\xa0current\\xa0tobacco\\xa0use(1.99),\\xa0former\\xa0tobacco\\xa0use\\xa0(1.55),\\xa0older\\xa0age\\xa0(1.67),\\xa0three\\xa0or\\xa0more\\xa0doctor\\xa0visits\\xa0in\\xa0a\\xa0year\\xa0(1.49),\\xa0coronary\\xa0heart\\xa0disease\\xa0(1.46),\\xa0former\\xa0alcohol\\xa0use\\xa0(1.29),African\\xadAmerican\\xa0race\\xa0(1.20),\\xa0obesity\\xa0(1.18),\\xa0and\\xa0diabetes\\xa0(1.13).\\xa0Selective\\xa0serotonin\\xa0reuptake\\xa0inhibitors\\xa0(SSRIs)\\xa0and\\xa0gastric\\xa0bypass\\xa0surgery\\xa0are\\xa0alsoassociated\\xa0with\\xa0an\\xa0increased\\xa0incidence\\xa0of\\xa0PUD.\\xa0A\\xa0rise\\xa0in\\xa0idiopathic\\xa0PUD\\xa0has\\xa0also\\xa0been\\xa0noted.\\xa0The\\xa0mechanisms\\xa0by\\xa0which\\xa0some\\xa0of\\xa0these\\xa0risk\\xa0factors\\xa0leadto\\xa0ulcer\\xa0disease\\xa0are\\xa0highlighted\\xa0below.EpidemiologyDUODENAL\\xa0ULCERSDUs\\xa0are\\xa0estimated\\xa0to\\xa0occur\\xa0in\\xa06–15%\\xa0of\\xa0the\\xa0Western\\xa0population.\\xa0The\\xa0incidence\\xa0of\\xa0DUs\\xa0declined\\xa0steadily\\xa0from\\xa01960\\xa0to\\xa01980\\xa0and\\xa0has\\xa0remained\\xa0stablesince\\xa0then.\\xa0The\\xa0death\\xa0rates,\\xa0need\\xa0for\\xa0surgery,\\xa0and\\xa0physician\\xa0visits\\xa0have\\xa0decreased\\xa0by\\xa0>50%\\xa0over\\xa0the\\xa0past\\xa030\\xa0years.\\xa0The\\xa0reason\\xa0for\\xa0the\\xa0reduction\\xa0in\\xa0the',\n",
       " 'since\\xa0then.\\xa0The\\xa0death\\xa0rates,\\xa0need\\xa0for\\xa0surgery,\\xa0and\\xa0physician\\xa0visits\\xa0have\\xa0decreased\\xa0by\\xa0>50%\\xa0over\\xa0the\\xa0past\\xa030\\xa0years.\\xa0The\\xa0reason\\xa0for\\xa0the\\xa0reduction\\xa0in\\xa0thefrequency\\xa0of\\xa0DUs\\xa0is\\xa0likely\\xa0related\\xa0to\\xa0the\\xa0decreasing\\xa0frequency\\xa0of\\xa0H.\\xa0pylori\\xa0in\\xa0turn\\xa0associated\\xa0with\\xa0overall\\xa0improved\\xa0sanitary\\xa0conditions\\xa0across\\xa0the\\xa0world.Before\\xa0the\\xa0discovery\\xa0of\\xa0H.\\xa0pylori,\\xa0the\\xa0natural\\xa0history\\xa0of\\xa0DUs\\xa0was\\xa0typified\\xa0by\\xa0frequent\\xa0recurrences\\xa0after\\xa0initial\\xa0therapy.\\xa0Eradication\\xa0of\\xa0H.\\xa0pylori\\xa0hasreduced\\xa0these\\xa0recurrence\\xa0rates\\xa0by\\xa0>80%.GASTRIC\\xa0ULCERSGUs\\xa0tend\\xa0to\\xa0occur\\xa0later\\xa0in\\xa0life\\xa0than\\xa0duodenal\\xa0lesions,\\xa0with\\xa0a\\xa0peak\\xa0incidence\\xa0reported\\xa0in\\xa0the\\xa0sixth\\xa0decade.\\xa0More\\xa0than\\xa0one\\xadhalf\\xa0of\\xa0GUs\\xa0occur\\xa0in\\xa0males\\xa0andare\\xa0less\\xa0common\\xa0than\\xa0DUs,\\xa0perhaps\\xa0due\\xa0to\\xa0the\\xa0higher\\xa0likelihood\\xa0of\\xa0GUs\\xa0being\\xa0silent\\xa0and\\xa0presenting\\xa0only\\xa0after\\xa0a\\xa0complication\\xa0develops.\\xa0Autopsystudies\\xa0suggest\\xa0a\\xa0similar\\xa0incidence\\xa0of\\xa0DUs\\xa0and\\xa0GUs.PathologyDUODENAL\\xa0ULCERSDUs\\xa0occur\\xa0most\\xa0often\\xa0in\\xa0the\\xa0first\\xa0portion\\xa0of\\xa0the\\xa0duodenum\\xa0(>95%),\\xa0with\\xa0~90%\\xa0located\\xa0within\\xa03\\xa0cm\\xa0of\\xa0the\\xa0pylorus.\\xa0They\\xa0are\\xa0usually\\xa0≤1\\xa0cm\\xa0in\\xa0diameter\\xa0butcan\\xa0occasionally\\xa0reach\\xa03–6\\xa0cm\\xa0(giant\\xa0ulcer).\\xa0Ulcers\\xa0are\\xa0sharply\\xa0demarcated,\\xa0with\\xa0depth\\xa0at\\xa0times\\xa0reaching\\xa0the\\xa0muscularis\\xa0propria.\\xa0The\\xa0base\\xa0of\\xa0the\\xa0ulceroften\\xa0consists\\xa0of\\xa0a\\xa0zone\\xa0of\\xa0eosinophilic\\xa0necrosis\\xa0with\\xa0surrounding\\xa0fibrosis.\\xa0Malignant\\xa0DUs\\xa0are\\xa0extremely\\xa0rare.GASTRIC\\xa0ULCERSIn\\xa0contrast\\xa0to\\xa0DUs,\\xa0GUs\\xa0can\\xa0represent\\xa0a\\xa0malignancy\\xa0and\\xa0should\\xa0be\\xa0biopsied\\xa0upon\\xa0discovery.\\xa0Benign\\xa0GUs\\xa0are\\xa0most\\xa0often\\xa0found\\xa0distal\\xa0to\\xa0the\\xa0junctionbetween\\xa0the\\xa0antrum\\xa0and\\xa0the\\xa0acid\\xa0secretory\\xa0mucosa.\\xa0Benign\\xa0GUs\\xa0are\\xa0quite\\xa0rare\\xa0in\\xa0the\\xa0gastric\\xa0fundus\\xa0and\\xa0are\\xa0histologically\\xa0similar\\xa0to\\xa0DUs.\\xa0Benign\\xa0GUsassociated\\xa0with\\xa0H.\\xa0pylori\\xa0are\\xa0also\\xa0associated\\xa0with\\xa0antral\\xa0gastritis.\\xa0In\\xa0contrast,\\xa0NSAID\\xadrelated\\xa0GUs\\xa0are\\xa0not\\xa0accompanied\\xa0by\\xa0chronic\\xa0active\\xa0gastritis\\xa0butYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle',\n",
       " \"Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 7 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,\",\n",
       " 'Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21e',\n",
       " \"EnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatin\",\n",
       " \"FUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'DUODENAL\\xa0ULCERSDUs\\xa0occur\\xa0most\\xa0often\\xa0in\\xa0the\\xa0first\\xa0portion\\xa0of\\xa0the\\xa0duodenum\\xa0(>95%),\\xa0with\\xa0~90%\\xa0located\\xa0within\\xa03\\xa0cm\\xa0of\\xa0the\\xa0pylorus.\\xa0They\\xa0are\\xa0usually\\xa0≤1\\xa0cm\\xa0in\\xa0diameter\\xa0butcan\\xa0occasionally\\xa0reach\\xa03–6\\xa0cm\\xa0(giant\\xa0ulcer).\\xa0Ulcers\\xa0are\\xa0sharply\\xa0demarcated,\\xa0with\\xa0depth\\xa0at\\xa0times\\xa0reaching\\xa0the\\xa0muscularis\\xa0propria.\\xa0The\\xa0base\\xa0of\\xa0the\\xa0ulceroften\\xa0consists\\xa0of\\xa0a\\xa0zone\\xa0of\\xa0eosinophilic\\xa0necrosis\\xa0with\\xa0surrounding\\xa0fibrosis.\\xa0Malignant\\xa0DUs\\xa0are\\xa0extremely\\xa0rare.GASTRIC\\xa0ULCERSIn\\xa0contrast\\xa0to\\xa0DUs,\\xa0GUs\\xa0can\\xa0represent\\xa0a\\xa0malignancy\\xa0and\\xa0should\\xa0be\\xa0biopsied\\xa0upon\\xa0discovery.\\xa0Benign\\xa0GUs\\xa0are\\xa0most\\xa0often\\xa0found\\xa0distal\\xa0to\\xa0the\\xa0junctionbetween\\xa0the\\xa0antrum\\xa0and\\xa0the\\xa0acid\\xa0secretory\\xa0mucosa.\\xa0Benign\\xa0GUs\\xa0are\\xa0quite\\xa0rare\\xa0in\\xa0the\\xa0gastric\\xa0fundus\\xa0and\\xa0are\\xa0histologically\\xa0similar\\xa0to\\xa0DUs.\\xa0Benign\\xa0GUsassociated\\xa0with\\xa0H.\\xa0pylori\\xa0are\\xa0also\\xa0associated\\xa0with\\xa0antral\\xa0gastritis.\\xa0In\\xa0contrast,\\xa0NSAID\\xadrelated\\xa0GUs\\xa0are\\xa0not\\xa0accompanied\\xa0by\\xa0chronic\\xa0active\\xa0gastritis\\xa0butmay\\xa0instead\\xa0have\\xa0evidence\\xa0of\\xa0a\\xa0chemical\\xa0gastropathy,\\xa0typified\\xa0by\\xa0foveolar\\xa0hyperplasia,\\xa0edema\\xa0of\\xa0the\\xa0lamina\\xa0propria,\\xa0and\\xa0epithelial\\xa0regeneration\\xa0in\\xa0theabsence\\xa0of\\xa0H.\\xa0pylori.\\xa0Extension\\xa0of\\xa0smooth\\xadmuscle\\xa0fibers\\xa0into\\xa0the\\xa0upper\\xa0portions\\xa0of\\xa0the\\xa0mucosa,\\xa0where\\xa0they\\xa0are\\xa0not\\xa0typically\\xa0found,\\xa0may\\xa0also\\xa0occur.PathophysiologyDUODENAL\\xa0ULCERSH.\\xa0pylori\\xa0and\\xa0NSAID\\xadinduced\\xa0injuries\\xa0account\\xa0for\\xa0the\\xa0majority\\xa0of\\xa0DUs.\\xa0Many\\xa0acid\\xa0secretory\\xa0abnormalities\\xa0have\\xa0been\\xa0described\\xa0in\\xa0DU\\xa0patients.\\xa0Of\\xa0these,average\\xa0basal\\xa0and\\xa0nocturnal\\xa0gastric\\xa0acid\\xa0secretion\\xa0appears\\xa0to\\xa0be\\xa0increased\\xa0in\\xa0DU\\xa0patients\\xa0as\\xa0compared\\xa0to\\xa0controls;\\xa0however,\\xa0the\\xa0level\\xa0of\\xa0overlapbetween\\xa0DU\\xa0patients\\xa0and\\xa0control\\xa0subjects\\xa0is\\xa0substantial.\\xa0The\\xa0reason\\xa0for\\xa0this\\xa0altered\\xa0secretory\\xa0process\\xa0is\\xa0unclear,\\xa0but\\xa0H.\\xa0pylori\\xa0infection\\xa0may\\xa0contribute.Bicarbonate\\xa0secretion\\xa0is\\xa0significantly\\xa0decreased\\xa0in\\xa0the\\xa0duodenal\\xa0bulb\\xa0of\\xa0patients\\xa0with\\xa0an\\xa0active\\xa0DU\\xa0as\\xa0compared\\xa0to\\xa0control\\xa0subjects.\\xa0H.\\xa0pylori\\xa0infectionmay\\xa0also\\xa0play\\xa0a\\xa0role\\xa0in\\xa0this\\xa0process\\xa0(see\\xa0below).GASTRIC\\xa0ULCERS',\n",
       " 'may\\xa0also\\xa0play\\xa0a\\xa0role\\xa0in\\xa0this\\xa0process\\xa0(see\\xa0below).GASTRIC\\xa0ULCERSAs\\xa0in\\xa0DUs,\\xa0the\\xa0majority\\xa0of\\xa0GUs\\xa0can\\xa0be\\xa0attributed\\xa0to\\xa0either\\xa0H.\\xa0pylori\\xa0or\\xa0NSAID\\xadinduced\\xa0mucosal\\xa0damage.\\xa0Prepyloric\\xa0GUs\\xa0or\\xa0those\\xa0in\\xa0the\\xa0body\\xa0associatedwith\\xa0a\\xa0DU\\xa0or\\xa0a\\xa0duodenal\\xa0scar\\xa0are\\xa0similar\\xa0in\\xa0pathogenesis\\xa0to\\xa0DUs.\\xa0Gastric\\xa0acid\\xa0output\\xa0(basal\\xa0and\\xa0stimulated)\\xa0tends\\xa0to\\xa0be\\xa0normal\\xa0or\\xa0decreased\\xa0in\\xa0GUpatients.\\xa0When\\xa0GUs\\xa0develop\\xa0in\\xa0the\\xa0presence\\xa0of\\xa0minimal\\xa0acid\\xa0levels,\\xa0impairment\\xa0of\\xa0mucosal\\xa0defense\\xa0factors\\xa0may\\xa0be\\xa0present.\\xa0GUs\\xa0have\\xa0been\\xa0classifiedbased\\xa0on\\xa0their\\xa0location:\\xa0type\\xa0I\\xa0occur\\xa0in\\xa0the\\xa0gastric\\xa0body\\xa0and\\xa0tend\\xa0to\\xa0be\\xa0associated\\xa0with\\xa0low\\xa0gastric\\xa0acid\\xa0production;\\xa0type\\xa0II\\xa0occur\\xa0in\\xa0the\\xa0antrum,\\xa0andgastric\\xa0acid\\xa0can\\xa0vary\\xa0from\\xa0low\\xa0to\\xa0normal;\\xa0type\\xa0III\\xa0occur\\xa0within\\xa03\\xa0cm\\xa0of\\xa0the\\xa0pylorus\\xa0and\\xa0are\\xa0commonly\\xa0accompanied\\xa0by\\xa0DUs\\xa0and\\xa0normal\\xa0or\\xa0high\\xa0gastricacid\\xa0production;\\xa0and\\xa0type\\xa0IV\\xa0are\\xa0found\\xa0in\\xa0the\\xa0cardia\\xa0and\\xa0are\\xa0associated\\xa0with\\xa0low\\xa0gastric\\xa0acid\\xa0production.H.\\xa0PYLORI\\xa0AND\\xa0ACID\\xa0PEPTIC\\xa0DISORDERSGastric\\xa0infection\\xa0with\\xa0the\\xa0bacterium\\xa0H.\\xa0pylori\\xa0accounts\\xa0for\\xa0the\\xa0majority\\xa0of\\xa0PUD\\xa0(Chap.\\xa0163).\\xa0This\\xa0organism\\xa0also\\xa0plays\\xa0a\\xa0role\\xa0in\\xa0the\\xa0development\\xa0ofgastric\\xa0mucosa\\xadassociated\\xa0lymphoid\\xa0tissue\\xa0(MALT)\\xa0lymphoma\\xa0and\\xa0gastric\\xa0adenocarcinoma.\\xa0Although\\xa0the\\xa0entire\\xa0genome\\xa0of\\xa0H.\\xa0pylori\\xa0has\\xa0beensequenced,\\xa0it\\xa0is\\xa0still\\xa0not\\xa0clear\\xa0how\\xa0this\\xa0organism,\\xa0which\\xa0resides\\xa0in\\xa0the\\xa0stomach,\\xa0causes\\xa0ulceration\\xa0in\\xa0the\\xa0duodenum.\\xa0H.\\xa0pylori\\xa0eradication\\xa0efforts\\xa0maylead\\xa0to\\xa0a\\xa0decrease\\xa0in\\xa0gastric\\xa0cancer\\xa0in\\xa0high\\xadrisk\\xa0populations,\\xa0particularly\\xa0in\\xa0individuals\\xa0who\\xa0have\\xa0not\\xa0developed\\xa0chronic\\xa0atrophic\\xa0gastritis\\xa0and\\xa0gastricmetaplasia.The\\xa0BacteriumThe\\xa0bacterium,\\xa0initially\\xa0named\\xa0Campylobacter\\xa0pyloridis,\\xa0is\\xa0a\\xa0gram\\xadnegative\\xa0microaerophilic\\xa0rod\\xa0found\\xa0most\\xa0commonly\\xa0in\\xa0the\\xa0deeper\\xa0portions\\xa0of\\xa0themucous\\xa0gel\\xa0coating\\xa0the\\xa0gastric\\xa0mucosa\\xa0or\\xa0between\\xa0the\\xa0mucous\\xa0layer\\xa0and\\xa0the\\xa0gastric\\xa0epithelium.\\xa0It\\xa0may\\xa0attach\\xa0to\\xa0gastric\\xa0epithelium\\xa0but\\xa0under\\xa0normalcircumstances\\xa0does\\xa0not\\xa0appear\\xa0to\\xa0invade\\xa0cells.\\xa0It\\xa0is\\xa0strategically\\xa0designed\\xa0to\\xa0live\\xa0within\\xa0the\\xa0aggressive\\xa0environment\\xa0of\\xa0the\\xa0stomach.\\xa0It\\xa0is\\xa0S\\xadshaped\\xa0(~0.5–',\n",
       " 'circumstances\\xa0does\\xa0not\\xa0appear\\xa0to\\xa0invade\\xa0cells.\\xa0It\\xa0is\\xa0strategically\\xa0designed\\xa0to\\xa0live\\xa0within\\xa0the\\xa0aggressive\\xa0environment\\xa0of\\xa0the\\xa0stomach.\\xa0It\\xa0is\\xa0S\\xadshaped\\xa0(~0.5–3\\xa0μm\\xa0in\\xa0size)\\xa0and\\xa0contains\\xa0multiple\\xa0sheathed\\xa0flagella.\\xa0Initially,\\xa0H.\\xa0pylori\\xa0resides\\xa0in\\xa0the\\xa0antrum\\xa0but,\\xa0over\\xa0time,\\xa0migrates\\xa0toward\\xa0the\\xa0more\\xa0proximalsegments\\xa0of\\xa0the\\xa0stomach.\\xa0The\\xa0organism\\xa0is\\xa0capable\\xa0of\\xa0transforming\\xa0into\\xa0a\\xa0coccoid\\xa0form,\\xa0which\\xa0represents\\xa0a\\xa0dormant\\xa0state\\xa0that\\xa0may\\xa0facilitate\\xa0survival\\xa0inadverse\\xa0conditions.\\xa0The\\xa0genome\\xa0of\\xa0H.\\xa0pylori\\xa0(1.65\\xa0million\\xa0base\\xa0pairs)\\xa0encodes\\xa0~1500\\xa0proteins.\\xa0Among\\xa0this\\xa0multitude\\xa0of\\xa0proteins\\xa0there\\xa0are\\xa0factors\\xa0thatare\\xa0essential\\xa0determinants\\xa0of\\xa0H.\\xa0pylori–mediated\\xa0pathogenesis\\xa0and\\xa0colonization\\xa0such\\xa0as\\xa0the\\xa0outer\\xa0membrane\\xa0protein\\xa0(Hop\\xa0proteins),\\xa0urease,\\xa0and\\xa0thevacuolating\\xa0cytotoxin\\xa0(Vac\\xa0A).\\xa0Moreover,\\xa0the\\xa0majority\\xa0of\\xa0H.\\xa0pylori\\xa0strains\\xa0contain\\xa0a\\xa0genomic\\xa0fragment\\xa0that\\xa0encodes\\xa0the\\xa0cag\\xa0pathogenicity\\xa0island\\xa0(cag\\xadPAI).\\xa0Several\\xa0of\\xa0the\\xa0genes\\xa0that\\xa0make\\xa0up\\xa0cag\\xadPAI\\xa0encode\\xa0components\\xa0of\\xa0a\\xa0type\\xa0IV\\xa0secretion\\xa0island\\xa0that\\xa0translocates\\xa0Cag\\xa0A\\xa0into\\xa0host\\xa0cells.\\xa0Once\\xa0in\\xa0the\\xa0cell,Cag\\xa0A\\xa0activates\\xa0a\\xa0series\\xa0of\\xa0cellular\\xa0events\\xa0important\\xa0in\\xa0cell\\xa0growth\\xa0and\\xa0cytokine\\xa0production.\\xa0H.\\xa0pylori\\xa0also\\xa0has\\xa0extensive\\xa0genetic\\xa0diversity\\xa0that\\xa0in\\xa0turnenhances\\xa0its\\xa0ability\\xa0to\\xa0promote\\xa0disease.\\xa0The\\xa0first\\xa0step\\xa0in\\xa0infection\\xa0by\\xa0H.\\xa0pylori\\xa0is\\xa0dependent\\xa0on\\xa0the\\xa0bacteria’s\\xa0motility\\xa0and\\xa0its\\xa0ability\\xa0to\\xa0produce\\xa0urease.Urease\\xa0produces\\xa0ammonia\\xa0from\\xa0urea,\\xa0an\\xa0essential\\xa0step\\xa0in\\xa0alkalinizing\\xa0the\\xa0surrounding\\xa0pH.\\xa0Additional\\xa0bacterial\\xa0factors\\xa0include\\xa0catalase,\\xa0lipase,adhesins,\\xa0platelet\\xadactivating\\xa0factor,\\xa0and\\xa0pic\\xa0B\\xa0(induces\\xa0cytokines).\\xa0Multiple\\xa0strains\\xa0of\\xa0H.\\xa0pylori\\xa0exist\\xa0and\\xa0are\\xa0characterized\\xa0by\\xa0their\\xa0ability\\xa0to\\xa0expressseveral\\xa0of\\xa0these\\xa0factors\\xa0(Cag\\xa0A,\\xa0Vac\\xa0A,\\xa0etc.).\\xa0It\\xa0is\\xa0possible\\xa0that\\xa0the\\xa0different\\xa0diseases\\xa0related\\xa0to\\xa0H.\\xa0pylori\\xa0infection\\xa0can\\xa0be\\xa0attributed\\xa0to\\xa0different\\xa0strains\\xa0ofthe\\xa0organism\\xa0with\\xa0distinct\\xa0pathogenic\\xa0features.Epidemiology',\n",
       " \"the\\xa0organism\\xa0with\\xa0distinct\\xa0pathogenic\\xa0features.EpidemiologyThe\\xa0prevalence\\xa0of\\xa0H.\\xa0pylori\\xa0varies\\xa0throughout\\xa0the\\xa0world\\xa0and\\xa0depends\\xa0largely\\xa0on\\xa0the\\xa0overall\\xa0standard\\xa0of\\xa0living\\xa0in\\xa0the\\xa0region.\\xa0In\\xa0developing\\xa0parts\\xa0of\\xa0theworld 80% of the population may be infected by the age of 20 whereas the prevalence is 20–50% in industrialized countries In contrast in the UnitedYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 8 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculus\",\n",
       " 'Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,',\n",
       " \"vessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.\",\n",
       " \"Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'Cag\\xa0A\\xa0activates\\xa0a\\xa0series\\xa0of\\xa0cellular\\xa0events\\xa0important\\xa0in\\xa0cell\\xa0growth\\xa0and\\xa0cytokine\\xa0production.\\xa0H.\\xa0pylori\\xa0also\\xa0has\\xa0extensive\\xa0genetic\\xa0diversity\\xa0that\\xa0in\\xa0turnenhances\\xa0its\\xa0ability\\xa0to\\xa0promote\\xa0disease.\\xa0The\\xa0first\\xa0step\\xa0in\\xa0infection\\xa0by\\xa0H.\\xa0pylori\\xa0is\\xa0dependent\\xa0on\\xa0the\\xa0bacteria’s\\xa0motility\\xa0and\\xa0its\\xa0ability\\xa0to\\xa0produce\\xa0urease.Urease\\xa0produces\\xa0ammonia\\xa0from\\xa0urea,\\xa0an\\xa0essential\\xa0step\\xa0in\\xa0alkalinizing\\xa0the\\xa0surrounding\\xa0pH.\\xa0Additional\\xa0bacterial\\xa0factors\\xa0include\\xa0catalase,\\xa0lipase,adhesins,\\xa0platelet\\xadactivating\\xa0factor,\\xa0and\\xa0pic\\xa0B\\xa0(induces\\xa0cytokines).\\xa0Multiple\\xa0strains\\xa0of\\xa0H.\\xa0pylori\\xa0exist\\xa0and\\xa0are\\xa0characterized\\xa0by\\xa0their\\xa0ability\\xa0to\\xa0expressseveral\\xa0of\\xa0these\\xa0factors\\xa0(Cag\\xa0A,\\xa0Vac\\xa0A,\\xa0etc.).\\xa0It\\xa0is\\xa0possible\\xa0that\\xa0the\\xa0different\\xa0diseases\\xa0related\\xa0to\\xa0H.\\xa0pylori\\xa0infection\\xa0can\\xa0be\\xa0attributed\\xa0to\\xa0different\\xa0strains\\xa0ofthe\\xa0organism\\xa0with\\xa0distinct\\xa0pathogenic\\xa0features.EpidemiologyThe\\xa0prevalence\\xa0of\\xa0H.\\xa0pylori\\xa0varies\\xa0throughout\\xa0the\\xa0world\\xa0and\\xa0depends\\xa0largely\\xa0on\\xa0the\\xa0overall\\xa0standard\\xa0of\\xa0living\\xa0in\\xa0the\\xa0region.\\xa0In\\xa0developing\\xa0parts\\xa0of\\xa0theworld,\\xa080%\\xa0of\\xa0the\\xa0population\\xa0may\\xa0be\\xa0infected\\xa0by\\xa0the\\xa0age\\xa0of\\xa020,\\xa0whereas\\xa0the\\xa0prevalence\\xa0is\\xa020–50%\\xa0in\\xa0industrialized\\xa0countries.\\xa0In\\xa0contrast,\\xa0in\\xa0the\\xa0UnitedStates,\\xa0this\\xa0organism\\xa0is\\xa0rare\\xa0in\\xa0childhood.\\xa0The\\xa0overall\\xa0prevalence\\xa0of\\xa0H.\\xa0pylori\\xa0in\\xa0the\\xa0United\\xa0States\\xa0is\\xa0~30%,\\xa0with\\xa0individuals\\xa0born\\xa0before\\xa01950\\xa0having\\xa0ahigher\\xa0rate\\xa0of\\xa0infection\\xa0than\\xa0those\\xa0born\\xa0later.\\xa0About\\xa010%\\xa0of\\xa0Americans\\xa0<30\\xa0years\\xa0of\\xa0age\\xa0are\\xa0colonized\\xa0with\\xa0the\\xa0bacteria.\\xa0The\\xa0rate\\xa0of\\xa0infection\\xa0with\\xa0H.pylori\\xa0in\\xa0industrialized\\xa0countries\\xa0has\\xa0decreased\\xa0substantially\\xa0in\\xa0recent\\xa0decades.\\xa0The\\xa0steady\\xa0increase\\xa0in\\xa0the\\xa0prevalence\\xa0of\\xa0H.\\xa0pylori\\xa0noted\\xa0withincreasing\\xa0age\\xa0is\\xa0due\\xa0primarily\\xa0to\\xa0a\\xa0cohort\\xa0effect,\\xa0reflecting\\xa0higher\\xa0transmission\\xa0during\\xa0a\\xa0period\\xa0in\\xa0which\\xa0the\\xa0earlier\\xa0cohorts\\xa0were\\xa0children.\\xa0It\\xa0has\\xa0beencalculated\\xa0through\\xa0mathematical\\xa0models\\xa0that\\xa0improved\\xa0sanitation\\xa0during\\xa0the\\xa0latter\\xa0half\\xa0of\\xa0the\\xa0nineteenth\\xa0century\\xa0dramatically\\xa0decreased\\xa0transmission',\n",
       " 'calculated\\xa0through\\xa0mathematical\\xa0models\\xa0that\\xa0improved\\xa0sanitation\\xa0during\\xa0the\\xa0latter\\xa0half\\xa0of\\xa0the\\xa0nineteenth\\xa0century\\xa0dramatically\\xa0decreased\\xa0transmissionof\\xa0H.\\xa0pylori.\\xa0Moreover,\\xa0with\\xa0the\\xa0present\\xa0rate\\xa0of\\xa0intervention,\\xa0the\\xa0organism\\xa0will\\xa0be\\xa0ultimately\\xa0eliminated\\xa0from\\xa0the\\xa0United\\xa0States.\\xa0Two\\xa0factors\\xa0thatpredispose\\xa0to\\xa0higher\\xa0colonization\\xa0rates\\xa0include\\xa0poor\\xa0socioeconomic\\xa0status\\xa0and\\xa0less\\xa0education.\\xa0These\\xa0factors,\\xa0not\\xa0race,\\xa0are\\xa0responsible\\xa0for\\xa0the\\xa0rate\\xa0ofH.\\xa0pylori\\xa0infection\\xa0in\\xa0blacks\\xa0and\\xa0Hispanic\\xa0Americans\\xa0being\\xa0double\\xa0the\\xa0rate\\xa0seen\\xa0in\\xa0whites\\xa0of\\xa0comparable\\xa0age.\\xa0Other\\xa0risk\\xa0factors\\xa0for\\xa0H.\\xa0pylori\\xa0infectionare\\xa0(1)\\xa0birth\\xa0or\\xa0residence\\xa0in\\xa0a\\xa0developing\\xa0country,\\xa0(2)\\xa0domestic\\xa0crowding,\\xa0(3)\\xa0unsanitary\\xa0living\\xa0conditions,\\xa0(4)\\xa0unclean\\xa0food\\xa0or\\xa0water,\\xa0and\\xa0(5)\\xa0exposureto\\xa0gastric\\xa0contents\\xa0of\\xa0an\\xa0infected\\xa0individual.Transmission\\xa0of\\xa0H.\\xa0pylori\\xa0occurs\\xa0from\\xa0person\\xa0to\\xa0person,\\xa0following\\xa0an\\xa0oral\\xadoral\\xa0or\\xa0fecal\\xadoral\\xa0route.\\xa0The\\xa0risk\\xa0of\\xa0H.\\xa0pylori\\xa0infection\\xa0is\\xa0declining\\xa0indeveloping\\xa0countries.\\xa0The\\xa0rate\\xa0of\\xa0infection\\xa0in\\xa0the\\xa0United\\xa0States\\xa0has\\xa0fallen\\xa0by\\xa0>50%\\xa0when\\xa0compared\\xa0to\\xa030\\xa0years\\xa0ago.PathophysiologyH.\\xa0pylori\\xa0infection\\xa0is\\xa0virtually\\xa0always\\xa0associated\\xa0with\\xa0a\\xa0chronic\\xa0active\\xa0gastritis,\\xa0but\\xa0only\\xa010–15%\\xa0of\\xa0infected\\xa0individuals\\xa0develop\\xa0frank\\xa0peptic\\xa0ulceration.The\\xa0basis\\xa0for\\xa0this\\xa0difference\\xa0is\\xa0unknown\\xa0but\\xa0is\\xa0likely\\xa0due\\xa0to\\xa0a\\xa0combination\\xa0of\\xa0host\\xa0and\\xa0bacterial\\xa0factors,\\xa0some\\xa0of\\xa0which\\xa0are\\xa0outlined\\xa0below.\\xa0Initialstudies\\xa0suggested\\xa0that\\xa0>90%\\xa0of\\xa0all\\xa0DUs\\xa0were\\xa0associated\\xa0with\\xa0H.\\xa0pylori,\\xa0but\\xa0H.\\xa0pylori\\xa0is\\xa0present\\xa0in\\xa0only\\xa030–60%\\xa0of\\xa0individuals\\xa0with\\xa0GUs\\xa0and\\xa050–70%\\xa0ofpatients\\xa0with\\xa0DUs.\\xa0The\\xa0pathophysiology\\xa0of\\xa0ulcers\\xa0not\\xa0associated\\xa0with\\xa0H.\\xa0pylori\\xa0or\\xa0NSAID\\xa0ingestion\\xa0(or\\xa0the\\xa0rare\\xa0Zollinger\\xadEllison\\xa0syndrome\\xa0[ZES])\\xa0isbecoming\\xa0more\\xa0relevant\\xa0as\\xa0the\\xa0incidence\\xa0of\\xa0H.\\xa0pylori\\xa0is\\xa0dropping,\\xa0particularly\\xa0in\\xa0the\\xa0Western\\xa0world\\xa0(see\\xa0below).The\\xa0particular\\xa0end\\xa0result\\xa0of\\xa0H.\\xa0pylori\\xa0infection\\xa0(gastritis,\\xa0PUD,\\xa0gastric\\xa0MALT\\xa0lymphoma,\\xa0gastric\\xa0cancer)\\xa0is\\xa0determined\\xa0by\\xa0a\\xa0complex\\xa0interplay\\xa0betweenbacterial\\xa0and\\xa0host\\xa0factors\\xa0(Fig.\\xa0324\\xad6).FIGURE\\xa0324\\xad6',\n",
       " \"The\\xa0particular\\xa0end\\xa0result\\xa0of\\xa0H.\\xa0pylori\\xa0infection\\xa0(gastritis,\\xa0PUD,\\xa0gastric\\xa0MALT\\xa0lymphoma,\\xa0gastric\\xa0cancer)\\xa0is\\xa0determined\\xa0by\\xa0a\\xa0complex\\xa0interplay\\xa0betweenbacterial\\xa0and\\xa0host\\xa0factors\\xa0(Fig.\\xa0324\\xad6).FIGURE\\xa0324\\xad6Outline\\xa0of\\xa0the\\xa0bacterial\\xa0and\\xa0host\\xa0factors\\xa0important\\xa0in\\xa0determining\\xa0H.\\xa0pylori–induced\\xa0gastrointestinal\\xa0disease.\\xa0MALT,\\xa0mucosal\\xadassociatedlymphoid\\xa0tissue.Bacterial\\xa0factors:\\xa0H.\\xa0pylori\\xa0is\\xa0able\\xa0to\\xa0facilitate\\xa0gastric\\xa0residence,\\xa0induce\\xa0mucosal\\xa0injury,\\xa0and\\xa0avoid\\xa0host\\xa0defense.\\xa0Different\\xa0strains\\xa0of\\xa0H.\\xa0pylori\\xa0producedifferent\\xa0virulence\\xa0factors\\xa0including\\xa0γ\\xadglutamyl\\xa0transpeptidase\\xa0(GGT),\\xa0cytotoxin\\xadassociated\\xa0gene\\xa0A\\xa0(Cag\\xa0A)\\xa0product,\\xa0and\\xa0virulence\\xa0componentsvacuolating\\xa0toxin\\xa0(Vac\\xa0A),\\xa0in\\xa0addition\\xa0to\\xa0pathogen\\xadassociated\\xa0molecular\\xa0patterns\\xa0(PAMPs)\\xa0such\\xa0as\\xa0flagella\\xa0and\\xa0lipopolysaccharide\\xa0(LPS).\\xa0A\\xa0specificregion\\xa0of\\xa0the\\xa0bacterial\\xa0genome,\\xa0the\\xa0pathogenicity\\xa0island\\xa0(cag\\xadPAI),\\xa0encodes\\xa0the\\xa0virulence\\xa0factors\\xa0Cag\\xa0A\\xa0and\\xa0pic\\xa0B.\\xa0Vac\\xa0A\\xa0also\\xa0contributes\\xa0toYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 9 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)\",\n",
       " 'Community-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison\\'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNerves',\n",
       " \"oxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommended\",\n",
       " \"exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'FIGURE\\xa0324\\xad6Outline\\xa0of\\xa0the\\xa0bacterial\\xa0and\\xa0host\\xa0factors\\xa0important\\xa0in\\xa0determining\\xa0H.\\xa0pylori–induced\\xa0gastrointestinal\\xa0disease.\\xa0MALT,\\xa0mucosal\\xadassociatedlymphoid\\xa0tissue.Bacterial\\xa0factors:\\xa0H.\\xa0pylori\\xa0is\\xa0able\\xa0to\\xa0facilitate\\xa0gastric\\xa0residence,\\xa0induce\\xa0mucosal\\xa0injury,\\xa0and\\xa0avoid\\xa0host\\xa0defense.\\xa0Different\\xa0strains\\xa0of\\xa0H.\\xa0pylori\\xa0producedifferent\\xa0virulence\\xa0factors\\xa0including\\xa0γ\\xadglutamyl\\xa0transpeptidase\\xa0(GGT),\\xa0cytotoxin\\xadassociated\\xa0gene\\xa0A\\xa0(Cag\\xa0A)\\xa0product,\\xa0and\\xa0virulence\\xa0componentsvacuolating\\xa0toxin\\xa0(Vac\\xa0A),\\xa0in\\xa0addition\\xa0to\\xa0pathogen\\xadassociated\\xa0molecular\\xa0patterns\\xa0(PAMPs)\\xa0such\\xa0as\\xa0flagella\\xa0and\\xa0lipopolysaccharide\\xa0(LPS).\\xa0A\\xa0specificregion\\xa0of\\xa0the\\xa0bacterial\\xa0genome,\\xa0the\\xa0pathogenicity\\xa0island\\xa0(cag\\xadPAI),\\xa0encodes\\xa0the\\xa0virulence\\xa0factors\\xa0Cag\\xa0A\\xa0and\\xa0pic\\xa0B.\\xa0Vac\\xa0A\\xa0also\\xa0contributes\\xa0topathogenicity,\\xa0although\\xa0it\\xa0is\\xa0not\\xa0encoded\\xa0within\\xa0the\\xa0pathogenicity\\xa0island.\\xa0These\\xa0virulence\\xa0factors,\\xa0in\\xa0conjunction\\xa0with\\xa0additional\\xa0bacterial\\xa0constituents,can\\xa0cause\\xa0mucosal\\xa0damage,\\xa0in\\xa0part\\xa0through\\xa0their\\xa0ability\\xa0to\\xa0target\\xa0the\\xa0host\\xa0immune\\xa0cells.\\xa0For\\xa0example,\\xa0Vac\\xa0A\\xa0targets\\xa0human\\xa0CD4\\xa0T\\xa0cells,\\xa0inhibiting\\xa0theirproliferation,\\xa0and\\xa0in\\xa0addition\\xa0can\\xa0disrupt\\xa0normal\\xa0function\\xa0of\\xa0B\\xa0cells,\\xa0CD8\\xa0T\\xa0cells,\\xa0macrophages,\\xa0and\\xa0mast\\xa0cells.\\xa0Multiple\\xa0studies\\xa0have\\xa0demonstrated\\xa0thatH.\\xa0pylori\\xa0strains\\xa0that\\xa0are\\xa0cag\\xadPAI\\xa0positive\\xa0are\\xa0associated\\xa0with\\xa0a\\xa0higher\\xa0risk\\xa0of\\xa0PUD,\\xa0premalignant\\xa0gastric\\xa0lesions,\\xa0and\\xa0gastric\\xa0cancer\\xa0than\\xa0are\\xa0strains\\xa0thatlack\\xa0the\\xa0cag\\xadPAI.\\xa0In\\xa0addition,\\xa0H.\\xa0pylori\\xa0may\\xa0directly\\xa0inhibit\\xa0parietal\\xa0cell\\xa0H+,K+\\xadATPase\\xa0activity\\xa0through\\xa0a\\xa0Cag\\xa0A–dependent\\xa0mechanism,\\xa0leading\\xa0in\\xa0part\\xa0tothe\\xa0low\\xa0acid\\xa0production\\xa0observed\\xa0after\\xa0acute\\xa0infection\\xa0with\\xa0the\\xa0organism.\\xa0Urease,\\xa0which\\xa0allows\\xa0the\\xa0bacteria\\xa0to\\xa0reside\\xa0in\\xa0the\\xa0acidic\\xa0stomach,\\xa0generatesNH3,\\xa0which\\xa0can\\xa0damage\\xa0epithelial\\xa0cells.\\xa0The\\xa0bacteria\\xa0produce\\xa0surface\\xa0factors\\xa0that\\xa0are\\xa0chemotactic\\xa0for\\xa0neutrophils\\xa0and\\xa0monocytes,\\xa0which\\xa0in\\xa0turncontribute\\xa0to\\xa0epithelial\\xa0cell\\xa0injury\\xa0(see\\xa0below).\\xa0H.\\xa0pylori\\xa0makes\\xa0proteases\\xa0and\\xa0phospholipases\\xa0that\\xa0break\\xa0down\\xa0the\\xa0glycoprotein\\xa0lipid\\xa0complex\\xa0of\\xa0the',\n",
       " 'contribute\\xa0to\\xa0epithelial\\xa0cell\\xa0injury\\xa0(see\\xa0below).\\xa0H.\\xa0pylori\\xa0makes\\xa0proteases\\xa0and\\xa0phospholipases\\xa0that\\xa0break\\xa0down\\xa0the\\xa0glycoprotein\\xa0lipid\\xa0complex\\xa0of\\xa0themucous\\xa0gel,\\xa0thus\\xa0reducing\\xa0the\\xa0efficacy\\xa0of\\xa0this\\xa0first\\xa0line\\xa0of\\xa0mucosal\\xa0defense.\\xa0H.\\xa0pylori\\xa0expresses\\xa0adhesins\\xa0(outer\\xa0membrane\\xa0proteins\\xa0like\\xa0BabA),\\xa0whichfacilitate\\xa0attachment\\xa0of\\xa0the\\xa0bacteria\\xa0to\\xa0gastric\\xa0epithelial\\xa0cells.\\xa0Although\\xa0LPS\\xa0of\\xa0gram\\xadnegative\\xa0bacteria\\xa0often\\xa0plays\\xa0an\\xa0important\\xa0role\\xa0in\\xa0the\\xa0infection,\\xa0H.pylori\\xa0LPS\\xa0has\\xa0low\\xa0immunologic\\xa0activity\\xa0compared\\xa0to\\xa0that\\xa0of\\xa0other\\xa0organisms.\\xa0It\\xa0may\\xa0promote\\xa0a\\xa0smoldering\\xa0chronic\\xa0inflammation.Host\\xa0factors:\\xa0Studies\\xa0in\\xa0twins\\xa0suggest\\xa0that\\xa0there\\xa0may\\xa0be\\xa0genetic\\xa0predisposition\\xa0to\\xa0acquire\\xa0H.\\xa0pylori.\\xa0The\\xa0inflammatory\\xa0response\\xa0to\\xa0H.\\xa0pylori\\xa0includesrecruitment\\xa0of\\xa0neutrophils,\\xa0lymphocytes\\xa0(T\\xa0and\\xa0B),\\xa0macrophages,\\xa0and\\xa0plasma\\xa0cells.\\xa0The\\xa0pathogen\\xa0leads\\xa0to\\xa0local\\xa0injury\\xa0by\\xa0binding\\xa0to\\xa0class\\xa0II\\xa0majorhistocompatibility\\xa0complex\\xa0(MHC)\\xa0molecules\\xa0expressed\\xa0on\\xa0gastric\\xa0epithelial\\xa0cells,\\xa0leading\\xa0to\\xa0cell\\xa0death\\xa0(apoptosis).\\xa0Moreover,\\xa0bacterial\\xa0strains\\xa0thatencode\\xa0cag\\xadPAI\\xa0can\\xa0introduce\\xa0Cag\\xa0A\\xa0into\\xa0the\\xa0host\\xa0cells,\\xa0leading\\xa0to\\xa0further\\xa0cell\\xa0injury\\xa0and\\xa0activation\\xa0of\\xa0cellular\\xa0pathways\\xa0involved\\xa0in\\xa0cytokine\\xa0productionand\\xa0repression\\xa0of\\xa0tumor\\xadsuppressor\\xa0genes.\\xa0Elevated\\xa0concentrations\\xa0of\\xa0multiple\\xa0cytokines\\xa0are\\xa0found\\xa0in\\xa0the\\xa0gastric\\xa0epithelium\\xa0of\\xa0H.\\xa0pylori–infectedindividuals,\\xa0including\\xa0interleukin\\xa0(IL)\\xa01α/β,\\xa0IL\\xad2,\\xa0IL\\xad6,\\xa0IL\\xad8,\\xa0tumor\\xa0necrosis\\xa0factor\\xa0(TNF)\\xa0α,\\xa0and\\xa0interferon\\xa0(IFN)\\xa0γ.\\xa0H.\\xa0pylori\\xa0infection\\xa0also\\xa0leads\\xa0to\\xa0both\\xa0amucosal\\xa0and\\xa0a\\xa0systemic\\xa0humoral\\xa0response,\\xa0which\\xa0does\\xa0not\\xa0lead\\xa0to\\xa0eradication\\xa0of\\xa0the\\xa0bacteria\\xa0but\\xa0further\\xa0compounds\\xa0epithelial\\xa0cell\\xa0injury.\\xa0Additionalmechanisms\\xa0by\\xa0which\\xa0H.\\xa0pylori\\xa0may\\xa0cause\\xa0epithelial\\xa0cell\\xa0injury\\xa0include\\xa0(1)\\xa0activated\\xa0neutrophil\\xadmediated\\xa0production\\xa0of\\xa0reactive\\xa0oxygen\\xa0or\\xa0nitrogenspecies\\xa0and\\xa0enhanced\\xa0epithelial\\xa0cell\\xa0turnover\\xa0and\\xa0(2)\\xa0apoptosis\\xa0related\\xa0to\\xa0interaction\\xa0with\\xa0T\\xa0cells\\xa0(T\\xa0helper\\xa01\\xa0[TH1]\\xa0cells)\\xa0and\\xa0IFN\\xadγ.\\xa0Finally,\\xa0the\\xa0human',\n",
       " 'species\\xa0and\\xa0enhanced\\xa0epithelial\\xa0cell\\xa0turnover\\xa0and\\xa0(2)\\xa0apoptosis\\xa0related\\xa0to\\xa0interaction\\xa0with\\xa0T\\xa0cells\\xa0(T\\xa0helper\\xa01\\xa0[TH1]\\xa0cells)\\xa0and\\xa0IFN\\xadγ.\\xa0Finally,\\xa0the\\xa0humanstomach\\xa0is\\xa0colonized\\xa0by\\xa0a\\xa0host\\xa0of\\xa0commensal\\xa0organisms\\xa0that\\xa0may\\xa0affect\\xa0the\\xa0likelihood\\xa0of\\xa0H.\\xa0pylori\\xa0infection\\xa0and\\xa0subsequent\\xa0mucosal\\xa0injury.\\xa0Moreover,colonization\\xa0of\\xa0the\\xa0stomach\\xa0with\\xa0H.\\xa0pylori\\xa0likely\\xa0alters\\xa0the\\xa0composition\\xa0of\\xa0the\\xa0gastric\\xa0microbiota.\\xa0The\\xa0impact\\xa0of\\xa0the\\xa0latter\\xa0on\\xa0gastric\\xa0pathophysiologyremains\\xa0unknown.\\xa0H.\\xa0pylori\\xa0also\\xa0appears\\xa0to\\xa0regulate\\xa0NO\\xa0formation\\xa0via\\xa0different\\xa0mechanisms\\xa0that\\xa0in\\xa0turn\\xa0may\\xa0contribute\\xa0to\\xa0the\\xa0organism’s\\xa0cytotoxiceffects.\\xa0Specifically,\\xa0H.\\xa0pylori–derived\\xa0factors,\\xa0such\\xa0as\\xa0urease,\\xa0or\\xa0the\\xa0bacterium\\xa0itself,\\xa0stimulate\\xa0NO\\xa0synthase\\xa0(NOS2)\\xa0expression\\xa0in\\xa0macrophages\\xa0and\\xa0ingastric\\xa0epithelial\\xa0cells\\xa0leading\\xa0to\\xa0NO\\xa0release\\xa0and\\xa0subsequent\\xa0cytotoxic\\xa0effect\\xa0on\\xa0surrounding\\xa0cells.\\xa0H.\\xa0pylori\\xa0also\\xa0leads\\xa0to\\xa0the\\xa0formation\\xa0of\\xa08\\xadnitroguanine\\xa0(8\\xadNO2\\xadGua),\\xa0which\\xa0in\\xa0conjunction\\xa0with\\xa0oncoprotein\\xa0Cag\\xa0A,\\xa0may\\xa0contribute\\xa0to\\xa0the\\xa0development\\xa0of\\xa0gastric\\xa0cancer.The\\xa0reason\\xa0for\\xa0H.\\xa0pylori–mediated\\xa0duodenal\\xa0ulceration\\xa0remains\\xa0unclear.\\xa0Studies\\xa0suggest\\xa0that\\xa0H.\\xa0pylori\\xa0associated\\xa0with\\xa0duodenal\\xa0ulceration\\xa0may\\xa0bemore\\xa0virulent.\\xa0In\\xa0addition,\\xa0certain\\xa0specific\\xa0bacterial\\xa0factors\\xa0such\\xa0as\\xa0the\\xa0DU\\xadpromoting\\xa0gene\\xa0A\\xa0(dupA)\\xa0may\\xa0be\\xa0associated\\xa0with\\xa0the\\xa0development\\xa0of\\xa0DUs.Another\\xa0potential\\xa0contributing\\xa0factor\\xa0is\\xa0that\\xa0gastric\\xa0metaplasia\\xa0in\\xa0the\\xa0duodenum\\xa0of\\xa0DU\\xa0patients,\\xa0which\\xa0may\\xa0be\\xa0due\\xa0to\\xa0high\\xa0acid\\xa0exposure\\xa0(see\\xa0below),permits\\xa0H.\\xa0pylori\\xa0to\\xa0bind\\xa0to\\xa0it\\xa0and\\xa0produce\\xa0local\\xa0injury\\xa0secondary\\xa0to\\xa0the\\xa0host\\xa0response.\\xa0Another\\xa0hypothesis\\xa0is\\xa0that\\xa0H.\\xa0pylori\\xa0antral\\xa0infection\\xa0could\\xa0leadto\\xa0increased\\xa0acid\\xa0production,\\xa0increased\\xa0duodenal\\xa0acid,\\xa0and\\xa0mucosal\\xa0injury.\\xa0Basal\\xa0and\\xa0stimulated\\xa0(meal,\\xa0gastrin\\xadreleasing\\xa0peptide\\xa0[GRP])\\xa0gastrinrelease\\xa0is\\xa0increased\\xa0in\\xa0H.\\xa0pylori–infected\\xa0individuals,\\xa0and\\xa0somatostatin\\xadsecreting\\xa0D\\xa0cells\\xa0may\\xa0be\\xa0decreased.\\xa0H.\\xa0pylori\\xa0infection\\xa0might\\xa0induce\\xa0increasedYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:',\n",
       " \"Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 10 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,\",\n",
       " 'Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21e',\n",
       " \"EnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatin\",\n",
       " \"FUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'remains\\xa0unknown.\\xa0H.\\xa0pylori\\xa0also\\xa0appears\\xa0to\\xa0regulate\\xa0NO\\xa0formation\\xa0via\\xa0different\\xa0mechanisms\\xa0that\\xa0in\\xa0turn\\xa0may\\xa0contribute\\xa0to\\xa0the\\xa0organism s\\xa0cytotoxiceffects.\\xa0Specifically,\\xa0H.\\xa0pylori–derived\\xa0factors,\\xa0such\\xa0as\\xa0urease,\\xa0or\\xa0the\\xa0bacterium\\xa0itself,\\xa0stimulate\\xa0NO\\xa0synthase\\xa0(NOS2)\\xa0expression\\xa0in\\xa0macrophages\\xa0and\\xa0ingastric\\xa0epithelial\\xa0cells\\xa0leading\\xa0to\\xa0NO\\xa0release\\xa0and\\xa0subsequent\\xa0cytotoxic\\xa0effect\\xa0on\\xa0surrounding\\xa0cells.\\xa0H.\\xa0pylori\\xa0also\\xa0leads\\xa0to\\xa0the\\xa0formation\\xa0of\\xa08\\xadnitroguanine\\xa0(8\\xadNO2\\xadGua),\\xa0which\\xa0in\\xa0conjunction\\xa0with\\xa0oncoprotein\\xa0Cag\\xa0A,\\xa0may\\xa0contribute\\xa0to\\xa0the\\xa0development\\xa0of\\xa0gastric\\xa0cancer.The\\xa0reason\\xa0for\\xa0H.\\xa0pylori–mediated\\xa0duodenal\\xa0ulceration\\xa0remains\\xa0unclear.\\xa0Studies\\xa0suggest\\xa0that\\xa0H.\\xa0pylori\\xa0associated\\xa0with\\xa0duodenal\\xa0ulceration\\xa0may\\xa0bemore\\xa0virulent.\\xa0In\\xa0addition,\\xa0certain\\xa0specific\\xa0bacterial\\xa0factors\\xa0such\\xa0as\\xa0the\\xa0DU\\xadpromoting\\xa0gene\\xa0A\\xa0(dupA)\\xa0may\\xa0be\\xa0associated\\xa0with\\xa0the\\xa0development\\xa0of\\xa0DUs.Another\\xa0potential\\xa0contributing\\xa0factor\\xa0is\\xa0that\\xa0gastric\\xa0metaplasia\\xa0in\\xa0the\\xa0duodenum\\xa0of\\xa0DU\\xa0patients,\\xa0which\\xa0may\\xa0be\\xa0due\\xa0to\\xa0high\\xa0acid\\xa0exposure\\xa0(see\\xa0below),permits\\xa0H.\\xa0pylori\\xa0to\\xa0bind\\xa0to\\xa0it\\xa0and\\xa0produce\\xa0local\\xa0injury\\xa0secondary\\xa0to\\xa0the\\xa0host\\xa0response.\\xa0Another\\xa0hypothesis\\xa0is\\xa0that\\xa0H.\\xa0pylori\\xa0antral\\xa0infection\\xa0could\\xa0leadto\\xa0increased\\xa0acid\\xa0production,\\xa0increased\\xa0duodenal\\xa0acid,\\xa0and\\xa0mucosal\\xa0injury.\\xa0Basal\\xa0and\\xa0stimulated\\xa0(meal,\\xa0gastrin\\xadreleasing\\xa0peptide\\xa0[GRP])\\xa0gastrinrelease\\xa0is\\xa0increased\\xa0in\\xa0H.\\xa0pylori–infected\\xa0individuals,\\xa0and\\xa0somatostatin\\xadsecreting\\xa0D\\xa0cells\\xa0may\\xa0be\\xa0decreased.\\xa0H.\\xa0pylori\\xa0infection\\xa0might\\xa0induce\\xa0increasedacid\\xa0secretion\\xa0through\\xa0both\\xa0direct\\xa0and\\xa0indirect\\xa0actions\\xa0of\\xa0H.\\xa0pylori\\xa0and\\xa0proinflammatory\\xa0cytokines\\xa0(IL\\xad8,\\xa0TNF,\\xa0and\\xa0IL\\xad1)\\xa0on\\xa0G,\\xa0D,\\xa0and\\xa0parietal\\xa0cells\\xa0(Fig.324\\xad7).\\xa0GUs,\\xa0in\\xa0contrast,\\xa0are\\xa0associated\\xa0with\\xa0H.\\xa0pylori–induced\\xa0pangastritis\\xa0and\\xa0normal\\xa0or\\xa0low\\xa0gastric\\xa0acid\\xa0secretion.\\xa0The\\xa0H.\\xa0pylori–mediated\\xa0decreasein\\xa0gastric\\xa0acid\\xa0secretion\\xa0after\\xa0long\\xadterm\\xa0infection\\xa0may\\xa0be\\xa0due\\xa0to\\xa0the\\xa0bacterium’s\\xa0ability\\xa0to\\xa0inhibit\\xa0H+,K+\\xadATPase\\xa0expression.\\xa0H.\\xa0pylori\\xa0infection\\xa0has\\xa0also',\n",
       " 'in\\xa0gastric\\xa0acid\\xa0secretion\\xa0after\\xa0long\\xadterm\\xa0infection\\xa0may\\xa0be\\xa0due\\xa0to\\xa0the\\xa0bacterium’s\\xa0ability\\xa0to\\xa0inhibit\\xa0H+,K+\\xadATPase\\xa0expression.\\xa0H.\\xa0pylori\\xa0infection\\xa0has\\xa0alsobeen\\xa0associated\\xa0with\\xa0decreased\\xa0duodenal\\xa0mucosal\\xa0bicarbonate\\xa0production.\\xa0Data\\xa0supporting\\xa0and\\xa0contradicting\\xa0each\\xa0of\\xa0these\\xa0interesting\\xa0theories\\xa0havebeen\\xa0demonstrated.\\xa0Thus,\\xa0the\\xa0mechanism\\xa0by\\xa0which\\xa0H.\\xa0pylori\\xa0infection\\xa0of\\xa0the\\xa0stomach\\xa0leads\\xa0to\\xa0duodenal\\xa0ulceration\\xa0remains\\xa0to\\xa0be\\xa0established.\\xa0Thedevelopment\\xa0of\\xa0in\\xa0vitro\\xa0organoids,\\xa0a\\xa0unique\\xa0tool\\xa0that\\xa0replicates\\xa0in\\xa0part\\xa0the\\xa0multicellular\\xa0structure\\xa0of\\xa0the\\xa0intact\\xa0organ,\\xa0provides\\xa0a\\xa0more\\xa0physiologicmodel\\xa0for\\xa0experimentation\\xa0in\\xa0an\\xa0invitro\\xa0system.\\xa0Moreover,\\xa0the\\xa0development\\xa0of\\xa0advanced\\xa0microscopic\\xa0optical\\xa0imaging\\xa0techniques\\xa0will\\xa0lead\\xa0to\\xa0increasedunderstanding\\xa0of\\xa0parietal\\xa0cell\\xa0adaptation\\xa0to\\xa0H.\\xa0pylori\\xa0infection.FIGURE\\xa0324\\xad7Summary\\xa0of\\xa0potential\\xa0mechanisms\\xa0by\\xa0which\\xa0H.\\xa0pylori\\xa0may\\xa0lead\\xa0to\\xa0gastric\\xa0secretory\\xa0abnormalities.\\xa0D,\\xa0somatostatin\\xa0cell;\\xa0ECL,enterochromaffin\\xadlike\\xa0cell;\\xa0G,\\xa0G\\xa0cell.\\xa0(Reproduced\\xa0with\\xa0permission\\xa0from\\xa0J\\xa0Calam\\xa0et\\xa0al:\\xa0How\\xa0does\\xa0Helicobacter\\xa0pylori\\xa0cause\\xa0mucosal\\xa0damage?\\xa0Its\\xa0effecton\\xa0acid\\xa0and\\xa0gastrin\\xa0physiology.\\xa0Gastroenterology\\xa0113:543,\\xa01997.)In\\xa0summary,\\xa0the\\xa0final\\xa0effect\\xa0of\\xa0H.\\xa0pylori\\xa0on\\xa0the\\xa0GI\\xa0tract\\xa0is\\xa0variable\\xa0and\\xa0determined\\xa0by\\xa0microbial\\xa0and\\xa0host\\xa0factors.\\xa0The\\xa0type\\xa0and\\xa0distribution\\xa0of\\xa0gastritiscorrelate\\xa0with\\xa0the\\xa0ultimate\\xa0gastric\\xa0and\\xa0duodenal\\xa0pathology\\xa0observed.\\xa0Specifically,\\xa0the\\xa0presence\\xa0of\\xa0antral\\xadpredominant\\xa0gastritis\\xa0is\\xa0associated\\xa0with\\xa0DUformation;\\xa0gastritis\\xa0involving\\xa0primarily\\xa0the\\xa0corpus\\xa0predisposes\\xa0to\\xa0the\\xa0development\\xa0of\\xa0GUs,\\xa0gastric\\xa0atrophy,\\xa0and\\xa0ultimately\\xa0gastric\\xa0carcinoma\\xa0(Fig.\\xa0324\\xad8).FIGURE\\xa0324\\xad8Natural\\xa0history\\xa0of\\xa0H.\\xa0pylori\\xa0infection.\\xa0MALT,\\xa0mucosal\\xadassociated\\xa0lymphoid\\xa0tissue.\\xa0(From\\xa0S\\xa0Suerbaum,\\xa0P\\xa0Michetti:\\xa0Helicobacter\\xa0pylori\\xa0infection.\\xa0NEngl\\xa0J\\xa0Med\\xa0347:1175,\\xa02002.\\xa0Copyright\\xa0©\\xa02002\\xa0Massachusetts\\xa0Medical\\xa0Society.\\xa0Reprinted\\xa0with\\xa0permission\\xa0from\\xa0Massachusetts\\xa0Medical\\xa0Society.)Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138',\n",
       " \"Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 11 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,\",\n",
       " 'Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21e',\n",
       " \"EnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatin\",\n",
       " \"FUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " '8).FIGURE\\xa0324\\xad8Natural\\xa0history\\xa0of\\xa0H.\\xa0pylori\\xa0infection.\\xa0MALT,\\xa0mucosal\\xadassociated\\xa0lymphoid\\xa0tissue.\\xa0(From\\xa0S\\xa0Suerbaum,\\xa0P\\xa0Michetti:\\xa0Helicobacter\\xa0pylori\\xa0infection.\\xa0NEngl\\xa0J\\xa0Med\\xa0347:1175,\\xa02002.\\xa0Copyright\\xa0©\\xa02002\\xa0Massachusetts\\xa0Medical\\xa0Society.\\xa0Reprinted\\xa0with\\xa0permission\\xa0from\\xa0Massachusetts\\xa0Medical\\xa0Society.)NSAID\\xadINDUCED\\xa0DISEASEEpidemiologyNSAIDs\\xa0represent\\xa0a\\xa0group\\xa0of\\xa0the\\xa0most\\xa0commonly\\xa0used\\xa0medications\\xa0in\\xa0the\\xa0world\\xa0and\\xa0the\\xa0United\\xa0States.\\xa0It\\xa0is\\xa0estimated\\xa0that\\xa07\\xa0billion\\xa0dollars\\xa0per\\xa0year\\xa0arespent\\xa0on\\xa0NSAIDs\\xa0worldwide,\\xa0with\\xa0>30\\xa0billion\\xa0over\\xadthe\\xadcounter\\xa0tablets\\xa0sold.\\xa0More\\xa0than\\xa030\\xa0million\\xa0individuals\\xa0take\\xa0NSAIDs,\\xa0with\\xa0>100\\xa0millionprescriptions\\xa0sold\\xa0yearly\\xa0in\\xa0the\\xa0United\\xa0States\\xa0alone.\\xa0In\\xa0fact,\\xa0after\\xa0the\\xa0introduction\\xa0of\\xa0COX\\xad2\\xa0inhibitors\\xa0in\\xa0the\\xa0year\\xa02000,\\xa0the\\xa0number\\xa0of\\xa0prescriptionswritten\\xa0for\\xa0NSAIDs\\xa0was\\xa0>111\\xa0million\\xa0at\\xa0a\\xa0cost\\xa0of\\xa0$4.8\\xa0billion.\\xa0Side\\xa0effects\\xa0and\\xa0complications\\xa0due\\xa0to\\xa0NSAIDs\\xa0are\\xa0considered\\xa0the\\xa0most\\xa0common\\xa0drug\\xadrelated\\xa0toxicities\\xa0in\\xa0the\\xa0United\\xa0States.\\xa0The\\xa0spectrum\\xa0of\\xa0NSAID\\xadinduced\\xa0morbidity\\xa0ranges\\xa0from\\xa0nausea\\xa0and\\xa0dyspepsia\\xa0(prevalence\\xa0reported\\xa0as\\xa0high\\xa0as50–60%)\\xa0to\\xa0a\\xa0serious\\xa0GI\\xa0complication\\xa0such\\xa0as\\xa0endoscopy\\xaddocumented\\xa0peptic\\xa0ulceration\\xa0(15–30%\\xa0of\\xa0individuals\\xa0taking\\xa0NSAIDs\\xa0regularly),\\xa0which\\xa0iscomplicated\\xa0by\\xa0bleeding\\xa0or\\xa0perforation\\xa0in\\xa0as\\xa0many\\xa0as\\xa01.5%\\xa0of\\xa0users\\xa0per\\xa0year.\\xa0It\\xa0is\\xa0estimated\\xa0that\\xa0NSAID\\xadinduced\\xa0GI\\xa0bleeding\\xa0accounts\\xa0for\\xa060,000–120,000\\xa0hospital\\xa0admissions\\xa0per\\xa0year,\\xa0and\\xa0deaths\\xa0related\\xa0to\\xa0NSAID\\xadinduced\\xa0toxicity\\xa0may\\xa0be\\xa0as\\xa0high\\xa0as\\xa016,000\\xa0per\\xa0year\\xa0in\\xa0the\\xa0United\\xa0States.Approximately\\xa04–5%\\xa0of\\xa0patients\\xa0develop\\xa0symptomatic\\xa0ulcers\\xa0within\\xa01\\xa0year.\\xa0Unfortunately,\\xa0dyspeptic\\xa0symptoms\\xa0do\\xa0not\\xa0correlate\\xa0with\\xa0NSAID\\xadinducedpathology.\\xa0Over\\xa080%\\xa0of\\xa0patients\\xa0with\\xa0serious\\xa0NSAID\\xadrelated\\xa0complications\\xa0did\\xa0not\\xa0have\\xa0preceding\\xa0dyspepsia.\\xa0In\\xa0view\\xa0of\\xa0the\\xa0lack\\xa0of\\xa0warning\\xa0signs,\\xa0it\\xa0isimportant\\xa0to\\xa0identify\\xa0patients\\xa0who\\xa0are\\xa0at\\xa0increased\\xa0risk\\xa0for\\xa0morbidity\\xa0and\\xa0mortality\\xa0related\\xa0to\\xa0NSAID\\xa0usage.\\xa0Even\\xa075\\xa0mg/d\\xa0of\\xa0aspirin\\xa0may\\xa0lead\\xa0to\\xa0serious',\n",
       " 'important\\xa0to\\xa0identify\\xa0patients\\xa0who\\xa0are\\xa0at\\xa0increased\\xa0risk\\xa0for\\xa0morbidity\\xa0and\\xa0mortality\\xa0related\\xa0to\\xa0NSAID\\xa0usage.\\xa0Even\\xa075\\xa0mg/d\\xa0of\\xa0aspirin\\xa0may\\xa0lead\\xa0to\\xa0seriousGI\\xa0ulceration;\\xa0thus,\\xa0no\\xa0dose\\xa0of\\xa0NSAID\\xa0is\\xa0completely\\xa0safe.\\xa0In\\xa0fact,\\xa0the\\xa0incidence\\xa0of\\xa0mucosal\\xa0injury\\xa0(ulcers\\xa0and\\xa0erosions)\\xa0in\\xa0patients\\xa0taking\\xa0low\\xaddoseaspirin\\xa0(75–325\\xa0mg)\\xa0has\\xa0been\\xa0estimated\\xa0to\\xa0range\\xa0from\\xa0as\\xa0low\\xa0as\\xa08\\xa0to\\xa0as\\xa0high\\xa0as\\xa060%.\\xa0It\\xa0appears\\xa0that\\xa0H.\\xa0pylori\\xa0infection\\xa0increases\\xa0the\\xa0risk\\xa0of\\xa0PUD\\xadassociated\\xa0GI\\xa0bleeding\\xa0in\\xa0chronic\\xa0users\\xa0of\\xa0low\\xaddose\\xa0aspirin.\\xa0Established\\xa0risk\\xa0factors\\xa0include\\xa0advanced\\xa0age,\\xa0history\\xa0of\\xa0ulcer,\\xa0concomitant\\xa0use\\xa0ofglucocorticoids,\\xa0high\\xaddose\\xa0NSAIDs,\\xa0multiple\\xa0NSAIDs,\\xa0concomitant\\xa0use\\xa0of\\xa0anticoagulants\\xa0or\\xa0clopidogrel,\\xa0and\\xa0serious\\xa0or\\xa0multisystem\\xa0disease.\\xa0Possiblerisk\\xa0factors\\xa0include\\xa0concomitant\\xa0infection\\xa0with\\xa0H.\\xa0pylori,\\xa0cigarette\\xa0smoking,\\xa0and\\xa0alcohol\\xa0consumption.\\xa0SSRIs\\xa0have\\xa0a\\xa0synergistic\\xa0effect\\xa0on\\xa0the\\xa0inductionof\\xa0GI\\xa0bleeding\\xa0believed\\xa0to\\xa0be\\xa0due\\xa0in\\xa0part\\xa0to\\xa0this\\xa0agent’s\\xa0ability\\xa0to\\xa0decrease\\xa0platelet\\xa0aggregation\\xa0by\\xa0decreasing\\xa0serotonin\\xa0content\\xa0in\\xa0platelets.PathophysiologyProstaglandins\\xa0play\\xa0a\\xa0critical\\xa0role\\xa0in\\xa0maintaining\\xa0gastroduodenal\\xa0mucosal\\xa0integrity\\xa0and\\xa0repair.\\xa0It\\xa0therefore\\xa0follows\\xa0that\\xa0interruption\\xa0of\\xa0prostaglandinsynthesis\\xa0can\\xa0impair\\xa0mucosal\\xa0defense\\xa0and\\xa0repair,\\xa0thus\\xa0facilitating\\xa0mucosal\\xa0injury\\xa0via\\xa0a\\xa0systemic\\xa0mechanism.\\xa0Animal\\xa0studies\\xa0have\\xa0demonstrated\\xa0thatneutrophil\\xa0adherence\\xa0to\\xa0the\\xa0gastric\\xa0microcirculation\\xa0plays\\xa0an\\xa0essential\\xa0role\\xa0in\\xa0the\\xa0initiation\\xa0of\\xa0NSAID\\xadinduced\\xa0mucosal\\xa0injury.\\xa0A\\xa0summary\\xa0of\\xa0thepathogenetic\\xa0pathways\\xa0by\\xa0which\\xa0systemically\\xa0administered\\xa0NSAIDs\\xa0may\\xa0lead\\xa0to\\xa0mucosal\\xa0injury\\xa0is\\xa0shown\\xa0in\\xa0Fig.\\xa0324\\xad9.\\xa0Single\\xa0nucleotidepolymorphisms\\xa0(SNPs)\\xa0have\\xa0been\\xa0found\\xa0in\\xa0several\\xa0genes,\\xa0including\\xa0those\\xa0encoding\\xa0certain\\xa0subtypes\\xa0of\\xa0cytochrome\\xa0P450\\xa0(see\\xa0below),\\xa0IL\\xad1β\\xa0(IL\\xad1β),angiotensinogen\\xa0(AGT),\\xa0and\\xa0an\\xa0organic\\xa0ion\\xa0transporting\\xa0polypeptide\\xa0(SLCO1B1),\\xa0but\\xa0these\\xa0findings\\xa0need\\xa0confirmation\\xa0in\\xa0larger\\xadscale\\xa0studies.FIGURE\\xa0324\\xad9',\n",
       " \"angiotensinogen\\xa0(AGT),\\xa0and\\xa0an\\xa0organic\\xa0ion\\xa0transporting\\xa0polypeptide\\xa0(SLCO1B1),\\xa0but\\xa0these\\xa0findings\\xa0need\\xa0confirmation\\xa0in\\xa0larger\\xadscale\\xa0studies.FIGURE\\xa0324\\xad9Effect of nonsteroidal anti inflammatory drugs (NSAIDs) on different target organs The action of NSAIDs on major organs includingYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 12 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrin\",\n",
       " 'CopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorins',\n",
       " \"Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculus\",\n",
       " \"Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'Prostaglandins\\xa0play\\xa0a\\xa0critical\\xa0role\\xa0in\\xa0maintaining\\xa0gastroduodenal\\xa0mucosal\\xa0integrity\\xa0and\\xa0repair.\\xa0It\\xa0therefore\\xa0follows\\xa0that\\xa0interruption\\xa0of\\xa0prostaglandinsynthesis\\xa0can\\xa0impair\\xa0mucosal\\xa0defense\\xa0and\\xa0repair,\\xa0thus\\xa0facilitating\\xa0mucosal\\xa0injury\\xa0via\\xa0a\\xa0systemic\\xa0mechanism.\\xa0Animal\\xa0studies\\xa0have\\xa0demonstrated\\xa0thatneutrophil\\xa0adherence\\xa0to\\xa0the\\xa0gastric\\xa0microcirculation\\xa0plays\\xa0an\\xa0essential\\xa0role\\xa0in\\xa0the\\xa0initiation\\xa0of\\xa0NSAID\\xadinduced\\xa0mucosal\\xa0injury.\\xa0A\\xa0summary\\xa0of\\xa0thepathogenetic\\xa0pathways\\xa0by\\xa0which\\xa0systemically\\xa0administered\\xa0NSAIDs\\xa0may\\xa0lead\\xa0to\\xa0mucosal\\xa0injury\\xa0is\\xa0shown\\xa0in\\xa0Fig.\\xa0324\\xad9.\\xa0Single\\xa0nucleotidepolymorphisms\\xa0(SNPs)\\xa0have\\xa0been\\xa0found\\xa0in\\xa0several\\xa0genes,\\xa0including\\xa0those\\xa0encoding\\xa0certain\\xa0subtypes\\xa0of\\xa0cytochrome\\xa0P450\\xa0(see\\xa0below),\\xa0IL\\xad1β\\xa0(IL\\xad1β),angiotensinogen\\xa0(AGT),\\xa0and\\xa0an\\xa0organic\\xa0ion\\xa0transporting\\xa0polypeptide\\xa0(SLCO1B1),\\xa0but\\xa0these\\xa0findings\\xa0need\\xa0confirmation\\xa0in\\xa0larger\\xadscale\\xa0studies.FIGURE\\xa0324\\xad9Effect\\xa0of\\xa0nonsteroidal\\xa0anti\\xadinflammatory\\xa0drugs\\xa0(NSAIDs)\\xa0on\\xa0different\\xa0target\\xa0organs.\\xa0The\\xa0action\\xa0of\\xa0NSAIDs\\xa0on\\xa0major\\xa0organs\\xa0includingstomach,\\xa0small\\xa0intestine,\\xa0heart,\\xa0liver,\\xa0kidney,\\xa0respiratory\\xa0tract,\\xa0and\\xa0brain\\xa0is\\xa0mainly\\xa0mediated\\xa0through\\xa0prostaglandin\\xa0endoperoxide\\xa0synthase\\xa0(PGHS)–dependent\\xa0prostanoid\\xa0modulation\\xa0and\\xa0alteration\\xa0of\\xa0mitochondrial\\xa0functional\\xa0integrity\\xa0leading\\xa0to\\xa0mitochondrial\\xa0oxidative\\xa0stress\\xa0(MOS)\\xa0generation,depolarization\\xa0of\\xa0mitochondrial\\xa0transmembrane\\xa0potential\\xa0(ΔΨm),\\xa0and\\xa0consequent\\xa0cell\\xa0death.\\xa0However,\\xa0in\\xa0heart,\\xa0low\\xaddose\\xa0aspirin\\xa0actually\\xa0offerscardioprotection\\xa0through\\xa0antithrombotic\\xa0effect.\\xa0Upward\\xa0arrows\\xa0indicate\\xa0upregulation/elevation;\\xa0downward\\xa0arrows\\xa0indicatedownregulation/depletion.\\xa0(From\\xa0S\\xa0Bindu\\xa0et\\xa0al:\\xa0Non\\xadsteroidal\\xa0anti\\xadinflammatory\\xa0drugs\\xa0(NSAIDs)\\xa0and\\xa0organ\\xa0damage:\\xa0A\\xa0current\\xa0perspective.\\xa0BiochemPharmacol\\xa0180:114147,\\xa02020.)Injury\\xa0to\\xa0the\\xa0mucosa\\xa0also\\xa0occurs\\xa0as\\xa0a\\xa0result\\xa0of\\xa0the\\xa0topical\\xa0use\\xa0of\\xa0NSAIDs,\\xa0leading\\xa0to\\xa0increased\\xa0epithelial\\xa0surface\\xa0permeability.\\xa0Aspirin\\xa0and\\xa0many\\xa0NSAIDs',\n",
       " 'Pharmacol\\xa0180:114147,\\xa02020.)Injury\\xa0to\\xa0the\\xa0mucosa\\xa0also\\xa0occurs\\xa0as\\xa0a\\xa0result\\xa0of\\xa0the\\xa0topical\\xa0use\\xa0of\\xa0NSAIDs,\\xa0leading\\xa0to\\xa0increased\\xa0epithelial\\xa0surface\\xa0permeability.\\xa0Aspirin\\xa0and\\xa0many\\xa0NSAIDsare\\xa0weak\\xa0acids\\xa0that\\xa0remain\\xa0in\\xa0a\\xa0nonionized\\xa0lipophilic\\xa0form\\xa0when\\xa0found\\xa0within\\xa0the\\xa0acid\\xa0environment\\xa0of\\xa0the\\xa0stomach.\\xa0Under\\xa0these\\xa0conditions,\\xa0NSAIDsmigrate\\xa0across\\xa0lipid\\xa0membranes\\xa0of\\xa0epithelial\\xa0cells,\\xa0leading\\xa0to\\xa0cell\\xa0injury\\xa0once\\xa0trapped\\xa0intracellularly\\xa0in\\xa0an\\xa0ionized\\xa0form.\\xa0Topical\\xa0NSAIDs\\xa0can\\xa0also\\xa0alterthe\\xa0surface\\xa0mucous\\xa0layer,\\xa0permitting\\xa0back\\xa0diffusion\\xa0of\\xa0H+\\xa0and\\xa0pepsin,\\xa0leading\\xa0to\\xa0further\\xa0epithelial\\xa0cell\\xa0damage.\\xa0Moreover,\\xa0enteric\\xadcoated\\xa0or\\xa0bufferedpreparations\\xa0are\\xa0also\\xa0associated\\xa0with\\xa0risk\\xa0of\\xa0peptic\\xa0ulceration.\\xa0NSAIDs\\xa0can\\xa0also\\xa0lead\\xa0to\\xa0mucosal\\xa0injury\\xa0via\\xa0production\\xa0of\\xa0additional\\xa0proinflammatorymediators\\xa0such\\xa0as\\xa0TNF\\xa0and\\xa0leukotrienes\\xa0through\\xa0simultaneous\\xa0activation\\xa0of\\xa0the\\xa0lipoxygenase\\xa0pathway.The\\xa0interplay\\xa0between\\xa0H.\\xa0pylori\\xa0and\\xa0NSAIDs\\xa0in\\xa0the\\xa0pathogenesis\\xa0of\\xa0PUD\\xa0is\\xa0complex.\\xa0Meta\\xadanalysis\\xa0supports\\xa0the\\xa0conclusion\\xa0that\\xa0each\\xa0of\\xa0theseaggressive\\xa0factors\\xa0is\\xa0an\\xa0independent\\xa0and\\xa0synergistic\\xa0risk\\xa0factor\\xa0for\\xa0PUD\\xa0and\\xa0its\\xa0complications\\xa0such\\xa0as\\xa0GI\\xa0bleeding.\\xa0For\\xa0example,\\xa0eradication\\xa0of\\xa0H.\\xa0pylorireduces\\xa0the\\xa0likelihood\\xa0of\\xa0GI\\xa0complications\\xa0in\\xa0high\\xadrisk\\xa0individuals\\xa0to\\xa0levels\\xa0observed\\xa0in\\xa0individuals\\xa0with\\xa0average\\xa0risk\\xa0of\\xa0NSAID\\xadinduced\\xa0complications.In\\xa0summary,\\xa0NSAID\\xadinduced\\xa0mucosal\\xa0injury\\xa0is\\xa0a\\xa0multifaceted\\xa0process\\xa0involving\\xa0the\\xa0interaction\\xa0of\\xa0multiple,\\xa0often\\xa0synergistic\\xa0pathophysiologicprocesses\\xa0at\\xa0the\\xa0epithelium\\xa0and\\xa0surrounding\\xa0interfaces.PATHOGENETIC\\xa0FACTORS\\xa0UNRELATED\\xa0TO\\xa0H.\\xa0PYLORI\\xa0AND\\xa0NSAIDS\\xa0IN\\xa0ACID\\xa0PEPTIC\\xa0DISEASECigarette\\xa0smoking\\xa0has\\xa0been\\xa0implicated\\xa0in\\xa0the\\xa0pathogenesis\\xa0of\\xa0PUD.\\xa0Not\\xa0only\\xa0have\\xa0smokers\\xa0been\\xa0found\\xa0to\\xa0have\\xa0ulcers\\xa0more\\xa0frequently\\xa0than\\xa0dononsmokers,\\xa0but\\xa0smoking\\xa0appears\\xa0to\\xa0decrease\\xa0healing\\xa0rates,\\xa0impair\\xa0response\\xa0to\\xa0therapy,\\xa0and\\xa0increase\\xa0ulcer\\xadrelated\\xa0complications\\xa0such\\xa0asperforation.\\xa0The\\xa0mechanism\\xa0responsible\\xa0for\\xa0increased\\xa0ulcer\\xa0diathesis\\xa0in\\xa0smokers\\xa0is\\xa0unknown.\\xa0Theories\\xa0have\\xa0included\\xa0altered\\xa0gastric\\xa0emptying,',\n",
       " 'perforation.\\xa0The\\xa0mechanism\\xa0responsible\\xa0for\\xa0increased\\xa0ulcer\\xa0diathesis\\xa0in\\xa0smokers\\xa0is\\xa0unknown.\\xa0Theories\\xa0have\\xa0included\\xa0altered\\xa0gastric\\xa0emptying,decreased\\xa0proximal\\xa0duodenal\\xa0bicarbonate\\xa0production,\\xa0increased\\xa0risk\\xa0for\\xa0H.\\xa0pylori\\xa0infection,\\xa0and\\xa0cigarette\\xadinduced\\xa0generation\\xa0of\\xa0noxious\\xa0mucosal\\xa0freeradicals.\\xa0Genetic\\xa0predisposition\\xa0may\\xa0play\\xa0a\\xa0role\\xa0in\\xa0ulcer\\xa0development.\\xa0First\\xaddegree\\xa0relatives\\xa0of\\xa0DU\\xa0patients\\xa0are\\xa0three\\xa0times\\xa0as\\xa0likely\\xa0to\\xa0develop\\xa0an\\xa0ulcer;however,\\xa0the\\xa0potential\\xa0role\\xa0of\\xa0H.\\xa0pylori\\xa0infection\\xa0in\\xa0contacts\\xa0is\\xa0a\\xa0major\\xa0consideration.\\xa0Increased\\xa0frequencies\\xa0of\\xa0blood\\xa0group\\xa0O\\xa0and\\xa0of\\xa0the\\xa0nonsecretorstatus\\xa0have\\xa0also\\xa0been\\xa0implicated\\xa0as\\xa0genetic\\xa0risk\\xa0factors\\xa0for\\xa0peptic\\xa0diathesis.\\xa0However,\\xa0H.\\xa0pylori\\xa0preferentially\\xa0binds\\xa0to\\xa0group\\xa0O\\xa0antigens.\\xa0Additionalgenetic\\xa0factors\\xa0have\\xa0been\\xa0postulated\\xa0to\\xa0predispose\\xa0certain\\xa0individuals\\xa0to\\xa0developing\\xa0PUD\\xa0and/or\\xa0upper\\xa0GI\\xa0bleeding.\\xa0Specifically,\\xa0genes\\xa0encoding\\xa0theNSAID\\xadmetabolizing\\xa0enzymes\\xa0cytochrome\\xa0P450\\xa02C9\\xa0and\\xa02C8\\xa0(CYP2C9\\xa0and\\xa0CYP2C8)\\xa0are\\xa0potential\\xa0susceptibility\\xa0genes\\xa0for\\xa0NSAID\\xadinduced\\xa0PUD,\\xa0butunfortunately,\\xa0the\\xa0studies\\xa0have\\xa0not\\xa0been\\xa0consistent\\xa0in\\xa0demonstrating\\xa0this\\xa0association.\\xa0In\\xa0a\\xa0United\\xa0Kingdom\\xa0study,\\xa0the\\xa0CYP2C19*17\\xa0gain\\xadof\\xadfunctionpolymorphism\\xa0was\\xa0associated\\xa0with\\xa0PUD\\xa0in\\xa0a\\xa0Caucasian\\xa0cohort,\\xa0irrespective\\xa0of\\xa0ulcer\\xa0etiology.\\xa0These\\xa0findings\\xa0need\\xa0to\\xa0be\\xa0confirmed\\xa0in\\xa0broader\\xa0studies.Psychological\\xa0stress\\xa0has\\xa0been\\xa0thought\\xa0to\\xa0contribute\\xa0to\\xa0PUD,\\xa0but\\xa0studies\\xa0examining\\xa0the\\xa0role\\xa0of\\xa0psychological\\xa0factors\\xa0in\\xa0its\\xa0pathogenesis\\xa0have\\xa0generatedconflicting\\xa0results.\\xa0Although\\xa0PUD\\xa0is\\xa0associated\\xa0with\\xa0certain\\xa0personality\\xa0traits\\xa0(neuroticism),\\xa0these\\xa0same\\xa0traits\\xa0are\\xa0also\\xa0present\\xa0in\\xa0individuals\\xa0withYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 13 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2Arachidonicacid',\n",
       " \"Page 13 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison's Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH'HCIpH20MucusHCOS2PH7.0MucusH'Unstirred layerofmucus and bicarbonate2）\",\n",
       " 'Gastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21e',\n",
       " \"ParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastric\",\n",
       " \"CopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'decreased\\xa0proximal\\xa0duodenal\\xa0bicarbonate\\xa0production,\\xa0increased\\xa0risk\\xa0for\\xa0H.\\xa0pylori\\xa0infection,\\xa0and\\xa0cigarette\\xadinduced\\xa0generation\\xa0of\\xa0noxious\\xa0mucosal\\xa0freeradicals.\\xa0Genetic\\xa0predisposition\\xa0may\\xa0play\\xa0a\\xa0role\\xa0in\\xa0ulcer\\xa0development.\\xa0First\\xaddegree\\xa0relatives\\xa0of\\xa0DU\\xa0patients\\xa0are\\xa0three\\xa0times\\xa0as\\xa0likely\\xa0to\\xa0develop\\xa0an\\xa0ulcer;however,\\xa0the\\xa0potential\\xa0role\\xa0of\\xa0H.\\xa0pylori\\xa0infection\\xa0in\\xa0contacts\\xa0is\\xa0a\\xa0major\\xa0consideration.\\xa0Increased\\xa0frequencies\\xa0of\\xa0blood\\xa0group\\xa0O\\xa0and\\xa0of\\xa0the\\xa0nonsecretorstatus\\xa0have\\xa0also\\xa0been\\xa0implicated\\xa0as\\xa0genetic\\xa0risk\\xa0factors\\xa0for\\xa0peptic\\xa0diathesis.\\xa0However,\\xa0H.\\xa0pylori\\xa0preferentially\\xa0binds\\xa0to\\xa0group\\xa0O\\xa0antigens.\\xa0Additionalgenetic\\xa0factors\\xa0have\\xa0been\\xa0postulated\\xa0to\\xa0predispose\\xa0certain\\xa0individuals\\xa0to\\xa0developing\\xa0PUD\\xa0and/or\\xa0upper\\xa0GI\\xa0bleeding.\\xa0Specifically,\\xa0genes\\xa0encoding\\xa0theNSAID\\xadmetabolizing\\xa0enzymes\\xa0cytochrome\\xa0P450\\xa02C9\\xa0and\\xa02C8\\xa0(CYP2C9\\xa0and\\xa0CYP2C8)\\xa0are\\xa0potential\\xa0susceptibility\\xa0genes\\xa0for\\xa0NSAID\\xadinduced\\xa0PUD,\\xa0butunfortunately,\\xa0the\\xa0studies\\xa0have\\xa0not\\xa0been\\xa0consistent\\xa0in\\xa0demonstrating\\xa0this\\xa0association.\\xa0In\\xa0a\\xa0United\\xa0Kingdom\\xa0study,\\xa0the\\xa0CYP2C19*17\\xa0gain\\xadof\\xadfunctionpolymorphism\\xa0was\\xa0associated\\xa0with\\xa0PUD\\xa0in\\xa0a\\xa0Caucasian\\xa0cohort,\\xa0irrespective\\xa0of\\xa0ulcer\\xa0etiology.\\xa0These\\xa0findings\\xa0need\\xa0to\\xa0be\\xa0confirmed\\xa0in\\xa0broader\\xa0studies.Psychological\\xa0stress\\xa0has\\xa0been\\xa0thought\\xa0to\\xa0contribute\\xa0to\\xa0PUD,\\xa0but\\xa0studies\\xa0examining\\xa0the\\xa0role\\xa0of\\xa0psychological\\xa0factors\\xa0in\\xa0its\\xa0pathogenesis\\xa0have\\xa0generatedconflicting\\xa0results.\\xa0Although\\xa0PUD\\xa0is\\xa0associated\\xa0with\\xa0certain\\xa0personality\\xa0traits\\xa0(neuroticism),\\xa0these\\xa0same\\xa0traits\\xa0are\\xa0also\\xa0present\\xa0in\\xa0individuals\\xa0withnonulcer\\xa0dyspepsia\\xa0(NUD)\\xa0and\\xa0other\\xa0functional\\xa0and\\xa0organic\\xa0disorders.Diet\\xa0has\\xa0also\\xa0been\\xa0thought\\xa0to\\xa0play\\xa0a\\xa0role\\xa0in\\xa0peptic\\xa0diseases.\\xa0Certain\\xa0foods\\xa0and\\xa0beverages\\xa0can\\xa0cause\\xa0dyspepsia,\\xa0but\\xa0no\\xa0convincing\\xa0studies\\xa0indicate\\xa0anassociation\\xa0between\\xa0ulcer\\xa0formation\\xa0and\\xa0a\\xa0specific\\xa0diet.\\xa0Specific\\xa0chronic\\xa0disorders\\xa0have\\xa0been\\xa0shown\\xa0to\\xa0have\\xa0a\\xa0strong\\xa0association\\xa0with\\xa0PUD:\\xa0(1)advanced\\xa0age,\\xa0(2)\\xa0chronic\\xa0pulmonary\\xa0disease,\\xa0(3)\\xa0chronic\\xa0renal\\xa0failure,\\xa0(4)\\xa0cirrhosis,\\xa0(5)\\xa0nephrolithiasis,\\xa0(6)\\xa0α1\\xadantitrypsin\\xa0deficiency,\\xa0and\\xa0(7)\\xa0systemic',\n",
       " 'advanced\\xa0age,\\xa0(2)\\xa0chronic\\xa0pulmonary\\xa0disease,\\xa0(3)\\xa0chronic\\xa0renal\\xa0failure,\\xa0(4)\\xa0cirrhosis,\\xa0(5)\\xa0nephrolithiasis,\\xa0(6)\\xa0α1\\xadantitrypsin\\xa0deficiency,\\xa0and\\xa0(7)\\xa0systemicmastocytosis.\\xa0Disorders\\xa0with\\xa0a\\xa0possible\\xa0association\\xa0are\\xa0(1)\\xa0hyperparathyroidism,\\xa0(2)\\xa0coronary\\xa0artery\\xa0disease,\\xa0(3)\\xa0polycythemia\\xa0vera,\\xa0(4)\\xa0chronicpancreatitis,\\xa0(5)\\xa0former\\xa0alcohol\\xa0use,\\xa0(6)\\xa0obesity,\\xa0(7)\\xa0African\\xadAmerican\\xa0race,\\xa0and\\xa0(8)\\xa0three\\xa0or\\xa0more\\xa0doctor\\xa0visits\\xa0in\\xa0a\\xa0year.Multiple\\xa0factors\\xa0play\\xa0a\\xa0role\\xa0in\\xa0the\\xa0pathogenesis\\xa0of\\xa0PUD.\\xa0The\\xa0two\\xa0predominant\\xa0causes\\xa0are\\xa0H.\\xa0pylori\\xa0infection\\xa0and\\xa0NSAID\\xa0ingestion.\\xa0PUD\\xa0not\\xa0related\\xa0to\\xa0H.pylori\\xa0or\\xa0NSAIDs\\xa0is\\xa0increasing.\\xa0Other\\xa0less\\xa0common\\xa0causes\\xa0of\\xa0PUD\\xa0are\\xa0shown\\xa0in\\xa0Table\\xa0324\\xad1.\\xa0These\\xa0etiologic\\xa0agents\\xa0should\\xa0be\\xa0considered\\xa0as\\xa0theincidence\\xa0of\\xa0H.\\xa0pylori\\xa0is\\xa0decreasing.\\xa0Independent\\xa0of\\xa0the\\xa0inciting\\xa0or\\xa0injurious\\xa0agent,\\xa0peptic\\xa0ulcers\\xa0develop\\xa0as\\xa0a\\xa0result\\xa0of\\xa0an\\xa0imbalance\\xa0between\\xa0mucosalprotection/repair\\xa0and\\xa0aggressive\\xa0factors.\\xa0Gastric\\xa0acid\\xa0plays\\xa0an\\xa0important\\xa0role\\xa0in\\xa0mucosal\\xa0injury.TABLE\\xa0324\\xad1Causes\\xa0of\\xa0Ulcers\\xa0Not\\xa0Caused\\xa0by\\xa0Helicobacter\\xa0pylori\\xa0and\\xa0NSAIDsPathogenesis\\xa0of\\xa0Non\\xadHp\\xa0and\\xa0Non\\xadNSAID\\xa0Ulcer\\xa0DiseaseInfection\\u2003Cytomegalovirus\\u2003Herpes\\xa0simplex\\xa0virus\\u2003Helicobacter\\xa0heilmanniiDrug/Toxin\\u2003Bisphosphonates\\u2003Chemotherapy\\u2003Clopidogrel\\u2003Crack\\xa0cocaine\\u2003Glucocorticoids\\xa0(when\\xa0combined\\xa0with\\xa0NSAIDs)\\u2003Mycophenolate\\xa0mofetil\\u2003Potassium\\xa0chlorideMiscellaneous\\u2003Basophilia\\xa0in\\xa0myeloproliferative\\xa0disease\\u2003Duodenal\\xa0obstruction\\xa0(e.g.,\\xa0annular\\xa0pancreas)\\u2003Infiltrating\\xa0disease\\u2003IschemiaYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 14 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2',\n",
       " \"PhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison's Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH'HCIpH20MucusHCOS2PH7.0MucusH'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCO\",\n",
       " 'Adrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietal',\n",
       " \"Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritis\",\n",
       " \"Antral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'Abbreviations:\\xa0Hp,\\xa0H.\\xa0pylori;\\xa0NSAIDs,\\xa0nonsteroidal\\xa0anti\\xadinflammatory\\xa0drugs.Multiple\\xa0factors\\xa0play\\xa0a\\xa0role\\xa0in\\xa0the\\xa0pathogenesis\\xa0of\\xa0PUD.\\xa0The\\xa0two\\xa0predominant\\xa0causes\\xa0are\\xa0H.\\xa0pylori\\xa0infection\\xa0and\\xa0NSAID\\xa0ingestion.\\xa0PUD\\xa0not\\xa0related\\xa0to\\xa0H.pylori\\xa0or\\xa0NSAIDs\\xa0is\\xa0increasing.\\xa0Other\\xa0less\\xa0common\\xa0causes\\xa0of\\xa0PUD\\xa0are\\xa0shown\\xa0in\\xa0Table\\xa0324\\xad1.\\xa0These\\xa0etiologic\\xa0agents\\xa0should\\xa0be\\xa0considered\\xa0as\\xa0theincidence\\xa0of\\xa0H.\\xa0pylori\\xa0is\\xa0decreasing.\\xa0Independent\\xa0of\\xa0the\\xa0inciting\\xa0or\\xa0injurious\\xa0agent,\\xa0peptic\\xa0ulcers\\xa0develop\\xa0as\\xa0a\\xa0result\\xa0of\\xa0an\\xa0imbalance\\xa0between\\xa0mucosalprotection/repair\\xa0and\\xa0aggressive\\xa0factors.\\xa0Gastric\\xa0acid\\xa0plays\\xa0an\\xa0important\\xa0role\\xa0in\\xa0mucosal\\xa0injury.TABLE\\xa0324\\xad1Causes\\xa0of\\xa0Ulcers\\xa0Not\\xa0Caused\\xa0by\\xa0Helicobacter\\xa0pylori\\xa0and\\xa0NSAIDsPathogenesis\\xa0of\\xa0Non\\xadHp\\xa0and\\xa0Non\\xadNSAID\\xa0Ulcer\\xa0DiseaseInfection\\u2003Cytomegalovirus\\u2003Herpes\\xa0simplex\\xa0virus\\u2003Helicobacter\\xa0heilmanniiDrug/Toxin\\u2003Bisphosphonates\\u2003Chemotherapy\\u2003Clopidogrel\\u2003Crack\\xa0cocaine\\u2003Glucocorticoids\\xa0(when\\xa0combined\\xa0with\\xa0NSAIDs)\\u2003Mycophenolate\\xa0mofetil\\u2003Potassium\\xa0chlorideMiscellaneous\\u2003Basophilia\\xa0in\\xa0myeloproliferative\\xa0disease\\u2003Duodenal\\xa0obstruction\\xa0(e.g.,\\xa0annular\\xa0pancreas)\\u2003Infiltrating\\xa0disease\\u2003Ischemia\\u2003Radiation\\xa0therapy\\u2003Eosinophilic\\xa0infiltration\\u2003Sarcoidosis\\u2003Crohn’s\\xa0disease\\u2003Idiopathic\\xa0hypersecretory\\xa0stateCLINICAL\\xa0FEATURESHistoryAbdominal pain is common to many GI disorders including DU and GU but it has a poor predictive value for the presence of either DU or GUYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 15 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal function',\n",
       " \"LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison's Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH'HCIpH20MucusHCOS2PH7.0MucusH'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4\",\n",
       " 'MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell',\n",
       " \"Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritis\",\n",
       " \"Antral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'Abbreviations:\\xa0Hp,\\xa0H.\\xa0pylori;\\xa0NSAIDs,\\xa0nonsteroidal\\xa0anti\\xadinflammatory\\xa0drugs.\\u2003Idiopathic\\xa0hypersecretory\\xa0stateCLINICAL\\xa0FEATURESHistoryAbdominal\\xa0pain\\xa0is\\xa0common\\xa0to\\xa0many\\xa0GI\\xa0disorders,\\xa0including\\xa0DU\\xa0and\\xa0GU,\\xa0but\\xa0it\\xa0has\\xa0a\\xa0poor\\xa0predictive\\xa0value\\xa0for\\xa0the\\xa0presence\\xa0of\\xa0either\\xa0DU\\xa0or\\xa0GU.Approximately\\xa0two\\xadthirds\\xa0of\\xa0patients\\xa0with\\xa0PUD\\xa0do\\xa0not\\xa0have\\xa0abdominal\\xa0pain,\\xa0and\\xa0up\\xa0to\\xa087%\\xa0of\\xa0patients\\xa0with\\xa0NSAID\\xadinduced\\xa0mucosal\\xa0disease\\xa0canpresent\\xa0with\\xa0a\\xa0complication\\xa0(bleeding,\\xa0perforation,\\xa0and\\xa0obstruction)\\xa0without\\xa0antecedent\\xa0symptoms.\\xa0Despite\\xa0this\\xa0poor\\xa0correlation,\\xa0a\\xa0careful\\xa0historyand\\xa0physical\\xa0examination\\xa0are\\xa0essential\\xa0components\\xa0of\\xa0the\\xa0approach\\xa0to\\xa0a\\xa0patient\\xa0suspected\\xa0of\\xa0having\\xa0peptic\\xa0ulcers.Epigastric\\xa0pain\\xa0described\\xa0as\\xa0a\\xa0burning\\xa0or\\xa0gnawing\\xa0discomfort\\xa0can\\xa0be\\xa0present\\xa0in\\xa0both\\xa0DU\\xa0and\\xa0GU.\\xa0The\\xa0discomfort\\xa0is\\xa0also\\xa0described\\xa0as\\xa0an\\xa0ill\\xaddefined,aching\\xa0sensation\\xa0or\\xa0as\\xa0hunger\\xa0pain.\\xa0The\\xa0typical\\xa0pain\\xa0pattern\\xa0in\\xa0DU\\xa0occurs\\xa090\\xa0min\\xa0to\\xa03\\xa0h\\xa0after\\xa0a\\xa0meal\\xa0and\\xa0is\\xa0frequently\\xa0relieved\\xa0by\\xa0antacids\\xa0or\\xa0food.\\xa0Painthat\\xa0awakes\\xa0the\\xa0patient\\xa0from\\xa0sleep\\xa0(between\\xa0midnight\\xa0and\\xa03\\xa0A.M.)\\xa0is\\xa0the\\xa0most\\xa0discriminating\\xa0symptom,\\xa0with\\xa0two\\xadthirds\\xa0of\\xa0DU\\xa0patients\\xa0describing\\xa0thiscomplaint.\\xa0Unfortunately,\\xa0this\\xa0symptom\\xa0is\\xa0also\\xa0present\\xa0in\\xa0one\\xadthird\\xa0of\\xa0patients\\xa0with\\xa0NUD\\xa0(see\\xa0below).\\xa0Elderly\\xa0patients\\xa0are\\xa0less\\xa0likely\\xa0to\\xa0have\\xa0abdominalpain\\xa0as\\xa0a\\xa0manifestation\\xa0of\\xa0PUD\\xa0and\\xa0may\\xa0instead\\xa0present\\xa0with\\xa0a\\xa0complication\\xa0such\\xa0as\\xa0ulcer\\xa0bleeding\\xa0or\\xa0perforation.\\xa0The\\xa0pain\\xa0pattern\\xa0in\\xa0GU\\xa0patients\\xa0maybe\\xa0different\\xa0from\\xa0that\\xa0in\\xa0DU\\xa0patients,\\xa0where\\xa0discomfort\\xa0may\\xa0actually\\xa0be\\xa0precipitated\\xa0by\\xa0food.\\xa0Nausea\\xa0and\\xa0weight\\xa0loss\\xa0occur\\xa0more\\xa0commonly\\xa0in\\xa0GUpatients.\\xa0Endoscopy\\xa0detects\\xa0ulcers\\xa0in\\xa0<30%\\xa0of\\xa0patients\\xa0who\\xa0have\\xa0dyspepsia.The\\xa0mechanism\\xa0for\\xa0development\\xa0of\\xa0abdominal\\xa0pain\\xa0in\\xa0ulcer\\xa0patients\\xa0is\\xa0unknown.\\xa0Several\\xa0possible\\xa0explanations\\xa0include\\xa0acid\\xadinduced\\xa0activation\\xa0ofchemical\\xa0receptors\\xa0in\\xa0the\\xa0duodenum,\\xa0enhanced\\xa0duodenal\\xa0sensitivity\\xa0to\\xa0bile\\xa0acids\\xa0and\\xa0pepsin,\\xa0and\\xa0altered\\xa0gastroduodenal\\xa0motility.',\n",
       " 'chemical\\xa0receptors\\xa0in\\xa0the\\xa0duodenum,\\xa0enhanced\\xa0duodenal\\xa0sensitivity\\xa0to\\xa0bile\\xa0acids\\xa0and\\xa0pepsin,\\xa0and\\xa0altered\\xa0gastroduodenal\\xa0motility.Variation\\xa0in\\xa0the\\xa0intensity\\xa0or\\xa0distribution\\xa0of\\xa0the\\xa0abdominal\\xa0pain,\\xa0as\\xa0well\\xa0as\\xa0the\\xa0onset\\xa0of\\xa0associated\\xa0symptoms\\xa0such\\xa0as\\xa0nausea\\xa0and/or\\xa0vomiting,\\xa0may\\xa0beindicative\\xa0of\\xa0an\\xa0ulcer\\xa0complication.\\xa0Dyspepsia\\xa0that\\xa0becomes\\xa0constant,\\xa0is\\xa0no\\xa0longer\\xa0relieved\\xa0by\\xa0food\\xa0or\\xa0antacids,\\xa0or\\xa0radiates\\xa0to\\xa0the\\xa0back\\xa0may\\xa0indicate\\xa0apenetrating\\xa0ulcer\\xa0(pancreas).\\xa0Sudden\\xa0onset\\xa0of\\xa0severe,\\xa0generalized\\xa0abdominal\\xa0pain\\xa0may\\xa0indicate\\xa0perforation.\\xa0Pain\\xa0worsening\\xa0with\\xa0meals,\\xa0nausea,\\xa0andvomiting\\xa0of\\xa0undigested\\xa0food\\xa0suggest\\xa0gastric\\xa0outlet\\xa0obstruction.\\xa0Tarry\\xa0stools\\xa0or\\xa0coffee\\xadground\\xa0emesis\\xa0indicate\\xa0bleeding.Physical\\xa0ExaminationEpigastric\\xa0tenderness\\xa0is\\xa0the\\xa0most\\xa0frequent\\xa0finding\\xa0in\\xa0patients\\xa0with\\xa0GU\\xa0or\\xa0DU.\\xa0Pain\\xa0may\\xa0be\\xa0found\\xa0to\\xa0the\\xa0right\\xa0of\\xa0the\\xa0midline\\xa0in\\xa020%\\xa0of\\xa0patients.Unfortunately,\\xa0the\\xa0predictive\\xa0value\\xa0of\\xa0this\\xa0finding\\xa0is\\xa0low.\\xa0Physical\\xa0examination\\xa0is\\xa0critically\\xa0important\\xa0for\\xa0discovering\\xa0evidence\\xa0of\\xa0ulcer\\xa0complication.Tachycardia\\xa0and\\xa0orthostasis\\xa0suggest\\xa0dehydration\\xa0secondary\\xa0to\\xa0vomiting\\xa0or\\xa0active\\xa0GI\\xa0blood\\xa0loss.\\xa0A\\xa0severely\\xa0tender,\\xa0board\\xadlike\\xa0abdomen\\xa0suggests\\xa0aperforation.\\xa0Presence\\xa0of\\xa0a\\xa0succussion\\xa0splash\\xa0indicates\\xa0retained\\xa0fluid\\xa0in\\xa0the\\xa0stomach,\\xa0suggesting\\xa0gastric\\xa0outlet\\xa0obstruction.PUD\\xadRelated\\xa0ComplicationsGASTROINTESTINAL\\xa0BLEEDINGGI\\xa0bleeding\\xa0is\\xa0the\\xa0most\\xa0common\\xa0complication\\xa0observed\\xa0in\\xa0PUD.\\xa0Bleeding\\xa0is\\xa0estimated\\xa0to\\xa0occur\\xa0in\\xa019.4–57\\xa0per\\xa0100,000\\xa0individuals\\xa0in\\xa0a\\xa0generalpopulation\\xa0or\\xa0in\\xa0~15%\\xa0of\\xa0patients.\\xa0Bleeding\\xa0and\\xa0complications\\xa0of\\xa0ulcer\\xa0disease\\xa0occur\\xa0more\\xa0often\\xa0in\\xa0individuals\\xa0>60\\xa0years\\xa0of\\xa0age.\\xa0The\\xa030\\xadday\\xa0mortalityrate\\xa0is\\xa0as\\xa0high\\xa0as\\xa02.5–10%.\\xa0The\\xa0higher\\xa0incidence\\xa0in\\xa0the\\xa0elderly\\xa0is\\xa0likely\\xa0due\\xa0to\\xa0the\\xa0increased\\xa0use\\xa0of\\xa0NSAIDs\\xa0in\\xa0this\\xa0group.\\xa0In\\xa0addition,\\xa0up\\xa0to\\xa080%\\xa0of\\xa0themortality\\xa0in\\xa0PUD\\xadrelated\\xa0bleeding\\xa0is\\xa0due\\xa0to\\xa0nonbleeding\\xa0causes\\xa0such\\xa0as\\xa0multiorgan\\xa0failure\\xa0(24%),\\xa0pulmonary\\xa0complications\\xa0(24%),\\xa0and\\xa0malignancy(34%).',\n",
       " 'mortality\\xa0in\\xa0PUD\\xadrelated\\xa0bleeding\\xa0is\\xa0due\\xa0to\\xa0nonbleeding\\xa0causes\\xa0such\\xa0as\\xa0multiorgan\\xa0failure\\xa0(24%),\\xa0pulmonary\\xa0complications\\xa0(24%),\\xa0and\\xa0malignancy(34%).Greater\\xa0than\\xa050%\\xa0of\\xa0patients\\xa0with\\xa0ulcer\\xadrelated\\xa0hemorrhage\\xa0bleed\\xa0without\\xa0any\\xa0preceding\\xa0warning\\xa0signs\\xa0or\\xa0symptoms.PERFORATIONThe\\xa0second\\xa0most\\xa0common\\xa0ulcer\\xadrelated\\xa0complication\\xa0is\\xa0perforation,\\xa0being\\xa0reported\\xa0in\\xa0as\\xa0many\\xa0as\\xa06–7%\\xa0of\\xa0PUD\\xa0patients\\xa0with\\xa0an\\xa0estimated\\xa030\\xaddaymortality\\xa0of\\xa0>20%.\\xa0Acute\\xa0abdominal\\xa0pain,\\xa0tachycardia,\\xa0and\\xa0abdominal\\xa0rigidity\\xa0compose\\xa0the\\xa0classic\\xa0triad\\xa0associated\\xa0with\\xa0this\\xa0complication.\\xa0It\\xa0is\\xa0essentialto\\xa0remember\\xa0that\\xa0elderly\\xa0patients\\xa0or\\xa0individuals\\xa0who\\xa0are\\xa0immunosuppressed\\xa0may\\xa0not\\xa0have\\xa0this\\xa0classic\\xa0presentation.\\xa0As\\xa0in\\xa0the\\xa0case\\xa0of\\xa0bleeding,\\xa0theincidence\\xa0of\\xa0perforation\\xa0in\\xa0the\\xa0elderly\\xa0appears\\xa0to\\xa0be\\xa0increasing\\xa0secondary\\xa0to\\xa0increased\\xa0use\\xa0of\\xa0NSAIDs.\\xa0Perforation\\xa0of\\xa0DUs\\xa0has\\xa0become\\xa0less\\xa0common\\xa0inlight\\xa0of\\xa0the\\xa0increased\\xa0rates\\xa0of\\xa0H.\\xa0pylori\\xa0eradication,\\xa0with\\xa0NSAID\\xadinduced\\xa0GUs\\xa0leading\\xa0to\\xa0perforation\\xa0occurring\\xa0more\\xa0commonly.\\xa0Penetration\\xa0is\\xa0a\\xa0form\\xa0ofperforation\\xa0in\\xa0which\\xa0the\\xa0ulcer\\xa0bed\\xa0tunnels\\xa0into\\xa0an\\xa0adjacent\\xa0organ.\\xa0DUs\\xa0tend\\xa0to\\xa0penetrate\\xa0posteriorly\\xa0into\\xa0the\\xa0pancreas,\\xa0leading\\xa0to\\xa0pancreatitis,\\xa0whereasGUs\\xa0tend\\xa0to\\xa0penetrate\\xa0into\\xa0the\\xa0left\\xa0hepatic\\xa0lobe.\\xa0Gastrocolic\\xa0fistulas\\xa0associated\\xa0with\\xa0GUs\\xa0have\\xa0also\\xa0been\\xa0described.\\xa0Mortality\\xa0for\\xa0this\\xa0complication\\xa0canbe\\xa0>20%\\xa0within\\xa030\\xa0days.GASTRIC\\xa0OUTLET\\xa0OBSTRUCTIONYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 16 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformation',\n",
       " \"PlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison's Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH'HCIpH20MucusHCOS2PH7.0MucusH'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosal\",\n",
       " 'mucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)Acid',\n",
       " \"CopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproduction\",\n",
       " \"H.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'mortality\\xa0of\\xa0>20%.\\xa0Acute\\xa0abdominal\\xa0pain,\\xa0tachycardia,\\xa0and\\xa0abdominal\\xa0rigidity\\xa0compose\\xa0the\\xa0classic\\xa0triad\\xa0associated\\xa0with\\xa0this\\xa0complication.\\xa0It\\xa0is\\xa0essentialto\\xa0remember\\xa0that\\xa0elderly\\xa0patients\\xa0or\\xa0individuals\\xa0who\\xa0are\\xa0immunosuppressed\\xa0may\\xa0not\\xa0have\\xa0this\\xa0classic\\xa0presentation.\\xa0As\\xa0in\\xa0the\\xa0case\\xa0of\\xa0bleeding,\\xa0theincidence\\xa0of\\xa0perforation\\xa0in\\xa0the\\xa0elderly\\xa0appears\\xa0to\\xa0be\\xa0increasing\\xa0secondary\\xa0to\\xa0increased\\xa0use\\xa0of\\xa0NSAIDs.\\xa0Perforation\\xa0of\\xa0DUs\\xa0has\\xa0become\\xa0less\\xa0common\\xa0inlight\\xa0of\\xa0the\\xa0increased\\xa0rates\\xa0of\\xa0H.\\xa0pylori\\xa0eradication,\\xa0with\\xa0NSAID\\xadinduced\\xa0GUs\\xa0leading\\xa0to\\xa0perforation\\xa0occurring\\xa0more\\xa0commonly.\\xa0Penetration\\xa0is\\xa0a\\xa0form\\xa0ofperforation\\xa0in\\xa0which\\xa0the\\xa0ulcer\\xa0bed\\xa0tunnels\\xa0into\\xa0an\\xa0adjacent\\xa0organ.\\xa0DUs\\xa0tend\\xa0to\\xa0penetrate\\xa0posteriorly\\xa0into\\xa0the\\xa0pancreas,\\xa0leading\\xa0to\\xa0pancreatitis,\\xa0whereasGUs\\xa0tend\\xa0to\\xa0penetrate\\xa0into\\xa0the\\xa0left\\xa0hepatic\\xa0lobe.\\xa0Gastrocolic\\xa0fistulas\\xa0associated\\xa0with\\xa0GUs\\xa0have\\xa0also\\xa0been\\xa0described.\\xa0Mortality\\xa0for\\xa0this\\xa0complication\\xa0canbe\\xa0>20%\\xa0within\\xa030\\xa0days.GASTRIC\\xa0OUTLET\\xa0OBSTRUCTIONGastric\\xa0outlet\\xa0obstruction\\xa0is\\xa0the\\xa0least\\xa0common\\xa0ulcer\\xadrelated\\xa0complication,\\xa0occurring\\xa0in\\xa01–2%\\xa0of\\xa0patients.\\xa0A\\xa0patient\\xa0may\\xa0have\\xa0relative\\xa0obstructionsecondary\\xa0to\\xa0ulcer\\xadrelated\\xa0inflammation\\xa0and\\xa0edema\\xa0in\\xa0the\\xa0peripyloric\\xa0and\\xa0duodenal\\xa0region.\\xa0This\\xa0process\\xa0often\\xa0resolves\\xa0with\\xa0ulcer\\xa0healing.\\xa0A\\xa0fixed,mechanical\\xa0obstruction\\xa0secondary\\xa0to\\xa0scar\\xa0formation\\xa0in\\xa0the\\xa0peripyloric\\xa0areas\\xa0is\\xa0also\\xa0possible.\\xa0The\\xa0latter\\xa0requires\\xa0endoscopic\\xa0(balloon\\xa0dilation\\xa0with\\xa0orwithout\\xa0placement\\xa0of\\xa0a\\xa0biodegradable\\xa0stent)\\xa0or\\xa0surgical\\xa0intervention\\xa0with\\xa0a\\xa0stricturoplasty\\xa0or\\xa0gastrojejunostomy.\\xa0Signs\\xa0and\\xa0symptoms\\xa0relative\\xa0tomechanical\\xa0obstruction\\xa0may\\xa0develop\\xa0insidiously.\\xa0New\\xa0onset\\xa0of\\xa0early\\xa0satiety,\\xa0nausea,\\xa0vomiting,\\xa0increase\\xa0of\\xa0postprandial\\xa0abdominal\\xa0pain,\\xa0and\\xa0weightloss\\xa0should\\xa0make\\xa0gastric\\xa0outlet\\xa0obstruction\\xa0a\\xa0possible\\xa0diagnosis.Differential\\xa0DiagnosisThe\\xa0list\\xa0of\\xa0GI\\xa0and\\xa0non\\xadGI\\xa0disorders\\xa0that\\xa0can\\xa0mimic\\xa0ulceration\\xa0of\\xa0the\\xa0stomach\\xa0or\\xa0duodenum\\xa0is\\xa0quite\\xa0extensive.\\xa0The\\xa0most\\xa0commonly\\xa0encountered',\n",
       " 'Differential\\xa0DiagnosisThe\\xa0list\\xa0of\\xa0GI\\xa0and\\xa0non\\xadGI\\xa0disorders\\xa0that\\xa0can\\xa0mimic\\xa0ulceration\\xa0of\\xa0the\\xa0stomach\\xa0or\\xa0duodenum\\xa0is\\xa0quite\\xa0extensive.\\xa0The\\xa0most\\xa0commonly\\xa0encountereddiagnosis\\xa0among\\xa0patients\\xa0seen\\xa0for\\xa0upper\\xa0abdominal\\xa0discomfort\\xa0is\\xa0functional\\xa0dyspepsia\\xa0(FD)\\xa0or\\xa0essential\\xa0dyspepsia,\\xa0which\\xa0refers\\xa0to\\xa0a\\xa0group\\xa0ofheterogeneous\\xa0disorders\\xa0typified\\xa0by\\xa0upper\\xa0abdominal\\xa0pain\\xa0without\\xa0the\\xa0presence\\xa0of\\xa0an\\xa0ulcer.\\xa0The\\xa0symptoms\\xa0can\\xa0range\\xa0from\\xa0postprandial\\xa0fullness\\xa0andearly\\xa0satiety\\xa0to\\xa0epigastric\\xa0burning\\xa0pain.\\xa0The\\xa0dichotomy\\xa0of\\xa0this\\xa0symptom\\xa0complex\\xa0has\\xa0led\\xa0to\\xa0the\\xa0identification\\xa0of\\xa0two\\xa0subcategories\\xa0of\\xa0FD\\xa0includingpostprandial\\xa0distress\\xa0syndrome\\xa0(PDS)\\xa0and\\xa0epigastric\\xa0pain\\xa0syndrome\\xa0(EPS).\\xa0Dyspepsia\\xa0has\\xa0been\\xa0reported\\xa0to\\xa0occur\\xa0in\\xa0up\\xa0to\\xa030%\\xa0of\\xa0the\\xa0U.S.\\xa0population.Up\\xa0to\\xa080%\\xa0of\\xa0patients\\xa0seeking\\xa0medical\\xa0care\\xa0for\\xa0dyspepsia\\xa0have\\xa0a\\xa0negative\\xa0diagnostic\\xa0evaluation.\\xa0The\\xa0etiology\\xa0of\\xa0FD\\xa0is\\xa0not\\xa0established,\\xa0but\\xa0recentstudies\\xa0suggest\\xa0that\\xa0postinfectious\\xa0states,\\xa0certain\\xa0foods,\\xa0and\\xa0H.\\xa0pylori\\xa0infection\\xa0may\\xa0contribute\\xa0to\\xa0the\\xa0pathogenesis\\xa0of\\xa0this\\xa0common\\xa0disorder.Several\\xa0additional\\xa0disease\\xa0processes\\xa0that\\xa0may\\xa0present\\xa0with\\xa0“ulcer\\xadlike”\\xa0symptoms\\xa0include\\xa0proximal\\xa0GI\\xa0tumors,\\xa0gastroesophageal\\xa0reflux,\\xa0vasculardisease,\\xa0pancreaticobiliary\\xa0disease\\xa0(biliary\\xa0colic,\\xa0chronic\\xa0pancreatitis),\\xa0and\\xa0gastroduodenal\\xa0Crohn’s\\xa0disease.Diagnostic\\xa0EvaluationIn\\xa0view\\xa0of\\xa0the\\xa0poor\\xa0predictive\\xa0value\\xa0of\\xa0abdominal\\xa0pain\\xa0for\\xa0the\\xa0presence\\xa0of\\xa0a\\xa0gastroduodenal\\xa0ulcer\\xa0and\\xa0the\\xa0multiple\\xa0disease\\xa0processes\\xa0that\\xa0can\\xa0mimicthis\\xa0disease,\\xa0the\\xa0clinician\\xa0is\\xa0often\\xa0confronted\\xa0with\\xa0having\\xa0to\\xa0establish\\xa0the\\xa0presence\\xa0of\\xa0an\\xa0ulcer.\\xa0Documentation\\xa0of\\xa0an\\xa0ulcer\\xa0requires\\xa0either\\xa0aradiographic\\xa0(barium\\xa0study,\\xa0rarely\\xa0done\\xa0in\\xa0today’s\\xa0environment)\\xa0or\\xa0an\\xa0endoscopic\\xa0procedure.\\xa0However,\\xa0a\\xa0large\\xa0percentage\\xa0of\\xa0patients\\xa0with\\xa0symptomssuggestive\\xa0of\\xa0an\\xa0ulcer\\xa0have\\xa0NUD;\\xa0testing\\xa0for\\xa0H.\\xa0pylori\\xa0and\\xa0antibiotic\\xa0therapy\\xa0(see\\xa0below)\\xa0are\\xa0appropriate\\xa0for\\xa0individuals\\xa0who\\xa0are\\xa0otherwise\\xa0healthy\\xa0and<45\\xa0years\\xa0of\\xa0age,\\xa0before\\xa0embarking\\xa0on\\xa0a\\xa0diagnostic\\xa0evaluation\\xa0(Chap.\\xa045).',\n",
       " \"<45\\xa0years\\xa0of\\xa0age,\\xa0before\\xa0embarking\\xa0on\\xa0a\\xa0diagnostic\\xa0evaluation\\xa0(Chap.\\xa045).Barium\\xa0studies\\xa0of\\xa0the\\xa0proximal\\xa0GI\\xa0tract\\xa0are\\xa0rarely\\xa0used\\xa0as\\xa0a\\xa0first\\xa0test\\xa0for\\xa0documenting\\xa0an\\xa0ulcer.\\xa0The\\xa0sensitivity\\xa0of\\xa0older\\xa0single\\xadcontrast\\xa0barium\\xa0meals\\xa0fordetecting\\xa0a\\xa0DU\\xa0is\\xa0as\\xa0high\\xa0as\\xa080%,\\xa0with\\xa0a\\xa0double\\xadcontrast\\xa0study\\xa0providing\\xa0detection\\xa0rates\\xa0as\\xa0high\\xa0as\\xa090%.\\xa0Sensitivity\\xa0for\\xa0detection\\xa0is\\xa0decreased\\xa0in\\xa0smallulcers\\xa0(<0.5\\xa0cm),\\xa0with\\xa0presence\\xa0of\\xa0previous\\xa0scarring,\\xa0or\\xa0in\\xa0postoperative\\xa0patients.\\xa0A\\xa0DU\\xa0appears\\xa0as\\xa0a\\xa0well\\xaddemarcated\\xa0crater,\\xa0most\\xa0often\\xa0seen\\xa0in\\xa0thebulb\\xa0(Fig.\\xa0324\\xad10A).\\xa0A\\xa0GU\\xa0may\\xa0represent\\xa0benign\\xa0or\\xa0malignant\\xa0disease.\\xa0Typically,\\xa0a\\xa0benign\\xa0GU\\xa0also\\xa0appears\\xa0as\\xa0a\\xa0discrete\\xa0crater\\xa0with\\xa0radiating\\xa0mucosalfolds\\xa0originating\\xa0from\\xa0the\\xa0ulcer\\xa0margin\\xa0(Fig.\\xa0324\\xad10B).\\xa0Ulcers\\xa0>3\\xa0cm\\xa0in\\xa0size\\xa0or\\xa0those\\xa0associated\\xa0with\\xa0a\\xa0mass\\xa0are\\xa0more\\xa0often\\xa0malignant.\\xa0Unfortunately,up\\xa0to\\xa08%\\xa0of\\xa0GUs\\xa0that\\xa0appear\\xa0to\\xa0be\\xa0benign\\xa0by\\xa0radiographic\\xa0appearance\\xa0are\\xa0malignant\\xa0by\\xa0endoscopy\\xa0or\\xa0surgery.\\xa0Radiographic\\xa0studies\\xa0that\\xa0show\\xa0a\\xa0GUmust\\xa0be\\xa0followed\\xa0by\\xa0endoscopy\\xa0and\\xa0biopsy.FIGURE\\xa0324\\xad10Barium\\xa0study\\xa0demonstrating\\xa0(A)\\xa0a\\xa0benign\\xa0duodenal\\xa0ulcer\\xa0and\\xa0(B)\\xa0a\\xa0benign\\xa0gastric\\xa0ulcer.Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 17 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffect\",\n",
       " 'Dan Longo,J.Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison\\'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide that',\n",
       " 'Alkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison\\'s Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: No',\n",
       " \"Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'must\\xa0be\\xa0followed\\xa0by\\xa0endoscopy\\xa0and\\xa0biopsy.FIGURE\\xa0324\\xad10Barium\\xa0study\\xa0demonstrating\\xa0(A)\\xa0a\\xa0benign\\xa0duodenal\\xa0ulcer\\xa0and\\xa0(B)\\xa0a\\xa0benign\\xa0gastric\\xa0ulcer.Endoscopy\\xa0provides\\xa0the\\xa0most\\xa0sensitive\\xa0and\\xa0specific\\xa0approach\\xa0for\\xa0examining\\xa0the\\xa0upper\\xa0GI\\xa0tract\\xa0(Fig.\\xa0324\\xad11).\\xa0In\\xa0addition\\xa0to\\xa0permitting\\xa0directvisualization\\xa0of\\xa0the\\xa0mucosa,\\xa0endoscopy\\xa0facilitates\\xa0photographic\\xa0documentation\\xa0of\\xa0a\\xa0mucosal\\xa0defect\\xa0and\\xa0tissue\\xa0biopsy\\xa0to\\xa0rule\\xa0out\\xa0malignancy\\xa0(GU)\\xa0or\\xa0H.pylori.\\xa0Endoscopic\\xa0examination\\xa0is\\xa0particularly\\xa0helpful\\xa0in\\xa0identifying\\xa0lesions\\xa0too\\xa0small\\xa0to\\xa0detect\\xa0by\\xa0radiographic\\xa0examination,\\xa0for\\xa0evaluation\\xa0of\\xa0atypicalradiographic\\xa0abnormalities,\\xa0or\\xa0to\\xa0determine\\xa0if\\xa0an\\xa0ulcer\\xa0is\\xa0a\\xa0source\\xa0of\\xa0blood\\xa0loss.FIGURE\\xa0324\\xad11Endoscopy\\xa0demonstrating\\xa0(A)\\xa0a\\xa0benign\\xa0duodenal\\xa0ulcer\\xa0and\\xa0(B)\\xa0a\\xa0benign\\xa0gastric\\xa0ulcer.Although\\xa0the\\xa0methods\\xa0for\\xa0diagnosing\\xa0H.\\xa0pylori\\xa0are\\xa0outlined\\xa0in\\xa0Chap.\\xa0163,\\xa0a\\xa0brief\\xa0summary\\xa0will\\xa0be\\xa0included\\xa0here\\xa0(Table\\xa0324\\xad2).\\xa0Several\\xa0biopsy\\xa0ureasetests\\xa0have\\xa0been\\xa0developed\\xa0(PyloriTek,\\xa0CLOtest,\\xa0Hpfast,\\xa0Pronto\\xa0Dry)\\xa0that\\xa0have\\xa0a\\xa0sensitivity\\xa0and\\xa0specificity\\xa0of\\xa0>90–95%.\\xa0Several\\xa0noninvasive\\xa0methods\\xa0fordetecting\\xa0this\\xa0organism\\xa0have\\xa0been\\xa0developed.\\xa0Three\\xa0types\\xa0of\\xa0studies\\xa0routinely\\xa0used\\xa0include\\xa0serologic\\xa0testing,\\xa0the\\xa013C\\xad\\xa0or\\xa014C\\xadurea\\xa0breath\\xa0test,\\xa0and\\xa0thefecal\\xa0H.\\xa0pylori\\xa0(Hp)\\xa0antigen\\xa0test\\xa0(monoclonal\\xa0antibody\\xa0test).\\xa0A\\xa0urinary\\xa0Hp\\xa0antigen\\xa0test\\xa0and\\xa0a\\xa0home\\xa0breath\\xa0test\\xa0appear\\xa0promising.TABLE\\xa0324\\xad2Tests\\xa0for\\xa0Detection\\xa0of\\xa0Helicobacter\\xa0pyloriTESTSENSITIVITY/SPECIFICITY,%COMMENTSInvasive\\xa0(Endoscopy/Biopsy\\xa0Required)Rapidurease80–95/95–100Simple,\\xa0false\\xa0negative\\xa0with\\xa0recent\\xa0use\\xa0of\\xa0PPIs,\\xa0antibiotics,\\xa0or\\xa0bismuth\\xa0compoundsHistology80–90/>95Requires\\xa0pathology\\xa0processing\\xa0and\\xa0staining;\\xa0provides\\xa0histologic\\xa0informationCulture—/—Time\\xadconsuming,\\xa0expensive,\\xa0dependent\\xa0on\\xa0experience;\\xa0allows\\xa0determination\\xa0of\\xa0antibiotic\\xa0susceptibilityYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle',\n",
       " \"Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 18 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,\",\n",
       " 'Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21e',\n",
       " \"EnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatin\",\n",
       " \"FUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'Abbreviation:\\xa0PPIs,\\xa0proton\\xa0pump\\xa0inhibitors.Although\\xa0the\\xa0methods\\xa0for\\xa0diagnosing\\xa0H.\\xa0pylori\\xa0are\\xa0outlined\\xa0in\\xa0Chap.\\xa0163,\\xa0a\\xa0brief\\xa0summary\\xa0will\\xa0be\\xa0included\\xa0here\\xa0(Table\\xa0324\\xad2).\\xa0Several\\xa0biopsy\\xa0ureasetests\\xa0have\\xa0been\\xa0developed\\xa0(PyloriTek,\\xa0CLOtest,\\xa0Hpfast,\\xa0Pronto\\xa0Dry)\\xa0that\\xa0have\\xa0a\\xa0sensitivity\\xa0and\\xa0specificity\\xa0of\\xa0>90–95%.\\xa0Several\\xa0noninvasive\\xa0methods\\xa0fordetecting\\xa0this\\xa0organism\\xa0have\\xa0been\\xa0developed.\\xa0Three\\xa0types\\xa0of\\xa0studies\\xa0routinely\\xa0used\\xa0include\\xa0serologic\\xa0testing,\\xa0the\\xa013C\\xad\\xa0or\\xa014C\\xadurea\\xa0breath\\xa0test,\\xa0and\\xa0thefecal\\xa0H.\\xa0pylori\\xa0(Hp)\\xa0antigen\\xa0test\\xa0(monoclonal\\xa0antibody\\xa0test).\\xa0A\\xa0urinary\\xa0Hp\\xa0antigen\\xa0test\\xa0and\\xa0a\\xa0home\\xa0breath\\xa0test\\xa0appear\\xa0promising.TABLE\\xa0324\\xad2Tests\\xa0for\\xa0Detection\\xa0of\\xa0Helicobacter\\xa0pyloriTESTSENSITIVITY/SPECIFICITY,%COMMENTSInvasive\\xa0(Endoscopy/Biopsy\\xa0Required)Rapidurease80–95/95–100Simple,\\xa0false\\xa0negative\\xa0with\\xa0recent\\xa0use\\xa0of\\xa0PPIs,\\xa0antibiotics,\\xa0or\\xa0bismuth\\xa0compoundsHistology80–90/>95Requires\\xa0pathology\\xa0processing\\xa0and\\xa0staining;\\xa0provides\\xa0histologic\\xa0informationCulture—/—Time\\xadconsuming,\\xa0expensive,\\xa0dependent\\xa0on\\xa0experience;\\xa0allows\\xa0determination\\xa0of\\xa0antibiotic\\xa0susceptibilityNoninvasiveSerology>80/>90Inexpensive,\\xa0convenient;\\xa0not\\xa0useful\\xa0for\\xa0early\\xa0follow\\xadupUrea\\xa0breathtest>90/>90Simple,\\xa0rapid;\\xa0useful\\xa0for\\xa0early\\xa0follow\\xadup;\\xa0false\\xa0negatives\\xa0with\\xa0recent\\xa0therapy\\xa0(see\\xa0rapid\\xa0urease\\xa0test);exposure\\xa0to\\xa0low\\xaddose\\xa0radiation\\xa0with\\xa014C\\xa0testStoolantigen>90/>90Inexpensive,\\xa0convenientOccasionally,\\xa0specialized\\xa0testing\\xa0such\\xa0as\\xa0serum\\xa0gastrin\\xa0and\\xa0gastric\\xa0acid\\xa0analysis\\xa0may\\xa0be\\xa0needed\\xa0in\\xa0individuals\\xa0with\\xa0complicated\\xa0or\\xa0refractory\\xa0PUD\\xa0(see“Zollinger\\xadEllison\\xa0Syndrome,”\\xa0below).\\xa0Screening\\xa0for\\xa0aspirin\\xa0or\\xa0NSAIDs\\xa0(blood\\xa0or\\xa0urine)\\xa0may\\xa0also\\xa0be\\xa0necessary\\xa0in\\xa0refractory\\xa0H.\\xa0pylori–negative\\xa0PUDpatients.TREATMENT\\xa0OF\\xa0PEPTIC\\xa0ULCER\\xa0DISEASEBefore\\xa0the\\xa0discovery\\xa0of\\xa0H.\\xa0pylori,\\xa0the\\xa0therapy\\xa0of\\xa0PUD\\xa0was\\xa0centered\\xa0on\\xa0the\\xa0old\\xa0dictum\\xa0by\\xa0Schwartz\\xa0of\\xa0“no\\xa0acid,\\xa0no\\xa0ulcer.”\\xa0Although\\xa0acid\\xa0secretion\\xa0is\\xa0stillimportant\\xa0in\\xa0the\\xa0pathogenesis\\xa0of\\xa0PUD,\\xa0eradication\\xa0of\\xa0H.\\xa0pylori\\xa0and\\xa0therapy/prevention\\xa0of\\xa0NSAID\\xadinduced\\xa0disease\\xa0is\\xa0the\\xa0mainstay\\xa0of\\xa0treatment.\\xa0A',\n",
       " \"important\\xa0in\\xa0the\\xa0pathogenesis\\xa0of\\xa0PUD,\\xa0eradication\\xa0of\\xa0H.\\xa0pylori\\xa0and\\xa0therapy/prevention\\xa0of\\xa0NSAID\\xadinduced\\xa0disease\\xa0is\\xa0the\\xa0mainstay\\xa0of\\xa0treatment.\\xa0Asummary\\xa0of\\xa0commonly\\xa0used\\xa0drugs\\xa0for\\xa0treatment\\xa0of\\xa0acid\\xa0peptic\\xa0disorders\\xa0is\\xa0shown\\xa0in\\xa0Table\\xa0324\\xad3.TABLE\\xa0324\\xad3Drugs\\xa0Used\\xa0in\\xa0the\\xa0Treatment\\xa0of\\xa0Peptic\\xa0Ulcer\\xa0DiseaseDRUG\\xa0TYPE/MECHANISMEXAMPLESDOSEAcid\\xadSuppressing\\xa0Drugs\\u2003AntacidsMylanta,\\xa0Maalox,\\xa0Tums,\\xa0Gaviscon100–140\\xa0meq/L\\xa01\\xa0and\\xa03\\xa0h\\xa0after\\xa0meals\\xa0and\\xa0hs\\u2003H2\\xa0receptor\\xa0antagonistsCimetidine400\\xa0mg\\xa0bidRanitidine300\\xa0mg\\xa0hsFamotidine40\\xa0mg\\xa0hsNizatidine300\\xa0mg\\xa0hs\\u2003Proton\\xa0pump\\xa0inhibitorsOmeprazole20\\xa0mg/dYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 19 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction\",\n",
       " '↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cells',\n",
       " \"maintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?\",\n",
       " \"triple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'Abbreviation:\\xa0hs,\\xa0at\\xa0bedtime\\xa0(hora\\xa0somni).TREATMENT\\xa0OF\\xa0PEPTIC\\xa0ULCER\\xa0DISEASEBefore\\xa0the\\xa0discovery\\xa0of\\xa0H.\\xa0pylori,\\xa0the\\xa0therapy\\xa0of\\xa0PUD\\xa0was\\xa0centered\\xa0on\\xa0the\\xa0old\\xa0dictum\\xa0by\\xa0Schwartz\\xa0of\\xa0“no\\xa0acid,\\xa0no\\xa0ulcer.”\\xa0Although\\xa0acid\\xa0secretion\\xa0is\\xa0stillimportant\\xa0in\\xa0the\\xa0pathogenesis\\xa0of\\xa0PUD,\\xa0eradication\\xa0of\\xa0H.\\xa0pylori\\xa0and\\xa0therapy/prevention\\xa0of\\xa0NSAID\\xadinduced\\xa0disease\\xa0is\\xa0the\\xa0mainstay\\xa0of\\xa0treatment.\\xa0Asummary\\xa0of\\xa0commonly\\xa0used\\xa0drugs\\xa0for\\xa0treatment\\xa0of\\xa0acid\\xa0peptic\\xa0disorders\\xa0is\\xa0shown\\xa0in\\xa0Table\\xa0324\\xad3.TABLE\\xa0324\\xad3Drugs\\xa0Used\\xa0in\\xa0the\\xa0Treatment\\xa0of\\xa0Peptic\\xa0Ulcer\\xa0DiseaseDRUG\\xa0TYPE/MECHANISMEXAMPLESDOSEAcid\\xadSuppressing\\xa0Drugs\\u2003AntacidsMylanta,\\xa0Maalox,\\xa0Tums,\\xa0Gaviscon100–140\\xa0meq/L\\xa01\\xa0and\\xa03\\xa0h\\xa0after\\xa0meals\\xa0and\\xa0hs\\u2003H2\\xa0receptor\\xa0antagonistsCimetidine400\\xa0mg\\xa0bidRanitidine300\\xa0mg\\xa0hsFamotidine40\\xa0mg\\xa0hsNizatidine300\\xa0mg\\xa0hs\\u2003Proton\\xa0pump\\xa0inhibitorsOmeprazole20\\xa0mg/dLansoprazole30\\xa0mg/dRabeprazole20\\xa0mg/dPantoprazole40\\xa0mg/dEsomeprazole20\\xa0mg/dDexlansoprazole30\\xa0mg/dMucosal\\xa0Protective\\xa0Agents\\u2003SucralfateSucralfate1\\xa0g\\xa0qid\\u2003Prostaglandin\\xa0analogueMisoprostol200\\xa0μg\\xa0qid\\u2003Bismuth\\xadcontaining\\xa0compoundsBismuth\\xa0subsalicylate\\xa0(BSS)See\\xa0anti–H.\\xa0pylori\\xa0regimens\\xa0(Table\\xa0324\\xad4)Acid\\xadNeutralizing/Inhibitory\\xa0DrugsAntacidsBefore\\xa0we\\xa0understood\\xa0the\\xa0important\\xa0role\\xa0of\\xa0histamine\\xa0in\\xa0stimulating\\xa0parietal\\xa0cell\\xa0activity,\\xa0neutralization\\xa0of\\xa0secreted\\xa0acid\\xa0with\\xa0antacids\\xa0constituted\\xa0themain\\xa0form\\xa0of\\xa0therapy\\xa0for\\xa0peptic\\xa0ulcers.\\xa0They\\xa0are\\xa0now\\xa0rarely,\\xa0if\\xa0ever,\\xa0used\\xa0as\\xa0the\\xa0primary\\xa0therapeutic\\xa0agent\\xa0but\\xa0instead\\xa0are\\xa0often\\xa0used\\xa0by\\xa0patients\\xa0forsymptomatic\\xa0relief\\xa0of\\xa0dyspepsia.\\xa0The\\xa0most\\xa0commonly\\xa0used\\xa0agents\\xa0are\\xa0mixtures\\xa0of\\xa0aluminum\\xa0hydroxide\\xa0and\\xa0magnesium\\xa0hydroxide.\\xa0Aluminumhydroxide\\xa0can\\xa0produce\\xa0constipation\\xa0and\\xa0phosphate\\xa0depletion;\\xa0magnesium\\xa0hydroxide\\xa0may\\xa0cause\\xa0loose\\xa0stools.\\xa0Many\\xa0of\\xa0the\\xa0commonly\\xa0used\\xa0antacids(e.g.,\\xa0Maalox,\\xa0Mylanta)\\xa0have\\xa0a\\xa0combination\\xa0of\\xa0both\\xa0aluminum\\xa0and\\xa0magnesium\\xa0hydroxide\\xa0in\\xa0order\\xa0to\\xa0avoid\\xa0these\\xa0side\\xa0effects.\\xa0The\\xa0magnesium\\xad',\n",
       " \"(e.g.,\\xa0Maalox,\\xa0Mylanta)\\xa0have\\xa0a\\xa0combination\\xa0of\\xa0both\\xa0aluminum\\xa0and\\xa0magnesium\\xa0hydroxide\\xa0in\\xa0order\\xa0to\\xa0avoid\\xa0these\\xa0side\\xa0effects.\\xa0The\\xa0magnesium\\xadcontaining\\xa0preparation\\xa0should\\xa0not\\xa0be\\xa0used\\xa0in\\xa0chronic\\xa0renal\\xa0failure\\xa0patients\\xa0because\\xa0of\\xa0possible\\xa0hypermagnesemia,\\xa0and\\xa0aluminum\\xa0may\\xa0cause\\xa0chronicneurotoxicity\\xa0in\\xa0these\\xa0patients.Calcium\\xa0carbonate\\xa0and\\xa0sodium\\xa0bicarbonate\\xa0are\\xa0potent\\xa0antacids\\xa0with\\xa0varying\\xa0levels\\xa0of\\xa0potential\\xa0problems.\\xa0The\\xa0long\\xadterm\\xa0use\\xa0of\\xa0calcium\\xa0carbonate(converts\\xa0to\\xa0calcium\\xa0chloride\\xa0in\\xa0the\\xa0stomach)\\xa0can\\xa0lead\\xa0to\\xa0milk\\xadalkali\\xa0syndrome\\xa0(hypercalcemia\\xa0and\\xa0hyperphosphatemia\\xa0with\\xa0possible\\xa0renal\\xa0calcinosisand\\xa0progression\\xa0to\\xa0renal\\xa0insufficiency).\\xa0Sodium\\xa0bicarbonate\\xa0may\\xa0induce\\xa0systemic\\xa0alkalosis.H Receptor AntagonistsYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 20 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling\",\n",
       " 'DanLongo,J.LarryJameson:Harrison\\'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllary',\n",
       " \"sensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillin\",\n",
       " \"treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'symptomatic\\xa0relief\\xa0of\\xa0dyspepsia.\\xa0The\\xa0most\\xa0commonly\\xa0used\\xa0agents\\xa0are\\xa0mixtures\\xa0of\\xa0aluminum\\xa0hydroxide\\xa0and\\xa0magnesium\\xa0hydroxide.\\xa0Aluminumhydroxide\\xa0can\\xa0produce\\xa0constipation\\xa0and\\xa0phosphate\\xa0depletion;\\xa0magnesium\\xa0hydroxide\\xa0may\\xa0cause\\xa0loose\\xa0stools.\\xa0Many\\xa0of\\xa0the\\xa0commonly\\xa0used\\xa0antacids(e.g.,\\xa0Maalox,\\xa0Mylanta)\\xa0have\\xa0a\\xa0combination\\xa0of\\xa0both\\xa0aluminum\\xa0and\\xa0magnesium\\xa0hydroxide\\xa0in\\xa0order\\xa0to\\xa0avoid\\xa0these\\xa0side\\xa0effects.\\xa0The\\xa0magnesium\\xadcontaining\\xa0preparation\\xa0should\\xa0not\\xa0be\\xa0used\\xa0in\\xa0chronic\\xa0renal\\xa0failure\\xa0patients\\xa0because\\xa0of\\xa0possible\\xa0hypermagnesemia,\\xa0and\\xa0aluminum\\xa0may\\xa0cause\\xa0chronicneurotoxicity\\xa0in\\xa0these\\xa0patients.Calcium\\xa0carbonate\\xa0and\\xa0sodium\\xa0bicarbonate\\xa0are\\xa0potent\\xa0antacids\\xa0with\\xa0varying\\xa0levels\\xa0of\\xa0potential\\xa0problems.\\xa0The\\xa0long\\xadterm\\xa0use\\xa0of\\xa0calcium\\xa0carbonate(converts\\xa0to\\xa0calcium\\xa0chloride\\xa0in\\xa0the\\xa0stomach)\\xa0can\\xa0lead\\xa0to\\xa0milk\\xadalkali\\xa0syndrome\\xa0(hypercalcemia\\xa0and\\xa0hyperphosphatemia\\xa0with\\xa0possible\\xa0renal\\xa0calcinosisand\\xa0progression\\xa0to\\xa0renal\\xa0insufficiency).\\xa0Sodium\\xa0bicarbonate\\xa0may\\xa0induce\\xa0systemic\\xa0alkalosis.H2\\xa0Receptor\\xa0AntagonistsFour\\xa0of\\xa0these\\xa0agents\\xa0are\\xa0presently\\xa0available\\xa0(cimetidine,\\xa0ranitidine,\\xa0famotidine,\\xa0and\\xa0nizatidine),\\xa0and\\xa0their\\xa0structures\\xa0share\\xa0homology\\xa0with\\xa0histamine.Although\\xa0each\\xa0has\\xa0different\\xa0potency,\\xa0all\\xa0will\\xa0significantly\\xa0inhibit\\xa0basal\\xa0and\\xa0stimulated\\xa0acid\\xa0secretion\\xa0to\\xa0comparable\\xa0levels\\xa0when\\xa0used\\xa0at\\xa0therapeuticdoses.\\xa0Moreover,\\xa0similar\\xa0ulcer\\xadhealing\\xa0rates\\xa0are\\xa0achieved\\xa0with\\xa0each\\xa0drug\\xa0when\\xa0used\\xa0at\\xa0the\\xa0correct\\xa0dosage.\\xa0Presently,\\xa0this\\xa0class\\xa0of\\xa0drug\\xa0is\\xa0often\\xa0used\\xa0fortreatment\\xa0of\\xa0active\\xa0ulcers\\xa0(4–6\\xa0weeks)\\xa0in\\xa0combination\\xa0with\\xa0antibiotics\\xa0directed\\xa0at\\xa0eradicating\\xa0H.\\xa0pylori\\xa0(see\\xa0below).Cimetidine\\xa0was\\xa0the\\xa0first\\xa0H2\\xa0receptor\\xa0antagonist\\xa0used\\xa0for\\xa0the\\xa0treatment\\xa0of\\xa0acid\\xa0peptic\\xa0disorders.\\xa0Cimetidine\\xa0may\\xa0have\\xa0weak\\xa0antiandrogenic\\xa0side\\xa0effectsresulting\\xa0in\\xa0reversible\\xa0gynecomastia\\xa0and\\xa0impotence,\\xa0primarily\\xa0in\\xa0patients\\xa0receiving\\xa0high\\xa0doses\\xa0for\\xa0prolonged\\xa0periods\\xa0of\\xa0time\\xa0(months\\xa0to\\xa0years).\\xa0In\\xa0viewof\\xa0cimetidine’s\\xa0ability\\xa0to\\xa0inhibit\\xa0cytochrome\\xa0P450,\\xa0careful\\xa0monitoring\\xa0of\\xa0drugs\\xa0such\\xa0as\\xa0warfarin,\\xa0phenytoin,\\xa0and\\xa0theophylline\\xa0is\\xa0indicated\\xa0with\\xa0long\\xad',\n",
       " 'of\\xa0cimetidine’s\\xa0ability\\xa0to\\xa0inhibit\\xa0cytochrome\\xa0P450,\\xa0careful\\xa0monitoring\\xa0of\\xa0drugs\\xa0such\\xa0as\\xa0warfarin,\\xa0phenytoin,\\xa0and\\xa0theophylline\\xa0is\\xa0indicated\\xa0with\\xa0long\\xadterm\\xa0usage.\\xa0Other\\xa0rare\\xa0reversible\\xa0adverse\\xa0effects\\xa0reported\\xa0with\\xa0cimetidine\\xa0include\\xa0confusion\\xa0and\\xa0elevated\\xa0levels\\xa0of\\xa0serum\\xa0aminotransferases,creatinine,\\xa0and\\xa0serum\\xa0prolactin.\\xa0Ranitidine,\\xa0famotidine,\\xa0and\\xa0nizatidine\\xa0are\\xa0more\\xa0potent\\xa0H2\\xa0receptor\\xa0antagonists\\xa0than\\xa0cimetidine.\\xa0Each\\xa0can\\xa0be\\xa0usedonce\\xa0a\\xa0day\\xa0at\\xa0bedtime\\xa0for\\xa0ulcer\\xa0prevention,\\xa0which\\xa0was\\xa0commonly\\xa0done\\xa0before\\xa0the\\xa0discovery\\xa0of\\xa0H.\\xa0pylori\\xa0and\\xa0the\\xa0development\\xa0of\\xa0proton\\xa0pumpinhibitors\\xa0(PPIs).\\xa0Patients\\xa0may\\xa0develop\\xa0tolerance\\xa0to\\xa0H2\\xa0blockers,\\xa0a\\xa0rare\\xa0event\\xa0with\\xa0PPIs\\xa0(see\\xa0below).\\xa0Comparable\\xa0nighttime\\xa0dosing\\xa0regimens\\xa0arecimetidine\\xa0800\\xa0mg,\\xa0ranitidine\\xa0300\\xa0mg,\\xa0famotidine\\xa040\\xa0mg,\\xa0and\\xa0nizatidine\\xa0300\\xa0mg.Additional\\xa0rare,\\xa0reversible\\xa0systemic\\xa0toxicities\\xa0reported\\xa0with\\xa0H2\\xa0receptor\\xa0antagonists\\xa0include\\xa0pancytopenia,\\xa0neutropenia,\\xa0anemia,\\xa0andthrombocytopenia,\\xa0with\\xa0a\\xa0prevalence\\xa0rate\\xa0varying\\xa0from\\xa00.01\\xa0to\\xa00.2%.\\xa0Cimetidine\\xa0and\\xa0ranitidine\\xa0(to\\xa0a\\xa0lesser\\xa0extent)\\xa0can\\xa0bind\\xa0to\\xa0hepatic\\xa0cytochromeP450;\\xa0famotidine\\xa0and\\xa0nizatidine\\xa0do\\xa0not.\\xa0Ranitidine\\xa0and\\xa0nizatidine\\xa0were\\xa0taken\\xa0off\\xa0of\\xa0the\\xa0market\\xa0due\\xa0to\\xa0contamination\\xa0of\\xa0the\\xa0drug\\xa0with\\xa0N\\xadnitrosodimethylamine\\xa0(NDMA),\\xa0a\\xa0known\\xa0carcinogen.Proton\\xa0Pump\\xa0(H+, K+\\xadATPase)\\xa0InhibitorsOmeprazole,\\xa0esomeprazole,\\xa0lansoprazole,\\xa0rabeprazole,\\xa0and\\xa0pantoprazole\\xa0are\\xa0substituted\\xa0benzimidazole\\xa0derivatives\\xa0that\\xa0covalently\\xa0bind\\xa0andirreversibly\\xa0inhibit\\xa0H+,K+\\xadATPase.\\xa0Esomeprazole\\xa0is\\xa0the\\xa0S\\xadenantiomer\\xa0of\\xa0omeprazole,\\xa0which\\xa0is\\xa0a\\xa0racemic\\xa0mixture\\xa0of\\xa0both\\xa0S\\xad\\xa0and\\xa0R\\xadoptical\\xa0isomers.\\xa0The\\xa0R\\xadisomer\\xa0of\\xa0lansoprazole,\\xa0dexlansoprazole,\\xa0is\\xa0the\\xa0most\\xa0recent\\xa0PPI\\xa0approved\\xa0for\\xa0clinical\\xa0use.\\xa0Its\\xa0reported\\xa0advantage\\xa0is\\xa0a\\xa0dual\\xa0delayed\\xadrelease\\xa0systemaimed\\xa0at\\xa0improving\\xa0treatment\\xa0of\\xa0gastroesophageal\\xa0reflux\\xa0disease\\xa0(GERD).\\xa0These\\xa0are\\xa0the\\xa0most\\xa0potent\\xa0acid\\xa0inhibitory\\xa0agents\\xa0available.\\xa0Omeprazole\\xa0and',\n",
       " 'aimed\\xa0at\\xa0improving\\xa0treatment\\xa0of\\xa0gastroesophageal\\xa0reflux\\xa0disease\\xa0(GERD).\\xa0These\\xa0are\\xa0the\\xa0most\\xa0potent\\xa0acid\\xa0inhibitory\\xa0agents\\xa0available.\\xa0Omeprazole\\xa0andlansoprazole\\xa0are\\xa0the\\xa0PPIs\\xa0that\\xa0have\\xa0been\\xa0used\\xa0for\\xa0the\\xa0longest\\xa0time.\\xa0Both\\xa0are\\xa0acid\\xadlabile\\xa0and\\xa0are\\xa0administered\\xa0as\\xa0enteric\\xadcoated\\xa0granules\\xa0in\\xa0a\\xa0sustained\\xadrelease\\xa0capsule\\xa0that\\xa0dissolves\\xa0within\\xa0the\\xa0small\\xa0intestine\\xa0at\\xa0a\\xa0pH\\xa0of\\xa06.\\xa0Lansoprazole\\xa0is\\xa0available\\xa0in\\xa0an\\xa0orally\\xa0disintegrating\\xa0tablet\\xa0that\\xa0can\\xa0be\\xa0taken\\xa0with\\xa0orwithout\\xa0water,\\xa0an\\xa0advantage\\xa0for\\xa0individuals\\xa0who\\xa0have\\xa0significant\\xa0dysphagia.\\xa0Absorption\\xa0kinetics\\xa0are\\xa0similar\\xa0to\\xa0the\\xa0capsule.\\xa0In\\xa0addition,\\xa0a\\xa0lansoprazole\\xadnaproxen\\xa0combination\\xa0preparation\\xa0that\\xa0has\\xa0been\\xa0made\\xa0available\\xa0is\\xa0targeted\\xa0at\\xa0decreasing\\xa0NSAID\\xadrelated\\xa0GI\\xa0injury\\xa0(see\\xa0below).\\xa0Omeprazole\\xa0is\\xa0availableas\\xa0non–enteric\\xadcoated\\xa0granules\\xa0mixed\\xa0with\\xa0sodium\\xa0bicarbonate\\xa0in\\xa0a\\xa0powder\\xa0form\\xa0that\\xa0can\\xa0be\\xa0administered\\xa0orally\\xa0or\\xa0via\\xa0gastric\\xa0tube.\\xa0The\\xa0sodiumbicarbonate\\xa0has\\xa0two\\xa0purposes:\\xa0to\\xa0protect\\xa0the\\xa0omeprazole\\xa0from\\xa0acid\\xa0degradation\\xa0and\\xa0to\\xa0promote\\xa0rapid\\xa0gastric\\xa0alkalinization\\xa0and\\xa0subsequent\\xa0protonpump\\xa0activation,\\xa0which\\xa0facilitates\\xa0rapid\\xa0action\\xa0of\\xa0the\\xa0PPI.\\xa0Pantoprazole\\xa0and\\xa0rabeprazole\\xa0are\\xa0available\\xa0as\\xa0enteric\\xadcoated\\xa0tablets.\\xa0Pantoprazole\\xa0is\\xa0alsoavailable\\xa0as\\xa0a\\xa0parenteral\\xa0formulation\\xa0for\\xa0intravenous\\xa0use.\\xa0These\\xa0agents\\xa0are\\xa0lipophilic\\xa0compounds;\\xa0upon\\xa0entering\\xa0the\\xa0parietal\\xa0cell,\\xa0they\\xa0are\\xa0protonatedand\\xa0trapped\\xa0within\\xa0the\\xa0acid\\xa0environment\\xa0of\\xa0the\\xa0tubulovesicular\\xa0and\\xa0canalicular\\xa0system.\\xa0These\\xa0agents\\xa0potently\\xa0inhibit\\xa0all\\xa0phases\\xa0of\\xa0gastric\\xa0acidsecretion.\\xa0Onset\\xa0of\\xa0action\\xa0is\\xa0rapid,\\xa0with\\xa0a\\xa0maximum\\xa0acid\\xa0inhibitory\\xa0effect\\xa0between\\xa02\\xa0and\\xa06\\xa0h\\xa0after\\xa0administration\\xa0and\\xa0duration\\xa0of\\xa0inhibition\\xa0lasting\\xa0up\\xa0to72–96\\xa0h.\\xa0With\\xa0repeated\\xa0daily\\xa0dosing,\\xa0progressive\\xa0acid\\xa0inhibitory\\xa0effects\\xa0are\\xa0observed,\\xa0with\\xa0basal\\xa0and\\xa0secretagogue\\xadstimulated\\xa0acid\\xa0production\\xa0beinginhibited\\xa0by\\xa0>95%\\xa0after\\xa01\\xa0week\\xa0of\\xa0therapy.\\xa0The\\xa0half\\xadlife\\xa0of\\xa0PPIs\\xa0is\\xa0~18\\xa0h;\\xa0thus,\\xa0it\\xa0can\\xa0take\\xa0between\\xa02\\xa0and\\xa05\\xa0days\\xa0for\\xa0gastric\\xa0acid\\xa0secretion\\xa0to\\xa0return\\xa0to',\n",
       " 'inhibited\\xa0by\\xa0>95%\\xa0after\\xa01\\xa0week\\xa0of\\xa0therapy.\\xa0The\\xa0half\\xadlife\\xa0of\\xa0PPIs\\xa0is\\xa0~18\\xa0h;\\xa0thus,\\xa0it\\xa0can\\xa0take\\xa0between\\xa02\\xa0and\\xa05\\xa0days\\xa0for\\xa0gastric\\xa0acid\\xa0secretion\\xa0to\\xa0return\\xa0tonormal\\xa0levels\\xa0once\\xa0these\\xa0drugs\\xa0have\\xa0been\\xa0discontinued.\\xa0Because\\xa0the\\xa0pumps\\xa0need\\xa0to\\xa0be\\xa0activated\\xa0for\\xa0these\\xa0agents\\xa0to\\xa0be\\xa0effective,\\xa0their\\xa0efficacy\\xa0ismaximized\\xa0if\\xa0they\\xa0are\\xa0administered\\xa0before\\xa0a\\xa0meal\\xa0(except\\xa0for\\xa0the\\xa0immediate\\xadrelease\\xa0formulation\\xa0of\\xa0omeprazole)\\xa0(e.g.,\\xa0in\\xa0the\\xa0morning\\xa0beforebreakfast).\\xa0Mild\\xa0to\\xa0moderate\\xa0hypergastrinemia\\xa0has\\xa0been\\xa0observed\\xa0in\\xa0patients\\xa0taking\\xa0these\\xa0drugs.\\xa0Carcinoid\\xa0tumors\\xa0developed\\xa0in\\xa0some\\xa0animals\\xa0giventhe\\xa0drugs\\xa0preclinically;\\xa0however,\\xa0extensive\\xa0experience\\xa0has\\xa0failed\\xa0to\\xa0demonstrate\\xa0gastric\\xa0carcinoid\\xa0tumor\\xa0development\\xa0in\\xa0humans.\\xa0Serum\\xa0gastrin\\xa0levelsreturn\\xa0to\\xa0normal\\xa0levels\\xa0within\\xa01–2\\xa0weeks\\xa0after\\xa0drug\\xa0cessation.\\xa0Rebound\\xa0gastric\\xa0acid\\xa0hypersecretion\\xa0has\\xa0been\\xa0described\\xa0in\\xa0H.\\xa0pylori–negativeindividuals\\xa0after\\xa0discontinuation\\xa0of\\xa0PPIs.\\xa0It\\xa0occurs\\xa0even\\xa0after\\xa0relatively\\xa0short\\xadterm\\xa0usage\\xa0(2\\xa0months)\\xa0and\\xa0may\\xa0last\\xa0for\\xa0up\\xa0to\\xa02\\xa0months\\xa0after\\xa0the\\xa0PPI\\xa0hasbeen\\xa0discontinued.\\xa0The\\xa0mechanism\\xa0involves\\xa0gastrin\\xadinduced\\xa0hyperplasia\\xa0and\\xa0hypertrophy\\xa0of\\xa0histamine\\xadsecreting\\xa0ECL\\xa0cells.\\xa0The\\xa0clinical\\xa0relevance\\xa0ofthis\\xa0observation\\xa0is\\xa0that\\xa0individuals\\xa0may\\xa0have\\xa0worsening\\xa0symptoms\\xa0of\\xa0GERD\\xa0or\\xa0dyspepsia\\xa0upon\\xa0stopping\\xa0the\\xa0PPI.\\xa0Gradual\\xa0tapering\\xa0of\\xa0the\\xa0PPI\\xa0andswitching\\xa0to\\xa0an\\xa0H2\\xa0receptor\\xa0antagonist\\xa0may\\xa0prevent\\xa0this\\xa0from\\xa0occurring.\\xa0H.\\xa0pylori–induced\\xa0inflammation\\xa0and\\xa0concomitant\\xa0decrease\\xa0in\\xa0acid\\xa0productionmay\\xa0explain\\xa0why\\xa0this\\xa0does\\xa0not\\xa0occur\\xa0in\\xa0H.\\xa0pylori–positive\\xa0patients.\\xa0IF\\xa0production\\xa0is\\xa0also\\xa0inhibited,\\xa0but\\xa0vitamin\\xa0B12\\xa0deficiency\\xa0anemia\\xa0is\\xa0uncommon,b bl bf th ltf thitiAitht th t ld tiifit hhlh d iPPIi tfith btifYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 21 / 49PharmacyACCESSRSILVERCHAIRINFORMATION',\n",
       " \"©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 21 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison's Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroids\",\n",
       " 'Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cells',\n",
       " \"Copyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21e\",\n",
       " \"+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'maximized\\xa0if\\xa0they\\xa0are\\xa0administered\\xa0before\\xa0a\\xa0meal\\xa0(except\\xa0for\\xa0the\\xa0immediate\\xadrelease\\xa0formulation\\xa0of\\xa0omeprazole)\\xa0(e.g.,\\xa0in\\xa0the\\xa0morning\\xa0beforebreakfast).\\xa0Mild\\xa0to\\xa0moderate\\xa0hypergastrinemia\\xa0has\\xa0been\\xa0observed\\xa0in\\xa0patients\\xa0taking\\xa0these\\xa0drugs.\\xa0Carcinoid\\xa0tumors\\xa0developed\\xa0in\\xa0some\\xa0animals\\xa0giventhe\\xa0drugs\\xa0preclinically;\\xa0however,\\xa0extensive\\xa0experience\\xa0has\\xa0failed\\xa0to\\xa0demonstrate\\xa0gastric\\xa0carcinoid\\xa0tumor\\xa0development\\xa0in\\xa0humans.\\xa0Serum\\xa0gastrin\\xa0levelsreturn\\xa0to\\xa0normal\\xa0levels\\xa0within\\xa01–2\\xa0weeks\\xa0after\\xa0drug\\xa0cessation.\\xa0Rebound\\xa0gastric\\xa0acid\\xa0hypersecretion\\xa0has\\xa0been\\xa0described\\xa0in\\xa0H.\\xa0pylori–negativeindividuals\\xa0after\\xa0discontinuation\\xa0of\\xa0PPIs.\\xa0It\\xa0occurs\\xa0even\\xa0after\\xa0relatively\\xa0short\\xadterm\\xa0usage\\xa0(2\\xa0months)\\xa0and\\xa0may\\xa0last\\xa0for\\xa0up\\xa0to\\xa02\\xa0months\\xa0after\\xa0the\\xa0PPI\\xa0hasbeen\\xa0discontinued.\\xa0The\\xa0mechanism\\xa0involves\\xa0gastrin\\xadinduced\\xa0hyperplasia\\xa0and\\xa0hypertrophy\\xa0of\\xa0histamine\\xadsecreting\\xa0ECL\\xa0cells.\\xa0The\\xa0clinical\\xa0relevance\\xa0ofthis\\xa0observation\\xa0is\\xa0that\\xa0individuals\\xa0may\\xa0have\\xa0worsening\\xa0symptoms\\xa0of\\xa0GERD\\xa0or\\xa0dyspepsia\\xa0upon\\xa0stopping\\xa0the\\xa0PPI.\\xa0Gradual\\xa0tapering\\xa0of\\xa0the\\xa0PPI\\xa0andswitching\\xa0to\\xa0an\\xa0H2\\xa0receptor\\xa0antagonist\\xa0may\\xa0prevent\\xa0this\\xa0from\\xa0occurring.\\xa0H.\\xa0pylori–induced\\xa0inflammation\\xa0and\\xa0concomitant\\xa0decrease\\xa0in\\xa0acid\\xa0productionmay\\xa0explain\\xa0why\\xa0this\\xa0does\\xa0not\\xa0occur\\xa0in\\xa0H.\\xa0pylori–positive\\xa0patients.\\xa0IF\\xa0production\\xa0is\\xa0also\\xa0inhibited,\\xa0but\\xa0vitamin\\xa0B12\\xa0deficiency\\xa0anemia\\xa0is\\xa0uncommon,probably\\xa0because\\xa0of\\xa0the\\xa0large\\xa0stores\\xa0of\\xa0the\\xa0vitamin.\\xa0As\\xa0with\\xa0any\\xa0agent\\xa0that\\xa0leads\\xa0to\\xa0significant\\xa0hypochlorhydria,\\xa0PPIs\\xa0may\\xa0interfere\\xa0with\\xa0absorption\\xa0ofdrugs\\xa0such\\xa0as\\xa0ketoconazole,\\xa0ampicillin,\\xa0iron,\\xa0and\\xa0digoxin.\\xa0Hepatic\\xa0cytochrome\\xa0P450\\xa0can\\xa0be\\xa0inhibited\\xa0by\\xa0the\\xa0earlier\\xa0PPIs\\xa0(omeprazole,\\xa0lansoprazole).Rabeprazole,\\xa0pantoprazole,\\xa0and\\xa0esomeprazole\\xa0do\\xa0not\\xa0appear\\xa0to\\xa0interact\\xa0significantly\\xa0with\\xa0drugs\\xa0metabolized\\xa0by\\xa0the\\xa0cytochrome\\xa0P450\\xa0system.\\xa0Theoverall\\xa0clinical\\xa0significance\\xa0of\\xa0this\\xa0observation\\xa0is\\xa0not\\xa0definitely\\xa0established.\\xa0Caution\\xa0should\\xa0be\\xa0taken\\xa0when\\xa0using\\xa0theophylline,\\xa0warfarin,\\xa0diazepam,atazanavir,\\xa0and\\xa0phenytoin\\xa0concomitantly\\xa0with\\xa0PPIs.',\n",
       " 'overall\\xa0clinical\\xa0significance\\xa0of\\xa0this\\xa0observation\\xa0is\\xa0not\\xa0definitely\\xa0established.\\xa0Caution\\xa0should\\xa0be\\xa0taken\\xa0when\\xa0using\\xa0theophylline,\\xa0warfarin,\\xa0diazepam,atazanavir,\\xa0and\\xa0phenytoin\\xa0concomitantly\\xa0with\\xa0PPIs.The\\xa0list\\xa0of\\xa0potential\\xa0side\\xa0effects\\xa0with\\xa0long\\xadterm\\xa0PPI\\xa0use\\xa0has\\xa0steadily\\xa0grown\\xa0over\\xa0the\\xa0years.\\xa0These\\xa0agents\\xa0are\\xa0commonly\\xa0used\\xa0since\\xa0several\\xa0formulationshave\\xa0become\\xa0available\\xa0as\\xa0over\\xadthe\\xadcounter\\xa0medications.\\xa0Moreover,\\xa0up\\xa0to\\xa070%\\xa0of\\xa0current\\xa0prescriptions\\xa0for\\xa0long\\xadterm\\xa0PPIs\\xa0may\\xa0be\\xa0unwarranted\\xa0andbetween\\xa035\\xa0and\\xa060%\\xa0of\\xa0in\\xadhospital\\xa0use\\xa0of\\xa0PPIs\\xa0may\\xa0be\\xa0inappropriate.\\xa0Interpretation\\xa0of\\xa0the\\xa0multiple\\xa0studies\\xa0should\\xa0take\\xa0into\\xa0consideration\\xa0that\\xa0the\\xa0vastmajority\\xa0were\\xa0retrospective\\xa0observational\\xa0studies\\xa0in\\xa0which\\xa0confounding\\xa0factors\\xa0could\\xa0not\\xa0be\\xa0accounted\\xa0for\\xa0entirely.Long\\xadterm\\xa0acid\\xa0suppression,\\xa0especially\\xa0with\\xa0PPIs,\\xa0has\\xa0been\\xa0associated\\xa0with\\xa0a\\xa0higher\\xa0incidence\\xa0of\\xa0community\\xadacquired\\xa0pneumonia\\xa0as\\xa0well\\xa0ascommunity\\xad\\xa0and\\xa0hospital\\xadacquired\\xa0Clostridium\\xa0difficile–associated\\xa0disease.\\xa0A\\xa0meta\\xadanalysis\\xa0showed\\xa0a\\xa074%\\xa0increased\\xa0risk\\xa0of\\xa0C.\\xa0difficile\\xa0infection\\xa0and\\xa0a2.5\\xadfold\\xa0higher\\xa0risk\\xa0of\\xa0reinfection\\xa0as\\xa0compared\\xa0to\\xa0nonusers.\\xa0In\\xa0light\\xa0of\\xa0these\\xa0concerns,\\xa0the\\xa0FDA\\xa0published\\xa0a\\xa0safety\\xa0alert\\xa0regarding\\xa0the\\xa0associationbetween\\xa0C.\\xa0difficile\\xa0infection\\xa0and\\xa0PPI\\xa0use.\\xa0Although\\xa0the\\xa0risk\\xa0of\\xa0spontaneous\\xa0bacterial\\xa0peritonitis\\xa0in\\xa0cirrhotics\\xa0was\\xa0thought\\xa0to\\xa0be\\xa0increased,\\xa0the\\xa0data\\xa0hereare\\xa0less\\xa0supportive.\\xa0The\\xa0impact\\xa0of\\xa0PPI\\xadinduced\\xa0changes\\xa0in\\xa0the\\xa0host\\xa0microbiome\\xa0is\\xa0postulated\\xa0to\\xa0play\\xa0a\\xa0role\\xa0in\\xa0the\\xa0increased\\xa0risk\\xa0of\\xa0infection,\\xa0but\\xa0thistheory\\xa0needs\\xa0to\\xa0be\\xa0confirmed.\\xa0These\\xa0observations\\xa0require\\xa0confirmation\\xa0but\\xa0should\\xa0alert\\xa0the\\xa0practitioner\\xa0to\\xa0take\\xa0caution\\xa0when\\xa0recommending\\xa0theseagents\\xa0for\\xa0long\\xadterm\\xa0use,\\xa0especially\\xa0in\\xa0elderly\\xa0patients\\xa0at\\xa0risk\\xa0for\\xa0developing\\xa0pneumonia\\xa0or\\xa0C.\\xa0difficile\\xa0infection.Diarrhea\\xa0is\\xa0also\\xa0associated\\xa0with\\xa0PPI\\xa0use,\\xa0which\\xa0in\\xa0some\\xa0cases\\xa0has\\xa0been\\xa0associated\\xa0with\\xa0the\\xa0development\\xa0of\\xa0collagenous\\xa0colitis\\xa0(hazard\\xa0ratio\\xa0of\\xa04.5),',\n",
       " 'Diarrhea\\xa0is\\xa0also\\xa0associated\\xa0with\\xa0PPI\\xa0use,\\xa0which\\xa0in\\xa0some\\xa0cases\\xa0has\\xa0been\\xa0associated\\xa0with\\xa0the\\xa0development\\xa0of\\xa0collagenous\\xa0colitis\\xa0(hazard\\xa0ratio\\xa0of\\xa04.5),particularly\\xa0with\\xa0lansoprazole.\\xa0The\\xa0mechanism\\xa0for\\xa0PPI\\xadinduced\\xa0collagenous\\xa0colitis\\xa0is\\xa0unclear,\\xa0but\\xa0in\\xa0vitro\\xa0studies\\xa0demonstrate\\xa0that\\xa0PPIs\\xa0may\\xa0inducecollagen\\xa0gene\\xa0expression.\\xa0The\\xa0colitis\\xa0usually\\xa0resolves\\xa0with\\xa0cessation\\xa0of\\xa0the\\xa0PPI.A\\xa0population\\xadbased\\xa0study\\xa0revealed\\xa0that\\xa0long\\xadterm\\xa0use\\xa0of\\xa0PPIs\\xa0was\\xa0associated\\xa0with\\xa0the\\xa0development\\xa0of\\xa0hip\\xa0fractures\\xa0in\\xa0older\\xa0women.\\xa0The\\xa0absolute\\xa0riskof\\xa0fracture\\xa0remained\\xa0low\\xa0and\\xa0may\\xa0be\\xa0zero\\xa0despite\\xa0an\\xa0observed\\xa0increase\\xa0associated\\xa0with\\xa0the\\xa0dose\\xa0and\\xa0duration\\xa0of\\xa0acid\\xa0suppression.\\xa0The\\xa0mechanismfor\\xa0this\\xa0observation\\xa0is\\xa0not\\xa0clear,\\xa0and\\xa0this\\xa0finding\\xa0must\\xa0be\\xa0confirmed\\xa0before\\xa0making\\xa0broad\\xa0recommendations\\xa0regarding\\xa0the\\xa0discontinuation\\xa0of\\xa0theseagents\\xa0in\\xa0patients\\xa0who\\xa0benefit\\xa0from\\xa0them.\\xa0Long\\xadterm\\xa0use\\xa0of\\xa0PPIs\\xa0has\\xa0also\\xa0been\\xa0implicated\\xa0in\\xa0the\\xa0development\\xa0of\\xa0iron,\\xa0vitamin\\xa0B12,\\xa0and\\xa0magnesiumdeficiency.\\xa0A\\xa0meta\\xadanalysis\\xa0of\\xa0nine\\xa0observational\\xa0studies\\xa0found\\xa0a\\xa040%\\xa0increase\\xa0in\\xa0hypomagnesemia\\xa0in\\xa0PPI\\xa0users\\xa0as\\xa0compared\\xa0to\\xa0nonusers.\\xa0Oneapproach\\xa0to\\xa0consider\\xa0in\\xa0patients\\xa0needing\\xa0to\\xa0take\\xa0PPIs\\xa0long\\xa0term\\xa0is\\xa0to\\xa0check\\xa0a\\xa0complete\\xa0blood\\xa0count\\xa0looking\\xa0for\\xa0evidence\\xa0of\\xa0anemia\\xa0due\\xa0to\\xa0iron\\xa0orvitamin\\xa0B12\\xa0deficiency,\\xa0vitamin\\xa0B12\\xa0level,\\xa0and\\xa0a\\xa0magnesium\\xa0level\\xa0after\\xa01–2\\xa0years\\xa0of\\xa0PPI\\xa0use,\\xa0but\\xa0these\\xa0recommendations\\xa0are\\xa0not\\xa0evidence\\xa0based\\xa0orrecommended\\xa0by\\xa0expert\\xa0opinion.\\xa0PPIs\\xa0may\\xa0exert\\xa0a\\xa0negative\\xa0effect\\xa0on\\xa0the\\xa0antiplatelet\\xa0effect\\xa0of\\xa0clopidogrel.\\xa0Although\\xa0the\\xa0evidence\\xa0is\\xa0mixed\\xa0andinconclusive,\\xa0a\\xa0small\\xa0increase\\xa0in\\xa0mortality\\xa0and\\xa0readmission\\xa0rate\\xa0for\\xa0coronary\\xa0events\\xa0was\\xa0seen\\xa0in\\xa0patients\\xa0receiving\\xa0a\\xa0PPI\\xa0while\\xa0on\\xa0clopidogrel\\xa0in\\xa0earlierstudies.\\xa0Subsequently,\\xa0three\\xa0meta\\xadanalyses\\xa0reported\\xa0an\\xa0inverse\\xa0correlation\\xa0between\\xa0clopidogrel\\xa0and\\xa0PPI\\xa0use;\\xa0therefore,\\xa0the\\xa0influence\\xa0of\\xa0this\\xa0druginteraction\\xa0on\\xa0mortality\\xa0is\\xa0not\\xa0clearly\\xa0established.\\xa0The\\xa0mechanism\\xa0involves\\xa0the\\xa0competition\\xa0of\\xa0the\\xa0PPI\\xa0and\\xa0clopidogrel\\xa0with\\xa0the\\xa0same\\xa0cytochrome\\xa0P450',\n",
       " 'interaction\\xa0on\\xa0mortality\\xa0is\\xa0not\\xa0clearly\\xa0established.\\xa0The\\xa0mechanism\\xa0involves\\xa0the\\xa0competition\\xa0of\\xa0the\\xa0PPI\\xa0and\\xa0clopidogrel\\xa0with\\xa0the\\xa0same\\xa0cytochrome\\xa0P450(CYP2C19).\\xa0Whether\\xa0this\\xa0is\\xa0a\\xa0class\\xa0effect\\xa0of\\xa0PPIs\\xa0is\\xa0unclear;\\xa0there\\xa0appears\\xa0to\\xa0be\\xa0at\\xa0least\\xa0a\\xa0theoretical\\xa0advantage\\xa0of\\xa0pantoprazole\\xa0over\\xa0the\\xa0other\\xa0PPIs,\\xa0butthis\\xa0has\\xa0not\\xa0been\\xa0confirmed.\\xa0This\\xa0drug\\xa0interaction\\xa0is\\xa0particularly\\xa0relevant\\xa0in\\xa0light\\xa0of\\xa0the\\xa0common\\xa0use\\xa0of\\xa0aspirin\\xa0and\\xa0clopidogrel\\xa0for\\xa0prevention\\xa0ofcoronary\\xa0events\\xa0and\\xa0the\\xa0efficacy\\xa0of\\xa0PPIs\\xa0in\\xa0preventing\\xa0GI\\xa0bleeding\\xa0in\\xa0these\\xa0patients.\\xa0The\\xa0FDA\\xa0has\\xa0made\\xa0several\\xa0recommendations\\xa0while\\xa0awaitingfurther\\xa0evidence\\xa0to\\xa0clarify\\xa0the\\xa0impact\\xa0of\\xa0PPI\\xa0therapy\\xa0on\\xa0clopidogrel\\xa0use.\\xa0Health\\xa0care\\xa0providers\\xa0should\\xa0continue\\xa0to\\xa0prescribe\\xa0clopidogrel\\xa0to\\xa0patients\\xa0whorequire\\xa0it\\xa0and\\xa0should\\xa0reevaluate\\xa0the\\xa0need\\xa0for\\xa0starting\\xa0or\\xa0continuing\\xa0treatment\\xa0with\\xa0a\\xa0PPI.\\xa0From\\xa0a\\xa0practical\\xa0standpoint,\\xa0additional\\xa0recommendations\\xa0toconsider\\xa0include\\xa0the\\xa0following:\\xa0Patients\\xa0taking\\xa0clopidogrel\\xa0with\\xa0aspirin,\\xa0especially\\xa0with\\xa0other\\xa0GI\\xa0risk\\xa0factors\\xa0for\\xa0bleeding,\\xa0should\\xa0receive\\xa0GI\\xa0protectivetherapy.\\xa0Although\\xa0high\\xaddose\\xa0H2\\xa0blockers\\xa0have\\xa0been\\xa0considered\\xa0an\\xa0option,\\xa0these\\xa0do\\xa0not\\xa0appear\\xa0to\\xa0be\\xa0as\\xa0effective\\xa0as\\xa0PPIs.\\xa0If\\xa0PPIs\\xa0are\\xa0to\\xa0be\\xa0given,\\xa0somehave\\xa0recommended\\xa0that\\xa0there\\xa0be\\xa0a\\xa012\\xadh\\xa0separation\\xa0between\\xa0administration\\xa0of\\xa0the\\xa0PPI\\xa0and\\xa0clopidogrel\\xa0to\\xa0minimize\\xa0competition\\xa0of\\xa0the\\xa0two\\xa0agents\\xa0withthe\\xa0involved\\xa0cytochrome\\xa0P450.\\xa0One\\xa0option\\xa0is\\xa0to\\xa0give\\xa0the\\xa0PPI\\xa030\\xa0min\\xa0before\\xa0breakfast\\xa0and\\xa0the\\xa0clopidogrel\\xa0at\\xa0bedtime.\\xa0Insufficient\\xa0data\\xa0are\\xa0available\\xa0tofirmly\\xa0recommend\\xa0one\\xa0PPI\\xa0over\\xa0another.\\xa0Additional\\xa0concerning\\xa0side\\xa0effects\\xa0with\\xa0long\\xadterm\\xa0PPI\\xa0use\\xa0include\\xa0increased\\xa0cardiac\\xa0risks\\xa0independent\\xa0ofclopidogrel\\xa0use,\\xa0dementia,\\xa0and\\xa0acute\\xa0and\\xa0chronic\\xa0kidney\\xa0injury.\\xa0Again,\\xa0the\\xa0data\\xa0are\\xa0often\\xa0retrospective\\xa0and\\xa0confounding\\xa0variables\\xa0were\\xa0notconsistently\\xa0eliminated,\\xa0thus\\xa0making\\xa0it\\xa0difficult\\xa0to\\xa0establish\\xa0a\\xa0definitive\\xa0association\\xa0between\\xa0PPIs\\xa0and\\xa0the\\xa0toxicities\\xa0outlined.\\xa0A\\xa0summary\\xa0of\\xa0the\\xa0side',\n",
       " \"consistently\\xa0eliminated,\\xa0thus\\xa0making\\xa0it\\xa0difficult\\xa0to\\xa0establish\\xa0a\\xa0definitive\\xa0association\\xa0between\\xa0PPIs\\xa0and\\xa0the\\xa0toxicities\\xa0outlined.\\xa0A\\xa0summary\\xa0of\\xa0the\\xa0sideeffects\\xa0with\\xa0the\\xa0corresponding\\xa0relative\\xa0risks\\xa0is\\xa0shown\\xa0in\\xa0Fig.\\xa0324–12.\\xa0Ultimately,\\xa0heightened\\xa0awareness\\xa0of\\xa0inappropriate\\xa0long\\xadterm\\xa0use\\xa0of\\xa0PPIs\\xa0isparamount.\\xa0Patients\\xa0aged\\xa0≥65\\xa0years\\xa0of\\xa0age\\xa0have\\xa0a\\xa0higher\\xa0risk\\xa0for\\xa0some\\xa0of\\xa0the\\xa0long\\xadterm\\xa0side\\xa0effects\\xa0of\\xa0PPIs\\xa0highlighted\\xa0above,\\xa0in\\xa0part\\xa0due\\xa0to\\xa0the\\xa0higherprevalence\\xa0of\\xa0concomitant\\xa0chronic\\xa0diseases.\\xa0It\\xa0is\\xa0therefore\\xa0essential\\xa0to\\xa0carefully\\xa0select\\xa0individuals,\\xa0especially\\xa0among\\xa0the\\xa0elderly,\\xa0who\\xa0need\\xa0long\\xadtermPPI\\xa0therapy\\xa0and\\xa0discontinue\\xa0it\\xa0in\\xa0those\\xa0individuals\\xa0who\\xa0do\\xa0not\\xa0need\\xa0it.\\xa0Abrupt\\xa0withdrawal\\xa0of\\xa0a\\xa0PPI\\xa0in\\xa0a\\xa0long\\xadterm\\xa0user\\xa0may\\xa0result\\xa0in\\xa0a\\xa0component\\xa0ofbd hidihhihld bddllhf2ki hibli iH blkfhYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 22 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21e\",\n",
       " 'kidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison\\'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)',\n",
       " \"aggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycin\",\n",
       " \"MCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'therapy.\\xa0Although\\xa0high\\xaddose\\xa0H2\\xa0blockers\\xa0have\\xa0been\\xa0considered\\xa0an\\xa0option,\\xa0these\\xa0do\\xa0not\\xa0appear\\xa0to\\xa0be\\xa0as\\xa0effective\\xa0as\\xa0PPIs.\\xa0If\\xa0PPIs\\xa0are\\xa0to\\xa0be\\xa0given,\\xa0somehave\\xa0recommended\\xa0that\\xa0there\\xa0be\\xa0a\\xa012\\xadh\\xa0separation\\xa0between\\xa0administration\\xa0of\\xa0the\\xa0PPI\\xa0and\\xa0clopidogrel\\xa0to\\xa0minimize\\xa0competition\\xa0of\\xa0the\\xa0two\\xa0agents\\xa0withthe\\xa0involved\\xa0cytochrome\\xa0P450.\\xa0One\\xa0option\\xa0is\\xa0to\\xa0give\\xa0the\\xa0PPI\\xa030\\xa0min\\xa0before\\xa0breakfast\\xa0and\\xa0the\\xa0clopidogrel\\xa0at\\xa0bedtime.\\xa0Insufficient\\xa0data\\xa0are\\xa0available\\xa0tofirmly\\xa0recommend\\xa0one\\xa0PPI\\xa0over\\xa0another.\\xa0Additional\\xa0concerning\\xa0side\\xa0effects\\xa0with\\xa0long\\xadterm\\xa0PPI\\xa0use\\xa0include\\xa0increased\\xa0cardiac\\xa0risks\\xa0independent\\xa0ofclopidogrel\\xa0use,\\xa0dementia,\\xa0and\\xa0acute\\xa0and\\xa0chronic\\xa0kidney\\xa0injury.\\xa0Again,\\xa0the\\xa0data\\xa0are\\xa0often\\xa0retrospective\\xa0and\\xa0confounding\\xa0variables\\xa0were\\xa0notconsistently\\xa0eliminated,\\xa0thus\\xa0making\\xa0it\\xa0difficult\\xa0to\\xa0establish\\xa0a\\xa0definitive\\xa0association\\xa0between\\xa0PPIs\\xa0and\\xa0the\\xa0toxicities\\xa0outlined.\\xa0A\\xa0summary\\xa0of\\xa0the\\xa0sideeffects\\xa0with\\xa0the\\xa0corresponding\\xa0relative\\xa0risks\\xa0is\\xa0shown\\xa0in\\xa0Fig.\\xa0324–12.\\xa0Ultimately,\\xa0heightened\\xa0awareness\\xa0of\\xa0inappropriate\\xa0long\\xadterm\\xa0use\\xa0of\\xa0PPIs\\xa0isparamount.\\xa0Patients\\xa0aged\\xa0≥65\\xa0years\\xa0of\\xa0age\\xa0have\\xa0a\\xa0higher\\xa0risk\\xa0for\\xa0some\\xa0of\\xa0the\\xa0long\\xadterm\\xa0side\\xa0effects\\xa0of\\xa0PPIs\\xa0highlighted\\xa0above,\\xa0in\\xa0part\\xa0due\\xa0to\\xa0the\\xa0higherprevalence\\xa0of\\xa0concomitant\\xa0chronic\\xa0diseases.\\xa0It\\xa0is\\xa0therefore\\xa0essential\\xa0to\\xa0carefully\\xa0select\\xa0individuals,\\xa0especially\\xa0among\\xa0the\\xa0elderly,\\xa0who\\xa0need\\xa0long\\xadtermPPI\\xa0therapy\\xa0and\\xa0discontinue\\xa0it\\xa0in\\xa0those\\xa0individuals\\xa0who\\xa0do\\xa0not\\xa0need\\xa0it.\\xa0Abrupt\\xa0withdrawal\\xa0of\\xa0a\\xa0PPI\\xa0in\\xa0a\\xa0long\\xadterm\\xa0user\\xa0may\\xa0result\\xa0in\\xa0a\\xa0component\\xa0ofrebound\\xa0hyperacidity;\\xa0thus,\\xa0this\\xa0agent\\xa0should\\xa0be\\xa0tapered\\xa0gradually\\xa0over\\xa0the\\xa0course\\xa0of\\xa01–2\\xa0weeks\\xa0with\\xa0possible\\xa0transition\\xa0to\\xa0an\\xa0H2\\xa0blocker\\xa0for\\xa0a\\xa0shortperiod\\xa0of\\xa0time.FIGURE\\xa0324\\xad12.Evidence\\xa0supporting\\xa0the\\xa0potential\\xa0adverse\\xa0effects\\xa0of\\xa0proton\\xa0pump\\xa0inhibitor\\xa0drugs. (Adapted\\xa0from\\xa0AJ\\xa0Schoenfeld,\\xa0D\\xa0Grady:\\xa0Adverse\\xa0effectsassociated\\xa0with\\xa0proton\\xa0pump\\xa0inhibitors.\\xa0JAMA\\xa0Intern\\xa0Med\\xa0176:172,\\xa02016.)Development\\xa0of\\xa0novel\\xa0acid\\xa0inhibitory\\xa0agents\\xa0continues\\xa0in\\xa0an\\xa0attempt\\xa0to\\xa0primarily\\xa0address\\xa0the\\xa0need\\xa0for\\xa0better\\xa0agents\\xa0to\\xa0treat\\xa0GERD.\\xa0For\\xa0example,',\n",
       " 'Development\\xa0of\\xa0novel\\xa0acid\\xa0inhibitory\\xa0agents\\xa0continues\\xa0in\\xa0an\\xa0attempt\\xa0to\\xa0primarily\\xa0address\\xa0the\\xa0need\\xa0for\\xa0better\\xa0agents\\xa0to\\xa0treat\\xa0GERD.\\xa0For\\xa0example,modified\\xa0H2\\xa0blockers\\xa0with\\xa0greater\\xa0potency\\xa0and\\xa0duration\\xa0as\\xa0well\\xa0as\\xa0novel\\xa0PPIs\\xa0with\\xa0longer\\xa0half\\xadlife\\xa0and\\xa0potency\\xa0are\\xa0under\\xa0study.\\xa0For\\xa0example,tenatoprazole\\xa0is\\xa0a\\xa0PPI\\xa0containing\\xa0an\\xa0imidazopyridine\\xa0ring\\xa0instead\\xa0of\\xa0a\\xa0benzimidazole\\xa0ring,\\xa0which\\xa0promotes\\xa0irreversible\\xa0proton\\xa0pump\\xa0inhibition.\\xa0Thisagent\\xa0has\\xa0a\\xa0longer\\xa0half\\xadlife\\xa0than\\xa0the\\xa0other\\xa0PPIs\\xa0and\\xa0may\\xa0be\\xa0beneficial\\xa0for\\xa0inhibiting\\xa0nocturnal\\xa0acid\\xa0secretion,\\xa0which\\xa0has\\xa0significant\\xa0relevance\\xa0in\\xa0GERD.Additional\\xa0PPIs\\xa0with\\xa0longer\\xa0half\\xadlife\\xa0and\\xa0combined\\xa0with\\xa0other\\xa0agents\\xa0are\\xa0being\\xa0studied,\\xa0but\\xa0the\\xa0details\\xa0are\\xa0beyond\\xa0the\\xa0scope\\xa0of\\xa0this\\xa0chapter.\\xa0A\\xa0secondnew\\xa0class\\xa0of\\xa0agents\\xa0is\\xa0the\\xa0potassium\\xadcompetitive\\xa0acid\\xa0pump\\xa0antagonists\\xa0(P\\xadCAPs).\\xa0These\\xa0compounds\\xa0inhibit\\xa0gastric\\xa0acid\\xa0secretion\\xa0via\\xa0potassiumcompetitive\\xa0binding\\xa0of\\xa0the\\xa0H+,K+\\xadATPase.\\xa0Revaprazan,\\xa0vonoprazan\\xa0and\\xa0tegoprazan\\xa0are\\xa0agents\\xa0approved\\xa0for\\xa0use\\xa0in\\xa0Korea\\xa0and\\xa0Japan.\\xa0Vonoprazan\\xa0maybe\\xa0superior\\xa0to\\xa0PPIs\\xa0when\\xa0combined\\xa0with\\xa0antibiotics\\xa0for\\xa0the\\xa0treatment\\xa0of\\xa0H.\\xa0pylori,\\xa0and\\xa0this\\xa0novel\\xa0agent\\xa0has\\xa0been\\xa0awarded\\xa0Fast\\xa0Track\\xa0status\\xa0by\\xa0the\\xa0FDAfor\\xa0the\\xa0treatment\\xa0of\\xa0H.\\xa0pylori\\xa0in\\xa0combination\\xa0with\\xa0both\\xa0amoxicillin\\xa0and\\xa0clarithromycin\\xa0and\\xa0with\\xa0amoxicillin\\xa0alone.Cytoprotective\\xa0AgentsSucralfateSucralfate\\xa0is\\xa0a\\xa0complex\\xa0sucrose\\xa0salt\\xa0in\\xa0which\\xa0the\\xa0hydroxyl\\xa0groups\\xa0have\\xa0been\\xa0substituted\\xa0by\\xa0aluminum\\xa0hydroxide\\xa0and\\xa0sulfate.\\xa0This\\xa0compound\\xa0isinsoluble\\xa0in\\xa0water\\xa0and\\xa0becomes\\xa0a\\xa0viscous\\xa0paste\\xa0within\\xa0the\\xa0stomach\\xa0and\\xa0duodenum,\\xa0binding\\xa0primarily\\xa0to\\xa0sites\\xa0of\\xa0active\\xa0ulceration.\\xa0Sucralfate\\xa0may\\xa0actby\\xa0several\\xa0mechanisms:\\xa0serving\\xa0as\\xa0a\\xa0physicochemical\\xa0barrier,\\xa0promoting\\xa0a\\xa0trophic\\xa0action\\xa0by\\xa0binding\\xa0growth\\xa0factors\\xa0such\\xa0as\\xa0EGF,\\xa0enhancingprostaglandin\\xa0synthesis,\\xa0stimulating\\xa0mucus\\xa0and\\xa0bicarbonate\\xa0secretion,\\xa0and\\xa0enhancing\\xa0mucosal\\xa0defense\\xa0and\\xa0repair.\\xa0Toxicity\\xa0from\\xa0this\\xa0drug\\xa0is\\xa0rare,\\xa0with',\n",
       " \"prostaglandin\\xa0synthesis,\\xa0stimulating\\xa0mucus\\xa0and\\xa0bicarbonate\\xa0secretion,\\xa0and\\xa0enhancing\\xa0mucosal\\xa0defense\\xa0and\\xa0repair.\\xa0Toxicity\\xa0from\\xa0this\\xa0drug\\xa0is\\xa0rare,\\xa0withconstipation\\xa0being\\xa0most\\xa0common\\xa0(2–3%).\\xa0It\\xa0should\\xa0be\\xa0avoided\\xa0in\\xa0patients\\xa0with\\xa0chronic\\xa0renal\\xa0insufficiency\\xa0to\\xa0prevent\\xa0aluminum\\xadinduced\\xa0neurotoxicity.Hypophosphatemia\\xa0and\\xa0gastric\\xa0bezoar\\xa0formation\\xa0have\\xa0also\\xa0been\\xa0reported\\xa0rarely.\\xa0Standard\\xa0dosing\\xa0of\\xa0sucralfate\\xa0is\\xa01\\xa0g\\xa0qid.Bismuth\\xadContaining\\xa0PreparationsSir\\xa0William\\xa0Osler\\xa0considered\\xa0bismuth\\xadcontaining\\xa0compounds\\xa0the\\xa0drug\\xa0of\\xa0choice\\xa0for\\xa0treating\\xa0PUD.\\xa0The\\xa0resurgence\\xa0in\\xa0the\\xa0use\\xa0of\\xa0these\\xa0agents\\xa0is\\xa0due\\xa0totheir\\xa0effect\\xa0against\\xa0H.\\xa0pylori.\\xa0Colloidal\\xa0bismuth\\xa0subcitrate\\xa0(CBS)\\xa0and\\xa0bismuth\\xa0subsalicylate\\xa0(BSS;\\xa0Pepto\\xadBismol)\\xa0are\\xa0the\\xa0most\\xa0widely\\xa0used\\xa0preparations.The\\xa0mechanism\\xa0by\\xa0which\\xa0these\\xa0agents\\xa0induce\\xa0ulcer\\xa0healing\\xa0is\\xa0unclear.\\xa0Adverse\\xa0effects\\xa0with\\xa0short\\xadterm\\xa0use\\xa0include\\xa0black\\xa0stools,\\xa0constipation,\\xa0anddarkening\\xa0of\\xa0the\\xa0tongue.\\xa0Long\\xadterm\\xa0use\\xa0with\\xa0high\\xa0doses,\\xa0especially\\xa0with\\xa0the\\xa0avidly\\xa0absorbed\\xa0CBS,\\xa0may\\xa0lead\\xa0to\\xa0neurotoxicity.\\xa0These\\xa0compounds\\xa0arecommonly\\xa0used\\xa0as\\xa0one\\xa0of\\xa0the\\xa0agents\\xa0in\\xa0an\\xa0anti–H.\\xa0pylori\\xa0regimen\\xa0(see\\xa0below).Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 23 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffect\",\n",
       " 'Dan Longo,J.Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison\\'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide that',\n",
       " 'Alkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison\\'s Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: No',\n",
       " \"Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'pgy,g,gpyg,constipation\\xa0being\\xa0most\\xa0common\\xa0(2–3%).\\xa0It\\xa0should\\xa0be\\xa0avoided\\xa0in\\xa0patients\\xa0with\\xa0chronic\\xa0renal\\xa0insufficiency\\xa0to\\xa0prevent\\xa0aluminum\\xadinduced\\xa0neurotoxicity.Hypophosphatemia\\xa0and\\xa0gastric\\xa0bezoar\\xa0formation\\xa0have\\xa0also\\xa0been\\xa0reported\\xa0rarely.\\xa0Standard\\xa0dosing\\xa0of\\xa0sucralfate\\xa0is\\xa01\\xa0g\\xa0qid.Bismuth\\xadContaining\\xa0PreparationsSir\\xa0William\\xa0Osler\\xa0considered\\xa0bismuth\\xadcontaining\\xa0compounds\\xa0the\\xa0drug\\xa0of\\xa0choice\\xa0for\\xa0treating\\xa0PUD.\\xa0The\\xa0resurgence\\xa0in\\xa0the\\xa0use\\xa0of\\xa0these\\xa0agents\\xa0is\\xa0due\\xa0totheir\\xa0effect\\xa0against\\xa0H.\\xa0pylori.\\xa0Colloidal\\xa0bismuth\\xa0subcitrate\\xa0(CBS)\\xa0and\\xa0bismuth\\xa0subsalicylate\\xa0(BSS;\\xa0Pepto\\xadBismol)\\xa0are\\xa0the\\xa0most\\xa0widely\\xa0used\\xa0preparations.The\\xa0mechanism\\xa0by\\xa0which\\xa0these\\xa0agents\\xa0induce\\xa0ulcer\\xa0healing\\xa0is\\xa0unclear.\\xa0Adverse\\xa0effects\\xa0with\\xa0short\\xadterm\\xa0use\\xa0include\\xa0black\\xa0stools,\\xa0constipation,\\xa0anddarkening\\xa0of\\xa0the\\xa0tongue.\\xa0Long\\xadterm\\xa0use\\xa0with\\xa0high\\xa0doses,\\xa0especially\\xa0with\\xa0the\\xa0avidly\\xa0absorbed\\xa0CBS,\\xa0may\\xa0lead\\xa0to\\xa0neurotoxicity.\\xa0These\\xa0compounds\\xa0arecommonly\\xa0used\\xa0as\\xa0one\\xa0of\\xa0the\\xa0agents\\xa0in\\xa0an\\xa0anti–H.\\xa0pylori\\xa0regimen\\xa0(see\\xa0below).Prostaglandin\\xa0AnaloguesIn\\xa0view\\xa0of\\xa0their\\xa0central\\xa0role\\xa0in\\xa0maintaining\\xa0mucosal\\xa0integrity\\xa0and\\xa0repair,\\xa0stable\\xa0prostaglandin\\xa0analogues\\xa0were\\xa0developed\\xa0for\\xa0the\\xa0treatment\\xa0of\\xa0PUD.\\xa0Themechanism\\xa0by\\xa0which\\xa0this\\xa0rapidly\\xa0absorbed\\xa0drug\\xa0provides\\xa0its\\xa0therapeutic\\xa0effect\\xa0is\\xa0through\\xa0enhancement\\xa0of\\xa0mucosal\\xa0defense\\xa0and\\xa0repair.\\xa0The\\xa0mostcommon\\xa0toxicity\\xa0noted\\xa0with\\xa0this\\xa0drug\\xa0is\\xa0diarrhea\\xa0(10–30%\\xa0incidence).\\xa0Other\\xa0major\\xa0toxicities\\xa0include\\xa0uterine\\xa0bleeding\\xa0and\\xa0contractions;\\xa0misoprostol\\xa0iscontraindicated\\xa0in\\xa0women\\xa0who\\xa0may\\xa0be\\xa0pregnant,\\xa0and\\xa0women\\xa0of\\xa0childbearing\\xa0age\\xa0must\\xa0be\\xa0made\\xa0clearly\\xa0aware\\xa0of\\xa0this\\xa0potential\\xa0drug\\xa0toxicity.\\xa0Thestandard\\xa0therapeutic\\xa0dose\\xa0is\\xa0200\\xa0μg\\xa0qid.Miscellaneous\\xa0DrugsA\\xa0number\\xa0of\\xa0drugs\\xa0including\\xa0anticholinergic\\xa0agents\\xa0and\\xa0tricyclic\\xa0antidepressants\\xa0were\\xa0used\\xa0for\\xa0treating\\xa0acid\\xa0peptic\\xa0disorders,\\xa0but\\xa0in\\xa0light\\xa0of\\xa0theirtoxicity\\xa0and\\xa0the\\xa0development\\xa0of\\xa0potent\\xa0antisecretory\\xa0agents,\\xa0these\\xa0are\\xa0rarely,\\xa0if\\xa0ever,\\xa0used\\xa0today.\\xa0Newer\\xa0agents\\xa0such\\xa0as\\xa0teprenone,\\xa0an\\xa0acyclic',\n",
       " 'toxicity\\xa0and\\xa0the\\xa0development\\xa0of\\xa0potent\\xa0antisecretory\\xa0agents,\\xa0these\\xa0are\\xa0rarely,\\xa0if\\xa0ever,\\xa0used\\xa0today.\\xa0Newer\\xa0agents\\xa0such\\xa0as\\xa0teprenone,\\xa0an\\xa0acyclicpolyisoprenoid\\xa0compound\\xa0used\\xa0as\\xa0a\\xa0gastric\\xa0mucosal\\xa0protector\\xa0that\\xa0is\\xa0employed\\xa0to\\xa0treat\\xa0gastritis\\xa0and\\xa0GUs\\xa0outside\\xa0of\\xa0the\\xa0United\\xa0States;\\xa0plant\\xadbasedtherapies;\\xa0and\\xa0CCK2\\xa0receptor\\xa0antagonists\\xa0are\\xa0intriguing\\xa0therapies\\xa0but\\xa0require\\xa0further\\xa0evaluation.Therapy\\xa0of\\xa0H.\\xa0PyloriThe\\xa0physician’s\\xa0goal\\xa0in\\xa0treating\\xa0PUD\\xa0is\\xa0to\\xa0provide\\xa0relief\\xa0of\\xa0symptoms\\xa0(pain\\xa0or\\xa0dyspepsia),\\xa0promote\\xa0ulcer\\xa0healing,\\xa0and\\xa0ultimately\\xa0prevent\\xa0ulcerrecurrence\\xa0and\\xa0complications.\\xa0The\\xa0greatest\\xa0influence\\xa0of\\xa0understanding\\xa0the\\xa0role\\xa0of\\xa0H.\\xa0pylori\\xa0in\\xa0peptic\\xa0disease\\xa0has\\xa0been\\xa0the\\xa0ability\\xa0to\\xa0preventrecurrence.\\xa0Documented\\xa0eradication\\xa0of\\xa0H.\\xa0pylori\\xa0in\\xa0patients\\xa0with\\xa0PUD\\xa0is\\xa0associated\\xa0with\\xa0a\\xa0dramatic\\xa0decrease\\xa0in\\xa0ulcer\\xa0recurrence\\xa0to\\xa0<10–20%\\xa0ascompared\\xa0to\\xa059%\\xa0in\\xa0GU\\xa0patients\\xa0and\\xa067%\\xa0in\\xa0DU\\xa0patients\\xa0when\\xa0the\\xa0organism\\xa0is\\xa0not\\xa0eliminated.\\xa0Eradication\\xa0of\\xa0the\\xa0organism\\xa0may\\xa0lead\\xa0to\\xa0diminishedrecurrent\\xa0ulcer\\xa0bleeding.\\xa0The\\xa0effect\\xa0of\\xa0its\\xa0eradication\\xa0on\\xa0ulcer\\xa0perforation\\xa0is\\xa0unclear.Extensive\\xa0effort\\xa0has\\xa0been\\xa0made\\xa0in\\xa0determining\\xa0who\\xa0of\\xa0the\\xa0many\\xa0individuals\\xa0with\\xa0H.\\xa0pylori\\xa0infection\\xa0should\\xa0be\\xa0treated.\\xa0The\\xa0common\\xa0conclusion\\xa0arrivedat\\xa0by\\xa0multiple\\xa0consensus\\xa0conferences\\xa0around\\xa0the\\xa0world\\xa0is\\xa0that\\xa0H.\\xa0pylori\\xa0should\\xa0be\\xa0eradicated\\xa0in\\xa0patients\\xa0with\\xa0documented\\xa0PUD.\\xa0This\\xa0holds\\xa0trueindependent\\xa0of\\xa0time\\xa0of\\xa0presentation\\xa0(first\\xa0episode\\xa0or\\xa0not),\\xa0severity\\xa0of\\xa0symptoms,\\xa0presence\\xa0of\\xa0confounding\\xa0factors\\xa0such\\xa0as\\xa0ingestion\\xa0of\\xa0NSAIDs,\\xa0orwhether\\xa0the\\xa0ulcer\\xa0is\\xa0in\\xa0remission.\\xa0Some\\xa0have\\xa0advocated\\xa0treating\\xa0patients\\xa0with\\xa0a\\xa0history\\xa0of\\xa0documented\\xa0PUD\\xa0who\\xa0are\\xa0found\\xa0to\\xa0be\\xa0H.\\xa0pylori\\xa0positive\\xa0bystool\\xa0antigen\\xa0or\\xa0breath\\xa0testing.\\xa0Between\\xa060\\xa0and\\xa090%\\xa0of\\xa0patients\\xa0with\\xa0gastric\\xa0MALT\\xa0lymphoma\\xa0experience\\xa0complete\\xa0remission\\xa0of\\xa0the\\xa0tumor\\xa0in\\xa0responseto\\xa0H.\\xa0pylori\\xa0eradication.\\xa0The\\xa0Maastricht\\xa0IV/Florence\\xa0Consensus\\xa0Report\\xa0recommends\\xa0a\\xa0test\\xadand\\xadtreat\\xa0approach\\xa0for\\xa0patients\\xa0with\\xa0uninvestigated',\n",
       " 'to\\xa0H.\\xa0pylori\\xa0eradication.\\xa0The\\xa0Maastricht\\xa0IV/Florence\\xa0Consensus\\xa0Report\\xa0recommends\\xa0a\\xa0test\\xadand\\xadtreat\\xa0approach\\xa0for\\xa0patients\\xa0with\\xa0uninvestigateddyspepsia\\xa0if\\xa0the\\xa0local\\xa0incidence\\xa0of\\xa0H.\\xa0pylori\\xa0is\\xa0>20%.\\xa0The\\xa0American\\xa0College\\xa0of\\xa0Gastroenterology\\xa0(ACG)\\xa0clinical\\xa0guidelines\\xa0(developed\\xa0for\\xa0North\\xa0America)recommend\\xa0that\\xa0individuals\\xa0aged\\xa0<60\\xa0years\\xa0with\\xa0uninvestigated\\xa0dyspepsia\\xa0should\\xa0be\\xa0tested\\xa0and\\xa0treated\\xa0for\\xa0H.\\xa0pylori.\\xa0In\\xa0addition,\\xa0recommendationsfrom\\xa0this\\xa0consensus\\xa0report\\xa0and\\xa0the\\xa0ACG\\xa0clinical\\xa0guidelines\\xa0include\\xa0testing\\xa0and\\xa0offering\\xa0eradication\\xa0of\\xa0H.\\xa0pylori\\xa0in\\xa0patients\\xa0who\\xa0will\\xa0be\\xa0using\\xa0NSAIDs(including\\xa0low\\xaddose\\xa0aspirin)\\xa0on\\xa0a\\xa0long\\xadterm\\xa0basis,\\xa0especially\\xa0if\\xa0there\\xa0is\\xa0a\\xa0prior\\xa0history\\xa0of\\xa0PUD.\\xa0These\\xa0individuals\\xa0will\\xa0require\\xa0continued\\xa0PPI\\xa0treatment\\xa0aswell\\xa0as\\xa0eradication\\xa0treatment,\\xa0because\\xa0eradication\\xa0of\\xa0the\\xa0organism\\xa0alone\\xa0does\\xa0not\\xa0eliminate\\xa0the\\xa0risk\\xa0of\\xa0gastroduodenal\\xa0ulcers\\xa0in\\xa0patients\\xa0alreadyreceiving\\xa0long\\xadterm\\xa0NSAIDs.\\xa0Treating\\xa0patients\\xa0with\\xa0NUD\\xa0to\\xa0prevent\\xa0gastric\\xa0cancer\\xa0or\\xa0patients\\xa0with\\xa0GERD\\xa0requiring\\xa0long\\xadterm\\xa0acid\\xa0suppression\\xa0remainscontroversial.\\xa0Guidelines\\xa0from\\xa0the\\xa0ACG\\xa0suggest\\xa0eradication\\xa0of\\xa0H.\\xa0pylori\\xa0in\\xa0patients\\xa0who\\xa0have\\xa0undergone\\xa0resection\\xa0of\\xa0early\\xa0gastric\\xa0cancer.\\xa0TheMaastricht\\xa0IV/Florence\\xa0Consensus\\xa0Report\\xa0also\\xa0evaluated\\xa0H.\\xa0pylori\\xa0treatment\\xa0in\\xa0gastric\\xa0cancer\\xa0prevention\\xa0and\\xa0recommends\\xa0that\\xa0eradication\\xa0should\\xa0beconsidered\\xa0in\\xa0the\\xa0following\\xa0situations:\\xa0first\\xaddegree\\xa0relatives\\xa0of\\xa0family\\xa0members\\xa0with\\xa0gastric\\xa0cancer;\\xa0patients\\xa0with\\xa0previous\\xa0gastric\\xa0neoplasm\\xa0treated\\xa0byendoscopic\\xa0or\\xa0subtotal\\xa0resection;\\xa0individuals\\xa0with\\xa0a\\xa0risk\\xa0of\\xa0gastritis\\xa0(severe\\xa0pangastritis\\xa0or\\xa0body\\xadpredominant\\xa0gastritis)\\xa0or\\xa0severe\\xa0atrophy;\\xa0patients\\xa0withgastric\\xa0acid\\xa0inhibition\\xa0for\\xa0>1\\xa0year;\\xa0individuals\\xa0with\\xa0strong\\xa0environmental\\xa0risk\\xa0factors\\xa0for\\xa0gastric\\xa0cancer\\xa0(heavy\\xa0smoking;\\xa0high\\xa0exposure\\xa0to\\xa0dust,\\xa0coal,quartz,\\xa0or\\xa0cement;\\xa0and/or\\xa0work\\xa0in\\xa0quarries);\\xa0and\\xa0H.\\xa0pylori–positive\\xa0patients\\xa0with\\xa0a\\xa0fear\\xa0of\\xa0gastric\\xa0cancer.\\xa0Finally,\\xa0the\\xa0ACG\\xa0clinical\\xa0guidelines\\xa0recommend',\n",
       " 'quartz,\\xa0or\\xa0cement;\\xa0and/or\\xa0work\\xa0in\\xa0quarries);\\xa0and\\xa0H.\\xa0pylori–positive\\xa0patients\\xa0with\\xa0a\\xa0fear\\xa0of\\xa0gastric\\xa0cancer.\\xa0Finally,\\xa0the\\xa0ACG\\xa0clinical\\xa0guidelines\\xa0recommendtesting\\xa0and\\xa0offering\\xa0H.\\xa0pylori\\xa0eradication\\xa0to\\xa0patients\\xa0with\\xa0unexplained\\xa0iron\\xa0deficiency\\xa0anemia\\xa0and\\xa0idiopathic\\xa0thrombocytopenic\\xa0purpura.\\xa0Despite\\xa0this,concerns\\xa0have\\xa0been\\xa0raised\\xa0about\\xa0the\\xa0widespread\\xa0use\\xa0of\\xa0antibiotics\\xa0for\\xa0the\\xa0therapy\\xa0of\\xa0all\\xa0cases\\xa0of\\xa0H.\\xa0pylori\\xa0positivity,\\xa0including\\xa0the\\xa0potential\\xa0forincreased\\xa0bacterial\\xa0resistance\\xa0rates,\\xa0reported\\xa0weight\\xa0gain,\\xa0and\\xa0alteration\\xa0of\\xa0the\\xa0microbiome.Multiple\\xa0drugs\\xa0have\\xa0been\\xa0evaluated\\xa0in\\xa0the\\xa0therapy\\xa0of\\xa0H.\\xa0pylori.\\xa0No\\xa0single\\xa0agent\\xa0is\\xa0effective\\xa0in\\xa0eradicating\\xa0the\\xa0organism.\\xa0Combination\\xa0therapy\\xa0for\\xa014\\xa0daysprovides\\xa0the\\xa0greatest\\xa0efficacy,\\xa0although\\xa0regimens\\xa0based\\xa0on\\xa0sequential\\xa0administration\\xa0of\\xa0antibiotics\\xa0also\\xa0appear\\xa0promising\\xa0(see\\xa0below).\\xa0A\\xa0shorteradministration\\xa0course\\xa0(7–10\\xa0days),\\xa0although\\xa0attractive,\\xa0has\\xa0not\\xa0proved\\xa0as\\xa0successful\\xa0as\\xa0the\\xa014\\xadday\\xa0regimens.\\xa0The\\xa0agents\\xa0used\\xa0with\\xa0the\\xa0greatestfrequency\\xa0include\\xa0amoxicillin,\\xa0metronidazole,\\xa0tetracycline,\\xa0clarithromycin,\\xa0and\\xa0bismuth\\xa0compounds.Suggested treatment regimens for H pylori are outlined in Table 324\\xad4 Choice of a particular regimen will be influenced by several factors includingYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 24 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,',\n",
       " \"PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison's Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH'HCIpH20MucusHCOS2PH7.0MucusH'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa and\",\n",
       " 'prostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundus',\n",
       " \"CopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproduction\",\n",
       " \"H.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'quartz,\\xa0or\\xa0cement;\\xa0and/or\\xa0work\\xa0in\\xa0quarries);\\xa0and\\xa0H.\\xa0pylori–positive\\xa0patients\\xa0with\\xa0a\\xa0fear\\xa0of\\xa0gastric\\xa0cancer.\\xa0Finally,\\xa0the\\xa0ACG\\xa0clinical\\xa0guidelines\\xa0recommendtesting\\xa0and\\xa0offering\\xa0H.\\xa0pylori\\xa0eradication\\xa0to\\xa0patients\\xa0with\\xa0unexplained\\xa0iron\\xa0deficiency\\xa0anemia\\xa0and\\xa0idiopathic\\xa0thrombocytopenic\\xa0purpura.\\xa0Despite\\xa0this,concerns\\xa0have\\xa0been\\xa0raised\\xa0about\\xa0the\\xa0widespread\\xa0use\\xa0of\\xa0antibiotics\\xa0for\\xa0the\\xa0therapy\\xa0of\\xa0all\\xa0cases\\xa0of\\xa0H.\\xa0pylori\\xa0positivity,\\xa0including\\xa0the\\xa0potential\\xa0forincreased\\xa0bacterial\\xa0resistance\\xa0rates,\\xa0reported\\xa0weight\\xa0gain,\\xa0and\\xa0alteration\\xa0of\\xa0the\\xa0microbiome.Multiple\\xa0drugs\\xa0have\\xa0been\\xa0evaluated\\xa0in\\xa0the\\xa0therapy\\xa0of\\xa0H.\\xa0pylori.\\xa0No\\xa0single\\xa0agent\\xa0is\\xa0effective\\xa0in\\xa0eradicating\\xa0the\\xa0organism.\\xa0Combination\\xa0therapy\\xa0for\\xa014\\xa0daysprovides\\xa0the\\xa0greatest\\xa0efficacy,\\xa0although\\xa0regimens\\xa0based\\xa0on\\xa0sequential\\xa0administration\\xa0of\\xa0antibiotics\\xa0also\\xa0appear\\xa0promising\\xa0(see\\xa0below).\\xa0A\\xa0shorteradministration\\xa0course\\xa0(7–10\\xa0days),\\xa0although\\xa0attractive,\\xa0has\\xa0not\\xa0proved\\xa0as\\xa0successful\\xa0as\\xa0the\\xa014\\xadday\\xa0regimens.\\xa0The\\xa0agents\\xa0used\\xa0with\\xa0the\\xa0greatestfrequency\\xa0include\\xa0amoxicillin,\\xa0metronidazole,\\xa0tetracycline,\\xa0clarithromycin,\\xa0and\\xa0bismuth\\xa0compounds.Suggested\\xa0treatment\\xa0regimens\\xa0for\\xa0H.\\xa0pylori\\xa0are\\xa0outlined\\xa0in\\xa0Table\\xa0324\\xad4.\\xa0Choice\\xa0of\\xa0a\\xa0particular\\xa0regimen\\xa0will\\xa0be\\xa0influenced\\xa0by\\xa0several\\xa0factors,\\xa0includingefficacy,\\xa0patient\\xa0tolerance,\\xa0existing\\xa0antibiotic\\xa0resistance,\\xa0prior\\xa0antibiotic\\xa0use,\\xa0and\\xa0cost\\xa0of\\xa0the\\xa0drugs.\\xa0The\\xa0aim\\xa0for\\xa0initial\\xa0eradication\\xa0rates\\xa0should\\xa0be\\xa085–90%.\\xa0Dual\\xa0therapy\\xa0(PPI\\xa0plus\\xa0amoxicillin,\\xa0PPI\\xa0plus\\xa0clarithromycin,\\xa0ranitidine\\xa0bismuth\\xa0citrate\\xa0[Tritec]\\xa0plus\\xa0clarithromycin)\\xa0is\\xa0not\\xa0recommended\\xa0in\\xa0view\\xa0ofstudies\\xa0demonstrating\\xa0eradication\\xa0rates\\xa0of\\xa0<80–85%.\\xa0The\\xa0combination\\xa0of\\xa0bismuth,\\xa0metronidazole,\\xa0and\\xa0tetracycline\\xa0was\\xa0the\\xa0first\\xa0triple\\xa0regimen\\xa0foundeffective\\xa0against\\xa0H.\\xa0pylori.\\xa0The\\xa0combination\\xa0of\\xa0two\\xa0antibiotics\\xa0plus\\xa0either\\xa0a\\xa0PPI,\\xa0H2\\xa0blocker,\\xa0or\\xa0bismuth\\xa0compound\\xa0has\\xa0comparable\\xa0success\\xa0rates.Addition\\xa0of\\xa0acid\\xa0suppression\\xa0assists\\xa0in\\xa0providing\\xa0early\\xa0symptom\\xa0relief\\xa0and\\xa0enhances\\xa0bacterial\\xa0eradication.TABLE\\xa0324\\xad4Recommended\\xa0First\\xadLine\\xa0Therapies\\xa0for\\xa0H.\\xa0pylori\\xa0Infection',\n",
       " \"Addition\\xa0of\\xa0acid\\xa0suppression\\xa0assists\\xa0in\\xa0providing\\xa0early\\xa0symptom\\xa0relief\\xa0and\\xa0enhances\\xa0bacterial\\xa0eradication.TABLE\\xa0324\\xad4Recommended\\xa0First\\xadLine\\xa0Therapies\\xa0for\\xa0H.\\xa0pylori\\xa0InfectionREGIMENDRUGS\\xa0(DOSES)DOSINGFREQUENCYDURATION(DAYS)FDAAPPROVALClarithromycin\\xa0triplePPI\\xa0(standard\\xa0or\\xa0double\\xa0dose)bid14YesaClarithromycin\\xa0(500\\xa0mg)Amoxicillin\\xa0(1\\xa0g)\\xa0or\\xa0metronidazole\\xa0(500\\xa0mg\\xa0tid)Bismuth\\xa0quadruplePPI\\xa0(standard\\xa0dose)bid10–14NobBismuth\\xa0subcitrate\\xa0(120–300\\xa0mg)\\xa0or\\xa0subsalicylate\\xa0(300\\xa0mg)qidTetracycline\\xa0(500\\xa0mg)qidMetronidazole\\xa0(250–500\\xa0mg)qid\\xa0(250\\xa0mg)tid\\xa0to\\xa0qid\\xa0(500\\xa0mg)ConcomitantPPI\\xa0(standard\\xa0dose)bid10–14NoClarithromycin\\xa0(500\\xa0mg)Amoxicillin\\xa0(1\\xa0g)Nitroimidazole\\xa0(500\\xa0mg)cSequentialPPI\\xa0(standard\\xa0dose)bid5–7NoPPI,\\xa0clarithromycin\\xa0(500\\xa0mg)\\xa0+\\xa0nitroimidazole\\xa0(500\\xa0mg)cbid5–7HybridPPI\\xa0(standard\\xa0dose)\\xa0+\\xa0amoxicillin\\xa0(1\\xa0g)bid7NoPPI,\\xa0amoxicillin,\\xa0clarithromycin\\xa0(500\\xa0mg),\\xa0nitroimidazole\\xa0(500mg)cbid7Levofloxacin\\xa0triplePPI\\xa0(standard\\xa0or\\xa0double\\xa0dose)\\xa0+\\xa0amoxicillin\\xa0(1\\xa0g)bid5–7NoLevofloxacin\\xa0(500\\xa0mg)qdAmoxicillin\\xa0(1\\xa0g)bidYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 25 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritis\",\n",
       " 'CopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison\\'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregation',\n",
       " \"is maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:No\",\n",
       " \"1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'aSeveral\\xa0PPI,\\xa0clarithromycin,\\xa0and\\xa0amoxicillin\\xa0combinations\\xa0have\\xa0achieved\\xa0FDA\\xa0approval.\\xa0The\\xa0regimen\\xa0of\\xa0a\\xa0PPI,\\xa0clarithromycin,\\xa0and\\xa0metronidazole\\xa0is\\xa0not\\xa0an\\xa0FDA\\xadapproved\\xa0treatment\\xa0regimen.\\xa0bThe\\xa0regimen\\xa0of\\xa0a\\xa0PPI,\\xa0bismuth,\\xa0tetracycline,\\xa0and\\xa0metronidazole\\xa0combined\\xa0with\\xa0a\\xa0PPI\\xa0for\\xa010\\xa0days\\xa0is\\xa0an\\xa0FDA\\xadapproved\\xa0treatmentregimen.\\xa0cMetronidazole\\xa0or\\xa0tinidazole.Abbreviations:\\xa0bid,\\xa0twice\\xa0daily;\\xa0FDA,\\xa0Food\\xa0and\\xa0Drug\\xa0Administration;\\xa0PPI,\\xa0proton\\xa0pump\\xa0inhibitor;\\xa0tid,\\xa0three\\xa0times\\xa0daily;\\xa0qd,\\xa0once\\xa0daily;\\xa0qid,\\xa0four\\xa0times\\xa0daily.Source:\\xa0Reproduced\\xa0with\\xa0permission\\xa0from\\xa0WD\\xa0Chey\\xa0et\\xa0al:\\xa0ACG\\xa0clinical\\xa0guideline:\\xa0Treatment\\xa0of\\xa0Helicobacter\\xa0pylori\\xa0infection.\\xa0Am\\xa0J\\xa0Gastroenterol\\xa0112:212,\\xa02017.HybridPPI\\xa0(standard\\xa0dose)\\xa0+\\xa0amoxicillin\\xa0(1\\xa0g)bid7NoPPI,\\xa0amoxicillin,\\xa0clarithromycin\\xa0(500\\xa0mg),\\xa0nitroimidazole\\xa0(500mg)cbid7Levofloxacin\\xa0triplePPI\\xa0(standard\\xa0or\\xa0double\\xa0dose)\\xa0+\\xa0amoxicillin\\xa0(1\\xa0g)bid5–7NoLevofloxacin\\xa0(500\\xa0mg)qdAmoxicillin\\xa0(1\\xa0g)bidLevofloxacinsequentialPPI\\xa0(standard\\xa0or\\xa0double\\xa0dose)\\xa0+\\xa0amoxicillin\\xa0(1\\xa0g)bid5–7NoPPI,\\xa0amoxicillin,\\xa0levofloxacin\\xa0(500\\xa0mg\\xa0qd),\\xa0nitroimidazole\\xa0(500mg)cbid5–7LOADLevofloxacin\\xa0(250\\xa0mg)qd7–10NoPPI\\xa0(double\\xa0dose)qdNitazoxanide\\xa0(500\\xa0mg)bidDoxycycline\\xa0(100\\xa0mg)qdTriple\\xa0therapy,\\xa0although\\xa0effective,\\xa0has\\xa0several\\xa0drawbacks,\\xa0including\\xa0the\\xa0potential\\xa0for\\xa0poor\\xa0patient\\xa0compliance\\xa0and\\xa0drug\\xadinduced\\xa0side\\xa0effects.Compliance\\xa0is\\xa0being\\xa0addressed\\xa0by\\xa0simplifying\\xa0the\\xa0regimens\\xa0so\\xa0that\\xa0patients\\xa0can\\xa0take\\xa0the\\xa0medications\\xa0twice\\xa0a\\xa0day.\\xa0Simpler\\xa0(dual\\xa0therapy)\\xa0and\\xa0shorterregimens\\xa0(7\\xa0and\\xa010\\xa0days)\\xa0are\\xa0not\\xa0as\\xa0effective\\xa0as\\xa0triple\\xa0therapy\\xa0for\\xa014\\xa0days.\\xa0Two\\xa0anti–H.\\xa0pylori\\xa0regimens\\xa0are\\xa0available\\xa0in\\xa0prepackaged\\xa0formulation:Prevpac\\xa0(lansoprazole,\\xa0clarithromycin,\\xa0and\\xa0amoxicillin)\\xa0and\\xa0Helidac\\xa0(BSS,\\xa0tetracycline,\\xa0and\\xa0metronidazole).\\xa0The\\xa0contents\\xa0of\\xa0the\\xa0Prevpac\\xa0are\\xa0to\\xa0be\\xa0takentwice\\xa0per\\xa0day\\xa0for\\xa014\\xa0days,\\xa0whereas\\xa0Helidac\\xa0constituents\\xa0are\\xa0taken\\xa0four\\xa0times\\xa0per\\xa0day\\xa0with\\xa0an\\xa0antisecretory\\xa0agent\\xa0(PPI\\xa0or\\xa0H2\\xa0blocker),\\xa0also\\xa0for\\xa0at\\xa0least\\xa014',\n",
       " 'twice\\xa0per\\xa0day\\xa0for\\xa014\\xa0days,\\xa0whereas\\xa0Helidac\\xa0constituents\\xa0are\\xa0taken\\xa0four\\xa0times\\xa0per\\xa0day\\xa0with\\xa0an\\xa0antisecretory\\xa0agent\\xa0(PPI\\xa0or\\xa0H2\\xa0blocker),\\xa0also\\xa0for\\xa0at\\xa0least\\xa014days.\\xa0Clarithromycin\\xadbased\\xa0triple\\xa0therapy\\xa0should\\xa0be\\xa0avoided\\xa0in\\xa0settings\\xa0where\\xa0H.\\xa0pylori\\xa0resistance\\xa0to\\xa0this\\xa0agent\\xa0exceeds\\xa015%.Side\\xa0effects\\xa0have\\xa0been\\xa0reported\\xa0in\\xa0up\\xa0to\\xa020–30%\\xa0of\\xa0patients\\xa0on\\xa0triple\\xa0therapy.\\xa0Bismuth\\xa0may\\xa0cause\\xa0black\\xa0stools,\\xa0constipation,\\xa0or\\xa0darkening\\xa0of\\xa0thetongue.\\xa0The\\xa0most\\xa0feared\\xa0complication\\xa0with\\xa0amoxicillin\\xa0is\\xa0pseudomembranous\\xa0colitis,\\xa0but\\xa0this\\xa0occurs\\xa0in\\xa0<1–2%\\xa0of\\xa0patients.\\xa0Amoxicillin\\xa0can\\xa0also\\xa0lead\\xa0toantibiotic\\xadassociated\\xa0diarrhea,\\xa0nausea,\\xa0vomiting,\\xa0skin\\xa0rash,\\xa0and\\xa0allergic\\xa0reaction.\\xa0Concomitant\\xa0use\\xa0of\\xa0probiotics\\xa0may\\xa0ameliorate\\xa0some\\xa0of\\xa0the\\xa0antibioticside\\xa0effects\\xa0(see\\xa0below).\\xa0Tetracycline\\xa0has\\xa0been\\xa0reported\\xa0to\\xa0cause\\xa0rashes\\xa0and,\\xa0very\\xa0rarely,\\xa0hepatotoxicity\\xa0and\\xa0anaphylaxis.One\\xa0important\\xa0concern\\xa0with\\xa0treating\\xa0patients\\xa0who\\xa0may\\xa0not\\xa0need\\xa0therapy\\xa0is\\xa0the\\xa0potential\\xa0for\\xa0development\\xa0of\\xa0antibiotic\\xadresistant\\xa0strains.\\xa0The\\xa0incidenceand\\xa0type\\xa0of\\xa0antibiotic\\xadresistant\\xa0H.\\xa0pylori\\xa0strains\\xa0vary\\xa0worldwide.\\xa0Strains\\xa0resistant\\xa0to\\xa0metronidazole,\\xa0clarithromycin,\\xa0amoxicillin,\\xa0and\\xa0tetracycline\\xa0havebeen\\xa0described,\\xa0with\\xa0the\\xa0latter\\xa0two\\xa0being\\xa0uncommon.\\xa0Antibiotic\\xadresistant\\xa0strains\\xa0are\\xa0the\\xa0most\\xa0common\\xa0cause\\xa0for\\xa0treatment\\xa0failure\\xa0in\\xa0compliantpatients.\\xa0Unfortunately,\\xa0in\\xa0vitro\\xa0resistance\\xa0does\\xa0not\\xa0predict\\xa0outcome\\xa0in\\xa0patients.\\xa0Culture\\xa0and\\xa0sensitivity\\xa0testing\\xa0of\\xa0H.\\xa0pylori\\xa0is\\xa0not\\xa0performed\\xa0routinely.Although\\xa0resistance\\xa0to\\xa0metronidazole\\xa0has\\xa0been\\xa0found\\xa0in\\xa0as\\xa0many\\xa0as\\xa030%\\xa0of\\xa0isolates\\xa0in\\xa0North\\xa0America\\xa0and\\xa080%\\xa0in\\xa0developing\\xa0countries,\\xa0triple\\xa0therapy\\xa0iseffective\\xa0in\\xa0eradicating\\xa0the\\xa0organism\\xa0in\\xa0>50%\\xa0of\\xa0patients\\xa0infected\\xa0with\\xa0a\\xa0resistant\\xa0strain.\\xa0Clarithromycin\\xa0resistance\\xa0is\\xa0seen\\xa0in\\xa013–16%\\xa0of\\xa0individuals\\xa0inthe\\xa0United\\xa0States,\\xa0with\\xa0resistance\\xa0to\\xa0amoxicillin\\xa0being\\xa0<1%\\xa0and\\xa0resistance\\xa0to\\xa0both\\xa0metronidazole\\xa0and\\xa0clarithromycin\\xa0in\\xa0the\\xa05%\\xa0range.\\xa0Resistance\\xa0to',\n",
       " \"the\\xa0United\\xa0States,\\xa0with\\xa0resistance\\xa0to\\xa0amoxicillin\\xa0being\\xa0<1%\\xa0and\\xa0resistance\\xa0to\\xa0both\\xa0metronidazole\\xa0and\\xa0clarithromycin\\xa0in\\xa0the\\xa05%\\xa0range.\\xa0Resistance\\xa0totetracycline\\xa0and\\xa0rifabutin\\xa0(see\\xa0below)\\xa0is\\xa0reported\\xa0to\\xa0be\\xa0<2%\\xa0in\\xa0the\\xa0United\\xa0States.\\xa0In\\xa0light\\xa0of\\xa0the\\xa0paucity\\xa0of\\xa0H.\\xa0pylori\\xa0antibiotic\\xa0real\\xadtime\\xa0resistance\\xa0data,asking\\xa0the\\xa0patient\\xa0about\\xa0prior\\xa0antibiotic\\xa0exposure\\xa0should\\xa0be\\xa0included\\xa0in\\xa0the\\xa0decision\\xadmaking\\xa0and\\xa0used\\xa0as\\xa0a\\xa0surrogate\\xa0for\\xa0potential\\xa0antibioticresistance,\\xa0especially\\xa0when\\xa0it\\xa0comes\\xa0to\\xa0prior\\xa0macrolide\\xa0use.\\xa0Clarithromycin\\xa0use\\xa0should\\xa0be\\xa0excluded\\xa0in\\xa0patients\\xa0with\\xa0prior\\xa0macrolide\\xa0usage.\\xa0Anapproach\\xa0to\\xa0antibiotic\\xa0selection\\xa0for\\xa0H.\\xa0pylori\\xa0therapy\\xa0has\\xa0been\\xa0recommended\\xa0in\\xa0the\\xa0ACG\\xa0clinical\\xa0guidelines\\xa0(Fig.\\xa0324\\xad13).FIGURE\\xa0324\\xad13Approach\\xa0to\\xa0selecting\\xa0antibiotics\\xa0for\\xa0patients\\xa0with\\xa0H.\\xa0pylori\\xa0infection.\\xa0LOAD,\\xa0levofloxacin,\\xa0omeprazole,\\xa0nitazoxanide,\\xa0anddoxycycline. (Reproduced\\xa0with\\xa0permission\\xa0from\\xa0WD\\xa0Chey\\xa0et\\xa0al:\\xa0ACG\\xa0clinical\\xa0guideline:\\xa0Treatment\\xa0of\\xa0Helicobacter\\xa0pylori\\xa0infection.\\xa0Am\\xa0J\\xa0Gastroenterol112:212,\\xa02017.)Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 26 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease5\",\n",
       " 'C.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison\\'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensory',\n",
       " \"Muscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:No\",\n",
       " \"allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'gygtetracycline\\xa0and\\xa0rifabutin\\xa0(see\\xa0below)\\xa0is\\xa0reported\\xa0to\\xa0be\\xa0<2%\\xa0in\\xa0the\\xa0United\\xa0States.\\xa0In\\xa0light\\xa0of\\xa0the\\xa0paucity\\xa0of\\xa0H.\\xa0pylori\\xa0antibiotic\\xa0real\\xadtime\\xa0resistance\\xa0data,asking\\xa0the\\xa0patient\\xa0about\\xa0prior\\xa0antibiotic\\xa0exposure\\xa0should\\xa0be\\xa0included\\xa0in\\xa0the\\xa0decision\\xadmaking\\xa0and\\xa0used\\xa0as\\xa0a\\xa0surrogate\\xa0for\\xa0potential\\xa0antibioticresistance,\\xa0especially\\xa0when\\xa0it\\xa0comes\\xa0to\\xa0prior\\xa0macrolide\\xa0use.\\xa0Clarithromycin\\xa0use\\xa0should\\xa0be\\xa0excluded\\xa0in\\xa0patients\\xa0with\\xa0prior\\xa0macrolide\\xa0usage.\\xa0Anapproach\\xa0to\\xa0antibiotic\\xa0selection\\xa0for\\xa0H.\\xa0pylori\\xa0therapy\\xa0has\\xa0been\\xa0recommended\\xa0in\\xa0the\\xa0ACG\\xa0clinical\\xa0guidelines\\xa0(Fig.\\xa0324\\xad13).FIGURE\\xa0324\\xad13Approach\\xa0to\\xa0selecting\\xa0antibiotics\\xa0for\\xa0patients\\xa0with\\xa0H.\\xa0pylori\\xa0infection.\\xa0LOAD,\\xa0levofloxacin,\\xa0omeprazole,\\xa0nitazoxanide,\\xa0anddoxycycline. (Reproduced\\xa0with\\xa0permission\\xa0from\\xa0WD\\xa0Chey\\xa0et\\xa0al:\\xa0ACG\\xa0clinical\\xa0guideline:\\xa0Treatment\\xa0of\\xa0Helicobacter\\xa0pylori\\xa0infection.\\xa0Am\\xa0J\\xa0Gastroenterol112:212,\\xa02017.)Failure\\xa0of\\xa0H.\\xa0pylori\\xa0eradication\\xa0with\\xa0triple\\xa0therapy\\xa0in\\xa0a\\xa0compliant\\xa0patient\\xa0is\\xa0usually\\xa0due\\xa0to\\xa0infection\\xa0with\\xa0a\\xa0resistant\\xa0organism.\\xa0A\\xa0series\\xa0of\\xa0salvagetherapies\\xa0for\\xa0H.\\xa0pylori\\xa0are\\xa0shown\\xa0in\\xa0Table\\xa0324\\xad5.\\xa0Quadruple\\xa0therapy\\xa0(Table\\xa0324\\xad4),\\xa0where\\xa0clarithromycin\\xa0is\\xa0substituted\\xa0for\\xa0metronidazole\\xa0(or\\xa0viceversa),\\xa0should\\xa0be\\xa0the\\xa0next\\xa0step.\\xa0The\\xa0combination\\xa0of\\xa0PPI,\\xa0amoxicillin,\\xa0and\\xa0rifabutin\\xa0for\\xa010\\xa0days\\xa0has\\xa0also\\xa0been\\xa0used\\xa0successfully\\xa0(86%\\xa0cure\\xa0rate)\\xa0inpatients\\xa0infected\\xa0with\\xa0resistant\\xa0strains.\\xa0Additional\\xa0regimens\\xa0considered\\xa0for\\xa0second\\xadline\\xa0therapy\\xa0include\\xa0levofloxacin\\xadbased\\xa0triple\\xa0therapy\\xa0(levofloxacin,amoxicillin,\\xa0PPI)\\xa0for\\xa010\\xa0days\\xa0and\\xa0furazolidone\\xadbased\\xa0triple\\xa0therapy\\xa0(furazolidone,\\xa0amoxicillin,\\xa0PPI)\\xa0for\\xa014\\xa0days.\\xa0Unfortunately,\\xa0there\\xa0is\\xa0no\\xa0universallyaccepted\\xa0treatment\\xa0regimen\\xa0recommended\\xa0for\\xa0patients\\xa0in\\xa0whom\\xa0two\\xa0courses\\xa0of\\xa0antibiotics\\xa0have\\xa0failed.\\xa0If\\xa0eradication\\xa0is\\xa0still\\xa0not\\xa0achieved\\xa0in\\xa0acompliant\\xa0patient,\\xa0then\\xa0culture\\xa0and\\xa0sensitivity\\xa0of\\xa0the\\xa0organism\\xa0should\\xa0be\\xa0considered.\\xa0One\\xa0challenge\\xa0with\\xa0this\\xa0approach\\xa0is\\xa0that\\xa0culture\\xa0and\\xa0sensitivity',\n",
       " 'compliant\\xa0patient,\\xa0then\\xa0culture\\xa0and\\xa0sensitivity\\xa0of\\xa0the\\xa0organism\\xa0should\\xa0be\\xa0considered.\\xa0One\\xa0challenge\\xa0with\\xa0this\\xa0approach\\xa0is\\xa0that\\xa0culture\\xa0and\\xa0sensitivitytesting\\xa0is\\xa0cumbersome\\xa0and\\xa0not\\xa0widely\\xa0available;\\xa0thus,\\xa0H.\\xa0pylori\\xa0resistance\\xa0data\\xa0within\\xa0specific\\xa0communities\\xa0are\\xa0often\\xa0not\\xa0available.\\xa0Non\\xadculture\\xadbasedapproaches\\xa0using\\xa0molecular\\xa0markers\\xa0to\\xa0determine\\xa0potential\\xa0resistance\\xa0through\\xa0stool\\xa0testing\\xa0are\\xa0being\\xa0developed\\xa0but\\xa0are\\xa0not\\xa0widely\\xa0available.Additional\\xa0factors\\xa0that\\xa0may\\xa0lower\\xa0eradication\\xa0rates\\xa0include\\xa0the\\xa0patient’s\\xa0country\\xa0of\\xa0origin\\xa0(higher\\xa0in\\xa0Northeast\\xa0Asia\\xa0than\\xa0other\\xa0parts\\xa0of\\xa0Asia\\xa0or\\xa0Europe)and\\xa0cigarette\\xa0smoking.\\xa0In\\xa0addition,\\xa0meta\\xadanalysis\\xa0suggests\\xa0that\\xa0even\\xa0the\\xa0most\\xa0effective\\xa0regimens\\xa0(quadruple\\xa0therapy\\xa0including\\xa0PPI,\\xa0bismuth,tetracycline,\\xa0and\\xa0metronidazole\\xa0and\\xa0triple\\xa0therapy\\xa0including\\xa0PPI,\\xa0clarithromycin,\\xa0and\\xa0amoxicillin)\\xa0may\\xa0have\\xa0suboptimal\\xa0eradication\\xa0rates\\xa0(<80%),\\xa0thusdemonstrating\\xa0the\\xa0need\\xa0for\\xa0the\\xa0development\\xa0of\\xa0more\\xa0efficacious\\xa0treatments.TABLE\\xa0324\\xad5Salvage\\xa0Therapies\\xa0for\\xa0H.\\xa0pylori\\xa0InfectionREGIMENDRUGS\\xa0(DOSES)DOSING\\xa0FREQUENCYDURATION\\xa0(DAYS)FDA\\xa0APPROVALBismuth\\xa0quadruplePPI\\xa0(standard\\xa0dose)bid14NoaBismuth\\xa0subcitrate\\xa0(120–300\\xa0mg)\\xa0or\\xa0subsalicylate\\xa0(300\\xa0mg)qidTetracycline\\xa0(500\\xa0mg)qidMetronidazole\\xa0(500\\xa0mg)tid\\xa0or\\xa0qidYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 27 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,',\n",
       " \"PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison's Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH'HCIpH20MucusHCOS2PH7.0MucusH'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa and\",\n",
       " 'prostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundus',\n",
       " \"CopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproduction\",\n",
       " \"H.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'aPPI,\\xa0bismuth,\\xa0tetracycline,\\xa0and\\xa0metronidazole\\xa0prescribed\\xa0separately\\xa0is\\xa0not\\xa0an\\xa0FDA\\xadapproved\\xa0treatment\\xa0regimen.\\xa0However,\\xa0Pylera,\\xa0a\\xa0combination\\xa0productcontaining\\xa0bismuth\\xa0subcitrate,\\xa0tetracycline,\\xa0and\\xa0metronidazole,\\xa0combined\\xa0with\\xa0a\\xa0PPI\\xa0for\\xa010\\xa0days\\xa0is\\xa0an\\xa0FDA\\xadapproved\\xa0treatment\\xa0regimen.Abbreviations:\\xa0bid,\\xa0twice\\xa0daily;\\xa0FDA,\\xa0Food\\xa0and\\xa0Drug\\xa0Administration;\\xa0PPI,\\xa0proton\\xa0pump\\xa0inhibitor;\\xa0tid,\\xa0three\\xa0times\\xa0daily;\\xa0qd,\\xa0once\\xa0daily;\\xa0qid,\\xa0four\\xa0times\\xa0daily.Source:\\xa0Reproduced\\xa0with\\xa0permission\\xa0from\\xa0WD\\xa0Chey\\xa0et\\xa0al:\\xa0ACG\\xa0clinical\\xa0guideline:\\xa0Treatment\\xa0of\\xa0Helicobacter\\xa0pylori\\xa0infection.\\xa0Am\\xa0J\\xa0Gastroenterol\\xa0112:212,\\xa02017.ppgpgggpyAdditional\\xa0factors\\xa0that\\xa0may\\xa0lower\\xa0eradication\\xa0rates\\xa0include\\xa0the\\xa0patient’s\\xa0country\\xa0of\\xa0origin\\xa0(higher\\xa0in\\xa0Northeast\\xa0Asia\\xa0than\\xa0other\\xa0parts\\xa0of\\xa0Asia\\xa0or\\xa0Europe)and\\xa0cigarette\\xa0smoking.\\xa0In\\xa0addition,\\xa0meta\\xadanalysis\\xa0suggests\\xa0that\\xa0even\\xa0the\\xa0most\\xa0effective\\xa0regimens\\xa0(quadruple\\xa0therapy\\xa0including\\xa0PPI,\\xa0bismuth,tetracycline,\\xa0and\\xa0metronidazole\\xa0and\\xa0triple\\xa0therapy\\xa0including\\xa0PPI,\\xa0clarithromycin,\\xa0and\\xa0amoxicillin)\\xa0may\\xa0have\\xa0suboptimal\\xa0eradication\\xa0rates\\xa0(<80%),\\xa0thusdemonstrating\\xa0the\\xa0need\\xa0for\\xa0the\\xa0development\\xa0of\\xa0more\\xa0efficacious\\xa0treatments.TABLE\\xa0324\\xad5Salvage\\xa0Therapies\\xa0for\\xa0H.\\xa0pylori\\xa0InfectionREGIMENDRUGS\\xa0(DOSES)DOSING\\xa0FREQUENCYDURATION\\xa0(DAYS)FDA\\xa0APPROVALBismuth\\xa0quadruplePPI\\xa0(standard\\xa0dose)bid14NoaBismuth\\xa0subcitrate\\xa0(120–300\\xa0mg)\\xa0or\\xa0subsalicylate\\xa0(300\\xa0mg)qidTetracycline\\xa0(500\\xa0mg)qidMetronidazole\\xa0(500\\xa0mg)tid\\xa0or\\xa0qidLevofloxacin\\xa0triplePPI\\xa0(standard\\xa0dose)bid14NoLevofloxacin\\xa0(500\\xa0mg)qdAmoxicillin\\xa0(1\\xa0g)bidConcomitantPPI\\xa0(standard\\xa0dose)bid10–14NoClarithromycin\\xa0(500\\xa0mg)bidAmoxicillin\\xa0(1\\xa0g)bidNitroimidazole\\xa0(500\\xa0mg)bid\\xa0or\\xa0tidRifabutin\\xa0triplePPI\\xa0(standard\\xa0dose)bid10NoRifabutin\\xa0(300\\xa0mg)qdAmoxicillin\\xa0(1\\xa0g)bidHigh\\xaddose\\xa0dualPPI\\xa0(standard\\xa0to\\xa0double\\xa0dose)tid\\xa0or\\xa0qid14NoAmoxicillin\\xa0(1\\xa0g\\xa0tid\\xa0or\\xa0750\\xa0mg\\xa0qid)tid\\xa0or\\xa0qidIn\\xa0view\\xa0of\\xa0the\\xa0observation\\xa0that\\xa015–25%\\xa0of\\xa0patients\\xa0treated\\xa0with\\xa0first\\xadline\\xa0therapy\\xa0may\\xa0still\\xa0remain\\xa0infected\\xa0with\\xa0the\\xa0organism,\\xa0new\\xa0approaches\\xa0to',\n",
       " '14NoAmoxicillin\\xa0(1\\xa0g\\xa0tid\\xa0or\\xa0750\\xa0mg\\xa0qid)tid\\xa0or\\xa0qidIn\\xa0view\\xa0of\\xa0the\\xa0observation\\xa0that\\xa015–25%\\xa0of\\xa0patients\\xa0treated\\xa0with\\xa0first\\xadline\\xa0therapy\\xa0may\\xa0still\\xa0remain\\xa0infected\\xa0with\\xa0the\\xa0organism,\\xa0new\\xa0approaches\\xa0totreatment\\xa0have\\xa0been\\xa0explored.\\xa0One\\xa0promising\\xa0approach\\xa0is\\xa0sequential\\xa0therapy.\\xa0Regimens\\xa0examined\\xa0consist\\xa0of\\xa05\\xa0days\\xa0of\\xa0amoxicillin\\xa0and\\xa0a\\xa0PPI,\\xa0followedby\\xa0an\\xa0additional\\xa05\\xa0days\\xa0of\\xa0PPI\\xa0plus\\xa0tinidazole\\xa0and\\xa0clarithromycin\\xa0or\\xa0levofloxacin.\\xa0One\\xa0promising\\xa0regimen\\xa0that\\xa0has\\xa0the\\xa0benefit\\xa0of\\xa0being\\xa0shorter\\xa0induration,\\xa0easier\\xa0to\\xa0take,\\xa0and\\xa0less\\xa0expensive\\xa0is\\xa05\\xa0days\\xa0of\\xa0concomitant\\xa0therapy\\xa0(PPI\\xa0twice\\xa0daily,\\xa0amoxicillin\\xa01\\xa0g\\xa0twice\\xa0daily,\\xa0levofloxacin\\xa0500\\xa0mg\\xa0twice\\xa0daily,and\\xa0tinidazole\\xa0500\\xa0mg\\xa0twice\\xa0daily).\\xa0Initial\\xa0studies\\xa0have\\xa0demonstrated\\xa0eradication\\xa0rates\\xa0of\\xa0>90%\\xa0with\\xa0good\\xa0patient\\xa0tolerance.\\xa0Confirmation\\xa0of\\xa0thesefindings\\xa0and\\xa0applicability\\xa0of\\xa0this\\xa0approach\\xa0in\\xa0the\\xa0United\\xa0States\\xa0are\\xa0needed,\\xa0although\\xa0some\\xa0experts\\xa0are\\xa0recommending\\xa0abandoning\\xa0clarithromycin\\xadbased\\xa0triple\\xa0therapy\\xa0in\\xa0the\\xa0United\\xa0States\\xa0for\\xa0the\\xa0concomitant\\xa0therapy\\xa0or\\xa0the\\xa0alternative\\xa0sequential\\xa0therapies\\xa0highlighted\\xa0above.Innovative\\xa0non\\xadantibiotic\\xadmediated\\xa0approaches\\xa0have\\xa0been\\xa0explored\\xa0in\\xa0an\\xa0effort\\xa0to\\xa0improve\\xa0eradication\\xa0rates\\xa0of\\xa0H.\\xa0pylori.\\xa0Pretreatment\\xa0of\\xa0patients\\xa0withN\\xadacetylcysteine\\xa0as\\xa0a\\xa0mucolytic\\xa0agent\\xa0to\\xa0destroy\\xa0the\\xa0H.\\xa0pylori\\xa0biofilm\\xa0and\\xa0therefore\\xa0impair\\xa0antibiotic\\xa0resistance\\xa0has\\xa0been\\xa0examined,\\xa0but\\xa0more\\xa0studiesare\\xa0needed\\xa0to\\xa0confirm\\xa0the\\xa0applicability\\xa0of\\xa0this\\xa0approach.\\xa0In\\xa0vitro\\xa0studies\\xa0suggest\\xa0that\\xa0certain\\xa0probiotics\\xa0like\\xa0Lactobacillus\\xa0or\\xa0its\\xa0metabolites\\xa0can\\xa0inhibitH.\\xa0pylori.\\xa0Administration\\xa0of\\xa0probiotics\\xa0has\\xa0been\\xa0attempted\\xa0in\\xa0several\\xa0clinical\\xa0studies\\xa0in\\xa0an\\xa0effort\\xa0to\\xa0maximize\\xa0antibiotic\\xadmediated\\xa0eradication\\xa0withYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 28 / 49PharmacyACCESSRSILVERCHAIRINFORMATION',\n",
       " \"©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 28 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison's Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroids\",\n",
       " 'Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cells',\n",
       " \"Copyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21e\",\n",
       " \"+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'Abbreviations:\\xa0COX\\xad2,\\xa0isoenzyme\\xa0of\\xa0cyclooxygenase;\\xa0NSAID,\\xa0nonsteroidal\\xa0anti\\xadinflammatory\\xa0drug;\\xa0PPI,\\xa0proton\\xa0pump\\xa0inhibitor.by\\xa0an\\xa0additional\\xa05\\xa0days\\xa0of\\xa0PPI\\xa0plus\\xa0tinidazole\\xa0and\\xa0clarithromycin\\xa0or\\xa0levofloxacin.\\xa0One\\xa0promising\\xa0regimen\\xa0that\\xa0has\\xa0the\\xa0benefit\\xa0of\\xa0being\\xa0shorter\\xa0induration,\\xa0easier\\xa0to\\xa0take,\\xa0and\\xa0less\\xa0expensive\\xa0is\\xa05\\xa0days\\xa0of\\xa0concomitant\\xa0therapy\\xa0(PPI\\xa0twice\\xa0daily,\\xa0amoxicillin\\xa01\\xa0g\\xa0twice\\xa0daily,\\xa0levofloxacin\\xa0500\\xa0mg\\xa0twice\\xa0daily,and\\xa0tinidazole\\xa0500\\xa0mg\\xa0twice\\xa0daily).\\xa0Initial\\xa0studies\\xa0have\\xa0demonstrated\\xa0eradication\\xa0rates\\xa0of\\xa0>90%\\xa0with\\xa0good\\xa0patient\\xa0tolerance.\\xa0Confirmation\\xa0of\\xa0thesefindings\\xa0and\\xa0applicability\\xa0of\\xa0this\\xa0approach\\xa0in\\xa0the\\xa0United\\xa0States\\xa0are\\xa0needed,\\xa0although\\xa0some\\xa0experts\\xa0are\\xa0recommending\\xa0abandoning\\xa0clarithromycin\\xadbased\\xa0triple\\xa0therapy\\xa0in\\xa0the\\xa0United\\xa0States\\xa0for\\xa0the\\xa0concomitant\\xa0therapy\\xa0or\\xa0the\\xa0alternative\\xa0sequential\\xa0therapies\\xa0highlighted\\xa0above.Innovative\\xa0non\\xadantibiotic\\xadmediated\\xa0approaches\\xa0have\\xa0been\\xa0explored\\xa0in\\xa0an\\xa0effort\\xa0to\\xa0improve\\xa0eradication\\xa0rates\\xa0of\\xa0H.\\xa0pylori.\\xa0Pretreatment\\xa0of\\xa0patients\\xa0withN\\xadacetylcysteine\\xa0as\\xa0a\\xa0mucolytic\\xa0agent\\xa0to\\xa0destroy\\xa0the\\xa0H.\\xa0pylori\\xa0biofilm\\xa0and\\xa0therefore\\xa0impair\\xa0antibiotic\\xa0resistance\\xa0has\\xa0been\\xa0examined,\\xa0but\\xa0more\\xa0studiesare\\xa0needed\\xa0to\\xa0confirm\\xa0the\\xa0applicability\\xa0of\\xa0this\\xa0approach.\\xa0In\\xa0vitro\\xa0studies\\xa0suggest\\xa0that\\xa0certain\\xa0probiotics\\xa0like\\xa0Lactobacillus\\xa0or\\xa0its\\xa0metabolites\\xa0can\\xa0inhibitH.\\xa0pylori.\\xa0Administration\\xa0of\\xa0probiotics\\xa0has\\xa0been\\xa0attempted\\xa0in\\xa0several\\xa0clinical\\xa0studies\\xa0in\\xa0an\\xa0effort\\xa0to\\xa0maximize\\xa0antibiotic\\xadmediated\\xa0eradication\\xa0withvarying\\xa0results.\\xa0Overall,\\xa0it\\xa0appears\\xa0that\\xa0the\\xa0use\\xa0of\\xa0certain\\xa0probiotics,\\xa0such\\xa0as\\xa0Lactobacillus\\xa0spp.,\\xa0Saccharomyces\\xa0spp.,\\xa0Bifidobacterium\\xa0spp.,\\xa0andBacillus\\xa0clausii,\\xa0did\\xa0not\\xa0alter\\xa0eradication\\xa0rates\\xa0but\\xa0importantly\\xa0decreased\\xa0antibiotic\\xadassociated\\xa0side\\xa0effects\\xa0including\\xa0nausea,\\xa0dysgeusia,\\xa0diarrhea,\\xa0andabdominal\\xa0discomfort/pain,\\xa0resulting\\xa0in\\xa0enhanced\\xa0tolerability\\xa0of\\xa0H.\\xa0pylori\\xa0therapies.\\xa0Additional\\xa0studies\\xa0are\\xa0needed\\xa0to\\xa0confirm\\xa0the\\xa0potential\\xa0benefits\\xa0of',\n",
       " 'abdominal\\xa0discomfort/pain,\\xa0resulting\\xa0in\\xa0enhanced\\xa0tolerability\\xa0of\\xa0H.\\xa0pylori\\xa0therapies.\\xa0Additional\\xa0studies\\xa0are\\xa0needed\\xa0to\\xa0confirm\\xa0the\\xa0potential\\xa0benefits\\xa0ofprobiotics\\xa0in\\xa0this\\xa0setting.\\xa0Statins,\\xa0specifically\\xa0atorvastatin,\\xa0have\\xa0been\\xa0used\\xa0with\\xa0some\\xa0success\\xa0as\\xa0an\\xa0adjunct\\xa0to\\xa0quadruple\\xa0therapy\\xa0in\\xa0patients\\xa0with\\xa0NUD.Reinfection\\xa0after\\xa0successful\\xa0eradication\\xa0of\\xa0H.\\xa0pylori\\xa0is\\xa0rare\\xa0in\\xa0the\\xa0United\\xa0States\\xa0(<1%\\xa0per\\xa0year).\\xa0If\\xa0recurrent\\xa0infection\\xa0occurs\\xa0within\\xa0the\\xa0first\\xa06\\xa0monthsafter\\xa0completing\\xa0therapy,\\xa0the\\xa0most\\xa0likely\\xa0explanation\\xa0is\\xa0recrudescence\\xa0as\\xa0opposed\\xa0to\\xa0reinfection.Therapy\\xa0of\\xa0Nsaid\\xadRelated\\xa0Gastric\\xa0or\\xa0Duodenal\\xa0InjuryMedical\\xa0intervention\\xa0for\\xa0NSAID\\xadrelated\\xa0mucosal\\xa0injury\\xa0includes\\xa0treatment\\xa0of\\xa0an\\xa0active\\xa0ulcer\\xa0and\\xa0primary\\xa0prevention\\xa0of\\xa0future\\xa0injury.\\xa0Recommendationsfor\\xa0the\\xa0treatment\\xa0and\\xa0primary\\xa0prevention\\xa0of\\xa0NSAID\\xadrelated\\xa0mucosal\\xa0injury\\xa0are\\xa0listed\\xa0in\\xa0Table\\xa0324\\xad6.\\xa0Ideally,\\xa0the\\xa0injurious\\xa0agent\\xa0should\\xa0be\\xa0stopped\\xa0asthe\\xa0first\\xa0step\\xa0in\\xa0the\\xa0therapy\\xa0of\\xa0an\\xa0active\\xa0NSAID\\xadinduced\\xa0ulcer.\\xa0If\\xa0that\\xa0is\\xa0possible,\\xa0then\\xa0treatment\\xa0with\\xa0one\\xa0of\\xa0the\\xa0acid\\xa0inhibitory\\xa0agents\\xa0(H2\\xa0blockers,\\xa0PPIs)is\\xa0indicated.\\xa0Cessation\\xa0of\\xa0NSAIDs\\xa0is\\xa0not\\xa0always\\xa0possible\\xa0because\\xa0of\\xa0the\\xa0patient’s\\xa0severe\\xa0underlying\\xa0disease.\\xa0Only\\xa0PPIs\\xa0can\\xa0heal\\xa0GUs\\xa0or\\xa0DUs,\\xa0independentof\\xa0whether\\xa0NSAIDs\\xa0are\\xa0discontinued.TABLE\\xa0324\\xad6Recommendations\\xa0for\\xa0Treatment\\xa0of\\xa0NSAID\\xadRelated\\xa0Mucosal\\xa0InjuryCLINICAL\\xa0SETTINGRECOMMENDATIONActive\\xa0ulcer\\u2003NSAID\\xa0discontinuedH2\\xa0receptor\\xa0antagonist\\xa0or\\xa0PPI\\u2003NSAID\\xa0continuedPPIProphylactic\\xa0therapyMisoprostolPPISelective\\xa0COX\\xad2\\xa0inhibitorH.\\xa0pylori\\xa0infectionEradication\\xa0if\\xa0active\\xa0ulcer\\xa0present\\xa0or\\xa0there\\xa0is\\xa0a\\xa0past\\xa0history\\xa0of\\xa0peptic\\xa0ulcer\\xa0diseaseThe\\xa0widespread\\xa0use\\xa0of\\xa0NSAIDs\\xa0has\\xa0created\\xa0some\\xa0concern\\xa0due\\xa0to\\xa0the\\xa0increasing\\xa0likelihood\\xa0of\\xa0GI\\xa0and\\xa0CV\\xa0side\\xa0effects\\xa0associated\\xa0with\\xa0these\\xa0agents.\\xa0Theapproach\\xa0to\\xa0primary\\xa0prevention\\xa0has\\xa0included\\xa0avoiding\\xa0the\\xa0agent,\\xa0using\\xa0the\\xa0lowest\\xa0possible\\xa0dose\\xa0of\\xa0the\\xa0agent\\xa0for\\xa0the\\xa0shortest\\xa0period\\xa0of\\xa0time\\xa0possible,',\n",
       " 'approach\\xa0to\\xa0primary\\xa0prevention\\xa0has\\xa0included\\xa0avoiding\\xa0the\\xa0agent,\\xa0using\\xa0the\\xa0lowest\\xa0possible\\xa0dose\\xa0of\\xa0the\\xa0agent\\xa0for\\xa0the\\xa0shortest\\xa0period\\xa0of\\xa0time\\xa0possible,using\\xa0NSAIDs\\xa0that\\xa0are\\xa0theoretically\\xa0less\\xa0injurious,\\xa0using\\xa0newer\\xa0topical\\xa0NSAID\\xa0preparations,\\xa0and/or\\xa0using\\xa0concomitant\\xa0medical\\xa0therapy\\xa0to\\xa0preventNSAID\\xadinduced\\xa0injury.\\xa0Several\\xa0nonselective\\xa0NSAIDs\\xa0that\\xa0are\\xa0associated\\xa0with\\xa0a\\xa0lower\\xa0likelihood\\xa0of\\xa0GI\\xa0and\\xa0CV\\xa0toxicity\\xa0include\\xa0naproxen\\xa0and\\xa0ibuprofen,although\\xa0the\\xa0beneficial\\xa0effect\\xa0may\\xa0be\\xa0eliminated\\xa0if\\xa0higher\\xa0dosages\\xa0of\\xa0the\\xa0agents\\xa0are\\xa0used.\\xa0Primary\\xa0prevention\\xa0of\\xa0NSAID\\xadinduced\\xa0ulceration\\xa0can\\xa0beaccomplished\\xa0by\\xa0a\\xa0PPI\\xa0and,\\xa0if\\xa0not\\xa0tolerated,\\xa0misoprostol\\xa0(200\\xa0μg\\xa0qid).\\xa0High\\xaddose\\xa0H2\\xa0blockers\\xa0(famotidine\\xa040\\xa0mg\\xa0bid)\\xa0have\\xa0also\\xa0shown\\xa0some\\xa0promise\\xa0inpreventing\\xa0endoscopically\\xa0documented\\xa0ulcers,\\xa0although\\xa0PPIs\\xa0are\\xa0superior.\\xa0The\\xa0highly\\xa0selective\\xa0COX\\xad2\\xa0inhibitors,\\xa0celecoxib\\xa0and\\xa0rofecoxib,\\xa0are\\xa0100times\\xa0more\\xa0selective\\xa0inhibitors\\xa0of\\xa0COX\\xad2\\xa0than\\xa0standard\\xa0NSAIDs,\\xa0leading\\xa0to\\xa0gastric\\xa0or\\xa0duodenal\\xa0mucosal\\xa0injury\\xa0that\\xa0is\\xa0comparable\\xa0to\\xa0placebo;\\xa0theirutilization\\xa0led\\xa0to\\xa0an\\xa0increase\\xa0in\\xa0CV\\xa0events\\xa0and\\xa0withdrawal\\xa0from\\xa0the\\xa0market.\\xa0Additional\\xa0caution\\xa0was\\xa0engendered\\xa0when\\xa0the\\xa0CLASS\\xa0study\\xa0demonstratedthat\\xa0the\\xa0advantage\\xa0of\\xa0celecoxib\\xa0in\\xa0preventing\\xa0GI\\xa0complications\\xa0was\\xa0offset\\xa0when\\xa0low\\xaddose\\xa0aspirin\\xa0was\\xa0used\\xa0simultaneously.\\xa0Therefore,\\xa0gastricprotection\\xa0therapy\\xa0is\\xa0required\\xa0in\\xa0individuals\\xa0taking\\xa0COX\\xad2\\xa0inhibitors\\xa0and\\xa0aspirin\\xa0prophylaxis.\\xa0Finally,\\xa0much\\xa0of\\xa0the\\xa0work\\xa0demonstrating\\xa0the\\xa0benefit\\xa0ofCOX\\xad2\\xa0inhibitors\\xa0and\\xa0PPIs\\xa0on\\xa0GI\\xa0injury\\xa0has\\xa0been\\xa0performed\\xa0in\\xa0individuals\\xa0of\\xa0average\\xa0risk;\\xa0it\\xa0is\\xa0unclear\\xa0if\\xa0the\\xa0same\\xa0level\\xa0of\\xa0benefit\\xa0will\\xa0be\\xa0achieved\\xa0inhigh\\xadrisk patients. For example, concomitant use of warfarin and a COX\\xad2 inhibitor was associated with rates of GI bleeding similar to those observed inYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle',\n",
       " \"Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 29 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,\",\n",
       " 'Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison\\'s Principles of Internal Medicine,21e',\n",
       " \"EnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatin\",\n",
       " \"FUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'Abbreviations:\\xa0CV,\\xa0cardiovascular;\\xa0GI,\\xa0gastrointestinal;\\xa0NSAID,\\xa0nonsteroidal\\xa0anti\\xadinflammatory\\xa0drug;\\xa0PPI,\\xa0proton\\xa0pump\\xa0inhibitor.Source:\\xa0Republished\\xa0with\\xa0permission\\xa0of\\xa0MJH\\xa0Life\\xa0Sciences,\\xa0LLC,\\xa0from\\xa0COX\\xad2\\xa0inhibitor\\xa0use\\xa0after\\xa0Vioxx:\\xa0careful\\xa0balance\\xa0orend\\xa0of\\xa0the\\xa0rope?,\\xa0Fendrick\\xa0AM,\\xa010(11\\xa0Pt\\xa01):2004;\\xa0permission\\xa0conveyed\\xa0through\\xa0Copyright\\xa0Clearance\\xa0Center,\\xa0Inc.using\\xa0NSAIDs\\xa0that\\xa0are\\xa0theoretically\\xa0less\\xa0injurious,\\xa0using\\xa0newer\\xa0topical\\xa0NSAID\\xa0preparations,\\xa0and/or\\xa0using\\xa0concomitant\\xa0medical\\xa0therapy\\xa0to\\xa0preventNSAID\\xadinduced\\xa0injury.\\xa0Several\\xa0nonselective\\xa0NSAIDs\\xa0that\\xa0are\\xa0associated\\xa0with\\xa0a\\xa0lower\\xa0likelihood\\xa0of\\xa0GI\\xa0and\\xa0CV\\xa0toxicity\\xa0include\\xa0naproxen\\xa0and\\xa0ibuprofen,although\\xa0the\\xa0beneficial\\xa0effect\\xa0may\\xa0be\\xa0eliminated\\xa0if\\xa0higher\\xa0dosages\\xa0of\\xa0the\\xa0agents\\xa0are\\xa0used.\\xa0Primary\\xa0prevention\\xa0of\\xa0NSAID\\xadinduced\\xa0ulceration\\xa0can\\xa0beaccomplished\\xa0by\\xa0a\\xa0PPI\\xa0and,\\xa0if\\xa0not\\xa0tolerated,\\xa0misoprostol\\xa0(200\\xa0μg\\xa0qid).\\xa0High\\xaddose\\xa0H2\\xa0blockers\\xa0(famotidine\\xa040\\xa0mg\\xa0bid)\\xa0have\\xa0also\\xa0shown\\xa0some\\xa0promise\\xa0inpreventing\\xa0endoscopically\\xa0documented\\xa0ulcers,\\xa0although\\xa0PPIs\\xa0are\\xa0superior.\\xa0The\\xa0highly\\xa0selective\\xa0COX\\xad2\\xa0inhibitors,\\xa0celecoxib\\xa0and\\xa0rofecoxib,\\xa0are\\xa0100times\\xa0more\\xa0selective\\xa0inhibitors\\xa0of\\xa0COX\\xad2\\xa0than\\xa0standard\\xa0NSAIDs,\\xa0leading\\xa0to\\xa0gastric\\xa0or\\xa0duodenal\\xa0mucosal\\xa0injury\\xa0that\\xa0is\\xa0comparable\\xa0to\\xa0placebo;\\xa0theirutilization\\xa0led\\xa0to\\xa0an\\xa0increase\\xa0in\\xa0CV\\xa0events\\xa0and\\xa0withdrawal\\xa0from\\xa0the\\xa0market.\\xa0Additional\\xa0caution\\xa0was\\xa0engendered\\xa0when\\xa0the\\xa0CLASS\\xa0study\\xa0demonstratedthat\\xa0the\\xa0advantage\\xa0of\\xa0celecoxib\\xa0in\\xa0preventing\\xa0GI\\xa0complications\\xa0was\\xa0offset\\xa0when\\xa0low\\xaddose\\xa0aspirin\\xa0was\\xa0used\\xa0simultaneously.\\xa0Therefore,\\xa0gastricprotection\\xa0therapy\\xa0is\\xa0required\\xa0in\\xa0individuals\\xa0taking\\xa0COX\\xad2\\xa0inhibitors\\xa0and\\xa0aspirin\\xa0prophylaxis.\\xa0Finally,\\xa0much\\xa0of\\xa0the\\xa0work\\xa0demonstrating\\xa0the\\xa0benefit\\xa0ofCOX\\xad2\\xa0inhibitors\\xa0and\\xa0PPIs\\xa0on\\xa0GI\\xa0injury\\xa0has\\xa0been\\xa0performed\\xa0in\\xa0individuals\\xa0of\\xa0average\\xa0risk;\\xa0it\\xa0is\\xa0unclear\\xa0if\\xa0the\\xa0same\\xa0level\\xa0of\\xa0benefit\\xa0will\\xa0be\\xa0achieved\\xa0inhigh\\xadrisk\\xa0patients.\\xa0For\\xa0example,\\xa0concomitant\\xa0use\\xa0of\\xa0warfarin\\xa0and\\xa0a\\xa0COX\\xad2\\xa0inhibitor\\xa0was\\xa0associated\\xa0with\\xa0rates\\xa0of\\xa0GI\\xa0bleeding\\xa0similar\\xa0to\\xa0those\\xa0observed\\xa0in',\n",
       " 'high\\xadrisk\\xa0patients.\\xa0For\\xa0example,\\xa0concomitant\\xa0use\\xa0of\\xa0warfarin\\xa0and\\xa0a\\xa0COX\\xad2\\xa0inhibitor\\xa0was\\xa0associated\\xa0with\\xa0rates\\xa0of\\xa0GI\\xa0bleeding\\xa0similar\\xa0to\\xa0those\\xa0observed\\xa0inpatients\\xa0taking\\xa0nonselective\\xa0NSAIDs.\\xa0A\\xa0combination\\xa0of\\xa0factors,\\xa0including\\xa0withdrawal\\xa0of\\xa0the\\xa0majority\\xa0of\\xa0COX\\xad2\\xa0inhibitors\\xa0from\\xa0the\\xa0market,\\xa0theobservation\\xa0that\\xa0low\\xaddose\\xa0aspirin\\xa0appears\\xa0to\\xa0diminish\\xa0the\\xa0beneficial\\xa0effect\\xa0of\\xa0COX\\xad2–selective\\xa0inhibitors,\\xa0and\\xa0the\\xa0growing\\xa0use\\xa0of\\xa0aspirin\\xa0forprophylaxis\\xa0of\\xa0CV\\xa0events,\\xa0has\\xa0significantly\\xa0altered\\xa0the\\xa0approach\\xa0to\\xa0gastric\\xa0protective\\xa0therapy\\xa0during\\xa0the\\xa0use\\xa0of\\xa0NSAIDs.\\xa0A\\xa0set\\xa0of\\xa0guidelines\\xa0for\\xa0theapproach\\xa0to\\xa0the\\xa0use\\xa0of\\xa0NSAIDs\\xa0was\\xa0published\\xa0by\\xa0the\\xa0ACG\\xa0and\\xa0is\\xa0shown\\xa0in\\xa0Table\\xa0324\\xad7.\\xa0Individuals\\xa0who\\xa0are\\xa0not\\xa0at\\xa0risk\\xa0for\\xa0CV\\xa0events,\\xa0do\\xa0not\\xa0use\\xa0aspirin,and\\xa0are\\xa0without\\xa0risk\\xa0for\\xa0GI\\xa0complications\\xa0can\\xa0receive\\xa0nonselective\\xa0NSAIDs\\xa0without\\xa0gastric\\xa0protection.\\xa0In\\xa0those\\xa0without\\xa0CV\\xa0risk\\xa0factors\\xa0but\\xa0with\\xa0a\\xa0highpotential\\xa0risk\\xa0(prior\\xa0GI\\xa0bleeding\\xa0or\\xa0multiple\\xa0GI\\xa0risk\\xa0factors)\\xa0for\\xa0NSAID\\xadinduced\\xa0GI\\xa0toxicity,\\xa0cautious\\xa0use\\xa0of\\xa0a\\xa0selective\\xa0COX\\xad2\\xa0inhibitor\\xa0and\\xa0co\\xadtherapy\\xa0withhigh\\xaddose\\xa0PPI\\xa0or\\xa0misoprostol\\xa0are\\xa0recommended.\\xa0Individuals\\xa0at\\xa0moderate\\xa0GI\\xa0risk\\xa0without\\xa0cardiac\\xa0risk\\xa0factors\\xa0can\\xa0be\\xa0treated\\xa0with\\xa0a\\xa0COX\\xad2\\xa0inhibitor\\xa0aloneor\\xa0with\\xa0a\\xa0nonselective\\xa0NSAID\\xa0with\\xa0PPI\\xa0or\\xa0misoprostol.\\xa0Individuals\\xa0with\\xa0CV\\xa0risk\\xa0factors,\\xa0who\\xa0require\\xa0low\\xaddose\\xa0aspirin\\xa0and\\xa0have\\xa0low\\xa0potential\\xa0for\\xa0NSAID\\xadinduced\\xa0toxicity,\\xa0should\\xa0be\\xa0considered\\xa0for\\xa0a\\xa0non\\xadNSAID\\xa0agent\\xa0or\\xa0use\\xa0of\\xa0a\\xa0traditional\\xa0NSAID\\xa0such\\xa0as\\xa0naproxen\\xa0(lower\\xa0CV\\xa0side\\xa0effects)\\xa0in\\xa0combinationwith\\xa0gastric\\xa0protection,\\xa0if\\xa0warranted.\\xa0Finally,\\xa0individuals\\xa0with\\xa0CV\\xa0and\\xa0GI\\xa0risks\\xa0who\\xa0require\\xa0aspirin\\xa0must\\xa0be\\xa0considered\\xa0for\\xa0non\\xadNSAID\\xa0therapy,\\xa0but\\xa0if\\xa0thatis\\xa0not\\xa0an\\xa0option,\\xa0then\\xa0gastric\\xa0protection\\xa0with\\xa0any\\xa0type\\xa0of\\xa0NSAID\\xa0must\\xa0be\\xa0considered.\\xa0Any\\xa0patient,\\xa0regardless\\xa0of\\xa0risk\\xa0status,\\xa0who\\xa0is\\xa0being\\xa0considered\\xa0forlong\\xadterm\\xa0traditional\\xa0NSAID\\xa0therapy\\xa0should\\xa0also\\xa0be\\xa0considered\\xa0for\\xa0H.\\xa0pylori\\xa0testing\\xa0and\\xa0treatment\\xa0if\\xa0positive.\\xa0Assuring\\xa0the\\xa0use\\xa0of\\xa0GI\\xa0protective\\xa0agents',\n",
       " 'long\\xadterm\\xa0traditional\\xa0NSAID\\xa0therapy\\xa0should\\xa0also\\xa0be\\xa0considered\\xa0for\\xa0H.\\xa0pylori\\xa0testing\\xa0and\\xa0treatment\\xa0if\\xa0positive.\\xa0Assuring\\xa0the\\xa0use\\xa0of\\xa0GI\\xa0protective\\xa0agentswith\\xa0NSAIDs\\xa0is\\xa0difficult,\\xa0even\\xa0in\\xa0high\\xadrisk\\xa0patients.\\xa0This\\xa0is\\xa0in\\xa0part\\xa0due\\xa0to\\xa0underprescribing\\xa0of\\xa0the\\xa0appropriate\\xa0protective\\xa0agent;\\xa0other\\xa0times,\\xa0the\\xa0difficultyis\\xa0related\\xa0to\\xa0patient\\xa0compliance.\\xa0The\\xa0latter\\xa0may\\xa0be\\xa0due\\xa0to\\xa0patients\\xa0forgetting\\xa0to\\xa0take\\xa0multiple\\xa0pills\\xa0or\\xa0preferring\\xa0not\\xa0to\\xa0take\\xa0the\\xa0extra\\xa0pill,\\xa0especially\\xa0ifthey\\xa0have\\xa0no\\xa0GI\\xa0symptoms.\\xa0Several\\xa0NSAID\\xa0gastroprotective\\xadcontaining\\xa0combination\\xa0pills\\xa0are\\xa0now\\xa0commercially\\xa0available,\\xa0including\\xa0double\\xaddosefamotidine\\xa0with\\xa0ibuprofen,\\xa0diclofenac\\xa0with\\xa0misoprostol,\\xa0and\\xa0naproxen\\xa0with\\xa0esomeprazole.\\xa0Although\\xa0initial\\xa0studies\\xa0suggested\\xa0improved\\xa0complianceand\\xa0a\\xa0cost\\xa0advantage\\xa0when\\xa0taking\\xa0these\\xa0combination\\xa0drugs,\\xa0their\\xa0clinical\\xa0benefit\\xa0over\\xa0the\\xa0use\\xa0of\\xa0separate\\xa0pills\\xa0has\\xa0not\\xa0been\\xa0established.\\xa0Oneadditional\\xa0concern\\xa0with\\xa0NSAID\\xadinduced\\xa0GI\\xa0complications\\xa0is\\xa0the\\xa0relatively\\xa0low\\xa0rate\\xa0of\\xa0primary\\xa0care\\xa0provider\\xa0compliance\\xa0with\\xa0established\\xa0guidelinesoutlining\\xa0preventative\\xa0measures.\\xa0An\\xa0intervention\\xa0including\\xa0professional\\xa0education,\\xa0informatics\\xa0to\\xa0facilitate\\xa0review,\\xa0and\\xa0financial\\xa0incentives\\xa0forpractices\\xa0to\\xa0review\\xa0patients’\\xa0charts\\xa0to\\xa0assess\\xa0appropriateness\\xa0showed\\xa0a\\xa0reduced\\xa0rate\\xa0of\\xa0high\\xadrisk\\xa0prescribing\\xa0of\\xa0antiplatelet\\xa0medications\\xa0and\\xa0NSAIDswith\\xa0a\\xa0tendency\\xa0toward\\xa0improved\\xa0clinical\\xa0outcomes.\\xa0Efforts\\xa0continue\\xa0toward\\xa0developing\\xa0safer\\xa0NSAIDs,\\xa0including\\xa0topical\\xa0NSAIDs,\\xa0NSAID\\xa0formulationsthat\\xa0are\\xa0rapidly\\xa0absorbed\\xa0(diclofenac\\xa0potassium\\xa0powder\\xa0mixed\\xa0with\\xa0a\\xa0buffering\\xa0agent,\\xa0Prosorb\\xa0and\\xa0SoluMatrix\\xa0technology),\\xa0NO\\xadreleasing\\xa0NSAIDs,hydrogen\\xa0sulfide–releasing\\xa0NSAIDs,\\xa0dual\\xa0COX/5\\xadLOX\\xa0inhibitors,\\xa0NSAID\\xa0prodrugs,\\xa0and\\xa0agents\\xa0that\\xa0can\\xa0effectively\\xa0sequester\\xa0unbound\\xa0NSAIDs\\xa0withoutinterfering\\xa0with\\xa0their\\xa0efficacy.TABLE\\xa0324\\xad7Guide\\xa0to\\xa0NSAID\\xa0TherapyNO/LOW\\xa0NSAID\\xa0GI\\xa0RISKNSAID\\xa0GI\\xa0RISKNo\\xa0CV\\xa0risk\\xa0(noaspirin)Traditional\\xa0NSAIDCoxib\\xa0orTraditional\\xa0NSAID\\xa0+\\xa0PPI\\xa0or misoprostolConsider\\xa0non\\xadNSAID\\xa0therapyCV\\xa0risk\\xa0(consideraspirin)',\n",
       " \"Guide\\xa0to\\xa0NSAID\\xa0TherapyNO/LOW\\xa0NSAID\\xa0GI\\xa0RISKNSAID\\xa0GI\\xa0RISKNo\\xa0CV\\xa0risk\\xa0(noaspirin)Traditional\\xa0NSAIDCoxib\\xa0orTraditional\\xa0NSAID\\xa0+\\xa0PPI\\xa0or misoprostolConsider\\xa0non\\xadNSAID\\xa0therapyCV\\xa0risk\\xa0(consideraspirin)Traditional\\xa0NSAID\\xa0+\\xa0PPI\\xa0or misoprostol\\xa0if\\xa0GI\\xa0risk\\xa0warrantsgastroprotectionConsider\\xa0non\\xadNSAID\\xa0therapyA\\xa0gastroprotective\\xa0agent\\xa0must\\xa0be\\xa0added\\xa0if\\xa0a\\xa0traditional\\xa0NSAID\\xa0isprescribedConsider\\xa0non\\xadNSAID\\xa0therapyApproach\\xa0and\\xa0Therapy:\\xa0SummaryControversy\\xa0continues\\xa0regarding\\xa0the\\xa0best\\xa0approach\\xa0to\\xa0the\\xa0patient\\xa0who\\xa0presents\\xa0with\\xa0dyspepsia\\xa0(Chap.\\xa045).\\xa0The\\xa0discovery\\xa0of\\xa0H.\\xa0pylori\\xa0and\\xa0its\\xa0role\\xa0inpathogenesis\\xa0of\\xa0ulcers\\xa0has\\xa0added\\xa0a\\xa0new\\xa0variable\\xa0to\\xa0the\\xa0equation.\\xa0Previously,\\xa0if\\xa0a\\xa0patient\\xa0<50\\xa0years\\xa0of\\xa0age\\xa0presented\\xa0with\\xa0dyspepsia\\xa0and\\xa0withoutalarming signs or symptoms suggestive of an ulcer complication or malignancy, an empirical therapeutic trial with acid suppression was commonlyYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 30 / 49PharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,\",\n",
       " 'HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison\\'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferent',\n",
       " \"and prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:\",\n",
       " \"PCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'Abbreviations:\\xa0CV,\\xa0cardiovascular;\\xa0GI,\\xa0gastrointestinal;\\xa0NSAID,\\xa0nonsteroidal\\xa0anti\\xadinflammatory\\xa0drug;\\xa0PPI,\\xa0proton\\xa0pump\\xa0inhibitor.Source:\\xa0Republished\\xa0with\\xa0permission\\xa0of\\xa0MJH\\xa0Life\\xa0Sciences,\\xa0LLC,\\xa0from\\xa0COX\\xad2\\xa0inhibitor\\xa0use\\xa0after\\xa0Vioxx:\\xa0careful\\xa0balance\\xa0orend\\xa0of\\xa0the\\xa0rope?,\\xa0Fendrick\\xa0AM,\\xa010(11\\xa0Pt\\xa01):2004;\\xa0permission\\xa0conveyed\\xa0through\\xa0Copyright\\xa0Clearance\\xa0Center,\\xa0Inc.Approach\\xa0and\\xa0Therapy:\\xa0SummaryControversy\\xa0continues\\xa0regarding\\xa0the\\xa0best\\xa0approach\\xa0to\\xa0the\\xa0patient\\xa0who\\xa0presents\\xa0with\\xa0dyspepsia\\xa0(Chap.\\xa045).\\xa0The\\xa0discovery\\xa0of\\xa0H.\\xa0pylori\\xa0and\\xa0its\\xa0role\\xa0inpathogenesis\\xa0of\\xa0ulcers\\xa0has\\xa0added\\xa0a\\xa0new\\xa0variable\\xa0to\\xa0the\\xa0equation.\\xa0Previously,\\xa0if\\xa0a\\xa0patient\\xa0<50\\xa0years\\xa0of\\xa0age\\xa0presented\\xa0with\\xa0dyspepsia\\xa0and\\xa0withoutalarming\\xa0signs\\xa0or\\xa0symptoms\\xa0suggestive\\xa0of\\xa0an\\xa0ulcer\\xa0complication\\xa0or\\xa0malignancy,\\xa0an\\xa0empirical\\xa0therapeutic\\xa0trial\\xa0with\\xa0acid\\xa0suppression\\xa0was\\xa0commonlyrecommended.\\xa0Although\\xa0this\\xa0approach\\xa0is\\xa0practiced\\xa0by\\xa0some\\xa0today,\\xa0an\\xa0approach\\xa0presently\\xa0gaining\\xa0approval\\xa0for\\xa0the\\xa0treatment\\xa0of\\xa0patients\\xa0withdyspepsia\\xa0is\\xa0outlined\\xa0in\\xa0Fig.\\xa0324\\xad14.\\xa0The\\xa0referral\\xa0to\\xa0a\\xa0gastroenterologist\\xa0is\\xa0for\\xa0the\\xa0potential\\xa0need\\xa0of\\xa0endoscopy\\xa0and\\xa0subsequent\\xa0evaluation\\xa0andtreatment\\xa0if\\xa0the\\xa0endoscopy\\xa0is\\xa0negative.FIGURE\\xa0324\\xad14Overview\\xa0of\\xa0new\\xadonset\\xa0dyspepsia.\\xa0GERD,\\xa0gastroesophageal\\xa0reflux\\xa0disease;\\xa0Hp,\\xa0Helicobacter\\xa0pylori;\\xa0IBS,\\xa0irritable\\xa0bowel\\xa0syndrome;\\xa0UBT,\\xa0ureabreath\\xa0test.\\xa0(Reproduced\\xa0with\\xa0permission\\xa0from\\xa0BS\\xa0Anand,\\xa0DY\\xa0Graham:\\xa0State\\xadof\\xadthe\\xadArt:\\xa0Ulcer\\xa0and\\xa0Gastritis,\\xa0Endoscopy\\xa031:215,\\xa01999.\\xa0©\\xa0Georg\\xa0ThiemeVerlag\\xa0KG.)Verlag\\xa0KG.)Once\\xa0an\\xa0ulcer\\xa0(GU\\xa0or\\xa0DU)\\xa0is\\xa0documented,\\xa0the\\xa0main\\xa0issue\\xa0at\\xa0stake\\xa0is\\xa0whether\\xa0H.\\xa0pylori\\xa0or\\xa0an\\xa0NSAID\\xa0is\\xa0involved.\\xa0With\\xa0H.\\xa0pylori\\xa0present,\\xa0independent\\xa0of\\xa0theNSAID\\xa0status,\\xa0triple\\xa0therapy\\xa0is\\xa0recommended\\xa0for\\xa014\\xa0days,\\xa0followed\\xa0by\\xa0continued\\xa0acid\\xadsuppressing\\xa0drugs\\xa0(H2\\xa0receptor\\xa0antagonist\\xa0or\\xa0PPIs)\\xa0for\\xa0a\\xa0total\\xa0of4–6\\xa0weeks.\\xa0H.\\xa0pylori\\xa0eradication\\xa0should\\xa0be\\xa0documented\\xa04\\xa0weeks\\xa0after\\xa0completing\\xa0antibiotics.\\xa0The\\xa0test\\xa0of\\xa0choice\\xa0for\\xa0documenting\\xa0eradication\\xa0is\\xa0the',\n",
       " '4–6\\xa0weeks.\\xa0H.\\xa0pylori\\xa0eradication\\xa0should\\xa0be\\xa0documented\\xa04\\xa0weeks\\xa0after\\xa0completing\\xa0antibiotics.\\xa0The\\xa0test\\xa0of\\xa0choice\\xa0for\\xa0documenting\\xa0eradication\\xa0is\\xa0thelaboratory\\xadbased\\xa0validated\\xa0monoclonal\\xa0stool\\xa0antigen\\xa0test\\xa0or\\xa0a\\xa0urea\\xa0breath\\xa0test\\xa0(UBT).\\xa0The\\xa0patient\\xa0must\\xa0be\\xa0off\\xa0antisecretory\\xa0agents\\xa0for\\xa0at\\xa0least\\xa07\\xa0dayswhen\\xa0being\\xa0tested\\xa0for\\xa0eradication\\xa0of\\xa0H.\\xa0pylori\\xa0with\\xa0UBT\\xa0or\\xa0stool\\xa0antigen.\\xa0Serologic\\xa0testing\\xa0is\\xa0not\\xa0useful\\xa0for\\xa0the\\xa0purpose\\xa0of\\xa0documenting\\xa0eradicationbecause\\xa0antibody\\xa0titers\\xa0fall\\xa0slowly\\xa0and\\xa0often\\xa0do\\xa0not\\xa0become\\xa0undetectable.\\xa0Some\\xa0recommend\\xa0that\\xa0patients\\xa0with\\xa0complicated\\xa0ulcer\\xa0disease\\xa0or\\xa0who\\xa0arefrail\\xa0should\\xa0be\\xa0treated\\xa0with\\xa0long\\xadterm\\xa0acid\\xa0suppression,\\xa0thus\\xa0making\\xa0documentation\\xa0of\\xa0H.\\xa0pylori\\xa0eradication\\xa0a\\xa0moot\\xa0point.\\xa0In\\xa0view\\xa0of\\xa0this\\xa0discrepancyin\\xa0practice,\\xa0it\\xa0would\\xa0be\\xa0best\\xa0to\\xa0discuss\\xa0with\\xa0the\\xa0patient\\xa0the\\xa0different\\xa0options\\xa0available.Several\\xa0issues\\xa0differentiate\\xa0the\\xa0approach\\xa0to\\xa0a\\xa0GU\\xa0versus\\xa0a\\xa0DU.\\xa0GUs,\\xa0especially\\xa0of\\xa0the\\xa0body\\xa0and\\xa0fundus,\\xa0have\\xa0the\\xa0potential\\xa0of\\xa0being\\xa0malignant.\\xa0Multiplebiopsies\\xa0of\\xa0a\\xa0GU\\xa0should\\xa0be\\xa0taken\\xa0initially;\\xa0even\\xa0if\\xa0these\\xa0are\\xa0negative\\xa0for\\xa0neoplasm,\\xa0repeat\\xa0endoscopy\\xa0to\\xa0document\\xa0healing\\xa0at\\xa08–12\\xa0weeks\\xa0should\\xa0beperformed,\\xa0with\\xa0biopsy\\xa0if\\xa0the\\xa0ulcer\\xa0is\\xa0still\\xa0present.\\xa0About\\xa070%\\xa0of\\xa0GUs\\xa0eventually\\xa0found\\xa0to\\xa0be\\xa0malignant\\xa0undergo\\xa0significant\\xa0(usually\\xa0incomplete)healing.\\xa0Repeat\\xa0endoscopy\\xa0is\\xa0warranted\\xa0in\\xa0patients\\xa0with\\xa0DU\\xa0if\\xa0symptoms\\xa0persist\\xa0despite\\xa0medical\\xa0therapy\\xa0or\\xa0a\\xa0complication\\xa0is\\xa0suspected.The\\xa0majority\\xa0(>90%)\\xa0of\\xa0GUs\\xa0and\\xa0DUs\\xa0heal\\xa0with\\xa0the\\xa0conventional\\xa0therapy\\xa0outlined\\xa0above.\\xa0A\\xa0GU\\xa0that\\xa0fails\\xa0to\\xa0heal\\xa0after\\xa012\\xa0weeks\\xa0and\\xa0a\\xa0DU\\xa0that\\xa0does\\xa0notheal\\xa0after\\xa08\\xa0weeks\\xa0of\\xa0therapy\\xa0should\\xa0be\\xa0considered\\xa0refractory.\\xa0Once\\xa0poor\\xa0compliance\\xa0and\\xa0persistent\\xa0H.\\xa0pylori\\xa0infection\\xa0have\\xa0been\\xa0excluded,\\xa0NSAID\\xa0use,either inadvertent or surreptitious must be excluded In addition cigarette smoking must be eliminated For a GU malignancy must be meticulouslyYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138',\n",
       " \"Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 31 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMSMembranephospholipidsPhospholipaseA2ArachidonicacidStomachMacrophagesKidneyCOX-1COX-2LeukocytesPlateletshousekeepinginflammationFibroblastsEndotheliumEndotheliumTXA2，PGl2，PGE2PGl,PGE2Gastrointestinal mucosalintegrityInflammationPlateletaggregationMitogenesisRenal functionBoneformationOtherfunctions?Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.BonefractureC.difficileinfectionCommunity-acquiredSideeffectpneumonia(2 studies)HypermagnesemiaAcuteinterstitialnephritisAcutekidneydiseaseChronickidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison'sPrinciples ofInternal Medicine,21e\",\n",
       " 'kidneydisease55866Adjustedoddsratio(95%confidenceinterval)Source:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,DanLongo,J.LarryJameson:Harrison\\'sPrinciples ofInternal Medicine,21eCopyriqhtMcGrawHill.Allriqhtsreserved.Gastrointestinalmucosalinjury↑Mitochondrialuncoupling↑Reactiveprooxidants↑MOS↓ATP↓△Ym↑Mitochondrialfission↓MucosalPGHS-1↓PGE2↓Mucosaldefense↓Intestinalmucosalbarrierfunction↑Mucosalinflammation↑ApoptosisSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison\\'s Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.RestingStimulatedCanaliculusH+,K+-ATPaSe→KCITubulovesicles→KCIActiveHO+ActivedwnddundCaCAMPnnGastrinAChHistamineSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison\\'s Principles ofInternal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.ABSource: Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,Dan Longo, J. Larry Jameson:Harrison\\'s Principles of Intemal Medicine,21eHormonal regulationGastrin,CCKCRF,TRF,melatoninVagal stimulationGhrelingrowthfactorsndcytokinesAdrenal corticosteroidsPepsinH\\'HCIpH20MucusHCOS2PH7.0MucusH\\'Unstirred layerofmucus and bicarbonate2）Surface epithelial cells secretemucusbicarbonate,generateprostaglandins, heat shockHCOantimicrobial cathelicidinsproteins,refoll peptides,and4Cell renewal frommucosalprogenitor cells is stimulated byHCOSgrowth factors(e.g.TGFa andTGF-1)utilizing EGF receptorAlkaline\"tide\"Mast cellsMicrocirculation through capillariesis maintained by continuousMuscularismucosageneration of prostaglandins,nitricoxide,and hydrogen sulfide thatprotect endothelial cells from injuryand prevent platelet and leukocyteaggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)',\n",
       " \"aggregationSubmucosal arterySensorySensory nerves.Gastric mucosaNervesand submucosal vessels areinnervated by primary afferentsensory neurons and nervesSubmucosal veinProstaglandins(PGEand PGI)mucosal base.The nerve fibersforming a dense plexus at themaintain and enhance all mucosalpropria（accompanying capllaryfrom this plexus enter the laminasynergistically with nitric oxidedelensive mechanisms workingsurface epithelial cellsvessels) and end just beneath theSoure:osephLoscaAnhoyFauciennisKaeSthen DanLongo,LayJameon:Hrison Pincipesofnemal MediineABSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J. Larry Jameson:Harrison's Principles of Intermal Medicine,21eBacterialfactorsHostfactorsStructureDurationAdhesinsLocationPorinsInflammatoryresponseEnzymesGenetics??(urease,vacA,cagA,etc.)ChronicgastritisPepticulcer diseaseGastricMALTlymphomaGastriccancerDan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGrawHill.AllrightsreservedGastricpit(foveolus)SurfacemucouscellsIsthmusMucousneckcellsNeckOxynticGlandParietalcellsEndocrinecellBase(fundus)Chief cellsSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGravVagusCGRPPACAPAChChGRPAChEC CellDCellG CellParietalDCell(ANP)(SST)(Gastrin)Cell(SST)HHPECLCell(ChronicAntrum)(Histamine)AcidHP (Acute)AntrumFundusSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo, J. Larry Jameson: Harrison's Principles of Intemal Medicine, 21eKey Questions:1. Is there a penicillin (PCN)allergy?2.Previous macrolide (MCL)exposure foranyreason?PCN allergy: NoPCN allergy: NoPCN allergy: YesPCN allergy:YesMCL exposure:NoMCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycin\",\n",
       " \"MCL exposure:Yes*MCL exposure:NoMCL exposure:Yes*RecommendedRecommendedRecommendedRecommendedtreatments:treatments:treatments:treatments:Bismuth quadrupleBismuthquadrupleClarithromycinBismuth quadrupleCONCOMITANTLevofloxacin tripletriple withmetronidazoleClarithromycin tripleLevofloxacinWith amoxicillinsequentialBismuth quadrupleOther options:Other options:SequentialConcomitanttherapy?HYBRIDSequential therapy?Levofloxacin tripleHybrid therapy?LevofloxacinLOAD?sequentialLOAD?*Inregionswhere clarithromycinresistance isknowntobe>15%,utilizerecommendationsforpatientswith a history of macrolide exposure.Dan Longo,.Larry Jameson:Harrison's Principles of Intemal Medicine,21eSource:3oseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,CoovrightParietal cellFUNDUSVagusCanaliculusAcetylcholineHistamine+H,KATPaseECLcellTubulovesiclesHistamineECLcellSomatostatinSomatostatinDcell+GastrinBloodvesselANTRUMGastrinGcellDcellSomatostatinSource:Joseph Loscalzo,AnthonyFauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.Allrightsreserved.HighlevelofacidproductionDuodenalulcerXMALTlymphomaAntral-predominantgastritisChronicNonatrophicAsymptomaticNormalgastricH.pyloripangastritisH.pylorimucosainfectioninfectionCorpus-predominantAcuteatrophicGastriculcerH.pylorigastritisinfectionIntestinalmetaplasiaDysplasiaLowlevelofacidproductionGastriccancerChildhoodAdvancedageSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper, Stephen Hauser,DanLongo,J. Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGraw Hill.Allriqhtsre\",\n",
       " 'frail\\xa0should\\xa0be\\xa0treated\\xa0with\\xa0long\\xadterm\\xa0acid\\xa0suppression,\\xa0thus\\xa0making\\xa0documentation\\xa0of\\xa0H.\\xa0pylori\\xa0eradication\\xa0a\\xa0moot\\xa0point.\\xa0In\\xa0view\\xa0of\\xa0this\\xa0discrepancyin\\xa0practice,\\xa0it\\xa0would\\xa0be\\xa0best\\xa0to\\xa0discuss\\xa0with\\xa0the\\xa0patient\\xa0the\\xa0different\\xa0options\\xa0available.Several\\xa0issues\\xa0differentiate\\xa0the\\xa0approach\\xa0to\\xa0a\\xa0GU\\xa0versus\\xa0a\\xa0DU.\\xa0GUs,\\xa0especially\\xa0of\\xa0the\\xa0body\\xa0and\\xa0fundus,\\xa0have\\xa0the\\xa0potential\\xa0of\\xa0being\\xa0malignant.\\xa0Multiplebiopsies\\xa0of\\xa0a\\xa0GU\\xa0should\\xa0be\\xa0taken\\xa0initially;\\xa0even\\xa0if\\xa0these\\xa0are\\xa0negative\\xa0for\\xa0neoplasm,\\xa0repeat\\xa0endoscopy\\xa0to\\xa0document\\xa0healing\\xa0at\\xa08–12\\xa0weeks\\xa0should\\xa0beperformed,\\xa0with\\xa0biopsy\\xa0if\\xa0the\\xa0ulcer\\xa0is\\xa0still\\xa0present.\\xa0About\\xa070%\\xa0of\\xa0GUs\\xa0eventually\\xa0found\\xa0to\\xa0be\\xa0malignant\\xa0undergo\\xa0significant\\xa0(usually\\xa0incomplete)healing.\\xa0Repeat\\xa0endoscopy\\xa0is\\xa0warranted\\xa0in\\xa0patients\\xa0with\\xa0DU\\xa0if\\xa0symptoms\\xa0persist\\xa0despite\\xa0medical\\xa0therapy\\xa0or\\xa0a\\xa0complication\\xa0is\\xa0suspected.The\\xa0majority\\xa0(>90%)\\xa0of\\xa0GUs\\xa0and\\xa0DUs\\xa0heal\\xa0with\\xa0the\\xa0conventional\\xa0therapy\\xa0outlined\\xa0above.\\xa0A\\xa0GU\\xa0that\\xa0fails\\xa0to\\xa0heal\\xa0after\\xa012\\xa0weeks\\xa0and\\xa0a\\xa0DU\\xa0that\\xa0does\\xa0notheal\\xa0after\\xa08\\xa0weeks\\xa0of\\xa0therapy\\xa0should\\xa0be\\xa0considered\\xa0refractory.\\xa0Once\\xa0poor\\xa0compliance\\xa0and\\xa0persistent\\xa0H.\\xa0pylori\\xa0infection\\xa0have\\xa0been\\xa0excluded,\\xa0NSAID\\xa0use,either\\xa0inadvertent\\xa0or\\xa0surreptitious,\\xa0must\\xa0be\\xa0excluded.\\xa0In\\xa0addition,\\xa0cigarette\\xa0smoking\\xa0must\\xa0be\\xa0eliminated.\\xa0For\\xa0a\\xa0GU,\\xa0malignancy\\xa0must\\xa0be\\xa0meticulouslyexcluded.\\xa0Next,\\xa0consideration\\xa0should\\xa0be\\xa0given\\xa0to\\xa0a\\xa0gastric\\xa0acid\\xa0hypersecretory\\xa0state\\xa0such\\xa0as\\xa0ZES\\xa0(see\\xa0“Zollinger\\xadEllison\\xa0Syndrome,”\\xa0below)\\xa0or\\xa0theidiopathic\\xa0form,\\xa0which\\xa0can\\xa0be\\xa0excluded\\xa0with\\xa0gastric\\xa0acid\\xa0analysis.\\xa0Although\\xa0a\\xa0subset\\xa0of\\xa0patients\\xa0has\\xa0gastric\\xa0acid\\xa0hypersecretion\\xa0of\\xa0unclear\\xa0etiology\\xa0as\\xa0acontributing\\xa0factor\\xa0to\\xa0refractory\\xa0ulcers,\\xa0ZES\\xa0should\\xa0be\\xa0excluded\\xa0with\\xa0a\\xa0fasting\\xa0gastrin\\xa0or\\xa0secretin\\xa0stimulation\\xa0test\\xa0(see\\xa0below).\\xa0More\\xa0than\\xa090%\\xa0ofrefractory\\xa0ulcers\\xa0(either\\xa0DUs\\xa0or\\xa0GUs)\\xa0heal\\xa0after\\xa08\\xa0weeks\\xa0of\\xa0treatment\\xa0with\\xa0higher\\xa0doses\\xa0of\\xa0PPI\\xa0(omeprazole\\xa040\\xa0mg/d;\\xa0lansoprazole\\xa030–60\\xa0mg/d).\\xa0Thishigher\\xa0dose\\xa0is\\xa0also\\xa0effective\\xa0in\\xa0maintaining\\xa0remission.\\xa0Surgical\\xa0intervention\\xa0may\\xa0be\\xa0a\\xa0consideration\\xa0at\\xa0this\\xa0point;\\xa0however,\\xa0other\\xa0rare\\xa0causes\\xa0of',\n",
       " 'higher\\xa0dose\\xa0is\\xa0also\\xa0effective\\xa0in\\xa0maintaining\\xa0remission.\\xa0Surgical\\xa0intervention\\xa0may\\xa0be\\xa0a\\xa0consideration\\xa0at\\xa0this\\xa0point;\\xa0however,\\xa0other\\xa0rare\\xa0causes\\xa0ofrefractory\\xa0ulcers\\xa0must\\xa0be\\xa0excluded\\xa0before\\xa0recommending\\xa0surgery.\\xa0Rare\\xa0etiologies\\xa0of\\xa0refractory\\xa0ulcers\\xa0that\\xa0may\\xa0be\\xa0diagnosed\\xa0by\\xa0gastric\\xa0or\\xa0duodenalbiopsies\\xa0include\\xa0ischemia,\\xa0Crohn’s\\xa0disease,\\xa0amyloidosis,\\xa0sarcoidosis,\\xa0lymphoma,\\xa0eosinophilic\\xa0gastroenteritis,\\xa0smoking\\xa0crack\\xa0cocaine,\\xa0or\\xa0infection(cytomegalovirus\\xa0[CMV],\\xa0tuberculosis,\\xa0or\\xa0syphilis).Surgical\\xa0TherapySurgical\\xa0intervention\\xa0in\\xa0PUD\\xa0can\\xa0be\\xa0viewed\\xa0as\\xa0being\\xa0either\\xa0elective,\\xa0for\\xa0treatment\\xa0of\\xa0medically\\xa0refractory\\xa0disease,\\xa0or\\xa0as\\xa0urgent/emergent,\\xa0for\\xa0thetreatment\\xa0of\\xa0an\\xa0ulcer\\xadrelated\\xa0complication.\\xa0The\\xa0development\\xa0of\\xa0pharmacologic\\xa0and\\xa0endoscopic\\xa0approaches\\xa0for\\xa0the\\xa0treatment\\xa0of\\xa0peptic\\xa0disease\\xa0and\\xa0itscomplications\\xa0has\\xa0led\\xa0to\\xa0a\\xa0substantial\\xa0decrease\\xa0in\\xa0the\\xa0number\\xa0of\\xa0operations\\xa0needed\\xa0for\\xa0this\\xa0disorder\\xa0with\\xa0a\\xa0drop\\xa0of\\xa0>90%\\xa0for\\xa0elective\\xa0ulcer\\xa0surgeryover\\xa0the\\xa0past\\xa0four\\xa0decades.\\xa0Refractory\\xa0ulcers\\xa0are\\xa0an\\xa0exceedingly\\xa0rare\\xa0occurrence.\\xa0Surgery\\xa0is\\xa0more\\xa0often\\xa0required\\xa0for\\xa0treatment\\xa0of\\xa0an\\xa0ulcer\\xadrelatedcomplication.Hemorrhage\\xa0is\\xa0the\\xa0most\\xa0common\\xa0ulcer\\xadrelated\\xa0complication,\\xa0occurring\\xa0in\\xa0~15–25%\\xa0of\\xa0patients.\\xa0Bleeding\\xa0may\\xa0occur\\xa0in\\xa0any\\xa0age\\xa0group\\xa0but\\xa0is\\xa0most\\xa0oftenseen\\xa0in\\xa0older\\xa0patients\\xa0(sixth\\xa0decade\\xa0or\\xa0beyond).\\xa0The\\xa0majority\\xa0of\\xa0patients\\xa0stop\\xa0bleeding\\xa0spontaneously,\\xa0but\\xa0endoscopic\\xa0therapy\\xa0(Chap.\\xa0322)\\xa0isnecessary\\xa0in\\xa0some.\\xa0Parenterally\\xa0and\\xa0orally\\xa0administered\\xa0PPIs\\xa0also\\xa0decrease\\xa0ulcer\\xa0rebleeding\\xa0in\\xa0patients\\xa0who\\xa0have\\xa0undergone\\xa0endoscopic\\xa0therapy.Patients\\xa0unresponsive\\xa0or\\xa0refractory\\xa0to\\xa0endoscopic\\xa0intervention\\xa0will\\xa0require\\xa0angiographic\\xa0intervention\\xa0or\\xa0surgery\\xa0(~5%\\xa0of\\xa0transfusion\\xadrequiringpatients).Free\\xa0peritoneal\\xa0perforation\\xa0occurs\\xa0in\\xa0~2–3%\\xa0of\\xa0DU\\xa0patients,\\xa0with\\xa0NSAID\\xadinduced\\xa0GU\\xa0perforations\\xa0occurring\\xa0more\\xa0commonly.\\xa0Sudden\\xa0onset\\xa0of\\xa0severeabdominal\\xa0pain\\xa0with\\xa0peritoneal\\xa0signs\\xa0and\\xa0evidence\\xa0of\\xa0pneumoperitoneum\\xa0on\\xa0abdominal\\xa0imaging\\xa0is\\xa0the\\xa0classic\\xa0presentation\\xa0of\\xa0a\\xa0perforated\\xa0viscous,',\n",
       " 'abdominal\\xa0pain\\xa0with\\xa0peritoneal\\xa0signs\\xa0and\\xa0evidence\\xa0of\\xa0pneumoperitoneum\\xa0on\\xa0abdominal\\xa0imaging\\xa0is\\xa0the\\xa0classic\\xa0presentation\\xa0of\\xa0a\\xa0perforated\\xa0viscous,but\\xa0this\\xa0presentation\\xa0occurs\\xa0in\\xa0only\\xa0two\\xadthirds\\xa0of\\xa0patients.\\xa0The\\xa0latter\\xa0is\\xa0especially\\xa0true\\xa0in\\xa0elderly\\xa0patients\\xa0(>70\\xa0years\\xa0old),\\xa0obese\\xa0individuals,\\xa0andimmunocompromised\\xa0patients.\\xa0It\\xa0is\\xa0important\\xa0to\\xa0keep\\xa0in\\xa0mind\\xa0that,\\xa0as\\xa0in\\xa0the\\xa0case\\xa0of\\xa0bleeding,\\xa0up\\xa0to\\xa010%\\xa0of\\xa0these\\xa0patients\\xa0will\\xa0not\\xa0have\\xa0antecedentulcer\\xa0symptoms.\\xa0Delay\\xa0in\\xa0diagnosis\\xa0clearly\\xa0leads\\xa0to\\xa0higher\\xa0mortality;\\xa0thus,\\xa0early\\xa0suspicion\\xa0and\\xa0intervention\\xa0with\\xa0nasogastric\\xa0suction,\\xa0intravenous\\xa0PPI,antibiotics\\xa0and\\xa0surgical\\xa0consultation\\xa0are\\xa0essential.\\xa0Concomitant\\xa0bleeding\\xa0may\\xa0occur\\xa0in\\xa0up\\xa0to\\xa010%\\xa0of\\xa0patients\\xa0with\\xa0perforation,\\xa0with\\xa0mortality\\xa0beingincreased\\xa0substantially.\\xa0Peptic\\xa0ulcer\\xa0can\\xa0also\\xa0penetrate\\xa0into\\xa0adjacent\\xa0organs,\\xa0especially\\xa0with\\xa0a\\xa0posterior\\xa0DU,\\xa0which\\xa0can\\xa0penetrate\\xa0into\\xa0the\\xa0pancreas,colon,\\xa0liver,\\xa0or\\xa0biliary\\xa0tree.Pyloric\\xa0channel\\xa0ulcers\\xa0or\\xa0DUs\\xa0can\\xa0lead\\xa0to\\xa0gastric\\xa0outlet\\xa0obstruction\\xa0in\\xa0~2–3%\\xa0of\\xa0patients.\\xa0This\\xa0can\\xa0result\\xa0from\\xa0chronic\\xa0scarring\\xa0or\\xa0from\\xa0impaired\\xa0motilitydue\\xa0to\\xa0inflammation\\xa0and/or\\xa0edema\\xa0with\\xa0pylorospasm.\\xa0Patients\\xa0may\\xa0present\\xa0with\\xa0early\\xa0satiety,\\xa0nausea,\\xa0vomiting\\xa0of\\xa0undigested\\xa0food,\\xa0and\\xa0weight\\xa0loss.Conservative\\xa0management\\xa0with\\xa0nasogastric\\xa0suction,\\xa0intravenous\\xa0hydration/nutrition,\\xa0and\\xa0antisecretory\\xa0agents\\xa0is\\xa0indicated\\xa0for\\xa07–10\\xa0days\\xa0with\\xa0the\\xa0hopethat\\xa0a\\xa0functional\\xa0obstruction\\xa0will\\xa0reverse.\\xa0If\\xa0a\\xa0mechanical\\xa0obstruction\\xa0persists,\\xa0endoscopic\\xa0intervention\\xa0with\\xa0balloon\\xa0dilation\\xa0may\\xa0be\\xa0effective.\\xa0Surgeryshould\\xa0be\\xa0considered\\xa0if\\xa0all\\xa0else\\xa0fails.Specific\\xa0Operations\\xa0for\\xa0Duodenal\\xa0UlcersSurgical\\xa0treatment\\xa0was\\xa0originally\\xa0designed\\xa0to\\xa0decrease\\xa0gastric\\xa0acid\\xa0secretion.\\xa0Operations\\xa0most\\xa0commonly\\xa0performed\\xa0include\\xa0(1)\\xa0vagotomy\\xa0anddrainage\\xa0(by\\xa0pyloroplasty,\\xa0gastroduodenostomy,\\xa0or\\xa0gastrojejunostomy),\\xa0(2)\\xa0highly\\xa0selective\\xa0vagotomy\\xa0(which\\xa0does\\xa0not\\xa0require\\xa0a\\xa0drainage\\xa0procedure),',\n",
       " \"drainage\\xa0(by\\xa0pyloroplasty,\\xa0gastroduodenostomy,\\xa0or\\xa0gastrojejunostomy),\\xa0(2)\\xa0highly\\xa0selective\\xa0vagotomy\\xa0(which\\xa0does\\xa0not\\xa0require\\xa0a\\xa0drainage\\xa0procedure),and\\xa0(3)\\xa0vagotomy\\xa0with\\xa0antrectomy.\\xa0The\\xa0specific\\xa0procedure\\xa0performed\\xa0is\\xa0dictated\\xa0by\\xa0the\\xa0underlying\\xa0circumstances:\\xa0elective\\xa0versus\\xa0emergency,\\xa0thedegree\\xa0and\\xa0extent\\xa0of\\xa0duodenal\\xa0ulceration,\\xa0the\\xa0etiology\\xa0of\\xa0the\\xa0ulcer\\xa0(H.\\xa0pylori,\\xa0NSAIDs,\\xa0malignancy),\\xa0and\\xa0the\\xa0expertise\\xa0of\\xa0the\\xa0surgeon.\\xa0Moreover,\\xa0thetrend\\xa0has\\xa0been\\xa0toward\\xa0a\\xa0dramatic\\xa0decrease\\xa0in\\xa0the\\xa0need\\xa0for\\xa0surgery\\xa0for\\xa0treatment\\xa0of\\xa0refractory\\xa0PUD,\\xa0and\\xa0when\\xa0needed,\\xa0minimally\\xa0invasive\\xa0andanatomy\\xadpreserving\\xa0operations\\xa0are\\xa0preferred.Vagotomy\\xa0is\\xa0a\\xa0component\\xa0of\\xa0each\\xa0of\\xa0these\\xa0procedures\\xa0and\\xa0is\\xa0aimed\\xa0at\\xa0decreasing\\xa0acid\\xa0secretion\\xa0through\\xa0ablating\\xa0cholinergic\\xa0input\\xa0to\\xa0the\\xa0stomach.Unfortunately,\\xa0both\\xa0truncal\\xa0and\\xa0selective\\xa0vagotomy\\xa0(preserves\\xa0the\\xa0celiac\\xa0and\\xa0hepatic\\xa0branches)\\xa0result\\xa0in\\xa0gastric\\xa0atony\\xa0despite\\xa0successful\\xa0reduction\\xa0ofboth\\xa0basal\\xa0acid\\xa0output\\xa0(BAO;\\xa0decreased\\xa0by\\xa085%)\\xa0and\\xa0maximal\\xa0acid\\xa0output\\xa0(MAO;\\xa0decreased\\xa0by\\xa050%).\\xa0Drainage\\xa0through\\xa0pyloroplasty\\xa0orgastroduodenostomy\\xa0is\\xa0required\\xa0in\\xa0an\\xa0effort\\xa0to\\xa0compensate\\xa0for\\xa0the\\xa0vagotomy\\xadinduced\\xa0gastric\\xa0motility\\xa0disorder.\\xa0This\\xa0procedure\\xa0has\\xa0an\\xa0intermediateYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 32 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist\",\n",
       " \">40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'Surgical\\xa0treatment\\xa0was\\xa0originally\\xa0designed\\xa0to\\xa0decrease\\xa0gastric\\xa0acid\\xa0secretion.\\xa0Operations\\xa0most\\xa0commonly\\xa0performed\\xa0include\\xa0(1)\\xa0vagotomy\\xa0anddrainage\\xa0(by\\xa0pyloroplasty,\\xa0gastroduodenostomy,\\xa0or\\xa0gastrojejunostomy),\\xa0(2)\\xa0highly\\xa0selective\\xa0vagotomy\\xa0(which\\xa0does\\xa0not\\xa0require\\xa0a\\xa0drainage\\xa0procedure),and\\xa0(3)\\xa0vagotomy\\xa0with\\xa0antrectomy.\\xa0The\\xa0specific\\xa0procedure\\xa0performed\\xa0is\\xa0dictated\\xa0by\\xa0the\\xa0underlying\\xa0circumstances:\\xa0elective\\xa0versus\\xa0emergency,\\xa0thedegree\\xa0and\\xa0extent\\xa0of\\xa0duodenal\\xa0ulceration,\\xa0the\\xa0etiology\\xa0of\\xa0the\\xa0ulcer\\xa0(H.\\xa0pylori,\\xa0NSAIDs,\\xa0malignancy),\\xa0and\\xa0the\\xa0expertise\\xa0of\\xa0the\\xa0surgeon.\\xa0Moreover,\\xa0thetrend\\xa0has\\xa0been\\xa0toward\\xa0a\\xa0dramatic\\xa0decrease\\xa0in\\xa0the\\xa0need\\xa0for\\xa0surgery\\xa0for\\xa0treatment\\xa0of\\xa0refractory\\xa0PUD,\\xa0and\\xa0when\\xa0needed,\\xa0minimally\\xa0invasive\\xa0andanatomy\\xadpreserving\\xa0operations\\xa0are\\xa0preferred.Vagotomy\\xa0is\\xa0a\\xa0component\\xa0of\\xa0each\\xa0of\\xa0these\\xa0procedures\\xa0and\\xa0is\\xa0aimed\\xa0at\\xa0decreasing\\xa0acid\\xa0secretion\\xa0through\\xa0ablating\\xa0cholinergic\\xa0input\\xa0to\\xa0the\\xa0stomach.Unfortunately,\\xa0both\\xa0truncal\\xa0and\\xa0selective\\xa0vagotomy\\xa0(preserves\\xa0the\\xa0celiac\\xa0and\\xa0hepatic\\xa0branches)\\xa0result\\xa0in\\xa0gastric\\xa0atony\\xa0despite\\xa0successful\\xa0reduction\\xa0ofboth\\xa0basal\\xa0acid\\xa0output\\xa0(BAO;\\xa0decreased\\xa0by\\xa085%)\\xa0and\\xa0maximal\\xa0acid\\xa0output\\xa0(MAO;\\xa0decreased\\xa0by\\xa050%).\\xa0Drainage\\xa0through\\xa0pyloroplasty\\xa0orgastroduodenostomy\\xa0is\\xa0required\\xa0in\\xa0an\\xa0effort\\xa0to\\xa0compensate\\xa0for\\xa0the\\xa0vagotomy\\xadinduced\\xa0gastric\\xa0motility\\xa0disorder.\\xa0This\\xa0procedure\\xa0has\\xa0an\\xa0intermediatecomplication\\xa0rate\\xa0and\\xa0a\\xa010%\\xa0ulcer\\xa0recurrence\\xa0rate.\\xa0To\\xa0minimize\\xa0gastric\\xa0dysmotility,\\xa0highly\\xa0selective\\xa0vagotomy\\xa0(also\\xa0known\\xa0as\\xa0parietal\\xa0cell,\\xa0super\\xadselective,\\xa0or\\xa0proximal\\xa0vagotomy)\\xa0was\\xa0developed.\\xa0Only\\xa0the\\xa0vagal\\xa0fibers\\xa0innervating\\xa0the\\xa0portion\\xa0of\\xa0the\\xa0stomach\\xa0that\\xa0contains\\xa0parietal\\xa0cells\\xa0are\\xa0transected,thus\\xa0leaving\\xa0fibers\\xa0important\\xa0for\\xa0regulating\\xa0gastric\\xa0motility\\xa0intact.\\xa0Although\\xa0this\\xa0procedure\\xa0leads\\xa0to\\xa0an\\xa0immediate\\xa0decrease\\xa0in\\xa0both\\xa0BAO\\xa0and\\xa0stimulatedacid\\xa0output,\\xa0acid\\xa0secretion\\xa0recovers\\xa0over\\xa0time.\\xa0By\\xa0the\\xa0end\\xa0of\\xa0the\\xa0first\\xa0postoperative\\xa0year,\\xa0basal\\xa0and\\xa0stimulated\\xa0acid\\xa0output\\xa0are\\xa0~30\\xa0and\\xa050%,',\n",
       " \"acid\\xa0output,\\xa0acid\\xa0secretion\\xa0recovers\\xa0over\\xa0time.\\xa0By\\xa0the\\xa0end\\xa0of\\xa0the\\xa0first\\xa0postoperative\\xa0year,\\xa0basal\\xa0and\\xa0stimulated\\xa0acid\\xa0output\\xa0are\\xa0~30\\xa0and\\xa050%,respectively,\\xa0of\\xa0preoperative\\xa0levels.\\xa0Ulcer\\xa0recurrence\\xa0rates\\xa0are\\xa0higher\\xa0with\\xa0highly\\xa0selective\\xa0vagotomy\\xa0(≥10%),\\xa0although\\xa0the\\xa0overall\\xa0complication\\xa0ratesare\\xa0the\\xa0lowest\\xa0of\\xa0the\\xa0three\\xa0procedures.The\\xa0procedure\\xa0that\\xa0provides\\xa0the\\xa0lowest\\xa0rates\\xa0of\\xa0ulcer\\xa0recurrence\\xa0(1%)\\xa0but\\xa0has\\xa0the\\xa0highest\\xa0complication\\xa0rate\\xa0is\\xa0vagotomy\\xa0(truncal\\xa0or\\xa0selective)\\xa0incombination\\xa0with\\xa0antrectomy.\\xa0Antrectomy\\xa0is\\xa0aimed\\xa0at\\xa0eliminating\\xa0an\\xa0additional\\xa0stimulant\\xa0of\\xa0gastric\\xa0acid\\xa0secretion,\\xa0gastrin.\\xa0Two\\xa0principal\\xa0types\\xa0ofreanastomoses\\xa0are\\xa0used\\xa0after\\xa0antrectomy:\\xa0gastroduodenostomy\\xa0(Billroth\\xa0I)\\xa0or\\xa0gastrojejunostomy\\xa0(Billroth\\xa0II)\\xa0(Fig.\\xa0324\\xad15).\\xa0Although\\xa0Billroth\\xa0I\\xa0is\\xa0oftenpreferred\\xa0over\\xa0II,\\xa0severe\\xa0duodenal\\xa0inflammation\\xa0or\\xa0scarring\\xa0may\\xa0preclude\\xa0its\\xa0performance.\\xa0Prospective,\\xa0randomized\\xa0studies\\xa0confirm\\xa0that\\xa0partialgastrectomy\\xa0followed\\xa0by\\xa0Roux\\xaden\\xadY\\xa0reconstruction\\xa0leads\\xa0to\\xa0a\\xa0significantly\\xa0better\\xa0clinical,\\xa0endoscopic,\\xa0and\\xa0histologic\\xa0outcome\\xa0than\\xa0Billroth\\xa0IIreconstruction.FIGURE\\xa0324\\xad15Schematic\\xa0representation\\xa0of\\xa0Billroth\\xa0I\\xa0and\\xa0II\\xa0procedures.Of\\xa0these\\xa0procedures,\\xa0highly\\xa0selective\\xa0vagotomy\\xa0may\\xa0be\\xa0the\\xa0procedure\\xa0of\\xa0choice\\xa0in\\xa0the\\xa0elective\\xa0setting,\\xa0except\\xa0in\\xa0situations\\xa0where\\xa0ulcer\\xa0recurrence\\xa0ratesare\\xa0high\\xa0(prepyloric\\xa0ulcers\\xa0and\\xa0those\\xa0refractory\\xa0to\\xa0medical\\xa0therapy).\\xa0Selection\\xa0of\\xa0vagotomy\\xa0and\\xa0antrectomy\\xa0may\\xa0be\\xa0more\\xa0appropriate\\xa0in\\xa0thesecircumstances.Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 33 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21e\",\n",
       " \"Page 33 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'reconstruction.FIGURE\\xa0324\\xad15Schematic\\xa0representation\\xa0of\\xa0Billroth\\xa0I\\xa0and\\xa0II\\xa0procedures.Of\\xa0these\\xa0procedures,\\xa0highly\\xa0selective\\xa0vagotomy\\xa0may\\xa0be\\xa0the\\xa0procedure\\xa0of\\xa0choice\\xa0in\\xa0the\\xa0elective\\xa0setting,\\xa0except\\xa0in\\xa0situations\\xa0where\\xa0ulcer\\xa0recurrence\\xa0ratesare\\xa0high\\xa0(prepyloric\\xa0ulcers\\xa0and\\xa0those\\xa0refractory\\xa0to\\xa0medical\\xa0therapy).\\xa0Selection\\xa0of\\xa0vagotomy\\xa0and\\xa0antrectomy\\xa0may\\xa0be\\xa0more\\xa0appropriate\\xa0in\\xa0thesecircumstances.These\\xa0procedures\\xa0have\\xa0been\\xa0traditionally\\xa0performed\\xa0by\\xa0standard\\xa0laparotomy.\\xa0The\\xa0advent\\xa0of\\xa0laparoscopic\\xa0surgery\\xa0has\\xa0led\\xa0several\\xa0surgical\\xa0teams\\xa0tosuccessfully\\xa0perform\\xa0highly\\xa0selective\\xa0vagotomy,\\xa0truncal\\xa0vagotomy/pyloroplasty,\\xa0and\\xa0truncal\\xa0vagotomy/antrectomy\\xa0through\\xa0this\\xa0approach.\\xa0An\\xa0increasein\\xa0the\\xa0number\\xa0of\\xa0laparoscopic\\xa0procedures\\xa0for\\xa0treatment\\xa0of\\xa0PUD\\xa0has\\xa0occurred.\\xa0Laparoscopic\\xa0repair\\xa0of\\xa0perforated\\xa0peptic\\xa0ulcers\\xa0is\\xa0safe,\\xa0feasible\\xa0for\\xa0theexperienced\\xa0surgeon,\\xa0and\\xa0associated\\xa0with\\xa0decreased\\xa0postoperative\\xa0pain,\\xa0although\\xa0it\\xa0does\\xa0take\\xa0longer\\xa0than\\xa0an\\xa0open\\xa0approach.\\xa0Moreover,\\xa0nodifference\\xa0between\\xa0the\\xa0two\\xa0approaches\\xa0is\\xa0noted\\xa0in\\xa0postoperative\\xa0complications\\xa0or\\xa0length\\xa0of\\xa0hospital\\xa0stay.Specific\\xa0Operations\\xa0for\\xa0GUsThe\\xa0location\\xa0and\\xa0presence\\xa0of\\xa0a\\xa0concomitant\\xa0DU\\xa0dictate\\xa0the\\xa0operative\\xa0procedure\\xa0performed\\xa0for\\xa0a\\xa0GU.\\xa0Antrectomy\\xa0(including\\xa0the\\xa0ulcer)\\xa0with\\xa0a\\xa0Billroth\\xa0Ianastomosis\\xa0is\\xa0the\\xa0treatment\\xa0of\\xa0choice\\xa0for\\xa0an\\xa0antral\\xa0ulcer.\\xa0Vagotomy\\xa0is\\xa0performed\\xa0only\\xa0if\\xa0a\\xa0DU\\xa0is\\xa0present.\\xa0Although\\xa0ulcer\\xa0excision\\xa0with\\xa0vagotomy\\xa0anddrainage\\xa0procedure\\xa0has\\xa0been\\xa0proposed,\\xa0the\\xa0higher\\xa0incidence\\xa0of\\xa0ulcer\\xa0recurrence\\xa0makes\\xa0this\\xa0a\\xa0less\\xa0desirable\\xa0approach.\\xa0Ulcers\\xa0located\\xa0near\\xa0theesophagogastric\\xa0junction\\xa0may\\xa0require\\xa0a\\xa0more\\xa0radical\\xa0approach,\\xa0a\\xa0subtotal\\xa0gastrectomy\\xa0with\\xa0a\\xa0Roux\\xaden\\xadY\\xa0esophagogastrojejunostomy\\xa0(Csendes’procedure).\\xa0A\\xa0less\\xa0aggressive\\xa0approach,\\xa0including\\xa0antrectomy,\\xa0intraoperative\\xa0ulcer\\xa0biopsy,\\xa0and\\xa0vagotomy\\xa0(Kelling\\xadMadlener\\xa0procedure),\\xa0may\\xa0beindicated\\xa0in\\xa0fragile\\xa0patients\\xa0with\\xa0a\\xa0high\\xa0GU.\\xa0Ulcer\\xa0recurrence\\xa0approaches\\xa030%\\xa0with\\xa0this\\xa0procedure.Surgery\\xadRelated\\xa0Complications',\n",
       " \"indicated\\xa0in\\xa0fragile\\xa0patients\\xa0with\\xa0a\\xa0high\\xa0GU.\\xa0Ulcer\\xa0recurrence\\xa0approaches\\xa030%\\xa0with\\xa0this\\xa0procedure.Surgery\\xadRelated\\xa0ComplicationsComplications\\xa0seen\\xa0after\\xa0surgery\\xa0for\\xa0PUD\\xa0are\\xa0related\\xa0primarily\\xa0to\\xa0the\\xa0extent\\xa0of\\xa0the\\xa0anatomic\\xa0modification\\xa0performed.\\xa0Minimal\\xa0alteration\\xa0(highlyselective\\xa0vagotomy)\\xa0is\\xa0associated\\xa0with\\xa0higher\\xa0rates\\xa0of\\xa0ulcer\\xa0recurrence\\xa0and\\xa0less\\xa0GI\\xa0disturbance.\\xa0More\\xa0aggressive\\xa0surgical\\xa0procedures\\xa0have\\xa0a\\xa0lower\\xa0rateof\\xa0ulcer\\xa0recurrence\\xa0but\\xa0a\\xa0greater\\xa0incidence\\xa0of\\xa0GI\\xa0dysfunction.\\xa0Overall,\\xa0morbidity\\xa0and\\xa0mortality\\xa0related\\xa0to\\xa0these\\xa0procedures\\xa0are\\xa0quite\\xa0low.\\xa0Morbidityassociated\\xa0with\\xa0vagotomy\\xa0and\\xa0antrectomy\\xa0or\\xa0pyloroplasty\\xa0is\\xa0≤5%,\\xa0with\\xa0mortality\\xa0~1%.\\xa0Highly\\xa0selective\\xa0vagotomy\\xa0has\\xa0lower\\xa0morbidity\\xa0and\\xa0mortalityrates\\xa0of\\xa01\\xa0and\\xa00.3%,\\xa0respectively.Idditit thtti llfi tbdild(bldii ftithbb li)tiddlYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 34 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'p)ggpp,gy,pp y,gy (gp),yindicated\\xa0in\\xa0fragile\\xa0patients\\xa0with\\xa0a\\xa0high\\xa0GU.\\xa0Ulcer\\xa0recurrence\\xa0approaches\\xa030%\\xa0with\\xa0this\\xa0procedure.Surgery\\xadRelated\\xa0ComplicationsComplications\\xa0seen\\xa0after\\xa0surgery\\xa0for\\xa0PUD\\xa0are\\xa0related\\xa0primarily\\xa0to\\xa0the\\xa0extent\\xa0of\\xa0the\\xa0anatomic\\xa0modification\\xa0performed.\\xa0Minimal\\xa0alteration\\xa0(highlyselective\\xa0vagotomy)\\xa0is\\xa0associated\\xa0with\\xa0higher\\xa0rates\\xa0of\\xa0ulcer\\xa0recurrence\\xa0and\\xa0less\\xa0GI\\xa0disturbance.\\xa0More\\xa0aggressive\\xa0surgical\\xa0procedures\\xa0have\\xa0a\\xa0lower\\xa0rateof\\xa0ulcer\\xa0recurrence\\xa0but\\xa0a\\xa0greater\\xa0incidence\\xa0of\\xa0GI\\xa0dysfunction.\\xa0Overall,\\xa0morbidity\\xa0and\\xa0mortality\\xa0related\\xa0to\\xa0these\\xa0procedures\\xa0are\\xa0quite\\xa0low.\\xa0Morbidityassociated\\xa0with\\xa0vagotomy\\xa0and\\xa0antrectomy\\xa0or\\xa0pyloroplasty\\xa0is\\xa0≤5%,\\xa0with\\xa0mortality\\xa0~1%.\\xa0Highly\\xa0selective\\xa0vagotomy\\xa0has\\xa0lower\\xa0morbidity\\xa0and\\xa0mortalityrates\\xa0of\\xa01\\xa0and\\xa00.3%,\\xa0respectively.In\\xa0addition\\xa0to\\xa0the\\xa0potential\\xa0early\\xa0consequences\\xa0of\\xa0any\\xa0intraabdominal\\xa0procedure\\xa0(bleeding,\\xa0infection,\\xa0thromboembolism),\\xa0gastroparesis,\\xa0duodenalstump\\xa0leak,\\xa0and\\xa0efferent\\xa0loop\\xa0obstruction\\xa0can\\xa0be\\xa0observed.Recurrent\\xa0UlcerationThe\\xa0risk\\xa0of\\xa0ulcer\\xa0recurrence\\xa0is\\xa0directly\\xa0related\\xa0to\\xa0the\\xa0procedure\\xa0performed.\\xa0Ulcers\\xa0that\\xa0recur\\xa0after\\xa0partial\\xa0gastric\\xa0resection\\xa0tend\\xa0to\\xa0develop\\xa0at\\xa0theanastomosis\\xa0(stomal\\xa0or\\xa0marginal\\xa0ulcer).\\xa0Epigastric\\xa0abdominal\\xa0pain\\xa0is\\xa0the\\xa0most\\xa0frequent\\xa0presenting\\xa0complaint\\xa0(>90%).\\xa0Severity\\xa0and\\xa0duration\\xa0of\\xa0paintend\\xa0to\\xa0be\\xa0more\\xa0progressive\\xa0than\\xa0observed\\xa0with\\xa0DUs\\xa0before\\xa0surgery.Ulcers\\xa0may\\xa0recur\\xa0for\\xa0several\\xa0reasons,\\xa0including\\xa0incomplete\\xa0vagotomy,\\xa0inadequate\\xa0drainage,\\xa0retained\\xa0antrum,\\xa0and,\\xa0less\\xa0likely,\\xa0persistent\\xa0or\\xa0recurrent\\xa0H.pylori\\xa0infection.\\xa0ZES\\xa0should\\xa0have\\xa0been\\xa0excluded\\xa0preoperatively.\\xa0Surreptitious\\xa0use\\xa0of\\xa0NSAIDs\\xa0is\\xa0an\\xa0important\\xa0reason\\xa0for\\xa0recurrent\\xa0ulcers\\xa0after\\xa0surgery,especially\\xa0if\\xa0the\\xa0initial\\xa0procedure\\xa0was\\xa0done\\xa0for\\xa0an\\xa0NSAID\\xadinduced\\xa0ulcer.\\xa0Once\\xa0H.\\xa0pylori\\xa0and\\xa0NSAIDs\\xa0have\\xa0been\\xa0excluded\\xa0as\\xa0etiologic\\xa0factors,\\xa0thequestion\\xa0of\\xa0incomplete\\xa0vagotomy\\xa0or\\xa0retained\\xa0gastric\\xa0antrum\\xa0should\\xa0be\\xa0explored.\\xa0For\\xa0the\\xa0latter,\\xa0fasting\\xa0plasma\\xa0gastrin\\xa0levels\\xa0should\\xa0be\\xa0determined.\\xa0If',\n",
       " 'question\\xa0of\\xa0incomplete\\xa0vagotomy\\xa0or\\xa0retained\\xa0gastric\\xa0antrum\\xa0should\\xa0be\\xa0explored.\\xa0For\\xa0the\\xa0latter,\\xa0fasting\\xa0plasma\\xa0gastrin\\xa0levels\\xa0should\\xa0be\\xa0determined.\\xa0Ifelevated,\\xa0retained\\xa0antrum\\xa0or\\xa0ZES\\xa0(see\\xa0below)\\xa0should\\xa0be\\xa0considered.\\xa0Incomplete\\xa0vagotomy\\xa0can\\xa0be\\xa0ruled\\xa0out\\xa0by\\xa0gastric\\xa0acid\\xa0analysis\\xa0coupled\\xa0with\\xa0shamfeeding.\\xa0In\\xa0this\\xa0test,\\xa0gastric\\xa0acid\\xa0output\\xa0is\\xa0measured\\xa0while\\xa0the\\xa0patient\\xa0sees,\\xa0smells,\\xa0and\\xa0chews\\xa0a\\xa0meal\\xa0(without\\xa0swallowing).\\xa0The\\xa0cephalic\\xa0phase\\xa0ofgastric\\xa0secretion,\\xa0which\\xa0is\\xa0mediated\\xa0by\\xa0the\\xa0vagus,\\xa0is\\xa0being\\xa0assessed\\xa0with\\xa0this\\xa0study.\\xa0An\\xa0increase\\xa0in\\xa0gastric\\xa0acid\\xa0output\\xa0in\\xa0response\\xa0to\\xa0sham\\xa0feeding\\xa0isevidence\\xa0that\\xa0the\\xa0vagus\\xa0nerve\\xa0is\\xa0intact.\\xa0A\\xa0rise\\xa0in\\xa0serum\\xa0pancreatic\\xa0polypeptide\\xa0>50%\\xa0within\\xa030\\xa0min\\xa0of\\xa0sham\\xa0feeding\\xa0is\\xa0also\\xa0suggestive\\xa0of\\xa0an\\xa0intact\\xa0vagusnerve.Medical\\xa0therapy\\xa0with\\xa0H2\\xa0blockers\\xa0will\\xa0heal\\xa0postoperative\\xa0ulceration\\xa0in\\xa070–90%\\xa0of\\xa0patients.\\xa0The\\xa0efficacy\\xa0of\\xa0PPIs\\xa0has\\xa0not\\xa0been\\xa0fully\\xa0assessed\\xa0in\\xa0this\\xa0group,but\\xa0one\\xa0may\\xa0anticipate\\xa0greater\\xa0rates\\xa0of\\xa0ulcer\\xa0healing\\xa0compared\\xa0to\\xa0those\\xa0obtained\\xa0with\\xa0H2\\xa0blockers.\\xa0Repeat\\xa0operation\\xa0(complete\\xa0vagotomy,\\xa0partialgastrectomy)\\xa0may\\xa0be\\xa0required\\xa0in\\xa0a\\xa0small\\xa0subgroup\\xa0of\\xa0patients\\xa0who\\xa0have\\xa0not\\xa0responded\\xa0to\\xa0aggressive\\xa0medical\\xa0management.Afferent\\xa0Loop\\xa0SyndromesAlthough\\xa0rarely\\xa0seen\\xa0today\\xa0as\\xa0a\\xa0result\\xa0of\\xa0the\\xa0decrease\\xa0in\\xa0the\\xa0performance\\xa0of\\xa0Billroth\\xa0II\\xa0anastomosis,\\xa0two\\xa0types\\xa0of\\xa0afferent\\xa0loop\\xa0syndrome\\xa0can\\xa0occur\\xa0inpatients\\xa0who\\xa0have\\xa0undergone\\xa0this\\xa0type\\xa0of\\xa0partial\\xa0gastric\\xa0resection.\\xa0The\\xa0more\\xa0common\\xa0of\\xa0the\\xa0two\\xa0is\\xa0bacterial\\xa0overgrowth\\xa0in\\xa0the\\xa0afferent\\xa0limb\\xa0secondaryto\\xa0stasis.\\xa0Patients\\xa0may\\xa0experience\\xa0postprandial\\xa0abdominal\\xa0pain,\\xa0bloating,\\xa0and\\xa0diarrhea\\xa0with\\xa0concomitant\\xa0malabsorption\\xa0of\\xa0fats\\xa0and\\xa0vitamin\\xa0B12.\\xa0Casesrefractory\\xa0to\\xa0antibiotics\\xa0may\\xa0require\\xa0surgical\\xa0revision\\xa0of\\xa0the\\xa0loop.\\xa0The\\xa0less\\xa0common\\xa0afferent\\xa0loop\\xa0syndrome\\xa0can\\xa0present\\xa0with\\xa0severe\\xa0abdominal\\xa0painand\\xa0bloating\\xa0that\\xa0occur\\xa020–60\\xa0min\\xa0after\\xa0meals.\\xa0Pain\\xa0is\\xa0often\\xa0followed\\xa0by\\xa0nausea\\xa0and\\xa0vomiting\\xa0of\\xa0bile\\xadcontaining\\xa0material.\\xa0The\\xa0pain\\xa0and\\xa0bloating\\xa0may',\n",
       " 'and\\xa0bloating\\xa0that\\xa0occur\\xa020–60\\xa0min\\xa0after\\xa0meals.\\xa0Pain\\xa0is\\xa0often\\xa0followed\\xa0by\\xa0nausea\\xa0and\\xa0vomiting\\xa0of\\xa0bile\\xadcontaining\\xa0material.\\xa0The\\xa0pain\\xa0and\\xa0bloating\\xa0mayimprove\\xa0after\\xa0emesis.\\xa0The\\xa0cause\\xa0of\\xa0this\\xa0clinical\\xa0picture\\xa0is\\xa0theorized\\xa0to\\xa0be\\xa0incomplete\\xa0drainage\\xa0of\\xa0bile\\xa0and\\xa0pancreatic\\xa0secretions\\xa0from\\xa0an\\xa0afferent\\xa0loopthat\\xa0is\\xa0partially\\xa0obstructed.\\xa0Cases\\xa0refractory\\xa0to\\xa0dietary\\xa0measures\\xa0may\\xa0need\\xa0surgical\\xa0revision\\xa0or\\xa0conversion\\xa0of\\xa0the\\xa0Billroth\\xa0II\\xa0anastomosis\\xa0to\\xa0a\\xa0Roux\\xaden\\xadYgastrojejunostomy.Dumping\\xa0SyndromeDumping\\xa0syndrome\\xa0consists\\xa0of\\xa0a\\xa0series\\xa0of\\xa0vasomotor\\xa0and\\xa0GI\\xa0signs\\xa0and\\xa0symptoms\\xa0and\\xa0occurs\\xa0in\\xa0patients\\xa0who\\xa0have\\xa0undergone\\xa0vagotomy\\xa0and\\xa0drainage(especially\\xa0Billroth\\xa0procedures).\\xa0Two\\xa0phases\\xa0of\\xa0dumping,\\xa0early\\xa0and\\xa0late,\\xa0can\\xa0occur.\\xa0Early\\xa0dumping\\xa0takes\\xa0place\\xa015–30\\xa0min\\xa0after\\xa0meals\\xa0and\\xa0consists\\xa0ofcrampy\\xa0abdominal\\xa0discomfort,\\xa0nausea,\\xa0diarrhea,\\xa0belching,\\xa0tachycardia,\\xa0palpitations,\\xa0diaphoresis,\\xa0light\\xadheadedness,\\xa0and,\\xa0rarely,\\xa0syncope.\\xa0These\\xa0signsand\\xa0symptoms\\xa0arise\\xa0from\\xa0the\\xa0rapid\\xa0emptying\\xa0of\\xa0hyperosmolar\\xa0gastric\\xa0contents\\xa0into\\xa0the\\xa0small\\xa0intestine,\\xa0resulting\\xa0in\\xa0a\\xa0fluid\\xa0shift\\xa0into\\xa0the\\xa0gut\\xa0lumen\\xa0withplasma\\xa0volume\\xa0contraction\\xa0and\\xa0acute\\xa0intestinal\\xa0distention.\\xa0Release\\xa0of\\xa0vasoactive\\xa0GI\\xa0hormones\\xa0(vasoactive\\xa0intestinal\\xa0polypeptide,\\xa0neurotensin,\\xa0motilin)is\\xa0also\\xa0theorized\\xa0to\\xa0play\\xa0a\\xa0role\\xa0in\\xa0early\\xa0dumping.The\\xa0late\\xa0phase\\xa0of\\xa0dumping\\xa0typically\\xa0occurs\\xa090\\xa0min\\xa0to\\xa03\\xa0h\\xa0after\\xa0meals.\\xa0Vasomotor\\xa0symptoms\\xa0(light\\xadheadedness,\\xa0diaphoresis,\\xa0palpitations,\\xa0tachycardia,and\\xa0syncope)\\xa0predominate\\xa0during\\xa0this\\xa0phase.\\xa0This\\xa0component\\xa0of\\xa0dumping\\xa0is\\xa0thought\\xa0to\\xa0be\\xa0secondary\\xa0to\\xa0hypoglycemia\\xa0from\\xa0excessive\\xa0insulin\\xa0release.Dumping\\xa0syndrome\\xa0is\\xa0most\\xa0noticeable\\xa0after\\xa0meals\\xa0rich\\xa0in\\xa0simple\\xa0carbohydrates\\xa0(especially\\xa0sucrose)\\xa0and\\xa0high\\xa0osmolarity.\\xa0Ingestion\\xa0of\\xa0large\\xa0amounts\\xa0offluids\\xa0may\\xa0also\\xa0contribute.\\xa0After\\xa0vagotomy\\xa0and\\xa0drainage,\\xa0up\\xa0to\\xa050%\\xa0of\\xa0patients\\xa0will\\xa0experience\\xa0dumping\\xa0syndrome\\xa0to\\xa0some\\xa0degree\\xa0early\\xa0on.\\xa0Signs\\xa0andsymptoms\\xa0often\\xa0improve\\xa0with\\xa0time,\\xa0but\\xa0a\\xa0severe\\xa0protracted\\xa0picture\\xa0can\\xa0occur\\xa0in\\xa0up\\xa0to\\xa01%\\xa0of\\xa0patients.',\n",
       " \"symptoms\\xa0often\\xa0improve\\xa0with\\xa0time,\\xa0but\\xa0a\\xa0severe\\xa0protracted\\xa0picture\\xa0can\\xa0occur\\xa0in\\xa0up\\xa0to\\xa01%\\xa0of\\xa0patients.Dietary\\xa0modification\\xa0is\\xa0the\\xa0cornerstone\\xa0of\\xa0therapy\\xa0for\\xa0patients\\xa0with\\xa0dumping\\xa0syndrome.\\xa0Small,\\xa0multiple\\xa0(six)\\xa0meals\\xa0devoid\\xa0of\\xa0simple\\xa0carbohydratescoupled\\xa0with\\xa0elimination\\xa0of\\xa0liquids\\xa0during\\xa0meals\\xa0is\\xa0important.\\xa0Antidiarrheals\\xa0and\\xa0anticholinergic\\xa0agents\\xa0are\\xa0complementary\\xa0to\\xa0diet.\\xa0Guar\\xa0and\\xa0pectin,Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 35 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'plasma\\xa0volume\\xa0contraction\\xa0and\\xa0acute\\xa0intestinal\\xa0distention.\\xa0Release\\xa0of\\xa0vasoactive\\xa0GI\\xa0hormones\\xa0(vasoactive\\xa0intestinal\\xa0polypeptide,\\xa0neurotensin,\\xa0motilin)is\\xa0also\\xa0theorized\\xa0to\\xa0play\\xa0a\\xa0role\\xa0in\\xa0early\\xa0dumping.The\\xa0late\\xa0phase\\xa0of\\xa0dumping\\xa0typically\\xa0occurs\\xa090\\xa0min\\xa0to\\xa03\\xa0h\\xa0after\\xa0meals.\\xa0Vasomotor\\xa0symptoms\\xa0(light\\xadheadedness,\\xa0diaphoresis,\\xa0palpitations,\\xa0tachycardia,and\\xa0syncope)\\xa0predominate\\xa0during\\xa0this\\xa0phase.\\xa0This\\xa0component\\xa0of\\xa0dumping\\xa0is\\xa0thought\\xa0to\\xa0be\\xa0secondary\\xa0to\\xa0hypoglycemia\\xa0from\\xa0excessive\\xa0insulin\\xa0release.Dumping\\xa0syndrome\\xa0is\\xa0most\\xa0noticeable\\xa0after\\xa0meals\\xa0rich\\xa0in\\xa0simple\\xa0carbohydrates\\xa0(especially\\xa0sucrose)\\xa0and\\xa0high\\xa0osmolarity.\\xa0Ingestion\\xa0of\\xa0large\\xa0amounts\\xa0offluids\\xa0may\\xa0also\\xa0contribute.\\xa0After\\xa0vagotomy\\xa0and\\xa0drainage,\\xa0up\\xa0to\\xa050%\\xa0of\\xa0patients\\xa0will\\xa0experience\\xa0dumping\\xa0syndrome\\xa0to\\xa0some\\xa0degree\\xa0early\\xa0on.\\xa0Signs\\xa0andsymptoms\\xa0often\\xa0improve\\xa0with\\xa0time,\\xa0but\\xa0a\\xa0severe\\xa0protracted\\xa0picture\\xa0can\\xa0occur\\xa0in\\xa0up\\xa0to\\xa01%\\xa0of\\xa0patients.Dietary\\xa0modification\\xa0is\\xa0the\\xa0cornerstone\\xa0of\\xa0therapy\\xa0for\\xa0patients\\xa0with\\xa0dumping\\xa0syndrome.\\xa0Small,\\xa0multiple\\xa0(six)\\xa0meals\\xa0devoid\\xa0of\\xa0simple\\xa0carbohydratescoupled\\xa0with\\xa0elimination\\xa0of\\xa0liquids\\xa0during\\xa0meals\\xa0is\\xa0important.\\xa0Antidiarrheals\\xa0and\\xa0anticholinergic\\xa0agents\\xa0are\\xa0complementary\\xa0to\\xa0diet.\\xa0Guar\\xa0and\\xa0pectin,which\\xa0increase\\xa0the\\xa0viscosity\\xa0of\\xa0intraluminal\\xa0contents,\\xa0may\\xa0be\\xa0beneficial\\xa0in\\xa0more\\xa0symptomatic\\xa0individuals.\\xa0Acarbose,\\xa0an\\xa0α\\xadglucosidase\\xa0inhibitor\\xa0thatdelays\\xa0digestion\\xa0of\\xa0ingested\\xa0carbohydrates,\\xa0has\\xa0also\\xa0been\\xa0shown\\xa0to\\xa0be\\xa0beneficial\\xa0in\\xa0the\\xa0treatment\\xa0of\\xa0the\\xa0late\\xa0phases\\xa0of\\xa0dumping.\\xa0The\\xa0somatostatinanalogue\\xa0octreotide\\xa0has\\xa0been\\xa0successful\\xa0in\\xa0diet\\xadrefractory\\xa0cases.\\xa0This\\xa0drug\\xa0is\\xa0administered\\xa0subcutaneously\\xa0(50\\xa0μg\\xa0tid),\\xa0titrated\\xa0according\\xa0to\\xa0clinicalresponse.\\xa0A\\xa0long\\xadacting\\xa0depot\\xa0formulation\\xa0of\\xa0octreotide\\xa0can\\xa0be\\xa0administered\\xa0once\\xa0every\\xa028\\xa0days\\xa0and\\xa0provides\\xa0symptom\\xa0relief\\xa0comparable\\xa0to\\xa0the\\xa0short\\xadacting\\xa0agent.\\xa0In\\xa0addition,\\xa0patient\\xa0weight\\xa0gain\\xa0and\\xa0quality\\xa0of\\xa0life\\xa0appear\\xa0to\\xa0be\\xa0superior\\xa0with\\xa0the\\xa0long\\xadacting\\xa0form.Postvagotomy\\xa0Diarrhea',\n",
       " 'acting\\xa0agent.\\xa0In\\xa0addition,\\xa0patient\\xa0weight\\xa0gain\\xa0and\\xa0quality\\xa0of\\xa0life\\xa0appear\\xa0to\\xa0be\\xa0superior\\xa0with\\xa0the\\xa0long\\xadacting\\xa0form.Postvagotomy\\xa0DiarrheaUp\\xa0to\\xa010%\\xa0of\\xa0patients\\xa0may\\xa0seek\\xa0medical\\xa0attention\\xa0for\\xa0the\\xa0treatment\\xa0of\\xa0postvagotomy\\xa0diarrhea.\\xa0This\\xa0complication\\xa0is\\xa0most\\xa0commonly\\xa0observed\\xa0aftertruncal\\xa0vagotomy,\\xa0which\\xa0is\\xa0rarely\\xa0performed\\xa0today.\\xa0Patients\\xa0may\\xa0complain\\xa0of\\xa0intermittent\\xa0diarrhea\\xa0that\\xa0occurs\\xa0typically\\xa01–2\\xa0h\\xa0after\\xa0meals.\\xa0Occasionally,the\\xa0symptoms\\xa0may\\xa0be\\xa0severe\\xa0and\\xa0relentless.\\xa0This\\xa0is\\xa0due\\xa0to\\xa0a\\xa0motility\\xa0disorder\\xa0from\\xa0interruption\\xa0of\\xa0the\\xa0vagal\\xa0fibers\\xa0supplying\\xa0the\\xa0luminal\\xa0gut.\\xa0Othercontributing\\xa0factors\\xa0may\\xa0include\\xa0decreased\\xa0absorption\\xa0of\\xa0nutrients\\xa0(see\\xa0below),\\xa0increased\\xa0excretion\\xa0of\\xa0bile\\xa0acids,\\xa0and\\xa0release\\xa0of\\xa0luminal\\xa0factors\\xa0thatpromote\\xa0secretion.\\xa0Diphenoxylate\\xa0or\\xa0loperamide\\xa0is\\xa0often\\xa0useful\\xa0in\\xa0symptom\\xa0control.\\xa0The\\xa0bile\\xa0salt–binding\\xa0agent\\xa0cholestyramine\\xa0may\\xa0be\\xa0helpful\\xa0insevere\\xa0cases.\\xa0Surgical\\xa0reversal\\xa0of\\xa0a\\xa010\\xadcm\\xa0segment\\xa0of\\xa0jejunum\\xa0may\\xa0yield\\xa0a\\xa0substantial\\xa0improvement\\xa0in\\xa0bowel\\xa0frequency\\xa0in\\xa0a\\xa0subset\\xa0of\\xa0patients.Bile\\xa0Reflux\\xa0GastropathyA\\xa0subset\\xa0of\\xa0post–partial\\xa0gastrectomy\\xa0patients\\xa0who\\xa0present\\xa0with\\xa0abdominal\\xa0pain,\\xa0early\\xa0satiety,\\xa0nausea,\\xa0and\\xa0vomiting\\xa0will\\xa0have\\xa0mucosal\\xa0erythema\\xa0of\\xa0thegastric\\xa0remnant\\xa0as\\xa0the\\xa0only\\xa0finding.\\xa0Histologic\\xa0examination\\xa0of\\xa0the\\xa0gastric\\xa0mucosa\\xa0reveals\\xa0minimal\\xa0inflammation\\xa0but\\xa0the\\xa0presence\\xa0of\\xa0epithelial\\xa0cellinjury.\\xa0This\\xa0clinical\\xa0picture\\xa0is\\xa0categorized\\xa0as\\xa0bile\\xa0or\\xa0alkaline\\xa0reflux\\xa0gastropathy/gastritis.\\xa0Although\\xa0reflux\\xa0of\\xa0bile\\xa0is\\xa0implicated\\xa0as\\xa0the\\xa0reason\\xa0for\\xa0thisdisorder,\\xa0the\\xa0mechanism\\xa0is\\xa0unknown.\\xa0Prokinetic\\xa0agents,\\xa0cholestyramine,\\xa0and\\xa0sucralfate\\xa0have\\xa0been\\xa0somewhat\\xa0effective\\xa0treatments.\\xa0Severe\\xa0refractorysymptoms\\xa0may\\xa0require\\xa0using\\xa0either\\xa0nuclear\\xa0scanning\\xa0with\\xa099mTc\\xadHIDA\\xa0to\\xa0document\\xa0reflux.\\xa0Surgical\\xa0diversion\\xa0of\\xa0pancreaticobiliary\\xa0secretions\\xa0awayfrom\\xa0the\\xa0gastric\\xa0remnant\\xa0with\\xa0a\\xa0Roux\\xaden\\xadY\\xa0gastrojejunostomy\\xa0consisting\\xa0of\\xa0a\\xa0long\\xa0(50–60\\xa0cm)\\xa0Roux\\xa0limb\\xa0has\\xa0been\\xa0used\\xa0in\\xa0severe\\xa0cases.\\xa0Biliousvomiting\\xa0improves,\\xa0but\\xa0early\\xa0satiety\\xa0and\\xa0bloating\\xa0may\\xa0persist\\xa0in\\xa0up\\xa0to\\xa050%\\xa0of\\xa0patients.',\n",
       " 'vomiting\\xa0improves,\\xa0but\\xa0early\\xa0satiety\\xa0and\\xa0bloating\\xa0may\\xa0persist\\xa0in\\xa0up\\xa0to\\xa050%\\xa0of\\xa0patients.Maldigestion\\xa0and\\xa0MalabsorptionWeight\\xa0loss\\xa0can\\xa0be\\xa0observed\\xa0in\\xa0up\\xa0to\\xa060%\\xa0of\\xa0patients\\xa0after\\xa0partial\\xa0gastric\\xa0resection.\\xa0Patients\\xa0can\\xa0experience\\xa0a\\xa010%\\xa0loss\\xa0of\\xa0body\\xa0weight,\\xa0which\\xa0stabilizes3\\xa0months\\xa0postoperatively.\\xa0A\\xa0significant\\xa0component\\xa0of\\xa0this\\xa0weight\\xa0reduction\\xa0is\\xa0due\\xa0to\\xa0decreased\\xa0oral\\xa0intake.\\xa0However,\\xa0mild\\xa0steatorrhea\\xa0can\\xa0alsodevelop.\\xa0Reasons\\xa0for\\xa0maldigestion/malabsorption\\xa0include\\xa0decreased\\xa0gastric\\xa0acid\\xa0production,\\xa0rapid\\xa0gastric\\xa0emptying,\\xa0decreased\\xa0food\\xa0dispersion\\xa0in\\xa0thestomach,\\xa0reduced\\xa0luminal\\xa0bile\\xa0concentration,\\xa0reduced\\xa0pancreatic\\xa0secretory\\xa0response\\xa0to\\xa0feeding,\\xa0and\\xa0rapid\\xa0intestinal\\xa0transit.Decreased\\xa0serum\\xa0vitamin\\xa0B12\\xa0levels\\xa0can\\xa0be\\xa0observed\\xa0after\\xa0partial\\xa0gastrectomy.\\xa0This\\xa0is\\xa0usually\\xa0not\\xa0due\\xa0to\\xa0deficiency\\xa0of\\xa0IF,\\xa0since\\xa0a\\xa0minimal\\xa0amount\\xa0ofparietal\\xa0cells\\xa0(source\\xa0of\\xa0IF)\\xa0is\\xa0removed\\xa0during\\xa0antrectomy.\\xa0Reduced\\xa0vitamin\\xa0B12\\xa0may\\xa0be\\xa0due\\xa0to\\xa0competition\\xa0for\\xa0the\\xa0vitamin\\xa0by\\xa0bacterial\\xa0overgrowth\\xa0orinability\\xa0to\\xa0split\\xa0the\\xa0vitamin\\xa0from\\xa0its\\xa0protein\\xadbound\\xa0source\\xa0due\\xa0to\\xa0hypochlorhydria.Iron\\xaddeficiency\\xa0anemia\\xa0may\\xa0be\\xa0a\\xa0consequence\\xa0of\\xa0impaired\\xa0absorption\\xa0of\\xa0dietary\\xa0iron\\xa0in\\xa0patients\\xa0with\\xa0a\\xa0Billroth\\xa0II\\xa0gastrojejunostomy.\\xa0Absorption\\xa0of\\xa0ironsalts\\xa0is\\xa0normal\\xa0in\\xa0these\\xa0individuals;\\xa0thus,\\xa0a\\xa0favorable\\xa0response\\xa0to\\xa0oral\\xa0iron\\xa0supplementation\\xa0can\\xa0be\\xa0anticipated.\\xa0Folate\\xa0deficiency\\xa0with\\xa0concomitantanemia\\xa0can\\xa0also\\xa0develop\\xa0in\\xa0these\\xa0patients.\\xa0This\\xa0deficiency\\xa0may\\xa0be\\xa0secondary\\xa0to\\xa0decreased\\xa0absorption\\xa0or\\xa0diminished\\xa0oral\\xa0intake.Malabsorption\\xa0of\\xa0vitamin\\xa0D\\xa0and\\xa0calcium\\xa0resulting\\xa0in\\xa0osteoporosis\\xa0and\\xa0osteomalacia\\xa0is\\xa0common\\xa0after\\xa0partial\\xa0gastrectomy\\xa0and\\xa0gastrojejunostomy(Billroth\\xa0II).\\xa0Osteomalacia\\xa0can\\xa0occur\\xa0as\\xa0a\\xa0late\\xa0complication\\xa0in\\xa0up\\xa0to\\xa025%\\xa0of\\xa0post–partial\\xa0gastrectomy\\xa0patients.\\xa0Bone\\xa0fractures\\xa0occur\\xa0twice\\xa0as\\xa0commonlyin\\xa0men\\xa0after\\xa0gastric\\xa0surgery\\xa0as\\xa0in\\xa0a\\xa0control\\xa0population.\\xa0It\\xa0may\\xa0take\\xa0years\\xa0before\\xa0x\\xadray\\xa0findings\\xa0demonstrate\\xa0diminished\\xa0bone\\xa0density.\\xa0Elevated\\xa0alkaline',\n",
       " \"in\\xa0men\\xa0after\\xa0gastric\\xa0surgery\\xa0as\\xa0in\\xa0a\\xa0control\\xa0population.\\xa0It\\xa0may\\xa0take\\xa0years\\xa0before\\xa0x\\xadray\\xa0findings\\xa0demonstrate\\xa0diminished\\xa0bone\\xa0density.\\xa0Elevated\\xa0alkalinephosphatase,\\xa0reduced\\xa0serum\\xa0calcium,\\xa0bone\\xa0pain,\\xa0and\\xa0pathologic\\xa0fractures\\xa0may\\xa0be\\xa0seen\\xa0in\\xa0patients\\xa0with\\xa0osteomalacia.\\xa0The\\xa0high\\xa0incidence\\xa0of\\xa0theseabnormalities\\xa0in\\xa0this\\xa0subgroup\\xa0of\\xa0patients\\xa0justifies\\xa0treating\\xa0them\\xa0with\\xa0vitamin\\xa0D\\xa0and\\xa0calcium\\xa0supplementation\\xa0indefinitely.\\xa0Therapy\\xa0is\\xa0especiallyimportant\\xa0in\\xa0females.\\xa0Copper\\xa0deficiency\\xa0has\\xa0also\\xa0been\\xa0reported\\xa0in\\xa0patients\\xa0undergoing\\xa0surgeries\\xa0that\\xa0bypass\\xa0the\\xa0duodenum,\\xa0where\\xa0copper\\xa0isprimarily\\xa0absorbed.\\xa0Patients\\xa0may\\xa0present\\xa0with\\xa0a\\xa0rare\\xa0syndrome\\xa0that\\xa0includes\\xa0ataxia,\\xa0myelopathy,\\xa0and\\xa0peripheral\\xa0neuropathy.Gastric\\xa0AdenocarcinomaThe\\xa0incidence\\xa0of\\xa0adenocarcinoma\\xa0in\\xa0the\\xa0gastric\\xa0stump\\xa0is\\xa0increased\\xa015\\xa0years\\xa0after\\xa0resection.\\xa0Some\\xa0have\\xa0reported\\xa0a\\xa0four\\xad\\xa0to\\xa0fivefold\\xa0increase\\xa0in\\xa0gastricYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 36 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'Malabsorption\\xa0of\\xa0vitamin\\xa0D\\xa0and\\xa0calcium\\xa0resulting\\xa0in\\xa0osteoporosis\\xa0and\\xa0osteomalacia\\xa0is\\xa0common\\xa0after\\xa0partial\\xa0gastrectomy\\xa0and\\xa0gastrojejunostomy(Billroth\\xa0II).\\xa0Osteomalacia\\xa0can\\xa0occur\\xa0as\\xa0a\\xa0late\\xa0complication\\xa0in\\xa0up\\xa0to\\xa025%\\xa0of\\xa0post–partial\\xa0gastrectomy\\xa0patients.\\xa0Bone\\xa0fractures\\xa0occur\\xa0twice\\xa0as\\xa0commonlyin\\xa0men\\xa0after\\xa0gastric\\xa0surgery\\xa0as\\xa0in\\xa0a\\xa0control\\xa0population.\\xa0It\\xa0may\\xa0take\\xa0years\\xa0before\\xa0x\\xadray\\xa0findings\\xa0demonstrate\\xa0diminished\\xa0bone\\xa0density.\\xa0Elevated\\xa0alkalinephosphatase,\\xa0reduced\\xa0serum\\xa0calcium,\\xa0bone\\xa0pain,\\xa0and\\xa0pathologic\\xa0fractures\\xa0may\\xa0be\\xa0seen\\xa0in\\xa0patients\\xa0with\\xa0osteomalacia.\\xa0The\\xa0high\\xa0incidence\\xa0of\\xa0theseabnormalities\\xa0in\\xa0this\\xa0subgroup\\xa0of\\xa0patients\\xa0justifies\\xa0treating\\xa0them\\xa0with\\xa0vitamin\\xa0D\\xa0and\\xa0calcium\\xa0supplementation\\xa0indefinitely.\\xa0Therapy\\xa0is\\xa0especiallyimportant\\xa0in\\xa0females.\\xa0Copper\\xa0deficiency\\xa0has\\xa0also\\xa0been\\xa0reported\\xa0in\\xa0patients\\xa0undergoing\\xa0surgeries\\xa0that\\xa0bypass\\xa0the\\xa0duodenum,\\xa0where\\xa0copper\\xa0isprimarily\\xa0absorbed.\\xa0Patients\\xa0may\\xa0present\\xa0with\\xa0a\\xa0rare\\xa0syndrome\\xa0that\\xa0includes\\xa0ataxia,\\xa0myelopathy,\\xa0and\\xa0peripheral\\xa0neuropathy.Gastric\\xa0AdenocarcinomaThe\\xa0incidence\\xa0of\\xa0adenocarcinoma\\xa0in\\xa0the\\xa0gastric\\xa0stump\\xa0is\\xa0increased\\xa015\\xa0years\\xa0after\\xa0resection.\\xa0Some\\xa0have\\xa0reported\\xa0a\\xa0four\\xad\\xa0to\\xa0fivefold\\xa0increase\\xa0in\\xa0gastriccancer\\xa020–25\\xa0years\\xa0after\\xa0resection.\\xa0The\\xa0pathogenesis\\xa0is\\xa0unclear\\xa0but\\xa0may\\xa0involve\\xa0alkaline\\xa0reflux,\\xa0bacterial\\xa0proliferation,\\xa0or\\xa0hypochlorhydria.\\xa0The\\xa0role\\xa0ofendoscopic\\xa0screening\\xa0is\\xa0not\\xa0clear,\\xa0and\\xa0most\\xa0guidelines\\xa0do\\xa0not\\xa0support\\xa0its\\xa0use.Additional\\xa0ComplicationsReflux\\xa0esophagitis\\xa0and\\xa0a\\xa0higher\\xa0incidence\\xa0of\\xa0gallstones\\xa0and\\xa0cholecystitis\\xa0have\\xa0been\\xa0reported\\xa0in\\xa0patients\\xa0undergoing\\xa0subtotal\\xa0gastrectomy.\\xa0The\\xa0latter\\xa0isthought\\xa0to\\xa0be\\xa0due\\xa0to\\xa0decreased\\xa0gallbladder\\xa0contractility\\xa0associated\\xa0with\\xa0vagotomy\\xa0and\\xa0bypass\\xa0of\\xa0the\\xa0duodenum,\\xa0leading\\xa0to\\xa0decreased\\xa0postprandialrelease\\xa0of\\xa0cholecystokinin.RELATED\\xa0CONDITIONSZOLLINGER\\xadELLISON\\xa0SYNDROMESevere\\xa0peptic\\xa0ulcer\\xa0diathesis\\xa0secondary\\xa0to\\xa0gastric\\xa0acid\\xa0hypersecretion\\xa0due\\xa0to\\xa0unregulated\\xa0gastrin\\xa0release\\xa0from\\xa0a\\xa0non–β\\xadcell,\\xa0often\\xa0well\\xaddifferentiated',\n",
       " 'RELATED\\xa0CONDITIONSZOLLINGER\\xadELLISON\\xa0SYNDROMESevere\\xa0peptic\\xa0ulcer\\xa0diathesis\\xa0secondary\\xa0to\\xa0gastric\\xa0acid\\xa0hypersecretion\\xa0due\\xa0to\\xa0unregulated\\xa0gastrin\\xa0release\\xa0from\\xa0a\\xa0non–β\\xadcell,\\xa0often\\xa0well\\xaddifferentiatedneuroendocrine\\xa0tumor\\xa0(NET;\\xa0gastrinoma)\\xa0defines\\xa0the\\xa0components\\xa0of\\xa0ZES.\\xa0Initially,\\xa0ZES\\xa0was\\xa0typified\\xa0by\\xa0aggressive\\xa0and\\xa0refractory\\xa0ulceration\\xa0in\\xa0whichtotal\\xa0gastrectomy\\xa0provided\\xa0the\\xa0only\\xa0chance\\xa0for\\xa0enhancing\\xa0survival.\\xa0Today,\\xa0it\\xa0can\\xa0be\\xa0cured\\xa0by\\xa0surgical\\xa0resection\\xa0in\\xa0up\\xa0to\\xa040%\\xa0of\\xa0patients\\xa0with\\xa0thesporadic\\xa0form\\xa0of\\xa0the\\xa0disease\\xa0(see\\xa0below).EpidemiologyThe\\xa0true\\xa0incidence\\xa0of\\xa0ZES\\xa0is\\xa0unknown,\\xa0but\\xa0estimates\\xa0suggest\\xa0that\\xa0it\\xa0varies\\xa0from\\xa00.1\\xa0to\\xa01%\\xa0of\\xa0individuals\\xa0presenting\\xa0with\\xa0PUD,\\xa0with\\xa00.1–3\\xa0individuals\\xa0peryear\\xa0having\\xa0this\\xa0rare\\xa0diagnosis.\\xa0Others\\xa0have\\xa0estimated\\xa0an\\xa0incidence\\xa0of\\xa00.5–3\\xa0per\\xa0million\\xa0population.\\xa0Females\\xa0are\\xa0slightly\\xa0more\\xa0commonly\\xa0affected\\xa0thanmales,\\xa0and\\xa0the\\xa0majority\\xa0of\\xa0patients\\xa0are\\xa0diagnosed\\xa0between\\xa0ages\\xa030\\xa0and\\xa050.\\xa0Gastrinomas\\xa0are\\xa0classified\\xa0into\\xa0sporadic\\xa0tumors\\xa0(80%)\\xa0and\\xa0those\\xa0associatedwith\\xa0multiple\\xa0endocrine\\xa0neoplasia\\xa0(MEN)\\xa0type\\xa01\\xa0(see\\xa0below).\\xa0The\\xa0widespread\\xa0availability\\xa0and\\xa0use\\xa0of\\xa0PPIs\\xa0have\\xa0led\\xa0to\\xa0a\\xa0decreased\\xa0patient\\xa0referral\\xa0forgastrinoma\\xa0evaluation,\\xa0delay\\xa0in\\xa0diagnosis,\\xa0and\\xa0an\\xa0increase\\xa0in\\xa0false\\xadpositive\\xa0diagnoses\\xa0of\\xa0ZES.\\xa0In\\xa0fact,\\xa0diagnosis\\xa0may\\xa0be\\xa0delayed\\xa0for\\xa0≥6\\xa0years\\xa0aftersymptoms\\xa0consistent\\xa0with\\xa0ZES\\xa0are\\xa0displayed.PathophysiologyHypergastrinemia\\xa0originating\\xa0from\\xa0an\\xa0autonomous\\xa0neoplasm\\xa0is\\xa0the\\xa0driving\\xa0force\\xa0responsible\\xa0for\\xa0the\\xa0clinical\\xa0manifestations\\xa0in\\xa0ZES.\\xa0Gastrin\\xa0stimulatesacid\\xa0secretion\\xa0through\\xa0gastrin\\xa0receptors\\xa0on\\xa0parietal\\xa0cells\\xa0and\\xa0by\\xa0inducing\\xa0histamine\\xa0release\\xa0from\\xa0ECL\\xa0cells.\\xa0Gastrin\\xa0also\\xa0has\\xa0a\\xa0trophic\\xa0action\\xa0on\\xa0gastricepithelial\\xa0cells.\\xa0Long\\xadstanding\\xa0hypergastrinemia\\xa0leads\\xa0to\\xa0markedly\\xa0increased\\xa0gastric\\xa0acid\\xa0secretion\\xa0through\\xa0both\\xa0parietal\\xa0cell\\xa0stimulation\\xa0andincreased\\xa0parietal\\xa0cell\\xa0mass.\\xa0The\\xa0increased\\xa0gastric\\xa0acid\\xa0output\\xa0leads\\xa0to\\xa0peptic\\xa0ulcer\\xa0diathesis,\\xa0erosive\\xa0esophagitis,\\xa0and\\xa0diarrhea.Tumor\\xa0Distribution',\n",
       " 'increased\\xa0parietal\\xa0cell\\xa0mass.\\xa0The\\xa0increased\\xa0gastric\\xa0acid\\xa0output\\xa0leads\\xa0to\\xa0peptic\\xa0ulcer\\xa0diathesis,\\xa0erosive\\xa0esophagitis,\\xa0and\\xa0diarrhea.Tumor\\xa0DistributionAlthough\\xa0early\\xa0studies\\xa0suggested\\xa0that\\xa0the\\xa0vast\\xa0majority\\xa0of\\xa0gastrinomas\\xa0occurred\\xa0within\\xa0the\\xa0pancreas,\\xa0a\\xa0significant\\xa0number\\xa0of\\xa0these\\xa0lesions\\xa0areextrapancreatic.\\xa0Between\\xa060\\xa0and\\xa090%\\xa0of\\xa0these\\xa0tumors\\xa0are\\xa0found\\xa0within\\xa0the\\xa0hypothetical\\xa0gastrinoma\\xa0triangle\\xa0(confluence\\xa0of\\xa0the\\xa0cystic\\xa0and\\xa0common\\xa0bileducts\\xa0superiorly,\\xa0junction\\xa0of\\xa0the\\xa0second\\xa0and\\xa0third\\xa0portions\\xa0of\\xa0the\\xa0duodenum\\xa0inferiorly,\\xa0and\\xa0junction\\xa0of\\xa0the\\xa0neck\\xa0and\\xa0body\\xa0of\\xa0the\\xa0pancreas\\xa0medially).Duodenal\\xa0tumors\\xa0constitute\\xa0the\\xa0most\\xa0common\\xa0nonpancreatic\\xa0lesion;\\xa0between\\xa060\\xa0and\\xa0100%\\xa0of\\xa0gastrinomas\\xa0are\\xa0found\\xa0here.\\xa0Duodenal\\xa0tumors\\xa0aresmaller,\\xa0slower\\xa0growing,\\xa0and\\xa0less\\xa0likely\\xa0to\\xa0metastasize\\xa0than\\xa0pancreatic\\xa0lesions.\\xa0Less\\xa0common\\xa0extrapancreatic\\xa0sites\\xa0include\\xa0stomach,\\xa0bones,\\xa0ovaries,heart,\\xa0liver,\\xa0and\\xa0lymph\\xa0nodes.\\xa0More\\xa0than\\xa060%\\xa0of\\xa0tumors\\xa0are\\xa0considered\\xa0malignant,\\xa0with\\xa0up\\xa0to\\xa030–50%\\xa0of\\xa0patients\\xa0having\\xa0multiple\\xa0lesions\\xa0or\\xa0metastaticdisease\\xa0at\\xa0presentation.\\xa0Histologically,\\xa0gastrin\\xadproducing\\xa0cells\\xa0appear\\xa0well\\xaddifferentiated\\xa0(grade\\xa01\\xa0or\\xa02\\xa0histologically),\\xa0expressing\\xa0markers\\xa0typicallyfound\\xa0in\\xa0endocrine\\xa0neoplasms\\xa0(chromogranin,\\xa0neuron\\xadspecific\\xa0enolase).\\xa0Although\\xa0not\\xa0clearly\\xa0established\\xa0in\\xa0gastrinomas,\\xa0histologic\\xa0grade\\xa0inpancreatic\\xa0NETs\\xa0generally\\xa0is\\xa0an\\xa0important\\xa0predictor\\xa0of\\xa0survival\\xa0in\\xa0these\\xa0rare\\xa0neoplasms\\xa0(Chap.\\xa084).Clinical\\xa0ManifestationsGastric\\xa0acid\\xa0hypersecretion\\xa0is\\xa0responsible\\xa0for\\xa0the\\xa0signs\\xa0and\\xa0symptoms\\xa0observed\\xa0in\\xa0patients\\xa0with\\xa0ZES.\\xa0The\\xa0most\\xa0common\\xa0clinical\\xa0presentation\\xa0forgastrinoma\\xa0patients\\xa0is\\xa0abdominal\\xa0pain\\xa0in\\xa0the\\xa0presence\\xa0of\\xa0acid\\xa0peptic\\xa0disorders.\\xa0Peptic\\xa0ulcer\\xa0is\\xa0the\\xa0most\\xa0common\\xa0clinical\\xa0manifestation,\\xa0occurring\\xa0in>90%\\xa0of\\xa0gastrinoma\\xa0patients.\\xa0Initial\\xa0presentation\\xa0and\\xa0ulcer\\xa0location\\xa0(duodenal\\xa0bulb)\\xa0may\\xa0be\\xa0indistinguishable\\xa0from\\xa0common\\xa0PUD.\\xa0Clinical\\xa0situationsYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138',\n",
       " \"Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 37 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'heart,\\xa0liver,\\xa0and\\xa0lymph\\xa0nodes.\\xa0More\\xa0than\\xa060%\\xa0of\\xa0tumors\\xa0are\\xa0considered\\xa0malignant,\\xa0with\\xa0up\\xa0to\\xa030–50%\\xa0of\\xa0patients\\xa0having\\xa0multiple\\xa0lesions\\xa0or\\xa0metastaticdisease\\xa0at\\xa0presentation.\\xa0Histologically,\\xa0gastrin\\xadproducing\\xa0cells\\xa0appear\\xa0well\\xaddifferentiated\\xa0(grade\\xa01\\xa0or\\xa02\\xa0histologically),\\xa0expressing\\xa0markers\\xa0typicallyfound\\xa0in\\xa0endocrine\\xa0neoplasms\\xa0(chromogranin,\\xa0neuron\\xadspecific\\xa0enolase).\\xa0Although\\xa0not\\xa0clearly\\xa0established\\xa0in\\xa0gastrinomas,\\xa0histologic\\xa0grade\\xa0inpancreatic\\xa0NETs\\xa0generally\\xa0is\\xa0an\\xa0important\\xa0predictor\\xa0of\\xa0survival\\xa0in\\xa0these\\xa0rare\\xa0neoplasms\\xa0(Chap.\\xa084).Clinical\\xa0ManifestationsGastric\\xa0acid\\xa0hypersecretion\\xa0is\\xa0responsible\\xa0for\\xa0the\\xa0signs\\xa0and\\xa0symptoms\\xa0observed\\xa0in\\xa0patients\\xa0with\\xa0ZES.\\xa0The\\xa0most\\xa0common\\xa0clinical\\xa0presentation\\xa0forgastrinoma\\xa0patients\\xa0is\\xa0abdominal\\xa0pain\\xa0in\\xa0the\\xa0presence\\xa0of\\xa0acid\\xa0peptic\\xa0disorders.\\xa0Peptic\\xa0ulcer\\xa0is\\xa0the\\xa0most\\xa0common\\xa0clinical\\xa0manifestation,\\xa0occurring\\xa0in>90%\\xa0of\\xa0gastrinoma\\xa0patients.\\xa0Initial\\xa0presentation\\xa0and\\xa0ulcer\\xa0location\\xa0(duodenal\\xa0bulb)\\xa0may\\xa0be\\xa0indistinguishable\\xa0from\\xa0common\\xa0PUD.\\xa0Clinical\\xa0situationsthat\\xa0should\\xa0create\\xa0suspicion\\xa0of\\xa0gastrinoma\\xa0are\\xa0ulcers\\xa0in\\xa0unusual\\xa0locations\\xa0(second\\xa0part\\xa0of\\xa0the\\xa0duodenum\\xa0and\\xa0beyond),\\xa0ulcers\\xa0refractory\\xa0to\\xa0standardmedical\\xa0therapy,\\xa0ulcer\\xa0recurrence\\xa0after\\xa0acid\\xadreducing\\xa0surgery,\\xa0ulcers\\xa0presenting\\xa0with\\xa0frank\\xa0complications\\xa0(bleeding,\\xa0obstruction,\\xa0and\\xa0perforation),\\xa0orulcers\\xa0in\\xa0the\\xa0absence\\xa0of\\xa0H.\\xa0pylori\\xa0or\\xa0NSAID\\xa0ingestion.\\xa0Symptoms\\xa0of\\xa0esophageal\\xa0origin\\xa0are\\xa0present\\xa0in\\xa0up\\xa0to\\xa0two\\xadthirds\\xa0of\\xa0patients\\xa0with\\xa0ZES,\\xa0with\\xa0aspectrum\\xa0ranging\\xa0from\\xa0mild\\xa0esophagitis\\xa0to\\xa0frank\\xa0ulceration\\xa0with\\xa0stricture\\xa0and\\xa0Barrett’s\\xa0mucosa.Diarrhea,\\xa0the\\xa0next\\xa0most\\xa0common\\xa0clinical\\xa0manifestation,\\xa0is\\xa0found\\xa0in\\xa0up\\xa0to\\xa070%\\xa0of\\xa0patients.\\xa0Although\\xa0diarrhea\\xa0often\\xa0occurs\\xa0concomitantly\\xa0with\\xa0acidpeptic\\xa0disease,\\xa0it\\xa0may\\xa0also\\xa0occur\\xa0independent\\xa0of\\xa0an\\xa0ulcer\\xa0and\\xa0classically\\xa0will\\xa0abate\\xa0with\\xa0PPI\\xa0therapy.\\xa0Etiology\\xa0of\\xa0the\\xa0diarrhea\\xa0is\\xa0multifactorial,\\xa0resultingfrom\\xa0marked\\xa0volume\\xa0overload\\xa0to\\xa0the\\xa0small\\xa0bowel,\\xa0pancreatic\\xa0enzyme\\xa0inactivation\\xa0by\\xa0acid,\\xa0and\\xa0damage\\xa0of\\xa0the\\xa0intestinal\\xa0epithelial\\xa0surface\\xa0by\\xa0acid.\\xa0The',\n",
       " 'from\\xa0marked\\xa0volume\\xa0overload\\xa0to\\xa0the\\xa0small\\xa0bowel,\\xa0pancreatic\\xa0enzyme\\xa0inactivation\\xa0by\\xa0acid,\\xa0and\\xa0damage\\xa0of\\xa0the\\xa0intestinal\\xa0epithelial\\xa0surface\\xa0by\\xa0acid.\\xa0Theepithelial\\xa0damage\\xa0can\\xa0lead\\xa0to\\xa0a\\xa0mild\\xa0degree\\xa0of\\xa0maldigestion\\xa0and\\xa0malabsorption\\xa0of\\xa0nutrients.\\xa0The\\xa0diarrhea\\xa0may\\xa0also\\xa0have\\xa0a\\xa0secretory\\xa0component\\xa0due\\xa0tothe\\xa0direct\\xa0stimulatory\\xa0effect\\xa0of\\xa0gastrin\\xa0on\\xa0enterocytes\\xa0or\\xa0the\\xa0co\\xadsecretion\\xa0of\\xa0additional\\xa0hormones\\xa0from\\xa0the\\xa0tumor\\xa0such\\xa0as\\xa0vasoactive\\xa0intestinal\\xa0peptide.Gastrinomas\\xa0can\\xa0develop\\xa0in\\xa0the\\xa0presence\\xa0of\\xa0MEN\\xa01\\xa0syndrome\\xa0(Chaps.\\xa084\\xa0and\\xa0388)\\xa0in\\xa0~25%\\xa0of\\xa0patients.\\xa0This\\xa0autosomal\\xa0dominant\\xa0disorder\\xa0involvesprimarily\\xa0three\\xa0organ\\xa0sites:\\xa0the\\xa0parathyroid\\xa0glands\\xa0(80–90%),\\xa0pancreas\\xa0(40–80%),\\xa0and\\xa0pituitary\\xa0gland\\xa0(30–60%).\\xa0The\\xa0syndrome\\xa0is\\xa0caused\\xa0by\\xa0inactivatingmutations\\xa0of\\xa0the\\xa0MEN1\\xa0tumor\\xadsuppressor\\xa0gene\\xa0found\\xa0on\\xa0the\\xa0long\\xa0arm\\xa0of\\xa0chromosome\\xa011q13.\\xa0The\\xa0gene\\xa0encodes\\xa0for\\xa0menin,\\xa0which\\xa0has\\xa0an\\xa0importantrole\\xa0in\\xa0DNA\\xa0replication\\xa0and\\xa0transcriptional\\xa0regulation.\\xa0A\\xa0genetic\\xa0diagnosis\\xa0is\\xa0obtained\\xa0by\\xa0sequencing\\xa0of\\xa0the\\xa0MEN1\\xa0gene,\\xa0which\\xa0can\\xa0reveal\\xa0mutations\\xa0in70–90%\\xa0of\\xa0typical\\xa0MEN\\xa01\\xa0cases.\\xa0A\\xa0family\\xa0may\\xa0have\\xa0an\\xa0unknown\\xa0mutation,\\xa0making\\xa0a\\xa0genetic\\xa0diagnosis\\xa0impossible,\\xa0and\\xa0therefore,\\xa0certain\\xa0individuals\\xa0willrequire\\xa0a\\xa0clinical\\xa0diagnosis,\\xa0which\\xa0is\\xa0determined\\xa0by\\xa0whether\\xa0a\\xa0patient\\xa0has\\xa0tumors\\xa0in\\xa0two\\xa0of\\xa0the\\xa0three\\xa0endocrine\\xa0organs\\xa0(parathyroid,pancreas/duodenum,\\xa0or\\xa0pituitary)\\xa0or\\xa0has\\xa0a\\xa0family\\xa0history\\xa0of\\xa0MEN\\xa01\\xa0and\\xa0one\\xa0of\\xa0the\\xa0endocrine\\xa0organ\\xa0tumors.\\xa0In\\xa0view\\xa0of\\xa0the\\xa0stimulatory\\xa0effect\\xa0of\\xa0calciumon\\xa0gastric\\xa0secretion,\\xa0the\\xa0hyperparathyroidism\\xa0and\\xa0hypercalcemia\\xa0seen\\xa0in\\xa0MEN\\xa01\\xa0patients\\xa0may\\xa0have\\xa0a\\xa0direct\\xa0effect\\xa0on\\xa0ulcer\\xa0disease.\\xa0Resolution\\xa0ofhypercalcemia\\xa0by\\xa0parathyroidectomy\\xa0reduces\\xa0gastrin\\xa0and\\xa0gastric\\xa0acid\\xa0output\\xa0in\\xa0gastrinoma\\xa0patients.\\xa0An\\xa0additional\\xa0distinguishing\\xa0feature\\xa0in\\xa0ZESpatients\\xa0with\\xa0MEN\\xa01\\xa0is\\xa0the\\xa0higher\\xa0incidence\\xa0of\\xa0gastric\\xa0carcinoid\\xa0tumor\\xa0development\\xa0(as\\xa0compared\\xa0to\\xa0patients\\xa0with\\xa0sporadic\\xa0gastrinomas).\\xa0ZES\\xa0presents',\n",
       " 'patients\\xa0with\\xa0MEN\\xa01\\xa0is\\xa0the\\xa0higher\\xa0incidence\\xa0of\\xa0gastric\\xa0carcinoid\\xa0tumor\\xa0development\\xa0(as\\xa0compared\\xa0to\\xa0patients\\xa0with\\xa0sporadic\\xa0gastrinomas).\\xa0ZES\\xa0presentsand\\xa0is\\xa0diagnosed\\xa0earlier\\xa0in\\xa0MEN\\xa01\\xa0patients,\\xa0and\\xa0they\\xa0have\\xa0a\\xa0more\\xa0indolent\\xa0course\\xa0as\\xa0compared\\xa0to\\xa0patients\\xa0with\\xa0sporadic\\xa0gastrinoma.\\xa0Gastrinomas\\xa0tendto\\xa0be\\xa0smaller,\\xa0multiple,\\xa0and\\xa0located\\xa0in\\xa0the\\xa0duodenal\\xa0wall\\xa0more\\xa0often\\xa0than\\xa0is\\xa0seen\\xa0in\\xa0patients\\xa0with\\xa0sporadic\\xa0ZES.\\xa0Establishing\\xa0the\\xa0diagnosis\\xa0of\\xa0MEN\\xa01\\xa0iscritical\\xa0in\\xa0order\\xa0to\\xa0provide\\xa0genetic\\xa0counseling\\xa0to\\xa0the\\xa0patient\\xa0and\\xa0his\\xa0or\\xa0her\\xa0family\\xa0and\\xa0also\\xa0to\\xa0determine\\xa0the\\xa0recommended\\xa0surgical\\xa0approach.Therefore,\\xa0gastrinoma\\xa0patients\\xa0should\\xa0be\\xa0screened\\xa0for\\xa0MEN\\xa01\\xa0by\\xa0performing\\xa0a\\xa0detailed\\xa0family\\xa0history\\xa0and\\xa0obtaining\\xa0several\\xa0serum\\xa0markers\\xa0includingcalcium,\\xa0parathyroid,\\xa0prolactin,\\xa0and\\xa0pancreatic\\xa0polypeptide\\xa0levels.DiagnosisEstablishing\\xa0an\\xa0early\\xa0diagnosis\\xa0is\\xa0important\\xa0in\\xa0order\\xa0to\\xa0minimize\\xa0the\\xa0long\\xadterm\\xa0sequelae\\xa0of\\xa0gastric\\xa0acid\\xa0hypersecretion,\\xa0prevent\\xa0metastatic\\xa0disease,and\\xa0counsel\\xa0family\\xa0members\\xa0if\\xa0a\\xa0diagnosis\\xa0of\\xa0MEN\\xa01\\xa0is\\xa0established.\\xa0Biochemical\\xa0measurements\\xa0of\\xa0gastrin\\xa0and\\xa0acid\\xa0secretion\\xa0in\\xa0patients\\xa0suspected\\xa0ofhaving\\xa0ZES\\xa0play\\xa0an\\xa0important\\xa0role\\xa0is\\xa0establishing\\xa0this\\xa0rare\\xa0diagnosis.\\xa0Often,\\xa0patients\\xa0suspected\\xa0of\\xa0having\\xa0ZES\\xa0will\\xa0be\\xa0treated\\xa0with\\xa0a\\xa0PPI\\xa0in\\xa0an\\xa0effort\\xa0toameliorate\\xa0symptoms\\xa0and\\xa0decrease\\xa0the\\xa0likelihood\\xa0of\\xa0possible\\xa0acid\\xadrelated\\xa0complications.\\xa0The\\xa0presence\\xa0of\\xa0the\\xa0PPI,\\xa0which\\xa0will\\xa0lower\\xa0acid\\xa0secretion\\xa0andpotentially\\xa0elevate\\xa0fasting\\xa0gastrin\\xa0levels\\xa0in\\xa0normal\\xa0individuals,\\xa0will\\xa0make\\xa0the\\xa0diagnostic\\xa0approach\\xa0in\\xa0these\\xa0individuals\\xa0somewhat\\xa0difficult.\\xa0Significantmorbidity\\xa0related\\xa0to\\xa0peptic\\xa0diathesis\\xa0has\\xa0been\\xa0described\\xa0when\\xa0stopping\\xa0PPIs\\xa0in\\xa0gastrinoma\\xa0patients;\\xa0therefore,\\xa0a\\xa0systematic\\xa0approach\\xa0in\\xa0stoppingthese\\xa0agents\\xa0is\\xa0warranted\\xa0(see\\xa0below).\\xa0The\\xa0first\\xa0step\\xa0in\\xa0the\\xa0evaluation\\xa0of\\xa0a\\xa0patient\\xa0suspected\\xa0of\\xa0having\\xa0ZES\\xa0is\\xa0to\\xa0obtain\\xa0a\\xa0fasting\\xa0gastrin\\xa0level.\\xa0A\\xa0list\\xa0ofclinical\\xa0scenarios\\xa0that\\xa0should\\xa0arouse\\xa0suspicion\\xa0regarding\\xa0this\\xa0diagnosis\\xa0is\\xa0shown\\xa0in\\xa0Table\\xa0324\\xad8.\\xa0Fasting\\xa0gastrin\\xa0levels\\xa0obtained\\xa0using\\xa0a\\xa0dependable',\n",
       " \"clinical\\xa0scenarios\\xa0that\\xa0should\\xa0arouse\\xa0suspicion\\xa0regarding\\xa0this\\xa0diagnosis\\xa0is\\xa0shown\\xa0in\\xa0Table\\xa0324\\xad8.\\xa0Fasting\\xa0gastrin\\xa0levels\\xa0obtained\\xa0using\\xa0a\\xa0dependableassay\\xa0are\\xa0usually\\xa0<150\\xa0pg/mL.\\xa0A\\xa0normal\\xa0fasting\\xa0gastrin,\\xa0on\\xa0two\\xa0separate\\xa0occasions,\\xa0especially\\xa0if\\xa0the\\xa0patient\\xa0is\\xa0on\\xa0a\\xa0PPI,\\xa0virtually\\xa0excludes\\xa0this\\xa0diagnosis.Virtually\\xa0all\\xa0gastrinoma\\xa0patients\\xa0will\\xa0have\\xa0a\\xa0gastrin\\xa0level\\xa0>150–200\\xa0pg/mL.\\xa0Measurement\\xa0of\\xa0fasting\\xa0gastrin\\xa0should\\xa0be\\xa0repeated\\xa0to\\xa0confirm\\xa0the\\xa0clinicalsuspicion.\\xa0Some\\xa0of\\xa0the\\xa0commercial\\xa0biochemical\\xa0assays\\xa0used\\xa0for\\xa0measuring\\xa0serum\\xa0gastrin\\xa0may\\xa0be\\xa0inaccurate.\\xa0Variable\\xa0specificity\\xa0of\\xa0the\\xa0antibodies\\xa0usedhave\\xa0led\\xa0to\\xa0both\\xa0false\\xadpositive\\xa0and\\xa0false\\xadnegative\\xa0fasting\\xa0gastrin\\xa0levels,\\xa0placing\\xa0in\\xa0jeopardy\\xa0the\\xa0ability\\xa0to\\xa0make\\xa0an\\xa0accurate\\xa0diagnosis\\xa0of\\xa0ZES.TABLE\\xa0324\\xad8When\\xa0to\\xa0Obtain\\xa0a\\xa0Fasting\\xa0Serum\\xa0Gastrin\\xa0LevelMultiple\\xa0ulcersUlcers\\xa0in\\xa0unusual\\xa0locations;\\xa0associated\\xa0with\\xa0severe\\xa0esophagitis;\\xa0resistant\\xa0to\\xa0therapy\\xa0with\\xa0frequent\\xa0recurrences;\\xa0in\\xa0the\\xa0absence\\xa0of\\xa0nonsteroidal\\xa0anti\\xadinflammatory\\xa0drug\\xa0ingestion\\xa0or\\xa0H.\\xa0pylori\\xa0infectionUlcer patients awaiting surgeryYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 38 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,\",\n",
       " \"Anti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'pgggg ggpassay\\xa0are\\xa0usually\\xa0<150\\xa0pg/mL.\\xa0A\\xa0normal\\xa0fasting\\xa0gastrin,\\xa0on\\xa0two\\xa0separate\\xa0occasions,\\xa0especially\\xa0if\\xa0the\\xa0patient\\xa0is\\xa0on\\xa0a\\xa0PPI,\\xa0virtually\\xa0excludes\\xa0this\\xa0diagnosis.Virtually\\xa0all\\xa0gastrinoma\\xa0patients\\xa0will\\xa0have\\xa0a\\xa0gastrin\\xa0level\\xa0>150–200\\xa0pg/mL.\\xa0Measurement\\xa0of\\xa0fasting\\xa0gastrin\\xa0should\\xa0be\\xa0repeated\\xa0to\\xa0confirm\\xa0the\\xa0clinicalsuspicion.\\xa0Some\\xa0of\\xa0the\\xa0commercial\\xa0biochemical\\xa0assays\\xa0used\\xa0for\\xa0measuring\\xa0serum\\xa0gastrin\\xa0may\\xa0be\\xa0inaccurate.\\xa0Variable\\xa0specificity\\xa0of\\xa0the\\xa0antibodies\\xa0usedhave\\xa0led\\xa0to\\xa0both\\xa0false\\xadpositive\\xa0and\\xa0false\\xadnegative\\xa0fasting\\xa0gastrin\\xa0levels,\\xa0placing\\xa0in\\xa0jeopardy\\xa0the\\xa0ability\\xa0to\\xa0make\\xa0an\\xa0accurate\\xa0diagnosis\\xa0of\\xa0ZES.TABLE\\xa0324\\xad8When\\xa0to\\xa0Obtain\\xa0a\\xa0Fasting\\xa0Serum\\xa0Gastrin\\xa0LevelMultiple\\xa0ulcersUlcers\\xa0in\\xa0unusual\\xa0locations;\\xa0associated\\xa0with\\xa0severe\\xa0esophagitis;\\xa0resistant\\xa0to\\xa0therapy\\xa0with\\xa0frequent\\xa0recurrences;\\xa0in\\xa0the\\xa0absence\\xa0of\\xa0nonsteroidal\\xa0anti\\xadinflammatory\\xa0drug\\xa0ingestion\\xa0or\\xa0H.\\xa0pylori\\xa0infectionUlcer\\xa0patients\\xa0awaiting\\xa0surgeryExtensive\\xa0family\\xa0history\\xa0for\\xa0peptic\\xa0ulcer\\xa0diseasePostoperative\\xa0ulcer\\xa0recurrenceBasal\\xa0hyperchlorhydriaUnexplained\\xa0diarrhea\\xa0or\\xa0steatorrheaHypercalcemiaFamily\\xa0history\\xa0of\\xa0pancreatic\\xa0islet,\\xa0pituitary,\\xa0or\\xa0parathyroid\\xa0tumorProminent\\xa0gastric\\xa0or\\xa0duodenal\\xa0foldsMultiple\\xa0processes\\xa0can\\xa0lead\\xa0to\\xa0an\\xa0elevated\\xa0fasting\\xa0gastrin\\xa0level,\\xa0the\\xa0most\\xa0frequent\\xa0of\\xa0which\\xa0are\\xa0gastric\\xa0hypochlorhydria\\xa0and\\xa0achlorhydria,\\xa0with\\xa0orwithout\\xa0pernicious\\xa0anemia.\\xa0Gastric\\xa0acid\\xa0induces\\xa0feedback\\xa0inhibition\\xa0of\\xa0gastrin\\xa0release.\\xa0A\\xa0decrease\\xa0in\\xa0acid\\xa0production\\xa0will\\xa0subsequently\\xa0lead\\xa0to\\xa0failureof\\xa0the\\xa0feedback\\xa0inhibitory\\xa0pathway,\\xa0resulting\\xa0in\\xa0net\\xa0hypergastrinemia.\\xa0Gastrin\\xa0levels\\xa0will\\xa0thus\\xa0be\\xa0high\\xa0in\\xa0patients\\xa0using\\xa0antisecretory\\xa0agents\\xa0for\\xa0thetreatment\\xa0of\\xa0acid\\xa0peptic\\xa0disorders\\xa0and\\xa0dyspepsia.\\xa0H.\\xa0pylori\\xa0infection\\xa0can\\xa0also\\xa0cause\\xa0hypergastrinemia.\\xa0Additional\\xa0causes\\xa0of\\xa0elevated\\xa0gastrin\\xa0includeretained\\xa0gastric\\xa0antrum;\\xa0G\\xadcell\\xa0hyperplasia;\\xa0gastric\\xa0outlet\\xa0obstruction;\\xa0renal\\xa0insufficiency;\\xa0massive\\xa0small\\xadbowel\\xa0obstruction;\\xa0and\\xa0conditions\\xa0such\\xa0as',\n",
       " 'retained\\xa0gastric\\xa0antrum;\\xa0G\\xadcell\\xa0hyperplasia;\\xa0gastric\\xa0outlet\\xa0obstruction;\\xa0renal\\xa0insufficiency;\\xa0massive\\xa0small\\xadbowel\\xa0obstruction;\\xa0and\\xa0conditions\\xa0such\\xa0asrheumatoid\\xa0arthritis,\\xa0vitiligo,\\xa0diabetes\\xa0mellitus,\\xa0and\\xa0pheochromocytoma.\\xa0Although\\xa0a\\xa0fasting\\xa0gastrin\\xa0>10\\xa0times\\xa0normal\\xa0is\\xa0highly\\xa0suggestive\\xa0of\\xa0ZES,\\xa0two\\xadthirds\\xa0of\\xa0patients\\xa0will\\xa0have\\xa0fasting\\xa0gastrin\\xa0levels\\xa0that\\xa0overlap\\xa0with\\xa0levels\\xa0found\\xa0in\\xa0the\\xa0more\\xa0common\\xa0disorders\\xa0outlined\\xa0above,\\xa0especially\\xa0if\\xa0a\\xa0PPI\\xa0is\\xa0beingtaken\\xa0by\\xa0the\\xa0patient.\\xa0The\\xa0effect\\xa0of\\xa0the\\xa0PPI\\xa0on\\xa0gastrin\\xa0levels\\xa0and\\xa0acid\\xa0secretion\\xa0will\\xa0linger\\xa0several\\xa0days\\xa0after\\xa0stopping\\xa0the\\xa0PPI;\\xa0therefore,\\xa0it\\xa0should\\xa0bestopped\\xa0for\\xa0a\\xa0minimum\\xa0of\\xa07\\xa0days\\xa0before\\xa0testing.\\xa0During\\xa0this\\xa0period,\\xa0the\\xa0patient\\xa0should\\xa0be\\xa0placed\\xa0on\\xa0a\\xa0histamine\\xa0H2\\xa0antagonist,\\xa0such\\xa0as\\xa0famotidine,twice\\xa0to\\xa0three\\xa0times\\xa0per\\xa0day.\\xa0Although\\xa0this\\xa0type\\xa0of\\xa0agent\\xa0has\\xa0a\\xa0short\\xadterm\\xa0effect\\xa0on\\xa0gastrin\\xa0and\\xa0acid\\xa0secretion,\\xa0it\\xa0needs\\xa0to\\xa0be\\xa0stopped\\xa024\\xa0h\\xa0beforerepeating\\xa0fasting\\xa0gastrin\\xa0levels\\xa0or\\xa0performing\\xa0some\\xa0of\\xa0the\\xa0tests\\xa0highlighted\\xa0below.\\xa0The\\xa0patient\\xa0may\\xa0take\\xa0antacids\\xa0for\\xa0the\\xa0final\\xa0day,\\xa0stopping\\xa0them\\xa0~12\\xa0hbefore\\xa0testing\\xa0is\\xa0performed.\\xa0Heightened\\xa0awareness\\xa0of\\xa0complications\\xa0related\\xa0to\\xa0gastric\\xa0acid\\xa0hypersecretion\\xa0during\\xa0the\\xa0period\\xa0of\\xa0PPI\\xa0cessation\\xa0is\\xa0critical.The\\xa0next\\xa0step\\xa0at\\xa0times\\xa0needed\\xa0for\\xa0establishing\\xa0a\\xa0biochemical\\xa0diagnosis\\xa0of\\xa0gastrinoma\\xa0is\\xa0to\\xa0assess\\xa0acid\\xa0secretion.\\xa0Nothing\\xa0further\\xa0needs\\xa0to\\xa0be\\xa0done\\xa0ifdecreased\\xa0acid\\xa0output\\xa0in\\xa0the\\xa0absence\\xa0of\\xa0a\\xa0PPI\\xa0is\\xa0observed.\\xa0A\\xa0pH\\xa0can\\xa0be\\xa0measured\\xa0on\\xa0gastric\\xa0fluid\\xa0obtained\\xa0either\\xa0during\\xa0endoscopy\\xa0or\\xa0throughnasogastric\\xa0aspiration;\\xa0a\\xa0pH\\xa0<3\\xa0is\\xa0suggestive\\xa0of\\xa0a\\xa0gastrinoma,\\xa0but\\xa0a\\xa0pH\\xa0>3\\xa0is\\xa0not\\xa0helpful\\xa0in\\xa0excluding\\xa0the\\xa0diagnosis.\\xa0In\\xa0those\\xa0situations\\xa0where\\xa0the\\xa0pH\\xa0is>3,\\xa0formal\\xa0gastric\\xa0acid\\xa0analysis\\xa0should\\xa0be\\xa0performed\\xa0if\\xa0available.\\xa0Normal\\xa0BAO\\xa0in\\xa0nongastric\\xa0surgery\\xa0patients\\xa0is\\xa0typically\\xa0<5\\xa0meq/h.\\xa0A\\xa0BAO\\xa0>15\\xa0meq/h\\xa0inthe\\xa0presence\\xa0of\\xa0hypergastrinemia\\xa0is\\xa0considered\\xa0pathognomonic\\xa0of\\xa0ZES,\\xa0but\\xa0up\\xa0to\\xa012%\\xa0of\\xa0patients\\xa0with\\xa0common\\xa0PUD\\xa0may\\xa0have\\xa0elevated\\xa0BAO\\xa0to\\xa0a\\xa0lesser',\n",
       " 'the\\xa0presence\\xa0of\\xa0hypergastrinemia\\xa0is\\xa0considered\\xa0pathognomonic\\xa0of\\xa0ZES,\\xa0but\\xa0up\\xa0to\\xa012%\\xa0of\\xa0patients\\xa0with\\xa0common\\xa0PUD\\xa0may\\xa0have\\xa0elevated\\xa0BAO\\xa0to\\xa0a\\xa0lesserdegree\\xa0that\\xa0can\\xa0overlap\\xa0with\\xa0levels\\xa0seen\\xa0in\\xa0ZES\\xa0patients.\\xa0In\\xa0an\\xa0effort\\xa0to\\xa0improve\\xa0the\\xa0sensitivity\\xa0and\\xa0specificity\\xa0of\\xa0gastric\\xa0secretory\\xa0studies,\\xa0a\\xa0BAO/MAOratio\\xa0was\\xa0established\\xa0using\\xa0pentagastrin\\xa0infusion\\xa0as\\xa0a\\xa0way\\xa0to\\xa0maximally\\xa0stimulate\\xa0acid\\xa0production,\\xa0with\\xa0a\\xa0BAO/MAO\\xa0ratio\\xa0>0.6\\xa0being\\xa0highly\\xa0suggestiveof\\xa0ZES.\\xa0Pentagastrin\\xa0is\\xa0no\\xa0longer\\xa0available\\xa0in\\xa0the\\xa0United\\xa0States,\\xa0making\\xa0measurement\\xa0of\\xa0MAO\\xa0virtually\\xa0impossible.\\xa0An\\xa0endoscopic\\xa0method\\xa0formeasuring\\xa0gastric\\xa0acid\\xa0output\\xa0has\\xa0been\\xa0developed\\xa0but\\xa0requires\\xa0further\\xa0validation.Gastrin\\xa0provocative\\xa0tests\\xa0have\\xa0been\\xa0developed\\xa0in\\xa0an\\xa0effort\\xa0to\\xa0differentiate\\xa0between\\xa0the\\xa0causes\\xa0of\\xa0hypergastrinemia\\xa0and\\xa0are\\xa0especially\\xa0helpful\\xa0inpatients\\xa0with\\xa0indeterminate\\xa0acid\\xa0secretory\\xa0studies.\\xa0The\\xa0tests\\xa0are\\xa0the\\xa0secretin\\xa0stimulation\\xa0test\\xa0and\\xa0the\\xa0calcium\\xa0infusion\\xa0study;\\xa0the\\xa0latter\\xa0is\\xa0rarely,\\xa0if\\xa0ever,utilized\\xa0in\\xa0our\\xa0current\\xa0environment\\xa0due\\xa0to\\xa0the\\xa0cumbersome\\xa0nature\\xa0of\\xa0the\\xa0test\\xa0and\\xa0its\\xa0lower\\xa0sensitivity\\xa0and\\xa0specificity\\xa0than\\xa0secretin\\xa0stimulation.\\xa0Themost\\xa0sensitive\\xa0and\\xa0specific\\xa0gastrin\\xa0provocative\\xa0test\\xa0for\\xa0the\\xa0diagnosis\\xa0of\\xa0gastrinoma\\xa0is\\xa0the\\xa0secretin\\xa0study.\\xa0An\\xa0increase\\xa0in\\xa0gastrin\\xa0of\\xa0≥120\\xa0pg\\xa0within\\xa015\\xa0minof\\xa0secretin\\xa0injection\\xa0has\\xa0a\\xa0sensitivity\\xa0and\\xa0specificity\\xa0of\\xa0>90%\\xa0for\\xa0ZES.\\xa0PPI\\xadinduced\\xa0hypochlorhydria\\xa0or\\xa0achlorhydria\\xa0may\\xa0lead\\xa0to\\xa0a\\xa0false\\xadpositive\\xa0secretintest;\\xa0thus,\\xa0this\\xa0agent\\xa0must\\xa0be\\xa0stopped\\xa0for\\xa01\\xa0week\\xa0before\\xa0testing.In light of the limited availability of the biochemical studies outlined above, more studies make a diagnosis of gastrinoma based on the presence ofYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 39 / 49AntrumFundusDuodenumBillrothIBillrothIl',\n",
       " \"©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 39 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'Abbreviations:\\xa0CT,\\xa0computed\\xa0tomography;\\xa0EUS,\\xa0endoscopic\\xa0ultrasonography;\\xa0MRI,\\xa0magnetic\\xa0resonance\\xa0imaging;\\xa0N/A,\\xa0not\\xa0applicable;\\xa0OctreoScan,\\xa0imaging\\xa0with\\xa0111In\\xadpentetreotide;\\xa0SASI,\\xa0selective\\xa0arterial\\xa0secretin\\xa0injection.of\\xa0ZES.\\xa0Pentagastrin\\xa0is\\xa0no\\xa0longer\\xa0available\\xa0in\\xa0the\\xa0United\\xa0States,\\xa0making\\xa0measurement\\xa0of\\xa0MAO\\xa0virtually\\xa0impossible.\\xa0An\\xa0endoscopic\\xa0method\\xa0formeasuring\\xa0gastric\\xa0acid\\xa0output\\xa0has\\xa0been\\xa0developed\\xa0but\\xa0requires\\xa0further\\xa0validation.Gastrin\\xa0provocative\\xa0tests\\xa0have\\xa0been\\xa0developed\\xa0in\\xa0an\\xa0effort\\xa0to\\xa0differentiate\\xa0between\\xa0the\\xa0causes\\xa0of\\xa0hypergastrinemia\\xa0and\\xa0are\\xa0especially\\xa0helpful\\xa0inpatients\\xa0with\\xa0indeterminate\\xa0acid\\xa0secretory\\xa0studies.\\xa0The\\xa0tests\\xa0are\\xa0the\\xa0secretin\\xa0stimulation\\xa0test\\xa0and\\xa0the\\xa0calcium\\xa0infusion\\xa0study;\\xa0the\\xa0latter\\xa0is\\xa0rarely,\\xa0if\\xa0ever,utilized\\xa0in\\xa0our\\xa0current\\xa0environment\\xa0due\\xa0to\\xa0the\\xa0cumbersome\\xa0nature\\xa0of\\xa0the\\xa0test\\xa0and\\xa0its\\xa0lower\\xa0sensitivity\\xa0and\\xa0specificity\\xa0than\\xa0secretin\\xa0stimulation.\\xa0Themost\\xa0sensitive\\xa0and\\xa0specific\\xa0gastrin\\xa0provocative\\xa0test\\xa0for\\xa0the\\xa0diagnosis\\xa0of\\xa0gastrinoma\\xa0is\\xa0the\\xa0secretin\\xa0study.\\xa0An\\xa0increase\\xa0in\\xa0gastrin\\xa0of\\xa0≥120\\xa0pg\\xa0within\\xa015\\xa0minof\\xa0secretin\\xa0injection\\xa0has\\xa0a\\xa0sensitivity\\xa0and\\xa0specificity\\xa0of\\xa0>90%\\xa0for\\xa0ZES.\\xa0PPI\\xadinduced\\xa0hypochlorhydria\\xa0or\\xa0achlorhydria\\xa0may\\xa0lead\\xa0to\\xa0a\\xa0false\\xadpositive\\xa0secretintest;\\xa0thus,\\xa0this\\xa0agent\\xa0must\\xa0be\\xa0stopped\\xa0for\\xa01\\xa0week\\xa0before\\xa0testing.In\\xa0light\\xa0of\\xa0the\\xa0limited\\xa0availability\\xa0of\\xa0the\\xa0biochemical\\xa0studies\\xa0outlined\\xa0above,\\xa0more\\xa0studies\\xa0make\\xa0a\\xa0diagnosis\\xa0of\\xa0gastrinoma\\xa0based\\xa0on\\xa0the\\xa0presence\\xa0ofelevated\\xa0gastrin\\xa0and\\xa0low\\xa0gastric\\xa0pH\\xa0in\\xa0the\\xa0right\\xa0clinical\\xa0setting\\xa0coupled\\xa0with\\xa0tumor\\xa0localization\\xa0tests\\xa0outlined\\xa0below\\xa0and\\xa0positive\\xa0histology\\xa0by\\xa0biopsy(difficult\\xa0to\\xa0obtain).\\xa0Revised\\xa0guidelines\\xa0for\\xa0the\\xa0best\\xa0approach\\xa0to\\xa0establishing\\xa0a\\xa0diagnosis\\xa0of\\xa0gastrinoma\\xa0taking\\xa0into\\xa0consideration\\xa0the\\xa0above\\xa0outlinedlimitations\\xa0are\\xa0being\\xa0considered,\\xa0but\\xa0none\\xa0have\\xa0replaced\\xa0the\\xa0established\\xa0guidelines\\xa0outlined\\xa0earlier\\xa0in\\xa0this\\xa0section.Tumor\\xa0LocalizationOnce\\xa0the\\xa0biochemical\\xa0diagnosis\\xa0of\\xa0gastrinoma\\xa0has\\xa0been\\xa0confirmed\\xa0(if\\xa0possible),\\xa0the\\xa0tumor\\xa0must\\xa0be\\xa0located.\\xa0Multiple\\xa0imaging\\xa0studies\\xa0have\\xa0been\\xa0used\\xa0in',\n",
       " 'Tumor\\xa0LocalizationOnce\\xa0the\\xa0biochemical\\xa0diagnosis\\xa0of\\xa0gastrinoma\\xa0has\\xa0been\\xa0confirmed\\xa0(if\\xa0possible),\\xa0the\\xa0tumor\\xa0must\\xa0be\\xa0located.\\xa0Multiple\\xa0imaging\\xa0studies\\xa0have\\xa0been\\xa0used\\xa0inan\\xa0effort\\xa0to\\xa0enhance\\xa0tumor\\xa0localization\\xa0(Table\\xa0324\\xad9).\\xa0The\\xa0broad\\xa0range\\xa0of\\xa0sensitivity\\xa0is\\xa0due\\xa0to\\xa0the\\xa0variable\\xa0success\\xa0rates\\xa0achieved\\xa0by\\xa0the\\xa0differentinvestigative\\xa0groups.\\xa0Endoscopic\\xa0ultrasound\\xa0(EUS)\\xa0permits\\xa0imaging\\xa0of\\xa0the\\xa0pancreas\\xa0with\\xa0a\\xa0high\\xa0degree\\xa0of\\xa0resolution\\xa0(<5\\xa0mm).\\xa0This\\xa0modality\\xa0isparticularly\\xa0helpful\\xa0in\\xa0excluding\\xa0small\\xa0neoplasms\\xa0within\\xa0the\\xa0pancreas\\xa0and\\xa0in\\xa0assessing\\xa0the\\xa0presence\\xa0of\\xa0surrounding\\xa0lymph\\xa0nodes\\xa0and\\xa0vascularinvolvement,\\xa0but\\xa0it\\xa0is\\xa0not\\xa0very\\xa0sensitive\\xa0(43%)\\xa0for\\xa0finding\\xa0duodenal\\xa0lesions.\\xa0This\\xa0latter\\xa0observation\\xa0has\\xa0led\\xa0some\\xa0to\\xa0not\\xa0include\\xa0EUS\\xa0in\\xa0the\\xa0routinepreoperative\\xa0evaluation\\xa0of\\xa0a\\xa0patient\\xa0suspected\\xa0of\\xa0having\\xa0a\\xa0gastrinoma.\\xa0Several\\xa0types\\xa0of\\xa0endocrine\\xa0tumors\\xa0express\\xa0cell\\xadsurface\\xa0receptors\\xa0forsomatostatin,\\xa0in\\xa0particular\\xa0the\\xa0subtype\\xa02\\xa0(SSTR2).\\xa0This\\xa0permits\\xa0the\\xa0localization,\\xa0staging,\\xa0and\\xa0prediction\\xa0of\\xa0therapeutic\\xa0response\\xa0to\\xa0somatostatinanalogues\\xa0(see\\xa0below)\\xa0by\\xa0gastrinomas.\\xa0The\\xa0original\\xa0functional\\xa0scinitigraphic\\xa0tool\\xa0developed\\xa0measuring\\xa0the\\xa0uptake\\xa0of\\xa0the\\xa0stable\\xa0somatostatin\\xa0analogue111In\\xadpentetreotide\\xa0(OctreoScan)\\xa0has\\xa0demonstrated\\xa0sensitivity\\xa0and\\xa0specificity\\xa0rates\\xa0of\\xa0>80%.\\xa0More\\xa0recently,\\xa0positron\\xa0emission\\xa0tomography\\xa0(PET)–computed\\xa0tomography\\xa0(CT)\\xa0with\\xa068Ga\\xadDOTATATE\\xa0has\\xa0been\\xa0developed\\xa0and\\xa0is\\xa0superior\\xa0than\\xa0OctreoScan\\xa0for\\xa0assessing\\xa0tumor\\xa0presence\\xa0in\\xa0patients\\xa0withwell\\xaddifferentiated\\xa0NETs\\xa0such\\xa0as\\xa0gastrinomas,\\xa0with\\xa0sensitivity\\xa0and\\xa0specificity\\xa0of\\xa0>90%,\\xa0making\\xa0it\\xa0the\\xa0functional\\xa0imaging\\xa0study\\xa0of\\xa0choice\\xa0when\\xa0available.18F\\xadFluordeoxyglucose\\xa0(18F\\xadFDG)\\xa0PET\\xa0imaging\\xa0has\\xa0been\\xa0found\\xa0to\\xa0be\\xa0useful\\xa0in\\xa0pancreatic\\xa0NETs,\\xa0including\\xa0gastrinomas,\\xa0particularly\\xa0as\\xa0a\\xa0prognosticmarker.TABLE\\xa0324\\xad9Sensitivity\\xa0of\\xa0Imaging\\xa0Studies\\xa0in\\xa0Zollinger\\xadEllison\\xa0SyndromeSENSITIVITY,\\xa0%STUDYPRIMARY\\xa0GASTRINOMAMETASTATIC\\xa0GASTRINOMAUltrasound21–2814CT\\xa0scan55–70>85Selective\\xa0angiography35–6833–86Portal\\xa0venous\\xa0sampling70–90N/ASASI55–78',\n",
       " \"SENSITIVITY,\\xa0%STUDYPRIMARY\\xa0GASTRINOMAMETASTATIC\\xa0GASTRINOMAUltrasound21–2814CT\\xa0scan55–70>85Selective\\xa0angiography35–6833–86Portal\\xa0venous\\xa0sampling70–90N/ASASI55–7841MRI55–70>85OctreoScan67–8680–100EUS80–100N/AUp\\xa0to\\xa050%\\xa0of\\xa0patients\\xa0have\\xa0metastatic\\xa0disease\\xa0at\\xa0diagnosis.\\xa0Success\\xa0in\\xa0controlling\\xa0gastric\\xa0acid\\xa0hypersecretion\\xa0has\\xa0shifted\\xa0the\\xa0emphasis\\xa0of\\xa0therapytoward\\xa0providing\\xa0a\\xa0surgical\\xa0cure.\\xa0Detecting\\xa0the\\xa0primary\\xa0tumor\\xa0and\\xa0excluding\\xa0metastatic\\xa0disease\\xa0are\\xa0critical\\xa0in\\xa0view\\xa0of\\xa0this\\xa0paradigm\\xa0shift.\\xa0Once\\xa0abiochemical\\xa0diagnosis\\xa0has\\xa0been\\xa0confirmed,\\xa0the\\xa0patient\\xa0should\\xa0first\\xa0undergo\\xa0an\\xa0abdominal\\xa0CT\\xa0scan,\\xa0magnetic\\xa0resonance\\xa0imaging\\xa0(MRI),\\xa0orYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 40 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'Abbreviations:\\xa0CT,\\xa0computed\\xa0tomography;\\xa0EUS,\\xa0endoscopic\\xa0ultrasonography;\\xa0MRI,\\xa0magnetic\\xa0resonance\\xa0imaging;\\xa0N/A,\\xa0not\\xa0applicable;\\xa0OctreoScan,\\xa0imaging\\xa0with\\xa0111In\\xadpentetreotide;\\xa0SASI,\\xa0selective\\xa0arterial\\xa0secretin\\xa0injection.computed\\xa0tomography\\xa0(CT)\\xa0with\\xa068Ga\\xadDOTATATE\\xa0has\\xa0been\\xa0developed\\xa0and\\xa0is\\xa0superior\\xa0than\\xa0OctreoScan\\xa0for\\xa0assessing\\xa0tumor\\xa0presence\\xa0in\\xa0patients\\xa0withwell\\xaddifferentiated\\xa0NETs\\xa0such\\xa0as\\xa0gastrinomas,\\xa0with\\xa0sensitivity\\xa0and\\xa0specificity\\xa0of\\xa0>90%,\\xa0making\\xa0it\\xa0the\\xa0functional\\xa0imaging\\xa0study\\xa0of\\xa0choice\\xa0when\\xa0available.18F\\xadFluordeoxyglucose\\xa0(18F\\xadFDG)\\xa0PET\\xa0imaging\\xa0has\\xa0been\\xa0found\\xa0to\\xa0be\\xa0useful\\xa0in\\xa0pancreatic\\xa0NETs,\\xa0including\\xa0gastrinomas,\\xa0particularly\\xa0as\\xa0a\\xa0prognosticmarker.TABLE\\xa0324\\xad9Sensitivity\\xa0of\\xa0Imaging\\xa0Studies\\xa0in\\xa0Zollinger\\xadEllison\\xa0SyndromeSENSITIVITY,\\xa0%STUDYPRIMARY\\xa0GASTRINOMAMETASTATIC\\xa0GASTRINOMAUltrasound21–2814CT\\xa0scan55–70>85Selective\\xa0angiography35–6833–86Portal\\xa0venous\\xa0sampling70–90N/ASASI55–7841MRI55–70>85OctreoScan67–8680–100EUS80–100N/AUp\\xa0to\\xa050%\\xa0of\\xa0patients\\xa0have\\xa0metastatic\\xa0disease\\xa0at\\xa0diagnosis.\\xa0Success\\xa0in\\xa0controlling\\xa0gastric\\xa0acid\\xa0hypersecretion\\xa0has\\xa0shifted\\xa0the\\xa0emphasis\\xa0of\\xa0therapytoward\\xa0providing\\xa0a\\xa0surgical\\xa0cure.\\xa0Detecting\\xa0the\\xa0primary\\xa0tumor\\xa0and\\xa0excluding\\xa0metastatic\\xa0disease\\xa0are\\xa0critical\\xa0in\\xa0view\\xa0of\\xa0this\\xa0paradigm\\xa0shift.\\xa0Once\\xa0abiochemical\\xa0diagnosis\\xa0has\\xa0been\\xa0confirmed,\\xa0the\\xa0patient\\xa0should\\xa0first\\xa0undergo\\xa0an\\xa0abdominal\\xa0CT\\xa0scan,\\xa0magnetic\\xa0resonance\\xa0imaging\\xa0(MRI),\\xa0orOctreoScan/PET\\xadCT\\xa0with\\xa068Ga\\xadDOTATATE\\xa0(depending\\xa0on\\xa0availability)\\xa0to\\xa0exclude\\xa0metastatic\\xa0disease.\\xa0Once\\xa0metastatic\\xa0disease\\xa0has\\xa0been\\xa0excluded,\\xa0anexperienced\\xa0endocrine\\xa0surgeon\\xa0may\\xa0opt\\xa0for\\xa0exploratory\\xa0laparotomy\\xa0with\\xa0intraoperative\\xa0ultrasound\\xa0or\\xa0transillumination.\\xa0In\\xa0other\\xa0centers,\\xa0carefulexamination\\xa0of\\xa0the\\xa0peripancreatic\\xa0area\\xa0with\\xa0EUS,\\xa0accompanied\\xa0by\\xa0endoscopic\\xa0exploration\\xa0of\\xa0the\\xa0duodenum\\xa0for\\xa0primary\\xa0tumors,\\xa0will\\xa0be\\xa0performedbefore\\xa0surgery.\\xa0Selective\\xa0arterial\\xa0secretin\\xa0injection\\xa0may\\xa0be\\xa0a\\xa0useful\\xa0adjuvant\\xa0for\\xa0localizing\\xa0tumors\\xa0in\\xa0a\\xa0subset\\xa0of\\xa0patients.\\xa0The\\xa0extent\\xa0of\\xa0the\\xa0diagnostic',\n",
       " 'before\\xa0surgery.\\xa0Selective\\xa0arterial\\xa0secretin\\xa0injection\\xa0may\\xa0be\\xa0a\\xa0useful\\xa0adjuvant\\xa0for\\xa0localizing\\xa0tumors\\xa0in\\xa0a\\xa0subset\\xa0of\\xa0patients.\\xa0The\\xa0extent\\xa0of\\xa0the\\xa0diagnosticand\\xa0surgical\\xa0approach\\xa0must\\xa0be\\xa0carefully\\xa0balanced\\xa0with\\xa0the\\xa0patient’s\\xa0overall\\xa0physiologic\\xa0condition\\xa0and\\xa0the\\xa0natural\\xa0history\\xa0of\\xa0a\\xa0slow\\xadgrowinggastrinoma.TREATMENT\\xa0OF\\xa0ZOLLINGER\\xadELLISON\\xa0SYNDROMETreatment\\xa0of\\xa0functional\\xa0endocrine\\xa0tumors\\xa0is\\xa0directed\\xa0at\\xa0ameliorating\\xa0the\\xa0signs\\xa0and\\xa0symptoms\\xa0related\\xa0to\\xa0hormone\\xa0overproduction,\\xa0curative\\xa0resectionof\\xa0the\\xa0neoplasm,\\xa0and\\xa0attempts\\xa0to\\xa0control\\xa0tumor\\xa0growth\\xa0in\\xa0metastatic\\xa0disease.PPIs\\xa0are\\xa0the\\xa0treatment\\xa0of\\xa0choice\\xa0and\\xa0have\\xa0decreased\\xa0the\\xa0need\\xa0for\\xa0total\\xa0gastrectomy.\\xa0Initial\\xa0PPI\\xa0doses\\xa0tend\\xa0to\\xa0be\\xa0higher\\xa0than\\xa0those\\xa0used\\xa0for\\xa0treatment\\xa0ofGERD\\xa0or\\xa0PUD.\\xa0The\\xa0initial\\xa0dose\\xa0of\\xa0omeprazole,\\xa0lansoprazole,\\xa0rabeprazole,\\xa0or\\xa0esomeprazole\\xa0should\\xa0be\\xa0in\\xa0the\\xa0range\\xa0of\\xa060\\xa0mg\\xa0in\\xa0divided\\xa0doses\\xa0in\\xa0a\\xa024\\xadhperiod.\\xa0When\\xa0gastric\\xa0acid\\xa0analysis\\xa0was\\xa0more\\xa0widely\\xa0available,\\xa0dosing\\xa0was\\xa0adjusted\\xa0to\\xa0achieve\\xa0a\\xa0BAO\\xa0<10\\xa0meq/h\\xa0(at\\xa0the\\xa0drug\\xa0trough)\\xa0in\\xa0surgery\\xadnaivepatients\\xa0and\\xa0to\\xa0<5\\xa0meq/h\\xa0in\\xa0individuals\\xa0who\\xa0have\\xa0previously\\xa0undergone\\xa0an\\xa0acid\\xadreducing\\xa0operation.\\xa0Close\\xa0monitoring\\xa0of\\xa0clinical\\xa0symptoms\\xa0whenstarting\\xa0PPIs\\xa0and\\xa0increasing\\xa0the\\xa0dose\\xa0accordingly\\xa0are\\xa0paramount.\\xa0Although\\xa0the\\xa0somatostatin\\xa0analogue\\xa0has\\xa0inhibitory\\xa0effects\\xa0on\\xa0gastrin\\xa0release\\xa0fromreceptor\\xadbearing\\xa0tumors\\xa0and\\xa0inhibits\\xa0gastric\\xa0acid\\xa0secretion\\xa0to\\xa0some\\xa0extent,\\xa0PPIs\\xa0have\\xa0the\\xa0advantage\\xa0of\\xa0reducing\\xa0parietal\\xa0cell\\xa0activity\\xa0to\\xa0a\\xa0greaterdegree.\\xa0Despite\\xa0this,\\xa0octreotide\\xa0or\\xa0lanreotide\\xa0may\\xa0be\\xa0considered\\xa0as\\xa0adjunctive\\xa0therapy\\xa0to\\xa0the\\xa0PPI\\xa0in\\xa0patients\\xa0with\\xa0tumors\\xa0that\\xa0express\\xa0somatostatinreceptors\\xa0and\\xa0have\\xa0peptic\\xa0symptoms\\xa0that\\xa0are\\xa0difficult\\xa0to\\xa0control\\xa0with\\xa0high\\xaddose\\xa0PPI.The\\xa0ultimate\\xa0goal\\xa0of\\xa0surgery\\xa0would\\xa0be\\xa0to\\xa0provide\\xa0a\\xa0definitive\\xa0cure.\\xa0Improved\\xa0understanding\\xa0of\\xa0tumor\\xa0distribution\\xa0has\\xa0led\\xa0to\\xa0immediate\\xa0cure\\xa0rates\\xa0ashigh\\xa0as\\xa033%\\xa0with\\xa010\\xadyear\\xa0disease\\xadfree\\xa0intervals\\xa0as\\xa0high\\xa0as\\xa095%\\xa0in\\xa0sporadic\\xa0gastrinoma\\xa0patients\\xa0undergoing\\xa0surgery.\\xa0A\\xa0positive\\xa0outcome\\xa0is\\xa0highly',\n",
       " \"high\\xa0as\\xa033%\\xa0with\\xa010\\xadyear\\xa0disease\\xadfree\\xa0intervals\\xa0as\\xa0high\\xa0as\\xa095%\\xa0in\\xa0sporadic\\xa0gastrinoma\\xa0patients\\xa0undergoing\\xa0surgery.\\xa0A\\xa0positive\\xa0outcome\\xa0is\\xa0highlydependent\\xa0on\\xa0the\\xa0experience\\xa0of\\xa0the\\xa0surgical\\xa0team\\xa0treating\\xa0these\\xa0rare\\xa0tumors.\\xa0Surgical\\xa0therapy\\xa0of\\xa0gastrinoma\\xa0patients\\xa0with\\xa0MEN\\xa01\\xa0remainscontroversial\\xa0because\\xa0of\\xa0the\\xa0difficulty\\xa0in\\xa0rendering\\xa0these\\xa0patients\\xa0disease\\xadfree\\xa0with\\xa0surgery.\\xa0In\\xa0contrast\\xa0to\\xa0the\\xa0encouraging\\xa0postoperative\\xa0resultsobserved\\xa0in\\xa0patients\\xa0with\\xa0sporadic\\xa0disease,\\xa0<5%\\xa0of\\xa0MEN\\xa01\\xa0patients\\xa0are\\xa0disease\\xadfree\\xa05\\xa0years\\xa0after\\xa0an\\xa0operation.\\xa0Moreover,\\xa0in\\xa0contrast\\xa0to\\xa0patients\\xa0withYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 41 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'starting\\xa0PPIs\\xa0and\\xa0increasing\\xa0the\\xa0dose\\xa0accordingly\\xa0are\\xa0paramount.\\xa0Although\\xa0the\\xa0somatostatin\\xa0analogue\\xa0has\\xa0inhibitory\\xa0effects\\xa0on\\xa0gastrin\\xa0release\\xa0fromreceptor\\xadbearing\\xa0tumors\\xa0and\\xa0inhibits\\xa0gastric\\xa0acid\\xa0secretion\\xa0to\\xa0some\\xa0extent,\\xa0PPIs\\xa0have\\xa0the\\xa0advantage\\xa0of\\xa0reducing\\xa0parietal\\xa0cell\\xa0activity\\xa0to\\xa0a\\xa0greaterdegree.\\xa0Despite\\xa0this,\\xa0octreotide\\xa0or\\xa0lanreotide\\xa0may\\xa0be\\xa0considered\\xa0as\\xa0adjunctive\\xa0therapy\\xa0to\\xa0the\\xa0PPI\\xa0in\\xa0patients\\xa0with\\xa0tumors\\xa0that\\xa0express\\xa0somatostatinreceptors\\xa0and\\xa0have\\xa0peptic\\xa0symptoms\\xa0that\\xa0are\\xa0difficult\\xa0to\\xa0control\\xa0with\\xa0high\\xaddose\\xa0PPI.The\\xa0ultimate\\xa0goal\\xa0of\\xa0surgery\\xa0would\\xa0be\\xa0to\\xa0provide\\xa0a\\xa0definitive\\xa0cure.\\xa0Improved\\xa0understanding\\xa0of\\xa0tumor\\xa0distribution\\xa0has\\xa0led\\xa0to\\xa0immediate\\xa0cure\\xa0rates\\xa0ashigh\\xa0as\\xa033%\\xa0with\\xa010\\xadyear\\xa0disease\\xadfree\\xa0intervals\\xa0as\\xa0high\\xa0as\\xa095%\\xa0in\\xa0sporadic\\xa0gastrinoma\\xa0patients\\xa0undergoing\\xa0surgery.\\xa0A\\xa0positive\\xa0outcome\\xa0is\\xa0highlydependent\\xa0on\\xa0the\\xa0experience\\xa0of\\xa0the\\xa0surgical\\xa0team\\xa0treating\\xa0these\\xa0rare\\xa0tumors.\\xa0Surgical\\xa0therapy\\xa0of\\xa0gastrinoma\\xa0patients\\xa0with\\xa0MEN\\xa01\\xa0remainscontroversial\\xa0because\\xa0of\\xa0the\\xa0difficulty\\xa0in\\xa0rendering\\xa0these\\xa0patients\\xa0disease\\xadfree\\xa0with\\xa0surgery.\\xa0In\\xa0contrast\\xa0to\\xa0the\\xa0encouraging\\xa0postoperative\\xa0resultsobserved\\xa0in\\xa0patients\\xa0with\\xa0sporadic\\xa0disease,\\xa0<5%\\xa0of\\xa0MEN\\xa01\\xa0patients\\xa0are\\xa0disease\\xadfree\\xa05\\xa0years\\xa0after\\xa0an\\xa0operation.\\xa0Moreover,\\xa0in\\xa0contrast\\xa0to\\xa0patients\\xa0withsporadic\\xa0ZES,\\xa0the\\xa0clinical\\xa0course\\xa0of\\xa0MEN\\xa01\\xa0patients\\xa0tends\\xa0to\\xa0be\\xa0benign\\xa0and\\xa0rarely\\xa0leads\\xa0to\\xa0disease\\xadrelated\\xa0mortality,\\xa0recommending\\xa0that\\xa0early\\xa0surgerybe\\xa0deferred.\\xa0Some\\xa0groups\\xa0suggest\\xa0surgery\\xa0only\\xa0if\\xa0a\\xa0clearly\\xa0identifiable,\\xa0nonmetastatic\\xa0lesion\\xa0is\\xa0documented\\xa0by\\xa0structural\\xa0studies.\\xa0Others\\xa0advocate\\xa0amore\\xa0aggressive\\xa0approach,\\xa0where\\xa0all\\xa0patients\\xa0free\\xa0of\\xa0hepatic\\xa0metastasis\\xa0are\\xa0explored\\xa0and\\xa0all\\xa0detected\\xa0tumors\\xa0in\\xa0the\\xa0duodenum\\xa0are\\xa0resected;\\xa0this\\xa0isfollowed\\xa0by\\xa0enucleation\\xa0of\\xa0lesions\\xa0in\\xa0the\\xa0pancreatic\\xa0head,\\xa0with\\xa0a\\xa0distal\\xa0pancreatectomy\\xa0to\\xa0follow.\\xa0The\\xa0outcome\\xa0of\\xa0the\\xa0two\\xa0approaches\\xa0has\\xa0not\\xa0beenclearly\\xa0defined.\\xa0Laparoscopic\\xa0surgical\\xa0interventions\\xa0may\\xa0provide\\xa0attractive\\xa0approaches\\xa0in\\xa0the\\xa0future\\xa0but\\xa0currently\\xa0seem\\xa0to\\xa0be\\xa0of\\xa0some\\xa0limited\\xa0benefit\\xa0in',\n",
       " 'clearly\\xa0defined.\\xa0Laparoscopic\\xa0surgical\\xa0interventions\\xa0may\\xa0provide\\xa0attractive\\xa0approaches\\xa0in\\xa0the\\xa0future\\xa0but\\xa0currently\\xa0seem\\xa0to\\xa0be\\xa0of\\xa0some\\xa0limited\\xa0benefit\\xa0inpatients\\xa0with\\xa0gastrinoma\\xa0because\\xa0a\\xa0significant\\xa0percentage\\xa0of\\xa0the\\xa0tumors\\xa0may\\xa0be\\xa0extrapancreatic\\xa0and\\xa0difficult\\xa0to\\xa0localize\\xa0with\\xa0a\\xa0laparoscopic\\xa0approach.Finally,\\xa0patients\\xa0selected\\xa0for\\xa0surgery\\xa0should\\xa0be\\xa0individuals\\xa0whose\\xa0health\\xa0status\\xa0would\\xa0lead\\xa0them\\xa0to\\xa0tolerate\\xa0a\\xa0more\\xa0aggressive\\xa0operation\\xa0and\\xa0obtainthe\\xa0long\\xadterm\\xa0benefits\\xa0from\\xa0such\\xa0aggressive\\xa0surgery,\\xa0which\\xa0are\\xa0often\\xa0witnessed\\xa0after\\xa010\\xa0years.Therapy\\xa0of\\xa0metastatic\\xa0endocrine\\xa0tumors\\xa0in\\xa0general\\xa0remains\\xa0suboptimal;\\xa0gastrinomas\\xa0are\\xa0no\\xa0exception.\\xa0In\\xa0light\\xa0of\\xa0the\\xa0observation\\xa0that\\xa0in\\xa0manyinstances\\xa0tumor\\xa0growth\\xa0is\\xa0indolent\\xa0and\\xa0that\\xa0many\\xa0individuals\\xa0with\\xa0metastatic\\xa0disease\\xa0remain\\xa0relatively\\xa0stable\\xa0for\\xa0significant\\xa0periods\\xa0of\\xa0time,\\xa0manyadvocate\\xa0not\\xa0instituting\\xa0systemic\\xa0tumor\\xadtargeted\\xa0therapy\\xa0until\\xa0evidence\\xa0of\\xa0tumor\\xa0progression\\xa0or\\xa0refractory\\xa0symptoms\\xa0not\\xa0controlled\\xa0with\\xa0PPIs\\xa0arenoted.\\xa0Medical\\xa0approaches,\\xa0including\\xa0biologic\\xa0therapy\\xa0(IFN\\xadα,\\xa0long\\xadacting\\xa0somatostatin\\xa0analogues,\\xa0and\\xa0peptide\\xa0receptor\\xa0radionuclides),\\xa0systemicchemotherapy\\xa0(streptozotocin,\\xa05\\xadfluorouracil,\\xa0and\\xa0doxorubicin),\\xa0and\\xa0hepatic\\xa0artery\\xa0embolization,\\xa0may\\xa0lead\\xa0to\\xa0significant\\xa0toxicity\\xa0without\\xa0a\\xa0substantialimprovement\\xa0in\\xa0overall\\xa0survival.\\xa0Use\\xa0of\\xa0temozolomide\\xa0with\\xa0capecitabine\\xa0has\\xa0demonstrated\\xa0radiographic\\xa0regression\\xa0and\\xa0progression\\xadfree\\xa0survival\\xa0inpatients\\xa0with\\xa0well\\xaddifferentiated\\xa0NETs\\xa0in\\xa0the\\xa0range\\xa0of\\xa070%\\xa0and\\xa018\\xa0months,\\xa0respectively.\\xa0Systemic\\xa0therapy\\xa0with\\xa0radiolabeled\\xa0somatostatin\\xa0analogues(peptide\\xa0receptor\\xa0radiotherapy\\xa0[PRRT])\\xa0has\\xa0been\\xa0used\\xa0in\\xa0the\\xa0therapy\\xa0of\\xa0metastatic\\xa0NETs\\xa0and\\xa0appears\\xa0to\\xa0be\\xa0very\\xa0promising\\xa0in\\xa0terms\\xa0of\\xa0radiographicregression,\\xa0symptoms,\\xa0and\\xa0progression\\xadfree\\xa0survival,\\xa0but\\xa0additional\\xa0studies\\xa0are\\xa0warranted.\\xa0Several\\xa0promising\\xa0therapies\\xa0are\\xa0being\\xa0explored,\\xa0includingradiofrequency\\xa0ablation\\xa0or\\xa0cryoablation\\xa0of\\xa0liver\\xa0lesions\\xa0and\\xa0use\\xa0of\\xa0agents\\xa0that\\xa0block\\xa0the\\xa0VEGF\\xa0receptor\\xa0pathway\\xa0(sunitinib),\\xa0the\\xa0mammalian\\xa0target\\xa0of',\n",
       " 'radiofrequency\\xa0ablation\\xa0or\\xa0cryoablation\\xa0of\\xa0liver\\xa0lesions\\xa0and\\xa0use\\xa0of\\xa0agents\\xa0that\\xa0block\\xa0the\\xa0VEGF\\xa0receptor\\xa0pathway\\xa0(sunitinib),\\xa0the\\xa0mammalian\\xa0target\\xa0ofrapamycin,\\xa0and\\xa0immune\\xa0checkpoint\\xa0inhibitors\\xa0(Chap.\\xa087).Surgical\\xa0approaches,\\xa0including\\xa0debulking\\xa0surgery\\xa0and\\xa0liver\\xa0transplantation\\xa0for\\xa0hepatic\\xa0metastasis,\\xa0have\\xa0also\\xa0produced\\xa0limited\\xa0benefit.The\\xa0overall\\xa05\\xad\\xa0and\\xa010\\xadyear\\xa0survival\\xa0rates\\xa0for\\xa0gastrinoma\\xa0patients\\xa0are\\xa062–75%\\xa0and\\xa047–53%,\\xa0respectively.\\xa0Individuals\\xa0with\\xa0the\\xa0entire\\xa0tumor\\xa0resected\\xa0orthose\\xa0with\\xa0a\\xa0negative\\xa0laparotomy\\xa0have\\xa05\\xad\\xa0and\\xa010\\xadyear\\xa0survival\\xa0rates\\xa0>90%.\\xa0Patients\\xa0with\\xa0incompletely\\xa0resected\\xa0tumors\\xa0have\\xa05\\xad\\xa0and\\xa010\\xadyear\\xa0survivalrates\\xa0of\\xa043\\xa0and\\xa025%,\\xa0respectively.\\xa0Patients\\xa0with\\xa0hepatic\\xa0metastasis\\xa0have\\xa0<20%\\xa0survival\\xa0at\\xa05\\xa0years.\\xa0Favorable\\xa0prognostic\\xa0indicators\\xa0include\\xa0primaryduodenal\\xa0wall\\xa0tumors,\\xa0isolated\\xa0lymph\\xa0node\\xa0tumor,\\xa0the\\xa0presence\\xa0of\\xa0MEN\\xa01,\\xa0and\\xa0undetectable\\xa0tumor\\xa0upon\\xa0surgical\\xa0exploration.\\xa0Poor\\xa0outcome\\xa0is\\xa0seen\\xa0inpatients\\xa0with\\xa0shorter\\xa0disease\\xa0duration;\\xa0female\\xa0sex;\\xa0older\\xa0age\\xa0at\\xa0diagnosis;\\xa0higher\\xa0gastrin\\xa0levels\\xa0(>10,000\\xa0pg/mL);\\xa0poor\\xa0histologic\\xa0differentiation;\\xa0highproliferative\\xa0index;\\xa0large\\xa0pancreatic\\xa0primary\\xa0tumors\\xa0(>3\\xa0cm);\\xa0metastatic\\xa0disease\\xa0to\\xa0lymph\\xa0nodes,\\xa0liver,\\xa0and\\xa0bone;\\xa0and\\xa0Cushing’s\\xa0syndrome.\\xa0Rapidgrowth\\xa0of\\xa0hepatic\\xa0metastases\\xa0is\\xa0also\\xa0predictive\\xa0of\\xa0poor\\xa0outcome.STRESS\\xadRELATED\\xa0MUCOSAL\\xa0INJURYPatients\\xa0suffering\\xa0from\\xa0shock,\\xa0sepsis,\\xa0massive\\xa0burns,\\xa0severe\\xa0trauma,\\xa0or\\xa0head\\xa0injury\\xa0can\\xa0develop\\xa0acute\\xa0erosive\\xa0gastric\\xa0mucosal\\xa0changes\\xa0or\\xa0frankulceration\\xa0with\\xa0bleeding.\\xa0Classified\\xa0as\\xa0stress\\xadinduced\\xa0gastritis\\xa0or\\xa0ulcers,\\xa0injury\\xa0is\\xa0most\\xa0commonly\\xa0observed\\xa0in\\xa0the\\xa0acid\\xadproducing\\xa0(fundus\\xa0and\\xa0body)portions\\xa0of\\xa0the\\xa0stomach.\\xa0The\\xa0most\\xa0common\\xa0presentation\\xa0is\\xa0GI\\xa0bleeding,\\xa0which\\xa0is\\xa0usually\\xa0minimal\\xa0but\\xa0can\\xa0occasionally\\xa0be\\xa0life\\xadthreatening.\\xa0Respiratoryfailure\\xa0requiring\\xa0mechanical\\xa0ventilation\\xa0and\\xa0underlying\\xa0coagulopathy\\xa0are\\xa0risk\\xa0factors\\xa0for\\xa0bleeding,\\xa0which\\xa0tends\\xa0to\\xa0occur\\xa048–72\\xa0h\\xa0after\\xa0the\\xa0acute\\xa0injuryor\\xa0insult.',\n",
       " 'failure\\xa0requiring\\xa0mechanical\\xa0ventilation\\xa0and\\xa0underlying\\xa0coagulopathy\\xa0are\\xa0risk\\xa0factors\\xa0for\\xa0bleeding,\\xa0which\\xa0tends\\xa0to\\xa0occur\\xa048–72\\xa0h\\xa0after\\xa0the\\xa0acute\\xa0injuryor\\xa0insult.Histologically,\\xa0stress\\xa0injury\\xa0does\\xa0not\\xa0contain\\xa0inflammation\\xa0or\\xa0H.\\xa0pylori;\\xa0thus,\\xa0“gastritis”\\xa0is\\xa0a\\xa0misnomer.\\xa0Although\\xa0elevated\\xa0gastric\\xa0acid\\xa0secretion\\xa0may\\xa0benoted\\xa0in\\xa0patients\\xa0with\\xa0stress\\xa0ulceration\\xa0after\\xa0head\\xa0trauma\\xa0(Cushing’s\\xa0ulcer)\\xa0and\\xa0severe\\xa0burns\\xa0(Curling’s\\xa0ulcer),\\xa0mucosal\\xa0ischemia,\\xa0breakdown\\xa0of\\xa0thenormal\\xa0protective\\xa0barriers\\xa0of\\xa0the\\xa0stomach,\\xa0systemic\\xa0release\\xa0of\\xa0cytokines,\\xa0poor\\xa0GI\\xa0motility,\\xa0and\\xa0oxidative\\xa0stress\\xa0also\\xa0play\\xa0an\\xa0important\\xa0role\\xa0in\\xa0thepathogenesis.\\xa0Acid\\xa0must\\xa0contribute\\xa0to\\xa0injury\\xa0in\\xa0view\\xa0of\\xa0the\\xa0significant\\xa0drop\\xa0in\\xa0bleeding\\xa0noted\\xa0when\\xa0acid\\xa0inhibitors\\xa0are\\xa0used\\xa0as\\xa0prophylaxis\\xa0for\\xa0stressgastritis.Improvement\\xa0in\\xa0the\\xa0general\\xa0management\\xa0of\\xa0intensive\\xa0care\\xa0unit\\xa0patients\\xa0has\\xa0led\\xa0to\\xa0a\\xa0significant\\xa0decrease\\xa0in\\xa0the\\xa0incidence\\xa0of\\xa0GI\\xa0bleeding\\xa0due\\xa0to\\xa0stressulceration.\\xa0The\\xa0estimated\\xa0decrease\\xa0in\\xa0bleeding\\xa0is\\xa0from\\xa020–30%\\xa0to\\xa0<5%.\\xa0This\\xa0improvement\\xa0has\\xa0led\\xa0to\\xa0some\\xa0debate\\xa0regarding\\xa0the\\xa0need\\xa0for\\xa0prophylactictherapy.\\xa0The\\xa0high\\xa0mortality\\xa0associated\\xa0with\\xa0stress\\xadinduced\\xa0clinically\\xa0important\\xa0GI\\xa0bleeding\\xa0(>40%)\\xa0and\\xa0the\\xa0limited\\xa0benefit\\xa0of\\xa0medical\\xa0(endoscopic,angiographic)\\xa0and\\xa0surgical\\xa0therapy\\xa0in\\xa0a\\xa0patient\\xa0with\\xa0hemodynamically\\xa0compromising\\xa0bleeding\\xa0associated\\xa0with\\xa0stress\\xa0ulcer/gastritis\\xa0support\\xa0the\\xa0use\\xa0ofpreventive\\xa0measures\\xa0in\\xa0high\\xadrisk\\xa0patients\\xa0(mechanically\\xa0ventilated,\\xa0coagulopathy,\\xa0multiorgan\\xa0failure,\\xa0or\\xa0severe\\xa0burns).\\xa0Meta\\xadanalysis\\xa0comparing\\xa0H2blockers\\xa0with\\xa0PPIs\\xa0for\\xa0the\\xa0prevention\\xa0of\\xa0stress\\xadassociated\\xa0clinically\\xa0important\\xa0and\\xa0overt\\xa0GI\\xa0bleeding\\xa0demonstrates\\xa0superiority\\xa0of\\xa0the\\xa0latter\\xa0withoutYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 42 / 49AntrumFundusDuodenumBillrothIBillrothIl',\n",
       " \"©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 42 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'normal\\xa0protective\\xa0barriers\\xa0of\\xa0the\\xa0stomach,\\xa0systemic\\xa0release\\xa0of\\xa0cytokines,\\xa0poor\\xa0GI\\xa0motility,\\xa0and\\xa0oxidative\\xa0stress\\xa0also\\xa0play\\xa0an\\xa0important\\xa0role\\xa0in\\xa0thepathogenesis.\\xa0Acid\\xa0must\\xa0contribute\\xa0to\\xa0injury\\xa0in\\xa0view\\xa0of\\xa0the\\xa0significant\\xa0drop\\xa0in\\xa0bleeding\\xa0noted\\xa0when\\xa0acid\\xa0inhibitors\\xa0are\\xa0used\\xa0as\\xa0prophylaxis\\xa0for\\xa0stressgastritis.Improvement\\xa0in\\xa0the\\xa0general\\xa0management\\xa0of\\xa0intensive\\xa0care\\xa0unit\\xa0patients\\xa0has\\xa0led\\xa0to\\xa0a\\xa0significant\\xa0decrease\\xa0in\\xa0the\\xa0incidence\\xa0of\\xa0GI\\xa0bleeding\\xa0due\\xa0to\\xa0stressulceration.\\xa0The\\xa0estimated\\xa0decrease\\xa0in\\xa0bleeding\\xa0is\\xa0from\\xa020–30%\\xa0to\\xa0<5%.\\xa0This\\xa0improvement\\xa0has\\xa0led\\xa0to\\xa0some\\xa0debate\\xa0regarding\\xa0the\\xa0need\\xa0for\\xa0prophylactictherapy.\\xa0The\\xa0high\\xa0mortality\\xa0associated\\xa0with\\xa0stress\\xadinduced\\xa0clinically\\xa0important\\xa0GI\\xa0bleeding\\xa0(>40%)\\xa0and\\xa0the\\xa0limited\\xa0benefit\\xa0of\\xa0medical\\xa0(endoscopic,angiographic)\\xa0and\\xa0surgical\\xa0therapy\\xa0in\\xa0a\\xa0patient\\xa0with\\xa0hemodynamically\\xa0compromising\\xa0bleeding\\xa0associated\\xa0with\\xa0stress\\xa0ulcer/gastritis\\xa0support\\xa0the\\xa0use\\xa0ofpreventive\\xa0measures\\xa0in\\xa0high\\xadrisk\\xa0patients\\xa0(mechanically\\xa0ventilated,\\xa0coagulopathy,\\xa0multiorgan\\xa0failure,\\xa0or\\xa0severe\\xa0burns).\\xa0Meta\\xadanalysis\\xa0comparing\\xa0H2blockers\\xa0with\\xa0PPIs\\xa0for\\xa0the\\xa0prevention\\xa0of\\xa0stress\\xadassociated\\xa0clinically\\xa0important\\xa0and\\xa0overt\\xa0GI\\xa0bleeding\\xa0demonstrates\\xa0superiority\\xa0of\\xa0the\\xa0latter\\xa0withoutincreasing\\xa0the\\xa0risk\\xa0of\\xa0nosocomial\\xa0infections,\\xa0increasing\\xa0mortality,\\xa0or\\xa0prolonging\\xa0intensive\\xa0care\\xa0unit\\xa0length\\xa0of\\xa0stay.\\xa0Therefore,\\xa0PPIs\\xa0are\\xa0the\\xa0treatment\\xa0ofchoice\\xa0for\\xa0stress\\xa0prophylaxis.\\xa0Oral\\xa0PPI\\xa0is\\xa0the\\xa0best\\xa0option\\xa0if\\xa0the\\xa0patient\\xa0can\\xa0tolerate\\xa0enteral\\xa0administration.\\xa0Pantoprazole\\xa0is\\xa0available\\xa0as\\xa0an\\xa0intravenousformulation\\xa0for\\xa0individuals\\xa0in\\xa0whom\\xa0enteral\\xa0administration\\xa0is\\xa0not\\xa0possible.\\xa0If\\xa0bleeding\\xa0occurs\\xa0despite\\xa0these\\xa0measures,\\xa0endoscopy,\\xa0intraarterialvasopressin,\\xa0and\\xa0embolization\\xa0are\\xa0options.\\xa0If\\xa0all\\xa0else\\xa0fails,\\xa0then\\xa0surgery\\xa0should\\xa0be\\xa0considered.\\xa0Although\\xa0vagotomy\\xa0and\\xa0antrectomy\\xa0may\\xa0be\\xa0used,\\xa0thebetter\\xa0approach\\xa0would\\xa0be\\xa0a\\xa0total\\xa0gastrectomy,\\xa0which\\xa0has\\xa0an\\xa0exceedingly\\xa0high\\xa0mortality\\xa0rate\\xa0in\\xa0this\\xa0setting.\\xa0Concerns\\xa0with\\xa0the\\xa0effect\\xa0of\\xa0PPIs\\xa0on\\xa0the',\n",
       " 'better\\xa0approach\\xa0would\\xa0be\\xa0a\\xa0total\\xa0gastrectomy,\\xa0which\\xa0has\\xa0an\\xa0exceedingly\\xa0high\\xa0mortality\\xa0rate\\xa0in\\xa0this\\xa0setting.\\xa0Concerns\\xa0with\\xa0the\\xa0effect\\xa0of\\xa0PPIs\\xa0on\\xa0theimmune\\xa0system\\xa0coupled\\xa0with\\xa0the\\xa0high\\xa0cost\\xa0of\\xa0this\\xa0agent\\xa0have\\xa0led\\xa0to\\xa0several\\xa0comparative\\xa0studies\\xa0of\\xa0PPIs\\xa0and\\xa0H2\\xa0receptor\\xa0antagonists\\xa0for\\xa0stressprophylaxis\\xa0in\\xa0patients\\xa0requiring\\xa0mechanical\\xa0ventilation.\\xa0Although\\xa0the\\xa0PEPTIC\\xa0trial\\xa0demonstrated\\xa0comparative\\xa0efficacy\\xa0between\\xa0the\\xa0two\\xa0agentsregarding\\xa0mortality,\\xa0technical\\xa0aspects\\xa0of\\xa0the\\xa0study\\xa0led\\xa0to\\xa0some\\xa0limitation\\xa0in\\xa0the\\xa0final\\xa0interpretation\\xa0of\\xa0the\\xa0results.GASTRITISThe\\xa0term\\xa0gastritis\\xa0should\\xa0be\\xa0reserved\\xa0for\\xa0histologically\\xa0documented\\xa0inflammation\\xa0of\\xa0the\\xa0gastric\\xa0mucosa.\\xa0Gastritis\\xa0is\\xa0not\\xa0the\\xa0mucosal\\xa0erythema\\xa0seenduring\\xa0endoscopy\\xa0and\\xa0is\\xa0not\\xa0interchangeable\\xa0with\\xa0“dyspepsia.”\\xa0The\\xa0etiologic\\xa0factors\\xa0leading\\xa0to\\xa0gastritis\\xa0are\\xa0broad\\xa0and\\xa0heterogeneous.\\xa0Gastritis\\xa0hasbeen\\xa0classified\\xa0based\\xa0on\\xa0time\\xa0course\\xa0(acute\\xa0vs\\xa0chronic),\\xa0histologic\\xa0features,\\xa0and\\xa0anatomic\\xa0distribution\\xa0or\\xa0proposed\\xa0pathogenic\\xa0mechanism\\xa0(Table324\\xad10).TABLE\\xa0324\\xad10Classification\\xa0of\\xa0GastritisI.\\xa0 Acute\\xa0gastritisA.\\xa0 Acute\\xa0Helicobacter\\xa0pylori\\xa0infectionB.\\xa0 Other\\xa0acute\\xa0infectious\\xa0gastritides1.\\xa0 Bacterial\\xa0(other\\xa0than\\xa0H.\\xa0pylori)2.\\xa0 Helicobacter\\xa0heilmannii3.\\xa0 Phlegmonous4.\\xa0 Mycobacterial5.\\xa0 Syphilitic6.\\xa0 Viral7.\\xa0 Parasitic8.\\xa0 FungalII.\\xa0 Chronic\\xa0atrophic\\xa0gastritisA.\\xa0 Type\\xa0A:\\xa0Autoimmune,\\xa0body\\xadpredominantB.\\xa0 Type\\xa0B:\\xa0H.\\xa0pylori–related,\\xa0antral\\xadpredominantC.\\xa0 IndeterminateIII.\\xa0 Uncommon\\xa0forms\\xa0of\\xa0gastritisA.\\xa0 LymphocyticB.\\xa0 EosinophilicC.\\xa0 Crohn’s\\xa0diseaseD.\\xa0 SarcoidosisE.\\xa0 Isolated\\xa0granulomatous\\xa0gastritisF.\\xa0 Russell\\xa0body\\xa0gastritisThe\\xa0correlation\\xa0between\\xa0the\\xa0histologic\\xa0findings\\xa0of\\xa0gastritis,\\xa0the\\xa0clinical\\xa0picture\\xa0of\\xa0abdominal\\xa0pain\\xa0or\\xa0dyspepsia,\\xa0and\\xa0endoscopic\\xa0findings\\xa0noted\\xa0ongross\\xa0inspection\\xa0of\\xa0the\\xa0gastric\\xa0mucosa\\xa0is\\xa0poor.\\xa0Therefore,\\xa0there\\xa0is\\xa0no\\xa0typical\\xa0clinical\\xa0manifestation\\xa0of\\xa0gastritis.Acute\\xa0Gastritis',\n",
       " \"gross\\xa0inspection\\xa0of\\xa0the\\xa0gastric\\xa0mucosa\\xa0is\\xa0poor.\\xa0Therefore,\\xa0there\\xa0is\\xa0no\\xa0typical\\xa0clinical\\xa0manifestation\\xa0of\\xa0gastritis.Acute\\xa0GastritisThe\\xa0most\\xa0common\\xa0causes\\xa0of\\xa0acute\\xa0gastritis\\xa0are\\xa0infectious.\\xa0Acute\\xa0infection\\xa0with\\xa0H.\\xa0pylori\\xa0induces\\xa0gastritis.\\xa0However,\\xa0H.\\xa0pylori\\xa0acute\\xa0gastritis\\xa0has\\xa0notYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 43 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'D.\\xa0 SarcoidosisE.\\xa0 Isolated\\xa0granulomatous\\xa0gastritisF.\\xa0 Russell\\xa0body\\xa0gastritisThe\\xa0correlation\\xa0between\\xa0the\\xa0histologic\\xa0findings\\xa0of\\xa0gastritis,\\xa0the\\xa0clinical\\xa0picture\\xa0of\\xa0abdominal\\xa0pain\\xa0or\\xa0dyspepsia,\\xa0and\\xa0endoscopic\\xa0findings\\xa0noted\\xa0ongross\\xa0inspection\\xa0of\\xa0the\\xa0gastric\\xa0mucosa\\xa0is\\xa0poor.\\xa0Therefore,\\xa0there\\xa0is\\xa0no\\xa0typical\\xa0clinical\\xa0manifestation\\xa0of\\xa0gastritis.Acute\\xa0GastritisThe\\xa0most\\xa0common\\xa0causes\\xa0of\\xa0acute\\xa0gastritis\\xa0are\\xa0infectious.\\xa0Acute\\xa0infection\\xa0with\\xa0H.\\xa0pylori\\xa0induces\\xa0gastritis.\\xa0However,\\xa0H.\\xa0pylori\\xa0acute\\xa0gastritis\\xa0has\\xa0notbeen\\xa0extensively\\xa0studied.\\xa0It\\xa0is\\xa0reported\\xa0as\\xa0presenting\\xa0with\\xa0sudden\\xa0onset\\xa0of\\xa0epigastric\\xa0pain,\\xa0nausea,\\xa0and\\xa0vomiting,\\xa0and\\xa0limited\\xa0mucosal\\xa0histologicstudies\\xa0demonstrate\\xa0a\\xa0marked\\xa0infiltrate\\xa0of\\xa0neutrophils\\xa0with\\xa0edema\\xa0and\\xa0hyperemia.\\xa0If\\xa0not\\xa0treated,\\xa0this\\xa0picture\\xa0will\\xa0evolve\\xa0into\\xa0one\\xa0of\\xa0chronic\\xa0gastritis.Hypochlorhydria\\xa0lasting\\xa0for\\xa0up\\xa0to\\xa01\\xa0year\\xa0may\\xa0follow\\xa0acute\\xa0H.\\xa0pylori\\xa0infection.Bacterial\\xa0infection\\xa0of\\xa0the\\xa0stomach\\xa0or\\xa0phlegmonous\\xa0gastritis\\xa0is\\xa0a\\xa0rare,\\xa0potentially\\xa0life\\xadthreatening\\xa0disorder\\xa0characterized\\xa0by\\xa0marked\\xa0and\\xa0diffuse\\xa0acuteinflammatory\\xa0infiltrates\\xa0of\\xa0the\\xa0entire\\xa0gastric\\xa0wall,\\xa0at\\xa0times\\xa0accompanied\\xa0by\\xa0necrosis.\\xa0Elderly\\xa0individuals,\\xa0alcoholics,\\xa0and\\xa0AIDS\\xa0patients\\xa0may\\xa0be\\xa0affected.Potential\\xa0iatrogenic\\xa0causes\\xa0include\\xa0polypectomy\\xa0and\\xa0mucosal\\xa0injection\\xa0with\\xa0India\\xa0ink.\\xa0Organisms\\xa0associated\\xa0with\\xa0this\\xa0entity\\xa0include\\xa0streptococci,staphylococci,\\xa0Escherichia\\xa0coli,\\xa0Proteus,\\xa0and\\xa0Haemophilus\\xa0species.\\xa0Failure\\xa0of\\xa0supportive\\xa0measures\\xa0and\\xa0antibiotics\\xa0may\\xa0result\\xa0in\\xa0gastrectomy.Other\\xa0types\\xa0of\\xa0infectious\\xa0gastritis\\xa0may\\xa0occur\\xa0in\\xa0immunocompromised\\xa0individuals\\xa0such\\xa0as\\xa0AIDS\\xa0patients.\\xa0Examples\\xa0include\\xa0herpetic\\xa0(herpes\\xa0simplex)\\xa0orCMV\\xa0gastritis.\\xa0The\\xa0histologic\\xa0finding\\xa0of\\xa0intranuclear\\xa0inclusions\\xa0would\\xa0be\\xa0observed\\xa0in\\xa0the\\xa0latter.Chronic\\xa0GastritisChronic\\xa0gastritis\\xa0is\\xa0identified\\xa0histologically\\xa0by\\xa0an\\xa0inflammatory\\xa0cell\\xa0infiltrate\\xa0consisting\\xa0primarily\\xa0of\\xa0lymphocytes\\xa0and\\xa0plasma\\xa0cells,\\xa0with\\xa0very\\xa0scant',\n",
       " 'Chronic\\xa0GastritisChronic\\xa0gastritis\\xa0is\\xa0identified\\xa0histologically\\xa0by\\xa0an\\xa0inflammatory\\xa0cell\\xa0infiltrate\\xa0consisting\\xa0primarily\\xa0of\\xa0lymphocytes\\xa0and\\xa0plasma\\xa0cells,\\xa0with\\xa0very\\xa0scantneutrophil\\xa0involvement.\\xa0Distribution\\xa0of\\xa0the\\xa0inflammation\\xa0may\\xa0be\\xa0patchy,\\xa0initially\\xa0involving\\xa0superficial\\xa0and\\xa0glandular\\xa0portions\\xa0of\\xa0the\\xa0gastric\\xa0mucosa.This\\xa0picture\\xa0may\\xa0progress\\xa0to\\xa0more\\xa0severe\\xa0glandular\\xa0destruction,\\xa0with\\xa0atrophy\\xa0and\\xa0metaplasia.\\xa0Chronic\\xa0gastritis\\xa0has\\xa0been\\xa0classified\\xa0according\\xa0tohistologic\\xa0characteristics.\\xa0These\\xa0include\\xa0superficial\\xa0atrophic\\xa0changes\\xa0and\\xa0gastric\\xa0atrophy.\\xa0The\\xa0association\\xa0of\\xa0atrophic\\xa0gastritis\\xa0with\\xa0the\\xa0development\\xa0ofgastric\\xa0cancer\\xa0has\\xa0led\\xa0to\\xa0the\\xa0development\\xa0of\\xa0endoscopic\\xa0and\\xa0serologic\\xa0markers\\xa0of\\xa0severity.\\xa0Some\\xa0of\\xa0these\\xa0include\\xa0gross\\xa0inspection\\xa0and\\xa0classification\\xa0ofmucosal\\xa0abnormalities\\xa0during\\xa0standard\\xa0endoscopy,\\xa0magnification\\xa0endoscopy,\\xa0endoscopy\\xa0with\\xa0narrow\\xa0band\\xa0imaging\\xa0and/or\\xa0autofluorescenceimaging,\\xa0and\\xa0measurement\\xa0of\\xa0several\\xa0serum\\xa0biomarkers\\xa0including\\xa0pepsinogen\\xa0I\\xa0and\\xa0II\\xa0levels,\\xa0gastrin\\xad17,\\xa0and\\xa0anti–H.\\xa0pylori\\xa0serologies.\\xa0The\\xa0clinicalutility\\xa0of\\xa0these\\xa0tools\\xa0is\\xa0currently\\xa0being\\xa0explored.The\\xa0early\\xa0phase\\xa0of\\xa0chronic\\xa0gastritis\\xa0is\\xa0superficial\\xa0gastritis.\\xa0The\\xa0inflammatory\\xa0changes\\xa0are\\xa0limited\\xa0to\\xa0the\\xa0lamina\\xa0propria\\xa0of\\xa0the\\xa0surface\\xa0mucosa,\\xa0withedema\\xa0and\\xa0cellular\\xa0infiltrates\\xa0separating\\xa0intact\\xa0gastric\\xa0glands.\\xa0The\\xa0next\\xa0stage\\xa0is\\xa0atrophic\\xa0gastritis.\\xa0The\\xa0inflammatory\\xa0infiltrate\\xa0extends\\xa0deeper\\xa0into\\xa0themucosa,\\xa0with\\xa0progressive\\xa0distortion\\xa0and\\xa0destruction\\xa0of\\xa0the\\xa0glands.\\xa0The\\xa0final\\xa0stage\\xa0of\\xa0chronic\\xa0gastritis\\xa0is\\xa0gastric\\xa0atrophy.\\xa0Glandular\\xa0structures\\xa0are\\xa0lost,and\\xa0there\\xa0is\\xa0a\\xa0paucity\\xa0of\\xa0inflammatory\\xa0infiltrates.\\xa0Endoscopically,\\xa0the\\xa0mucosa\\xa0may\\xa0be\\xa0substantially\\xa0thin,\\xa0permitting\\xa0clear\\xa0visualization\\xa0of\\xa0the\\xa0underlyingblood\\xa0vessels.Gastric\\xa0glands\\xa0may\\xa0undergo\\xa0morphologic\\xa0transformation\\xa0in\\xa0chronic\\xa0gastritis.\\xa0Intestinal\\xa0metaplasia\\xa0denotes\\xa0the\\xa0conversion\\xa0of\\xa0gastric\\xa0glands\\xa0to\\xa0a\\xa0small',\n",
       " 'blood\\xa0vessels.Gastric\\xa0glands\\xa0may\\xa0undergo\\xa0morphologic\\xa0transformation\\xa0in\\xa0chronic\\xa0gastritis.\\xa0Intestinal\\xa0metaplasia\\xa0denotes\\xa0the\\xa0conversion\\xa0of\\xa0gastric\\xa0glands\\xa0to\\xa0a\\xa0smallintestinal\\xa0phenotype\\xa0with\\xa0small\\xadbowel\\xa0mucosal\\xa0glands\\xa0containing\\xa0goblet\\xa0cells.\\xa0The\\xa0metaplastic\\xa0changes\\xa0may\\xa0vary\\xa0in\\xa0distribution\\xa0from\\xa0patchy\\xa0to\\xa0fairlyextensive\\xa0gastric\\xa0involvement.\\xa0Intestinal\\xa0metaplasia\\xa0is\\xa0an\\xa0important\\xa0predisposing\\xa0factor\\xa0for\\xa0gastric\\xa0cancer\\xa0(Chap.\\xa080).Chronic\\xa0gastritis\\xa0is\\xa0also\\xa0classified\\xa0according\\xa0to\\xa0the\\xa0predominant\\xa0site\\xa0of\\xa0involvement.\\xa0Type\\xa0A\\xa0refers\\xa0to\\xa0the\\xa0body\\xadpredominant\\xa0form\\xa0(autoimmune),\\xa0andtype\\xa0B\\xa0is\\xa0the\\xa0antral\\xadpredominant\\xa0form\\xa0(H.\\xa0pylori–related).\\xa0This\\xa0classification\\xa0is\\xa0artificial\\xa0in\\xa0view\\xa0of\\xa0the\\xa0difficulty\\xa0in\\xa0distinguishing\\xa0between\\xa0these\\xa0twoentities.\\xa0The\\xa0term\\xa0AB\\xa0gastritis\\xa0has\\xa0been\\xa0used\\xa0to\\xa0refer\\xa0to\\xa0a\\xa0mixed\\xa0antral/body\\xa0picture.TYPE\\xa0A\\xa0GASTRITISThe\\xa0less\\xa0common\\xa0of\\xa0the\\xa0two\\xa0forms\\xa0involves\\xa0primarily\\xa0the\\xa0fundus\\xa0and\\xa0body,\\xa0with\\xa0antral\\xa0sparing.\\xa0Traditionally,\\xa0this\\xa0form\\xa0of\\xa0gastritis\\xa0has\\xa0been\\xa0associatedwith\\xa0pernicious\\xa0anemia\\xa0(Chap.\\xa095)\\xa0in\\xa0the\\xa0presence\\xa0of\\xa0circulating\\xa0antibodies\\xa0against\\xa0parietal\\xa0cells\\xa0and\\xa0IF;\\xa0thus,\\xa0it\\xa0is\\xa0also\\xa0called\\xa0autoimmune\\xa0gastritis.\\xa0H.pylori\\xa0infection\\xa0can\\xa0lead\\xa0to\\xa0a\\xa0similar\\xa0distribution\\xa0of\\xa0gastritis.\\xa0The\\xa0characteristics\\xa0of\\xa0an\\xa0autoimmune\\xa0picture\\xa0are\\xa0not\\xa0always\\xa0present.Antibodies\\xa0to\\xa0parietal\\xa0cells\\xa0have\\xa0been\\xa0detected\\xa0in\\xa0>90%\\xa0of\\xa0patients\\xa0with\\xa0pernicious\\xa0anemia\\xa0and\\xa0in\\xa0up\\xa0to\\xa050%\\xa0of\\xa0patients\\xa0with\\xa0type\\xa0A\\xa0gastritis.\\xa0Theparietal\\xa0cell\\xa0antibody\\xa0is\\xa0directed\\xa0against\\xa0H+,K+\\xadATPase.\\xa0T\\xa0cells\\xa0are\\xa0also\\xa0implicated\\xa0in\\xa0the\\xa0injury\\xa0pattern\\xa0of\\xa0this\\xa0form\\xa0of\\xa0gastritis.\\xa0A\\xa0subset\\xa0of\\xa0patientsinfected\\xa0with\\xa0H.\\xa0pylori\\xa0develop\\xa0antibodies\\xa0against\\xa0H+,K+\\xadATPase,\\xa0potentially\\xa0leading\\xa0to\\xa0the\\xa0atrophic\\xa0gastritis\\xa0pattern\\xa0seen\\xa0in\\xa0some\\xa0patients\\xa0infected\\xa0withthis\\xa0organism.\\xa0The\\xa0mechanism\\xa0is\\xa0thought\\xa0to\\xa0involve\\xa0molecular\\xa0mimicry\\xa0between\\xa0H.\\xa0pylori\\xa0LPS\\xa0and\\xa0H+,K+\\xadATPase.Parietal\\xa0cell\\xa0antibodies\\xa0and\\xa0atrophic\\xa0gastritis\\xa0are\\xa0observed\\xa0in\\xa0family\\xa0members\\xa0of\\xa0patients\\xa0with\\xa0pernicious\\xa0anemia.\\xa0These\\xa0antibodies\\xa0are\\xa0observed\\xa0in\\xa0up',\n",
       " \"Parietal\\xa0cell\\xa0antibodies\\xa0and\\xa0atrophic\\xa0gastritis\\xa0are\\xa0observed\\xa0in\\xa0family\\xa0members\\xa0of\\xa0patients\\xa0with\\xa0pernicious\\xa0anemia.\\xa0These\\xa0antibodies\\xa0are\\xa0observed\\xa0in\\xa0upto\\xa020%\\xa0of\\xa0individuals\\xa0aged\\xa0>60\\xa0and\\xa0in\\xa0~20%\\xa0of\\xa0patients\\xa0with\\xa0vitiligo\\xa0and\\xa0Addison’s\\xa0disease.\\xa0About\\xa0one\\xadhalf\\xa0of\\xa0patients\\xa0with\\xa0pernicious\\xa0anemia\\xa0haveantibodies\\xa0to\\xa0thyroid\\xa0antigens,\\xa0and\\xa0~30%\\xa0of\\xa0patients\\xa0with\\xa0thyroid\\xa0disease\\xa0have\\xa0circulating\\xa0anti–parietal\\xa0cell\\xa0antibodies.\\xa0Anti\\xadIF\\xa0antibodies\\xa0are\\xa0moreifi thi t llltib diftAt itib it i40% ftitithi iiAthti ttithYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 44 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'pylori\\xa0infection\\xa0can\\xa0lead\\xa0to\\xa0a\\xa0similar\\xa0distribution\\xa0of\\xa0gastritis.\\xa0The\\xa0characteristics\\xa0of\\xa0an\\xa0autoimmune\\xa0picture\\xa0are\\xa0not\\xa0always\\xa0present.Antibodies\\xa0to\\xa0parietal\\xa0cells\\xa0have\\xa0been\\xa0detected\\xa0in\\xa0>90%\\xa0of\\xa0patients\\xa0with\\xa0pernicious\\xa0anemia\\xa0and\\xa0in\\xa0up\\xa0to\\xa050%\\xa0of\\xa0patients\\xa0with\\xa0type\\xa0A\\xa0gastritis.\\xa0Theparietal\\xa0cell\\xa0antibody\\xa0is\\xa0directed\\xa0against\\xa0H+,K+\\xadATPase.\\xa0T\\xa0cells\\xa0are\\xa0also\\xa0implicated\\xa0in\\xa0the\\xa0injury\\xa0pattern\\xa0of\\xa0this\\xa0form\\xa0of\\xa0gastritis.\\xa0A\\xa0subset\\xa0of\\xa0patientsinfected\\xa0with\\xa0H.\\xa0pylori\\xa0develop\\xa0antibodies\\xa0against\\xa0H+,K+\\xadATPase,\\xa0potentially\\xa0leading\\xa0to\\xa0the\\xa0atrophic\\xa0gastritis\\xa0pattern\\xa0seen\\xa0in\\xa0some\\xa0patients\\xa0infected\\xa0withthis\\xa0organism.\\xa0The\\xa0mechanism\\xa0is\\xa0thought\\xa0to\\xa0involve\\xa0molecular\\xa0mimicry\\xa0between\\xa0H.\\xa0pylori\\xa0LPS\\xa0and\\xa0H+,K+\\xadATPase.Parietal\\xa0cell\\xa0antibodies\\xa0and\\xa0atrophic\\xa0gastritis\\xa0are\\xa0observed\\xa0in\\xa0family\\xa0members\\xa0of\\xa0patients\\xa0with\\xa0pernicious\\xa0anemia.\\xa0These\\xa0antibodies\\xa0are\\xa0observed\\xa0in\\xa0upto\\xa020%\\xa0of\\xa0individuals\\xa0aged\\xa0>60\\xa0and\\xa0in\\xa0~20%\\xa0of\\xa0patients\\xa0with\\xa0vitiligo\\xa0and\\xa0Addison’s\\xa0disease.\\xa0About\\xa0one\\xadhalf\\xa0of\\xa0patients\\xa0with\\xa0pernicious\\xa0anemia\\xa0haveantibodies\\xa0to\\xa0thyroid\\xa0antigens,\\xa0and\\xa0~30%\\xa0of\\xa0patients\\xa0with\\xa0thyroid\\xa0disease\\xa0have\\xa0circulating\\xa0anti–parietal\\xa0cell\\xa0antibodies.\\xa0Anti\\xadIF\\xa0antibodies\\xa0are\\xa0morespecific\\xa0than\\xa0parietal\\xa0cell\\xa0antibodies\\xa0for\\xa0type\\xa0A\\xa0gastritis,\\xa0being\\xa0present\\xa0in\\xa0~40%\\xa0of\\xa0patients\\xa0with\\xa0pernicious\\xa0anemia.\\xa0Another\\xa0parameter\\xa0consistent\\xa0withthis\\xa0form\\xa0of\\xa0gastritis\\xa0being\\xa0autoimmune\\xa0in\\xa0origin\\xa0is\\xa0the\\xa0higher\\xa0incidence\\xa0of\\xa0specific\\xa0familial\\xa0histocompatibility\\xa0haplotypes\\xa0such\\xa0as\\xa0HLA\\xadB8\\xa0and\\xa0HLA\\xadDR3.Low\\xa0pepsinogen\\xa0levels\\xa0have\\xa0also\\xa0been\\xa0observed;\\xa0thus,\\xa0this\\xa0marker\\xa0has\\xa0been\\xa0used\\xa0as\\xa0an\\xa0additional\\xa0diagnostic\\xa0tool\\xa0in\\xa0autoimmune\\xa0gastritis.The\\xa0parietal\\xa0cell–containing\\xa0gastric\\xa0gland\\xa0is\\xa0preferentially\\xa0targeted\\xa0in\\xa0this\\xa0form\\xa0of\\xa0gastritis,\\xa0and\\xa0achlorhydria\\xa0results.\\xa0Parietal\\xa0cells\\xa0are\\xa0the\\xa0source\\xa0of\\xa0IF,the\\xa0lack\\xa0of\\xa0which\\xa0will\\xa0lead\\xa0to\\xa0vitamin\\xa0B12\\xa0deficiency\\xa0and\\xa0its\\xa0sequelae\\xa0(megaloblastic\\xa0anemia,\\xa0neurologic\\xa0dysfunction).Gastric\\xa0acid\\xa0plays\\xa0an\\xa0important\\xa0role\\xa0in\\xa0feedback\\xa0inhibition\\xa0of\\xa0gastrin\\xa0release\\xa0from\\xa0G\\xa0cells.\\xa0Achlorhydria,\\xa0coupled\\xa0with\\xa0relative\\xa0sparing\\xa0of\\xa0the\\xa0antral',\n",
       " 'Gastric\\xa0acid\\xa0plays\\xa0an\\xa0important\\xa0role\\xa0in\\xa0feedback\\xa0inhibition\\xa0of\\xa0gastrin\\xa0release\\xa0from\\xa0G\\xa0cells.\\xa0Achlorhydria,\\xa0coupled\\xa0with\\xa0relative\\xa0sparing\\xa0of\\xa0the\\xa0antralmucosa\\xa0(site\\xa0of\\xa0G\\xa0cells),\\xa0leads\\xa0to\\xa0hypergastrinemia.\\xa0Gastrin\\xa0levels\\xa0can\\xa0be\\xa0markedly\\xa0elevated\\xa0(>500\\xa0pg/mL)\\xa0in\\xa0patients\\xa0with\\xa0pernicious\\xa0anemia.\\xa0ECL\\xa0cellhyperplasia\\xa0with\\xa0frank\\xa0development\\xa0of\\xa0gastric\\xa0carcinoid\\xa0tumors\\xa0may\\xa0result\\xa0from\\xa0gastrin\\xa0trophic\\xa0effects.\\xa0Hypergastrinemia\\xa0and\\xa0achlorhydria\\xa0may\\xa0alsobe\\xa0seen\\xa0in\\xa0nonpernicious\\xa0anemia–associated\\xa0type\\xa0A\\xa0gastritis.TYPE\\xa0B\\xa0GASTRITISType\\xa0B,\\xa0or\\xa0antral\\xadpredominant,\\xa0gastritis\\xa0is\\xa0the\\xa0more\\xa0common\\xa0form\\xa0of\\xa0chronic\\xa0gastritis.\\xa0H.\\xa0pylori\\xa0infection\\xa0is\\xa0the\\xa0cause\\xa0of\\xa0this\\xa0entity.\\xa0Although\\xa0describedas\\xa0“antral\\xadpredominant,”\\xa0this\\xa0is\\xa0likely\\xa0a\\xa0misnomer\\xa0in\\xa0view\\xa0of\\xa0studies\\xa0documenting\\xa0the\\xa0progression\\xa0of\\xa0the\\xa0inflammatory\\xa0process\\xa0toward\\xa0the\\xa0body\\xa0andfundus\\xa0of\\xa0infected\\xa0individuals.\\xa0The\\xa0conversion\\xa0to\\xa0a\\xa0pangastritis\\xa0is\\xa0time\\xa0dependent\\xa0and\\xa0estimated\\xa0to\\xa0require\\xa015–20\\xa0years.\\xa0This\\xa0form\\xa0of\\xa0gastritisincreases\\xa0with\\xa0age,\\xa0being\\xa0present\\xa0in\\xa0up\\xa0to\\xa0100%\\xa0of\\xa0persons\\xa0aged\\xa0>70.\\xa0Histology\\xa0improves\\xa0after\\xa0H.\\xa0pylori\\xa0eradication.\\xa0The\\xa0number\\xa0of\\xa0H.\\xa0pylori\\xa0organismsdecreases\\xa0dramatically\\xa0with\\xa0progression\\xa0to\\xa0gastric\\xa0atrophy,\\xa0and\\xa0the\\xa0degree\\xa0of\\xa0inflammation\\xa0correlates\\xa0with\\xa0the\\xa0level\\xa0of\\xa0these\\xa0organisms.\\xa0Early\\xa0on,\\xa0withantral\\xadpredominant\\xa0findings,\\xa0the\\xa0quantity\\xa0of\\xa0H.\\xa0pylori\\xa0is\\xa0highest\\xa0and\\xa0a\\xa0dense\\xa0chronic\\xa0inflammatory\\xa0infiltrate\\xa0of\\xa0the\\xa0lamina\\xa0propria\\xa0is\\xa0noted,accompanied\\xa0by\\xa0epithelial\\xa0cell\\xa0infiltration\\xa0with\\xa0polymorphonuclear\\xa0leukocytes\\xa0(Fig.\\xa0324\\xad16).FIGURE\\xa0324\\xad16Chronic\\xa0gastritis\\xa0and\\xa0H.\\xa0pylori\\xa0organisms.\\xa0Steiner\\xa0silver\\xa0stain\\xa0of\\xa0superficial\\xa0gastric\\xa0mucosa\\xa0showing\\xa0abundant\\xa0darkly\\xa0stained\\xa0microorganismslayered\\xa0over\\xa0the\\xa0apical\\xa0portion\\xa0of\\xa0the\\xa0surface\\xa0epithelium.\\xa0Note\\xa0that\\xa0there\\xa0is\\xa0no\\xa0tissue\\xa0invasion.Multifocal\\xa0atrophic\\xa0gastritis,\\xa0gastric\\xa0atrophy\\xa0with\\xa0subsequent\\xa0metaplasia,\\xa0has\\xa0been\\xa0observed\\xa0in\\xa0chronic\\xa0H.\\xa0pylori–induced\\xa0gastritis.\\xa0This\\xa0may\\xa0ultimately',\n",
       " \"Multifocal\\xa0atrophic\\xa0gastritis,\\xa0gastric\\xa0atrophy\\xa0with\\xa0subsequent\\xa0metaplasia,\\xa0has\\xa0been\\xa0observed\\xa0in\\xa0chronic\\xa0H.\\xa0pylori–induced\\xa0gastritis.\\xa0This\\xa0may\\xa0ultimatelylead\\xa0to\\xa0development\\xa0of\\xa0gastric\\xa0adenocarcinoma\\xa0(Fig.\\xa0324\\xad8;\\xa0Chap.\\xa080).\\xa0H.\\xa0pylori\\xa0infection\\xa0is\\xa0now\\xa0considered\\xa0an\\xa0independent\\xa0risk\\xa0factor\\xa0for\\xa0gastriccancer.\\xa0Worldwide\\xa0epidemiologic\\xa0studies\\xa0have\\xa0documented\\xa0a\\xa0higher\\xa0incidence\\xa0of\\xa0H.\\xa0pylori\\xa0infection\\xa0in\\xa0patients\\xa0with\\xa0adenocarcinoma\\xa0of\\xa0the\\xa0stomachas\\xa0compared\\xa0to\\xa0control\\xa0subjects.\\xa0Seropositivity\\xa0for\\xa0H.\\xa0pylori\\xa0is\\xa0associated\\xa0with\\xa0a\\xa0three\\xad\\xa0to\\xa0sixfold\\xa0increased\\xa0risk\\xa0of\\xa0gastric\\xa0cancer.\\xa0This\\xa0risk\\xa0may\\xa0be\\xa0ashigh\\xa0as\\xa0ninefold\\xa0after\\xa0adjusting\\xa0for\\xa0the\\xa0inaccuracy\\xa0of\\xa0serologic\\xa0testing\\xa0in\\xa0the\\xa0elderly.\\xa0The\\xa0mechanism\\xa0by\\xa0which\\xa0H.\\xa0pylori\\xa0infection\\xa0leads\\xa0to\\xa0cancer\\xa0isunknown,\\xa0but\\xa0it\\xa0appears\\xa0to\\xa0be\\xa0related\\xa0to\\xa0the\\xa0chronic\\xa0inflammation\\xa0induced\\xa0by\\xa0the\\xa0organism.\\xa0Eradication\\xa0of\\xa0H.\\xa0pylori\\xa0as\\xa0a\\xa0general\\xa0preventative\\xa0measurefor\\xa0gastric\\xa0cancer\\xa0is\\xa0being\\xa0evaluated\\xa0but\\xa0is\\xa0not\\xa0yet\\xa0recommended.Infection with H pylori is also associated with development of a low grade B cell lymphoma gastric MALT lymphoma (Chap 108) The chronic T cellYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 45 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecur\",\n",
       " \"pain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'Multifocal\\xa0atrophic\\xa0gastritis,\\xa0gastric\\xa0atrophy\\xa0with\\xa0subsequent\\xa0metaplasia,\\xa0has\\xa0been\\xa0observed\\xa0in\\xa0chronic\\xa0H.\\xa0pylori–induced\\xa0gastritis.\\xa0This\\xa0may\\xa0ultimatelylead\\xa0to\\xa0development\\xa0of\\xa0gastric\\xa0adenocarcinoma\\xa0(Fig.\\xa0324\\xad8;\\xa0Chap.\\xa080).\\xa0H.\\xa0pylori\\xa0infection\\xa0is\\xa0now\\xa0considered\\xa0an\\xa0independent\\xa0risk\\xa0factor\\xa0for\\xa0gastriccancer.\\xa0Worldwide\\xa0epidemiologic\\xa0studies\\xa0have\\xa0documented\\xa0a\\xa0higher\\xa0incidence\\xa0of\\xa0H.\\xa0pylori\\xa0infection\\xa0in\\xa0patients\\xa0with\\xa0adenocarcinoma\\xa0of\\xa0the\\xa0stomachas\\xa0compared\\xa0to\\xa0control\\xa0subjects.\\xa0Seropositivity\\xa0for\\xa0H.\\xa0pylori\\xa0is\\xa0associated\\xa0with\\xa0a\\xa0three\\xad\\xa0to\\xa0sixfold\\xa0increased\\xa0risk\\xa0of\\xa0gastric\\xa0cancer.\\xa0This\\xa0risk\\xa0may\\xa0be\\xa0ashigh\\xa0as\\xa0ninefold\\xa0after\\xa0adjusting\\xa0for\\xa0the\\xa0inaccuracy\\xa0of\\xa0serologic\\xa0testing\\xa0in\\xa0the\\xa0elderly.\\xa0The\\xa0mechanism\\xa0by\\xa0which\\xa0H.\\xa0pylori\\xa0infection\\xa0leads\\xa0to\\xa0cancer\\xa0isunknown,\\xa0but\\xa0it\\xa0appears\\xa0to\\xa0be\\xa0related\\xa0to\\xa0the\\xa0chronic\\xa0inflammation\\xa0induced\\xa0by\\xa0the\\xa0organism.\\xa0Eradication\\xa0of\\xa0H.\\xa0pylori\\xa0as\\xa0a\\xa0general\\xa0preventative\\xa0measurefor\\xa0gastric\\xa0cancer\\xa0is\\xa0being\\xa0evaluated\\xa0but\\xa0is\\xa0not\\xa0yet\\xa0recommended.Infection\\xa0with\\xa0H.\\xa0pylori\\xa0is\\xa0also\\xa0associated\\xa0with\\xa0development\\xa0of\\xa0a\\xa0low\\xadgrade\\xa0B\\xadcell\\xa0lymphoma,\\xa0gastric\\xa0MALT\\xa0lymphoma\\xa0(Chap.\\xa0108).\\xa0The\\xa0chronic\\xa0T\\xadcellstimulation\\xa0caused\\xa0by\\xa0the\\xa0infection\\xa0leads\\xa0to\\xa0production\\xa0of\\xa0cytokines\\xa0that\\xa0promote\\xa0the\\xa0B\\xadcell\\xa0tumor.\\xa0The\\xa0tumor\\xa0should\\xa0be\\xa0initially\\xa0staged\\xa0with\\xa0a\\xa0CT\\xa0scanof\\xa0the\\xa0abdomen\\xa0and\\xa0EUS.\\xa0Tumor\\xa0growth\\xa0remains\\xa0dependent\\xa0on\\xa0the\\xa0presence\\xa0of\\xa0H.\\xa0pylori,\\xa0and\\xa0its\\xa0eradication\\xa0is\\xa0often\\xa0associated\\xa0with\\xa0completeregression\\xa0of\\xa0the\\xa0tumor.\\xa0The\\xa0tumor\\xa0may\\xa0take\\xa0more\\xa0than\\xa0a\\xa0year\\xa0to\\xa0regress\\xa0after\\xa0treating\\xa0the\\xa0infection.\\xa0Such\\xa0patients\\xa0should\\xa0be\\xa0followed\\xa0by\\xa0EUS\\xa0every\\xa02–3\\xa0months.\\xa0If\\xa0the\\xa0tumor\\xa0is\\xa0stable\\xa0or\\xa0decreasing\\xa0in\\xa0size,\\xa0no\\xa0other\\xa0therapy\\xa0is\\xa0necessary.\\xa0If\\xa0the\\xa0tumor\\xa0grows,\\xa0it\\xa0may\\xa0have\\xa0become\\xa0a\\xa0high\\xadgrade\\xa0B\\xadcelllymphoma.\\xa0When\\xa0the\\xa0tumor\\xa0becomes\\xa0a\\xa0high\\xadgrade\\xa0aggressive\\xa0lymphoma\\xa0histologically,\\xa0it\\xa0loses\\xa0responsiveness\\xa0to\\xa0H.\\xa0pylori\\xa0eradication.TREATMENT\\xa0OF\\xa0CHRONIC\\xa0GASTRITISTreatment\\xa0in\\xa0chronic\\xa0gastritis\\xa0is\\xa0aimed\\xa0at\\xa0the\\xa0sequelae\\xa0and\\xa0not\\xa0the\\xa0underlying\\xa0inflammation.\\xa0Patients\\xa0with\\xa0pernicious\\xa0anemia\\xa0will\\xa0require\\xa0parenteral',\n",
       " 'TREATMENT\\xa0OF\\xa0CHRONIC\\xa0GASTRITISTreatment\\xa0in\\xa0chronic\\xa0gastritis\\xa0is\\xa0aimed\\xa0at\\xa0the\\xa0sequelae\\xa0and\\xa0not\\xa0the\\xa0underlying\\xa0inflammation.\\xa0Patients\\xa0with\\xa0pernicious\\xa0anemia\\xa0will\\xa0require\\xa0parenteralvitamin\\xa0B12\\xa0supplementation\\xa0on\\xa0a\\xa0long\\xadterm\\xa0basis.\\xa0Eradication\\xa0of\\xa0H.\\xa0pylori\\xa0is\\xa0often\\xa0recommended\\xa0even\\xa0if\\xa0PUD\\xa0or\\xa0a\\xa0low\\xadgrade\\xa0MALT\\xa0lymphoma\\xa0is\\xa0notpresent.\\xa0Expert\\xa0opinion\\xa0suggests\\xa0that\\xa0patients\\xa0with\\xa0atrophic\\xa0gastritis\\xa0complicated\\xa0by\\xa0intestinal\\xa0metaplasia\\xa0without\\xa0dysplasia\\xa0should\\xa0undergosurveillance\\xa0endoscopy\\xa0every\\xa03\\xa0years.Miscellaneous\\xa0Forms\\xa0of\\xa0GastritisLymphocytic\\xa0gastritis\\xa0is\\xa0characterized\\xa0histologically\\xa0by\\xa0intense\\xa0infiltration\\xa0of\\xa0the\\xa0surface\\xa0epithelium\\xa0with\\xa0lymphocytes.\\xa0The\\xa0infiltrative\\xa0process\\xa0isprimarily\\xa0in\\xa0the\\xa0body\\xa0of\\xa0the\\xa0stomach\\xa0and\\xa0consists\\xa0of\\xa0mature\\xa0T\\xa0cells\\xa0and\\xa0plasmacytes.\\xa0The\\xa0etiology\\xa0of\\xa0this\\xa0form\\xa0of\\xa0chronic\\xa0gastritis\\xa0is\\xa0unknown.\\xa0It\\xa0hasbeen\\xa0described\\xa0in\\xa0patients\\xa0with\\xa0celiac\\xa0sprue,\\xa0but\\xa0whether\\xa0there\\xa0is\\xa0a\\xa0common\\xa0factor\\xa0associating\\xa0these\\xa0two\\xa0entities\\xa0is\\xa0unknown.\\xa0No\\xa0specific\\xa0symptomssuggest\\xa0lymphocytic\\xa0gastritis.\\xa0A\\xa0subgroup\\xa0of\\xa0patients\\xa0has\\xa0thickened\\xa0folds\\xa0noted\\xa0on\\xa0endoscopy.\\xa0These\\xa0folds\\xa0are\\xa0often\\xa0capped\\xa0by\\xa0small\\xa0nodules\\xa0thatcontain\\xa0a\\xa0central\\xa0depression\\xa0or\\xa0erosion;\\xa0this\\xa0form\\xa0of\\xa0the\\xa0disease\\xa0is\\xa0called\\xa0varioliform\\xa0gastritis.\\xa0H.\\xa0pylori\\xa0probably\\xa0plays\\xa0no\\xa0significant\\xa0role\\xa0inlymphocytic\\xa0gastritis.\\xa0Therapy\\xa0with\\xa0glucocorticoids\\xa0or\\xa0sodium\\xa0cromoglycate\\xa0has\\xa0obtained\\xa0unclear\\xa0results.Marked\\xa0eosinophilic\\xa0infiltration\\xa0involving\\xa0any\\xa0layer\\xa0of\\xa0the\\xa0stomach\\xa0(mucosa,\\xa0muscularis\\xa0propria,\\xa0and\\xa0serosa)\\xa0is\\xa0characteristic\\xa0of\\xa0eosinophilic\\xa0gastritis.Affected\\xa0individuals\\xa0will\\xa0often\\xa0have\\xa0circulating\\xa0eosinophilia\\xa0with\\xa0clinical\\xa0manifestation\\xa0of\\xa0systemic\\xa0allergy.\\xa0Involvement\\xa0may\\xa0range\\xa0from\\xa0isolated\\xa0gastricdisease\\xa0to\\xa0diffuse\\xa0eosinophilic\\xa0gastroenteritis.\\xa0Antral\\xa0involvement\\xa0predominates,\\xa0with\\xa0prominent\\xa0edematous\\xa0folds\\xa0being\\xa0observed\\xa0on\\xa0endoscopy.These\\xa0prominent\\xa0antral\\xa0folds\\xa0can\\xa0lead\\xa0to\\xa0outlet\\xa0obstruction.\\xa0Patients\\xa0can\\xa0present\\xa0with\\xa0epigastric\\xa0discomfort,\\xa0nausea,\\xa0and\\xa0vomiting.\\xa0Treatment\\xa0withglucocorticoids\\xa0has\\xa0been\\xa0successful.',\n",
       " 'These\\xa0prominent\\xa0antral\\xa0folds\\xa0can\\xa0lead\\xa0to\\xa0outlet\\xa0obstruction.\\xa0Patients\\xa0can\\xa0present\\xa0with\\xa0epigastric\\xa0discomfort,\\xa0nausea,\\xa0and\\xa0vomiting.\\xa0Treatment\\xa0withglucocorticoids\\xa0has\\xa0been\\xa0successful.Several\\xa0systemic\\xa0disorders\\xa0may\\xa0be\\xa0associated\\xa0with\\xa0granulomatous\\xa0gastritis.\\xa0Gastric\\xa0involvement\\xa0has\\xa0been\\xa0observed\\xa0in\\xa0Crohn’s\\xa0disease.\\xa0Involvementmay\\xa0range\\xa0from\\xa0granulomatous\\xa0infiltrates\\xa0noted\\xa0only\\xa0on\\xa0gastric\\xa0biopsies\\xa0to\\xa0frank\\xa0ulceration\\xa0and\\xa0stricture\\xa0formation.\\xa0Gastric\\xa0Crohn’s\\xa0disease\\xa0usuallyoccurs\\xa0in\\xa0the\\xa0presence\\xa0of\\xa0small\\xadintestinal\\xa0disease.\\xa0Several\\xa0rare\\xa0infectious\\xa0processes\\xa0can\\xa0lead\\xa0to\\xa0granulomatous\\xa0gastritis,\\xa0including\\xa0histoplasmosis,candidiasis,\\xa0syphilis,\\xa0and\\xa0tuberculosis.\\xa0Other\\xa0unusual\\xa0causes\\xa0of\\xa0this\\xa0form\\xa0of\\xa0gastritis\\xa0include\\xa0sarcoidosis,\\xa0idiopathic\\xa0granulomatous\\xa0gastritis,\\xa0andeosinophilic\\xa0granulomas\\xa0involving\\xa0the\\xa0stomach.\\xa0Establishing\\xa0the\\xa0specific\\xa0etiologic\\xa0agent\\xa0in\\xa0this\\xa0form\\xa0of\\xa0gastritis\\xa0can\\xa0be\\xa0difficult,\\xa0at\\xa0times\\xa0requiringrepeat\\xa0endoscopy\\xa0with\\xa0biopsy\\xa0and\\xa0cytology.\\xa0Occasionally,\\xa0a\\xa0surgically\\xa0obtained\\xa0full\\xadthickness\\xa0biopsy\\xa0of\\xa0the\\xa0stomach\\xa0may\\xa0be\\xa0required\\xa0to\\xa0excludemalignancy.Russell\\xa0body\\xa0gastritis\\xa0(RBG)\\xa0is\\xa0a\\xa0mucosal\\xa0lesion\\xa0of\\xa0unknown\\xa0etiology\\xa0that\\xa0has\\xa0a\\xa0pseudotumoral\\xa0endoscopic\\xa0appearance.\\xa0Histologically,\\xa0it\\xa0is\\xa0defined\\xa0bythe\\xa0presence\\xa0of\\xa0numerous\\xa0plasma\\xa0cells\\xa0containing\\xa0Russell\\xa0bodies\\xa0(RBs)\\xa0that\\xa0express\\xa0kappa\\xa0and\\xa0lambda\\xa0light\\xa0chains.\\xa0Only\\xa010\\xa0cases\\xa0have\\xa0been\\xa0reported,and\\xa07\\xa0of\\xa0these\\xa0have\\xa0been\\xa0associated\\xa0with\\xa0H.\\xa0pylori\\xa0infection.\\xa0The\\xa0lesion\\xa0can\\xa0be\\xa0confused\\xa0with\\xa0a\\xa0neoplastic\\xa0process,\\xa0but\\xa0it\\xa0is\\xa0benign\\xa0in\\xa0nature,\\xa0and\\xa0thenatural\\xa0history\\xa0of\\xa0the\\xa0lesion\\xa0is\\xa0not\\xa0known.\\xa0There\\xa0have\\xa0been\\xa0cases\\xa0of\\xa0resolution\\xa0of\\xa0the\\xa0lesion\\xa0when\\xa0H.\\xa0pylori\\xa0was\\xa0eradicated.Immune\\xa0checkpoint\\xa0inhibitor–induced\\xa0enterocolitis\\xa0and\\xa0gastritis\\xa0are\\xa0recognized\\xa0sequelae\\xa0of\\xa0these\\xa0oncologic\\xa0therapies.\\xa0The\\xa0gastritis\\xa0typically\\xa0occurslater\\xa0in\\xa0the\\xa0course\\xa0of\\xa0therapy.\\xa0The\\xa0diagnosis\\xa0is\\xa0made\\xa0by\\xa0the\\xa0histologic\\xa0findings\\xa0on\\xa0gastric\\xa0mucosal\\xa0biopsies\\xa0obtained\\xa0endoscopically.\\xa0This\\xa0is\\xa0an',\n",
       " \"later\\xa0in\\xa0the\\xa0course\\xa0of\\xa0therapy.\\xa0The\\xa0diagnosis\\xa0is\\xa0made\\xa0by\\xa0the\\xa0histologic\\xa0findings\\xa0on\\xa0gastric\\xa0mucosal\\xa0biopsies\\xa0obtained\\xa0endoscopically.\\xa0This\\xa0is\\xa0animportant\\xa0diagnosis\\xa0to\\xa0make\\xa0since\\xa0therapy\\xa0with\\xa0glucocorticoids\\xa0and\\xa0potentially\\xa0IL\\xad6\\xa0receptor\\xa0blockers\\xa0will\\xa0be\\xa0required.\\xa0Moreover,\\xa0this\\xa0side\\xa0effect\\xa0willhave\\xa0an\\xa0effect\\xa0on\\xa0the\\xa0oncologic\\xa0therapy\\xa0prescribed.MÉNÉTRIER’S\\xa0DISEASEMénétrier’s\\xa0disease\\xa0(MD)\\xa0is\\xa0a\\xa0very\\xa0rare\\xa0gastropathy\\xa0characterized\\xa0by\\xa0large,\\xa0tortuous\\xa0mucosal\\xa0folds.\\xa0MD\\xa0has\\xa0an\\xa0average\\xa0age\\xa0of\\xa0onset\\xa0of\\xa040–60\\xa0years\\xa0witha\\xa0male\\xa0predominance.\\xa0The\\xa0differential\\xa0diagnosis\\xa0of\\xa0large\\xa0gastric\\xa0folds\\xa0includes\\xa0ZES,\\xa0malignancy\\xa0(lymphoma,\\xa0infiltrating\\xa0carcinoma),\\xa0infectiousetiologies\\xa0(CMV,\\xa0histoplasmosis,\\xa0syphilis,\\xa0tuberculosis),\\xa0gastritis\\xa0polyposa\\xa0profunda,\\xa0and\\xa0infiltrative\\xa0disorders\\xa0such\\xa0as\\xa0sarcoidosis.\\xa0MD\\xa0is\\xa0mostYonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 46 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'Immune\\xa0checkpoint\\xa0inhibitor–induced\\xa0enterocolitis\\xa0and\\xa0gastritis\\xa0are\\xa0recognized\\xa0sequelae\\xa0of\\xa0these\\xa0oncologic\\xa0therapies.\\xa0The\\xa0gastritis\\xa0typically\\xa0occurslater\\xa0in\\xa0the\\xa0course\\xa0of\\xa0therapy.\\xa0The\\xa0diagnosis\\xa0is\\xa0made\\xa0by\\xa0the\\xa0histologic\\xa0findings\\xa0on\\xa0gastric\\xa0mucosal\\xa0biopsies\\xa0obtained\\xa0endoscopically.\\xa0This\\xa0is\\xa0animportant\\xa0diagnosis\\xa0to\\xa0make\\xa0since\\xa0therapy\\xa0with\\xa0glucocorticoids\\xa0and\\xa0potentially\\xa0IL\\xad6\\xa0receptor\\xa0blockers\\xa0will\\xa0be\\xa0required.\\xa0Moreover,\\xa0this\\xa0side\\xa0effect\\xa0willhave\\xa0an\\xa0effect\\xa0on\\xa0the\\xa0oncologic\\xa0therapy\\xa0prescribed.MÉNÉTRIER’S\\xa0DISEASEMénétrier’s\\xa0disease\\xa0(MD)\\xa0is\\xa0a\\xa0very\\xa0rare\\xa0gastropathy\\xa0characterized\\xa0by\\xa0large,\\xa0tortuous\\xa0mucosal\\xa0folds.\\xa0MD\\xa0has\\xa0an\\xa0average\\xa0age\\xa0of\\xa0onset\\xa0of\\xa040–60\\xa0years\\xa0witha\\xa0male\\xa0predominance.\\xa0The\\xa0differential\\xa0diagnosis\\xa0of\\xa0large\\xa0gastric\\xa0folds\\xa0includes\\xa0ZES,\\xa0malignancy\\xa0(lymphoma,\\xa0infiltrating\\xa0carcinoma),\\xa0infectiousetiologies\\xa0(CMV,\\xa0histoplasmosis,\\xa0syphilis,\\xa0tuberculosis),\\xa0gastritis\\xa0polyposa\\xa0profunda,\\xa0and\\xa0infiltrative\\xa0disorders\\xa0such\\xa0as\\xa0sarcoidosis.\\xa0MD\\xa0is\\xa0mostcommonly\\xa0confused\\xa0with\\xa0large\\xa0or\\xa0multiple\\xa0gastric\\xa0polyps\\xa0(prolonged\\xa0PPI\\xa0use)\\xa0or\\xa0familial\\xa0polyposis\\xa0syndromes.\\xa0The\\xa0mucosal\\xa0folds\\xa0in\\xa0MD\\xa0are\\xa0often\\xa0mostprominent\\xa0in\\xa0the\\xa0body\\xa0and\\xa0fundus,\\xa0sparing\\xa0the\\xa0antrum.\\xa0Histologically,\\xa0massive\\xa0foveolar\\xa0hyperplasia\\xa0(hyperplasia\\xa0of\\xa0surface\\xa0and\\xa0glandular\\xa0mucouscells)\\xa0and\\xa0a\\xa0marked\\xa0reduction\\xa0in\\xa0oxyntic\\xa0glands\\xa0and\\xa0parietal\\xa0cells\\xa0and\\xa0chief\\xa0cells\\xa0are\\xa0noted.\\xa0This\\xa0hyperplasia\\xa0produces\\xa0the\\xa0prominent\\xa0folds\\xa0observed.The\\xa0pits\\xa0of\\xa0the\\xa0gastric\\xa0glands\\xa0elongate\\xa0and\\xa0may\\xa0become\\xa0extremely\\xa0dilated\\xa0and\\xa0tortuous.\\xa0Although\\xa0the\\xa0lamina\\xa0propria\\xa0may\\xa0contain\\xa0a\\xa0mild\\xa0chronicinflammatory\\xa0infiltrate\\xa0including\\xa0eosinophils\\xa0and\\xa0plasma\\xa0cells,\\xa0MD\\xa0is\\xa0not\\xa0considered\\xa0a\\xa0form\\xa0of\\xa0gastritis.\\xa0The\\xa0etiology\\xa0of\\xa0this\\xa0unusual\\xa0clinical\\xa0picture\\xa0inchildren\\xa0is\\xa0often\\xa0CMV,\\xa0but\\xa0the\\xa0etiology\\xa0in\\xa0adults\\xa0is\\xa0unknown.\\xa0Overexpression\\xa0of\\xa0the\\xa0growth\\xa0factor\\xa0TGF\\xadα\\xa0has\\xa0been\\xa0demonstrated\\xa0in\\xa0patients\\xa0with\\xa0MD.The\\xa0overexpression\\xa0of\\xa0TGF\\xadα\\xa0in\\xa0turn\\xa0results\\xa0in\\xa0overstimulation\\xa0of\\xa0the\\xa0epidermal\\xa0growth\\xa0factor\\xa0receptor\\xa0(EGFR)\\xa0pathway\\xa0and\\xa0increased\\xa0proliferation\\xa0of',\n",
       " 'The\\xa0overexpression\\xa0of\\xa0TGF\\xadα\\xa0in\\xa0turn\\xa0results\\xa0in\\xa0overstimulation\\xa0of\\xa0the\\xa0epidermal\\xa0growth\\xa0factor\\xa0receptor\\xa0(EGFR)\\xa0pathway\\xa0and\\xa0increased\\xa0proliferation\\xa0ofmucus\\xa0cells,\\xa0resulting\\xa0in\\xa0the\\xa0observed\\xa0foveolar\\xa0hyperplasia.The\\xa0clinical\\xa0presentation\\xa0in\\xa0adults\\xa0is\\xa0usually\\xa0insidious\\xa0and\\xa0progressive.\\xa0Epigastric\\xa0pain,\\xa0nausea,\\xa0vomiting,\\xa0anorexia,\\xa0peripheral\\xa0edema,\\xa0and\\xa0weight\\xa0lossare\\xa0signs\\xa0and\\xa0symptoms\\xa0in\\xa0patients\\xa0with\\xa0MD.\\xa0Occult\\xa0GI\\xa0bleeding\\xa0may\\xa0occur,\\xa0but\\xa0overt\\xa0bleeding\\xa0is\\xa0unusual\\xa0and,\\xa0when\\xa0present,\\xa0is\\xa0due\\xa0to\\xa0superficialmucosal\\xa0erosions.\\xa0In\\xa0fact,\\xa0bleeding\\xa0is\\xa0more\\xa0often\\xa0seen\\xa0in\\xa0one\\xa0of\\xa0the\\xa0common\\xa0mimics\\xa0of\\xa0MD,\\xa0gastric\\xa0polyposis.\\xa0Twenty\\xa0to\\xa0100%\\xa0of\\xa0patients\\xa0(dependingon\\xa0time\\xa0of\\xa0presentation)\\xa0develop\\xa0a\\xa0protein\\xadlosing\\xa0gastropathy\\xa0due\\xa0to\\xa0hypersecretion\\xa0of\\xa0gastric\\xa0mucus\\xa0accompanied\\xa0by\\xa0hypoalbuminemia\\xa0and\\xa0edema.Gastric\\xa0acid\\xa0secretion\\xa0is\\xa0usually\\xa0reduced\\xa0or\\xa0absent\\xa0because\\xa0of\\xa0the\\xa0decreased\\xa0parietal\\xa0cells.\\xa0Large\\xa0gastric\\xa0folds\\xa0are\\xa0readily\\xa0detectable\\xa0by\\xa0eitherradiographic\\xa0(barium\\xa0meal)\\xa0or\\xa0endoscopic\\xa0methods.\\xa0Endoscopy\\xa0with\\xa0deep\\xa0mucosal\\xa0biopsy,\\xa0preferably\\xa0full\\xa0thickness\\xa0with\\xa0a\\xa0snare\\xa0technique,\\xa0isrequired\\xa0to\\xa0establish\\xa0the\\xa0diagnosis\\xa0and\\xa0exclude\\xa0other\\xa0entities\\xa0that\\xa0may\\xa0present\\xa0similarly.\\xa0A\\xa0nondiagnostic\\xa0biopsy\\xa0may\\xa0lead\\xa0to\\xa0a\\xa0surgically\\xa0obtained\\xa0full\\xadthickness\\xa0biopsy\\xa0to\\xa0exclude\\xa0malignancy.\\xa0Although\\xa0MD\\xa0is\\xa0considered\\xa0premalignant\\xa0by\\xa0some,\\xa0the\\xa0risk\\xa0of\\xa0neoplastic\\xa0progression\\xa0is\\xa0not\\xa0defined.\\xa0Completeblood\\xa0count,\\xa0serum\\xa0gastrin,\\xa0serum\\xa0albumin,\\xa0CMV\\xa0and\\xa0H.\\xa0pylori\\xa0serology,\\xa0and\\xa0pH\\xa0testing\\xa0of\\xa0gastric\\xa0aspirate\\xa0during\\xa0endoscopy\\xa0should\\xa0be\\xa0included\\xa0aspart\\xa0of\\xa0the\\xa0initial\\xa0evaluation\\xa0of\\xa0patients\\xa0with\\xa0large\\xa0gastric\\xa0folds.TREATMENT\\xa0OF\\xa0MéNéTRIER’S\\xa0DISEASEMedical\\xa0therapy\\xa0with\\xa0anticholinergic\\xa0agents,\\xa0prostaglandins,\\xa0PPIs,\\xa0prednisone,\\xa0somatostatin\\xa0analogues\\xa0(octreotide),\\xa0and\\xa0H2\\xa0receptor\\xa0antagonistsyields\\xa0varying\\xa0results.\\xa0Ulcers\\xa0should\\xa0be\\xa0treated\\xa0with\\xa0a\\xa0standard\\xa0approach.\\xa0The\\xa0discovery\\xa0that\\xa0MD\\xa0is\\xa0associated\\xa0with\\xa0overstimulation\\xa0of\\xa0the\\xa0EGFR',\n",
       " 'yields\\xa0varying\\xa0results.\\xa0Ulcers\\xa0should\\xa0be\\xa0treated\\xa0with\\xa0a\\xa0standard\\xa0approach.\\xa0The\\xa0discovery\\xa0that\\xa0MD\\xa0is\\xa0associated\\xa0with\\xa0overstimulation\\xa0of\\xa0the\\xa0EGFRpathway\\xa0has\\xa0led\\xa0to\\xa0the\\xa0successful\\xa0use\\xa0of\\xa0the\\xa0EGF\\xa0inhibitory\\xa0antibody,\\xa0cetuximab,\\xa0in\\xa0these\\xa0patients.\\xa0Specifically,\\xa0four\\xa0of\\xa0seven\\xa0patients\\xa0who\\xa0completed\\xa0a1\\xadmonth\\xa0trial\\xa0with\\xa0this\\xa0agent\\xa0demonstrated\\xa0near\\xa0complete\\xa0histologic\\xa0remission\\xa0and\\xa0improvement\\xa0in\\xa0symptoms.\\xa0Cetuximab\\xa0is\\xa0now\\xa0considered\\xa0the\\xa0first\\xadline\\xa0treatment\\xa0for\\xa0MD,\\xa0leaving\\xa0partial\\xa0or\\xa0total\\xa0gastrectomy\\xa0for\\xa0severe\\xa0disease\\xa0with\\xa0persistent\\xa0and\\xa0substantial\\xa0protein\\xa0loss\\xa0despite\\xa0therapy\\xa0with\\xa0thisagent.FURTHER\\xa0READINGBindu\\xa0\\xa0S\\xa0\\xa0et\\xa0al:\\xa0Non\\xadsteroidal\\xa0anti\\xadinflammatory\\xa0drugs\\xa0(NSAIDs)\\xa0and\\xa0organ\\xa0damage:\\xa0A\\xa0current\\xa0perspective.\\xa0Biochem\\xa0Pharmacol\\xa0180:114147,\\xa02020.\\xa0[PubMed:\\xa032653589]\\xa0Bjarnason\\xa0\\xa0I\\xa0\\xa0et\\xa0al:\\xa0Mechanisms\\xa0of\\xa0damage\\xa0to\\xa0the\\xa0gastrointestinal\\xa0tract\\xa0from\\xa0nonsteroidal\\xa0anti\\xadinflammatory\\xa0drugs.\\xa0Gastroenterology\\xa0154:500,\\xa02018.\\xa0[PubMed:\\xa029221664]\\xa0Brandi\\xa0\\xa0ML\\xa0\\xa0et\\xa0al:\\xa0Multiple\\xa0endocrine\\xa0neoplasia\\xa0type\\xa01:\\xa0Latest\\xa0insights.\\xa0Endocr\\xa0Rev\\xa042:133,\\xa02021.\\xa0 [PubMed:\\xa033249439]\\xa0Chey\\xa0\\xa0WD\\xa0\\xa0et\\xa0al:\\xa0ACG\\xa0clinical\\xa0guideline:\\xa0Treatment\\xa0of\\xa0Helicobacter\\xa0pylori\\xa0infection.\\xa0Am\\xa0J\\xa0Gastroenterol\\xa0112:212,\\xa02017.\\xa0 [PubMed:\\xa028071659]\\xa0Engevik\\xa0 AC \\xa0et\\xa0al:\\xa0The\\xa0physiology\\xa0of\\xa0the\\xa0gastric\\xa0parietal\\xa0cell.\\xa0Physiol\\xa0Rev\\xa0100:573,\\xa02019.\\xa0 [PubMed:\\xa031670611]\\xa0Jensen\\xa0\\xa0RT,\\xa0Ito\\xa0\\xa0T:\\xa0Gastrinoma;\\xa0Endotext\\xa0[internet].\\xa0South\\xa0Dartmouth,\\xa0MA,\\xa02020.\\xa0https://europepmc.org/article/NBK/nbk279075.Kavitt\\xa0\\xa0RT\\xa0\\xa0et\\xa0al:\\xa0Diagnosis\\xa0and\\xa0treatment\\xa0of\\xa0peptic\\xa0ulcer\\xa0disease.\\xa0Am\\xa0J\\xa0Med\\xa0132:447,\\xa02019.\\xa0 [PubMed:\\xa030611829]\\xa0Pennelli\\xa0\\xa0G\\xa0\\xa0et\\xa0al:\\xa0Gastritis:\\xa0Update\\xa0on\\xa0etiological\\xa0features\\xa0and\\xa0histological\\xa0practice\\xa0approach.\\xa0Pathologica\\xa0112:153,\\xa02020.\\xa0 [PubMed:\\xa033179619]\\xa0Savarino\\xa0\\xa0V\\xa0\\xa0et\\xa0al:\\xa0Proton\\xa0pump\\xa0inhibitors:\\xa0Use\\xa0and\\xa0misuse\\xa0in\\xa0the\\xa0clinical\\xa0setting.\\xa0Expert\\xa0Rev\\xa0Clin\\xa0Pharmacol\\xa011:1123,\\xa02018.\\xa0 [PubMed:\\xa030295105]\\xa0Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138',\n",
       " \"Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 47 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'ygpy,Engevik\\xa0 AC \\xa0et\\xa0al:\\xa0The\\xa0physiology\\xa0of\\xa0the\\xa0gastric\\xa0parietal\\xa0cell.\\xa0Physiol\\xa0Rev\\xa0100:573,\\xa02019.\\xa0 [PubMed:\\xa031670611]\\xa0Jensen\\xa0\\xa0RT,\\xa0Ito\\xa0\\xa0T:\\xa0Gastrinoma;\\xa0Endotext\\xa0[internet].\\xa0South\\xa0Dartmouth,\\xa0MA,\\xa02020.\\xa0https://europepmc.org/article/NBK/nbk279075.Kavitt\\xa0\\xa0RT\\xa0\\xa0et\\xa0al:\\xa0Diagnosis\\xa0and\\xa0treatment\\xa0of\\xa0peptic\\xa0ulcer\\xa0disease.\\xa0Am\\xa0J\\xa0Med\\xa0132:447,\\xa02019.\\xa0 [PubMed:\\xa030611829]\\xa0Pennelli\\xa0\\xa0G\\xa0\\xa0et\\xa0al:\\xa0Gastritis:\\xa0Update\\xa0on\\xa0etiological\\xa0features\\xa0and\\xa0histological\\xa0practice\\xa0approach.\\xa0Pathologica\\xa0112:153,\\xa02020.\\xa0 [PubMed:\\xa033179619]\\xa0Savarino\\xa0\\xa0V\\xa0\\xa0et\\xa0al:\\xa0Proton\\xa0pump\\xa0inhibitors:\\xa0Use\\xa0and\\xa0misuse\\xa0in\\xa0the\\xa0clinical\\xa0setting.\\xa0Expert\\xa0Rev\\xa0Clin\\xa0Pharmacol\\xa011:1123,\\xa02018.\\xa0 [PubMed:\\xa030295105]\\xa0Yao\\xa0\\xa0X,\\xa0Smolka\\xa0\\xa0AJ:\\xa0Gastric\\xa0parietal\\xa0cell\\xa0physiology\\xa0and\\xa0Helicobacter\\xa0pylori\\xadinduced\\xa0disease.\\xa0Gastroenterology\\xa0156:2158,\\xa02019.\\xa0 [PubMed:\\xa030831083]\\xa0Additional\\xa0Online\\xa0ReferencesDavis\\xa0\\xa0JL,\\xa0Ripley\\xa0\\xa0RT:\\xa0Postgastrectomy\\xa0syndromes\\xa0and\\xa0nutritional\\xa0considerations\\xa0following\\xa0gastric\\xa0surgery.\\xa0Surg\\xa0Clin\\xa0N\\xa0Am\\xa097:277,\\xa02017.\\xa0 [PubMed:28325187]\\xa0Dreischulte\\xa0\\xa0T:\\xa0Safer\\xa0prescribing—A\\xa0trial\\xa0of\\xa0education,\\xa0informatics,\\xa0and\\xa0financial\\xa0incentives.\\xa0N\\xa0Engl\\xa0J\\xa0Med\\xa0374:1053,\\xa02016.\\xa0 [PubMed:\\xa026981935]\\xa0Graham\\xa0\\xa0DY:\\xa0Helicobacter\\xa0pylori\\xa0update:\\xa0Gastric\\xa0cancer,\\xa0reliable\\xa0therapy,\\xa0and\\xa0possible\\xa0benefits.\\xa0Gastroenterology\\xa0148:719,\\xa02015.\\xa0 [PubMed:\\xa025655557]\\xa0Kinoshita\\xa0\\xa0Y\\xa0\\xa0et\\xa0al:\\xa0Advantages\\xa0and\\xa0disadvantages\\xa0of\\xa0long\\xadterm\\xa0proton\\xa0pump\\xa0inhibitor\\xa0use.\\xa0J\\xa0Neurogastroenterol\\xa0Motil\\xa024:182,\\xa02018.\\xa0 [PubMed:29605975]\\xa0Laine\\xa0\\xa0L:\\xa0Upper\\xa0gastrointestinal\\xa0bleeding\\xa0due\\xa0to\\xa0a\\xa0peptic\\xa0ulcer.\\xa0N\\xa0Engl\\xa0J\\xa0Med\\xa0374:2367,\\xa02016.\\xa0 [PubMed:\\xa027305194]\\xa0Lenti\\xa0\\xa0MV\\xa0\\xa0et\\xa0al:\\xa0Autoimmune\\xa0gastritis.\\xa0Nat\\xa0Rev\\xa0Dis\\xa0Primers\\xa06:56,\\xa02020.\\xa0 [PubMed:\\xa032647173]\\xa0McCarberg\\xa0\\xa0BH,\\xa0Cryer\\xa0\\xa0B:\\xa0Evolving\\xa0therapeutic\\xa0strategies\\xa0to\\xa0improve\\xa0nonsteroidal\\xa0anti\\xadinflammatory\\xa0drug\\xa0safety.\\xa0Am\\xa0J\\xa0Ther\\xa022:167,\\xa02015.\\xa0 [PubMed:25943389]\\xa0Melcarne\\xa0\\xa0L\\xa0\\xa0et\\xa0al:\\xa0Management\\xa0of\\xa0NSAID\\xadassociated\\xa0peptic\\xa0ulcer\\xa0disease.\\xa0Expert\\xa0Rev\\xa0Gastroenterol\\xa0Hepatol\\xa06:723,\\xa02016.',\n",
       " '25943389]\\xa0Melcarne\\xa0\\xa0L\\xa0\\xa0et\\xa0al:\\xa0Management\\xa0of\\xa0NSAID\\xadassociated\\xa0peptic\\xa0ulcer\\xa0disease.\\xa0Expert\\xa0Rev\\xa0Gastroenterol\\xa0Hepatol\\xa06:723,\\xa02016.Norton\\xa0\\xa0JA\\xa0\\xa0et\\xa0al:\\xa0Gastrinomas:\\xa0Medical\\xa0or\\xa0surgical\\xa0treatment.\\xa0Endocrinol\\xa0Metab\\xa0Clin\\xa0North\\xa0Am\\xa047:577,\\xa02018.\\xa0 [PubMed:\\xa030098717]\\xa0Patel\\xa0\\xa0KA,\\xa0Howden\\xa0\\xa0CW:\\xa0Update\\xa0on\\xa0the\\xa0diagnosis\\xa0and\\xa0management\\xa0of\\xa0Helicobacter\\xa0pylori\\xa0infection\\xa0in\\xa0adults.\\xa0J\\xa0Clin\\xa0Gastroenterol\\xa049:461,\\xa02015.\\xa0[PubMed:\\xa025811119]\\xa0Pelletier\\xa0\\xa0JP\\xa0\\xa0et\\xa0al:\\xa0Efficacy\\xa0and\\xa0safety\\xa0of\\xa0oral\\xa0and\\xa0analgesics\\xa0in\\xa0the\\xa0management\\xa0of\\xa0osteoarthritis:\\xa0Evidence\\xa0from\\xa0real\\xadlife\\xa0setting\\xa0trials\\xa0and\\xa0surveys.Semin\\xa0Arthritis\\xa0Rheum\\xa045:S22,\\xa02016.\\xa0 [PubMed:\\xa026806184]\\xa0Scarpignato\\xa0\\xa0C\\xa0\\xa0et\\xa0al:\\xa0Effective\\xa0and\\xa0safe\\xa0proton\\xa0pump\\xa0inhibitor\\xa0therapy\\xa0in\\xa0acid\\xadrelated\\xa0disease—A\\xa0position\\xa0paper\\xa0addressing\\xa0benefits\\xa0and\\xa0potentialharms\\xa0of\\xa0acid\\xa0suppression.\\xa0BMC\\xa0Med\\xa014:179,\\xa02016.\\xa0 [PubMed:\\xa027825371]\\xa0Schubert\\xa0\\xa0ML:\\xa0Physiologic,\\xa0pathophysiologic,\\xa0and\\xa0pharmacologic\\xa0regulation\\xa0of\\xa0gastric\\xa0acid\\xa0secretion.\\xa0Curr\\xa0Opin\\xa0Gastroenterol\\xa033:430,\\xa02017.\\xa0 [PubMed:28787289]\\xa0Singh\\xa0\\xa0S\\xa0\\xa0et\\xa0al:\\xa0Diagnosis\\xa0and\\xa0management\\xa0of\\xa0gastrointestinal\\xa0neuroendocrine\\xa0tumors:\\xa0An\\xa0evidence\\xadbased\\xa0Canadian\\xa0consensus.\\xa0Cancer\\xa0Treat\\xa0Rev47:32,\\xa02016.\\xa0 [PubMed:\\xa027236421]\\xa0Sugano\\xa0\\xa0K\\xa0\\xa0et\\xa0al:\\xa0Kyoto\\xa0global\\xa0consensus\\xa0report\\xa0on\\xa0Helicobacter\\xa0pylori\\xa0gastritis.\\xa0Gut\\xa064:1353,\\xa02015.\\xa0 [PubMed:\\xa026187502]\\xa0Sverden\\xa0\\xa0E\\xa0\\xa0et\\xa0al:\\xa0Peptic\\xa0ulcer\\xa0disease.\\xa0BMJ\\xa0367:15495,\\xa02019.Talley\\xa0\\xa0NJ:\\xa0Functional\\xa0dyspepsia:\\xa0New\\xa0insights\\xa0into\\xa0pathogenesis\\xa0and\\xa0therapy.\\xa0Korean\\xa0J\\xa0Intern\\xa0Med\\xa031:444,\\xa02016.\\xa0 [PubMed:\\xa027048251]\\xa0Vinik\\xa0\\xa0AI,\\xa0Chaya\\xa0\\xa0C:\\xa0Clinical\\xa0presentation\\xa0and\\xa0diagnosis\\xa0of\\xa0neuroendocrine\\xa0tumors.\\xa0Hematol\\xa0Oncol\\xa0Clin\\xa0N\\xa0Am\\xa030:21,\\xa02016.Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 48 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,',\n",
       " \"Page 48 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " \",Sugano\\xa0\\xa0K\\xa0\\xa0et\\xa0al:\\xa0Kyoto\\xa0global\\xa0consensus\\xa0report\\xa0on\\xa0Helicobacter\\xa0pylori\\xa0gastritis.\\xa0Gut\\xa064:1353,\\xa02015.\\xa0 [PubMed:\\xa026187502]\\xa0Sverden\\xa0\\xa0E\\xa0\\xa0et\\xa0al:\\xa0Peptic\\xa0ulcer\\xa0disease.\\xa0BMJ\\xa0367:15495,\\xa02019.Talley\\xa0\\xa0NJ:\\xa0Functional\\xa0dyspepsia:\\xa0New\\xa0insights\\xa0into\\xa0pathogenesis\\xa0and\\xa0therapy.\\xa0Korean\\xa0J\\xa0Intern\\xa0Med\\xa031:444,\\xa02016.\\xa0 [PubMed:\\xa027048251]\\xa0Vinik\\xa0\\xa0AI,\\xa0Chaya\\xa0\\xa0C:\\xa0Clinical\\xa0presentation\\xa0and\\xa0diagnosis\\xa0of\\xa0neuroendocrine\\xa0tumors.\\xa0Hematol\\xa0Oncol\\xa0Clin\\xa0N\\xa0Am\\xa030:21,\\xa02016.Yonsei\\xa0University\\xa0Medical\\xa0LibraryAccess\\xa0Provided\\xa0by:Downloaded\\xa02024\\xad5\\xad29\\xa03:6\\xa0A\\xa0\\xa0Your\\xa0IP\\xa0is\\xa0116.89.178.138Chapter\\xa0324:\\xa0Peptic\\xa0Ulcer\\xa0Disease\\xa0and\\xa0Related\\xa0Disorders,\\xa0John\\xa0Del\\xa0Valle©2024\\xa0McGraw\\xa0Hill.\\xa0All\\xa0Rights\\xa0Reserved.\\xa0\\xa0\\xa0Terms\\xa0of\\xa0Use\\xa0•\\xa0Privacy\\xa0Policy\\xa0•\\xa0Notice\\xa0•\\xa0AccessibilityPage 49 / 49AntrumFundusDuodenumBillrothIBillrothIlSource:Joseph Loscalzo,Anthony Fauci,Dennis Kasper,Stephen Hauser,Dan Longo,J.LarryJameson:Harrison's Principles of Internal Medicine,21eCopyriqht McGraw Hill.AllriqhtsreservedDanLongo,J.Larry Jameson:Harrison's Principles ofInternal Medicine,21eCopvriahtQMcGrawHill.AllriqhtsreservedNew-OnsetDyspepsia>40yearsoldAlarmsymptomsExcludebyhistoryGERD,biliarypain,IBS,aerophagia,medication-relatedNoninvasive Hp testingAnti-HpEmpirictrialorRefertotherapyHblockergastroenterologist4weeksaftertherapyConfirmeradicationUBTSymptomsremainorrecurSource:Joseph Loscalzo,Anthony Fauci,DennisKasper,Stephen Hauser,Dan Longo,J.Larry Jameson:Harrison's Principles of Internal Medicine,21eCopyriqhtMcGrawHill.AllriqhtsreservedPharmacyACCESSRSILVERCHAIRINFORMATIONSYSTEMS\",\n",
       " 'CHAPTER\\u2003 141\\u2003ACID PEPTIC DISEASE886cobblestone appearance, termed nodular gastritis (a lesion found particularly in children colonized by Helicobacter pylori), or grossly enlarged folds without evidence of cancer, termed hypertrophic gastritis.A peptic ulcer is a mucosal defect at least 0.5\\u202fcm in diameter that penetrates the muscularis mucosae. Smaller mucosal defects are called erosions (Fig. 141-1). Gastric ulcers are subdivided into proximal ulcers, located in the body of the stomach, and distal ulcers, located in the antrum and angulus of the stomach. Gastric ulcers are located mainly along the lesser curvature, in particular at the transitional zone of corpus- to antral-type mucosa. This transitional zone is often in the area of the angulus but may shift proximally. Duodenal ulcers usually are located on the anterior or posterior wall of the duodenal bulb (Fig. 141-2), or occasionally at both sites (“kissing” ulcers). Lesions distal to the duodenal bulb are termed postbulbar ulcers. Patients who previously underwent a distal gastric resection (Billroth I or II procedure) can develop ulceration at the gastroduodenal anastomosis (anastomotic ulcer). However, ulcers occurring after Billroth II resection are located pre\\xaddominantly in the jejunal mucosa at the junction between the afferent and efferent loops. Other peptic ulcers can occur at sites of metaplastic or hetero\\xadtopic gastric mucosa, for example, in Meckel’s diverticulum, the rectum, or Barrett’s esophagus. Patients with a large hiatal hernia can develop gastric ulceration, known as Cameron’s ulcers, at the level of the herniation. Dieulafoy’s ulcers, which are small mucosal defects over an intramural arteriole, can lead to severe bleeding. Although these lesions can occur throughout the gastro\\xadintestinal tract, two thirds occur in the stomach.141\\u2003ACID PEPTIC DISEASEERNST J. KUIPERS AND MARTIN J. BLASERAcid peptic diseases can involve the esophagus (Chapter 140), the stomach,',\n",
       " 'intestinal tract, two thirds occur in the stomach.141\\u2003ACID PEPTIC DISEASEERNST J. KUIPERS AND MARTIN J. BLASERAcid peptic diseases can involve the esophagus (Chapter 140), the stomach, and the duodenum. Dyspeptic symptoms also can occur in patients who have no endoscopic abnormalities, in whom it is termed nonulcer dyspepsia (Chapter 139).DEFINITIONSGastric and duodenal ulcers usually occur in an area of inflamed mucosa. This inflammation, termed gastritis, duodenitis, or bulbitis, can sometimes be rec\\xadognized during endoscopy by signs of edema, reddening, and swelling of the mucosa, but microscopic evaluation of endoscopic biopsy specimens is required for a definitive diagnosis of mucosal inflammation.Gastritis is categorized by endoscopic and histologic criteria, with granu\\xadlocytes predominating in active gastritis and mononuclear cells in chronic gastritis. Gastritis is also classified by the segment of involved stomach: antral-predominant gastritis, corpus-predominant gastritis, or pangastritis. Finally, the absence or presence of premalignant stages of damage to the mucosa as a result of long-standing inflammation defines the categories of nonatrophic and atrophic gastritis, respectively. Endoscopic findings are usually nonspecific, unless the gastric mucosa has either a typical miniature FIGURE\\u202f141-1.\\u2002 Endoscopic view of uncomplicated erosive gastritis. The erosion appears as a small, superficial mucosal break with a black base (arrow). FIGURE\\u202f141-2.\\u2002 Endoscopic view of an ulcer at the anterior wall of the duodenal bulb. The ulcer has a clean base, with a visible vessel appearing as a dark red protruding spot close to the lower ulcer rim. The surrounding mucosa is inflamed and swollen. 1933ik,R. J. ThSEonderzoek loopt',\n",
       " 'CHAPTER\\u2003 141\\u2003ACID PEPTIC DISEASE887EPIDEMIOLOGYThe worldwide prevalence of gastritis reflects the prevalence of H. pylori. Colonization with this bacterium is virtually always associated with chronic active gastritis, which persists as long as an individual remains colonized and only slowly disappears 6 to 24 months after the eradication of H. pylori. In developing countries and among first-generation immigrants from these countries, the prevalence of H. pylori gastritis is high (often ≥80%) in all age groups, including children. In Western countries, the prevalence of H. pylori gastritis increases with age; it is currently less than 20% in young adults but 40 to 60% in elderly persons.Although peptic ulcer disease is strongly related to H. pylori gastritis and duodenitis, the epidemiology of ulcer disease has shown secular variations even when H. pylori was ubiquitous. The incidence of peptic ulcer disease rose steeply in Western countries in the late 19th and early 20th centuries and has decreased over the past 30 years, yet peptic ulceration remains a common disorder. The decline in incidence, associated with a decrease in hospital admissions and surgery for ulcer disease, is believed to reflect mainly the decreasing prevalence of gastric colonization with H. pylori. The declining incidence of ulcer disease is also the result of the widespread application of eradication therapy, which strongly reduced recurrent ulcers in H. pylori–positive patients. Other factors may include the widespread use of acid sup\\xadpressive medication. Nevertheless, hospital admissions for complications of ulcers and mortality from ulcer disease have remained relatively stable in both the United States and other countries, as the reduction in H. pylori–associated ulcers in younger persons has been counterbalanced by an increase in ulcers related to nonsteroidal anti-inflammatory drugs (NSAIDs) in older persons.In Western countries, duodenal ulcers occur more frequently than gastric',\n",
       " 'related to nonsteroidal anti-inflammatory drugs (NSAIDs) in older persons.In Western countries, duodenal ulcers occur more frequently than gastric ulcers. The predominant age at which duodenal ulcers occur is between 20 and 50 years, whereas gastric ulcers most commonly occur in patients older than 40 years. The incidence of gastroduodenal ulcer disease is approximately 1 to 2 per 1000 inhabitants per year. Two thirds of patients with ulcers are male, and the disease is more common in smokers. The risk of recurrent disease after initial healing is high; more than 50% of patients have a recurrent ulcer within 12 months of healing in the absence of treatment. Maintenance acid suppressive therapy reduces this recurrence rate, but only therapeutic measures that remove the underlying cause of the ulcer can prevent most ulcer recurrences.PATHOBIOLOGYHelicobacter pyloriMost peptic ulcers are associated with colonization with H. pylori (Fig. 141-3). Initial clinical studies of the association between H. pylori and ulcer disease reported that approximately 85% of patients with gastric ulcer disease and 95% of patients with duodenal ulcer disease were colonized by H. pylori. Most persons who are H. pylori positive do not have any specific complaints, nor do they develop ulcer disease. The estimated risk for the development of ulcer disease during persistent H. pylori colonization is 5 to 15%—that is, three- to eight-fold higher than the risk for patients who are H. pylori negative. The risk for the development of an ulcer in the presence of H. pylori is deter\\xadmined by a combination of host- and bacteria-related factors. Host factors include immune response, smoking, and stress. Bacterial factors that increase the risk of ulcer include a high production of the VacA product, which reflects the presence of the s1m1 genotype; a high level of cytokine induction, owing to the presence of genes in the cag pathogenicity island; and enhanced adher\\xadence, resulting from babA.',\n",
       " 'the presence of the s1m1 genotype; a high level of cytokine induction, owing to the presence of genes in the cag pathogenicity island; and enhanced adher\\xadence, resulting from babA.Nonsteroidal Anti-inflammatory Drugs and AspirinThe other common cause of gastroduodenal ulcer disease is the use of NSAIDs. At least 2 to 4% of the population in many countries use acetylsali\\xadcylic acid, acetic acid derivatives (diclofenac, indomethacin, sulindac), or propionic acid derivatives (ibuprofen, ketoprofen, naproxen) on a daily basis. Within 14 days after the start of such treatment, about 5% of patients develop mucosal breaks, that is, erosions and ulcers. In patients who continue therapy for 4 weeks or longer, this proportion increases to 10%. The concomitant presence of H. pylori infection increases the incidence of NSAID-related ulcers. The risk of developing an ulcer during NSAID use is also higher in patients who are older than 60 years, those with a previous ulcer, patients who use corticosteroids or high-dose NSAIDs, and those with major comor\\xadbid diseases. In patients who use anticoagulants, such as warfarin, or who have severe comorbid disease, an NSAID-induced ulcer is more likely to lead to life-threatening gastroduodenal hemorrhage.On the basis of their activities, NSAIDs are divided into cyclooxygenase 1 (COX1) and COX2 inhibitors (Chapter 36). The COX1 enzyme is involved in the production of prostaglandins, which play a role in normal cell regula\\xadtion. The COX2 enzyme, which is also involved in the production of prosta\\xadglandins, is induced by inflammatory responses. Most NSAIDs have a nonselective COX inhibitory effect; selective COX2 inhibitors are associated with fewer gastroduodenal ulcers, but their use is limited by their adverse coronary effects (Chapter 36). Because of the strong association between NSAIDs and ulcer disease and the risk for recurrence of ulcers with their continued use, patients with ulcers must be thoroughly assessed for the use',\n",
       " 'NSAIDs and ulcer disease and the risk for recurrence of ulcers with their continued use, patients with ulcers must be thoroughly assessed for the use of NSAIDs.Helicobacter pylori–Negative, Non-NSAID Ulcer DiseaseIn most series, H. pylori and NSAID use account for 80 to 95% of cases of ulcer disease. The remaining cases are often referred to as idiopathic or H. pylori–negative, non-NSAID acid peptic disease. The proportion of ulcer disease that is idiopathic is increasing throughout the world as the prevalence of H. pylori decreases. Further, it is likely that some ulcers in H. pylori–positive patients were not caused by H. pylori. Consistent with this notion is the fact that some H. pylori–positive patients develop recurrent ulcers after successful bacterial eradication, so presumably their ulcer disease was idio\\xadpathic. It is not known whether the increase in idiopathic ulcer disease is simply proportional to the decrease in H. pylori–associated ulcers or whether it reflects a true increase in the incidence of idiopathic ulcers.In patients with idiopathic ulcer disease, specific clues to the underlying cause are often provided by the medical history, including comorbidity and drug use; the endoscopic appearance of the ulcer; and the histologic features of the ulcer’s margins and surroundings. In most cases, these initial data can direct further diagnostic studies (Table 141-1).Malignant Ulcer DiseaseGastroduodenal ulcers can result from underlying malignant disease. In the stomach, these tumors are related to gastric adenocarcinoma and, rarely, to mucosa-associated lymphoid tissue (MALT) lymphomas (Chapter 198). Malignant ulcers in the duodenum may result from primary duodenal carci\\xadnomas or from penetrating pancreatic cancers. Duodenal cancers have an association with polyposis syndromes, especially familial adenomatous polyposis and, to a much lesser extent, MUTYH-associated polyposis and',\n",
       " 'association with polyposis syndromes, especially familial adenomatous polyposis and, to a much lesser extent, MUTYH-associated polyposis and Peutz-Jeghers syndrome (Chapter 199). In both the stomach and the duode\\xadnum, ulcer disease can also be caused by metastatic tumors, including cancers of the breast, colon, thyroid, or kidney, or by melanoma, disseminated lym\\xadphoma, or Kaposi’s sarcoma. Malignant ulcers are characteristically irregular in shape with heaped borders, but they may also be flat or depressed lesions. Current high-resolution and magnification endoscopes allow visualization of the altered mucosal structure surrounding an ulcer, including changes in the microvascular pattern. For a definite diagnosis of malignancy, multiple biopsy specimens are needed, usually from the ulcer margins.Systemic Inflammatory DisordersA few gastroduodenal ulcers are caused by systemic inflammatory diseases, in particular, Crohn’s disease (Chapter 143). Patients with Crohn’s disease affecting the proximal gastrointestinal tract often have multiple ulcers FIGURE\\u202f141-3.\\u2002 Gastric mucosa colonized with Helicobacter pylori appearing as curved bacilli on the mucosal surface.',\n",
       " 'CHAPTER\\u2003 141\\u2003ACID PEPTIC DISEASE888characterized by irregular longitudinal shapes. Ulcers in the duodenum occur atop Kerckring’s folds. Patients with gastroduodenal ulcers from Crohn’s disease do not invariably have evidence of disease elsewhere in the digestive tract, nor do blood tests always suggest an active inflammatory bowel disor\\xadder. The demonstration of ulcerative inflammation elsewhere in the digestive tract, in particular in the terminal ileum and colon, strongly supports the diagnosis of Crohn’s disease, as do granulomas on a biopsy specimen. However, the absence of granulomas does not exclude Crohn’s disease, and these lesions are not specific for Crohn’s disease; they are also associated with H. pylori gastritis and other conditions, particularly sarcoidosis (Chapter 95). Sarcoidosis can also lead to gastroduodenal ulcer disease.Other inflammatory disorders that can cause gastritis or gastroduodenal ulcers include various forms of vasculitis affecting the mesenteric system, in particular Behçet’s disease (Chapter 278), Henoch-Schönlein purpura (Chapter 278), Takayasu’s arteritis (Chapter 278), polyarteritis nodosa (Chapter 278), systemic lupus erythematosus (Chapter 274), Churg-Strauss syndrome (Chapter 278), and Wegener’s granulomatosis (Chapter 278). Lymphocytic gastroduodenitis, which is strongly associated with celiac disease (Chapter 142), may lead to duodenal ulceration and subsequent ste\\xadnotic web formation. Ulcer disease also may occur in patients with polycy\\xadthemia vera (Chapter 169), possibly in relation to reduced mucosal blood flow. Vasculitis underlying ulcer disease should be considered in patients with chronic or recurrent ulceration in whom other causes have been excluded. Lymphocytic phlebitis, which is a rare vasculitic inflammatory disorder affecting the mesenteric veins, may cause gastric ulcer disease. Systemic amyloidosis (Chapter 194) affecting the stomach wall may lead to gastric',\n",
       " 'affecting the mesenteric veins, may cause gastric ulcer disease. Systemic amyloidosis (Chapter 194) affecting the stomach wall may lead to gastric ulcer disease. Rare cases of duodenal ulceration have been described in the presence of annular pancreas or congenital bands obstructing the descending duodenum.Hypergastrinemic SyndromesPeptic ulcers can result from chronic gastric hyperacidity related to hypergas\\xadtrinemia. The most important hypergastrinemic disorder is Zollinger-Ellison syndrome (Chapter 201), a condition of marked hyperacidity leading to severe peptic ulcer disease caused by a gastrin-producing endocrine tumor. These patients usually have multiple therapy-resistant bulbar and postbulbar duodenal ulcers. The diagnosis can be confirmed by the presence of a high fasting serum gastrin level (often but not always ≥10-fold increased and >1000\\u202fpg/mL). Similar gastrin levels are sometimes seen in patients treated for chronic ulcer disease with high-dose proton pump inhibitors. For clarifi\\xadcation, secretin testing can be performed: in patients with Zollinger-Ellison syndrome, the injection of secretin (1\\u202fU/kg) increases serum gastrin levels by more than 50%, or 120\\u202fpg/mL or greater in those with fasting gastrin levels less than 10-fold above normal. Imaging techniques, such as computed tomography (CT), magnetic resonance imaging, isotope scanning, endo\\xadscopic ultrasonography, videocapsule endoscopy, and balloon-assisted enter\\xadoscopy, may be used to detect the primary tumor, which is often located in either the pancreas or the proximal small bowel. In some patients, Zollinger-Ellison syndrome occurs as part of multiple endocrine neoplasia (Chapter 239), particularly in association with hyperparathyroidism. Other TABLE 141-1 DIFFERENTIAL DIAGNOSIS OF PEPTIC ULCER DISEASEORIGINCONDITIONFREQUENCY*DIAGNOSTIC TESTFINDINGSMicrobesHelicobacter pyloriVery commonHelicobacter pylori testsBacteria, enzymes, antigens, antibodiesHistologyGastritis',\n",
       " 'ORIGINCONDITIONFREQUENCY*DIAGNOSTIC TESTFINDINGSMicrobesHelicobacter pyloriVery commonHelicobacter pylori testsBacteria, enzymes, antigens, antibodiesHistologyGastritisHelicobacter heilmanniiRareHistologySpiral bacteria, gastritisTreponema pallidumVery rareSerologyAntibodiesMycobacterial infectionVery rareHistology, immune response testing, chest radiographAcid-fast bacteria, granuloma,\\u202fimmune response, pulmonary infiltrateCytomegalovirus, herpes simplex virus type 1RareHistology, serologyVirus inclusions, antibodiesDrug useNSAIDs, aspirinVery commonHistory, urine testNSAID useBisphosphonatesRareHistoryBisphosphonate useCorticosteroidsRareHistoryCorticosteroid use, comorbidityAmphetamines, cocaineRareHistory, drug testingDrug useAnticoagulants, coagulopathyRareEndoscopyUlcer after intramural bleedMalignancyGastric cancerCommonHistologyMalignancyDuodenal cancerRareHistology, CTMalignancyPancreatic cancerCommonHistology, CTMalignancyMucosa-associated lymphoid tissue lymphomaRareHistologyMalignancyMetastatic cancerRareHistologyMalignancyGastritis syndromesEosinophilic gastritisRareHistologyEosinophilic infiltrationLymphocytic gastritisRareHistology, celiac disease screeningLymphocytic infiltration, villous atrophyHyperacidic syndromesZollinger-Ellison syndromeRareSerum gastrin, secretin testExtreme hypergastrinemia, positive secretin testAntral G-cell hyperfunctionVery rareSerum gastrin, secretin testModerate hypergastrinemia, negative secretin testRetained gastric antrumVery rareMedical history, gastrinBillroth II resection, hypergastrinemiaSystemic mastocytosisVery rareHistology of affected sitesMast cell infiltrationChronic myelogenous leukemiaVery rareLeukemia evaluationLeukemiaIschemiaMesenteric vascular occlusionCommonAngiographyVascular diseasePolycythemia veraRareBlood countsPolycythemiaSpecific ulcer typesCameron’s ulcerCommonEndoscopyUlcer in large hiatal hernia',\n",
       " 'Mesenteric vascular occlusionCommonAngiographyVascular diseasePolycythemia veraRareBlood countsPolycythemiaSpecific ulcer typesCameron’s ulcerCommonEndoscopyUlcer in large hiatal herniaMarginal ulcerCommonEndoscopyUlcer at anastomosisDieulafoy’s ulcerCommonEndoscopySingular bleeding focus with minimal mucosal disruptionSystemic inflammationCrohn’s diseaseCommonHistology, ileocolonoscopyInflammation, granulomasVasculitidesRareHistology, systemic evaluationVasculitis, signs of systemic diseaseGastric amyloidosisVery rareHistologyAmyloid depositionOther conditionsStress ulcerFairly common in patients in intensive care unitsEndoscopy—Radiation therapy, chemotherapyRareEndoscopy, history—*Frequency as a cause of gastroduodenal ulcer disease.CT = computed tomography; NSAID = nonsteroidal anti-inflammatory drug.',\n",
       " 'CHAPTER\\u2003 141\\u2003ACID PEPTIC DISEASE889hypergastrinemic hyperacidity syndromes are the retained gastric antrum syndrome (see later) and antral G-cell hyperfunction. In the latter, fasting serum gastrin levels are only modestly increased and do not rise after the injection of secretin, but they respond in an exaggerated way to meals, thereby leading to hyperacidity. When the condition occurs in an H. pylori–positive patient, bacterial eradication therapy may be curative. However, some patients with G-cell hyperfunction are H. pylori negative.IschemiaStenosis or occlusion of the celiac trunk or the superior mesenteric artery (Chapter 145) also can lead to ulceration in the mucosa of the proximal digestive tract (Fig. 141-4). These ulcers typically occur in elderly patients with risk factors for atherosclerosis, but they can also occur in younger sub\\xadjects with mesenteric obstruction due to other causes. Ischemic ulcers tend to heal slowly and recur. Pallor of the mucosa, consistent with decreased mucosal blood flow, may be noted at endoscopy. Upper mesenteric isch\\xademia is often associated with upper abdominal pain, which can be elicited by a meal or by physical activity. These symptoms may cause patients to decrease their food intake, leading to weight loss before their clinical pre\\xadsentation. The prevalence of upper mesenteric ischemia with secondary ulcer disease is unknown, in part owing to its variable presentation, often with a history of gradual symptoms; the lack of standardized and reliable diagnostic tests; and clinicians’ unfamiliarity with the condition. Diagnostic evaluation includes a duplex ultrasound scan for vascular flow and conven\\xadtional or CT angiography of the affected arteries. Validated functional tests for gastroduodenal mucosal perfusion are not widely available, but a tech\\xadnique for directly measuring mucosal oxygen saturation during endoscopy is investigational.Stress Ulcers',\n",
       " 'for gastroduodenal mucosal perfusion are not widely available, but a tech\\xadnique for directly measuring mucosal oxygen saturation during endoscopy is investigational.Stress UlcersPatients with severe medical conditions, such as major trauma, sepsis, exten\\xadsive burns, head injury, or multiorgan failure, can develop stress ulcers in the stomach or duodenum. Major risk factors for stress ulceration in severely ill patients include mechanical ventilation, coagulopathy, and hypotension, but factors such as hepatic and renal failure and the use of ulcerogenic medica\\xadtions may contribute. Stress ulcers occur independently of H. pylori coloniza\\xadtion. Ulcers associated with head injury are known as Cushing’s ulcers, and ulcers associated with extensive burns are known as Curling’s ulcers. Stress ulcers were once common in patients in intensive care units, but improve\\xadments in overall management, including respiratory and hemodynamic care, acid inhibition, and emphasis on adequate feeding, have reduced the inci\\xaddence of these ulcers, which currently affect 1 to 2% of these patients. Stress ulcers may be asymptomatic, but they can also cause complications, espe\\xadcially bleeding.Other FactorsCameron’s UlcerPatients with large hiatal hernias (Chapter 140) may present with proximal gastric ulcers, termed Cameron’s ulcers, at the level of the hiatus, where the stomach is compressed. These ulcers are usually asymptomatic but may cause occult or overt bleeding. During upper gastrointestinal endoscopy, patients with large hiatal hernias and iron deficiency anemia should be carefully exam\\xadined in normal and retroverted positions for the presence of Cameron’s ulcers.Anastomotic or Marginal UlcerationPatients who have undergone partial gastrectomy sometimes develop recur\\xadrent ulcers, often located at the anastomosis or within the jejunum immedi\\xadately opposite the anastomosis. Ischemia and chronic inflammation resulting',\n",
       " 'rent ulcers, often located at the anastomosis or within the jejunum immedi\\xadately opposite the anastomosis. Ischemia and chronic inflammation resulting from H. pylori and biliary reflux may cause such ulcers, as may underlying cancer. If biopsy excludes cancer, treatment includes acid suppression and H. pylori eradication, if needed. Ulcer disease can be caused by the retained gastric antrum syndrome after partial gastrectomy when the antrum is not completely excised from the detached duodenum. Because it then lacks expo\\xadsure to acid and is thus not physiologically downregulated, it continues to secrete gastrin despite normal or even high acid levels. Marginal ulcers can also occur after bariatric Roux-en-Y gastric bypass surgery.Other MicrobesColonization with Helicobacter heilmannii (formerly known as Gastrospirillum hominis), which is probably a zoonotic organism, is associated with mild gastritis and sometimes with transient ulcer disease. Ulcer disease also may be infectious, resulting from secondary syphilis (Chapter 327), mycobacterial infection (Chapter 332), infection with herpes simplex virus type 1 (Chapter 382), or cytomegalovirus infection (Chapter 384).AlcoholShort-term heavy alcohol use or long-term moderate to heavy alcohol use can lead to signs of acute and chronic gastritis. No evidence indicates that this gastritis is associated with a significant risk for peptic ulceration, although alcohol use increases the risk of bleeding in patients with peptic ulcer disease.Hyperhistaminic SyndromesSimilar to the hypergastrinemic syndromes, persistent elevation of histamine can lead to hyperacidity as a result of the chronic stimulation of parietal cells. Elevated histamine levels are observed in two rare syndromes. Systemic mas\\xadtocytosis (Chapter 263) is characterized by a proliferation of mast cells in the bone marrow, skin, liver, spleen, and gastrointestinal tract, often associated',\n",
       " 'tocytosis (Chapter 263) is characterized by a proliferation of mast cells in the bone marrow, skin, liver, spleen, and gastrointestinal tract, often associated with both spontaneous and trigger-induced (e.g., alcohol) release of hista\\xadmine and other vasoactive substances. Patients with systemic mastocytosis often have gastrointestinal symptoms, including pain, diarrhea, and blood loss. Ulceration results from chronic gastric acid hypersecretion. Clues to the diagnosis include symptoms of pruritus, urticaria, or rash. The bone marrow and affected organ mast cell infiltrates carry a specific C-kit mutation and express CD2 and CD25. Histamine hypersecretion leading to peptic ulcer disease can also occur in chronic myelogenous leukemia (Chapter 190) with basophilia.Other DrugsTreatment with oral bisphosphonates, widely used for osteoporosis (Chapter 251), is complicated by gastric erosions and ulceration in an estimated 3 to 10% of treated patients. The risk for ulcer disease may be synergistically increased by NSAID use but is probably independent of H. pylori coloniza\\xadtion. Although corticosteroid treatment can be complicated by peptic ulcer disease, the relative risk is only slightly increased, except in patients with serious comorbid diseases, using long-term or high-dose therapy, or with prior ulcers. Other patients who use corticosteroids are not at serious risk for ulcer disease and therefore do not require measures to prevent ulcers.Persons who use amphetamines and crack cocaine (Chapter 33) frequently develop ulcer disease, often with perforation, possibly as a result of vascular insufficiency. Chemotherapy, particularly when given selectively as a high-dose intra-arterial infusion in the celiac system, can be complicated by ulcer disease. Patients on anticoagulant therapy and those with other coagulopa\\xadthies may rarely develop intramural hematoma of the gastrointestinal tract. Depending on the location, these hematomas may cause obstruction, but',\n",
       " 'thies may rarely develop intramural hematoma of the gastrointestinal tract. Depending on the location, these hematomas may cause obstruction, but they can also leave large ulcers when they rupture into the lumen. Radiation therapy of the upper abdomen is sometimes complicated by chronic ischemic ulceration, especially in long-term follow-up.CLINICAL MANIFESTATIONSThe clinical manifestations of acid peptic disease (Table 141-2) do not always predict the various morphologic presentations found at endoscopy. Indeed, FIGURE\\u202f141-4.\\u2002 Endoscopic view of an irregular gastric ulcer at the posterior wall and smaller curvature in a patient with chronic mesenteric ischemia due to subtotal stenosis of the celiac trunk.',\n",
       " 'CHAPTER\\u2003 141\\u2003ACID PEPTIC DISEASE890a silent ulcer may be recognized only when it presents abruptly with a com\\xadplication, most commonly hemorrhage or perforation, or it may be discov\\xadered incidentally when a diagnostic test is performed for other reasons. Nevertheless, the typical presentation of acid peptic disease is recurrent epi\\xadsodes of pain. The pain is almost invariably located in the epigastrium and may radiate to the back or, less commonly, to the thorax or other regions of the abdomen (see Table 141-2). Some patients describe the pain as burning or piercing, whereas others describe it as an uncomfortable feeling of empti\\xadness of the stomach, referred to as painful hunger. Indeed, the pain may improve with the ingestion of food, only to return in the postprandial period. The timing of the pain in relation to meals and the soothing effects of food are nonspecific, however, and may also occur in patients with functional dyspepsia without ulcer. Nocturnal epigastric pain that awakens a patient several hours after a late meal is more likely to represent ulcer pain.Besides the pain during symptomatic episodes, patients may complain of retrosternal burning (heartburn) or acidic regurgitation into the throat, symptoms that reflect associated gastroesophageal reflux (Chapter 140), which is aggravated by hyperacidity or delayed gastric emptying. Nausea and vomiting may also occur but are nonspecific. The presence of significant diar\\xadrhea should raise the possibility of Zollinger-Ellison syndrome (Chapter 201), but diarrhea also may result from the heavy use of magnesium-containing antacids. In untreated patients, symptoms tend to be intermittent, with flares of daily pain lasting 2 to 8 weeks, separated by prolonged asymp\\xadtomatic intervals. During periods of remission, patients may feel well and may be able to eat even heavy or spicy meals without apparent discomfort.Physical Examination',\n",
       " 'tomatic intervals. During periods of remission, patients may feel well and may be able to eat even heavy or spicy meals without apparent discomfort.Physical ExaminationThe physical examination is usually unrevealing. If significant bleeding has occurred (Chapter 137), the patient may present with pallor and may be hypovolemic (Chapter 106). It is always useful to inquire about the charac\\xadteristics of the stool, because ulcer-related bleeding may manifest not only obviously in the form of hematemesis but also insidiously as melena (black feces). In the case of massive ulcer bleeding with the rapid bowel passage of blood, patients may also present with red rectal blood loss. When a patient has acute perforation, severe epigastric and abdominal pain develops, and the patient appears distressed. Characteristically, intense contracture of the abdominal muscles is apparent on palpation, together with rebound tender\\xadness and other signs of peritoneal irritation. With large amounts of intra-abdominal air, percussion may reveal hypertympany over the liver.DIAGNOSISIn a patient who presents with symptoms consistent with ulcer disease, the diagnostic evaluation should proceed along two different but complementary paths: confirmation of the anatomic abnormality and investigation of its cause (Table 141-3). In most patients, it is advisable to follow both diagnostic paths simultaneously, but sometimes it is reasonable to skip the anatomic verification as a cost-saving strategy and proceed to management based on the probable cause.Anatomic DiagnosisEndoscopy (Chapter 136) is the primary investigative tool in patients sus\\xadpected of having acid peptic disease. This technique can detect erosive gas\\xadtritis (see Fig. 141-1) or an ulcer in the gastric wall or duodenal bulb (see Fig. 141-2). Because of the high prevalence and the often spontaneous improve\\xadment of dyspeptic symptoms, endoscopy usually should not be performed',\n",
       " '141-2). Because of the high prevalence and the often spontaneous improve\\xadment of dyspeptic symptoms, endoscopy usually should not be performed immediately; rather its use should be restricted to patients with persistent or recurrent symptoms. However, immediate endoscopy is indicated in patients with alarm symptoms such as weight loss, dysphagia, anorexia, considerable vomiting, anemia, or signs of overt bleeding.Endoscopy is both highly sensitive and highly specific for the detection of ulcer disease. The most common locations for a peptic ulcer are the stomach and duodenal bulb, but peptic ulcers sometimes occur in the esophagus, the small bowel, and a Meckel’s diverticulum lined with heterotopic gastric mucosa. Endoscopic ultrasound may detect an unsuspected submucosal component or enlarged lymph nodes, such as may occur in gastric neoplasia, especially lymphoma and linitis plastica (Chapter 198). Ulcers in the dorsal wall of the duodenal bulb, especially at the transition from the bulb to the postbulbar descending portion of the duodenum, are most difficult to visual\\xadize, and they sometimes require a side-viewing endoscope, particularly when endoscopic treatment is needed. Other regions where gastroduodenal ulcers can be easily missed are the cardia and the gastric angulus. Dieulafoy’s lesions may be difficult to diagnose because of their small mucosal defects and inter\\xadmittent bleeding. Some patients require more than one endoscopy, prefera\\xadbly during acute bleeding, to localize the lesion. Endoscopy is also useful for ascertaining the presence of concomitant disorders, including esophagitis and duodenitis, or complications, such as bleeding or a visible vessel (see Fig. 141-2); obtaining biopsy specimens, such as for histologic examination and to assess for H. pylori (see Fig. 141-3); and performing therapeutic interventions.In rare cases, such as stenosis that blocks the advancing endoscope,',\n",
       " 'and to assess for H. pylori (see Fig. 141-3); and performing therapeutic interventions.In rare cases, such as stenosis that blocks the advancing endoscope, conventional barium contrast radiographs (Chapter 135) are indicated. Additional investigations by endosonography or CT are needed when an underlying malignant disease is suspected. The endoscopist should obtain biopsy samples from all gastric ulcers, especially those with a suspicious appearance, to exclude potential malignant disease. Because duodenal ulcers are less likely to be malignant, biopsies are usually not required unless malig\\xadnancy is specifically suspected.TABLE 141-2 KEY SYMPTOMS AND SIGNS OF PEPTIC ULCERUNCOMPLICATED ULCERNo symptoms (“silent ulcer” in up to 40% of cases)Epigastric painPain may radiate to the back, thorax, other parts of abdomen (cephalad most likely, caudad least likely)Pain may be nocturnal (most specific), “painful hunger” relieved by food, or continuous (least specific)NauseaVomitingHeartburn (mimics or associated with gastroesophageal reflex)COMPLICATED ULCERAcute perforationSevere abdominal painShockAbdominal board-like rigidity (and rebound and other signs of peritoneal irritation)Free intraperitoneal airHemorrhageHematemesis and/or melenaHemodynamic changes, anemiaPrevious history of ulcer symptoms (80%)Gastric outlet obstructionSatiation, inability to ingest food, eructationNausea, vomiting (and related disturbances)Weight lossTABLE 141-3 DIAGNOSTIC PATHS AND TOOLS IN ULCER DISEASEPATH 1: MORPHOLOGIC DIAGNOSISGastroduodenoscopyBarium contrast (inferior alternative)Endoscopic ultrasound (selected cases only)Computed tomography (useful in selected cases)PATH 2: ETIOLOGIC DIAGNOSISHelicobacter pylori TestingHistologic examination of gastric mucosaStool antigen testCarbon-13 urea breath testSerum antibodiesUlcer Associated with Nonsteroidal Anti-inflammatory Drug UseHistory of drug ingestionDecreased platelet adherence',\n",
       " 'Stool antigen testCarbon-13 urea breath testSerum antibodiesUlcer Associated with Nonsteroidal Anti-inflammatory Drug UseHistory of drug ingestionDecreased platelet adherenceMolecular identification (complex, expensive)Acid Hypersecretory SyndromesSerum gastrin elevationGastrin provocative tests (intravenous secretin, meal)Gastric analysis',\n",
       " 'CHAPTER\\u2003 141\\u2003ACID PEPTIC DISEASE891Etiologic DiagnosisDiagnosis also must focus on establishing the cause of the ulcer. The first step is to determine whether H. pylori or NSAID use is present, because these are the major risk factors for peptic ulcers and can be contributing factors in ulcers with other precipitating causes.Testing for Helicobacter pyloriIn populations with a high prevalence of H. pylori, nearly all patients with peptic ulcer disease are positive for H. pylori, so diagnostic testing has little value except when antimicrobial susceptibility testing is needed. The preva\\xadlence of H. pylori remains high in immigrants from developing countries, where most people become H. pylori positive in youth. In Western countries, approximately 50% of individuals who are older than 65 years are colonized with H. pylori, but the prevalence is less than 20% in those younger than 30 years. In these younger persons, the proportion of patients with ulcers who are H. pylori negative is higher than in older patients, making diagnostic testing for H. pylori, followed by targeted therapy in those who are positive for the bacterium, more attractive than empirical therapy.The presence of H. pylori can be ascertained by four possible approaches. Histologic examination of gastric mucosal biopsies, which is the standard procedure when diagnostic endoscopy is initially performed, is quite sensi\\xadtive and specific for H. pylori. However, the accuracy of this technique may be affected by sampling error, improper orientation of the specimen, and recent therapy with proton pump inhibitors or antibiotics.A second option is serology, which is a relatively simple, inexpensive test that has reduced predictive value in areas where the prevalence of H. pylori is low. Serology is not helpful to verify whether H. pylori has been eradicated with antibiotics because it may take many months or even years for H. pylori',\n",
       " 'low. Serology is not helpful to verify whether H. pylori has been eradicated with antibiotics because it may take many months or even years for H. pylori antibodies to fall to undetectable levels. None of the diagnostic tests that do not involve endoscopy can determine whether an ulcer is present.A third option is a stool antigen test, which is more accurate than serology. Finally, the carbon-13 or carbon -14 urea breath test, which relies on the detec\\xadtion of H. pylori urease activity, is a noninvasive and relatively simple test, but it is more expensive than stool or blood testing. Although the test becomes negative as soon as H. pylori is eradicated, a minimum interval of 4 to 6 weeks after antibiotic treatment is recommended to reduce false-negative results.Nonsteroidal Anti-inflammatory DrugsNSAIDs are usually established as the putative cause of an ulcer based on information obtained from the patient. Assessment of NSAID use in an indi\\xadvidual patient presenting with ulcer disease can be difficult, both because NSAID use is common and often intermittent and because many different NSAIDs are widely available over the counter in most countries. NSAID use is usually evaluated by detailed medical history, focusing not only on current and recent drug use but also on symptoms of pain, including musculoskeletal complaints. Further information from family members, family practitioners, and pharmacists is sometimes helpful. If surreptitious use of NSAIDs is sus\\xadpected, direct serum and urine testing for aspirin and NSAID derivatives is feasible, or aspirin use can be assessed indirectly by a platelet adherence assay; however, these tests are not commonly used in clinical practice.Hypersecretory SyndromesHypersecretory syndromes not related to H. pylori or NSAIDs are rare causes of ulcer disease and are diagnosed by special tests (see Table 141-3). Zollinger-Ellison syndrome should be strongly considered in patients with multiple',\n",
       " 'of ulcer disease and are diagnosed by special tests (see Table 141-3). Zollinger-Ellison syndrome should be strongly considered in patients with multiple ulcers, particularly in atypical locations such as distal to the duodenal bulb, and when diarrhea is present, because these finding are uncommon in H. pylori–related peptic ulcer disease. Hypergastrinemic syndromes (e.g., Zollinger-Ellison syndrome, antral G-cell hyperplasia) are best diagnosed by a determination of serum gastrin levels, both basal and after stimulation with intravenous secretin (gastrinoma detection) or a test meal (antral G-cell hyperplasia detection). When detected early, gastrinomas may be resectable (Chapter 201).Gastric analysis, which is performed by placing a nasogastric tube to aspi\\xadrate gastric juice and to quantify gastric acid output (both basal and after stimulation with subcutaneous pentagastrin), is indicated in only two rare circumstances: patients with elevated serum gastrin levels suggestive of Zollinger-Ellison syndrome or antral G-cell hyperplasia, but with equivocal responses to standard gastric provocative tests, and patients with indirect signs of gastric hypersecretion (e.g., enlarged folds and abundant clear fluid at endoscopy), normal gastrin levels, and negative provocative gastrin tests but who may still be hypersecretors, such as patients with recurrent ulcer disease despite a prior vagotomy with or without antrectomy. A basal acid output greater than 15\\u202fmEq/hour or greater than 5\\u202fmEq/hour in a post\\xadoperative patient is considered a positive test result.The diagnosis of Zollinger-Ellison syndrome is best confirmed by gastric analysis showing a basal acid output greater than 15\\u202fmEq/hour in conjunc\\xadtion with a fasting serum gastrin level exceeding 1000\\u202fpg/mL in the presence of gastric pH less than 2. To skip the cumbersome gastric analysis, a gastric pH determination showing a fasting pH of 2 or less is adequate. For serum',\n",
       " 'of gastric pH less than 2. To skip the cumbersome gastric analysis, a gastric pH determination showing a fasting pH of 2 or less is adequate. For serum gastrin levels in the range 100 to 1000\\u202fpg/mL and intragastric pH greater than 2, an increase in the serum gastrin to more than 200\\u202fpg/mL after a secretin stimulation test is suggestive of the diagnosis. An elevated serum gastrin level alone is not sufficient to diagnose Zollinger-Ellison syndrome, because serum gastrin levels tend to increase over time with atrophic gastritis and are also increased in patients receiving proton pump inhibitor therapy.Other CausesIn patients in whom a gastroduodenal ulcer cannot be ascribed to coloniza\\xadtion with H. pylori, use of NSAIDs, or a hypersecretory syndrome, the estab\\xadlishment of a definite etiologic diagnosis may require a more thorough evaluation, starting with a medical history that focuses on the use of other ulcerogenic agents and the presence of symptoms that could suggest an underlying systemic disease. The next step is to evaluate biopsy samples from ulcer borders and from the antrum, corpus, and duodenum. The ulcer speci\\xadmens may reveal overt or suspicious signs of malignancy, in particular adeno\\xadcarcinoma (Chapter 198) or lymphoma. In these cases, further diagnostic evaluation should include staging of the malignancy. Alternatively, the biop\\xadsies may provide evidence of other infectious conditions, specific types of gastritis, celiac disease, ischemia, amyloidosis, or a systemic inflammatory condition. These data can be combined with clues provided by the endo\\xadscopic evaluation, including the character and location of the ulcer, signs of ischemia, and signs of inflammation at other locations. Further evaluation should focus on the presence of systemic disorders and may include a chest radiograph, angiography, ileocolonoscopy, and abdominal CT.Differential DiagnosisThe differential diagnosis of ulcer-like symptoms includes many disorders of',\n",
       " 'radiograph, angiography, ileocolonoscopy, and abdominal CT.Differential DiagnosisThe differential diagnosis of ulcer-like symptoms includes many disorders of the upper abdominal organs, including malignant diseases of the stomach (Chapter 198), duodenum (Chapter 199), pancreas (Chapter 200), or bile ducts (Chapter 202). The differential diagnosis of upper abdominal symp\\xadtoms also includes liver and gallstone disease (Chapter 158), pancreatitis (Chapter 146), and motility disorders (Chapter 138). In many patients with upper abdominal dyspeptic complaints, no underlying cause can be identi\\xadfied. In this “nonulcer” or functional dyspepsia group, complaints character\\xadistic of gastroesophageal reflux, ulcer symptoms, or dysmotility symptoms may be prominent. A few of these patients (generally 5%) benefit from eradi\\xadcation of H. pylori, with a slow decrease of dyspeptic complaints over 12 to 24 months, but functional dyspepsia is not a proven or widely accepted indication for treatment of H. pylori. If such treatment is considered, both the patient and the physician should be prepared for persistent symptoms despite eradication of H. pylori.Diagnostic Scenarios: Acute or Initial Clinical PresentationYounger (≤45 years old) patients without alarm symptoms or signs such as anemia, rapid weight loss, or other evidence of serious disease do not neces\\xadsarily require endoscopy, and evidence indicates that malignant gastric disease is unlikely. When a generalist physician is treating a patient who lives in an area of the world with a relatively high prevalence of H. pylori infection (>10% of the population is positive), a test-and-treat approach can begin with an H. pylori stool antigen determination, urea breath test, or H. pylori sero\\xadlogic examination. If the test is positive, the patient can be treated with the appropriate H. pylori eradication drugs (see later) and observed for 4 to 6 weeks. If the patient is also taking an NSAID, either orally or parenterally, the',\n",
       " 'appropriate H. pylori eradication drugs (see later) and observed for 4 to 6 weeks. If the patient is also taking an NSAID, either orally or parenterally, the same approach is appropriate, but the NSAID should be discontinued. If the H. pylori test is negative in a person taking NSAIDs, these drugs should be discontinued, and the patient should be treated with a proton pump inhibitor for 4 to 6 weeks. In patients who are not taking NSAIDs or who do not improve after these drugs are discontinued, endoscopy is indicated to deter\\xadmine whether an ulcer is present.Conversely, gastroenterologists more commonly proceed directly to endoscopy. If no abnormalities are apparent or the endoscopic study shows only “gastritis” without an overt ulcer, a biopsy should be obtained to',\n",
       " 'CHAPTER\\u2003 141\\u2003ACID PEPTIC DISEASE892TABLE 141-4 OVERVIEW OF ANTIBIOTICS USED FOR HELICOBACTER PYLORI ERADICATIONDRUG CLASSDRUGTRIPLE THERAPY* DOSEQUADRUPLE THERAPY† DOSESEQUENTIAL THERAPY‡ DOSEAcid suppressionProton pump inhibitor20-40\\u202fmg bid§20-40\\u202fmg bid§20-40\\u202fmg bid§Standard antimicrobialsBismuth compound||2 tablets bid2 tablets bidAmoxicillin1\\u202fg bid1\\u202fg bidMetronidazole¶500\\u202fmg bid500\\u202fmg tid500\\u202fmg bidClarithromycin500\\u202fmg bid500\\u202fmg bidTetracycline500\\u202fmg qidSalvage antimicrobialsLevofloxacin300\\u202fmg bid300\\u202fmg bidRifabutin150\\u202fmg bidFurazolidone100\\u202fmg bidDoxycycline100\\u202fmg bidNitazoxanide1\\u202fg bid*Triple therapy consists of a proton pump inhibitor or bismuth compound, together with two of the listed antibiotics, usually given for 7-14 days.†Quadruple therapy consists of a proton pump inhibitor plus either the combination of a bismuth compound, metronidazole, and tetracycline given for 4-10 days, or the combination of levofloxacin, doxycycline, and nitazoxanide for 10 days.‡Sequential therapy consists of 10 days of proton pump inhibitor treatment, plus amoxicillin during days 1-5 and a combination of clarithromycin and an imidazole (when available, tinidazole; otherwise, metronidazole) during days 6-10.§Proton pump inhibitor dose equivalent to omeprazole 20\\u202fmg bid.||Bismuth subsalicylate or subcitrate.¶An alternative is tinidazole 500\\u202fmg bid.urea breath test, stool H. pylori antigen, or repeated serology. Serologic deter\\xadmination is based on a more than 40 to 50% decrease in immunoglobulin G antibody levels in the first 6 months after treatment compared with pretreat\\xadment levels in that patient.After successful H. pylori eradication, the risk of recurrent infection in most populations is small. In a minority of patients, ulcers recur either owing to re-infection or in the presence of another ulcerogenic factor, par\\xadticularly NSAID use.Disease Related to Nonsteroidal Anti-inflammatory Drug Use',\n",
       " 'owing to re-infection or in the presence of another ulcerogenic factor, par\\xadticularly NSAID use.Disease Related to Nonsteroidal Anti-inflammatory Drug UseIn patients who are diagnosed with acid peptic disease while they are taking NSAIDs or aspirin, the first step is to stop such therapy. Acid suppression with a proton pump inhibitor (in doses similar to those used for H. pylori) leads to healing of 85% of NSAID-induced gastric ulcers and more than 90% of duodenal ulcers within 8 weeks of therapy, whereas acid suppression with an H2-blocker, equivalent to ranitidine 300\\u202fmg twice daily, heals approximately 70% of ulcers within 8 weeks. The mucosal protective drug misoprostol (200\\u202fmg four times daily) has a similar effect. Treatment must be continued for at least 8 weeks, and maintenance therapy is needed in patients who continue to take NSAIDs. Gastric ulcers, larger lesions, and recurrent lesions heal more slowly.Ulcer occurrence during NSAID therapy suggests a causative relationship, but patients should also be tested for H. pylori. In patients who are H. pylori positive, eradication therapy should be considered because there are no clear clinical parameters distinguishing between these etiologic factors. In patients who continue to take NSAIDs, maintenance therapy with a proton pump inhibitor is superior to H. pylori eradication for the prevention of recurrent ulcer,\\u20026\\u2002 except in patients who use aspirin, for whom H. pylori eradication alone may be curative.Idiopathic Ulcer DiseasePatients with idiopathic ulcer disease despite a thorough assessment for underlying causes are treated primarily with an acid suppressant, usually a proton pump inhibitor, because they are at considerable risk for recurrent ulcer disease. After the underlying cause is identified and adequately treated, acid suppressive therapy can be withdrawn if there are no additional risk factors for ulcer disease, such as NSAID therapy or H. pylori infection.',\n",
       " 'suppressive therapy can be withdrawn if there are no additional risk factors for ulcer disease, such as NSAID therapy or H. pylori infection.ascertain by histologic examination or urease testing whether H. pylori is present. If H. pylori is found by endoscopic biopsy, eradication treatment may be given; however, the effect of H. pylori eradication on relief of functional dyspeptic symptoms is only about 5% greater than with placebo.\\u20021\\u2002If endoscopic examination shows an ulcer, its location determines the subsequent approach. An ulcer in the duodenal bulb has only a remote chance of representing a malignant lesion and need not routinely be exam\\xadined by biopsy. By contrast, biopsy is mandatory for a gastric ulcerative lesion identified at endoscopy, because malignant gastric disease may present with similar clinical manifestations and may resemble benign ulcer disease mor\\xadphologically; even if histologic assessment does not identify a malignant process, repeat endoscopy is recommended about 1 month after therapy to verify complete healing and for biopsy of the scar.Helicobacter pylori InfectionH. pylori–associated ulcers often heal spontaneously, but acid suppressive therapy accelerates healing and ameliorates symptoms. Four weeks of acid suppressive therapy heals 70 to 80% of ulcers, and this number increases to more than 90% after 8 weeks of therapy. If H. pylori infection persists, however, ulcers recur in 50 to 90% of patients within 12 to 24 months; this rate can be reduced to 20 to 30% with maintenance acid suppression and to less than 5% with H. pylori eradication.\\u20022\\u2002 Eradication treatment is therefore mandatory (Table 141-4). Treatment for 10 to 14 days has about a 5 to 10% advantage over 7- to 10-day therapy,\\u20023\\u2002 and quadruple drug therapy is probably better than triple therapy.\\u20024\\u2002 Nevertheless, 7-day treatment may be acceptable in regions where local studies have shown that a particular treatment is very',\n",
       " 'than triple therapy.\\u20024\\u2002 Nevertheless, 7-day treatment may be acceptable in regions where local studies have shown that a particular treatment is very effective, and it is probably the most economical option in countries with low health care budgets. For patients in whom such therapy fails, a 4- to 10-day course of quadruple therapy is advised. This second-line regimen eradicates H. pylori in an additional 80 to 90% of patients. Resistance of H. pylori to met\\xadronidazole varies between 10 and 80% throughout the world. Clarithromycin resistance is increasing and is now estimated to be 5 to 10% in the United States because of the widespread use of macrolides to treat upper respiratory infections. Resistance to amoxicillin and tetracycline is rare and is not usually relevant in clinical practice. Sequential therapy may be superior to standard triple therapy and is a good alternative for both first- and second-line treatment.Continuation of acid suppressive therapy after antibiotic treatment is needed only when symptoms persist\\u20025\\u2002 or in cases of complicated ulcer disease until eradication of H. pylori has been confirmed. Ascertainment of therapeutic efficacy must be delayed at least 1 month after the end of treatment to prevent false-negative results related to the organism’s temporary suppression but not eradication. When repeat endoscopy is needed (e.g., a gastric ulcer requires repeated histologic examination to exclude underlying malignancy), repeat screening for H. pylori can be performed using the gastric biopsy specimens for histologic examination, culture, or urease testing. If no clinical indication exists for repeat endoscopy, H. pylori status can be determined by a carbon-13 TREATMENTPREVENTIONPrimary PreventionA test-and-treat strategy for H. pylori colonization may be considered for patients with dyspeptic symptoms, but there is no specific way to prevent H. pylori–associated ulcer disease. In contrast, primary prevention of NSAID-',\n",
       " 'patients with dyspeptic symptoms, but there is no specific way to prevent H. pylori–associated ulcer disease. In contrast, primary prevention of NSAID-associated ulcer disease is widely advocated for patients at high risk because of a prior ulcer, severe concomitant disease, use of warfarin or high-dose corticosteroids, or older age (>65 years). H2-blockers (at a dose equivalent to ranitidine 300\\u202fmg twice daily) partially prevents duodenal ulcer disease during NSAID therapy but has no effect on preventing gastric ulcers unless a higher dose (equivalent to famotidine 40\\u202fmg twice daily) is given. Proton',\n",
       " 'CHAPTER\\u2003 141\\u2003ACID PEPTIC DISEASE893pump inhibitors (at a dose equivalent to omeprazole 20\\u202fmg once daily) and misoprostol (in doses varying between 400 and 800\\u202fmg/day) partially protect against both gastric and duodenal ulcers during NSAID use. Miso\\xadprostol and proton pump inhibitors are equally effective,\\u20027\\u2002 but adherence with therapy is lower with misoprostol owing to its side effects. Patients should be advised of the importance of adherence because less than 80% adherence to gastroprotection is associated with a more than two-fold increased risk for ulcer disease compared with those who are fully adherent. During low-dose aspirin therapy, primary prevention of ulcers is advocated for the same risk groups, using a proton pump inhibitor or an H2-receptor antagonist.\\u20028\\u2002Secondary PreventionSecondary prevention of H. pylori–associated ulcer disease is mandatory and consists of successful bacterial eradication. Testing to ascertain H. pylori status after eradication therapy is indicated in patients with prior complicated ulcer disease or with persistent or recurrent symptoms after therapy, as well as in patients who fail to complete the therapeutic course.Secondary prevention of NSAID-related ulcer disease is preferentially achieved by the withdrawal of NSAIDs. In patients who must continue taking NSAIDs, a change to a selective COX2 inhibitor in combination with a proton pump inhibitor at a dose equivalent to esomeprazole 20\\u202fmg twice daily is advocated, especially for patients with complicated ulcer disease.\\u20029\\u2002 This combination is associated with a lower risk of secondary peptic ulcer complications than treatment with a COX2 inhibitor alone.Secondary prevention of recurrent ulcers in patients who use aspirin may depend on H. pylori status. In H. pylori–positive patients, H. pylori eradication is as effective as a proton pump inhibitor for the prevention of recurrent ulcers.\\u20026\\u2002 In H. pylori–negative patients, additional acid suppressive therapy at',\n",
       " 'is as effective as a proton pump inhibitor for the prevention of recurrent ulcers.\\u20026\\u2002 In H. pylori–negative patients, additional acid suppressive therapy at a dose equivalent to esomeprazole 20\\u202fmg twice daily should be prescribed. Secondary prevention of idiopathic ulcer disease consists primarily of main\\xadtenance therapy with a proton pump inhibitor and treatment of the underly\\xading condition.PROGNOSISThe majority of peptic ulcers heal spontaneously within weeks to months. However, if the underlying condition is not adequately treated, a large pro\\xadportion of ulcers recur. Both initial and recurrent ulcers can give rise to complications. The four major complications are intractability, perforation, hemorrhage, and stenosis. Each distinct situation requires specific manage\\xadment approaches. Patients with complicated ulcer disease are at particular risk for recurrent complications and need careful assessment for secondary prevention.HemorrhageHemorrhage (Chapter 137), which is the most common complication of peptic ulcer disease, occurs in about one in six patients with ulcers over the course of their ulcer activity. Ulcers caused by NSAIDs account for a larger proportion of these hemorrhages. Peptic ulcer is thus the most common cause of nonvariceal upper gastrointestinal bleeding, accounting for 40 to 60% of cases in most populations. Bleeding is associated with a 5 to 15% risk of rebleeding and up to a 10% risk of mortality. Hemorrhage may occur along a continuum from a serious acute event associated with hemodynamic shock and high mortality to slow or intermittent blood loss leading to chronic anemia. Approximately 80% of patients with bleeding ulcers describe a prior history of symptomatic disease, and about 20 to 30% have suffered a previous hemorrhage. Assessment of the magnitude of bleeding is of paramount importance in determining the need for transfusion and subsequent manage\\xadment (Table 141-5). Initial hematocrit levels may be misleading and are likely',\n",
       " 'importance in determining the need for transfusion and subsequent manage\\xadment (Table 141-5). Initial hematocrit levels may be misleading and are likely to fall because of hemodilution. Rapid bleeding is usually apparent on the basis of clinical signs (pallor, systolic blood pressure ≤100\\u202fmm\\u202fHg, pulse ≥100/minute); immediate fluid resuscitation and transfusions are indicated to prevent circulatory collapse. Mortality is particularly related to complica\\xadtions of the bleed, such as aspiration, and exacerbation of underlying disease, such as pulmonary, cardiovascular, renal, and hepatic disease. On rare occa\\xadsions, patients may actually bleed to death, especially when a larger artery is affected, such as when an ulcer in the posterior wall of the duodenal bulb perforates the gastroduodenal artery.Initial treatment aims at hemodynamic stabilization. Endoscopy is the mainstay of therapy and should be performed within 24 hours of presentation in high-risk cases, especially patients who are hemodynamically unstable, require transfusion, or have more severe comorbidities. Endoscopy can be TABLE 141-5 BLATCHFORD SCORING SYSTEM TO DETERMINE THE NEED FOR INTERVENTION IN PEPTIC ULCER BLEEDINGVARIABLEVALUE AT ADMISSIONSCORE COMPONENT VALUEBlood urea (mmol/L)6.5-7.928.0-9.9310.0-24.94≥25.06Hemoglobin (g/L)\\u2003Men120-1291100-1192<1006\\u2003Women100-1191<1006Systolic blood pressure (mm Hg)100-109190-992<903Other markersPulse ≥100/min1Presentation with melena1Presentation with syncope2Hepatic disease2Cardiac failure2Data from Stanley AJ, Ashley D, Dalton HR, et\\u202fal. Outpatient management of patients with low-risk upper gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet. 2009;373:42-47. Intervention (endoscopic hemostasis, surgery, transfusion) is rarely needed for patients with an admission score ≤2 but is required in more than 40% of patients with a score ≥6.TABLE 141-6 ENDOSCOPY RESULTS IN PATIENTS',\n",
       " 'patients with an admission score ≤2 but is required in more than 40% of patients with a score ≥6.TABLE 141-6 ENDOSCOPY RESULTS IN PATIENTS WITH BLEEDING ULCERSENDOSCOPY RESULTULCER CHARACTERISTICS*RISK OF RECURRENT BLEEDING (%)Active bleedingArterial bleeding80-90Oozing bleeding10-30Stigmata of recent bleedingNonbleeding visible vessel50-60Adherent clot25-35Flat pigmented spot0-8No signs of bleedingClean ulcer base0-12*The ulcer characteristics determine the risk of recurrent bleeding during follow-up.performed to ascertain the origin of the bleeding, and, if necessary, provide therapy to stop the bleed and reduce the risk of rebleeding.The appearance of the ulcer determines the need for endoscopic treatment and the risk of rebleeding (Table 141-6) and mortality. “Clean base” ulcers and those with flat pigmented spots carry a low risk of rebleeding and do not require endoscopic treatment. In contrast, ulcers with active bleeding or stigmata of recent bleeding, in particular a visible vessel or adherent clot, require treatment to stop the bleed and reduce the otherwise high risk of recurrence.Endoscopic therapy may lead to a three-fold reduction in episodes of recurrent bleeding and in the need for surgical intervention, as well as a 40% reduction in mortality.\\u200210\\u2002 Treatment modalities include injection therapy with epinephrine or a sclerosant, thermocoagulation, and mechanical pres\\xadsure by means of clips. Thermocoagulation can be performed by direct contact, such as with a heater probe, or by a noncontact method, such as argon plasma coagulation. The efficacy of these methods is generally compa\\xadrable, except that epinephrine injection alone is inferior to the other modali\\xadties but can be useful when combined with any of the others.\\u200210,11\\u2002 If an adherent clot is found, an attempt should be made to remove it by water flushing or snaring to allow an assessment of the underlying ulcer base',\n",
       " 'adherent clot is found, an attempt should be made to remove it by water flushing or snaring to allow an assessment of the underlying ulcer base and the treatment of any underlying visible vessels to reduce the risk of rebleeding.\\u200212\\u2002The pre-endoscopy administration of intravenous proton pump inhibitor therapy (at a dose equivalent to a bolus of 80\\u202fmg esomeprazole, followed by a continuous infusion of 8\\u202fmg/hour until endoscopy) reduces bleeding and the need for emergent endoscopic treatment, but it has no effect on the need',\n",
       " 'CHAPTER\\u2003 141\\u2003ACID PEPTIC DISEASE894for transfusion or the occurrence of rebleeding or death. For patients with active bleeding or stigmata of recent bleeding, endoscopic treatment should be followed by an intravenous proton pump inhibitor given as a bolus at a dose equivalent to 80\\u202fmg esomeprazole over 30 minutes, followed by a con\\xadtinuous infusion at a dose equivalent to esomeprazole 8\\u202fmg/hour for 72 hours, to reduce rebleeding and the need for further intervention.\\u200213\\u2002 Other therapies, including tranexamic acid, vasopressin, somatostatin, and octreo\\xadtide, should be considered experimental (Chapter 137). Second-look endos\\xadcopy is not routinely indicated but can be considered in very high-risk cases, particularly when there is doubt about the adequacy of initial visualization or treatment.About 70 to 80% of rebleeds occur within the first 3 days and generally should be managed by repeat endoscopy. If endoscopy fails to stop the bleed or prevent further rebleeding, surgery and interventional radiology are equiv\\xadalent options. Surgery includes stitching of the ulcer and occlusion of the feeding artery, usually the gastroduodenal artery. Interventional radiology uses angiography to insert a coil in the culprit vessel at the site of the bleed. Single-center observational experience suggests that each of these methods is equally effective in the hands of experienced clinicians, and the choice depends on local availability and expertise.The risk for a fatal outcome of an upper gastrointestinal hemorrhage can be estimated based on five clinical and endoscopic parameters (Table 141-7). In several studies, mortality in patients with a bleeding peptic ulcer was less than 2% among those with a score of 2 points or less, 10% in those with 3 to 5 points, and up to 46% in those with 6 points or more. Management of patients who recover after a peptic ulcer hemorrhage is similar to the treat\\xadment of patients with uncomplicated ulcers. Eradication of H. pylori provides',\n",
       " 'patients who recover after a peptic ulcer hemorrhage is similar to the treat\\xadment of patients with uncomplicated ulcers. Eradication of H. pylori provides excellent protection against both recurrence and rebleeding of H. pylori–related ulcers. NSAID-induced ulcers are preferentially managed by the with\\xaddrawal of NSAIDs or, if this is not feasible, by the combination of a COX2 inhibitor and a proton pump inhibitor at a dose equivalent to esomeprazole 20\\u202fmg twice daily. In patients with a history of ulcer bleeding and concomi\\xadtant cardiovascular disease requiring antiplatelet therapy, the combination of low-dose aspirin and a proton pump inhibitor at a dose equivalent to eso\\xadmeprazole 20\\u202fmg twice daily is associated with a lower risk of complicated ulcer than is clopidogrel monotherapy.\\u200214\\u2002 If a patient who requires antiplate\\xadlet therapy presents with a bleeding ulcer, antiplatelet therapy should be continued or restarted as soon as possible if the risk of a cardiovascular event outweighs the risk of recurrent bleeding.\\u200215\\u2002PerforationPerforation may manifest as an acute event, whereby gastric contents spill into the peritoneal cavity, or more insidiously as the ulcer slowly penetrates into surrounding tissues. Acute free perforation typically causes abrupt and severe abdominal pain associated with abdominal muscular spasm that produces board-like rigidity of the abdomen and other manifestations of peritoneal irritation. Secondary hemodynamic shock is common. The clini\\xadcal diagnosis can be confirmed in approximately 80% of patients by a plain chest radiograph with the patient standing (Fig. 141-5); a CT scan can be obtained if doubt persists. Leukocytosis and elevated C-reactive protein levels develop rapidly, and mild hyperamylasemia may occur. Treatment begins by correcting hemodynamic, fluid, and electrolyte imbalances. Naso\\xadgastric suction is helpful, and prophylactic antibiotics (e.g., amoxicillin-',\n",
       " 'begins by correcting hemodynamic, fluid, and electrolyte imbalances. Naso\\xadgastric suction is helpful, and prophylactic antibiotics (e.g., amoxicillin-clavulanic acid 1\\u202fg every 8 hours intra\\xadvenously) are usually administered. Unless a specific contraindication exists, emergency surgery is usually indi\\xadcated, although more conservative approaches are sometimes appropriate. Given the success in achieving the long-term cure of ulcer disease through the eradication of H. pylori and the withdrawal of NSAIDs, suturing of the perforated ulcer may be adequate, permitting the patient to avoid a more radical vagotomy with or without gastric resection.IntractabilityIntractability is a term strictly applied to an ulcer that persists even after intensive and prolonged proton pump inhibitor therapy. Symptoms may or may not be present. These rare cases may result from poor compliance with recommended treatment, surreptitious use of ulcerogenic drugs, or other diseases (e.g., Crohn’s disease, ischemia, infection with bacteria other than H. pylori, viral infection). If these issues are recognized and these diagnoses are pursued, further complications and interventions such as surgical vagot\\xadomy and pyloroplasty can almost always be avoided.Acid peptic disease related to alcohol or bisphosphonates should be addressed by discontinuing the precipitating agent. Treatment of Zollinger-Ellison syndrome requires high-dose proton pump inhibitors and/or surgery (Chapter 201). Those rare ulcers caused by Crohn’s disease (Chapter 143), vasculitis (Chapter 278), sarcoidosis (Chapter 95), polycythemia vera (Chapter 169), amyloidosis (Chapter 194), and other rare disorders should be addressed by treating the underlying condition. Stress ulcers and Cameron’s ulcers are treated by potent acid suppression therapy (e.g., omeprazole 20\\u202fmg twice daily).StenosisGastric outlet obstruction is now a rare complication of ulcer disease',\n",
       " 'Cameron’s ulcers are treated by potent acid suppression therapy (e.g., omeprazole 20\\u202fmg twice daily).StenosisGastric outlet obstruction is now a rare complication of ulcer disease because of the early detection and treatment of most ulcers. Most patients who develop clinically relevant gastric outlet obstruction have had an ulcer in the duodenal bulb and/or pyloric channel. Edema and inflammation play an important role, and occasionally a patient with active disease presents with symptoms of outlet obstruction as manifested by nausea, vomiting, and gastric stasis without a tight, chronic stenosis. Management therefore involves three key steps. This first is nasogastric tube aspiration and gastric lavage to clean the stomach of retained debris, followed by early endoscopy. FIGURE\\u202f141-5.\\u2002 Plain chest radiograph in an upright patient with a perforated ulcer. The radiograph shows free air under the diaphragm. TABLE 141-7 ROCKALL SCORING SYSTEM FOR THE RISK OF MORTALITY FOLLOWING PEPTIC ULCER BLEEDINGVARIABLEScore0123Age (yr)<6060-7980—ShockNot presentPulse >100Systolic BP <100\\u202fmm\\u202fHg—ComorbidityNoneCardiac failureCoronary insufficiencyOther serious illnessRenal insufficiencyLiver failureMetastatic malignancyDiagnosisMallory-Weiss syndrome or no identifiable causeUlcerVaricesMalignancy of proximal digestive tract—EndoscopyNo signs of recent bleedingBleeding, clot, or visible vessel—BP = blood pressure.Data from Rockall TA, Logan RFA, Devlin HB, et\\u202fal. Risk assessment after acute upper gastrointestinal haemorrhage. Gut. 1996;38:316-321.PaP700',\n",
       " 'This step facilitates an accurate diagnosis. Nasogastric suction may need to be maintained for several days if vomiting resumes when the tube is clamped. The second step consists of intense antisecretory therapy using intravenous proton pump inhibitors in a dose equivalent to a bolus of 80\\u202fmg esomeprazole over 30 minutes, followed by a continuous infusion of 8\\u202fmg/hour. Finally, the cause of the ulcer needs to be addressed, usually by eradicating H. pylori and withdrawing NSAIDs. If the initial treatment resolves the clinical situation and the patient can resume eating, it is often not necessary to undertake further treatment of the outlet stenosis; however, tight, fibrous scarring may require endoscopic balloon dilation or surgery.1. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;2:CD002096.2. Ford AC, Delaney BC, Forman D, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive patients. Cochrane Database Syst Rev. 2006;2:CD003840.3. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for the Helicobacter pylori eradication. Ann Intern Med. 2007;147:553-562.4. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule contain\\xading bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377:905-913.5. Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther. 2005;21:795-804.6. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967-973.',\n",
       " 'with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967-973.7. Graham DY, Agrawal NM, Campbell DR, et al. NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of non-steroidal anti-inflammatory drugs: results of a double blind, randomized, multicenter, active- and placebo-controlled study of misoprostol versus lansoprazole. Arch Intern Med. 2002;162:169-175.8. Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesopha\\xadgitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:119-125.9. Barkun A, Bardou M, Kuipers EJ, et al. International consensus recommendations on the manage\\xadment of patients with non-variceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101-113.10. Barkun AN, Martel M, Toubouti Y, et al. Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of meta-analyses. Gastrointest Endosc. 2009;69:786-799.11. Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol. 2009;7:33-47.12. Kahi CJ, Jansen DM, Sung JJ, et al. Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Gastroenterology. 2005;129:855-862.13. Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009:150;455-464.14. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recur\\xadrent ulcer bleeding. N Engl J Med. 2005;352:238-244.15. Sung JJ, Lau YW, Ching JYL, et al. Continuation of low-dose aspirin in peptic ulcer bleeding: a randomized, controlled trial. Ann Intern Med. 2010;152:1-9.SUGGESTED READINGS',\n",
       " '15. Sung JJ, Lau YW, Ching JYL, et al. Continuation of low-dose aspirin in peptic ulcer bleeding: a randomized, controlled trial. Ann Intern Med. 2010;152:1-9.SUGGESTED READINGSLanza FL, Chan FL, Quigley EM, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728-738. International consensus guidelines on the prevention of NSAID-related ulcer disease.Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleve Clin J Med. 2011;78:39-49. Review.Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374:1449-1461. Review.McColl KE. Helicobacter pylori infection. N Engl J Med. 2010;362;1597-1604. Review.',\n",
       " '219Upper GI TractCHAPTER 32Peptic ulcerC. J. Hawkey and John C. AthertonNottingham Digestive Diseases Centre, University of Nottingham and Nottingham University Hospitals, Nottingham, UKTextbook of Clinical Gastroenterology and Hepatology, Second Edition. Edited by C. J. Hawkey, Jaime Bosch, Joel E. Richter, Guadalupe Garcia-Tsao, Francis K. L. Chan.© 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.Introduction and definitionPeptic ulcers are localized breaches of the gastric or duodenal mucosa with tissue destruction at least to the depth of the muscularis mucosa (Figure 32.1).The word “peptic” reflects a belief (probably misplaced) that peptic activity is involved in pathogenesis. Peptic ulcers include ulcers in the stomach, pylorus, duodenum, or a Meckel’s diverticulum, as well as ulcers at sites of gastrointestinal anastomosis (stomal ulcers) and at the gastroesophageal junction.The commonest symptom is pain. The most serious complications are bleeding and perforation.Causes of peptic ulcerationIt is only in the past 25 years that the causes of peptic ulcers have been identified and rational management defined.Common causesMost ulcers are directly caused by infection with Helicobacter pylori [1] or by nonsteroidal anti-inflammatory drugs (NSAIDs) [2,3], including aspirin [4] (Figure 32.2), which inhibit prostag-landin synthesis and abrogate mucosal defence mechanisms. In developed countries, duodenal ulcers are proportionally caused more commonly by H. pylori and gastric ulcers by NSAIDs, but either factor may produce an ulcer at either site. Absence of a history of NSAID use and a negative test for H. pylori should prompt a search for other causes, although in such patients H. pylori and NSAIDs are still the most likely causes. Tests for H. pylori have a low but measurable false negative rate and NSAIDs purchased directly and sometimes unknowingly in compound preparations, are easily ignored by doctors and patients.',\n",
       " 'causes. Tests for H. pylori have a low but measurable false negative rate and NSAIDs purchased directly and sometimes unknowingly in compound preparations, are easily ignored by doctors and patients.Uncommon causesUncommon, but significant, causes of peptic ulcers include Crohn’s disease, conditions causing acid hypersecretion (Zollinger-Ellison syndrome, multiple endocrine neoplasia, and mastocytosis [9]; see Chapter 112) severe physical stress such as being in intensive care, and mucosal ischemia due to ESSENTIALS OF PATHOGENESIS• Helicobacter pylori and NSAIDs are the commonest causes of peptic ulceration• Most duodenal ulcers are caused by H. pylori• Most gastric ulcers in developed countries are caused by NSAIDs• Smoking is an important cofactor particularly for H. pylori-induced ulcers• Virulence factors (CagA, VacA and others) influence whether H. pylori colonization leads to ulceration• NSAIDs inhibit the synthesis of gastroprotective prostaglandinsESSENTIALS OF DIAGNOSIS• Typical ulcer symptoms are localized epigastric pain occurring overnight or pre-prandially and relieved by milk or antacids• Symptoms are however often atypical, especially with gastric ulcers and/or NSAID use• Many ulcers are now treated without a formal diagnosis°\\u2002 In younger patients without alarm features, H. pylori infection is usually detected and eradicated in the community° For NSAID patients, prophylactic measures in at risk patients rather than diagnosis is key to management• Where formal diagnosis is needed endoscopy is the method of choice• Biopsy of gastric ulcers is traditionally recommended to detect gastric cancer or lymphoma but duodenal ulcers should also be biopsied if there is a possibility of Crohn’s disease (e.g., H. pylori and NSAID negative)ESSENTIALS OF TREATMENT  AND PROGNOSIS• Successful H. pylori eradication results in permanent ulcer healing in the vast majority of patients if there are no other risk factors (including NSAID use)',\n",
       " 'ESSENTIALS OF TREATMENT  AND PROGNOSIS• Successful H. pylori eradication results in permanent ulcer healing in the vast majority of patients if there are no other risk factors (including NSAID use)• H. pylori eradication prior to NSAID initiation may reduce ulcer risk. Risk can be further reduced by co-prescription of PPIs.• Ulcers and ulcer complications are much less likely if patients take selective COX-2 inhibitorsHawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Upper GI TractPart 2:\\u2002 Diseases of the Gut and Liver220pylori remains common, the prevalence of peptic ulcer also remains high. As the prevalence of H. pylori infection has fallen, the importance of NSAIDs as a cause of peptic ulcera-tion has increased, and low-dose aspirin is now the fastest growing cause of ulcer complications [8]. Recent studies [9–14] suggest that whilst uncomplicated ulcers continue to fall, this may not be so for ulcer complications.Risk factorsThe influence of risk factors depends largely but not entirely on whether the peptic ulcer is caused by H. pylori or NSAIDs [15–22] Peptic ulcer is an age-related disease for both H. pylori and NSAIDs (see Figure 32.3). In H. pylori-infected patients, smoking enhances the risk considerably [16]. Family history largely reflects “shared” H. pylori infection. A previous history of peptic ulcer increases risk for ulcers caused both by H. pylori infection and NSAID use. Risk may persist after NSAID ces-sation [8] which might explain some “idiopathic” ulceration. It is clear that different NSAIDs affect the risk of peptic ulcer to different extents, and that risk is highly dose dependent [19] (Figure 32.4). Risk factors in patients using low-dose aspirin are less well defined, but rates of ulcer bleeding are higher in patients with a past history and in elderly patients [22]. Risk factors for rare causes are unclear, and in some instances (e.g., Zollinger-Ellison syndrome) the underlying disease is a domi-nant influence.Disease associationsPeptic ulcer is more common in patients with chronic obstruc-tive lung disease, cirrhosis, coronary artery disease, and renal failure [7] and in coal miners, possibly because of shared risk factors, including H. pylori infection or hypergastrinemia.PathogenesisIt is a truism that mucosal integrity represents a balance between aggressive and protective factors. H. pylori infection and acid are the main aggressive factors. The main protective',\n",
       " 'PathogenesisIt is a truism that mucosal integrity represents a balance between aggressive and protective factors. H. pylori infection and acid are the main aggressive factors. The main protective factors are mucus and bicarbonate secretion, hydrophobicity (waxiness) of epithelial cells, and mucosal blood flow. These are mediated by prostaglandins (and other mediators such as nitric oxide) and abrogated when their synthesis is inhibited by NSAIDs [2].Figure 32.1\\u2002 Large pyloric ulcer with red spot (minor bleeding stigma).Figure 32.2\\u2002 First demonstration of aspirin-induced gastric damage. (Reproduced with permission from Douthwaite AH, Lintott SAM. Gastropic observation of the effect of aspirin and certain other substances on the stomach. Lancet. 1938;ii:1222–1225.)critical celiac axis vascular disease and radiation. Gastric ulcer-ation may also indicate gastric adenocarcinoma or gastric lymphomaThere is continuing debate about whether corticosteroids alone can cause ulcers [10,11], although the ability of corticos-teroids to enhance NSAID-associated ulcers is well established (see below) [2,5]. Idiopathic ulcers are rare. Most are probably due to falsely negative H. pylori tests or sporadic or surrepti-tious NSAID use. If these causes are confidently excluded, rare conditions such as those described above should be sought. However, a small group of idiopathic peptic ulcers still existsEpidemiologyThe epidemiology of peptic ulceration reflects that of the main underlying causes (see Chapter 22 for H. pylori and Chapter 23 for NSAIDs). The early twentieth century saw a rapid rise in the incidence of duodenal ulceration in westernized socie-ties [6]. H. pylori has been ubiquitous in the population for centuries, so a change in environment appears the most likely cause, and one possibility is the widespread adoption of smoking – an important co-factor for duodenal ulceration in H. pylori-colonized people. The prevalence of both H. pylori',\n",
       " 'cause, and one possibility is the widespread adoption of smoking – an important co-factor for duodenal ulceration in H. pylori-colonized people. The prevalence of both H. pylori and peptic ulcer is falling in westernized societies [7], probably due to improvements in hygiene in the twentieth century(Figure 32.3). In other parts of the world such as Hong Kong where H. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.安',\n",
       " 'Chapter 32:\\u2002 Peptic ulcer221Upper GI TractFigure 32.3\\u2002 Recent trends in ulcer epidemiology. Top: Deaths from gastric ulcer and unspecified peptic ulcer. Bottom: Deaths from duodenal ulcer. (Reproduced with permission from Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg. 2010;251(1):51–58.)Gastric ulcer19935.0%4.5%3.5%2.5%1.5%0.5%0.0%2.0%In-hospital deaths, %1.0%3.0%4.0%1994 1995 1996 1997 1998 1999 2000Year2001 2002 2003 2004 2005 2006Duodenal ulcerPeptic ulcer, site unspecified199318.0%16.0%12.0%8.0%4.0%0.0%6.0%In-hospital deaths, %2.0%10.0%14.0%1994 1995 1996 1997 1998 1999 2000Year2001 2002 2003 2004 2005 2006HemorrhagePerforationObstructionH. pylori-associated ulcersH. pylori colonization is lifelong in the absence of effective treatment [24] yet only about 15% of infected people develop peptic ulceration in their lifetime. The development of ulcera-tion is due to a combination of bacterial virulence, host genetic susceptibility, and environmental co-factors.Bacterial virulenceThe best understood bacterial virulence factor is the cag patho-genicity island (cag PAI). H. pylori strains possessing this factor induce more inflammation and are more closely associated with peptic ulceration and gastric adenocarcinoma than cag-negative strains [23]. The cag PAI is a collection of genes encod-ing a bacterial type IV secretion system, a sort of molecular syringe through which at least one protein, CagA, is “injected” into epithelial cells [24]. Several signalling pathways are acti-vated, resulting in epithelial cell changes and pro-inflammatory cytokine release, which induces inflammation [25]. A second virulence factor is the vacuolating cytotoxin, VacA. H. pylori strains producing more active forms are more closely associated with disease [23,26]. Other factors that have been',\n",
       " 'virulence factor is the vacuolating cytotoxin, VacA. H. pylori strains producing more active forms are more closely associated with disease [23,26]. Other factors that have been associated with increased strain pathogenicity include an adhesin, BabA, an outer membrane inflammatory protein, OipA [28], and a genetic marker of another type IV secretion system, dupA [27].Host susceptibilityGenetic polymorphisms in some cytokine genes, such as interleukin-1β, increase the level of inflammation induced by H. pylori [27], induce the pan-gastritic pattern of inflamma-tion, and increase the risk of H. pylori-associated gastric atrophy and adenocarcinoma. Peptic ulcer disease has been associated with inadequate regulatory T cell responses [28] and there is growing interest in the role of the innate immune responses [29].Environmental factorsSmoking is an important risk factor for peptic ulceration in H. pylori-colonized people [16]. Its role in NSAID-associated ulcers is less clear.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Upper GI TractPart 2:\\u2002 Diseases of the Gut and Liver222hypergastrinemia [30]. Gastrin stimulates the healthy gastric corpus to produce more acid. The increased acid load in the duodenum contributes to the formation of gastric metaplasia – a (possibly adaptive) change in the duodenal mucosa to resemble that in the stomach. H. pylori, which can colonize only gastric-type mucosa, can now colonize the duodenum and cause inflammation, damage, and ulceration (Figure 32.5).Gastric ulcerationGastric ulcers occur in H. pylori-colonized people with a corpus-predominant or pangastritis (Figure 32.5). Such persons also have hypergastrinemia, but acid production is unchanged or reduced because of the inflamed and damaged gastric corpus. This leads to a cycle of chronic damage with progres-sive atrophy of gastric glands and further hypochlorhydria. The pathogenesis of gastric ulceration in this environment is poorly understood, but ulcers usually occur in the transitional zone, between antrum and corpus mucosa, often on the lesser curve, where inflammation can be heavy. These people are also predisposed to develop distal gastric adenocarcinoma.Nonsteroidal anti-inflammatory drugs (NSAIDs)Mucosal defenceNSAIDs inhibit the synthesis of gastroduodenal prostagland-ins, which are centrally important for mucosal protection via mucus and bicarbonate secretion and mucosal blood flow [2]. Abrogation of prostaglandin-dependent mechanisms is suffi-cient to cause local erosions, which deepen to form ulcers in the presence of acid and pepsin. A central role for pepsin is more likely in NSAID ulcers than in ulcers caused by H. pylori, as much greater changes in pH are needed to prevent damage [35] or heal ulcers [31,32].Localization of H. pylori-associated ulcersDuodenal ulcerationDuodenal ulcers occur against a background of H. pylori colo-nization with a predominantly antral pattern of gastritis (Figure 32.5). Antral inflammation results in reduced somato-',\n",
       " 'Duodenal ulcerationDuodenal ulcers occur against a background of H. pylori colo-nization with a predominantly antral pattern of gastritis (Figure 32.5). Antral inflammation results in reduced somato-statin production by antral D cells and, as somatostatin nor-mally has a negative feedback on gastrin, this results in Figure 32.5\\u2002 Hormonal changes in duodenal and gastric ulceration. (a) In H. pylori-induced antral predominant gastritis, the illustrated hormonal changes lead to hypergastrinemia and increased acid production from the uninflamed gastric corpus. The increased acid load on the duodenum may lead to ulceration (see text for full explanation). (b) In pangastritis, the same hormonal changes pertain, but the inflamed corpus produces reduced acid despite the hypergastrinemia. Such stomachs are at increased risk of gastric ulceration and adenocarcinoma.↓Somatostatin ↑Gastrin↑HistamineInflammation↑AcidD cellG cellECL cellParietal cellH. pylori-inducedcentral predominantgastritis++-+++↓Somatostatin ↑Gastrin↑HistamineInflammation↓AcidD cellG cellECL cellParietal cellH. pylori-inducedpan gastritis++---+++(a)(b)Figure 32.4\\u2002 Differences in odds ratio for peptic ulcer bleeding with individual NSAIDs and doses. Paracetamol (acetaminophen) is also shown for comparison. Note: Confidence intervals were wide (not shown for groups). (Reproduced with permission from Lewis SC, Langman MJS, Laporte JR, et al. Dose-response relationships between individual nonaspirin nonsteroidal antiinflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320–326.)ParaOdds ratioIbuDicloNapIndoPirox80030201040506070Low doseMediumHighHawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.',\n",
       " '70Low doseMediumHighHawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Chapter 32:\\u2002 Peptic ulcer223Upper GI Tractunderstood. The mucosa is normally anesthetic, but contains fibers with the characteristics of acid-receptive nociceptors, which may be activated during mucosal injury and inflammation.PathologyHistologically, for a lesion to be an ulcer it must extend beneath the muscularis mucosa. More superficial lesions are classified as erosions (Figure 32.6). Endoscopically, a rough pragmatic equivalence is applied and erosions are commonly defined as lesions that are less than 3\\u2009mm in diameter and/or without discernible depth (Figure 32.6), whereas other lesions are clas-sified as ulcers. Endoscopists are poor at discriminating NSAID-associated erosions and ulcers from those caused by H. pylori [39]. Histologically, erosions show localized superfi-cial mucosal destruction with acute inflammation and local congestion. Acute ulcers are similar but with extension below the muscularis mucosa. Chronic peptic ulcers are additionally characterized by collagenous tissue in the base.HemostasisAspirin inhibits thromboxane synthesis and platelet aggrega-tion and reduced hemostasis likely contributes to ulcer bleed-ing in patients on low-dose aspirin.Other ulcer typesAcid plays a dominant role in ulcers associated with gastrino-mas, whether sporadic or occurring in the multiple endocrine neoplasia (MEN) 1 syndrome, and in systemic mastocytosis, where histamine stimulates acid secretion. Acid output is often increased in ulcers designated as idiopathic. Conversely, stress ulcers are associated with mucosal underperfusion and abro-gation of defence mechanisms. Inflammatory pathogenic mechanisms in Crohn’s disease and radiation are considered in Chapters 50 and 116 respectively.Pathogenesis of symptomsPain is the hallmark symptom of peptic ulceration. The origin and pathogenesis of ulcer pain and ulcer-like pain are poorly',\n",
       " 'in Chapters 50 and 116 respectively.Pathogenesis of symptomsPain is the hallmark symptom of peptic ulceration. The origin and pathogenesis of ulcer pain and ulcer-like pain are poorly Figure 32.6\\u2002 Differences between ulcers and erosions. (a) Ulcer with clear depth. (b–d) Superficial erosions. (b) Magnifying endoscopy shows erosions in villous duodenal mucosa.(a)(b)(c)(d)Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.1.',\n",
       " 'Upper GI TractPart 2:\\u2002 Diseases of the Gut and Liver224Empiric management of dyspepsiaIn patients with “simple dyspepsia”, causes outside the gas-trointestinal tract are excluded as far as possible by history and examination, and stopping any drugs that may be contributing to dyspepsia. In areas of high H. pylori prevalence, patients are then managed by testing for H. pylori using non-endoscopy-based tests such as the urea breath test, stool antigen test or (less accurately) serology, and treating those positive. This “test and treat” approach effectively treats ulcers (and those without ulcers) even when a firm diagnosis is never made [36–38]. Where the prevalence of H. pylori infection is low, empiric proton pump inhibitor (PPI) treatment is an alterna-tive [37]. Management of dyspepsia is discussed further in Chapter 4.Diagnostic testsWhere diagnosis is considered necessary, upper gastrointesti-nal endoscopy (see Chapter 123) is the investigation of choice. It is safe, accurate, and well tolerated by patients under light or no sedation. If possible, patients should avoid acid-suppressing agents for 4 weeks before endoscopy, as these drugs may heal ulcers and esophagitis, leading to a falsely negative endoscopy result. If possible, PPIs, antibiotics, and bismuth compounds should also be avoided for 4 weeks before endoscopy as these render biopsy-based tests for H. pylori unreliable. If a duodenal ulcer is found at endoscopy, biopsy samples should be taken from the gastric antrum and corpus to test for H. pylori (usually by biopsy urease test and/or histologic examination and from the duodenum if Crohn’s disease is suspected. In patients with previous H. pylori treat-ment or multiple antibiotic courses for other conditions, biop-sies should also be taken for microbiologic culture and antibiotic sensitivity testing, if this service is available. Where PPIs, bismuth compounds or antibiotics have recently been',\n",
       " 'sies should also be taken for microbiologic culture and antibiotic sensitivity testing, if this service is available. Where PPIs, bismuth compounds or antibiotics have recently been consumed, a positive biopsy urease test for H. pylori is still useful but a negative test is unreliable. The best approach is later to perform a reliable non-invasive test (urea breath test or stool antigen test) one month after stopping these agents. However, many practitioners use serology, which although less accurate can be done without waiting.Similar tests are indicated for gastric ulceration, but addi-tional biopsies should be taken from the ulcer rim to exclude carcinoma or lymphoma. The usual practice is also to check gastric ulcer healing 6–8 weeks after treatment is started and take further biopsies if healing is incomplete (although the pick-up rate for cancer if original biopsies are negative is very low). Barium radiology (see Chapter 132) is less accu-rate for picking up small ulcers and does not allow gastric biopsies to be taken to test for H. pylori or to exclude malignancy.Diagnosis of the cause of an ulcerH. pyloriThis is most conveniently established at the time of endos-copy by urease testing and/or histology of antral and corpus Clinical presentation of uncomplicated ulcersDuodenal ulcerationThe classical symptom of duodenal ulceration caused by H. pylori is epigastric pain occurring before meals or overnight, relieved by antacids, milk, food, and acid-suppressing treat-ments [33,34]. The pain may radiate to the back, particularly in patients with posterior duodenal ulcers. If present, the pointing sign, in which a patient points to a discrete epigastric site of pain, is moderately predictive of duodenal ulceration. Because ulcers naturally form and heal, pain is classically epi-sodic, typically with clusters of pain lasting for 1–3 months with asymptomatic spells in between. Duodenal ulcer pain is',\n",
       " 'Because ulcers naturally form and heal, pain is classically epi-sodic, typically with clusters of pain lasting for 1–3 months with asymptomatic spells in between. Duodenal ulcer pain is classically described as gnawing or a “hunger” pain, but the qualitative description of the pain is not very helpful in diag-nosis. Moreover many presentations are atypical and uncom-plicated duodenal ulcers may present with any combination of heartburn, anorexia, weight loss, or vomiting.Gastric ulcerPatients with gastric ulcer have a less stereotypical presenta-tion. An epigastric location is common, but pointing is less so. Pain is more likely to occur soon after meals and somewhat less likely to be relieved by food. Anorexia, nausea, vomiting, and weight loss are more common than in duodenal ulcer and often lead to a suspicion of gastric cancer.NSAID-associated ulcersThese are difficult to diagnose on the basis of symptoms. Drug-induced non-ulcer dyspepsia is common in NSAID users [35], whereas most peptic ulcers are silent, making  dyspepsia a poor predictor. Nevertheless, the onset of epigas-tric pain in an NSAID user is associated with an increased likelihood of finding an endoscopic ulcer or the development of complications.Differential diagnosisAny cause of chronic recurrent upper abdominal pain (see Chapter 3) or “dyspepsia” (see Chapter 4) enters into the dif-ferential diagnosis of peptic ulcer disease.Diagnostic approachSeveral conditions (including functional dyspepsia, gastro-esophageal reflux disease, and gastric adenocarcinoma) com-monly present with pain or discomfort centered predominantly in the upper abdomen and sometimes accompanied by the other symptoms detailed above. Examination is rarely helpful, and a definite diagnosis can be made only after investigation, usually upper gastrointestinal endoscopy. Because dyspeptic symptoms are so common, most healthcare systems reserve endoscopy for patients at higher risk of malignancy. This',\n",
       " 'usually upper gastrointestinal endoscopy. Because dyspeptic symptoms are so common, most healthcare systems reserve endoscopy for patients at higher risk of malignancy. This includes dyspeptic patients with “alarm” features such as overt GI bleeding, anemia due to GI blood loss, dysphagia, weight loss, persistent vomiting, or an upper GI mass. It also usually includes patients with new onset persistent dyspepsia above a specific age cut-off, typically 55 years.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Chapter 32:\\u2002 Peptic ulcer225Upper GI Tractraised serum tryptase, and expression of CD2 and CD25 in c-kit positive mast cells [39].Duodenal Crohn’s diseaseDuodenal involvement is reported in 0.5–13% of patients with Crohn’s disease and recognized to cause duodenal ulcer  with or without typical symptoms [40]. Thus, any patient not taking NSAIDs who is H. pylori negative should have duode-nal biopsies and the possibility of Crohn’s disease should be considered.Stress ulcerUlcer bleeding occurring in the context of current or recent severe illness and/or intensive care should be assumed to be a stress ulcer (see below).Celiac axis stenosisThe site may be atypical and pain-intense. Celiac axis angiog-raphy is necessary to establish this diagnosis.Treatment and preventionH. pylori-associated ulcersEradication of H. pyloriH. pylori eradication heals ulcers and prevents recurrence (Figure 32.8) [40]. Unfortunately, antibiotic resistance is increasing, and is a major problem in some countries [41,42,43]. Resistance to metronidazole is very common but is only partial and multi-drug regimens containing metronidazole retain near full efficacy. In contrast, resistance to clarithromycin (which is becoming common due to use of the drug for other infections, notably chest infections) leads to frequent treatment failure. In countries where clarithromycin resistance is less than 15%, triple therapy with a full dose PPI, clarithromycin 500\\u2009mg, metronidazole 400\\u2009mg, all twice daily is still commonly used. Two weeks treatment is slightly more effective than one, although it is unclear if this is cost-effective and side effects may be increased.Where clarithromycin resistance is common, other regimens are becoming more widely used, for example quadruple therapy where amoxicillin 1\\u2009g twice a day is added to the above regimen (giving three effective drugs even if clarithro-mycin resistance is present) or alternatively the same drugs are',\n",
       " 'therapy where amoxicillin 1\\u2009g twice a day is added to the above regimen (giving three effective drugs even if clarithro-mycin resistance is present) or alternatively the same drugs are used sequentially over 10 days with the PPI given over the whole period, amoxicillin 1\\u2009g twice a day, given for days 1–5, and clarithromycin 500\\u2009mg twice a day and metronidazole 400\\u2009mg three times a day given for days 6–10. Some physicians routinely check treatment success by urea breath test one month after the end of treatment, but others check only for large or complicated ulcers or if symptoms recur. When H. pylori status is not known, PPIs can be started and antibiotics added once H. pylori test results are available. If treatment fails, the most commonly-used second line regimen is full dose PPI twice a day, bismuth subcitrate or subsalicylate one tablet four times a day, tetracycline HCl 500\\u2009mg four times a day and biopsies. Serology is less accurate. Other non-invasive testing (urea breath test or stool antigen test) is accurate but less convenient in situations where endoscopy is being performed anyway.NSAIDsDiagnosis depends on an accurate history, though this is not always forthcoming. There are no diagnostic tests for NSAID involvement, although measurement of serum thromboxane concentration has been considered.Zollinger-Ellison syndromeA random serum gastrin estimation is a useful screen but can be affected by food and PPIs. A fasting gastrin is more specific. The diagnosis is formally established by showing increased basal gastric acid output and a fasting gastrin level of less than 1000\\u2009pg/mL (10-fold increase) with an intragastric pH of  2.0, sometimes backed up by a secretin test (see Chapters 56 and 112).Multiple endocrine neoplasiaThis should be suspected where Zollinger-Ellison syndrome is associated with hyperparathyroidism (see Chapter 112).Systemic mastocytosisSystemic mastocytosis should be suspected in the presence of',\n",
       " 'This should be suspected where Zollinger-Ellison syndrome is associated with hyperparathyroidism (see Chapter 112).Systemic mastocytosisSystemic mastocytosis should be suspected in the presence of pruritus, urticaria or a characteristic rash (Figure 32.7). Diag-nosis is based on the presence of infiltrates in bone marrow and/or extracutaneous organs, detection of c-kit mutations, Figure 32.7\\u2002 Cutaneous manifestations of systemic mastocytosis (urticaria pigmentosa). Patient presented with duodenal ulceration attributable to acid hypersecretion and diarrhea associated with intestinal involvement.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Upper GI TractPart 2:\\u2002 Diseases of the Gut and Liver226lumiracoxib. The VIGOR and CLASS studies of rofecoxib and lumiracoxib showed a reduction in the risk of all ulcers of between 27% (celecoxib) and 57% (rofecoxib), and the TARGET study showed a 79% reduction in ulcer complications for lumi-racoxib compared with ibuprofen or naproxen (Figure 32.9). Benefits are seen within a week [48] and across most risk factors [49]. While there has been some concern about the pos-sibility that COX-2 inhibitors may enhance thrombotic compli-cations of vascular disease, these properties may well be shared by non-selective NSAIDs and the balance of risks ben-efits clearly favours reduced gastrotoxicity [51]. The MEDAL study program showed etoricoxib to reduce the incidence of uncomplicated, but not complicated, ulcers, though this may be because PPI co-prescription was allowed [47].Prophylactic co-prescriptionProton pump inhibitors have been shown to reduce develop-ment of endoscopic ulcers and relapse of endoscopic and clini-cally significant ulcers including those causing ulcer complications [52–58]. When combined with a COX-2 inhibitor the use of proton pump inhibitor has been associated with a zero rate of recurrent ulcer bleeding in patients who have already experienced one life threatening episode [58]. Generi-cally available proton pump inhibitors have been sufficiently inexpensive that they offer highly cost effective ulcer prophy-laxis in users of both NSAIDs and COX-2 inhibitors [54]. Standard doses of H2 antagonists are not effective in prevent-ing NSAID-associated gastric ulcer development [32]. The PGE-1 analogue misoprostol is effective against endoscopic and clinically complicated ulcers but seldom used because of the high level of drug related adverse effects [59].H. pylori -positive NSAID or aspirin associated ulcersNSAIDsThis is a controversial area. The evidence ranges from showing a benefit for H. pylori eradication in patients starting NSAIDs',\n",
       " 'H. pylori -positive NSAID or aspirin associated ulcersNSAIDsThis is a controversial area. The evidence ranges from showing a benefit for H. pylori eradication in patients starting NSAIDs metronidazole 400\\u2009mg three times a day. This more complex regimen is now also used first-line by some practitioners. The further management of H. pylori treatment failures is discussed in Chapter 22.Ancillary drug treatmentFor duodenal ulcers, continuation of acid suppression after the antibiotic course is unnecessary, but some physicians give PPIs for a total of one month for very large or complicated ulcers. If this is done, checking for H. pylori eradication must be delayed for a further month. For gastric ulcers, which often heal more slowly, PPIs are usually continued until the repeat endoscopy.Management of patients taking NSAIDsUlcer healingPPIs accelerate healing compared with standard doses of H2 antagonists [32]. Misoprostol heals NSAID-associated ulcers but causes more side effects and is now seldom used.Strategies to reduce risk of ulcer developmentFor NSAID users, removing the cause of the ulcer, by stopping the drug or switching to one that does not damage the stomach or duodenum, is the equivalent of H. pylori eradication. An alternative is to continue the NSAID where needed, at the lowest possible dose, and to give concurrent antiulcer prophy-laxis, usually with a PPI.Low-toxicity drugsIbuprofen at dosages of less than 1200\\u2009mg per day appears to confer less risk of bleeding peptic ulcer [23] than other NSAIDs (see Figure 32.4). Alternatively, and where higher doses are needed, selective COX-2 inhibitors have been shown to reduce the risk of ulcers that are detected endoscopically and clini-cally [44–53]. Clinical outcomes have been studied in large cohorts of patients (up to 18\\u2009500) for celecoxib, rofecoxib, and Figure 32.8\\u2002 Ulcer relapse following H. pylori eradication. There is a marked reduction in relapse rates for duodenal and gastric ulcer',\n",
       " 'Figure 32.8\\u2002 Ulcer relapse following H. pylori eradication. There is a marked reduction in relapse rates for duodenal and gastric ulcer following H. pylori eradication. (Reproduced with permission from Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology. 1999;116:248–253.)Patients in remission (%)Years after termination of treatmentMonths after termination of treatment00.511.520246108121000255075H. pylori eradicatedH. pylori positiveGastric ulcerDuodenal ulcerHawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Chapter 32:\\u2002 Peptic ulcer227Upper GI Tractmyocardial infarction (as is the case for aspirin plus NSAID [64,65]) is not known. Therefore where local rules allow, pre-scribers should consider using a selective COX-2 inhibitor with aspirin to avoid an adverse pharmacodynamic interac-tion [63]. In patients taking aspirin and a coxib, a PPI should be used where the risk of aspirin alone would warrant it.Complications and their managementBleeding (Figure 32.10)EpidemiologyPeptic ulcer is the commonest cause of acute upper gastroin-testinal bleeding (see Chapters 20 and 146), accounting for nearly half of all instances and occurring in approximately 2–5 per 1000 of people aged over 60 years [5].Clinical presentationHematemesis and/or melena are usually obvious, especially when accompanied by tachycardia or hypotension, usually leading to emergency hospital admission. Retrospective accounts of “melena” in well patients only occasionally indi-cate significant gastrointestinal bleeding.Diagnosis and managementAfter resuscitation, patients with a significant bleed should undergo endoscopy, both to establish the diagnosis and to institute endoscopic management if stigmata of hemorrhage are present [66]. About 20–25% of patients, however, have  no abnormality of pulse, blood pressure, hemoglobin, platelet count or urea, and in the absence of any suspicious past  history such patients are at low risk of further bleeding, and can be discharged for subsequent out-patient endoscopic assessment [67].[60,61] through to greater effectiveness of PPI prophylaxis in patients who remain infected [62]. Overall, H. pylori eradica-tion alone is not sufficient protection against ulcer complica-tions and such patients should receive a PPI and/or a COX-2 inhibitor.AspirinIt is possible that H. pylori eradication may be sufficiently effective to protect low-dose aspirin users [55], but until there are further data this cannot be recommended above PPI',\n",
       " 'inhibitor.AspirinIt is possible that H. pylori eradication may be sufficiently effective to protect low-dose aspirin users [55], but until there are further data this cannot be recommended above PPI prophylaxis [55,57]. Reductions in the price of generic PPIs mean that it is probably cost effective to give all patients on low dose aspirin a PPI and certainly those with age over 65 or a past ulcer history. If funds allow, patients taking low-dose aspirin should receive PPI prophylaxis if they have any significant risk factor, such as age over 65 years or a past ulcer history.Patients taking prophylactic aspirin and  a non-aspirin NSAIDBy competing at the level of the platelet, nonselective NSAIDs such as ibuprofen may substantially interfere with aspirin’s ability to inhibit platelet aggregation and thereby prevent coronary heart disease [63–65]. These patients should use naproxen or diclofenac where there is either no evidence for such an inhibition (dicofenac) [63] or its consequences. Selec-tive COX-2 inhibitors also avoid any pharmacodynamic inter-action but in Europe their use in patients with established coronary heart disease is contraindicated. The USA FDA by contrast rules that non-selective NSAIDs and selective COX-2 inhibitors both increase the risk of myocardial infarction. Whether patients with cardiovascular risk factors who take aspirin as well as a COX-2 inhibitor have an increased risk of Figure 32.9\\u2002 Results of VIGOR and TARGET outcome studies (primary outcomes). (a) VIGOR – perforations, ulcers, and bleeds. (b) TARGET – ulcer complications. Reproduced with data from [44] and [46].Cumulative incidence (%)Months of follow-up1.501.251.000.750.500.250NaproxenRofecoxibCumulative incidence (%)Study day0246810120901802703604201.41.01.20.80.60.40.20Non-steroidal anti-inflammatory drugsLumiracoxibLogrank p < 0.0001(a)(b)',\n",
       " '0NaproxenRofecoxibCumulative incidence (%)Study day0246810120901802703604201.41.01.20.80.60.40.20Non-steroidal anti-inflammatory drugsLumiracoxibLogrank p < 0.0001(a)(b)Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Upper GI TractPart 2:\\u2002 Diseases of the Gut and Liver228variation. Many perforated ulcers are H. pylori negative [72,73]. The reported incidence of H. pylori infection ranges from 0% to 100%.Clinical presentationThis is usually stereotypical and obvious, with an abrupt onset of severe upper abdominal pain, rapidly spreading through the abdomen, and the development of symptoms and signs of peritonitis (see Chapter 156), hypotension, and shock.DiagnosisDiagnosis is largely based on history, examination, and plain radiography. Air within the abdominal cavity under the dia-phragm is seen on plain abdominal and erect chest radio-graphs in most cases (Figure 32.11). Endoscopy is avoided because of theoretical risks of increased peritoneal soiling.As detailed in Chapters 20 and 146, endoscopic therapy of bleeding peptic ulcers reduces rebleeding and the need for surgery, and may reduce mortality. The choices are injection therapy with epinephrine (adrenaline), light- or heat-based coagulation of the vessel, clipping (Figure 32.10) or a combina-tion – using at least two modalities is better than using one alone. Patients with endoscopic stigmata suggesting high risk of rebleed are given a 72-hour infusion of intravenous proton pump inhibitor [66]. Conventionally, aspirin is stopped but this is ill-advised as patients are at particular risk of thrombo-sis, and mortality is much higher if aspirin is stopped in those who need it [68]. Pragmatically aspirin may be stopped for 48 hours and restarted once the patient is on PPI therapy.Where H. pylori is the cause of the ulcer, eradication results in a substantial reduction in the subsequent risk of rebleeding [40]. Patients taking NSAIDs can resume these drugs if needed after healing if they take a PPI, as this has been shown sub-stantially to reduce the readmission rate for ulcer complica-tions over 6 months [54–58].MortalityIn a large, comprehensive British survey the mortality rate was',\n",
       " 'stantially to reduce the readmission rate for ulcer complica-tions over 6 months [54–58].MortalityIn a large, comprehensive British survey the mortality rate was 8% in patients admitted because of bleeding peptic ulcer [69]. Patients die mainly as a result of pneumonia and the throm-botic complications of bleeding or surgery (deep vein throm-bosis and pulmonary embolism, myocardial infarction), rather than exsanguination.Perforation(see also Chapters 22–24 and 156).EpidemiologyThe incidence of ulcer perforation is conventionally reported as about 7–10 per 100\\u2009000 population per annum [70]. A recent report suggests a higher incidence [71]. Perforation is more common in men than in women, in those with duodenal versus gastric ulcers, in cigarette smokers and in users of aspirin and NSAIDs [71] but presentation in the absence of risk factors is not uncommon. There is a diurnal and seasonal Figure 32.11\\u2002 Chest radiograph showing air under the diaphragm in a patient with perforated peptic ulcer.Figure 32.10\\u2002 Bleeding ulcer. Arterial bleeding from a visible vessel in an ulcer (a) before and (b) after control by application of a hemoclip.(a)(b)Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.R',\n",
       " 'Chapter 32:\\u2002 Peptic ulcer229Upper GI Tractor treatment with acid suppression can restore gastric empty-ing. Some patients require surgery by antrectomy and Billroth 1 or 2 procedures (see Chapter 156).Surgery for peptic ulcerNowadays, surgical intervention is rarely used for gastric or duodenal ulcers, except in the context of complications (see above).Postoperative syndromesPeptic ulcer surgery was an unphysiologic intervention  that resulted in significant morbidity [78] including the following.Dumping syndromesThese are characterized by flushing, palpitations, sweating, light-headedness, tachycardia, postural hypotension, and fatigue, likely due to rapid fluid shifts if symptoms occur within an hour or rebound hypoglycemia if they occurs 2–3 hours after a meal (see Chapter 37). The early dumping syn-drome occurs 30–60 minutes after eating in patients who have had a gastrectomy. Dumping of food into the duodenum is thought to cause rapid fluid shifts, leading to faintness. Exces-sive release of vasoactive hormones may play a role. Octre-otide may have therapeutic value. In the late dumping syndrome, dumping of food into the duodenum stimulates excessive insulin secretion resulting in rebound hypoglycemia 2–3 hours after a meal.Postgastrectomy malnutritionMost patients who have had a gastrectomy lose weight and/or become anemic or malnourished because of a combination of early satiety, impaired control of nutritional digestion and absorption, inadequate production of co-factors such as vitamin B12, and altered iron absorption. Problems develop over years and also include metabolic bone disease (vitamin D) and neuropathy (vitamin B12).Stomal ulcerationAfter partial gastrectomy, ulcers may develop at the site of anastomosis and present with pain or sometimes complica-tions. They can be managed with acid-suppressing drugs.  The role of H. pylori in this situation is unclear, but eradication is wise.Postgastrectomy neoplasia',\n",
       " 'tions. They can be managed with acid-suppressing drugs.  The role of H. pylori in this situation is unclear, but eradication is wise.Postgastrectomy neoplasiaSurgery for peptic ulcer is associated with an increased risk of later gastric cancer. This is discussed in Chapter 32.Postvagotomy syndromesTruncal vagotomy results in diarrhea in many patients  [78]. Pathogenesis is multifactorial and management is symptomatic.ManagementPatients should be resuscitated with intravenous fluids and given broad-spectrum antibiotics (e.g., cefuroxime and metro-nidazole). Laparotomy to close the perforation should be carried out as soon as possible after resuscitation, although in patients with a high operative risk who are improving on conservative treatment, continued nonoperative management may be possible.Prevention of recurrenceAfter successful recovery, management to prevent recurrence is standard (H. pylori eradication, NSAID avoidance). There are no direct data on the benefits of switching to a COX-2 inhibitor or taking PPI prophylaxis after perforation.MortalityThe overall mortality rate is about 10%. Risk factors for death are age, co-morbid illness, delayed surgery, preoperative shock, heart rate, and a high serum creatinine level [70].PenetrationPosterior perforation may result in digestive penetration into an adjacent organ rather than free perforation. Posterior duo-denal ulcer penetration most commonly involves the pancreas, often resulting in different, more severe, pain than is typical. Other organs that may be involved include the left lobe of the liver, common bile duct (choledochoduodenal fistula), colon (gastrocolic fistula), lung, and pericardium. Except where fis-tulae have formed, treatment is by acid suppression with H. pylori eradication or NSAID cessation, as appropriate.Gastric outlet obstructionEpidemiologyGastric outlet obstruction by peptic ulcers is relatively uncom-mon, probably affecting less than the quoted 2% of patients',\n",
       " 'Gastric outlet obstructionEpidemiologyGastric outlet obstruction by peptic ulcers is relatively uncom-mon, probably affecting less than the quoted 2% of patients with ulceration. Obstruction occurs with (pre)pyloric or duo-denal ulcers, especially in patients with a long history, and is thought particularly to be associated with NSAID use.Clinical featuresObstruction should be suspected in patients with an ulcer who develop vomiting, particularly if projectile or occurring daily. Early satiety (60%), upper abdominal pain and distention (87%), and weight loss (65%) are common. A succussion splash is present in 25% or more of patients. Depending on severity, increases in serum urea concentration and electrolyte abnor-malities (low K+, metabolic alkalosis, low Na+) are common.ManagementNasogastric aspiration should be performed to empty the stomach prior to endoscopy. Aspiration of more than 200\\u2009mL after an overnight fast suggests delayed gastric emptying. At endoscopy, biopsy samples should be taken to exclude malig-nancy. Endoscopic balloon dilatation (see Chapter 150) and/Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Upper GI TractPart 2:\\u2002 Diseases of the Gut and Liver230ProphylaxisTreatment with H2 receptor antagonists, proton pump inhibi-tors and sucralfate have been shown to reduce endoscopic appearances of injury and/or blood in gastric aspirates but there is no clear evidence of an effect on survival or clinical outcome in either children or adults [76,77]. Where there is good general intensive care management, including with enteral nutrition, other specific measures are seldom needed.Practical managementThe following guidelines, updated from Tryba and Cook [78] are suggested:• Stress ulcer prophylaxis should be restricted to patients with risk factors, particularly respiratory failure, coagulopa-thy, sepsis, shock, burns, head injury, or a history of peptic ulcer disease.• Enteral nutrition, where given, probably reduces the inci-dence of ulcer bleeding.• Where there is good general intensive care management, other specific measures are seldom needed.• Alternatives are:1.\\u2002 Sucralfate 1\\u2009g six times daily by mouth.2. Enteral nutrition with sucralfate 1\\u2009g twice daily during a rest period when enteral nutrition is suspended.3. Ranitidine 50\\u2009mg by slow intravenous injection, then 125–250\\u2009mg/kg/h by infusion.Cameron’s ulcerThese ulcers typically occur in the neck of a big hiatus hernia, and are believed to arise on an ischemic basis [79]. They may be associated with iron deficiency anemia. They often respond to PPI therapy, but non-responsive ulcers can be cured by surgical intervention.Prognosis and advice to patients with  peptic ulcer• Patients should be told the cause of their ulcer and be told to eat a normal diet.• They should understand that the prognosis is very good in the absence of complications and particularly with defini-tive therapy.• Patients given H. pylori treatment should be told of the importance of close compliance, warned of the common side effects with these multi-drug regimens, but told to con-',\n",
       " 'tive therapy.• Patients given H. pylori treatment should be told of the importance of close compliance, warned of the common side effects with these multi-drug regimens, but told to con-tinue despite these, unless they are very severe. The problem with failed treatment is that it very commonly results in antibiotic resistance making future treatment more difficult. After proven eradication of H. pylori in patients not taking NSAIDs, the relapse rate falls to less than 5%.• Similarly, for patients using NSAIDs who stop these drugs, relapse is rare if they have no other risk factors such as H. pylori infection.Meckel’s diverticulumThis is an ileal diverticulum with acid-secreting heterotopic gastric mucosa that arises because of developmental abnor-mality in approximately 2% of the population. It can cause ulceration with pain or bleeding, as well as obstruction due to intussusception or volvulus. Diagnosis is often made inciden-tally during barium radiology. Technetium (99mTc) pertech-netate, which has an affinity for parietal cells, is the basis of the scan. Treatment is by surgical removal.Stress ulcersSevere medical stresses such as burns, head injuries, major trauma, sepsis, multisystem organ failure, or ventilation on an intensive care unit are associated with the development of stress ulcers in the stomach or duodenum that may bleed and are associated with a high mortality rate. Curling’s ulcers are those associated with burns, and Cushing’s ulcers with head injury. Stress ulcers are seen less commonly now than previ-ously, possibly due to preventive measures in intensive care. In one large study, 31 of 2252 patients (1.4%) on an intensive care unit experienced clinically important bleeding [74].Risk factorsA need for ventilation because of respiratory failure is the most important risk factor, increasing the chance of upper gastroin-testinal bleeding by 15-fold [75,76]. The main ancillary risk',\n",
       " 'A need for ventilation because of respiratory failure is the most important risk factor, increasing the chance of upper gastroin-testinal bleeding by 15-fold [75,76]. The main ancillary risk factors are prolonged ventilation and coagulopathy. Sepsis, hepatic and renal failure, and glucocorticoids may enhance risk, although the evidence is less secure. Clinically important bleeding is extremely rare in patients with no risk factors [75–78].PathogenesisThe pathogenesis varies according to etiology. Reduced mucosal defence, largely because of poor blood flow that allows increased acid back diffusion, predisposes to stress ulcers in ventilated patients and after severe burns, despite an overall reduction in acid secretion. Cushing’s ulcers differ in being associated with hypergastrinemia and hypersecretion  of acid.Clinical presentationThe most common presentation is with bleeding, manifesting as shock, hematemesis, or melena. This may occur at any time during a stressful illness, but is common at 10–14 days and may therefore present as the patient is improving in other respects. Perforation and penetration are much less common. Some patients may complain of antecedent pain.Treatment and preventionOnce severe stress ulcer bleeding has occurred, the patient should be managed as for other ulcer bleeding; however, the mortality rate is high. Consequently, attention has focused on prophylaxis.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Chapter 32:\\u2002 Peptic ulcer231Upper GI Tractfor the first time in our evolutionary history have any dis-advantages [15]?• Can an effective vaccine for H. pylori be developed, and is it desirable?References\\u2002 1.\\u2002 Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;i:1273–1275.\\u2002 2.\\u2002 Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology. 2000;119:521–535.\\u2002 3.\\u2002 Hawkey CJ, Langman MJ. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX- 2 inhibitors and proton pump inhibitors. Gut. 2003;52:600–608.\\u2002 4.\\u2002 Douthwaite AH, Lintott SAM. Gastropic observation of the effect of aspirin and certain other substances on the stomach. Lancet. 1938;ii:1222–1225.\\u2002 5.\\u2002 Weil J, Langman MJ,Wainwright P et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal antiin-flammatory drugs. Gut. 2000;46:27–31.\\u2002 6.\\u2002 Susser S. Civilisation and peptic ulcer. Lancet. 1962;i:115–118.\\u2002 7.\\u2002 Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of hemorrhage among older subjects. Gut. 2002;50:460–464.\\u2002 8.\\u2002 Taha AS, Angerson WJ, Prasad R, et al. Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. APT. 2007;26(8):1171–1178.\\u2002 9.\\u2002 Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands. Aliment Pharmacol Ther. 2006; 23(11):1587–1593.10.\\u2002 Lassen Annmarie, Hallas Jesper, de Muckadell Ove, et al. Com-plicated and Uncomplicated Peptic Ulcers in a Danish County 1993–2002: a Population-Based Cohort Study. Am J Gastroenterol. 2006;101(5):945–953.11.\\u2002 Cai S, Garcia Rodriguez LA, Masso-Gonzalez EL, Hernandez-Diaz S. Uncomplicated peptic ulcer in the UK: Trends from 1997 to 2005. Aliment Pharmacol Ther. 2009;30(10):1039–1048.',\n",
       " '2006;101(5):945–953.11.\\u2002 Cai S, Garcia Rodriguez LA, Masso-Gonzalez EL, Hernandez-Diaz S. Uncomplicated peptic ulcer in the UK: Trends from 1997 to 2005. Aliment Pharmacol Ther. 2009;30(10):1039–1048.12.\\u2002 Sadic J, Borgstrom A, Manjer J, et al. Bleeding peptic ulcer – time trends in incidence, treatment and mortality in Sweden. Aliment Pharmacol Ther. 2009;30(4):392–398.13.\\u2002 Ahsberg K, Hoglund P, Stael von Holstein C. Mortality from peptic ulcer bleeding: the impact of comorbidity and the use of drugs that promote bleeding. Aliment Pharmacol Ther. 2010;32(6):801–810.14.\\u2002 Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg. 2010;251(1):51–58.15.\\u2002 Atherton JC, Blaser MJ. Co-adaptation of Helicobacter pylori and humans: ancient history and modern implications. J Clin Invest. 2009;119(9):2475–2487.16.\\u2002 Borody TJ, George LL, Brandl S, et al. Smoking does not contrib-ute to duodenal ulcer relapse after Helicobacter pylori eradica-tion. Am J Gastroenterol. 1992;87:1390–1393.17.\\u2002 Hawkey CJ, Laine L, Harper SE, et al. Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharma-col Ther. 2001;15:1593–1601.• All patients on an NSAID should receive PPI prophylaxis with additionally a COX-2 inhibitor if they have significant risk. These patients should be told about the adverse effects of PPIs and COX-2 inhibitors, with an emphasis that the benefits of each therapy outweigh the risks.SOURCES OF INFORMATION FOR PATIENTS AND DOCTORSwww.nlm.nih.gov/medlineplus/pepticulcer.html www.kidshealth.org/parent/medical/digestive/peptic_ulcers.html www.digestive.niddk.nih.gov/ddiseases/pubs/hpylori/ www.digestive.niddk.nih.gov/ddiseases/pubs/nsaids/ www.netdoctor.co.uk/diseases/facts/pepticulcertreatment. htm',\n",
       " 'www.digestive.niddk.nih.gov/ddiseases/pubs/hpylori/ www.digestive.niddk.nih.gov/ddiseases/pubs/nsaids/ www.netdoctor.co.uk/diseases/facts/pepticulcertreatment. htm patients.uptodate.com/topic.asp?file=digestiv/9148Current controversiesA number of recent findings may challenge conservative pre-scribers. These include fairly clear demonstrations suggesting that:• All patients taking NSAIDs have reduced ulcer risk if they take a PPI. PPIs are not co-prescribed as commonly as they should be.• The gastroduodenal benefits of selective COX-2 inhibitors outweigh any cardiac risks. However, vascular risks domi-nate current thinking.• The risk of vascular thrombotic events may be similar for non-selective NSAIDs (except naproxen) and selective COX-2 inhibitors. However there is generally greater concern about COX-2 inhibitors.• COX-2 inhibitors may be more suitable for patients needing aspirin for vascular protection because they lack the ability of non-selective NSAIDs to abrogate the effectiveness of aspirin. However the EMA contra-indicate COX-2 inhibitors in patients with vascular disease.• Stopping aspirin in patients with bleeding peptic ulcers has been shown to increase mortality. Despite this, most doctors stop aspirin in these patients.• Antibiotic resistance of H. pylori is increasing and varies between individuals and populations: the most effective treatment therefore also varies between individuals and populations.There are also some wider controversies surrounding H. pylori management, which include:• Should H. pylori (or at least pathogenic strains of H. pylori) be screened for and treated in some populations, with the aim of primary prevention of peptic ulcers and gastric cancer?• H. pylori has co-evolved with humans over millennia. Does its absence from the human stomach of many individuals',\n",
       " 'aim of primary prevention of peptic ulcers and gastric cancer?• H. pylori has co-evolved with humans over millennia. Does its absence from the human stomach of many individuals Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Upper GI TractPart 2:\\u2002 Diseases of the Gut and Liver232selective COX-2 inhibitors (NASA1 – SPACE1). Am J Gastro. 2005;100(5):1028–1036.36.\\u2002 Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: The Maas-tricht III Concensus Report. Gut. 2007;56:772–781.37.\\u2002 Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ. 2008;336(7645): 651–654.38.\\u2002 Duggan AE, Elliott CA, Miller P, et al. Clinical trial: a rand-omized trial of early endoscopy, Helicobacter pylori testing and empirical therapy for the management of dyspepsia in primary care. APT. 2009;29;1:55–68.39.\\u2002 Castells MC. Mastocytosis: classification, diagnosis, and clinical presentation. Allergy Asthma Proc. 2004;25:33–36.40.\\u2002 Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology. 1999;116:248–253.41.\\u2002 van Hogezand RA,Witte AM,Veenendaal RA, et al. Crohn’s disease: review of the clinicopathologic features and therapy. Inflamm Bowel Dis. 2001;7:328–337.42.\\u2002 Gerrits MM, van Vliet AH, Kuipers EJ, et al. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis. 2006;6(11):699–709.43.\\u2002 Raymond J, Lamarque D, Kalach N, et al. High level of antimi-crobial resistance in French Helicobacter pylori isolates. Helico-bacter. 2010;15(1):21–2744.\\u2002 Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–1528.45.\\u2002 Silverstein F, Simon L, Faich G. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2002;286:2399.46.\\u2002 Schnitzer TJ, Burmester GR, Mysier E, et al. Comparison of lumi-',\n",
       " '45.\\u2002 Silverstein F, Simon L, Faich G. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2002;286:2399.46.\\u2002 Schnitzer TJ, Burmester GR, Mysier E, et al. Comparison of lumi-racoxib with naproxen and ibuprofen in the Therapeutic Arthri-tis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364;665–674.47.\\u2002 Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastroin-testinal safety of etoricoxib and diclofenac in patients with oste-oarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) pro-gramme: a randomised comparison. Lancet. 2007;369 (9560):465–473.48.\\u2002 Hawkey CJ, Weinstein WM, Stricker K, et al. Clinical trial: Com-parison of the gastrointestinal safety of lumiracoxib with tradi-tional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment – Findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial.49.\\u2002 Hawkey CJ, Weinstein WM, Smalley W, et al. Effect of Risk Factors on Complicated and Uncomplicated Ulcers in the TARGET Lumiracoxib Outcomes Study. Gastroenterology. 2007;133 (1):57–64.50.\\u2002 Rostom A, Muir K, Dube C, et al. Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: a Cochrane Collaboration System-atic Review. Clin Gastroenterol Hepatol. 2007;5(7):818–828.e5.51.\\u2002 Van Der Linden MW, Van Der Bij S, Welsing P, et al. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2009;68(5):668–673.18.\\u2002 Hawkey CJ, Laine L, Harper SE, et al. Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharma-col Ther. 2001; 15:1593–1601.',\n",
       " 'on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharma-col Ther. 2001; 15:1593–1601.19.\\u2002 Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest. 2004;113:321–333.20.\\u2002 Crabtree JE,Taylor JD,Wyatt JI, et al. Mucosal IgA recognition of Helicobacter pylori 120\\u2009kDa protein, peptic ulceration, and gastric pathology. Lancet. 1991;338:332–335.21.\\u2002 Lewis SC, Langman MJS, Laporte JR, et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastroin-testinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320–326.22.\\u2002 Stack WA, Atherton JC, Hawkey GM, et al. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleed-ing. Aliment Pharmacol Ther. 2002;16:497–506.23.\\u2002 Atherton JC. The pathogenesis of Helicobacter pylori-induced gastroduodenal disease. Ann Rev Pathol Mech Dis. 2006;1:63–96.24.\\u2002 Odenbreit S, Puls J, Sedlmaier B, et al. Translocation of Helico-bacter pylori CagA into gastric epithelial cells by type IV secre-tion. Science. 2000;287:1497–1500.25.\\u2002 Argent RH, Kidd M, Owen RJ, et al. Determinants and conse-quences of different levels of CagA phosphorylation for clinical isolates of Helicobacter pylori. Gastroenterology. 2004;127:514–523.26.\\u2002 Atherton J, Cao P, Peek RM, et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori: association of specific vacA types with cytotoxin production and peptic ulceration.  J Biol Chem. 1995;270:17771–17777.27.\\u2002 Macarthur M, Hold GL, El-Omar EM. Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymor-phisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol. 2004;286:G515–G520.28.\\u2002 Robinson K, Kenefeck R, Pidgeon EL, et al. Helicobacter pylori-',\n",
       " 'phisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol. 2004;286:G515–G520.28.\\u2002 Robinson K, Kenefeck R, Pidgeon EL, et al. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regu-latory T cell responses. Gut. 2008;57:1375–1385.29.\\u2002 Peek RM, Fiske C, Wilson KT. The role of innate immunity in Helicobacter pylori-induced gastric malignancy. Physiol Rev. 2010;90:831–858.30.\\u2002 Moss SF, Legon S, Bishop AE, et al. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet. 1992;340:930–932.31.\\u2002 Elliott SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol. 1996;23:432–434.32.\\u2002 Yeomans ND,Tulassay Z, Juhasz L, et al. A comparison of ome-prazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998;338:719–726.33.\\u2002 Earlam R. Computerized questionnaire analysis of duodenal ulcer symptoms. Gastroenterology. 1976;71:314–317.34.\\u2002 Horrocks JC, De Dombal FT. Clinical presentation of patients with “dyspepsia.” Detailed symptomatic study of 360 patients. Gut. 1978;19:19–26.35.\\u2002 Hawkey CJ, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in upper gastrointestinal symptoms in patients taking non-steroidal anti-inflammatory drugs including Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Chapter 32:\\u2002 Peptic ulcer233Upper GI Tract64.\\u2002 MacDonald TM,Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573–574.65.\\u2002 Patel TN, Goldberg KC. Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med. 2004;164:852–856.66.\\u2002 Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with non-variceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152(2):101–113.67.\\u2002 Stanley AJ, Ashley D, Dalton HR, et al. Outpatient management of patients with low-risk upper-gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet. 2009;373(9657):42–47.68.\\u2002 Sung JJY, Lau JYW, Ching JYL, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152(1):1–9.69.\\u2002 Hearnshaw SA, Logan RFA, Lowe D, et al. Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut. 2010;59(8):1022–1029.70.\\u2002 Svanes C. Trends in perforated peptic ulcer: incidence, etiology, treatment, and prognosis. World J Surg. 2000;24:277–283.71.\\u2002 Taha AS, Angerson WJ, Prasad R, et al. Clinical trial: The inci-dence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;28(7):878–885.72.\\u2002 Reinbach DH, Cruickshank G, McColl KE. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infec-tion. Gut. 1993;34:1344–1347.73.\\u2002 Gisbert JP, Pajares JM. Helicobacter pylori infection and perfo-rated peptic ulcer: prevalence of the infection and role of anti-microbial treatment. Helicobacter. 2003;8:159–167.74.\\u2002 Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit',\n",
       " '74.\\u2002 Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med. 1999;27:2812–2817.75.\\u2002 Cook DJ, Fuller HD, Guyatt GH et al. Risk factors for gastroin-testinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994;339:377–381.76.\\u2002 Janicki T, Stewart S. Stress-ulcer prophylaxis for general medical patients: a review of the evidence. J Hosp Med. 2007;2(2):86–92.77.\\u2002 Quenot JP. When should stress ulcer prophylaxis be used in the ICU? Curr Opin Crit Care. 2009;15:139–143.78.\\u2002 Tryba M, Cook D. Current guidelines on stress ulcer prophy-laxis. Drugs. 1997;54:581–596.79.\\u2002 Cameron AJ, Higgins JA. Linear gastric erosion: a lesion associ-ated with large diaphragmatic hernia and chronic blood loss. Gastroenterology. 1986;91:338–342.52.\\u2002 Rostom A, Muir K, Dube C, et al. Prevention of NSAID-related upper gastrointestinal toxicity: A meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf. 2009;1(1):47–71.53.\\u2002 Hawkey CJ, Karrasch JA, Szczepanski L et al. Omeprazole com-pared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727–734.54.\\u2002 Latimer N, Lord J, Grant RL, et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combina-tion with a proton pump inhibitor for people with osteoarthritis. BMJ. (Clinical research ed.) 2009;339:b2538.55.\\u2002 Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967–973.56.\\u2002 Chan FK, Hung LC, Suen BY et al. Celecoxib versus diclof\\xadenac and omeprazole in reducing the risk of recurrent ulcer',\n",
       " 'J Med. 2001;344:967–973.56.\\u2002 Chan FK, Hung LC, Suen BY et al. Celecoxib versus diclof\\xadenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104–2110.57.\\u2002 Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033–2038.58.\\u2002 Chan FKL, Wong VWS, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for pre\\xadvention of recurrent ulcer bleeding in patients at very high  risk: a double-blind, randomised trial. Lancet. 2007;369(9573):1621–1626.59.\\u2002 Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheuma-toid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123(4):241–249.60.\\u2002 Chan FKL, Sung JJY, Chung SCS, et al. Randomised trial of eradication of Helicobacter pylori before nonsteroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350(9083):975–979.61.\\u2002 Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infec-tion and nonsteroidal anti-inflammatory drugs in peptic ulcer disease: a meta analysis. Lancet. 2002;359:14–22.62.\\u2002 Hawkey CJ,Tulassay Z, Szczepanski L et al. Randomised control-led trial of Helicobacter pylori eradication in patients on nons-teroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet. 1998;352:1016–1021 (Erratum, Lancet 1998;352:1634).63.\\u2002 Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809–1817.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.',\n",
       " '2001;345:1809–1817.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " '234Upper GI TractCHAPTER 33GastritisRichard H. Lash and Robert M. GentaCaris Diagnostics/Miraca; University of Texas Southwestern Medical Center, Irving, TX, USATextbook of Clinical Gastroenterology and Hepatology, Second Edition. Edited by C. J. Hawkey, Jaime Bosch, Joel E. Richter, Guadalupe Garcia-Tsao, Francis K. L. Chan.© 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.Introduction, including definitionThe discovery of Helicobacter pylori catapulted gastritis onto centre stage [1]. Intensive research and voluminous literature followed. In this chapter the terms “body” or “gastric body” are used as synonymous with “corpus.” The gastric mucosa is divided into four major regions, comprising different glandu-lar components in differing proportions. From proximal to distal, they are: the cardia, fundus, body (corpus), and antrum. Histologically, the gastric cardia is a narrow band of mucosa juxtaposed to the squamous mucosa of the esophagus at the Z-line. Typical cardiac glands are of the mucous type, similar to those of the gastric antrum, but they often contain scattered acid-secreting gland elements. The gastric fundus and body contain a surface layer of mucus-producing glands with deeper layers of oxyntic glands. These oxyntic glands include parietal (acid-secreting) and chief (enzyme-secreting) cells as well as scattered endocrine cells. In the gastric antrum, the glands are of the mucous type, also with gastrin-producing endocrine cells. These histologic regions, however, do not nec-essarily correspond exactly to the gross anatomic landmarks.Gastritis, simply defined as inflammation of the gastric mucosa, is a condition, not a disease [2]. With few exceptions, the inflammation of the gastric mucosa per se does not produce signs or symptoms. A subset of patients may have symptoms due to gastritis, but no independent tests are available to make that prediction in an individual patient. A second group of',\n",
       " 'signs or symptoms. A subset of patients may have symptoms due to gastritis, but no independent tests are available to make that prediction in an individual patient. A second group of conditions characterized by gastric mucosal aberrations with little or no inflammation were historically included in classifi-cations of gastritis, but are now categorized as gastropathies [2]. In some gastropathies there may be an inflammatory com-ponent, but the abnormal architectural changes are considered the dominant feature structurally and pathogenetically.ClassificationThe classification of gastritis, outlined in Table 33.1, represents a modification of the Updated Sydney System and reflects current practice by most gastrointestinal pathologists and gas-troenterologists [2]. Details of each type are provided in the following text.Helicobacter pylori gastritis (see Chapter 22)DefinitionH. pylori infection is predicated on the identification of H. pylori organisms via a variety of diagnostic methods. Histologically, the typical findings are chronic active gastritis. “Chronic” refers to mononuclear cell infiltrates, especially lymphocytes and plasma cells, as well as eosinophils, with or without accompanying architectural distortion. “Active” refers to the presence of neutrophils infiltrating the epithelium and lamina propria. It is noteworthy that chronic active gastritis is neither specific for H. pylori infection nor is it present in all cases.KEY POINTS• Inflammation of the gastric mucosa per se does not usually produce symptoms• H. pylori gastritis– Is the most common chronic infection in humans– Antrum-predominant H. pylori gastritis carries a 15–20% lifetime risk of peptic ulcer– Atrophic pangastritis is more common in less industrialized countries and populations with a high incidence of gastric adenocarcinoma– Carcinoma and lymphoma may present years after eradication of H. pylori infection',\n",
       " 'countries and populations with a high incidence of gastric adenocarcinoma– Carcinoma and lymphoma may present years after eradication of H. pylori infection• Autoimmune gastritis can cause iron deficiency or pernicious anemia• Lymphocytic gastritis may be associated with celiac disease, H. pylori infection, varioliform gastritis, and Ménétrier’s disease• Chemical gastropathy, caused by NSAIDs, alkaline reflux (bile or pancreatic secretion), or other chemical injury, is the most common pathologic finding in gastric biopsy specimens in the industrialized worldESSENTIAL FACTS ABOUT H. PYLORI GASTRITIS• It is the most common chronic infection in humans• Mechanisms of transmission are unknown; prevalence is related to level of sanitation (15% to 80% in different populations)• Two main types of pathology: antral-predominant non-atrophic (associated with risk for peptic ulcer) and atrophic pangastritis (associated with increased risk for gastric cancer)• Treatment hinges on eradication of organism; therapies include combinations of antibiotics and proton pump inhibitors• Eradication of H. pylori results in greatly decreased risk for peptic ulcer and decreased risk for intestinal-type gastric adenocarcinoma.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Chapter 33:\\u2002 Gastritis235Upper GI TractCauses, risk factors, disease associationsHumans are the only important reservoir for H. pylori. Helico-bacter heilmannii, a pathogen of dogs and cats, is responsible for approximately 1% of human Helicobacter infections; its his-topathologic aspects and clinical associations are similar to those of H. pylori gastritis [4]. Transmission occurs primarily from human to human and is most efficient in childhood, as suggested by the finding that children and their parents are often infected by strains with identical genetic fingerprints [5–8]. H. pylori is a spiral, microaerophilic, urease-producing, Gram-negative bacterium. A number of proteins expressed by H. pylori, collectively known as pathogenicity factors, have EpidemiologyH. pylori gastritis is the most common chronic infection in humans [3]. It affects between three and four billion people, with a prevalence that varies from less than 20% in industrial-ized Western regions with ethnically homogeneous popula-tions (e.g., Scandinavia) to more than 80% in developing areas of the world (e.g., parts of South America, equatorial Africa, Southeast Asia). Within countries, the most important predictor of high prevalence is low socioeconomic status. Improved socioeconomic conditions have resulted in a decreased prevalence of H. pylori in most Western countries and Japan.Table 33.1\\u2002 Classification of gastritis with histologic correlationsType of gastritisEtiologic factorsKey Pathologic findingsNon-atrophicHelicobacter gastritisHelicobacter pyloriHelicobacter heilmanniiMultifocal chronic active gastritis with or without erosion/ulcerLymphoid follicles characteristicMust exclude dysplasia and lymphomaOther infectious gastritidesBacteria (other than H. pylori)VirusesFungiParasitesGastritis with or without ulcer/granuloma and identifiable organisms/viral cytopathic efffectChemical gastropathyChemical irritationBileNSAIDs? Other agentsFoveolar hyperplasia',\n",
       " 'FungiParasitesGastritis with or without ulcer/granuloma and identifiable organisms/viral cytopathic efffectChemical gastropathyChemical irritationBileNSAIDs? Other agentsFoveolar hyperplasiaFibromuscular change of lamina propriaVascular dilatationLymphocyticIdiopathic? Immune mechanismsGluten sensitivityDrug (e.g., ticlopidine)? H. pyloriIncreased intraepithelial lymphocytesMust exclude H. pylori and lymphomaNon-infectiousgranulomatousCrohn’s diseaseSarcoidosisWegener’s granulomatosisand other vasculitidesForeign substancesIdiopathicGranulomas, typically non-caseatingOccasionally identifiable organisms and foreign materialEosinophilicFood sensitivity? Other allergiesMarked eosinophilia in mucosa and submucosaRadiationChemotherapyRadiation injury (external and SIR spheres)Hepatic arterial infusion chemotherapyCytologically bizarre cells (both stromal and epithelial) with normal architectureVascular changesYttrium-90 spheres occasionally identifiable, often with ulcerationAtrophicAutoimmuneAutoimmunityCross-reactivity with H. pylori antigensDiffuse corporal atrophic gastritis with antral sparingIgG4-positive plasma cells in a minorityMultifocal atrophicHelicobacter pylori, in association with dietary, environmental, and host factorsPatchy intestinal metaplasia/atrophy with involvement of corpus and antrumHawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Part 2: Diseases of the Gut and Liver236Upper GI Tractbeen suspected of an association with particular manifesta-tions of the infection (Table 33.2). However the virulence of  H. pylori seems to be largely host-dependent, and none of these factors is unequivocally disease-specific [9,10]. H. pylori infec-tion is associated with most duodenal and gastric ulcers that are not related to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and almost all primary gastric lymphomas of the mucosa-associated lymphoid tissue (MALT) [11]. In certain populations, a considerable proportion of infected subjects develop atrophic gastritis, a documented precursor of gastric adenocarcinoma [12,13].Pathogenesis and pathologyStudies of the initial phases of H. pylori infection reveal acute mucosal inflammatory responses that usually involve all gastric regions and may be accompanied by antral erosions and subepithelial hemorrhages. The chronic phase is charac-terized by a mixed infiltrate in the lamina propria (usually most intense in its most superficial portions), consisting of lymphocytes, plasma cells, and variable amounts of eosi-nophils, with ongoing activity evidenced by neutrophilic infil-tration (Figure 33.1).The intensity of inflammation is generally greater in the antrum and the cardia than in the gastric body, where it may be minimal despite visible bacterial colonization. This distribution of inflammation is described as antrum-predominant gastritis, the most common type of gastritis in Western populations.In a proportion of infected subjects, the inflammation is equally intense in all gastric regions. This pattern, known as pangastritis, is associated with a progression toward glandu-lar destruction with resulting atrophy and intestinal metapla-sia. Atrophic pangastritis is the predominant phenotype in subjects from less industrialized areas of the world and par-ticularly in populations with high incidence of gastric adeno-',\n",
       " 'sia. Atrophic pangastritis is the predominant phenotype in subjects from less industrialized areas of the world and par-ticularly in populations with high incidence of gastric adeno-carcinoma [2]. Lymphoid follicles, an expression of MALT (see Chapter 35), are virtually always found in infected stom-achs, and their presence is a reliable indication of active or recently treated H. pylori gastritis. Their greatest density is in the region of the incisura angularis and the lowest in the proximal body greater curvature [14]. H. pylori pangastritis can usually be distinguished from classical autoimmune gastritis by the presence of disease in the antrum (not found in pure autoimmune gastritis) as well as less uniform atrophy/inflammation of the body and fundus (hence the former term “multifocal atrophic gastritis”) [15]. Such an assessment requires adequate biopsy sampling (see “Diagnostic methods” below).Clinical presentationThe relationship of chronic H. pylori gastritis with dyspepsia (see Chapter 4) remains unclear. H. pylori eradication in patients with nonulcer dyspepsia has not been shown conclu-sively to improve the dyspeptic symptoms. A subset may respond, but prediction of which patients belong to that subset is not possible at this time. Subjects with antrum-predominant Table 33.2\\u2002 Putative pathogenicity factors of H. pylori and their alleged associationsPutative pathogenicity factorCharacteristicsAssociationsVacA (vacuolating cytotoxin)Genotypes s1 (associated with CagA positivity and s2)Not useful for predicting symptoms, presentation, degree of inflammation, or response to therapyCagA(cytotoxin-associated gene product A)Product of one of the genes in the cag pathogenicity islandInduction of cytokine expression in gastric epithelial cells, with raised mucosal levels of interleukin-8 and marked neutrophil infiltrationIncrease risk of a symptomatic outcome (peptic ulcer and gastric cancer), but not in all populations',\n",
       " 'mucosal levels of interleukin-8 and marked neutrophil infiltrationIncrease risk of a symptomatic outcome (peptic ulcer and gastric cancer), but not in all populationsNo predictive value in individual patients)iceA (induced by contact with epithelium)Bacterial restriction enzymeNo known biologic or epidemiologic evidence of a role for iceA as a virulence factor in H. pylori-related diseasebabA (blood group antigen-binding adhesin)Outer membrane protein, involved in adherence of  H. pylori to Lewis-b (Leb) blood group antigens on gastric epithelial cellsNo individual predictive valueInfection with babA2 gene, cagA+ and vocA s1 (“triple-positive strains”) may be related to duodenal ulcer riskFigure 33.1\\u2002 Biopsy of the gastric antrum showing moderate chronic active gastritis. The dark staining mixed inflammatory infiltrate is concentrated mostly in the upper portions of the mucosa. Various degrees of clear-staining edema and hemorrhage are seen in the subepithelial zone.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Chapter 33:\\u2002 Gastritis237Upper GI Tractorganisms have a characteristic tight spiral morphology and are two to three times longer (10 microns) than H. pylori.A urease test on an antral biopsy specimen (Clotest®) permits the rapid detection of urease activity in the biopsy material, with a sensitivity of 80–100% and a specificity of 92–100%, although it is not known how well such tests work post-treatment. The urea breath test (UBT) is based on the detection of labelled carbon dioxide in a sample of the subject’s breath after the ingestion of a meal containing 13C and 14C labeled urea. Although highly sensitive and specific, its use is largely limited by the need of administering the meal to the H. pylori gastritis have a lifetime risk for peptic ulcer disease of 15–20% (see Chapter 32). Most subjects who do not develop ulcer disease remain asymptomatic and are believed to have no increased risk for gastric adenocarcinoma (see Chapter 34); those with pangastritis also remain asymptomatic, but their gastric mucosa develops progressive destructive and repara-tive changes that result in expanding areas of glandular loss (atrophy) and replacement of the native gastric mucosa with an intestinal-type epithelium (intestinal metaplasia).Atrophic gastritis is epidemiologically and biologically asso-ciated with gastric adenocarcinoma of the intestinal type, and patients with this phenotype account for much of the increased risk of cancer related to H. pylori infection [15]. Based on case-controlled and other retrospective epidemiologic studies, the overall gastric cancer risk for H. pylori-infected subjects has been estimated as 3- to 10-fold that of the uninfected popula-tion [16]. H. pylori infection is also related to diffuse (signet ring cell) gastric cancer of the stomach, which accounts for 50% or more of all gastric cancers in some populations. Here there is no diffuse intestinal metaplasia or atrophy and no',\n",
       " 'ring cell) gastric cancer of the stomach, which accounts for 50% or more of all gastric cancers in some populations. Here there is no diffuse intestinal metaplasia or atrophy and no apparent dysplastic “soil.” The risk for primary gastric B-cell lymphoma, a rare condition, is in the range of 5- to 7-fold that of noninfected subjects.Both carcinoma and lymphoma may be diagnosed years or even decades after H. pylori infection has disappeared, possi-bly because of the combined effects of the hypochlorhydria related to atrophy, an inhospitable gastric environment brought upon by metaplasia and incipient epithelial and lymphoid neoplasia, and possibly incidental antibiotic treatments. Thus, it is likely that retrospective studies significantly underesti-mate the risk of neoplasia conferred by H. pylori infection. Studies taking into account the infecting strain of H. pylori (with regard to pathogenicity factors), the phenotype of gas-tritis, and the time elapsed between detection of the infection and the diagnosis of carcinoma, have raised the estimated risk to as much as 23-fold.Diagnostic methods (Table 33.3)Testing for H. pylori should be performed only if treatment is intended. The diagnosis can be made by endoscopic biopsy of the gastric mucosa or by noninvasive methods, depending on the clinical setting. Biopsy specimens (ideally at least two from the antrum and two separately identified and submitted from the gastric body along the greater curve) are examined for the detection of H. pylori and for the diagnosis of gastritis (Figure 33.2). Special stains have been employed to identify the curved bacillary organisms with facility. A variety of his-tochemical stains have been employed, but the most sensitive and specific (both near 100%) is the immunohistochemical stain, which can also identify organisms after treatment with proton pump inhibitors and antibiotics (Figure 33.3). Organ-isms are typically found extracellularly in the lumen at the',\n",
       " 'stain, which can also identify organisms after treatment with proton pump inhibitors and antibiotics (Figure 33.3). Organ-isms are typically found extracellularly in the lumen at the surface and in the superficial pit layer. After treatment, organ-isms can sometimes only be found in deep glands and intracel-lularly, often with atypical (coccoid) morphology. H. heilmannii Figure 33.2\\u2002 Biopsy protocol. Schematic representation of the biopsy protocol recommended by the Updated Sydney System when the objective is to map the severity and extent of gastritis. A minimum of two specimens is obtained from each of the antrum (A1 and A2 – lesser and greater curvature) and the corpus (B1 and B2 – lesser and greater curvature). In addition, one biopsy specimen from the incisura angularis (IA) is recommended to detect early atrophic and metaplastic changes, represented in blue. (This figure was published in Clinical Gastroenterology and Hepatology, Wilfred M. Weinstein, Christopher J. Hawkey, Jaime Bosch, Gastritis, Pages 223–232, Copyright Elsevier, 2005.)B1A1IncisuraB2A2Figure 33.3\\u2002 Anti-Helicobacter immunohistochemical stain. High-power photomicrograph of gastric mucosa with few H. pylori organisms, stained brown by an anti-Helicobacter immunohistochemical stain.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Part 2: Diseases of the Gut and Liver238Upper GI TractTable 33.3\\u2002 Invasive and non-invasive tests for the diagnosis of H. pylori infectionTestCharacteristicsAdvantagesDisadvantagesInvasive methodsHistopathologic examination of gastric mucosal biopsyDetects current infection by direct observation with or without special staining techniques (immunohistochemistry is the most sensitive and specific)Highly sensitive and specificCan discern H. pylori from H. heilmanniiAllows the evaluation of associated conditions (intestinal metaplasia, dysplasia, carcinoma, lymphoma)Guarantees a permanent recordInvasiveSampling may affect yieldSmear, brush, and touch preparations (cytopathology)Detects bacteria by direct observation of gastric exfoliated cells harvested by brushingInexpensiveInvasiveGenerally inaccurate, even with skilled operatorsLimited information on pathology of gastric mucosaBacterial cultureDetects bacterial growth in special media100% specificAllows antibiotic sensitivity testsInvasiveSensitivity is laboratory-dependentNo information on pathology of gastric mucosaRapid urease testsDetect current infection by bacteria-produced urease in fresh biopsy specimensHighly sensitiveHighly specificRapid results (<2 hours)InvasiveNo information on pathology of gastric mucosaNon-invasive methodsUrea breath testsDetects current infection, relying on H. pylori-derived urease activity in the stomachSensitivity and specificity >90%Can be used in childrenUseful for initial diagnosis and to evaluate treatmentRequires 13C or 14C detection equipmentExpensive in some settingsNo information on pathology of gastric mucosaLaboratory-based serologic testsDetect anti-H. pylori IgG in serumApproved tests have high sensitivity and specificity (85%−90%)InexpensiveUseful for initial diagnosisSpecificity may be “population-specific”Detect evidence of past infectionNo information on pathology of gastric mucosa,',\n",
       " 'and specificity (85%−90%)InexpensiveUseful for initial diagnosisSpecificity may be “population-specific”Detect evidence of past infectionNo information on pathology of gastric mucosa, except indirectly when combined with gastrin and pepsinogen ratio measurements (“serologic biopsy”)Simplified “in-office” immunoenzymatic testsDetect anti-H. pylori IgG in serum or whole bloodInexpensiveImmediate results (<10 minutes)Moderate specificity and sensitivity (∼85%)Detect evidence of past infectionNo information on current infectionSensitivity and specificity <90%No information on pathology of gastric mucosaStool antigen assaysDetect H. pylori antigens in stoolsDetects current infectionUseful for determining eradication (8 weeks after therapy)Excellent specificity and sensitivity (>95%)InexpensiveSpecimen collection inconvenientNo information on pathology of gastric mucosaUrine testsDetect anti-H. pylori IgG in urineInexpensive disposable kitsQuick results (20 minutes)Recently developed tests (e.g., RAPIRUN, URINELISA) have moderate specificity and sensitivity (∼ 85%)Not yet completely validatedSensitivity and specificity may be too low for clinical useLow specificity in childrenNo information on pathology of gastric mucosaSaliva testsDetect anti-H. pylori IgA or IgG in salivaConvenient collection of salivaLow specificity and sensitivity (70% to 85% reported)Not approved, not readily availableHawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Chapter 33:\\u2002 Gastritis239Upper GI Tract14 days has a reported efficacy between 75% and 95% in patients who failed first-line therapy. Levofloxacin-based therapy has grown in popularity in recent years; however, the rapidly increasing rate of quinolone resistance reported in several countries may soon limit its use [19].Patients who fail both first and second-line therapy for H. pylori have been treated with empiric rescue regimens (“third-line therapy”) that most commonly include rifabutin or furi-zoladone. These antibiotics have, however, serious side effects (including myelotoxicity) and their use may be limited to selected patients.Recently, sequential therapy has been proposed to overcome clarithromycin resistance [20,21]. Hypothetically, during the first part of therapy, amoxicillin weakens the bacterial cell wall, which prevents the formation of the channels that block clarithromycin from binding to the bacterium and hence causes resistance to the antibiotic. A meta-analysis published in 2008 reported 93.4% eradication rates, compared with 76.9% for standard triple therapy [22]. Sequential therapy is not affected by bacterial factors (CagA status, bacterial load) and host factors (underlying disease, smoking), which until now have predicted the outcome of conventional eradication treat-ments. Even when strains were clarithromycin-resistant, the eradication rate with sequential therapy was 82.2% compared with 40.6% for triple therapy. Most studies on sequential therapy have been performed in Italy and this regimen is still untested in most countries. The American College of Gastro-enterology “Guideline on the Management of H. pylori Infec-tion” states that “sequential therapy may provide an alternative to clarithromycin-based triple therapy but requires validation within the United States before it can be recommended as a first-line therapy;” the European Maastricht III Consensus Report points out that “sequential treatment deserves further',\n",
       " 'within the United States before it can be recommended as a first-line therapy;” the European Maastricht III Consensus Report points out that “sequential treatment deserves further evaluation in different regions” [17,18].Probiotics and vaccines may offer some alternatives in the future, but at the moment they are still in the early phases of evaluation.A sensible approach for therapy in patients who fail a first- and second-line treatment involves H. pylori culture and anti-biotic testing. However, susceptibility testing is limited by the fact that in vivo resistance may not accurately reflect in vitro resistance, notably with respect to metronidazole. Currently such an approach is carried out almost exclusively in special-ized centres with research interest and expertise in the treat-ment of H. pylori; however, the development of newer technologies in the field of susceptibility testing may encour-age this practice to become more widespread. This is likely to have substantial benefits and lead to more accurate prescribing and lower rates of resistance.Autoimmune gastritis and pernicious anemiaDefinitionAutoimmune gastritis is a chronic atrophic gastritis affecting the oxyntic gland mucosa (gastric body and fundus) and patient and the relatively expensive analysers required for the evaluation of the breath sample. Culture of H. pylori with anti-biotic sensitivity testing is not performed routinely for the initial diagnosis of H. pylori infection. Some laboratories have high-quality culture facilities for H. pylori, and culture may be used if a second course of therapy also fails to eradicate the organisms.Indications for therapyPrimary indications for testing and treatment include:• active peptic ulcer disease• a history of documented peptic ulcer• gastric MALT lymphoma.Testing of asymptomatic subjects and patients with non-ulcer dyspepsia are not recommended, except when there is a docu-',\n",
       " '• a history of documented peptic ulcer• gastric MALT lymphoma.Testing of asymptomatic subjects and patients with non-ulcer dyspepsia are not recommended, except when there is a docu-mented history of gastric cancer in first-degree relatives. Despite the absence of data, many patients with life-dominating non-ulcer dyspepsia are treated if they have evidence of H. pylori. In children, testing for H. pylori is recommended when the symptoms are severe enough to justify therapy. In spite of, or perhaps because of, the many recommendations issued by gastroenterological associations and consensus groups, several issues regarding indications for therapy remain unresolved. In practice, treatment decisions are rarely based on evidence alone; frequently a number of patient- and doctor-driven con-siderations have the greatest weight in making these choices.TherapyThe Maastricht-III consensus stated that for an eradication treatment regime to be considered effective, it should achieve an intention-to-treat eradication rate in excess of 80% [17]. However, eradication rates in practice for many of the most common regimens have fallen well below these levels in recent years, generally due to a combination of poor compliance and antibiotic resistance.The recommended first-line treatment in published Euro-pean and North American guidelines consists of a proton pump inhibitor (PPI) combined with amoxicillin and clarithromycin. However, while in 2000, eradication rates for standard triple therapy were in excess of 90%, recent studies have shown that this level has fallen below 70% and even as low as 60% in some areas. Therefore, Maastricht III guidelines [17] recommend sub-stituting metronidazole for clarithromycin where resistance to that antibiotic, increasing in most countries, exceeds 15–20%. Although there has been debate on the optimal duration of therapy, the 2007 American College of Gastroenterology guide-',\n",
       " 'that antibiotic, increasing in most countries, exceeds 15–20%. Although there has been debate on the optimal duration of therapy, the 2007 American College of Gastroenterology guide-lines recommended 10-day treatment courses [18] and the most recent Maastricht consensus stated that 14 days of treatment had an advantage over 7 days in terms of eradication.Since first-line therapy fails in approximately 20% of patients, several second-line therapy regimens have been developed. The most common are bismuth-based and levofloxacin-based therapies. Bismuth-based quadruple therapy consisting of a PPI, bismuth, tetracycline, and metronidazole for 10 days or Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Part 2: Diseases of the Gut and Liver240Upper GI TractESSENTIAL FACTS ABOUT AUTOIMMUNE  GASTRITIS• Chronic corpus-restricted atrophic gastritis is associated with circulating serum anti-parietal cell and anti-intrinsic factor antibodies along with intrinsic factor deficiency• Affects predominantly older women. The prevalence is 1%−5% in persons over 60 years of age; higher in subjects with specific familial histocompatibility haplotypes (HLA-B8 and -DR3)• Pathology: dense mononuclear infiltrates in the corpus leading to progressive disappearance of oxyntic glands and intestinal metaplasia with resultant hypochlorhydria. Endocrine cell hyperplasia, carcinoid tumours, and inflammatory polyps are common• Vitamin B12 deficiency and macrocytic anemia (“pernicious anemia”) characterize the advanced stageautoantibodies to the parietal cell antigen and to intrinsic factor. In the initial phases of the disease, individual parietal cells may be surrounded by lymphocytes or drop out from oxyntic glands.As the disease progresses over a period of two to three decades, the oxyntic mucosa may be completely replaced by pyloric/antral-type mucous glands, “pyloric metaplasia,” and intestinal metaplasia. At this stage the inflammation becomes less intense. In patients with classic pernicious anemia, residual small nests of parietal and chief cells may persist, but their numbers are greatly reduced. The hypochlo-rhydria induces gastrin production from endocrine cells in the antrum, which in turn stimulates enterochromaffin-like (ECL) cell hyperplasia. This common finding is often subtle histo-logically but can be highlighted with the use of immunohisto-chemical stains for neuroendocrine differentiation. The range of ECL proliferation ranges from linear hyperplasia to micro-carcinoid tumours. Such tumours are often multiple, are  associated with various levels of background endocrine pro-liferation, and almost always are innocuous. In addition,',\n",
       " 'carcinoid tumours. Such tumours are often multiple, are  associated with various levels of background endocrine pro-liferation, and almost always are innocuous. In addition, benign gastric hyperplastic polyps are frequently seen in end-stage patients [28].Clinical presentationMost clinical manifestations of autoimmune gastritis become apparent when the parietal cell mass decreases beyond the critical point when the stomach becomes unable to produce sufficient amounts of acid, pepsinogens, and intrinsic factor. Achlorhydria occurs in the most advanced stages of the disease, but hypochlorhydria may also occur in patients with moderate numbers of surviving parietal cells, suggesting that anti-proton pump antibodies or inhibitory lymphokines released by subsets of inflammatory cells may participate in the inhibition of acid secretion. Patients with oxyntic gland atrophy and achlorhydria undergo hyperplasia of gastrin-secreting endocrine cells in the gastric antrum with resultant commonly associated with circulating serum antiparietal cell and anti-intrinsic factor antibodies and intrinsic factor defi-ciency. In its endstage it is associated with vitamin B12 deficiency. Pernicious anemia is the vitamin B12 deficiency associated with chronic atrophic autoimmune gastritis.Figure 33.4\\u2002 Autoimmune gastritis. Corpus mucosa with metaplastic atrophy, complete absence of oxyntic gland, and a dense mononuclear inflammatory infiltrate.EpidemiologyAutoimmune gastritis and pernicious anemia are diseases of older age, especially in women. The prevalence of pernicious anemia among Americans aged 60 years or older is 2.7% in women and 1.4% in men. There is a strong family association (see below) [23].PathogenesisThe high prevalence of specific familial histocompatibility haplotypes (HLA-B8 and -DR3) in patients with corpus-restricted atrophic gastritis and its association with other autoimmune conditions, strongly indicate an autoimmune',\n",
       " 'haplotypes (HLA-B8 and -DR3) in patients with corpus-restricted atrophic gastritis and its association with other autoimmune conditions, strongly indicate an autoimmune origin [24]. Autoantibodies to parietal cells and to their secre-tory product, intrinsic factor, are present in the serum and gastric juice. The antigen recognized by parietal cell autoanti-bodies is gastric H+/K+-ATPase, the major protein of the mem-brane lining the secretory canaliculi of parietal cells, that secretes hydrogen ions in exchange for potassium ions [25]. During the course of the disease, both parietal and chief cells disappear progressively from the oxyntic glands. H. pylori infection may induce the formation of antibodies that cross react with parietal-cell antigens, and has been proposed as a possible etiologic factor in the pathogenesis of autoimmune gastritis. This correlation, however, remains unproven, and similarly, much stronger biologic, clinical, and epidemiologic evidence is needed before H. pylori can be viewed as the cause of autoimmune gastritis [26,27].PathologyPatients with autoimmune gastritis have a corpus-restricted chronic atrophic gastritis, and therefore the antral (and cardiac) mucosa is usually spared. Mononuclear cell infiltrates (plasma cells and lymphocytes) are found in the lamina propria between the gastric glands and may extend into the sub\\xadmucosa (Figure 33.4). Infiltrating plasma cells contain Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Chapter 33:\\u2002 Gastritis241Upper GI TractThe atrophic gastritis is characterized histologically by chronic inflammation of the glandular mucosa with marked or complete depletion of the parietal cell mass, and intestinal and pyloric metaplasia. These findings can mimic antral gas-tritis and warrant the separate labeling of biopsies from these regions.Serum antibodies to gastric parietal cells are found in 90% of patients with pernicious anemia and in about 30% of their non-anemic first-degree relatives. The demonstration of circu-lating intrinsic factor autoantibodies is almost diagnostic of autoimmune gastritis and is present in approximately 50%. Hypergastrinemia is the result of sparing of the antrum and stimulation of the gastrin-producing G cells by achlorhydria. A low serum pepsinogen concentration results from destruc-tion of the chief cells.TreatmentThe standard treatment is regular monthly intramuscular injections of at least 100\\u2009µg vitamin B12 to correct the vitamin deficiency. Hydroxycobalamin 1\\u2009mg every 3 months is a common regimen. When indicated, iron supplements are given prior to B12 administration.Other gastritidesInfectious gastritides due to agents other than Helicobacter sppThe acid environment of the normal stomach is inhospitable to most infectious agents. However, in subjects with atrophic gastritis and decreased acid secretion, in patients with impaired immune responses, or as part of systemic infections, a number of viruses, bacteria, and parasites can infect the stomach. These infectious gastritides (see Chapter 31, “Infec-tions of the esophagus and stomach”) are rare in otherwise healthy persons, but some (e.g., cytomegalovirus) are not uncommon in immunocompromised patients. Their most important clinical and pathologic features are summarized in Table 33.4.Lymphocytic gastritisThis is a distinctive type of pangastritis characterized by the presence of large numbers of mature lymphocytes infiltrating',\n",
       " 'Table 33.4.Lymphocytic gastritisThis is a distinctive type of pangastritis characterized by the presence of large numbers of mature lymphocytes infiltrating the surface and foveolar epithelium. The lamina propria is infiltrated by an often dense population of inflammatory cells in which lymphocytes and plasma cells predominate, although significant numbers of neutrophils and eosinophils are also present [31].hypergastrinemia, typically correlating with the severity of the mucosal damage. Injury to chief cells leads to a reduction of pepsin activity in gastric juice and of pepsinogens in blood. Reduced pepsinogen I concentration (<20\\u2009ng/mL) is a sensi-tive and specific indicator of atrophic gastritis. Patients with advanced autoimmune gastritis may develop:• iron deficiency anemia• pernicious anemia or• combined anemia.Hypochromic microcytic anemia (15% of patients) may be caused by achlorhydria, as gastric acid is important in the absorption of non-heme iron, which in Western diets sup-plies at least two-thirds of nutritional iron needs. Frank perni-cious (macrocytic) anemia is usually preceded by chronic atrophic gastritis and reduced or absent acid secretion by approximately a decade, and is generally associated with a histologic pattern of end-stage atrophic gastritis. Thus a com-bined anemia may be present, and a considerable number of patients with severe atrophic oxyntic gland gastritis may still not fulfill the criteria for the diagnosis of pernicious anemia, but are clearly at risk for the development of vitamin B12 deficiency.Disease associationsAutoimmune gastritis is a risk factor for:• hyperplastic and adenomatous polyps• carcinomas• endocrine tumoursof the stomach. Polyps, found in 20–40% of patients with per-nicious anemia, are mostly sessile, small, and multiple. Most are hyperplastic, but up to 10% may contain dysplastic foci [29]. The risk of gastric carcinoma is believed to be increased',\n",
       " 'nicious anemia, are mostly sessile, small, and multiple. Most are hyperplastic, but up to 10% may contain dysplastic foci [29]. The risk of gastric carcinoma is believed to be increased 3-fold, and that of gastric carcinoid tumours 13-fold, in patients with pernicious anemia [28]. The trophic action of gastrin may be responsible for the transformation of endocrine cells from hyperplastic to neoplastic.Diagnostic methodsThe diagnosis of autoimmune gastritis is frequently missed because patients (elderly people with anemia) are typically successfully treated by hematologists or general practitioners with iron and vitamin B12 supplements, and are not referred to gastroenterologists for the evaluation of atrophic gastritis, pepsinogen levels, or antiparietal cell antibodies. The diagno-sis can be confirmed by a combination of histopathologic and serologic studies. A set of at least four biopsy specimens from the gastric mid-body on the greater curvature, along with two separately submitted from the antrum, should be obtained. The coexistence of severe and diffuse atrophic gastritis of the corpus with a normal antrum is virtually pathognomonic of autoimmune atrophic gastritis [2,30].ESSENTIAL FACTS ABOUT LYMPHOCYTIC  GASTRITIS• Pangastritis characterized by large numbers of mature CD8+ lymphocytes infiltrating the surface and foveolar epithelium• Prevalence: 0.1−1% of subjects undergoing gastric biopsies• Etiology is unknown; it is not caused by H. pylori infectionHawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Part 2: Diseases of the Gut and Liver242Upper GI TractTable 33.4\\u2002 Infectious gastritides caused by agents other than Helicobacter spp.AgentMain characteristicsPathologyViralRotaviruses, calicivirusesStomach may be infected during gastroenteritisNone knownCytomegalovirusChildrenImmunocompromised patientsMegaloblastic inclusionsMucosal erosions, ulcerationsRarely large-fold gastropathyBacteriaVariousOvergrowth only in achlorhydric subjectsNo detectable changesPyogenic bacteria (streptococci, staphylococci, Escherichia coli, Proteus, and Haemophilus spp.)Phlegmonous gastritisExceedingly rareLarge areas of purulent necrosis involving the full thickness of the gastric wallMycobacterium tuberculosisPrimary gastric tuberculosis rareStomach may be involved in disseminated infectionsNecrotizing granulomas may be found in the gastric mucosaTreponema pallidumGastric involvement in secondary syphilisRare, more common in HIV patientsMixed inflammatory infiltrate, mostly plasma cells, and mucosal ulcerations. Swelling of gastric folds with erosions and ulcerations may mimic endoscopic appearance of lymphoma or carcinomaFungiCandida speciesHistoplasma capsulatumMucoraceaeOnly in immunocompromised patientsParasitesCryptosporidium spp.Giardia intestinalisStrongyloides stercoralisRarely found in the stomach, mostly immunocompromised patientsNo inflammatory responsesAnisakidae“Sushi worm”Many species of edible fishes have larvae of Anisakidae in their muscles. In a small proportion of individuals who eat infected fish, larvae penetrate the gastric wall causing a sudden onset of epigastric painMostly eosinophilic response around penetrating larvaeDead larvae may elicit granulomaslymphocytosis are similar. The first reports of lymphocytic gastritis featured endoscopic descriptions of large gastric folds with nodules and erosions, clinically accompanied by nausea, vomiting, and weight loss. These findings were presented as',\n",
       " 'gastritis featured endoscopic descriptions of large gastric folds with nodules and erosions, clinically accompanied by nausea, vomiting, and weight loss. These findings were presented as the signature lesions of a now rare disorder: diffuse variolif-orm (“octopus-sucker”) gastritis [32].Another unusual and hypertrophic variant of lymphocytic gastritis resembles Ménétrier’s disease endoscopically, also in patients with protein loss. Case reports describe resolution of the intraepithelial lymphocytosis and symptomatology fol-lowing a regimen of proton pump inhibitors. H. pylori has been found in some of these patients, and in a subset of these, eradication resulted in disappearance of the thick folds and lymphocytic gastritis. Although other putative disease asso-ciations include non-Helicobacter infections and Crohn’s EpidemiologyLymphocytic gastritis is uncommon, found in 0.1–1% of sub-jects who undergo endoscopy with biopsy sampling.Causes and pathogenesisBecause virtually all intraepithelial lymphocytes are CD8+ suppressor T cells (the same cells that form the intraepithelial infiltrate in celiac disease and lymphocytic colitis), an immune mechanism has been proposed. Lymphocytic gastritis is of interest primarily because of its clinical associations: approxi-mately one-third of adults and up to half of children with celiac disease (see Chapter 40) have increased gastric intraepi-thelial lymphocytes, usually concentrated in the antrum. In most cases of lymphocytic gastritis H. pylori cannot be impli-cated, as the rate of infection in those with and without Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Chapter 33:\\u2002 Gastritis243Upper GI TractPrimary gastric tuberculosis has been reported mostly from developing countries, typically manifesting as a large non-healing ulcer; disseminated tuberculosis also causes caseating granulomas (see Chapter 47). Histoplasma capsulatum rarely can cause gastric granulomatous inflammation. In gastric ani-sakiasis, fragments of helminthic cuticles may elicit the forma-tion of foreign body granulomas.The stomach may be involved in patients with Crohn’s disease (see Chapter 50) and sarcoidosis. In Crohn’s disease, the prevalence of gastric granulomas may be as high as 10%. However, more commonly, gastric biopsies appear largely normal but feature a focal chronic active inflammatory response, often limited to a few foveolae or oxyntic glands, termed “focally enhanced gastritis;” granulomas are not part of this response. While highly non-specific, this pattern of injury may be the first manifestation of Crohn’s disease.In sarcoidosis, involvement of the gastrointestinal tract rarely has any clinical importance, although outlet obstruction and bleeding have occasionally been reported. Endoscopic findings include nodularity, polypoid mucosal irregularity, erosions, ulcers, and segmental, usually distal, rigidity resem-bling linitis plastica. These gross changes reflect the presence of numerous small mucosal granulomas. Since the finding  of gastric mucosal granulomas may precede the discovery of these diseases in other organs, the careful interpretation of gastric biopsy findings together with radiologic and serologic testing may lead to the diagnosis.Other causes of granulomas include foreign material, such as suture material in patients who have undergone a partial gastrectomy, and food particles that may become engulfed in an ulcer crater. Rare entities causing gastric granuloma include immune-mediated vasculitis syndromes (see Chapter 111) and Wegener’s granulomatosis.',\n",
       " 'an ulcer crater. Rare entities causing gastric granuloma include immune-mediated vasculitis syndromes (see Chapter 111) and Wegener’s granulomatosis.The term “isolated (or idiopathic) granulomatous gastritis” should be applied only as a temporary diagnostic label to cases of granulomatous gastric inflammation for which no etiology has yet been determined. Even after careful evaluation, a large proportion of gastric granulomas will remain unexplained. These lesions are usually asymptomatic; as there is no infor-mation on their natural history or evolution, no treatment can be recommended [33,34].GastropathiesReactive (or chemical) gastropathyReactive (or chemical) gastropathy is defined as the constella-tion of endoscopic and histologic changes caused by chemical injury to the gastric mucosa [35]. The term “chemical” is used broadly and refers to the gastric mucosa in some patients who take NSAIDs (see Chapter 23); it also includes patients with alkaline reflux after partial gastrectomy or those with poorly understood motility disorders resulting in bile reflux. No rela-tionship has been established between the endoscopic or his-tologic appearance of the mucosa in patients who take NSAIDs and either dyspeptic symptoms or risk for gastric hemorrhage. disease, lymphocytic gastritis is most commonly seen in gastric biopsies where there is no known association.Diagnostic methodsA substantial increase in intraepithelial lymphocytes (Figure 33.5) is accompanied by a spectrum of inflammation in the lamina propria ranging from a minor increase in chronic inflammatory cells with no activity to a marked chronic and active inflammation with erosions. In most cases the histologic picture can readily be distinguished from that of H. pylori chronic gastritis, in which (exclusive of focal lymphoepithelial lesions) few intraepithelial lymphocytes are present. The diag-nostic threshold for lymphocytic gastritis is generally accepted',\n",
       " 'chronic gastritis, in which (exclusive of focal lymphoepithelial lesions) few intraepithelial lymphocytes are present. The diag-nostic threshold for lymphocytic gastritis is generally accepted as more than 25 intraepithelial lymphocytes per 100 epithelial cells, but in most cases the counts are greater than 50 [31].Granulomatous gastritisGranulomatous gastritis can be considered as a histopatho-logic placeholder to which gastric biopsies bearing granulo-mas are temporarily assigned while the condition responsible for their development is identified. In most cases the morpho-logic appearance of granulomas does not provide a useful clue to their etiology, except when• foreign materials• acid-fast bacilli or• fungal formsare found. Thus, a specific diagnosis can be made only by integrating histopathologic findings with clinical and labora-tory information [33,34].Etiology and pathogenesisGranulomatous inflammation in the gastrointestinal mucosa can be found in patients with a variety of bacterial, fungal, and parasitic infections as well as certain immune disorders. Figure 33.5\\u2002 Lymphocytic gastritis. This is characterized by marked intraepithelial lymphocytosis and a variable plasma cell and lymphocyte infiltrate in the lamina propria.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Part 2: Diseases of the Gut and Liver244Upper GI TractESSENTIAL FACTS ABOUT REACTIVE  GASTROPATHY• Also known as chemical gastropathy, it is the constellation of endoscopic and histologic changes caused by chemical injury to the gastric mucosa• Most commonly associated with used of NSAIDs• Highly prevalent (15% to 25%) in populations living in the industrialized world, particularly in the elderly• Pathology: minimal or no inflammation, epithelial regeneration with foveolar hyperplasia, edema of the lamina propria, vascular congestion, and proliferation of the smooth muscle fibresHemorrhagic gastropathiesThis group of conditions, characterized by subepithelial hem-orrhages and erosions, is related to:• severe physical stress (see Chapter 32)• the use of NSAIDs (see Chapter 23)• the ingestion of large quantities of alcohol.The most severe degrees of hemorrhagic gastropathy are those induced by stress in critically ill patients. Most patients admit-ted to an intensive care unit have mucosal lesions; approxi-mately 20% of them have overt bleeding and 2–5% have life-threatening hemorrhage (see Chapter 32). The pathogen-esis of stress-induced hemorrhagic gastropathy is incompletely understood, but when the mucosal defense mechanisms lose their integrity, luminal acid may exert a damaging effect. Vas-cular disturbances, in association with stasis, vasoconstriction, and increased vascular permeability, may contribute further to mucosal vulnerability [37].Aspirin or other NSAIDs may induce acute mucosal injury, ranging from edema and hyperemia to multiple erosions and ulcerations. Such lesions may occur without warning symp-toms in both first-time NSAID users and patients who have taken NSAIDs regularly for years. Except for generic risk factors (older age, female sex, and previous episodes), there is no way prospectively to identify NSAID users who are sus-ceptible to severe gastric injury. Similar mucosal lesions,',\n",
       " 'factors (older age, female sex, and previous episodes), there is no way prospectively to identify NSAID users who are sus-ceptible to severe gastric injury. Similar mucosal lesions, although usually less severe and only rarely eventuating to ulcer, can be caused by the ingestion of large quantities of alcohol. NSAIDs act by interfering with prostaglandin synthe-sis, while alcohol causes direct damage to the gastric mucosa, particularly at higher concentrations.Acute hemorrhagic gastropathy is characterized by a hyper-emic edematous mucosa with erosions and active bleeding. As the diagnosis is usually realized from the clinical context, gastric biopsies are rarely obtained. Nevertheless, in immuno-compromised patients, it may be prudent to obtain biopsies to look for evidence of infection such as cytomegalovirus. Similarly, if hemorrhagic gastropathy is encountered outside of an expected clinical setting, biopsy to exclude a diffuse process like lymphoma or carcinoma should be performed.Vascular gastropathiesThis heterogeneous group of conditions is characterized by alterations in the gastric circulation and their effects on the gastric mucosa. From a morphologic and pathogenetic view-point, gastric antral vascular ectasia (GAVE) and portal hyper-tensive gastropathy are the best characterized.Gastric antral vascular ectasia (GAVE)GAVE, or “watermelon stomach,” is a condition of unknown etiology frequently associated with atrophic gastritis, connec-tive tissue disorders (particularly scleroderma), and some-times portal hypertension. More than 70% of reported cases have occurred in women older than 65 years of age. Occult Interestingly, reactive gastropathy is only seen in 10–45% of those who take NSAIDs regularly. Biopsies at the edges of gastric erosions and ulcers often reveal the features of reactive or chemical gastropathy, even in settings other than those of NSAID ingestion.Figure 33.6\\u2002 Reactive (“chemical”) gastropathy. Hyperplastic “corkscrew”',\n",
       " 'or chemical gastropathy, even in settings other than those of NSAID ingestion.Figure 33.6\\u2002 Reactive (“chemical”) gastropathy. Hyperplastic “corkscrew” gastric foveolae and absence of inflammation: these features are seen in up to 45% of patients on chronic NSAIDs and in alkaline reflux gastropathy. They are virtually always present in the gastric mucosa adjacent to a Bilroth II anastomotic site.Histopathologic changes associated with reactive gastropathy include:• Epithelial regeneration.• Foveolar hyperplasia.• Edema of the lamina propria.• Proliferation of the smooth muscle fibres from the muscula-ris mucosae into the upper third of the mucosa (Figure 33.6).However, both the specificity and predictive value of these features are low, and the diagnosis rests on the integration of clinical and histopathologic data [36]. When reactive gastropa-thy is found unexpectedly in a biopsy of normal-appearing gastric mucosa sampled to exclude H. pylori, the clinician should solicit a history that might reveal the etiology, usually chronic NSAID use or symptoms compatible with bile reflux.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Chapter 33:\\u2002 Gastritis245Upper GI Tractnized and better understood. The three classic types of hyper-trophic gastropathy are:1. Superficial foveolar (mucous neck region) hyperplasia with normal or atrophic deep oxyntic glands.2. Hyperplasia of oxyntic glands with a largely unaffected mucous neck region.3. A mixed type, in which both mucous neck and oxyntic glands show variable degrees of hyperplasia.Type 1 corresponds to Ménétrier’s disease, Type 2 to Zollinger-Ellison syndrome (see Chapter 112), and Type 3 incorporates a variety of conditions that may result from mixed glandular and foveolar hyperplasia, including:• infections (e.g., H. pylori infection, cytomegalovirus in chil-dren, syphilis)• other diseases of uncertain etiology such as:– lymphocytic gastritis– eosinophilic gastroenteritis– sarcoidosis and– Cronkhite-Canada syndrome.Ménétrier’s diseaseThis rare condition is defined as an idiopathic diffuse enlarge-ment of the gastric folds largely confined to the gastric body and fundus. When well established, the massive foveolar cell (mucous neck region) hyperplasia is associated with underly-ing loss of parietal and chief cells. The amount of inflamma-tion is variable; some patients have multifocal superficial erosions whereas others have polypoid configurations of the hypertrophic mucosa. When accompanied by chronic active inflammation or intraepithelial lymphocytic infiltration, the large-fold variant of H. pylori gastritis or lymphocytic gastritis should be considered.Clinical featuresMost patients are men in their fifth or sixth decade who present with weight loss, epigastric and abdominal pain, nausea, and vomiting. The disease evolves over several years or decades, and eventually patients develop severe hypoalbu-minemia as a consequence of the chronic protein loss. Child-hood Ménétrier’s disease is due to gastric cytomegalovirus infection, which may sometimes produce localized hyper-',\n",
       " 'minemia as a consequence of the chronic protein loss. Child-hood Ménétrier’s disease is due to gastric cytomegalovirus infection, which may sometimes produce localized hyper-trophic gastropathy in the gastric antrum or body of immu-nocompromised adults.PathologyProtein loss is caused by the large amounts of mucus and fluid secreted by hyperplastic foveolar cells. Hypochlorhydria is the rule in well-established cases. The pathogenesis is unknown, but it has been hypothesized that overproduction of transforming growth factor (TGF)α might explain several of the disturbances occurring in Ménétrier’s disease. TGF, a mediator of gastric mucosal homeostasis produced by the bleeding with iron deficiency anemia is present in almost 90% of patients, with melena or hematemesis in 60%. The pictur-esque name was inspired by the endoscopic appearance of “longitudinal antral folds seen converging on the pylorus, con-taining visible and ectatic vessels resembling the stripes on a watermelon.” The prominent dilated vessels have also been compared to a large flat mushroom or honeycomb [38].HistopathologyThe lamina propria is expanded by smooth muscle prolifera-tion and fibrosis, and contains dilated mucosal capillaries whose cross-sectional area is of the caliber of adjacent antral glands. Fibrin thrombi are characteristically found within at least some of the dilated capillaries. Other localized conditions (e.g., gastric hyperplastic inflammatory polyps) may share some of these histopathologic characteristics; therefore, a diag-nosis is possible only if there is appropriate endoscopic  correlation. Sometimes the degree of histologic changes, par-ticularly dilated capillaries, is minimal relative to the striking endoscopic appearance. This may be due to shrinkage of the vessels in biopsies with formalin fixation, and also reflects the fact that the primary and most striking leashes of abnormal vessels are in the submucosa.Treatment',\n",
       " 'vessels in biopsies with formalin fixation, and also reflects the fact that the primary and most striking leashes of abnormal vessels are in the submucosa.TreatmentEndoscopic obliteration of the dilated vessels by electrocoagu-lation or argon plasma coagulation is effective and has greatly reduced the need for antrectomy. Recurrence (and the need for retreatment) is not uncommon. Because atrophic gastritis is a common accompaniment, patients with watermelon stomach should have biopsies taken from the mid-body greater curvature. If atrophic gastritis is present, the patient should be monitored for the development of vitamin B12 deficiency and dysplasia [39].Portal hypertensive gastropathyA proportion of patients with cirrhosis of the liver (see Chapter 97) have dilatation of the gastric mucosal vessels, more promi-nent in the proximal stomach; its prevalence parallels the severity of portal hypertension. Bleeding is relatively uncom-mon and rarely severe, except in patients with severe portal hypertension (see Chapter 97). The endoscopic appearance of portal hypertensive gastropathy (variously described as snake skin, mosaic, scarlatina rash, and cherry-red spots) is nonspe-cific and does not correlate well with the degree of portal hypertension. Because of the understandable reluctance to biopsy the stomach of a patient with apparent portal hyper-tensive gastropathy, the contribution of histopathology to the diagnosis of portal hypertensive gastropathy is of negligible importance.Hypertrophic gastropathiesThe classic description of hypertrophic gastropathies pro-posed by Ming is still useful because it serves as a scaffold that can be adapted to new and existing entities as they are recog-Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.',\n",
       " 'Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Part 2: Diseases of the Gut and Liver246Upper GI Tract\\u2002 9.\\u2002 Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Heli\\xadcobacter pylori strains. Intern Med. 2008;47:1077–1083.10.\\u2002 Yamaoka Y, Ojo O, Fujimoto S, et al. Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut. 2006;55:775–781.11.\\u2002 Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer. 2004;4:644–653.12.\\u2002 Correa P. A new paradigm for human carcinogenesis. J Clin Gastroenterol. 2000;30:341–342.13.\\u2002 Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136:1863–1873.14.\\u2002 Genta RM, Hamner HW, Graham DY. Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol. 1993;24:577–583.15.\\u2002 Correa P, Piazuelo MB. Natural history of Helicobacter pylori infection. Dig Liver Dis. 2008;40:490–496.16.\\u2002 Sepulveda AR, Graham DY. Role of Helicobacter pylori in gastric carcinogenesis. Gastroenterol Clin North Am. 2002;31:517–35, x.17.\\u2002 Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–781.18.\\u2002 Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–1825.19.\\u2002 Graham DY, Yamaoka Y. One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm. Gut. 2007;56:1021–1023.20.\\u2002 Francavilla R, Lionetti E, Cavallo L. Sequential treatment for Helicobacter pylori eradication in children. Gut. 2008;57:1178.21.\\u2002 Marshall B. Sequential therapy for Helicobacter pylori: a worth-while effort for your patients. Ann Intern Med. 2008;148:962–963.22.\\u2002 Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential',\n",
       " '21.\\u2002 Marshall B. Sequential therapy for Helicobacter pylori: a worth-while effort for your patients. Ann Intern Med. 2008;148:962–963.22.\\u2002 Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med. 2008;148:923–931.23.\\u2002 Toh BH, van D, I, Gleeson PA. Pernicious anemia. N Engl J Med. 1997;337:1441–1448.24.\\u2002 Marshall AC, Alderuccio F, Murphy K, et al. Mechanisms of gastric mucosal cell loss in autoimmune gastritis. Int Rev Immunol. 2005;24:123–134.25.\\u2002 Amedei A, Bergman MP, Appelmelk BJ, et al. Molecular mimicry between Helicobacter pylori antigens and H+, K+ -adenosine tri-phosphatase in human gastric autoimmunity. J Exp Med. 2003;198:1147–1156.26.\\u2002 Appelmelk BJ, Faller G, Claeys D, et al. Bugs on trial: the case of Helicobacter pylori and autoimmunity. Immunol Today. 1998;19:296–299.27.\\u2002 Negrini R. Is autoimmunity involved in the relationship between Helicobacter pylori infection, atrophic gastritis and gastric cancer? Ital J Gastroenterol Hepatol.1999;31:842–845.28.\\u2002 Solcia E, Rindi G, Fiocca R, et al. Distinct patterns of chronic gastritis associated with carcinoid and cancer and their role in tumorigenesis. Yale J Biol Med. 1992;65:793–804.29.\\u2002 Carmack SW, Genta RM, Graham DY, et al. Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol. 2009;6:331–341.30.\\u2002 Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther. 2002;16:1249–1259.gastric mucosa, inhibits acid secretion, stimulates mucosal repair after injury, and augments gastric mucin levels.TreatmentA monoclonal antibody against the TGF receptor may hold some promise as a therapeutic agent. A variety of other treat-ments have been tried without uniform success. Occasionally,',\n",
       " 'TreatmentA monoclonal antibody against the TGF receptor may hold some promise as a therapeutic agent. A variety of other treat-ments have been tried without uniform success. Occasionally, total gastrectomy is required because of the relentless hypoalbuminemia and the development of persistent ana-sarca. Ménétrier’s disease appears to be associated with an increased risk of gastric adenocarcinoma; however, given the rarity of the disorder, it is unlikely that any cogent surveillance strategy will emerge.Zollinger-Ellison syndrome (see Chapter 112)The oxyntic mucosa in Zollinger-Ellison syndrome shows hyperplasia of the oxyntic compartment due to the trophic effect of circulating gastrin. As with atrophic gastritis, the hypergastrinemia can also stimulate proliferation of the ECL cells of the oxyntic mucosa, ranging from hyperplasia to the formation of gastric carcinoids.Iatrogenic gastritis and gastropathiesInjury due to NSAIDs (hemorrhagic gastritis, erosion, ulcer, and reactive gastropathy) has been discussed above. However, a variety of therapeutic agents, including radioactive and chemical, administered orally, intravenously, and intra-arterially, can also cause damage to the gastric mucosa that is detectable endoscopically and histologically.References\\u2002 1.\\u2002 Marshall BJ. The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer. JAMA. 1995;274:1064–1066.\\u2002 2.\\u2002 Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161–1181.\\u2002 3.\\u2002 Fennerty MB. Helicobacter pylori: why it still matters in 2005. Cleve Clin J Med. 2005;72 Suppl 2:S1–7; discussion S14–21.\\u2002 4.\\u2002 Stolte M, Kroher G, Meining A, et al. A comparison of Helico\\xadbacter pylori and H. heilmannii gastritis. A matched control study involving 404 patients. Scand J Gastroenterol. 1997;32:28–33.',\n",
       " '4.\\u2002 Stolte M, Kroher G, Meining A, et al. A comparison of Helico\\xadbacter pylori and H. heilmannii gastritis. A matched control study involving 404 patients. Scand J Gastroenterol. 1997;32:28–33.\\u2002 5.\\u2002 Elitsur Y, Adkins L, Saeed D, et al. Helicobacter pylori antibody profile in household members of children with H. pylori infec-tion. J Clin Gastroenterol. 1999;29:178–182.\\u2002 6.\\u2002 Luzza F, Mancuso M, Imeneo M, et al. Evidence favouring the gastro-oral route in the transmission of Helicobacter pylori infection in children. Eur J Gastroenterol Hepatol. 2000;12:623–627.\\u2002 7.\\u2002 Malaty HM, Graham DY, Wattigney WA, et al. Natural history of Helicobacter pylori infection in childhood: 12-year follow-up cohort study in a biracial community. Clin Infect Dis. 1999;28:279–282.\\u2002 8.\\u2002 Weyermann M, Adler G, Brenner H, et al. The mother as source of Helicobacter pylori infection. Epidemiology. 2006;17:332–334.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Chapter 33:\\u2002 Gastritis247Upper GI Tract35.\\u2002 Genta RM. Differential diagnosis of reactive gastropathy. Semin Diagn Pathol. 2005;22:273–283.33.\\u2002 El-Zimaity HM, Genta RM, Graham DY. Histological features  do not define NSAID-induced gastritis. Hum Pathol. 1996;27:1348–1354.37.\\u2002 Laine L, Weinstein WM. Subepithelial hemorrhages and ero-sions of human stomach. Dig Dis Sci. 1988;33:490–503.38.\\u2002 Gostout CJ, Viggiano TR, Ahlquist DA, et al. The clinical and endoscopic spectrum of the watermelon stomach. J Clin Gastro\\xadenterol. 1992;15:256–263.39.\\u2002 Labenz J, Borsch G. Bleeding watermelon stomach treated by Nd-YAG laser photocoagulation. Endoscopy. 1993;25:240–242.31.\\u2002 Carmack SW, Lash RH, Gulizia JM, et al. Lymphocytic disorders of the gastrointestinal tract: a review for the practicing patholo-gist. Adv Anat Pathol. 2009;16:290–306.32.\\u2002 Haot J, Berger F, Andre C, et al. Lymphocytic gastritis versus varioliform gastritis. A historical series revisited. J Pathol. 1989;158:19–22.33.\\u2002 Ectors NL, Dixon MF, Geboes KJ, et al. Granulomatous gastritis: a morphological and diagnostic approach. Histopathology. 1993;23:55–61.34.\\u2002 Shapiro JL, Goldblum JR, Petras RE. A clinicopathologic study of 42 patients with granulomatous gastritis. Is there really an “idiopathic” granulomatous gastritis? Am J Surg Pathol. 1996;20:462–470.Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.Created from yonseimed-ebooks on 2024-05-29 06:58:08.Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.',\n",
       " 'Gastrointestinal bleeding is a medical emergency and represents the most common cause of hospitalizations associated with digestive diseases in most countries1,2. Upper gastrointestinal bleeding (UGIB) is defined by any gastrointestinal bleeding above the ligament of Treitz, which includes the oesophagus, stomach and proximal duodenum. By contrast, middle and lower gastrointesti\\xadnal bleeding originate in the small bowel below the liga\\xadment of Treitz or in the colorectum3. UGIB events can be classified as non-variceal UGIB (NVUGIB) and variceal UGIB (VUGIB). NVUGIB is most often caused by peptic ulcers (a break of the mucosal barrier that exposes the submucosa to the damaging effects of acid and pepsin present in the gastroduodenal lumen), which are com\\xadmonly associated with Helicobacter pylori infection and the use of NSAIDs (including aspirin doses of ≥500\\u2009mg) or low-dose aspirin (LDA; which is a dose of ≤325\\u2009mg but is typically 75–100\\u2009mg). By contrast, VUGIB is caused by oesophageal or gastric varices (dilated sub\\xadmucosal veins), which are usually associated with chronic liver diseases and/or portal hypertension. The incidence of NVUGIB in most countries is fivefold higher than that of VUGIB (BOX\\xa01), and NVUGIB represents a serious clinical \\xadchallenge with considerable mortality4.In this Primer, we focus on NVUGIB in the com\\xadmunity setting, which is more common and less severe than NVUGIB in inpatient hospital settings, which occurs in association with hospitalizations due to other serious conditions (such as neurological, renal, cardiac, pulmonary, metabolic, traumatic or septic conditions). Although both conditions are life threatening, the mortality associated with NVUGIB is fourfold higher in\\xa0patients who develop bleeding in the hospital than in those who develop bleeding in the community setting4,5.EpidemiologyThe most common cause of NVUGIB is gastroduo\\xaddenal peptic ulcers followed by gastroduodenal ero\\xad',\n",
       " 'those who develop bleeding in the community setting4,5.EpidemiologyThe most common cause of NVUGIB is gastroduo\\xaddenal peptic ulcers followed by gastroduodenal ero\\xadsions, \\xadpeptic oesophageal lesions (oesophagitis or oesophageal ulcers), vascular lesions (such as Dieulafoy lesions; a\\xa0medical condition associated with an abnormal tortuous arteriole that penetrates into the gastrointesti\\xadnal mucosa) and vascular ectasias such as angio\\xaddys\\xadplasia (a small vascular malformation in the gut)), Mallory–Weiss tears (lacerations in the mucosa at the gastro-\\xadoesophageal junction that occur associated with recurrent vomiting often after excessive alcohol intake or a heavy meal) and, less often, neoplastic lesions6,7. Correspondence to A.L.Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of\\xa0Zaragoza, IIS Aragón, Zaragoza, Spain.alanas@unizar.esArticle number: 18020doi:10.1038/nrdp.2018.20Published online 19 Apr 2018Non-variceal upper gastrointestinal bleedingAngel Lanas1,2, Jean-Marc Dumonceau3, Richard H.\\xa0Hunt4, Mitsuhiro Fujishiro5, James\\xa0M.\\xa0Scheiman6, Ian M.\\xa0Gralnek7, Helen E.\\xa0Campbell8, Alaa Rostom9, Càndid\\xa0Villanueva2,10 and Joseph J. Y.\\xa0Sung11Abstract | Non-variceal upper gastrointestinal bleeding (NVUGIB) is bleeding that develops in the oesophagus, stomach or proximal duodenum. Peptic ulcers, caused by Helicobacter pylori infection or\\xa0use of NSAIDs and low-dose aspirin (LDA), are the most common cause. Although the incidence and\\xa0mortality associated with NVUGIB have been decreasing owing to considerable advances in the prevention and management of NVUGIB over the past 20\\xa0years, it remains a common clinical problem with an annual incidence of ~67 per 100,000 individuals in the United States in 2012. NVUGIB is a medical emergency, and mortality is in the range ~1–5%. After resuscitation and initial assessment, early\\xa0(within 24\\xa0hours) diagnostic and therapeutic endoscopy together with intragastric pH control',\n",
       " 'medical emergency, and mortality is in the range ~1–5%. After resuscitation and initial assessment, early\\xa0(within 24\\xa0hours) diagnostic and therapeutic endoscopy together with intragastric pH control with proton pump inhibitors (PPIs) form the basis of treatment. With a growing ageing population treated with antiplatelet and/or anticoagulant medications, the clinical management of NVUGIB is complex as\\xa0the risk between gastrointestinal bleeding events and adverse cardiovascular events needs to be balanced. The best clinical approach includes identification of risk factors and prevention of bleeding; available strategies include continuous treatment with PPIs or H.\\xa0pylori eradication in those at\\xa0increased risk of developing NVUGIB. Treatment with PPIs and/or use of cyclooxygenase‑2‑selective NSAIDs should be implemented in those patients at risk of NVUGIB who need NSAIDs and/or LDA.NATURE REVIEWS | DISEASE PRIMERS VOLUME 4 | ARTICLE NUMBER 18020 | 1PRIMER© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'Important developments in medicine in the past 20\\xa0years have affected the incidence and outcomes of NVUGIB. On the one hand, the introduction of potent medications to suppress acid secretion, the recognition of H.\\xa0pylori as an important aetiological factor of peptic ulcers with subsequent eradication therapy, the progress in diag\\xadnostic and therapeutic endoscopy, the introduction of restrictive blood transfusion policies and improvements in the management of critically ill patients are key fac\\xadtors that have reduced the risk of developing NVUGIB and have improved the management and outcomes8–11. On the other hand, some risk factors are becoming more common, including an ageing population (which results in increasing prevalence of cardiovascular dis\\xadeases and other comorbidities that increase the risk of mortality associated with NVUGIB) and the increas\\xading use of LDA, NSAIDs and other antiplatelet and anticoagulant\\xa0agents8–11.IncidenceThe overall incidence of NVUGIB, particularly bleeding events associated with peptic ulcers (that is, peptic ulcer bleeding (PUB)), has decreased during the past 20\\xa0years and has now stabilized globally9,12,13. In the United States, the incidence of NVUGIB associated with any cause has decreased from 78.4 per 100,000 individuals in 2001 to 60.6 per 100,000 individuals in 2009 (P\\u2009=\\u20090.004), and the incidence of PUB has decreased from 48.7 per 100,000 individuals in 2001 to 32.1 per 100,000 individuals in 2009 (P\\u2009<0.001) on the basis of hospital discharge data9,14. More recent data also show a 21% decrease in the inci\\xaddence of NVUGIB from 2002 to 2012, from 81\\xa0to 67 cases per 100,000 individuals15. Similar trends have been reported in Europe (FIG.\\xa01), with an incidence of NVUGIB of ~55–60 per 100,000 people in the 1990s to ~25–35 per 100,000 people in the early 2000s16–19. However, data are difficult to compare between stud\\xadies owing to variability in the methodology used. Time',\n",
       " 'to ~25–35 per 100,000 people in the early 2000s16–19. However, data are difficult to compare between stud\\xadies owing to variability in the methodology used. Time trends of NVUGIB are less well documented outside Europe and the United States, but a few studies show a similar decline in incidence20.Although differences in incidence might be evident between ethnicities, studies are limited21. For example, in New Zealand, age-adjusted incidence seems higher among people of Maori descent than in those of European descent (91.3 versus 37.0 per 100,000 \\xadindividuals, rate ratio of 2.47, P\\u2009<0.001)22.Causes of NVUGIBThe causes of NVUGIB have changed over time. Erosive gastritis as a cause of NVUGIB declined by 55% in the United States between 2001 and 2009 and peptic ulcers as a cause declined by 30%. By contrast, NVUGIB due to neoplasm increased by 50%, as did Dieulafoy lesions (33%), angiodysplasia (32%) and oesophagitis (20%)15. The decreased incidence of PUB in developed countries is linked to a decreased prevalence of H.\\xa0pylori and an increased use of gastric-acid-suppressing drugs, which protects against peptic ulcer diseases3. Globally, the life\\xadtime prevalence of peptic ulcer disease in the general population has been estimated at ~5–10% and the inci\\xaddence at 0.1–0.3% per year3,11–13. However, despite the decrease in PUB in the general population in developed countries, the incidence of PUB in elderly individuals is increasing (on the basis of hospital admissions for ulcer complications), which can probably be attributed to the ageing population3,18,23. Overall, compared with decades ago, fewer individuals with PUB are positive for H.\\xa0pylori, whereas PUB associated with NSAID use or not related to either NSAIDs or H.\\xa0pylori has increased24,25. In a multicentre study in France, 40% of PUB events were related to H.\\xa0pylori infection, 18.7% to gastrotoxic drug use, 19.8% to both factors and 21.6% were unrelated to either H.\\xa0pylori infection or gastrotoxic',\n",
       " 'PUB events were related to H.\\xa0pylori infection, 18.7% to gastrotoxic drug use, 19.8% to both factors and 21.6% were unrelated to either H.\\xa0pylori infection or gastrotoxic drug\\xa0use26.Similar trends can be observed in some Asian popu\\xadlations. In 2001, one study conducted in Hong Kong reported that only 4.1% of PUB cases were unrelated to NSAID use, LDA use or H.\\xa0pylori infection, whereas the remaining 51.9% of cases were related to H.\\xa0pylori infection and 44% to NSAID or LDA use27. However, other studies conducted more recently have reported rates of idiopathic peptic ulcers of 23.5% in Korea28 and 13.8–18.8% in Hong\\xa0Kong29,30. In\\xa0a 2014 review, the prevalence of idiopathic ulcers in Asia was reported as 10–30% since the year 2000 (REF.\\xa031).MortalityOverall global mortality associated with NVUGIB has decreased over time6,13. A large case–control study including >500,000 individuals with NVUGIB in England showed that mortality within 28\\xa0days of hos\\xadpital admission significantly decreased from 14.7% in 1999 to 13.1% in 2007, even after adjusting for age, sex and comorbidities32. Large observational studies docu\\xadmented an improvement in survival in the United States across various age groups along a similar time range9,33,34. Mortality associated with gastric and duo\\xaddenal ulcers also declined in Argentina, Australia, Chile, Hong Kong, Japan, Mexico, Singapore and Taiwan between 1971 and 2004 (REF.\\xa020). Interestingly, mortality associ\\xadated with gastric ulcers compared with duodenal ulcers Author addresses1Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, Zaragoza, Spain.2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.3Gedyt Endoscopy Center, Buenos Aires, Argentina.4Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.',\n",
       " 'Madrid, Spain.3Gedyt Endoscopy Center, Buenos Aires, Argentina.4Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.5Department of Endoscopy and Endoscopic Surgery, Graduate School of Medicine, The\\xa0University of Tokyo, Tokyo, Japan.6Division of Gastroenterology, University of Virginia, Charlottesville, VA, USA.7Ellen and Pinchas Mamber Institute of Gastroenterology, Emek Medical Center, Afula, Israel.8National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.9Division of Gastroenterology, University of Ottawa, Ottawa, Ontario, Canada.10Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain.11Division of Gastroenterology, The Chinese University of Hong Kong, Hong Kong, China.PRIMER2 | ARTICLE NUMBER 18020 | VOLUME 4www.nature.com/nrdp© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'was threefold higher in Mexico, twofold higher in Argentina and Chile and only slightly higher in Taiwan and Singapore, whereas no difference was observed in Hong\\xa0Kong.Despite these improvements, mortality associ\\xadated with NVUGIB remains high, with values varying between different studies and stable, non-\\xaddecreasing \\xadvalues over time in some countries (for example, Spain)17. A systematic review of 18 studies showed mortality of NVUGIB ranging from 1.1% in Japan to 11% in Denmark, although most studies included in the review placed that figure closer to 5%35. These dis\\xadcrepancies in the reported mortality of NVUGIB are attributable to differences in study methodologies and populations\\xa0studied.Improvement in NVUGIB outcomes is likely due to factors such as advances in endoscopic and med\\xadical manage\\xadment and improvements in emergency and critical care or geriatric medicine8,10,11. Risk factors for mortality linked to NVUGIB include increased age, comorbidities (such as respiratory or cardiac insufficiency, renal failure and sepsis), severe haemo\\xaddynamic instability or develop\\xadment of further bleed\\xading36. However, at present, most deaths associated with NVUGIB are not due to uncontrolled bleeding but are the consequence of complications induced by bleeding (for example, organ \\xadfailure), comorbidities or older\\xa0age4.Mechanisms/pathophysiologyThe mechanisms involved in the development of NVUGIB are not well understood. The mucosal \\xadbarrier and submucosal blood vessels must be damaged for the bleeding event to occur. Disruption of the mucosal \\xadbarrier is commonly associated with H.\\xa0pylori infection and/or NSAID or LDA use, but exposure of the blood vessels to the luminal content can also be the conse\\xadquence of causes such as Mallory–Weis syndrome, vascular lesions and neoplastic lesions. Whatever the cause, exposure of the underlying blood vessels to the\\xa0action of acid and pepsin further erodes the vessel wall and interferes with blood coagulation3 (FIG.\\xa02).',\n",
       " 'cause, exposure of the underlying blood vessels to the\\xa0action of acid and pepsin further erodes the vessel wall and interferes with blood coagulation3 (FIG.\\xa02).Mucosal damageH.\\xa0pylori infection. Mucosal damage and ulcer forma\\xadtion are considered to be consequences of the inter\\xadaction between H.\\xa0pylori and the host immune response. H.\\xa0pylori strains show genetic diversity, but those that exhibit a cag pathogenic island encoding virulence fac\\xadtors such as cytotoxicity-associated immunodominant antigen (CagA), vacuolating cytotoxin autotransporter (VacA), blood group antigen-binding adhesin (BabA) or outer inflammatory protein adhesin (OipA) strongly induce the host immune response3,37,38. This immune response is initiated in the gastric epithelium, where these bacterial virulence factors elicit an intracellu\\xadlar cascade of events that activate kinases involved in the\\xa0regulation of cell growth and differentiation and the nuclear factor-κB (NF-κB) signalling pathway. Cytokines that have a key role in the immune and inflammatory response to H.\\xa0pylori infection include IL‑1β, IL‑1 recep\\xadtor antagonist protein (IL1RN), tumour necrosis factor (TNF), IL‑6, IL‑8 and IL‑10\\xa0(REFS\\xa03,38).H.\\xa0pylori induces different types of lesions in the \\xadlining of the stomach and duodenum, most commonly mild asymptomatic gastritis. Pan-gastritis is associ\\xadated with hyposecretion of gastric acid and is linked to the development of gastric ulcers. However, some patients develop an antrum-predominant gastritis that is associ\\xadated with duodenal ulcers and increased \\xadgastric acid\\xa0secretion due to hypersecretion of gastrin and hypo\\xadsecretion of somatostatin3,39. Gastric acid hyper\\xadsecretion in antrum-\\xadpredominant gastritis is associated with the development of gastric metaplasia in the duo\\xaddenal bulb, which may be colonized by H.\\xa0pylori and favour ulcer\\xa0formation3,40.NSAID and LDA use. Studies have shown that NSAIDs and LDA induce damage to the gastroduodenal mucosa',\n",
       " 'denal bulb, which may be colonized by H.\\xa0pylori and favour ulcer\\xa0formation3,40.NSAID and LDA use. Studies have shown that NSAIDs and LDA induce damage to the gastroduodenal mucosa by both systemic and local effects41. Locally, NSAIDs and LDA can decrease the hydrophobicity of the mucous layer owing to their amphiphilic properties, thereby exposing the underlying epithelium to luminal acid and pepsin. NSAIDs also uncouple mitochondrial oxid\\xadative phosphorylation in the epithelial cells, lead\\xading to cellular dysfunction with decreased levels of ATP and glutathione, mitochondrial swelling, generation of free radicals, calcium release into the cytosol and, eventually, loss of integrity of tight junctions, apop\\xadtosis and cell death, all contributing to increased mucosal \\xadpermeability and disruption.The local effects of NSAIDs depend on their acid dissociation constant; acidic NSAIDs are not ionized at the low pH of the gastric lumen and can, therefore, be absorbed by epithelial cells, where they become ‘trapped’ because of the neutral intracellular pH. The ability of an NSAID to uncouple mitochondrial oxid\\xadative phosphoryl\\xadation (that is, its uncoupling potency) is also directly proportional to its acid dissociation Box 1 | Variceal upper gastrointestinal bleedingVariceal upper gastrointestinal bleeding (VUGIB) is due to portal hypertension and/or chronic liver diseases and in most cases is associated with liver cirrhosis. Presentation often involves vomiting large amounts of ‘fresh’ red blood. The first-line therapy combines vasoactive drugs and variceal ligation. Drugs with vasoactive properties, such\\xa0as terlipressin, somatostatin or octreotide, should be given as soon as acute VUGIB is suspected. Upper gastrointestinal endoscopy should be performed within the first 12\\xa0hours after admission once haemodynamic stability has been achieved to ascertain the cause of haemorrhage; when VUGIB is confirmed, ligation should be performed',\n",
       " '12\\xa0hours after admission once haemodynamic stability has been achieved to ascertain the cause of haemorrhage; when VUGIB is confirmed, ligation should be performed within the same procedure. Early pre-emptive insertion of a covered (that is, with fabric or graft material over the metal structure) transjugular intrahepatic portosystemic shunt to treat portal hypertension should be considered in patients with high risk of failure of endoscopic ligation or when failure develops. Balloon tamponade (in which an inflated balloon applies pressure to compress bleeding varices) in the oesophagus or stomach should be used in cases of uncontrolled bleeding as a temporary measure (<24\\xa0hours) until definitive treatment can be instituted. Removable, covered and self-expanding oesophageal stents are a promising alternative to balloon tamponade. Eventually, liver transplantation should be considered when bleeding is not controlled after transjugular intrahepatic portosystemic shunt insertion and when liver function has deteriorated. Peptic ulcer bleeding (that is, non-variceal bleeding) in patients with cirrhosis has a mortality similar to that of VUGIB with a similar incidence of complications and decompensation of liver disease, which account for a great proportion of fatalities201,202.PRIMERNATURE REVIEWS | DISEASE PRIMERS VOLUME 4 | ARTICLE NUMBER 18020 | 3© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'constant, with acidic NSAIDs being the most potent. Consequently, use of acidic NSAIDs (including aspirin) may need to be combined with proton pump inhibitors (PPIs) in some high-risk patients (see below); non-acidic NSAIDs (such as paracetamol) are \\xadconsidered safer for the gastrointestinal tract41.Systemically, NSAIDs contribute to mucosal dam\\xadage by inhibiting the prostaglandin secretion associated with cyclooxygenase 1 (COX1; also known as PTGS1) and COX2. The reduction in prostaglandin levels dis\\xadrupts the mucosal barrier as prostaglandins stimulate mucous and bicarbonate secretion by epithelial cells, inhibit acid secretion and promote cell proliferation and mucosal blood flow. The ischaemic effect of NSAIDs leads to increased leukocyte adherence, damaging blood \\xadvessels. The gastric mucosa is especially sensitive to the reduced COX1‑derived prostaglandin levels compared with other segments of the gastrointestinal tract42 for reasons that are not yet\\xa0clear. COX2 is not expressed in the absence of a pre-existing lesion or H.\\xa0pylori infec\\xadtion. However, given that H.\\xa0pylori infections are fre\\xadquent, many patients who take NSAIDs or LDA may be infected, which seems to exacerbate the potential \\xaddamaging effects of these drugs41,43.BleedingRole of pH. The coagulation system is extremely sen\\xadsitive to minor pH changes. In vitro studies show that coagulation becomes abnormal at pH 6.8, platelet aggregation reduces by >50% at pH 6.4 and platelet aggregation and plasma coagulation are abolished and previously aggregated platelets disaggregate at a pH <5.9  (REF.\\xa044). In addition, an increase in pH to 6.8 (or\\xa0even slightly higher) induces platelet aggregation, calcium release and serotonin release from the platelets as well as normaliza\\xadtion of the blood clotting time (meas\\xadured using \\xadprothrombin and partial \\xadthromboplastin times)44\\xa0(FIG.\\xa03).Pepsin, a proteolytic enzyme that becomes activated at pH <6, further enhances platelet disaggregation and',\n",
       " 'ured using \\xadprothrombin and partial \\xadthromboplastin times)44\\xa0(FIG.\\xa03).Pepsin, a proteolytic enzyme that becomes activated at pH <6, further enhances platelet disaggregation and clot disintegration44. Acid, pepsin and other proteolytic enzymes are present in abundance in the gastric lumen; these circumstances make the stomach and proximal duodenum a hostile environment that facilitates contin\\xadued bleeding once the blood vessel is breached. Thus, the medical treatment of bleeding lesions aims at attempt\\xading to keep the gastric pH above the proteolytic range for pepsin (that is, pH >6). Current medical treatment with a high-dose PPI is able to achieve this pH target45–47. As\\xa0PPIs suppress acid secretion by covalent binding of the protonated drug to activated proton pumps, which are at rest in the cytoplasm in the fasting patient, the use of PPI therapy provides highly effective pH control following endoscopic treatment.Some studies have shown clinical benefits of main\\xadtaining an intragastric pH >6 during the bleeding epi\\xadsode. A meta-analysis48 showed a significant decrease in further bleeding, need for surgery and mortality among patients with high-risk bleeding ulcers after endoscopic therapy and high-dose continuous infusion with PPIs when compared with placebo.Inhibition of platelets. In addition to mucosal damage, NSAIDs and LDA might also contribute to bleeding by inhibiting the formation of thromboxane A2 in platelets. Platelet COX1‑derived thromboxane A2 is activated to control bleeding following damage to blood\\xa0vessels (FIG.\\xa02). A similar mechanism has been proposed for non-aspirin antiplatelet agents49.Some have questioned the mucosal-damaging \\xadcapacity of LDA and have suggested that the role of LDA in NVUGIB is mainly due to its antiplatelet effect. In this context, the antiplatelet effect would be similar to that of anticoagulants such as vitamin\\xa0K antagonists, which do not produce mucosal damage but may induce severe',\n",
       " 'context, the antiplatelet effect would be similar to that of anticoagulants such as vitamin\\xa0K antagonists, which do not produce mucosal damage but may induce severe bleeding of gastrointestinal lesions caused by other agents (such as NSAIDs and H.\\xa0pylori). If so, LDA and non-aspirin antiplatelet agents would induce bleeding only in patients with pre-existing lesions. This hypoth\\xadesis is supported by one study involving individuals with osteoarthritis, in whom the rate of peptic ulcers did not differ between those taking LDA and those \\xadtaking \\xadplacebo50. However, this finding must be interpreted with caution because other studies have shown that even LDA can damage the gastrointestinal mucosa42.Another intriguing question is why NSAIDs and LDA have a universal effect on platelet and COX inhib\\xadition, but only 1 in 1,000 individuals51 receiving these agents eventually develop NVUGIB, prompting an examin\\xadation of susceptibility\\xa0factors. One study found that some patients who developed a bleeding event after LDA use were hyper-responsive to the drug, as\\xa0demonstrated by an abnormal prolonged bleeding time due to an \\xadunexplained intrinsic defect, subclin\\xadical\\xa0von\\xa0Willebrand\\xa0disease (in\\xa0which the clotting protein von Willebrand factor (vWF) is missing or defective) or abnormalities in aspi\\xadrin metabolism52. Polymorphisms in genes encoding proteins involved in drug metabolism, mucosal defence or coagulation have been proposed to increase the risk of PUB in NSAID or LDA users, but more studies are needed before these factors can be taken into account for clinical purposes3,53.Nature Reviews | Disease PrimersChange in the incidence of NVUGIB (%)–60–50–40–30–20–100Netherlands1993–2000Italy2001–2010Sweden1987–2005Spain1996–2005United States1994–2009New Zealand2001–2010Figure 1 | The decline in incidence of NVUGIB over time. Percentage decrements in\\xa0the incidence of non-variceal upper gastrointestinal bleeding (NVUGIB) in different',\n",
       " '1994–2009New Zealand2001–2010Figure 1 | The decline in incidence of NVUGIB over time. Percentage decrements in\\xa0the incidence of non-variceal upper gastrointestinal bleeding (NVUGIB) in different countries over different time periods as indicated. Graph based on data presented in\\xa0REFS\\xa09,11–14,16–20,22,23,218,219.PRIMER4 | ARTICLE NUMBER 18020 | VOLUME 4www.nature.com/nrdp© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'Mallory–Weiss syndrome. In Mallory–Weiss syn\\xaddrome, mucosal disruption and laceration result from several factors, including a rapid increase of pressure in the upper part of the stomach (the cardia)54,55. The consequent hyperextension of the stomach limits the mobility between the mucosa and submucosa, resulting in insuffi\\xadcient closure of the cardia. Furthermore, dis\\xadcoordinated muscle contractions of the different layers in the lower part of the oesophagus and cardia, together with the longitudinal disposition of gastric mucosal folds at the\\xa0gastro-oesophageal junction, lead to deep linear lacerations of the mucosa that expose submucosal vessels that are also damaged in this process. Age-related loss of collagen in the submucosal layers may contribute to loss of mucosal–submucosal mobility55. The common location of the most severe lacerations is the right lateral wall of the stomach, where the oesophagus is aligned with the lesser curvature of the stomach54 owing to dif\\xadferent thicknesses and ligament arrangements of the gastric\\xa0tissues55.Vascular lesions. Vascular lesions such as those that occur in Dieulafoy syndrome and vascular ectasias are associated with NVUGIB15. The Dieulafoy lesion involves an artery with an abnormally large diameter (1–3\\u2009mm) that penetrates the submucosa, runs a tor\\xadtuous course and protrudes into the mucosa, where a small defect with fibrinoid necrosis initiates a subse\\xadquent severe bleeding event. The bleeding lesion may be induced by local thrombosis or by ischaemia in the artery due to pulsation of the vessel, which damages the overlying epithelium and exposes the vessel to the gastrointestinal lumen. Dieulafoy and vascular lesions often occur in elderly individuals and are associated with severe comorbidities56.Bleeding from vascular ectasias such as angiodys\\xadplasia of the stomach may have a similar pathogenetic profile as Dieulafoy lesions. Intermittent submucosal venous obstruction, intermittent arterial blood flow',\n",
       " 'plasia of the stomach may have a similar pathogenetic profile as Dieulafoy lesions. Intermittent submucosal venous obstruction, intermittent arterial blood flow and local vascular degeneration with local hypox\\xadaemia and vascular endothelial growth factor-dependent proliferation have been proposed as being involved in these bleeding events. Association with cardiac, renal and other comorbidities is also common. Vascular \\xadectasias, often multiple or diffuse, predominantly occur in the gastric antrum, which may be linked with the more vigor\\xadous muscular contraction of the antrum, \\xadpredisposing to venous obstruction57,58 (FIG.\\xa04).Other comorbidities. Several non-gastrointestinal comorbidities are independent risk factors for developing NVUGIB59; the mechanisms involved depend on the type of comorbidity. Reduced mucosal microperfusion and hypoxia can be important in patients with heart failure60; furthermore, chronic hypoxia and increased concentra\\xadtion of mucosal free radicals, corresponding to systemic inflammation, have been identified as important fac\\xadtors in patients with chronic pulmonary obstruction61, GreatercurvatureLessercurvatureNature Reviews | Disease PrimersSubmucosalarteryH. pyloriMucousNecrotic cellActivated plateletsAspirinPlateletsNSAIDsLDALocaleﬀectsAcid PepsinBodyDuodenumOesophagusLigamentof TreitzMucosal breakBleedingGastric lumen↓ Cell proliferation↓ HCO3– secretion↓ MucusSystemic eﬀects↓ COX1↓ ProstaglandinsMucosaldamageBlood clotInhibition of thrombosis↓ pHFundusAntrumCardiaInﬂammatory responseH. pyloriFigure 2 | Mechanisms of upper gastrointestinal bleeding induced by NSAIDs, LDA or H.\\xa0pylori infection. NSAIDs (including aspirin doses of ≥500\\u2009mg) or low-dose aspirin (LDA; which is a dose of ≤325\\u2009mg but is typically 75–100\\u2009mg) induce a break in the mucosa by acting both locally and systemically, whereas Helicobacter pylori damages the epithelial',\n",
       " 'induce a break in the mucosa by acting both locally and systemically, whereas Helicobacter pylori damages the epithelial barrier by inducing a cytokine-mediated host immune response. Once the mucosal barrier is disrupted, the underlying blood vessels are exposed to gastric acid and pepsin, which affect blood vessel integrity and can induce bleeding. Platelets and the coagulation system, which should be activated to stop the bleeding, are inhibited by the low pH and pepsin. In addition, platelet cyclooxygenase 1 (COX1) activity suppression by LDA inhibits thromboxane formation and,\\xa0therefore, platelet aggregation and clot formation. HCO3−, bicarbonate.PRIMERNATURE REVIEWS | DISEASE PRIMERS VOLUME 4 | ARTICLE NUMBER 18020 | 5© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'whereas platelet and clotting dysfunction, platelet–\\xadvessel interaction and haemodynamic instability are mech\\xadanisms involved in end-stage renal disease-\\xadassociated gastrointestinal bleeding62. Most of these conditions are also associated with poor nutritional \\xadstatus, which, together with the common use of LDA, antiplatelet thera\\xadpies, anticoagulants and NSAIDs in these conditions, may contribute to gastrointestinal mucosa \\xaddamage. Most of these mechanisms, especially those related to altered microperfusion, hypoxia, free radical concen\\xadtration and pH, are also involved in diffuse mucosal damage or stress ulcers in patients needing \\xadrespiratory assistance in the intensive care setting60,61 (FIG.\\xa04).Diagnosis, screening and preventionPreventionRisk stratification. Prevention of bleeding events is the best clinical approach in NVUGIB. A careful medical history, physical examination and laboratory investi\\xadgations provide the basis to identify risk factors and comorbid conditions (BOX\\xa02) and to select a sound pre\\xadvention strategy, which should balance the benefits and risks of preventive measures. In NSAID and LDA users, balancing risks is especially important when cardio\\xadvascular and gastrointestinal risk factors are both present. Some risk factors can be easily identified and prevented or discontinued63,64, whereas others are not (such as advanced age or the presence of comorbidi\\xadties)59 (FIG.\\xa04). The risk of developing bleeding increases with the presence and number of risk factors, in addi\\xadtion to NSAID and LDA use, and appreciation of these factors offers the opportunity to stratify patients into risk categor\\xadies65,66. Those taking NSAIDs or LDA with no other identified risk factors are at low risk of ulcer bleeding complications, whereas individuals with one or more risk factors have increased risk. A history of previ\\xadous ulcers puts any patient \\xadreceiving NSAIDs or LDA at high risk of NVUGIB67.Preventive strategies. The role of preventive treat\\xad',\n",
       " 'more risk factors have increased risk. A history of previ\\xadous ulcers puts any patient \\xadreceiving NSAIDs or LDA at high risk of NVUGIB67.Preventive strategies. The role of preventive treat\\xadment has not been systematically evaluated but should be considered in patients with one or more risk factor when using NSAIDs or LDA67; however, prevention is rarely required for low-risk patients. Acid suppression with antisecretory drugs is recommended in the pres\\xadence of risk factors; PPIs are preferred and are superior to histamine H2 receptor antagonists67. Prostaglandins (such as misoprostol) are cytoprotective and effec\\xadtive in reducing acid secretion, but at the expense of adverse events that reduce their tolerability67. In those who have a history of peptic ulcers, the risk associ\\xadated with NSAID use can be modified first by treating H.\\xa0pylori infection if present and then by switching to a COX2‑selective NSAID. Eradication of H.\\xa0pylori infec\\xadtion in those taking NSAIDs\\xa0or LDA can considerably reduce, although not abolish, the risk of ulcers, bleeding or re‑bleeding\\xa0events68,69.Concomitant NSAID treatment with several other drugs increases the risk of developing gastrointestinal bleeding64,66,70 (BOX\\xa02;\\xa0FIG.\\xa05), but the risk might be modi\\xadfied by co‑treatment with antisecretory drugs. Indeed, use of omeprazole (a PPI) while continuing clopidogrel treatment decreases the number of gastrointestinal bleeding events without an increase in cardiovascular adverse events71. Monitoring international normal\\xadized ratio (INR; a parameter used to standardize pro\\xadthrombin time) is indicated when a PPI is started or stopped in patients on vitamin\\xa0K antagonists. Indeed, the metabolism of PPIs involves the hepatic cytochrome P450 (CYP) enzyme system, which might affect metabo\\xadlism or activation of drugs taken concomitantly. How different PPIs interact with different CYPs might inform PPI choice. For example, the selection of pantoprazole',\n",
       " 'lism or activation of drugs taken concomitantly. How different PPIs interact with different CYPs might inform PPI choice. For example, the selection of pantoprazole and rabeprazole rather than other PPIs has been recom\\xadmended in patients taking vitamin\\xa0K antagonists, but the real clinical impact of this recommendation remains to be shown72. The identification of polymorphisms lead\\xading to poor metabolism of PPIs in the CYP2C19 gene in a Japanese population could be predictive of adverse events73. These findings could also be extended to other populations, but additional studies are needed. To date, no interaction has been reported with novel direct oral anticoagulants (DOACs) and CYP enzymes. When using corticosteroids, PPI treatment should be considered if an individual has a history of peptic ulcers or in the case of combined corticosteroid and NSAID or LDA use67.Identification of a history of uncomplicated or com\\xadplicated ulcers should prompt a test-and-treat strategy for H.\\xa0pylori infection to prevent a first-bleeding or re‑\\xadbleeding event74,75. Identification of H.\\xa0pylori infec\\xadtion during a bleeding event represents a clin\\xadical chal\\xadlenge, as an invasive test such as urease testing during the endoscopic procedure may provide false-\\xadnegative results owing to the presence of blood in the gastric lumen, \\xadinadequate sampling or the previous use of\\xa0PPIs. Nature Reviews | Disease PrimersAggregation (%)100706050403020100214Time (minutes)0908035pH 7.4pH 5.9pH 6.8AADPFigure 3 | Effects of an acidic environment on platelet aggregation. At pH 7.4, platelet aggregation induced by ADP is normal and occurs rapidly. Arrow A denotes the time point at which the pH of plasma is decreased by the addition of hydrochloric acid in an experimental setting. At\\xa0pH 6.8, platelet aggregation is negatively affected, and\\xa0at pH 5.9, it is completely abolished. Adapted with permission from REF.\\xa044.PRIMER6 | ARTICLE NUMBER 18020 | VOLUME 4',\n",
       " 'At\\xa0pH 6.8, platelet aggregation is negatively affected, and\\xa0at pH 5.9, it is completely abolished. Adapted with permission from REF.\\xa044.PRIMER6 | ARTICLE NUMBER 18020 | VOLUME 4www.nature.com/nrdp© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'Histological analysis and/or culture of biopsy speci\\xadmens may also provide false-negative results76. In this clinical scenario, the presence of H.\\xa0pylori infection should be tested or retested if negative after ulcer healing (4–8\\xa0weeks after the bleeding event) with patients being off PPI for at least 7\\xa0days and no antibiotic therapy the month before. A positive test should prompt eradication therapy with a confirmatory negative test performed at\\xa0least 1\\xa0month after therapy3,75,76.DiagnosisIn clinical practice, the diagnosis and management of NVUGIB are intermingled. Following resuscitation and initial assessment, pre-endoscopic management is per\\xadformed followed by endoscopic diagnosis and endoscopic management. For example, medical treatment with, for example, PPIs, is often started before endoscopic diag\\xadnosis and treatment. In this Primer, we \\xaddiscuss the \\xaddiagnosis and management options separately.Initial, pre-endoscopic assessment. The presentation of overt NVUGIB varies considerably from asymptomatic outpatients with melena (black faeces due to the pres\\xadence of blood) to those presenting with large-volume haematemesis (vomiting of blood), passage of ‘fresh’ red blood, severe hypotension and a compromised airway. The presence of haematemesis indicates that the source of the bleeding is the upper gastrointestinal tract (above the ligament of Treitz), whereas the source of bleeding in most individuals with melena is also the upper gastro\\xadintestinal tract (90%), but the small bowel and ascending colon cannot be excluded. Caution should be taken to exclude oral or nasopharyngeal sources of bleeding as patients who swallow fresh blood might present with haematemesis or melena. The probability that a patient has NVUGIB is higher when melena is observed on rectal examination than with patient-reported history of melena or the presence of blood clots in the stool77.The initial assessment and management of these',\n",
       " 'rectal examination than with patient-reported history of melena or the presence of blood clots in the stool77.The initial assessment and management of these patients is focused on emergency assessment and stabiliza\\xadtion protocols aimed at restoring and protect\\xading the airway and maintaining the circulation followed by NVUGIB-specific pre-endoscopic assessment and interventions. In a minority of patients who present with large-volume haematemesis and/or diminished level of consciousness, orotracheal intubation should be consid\\xadered to protect the airway and to facilitate initial resusci\\xadtation and subsequent endoscopy in the emergency setting. Blood should be drawn during catheter insertion to analyse complete blood count, INR, electrolytes, urea, albumin, creatinine and liver enzymes. Additional blood tests or investigations can be performed depending on the underlying comorbidities5,78.During initial resuscitation, a directed history and physical exam is conducted and aimed at ascertaining the potential aetiology for the gastrointestinal bleeding and identifying important risk factors and comorbidi\\xadties that modify survival and warrant lowered thresh\\xadolds for transfusion or early endoscopy. A digital rectal examination enables verification of the presence of either melena or blood and may avoid unnecessary \\xadconfirmatory\\xa0tests79.Nature Reviews | Disease PrimersRisk factorsComorbiditiesDysregulated processesGastrointestinal pathologyNVUGIB• Renal insuﬃciency• Cardiovascular  disease• Pulmonary  insuﬃciency• Coagulopathy• Organ failure• Age• Other  comorbiditiesGenetic predisposition• Angiodysplasia• Vascular lesions• Ischaemia• Fibrinoid necrosis• DegenerationMucosal damage• Chronic hypoxia• Free radicals• Clotting  dysfunction• Altered  microperfusion• Systemic  inﬂammatory  statusGastric cancerGenetic predisposition• COX inhibition• Vascular damage• Non-selective NSAIDs• LDA• COX2 inhibitorsInﬂammationH. pylori',\n",
       " '• Altered  microperfusion• Systemic  inﬂammatory  statusGastric cancerGenetic predisposition• COX inhibition• Vascular damage• Non-selective NSAIDs• LDA• COX2 inhibitorsInﬂammationH. pyloriinfectionPrevious inﬂammatoryconditionsVirulencefactorsImmune responsecytokinesSmokingInhibition ofcoagulating factorsInhibition ofplatelet activationMallory–WeissSyndrome• Vitamin K  antagonists• DOACs• P2Y12\\xa0antagonists• SSRIs• LDA• NSAIDs• Excessive alcohol intake• Heavy meals• Other conditionsSteroidsVomitingFigure 4 | Complex pathophysiology of NVUGIB. Many factors contribute to the development of non-variceal upper gastrointestinal bleeding (NVUGIB). Bleeding is usually the result of mucosal damage induced by drugs such as NSAIDs or\\xa0low-dose aspirin (LDA; typically 75–100\\u2009mg) or is often associated with Helicobacter pylori infection. Additional risk factors\\xa0or comorbidities might make the gastrointestinal mucosa more susceptible to bleeding. NVUGIB can also be the consequence of vascular lesions, which are also often associated with ageing or comorbidities. Bleeding from these lesions may be precipitated by antiplatelet or anticoagulation agents, which can also act on pre-existing mucosal damage induced by other factors, or other pathogenetic mechanisms, such as Mallory–Weiss syndrome or gastric carcinoma59. COX, cyclooxygenase; DOAC, direct oral anticoagulant; P2Y12, P2Y purinoceptor 12; SSRI, selective serotonin reuptake inhibitor.PRIMERNATURE REVIEWS | DISEASE PRIMERS VOLUME 4 | ARTICLE NUMBER 18020 | 7© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'Each patient presenting with NVUGIB should have pre-endoscopic risk stratification. Among the different risk-scoring systems (BOX\\xa03), the Glasgow–Blatchford Score (GBS) performs well80 and is used globally. The GBS performs better at predicting intervention, compli\\xadcations or death than the full (preadmission and post-\\xadendoscopy) Rockall score, the admission Rockall score, the AIMS65 score and the Progetto Nazionale Emorragia Digestiva (PNED) score80. The PNED and AIMS65 scores perform best at predicting mortality80. In general, high-risk patients are those who present with hypotension, vomiting of bright red (fresh) blood, passage of red blood per rectum (in the setting of NVUGIB) and/or have con\\xadsiderable comorbidities and are of advanced age. These patients have an increased risk of mortality and require careful assessment and early management.In individuals who develop NVUGIB when on anti\\xadplatelet or anticoagulation therapy to prevent cardio\\xadvascular events, this treatment should generally be stopped and/or reversed. However, endoscopy should usually not be delayed until the action of the anticoagu\\xadlant is completely reversed. An INR <2.5 is adequate and enables successful endoscopic management if needed5,81. The decision to stop and when to resume antiplatelet anticoagulant agents at the time of NVUGIB is difficult and should be guided by post-endoscopy risk assess\\xadment and \\xadconsultation with a cardiologist (discussed in detail\\xa0below).Endoscopy. Endoscopy is essential to reveal the cause of NVUGIB, and early upper gastrointestinal endoscopy within 24\\xa0hours of presentation improves patient out\\xadcomes82–84. Several studies have found no differences in outcomes between patients who undergo early endoscopy and those undergoing very early endoscopy (<12\\xa0hours of patient presentation)85–87. Nevertheless, controversy per\\xadsists because very early endoscopy reveals active bleed\\xading stigmata and need of endoscopic treatment of lesions',\n",
       " 'patient presentation)85–87. Nevertheless, controversy per\\xadsists because very early endoscopy reveals active bleed\\xading stigmata and need of endoscopic treatment of lesions without evidence of reduction of the risk of re-bleeding or improved survival88,89.Endoscopy should be used to diagnose the cause of the bleeding and evaluate stigmata of recent haemorrhage (such as active bleeding, a visible blood vessel, presence of clots or red or black spots covering the ulcer lesion) and to classify them according the Forrest classification, which enables patient selection for endoscopic treatment and stratification of the risks of re-bleeding, surgery and mor\\xadtality90–92 (TABLE\\xa01). Of note, the interobserver agreement for the Forrest classification is low to moderate93. Vigorous water irrigation on the ulcer base is \\xadrecommended to improve the accuracy of Forrest\\xa0classification.Endoscopic treatment should be provided to patients with bleeding of Forrest types Ia, Ib and IIa. A meta-\\xadanalysis of randomized clinical trials (RCTs) confirmed that endoscopic therapy was effective in preventing per\\xadsistent or recurrent bleeding in Forrest types Ia and\\xa0Ib (relative risk (RR) 0.29, 95%\\xa0CI 0.20–0.43; \\xadnumber needed to treat (NNT) 2, 95%\\xa0CI 2–2) and Forrest type\\xa0IIa (RR\\xa00.49, 95%\\xa0CI 0.40–0.59; NNT 5, 95%\\xa0CI 4–6) compared with no endoscopic therapy94. The necessity for endoscopic treatment in patients with Forrest type\\xa0IIb bleeding, which is defined as a lesion with a clot that is red, maroon or black in colour and amorphous in \\xadtexture and that cannot be dislodged by suction or forceful water irrigation, remains controversial. The above-mentioned meta-analysis showed no benefit for endoscopic ther\\xadapy in Forrest type\\xa0IIb bleeding94; however, the studies included showed significant hetero\\xadgeneity, with two concluding that there was a bene\\xadficial effect of com\\xadbining therapeutic endoscopy with intra\\xadvenous PPI therapy compared with PPI alone95,96. Thus, at\\xa0present,',\n",
       " 'concluding that there was a bene\\xadficial effect of com\\xadbining therapeutic endoscopy with intra\\xadvenous PPI therapy compared with PPI alone95,96. Thus, at\\xa0present, the approach to managing patients with Forrest type\\xa0IIb bleeding should be determined on a case‑by‑case basis, considering, among others, medical resources, \\xadendoscopist experience and patient\\xa0status.Stigmata of recent haemorrhage, which are visible on endoscopy, have been used for decades to make risk stratification and treatment decisions in NVUGIB, but Doppler assessments of arterial blood flow in the gastro\\xadintestinal wall, which can be measured using endoscopy, could revolutionize the field. Detection rates of arterial Box 2 | Risk factors for increased bleeding riskDrugs•Compared with non-use, NSAID use increases the risk of developing non-variceal upper gastrointestinal bleeding (NVUGIB) fourfold, and low-dose aspirin (LDA) use increases the risk twofold3,66,203. The risk progressively increases with increasing drug dose; dangers of ‘dose creep’ or surreptitious addition of over-the-counter NSAIDs should be considered66. The risk associated with different NSAIDs is not the same in clinical practice and seems to be higher in drugs with longer half-lives, slow-release formulations or cyclooxygenase 1 (COX1) selectivity; COX2‑selective antagonists have been associated with lower NVUGIB risk67.•Anticoagulants and non-aspirin antiplatelet agentsa (such as clopidogrel) increase the risk of NVUGIB twofold204.•Other drugsa (such as serotonin reuptake inhibitors70, metamizole, calcium channel blockers and aldosterone antagonists) have also been associated with NVUGIB, but less consistently. •Combined use of NSAIDs (both unselective COX inhibitors and COX2‑selective inhibitors) with LDA, thienopyridine antiplatelet agents (for example, clopidogrel), warfarin, novel antiplatelet drugs (for example, prasugrel and ticagrelor), direct oral',\n",
       " 'inhibitors) with LDA, thienopyridine antiplatelet agents (for example, clopidogrel), warfarin, novel antiplatelet drugs (for example, prasugrel and ticagrelor), direct oral anticoagulants, corticosteroids67 or serotonin reuptake inhibitors70 increases the risk of NVUGIB. Combining NSAIDs and aldosterone antagonists might increase the risk\\xa0of developing NVUGIB more than the risk associated with individual drug use64,66,70.Gastrointestinal comorbidities•Eradication of Helicobacter pylori infection before NSAID use reduces ulcer risk by 2.8‑fold and ulcer bleeding risk by 6.4‑fold205.•The single most important risk factor for bleeding is a history of ulcer complications, especially in patients treated with NSAIDs or LDA67.•A history of uncomplicated ulcers increases the risk of complications; eradication of H.\\xa0pylori may not reduce the risk completely in patients treated with NSAIDs or LDA67.•History of dyspepsia, which may be a marker of underlying peptic ulcer disease, increases the risk of NVUGIB.Other comorbidities•Bleeding risk increases with age; >75\\xa0years of age is considered high risk67.•Concomitant disability; for example, the prevalence of gastrointestinal bleeding events is higher in those with rheumatoid arthritis than in those with osteoarthritis65,206.•The risk of NVUGIB increases with an increasing number of comorbidities65,66.aThese drugs do not induce damage to the gastrointestinal tract; patients must have lesions caused by other aetiology.PRIMER8 | ARTICLE NUMBER 18020 | VOLUME 4www.nature.com/nrdp© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'signals on ulcer bases using a Doppler probe in patients with Forrest type Ia bleeding are high (100%) but are lower in those with Forrest types Ib (46.7%), IIa (90.7%), IIb (68.4%), IIc (40.5%) and III (8.3%) bleeding97. These data could explain the finding that patients with Forrest type\\xa0Ib bleeding had a very low re-bleeding rate after success\\xadful endoscopic haemostasis in a recent RCT, although both Forrest types Ia and Ib are often included together as ‘active bleeding’ (REF.\\xa098). Furthermore, the use of the Doppler probe facilitates tracing of the under\\xadlying artery for effective endoscopic haemostasis, which improves patient outcomes99.Recently, iatrogenic ulcers following mucosal or sub\\xadmucosal endoscopic tumour resection have become a substantial cause of NVUGIB, especially in east Asia, where endoscopic tumour resection for upper gastro\\xadintestinal neoplasia is more frequent than in other parts of the world100. Although evidence is limited, endoscopic evaluation and management of bleeding from these ulcers should be considered on a similar basis to those with peptic ulcers100. Literature regarding endoscopic evaluation and management methods for bleeding from other causes such as Mallory–Weiss tear, oesophagitis, erosive gastritis, duodenitis, vascular abnormalities, anasto\\xadmotic wounds after surgery and upper gastro\\xadintestinal neoplasia are sparse. Spontaneous haemostasis is usually achieved in these conditions, and endoscopic treatment should be considered only in cases of active bleeding\\xad101. In cases of curative-intent treatment for neo\\xadplastic lesion, endoscopic or surgical removal of the entire lesion should be prioritized over endoscopic \\xadhaemostasis to control\\xa0bleeding.Second-look endoscopy. Re-bleeding after endoscopic treatment occurs in 10–15% of individuals with PUB and results in a twofold to fivefold increase in mortality5. However, current evidence-based guidelines do not recommend a routine second-look endoscopy5,8,10,11,78,',\n",
       " 'and results in a twofold to fivefold increase in mortality5. However, current evidence-based guidelines do not recommend a routine second-look endoscopy5,8,10,11,78, which is defined as scheduled endoscopic assess\\xadment within 24\\xa0hours of the initial diagnosis. A meta-\\xadanalysis reported a significant reduction in re-bleeding (OR\\xa00.55; 95%\\xa0CI 0.37–0.81) and need for emergency surgery (OR\\xa00.43; 95%\\xa0CI 0.19–0.96), but not mortality (OR\\xa00.65; 95%\\xa0CI 0.26–1.62), when routine second-look endoscopy was performed compared with an as‑needed endoscopy102. Further analysis showed that any protec\\xadtive effect for second-look endoscopy was limited to high-risk patients (that is, those with active bleeding at index endoscopy). In addition, scheduled second-look endoscopy is cost effective only in patients at high risk of recurrent ulcer bleeding, defined as those with high-risk endoscopic stigmata103.ManagementInitial, pre-endoscopic managementPeripheral intravenous access should be obtained soon after or at the same time as initial assessment and be of sufficient size to allow rapid blood transfusion if required. Resuscitation with crystalloid fluid should be guided by the haemodynamic status of the patient. The decision to provide additional blood transfusion should be individualized on the basis of the patient’s clinical \\xadstatus and should take ongoing bleeding, haemoglobin level and presence of underlying comorbidities that make the patient sensitive to reduced oxygen-\\xadcarrying capacity into consideration. In general, a restrictive blood transfusion strategy is recommended. Guidelines5 typically recommend blood transfusion for patients who have a haemoglobin level <70\\u2009g per litre and recommend targeting a haemoglobin value of 70–90\\u2009g per litre104. These targets can be individualized for patients who are sensitive to low oxygen-carrying capacity, but overtrans\\xadfusion should be avoided as it can be associated with harm (such as congestive heart failure)5,78.',\n",
       " 'sensitive to low oxygen-carrying capacity, but overtrans\\xadfusion should be avoided as it can be associated with harm (such as congestive heart failure)5,78.Guidelines recommend administration of intra\\xadvenous high-dose PPI pre-endoscopy to stabilize clots, downgrade endoscopic stigmata of recent \\xadhaemorrhage and reduce the need for endoscopic therapy5,10,78. However, the use of intravenous pre-endoscopy PPIs has not shown reductions in the rates of re-bleeding, surgi\\xadcal intervention or mortality in meta-analyses, therefore, its use should not delay endoscopy5,78,105,106. The use of pre-endoscopy PPIs is considered to be cost effective in high-risk patients and in low-risk patients with expected short hospitalizations or outpatient manage\\xadment107. The cost effectiveness of pre-endoscopic intravenous PPIs is likely maximized in patients with the likelihood of a high-risk lesion on initial assessment or in those in whom a delay in endoscopic therapy is expected. By\\xa0con\\xadtrast, post-endoscopy intravenous PPI use reduces the risk of re-bleeding and need for surgical intervention (see below).Guidelines do not support the routine use of somato\\xadstatin or somatostatin analogues (aimed mainly at splanchnic vasoconstriction) or tranexamic acid (an\\xa0antifibrinolytic agent) in NVUGIB. Although not \\xadroutinely recommended, a single dose of the anti\\xadbiotic Figure 5 | Risk of developing NVUGIB associated with certain drugs. Relative risk and\\xa095% CIs of developing non-variceal upper gastrointestinal bleeding (NVUGIB) associated with the use of various types of drugs alone or combined with non-selective NSAIDs (nsNSAIDS) compared with no drug use. Based on data reported in European databases64. The different colours refer to the different drug classes; the dashed line highlights a relative risk=\\u20091. COX2, cyclooxygenase 2; LDA, low-dose aspirin; SSRI, selective serotonin reuptake inhibitor.Nature Reviews | Disease PrimersTreatments  No drug useCOX2 inhibitors Corticosteroids',\n",
       " 'selective serotonin reuptake inhibitor.Nature Reviews | Disease PrimersTreatments  No drug useCOX2 inhibitors CorticosteroidsSSRIsCalcium antagonistsAldosterone antagonistsAnticoagulantsNon-aspirin antiplatelet agentsNon-aspirin antiplatelet agents + nsNSAIDs714311Relative risk0nsNSAIDsLDACorticosteroids + nsNSAIDsSSRIs + nsNSAIDsCalcium antagonists + nsNSAIDsAldosterone antagonists + nsNSAIDsAnticoagulants + nsNSAIDs5198412621013ReferencePRIMERNATURE REVIEWS | DISEASE PRIMERS VOLUME 4 | ARTICLE NUMBER 18020 | 9© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'erythromycin 30–120\\xa0minutes before endoscopy, \\xadespecially in those with severe and ongoing bleeding, can improve endoscopic visualization, reduce the need for blood transfusion and second-look endoscopy and reduce the length of hospitalization5,78,108.Endoscopic managementVarious modalities to achieve endoscopic haemostasis aimed at stopping active bleeding in those with UGIB associated with peptic ulcers or other causes exist and are detailed in BOX\\xa04.PUB. Meta-analyses show that injection therapy with solutions other than adrenaline, thermal therapy and haemoclip therapy (BOX\\xa04) are all effective methods for achieving haemostasis in PUB with no single modality being superior109–114. For high-risk PUB, adrenaline plus any second haemostasis modality (except spray ther\\xadapy) significantly reduced re-bleeding (OR\\xa00.53; 95%\\xa0CI 0.35\\u200a–\\u200a0.81) and need for emergency surgery (OR\\xa00.68; 95%\\xa0CI 0.50\\u200a–\\u200a0.93), but not mortality, as compared with adrenaline injection monotherapy113. Thus, if adrenaline injection is used to treat PUB with high-risk stigmata, it should be used only in combination with a second endoscopic haemostasis modality. The use of soft coagu\\xadlation using haemostatic forceps (FIG.\\xa06) has become more frequent along with development of endoscopic \\xadsubmucosal dissection115.Over-the-scope clip (OTSC system; OVESCO Endo\\xadscopy AG, Tübingen, Germany) and haemo\\xadstatic powders such as TC‑325 (Haemospray; Cook Medical, Bloomington, IN, USA) and the EndoClot polysacchar\\xadide haemostatic system (EndoClot Plus, Santa Clara, CA, USA) are newly developed devices or substances with promising outcomes, but they still lack sufficient data to draw robust conclusions concerning efficacy116–118. Over-the-scope clips overcome the limita\\xadtions of haemoclips, such as smaller size and lower capacity to include the whole lesion and induce pres\\xadsure, and are good options for salvage or rescue endo\\xadscopic haemo\\xadstasis interventions after conventional',\n",
       " 'capacity to include the whole lesion and induce pres\\xadsure, and are good options for salvage or rescue endo\\xadscopic haemo\\xadstasis interventions after conventional endoscopic therapies have failed before surgical or radio\\xadlogical intervention. Haemostatic powders mainly act as a tamponade and a physical barrier from factors such as gastric acid and might be more effective than conventional endoscopic therapies in cases in which targeting the bleeding point is difficult. Notably, bleed\\xading duodenal ulcers at the posterior wall may require subsequent vigilance after endoscopic therapy; if the gastroduodenal artery is affected, radiological coiling or surgery may be needed to stop\\xa0the bleeding1.Non-PUB NVUGIB. For NVUGIB other than PUB, endoscopic haemostasis should be selected according to the nature of the disease, severity of bleeding and preference of the endoscopist because of the low quality Box 3 | Risk-scoring systems for NVUGIBGlasgow–Blatchford bleeding scoreThe Glasgow–Blatchford bleeding scoring system80,207 (0–23 points) aims to predict the need for hospital-based interventions (such as endoscopic or surgical intervention and blood transfusion) or the risk of hospital-based complications (such as in‑hospital re-bleeding and substantial decrease in haemoglobin concentration after admission) or mortality. Although studies use different cut-off values, a score of ≤1 is usually considered low risk and discharge is considered safe, whereas a score of >7 is usually considered high risk. Parameters included in the scoring system are haemoglobin level, blood urea concentration, systolic blood pressure, heart rate, sex, presence of melena, recent syncope, presence of liver disease and heart failure.Admission Rockall score for NVUGIB (pre-endoscopy)This scoring system (0–7 points) aims to predict the risk of re-bleeding and mortality80,208. Parameters included in the scoring',\n",
       " 'Admission Rockall score for NVUGIB (pre-endoscopy)This scoring system (0–7 points) aims to predict the risk of re-bleeding and mortality80,208. Parameters included in the scoring system are age, presence of hypovolaemic shock, pulse, systolic blood pressure, minor comorbidities (such as congestive cardiac failure and ischaemic heart disease) and major comorbidities (such as renal failure, liver failure and cancer).AIMS65This scoring system (0–5 points) aims to predict the risk of re-bleeding and mortality80,209,210; a score of ≥2 is considered high\\xa0risk. Parameters included in the scoring system are albumin, international normalized ratio for prothrombin time, mental status, systolic blood pressure and age, which are the basis of the name of the score.PNEDThe Progetto Nazoinale Emorragia Digestiva (PNED) scoring system (0–21 points) aims to predict mortality risk80,211. A\\xa0score of ≤4 is considered low risk, 5–8 is considered intermediate risk and ≥9 is considered high risk. Parameters included in class 3 and 4 of the scoring system are the American Society of Anesthesiologists Physical Status score, time since admission (<8\\xa0hours), haemoglobin level (<7\\u2009g per dl), renal failure, advanced age (>80\\xa0years), re-bleeding, cirrhosis, advanced-stage cancer and failure of endoscopic treatment.Full Rockall score for NVUGIB (post-endoscopy)This scoring system (0–11 points) aims to predict the risk of re-bleeding and mortality80,212. A score of ≤2 is considered low risk, 3–4 is considered intermediate risk and ≥5 is considered high risk. Parameters included in the scoring system are the same as those of the preadmission score and those related endoscopic diagnosis and endoscopic stigmata. The presence or absence of Mallory–Weiss tears, gastrointestinal malignancy or all other diagnoses are also included in the scoring system alongside endoscopic stigmata (absence of stigmata or dark spots on ulcers, blood in the upper gastrointestinal',\n",
       " 'system alongside endoscopic stigmata (absence of stigmata or dark spots on ulcers, blood in the upper gastrointestinal tract, adherent clots or visible or spurting vessels).NVUGIB, non-variceal upper gastrointestinal bleeding.PRIMER10 | ARTICLE NUMBER 18020 | VOLUME 4www.nature.com/nrdp© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'of evidence and scarcity of comparative data. Bleeding associated with Mallory–Weiss tears is \\xadusually self-\\xadlimited, and endoscopic haemostasis would be applied only when active bleeding is detected. Among various endoscopic haemostatic modalities, haemoclip and band ligation therapy are preferred as they achieve haemostasis and closing of the mucosal tear without thermal damage to the thinner lacerated tissue119,120. Endoscopic haemostasis to control bleeding associated with vascular abnormalities is usually carried out using coagulation therapy such as argon plasma coagula\\xadtion, laser therapy or radiofrequency ablation. Argon plasma coagulation is especially useful for lesions that are spread (for example, gastric antral vascular ectasia (longitudinal antral folds converging on the pylorus that contain visible columns of tortuous red ectatic vessels)) or for multiple lesions (arteriovenous malfor\\xadmations or telangiectases) as its coagulation depth is uniform and the risk of perforation is lower than that of laser\\xa0therapy121.For patients with a few or localized lesions, haemo\\xadstasis using mechanical therapy or injection therapy are also applicable. As a new approach for refractory gastric antral vascular ectasia, radiofrequency ablation using the HALO90 Ablation Catheter System (Covidien GI Solutions, Sunnyvale, CA, USA) has been tested with promising outcomes122–125. In Dieulafoy lesions, either mechanical therapy (such as band ligation) or\\xa0haemo\\xadclips are considered to be the first-line treatment and over-the-scope clips are a rescue treatment for refractory\\xa0cases126.Medical therapy after endoscopyThe goals of medical treatment are to reduce the risk of re-bleeding while healing the ulcer and preventing long-term recurrence. The rationale for raising intra\\xadgastric pH to >6 is based on studies that demonstrated that acidity affects platelet aggregation and destabilizes clot formation44,127,128. A meta-analysis of RCTs found a',\n",
       " 'gastric pH to >6 is based on studies that demonstrated that acidity affects platelet aggregation and destabilizes clot formation44,127,128. A meta-analysis of RCTs found a significant reduction in re-bleeding (RR\\xa00.40, 95%\\xa0CI 0.28–0.59; NNT 12, 95%\\xa0CI 10–18), surgery (RR\\xa00.43, 95%\\xa0CI 0.24–0.76; NNT 28, 95%\\xa0CI 21–67) and mor\\xadtality (RR\\xa00.41, 95%\\xa0CI 0.20–0.84; NNT 45, 95%\\xa0CI 33–167) with intravenous post-endoscopic PPI ther\\xadapy (bolus injection followed by continuous infusion versus placebo or no treatment for 72\\xa0hours after endo\\xadscopic therapy)94. High-dose intravenous omeprazole (a PPI) was superior to intravenous administration of ranitidine (a histamine H2 receptor antagonist) in maintaining gastric pH >6 (percentage of time gastric pH <6 in the study period was 15.3\\u2009±\\u20095.9% (mean\\u2009±\\u2009standard deviation) for omeprazole versus 61.8\\u2009±\\u20095.6% (mean\\u2009±\\u2009standard deviation) for ranitidine, P\\u2009<0.0001)45.Given the cost of continuous intravenous ther\\xadapy, less costly intermittent (including oral) therapy is a \\xadlogical consideration, although a recent study has shown that the timing or dosing of PPI has little impact on cost, much less than efficient triage and dis\\xadcharge of patients129,130. Several meta-analyses found that intermittent PPI use was non-inferior compared with bolus plus continuous infusion of PPIs in terms of re-bleeding (at 3, 7 and 30\\xa0days), the need for blood transfusion and urgent intervention and mortality131,132. Intermittent oral PPI may be as effective in pH control as equivalent doses of intravenous PPIs given intermit\\xadtently. Both oral and intravenous PPIs (lansoprazole) given intermittently achieved similar pH control during the study period (percentage time gastric pH <6 was 67.8\\u2009±\\u20094.5% (mean\\u2009±\\u2009standard error) for intravenous PPI versus 64.8\\u2009±\\u20094.2% (mean\\u2009±\\u2009standard error) for oral PPI), although intravenous PPI increased pH to >6 sooner than oral PPI (by 1\\xa0hour)47, but the ranges are wide.',\n",
       " 'versus 64.8\\u2009±\\u20094.2% (mean\\u2009±\\u2009standard error) for oral PPI), although intravenous PPI increased pH to >6 sooner than oral PPI (by 1\\xa0hour)47, but the ranges are wide. Thus, intermittent, high-dose PPIs given at least twice daily are an option, using oral PPIs in patients able to tolerate oral medications94.Table 1 | Risk prediction using the Forrest classificationEndoscopic stigmataForrest classificationRisk of persistent bleeding or re-bleeding without\\xa0endoscopic treatmentRisk of re-bleeding after endoscopic haemostasisRisk of needing surgery for bleeding\\xa0without endoscopic treatmentRisk of mortality without endoscopic treatmentAcute bleedingSpurting haemorrhageType\\xa0IaVery highHighHighLowOozing haemorrhageType\\xa0IbVery lowaSigns of recent bleedingNon-bleeding visible vesselType\\xa0IIaHighHighHighLowAdherent clotType\\xa0IIbHighVery lowLowLowFlat pigmented spotType\\xa0IIcLowNot applicablebVery lowVery lowLesion without active bleeding or signs of bleedingClean base (no vessel, blood or clot on the base)Type\\xa0IIIVery lowNot applicablebExtremely lowVery lowTable based on data in REF.\\xa0220. aA recent study demonstrates that Forrest type\\xa0Ib has a very low re-bleeding rate within 72\\xa0hours after successful endoscopic haemostasis98. bIn patients with Forrest type IIc and type III, the risk of re-bleeding is <10%; thus, endoscopic haemostasis provides no advantage.PRIMERNATURE REVIEWS | DISEASE PRIMERS VOLUME 4 | ARTICLE NUMBER 18020 | 11© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'Patients with PUB have an unacceptably high rate of recurrent bleeding. In an RCT of patients with H.\\xa0pylori-associated PUB, the rate of recurrent bleed\\xading after 12‑month follow‑up was 27% in patients who did not undergo H.\\xa0pylori eradication therapy com\\xadpared with 0% in those who did133. H.\\xa0pylori eradication is more effective than long-term maintenance anti\\xadsecretory therapy in reducing recurrence; a systematic review of studies assessing re-bleeding in patients with documented H.\\xa0pylori eradication revealed a 1.1% inci\\xaddence of re-bleeding over mean follow‑up periods of 11–53\\xa0months. However, the re-bleeding rate in patients who did not undergo H.\\xa0pylori eradication therapy but were maintained with long-term anti\\xadsecretory therapy was 5.6%134. These findings set the current Cochrane rec\\xadommendations to test all patients with PUB for H.\\xa0pylori and provide eradication therapy if\\xa0needed134.When patients have to use NSAIDs after PUB, RCTs have shown that maintenance PPI therapy significantly lowers the risk of recurrent ulcer bleeding at 6\\xa0months compared with H.\\xa0pylori eradication alone (4.4% ver\\xadsus 18.8%, P\\u2009=\\u20090.005; NNT\\u2009=\\u20097)68,135. In a 12‑month double-blind study, patients taking celecoxib (a COX2 inhibitor) plus twice-daily PPI had fewer recurrent ulcer bleeding\\xa0events than those taking celecoxib plus \\xadplacebo (0% versus 8.9%, P\\u2009=\\u20090.0004; NNT\\u2009=\\u200912)69. Another meta-analysis also found that the combination of selective COX2 inhibitors plus PPIs provides the best gastro\\xadintestinal protection, followed by selective COX2 inhibitors alone and non-selective NSAIDs plus PPI136. Thus, the current best practice for those patients with a PUB who must remain on NSAIDs is that they should receive a COX2‑selective NSAID at the lowest effective dose plus PPI therapy68,69.Recurrent bleedingIn patients with clinical evidence of re-bleeding, repeat upper endoscopy should be performed with haemo\\xadstasis of high-risk endoscopic stigmata of haemorrhage, if pres\\xad',\n",
       " 'Recurrent bleedingIn patients with clinical evidence of re-bleeding, repeat upper endoscopy should be performed with haemo\\xadstasis of high-risk endoscopic stigmata of haemorrhage, if pres\\xadent. A seminal RCT comparing endoscopic therapy with surgery for recurrent PUB following successful initial endoscopic control of PUB showed that 73% of patients randomly assigned to endoscopic re-treatment had long-term control of their bleeding and avoided \\xadsurgery com\\xadpared with 93.1% of surgery-treated patients137. Patients in the endoscopy group had a lower rate of complica\\xadtions than those in the surgery group (14.5% versus 36%; P\\u2009=\\u20090.03)137. If further bleeding occurs following a second endoscopic treatment, transcatheter angiographic embo\\xadlization or surgery should be considered5,10,11. In those with PUB after failed endoscopic haemostasis, a higher re-bleeding rate was observed following transcatheter Box 4 | Examples of endoscopic therapy for NVUGIBInjection therapy•Endoscopic injection of small volumes of treatment solution close to the bleeding site•Several types of treatment solutions can be used:-- Absolute ethanol: aimed at inducing dehydration and fixation of the bleeding blood vessel, with subsequent vasoconstriction and necrosis-- Adrenaline in an isotonic or hypertonic saline solution: adrenaline induces vasoconstriction and vascular tamponade and hypertonic saline solution induces tissue swelling, fibrinoid necrosis and thrombogenesis-- Polidocanol: a sclerosant that irritates and induces endothelial cell damage and thrombogenesisMechanical therapy•Haemoclip: mechanical compression of the bleeding vessel using a metallic clip•Band ligation: mechanical compression of the bleeding vessel using a rubber band commonly used for oesophageal variceal ligation•Over-the-scope clip (OTSC system; OVESCO Endoscopy AG, Tübingen, Germany): a large superelastic nitinol clip',\n",
       " 'variceal ligation•Over-the-scope clip (OTSC system; OVESCO Endoscopy AG, Tübingen, Germany): a large superelastic nitinol clip with\\xa0a bear-trap shape that fits on the endoscope tip and is commonly used for closures of perforations and fistulasThermal therapy•Soft coagulation using haemostatic forceps: monopolar or bipolar electrocautery or heat probe are contact devices that use heat or electrical current to coagulate the bleeding vessel•Argon plasma coagulation: a stream of ionized argon gas conducts electricity, without direct contact, resulting in coagulation of superficial tissues•Laser therapy: a stream of intense, small and nearly non-divergent beams of monochromatic radiation in the visible region induces heat and coagulates or cuts tissues•Radiofrequency ablation: a flexible strap that slides over the endoscope tip and generates radiofrequency energy, commonly used for ablation of Barrett oesophagusSpray therapy•Thrombin or fibrin glue: acceleration of the blood coagulation cascade by thrombin or supply of fibrinogen and thrombin (that is, fibrin) to create a primary tissue seal at a bleeding site•TC‑325 (Haemospray; Cook Medical, Bloomington, IN, USA): a mineral blend powder that absorbs and acts both cohesively and adhesively by forming a mechanical barrier over the bleeding site•EndoClot polysaccharide haemostatic system (EndoClot Plus, Santa Clara, CA, USA): a polysaccharide powder modified from plant starch that forms a gel in the presence of blood and adheres to and seals the bleeding tissuePRIMER12 | ARTICLE NUMBER 18020 | VOLUME 4www.nature.com/nrdp© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'angiographic embolization than surgery, but no signifi\\xadcant difference in mortality or need for additional interventions was observed138,139. Emerging data sug\\xadgest that haemostatic powders and over-the-scope clips can be successfully employed as salvage haemostasis \\xadtherapy140,141, but more data are needed10,11,118,142,143.Patients on antiplatelet therapyThe evidence to guide practice in those with NVUGIB who are using antiplatelet agents is very limited and mostly restricted to LDA monotherapy. The risk of recurrent PUB, most of which occurred within the first 5\\xa0days after the index bleeding event, was increased in those on continued LDA before endoscopy (HR\\xa01.9) compared with discontinuing LDA use for 8\\xa0weeks after PUB144. However, none of these bleeding events were fatal, whereas all-cause mortality in those who discontinued receiving LDA was increased owing to thrombo\\xadembolic events. In a smaller retrospective study, individuals with cardiovascular disease who stopped LDA therapy had an increased risk of death or cardio\\xadvascular event (HR\\xa06.8) in the first 6\\xa0months of follow-up compared with those who continued LDA therapy. Early resumption of LDA after the bleeding event was not associated with a signifi\\xadcant increase in mortality related to PUB. These studies144–146, albeit small, provide strong evidence to continue LDA in individ\\xaduals who develop a PUB \\xadduring treatment or at least to resume treatment\\xa0early.Indeed, the time interval from discontinuation of LDA to an adverse cardiovascular event was ~8\\xa0days for acute coronary syndrome, 14\\xa0days for cerebrovascular syndromes and 25\\xa0days for acute peripheral arterial syndromes147, whereas the risk of recurrent gastro\\xadintestinal bleeding is highest in the first 3\\xa0days after the index event135. As a consequence, antiplatelet therapy is often stopped and resumed after 3–5\\xa0days in those at high risk of recurrent NVUGIB to avoid the period of high risk of recurrent bleeding while the antiplatelet',\n",
       " 'is often stopped and resumed after 3–5\\xa0days in those at high risk of recurrent NVUGIB to avoid the period of high risk of recurrent bleeding while the antiplatelet function of LDA to prevent cardiovascular events may persist. On the basis of existing evidence, several guide\\xadlines have been formulated5,49 (FIG.\\xa07). To our knowledge, no study designed to investigate the withdrawal and/or resumption of antiplatelet agents other than LDA has been carried\\xa0out.Patients on anticoagulant therapyThe management of patients on anticoagulant therapy who develop an NVUGIB represents a clinical challenge, and two clinical scenarios should be considered: treat\\xadment before endoscopy and treatment after diagnosis has been established and the bleeding event has been controlled. Irrespective of whether patients are taking vitamin\\xa0K antagonists or DOACs, treatment should be stopped immediately and pre-endoscopic management should be initiated as usual. Endoscopy should not be delayed in patients with an INR <2.5 as outcomes (such\\xa0as need for intervention or death) are similar in those with normal versus elevated INR at admission if INR is corrected to values <2.5 before endoscopy5,81,148,149. Conversely, a retrospective study in 134 patients with bleeding events with INR ≥3.5 suggested that effec\\xadtive therapeutic endoscopic intervention becomes less frequently possible as the INR increases150. Under these circumstances, reversal of INR (see below) seems \\xadappropriate before endoscopy.Vitamin\\xa0K antagonists. For patients on vitamin\\xa0K antagonists (such as warfarin and dicumarinics), pro\\xadlonged INR can be reversed with vitamin\\xa0K, which acts slowly (INR begins to decrease within 2–4\\xa0hours and normalizes within 24\\xa0hours) but more dur\\xadably than pro\\xadthrombin complex concentrates (PCCs) or fresh frozen plasma (FFP)151. Vitamin\\xa0K should be injected slowly to minimize severe (anaphylactic or anaphy\\xadlactoid) reactions152 and INR should be monitored as vitamin\\xa0K',\n",
       " 'plasma (FFP)151. Vitamin\\xa0K should be injected slowly to minimize severe (anaphylactic or anaphy\\xadlactoid) reactions152 and INR should be monitored as vitamin\\xa0K antagonists have a long half-life153. Haemostatic factors (such as PCCs and FFP) can also be used to normal\\xadize haemostasis when reversal of anticoagulation is urgent. PCCs are preferred over FFP because they can be administered more rapidly without blood group test\\xading or thawing in smaller volumes and are associated with lower mortality, quicker INR normalization (dif\\xadference of 6.5\\xa0hours) and a similarly low risk of throm\\xadboembolism154. Four-factor PCC provides more reliable INR correction than three‑factor PCC155, but reported differences in mortality are inconsistent156,157. FFP is still widely used because of perceived lower cost than PCCs158; however, the difference in price for identical INR correction is only 50%159. Recombinant factor\\xa0VIIa Figure 6 | Management of using soft coagulation. a\\xa0|\\xa0Fresh blood flows from the ulcer to the greater curvature of the gastric body (arrow). b\\xa0|\\xa0Bleeding point under the clot is\\xa0near the upper rim of the ulcer (arrow). c\\xa0|\\xa0Slight removal of the clot shows spurting bleeding (arrow). d\\xa0|\\xa0Soft coagulation by using haemostatic forceps successfully stops\\xa0the\\xa0bleeding (arrow). Images courtesy of Prof. M. Fujishiro, The University of Tokyo Hospital, Japan.acdbNature Reviews | Disease PrimersPRIMERNATURE REVIEWS | DISEASE PRIMERS VOLUME 4 | ARTICLE NUMBER 18020 | 13© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'is not recommended (high cost and 11% thromboembo\\xadlism risk)160. FIGURE\\xa08 summarizes commonly accepted recommendations for patients on vitamin\\xa0K antagonists who develop\\xa0NVUGIB161–163.DOACs. DOACs target single enzymes of the coagu\\xadlation process; apixaban, edoxaban and rivaroxaban inhibit factor Xa whereas dabigatran directly inhibits thrombin72. Plasma monitoring of coagulation factors is not needed, which is a clinical advantage over vita\\xadmin\\xa0K antagonists. However, unlike vitamin\\xa0K antago\\xadnists and dabigatran, anti-factor Xa agents currently have no widely available reversal agents, are not yet approved and normalization of clotting factor levels takes 12–24\\xa0hours164.Routine coagulation tests may be conducted, but they are unreliable (BOX\\xa05). Renal function should be monitored as it is frequently compromised in those with UGIB on DOACs, and aggressive fluid replace\\xadment may be needed to maintain renal function165,166. Creatinine clearance enables the estimation of the per\\xadsisting DOAC effect167. Haemodialysis can be of help for dabigatran clearance treatment only but requires haemodynamic stability. Prolonged continuous haemo\\xaddialysis may help to prevent bleeding rebound effects168. Finally, activated charcoal can also be used in the case of a recent (≤3\\xa0hours) overdose and when no emergency UGIB endoscopy is contemplated169–171.Haemostatic agents such as PCCs or activated PCCs have been shown to be effective at restoring coagula\\xadtion in patients with NVUGIB who are taking DOACs, although evidence is limited172–174. By contrast, FFP is not recommended as clotting factors are 25‑fold more dilute than in PPCs, and very large volumes are required to overwhelm the binding capacity of DOACs. The most promising therapeutic options rely on the availability of reversal agents, which could be used in the case of life-threatening gastrointestinal bleeding, but reliable data are needed because of the risk of thromboembolism175,176.',\n",
       " 'of reversal agents, which could be used in the case of life-threatening gastrointestinal bleeding, but reliable data are needed because of the risk of thromboembolism175,176. Dabigatran has a specific antidote (idarucizumab), which works effectively in minutes with thromboembolism and a rebound effect reported in 6.8% and 23% of patients, respectively171. In this cohort study171, including patients who had uncontrolled bleeding (45.5% of whom had gastro\\xadintestinal bleeding and 32.6% had intracranial haemorrhage), the median maximum percentage reversal of dabigatran was 100% on the basis of either the diluted thrombin time or the ecarin clotting time; the median time to cessation of bleeding was 2.5\\xa0hours. In those undergoing emergency procedures, haemostasis was Nature Reviews | Disease PrimersResumeby day 3–5Second-look endoscopy atthe discretion of endoscopist or if re-bleeding is suspected• Continue LDA• Consult cardiologist before restarting  additional antiplatelet agent• Withhold antiplatelet agents• Re-evaluate indication• Reintroduce before discharge  if indicatedContinueaspirinor DAPT• Withhold antiplatelet agents• Re-evaluate indication• Reintroduce after ulcer healing or earlier if neededAspirinDAPTAntiplatelet agentsfor primary preventionAntiplatelet agentsfor secondary preventionAntiplatelet agentsfor primary preventionAntiplatelet agentsfor secondary preventionHigh-risk stigmata on endoscopy(Forrest classiﬁcation Ia, Ib, IIa or IIb)Low-risk stigmata on endoscopy(Forrest classiﬁcation IIc or III)NVUGIB in patients taking antiplatelet agentsSuccessful endoscopic treatmentFigure 7 | Management of NVUGIB in those using antiplatelet agents. If the antiplatelet therapy is taken for primary prevention of cardiovascular events, it should be discontinued in patients with a history of peptic ulcer bleeding (PUB);',\n",
       " 'prevention of cardiovascular events, it should be discontinued in patients with a history of peptic ulcer bleeding (PUB); if\\xa0an indication for continuing antiplatelet therapy exists, the risk of recurrent bleeding should be assessed by clinical and\\xa0endoscopic criteria. Antiplatelet agents should not be stopped or, if stopped, they should be resumed a few days after endoscopy in those with non-variceal upper gastrointestinal bleeding (NVUGIB) who are on secondary cardiovascular prevention (for example, those with a previous ischaemic vascular event). In patients with PUB at low risk of recurrent bleeding, antiplatelet treatment should not be discontinued as the risk of a thromboembolic event outweighs the risk of\\xa0recurrent bleeding from the gastrointestinal tract. In patients at high risk of recurrent bleeding, antiplatelet treatment should be stopped and can be resumed within 3–5\\xa0days. If the patient is receiving dual antiplatelet therapy (DAPT; combination of low-dose aspirin (LDA) and a P2Y purinoceptor 12 inhibitor), then the least potent antiplatelet drug should be restarted and a cardiologist’s opinion should be sought for resuming the second antiplatelet agent3. Algorithm based on recommendation of the European Society of Cardiology Working Group on Thrombosis49 and the European Society of Gastrointestinal Endoscopy guidelines5.PRIMER14 | ARTICLE NUMBER 18020 | VOLUME 4www.nature.com/nrdp© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'assessed as normal in 93.4% at the start of the intended procedure (1.6\\xa0hours after idarucizumab administration). At 90\\xa0days, thrombotic events had occurred in 6.3% and 7.4% of patients and the mortality was 18.8% and 18.9% in those with uncontrolled bleeding and those under\\xadgoing emergency surgery, respectively. Rebound effects may occur for up to 6\\xa0days and require repeat dosing177. The costs of these compounds may hamper the use in clinical practice. Other investigational antidotes include andexa\\xadnet alfa (for anti-factor Xa agents) and ciraparan\\xadtag (for many DOACs)178,179. FIGURE\\xa0 9 summarizes current\\xa0recommendations167,176,180.Continuing therapy following bleeding control. Once the bleeding event has been controlled, the decision to resume anticoagulation should involve a multi\\xaddisci\\xadplinary team and the patient; the need for anti\\xadcoagu\\xadlants should be reassessed using available risk scores (for example, CHA2DS2‑VASc and HAS-BLED)181,182. The implementation of alternative management (for\\xa0example, ablation therapy for atrial fibrillation or catheter-\\xadbased atrial appendage occlusion), change of anti\\xadcoagulants (for example, apixaban may have a lower risk of gastro\\xadintestinal bleeding than other DOACs in indirect com\\xadparison studies)72 and optimization of treatment (for example, PPI, H.\\xa0pylori eradication, stricter INR control or DOAC dose adaptation) should also be considered. Data, mostly involving vitamin\\xa0K antago\\xadnists72,183, show that resuming oral anticoagulation is associated with a lower mortality despite more frequent major bleeding184. A recent study involving 1,539\\xa0patients suggested that dabigatran offers simi\\xadlar protection against thrombo\\xadembolism with less re-\\xadbleeding than warfarin after major bleeding185. With respect to timing, although it is still a matter of debate, war\\xadfarin should be restarted 7–14\\xa0days following NVUGIB on the basis of a single available study, whereas DOACs act more rapidly186.',\n",
       " 'is still a matter of debate, war\\xadfarin should be restarted 7–14\\xa0days following NVUGIB on the basis of a single available study, whereas DOACs act more rapidly186. If\\xa0early anticoagulation is indicated (for example, in those with a high thrombo\\xadembolic risk), a bridge approach with heparin may be used. A\\xa0recent joint con\\xadsensus document composed by several international cardiology societies advocates an earlier resumption of vitamin\\xa0K antago\\xadnists —\\xa0within the first week for patients with atrial \\xadfibrillation \\xadassociated with valvular heart disease187.Quality of lifeAt the time of an NVUGIB, symptoms can include vomit\\xading of blood and blood in stools, abdominal pain, chest pain, cramping, burning, fatigue, dizziness, palpi\\xadtations and diarrhoea. Thus, the burden on patients during a bleeding event and hospitalization is con\\xadsiderable, and health-related quality of life (HRQOL) is\\xa0substantially impaired105,188,189. A negative associ\\xadation exists between the number of symptoms experi\\xadenced by patients and self-reported levels of HRQOL189. Impairment to physical health accounts for most of the decrement in HRQOL experienced by individuals at the time of a bleeding event. Issues with mobility, performing daily activities, pain and discomfort have all been more frequently cited by patients than issues with \\xadanxiety and depression, and following hospital Determine INRNature Reviews | Disease PrimersReverse vitamin K antagonistsa• Stop treatment with vitamin K antagonists• Administer vitamin K:  5–10 mg intravenous infusion over 30 minutesReverse vitamin K antagonistsa• Stop treatment with vitamin K antagonists• Administer vitamin K: 5–10 mg intravenous infusion over 30 minutes)• PCC according to baseline INR valueb Check INR 20–30 minutes after PCC infusion• INR <1.5: recheck in 6 hours, then daily• INR >1.5: seek advice and consider PCC reinfusionNo haemodynamic compromiseHaemodynamic compromiseINR >2.5Stop vitamin K antagonist',\n",
       " '• INR <1.5: recheck in 6 hours, then daily• INR >1.5: seek advice and consider PCC reinfusionNo haemodynamic compromiseHaemodynamic compromiseINR >2.5Stop vitamin K antagonistNVUGIB in patients taking vitamin K antagonistsINR <2.5EndoscopyFigure 8 | Management of NVUGIB in those using vitamin\\xa0K antagonists. Vitamin\\xa0K antagonists such as warfarin or\\xa0coumadin should be stopped in patients who develop upper gastrointestinal bleeding and resumed soon after the\\xa0bleeding is controlled. The international normalized ratio (INR) should be determined, and if INR is <2.5, diagnostic and therapeutic endoscopy can be performed safely. If INR is >2.5, endoscopy can be delayed until therapy to reverse the effect of the vitamin\\xa0K antagonist has been implemented. The haemodynamic compromise (that is, blood pressure and volume that are not adequate to support normal organ function) will determine the type of therapy needed. The\\xa0INR\\xa0can be tested at intervals of 4, 12, 24, 28 and 72\\xa0hours, but this is based on little evidence. aBalancing with\\xa0the\\xa0risk\\xa0of thrombosis, which is highest in patients who have atrial fibrillation, a CHA2DS2‑VASc score of ≥6, a\\xa0mechanical\\xa0mitral valve or a cardiac assist device. bFresh frozen plasma can be given at 15\\u2009ml per kg if PCC is unavailable. Algorithm based on expert consensus49,161–163. NVUGIB, non-variceal upper gastrointestinal bleeding; PCC,\\xa0prothrombin complex concentrate.PRIMERNATURE REVIEWS | DISEASE PRIMERS VOLUME 4 | ARTICLE NUMBER 18020 | 15© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'admission for NVUGIB, patients have reported levels of general and physical fatigue to be considerably higher than mental and motivational\\xa0fatigue105,188,190.With clinically effective endoscopic, surgical and medical therapies to stop and prevent bleeding, many physical symptoms can be resolved and improvements in HRQOL following the bleeding event can be \\xadrealized. The few studies taking repeated HRQOL measures from patients who have had an NVUGIB have shown a signifi\\xadcant reduction in symptoms and improvements in the physical dimensions of health following discharge compared with during the hospital stay105,188,189.The long-term consequences of an NVUGIB for patients often include anaemia, which is associated with fatigue, heart palpitations, pallor and shortness of breath191. The already high prevalence of anaemia (50–80%)192,193 in patients discharged from the hospital following a bleeding event is likely to increase, with more restrictive blood transfusion strategies being adopted for NVUGIB104,194,195. Iron supplementation in the months following an NVUGIB can help increase haemoglobin levels and correct anaemia, but little is known about whether this directly translates into improvements in HRQOL196. One small study in 97 patients diagnosed with anaemia following NVUGIB showed that 6\\xa0months after the NVUGIB, the proportion of patients who reached the normalized HRQOL score was higher and general and physical fatigue levels were lower in those patients for whom anaemia had been resolved than in those with persistent anaemia; differences at other time points were non-significant188. Iron supplemen\\xadtation can be provided intravenously before discharge, which will reduce the time to recover to appropriate haemoglobin\\xa0levels197.HRQOL generally follows an upward trajectory in the weeks and months following hospital discharge for NVUGIB. However, a return to general popula\\xadtion normal levels seems unlikely, probably because',\n",
       " 'HRQOL generally follows an upward trajectory in the weeks and months following hospital discharge for NVUGIB. However, a return to general popula\\xadtion normal levels seems unlikely, probably because of the considerable role of pre-existing comorbidi\\xadties and their associated treatments in the aetiology of NVUGIB105,188–190. For patients with NVUGIB, the increased risk of re-bleeding associated with NSAIDs and antiplatelet and anticoagulant therapies must be carefully considered when planning subsequent\\xa0care.NVUGIB can have a substantial impact on other aspects of quality of life (QOL) in patients and their families. Patients can require many days of informal care from family members at home during the first few weeks following a bleeding event190. In providing this help, caregivers must take time away from their usual activities, which may incur costs (financial or otherwise). In addition, for patients who are in paid employment at the time of NVUGIB, an immediate return to work is unlikely, resulting in a loss of working hours and possible earnings190. The consequences of NVUGIB can, therefore, be substantial and wide rang\\xading, affecting aspects of HRQOL and QOL for patients and their\\xa0families.OutlookNVUGIB is one of the most frequent causes of hos\\xadpitalization, morbidity and mortality associated with digestive diseases. Despite the important advances observed in the field, the management of patients with NVUGIB has become ever more challenging owing to an ageing population with comorbidities and complex therapies. PUB remains the main cause of NVUGIB, and most advances in NVUGIB have been focused on this pathology. However, the face and profile of NVUGIB events are changing, which demands new approaches in \\xadprevention, diagnosis and therapy9,23.ManagementFrom a pathogenetic point of view and in addition to the appropriate endoscopic management of bleeding lesions, stabilization of the clotting process in the acidic',\n",
       " 'ManagementFrom a pathogenetic point of view and in addition to the appropriate endoscopic management of bleeding lesions, stabilization of the clotting process in the acidic environment of the upper gastrointestinal tract is a goal that should be achieved for the successful control of the bleeding event. Although the route of administra\\xadtion and best dosing regimen are still matters of debate, there is consensus that PPIs are the drug of choice. The development of new compounds such as a new class of potassium-competitive acid blockers may facilitate emergency treatment of NVUGIB as they have a faster onset and greater, more consistent and longer acid \\xadcontrol198 than\\xa0PPIs.Endoscopic diagnosis and treatment of gastro\\xadintestinal bleeding lesions probably represent the most important advances in the control of bleeding events. Innovation in endoscopic techniques continues to provide new tools for the management of NVUGIB. New therapies with compounds or devices that can be safely applied during the endoscopic procedures or new diagnostic tools such as the endoscopic Doppler probe that can improve the localization of the blood vessel responsible for the bleeding97 will probably be imple\\xadmented in our routine clinical practice in the future once they prove to be safe and useful in clinical trials. Patients with ongoing bleeding despite initial volume restitution could benefit from very early endoscopy (<12\\xa0hours or even <6\\xa0hours), but this should be clarified in future studies. New studies should also define whether \\xadroutine second-look endoscopy can be performed in selected patients at high risk of therapeutic failure after first-line\\xa0therapy.Box 5 | Coagulation tests for DOACsResults of routine coagulation tests in patients taking direct oral anticoagulants (DOACs) are unreliable and vary depending on the reagents used. Approximately 20% of patients who take dabigatran have a normal activated partial thromboplastin time213,214. However,',\n",
       " 'vary depending on the reagents used. Approximately 20% of patients who take dabigatran have a normal activated partial thromboplastin time213,214. However, the\\xa0American Society of Hematology states in its practice guide that dabigatran is unlikely to contribute to bleeding if partial thromboplastin time is normal215. Similar findings have been reported with prothrombin time for rivaroxaban216. In some specialized laboratories, activity assays calibrated to the specific drug can be performed (that is, diluted thrombin time specific for\\xa0dabigatran and anti-factor Xa assays specific for rivaroxaban, apixaban and edoxaban)217.PRIMER16 | ARTICLE NUMBER 18020 | VOLUME 4www.nature.com/nrdp© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " 'Patients on antiplatelet or anticoagulation agentsThe clearest changes are the progressive decline in H.\\xa0pylori-related PUB in developed countries and a pro\\xadgressive increase in elderly patients with NVUGIB, who often take antiplatelet and anticoagulant agents. These changes demand specific approaches in both prevention and therapeutic management owing to the increased risk of thromboembolic events when these therapies are withheld during a bleeding event. In our experience, the proportion of patients with this problem is growing. The new DOACs will progressively replace vitamin\\xa0K antagonists, and the development of agents to reverse each specific DOAC will be a challenge in terms of the appropriate management and costs. The opportunity to improve adherence to guideline recommendations for PPI prophylaxis for those patients on antiplatelet and/or anticoagulant therapy remains a challenge in daily \\xadclinical practice199.Prognostic scoring systemsSeveral prognostic scores have been developed to facili\\xadtate the clinical decision path at the time of emergency admission before and/or after endoscopy. When sev\\xaderal prognostic scores are used or proposed, or when they are infrequently used in most emergency rooms200, the logical conclusion is to assume that none of them fulfils all demands required by the clinicians. The GBS seems to be the best at predicting most outcomes but not mortality. A low GBS score (0–1) would mandate ambulatory treatment, but few patients present at emergency rooms with such a low score, which limits its impact. With new statistical approaches, learning machines and artificial intelligence systems, efforts should be made to find the best tool to predict the best management\\xa0approach.PrognosisAlthough overall mortality associated with NVUGIB has declined over time owing to a parallel decrease in the number of events, mortality linked to the bleeding event itself is resistant because the majority of patients',\n",
       " 'has declined over time owing to a parallel decrease in the number of events, mortality linked to the bleeding event itself is resistant because the majority of patients with NVUGIB die from non-bleeding-related causes4. Clearly, further improvements of this outcome will be a challenge and probably require a multidisciplinary approach by specialized\\xa0teams.Finally, one aspect often overlooked and rarely investigated is the prognosis of patients with NVUGIB beyond the event. Thus far, little attention has been paid to the QOL of patients following a gastrointesti\\xadnal bleeding event because this aspect requires con\\xadtact to be maintained with patients and actions to be implemented after hospital discharge. The appropriate management of anaemia and iron deficiency has the potential to directly affect the QOL and performance of most patients. Implications for physical health, mobility, performance of daily activities, pain, discomfort, \\xadanxiety and depression following hospital admission and dis\\xadcharge have not been as adequately investigated and are as important to patients and families as the bleed\\xading itself. These aspects need to be featured within our agenda when \\xadconsidering the appropriate management of patients105,188,190.Figure 9 | Management of NVUGIB in those on DOACs. Direct oral anticoagulant (DOAC) treatment should be withheld in patients with an ongoing non-variceal upper gastrointestinal bleeding (NVUGIB) episode. Depending on the severity of bleeding and the specific DOAC taken, other measures might be needed. UGIB, upper gastrointestinal bleeding. aIf idarucizumab is not available (in case of dabigatran use) or the patient is treated with anti-factor Xa, use four‑factor prothrombin complex concentrate (PCC). Algorithm based on expert consensus and recommendations of the European Hearth Rhythm Association167,176,180.Nature Reviews | Disease PrimersUndergo measures to control mild bleeding plus• Aggressive ﬂuid replacement',\n",
       " 'Rhythm Association167,176,180.Nature Reviews | Disease PrimersUndergo measures to control mild bleeding plus• Aggressive ﬂuid replacement • Consider charcoal (DOAC overdose  <3 hours) For dabigatran, consider• Haemodialysis • Intravenous idarucizumabFor anti-factor Xaa, consider four-factor PCC Delay orinterruptDOACInquire about type and last dose of DOACBlood sample to measure creatinine and speciﬁc coagulation test (if available)UGIB in patients taking DOACsModerate to severe bleedingUndergo measures to control moderate or severe bleeding plus• For dabigatran:  intravenous idarucizumab• For anti-factor Xaa:  four-factor PCCLife-threatening bleedingor ongoing bleeding despiteadequate measuresMildbleeding1.Laine,\\xa0L. Upper gastrointestinal bleeding due to a\\xa0peptic ulcer. N.\\xa0Engl. J.\\xa0Med. 374, 2367–2376 (2016).2.Gralnek,\\xa0I.\\xa0M., Neeman,\\xa0Z. & Strate,\\xa0L.\\xa0L. Acute lower gastrointestinal bleeding. N.\\xa0Engl. J.\\xa0Med. 376, 1054–1063 (2017).3.Lanas,\\xa0A. & Chan,\\xa0F.\\xa0K. Peptic ulcer disease. Lancet 390, 613–624 (2017).4.Sung,\\xa0J.\\xa0J. et\\xa0al. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am. J.\\xa0Gastroenterol. 105, 84–89 (2010).5.Gralnek,\\xa0I.\\xa0M. et\\xa0al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 47, a1–a46 (2015).This paper presents the most recent European guidelines based on the best available evidence for\\xa0the complete management of NVUGIB.6.Rotondano,\\xa0G. Epidemiology and diagnosis of acute\\xa0nonvariceal upper gastrointestinal bleeding. Gastroenterol. Clin. North Am. 43, 643–663 (2014).7.Hreinsson,\\xa0J.\\xa0P., Kalaitzakis,\\xa0E., Gudmundsson,\\xa0S. &\\xa0Björnsson,\\xa0E.\\xa0S. Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based setting. Scand. J.\\xa0Gastroenterol. 48, 439–447 (2013).8.Gralnek,\\xa0I.\\xa0M., Barkun,\\xa0A.\\xa0N. & Bardou,\\xa0M.',\n",
       " 'incidence, etiology and outcomes in a population-based setting. Scand. J.\\xa0Gastroenterol. 48, 439–447 (2013).8.Gralnek,\\xa0I.\\xa0M., Barkun,\\xa0A.\\xa0N. & Bardou,\\xa0M. Management of acute bleeding from a peptic ulcer. N.\\xa0Engl. J.\\xa0Med. 359, 928–937 (2008).9.Laine,\\xa0L., Yang,\\xa0H., Chang,\\xa0S.\\xa0C. & Datto,\\xa0C. Trends for\\xa0incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am. J.\\xa0Gastroenterol. 107, 1190–1195 (2012).10. Laine,\\xa0L. & Jensen,\\xa0D.\\xa0M. Management of patients with ulcer bleeding. Am. J.\\xa0Gastroenterol. 107, 345–360 (2012).11. Lau,\\xa0J.\\xa0Y. et\\xa0al. Challenges in the management of acute peptic ulcer bleeding. Lancet 381, 2033–2043 (2013).12. Quan,\\xa0S. et\\xa0al. Upper-gastrointestinal bleeding secondary to peptic ulcer disease: incidence and\\xa0outcomes. World J.\\xa0Gastroenterol. 20, 17568–17577 (2014).13. Tielleman,\\xa0T., Bujanda,\\xa0D. & Cryer,\\xa0B. Epidemiology and risk factors for upper gastrointestinal bleeding. Gastrointest. Endosc. Clin. N.\\xa0Am. 25, 415–428 (2015).14. Everhart,\\xa0J.\\xa0E. & Ruhl,\\xa0C.\\xa0E. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology 136, 376–386 (2009).15. Wuerth,\\xa0B.\\xa0A. & Rockey,\\xa0D.\\xa0C. Changing epidemiology of upper gastrointestinal hemorrhage in the last decade: a nationwide analysis. Dig. Dis. Sci. (2017).16. van Leerdam,\\xa0M.\\xa0E. et\\xa0al. Acute upper GI bleeding: did\\xa0anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am. J.\\xa0Gastroenterol. 98, 1494–1499 (2003).17. Lanas,\\xa0A. et\\xa0al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am.\\xa0J.\\xa0Gastroenterol. 100, 1685–1693 (2005).18. Ahsberg,\\xa0K., Ye,\\xa0W., Lu,\\xa0Y., Zheng,\\xa0Z. &\\xa0Staël\\xa0von\\xa0Holstein,\\xa0C. Hospitalisation of and mortality from bleeding peptic ulcer in Sweden:',\n",
       " 'Am.\\xa0J.\\xa0Gastroenterol. 100, 1685–1693 (2005).18. Ahsberg,\\xa0K., Ye,\\xa0W., Lu,\\xa0Y., Zheng,\\xa0Z. &\\xa0Staël\\xa0von\\xa0Holstein,\\xa0C. Hospitalisation of and mortality from bleeding peptic ulcer in Sweden: a\\xa0nationwide time-trend analysis. Aliment. Pharmacol. Ther. 33, 578–584 (2011).19. Cavallaro,\\xa0L.\\xa0G. et\\xa0al. Time trends and outcome of\\xa0gastrointestinal bleeding in the Veneto region: a\\xa0retrospective population based study from 2001 to\\xa02010. Dig. Liver Dis. 46, 313–317 (2014).PRIMERNATURE REVIEWS | DISEASE PRIMERS VOLUME 4 | ARTICLE NUMBER 18020 | 17© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " '20. Sonnenberg,\\xa0A. Time trends of ulcer mortality in non-European countries. Am. J.\\xa0Gastroenterol. 102, 1101–1107 (2007).21. Wollenman,\\xa0C.\\xa0S., Chason,\\xa0R., Reisch,\\xa0J.\\xa0S. &\\xa0Rockey,\\xa0D.\\xa0C. Impact of ethnicity in upper gastrointestinal hemorrhage. J.\\xa0Clin. Gastroenterol. 48, 343–350 (2014).22. Irwin,\\xa0J., Ferguson,\\xa0R., Weilert,\\xa0F. & Smith,\\xa0A. Incidence of upper gastrointestinal haemorrhage in\\xa0Maori and New Zealand European ethnic groups, 2001–2010. Intern. Med. J. 44, 735–741 (2014).23. Lanas,\\xa0A. et\\xa0al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment. Pharmacol. Ther. 33, 585–591 (2011).24. Papatheodoridis,\\xa0G.\\xa0V., Sougioultzis,\\xa0S. &\\xa0Archimandritis,\\xa0A.\\xa0J. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin. Gastroenterol. Hepatol. 4, 130–142 (2006).25. Gisbert,\\xa0J.\\xa0P. & Calvet,\\xa0X. Review article: Helicobacter\\xa0pylori-negative duodenal ulcer disease. Aliment.\\xa0Pharmacol. Ther. 30, 791–815 (2009).26. Charpignon,\\xa0C. et\\xa0al. Peptic ulcer disease: one in five\\xa0is\\xa0related to neither Helicobacter pylori nor aspirin/NSAID intake. Aliment. Pharmacol. Ther. 38, 946–954 (2013).27. Chan,\\xa0H.\\xa0L. et\\xa0al. Is non-Helicobacter pylori, non‑NSAID peptic ulcer a common cause of upper GI\\xa0bleeding? A prospective study of 977 patients. Gastrointest. Endosc. 53, 438–442 (2001).28. Yoon,\\xa0H., Kim,\\xa0S.\\xa0G., Jung,\\xa0H.\\xa0C. & Song,\\xa0I.\\xa0S. High recurrence rate of idiopathic peptic ulcers in long-term follow‑up. Gut Liver 7, 175–181 (2013).29. Wong,\\xa0G.\\xa0L. et\\xa0al. Gastroprotective therapy does not\\xa0improve outcomes of patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Clin.\\xa0Gastroenterol. Hepatol. 10, 1124–1129 (2012).30. Wong,\\xa0G.\\xa0L. et\\xa0al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 137, 525–531 (2009).31. Iijima,\\xa0K., Kanno,\\xa0T., Koike,\\xa0T. & Shimosegawa,\\xa0T.',\n",
       " 'recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 137, 525–531 (2009).31. Iijima,\\xa0K., Kanno,\\xa0T., Koike,\\xa0T. & Shimosegawa,\\xa0T. Helicobacter pylori-negative, non-steroidal anti-inflammatory drug: negative idiopathic ulcers in Asia. World J.\\xa0Gastroenterol. 20, 706–713 (2014).32. Crooks,\\xa0C., Card,\\xa0T. & West,\\xa0J. Reductions in 28‑day mortality following hospital admission for upper gastrointestinal hemorrhage. Gastroenterology 141, 62–70 (2011).33. Abougergi,\\xa0M.\\xa0S., Travis,\\xa0A.\\xa0C. & Saltzman,\\xa0J.\\xa0R. The\\xa0in‑hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a\\xa0nationwide analysis. Gastrointest. Endosc. 81, 882–888.e1 (2015).34. Taefi,\\xa0A., Cho,\\xa0W.\\xa0K. & Nouraie,\\xa0M. Decreasing trend of\\xa0upper gastrointestinal bleeding mortality risk over three decades. Dig. Dis. Sci. 58, 2940–2948 (2013).35. Jairath,\\xa0V., Martel,\\xa0M., Logan,\\xa0R.\\xa0F. & Barkun,\\xa0A.\\xa0N. Why do mortality rates for nonvariceal upper gastrointestinal bleeding differ around the world? A\\xa0systematic review of cohort studies. Can.\\xa0J.\\xa0Gastroenterol. 26, 537–543 (2012).36. Sostres,\\xa0C. & Lanas,\\xa0A. Epidemiology and demographics of upper gastrointestinal bleeding: prevalence, incidence, and mortality. Gastrointest. Endosc. Clin. N.\\xa0Am. 21, 567–581 (2011).37. Wang,\\xa0F., Meng,\\xa0W., Wang,\\xa0B. & Qiao,\\xa0L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 345, 196–202 (2014).38. Datta De,\\xa0D. & Roychoudhury,\\xa0S. To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases. World\\xa0J.\\xa0Gastroenterol. 21, 2883–2895 (2015).39. Zaki,\\xa0M. et\\xa0al. H.\\xa0pylori acutely inhibits gastric secretion by activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine secretion. Am. J.\\xa0Physiol. Gastrointest. Liver Physiol. 304, G715–722 (2013).40. Moss,\\xa0S.\\xa0F., Legon,\\xa0S., Bishop,\\xa0A.\\xa0E., Polak,\\xa0J.\\xa0M.',\n",
       " 'to stimulation of somatostatin and inhibition of histamine secretion. Am. J.\\xa0Physiol. Gastrointest. Liver Physiol. 304, G715–722 (2013).40. Moss,\\xa0S.\\xa0F., Legon,\\xa0S., Bishop,\\xa0A.\\xa0E., Polak,\\xa0J.\\xa0M. &\\xa0Calam,\\xa0J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 340, 930–932 (1992).41. Bjarnason,\\xa0I. et\\xa0al. Mechanisms of damage to the gastrointestinal tract from\\xa0nonsteroidal anti-inflammatory drugs. Gastroenterology 154, 500–514 (2018).42. Cryer,\\xa0B. & Feldman,\\xa0M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and\\xa0rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117, 17–25 (1999).43. Sostres,\\xa0C. et\\xa0al. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am. J.\\xa0Gastroenterol. 110, 684–689 (2015).44. Green,\\xa0F.\\xa0W., Kaplan,\\xa0M.\\xa0M., Curtis,\\xa0L.\\xa0E. &\\xa0Levine,\\xa0P.\\xa0H. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 74, 38–43 (1978).45. Lanas,\\xa0A. et\\xa0al. Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J.\\xa0Clin. Gastroenterol. 21, 103–106 (1995).46. van Rensburg,\\xa0C.\\xa0J. et\\xa0al. Intragastric pH during continuous infusion with pantoprazole in patients with\\xa0bleeding peptic ulcer. Am. J.\\xa0Gastroenterol. 98, 2635–2641 (2003).47. Laine,\\xa0L., Shah,\\xa0A. & Bemanian,\\xa0S. Intragastric pH with\\xa0oral versus intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. Gastroenterology 134, 1836–1841 (2008).48. Bardou,\\xa0M., Toubouti,\\xa0Y., Benhaberou-Brun,\\xa0D., Rahme,\\xa0E. & Barkun,\\xa0A.\\xa0N. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic\\xa0ulcer bleeding. Aliment. Pharmacol. Ther. 21, 677–686 (2005).49. Halvorsen,\\xa0S. et\\xa0al. Management of antithrombotic therapy after bleeding in patients with coronary artery',\n",
       " 'peptic\\xa0ulcer bleeding. Aliment. Pharmacol. Ther. 21, 677–686 (2005).49. Halvorsen,\\xa0S. et\\xa0al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur. Heart J. 38, 1455–1462 (2017).50. Laine,\\xa0L., Maller,\\xa0E.\\xa0S., Yu,\\xa0C., Quan,\\xa0H. & Simon,\\xa0T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX‑2 selective inhibition: a double-blind trial. Gastroenterology 127, 395–402 (2004).51. Hernández-Díaz,\\xa0S. & García Rodríguez,\\xa0L.\\xa0A. Cardioprotective aspirin users and their excess risk of\\xa0upper gastrointestinal complications. BMC Med. 4, 22 (2006).52. Lanas,\\xa0A.\\xa0I. et\\xa0al. Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Gut 39, 654–660 (1996).53. García-González,\\xa0M.\\xa0A. et\\xa0al. Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. Clin. Exp. Immunol. 134, 525–531 (2003).54. Okada,\\xa0M. et\\xa0al. Circumferential distribution and location of Mallory-Weiss tears: recent trends. Endosc.\\xa0Int. Open 3, E418–424 (2015).55. Cherednikov,\\xa0E.\\xa0F., Kunin,\\xa0A.\\xa0A., Cherednikov,\\xa0E.\\xa0E. &\\xa0Moiseeva,\\xa0N.\\xa0S. The role of etiopathogenetic aspects in prediction and prevention of discontinuous-hemorrhagic (Mallory-Weiss) syndrome. EPMA J. 7, 7 (2016).56. Baxter,\\xa0M. & Aly,\\xa0E.\\xa0H. Dieulafoy’s lesion: current trends in diagnosis and management. Ann. R.\\xa0Coll. Surg. Engl. 92, 548–554 (2010).57. Sami,\\xa0S.\\xa0S., Al‑Araji,\\xa0S.\\xa0A. & Ragunath,\\xa0K. Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management. Aliment. Pharmacol. Ther. 39, 15–34 (2014).58. Kim,\\xa0D.\\xa0B. et\\xa0al. Analysis of risk factor and clinical characteristics of angiodysplasia presenting as upper gastrointestinal bleeding. Kor. J.\\xa0Intern. Med. 31, 669–677 (2016).59. Crooks,\\xa0C.\\xa0J., West,\\xa0J. & Card,\\xa0T.\\xa0R. Comorbidities',\n",
       " 'characteristics of angiodysplasia presenting as upper gastrointestinal bleeding. Kor. J.\\xa0Intern. Med. 31, 669–677 (2016).59. Crooks,\\xa0C.\\xa0J., West,\\xa0J. & Card,\\xa0T.\\xa0R. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 144, 1384–1393.e2 (2013).60. De Backer,\\xa0D., Creteur,\\xa0J., Dubois,\\xa0M.\\xa0J., Sakr,\\xa0Y. &\\xa0Vincent,\\xa0J.\\xa0L. Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. Am. Heart J. 147, 91–99 (2004).61. Huang,\\xa0K.\\xa0W. et\\xa0al. Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study. Aliment. Pharmacol. Ther. 35, 796–802 (2012).62. Luo,\\xa0J.\\xa0C. et\\xa0al. Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal\\xa0disease receiving hemodialysis. CMAJ 183, E1345–E1351 (2011).63. Hunt,\\xa0R.\\xa0H., Lanas,\\xa0A., Stichtenoth,\\xa0D.\\xa0O. &\\xa0Scarpignato,\\xa0C. Myths and facts in the use of anti-inflammatory drugs. Ann. Med. 41, 423–437 (2009).64. Masclee,\\xa0G.\\xa0M. et\\xa0al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 147, 784–792.e9 (2014).65. Laine,\\xa0L. et\\xa0al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a\\xa0double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 123, 1006–1012 (2002).66. Lanas,\\xa0A. & Hunt,\\xa0R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and\\xa0risks of therapeutic strategies. Ann. Med. 38, 415–428 (2006).67. Scarpignato,\\xa0C. et\\xa0al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis — an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 13, 55 (2015).68. Chan,\\xa0F.\\xa0K. et\\xa0al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N.\\xa0Engl. J.\\xa0Med. 344, 967–973 (2001).',\n",
       " 'gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N.\\xa0Engl. J.\\xa0Med. 344, 967–973 (2001).69. Chan,\\xa0F.\\xa0K. et\\xa0al. Combination of a cyclo-oxygenase‑2 inhibitor and a proton-pump inhibitor for prevention of\\xa0recurrent ulcer bleeding in patients at very high risk: a\\xa0double-blind, randomised trial. Lancet 369, 1621–1626 (2007).This article presents the first RCT that demonstrated the combination of a COX2 inhibitor and a PPI is the best strategy to reduce the risk of recurrent PUB in patients at very high risk (that is, those who have had a previous ulcer bleeding event) who need NSAIDs.70. Anglin,\\xa0R. et\\xa0al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am. J.\\xa0Gastroenterol. 109, 811–819 (2014).71. Bhatt,\\xa0D.\\xa0L. et\\xa0al. Clopidogrel with or without omeprazole in coronary artery disease. N.\\xa0Engl. J.\\xa0Med. 363, 1909–1917 (2010).This is the only double-blind RCT that tested both\\xa0cardiovascular and gastrointestinal events\\xa0in\\xa0patients who receive clopidogrel plus LDA\\xa0and\\xa0omeprazole versus clopidogrel and LDA. Omeprazole reduced the number of gastrointestinal events and did not increase the\\xa0risk of cardiovascular events.72. Lanas-Gimeno,\\xa0A. & Lanas,\\xa0A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin. Drug Saf 16, 673–685 (2017).73. Nuki,\\xa0Y. et\\xa0al. The influence of CYP2C19 polymorphisms on exacerbating effect of rabeprazole\\xa0in celecoxib-induced small bowel injury. Aliment.\\xa0Pharmacol. Ther. 46, 331–336 (2017).74. Moayyedi,\\xa0P.\\xa0M. et\\xa0al. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am. J.\\xa0Gastroenterol. 112, 988–1013 (2017).75. Malfertheiner,\\xa0P. et\\xa0al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66, 6–30 (2017).76. Huang,\\xa0T.\\xa0C. & Lee,\\xa0C.\\xa0L. Diagnosis, treatment, and',\n",
       " '75. Malfertheiner,\\xa0P. et\\xa0al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66, 6–30 (2017).76. Huang,\\xa0T.\\xa0C. & Lee,\\xa0C.\\xa0L. Diagnosis, treatment, and outcome in patients with bleeding peptic ulcers and Helicobacter pylori infections. Biomed. Res. Int. 2014, 658108 (2014).77. Srygley,\\xa0F.\\xa0D., Gerardo,\\xa0C.\\xa0J., Tran,\\xa0T. & Fisher,\\xa0D.\\xa0A. Does this patient have a severe upper gastrointestinal bleed? JAMA 307, 1072–1079 (2012).78. Barkun,\\xa0A. et\\xa0al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann.\\xa0Intern. Med. 152, 101–113 (2010).79. Shrestha,\\xa0M.\\xa0P., Borgstrom,\\xa0M. & Trowers,\\xa0E. Digital rectal examination reduces hospital admissions, endoscopies, and medical therapy in patients with acute gastrointestinal bleeding. Am. J.\\xa0Med. 130, 819–825 (2017).80. Stanley,\\xa0A.\\xa0J. et\\xa0al. Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study. BMJ 356, i6432 (2017).This prospective study of 3,012 consecutive patients  analysed the predictive accuracy and clinical utility of five risk-scoring systems in the assessment of patients with NVUGIB. The GBS was the best of all, showing high accuracy at predicting the need for hospital-based intervention or death.81. Wolf,\\xa0A.\\xa0T., Wasan,\\xa0S.\\xa0K. & Saltzman,\\xa0J.\\xa0R. Impact of\\xa0anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am. J.\\xa0Gastroenterol. 102, 290–296 (2007).82. Jairath,\\xa0V. et\\xa0al. Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to\\xa0endoscopy: results from a nationwide study. Endoscopy 44, 723–730 (2012).PRIMER18 | ARTICLE NUMBER 18020 | VOLUME 4www.nature.com/nrdp© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " '83. Hearnshaw,\\xa0S.\\xa0A. et\\xa0al. Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut 59, 1022–1029 (2010).84. Sarin,\\xa0N., Monga,\\xa0N. & Adams,\\xa0P.\\xa0C. Time to endoscopy and outcomes in upper gastrointestinal bleeding. Can. J.\\xa0Gastroenterol. 23, 489–493 (2009).85. Targownik,\\xa0L.\\xa0E., Murthy,\\xa0S., Keyvani,\\xa0L. & Leeson,\\xa0S. The role of rapid endoscopy for high-risk patients with\\xa0acute nonvariceal upper gastrointestinal bleeding. Can. J.\\xa0Gastroenterol. 21, 425–429 (2007).86. Tai,\\xa0C.\\xa0M. et\\xa0al. High-risk ED patients with nonvariceal upper gastrointestinal hemorrhage undergoing emergency or urgent endoscopy: a retrospective analysis. Am. J.\\xa0Emerg. Med. 25, 273–278 (2007).87. Spiegel,\\xa0B.\\xa0M., Vakil,\\xa0N.\\xa0B. & Ofman,\\xa0J.\\xa0J. Endoscopy for acute nonvariceal upper gastrointestinal tract hemorrhage: is sooner better? A systematic review. Arch. Intern. Med. 161, 1393–1404 (2001).88. Tsoi,\\xa0K.\\xa0K., Ma,\\xa0T.\\xa0K. & Sung,\\xa0J.\\xa0J. Endoscopy for upper gastrointestinal bleeding: how urgent is it? Nat. Rev. Gastroenterol. Hepatol. 6, 463–469 (2009).89. Kumar,\\xa0N.\\xa0L., Cohen,\\xa0A.\\xa0J., Nayor,\\xa0J., Claggett,\\xa0B.\\xa0L. &\\xa0Saltzman,\\xa0J.\\xa0R. Timing of upper endoscopy influences outcomes in patients with acute nonvariceal\\xa0upper GI bleeding. Gastrointest. Endosc. 85, 945–952.e1 (2017).90. Forrest,\\xa0J.\\xa0A., Finlayson,\\xa0N.\\xa0D. & Shearman,\\xa0D.\\xa0J. Endoscopy in gastrointestinal bleeding. Lancet 2, 394–397 (1974).91. Heldwein,\\xa0W., Schreiner,\\xa0J., Pedrazzoli,\\xa0J. & Lehnert,\\xa0P. Is the Forrest classification a useful tool for planning endoscopic therapy of bleeding peptic ulcers? Endoscopy 21, 258–262 (1989).92. Lau,\\xa0J.\\xa0Y. et\\xa0al. The evolution of stigmata of hemorrhage in bleeding peptic ulcers: a sequential endoscopic study. Endoscopy 30, 513–518 (1998).93. Lau,\\xa0J.\\xa0Y. et\\xa0al. Stigmata of hemorrhage in bleeding peptic ulcers: an interobserver agreement study among international experts. Gastrointest. Endosc. 46, 33–36 (1997).',\n",
       " '93. Lau,\\xa0J.\\xa0Y. et\\xa0al. Stigmata of hemorrhage in bleeding peptic ulcers: an interobserver agreement study among international experts. Gastrointest. Endosc. 46, 33–36 (1997).94. Laine,\\xa0L. & McQuaid,\\xa0K.\\xa0R. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on\\xa0meta-analyses of randomized controlled trials. Clin.\\xa0Gastroenterol. Hepatol. 7, 33–47 (2009).This meta-analysis of RCTs determined the best endoscopic treatment of patients with bleeding ulcers.95. Sung,\\xa0J.\\xa0J. et\\xa0al. The effect of endoscopic therapy in\\xa0patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: a\\xa0randomized comparison. Ann. Intern. Med. 139, 237–243 (2003).96. Jensen,\\xa0D.\\xa0M. et\\xa0al. Randomized trial of medical or\\xa0endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology 123, 407–413 (2002).97. Jensen,\\xa0D.\\xa0M. et\\xa0al. Doppler endoscopic probe as a guide to risk stratification and definitive hemostasis of\\xa0peptic ulcer bleeding. Gastrointest. Endosc. 83, 129–136 (2016).98. Jensen,\\xa0D.\\xa0M. et\\xa0al. Reassessment of rebleeding risk of Forrest IB (oozing) peptic ulcer bleeding in a large international randomized trial. Am. J.\\xa0Gastroenterol. 112, 441–446 (2017).99. Jensen,\\xa0D.\\xa0M. et\\xa0al. Doppler endoscopic probe monitoring of blood flow improves risk stratification and outcomes of patients with severe nonvariceal upper gastrointestinal hemorrhage. Gastroenterology 152, 1310–1318.e1 (2017).100.Fujishiro,\\xa0M. et\\xa0al. Current managements and outcomes of peptic and artificial ulcer bleeding in Japan. Dig. Endosc. 22 (Suppl. 1), S9–S14 (2010).101.Fujishiro,\\xa0M. et\\xa0al. Guidelines for endoscopic management of non-variceal upper gastrointestinal bleeding. Dig. Endosc. 28, 363–378 (2016).102.El Ouali,\\xa0S. et\\xa0al. Is routine second-look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding? A meta-analysis. Gastrointest. Endosc. 76, 283–292 (2012).',\n",
       " '102.El Ouali,\\xa0S. et\\xa0al. Is routine second-look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding? A meta-analysis. Gastrointest. Endosc. 76, 283–292 (2012).This meta-analysis of randomized trials concluded that in unselected patients and in the era of high-dose PPI, second-look endoscopy does not offer significant benefit.103.Imperiale,\\xa0T.\\xa0F. & Kong,\\xa0N. Second-look endoscopy for bleeding peptic ulcer disease: a decision-effectiveness and cost-effectiveness analysis. J.\\xa0Clin. Gastroenterol. 46, e71–e75 (2012).104.Villanueva,\\xa0C. et\\xa0al. Transfusion strategies for acute upper gastrointestinal bleeding. N.\\xa0Engl. J.\\xa0Med. 368, 11–21 (2013).This seminal study shows that, compared with a liberal blood transfusion policy, a restrictive blood transfusion policy in patients with UGIB is associated with better survival.105.Leontiadis,\\xa0G.\\xa0I. et\\xa0al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol. Assess. 11, 1–164 (2007).106.Sreedharan,\\xa0A. et\\xa0al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst. Rev. 7, CD005415 (2010).107.Al‑Sabah,\\xa0S. et\\xa0al. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding. Clin. Gastroenterol. Hepatol. 6, 418–425 (2008).108.Theivanayagam,\\xa0S. et\\xa0al. Administration of erythromycin before endoscopy in upper gastrointestinal bleeding: a meta-analysis of randomized controlled trials. Saudi J.\\xa0Gastroenterol. 19, 205–210 (2013).109.Barkun,\\xa0A.\\xa0N., Martel,\\xa0M., Toubouti,\\xa0Y., Rahme,\\xa0E. &\\xa0Bardou,\\xa0M. Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of\\xa0meta-analyses. Gastrointest. Endosc. 69, 786–799 (2009).110. Sung,\\xa0J.\\xa0J., Tsoi,\\xa0K.\\xa0K., Lai,\\xa0L.\\xa0H., Wu,\\xa0J.\\xa0C. & Lau,\\xa0J.\\xa0Y. Endoscopic clipping versus injection and thermo-',\n",
       " 'of\\xa0meta-analyses. Gastrointest. Endosc. 69, 786–799 (2009).110. Sung,\\xa0J.\\xa0J., Tsoi,\\xa0K.\\xa0K., Lai,\\xa0L.\\xa0H., Wu,\\xa0J.\\xa0C. & Lau,\\xa0J.\\xa0Y. Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta-analysis. Gut 56, 1364–1373 (2007).111. Calvet,\\xa0X., Vergara,\\xa0M., Brullet,\\xa0E., Gisbert,\\xa0J.\\xa0P. &\\xa0Campo,\\xa0R. Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers. Gastroenterology 126, 441–450 (2004).112.Marmo,\\xa0R. et\\xa0al. Dual therapy versus monotherapy in\\xa0the endoscopic treatment of high-risk bleeding ulcers: a meta-analysis of controlled trials. Am.\\xa0J.\\xa0Gastroenterol. 102, 279–289 (2007).113.Vergara,\\xa0M., Bennett,\\xa0C., Calvet,\\xa0X. & Gisbert,\\xa0J.\\xa0P. Epinephrine injection versus epinephrine injection and\\xa0a second endoscopic method in high-risk bleeding ulcers. Cochrane Database Syst. Rev. 2, CD005584 (2014).114.Hwang,\\xa0J.\\xa0H. et\\xa0al. The role of endoscopy in the management of acute non-variceal upper GI bleeding. Gastrointest. Endosc. 75, 1132–1138 (2012).115.Fujishiro,\\xa0M. et\\xa0al. Retrospective multicenter study concerning electrocautery forceps with soft coagulation for nonmalignant gastroduodenal ulcer\\xa0bleeding in Japan. Dig. Endosc. 22 (Suppl. 1), S15–S18 (2010).116.Wedi,\\xa0E. et\\xa0al. Use of the over-the-scope-clip (OTSC) in\\xa0non-variceal upper gastrointestinal bleeding in patients with severe cardiovascular comorbidities: a\\xa0retrospective study. Endosc. Int. Open 5, E875–E882 (2017).117.Prei,\\xa0J.\\xa0C. et\\xa0al. EndoClot polysaccharide hemostatic system in nonvariceal gastrointestinal bleeding: results of a prospective multicenter observational pilot study. J.\\xa0Clin. Gastroenterol. 50, e95–e100 (2016).118.Haddara,\\xa0S. et\\xa0al. A novel hemostatic powder for upper gastrointestinal bleeding: a multicenter study (the “GRAPHE” registry). Endoscopy 48, 1084–1095 (2016).119.Lecleire,\\xa0S. et\\xa0al. Endoscopic band ligation could',\n",
       " 'upper gastrointestinal bleeding: a multicenter study (the “GRAPHE” registry). Endoscopy 48, 1084–1095 (2016).119.Lecleire,\\xa0S. et\\xa0al. Endoscopic band ligation could decrease recurrent bleeding in Mallory-Weiss syndrome as compared to haemostasis by hemoclips plus epinephrine. Aliment. Pharmacol. Ther. 30, 399–405 (2009).120.Yamaguchi,\\xa0Y. et\\xa0al. Endoscopic hemoclipping for upper GI bleeding due to Mallory-Weiss syndrome. Gastrointest. Endosc. 53, 427–430 (2001).121.Silverstein,\\xa0F.\\xa0E. et\\xa0al. Argon versus neodymium YAG laser photocoagulation of experimental canine gastric ulcers. Gastroenterology 77, 491–496 (1979).122.Kwan,\\xa0V. et\\xa0al. Argon plasma coagulation in the management of symptomatic gastrointestinal vascular lesions: experience in 100 consecutive patients with\\xa0long-term follow‑up. Am. J.\\xa0Gastroenterol. 101, 58–63 (2006).123.Sargeant,\\xa0I.\\xa0R., Loizou,\\xa0L.\\xa0A., Rampton,\\xa0D., Tulloch,\\xa0M. & Bown,\\xa0S.\\xa0G. Laser ablation of upper gastrointestinal vascular ectasias: long term results. Gut 34, 470–475 (1993).124.Zulli,\\xa0C. et\\xa0al. Refractory gastric antral vascular ectasia: a new endoscopic approach. Eur. Rev. Med. Pharmacol. Sci. 19, 4119–4122 (2015).125.Maida,\\xa0M., Camilleri,\\xa0S., Manganaro,\\xa0M., Garufi,\\xa0S. &\\xa0Scarpulla,\\xa0G. Radiofrequency ablation for treatment\\xa0of refractory gastric antral vascular ectasia:\\xa0a\\xa0systematic review of the literature. Gastroenterol.\\xa0Res. Pract. 2017, 5609647 (2017).126.Park,\\xa0C.\\xa0H. et\\xa0al. A prospective, randomized trial of endoscopic band ligation versus endoscopic hemoclip placement for bleeding gastric Dieulafoy’s lesions. Endoscopy 36, 677–681 (2004).127.Chaimoff,\\xa0C., Creter,\\xa0D. & Djaldetti,\\xa0M. The effect of\\xa0pH on platelet and coagulation factor activities. Am.\\xa0J.\\xa0Surg. 136, 257–259 (1978).128.Vorder Bruegge,\\xa0W.\\xa0F. & Peura,\\xa0D.\\xa0A. Stress-related mucosal damage: review of drug therapy. J.\\xa0Clin. Gastroenterol. 12 (Suppl. 2), S35–S40 (1990).129.Peterson,\\xa0K. & Bjorkman,\\xa0D.\\xa0J. Editorial: Intravenous',\n",
       " 'mucosal damage: review of drug therapy. J.\\xa0Clin. Gastroenterol. 12 (Suppl. 2), S35–S40 (1990).129.Peterson,\\xa0K. & Bjorkman,\\xa0D.\\xa0J. Editorial: Intravenous proton pump inhibitors for bleeding peptic ulcer: what\\xa0is the most cost-effective approach? Am.\\xa0J.\\xa0Gastroenterol. 111, 1399–1401 (2016).130.Lu,\\xa0Y., Adam,\\xa0V., Teich,\\xa0V. & Barkun,\\xa0A. Timing or dosing of intravenous proton pump inhibitors in acute\\xa0upper gastrointestinal bleeding has low impact on costs. Am. J.\\xa0Gastroenterol. 111, 1389–1398 (2016).131.Sachar,\\xa0H., Vaidya,\\xa0K. & Laine,\\xa0L. Intermittent versus continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern. Med. 174, 1755–1762 (2014).This meta-analysis of available RCTs shows that intermittent PPI therapy is comparable to the current guideline-recommended regimen of intravenous bolus plus a continuous infusion in patients with endoscopically treated high-risk bleeding ulcers.132.Jian,\\xa0Z. et\\xa0al. Is the era of intravenous proton pump inhibitors coming to an end in patients with bleeding peptic ulcers? Meta-analysis of the published literature. Br. J.\\xa0Clin. Pharmacol. 82, 880–889 (2016).133.Jaspersen,\\xa0D. et\\xa0al. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. Gastrointest. Endosc. 41, 5–7 (1995).134.Gisbert,\\xa0J.\\xa0P. et\\xa0al. H.\\xa0pylori eradication therapy versus antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst. Rev. 2, CD004062 (2004).135.Sung,\\xa0J.\\xa0J. et\\xa0al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a\\xa0randomized trial. Ann. Intern. Med. 150, 455–464 (2009).136.Yuan,\\xa0J.\\xa0Q. et\\xa0al. Systematic review with network meta-analysis: comparative effectiveness and safety of\\xa0strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment. Pharmacol. Ther. 43, 1262–1275 (2016).',\n",
       " 'meta-analysis: comparative effectiveness and safety of\\xa0strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment. Pharmacol. Ther. 43, 1262–1275 (2016).137.Lau,\\xa0J.\\xa0Y. et\\xa0al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N.\\xa0Engl. J.\\xa0Med. 340, 751–756 (1999).138.Kyaw,\\xa0M., Tse,\\xa0Y., Ang,\\xa0D., Ang,\\xa0T.\\xa0L. & Lau,\\xa0J. Embolization versus surgery for peptic ulcer bleeding after failed endoscopic hemostasis: a meta-analysis. Endosc. Int. Open 2, E6–E14 (2014).139.Beggs,\\xa0A.\\xa0D., Dilworth,\\xa0M.\\xa0P., Powell,\\xa0S.\\xa0L., Atherton,\\xa0H. & Griffiths,\\xa0E.\\xa0A. A systematic review of\\xa0transarterial embolization versus emergency surgery in treatment of major nonvariceal upper gastrointestinal bleeding. Clin. Exp. Gastroenterol. 7, 93–104 (2014).140.Sung,\\xa0J.\\xa0J. et\\xa0al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 43, 291–295 (2011).141.Smith,\\xa0L.\\xa0A. et\\xa0al. Hemospray application in nonvariceal upper gastrointestinal bleeding: results\\xa0of\\xa0the Survey to Evaluate the Application of Hemospray in the Luminal Tract. J.\\xa0Clin. Gastroenterol. 48, e89–92 (2014).142.Manta,\\xa0R. et\\xa0al. Over-the-scope clip (OTSC) represents an effective endoscopic treatment for acute GI bleeding after failure of conventional techniques. Surg.\\xa0Endosc. 27, 3162–3164 (2013).143.Manno,\\xa0M. et\\xa0al. First-line endoscopic treatment with OTSC in patients with high-risk non-variceal upper gastrointestinal bleeding: preliminary experience in\\xa040 cases. Surg. Endosc. 30, 2026–2029 (2016).PRIMERNATURE REVIEWS | DISEASE PRIMERS VOLUME 4 | ARTICLE NUMBER 18020 | 19© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " '144.Sung,\\xa0J.\\xa0J. et\\xa0al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann. Intern. Med. 152, 1–9 (2010).This RCT is the first to show that, compared with withholding LDA, continuation and no interruption of LDA in patients who develop NVUGIB is associated with a lower 30‑day mortality (mostly\\xa0owing to cardiovascular events) at the expense of a minor and nonsignificant increase of\\xa0gastrointestinal bleeding.145.Derogar,\\xa0M. et\\xa0al. Discontinuation of low-dose aspirin\\xa0therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. Clin.\\xa0Gastroenterol. Hepatol. 11, 38–42 (2013).146.Kim,\\xa0S.\\xa0Y. et\\xa0al. Risk of vascular thrombotic events following discontinuation of antithrombotics after peptic ulcer bleeding. J.\\xa0Clin. Gastroenterol. 50, e40–e44 (2016).147.Burger,\\xa0W., Chemnitius,\\xa0J.\\xa0M., Kneissl,\\xa0G.\\xa0D. &\\xa0Rücker,\\xa0G. Low-dose aspirin for secondary cardiovascular prevention — cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation — review and meta-analysis. J.\\xa0Intern. Med. 257, 399–414 (2005).148.Choudari,\\xa0C.\\xa0P., Rajgopal,\\xa0C. & Palmer,\\xa0K.\\xa0R. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut 35, 464–466 (1994).149.Rubin,\\xa0T.\\xa0A., Murdoch,\\xa0M. & Nelson,\\xa0D.\\xa0B. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest. Endosc. 58, 369–373 (2003).150.Peloquin,\\xa0J.\\xa0M. et\\xa0al. Diagnostic and therapeutic yield of endoscopy in patients with elevated INR and gastrointestinal bleeding. Am. J.\\xa0Med. 129, 628–634 (2016).151.Holbrook,\\xa0A. et\\xa0al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of\\xa0Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (Suppl.), e152S–e184S (2012).',\n",
       " 'Prevention of Thrombosis, 9th ed: American College of\\xa0Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (Suppl.), e152S–e184S (2012).152.Britt,\\xa0R.\\xa0B. & Brown,\\xa0J.\\xa0N. Characterizing the severe reactions of parenteral vitamin\\xa0K1. Clin. Appl. Thromb. Hemost 24, 5–12 (2018).153.Dhakal,\\xa0P., Rayamajhi,\\xa0S., Verma,\\xa0V., Gundabolu,\\xa0K. &\\xa0Bhatt,\\xa0V.\\xa0R. Reversal of anticoagulation and\\xa0management of bleeding in patients on anticoagulants. Clin. Appl. Thromb. Hemost. 23, 410–415 (2017).154.Chai-Adisaksopha,\\xa0C. et\\xa0al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb. Haemost. 116, 879–890 (2016).155.Voils,\\xa0S.\\xa0A. & Baird,\\xa0B. Systematic review: 3‑factor versus 4‑factor prothrombin complex concentrate for warfarin reversal: does it matter? Thromb. Res. 130, 833–840 (2012).156.Voils,\\xa0S.\\xa0A., Holder,\\xa0M.\\xa0C., Premraj,\\xa0S., Catlin,\\xa0J.\\xa0R. &\\xa0Allen,\\xa0B.\\xa0R. Comparative effectiveness of 3- versus 4‑factor prothrombin complex concentrate for emergent warfarin reversal. Thromb. Res. 136, 595–598 (2015).157.Kuroski,\\xa0J.\\xa0E. & Young,\\xa0S. Comparison of the safety and efficacy between 3‑factor and 4‑factor prothrombin complex concentrates for the reversal of\\xa0warfarin. Am. J.\\xa0Emergency Med. 35, 871–874 (2017).158.Majeed,\\xa0A. et\\xa0al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 128, 2325–2332 (2013).159.Steiner,\\xa0T., Rosand,\\xa0J. & Diringer,\\xa0M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 37, 256–262 (2006).160.Zatta,\\xa0A. et\\xa0al. The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII. Blood Transfus 13, 86–99 (2015).161.Witt,\\xa0D.\\xa0M., Clark,\\xa0N.\\xa0P., Kaatz,\\xa0S., Schnurr,\\xa0T. &\\xa0Ansell,\\xa0J.\\xa0E. Guidance for the practical management of warfarin therapy in the treatment of venous',\n",
       " '13, 86–99 (2015).161.Witt,\\xa0D.\\xa0M., Clark,\\xa0N.\\xa0P., Kaatz,\\xa0S., Schnurr,\\xa0T. &\\xa0Ansell,\\xa0J.\\xa0E. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J.\\xa0Thromb. Thrombolysis 41, 187–205 (2016).162.Makris,\\xa0M. et\\xa0al. Guideline on the management of bleeding in patients on antithrombotic agents. Br.\\xa0J.\\xa0Haematol. 160, 35–46 (2013).163.Radaelli,\\xa0F. et\\xa0al. Management of anticoagulation in\\xa0patients with acute gastrointestinal bleeding. Dig.\\xa0Liver Dis. 47, 621–627 (2015).164.Lubetsky,\\xa0A. et\\xa0al. Comparison of oral versus intravenous phytonadione (vitamin\\xa0K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch. Intern. Med. 163, 2469–2473 (2003).165.Heublein,\\xa0V., Pannach,\\xa0S., Daschkow,\\xa0K., Tittl,\\xa0L. &\\xa0Beyer-Westendorf,\\xa0J. Gastrointestinal endoscopy in\\xa0patients receiving novel direct oral anticoagulants: results from the prospective Dresden NOAC registry. J.\\xa0Gastroenterol. 53, 236–246 (2018).166.Bouget,\\xa0J. & Oger,\\xa0E. Emergency admissions for major\\xa0haemorrhage associated with direct oral anticoagulants. Thromb. Res. 136, 1190–1194 (2015).167.Abraham,\\xa0N.\\xa0S. & Horsley-Silva,\\xa0J.\\xa0L. Gastrointestinal bleeding secondary to the new anticoagulants. Curr.\\xa0Opin. Gastroenterol. 32, 474–480 (2016).168.Liesenfeld,\\xa0K.‑H., Gruenenfelder,\\xa0F. & Clemens,\\xa0A. Enhanced elimination of dabigatran: Identifying the\\xa0appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysis‑A simulation analysis. J.\\xa0Clin. Pharmacol. 56, 597–608 (2016).169.van Ryn,\\xa0J., Sieger,\\xa0P., Kink-Eiband,\\xa0M., Gansser,\\xa0D. &\\xa0Clemens,\\xa0A. Adsorption of dabigatran etexilate in\\xa0water or dabigatran in pooled human plasma by activated charcoal in\\xa0vitro. Blood 114, 1065–1065 (2009).170.Wang,\\xa0X. et\\xa0al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am.\\xa0J.\\xa0Cardiovasc. Drugs 14, 147–154 (2013).171.Pollack,\\xa0C.\\xa0V. et\\xa0al. Idarucizumab for dabigatran',\n",
       " '170.Wang,\\xa0X. et\\xa0al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am.\\xa0J.\\xa0Cardiovasc. Drugs 14, 147–154 (2013).171.Pollack,\\xa0C.\\xa0V. et\\xa0al. Idarucizumab for dabigatran reversal — full cohort analysis. N.\\xa0Engl. J.\\xa0Med. 377, 431–441 (2017).This large cohort study is the first to show the high efficacy and safety of the infusion of idarucizumab for dabigatran reversal in patients who had either uncontrolled bleeding or the need to undergo an urgent procedure.172.Dager,\\xa0W.\\xa0E. & Banares,\\xa0L. Reversing the anticoagulation effects of dabigatran. Hosp. Pract. 45, 29–38 (2017).173.Schulman,\\xa0S. et\\xa0al. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: a prospective cohort study. Thromb. Res. 152, 44–48 (2017).174.Zahir,\\xa0H. et\\xa0al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4‑factor prothrombin complex concentrate. Circulation 131, 82–90 (2015).175.Deutsch,\\xa0D. et\\xa0al. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therap. Adv. Gastroenterol. 10, 495–505 (2017).176.Heidbuchel,\\xa0H. et\\xa0al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin‑K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur.\\xa0Heart J. 38, 2137–2149 (2017).177.Rottenstreich,\\xa0A., Jahshan,\\xa0N., Avraham,\\xa0L. &\\xa0Kalish,\\xa0Y. Idarucizumab for dabigatran reversal —\\xa0does one dose fit all? Thromb. Res. 146, 103–104 (2016).178.Connolly,\\xa0S.\\xa0J. et\\xa0al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N.\\xa0Engl. J.\\xa0Med. 375, 1131–1141 (2016).179.Ansell,\\xa0J.\\xa0E. et\\xa0al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb. Haemost. 117, 238–245 (2017).180.Chatterjee,\\xa0P. & Weitz,\\xa0J.\\xa0I. Assessment and management of gastrointestinal hemorrhage in the setting of direct oral anticoagulants: the hematology',\n",
       " 'Thromb. Haemost. 117, 238–245 (2017).180.Chatterjee,\\xa0P. & Weitz,\\xa0J.\\xa0I. Assessment and management of gastrointestinal hemorrhage in the setting of direct oral anticoagulants: the hematology perspective. Am. J.\\xa0Gastroenterol. Suppl. 3, 29–35 (2016).181.Qureshi,\\xa0W.\\xa0T. & Nasir,\\xa0U. Restarting oral anticoagulation among patients with atrial fibrillation\\xa0with gastrointestinal bleeding was associated with lower risk of all-cause mortality and thromboembolism. Evid. Based Med. 21, 152 (2016).182.Zulkifly,\\xa0H., Lip,\\xa0G.\\xa0Y.\\xa0H. & Lane,\\xa0D.\\xa0A. Bleeding risk scores in atrial fibrillation and venous thromboembolism. Am. J.\\xa0Cardiol. 120, 1139–1145 (2017).183.Scott,\\xa0M.\\xa0J., Veitch,\\xa0A. & Thachil,\\xa0J. Reintroduction of\\xa0anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when? Br. J.\\xa0Haematol. 177, 185–197 (2017).184.Staerk,\\xa0L. et\\xa0al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ 351, h5876 (2015).185.Hernandez,\\xa0I., Zhang,\\xa0Y., Brooks,\\xa0M.\\xa0M., Chin,\\xa0P.\\xa0K.\\xa0L. & Saba,\\xa0S. Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in\\xa0atrial fibrillation. Stroke 48, 159–166 (2017).186.Qureshi,\\xa0W. et\\xa0al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am. J.\\xa0Cardiol. 113, 662–668 (2014).187.Lip,\\xa0G.\\xa0Y.\\xa0H. et\\xa0al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a\\xa0joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología',\n",
       " '(CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 19, 1757–1758 (2017).188.Bager,\\xa0P. & Dahlerup,\\xa0J.\\xa0F. Patient-reported outcomes after acute nonvariceal upper gastrointestinal hemorrhage. Scand. J.\\xa0Gastroenterol. 49, 909–916 (2014).189.Sousa,\\xa0K.\\xa0H. & Williamson,\\xa0A. Symptom status and health-related quality of life: clinical relevance. J.\\xa0Adv. Nurs. 42, 571–577 (2003).190.Campbell,\\xa0H.\\xa0E. et\\xa0al. Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open 5, e007230 (2015).191.World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. WHO http://www.who.int/vmnis/indicators/haemoglobin/en/ (2011).192.Mearin,\\xa0F. et\\xa0al. Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding. Gastroenterol.\\xa0Hepatol. 41, 63–76 (2018).193.Lee,\\xa0J.\\xa0M. et\\xa0al. Discharge hemoglobin and outcome in patients with acute nonvariceal upper gastrointestinal bleeding. Endosc. Int. Open 4, E865–869 (2016).194.Bager,\\xa0P. & Dahlerup,\\xa0J.\\xa0F. Lack of follow‑up of\\xa0anaemia after discharge from an upper gastrointestinal bleeding centre. Danish Med. J. 60, A4583 (2013).195.Jairath,\\xa0V. et\\xa0al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet 386, 137–144 (2015).196.Bager,\\xa0P. & Dahlerup,\\xa0J.\\xa0F. Randomised clinical trial:\\xa0oral versus intravenous iron after upper gastrointestinal haemorrhage — a placebo-controlled study. Aliment. Pharmacol. Ther. 39, 176–187 (2014).197.De Franceschi,\\xa0L., Iolascon,\\xa0A., Taher,\\xa0A. &\\xa0Cappellini,\\xa0M.\\xa0D. Clinical management of iron',\n",
       " 'study. Aliment. Pharmacol. Ther. 39, 176–187 (2014).197.De Franceschi,\\xa0L., Iolascon,\\xa0A., Taher,\\xa0A. &\\xa0Cappellini,\\xa0M.\\xa0D. Clinical management of iron deficiency anemia in adults: systemic review on advances in diagnosis and treatment. Eur. J.\\xa0Intern. Med. 42, 16–23 (2017).198.Hunt,\\xa0R.\\xa0H. & Scarpignato,\\xa0C. Potassium-competitive acid blockers (P‑CABs): are they finally ready for prime\\xa0time in acid-related disease? Clin. Transl Gastroenterol. 6, e119 (2015).199.Casado-Arroyo,\\xa0R. et\\xa0al. Underutilization of gastroprotection for at‑risk patients undergoing percutaneous coronary intervention: Spain compared with the United States. Aliment. Pharmacol. Ther. 32, 689–695 (2010).200.Lanas,\\xa0A. et\\xa0al. Variability in the management of nonvariceal upper gastrointestinal bleeding in Europe: an observational study. Adv. Ther. 29, 1026–1036 (2012).201.Ardevol,\\xa0A. et\\xa0al. Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies. Hepatology https://doi.org/10.1002/hep.29370 (2018).202.Mallet,\\xa0M., Rudler,\\xa0M. & Thabut,\\xa0D. Variceal bleeding in cirrhotic patients. Gastroenterol. Rep. 5, 185–192 (2017).203.Hunt,\\xa0R.\\xa0H. & Bazzoli,\\xa0F. Review article: should NSAID/low-dose aspirin takers be tested routinely for H.\\xa0pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment. Pharmacol. Ther. 19 (Suppl. 1), 9–16 (2004).204.Lanas,\\xa0Á. et\\xa0al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin. Gastroenterol. Hepatol. 13, 906–912.e2 (2015).PRIMER20 | ARTICLE NUMBER 18020 | VOLUME 4www.nature.com/nrdp© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " '205.Chan,\\xa0F.\\xa0K. et\\xa0al. Eradication of Helicobacter pylori and\\xa0risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a\\xa0randomised trial. Lancet 359, 9–13 (2002).206.Scarpignato,\\xa0C. & Hunt,\\xa0R.\\xa0H. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and\\xa0prevention. Gastroenterol. Clin. North Am. 39, 433–464 (2010).207.Blatchford,\\xa0O., Murray,\\xa0W.\\xa0R. & Blatchford,\\xa0M. A\\xa0risk\\xa0score to predict need for treatment for upper‑gastrointestinal haemorrhage. Lancet 356, 1318–1321 (2000).208.Rockall,\\xa0T.\\xa0A., Logan,\\xa0R.\\xa0F., Devlin,\\xa0H.\\xa0B. &\\xa0Northfield,\\xa0T.\\xa0C. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 311, 222–226 (1995).209.Hyett,\\xa0B.\\xa0H. et\\xa0al. The AIMS65 score compared with the Glasgow-Blatchford score in predicting outcomes in upper GI bleeding. Gastrointest. Endosc. 77, 551–557 (2013).210.Saltzman,\\xa0J.\\xa0R. et\\xa0al. A simple risk score accurately predicts in‑hospital mortality, length of stay, and cost in\\xa0acute upper GI bleeding. Gastrointest. Endosc. 74, 1215–1224 (2011).211. Marmo,\\xa0R. et\\xa0al. Predicting mortality in non-variceal upper gastrointestinal bleeders: validation of the Italian PNED score and prospective comparison with the Rockall score. Am. J.\\xa0Gastroenterol. 105, 1284–1291 (2010).212.Rockall,\\xa0T.\\xa0A., Logan,\\xa0R.\\xa0F., Devlin,\\xa0H.\\xa0B. &\\xa0Northfield,\\xa0T.\\xa0C. Risk assessment after acute upper\\xa0gastrointestinal haemorrhage. Gut 38, 316–321 (1996).213.Adcock,\\xa0D.\\xa0M. & Gosselin,\\xa0R. Direct Oral anticoagulantDOACs) in the laboratory: 2015 review. Thromb. Res. 136, 7–12 (2015).214.Gosselin,\\xa0R.\\xa0C. et\\xa0al. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. Thromb. Haemost. 113, 77–84 (2015).',\n",
       " 'drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. Thromb. Haemost. 113, 77–84 (2015).215.The American Society of Hemotology. Clinical practice guide on antithrombotic drug dosing and management of\\xa0antithrombotic drug-associated bleeding complications in adults. Clot Connect http://files.www.clotconnect.org/healthcare-professionals/resources-for-health-care-professionals/AnticoagPocketGuide-1.pdf (2014).216.Bonar,\\xa0R. et\\xa0al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in\\xa0vitro and\\xa0ex\\xa0vivo samples. Pathology 48, 60–71 (2016).217.Douxfils,\\xa0J. & Gosselin,\\xa0R.\\xa0C. Laboratory assessment of\\xa0direct oral anticoagulants. Semin. Thromb. Hemost. 43, 277–290 (2017).218.Lanas,\\xa0A. et\\xa0al. Time trends and impact of upper and\\xa0lower gastrointestinal bleeding and perforation in\\xa0clinical practice. Am. J.\\xa0Gastroenterol. 104, 1633–1641 (2009).219.Pérez-Aisa,\\xa0M.\\xa0A., Del Pino,\\xa0D., Siles,\\xa0M. & Lanas,\\xa0A. Clinical trends in ulcer diagnosis in a population with\\xa0high prevalence of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 21, 65–72 (2005).220.Klein,\\xa0A. & Gralnek,\\xa0I.\\xa0M. Acute, nonvariceal upper gastrointestinal bleeding. Curr. Opin. Crit. Care 21, 154–162 (2015).AcknowledgementsA.L. declares that his work on this manuscript was partially funded by a grant from the Spanish Instituto de Salud Carlos III PI/PI08/1301 and “Fondo Europeo de Desarrollo Regional (FEDER) de la Unión Europea. – Una manera de hacer Europa –”. The authors thank M. Fujishiro, The University of Tokyo Hospital, for the images used in Fig.\\xa06.Author contributionsIntroduction (A.L.); Epidemiology (C.V.); Mechanisms/pathophysiology (A.L. and R.H.H.); Diagnosis, screening and prevention (R.H.H., A.L., A.R. and M.F.); Management (J.J.Y.S., I.M.G., J.M.S. and J.-M.D.); Quality of life (H.E.C.); Outlook (all authors); Overview of the Primer (A.L.).',\n",
       " 'prevention (R.H.H., A.L., A.R. and M.F.); Management (J.J.Y.S., I.M.G., J.M.S. and J.-M.D.); Quality of life (H.E.C.); Outlook (all authors); Overview of the Primer (A.L.).Competing interestsA.L. is an adviser to Bayer Healthcare and Bayer AG. J.M.S. is an adviser to Aralez Pharmaceuticals. All other authors declare no competing interest.Publisher’s noteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Reviewer informationNature Reviews Disease Primers thanks E.J. Kuipers, P.\\xa0Malfertheiner, R. Marmo, F. Radaelli and other, anonymous reviewer(s) for\\xa0their contribution to the peer review of this\\xa0work.How to cite this PrimerLanas, A. et\\xa0al. Non-variceal upper gastrointestinal bleeding. Nat. Rev. Dis. Primers 4, 18020 (2018).PRIMERNATURE REVIEWS | DISEASE PRIMERS VOLUME 4 | ARTICLE NUMBER 18020 | 21© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.',\n",
       " '1062 \\u2003|\\u2003 wileyonlinelibrary.com/journal/aptAliment Pharmacol Ther. 2024;59:1062–1081.© 2024 John Wiley & Sons Ltd.1\\u2003|\\u2003INTRODUCTIONAcute upper gastrointestinal bleeding (UGIB) is a common emer-gency defined by symptoms of overt bleeding (haematemesis, melaena and haematochezia) with the source of bleeding in the oe-sophagus, stomach or duodenum. While the incidence of UGIB had been reported to be decreasing for decades, a recent evaluation of emergency department (ED) visits found that the trend has recently Received: 13 September 2023\\u2003 |\\u2003 First decision: 27 October 2023\\u2003 |\\u2003 Accepted: 4 March 2024DOI: 10.1111/apt.17949  Review article: Upper gastrointestinal bleeding – review of current evidence and implications for managementDennis L.\\xa0Shung1\\u2003|   Loren\\xa0Laine1,2The Handling Editor for this article was Professor Colin Howden, and this commissioned review was accepted for publication after full peer-\\xadreview.  1Yale School of Medicine, New Haven, Connecticut, USA2West Haven Veterans Affairs Medical Center, West Haven, Connecticut, USACorrespondenceDennis L. Shung, Yale School of Medicine, New Haven, CT, USA.Email: dennis.shung@yale.eduFunding informationNational Institutes of Health, Grant/Award Number: DK125718SummaryBackground: Acute upper gastrointestinal bleeding (UGIB) is a common emergency requiring hospital-\\xadbased care. Advances in care across pre-\\xadendoscopic, endoscopic and post-\\xadendoscopic phases have led to improvements in clinical outcomes.Aims: To provide a detailed, evidence-\\xadbased update on major aspects of care across pre-\\xadendoscopic, endoscopic and post-\\xadendoscopic phases.Methods: We performed a structured bibliographic database search for each topic. If a recent high-\\xadquality meta-\\xadanalysis was not available, we performed a meta-\\xadanalysis with random effects methods and odds ratios with 95% confidence intervals.Results: Pre-\\xadendoscopic management of UGIB includes risk stratification, a restric-',\n",
       " 'meta-\\xadanalysis with random effects methods and odds ratios with 95% confidence intervals.Results: Pre-\\xadendoscopic management of UGIB includes risk stratification, a restric-tive red blood cell transfusion policy unless the patient has cardiovascular disease, and pharmacologic therapy with erythromycin and a proton pump inhibitor. Patients with cirrhosis should be treated with prophylactic antibiotics and vasoactive medica-tions. Tranexamic acid should not be used. Endoscopic management of UGIB depends on the aetiology. For peptic ulcer disease (PUD) with high-\\xadrisk stigmata, endoscopic therapy, including over-\\xadthe-\\xadscope clips (OTSCs) and TC-\\xad325 powder spray, should be performed. For variceal bleeding, treatment should be customised by severity and anatomic location. Post-\\xadendoscopic management includes early enteral feeding for all UGIB patients. For high-\\xadrisk PUD, PPI should be continued for 72\\u2009h, and rebleeding should initially be evaluated with a repeat endoscopy. For variceal bleeding, high-\\xadrisk patients or those with further bleeding, a transjugular intrahepatic portosystemic shunt can be considered.Conclusions: Management of acute UGIB should include treatment plans for pre-\\xadendoscopic, endoscopic and post-\\xadendoscopic phases of care, and customise treat-ment decisions based on aetiology and severity of bleeding.Check for updates',\n",
       " '| \\u20031063SHUNG and LAINEreversed.1 Furthermore, despite increasing co-\\xadmorbidities and anti-\\xadthrombotic drug use in patients with UGIB, case fatality rates have been decreasing.1This review uniquely synthesises recommendations from numer-ous recent guidelines and consensus documents, together with the most recent evidence from systematic reviews of original research – both published and performed by the authors – to provide updated guidance on the management of acute UGIB from presentation in the ED throughout hospitalisation, dividing the management into three stages: pre-\\xadendoscopic, endoscopic and post-\\xadendoscopic.This review focuses on management from presentation in the ED throughout hospitalisation for acute UGIB, dividing the management into three stages: pre-\\xadendoscopic, endoscopic and post-\\xadendoscopic.We performed a structured bibliographic database search on Medline (details in Appendix\\xa0A) for each topic to identify rele-vant systematic reviews and meta-\\xadanalyses for topics within each stage. When systematic reviews were not available or sufficient, we searched for randomised trials or other relevant studies in the absence of randomised trials, and we presented either the findings from individual trials or results from our own meta-\\xadanalyses. All meta-\\xadanalyses were performed with RevMan 5.4.1 using random ef-fects methods. We present odds ratios (ORs) with 95% confidence intervals (CIs) for dichotomous outcomes and mean differences with 95% CIs for continuous outcomes.The structure of this review is to present available recommendations from existing U.S. and international guidelines for the care of patients with UGIB, followed by a synthesis of the best available data and a suc-cinct statement summarising our take-\\xadhome point for each topic. Our take-\\xadhome points are collated in a table, separated by different phases of care. (Table\\xa01) We provide a management flowchart for pre-\\xadendoscopic',\n",
       " \"take-\\xadhome points are collated in a table, separated by different phases of care. (Table\\xa01) We provide a management flowchart for pre-\\xadendoscopic (Figure\\xa01) and endoscopic/post-\\xadendoscopic phases (Figures\\xa02–4).2\\u2003|\\u2003PRE-\\xadENDOSCOPIC MANAGEMENTResuscitation and stabilisation of underlying comorbid conditions are cornerstones of pre-\\xadendoscopic management. Rushing to en-doscopy without first attending to haemodynamic instability and comorbidities may worsen patient outcomes.2,3 These management concepts are discussed below in sections on blood transfusion and timing of endoscopy.The increased use of antithrombotic medications among patients with UGIB requires careful consideration of the individual's cardio-vascular/thrombotic and bleeding risks. A full review of this topic is beyond the scope of this article, but is well covered in a recent U.S./Canadian guideline.4 Briefly, in addition to holding anticoagu-lants, reversal agents for direct oral anticoagulants are only recom-mended for life-\\xadthreatening bleeding, while prothrombin complex concentrate may be considered for select patients on warfarin—for example, life-\\xadthreatening bleeding, markedly supratherapeutic INR.4 Although some have suggested INR should be <2.5 before apply-ing endoscopic therapy, INR level does not predict rebleeding and recent European guidelines indicate an INR cutoff should not guide the timing of endoscopy.8 In contrast, aspirin does not need to be held in patients taking aspirin for secondary prevention (i.e., estab-lished cardiovascular disease), but those taking aspirin for primary prevention should discontinue aspirin.42.1\\u2003|\\u2003Risk stratification scores for very-\\xadlow-\\xadrisk patients2.1.1\\u2003|\\u2003GuidelinesGuidelines are uniform in recommending that patients with a Glasgow-\\xadBlatchford Score (GBS) of 0–1 are candidates for discharge from the emergency department with outpatient follow-\\xadup and endoscopy.5–8 U.S. guidelines also define very-\\xadlow-\\xadrisk patients as\",\n",
       " 'Glasgow-\\xadBlatchford Score (GBS) of 0–1 are candidates for discharge from the emergency department with outpatient follow-\\xadup and endoscopy.5–8 U.S. guidelines also define very-\\xadlow-\\xadrisk patients as those with a ≤1% false negative rate for the outcome of hospital-\\xadbased intervention or death.52.1.2\\u2003|\\u2003Best available evidenceIn order to ensure patients who are discharged have an extremely low risk of poor outcomes, a high sensitivity cutoff (e.g., 99% or 100%) has been adopted to minimise false negative results, meaning that 0%–1% of patients who are deemed very low risk will require hospital-\\xadbased intervention (red-\\xadblood-\\xadcell (RBC) transfusion or endoscopic, inter-ventional radiologic or surgical haemostatic intervention) or die. The GBS, with a cutoff threshold of ≤1 is the only clinical risk assessment tool demonstrated to achieve this sensitivity threshold.5 The level of evidence to support this practice is very low, with only one multicentre prospective pre/post study that demonstrated the use of GBS with a cutoff of 0 decreased hospitalisations without any adverse outcomes detected at 28\\u2009days post evaluation.9 Another retrospective study ap-plying the GBS at ≤1 also found that none of the patients identified at very low risk required a hospital based intervention or died within 30\\u2009days.10 A machine learning model has been reported to outperform the GBS, with greater specificity at equivalent sensitivities of 99 or 100%, but has not been studied in real-\\xadworld settings.112.1.3\\u2003|\\u2003Take-\\xadhome pointVery low risk patients (e.g., GBS\\u2009≤\\u20091) may be considered for discharge from the emergency department with outpatient management.2.2\\u2003|\\u2003Risk stratification scores for high-\\xadrisk patients2.2.1\\u2003|\\u2003GuidelinesThere are no recommendations across the U.S., European or inter-national guidelines for the use of high-\\xadrisk scores to guide clinical',\n",
       " '2.2.1\\u2003|\\u2003GuidelinesThere are no recommendations across the U.S., European or inter-national guidelines for the use of high-\\xadrisk scores to guide clinical  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '1064\\u2003 |\\u2003 \\u2003\\u2002SHUNG and LAINETA B LE 1\\u2003Summary of take-\\xadhome points by pre-\\xadendoscopic, endoscopic and post-\\xadendoscopic management phases.Pre-\\xadendoscopic managementRisk assessmentVery low risk patients (e.g., GBS\\u2009≤\\u20091) may be considered for discharge from the emergency department with outpatient management.No risk scores are robust enough to consistently identify high-\\xadrisk patients.Red blood cell transfusionTransfuse at a threshold of haemoglobin <7\\u2009g/dL unless patient has cardiovascular disease (transfuse at haemoglobin <8\\u2009g/dL) or is haemodynamically unstable.Prokinetic therapyErythromycin may be given before the endoscopy to reduce the need for a second endoscopy and the length of the hospital stay.Proton pump inhibitor therapyProviders who value a small reduction in endoscopic therapy may choose to give pre-\\xadendoscopic PPIs, despite the fact that they do not improve clinical outcomes.Tranexamic acidModern studies do not suggest that tranexamic acid should be used in patients with acute UGIB.Patients with cirrhosisTreat with antibiotics and vasoactive medications beginning soon after presentation.Endoscopic managementTiming of endoscopyPerform an endoscopy within 24\\u2009h. Urgent endoscopy in high-\\xadrisk patients is not recommended before resuscitation is initiated and other co-\\xadmorbidities are addressed.Peptic Ulcer DiseaseEndoscopic therapy should be performed for patients with active bleeding and non-\\xadbleeding visible vessels, while its use for adherent clots may be individualised.Epinephrine injection should not be used alone; it should only be used in combination with a second modality. Thermal therapies, absolute ethanol injection and clips are all appropriate endoscopic haemostatic modalities.OTSCs are suggested as a treatment option for recurrent bleeding after conventional endoscopic haemostatic therapy and may be considered for initial haemostatic therapy.',\n",
       " 'modalities.OTSCs are suggested as a treatment option for recurrent bleeding after conventional endoscopic haemostatic therapy and may be considered for initial haemostatic therapy.TC-\\xad325 powder spray is an option for the treatment of actively bleeding ulcers and other non-\\xadvariceal lesions.Severe refractory variceal bleedingFully-\\xadcovered, self-\\xadexpanding metal stents are preferred over balloon tamponade for severe refractory variceal bleeding.Oesophageal variceal bleedingTreat with oesophageal variceal ligation as well as intravenous vasoactive medications and antibiotic therapy.Gastric variceal bleedingEndoscopic therapy with butyl-\\xadcyanoacrylate is more effective than ligation for gastric variceal bleeding, although ligation may be considered for GOV1 bleeding because of fewer adverse events. TIPS and BRTO are superior to endoscopic therapy for the prevention of recurrent gastric variceal bleeding. BRTO may be performed if a gastrorenal shunt is present based on clinical factors (e.g. MELD score, hepatic encephalopathy).Further evidence is needed before recommendations regarding endoscopic ultrasound-\\xadguided therapy or the use of thrombin for gastric variceal bleeding can be made.Gastric antral vascular ectasiaBleeding from GAVE is commonly treated with APC, but ligation appears to be a superior option.Mallory-\\xadWeiss tearPatients with actively bleeding Mallory-\\xadWeiss tears should receive endoscopic therapy, probably employing endoscopic therapies suggested for ulcer bleeding.Dieulafoy lesionPatients with Dieulafoy lesions should undergo endoscopic therapy, employing therapies suggested for ulcer bleeding. Epinephrine should not be used alone.Malignancy-\\xadrelated bleedingAcute UGIB due to malignancy may be treated with endoscopic therapy, but results are variable and rebleeding is common. Treatment with TC-\\xad325 haemostatic powder spray may hold promise, but therapy for the underlying malignancy, if possible, is most important to prevent rebleeding.',\n",
       " 'is common. Treatment with TC-\\xad325 haemostatic powder spray may hold promise, but therapy for the underlying malignancy, if possible, is most important to prevent rebleeding.Post-\\xadendoscopic managementEarly versus delayed feedingPatients with low-\\xadrisk endoscopic findings (e.g., clean-\\xadbased ulcers) may begin a regular diet soon after endoscopy and be discharged home if they have no other reason for hospitalisation. Patients with higher risk endoscopic findings, even after endoscopic therapy, may be fed in less than 72\\u2009h, although the exact time and initial form of refeeding are uncertain.Peptic ulcerAfter endoscopic haemostatic treatment of UGIB due to ulcers, treat with either continuous infusion or intermittent intravenous or oral high-\\xaddose PPI for 3\\u2009days. Twice-\\xaddaily oral PPI therapy should then be given for at least 14\\u2009days after the index endoscopy.Rebleeding after initial endoscopic haemostatic therapy should first be evaluated and treated with a repeat endoscopy. For those who fail endoscopic therapy, arteriography with transcatheter arterial embolisation should be performed.VaricesPreemptive TIPS should be considered in high-\\xadrisk patients (Child-\\xadPugh class B or C with score <14) after initial endoscopic ligation and vasoactive medical therapy, if interventional radiology services are available.Patients with further variceal bleeding despite endoscopic and medical therapy should undergo TIPS (BRTO may be performed for gastric variceal bleeding).Abbreviations: APC, argon plasma coagulation; BRTO, balloon retrograde transvenous obliteration; GBS, Glasgow-\\xadBlatchford Score; MELD, Model for End-\\xadStage Liver Disease; OTSC, over-\\xadthe-\\xadscope-\\xadclips; PPI, proton pump inhibitor therapy; TIPS, transjugular intrahepatic portosystemic shunt; UGIB, upper gastrointestinal bleeding.',\n",
       " 'for End-\\xadStage Liver Disease; OTSC, over-\\xadthe-\\xadscope-\\xadclips; PPI, proton pump inhibitor therapy; TIPS, transjugular intrahepatic portosystemic shunt; UGIB, upper gastrointestinal bleeding. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '| \\u20031065SHUNG and LAINEpractice.5,6,8 The Asia-\\xadPacific guidelines do not recommend use of risk scores to identify high-\\xadrisk bleeding ulcers after endoscopic therapy for second-\\xadlook endoscopy.72.2.2\\u2003|\\u2003Best available evidenceThe Rockall score and AIMS65 score were developed to predict all-\\xadcause mortality for patients with UGIB.12,13 The ABC score uses pre-\\xadendoscopic factors to identify patients with UGIB or lower GIB at risk for mortality,14 while the Re.\\u200bCo.\\u200bDe score inte-grates findings during hospitalisation to predict all-\\xadcause 30-\\xadday mortality.15 Yet another score focused on intensive care unit (ICU) patients with acute GIB uses a machine learning model to predict in-\\xadhospital mortality.16 Finally, two studies have evaluated the dynamic risk of patients with acute GIB in the ICU by predict-ing the need for transfusion in 5-\\xadh increments17 and within the first 24\\u2009h of ICU admission.18 The one study that integrates a risk score into direct clinical care used a semi-\\xadautomated GBS with a cutoff of 7 to identify higher risk patients and examine the im-pact on patient placement in a monitored versus unmonitored bed and clinical outcomes.19 These currently available tools are of unclear clinical utility, and their performance characteristics are not sufficient to recommend their use in clinical practice.2.2.3\\u2003|\\u2003Take-\\xadhome pointNo risk scores are robust enough to consistently identify high-\\xadrisk patients.2.3\\u2003|\\u2003Restrictive versus Liberal red blood cell transfusion strategy2.3.1\\u2003|\\u2003GuidelinesFor patients with UGIB U.S. and European guidelines recommend a re-strictive policy of RBC transfusion for patients with UGIB at a thresh-old haemoglobin <7\\u2009g/dL.5,8 For patients with acute or pre-\\xadexisting cardiovascular disease, they suggest red blood cell transfusion at a haemoglobin threshold of <8\\u2009g/dL. International guidelines suggest that RBC transfusions be given at a haemoglobin <8\\u2009mg/dL, with a',\n",
       " 'cardiovascular disease, they suggest red blood cell transfusion at a haemoglobin threshold of <8\\u2009g/dL. International guidelines suggest that RBC transfusions be given at a haemoglobin <8\\u2009mg/dL, with a higher unspecified haemoglobin threshold for patients with underlying FI G U R E 1\\u2003Pre-\\xadendoscopic management for patients with acute upper gastrointestinal bleeding. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons LicenseRisk AssessmentVery low risk (Glasgow-Not very low riskBlatchford Score 0-1)Consider discharge fromConsider hospitalizationED with outpatientmanagementHemoglobin >7No; Hemoglobin <7YesTransfuse pRBCDo not transfuse unlesscardiovascular disease orhemodynamically unstableDoes the patient havecirrhosis or suspectedportal hypertension?YesNoConsider IV erythromycinConsider IV erythromycinProphylactic antibioticsePPItherapyIndividualizeVasoactive medicationsUpper endoscopy within24 hours',\n",
       " '1066\\u2003 |\\u2003 \\u2003\\u2002SHUNG and LAINEcardiovascular disease.8 U.S. guidelines also noted that it is reasonable to transfuse hypotensive patients before haemoglobin reaches 7\\u2009g/dL because haemoglobin levels in these patients will be lower after fluid resuscitation even in the absence of further bleeding.5 Asia-\\xadPacific guidelines recommend a restrictive transfusion strategy without a spe-cific haemoglobin target or threshold.7 For patients with cirrhosis and possible acute variceal bleeding, Baveno VII guidelines recommend transfusion with a target haemoglobin between 7 and 8\\u2009g/dL.202.3.2\\u2003|\\u2003Best available evidenceThe transfusion threshold of haemoglobin <7\\u2009g/dL was found to have a benefit as compared to haemoglobin <9\\u2009g/dL in mortality (5 vs. 9%, p\\u2009=\\u20090.02) with decreased further bleeding (10 vs. 16%, p\\u2009=\\u20090.01) and less transfusion reactions (3 vs. 9%, p\\u2009=\\u20090.001) in a large single-\\xadcentre randomised controlled trial.21A multicentre cluster-\\xadrandomised trial compared an 8\\u2009g/dL threshold to a 10\\u2009g/dL threshold.22 Methodological limitations included unequal distribution in the study arms (restrictive 43%, liberal 57%) and poorer adherence in the liberal transfusion arm.22 Differences were not significant for the restrictive versus liberal transfusion strategy groups in mortality (5 vs. 7%) or fur-ther bleeding (5 vs. 9%).22 A recent small single-\\xadcentre trial com-pared transfusion thresholds of 7\\u2009g/dL (with transfusions given to reach haemoglobin of 9\\u2009g/dL) versus 8\\u2009g/dL (with a transfusion target of 10\\u2009g/dL) and found relatively similar clinical outcomes in the study arms (mortality hazard ratio\\u2009=\\u20090.83, p\\u2009=\\u20090.33).23Current transfusion guidelines for patients with anaemia due to any cause suggest a haemoglobin threshold of 8\\u2009g/dL in patients with pre-\\xadexisting cardiovascular disease because trials in this population used a restrictive threshold of 8 rather than 7\\u2009g/dL. In addition, a recent randomised trial in patients with acute myocar-',\n",
       " 'with pre-\\xadexisting cardiovascular disease because trials in this population used a restrictive threshold of 8 rather than 7\\u2009g/dL. In addition, a recent randomised trial in patients with acute myocar-dial infarction and anaemia due to any cause found a transfusion threshold of 8\\u2009g/dL to be non-\\xadinferior to a threshold of 10\\u2009g/dL for an outcome of cardiovascular events or death, suggesting that 8\\u2009g/dL is an appropriate threshold in patients with acute coronary syn-drome as well.24FI G U R E 2\\u2003(A) Endoscopic management and post-\\xadendoscopic management for patients with acute upper gastrointestinal bleeding from peptic ulcer disease. (B) Endoscopic management and post-\\xadendoscopic management for patients with recurrent upper gastrointestinal bleeding from peptic ulcer disease. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License(A)Timing of EndoscopyWithin 24 hoursClean base or flatAdherent clotActive bleedingg and non-pigmented spotbleeding visible vesselsNo endoscopicIndividualizedThermal therapies, absolutetherapyendoscopic therapyethanol injection or clipsEpinephrine injection shouldnot be used alone, but onlyin combination with asecond modalityTC-325 powder spray maybe used for actively bleedingulcersResume oral feedingResume: oralImmediately or as soon asfeedingpossibleWithin 72 hours(B)Recurrent Bleeding?NoYesClean base, flatRepeat endoscopy andAdherent clot, visibleendoscopictherapypigmented spotvessel, or activebleedingOnce daily oral PPIContinuous infusion ortherapyintermittent intravenous orI high-dose PPl for 3 daysoralTwice-daily oral PPItherapy for at least 14 daysFurther Bleeding?Arteriography/ with transcatheter',\n",
       " 'Continuous infusion ortherapyintermittent intravenous orI high-dose PPl for 3 daysoralTwice-daily oral PPItherapy for at least 14 daysFurther Bleeding?Arteriography/ with transcatheterarterial embolization',\n",
       " \"| \\u20031067SHUNG and LAINEFI G U R E 3\\u2003Endoscopic management and post-\\xadendoscopic management for patients with acute upper gastrointestinal bleeding from varices.FI G U R E 4\\u2003Endoscopic management and post-\\xadendoscopic management for patients with acute upper gastrointestinal bleeding from other aetiologies. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons LicenseTiming of EndoscopyWithin 24 hoursRefractory VaricealBleeding?NoYesEsophageal Variceal BleedingGastric Variceal BleedingFully covered self-Esophageal variceal ligationexpanding coveredGOV2/IGVGOV-1?metal stentsHigh riskpreferred overInjection of butyl-Variceal ligation or(Child-PughClass B >7 orballoon tamponadecyanoacrylate,, TIPS orButyl-cyanoacrylateChild-PughClass C <14)BRTOTIPSNoYesIf TIPS or BRTO:Gastrorenal shuntConsider pre-emptivewith high 1MELDTIPSscore, hepaticencephalopathy?NoYesConsider TiPSConsider BRTOAntibiotics up to 5 daysVasoactive medications for 2-5 daysResume oral feeding<72hoursFurther Bleeding?TIPSBRTOcan be used for gastric varicesTiming of EndoscopyWithin 24 hoursMallory-Weiss tearMalignancy-related bleedingDieulafoy LesionGastric antral vascular ectasiaLigation maybe preferred overActive bleeding?Temporization: EndoscopicEndoscopic therapiesargonplasmacoagulationtherapies for bleedingulcersfor bleedingg ulcers;don't use epinephrinealoneDefinitivee Therapy for MalignancyNoYesNo endoscopic therapyEndoscopic therapies s forbleedingulcersRecurrentBleeding?Repeat endoscopyRepeat endoscopyDefinitive or palliative ttherapyI (e.g.Repeat endoscopyand continuetherapy)surgery, radiationendoscopic therapyTattoo for potentialsurgery\",\n",
       " 'RecurrentBleeding?Repeat endoscopyRepeat endoscopyDefinitive or palliative ttherapyI (e.g.Repeat endoscopyand continuetherapy)surgery, radiationendoscopic therapyTattoo for potentialsurgeryRepeat endoscopyy or arteriography/ withtranscatheter arterial embolizationConsider clip for potentialarteriography',\n",
       " '1068\\u2003 |\\u2003 \\u2003\\u2002SHUNG and LAINE2.3.3\\u2003|\\u2003Take-\\xadhome pointTransfuse at a threshold of haemoglobin <7\\u2009g/dL unless the patient has cardiovascular disease (transfuse at haemoglobin <8\\u2009g/dL) or is haemodynamically unstable.2.4\\u2003|\\u2003Pre-\\xadendoscopic pharmacologic therapy2.4.1\\u2003|\\u2003Prokinetic therapyGuidelinesU.S. guidelines suggest an infusion of erythromycin 250\\u2009mg 20–90\\u2009min before endoscopy and indicated their review did not sug-gest benefit was restricted to a specific subgroup of patients, while European guidelines recommend pre-\\xadendoscopic administration of intravenous erythromycin only in UGIB patients with clinically se-vere or ongoing active bleeding.5,8 International guidelines do not recommend routine use of promotility agents to increase diagnostic yield.6Best available evidenceA meta-\\xadanalysis of randomised trials showed a reduced rate of repeat endoscopy (odds ratio [OR]\\u2009=\\u20090.51, 0.34–0.77) and shorter hospital length of stay (mean difference\\u2009=\\u2009−1.75, −2.43 to −1.06\\u2009days).25 Reductions in further bleeding and death have not been documented. No randomised controlled trials have evalu-ated the role of azithromycin or other macrolide antibiotics for this purpose, and the limited data regarding metoclopramide does not provide support for its use. A 2023 abstract of a randomised, placebo-\\xadcontrolled trial of metoclopramide in 64 patients with UGIB did not document the benefit of metoclopramide in the pri-mary outcome of ‘clear stomach’ (77 vs. 64%; p\\u2009=\\u20090.22), in repeat endoscopy (10 vs. 21%, p\\u2009=\\u20090.30) or in mean hospital stay (5.4 vs. 6.3\\u2009days, p\\u2009=\\u20090.59).26Take-\\xadhome pointErythromycin may be given before an endoscopy to reduce the need for a second endoscopy and the length of the hospital stay.2.5\\u2003|\\u2003Proton pump inhibitor (PPI) therapy2.5.1\\u2003|\\u2003GuidelinesU.S. guidelines did not provide a recommendation for or against pre-\\xadendoscopic PPI therapy.5 European and international guidelines sug-gest pre-\\xadendoscopic PPI therapy may be considered to downstage',\n",
       " 'U.S. guidelines did not provide a recommendation for or against pre-\\xadendoscopic PPI therapy.5 European and international guidelines sug-gest pre-\\xadendoscopic PPI therapy may be considered to downstage endoscopic stigmata and reduce the need for endoscopic therapy, but this should not delay endoscopy.6,8 Asia-\\xadPacific guidelines do not recommend pre-\\xadendoscopic PPIs.72.5.2\\u2003|\\u2003Best available evidenceA recent meta-\\xadanalysis of randomised trials did not document re-ductions in the primary endpoint of mortality (OR\\u2009=\\u20091.14, 0.76–1.70) or other clinical outcomes.27 A closer assessment of the component studies is needed because two studies used H2-\\xadreceptor antagonists as a comparator rather than placebo one study was an abstract from 2005 that has never been published in full form and two of the three placebo-\\xadcontrolled trials used a poor study design that was biased in favour of the PPI arm. The single large, well-\\xaddesigned, randomised, placebo-\\xadcontrolled trial showed no suggestion of a benefit for PPI in further bleeding (11/314 [3.5%] vs. 8/317 [2.5%]), mortality (8/314 [2.5%] vs. 7/317 [2.2%]), or other clinical outcomes.28 PPI therapy does appear to reduce the proportion of patients with stigmata of haemorrhage identified at endoscopy and the proportion requir-ing endoscopic haemostatic therapy.27 Guideline panels generally agree that available evidence indicates pre-\\xadendoscopic PPIs do not improve clinical outcomes such as further bleeding or mortality, but reduce the proportion receiving endoscopic therapy (−3%, −1 to −6% in a meta-\\xadanalysis of 3 randomised trials).5 The guideline recommen-dations vary based on the value panellists felt that providers and patients may place on this outcome.2.5.3\\u2003|\\u2003Take-\\xadhome pointProviders who value a small reduction in endoscopic therapy may choose to give pre-\\xadendoscopic PPIs, despite the fact that they do not improve clinical outcomes.2.6\\u2003|\\u2003Tranexamic acid2.6.1\\u2003|\\u2003Guidelines',\n",
       " 'choose to give pre-\\xadendoscopic PPIs, despite the fact that they do not improve clinical outcomes.2.6\\u2003|\\u2003Tranexamic acid2.6.1\\u2003|\\u2003GuidelinesU.S., international and Asia-\\xadPacific guidelines have no recommen-dation regarding tranexamic acid.5–7 European guidelines recom-mend against the use of tranexamic acid.8 Baveno VII guidelines recommend against tranexamic acid in patients with acute variceal bleeding.202.6.2\\u2003|\\u2003Best available evidenceMultiple small randomised trials assessing tranexamic acid versus placebo have been done, and prior meta-\\xadanalysis including, 1701 participants showed a reduction in mortality (risk ratio\\u2009=\\u20090.60, 0.42–0.87) and a possible trend to less further bleeding (risk ratio\\u2009=\\u20090.80, 0.64–1.00 with heterogeneity (I2\\u2009=\\u200949%)).29 This uncertainty led to the large multicentre double-\\xadblind HALT-\\xadIT trial, which randomly as-signed approximately 12,000 patients with GIB to intravenous bolus  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '| \\u20031069SHUNG and LAINEand constant infusion tranexamic versus placebo. No suggestion of a benefit in all-\\xadcause mortality, death due to bleeding or rebleeding was identified, and thromboembolic events were also similar in the two arms.30 A new meta-\\xadanalysis that we performed incorporating the HALT-\\xadIT trial and other recent studies showed no difference in further bleeding (OR: 0.87, 95% CI: 0.69–1.11)30–37 (Figure\\xa0S1) with a slight decrease in all-\\xadcause mortality (OR: 0.83, 95% CI: 0.71–0.98).30–41 (Figure\\xa0S2) However, we note that the trials used for the meta-\\xadanalysis are heterogeneous in their dosage, duration and route of administration, and many of the trials were performed decades ago before advancements in the care of acute UGIB. In a sensitiv-ity analysis including only studies published after 2000, a benefit in all-\\xadcause mortality was not seen (OR: 0.90, 95% CI: 0.75–1.07) (Figure\\xa0S3).2.6.3\\u2003|\\u2003Take-\\xadhome pointModern studies do not suggest that tranexamic acid should be used in patients with acute UGIB.2.7\\u2003|\\u2003Pharmacologic therapy in patients with cirrhosis2.7.1\\u2003|\\u2003GuidelinesBaveno VII and U.S. guidance recommend antibiotic prophylaxis be instituted from admission, with ceftriaxone 1\\u2009g/24\\u2009h for up to 5\\u2009days as the first choice in patients with advanced cirrhosis, in hospital set-tings with a high prevalence of quinolone-\\xadresistant bacterial infec-tions, and for patients on previous quinolone prophylaxis. Initiation of vasoactive drugs (e.g., somatostatin, octreotide and terlipressin) as soon as possible is also recommended, with therapy continued for 2 to 5\\u2009days.20,422.7.2\\u2003|\\u2003Best available evidenceA meta-\\xadanalysis of antibiotic prophylaxis with data from 12 ran-domised controlled trials suggested reduced all-\\xadcause mortality, rebleeding and bacterial infections, with no clear preference for quinolones or cephalosporins.43 In patients with advanced cirrhosis, a randomised trial found that intravenous ceftriaxone 1\\u2009g daily re-',\n",
       " 'quinolones or cephalosporins.43 In patients with advanced cirrhosis, a randomised trial found that intravenous ceftriaxone 1\\u2009g daily re-duced infections as compared to oral norfloxacin 400\\u2009mg twice daily over 7\\u2009days.44Multiple randomised trials of vasoactive therapy for acute var-iceal bleeding have been performed, and meta-\\xadanalysis demon-strates benefits in mortality, haemostasis and rebleeding as compared to placebo or routine management.45 However, only three randomised trials (all double-\\xadblind and placebo-\\xadcontrolled) have assessed immediate vasoactive therapy (somatostatin, vap-reotide and terlipressin) in patients with potential variceal bleeding prior to endoscopic diagnosis.46–48 Due to study design in which patients found to have varices at endoscopy continued on placebo (a deviation from standard appropriate care in which vasoactive therapy is given to patients with confirmed variceal bleeding), only outcomes up to the time of endoscopy can be used to assess the potential benefit of pre-\\xadendoscopic vasoactive therapy. One study showed improved bleeding control at 12\\u2009h with vasoactive ther-apy, and the other two studies showed less active bleeding at the time of endoscopy.492.7.3\\u2003|\\u2003Take-\\xadhome pointPatients with cirrhosis and UGIB should be treated with antibiotics and vasoactive medications beginning soon after presentation.3\\u2003|\\u2003ENDOSCOPIC MANAGEMENT3.1\\u2003|\\u2003Timing of endoscopy3.1.1\\u2003|\\u2003GuidelinesU.S., European, international and Asia-\\xadPacific guidelines suggest performing an early endoscopy within 24\\u2009h of presentation for pa-tients with UGIB in the hospital.5–8 European guidelines specifi-cally do not recommend urgent endoscopy (≤12\\u2009h) and recommend against emergent upper endoscopy (≤6\\u2009h).8 Baveno VII and U.S. guidance recommend that patients with suspected acute variceal bleeding should undergo endoscopy within 12\\u2009h.20,42 U.S. guidelines also suggest endoscopy as soon as possible within routine hours',\n",
       " 'guidance recommend that patients with suspected acute variceal bleeding should undergo endoscopy within 12\\u2009h.20,42 U.S. guidelines also suggest endoscopy as soon as possible within routine hours in haemodynamically stable patients without severe comorbidities because it may allow early discharge in a substantial proportion of patients with low-\\xadrisk endoscopic findings.53.1.2\\u2003|\\u2003Best available evidenceObservational studies suggest that performing an endoscopy within 24\\u2009h may reduce the length of hospital stay, the need for surgery and all-\\xadcause mortality. A randomised trial comparing endoscopy ≤12 versus >12\\u2009hours after presentation in consecutive patients with UGIB showed no benefit for earlier endoscopy in mortality or further bleeding. Among high-\\xadrisk patients (e.g., haemodynamically unstable, need for endoscopic therapy), observational studies with statistical adjustment show that endoscopy within 6\\u2009h or beyond 24\\u2009h is associated with higher mortality.3,50 In contrast, a single-\\xadcentre observational study from Asia reported reduced mortality with endoscopy within 6 versus 6–48\\u2009h after presentation in higher-\\xadrisk patients with GBS\\u2009≥\\u20098.51 A randomised trial comparing endos-copy within 6\\u2009hours of gastroenterology consultation versus 6–24\\u2009h after consultation (mean of 10 vs. 25\\u2009h after presentation) in 516 high-\\xadrisk patients with GBS\\u2009≥\\u200912 showed no suggestion of a benefit  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '1070\\u2003 |\\u2003 \\u2003\\u2002SHUNG and LAINEof earlier endoscopy: further bleeding 10.9 versus 7.8%; mortality 8.9 versus 6.6%.52Two randomised trials in low-\\xadrisk patients (haemodynamically stable, no severe comorbidities) assessed endoscopy within 2–6\\u2009h of evaluation versus elective endoscopy after admission and found low-\\xadrisk endoscopic findings (e.g., clean-\\xadbased ulcer) that should allow discharge in ≥40% of patients undergoing early endoscopy.53,54 Following recommendations for discharge of such patients reduced length of stay and costs without increasing readmissions.53Although guidelines suggest endoscopy in patients with suspected variceal bleeding within 12\\u2009h, we do not believe current evidence provides support for this suggestion. An observational study with statistical adjustment reports reduced mortality in patients with var-iceal bleeding when endoscopy was performed within 24\\u2009hours after admission (OR\\u2009=\\u20090.85, 95% CI: 0.76–0.93).55 In addition, subgroup analysis of another observational study showing increased mortality with endoscopy ≤6 or >24\\u2009h after admission showed the magnitude of the increase was comparable for variceal and non-\\xadvariceal bleeding.3 Furthermore, a meta-\\xadanalysis of observational studies without statisti-cal adjustment did not demonstrate the benefit of endoscopy ≤12 ver-sus >12\\u2009h in mortality, further bleeding, hospital stay or transfusions.563.1.3\\u2003|\\u2003Take-\\xadhome pointPatients presenting with UGIB should undergo endoscopy within 24\\u2009hours. Urgent endoscopy in high-\\xadrisk patients is not recom-mended before resuscitation is initiated and other co-\\xadmorbidities are addressed.3.2\\u2003|\\u2003Candidates for endoscopic therapy of peptic ulcer disease3.2.1\\u2003|\\u2003GuidelinesEndoscopic therapy is recommended for ulcers with active bleeding (spurting or oozing) and non-\\xadbleeding visible vessels by U.S., European and international guidelines.5,6,8 For patients with an adherent clot re-sistant to vigorous irrigation, these guidelines largely leave treatment',\n",
       " 'and international guidelines.5,6,8 For patients with an adherent clot re-sistant to vigorous irrigation, these guidelines largely leave treatment decisions up to providers: they either did not reach a recommendation or indicate endoscopic therapy may be considered.57,583.2.2\\u2003|\\u2003Best available evidenceMeta-\\xadanalyses of randomised trials document reduced further bleeding with endoscopic therapy versus no endoscopic therapy in patients with active bleeding (RR\\u2009=\\u20090.29, 0.20–0.43) and non-\\xadbleeding visible vessels (RR\\u2009=\\u20090.49, 0.40–0.59).57 In contrast, the meta-\\xadanalysis did not document the benefit of endoscopic therapy in patients with adherent clots (RR\\u2009=\\u20090.31, 0.06–1.77). However, studies were small and heterogeneity was present. In addition, two randomised, double-\\xadblind Asian studies suggested high-\\xaddose PPI therapy alone (without endoscopic therapy) may prevent rebleeding in patients with adherent clots.3.2.3\\u2003|\\u2003Take-\\xadhome pointEndoscopic therapy should be performed for patients with active bleeding and non-\\xadbleeding visible vessels, while its use for adherent clots may be individualised.3.3\\u2003|\\u2003Standard forms of endoscopic therapy for peptic ulcer disease3.3.1\\u2003|\\u2003GuidelinesEndoscopic modality recommended or suggested by one of the guidelines include bipolar electrocoagulation, heater probes, injec-tions of absolute ethanol, clips, argon plasma coagulation and soft monopolar electrocoagulation. U.S., European and international guidelines recommend epinephrine not be used alone but only in combination with another modality.5,6,8 European guidelines recom-mend a combination of epinephrine and a second modality for ac-tively bleeding ulcers, while U.S. and international guidelines do not indicate epinephrine therapy is required in such cases.83.3.2\\u2003|\\u2003Best available evidenceRandomised controlled trials support each of the endoscopic thera-pies listed above in guideline recommendations, but details are be-',\n",
       " '3.3.2\\u2003|\\u2003Best available evidenceRandomised controlled trials support each of the endoscopic thera-pies listed above in guideline recommendations, but details are be-yond the scope of this review. Little high-\\xadquality evidence is available to inform the appropriate techniques for endoscopic haemostatic therapies. Larger volumes (e.g., 30–45\\u2009mL) appear to improve efficacy in randomised trials of epinephrine monotherapy, but information on the volume when epinephrine is combined with other modalities is not available.59 A recent randomised trial did provide support for prior recommendations to apply thermal contact devices such as bipolar and heater probes around the bleeding site or visible vessel and then centrally on the bleeding site or visible vessel. Application of a bipolar probe at 3 peripheral sites equidistant from the site of bleeding, followed by application at the centre of the bleeding area, was compared to application solely at the centre of the bleeding site. Despite the total number of applications per patient being similar in the two study groups, the haemostasis rate was higher with the addi-tion of peripheral applications: 91% versus 71%; p\\u2009=\\u20090.002.603.3.3\\u2003|\\u2003Take-\\xadhome pointEpinephrine injection should not be used alone; it should only be used in combination with a second modality. Thermal therapies,  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '| \\u20031071SHUNG and LAINEabsolute ethanol injection and clips are all appropriate endoscopic haemostatic modalities.3.4\\u2003|\\u2003Newer endoscopic therapies for peptic ulcer disease3.4.1\\u2003|\\u2003Over the scope clipsGuidelinesU.S. guidelines suggest the use of over-\\xadthe-\\xadscope clips (OTSCs) for patients who develop recurrent bleeding due to ulcers after previous successful endoscopic haemostasis.5 European guidelines suggest OTSCs may be considered as first-\\xadline therapy in selected patients (e.g., ulcer >2\\u2009cm, excavated/fibrotic ulcers). Asia-\\xadPacific guidelines recommend using OTSCs for lesions refractory to conventional en-doscopic haemostatic therapy.7Best available evidenceA randomised trial of OTSC versus standard therapy in patients with recurrent bleeding after successful endoscopic haemostatic therapy found reduced further bleeding with OTSC (15.2 vs. 57.6%; p\\u2009=\\u20090.001).61 More recently, OTSCs have been proposed as first-\\xadline therapy. Among four randomised controlled trials performed in all aeti-ologies of severe acute non-\\xadvariceal UGIB, three show benefit and one does not.62–65 A pooled meta-\\xadanalysis that we performed incorporat-ing these trials showed decreased further bleeding (OR: 0.32, 95% CI: 0.17–0.59) and no difference in all-\\xadcause 30-\\xadday mortality (OR: 0.60, 95% CI: 0.23–1.56) (Figures\\xa0S4 and S5). However, important methodo-logical limitations in the positive trials have led to some hesitation in recommending OTSC as a routine first-\\xadline therapy in all patients.Take-\\xadhome pointOTSCs are suggested as a treatment option for recurrent bleeding after conventional endoscopic haemostatic therapy and may be con-sidered for initial haemostatic therapy.3.4.2\\u2003|\\u2003Topical haemostatic therapiesGuidelinesU.S. guidelines suggest TC-\\xad325 haemostatic powder spray as treat-ment for patients with actively bleeding ulcers. European, interna-tional and Asia-\\xadPacific guidelines suggest haemostatic powder spray',\n",
       " 'ment for patients with actively bleeding ulcers. European, interna-tional and Asia-\\xadPacific guidelines suggest haemostatic powder spray for patients with bleeding refractory to conventional therapy.Best available evidenceSeveral topical haemostatic products have been studied (e.g., TC-\\xad325, UI-\\xadEWD, TDM-\\xad621, CEGP-\\xad003, Ankaferd Blood Stopper and Endoclot). TC-\\xad325, a haemostatic powder with aluminium phyllosilicate clay that forms a barrier at the site of bleeding, is the best studied at present.An adequately powered randomised trial in patients with active non-\\xadvariceal UGIB showed non-\\xadinferiority of TC-\\xad325 haemostatic powder therapy compared to standard endoscopic therapy for 30-\\xadday further bleeding: 9.9 versus 18.6% (difference\\u2009=\\u20098.7%, 1-\\xadsided 95% CI: 0.95%); results for ulcers (accounting for 61% of patients in the trial) were 11.7 versus 16.2%.66 These results were the basis for the U.S. guidelines suggesting TC-\\xad325 powder could be used as first-\\xadline therapy in actively bleeding lesions. A randomised trial compar-ing UI-\\xadEWD after standard endoscopic therapy to standard therapy alone in 340 patients with non-\\xadvariceal UGIB was recently presented in abstract form. Rebleeding was reduced with the addition of UI-\\xadEWD at 3\\u2009days (2.9 vs. 11.3%, p\\u2009=\\u20090.005) and 30\\u2009days (7.0 vs. 18.5%, p\\u2009=\\u20090.003).67Take-\\xadhome pointTC-\\xad325 powder spray is an option for treatment of actively bleeding ulcers and other non-\\xadvariceal lesions.3.5\\u2003|\\u2003Variceal bleeding3.5.1\\u2003|\\u2003Severe refractory variceal bleedingGuidelinesBaveno VII and updated U.S. guidance recommend balloon tampon-ade or self-\\xadexpandable metal stents as a bridge therapy to more def-inite treatment with transjugular intrahepatic portosystemic shunt (TIPS), noting that SEMS are a safer and more durable option than balloon tamponade.20,42Best available evidenceIn patients with severe refractory variceal bleeding, fully-\\xadcovered self-\\xadexpanding metal stents are now generally preferred to balloon',\n",
       " 'balloon tamponade.20,42Best available evidenceIn patients with severe refractory variceal bleeding, fully-\\xadcovered self-\\xadexpanding metal stents are now generally preferred to balloon tamponade because they appear to be more efficacious, safer and can be maintained for a longer period of time (1\\u2009week) than balloon tamponade (24\\u2009h). A randomised controlled trial in 28 patients with massive or refractory variceal bleeding found suggestions of benefit for stent versus balloon tamponade in the composite outcome of GIB, serious adverse event or death (34% vs. 80%; p\\u2009=\\u20090.051), bleeding (15% vs. 53%; p\\u2009=\\u20090.055), device-\\xadrelated serious adverse events (8% vs. 40%; p\\u2009=\\u20090.084) and median red-\\xadblood-\\xadcell transfusions (2 vs. 6\\u2009units; p\\u2009=\\u20090.08).68,69Take-\\xadhome pointFully-\\xadcovered self-\\xadexpanding metal stents are preferred over balloon tamponade for severe refractory variceal bleeding.3.6\\u2003|\\u2003Ligation and medical therapy for acute Oesophageal Variceal bleeding3.6.1\\u2003|\\u2003GuidelinesU.S. guidance and Baveno VII recommend ligation therapy for the treatment of acute oesophageal variceal bleeding.20,42 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '1072\\u2003 |\\u2003 \\u2003\\u2002SHUNG and LAINE3.6.2\\u2003|\\u2003Best available evidenceA recent meta-\\xadanalysis of 10 randomised trials comparing sclerother-apy with ligation for acute variceal bleeding reported ligation had an increased bleeding control rate within the first 8–120\\u2009h (RR\\u2009=\\u20091.08, 1.02–1.15) and less subsequent rebleeding (RR\\u2009=\\u20090.71, 0.52–0.97), as well as lower mortality (RR\\u2009=\\u20090.72, 0.54–0.97) and fewer complica-tions (RR\\u2009=\\u20090.29, 0.20–0.44).70 In patients hospitalised with acute variceal bleeding, randomised trials indicate that ligation is superior to medical therapy alone,71–73 and combination therapy with ligation plus a vasoactive drug (terlipressin) was more effective than a vaso-active drug alone.74 Combination therapy with ligation plus octreo-tide reduced rebleeding rate (9% vs. 38%) but not inpatient mortality (9% vs. 19%) as compared with ligation alone in a randomised trial of 94 patients.75 Other published randomised trials do not show the benefit of combined therapy (ligation plus somatostatin or octreo-tide) versus ligation alone in outcomes such as fresh hematemesis within 5\\u2009days (8/31 (26%) vs. 7/30 (23%)), further bleeding or death within 5\\u2009days (2/60 (3%) vs. 1/58 (2%)) or 5-\\xadday rebleeding (0/24 vs. 2/30 (7%)).76–78Patients with cirrhosis found to have a non-\\xadvariceal source of bleeding should have their vasoactive medication discontinued given no benefit documented in non-\\xadvariceal bleeding, but continue antibiotic therapy given the benefit in cirrhotic patients with all sources of UGIB.3.6.3\\u2003|\\u2003Take-\\xadhome pointAcute oesophageal variceal bleeding should be treated with oesoph-ageal variceal ligation as well as intravenous vasoactive medications and antibiotic therapy.3.7\\u2003|\\u2003Gastric varices3.7.1\\u2003|\\u2003Overall management of gastric variceal bleedingGuidelinesBaveno VII suggests endoscopic therapy with tissue adhesives for bleeding from IGV and GOV-\\xad2,20 while U.S. guidance suggests ei-ther endoscopic cyanoacrylate injection, TIPS or retrograde trans-',\n",
       " 'Baveno VII suggests endoscopic therapy with tissue adhesives for bleeding from IGV and GOV-\\xad2,20 while U.S. guidance suggests ei-ther endoscopic cyanoacrylate injection, TIPS or retrograde trans-venous obliteration (RTO) can be considered first-\\xadline therapies to control bleeding and prevent rebleeding for GOV2 or IGV; RTO is preferred when TIPS is contraindicated.42,79 Both Baveno VII and U.S. guidelines suggest either ligation or tissue adhesive for GOV-\\xad1.Best available evidenceGastric varices are categorised by location. Gastroesophageal varices are labelled GOV-\\xad1 if they extend from the oesophagus along the lesser curvature of the stomach and GOV-\\xad2 if they extend along the greater curvature. Isolated gastric varices without connection to oesophageal varices are labelled IGV-\\xad1 if in the fundus and IGV-\\xad2 if elsewhere in the stomach.A meta-\\xadanalysis of randomised trials of endoscopic injection of butyl-\\xadcyanoacrylate glue injection compared to band ligation showed no benefit in control of active bleeding (RR\\u2009=\\u20091.13; 0.23–5.69), but decreased re-\\xadbleeding after control of bleeding on initial interven-tion (RR\\u2009=\\u20090.60; 0.41–0.88).80 Two randomised trials81,82 reported no significant difference in post-\\xadprocedural complications between butyl-\\xadcyanoacrylate and ligation, but one found more bleeding gas-tric ulcers with ligation (28% vs. 7%).83 A randomised trial found that TIPS decreased rebleeding from gastric varices (4/35 (11%) versus 14/37 (38%); p\\u2009=\\u20090.01) compared to glue injection, although the dif-ference lessened when all-\\xadcause UGIB was assessed (15/35 (43%) vs. 22/37 (59%); p\\u2009=\\u20090.12).84Balloon Retrograde Transvenous Obliteration (BRTO) is an inter-ventional radiologic procedure that provides transvenous sclerosis/occlusion of gastric varices via a spontaneous gastrorenal shunt and does not divert blood from the portal system as TIPS does. A ran-domised trial showed BRTO increased the likelihood of remaining free',\n",
       " 'does not divert blood from the portal system as TIPS does. A ran-domised trial showed BRTO increased the likelihood of remaining free of all-\\xadcause UGIB compared to cyanoacrylate (1-\\xadyear 77% vs. 96%, 2-\\xadyear 65% vs. 93%; p\\u2009=\\u20090.004).85 A systematic review of BRTO com-pared to TIPS for treatment of gastric varices, comprised of 6 cohort studies (N\\u2009=\\u2009655) and 1 randomised trial (N\\u2009=\\u200921) reported reductions in rebleeding (OR\\u2009=\\u20090.30, 0.18–0.48), 1-\\xadyear mortality (OR\\u2009=\\u20090.43, 0.21–0.87) and hepatic encephalopathy (OR\\u2009=\\u20090.06, 0.02–0.15) with BRTO, although the evidence must be considered very low quality.86 Although BRTO is the RTO that is best studied, other observational studies use alternative forms of RTO, which may have fewer complications.79GOV-\\xad1 obliteration.\\u2003For acute gastric variceal bleeding secondary to GOV-\\xad1, ligation was inferior to butyl-\\xadcyanoacrylate for initial haemostasis in a meta-\\xadanalysis across two randomised trials83,87 (OR: 0.37; 0.15–0.89), with more frequent rebleeding in a meta-\\xadanalysis across three randomised trials82,83,87 (OR: 2.62; 1.32–5.22).69 However, one randomised trial found a higher frequency of immediate adverse symptoms (fever, chest pain, dysphagia: 41% vs 8%) and long-\\xadterm complications (spontaneous bacterial peritonitis, hepatic encephalopathy and hepatorenal syndrome) for patients with GOV-\\xad1 who underwent butyl-\\xadcyanoacrylate injection compared to ligation.87GOV-\\xad2 obliteration.\\u2003For GOV2, no difference in rebleeding was seen when comparing butyl-\\xadcyanoacrylate and ligation in a meta-\\xadanalysis of available data from two randomised trials82,83 (OR: 1.10; 95% CI: 0.28–4.36), though the numbers are very small (N\\u2009=\\u200938).69IGV obliteration.\\u2003For IGV, the data are even more limited but in a meta-\\xadanalysis of available data from two randomised trials (N\\u2009=\\u200924)82,83 more rebleeding occurred with ligation than with butyl-\\xadcyanoacrylate in IGV (OR: 15.98; 95% CI: 1.71–149.12).69Take-\\xadhome point',\n",
       " '(N\\u2009=\\u200924)82,83 more rebleeding occurred with ligation than with butyl-\\xadcyanoacrylate in IGV (OR: 15.98; 95% CI: 1.71–149.12).69Take-\\xadhome pointEndoscopic therapy with butyl-\\xadcyanoacrylate is more effective than ligation for gastric variceal bleeding although ligation may be  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '| \\u20031073SHUNG and LAINEconsidered for GOV1 bleeding because of fewer adverse events. TIPS and BRTO are superior to endoscopic therapy for the prevention of recurrent gastric variceal bleeding. BRTO may be performed if a gas-trorenal shunt is present based on clinical factors (e.g. MELD score, hepatic encephalopathy).3.8\\u2003|\\u2003Novel therapies with endoscopic ultrasound-\\xadenhanced obliteration or thrombin injection3.8.1\\u2003|\\u2003GuidelinesNo recommendations exist yet for the use of endoscopic ultrasound or thrombin injection for the treatment of gastric varices.3.8.2\\u2003|\\u2003Best available evidenceThe use of endoscopic ultrasound to guide treatment for gastric varices has been studied in two small randomised controlled trials, but the heterogeneity of practice limits the pooled analysis of avail-able data. One trial shows that patients treated with EUS-\\xadguided cyanoacrylate glue injection with coils tended to have less reinter-vention (16.7% vs. 40%; p\\u2009=\\u20090.01) and less rebleeding (3.3% vs. 20%; p\\u2009=\\u20090.04) compared to EUS-\\xadcoil treatment alone.88 The other very small randomised trial evaluated EUS-\\xadguided cyanoacrylate glue in-jection with coil versus EUS-\\xadguided cyanoacrylate glue injection alone and a found flow reduction of 37.5% versus 50% (p\\u2009=\\u20090.48) and post-\\xadprocedure pulmonary embolism in 25% versus 50% (p\\u2009=\\u20090.14).89 Two systematic reviews and meta-\\xadanalyses, including observational evi-dence suggest that EUS-\\xadguided cyanoacrylate glue injection with coil embolisation has a higher technical success rate and lower rebleeding rate compared to other EUS modalities.90,91 The use of thrombin in-jection compared to cyanoacrylate glue injection has been studied in a randomised trial, which found no difference in 5-\\xadday treatment failure (2/33 vs. 2/35; p\\u2009=\\u20090.99) but increased complications (4/33 vs. 18/35; p\\u2009<\\u20090.001), including gastric ulcers, in the cyanoacrylate group.923.8.3\\u2003|\\u2003Take-\\xadhome pointFurther evidence is needed before recommendations regarding en-',\n",
       " 'p\\u2009<\\u20090.001), including gastric ulcers, in the cyanoacrylate group.923.8.3\\u2003|\\u2003Take-\\xadhome pointFurther evidence is needed before recommendations regarding en-doscopic ultrasound-\\xadguided therapy or use of thrombin for gastric variceal bleeding can be made.3.9\\u2003|\\u2003Gastric antral vascular ectasia (GAVE)3.9.1\\u2003|\\u2003GuidelinesRecent guidelines do not provide recommendations for treatment of UGIB due to GAVE.3.9.2\\u2003|\\u2003Best available evidenceGAVE has traditionally been treated with thermal therapy, primar-ily APC. A systematic review of outcomes in cohorts of patients treated with APC reported a mean haemoglobin increase of 3.1\\u2009g/dL, with 88% of 110 RBC transfusion-\\xaddependent patients becom-ing transfusion-\\xadfree post-\\xadtherapy; a mean of 3.4 treatment sessions were required, and the complication rate was 5.1% (31% of compli-cations were bleeding ulcers).93 However, ligation may be a better option based on observational studies and randomised controlled trials. A meta-\\xadanalysis of 4 randomised trials reported a higher eradi-cation rate (absolute risk difference\\u2009=\\u200929%, 14%–44%), less recur-rent bleeding (absolute risk difference\\u2009=\\u200929%, 15%–44%) and fewer transfusions (mean difference\\u2009=\\u20091.49\\u2009units, 0.28–2.71), with oblitera-tion of lesions requiring fewer sessions with ligation (mean differ-ence\\u2009=\\u20091.38, 0.35–2.42).943.9.3\\u2003|\\u2003Take-\\xadhome pointBleeding from GAVE is commonly treated with APC, but ligation ap-pears to be a superior option.3.10\\u2003|\\u2003Mallory-\\xadWeiss tear3.10.1\\u2003|\\u2003GuidelinesRecent guidelines do not provide recommendations for the treat-ment of UGIB due to Mallory-\\xadWeiss tears, although older European and U.S. guidelines suggest only those with active ongoing bleeding require endoscopic therapy, with U.S. guidelines indicating multipo-lar (bipolar) electrocoagulation appears most effective and European guidelines stating evidence is inadequate to recommend a specific modality.95,963.10.2\\u2003|\\u2003Best available evidenceMany forms of endoscopic therapy have been reported to be ef-',\n",
       " 'guidelines stating evidence is inadequate to recommend a specific modality.95,963.10.2\\u2003|\\u2003Best available evidenceMany forms of endoscopic therapy have been reported to be ef-fective for bleeding from Mallory-\\xadWeiss tears in observational studies, including epinephrine, sclerosant, bipolar electrocoagula-tion, heater probe, ligation, clips and haemostatic powder spray. A randomised controlled trial showed bipolar electrocoagulation was superior to sham endoscopic therapy in 17 patients with ac-tively bleeding Mallory-\\xadWeiss tears: haemostasis in 9/9 versus 0/8, emergency intervention in 0/9 versus 4/8, units of RBCs transfused of 1.0 versus 4.8.97 Another randomised trial compared epinephrine plus polidocanol injection versus no endoscopic ther-apy: among those with active bleeding, further bleeding occurred in 1/23 receiving therapy versus 5/23 controls, and among those with non-\\xadbleeding visible vessels, further bleeding occurred in  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '1074\\u2003 |\\u2003 \\u2003\\u2002SHUNG and LAINE1/9 with endoscopic therapy and 3/8 controls – none of the fur-ther bleeding episodes was associated with hypotension.98 A ran-domised trial compared endoscopic therapy for actively bleeding Mallory-\\xadWeiss tears and showed further bleeding in 4/9 with epi-nephrine versus 0/11 with clips,99 while two other randomised tri-als in patients with actively bleeding Mallory-\\xadWeiss tears showed epinephrine comparable to clips in 35 patients (100% haemostasis and 6% rebleeding in both groups) and to ligation in 34 patients (100% haemostasis with no rebleeding in either group).100,101 The very low risk for rebleeding in non-\\xadbleeding Mallory-\\xadWeiss tears was shown in a more recent study that included 66 patients with non-\\xadbleeding Mallory-\\xadWeiss tears managed without endoscopic haemostatic therapy; only 1 patient experienced rebleeding and did not require intervention.1023.10.3\\u2003|\\u2003Take-\\xadhome pointPatients with actively bleeding Mallory-\\xadWeiss tears should receive endoscopic therapy, probably employing endoscopic therapies sug-gested for ulcer bleeding.3.11\\u2003|\\u2003Dieulafoy lesion3.11.1\\u2003|\\u2003GuidelinesOlder European guidelines suggest treatment of Dieulafoy lesions with thermal therapy, clips or ligation – with or without epinephrine injection, with transcatheter embolisation or surgery if endoscopic treatment fails or is not technically feasible.953.11.2\\u2003|\\u2003Best available evidenceMultiple endoscopic haemostatic modalities are reported to be ef-fective for Dieulafoy lesions in observational studies, including epinephrine, sclerosant, cyanoacrylate, bipolar electrocoagulation, heater probe, APC, clips and ligation. Small randomised controlled trials suggest epinephrine therapy is inferior to mechanical therapy with ligation or clips, with further bleeding rates >40% versus 0%–17%.103–105 Small randomised comparisons of clips versus ligation reveal excellent results for both therapies, with further bleeding in <8% of patients.106,107',\n",
       " '17%.103–105 Small randomised comparisons of clips versus ligation reveal excellent results for both therapies, with further bleeding in <8% of patients.106,1073.11.3\\u2003|\\u2003Take-\\xadhome pointPatients with Dieulafoy lesions should undergo endoscopic therapy, employing therapies suggested for ulcer bleeding. Similar to ulcer bleeding, epinephrine should not be used alone.3.12\\u2003|\\u2003Malignancy3.12.1\\u2003|\\u2003GuidelinesOlder European guidelines suggest considering endoscopic hae-mostatic therapy for bleeding from UGI neoplasia to potentially reduce the need for urgent surgery and provide a bridge to other therapy, although no endoscopic treatment appears to have long-\\xadterm efficacy.953.12.2\\u2003|\\u2003Best available evidenceCase series suggest endoscopic therapy may achieve haemostasis in many patients with UGIB due to malignancy, although rates are highly variable. Rebleeding rates tend to be high, which would be expected if the underlying lesion is not able to be treated effec-tively. For example, a case series from Korea of 113 patients with UGIB from unresectable gastric cancer treated with endoscopic therapy revealed a haemostasis rate of 93% but rebleeding in 41% (30% at 30\\u2009days) and a median survival of 3\\u2009months.108 In a case series of 106 consecutive patients hospitalised with UGIB due to malignancy in the United States, haemostasis was achieved in 86% of patients with active bleeding at endoscopy who received endo-scopic therapy, but 18 patients with active bleeding who did not receive endoscopic therapy had spontaneous resolution of bleeding as well. Hospitalisation for rebleeding occurred in 49% of patients at a median of 30\\u2009days.109TC-\\xad325 haemostatic powder spray has recently been considered to have promise for malignancy-\\xadrelated UGIB. A randomised trial was done in 59 patients with UGIB due to malignancy (19 with active bleed-ing from the malignant lesion): all 28 patients in the TC-\\xad325 group re-ceived therapy and had haemostasis, while only 6 patients of 31 in the',\n",
       " 'ing from the malignant lesion): all 28 patients in the TC-\\xad325 group re-ceived therapy and had haemostasis, while only 6 patients of 31 in the control group received endoscopic therapy. Rebleeding at 30\\u2009days was not reduced with TC-\\xad325 versus control (32% vs. 19.4%), nor was hos-pital stay (17.4 vs. 12.8\\u2009days) or 30-\\xadday mortality (28.6% vs. 19.4%).110 In contrast, subgroup analysis of patients with cancer in a recent large randomised trial comparing TC-\\xad325 to standard endoscopic therapy for active UGIB reported 30-\\xadday further bleeding in 3/29 (10%) receiv-ing TC-\\xad325 versus 6/13 (46%) receiving standard therapy.66Therapy with transcatheter embolisation may be employed, and treatment of the underlying malignancy (e.g., palliative or curative surgery, radiation therapy) where possible is the best option to pre-vent rebleeding.3.12.3\\u2003|\\u2003Take-\\xadhome pointAcute UGIB due to malignancy may be treated with endoscopic ther-apy but results are variable and rebleeding is common. Treatment with TC-\\xad325 haemostatic powder spray may hold promise but  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '| \\u20031075SHUNG and LAINEtherapy for the underlying malignancy, if possible, is most important to prevent rebleeding.4\\u2003|\\u2003POST-\\xadENDOSCOPIC MANAGEMENT4.1\\u2003|\\u2003Early versus delayed oral intake for moderate to severe UGIB4.1.1\\u2003|\\u2003GuidelinesInternational guidelines recommend that patients at low risk can eat within 24\\u2009h after endoscopy.6 No specific recommendations exist for the timing of resuming a diet for patients hospitalised with moderate to severe UGIB, though U.S. guidance for portal hypertensive bleed-ing recommends initiating enteral feeding once the variceal haemor-rhage has been controlled.424.1.2\\u2003|\\u2003Best available evidenceA randomised trial in 251 patients with UGIB with lower-\\xadrisk en-doscopic findings showed no difference in rebleeding or need for urgent intervention in those immediately given a regular diet ver-sus delaying resumption of a regular diet (clear liquids started at 36\\u2009h and regular diet at 48\\u2009h after endoscopy). Overall, rebleeding occurred in only 3/162 (2%) of patients with Mallory-\\xadWeiss tears or clean-\\xadbased ulcers. Several randomised trials have assessed different dietary regimens in patients with higher-\\xadrisk endoscopic findings. One small trial in 22 patients with variceal bleeding that compared a liquid diet versus nothing by mouth for 3\\u2009days reported 7-\\xadday rebleeding rates of 4/12 versus 0/10. However, other pub-lished trials in high-\\xadrisk ulcer bleeding or varices (ranging in size up to 209 patients) showed nearly identical rebleeding rates when comparing regimens including liquid diet (or liquid followed by mixed diet) versus nothing by mouth for 2–3\\u2009days, immediate solid diet versus liquids for 1\\u2009day followed by soft diet for 2\\u2009days, imme-diate normal diet vs. normal diet at day 1, or refeeding at 1 versus 2\\u2009days with liquids for 1\\u2009day followed by soft diet for 1\\u2009day. Although aggregating these trials may be questionable due to differences in refeeding regimens and populations, we performed a meta-\\xadanalysis',\n",
       " 'aggregating these trials may be questionable due to differences in refeeding regimens and populations, we performed a meta-\\xadanalysis of the 7 randomised trials in higher-\\xadrisk patients and found earlier initiation of a regular diet was not associated with more rebleed-ing (OR\\u2009=\\u20091.05, 0.51–2.13) or deaths (0.53, 0.26–1.10) than delayed resumption of a regular diet (Figures\\xa0S6 and S7). Hospital stay was shorter across 6 trials that reported the length of stay (mean differ-ence: −1.55\\u2009days, −2.07 to −1.03) (Figure\\xa0S8).4.1.3\\u2003|\\u2003Take-\\xadhome pointPatients with low-\\xadrisk endoscopic findings (e.g., clean-\\xadbased ulcers) may begin a regular diet soon after endoscopy and be discharged home if they have no other reason for hospitalisation. Patients with higher risk endoscopic findings, even after endoscopic therapy, may be fed in less than 72\\u2009h, although the exact time and initial dietary regimen are uncertain.4.2\\u2003|\\u2003Peptic ulcer disease4.2.1\\u2003|\\u2003Proton pump inhibitor (PPI) therapy after endoscopic haemostatic therapyGuidelinesU.S. and European guidelines recommend either continuous intrave-nous PPI therapy (80\\u2009mg bolus followed by 8\\u2009mg per hour infusion) or intermittent high-\\xaddose intravenous or oral PPI therapy (e.g., 40\\u2009mg 2–4 times daily, possibly with an initial 80\\u2009mg bolus) for 3\\u2009days after successful endoscopic haemostatic therapy (or for those with clots not receiving endoscopic therapy).5,8 Earlier international guidelines only recommended intravenous PPIs with a loading dose and con-tinuous infusion for 3\\u2009days in patients with high-\\xadrisk stigmata who have undergone successful endoscopic therapy.6 Asia-\\xadPacific guide-lines recommend high-\\xaddose oral PPI therapy for at least 3\\u2009days as an adjunct to endoscopic therapy.7U.S. and international guidelines recommend that after this ini-tial 3-\\xadday period, twice-\\xaddaily PPI therapy should be given through 14\\u2009days after the index endoscopy.5,6Best available evidence',\n",
       " 'U.S. and international guidelines recommend that after this ini-tial 3-\\xadday period, twice-\\xaddaily PPI therapy should be given through 14\\u2009days after the index endoscopy.5,6Best available evidenceHigh-\\xaddose PPI therapy, defined as ≥80\\u2009mg daily for at least 3\\u2009days after endoscopic treatment, decreased further bleed-ing (RR\\u2009=\\u20090.43; 0.33–0.56) and mortality (RR\\u2009=\\u20090.41; 0.22–0.79) compared to placebo/no treatment in a meta-\\xadanalysis of 8 ran-domised comparisons.5 Furthermore, subgroup analysis showed that trials with continuous infusion and intermittent therapy had virtually identical risk ratios for further bleeding and mortality. Meta-\\xadanalysis of 9 randomised trials comparing high-\\xaddose PPI to H2-\\xadreceptor-\\xadantagonist therapy showed a reduction in further bleeding with high-\\xaddose PPI (RR\\u2009=\\u20090.56; 0.41–0.77) but not in mortality.5A single randomised trial performed in high-\\xadrisk patients (Rockall score ≥6) who had successful endoscopic haemostatic therapy for ulcers with high-\\xadrisk stigmata and 3\\u2009days of continu-ous infusion PPI therapy compared esomeprazole 40\\u2009mg twice daily to once daily for days 4–14 after the index endoscopy, with all patients receiving once-\\xaddaily PPI after 14\\u2009days. Further bleed-ing was lower at 2\\u2009weeks and at 4\\u2009weeks (10.8% vs. 28.7%, differ-ence\\u2009=\\u2009−18%, −29 to −7%).111Take-\\xadhome pointAfter endoscopic haemostatic treatment of UGIB due to ulcers, treat with either continuous infusion or intermittent intravenous or oral high-\\xaddose PPI for 3\\u2009days. Twice-\\xaddaily oral PPI therapy should then be given for at least 14\\u2009days after the index endoscopy. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '1076\\u2003 |\\u2003 \\u2003\\u2002SHUNG and LAINE4.3\\u2003|\\u2003Treatment of recurrent ulcer bleeding4.3.1\\u2003|\\u2003GuidelinesInternational, U.S. and European guidelines recommend that pa-tients with recurrent bleeding after endoscopic therapy for a bleed-ing ulcer have repeat endoscopy and endoscopic therapy rather than surgery or transcatheter arterial embolisation.5,6,8 For those who fail endoscopic therapy, U.S. and European guidelines suggest tran-scatheter arterial embolisation over surgery.5,84.3.2\\u2003|\\u2003Best available evidenceA randomised trial comparing repeat endoscopy versus surgery for patients with recurrent ulcer bleeding after initially successful endo-scopic therapy, further bleeding was more frequent with endoscopy (11/48 (23%) vs. 3/44 (7%)), but complications were less common with endoscopy (15% vs. 36%) and mortality was not significantly different (10% vs. 18%).112 Given that endoscopy prevented the need for surgery in 73% of patients in this study with a lower rate of complications and no negative impact on mortality, guideline panels suggested repeat endoscopy.A meta-\\xadanalysis of observational studies comparing transcatheter arterial embolisation to surgery after failed endoscopic therapy found that further bleeding was more common with embolisation (OR\\u2009=\\u20092.44, 1.77–3.36) but major complications were lower (OR\\u2009=\\u20090.45, 0.30–0.67) without an increase in mortality (OR\\u2009=\\u20090.77, 0.50–1.18).113 In addition, a cohort study showed hospital stays to be lower with embolisation (median 8 vs. 16\\u2009days).114 Guideline panels concluded that despite the higher risk of further bleeding, the benefits of fewer complications and a shorter hospital stays along with no increase in mortality, would sup-port initial embolisation, with surgery as a backup in those who failed embolisation. Nevertheless, patients and providers who place greater value on avoiding further bleeding over complications and hospital stays may choose differently.4.3.3\\u2003|\\u2003Take-\\xadhome point',\n",
       " 'embolisation. Nevertheless, patients and providers who place greater value on avoiding further bleeding over complications and hospital stays may choose differently.4.3.3\\u2003|\\u2003Take-\\xadhome pointRebleeding after initial endoscopic haemostatic therapy should first be evaluated and treated with repeat endoscopy. For those who fail endoscopic therapy arteriography with transcatheter arterial embo-lisation should be performed.4.4\\u2003|\\u2003Pre-\\xademptive transjugular intrahepatic portosystemic shunt (TIPS) for acute variceal bleeding4.4.1\\u2003|\\u2003GuidelinesU.S. guidance and Baveno VII recommend pre-\\xademptive TIPS within 72\\u2009h (ideally 24\\u2009h per Baveno VII) for high-\\xadrisk patients (Child-\\xadPugh class B\\u2009>\\u20097 with active bleeding or Child-\\xadPugh class C with score <14) without contraindications for TIPS.20,42,794.4.2\\u2003|\\u2003Best available evidenceA pre-\\xademptive transjugular intrahepatic portosystemic shunt (TIPS) can be considered therapy for acute variceal bleeding episodes in selected high-\\xadrisk patients based on two randomised controlled tri-als comparing pre-\\xademptive TIPS within 72\\u2009h after initial endoscopic ligation therapy and vasoactive medication infusion in patients with Child-\\xadPugh Class B and Child-\\xadPugh Class C cirrhosis (excluding those with a Child-\\xadPugh score >13). One trial found that in 63 patients, fur-ther bleeding was reduced with TIPS (3% vs. 45%, p\\u2009=\\u20090.001), as was mortality (13% vs. 39%, p\\u2009=\\u20090.001).115 The second trial in 129 patients also showed reductions in further bleeding (HR\\u2009=\\u20090.26, 0.12–0.55) and mortality (HR\\u2009=\\u20090.47, 0.23–0.96).116 The first study only included Child-\\xadPugh Class B patients if they had active bleeding, and this forms part of the rationale for guideline recommendations that high-\\xadrisk patients be defined as Child-\\xadPugh Class B with active bleeding. However, the second trial included Child-\\xadPugh Class B patients with and without active bleeding, and subgroup analysis showed the magnitude of the',\n",
       " 'second trial included Child-\\xadPugh Class B patients with and without active bleeding, and subgroup analysis showed the magnitude of the treatment effect to be similar in those with and without active bleed-ing, suggesting that any Child-\\xadPugh Class B may be considered for pre-\\xademptive TIPS. A third small similarly-\\xaddesigned trial failed to show a benefit of pre-\\xademptive TIPS. However, 6 of the 29 patients assigned to TIPS did not receive them, and another 10 received them beyond the 72-\\xadh window for pre-\\xademptive TIPS. A per-\\xadprotocol analysis of those re-ceiving TIPS within 72\\u2009hours revealed less rebleeding (0% vs. 28%) but similar 1-\\xadyear survival (77% vs. 76%) with TIPS versus standard care.117Recent guidance to restrict pre-\\xademptive TIPS in Child-\\xadPugh Class B patients to those with active bleeding and a Child-\\xadPugh score >7 is based largely on an individual patient data meta-\\xadanalysis, with 83% of the patients from observational studies, which we believe is in-sufficient to justify this conclusion. The meta-\\xadanalysis only included patients with active bleeding, so it could not address the potential benefit to patients without active bleeding. Furthermore, outcomes for Child-\\xadPugh Class B stratified by score of 7 (N\\u2009=\\u200939 TIPS) and >7 (N\\u2009=\\u200999 TIPS) were assessed only in a post hoc analysis: benefit for TIPS was noted in mortality only in the score >7 group, but less re-bleeding with TIPS was seen in both groups.118 Given that the only randomised trial assessing active and non-\\xadactive bleeding in Childs-\\xadPugh Class B patients showed a similar effect, we suggest that TIPS might be considered in any Childs-\\xadPugh Class B patient. More in-formation is necessary to make a more definitive recommendation.4.4.3\\u2003|\\u2003Take-\\xadhome pointPre-\\xademptive TIPS should be considered in high-\\xadrisk patients (Child-\\xadPugh class B or C with score <14) after initial endoscopic ligation and vasoactive medical therapy, if interventional radiology services are available.',\n",
       " 'Pugh class B or C with score <14) after initial endoscopic ligation and vasoactive medical therapy, if interventional radiology services are available. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '| \\u20031077SHUNG and LAINE4.5\\u2003|\\u2003Treatment of recurrent variceal bleeding4.5.1\\u2003|\\u2003GuidelinesIf further bleeding occurs despite medical and endoscopic therapy, TIPS is recommended by U.S. guidance and Baveno VII.20,42 Both TIPS and BRTO are suggested as treatments for gastric varices as discussed above.4.5.2\\u2003|\\u2003Best available evidenceAs mentioned above, in addition to endoscopic ligation, vasoactive medications are continued for a total of 2–5\\u2009days and antibiotics for up to 7\\u2009days to reduce further bleeding. In patients who fail to achieve haemostasis despite adequate endoscopic and pharmaco-logical therapy, meta-\\xadanalysis of trials of TIPS revealed rebleeding of 16% within 30–42\\u2009days; mortality was 33% at 30–42\\u2009days and 46% at 1\\u2009year, although mortality due to rebleeding was only 9%.119 A meta-\\xadanalysis of 17 randomised trials comparing TIPS and endo-scopic therapy in patients with variceal bleeding indicates TIPS is more effective in reducing rebleeding (OR\\u2009=\\u20090.28, 0.22–0.37) but not mortality (OR\\u2009=\\u20091.04, 0.81–1.33) and is associated with more hepatic encephalopathy (OR\\u2009=\\u20092.04, 1.57–2.66).1204.5.3\\u2003|\\u2003Take-\\xadhome pointPatients with further variceal bleeding despite endoscopic and medical therapy should undergo TIPS (BRTO may be performed for gastric variceal bleeding).AUTHOR CONTRIBUTIONSDennis L. Shung: Conceptualization; data curation; formal analysis; funding acquisition; investigation; methodology; project adminis-tration; resources; software; visualization; writing – original draft; writing – review and editing. Loren Laine: Conceptualization; data curation; formal analysis; investigation; methodology; project ad-ministration; resources; software; supervision; validation; visuali-zation; writing – original draft; writing – review and editing.ACKNOWLEDGEMENTSWe acknowledge the assistance of Alyssa Grimshaw, medical librar-ian at Yale, in crafting the structured searches for the systematic reviews.FUNDING INFORMATION',\n",
       " 'ACKNOWLEDGEMENTSWe acknowledge the assistance of Alyssa Grimshaw, medical librar-ian at Yale, in crafting the structured searches for the systematic reviews.FUNDING INFORMATIONWork for DLS was funded in part through the National Institutes of Health, DK125718.AUTHORSHIPGuarantor of the article: Dennis L. Shung. Both authors approved the final version of the manuscript.CONFLICT OF INTEREST STATEMENTDLS has no conflicts of interests. LL serves as a consultant for Phathom Pharmaceuticals and Medtronic.ORCIDDennis L. Shung\\xa0 https://orcid.org/0000-0001-8226-1842 Loren Laine\\xa0 https://orcid.org/0000-0002-4296-7901 REFERENCES1. Zheng NS, Tsay C, Laine L, Shung DL. Trends in characteristics, man-agement, and outcomes of patients presenting with gastrointesti-nal bleeding to emergency departments in the United States from 2006 to 2019. Aliment Pharmacol Ther. 2022;56(11–12):1543–55.2. Taha AS, Saffouri E, McCloskey C, Craigen T, Angerson WJ. Falling mortality when adjusted for comorbidity in upper gastro-intestinal bleeding: relevance of multi-\\xaddisciplinary care. Frontline Gastroenterol. 2014;5(4):243–8.3. Guo CLT, Wong SH, Lau LHS, Lui RNS, Mak JWY, Tang RSY, et\\xa0al. Timing of endoscopy for acute upper gastrointestinal bleeding: a territory-\\xadwide cohort study. Gut. 2022;71(8):1544–50.4. Abraham NS, Barkun AN, Sauer BG, Douketis J, Laine L, Noseworthy PA, et\\xa0 al. American College of Gastroenterology-\\xadCanadian Association of Gastroenterology clinical practice guide-line: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period. Am J Gastroenterol. 2022;117(4):542–58.5. Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol. 2021;116(5):899–917.6. Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F, et\\xa0 al. Management of nonvariceal upper gastrointestinal bleeding: guide-',\n",
       " 'Gastroenterol. 2021;116(5):899–917.6. Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F, et\\xa0 al. Management of nonvariceal upper gastrointestinal bleeding: guide-line recommendations from the international consensus group. Ann Intern Med. 2019;171:805–22. https://\\u200bdoi.\\u200borg/\\u200b10.\\u200b7326/\\u200bM7319-\\u200b17957. Sung JJ, Chiu PW, Chan FK, Lau JY, Goh KL, Ho LH, et\\xa0al. Asia-\\xadPacific working group consensus on non-\\xadvariceal upper gastroin-testinal bleeding: an update 2018. Gut. 2018;67(10):1757–68.8. Gralnek IM, Stanley AJ, Morris AJ, Camus M, Lau J, Lanas A, et\\xa0 al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) guideline – update 2021. Endoscopy. 2021;53(3):300–32.9. Stanley AJ, Ashley D, Dalton HR, Mowat C, Gaya DR, Thompson E, et\\xa0al. Outpatient management of patients with low-\\xadrisk upper-\\xadgastrointestinal haemorrhage: multicentre validation and prospec-tive evaluation. Lancet. 2009;373(9657):42–7. 10. Banister T, Spiking J, Ayaru L. Discharge of patients with an acute upper gastrointestinal bleed from the emergency depart-ment using an extended Glasgow-\\xadBlatchford Score. BMJ Open Gastroenterol. 2018;5(1):e000225. 11. Shung D, Au B, Taylor R, Tay JK, Laursen SB, Stanley AJ, et\\xa0 al. Validation of a machine learning model that outperforms clin-ical risk scoring systems for upper gastrointestinal bleeding. Gastroenterology. 2019;158:160–7. 12. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut. 1996;38(3):316–21. 13. Saltzman JR, Tabak YP, Hyett BH, Sun X, Travis AC, Johannes RS. A simple risk score accurately predicts in-\\xadhospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc. 2011;74(6):1215–24. 14. Laursen SB, Oakland K, Laine L, Bieber V, Marmo R, Redondo-\\xadCerezo E, et\\xa0al. ABC score: a new risk score that accurately pre-',\n",
       " '2011;74(6):1215–24. 14. Laursen SB, Oakland K, Laine L, Bieber V, Marmo R, Redondo-\\xadCerezo E, et\\xa0al. ABC score: a new risk score that accurately pre-dicts mortality in acute upper and lower gastrointestinal bleeding: an international multicentre study. Gut. 2020;70:707–16. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '1078\\u2003 |\\u2003 \\u2003\\u2002SHUNG and LAINE 15. Marmo R, Soncini M, Bucci C, Occhipinti V, Pellegrini L, Zullo A. Derivation and validation of Re.Co.De death score risk in patients with acute nonvariceal upper GI bleeding. Gastrointest Endosc. 2022;96(1):36–43.e38. 16. Deshmukh F, Merchant SS. Explainable machine learning model for predicting GI bleed mortality in the intensive care unit. Am J Gastroenterol. 2020;115(10):1657–68. 17. Levi R, Carli F, Arévalo AR, Altinel Y, Stein DJ, Naldini MM, et\\xa0al. Artificial intelligence-\\xadbased prediction of transfusion in the in-tensive care unit in patients with gastrointestinal bleeding. BMJ Health Care Inform. 2021;28(1):e100245. 18. Shung D, Huang J, Castro E, Tay JK, Simonov M, Laine L, et\\xa0al. Neural network predicts need for red blood cell transfusion for patients with acute gastrointestinal bleeding admitted to the in-tensive care unit. Sci Rep. 2021;11(1):8827. 19. Schembre DB, Ely RE, Connolly JM, Padhya KT, Sharda R, Brandabur JJ. Semiautomated Glasgow-\\xadBlatchford Bleeding Score helps direct bed placement for patients with upper gastrointesti-nal bleeding. BMJ Open Gastroenterol. 2020;7(1):e000479. 20. de Franchis R, Bosch J, Garcia-\\xadTsao G, Reiberger T, Ripoll C. Baveno VII – renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74. 21. Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-\\xadGea V, Aracil C, et\\xa0al. Transfusion strategies for acute upper gastroin-testinal bleeding. N Engl J Med. 2013;368(1):11–21. 22. Jairath V, Kahan BC, Gray A, Doré CJ, Mora A, James MW, et\\xa0al. Restrictive versus liberal blood transfusion for acute upper gas-trointestinal bleeding (TRIGGER): a pragmatic, open-\\xadlabel, cluster randomised feasibility trial. Lancet. 2015;386(9989):137–44. 23. Kola G, Sureshkumar S, Mohsina S, Sreenath GS, Kate V. Restrictive versus liberal transfusion strategy in upper gastrointestinal bleeding: a randomized controlled trial. Saudi J Gastroenterol. 2021;27(1):13–9.',\n",
       " 'versus liberal transfusion strategy in upper gastrointestinal bleeding: a randomized controlled trial. Saudi J Gastroenterol. 2021;27(1):13–9. 24. Ducrocq G, Gonzalez-\\xadJuanatey JR, Puymirat E, Lemesle G, Cachanado M, Durand-\\xadZaleski I, et\\xa0 al. Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial. JAMA. 2021;325(6):552–60. 25. Rahman R, Nguyen DL, Sohail U, Almashhrawi AA, Ashraf I, Puli SR, et\\xa0 al. Pre-\\xadendoscopic erythromycin administration in upper gastrointestinal bleeding: an updated meta-\\xadanalysis and system-atic review. Ann Gastroenterol. 2016;29(3):312–7. 26. Vimonsuntirungsri T, Thungsuk R, Nopjaroonsri P, Faknak N, Pittayanon R. The efficacy of metoclopramide of gastric visualiza-tion by endoscopy in patients with active upper gastrointestinal bleeding: double-\\xadblind randomized controlled trial. Paper pre-sented at: digestive diseases Week2023; Chicago, IL, USA. 27. Kanno T, Yuan Y, Tse F, Howden CW, Moayyedi P, Leontiadis GI. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2022;2020:CD005415. 28. Lau JY, Leung WK, Wu JCY, Chan FKL, Wong VWS, Chiu PWY, et\\xa0al. Omeprazole before endoscopy in patients with gastrointesti-nal bleeding. N Engl J Med. 2007;356(16):1631–40. 29. Bennett C, Klingenberg SL, Langholz E, Gluud LL. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2014;2014(11):CD006640. 30. Roberts I, Shakur-\\xadStill H, Afolabi A, Akere A, Arribas M, Brenner A, et\\xa0al. Effects of a high-\\xaddose 24-\\xadh infusion of tranexamic acid on death and thromboembolic events in patients with acute gastroin-testinal bleeding (HALT-\\xadIT): an international randomised, double-\\xadblind, placebo-\\xadcontrolled trial. Lancet. 2020;395(10241):1927–36.',\n",
       " 'death and thromboembolic events in patients with acute gastroin-testinal bleeding (HALT-\\xadIT): an international randomised, double-\\xadblind, placebo-\\xadcontrolled trial. Lancet. 2020;395(10241):1927–36. 31. Barer D, Ogilvie A, Henry D, Dronfield M, Coggon D, French S, et\\xa0 al. Cimetidine and tranexamic acid in the treatment of acute upper-\\xadgastrointestinal-\\xadtract bleeding. N Engl J Med. 1983;308(26):1571–5. 32. Cormack F, Chakrabarti RR, Jouhar AJ, Fearnley GR. Tranexamic acid in upper gastrointestinal haemorrhage. Lancet. 1973;301(7814):1207–8. 33. Hawkey GM, Cole AT, McIntyre AS, Long RG, Hawkey CJ. Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points. Gut. 2001;49(3):372–9. 34. von Holstein CC, Eriksson SB, Källén R. Tranexamic acid as an aid to reducing blood transfusion requirements in gastric and duode-nal bleeding. Br Med J (Clin Res Ed). 1987;294(6563):7–10. 35. Karadas A, Dogan NO, Pinar SG, Yesil O, Pekdemir M, Yilmaz S, et\\xa0 al. A randomized controlled trial of the effects of local tranexamic acid on mortality, rebleeding, and recurrent endos-copy need in patients with upper gastrointestinal hemorrhage. Eur J Gastroenterol Hepatol. 2020;32(1):26–31. 36. Saidi H, Shojaie S, Ghavami Y, Mirafzal A, Sisakht MT, Sotudehnia M. Role of intra-\\xadgastric tranexamic acid in management of acute upper gastrointestinal bleeding. IIOAB J. 2017;8:76–81. 37. Tavakoli N, Mokhtare M, Agah S, Azizi A, Masoodi M, Amiri H, et\\xa0al. Comparison of the efficacy of intravenous tranexamic acid with and without topical administration versus placebo in urgent endoscopy rate for acute gastrointestinal bleeding: a double-\\xadblind randomized controlled trial. United European Gastroenterol J. 2018;6(1):46–54. 38. Bagnenko SF, Verbitskiĭ VG. Antifibrinolitic therapy for the treat-ment of massive ulcerative gastro-\\xadintestinal bleedings. Khirurgiia (Mosk). 2011;4:42–6.',\n",
       " '2018;6(1):46–54. 38. Bagnenko SF, Verbitskiĭ VG. Antifibrinolitic therapy for the treat-ment of massive ulcerative gastro-\\xadintestinal bleedings. Khirurgiia (Mosk). 2011;4:42–6. 39. Bergqvist D, Dahlgren S, Hessman Y. Local inhibition of the fi-brinolytic system in patients with massive upper gastrointestinal hemorrhage. Ups J Med Sci. 1980;85(2):173–8. 40. Biggs JC, Hugh TB, Dodds AJ. Tranexamic acid and upper gastroin-testinal haemorrhage-\\xad-\\xada double-\\xadblind trial. Gut. 1976;17(9):729–34. 41. Engqvist A, Broström O, Feilitzen FV, Halldin M, Nyström B, Öst Å, et\\xa0al. Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-\\xadblind study. Scand J Gastroenterol. 1979;14(7):839–44. 42. Kaplan DE, Bosch J, Ripoll C, Thiele M, Fortune BE, Simonetto DA, et\\xa0al. AASLD practice guidance on risk stratification and manage-ment of portal hypertension and varices in cirrhosis. Hepatology. 2023. https://\\u200bdoi.\\u200borg/\\u200b10.\\u200b1097/\\u200bHEP.\\u200b00000\\u200b00000\\u200b000647 43. Chavez-\\xadTapia NC, Barrientos-\\xadGutierrez T, Tellez-\\xadAvila F, Soares-\\xadWeiser K, Mendez-\\xadSanchez N, Gluud C, et\\xa0al. Meta-\\xadanalysis: anti-biotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding – an updated Cochrane review. Aliment Pharmacol Ther. 2011;34(5):509–18. 44. Fernández J, Ruiz del Arbol L, Gómez C, Durandez R, Serradilla R, Guarner C, et\\xa0al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006;131(4):1049–56. quiz 1285. 45. Wells M, Chande N, Adams P, Beaton M, Levstik M, Boyce E, et\\xa0 al. Meta-\\xadanalysis: vasoactive medications for the man-agement of acute variceal bleeds. Aliment Pharmacol Ther. 2012;35(11):1267–78. 46. Avgerinos A, Nevens F, Raptis S, Fevery J. Early administra-tion of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet.',\n",
       " 'tion of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet. 1997;350(9090):1495–9. 47. Calès P, Masliah C, Bernard B, Garnier PP, Silvain C, Szostak-\\xadTalbodec N, et\\xa0 al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med. 2001;344(1):23–8. 48. Levacher S, Letoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat JL. Early administration of terlipressin plus glyceryl trini-trate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet. 1995;346(8979):865–8. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '| \\u20031079SHUNG and LAINE 49. Huaringa-\\xadMarcelo J, Huaman MR, Brañez-\\xadCondorena A, Villacorta-\\xadLandeo P, Pinto-\\xadRuiz DF, Urday-\\xadIpanaqué D, et\\xa0 al. Vasoactive agents for the management of acute variceal bleeding: a systematic review and meta-\\xadanalysis. J Gastrointestin Liver Dis. 2021;30(1):110–21. 50. Laursen SB, Leontiadis GI, Stanley AJ, Møller MH, Hansen JM, Schaffalitzky de Muckadell OB. Relationship between timing of endoscopy and mortality in patients with peptic ulcer bleeding: a nationwide cohort study. Gastrointest Endosc. 2017;85(5):936–944.e933. 51. Cho SH, Lee YS, Kim YJ, Sohn CH, Ahn S, Seo DW, et\\xa0al. Outcomes and role of urgent endoscopy in high-\\xadrisk patients with acute non-variceal gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2018;16(3):370–7. 52. Lau JYW, Yu Y, Tang RSY, Chan HCH, Yip HC, Chan SM, et\\xa0 al. Timing of endoscopy for acute upper gastrointestinal bleeding. N Engl J Med. 2020;382(14):1299–308. 53. Lee JG, Turnipseed S, Romano PS, Vigil H, Azari R, Melnikoff N, et\\xa0al. Endoscopy-\\xadbased triage significantly reduces hospitalization rates and costs of treating upper GI bleeding: a randomized con-trolled trial. Gastrointest Endosc. 1999;50(6):755–61. 54. Bjorkman DJ, Zaman A, Fennerty MB, Lieberman D, Disario JA, Guest-\\xadWarnick G. Urgent vs. elective endoscopy for acute non-\\xadvariceal upper-\\xadGI bleeding: an effectiveness study. Gastrointest Endosc. 2004;60(1):1–8. 55. Wysocki JD, Srivastav S, Winstead NS. A nationwide analysis of risk factors for mortality and time to endoscopy in upper gastroin-testinal haemorrhage. Aliment Pharmacol Ther. 2012;36(1):30–6. 56. Bai Z, Wang R, Cheng G, Ma D, Ibrahim M, Chawla S, et\\xa0al. Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: a systematic review with meta-\\xadanalysis. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1):e868–e876. 57. Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an',\n",
       " 'variceal bleeding: a systematic review with meta-\\xadanalysis. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1):e868–e876. 57. Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-\\xadbased approach based on meta-\\xadanalyses of randomized controlled trials. Clin Gastroenterol Hepatol. 2009;7(1):33–47. quiz 31–32. 58. Cook DJ, Guyatt GH, Salena BJ, Laine LA. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-\\xadanalysis. Gastroenterology. 1992;102(1):139–48. 59. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107(3):345–60. quiz 361. 60. Qian O, Zhang Q, Pan Y, Cheng C, Xu L, Guan J, et\\xa0al. Endoscopic thermocoagulation hemostasis for acute non-\\xadvaricose upper gas-trointestinal hemorrhage: a randomized controlled study. Surg Endosc. 2022;36(2):1578–83. 61. Schmidt A, Golder S, Goetz M, Meining A, Lau J, von Delius S, et\\xa0al. Over-\\xadthe-\\xadscope clips are more effective than standard endoscopic therapy for patients with recurrent bleeding of peptic ulcers. Gastroenterology. 2018;155(3):674–686.e6. 62. Meier B, Wannhoff A, Denzer U, Stathopoulos P, Schumacher B, Albers D, et\\xa0 al. Over-\\xadthe-\\xadscope-\\xadclips versus standard treat-ment in high-\\xadrisk patients with acute non-\\xadvariceal upper gastro-intestinal bleeding: a randomised controlled trial (STING-\\xad2). Gut. 2022;71(7):1251–8. 63. Jensen DM, Kovacs T, Ghassemi KA, Kaneshiro M, Gornbein J. Randomized controlled trial of over-\\xadthe-\\xadscope clip as initial treat-ment of severe nonvariceal upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2021;19(11):2315–2323.e12. 64. Lau JY, Li R, Tan CH, Sun XJ, Song HJ, Li L, et\\xa0al. Comparison of over-\\xadthe-\\xadscope clips to standard endoscopic treatment as the ini-tial treatment in patients with bleeding from a nonvariceal upper gastrointestinal cause. Ann Intern Med. 2023;176:455–62. 65. Chan S, Pittayanon R, Wang HP, Chen JH, Teoh AY, Kuo YT, et\\xa0al.',\n",
       " 'tial treatment in patients with bleeding from a nonvariceal upper gastrointestinal cause. Ann Intern Med. 2023;176:455–62. 65. Chan S, Pittayanon R, Wang HP, Chen JH, Teoh AY, Kuo YT, et\\xa0al. Use of over-\\xadthe-\\xadscope clip (OTSC) versus standard therapy for the prevention of rebleeding in large peptic ulcers (size ≥1.5 cm): an open-\\xadlabelled, multicentre international randomised controlled trial. Gut. 2023;72(4):638–43. 66. Lau JYW, Pittayanon R, Kwek A, Tang RS, Chan H, Rerknimitr R, et\\xa0al. Comparison of a hemostatic powder and standard treatment in the control of active bleeding from upper nonvariceal lesions: a multicenter, noninferiority, randomized trial. Ann Intern Med. 2022;175(2):171–8. 67. Lee E, Kim KO, Kim H, Hong SJ, Shin J, Cha B. A randomized con-trol study evaluating the efficacy of a hemostatic powder (UI-\\xadEWD) in decreasing the rate of upper gastrointestinal RE-\\xadbleeding in patients treated with endoscopic therapy for high-\\xadrisk lesions. 2023 Paper presented at: digestive diseases Week 2023; Chicago, IL, USA. 68. Escorsell À, Pavel O, Cárdenas A, Morillas R, Llop E, Villanueva C, et\\xa0al. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: a multicenter ran-domized, controlled trial. Hepatology. 2016;63(6):1957–67. 69. Laine L. Is there a role for combined sclerotherapy and liga-tion in the endoscopic treatment of gastroesophageal varices? Gastrointest Endosc. 2017;86(2):316–8. 70. Onofrio FQ, Pereira-\\xadLima JC, Valenca FM, Azeredo-\\xadda-\\xadSilva ALF, Stein AT. Efficacy of endoscopic treatments for acute esopha-geal variceal bleeding in cirrhotic patients: systematic review and meta-\\xadanalysis. Endosc Int Open. 2019;7(11):E1503–E1514. 71. Lo GH, Lai KH, Cheng JS, Lin CK, Huang JS, Hsu PI, et\\xa0al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology. 1997;25(5):1101–4.',\n",
       " 'banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology. 1997;25(5):1101–4. 72. Villanueva C, Piqueras M, Aracil C, Gómez C, López-\\xadBalaguer JM, Gonzalez B, et\\xa0 al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol. 2006;45(4):560–7. 73. Chen WC, Lo GH, Tsai WL, Hsu PI, Lin CK, Lai KH. Emergency endoscopic variceal ligation versus somatostatin for acute esoph-ageal variceal bleeding. J Chin Med Assoc. 2006;69(2):60–7. 74. Lo GH, Chen WC, Wang HM, Lin CK, Chan HH, Tsai WL, et\\xa0al. Low-\\xaddose terlipressin plus banding ligation versus low-\\xaddose terlipressin alone in the prevention of very early rebleeding of oesophageal varices. Gut. 2009;58(9):1275–80. 75. Sung JJ, Lai CW, Lee YT, Leung VK, Li MK, Chung SC, et\\xa0 al. Prospective randomised study of effect of octreotide on rebleed-ing from oesophageal varices after endoscopic ligation. Lancet. 1995;346(8991–8992):1666–9. 76. Kumar A, Jha SK, Mittal VV, Sharma P, Sharma BC, Sarin SK. Addition of somatostatin after successful endoscopic variceal liga-tion does not prevent early rebleeding in comparison to placebo: a double blind randomized controlled trial. J Clin Exp Hepatol. 2015;5(3):204–12. 77. Lo GH, Perng DS, Chang CY, Tai CM, Wang HM, Lin HC. Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding. J Gastroenterol Hepatol. 2013;28(4):684–9. 78. Lee GH, Cho SW, Kim HJ, Ko KH, Ko JH, Ko YY, et\\xa0al. Endoscopic variceal ligation plus octreotide versus variceal ligation alone for the prevention of early rebleeding from esophageal varices. Korean J Hepatol. 1999;5(4):299–305. 79. Lee EW, Eghtesad B, Garcia-\\xadTsao G, Haskal ZJ, Hernandez-\\xadGea V, Jalaeian H, et\\xa0al. AASLD practice guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliter-',\n",
       " '79. Lee EW, Eghtesad B, Garcia-\\xadTsao G, Haskal ZJ, Hernandez-\\xadGea V, Jalaeian H, et\\xa0al. AASLD practice guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliter-ation in the management of variceal hemorrhage. Hepatology. 2023;79:224–50. 80. Ríos Castellanos E, Seron P, Gisbert JP, Cosp XB. Endoscopic injec-tion of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension. Cochrane Database Syst Rev. 2015;2015:CD010180. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '1080\\u2003 |\\u2003 \\u2003\\u2002SHUNG and LAINE 81. Tantau M, Crisan D, Popa D, Vesa S, Tantau A. Band ligation vs. N-\\xadButyl-\\xad2-\\xadcyanoacrylate injection in acute gastric vari-ceal bleeding: a prospective follow-\\xadup study. Ann Hepatol. 2014;13(1):75–83. 82. Tan PC, Hou MC, Lin HC, Liu TT, Lee FY, Chang FY, et\\xa0al. A ran-domized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-\\xadbutyl-\\xad2-\\xadcyanoacrylate injection versus band liga-tion. Hepatology. 2006;43(4):690–7. 83. Lo G-\\xadH, Lai K-\\xadH, Cheng J-\\xadS, Chen M-\\xadH, Chiang H-\\xadT. A prospective, randomized trial of butyl cyanoacrylate injection versus band liga-tion in the management of bleeding gastric varices. Hepatology. 2001;33(5):1060–4. 84. Lo GH, Liang HL, Chen WC, Chen MH, Lai KH, Hsu PI, et\\xa0al. A pro-spective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the preven-tion of gastric variceal rebleeding. Endoscopy. 2007;39(8):679–85. 85. Luo X, Xiang T, Wu J, Wang X, Zhu Y, Xi X, et\\xa0al. Endoscopic cy-anoacrylate injection versus balloon-\\xadoccluded retrograde trans-venous obliteration for prevention of gastric variceal bleeding: a randomized controlled trial. Hepatology. 2021;74(4):2074–84. 86. Paleti S, Nutalapati V, Fathallah J, Jeepalyam S, Rustagi T. Balloon-\\xadoccluded retrograde transvenous obliteration (BRTO) versus tran-sjugular intrahepatic portosystemic shunt (TIPS) for treatment of gastric varices because of portal hypertension: a systematic re-view and meta-\\xadanalysis. J Clin Gastroenterol. 2020;54(7):655–60. 87. El Amin H, Abdel Baky L, Sayed Z, Eid K, Fouad Y, El Khayat H. A randomized trial of endoscopic variceal ligation versus cyanoac-rylate injection for treatment of bleeding junctional varices. Trop Gastroenterol. 2010;31(4):279–84. 88. Robles-\\xadMedranda C, Oleas R, Valero M, Puga-\\xadTejada M, Baquerizo-\\xadBurgos J, Ospina J, et\\xa0 al. Endoscopic ultrasonography-\\xadguided',\n",
       " 'Gastroenterol. 2010;31(4):279–84. 88. Robles-\\xadMedranda C, Oleas R, Valero M, Puga-\\xadTejada M, Baquerizo-\\xadBurgos J, Ospina J, et\\xa0 al. Endoscopic ultrasonography-\\xadguided deployment of embolization coils and cyanoacrylate injection in gastric varices versus coiling alone: a randomized trial. Endoscopy. 2020;52(4):268–75. 89. Lôbo MR, Chaves DM, De Moura DT, Ribeiro IB, Ikari E, De Moura EG. Safety and efficacy of EUS-\\xadguided coil plus cyanoacrylate versus conventional cyanoacrylate technique in the treatment of gastric varices: a randomized controlled trial. Arq Gastroenterol. 2019;56(1):99–105. 90. McCarty TR, Bazarbashi AN, Hathorn KE, Thompson CC, Ryou M. Combination therapy versus monotherapy for EUS-\\xadguided man-agement of gastric varices: a systematic review and meta-\\xadanalysis. Endosc Ultrasound. 2020;9(1):6–15. 91. Mohan BP, Chandan S, Khan SR, Kassab LL, Trakroo S, Ponnada S, et\\xa0 al. Efficacy and safety of endoscopic ultrasound-\\xadguided therapy versus direct endoscopic glue injection therapy for gas-tric varices: systematic review and meta-\\xadanalysis. Endoscopy. 2020;52(4):259–67. 92. Lo G-\\xadH, Lin C-\\xadW, Tai C-\\xadM, Perng DS, Chen IL, Yeh JH, et\\xa0 al. A prospective, randomized trial of thrombin versus cyanoacrylate injection in the control of acute gastric variceal hemorrhage. Endoscopy. 2020;52(7):548–55. 93. McCarty TR, Rustagi T. Comparative effectiveness and safety of radiofrequency ablation versus argon plasma coagulation for treatment of gastric antral vascular ectasia: a systematic review and meta-\\xadanalysis. J Clin Gastroenterol. 2019;53(8):599–606. 94. Hirsch BS, Ribeiro IB, Funari MP, de Moura DTH, Matuguma SE, Sánchez-\\xadLuna SA, et\\xa0 al. Endoscopic band ligation versus argon plasma coagulation in the treatment of gastric antral vascular ec-tasia: a systematic review and meta-\\xadanalysis of randomized con-trolled trials. Clin Endosc. 2021;54(5):669–77. 95. Gralnek IM, Dumonceau JM, Kuipers EJ, Lanas A, Sanders DS,',\n",
       " 'tasia: a systematic review and meta-\\xadanalysis of randomized con-trolled trials. Clin Endosc. 2021;54(5):669–77. 95. Gralnek IM, Dumonceau JM, Kuipers EJ, Lanas A, Sanders DS, Kurien M, et\\xa0al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2015;47(10):a1–a46. 96. Hwang JH, Fisher DA, Ben-\\xadMenachem T, Chandrasekhara V, Chathadi K, Decker GA, et\\xa0al. The role of endoscopy in the man-agement of acute non-\\xadvariceal upper GI bleeding. Gastrointest Endosc. 2012;75(6):1132–8. 97. Laine L. Multipolar electrocoagulation in the treatment of active upper gastrointestinal tract hemorrhage. A prospective controlled trial. N Engl J Med. 1987;316(26):1613–7. 98. Llach J, Elizalde JI, Guevara MC, Pellisé M, Castellot A, Ginès A, et\\xa0 al. Endoscopic injection therapy in bleeding Mallory-\\xadWeiss syndrome: a randomized controlled trial. Gastrointest Endosc. 2001;54(6):679–81. 99. Chung IK, Kim EJ, Hwang KY, Kim IH, Kim HS, Park SH, et\\xa0 al. Evaluation of endoscopic hemostasis in upper gastrointesti-nal bleeding related to Mallory-\\xadWeiss syndrome. Endoscopy. 2002;34(6):474–9.100. Huang SP, Wang HP, Lee YC, Lin CC, Yang CS, Wu MS, et\\xa0 al. Endoscopic hemoclip placement and epinephrine injection for Mallory-\\xadWeiss syndrome with active bleeding. Gastrointest Endosc. 2002;55(7):842–6.101. Park CH, Min SW, Sohn YH, Lee WS, Joo YE, Kim HS, et\\xa0 al. A prospective, randomized trial of endoscopic band ligation vs. epi-nephrine injection for actively bleeding Mallory-\\xadWeiss syndrome. Gastrointest Endosc. 2004;60(1):22–7.102. Laine L, Cohen H, Brodhead J, Cantor D, Garcia F, Mosquera M. Prospective evaluation of immediate versus delayed refeeding and prognostic value of endoscopy in patients with upper gastrointes-tinal hemorrhage. Gastroenterology. 1992;102(1):314–6.103. Park CH, Sohn YH, Lee WS, Joo YE, Choi SK, Rew JS, et\\xa0al. The use-',\n",
       " \"prognostic value of endoscopy in patients with upper gastrointes-tinal hemorrhage. Gastroenterology. 1992;102(1):314–6.103. Park CH, Sohn YH, Lee WS, Joo YE, Choi SK, Rew JS, et\\xa0al. The use-fulness of endoscopic hemoclipping for bleeding Dieulafoy lesions. Endoscopy. 2003;35(5):388–92.104. Alis H, Oner OZ, Kalayci MU, Dolay K, Kapan S, Soylu A, et\\xa0al. Is en-doscopic band ligation superior to injection therapy for Dieulafoy lesion? Surg Endosc. 2009;23(7):1465–9.105. Chung IK, Kim EJ, Lee MS, Kim HS, Park SH, Lee MH, et\\xa0al. Bleeding Dieulafoy's lesions and the choice of endoscopic method: compar-ing the hemostatic efficacy of mechanical and injection methods. Gastrointest Endosc. 2000;52(6):721–4.106. Park CH, Joo YE, Kim HS, Choi SK, Rew JS, Kim SJ. A prospective, randomized trial of endoscopic band ligation versus endoscopic hemoclip placement for bleeding gastric Dieulafoy's lesions. Endoscopy. 2004;36(8):677–81.107. Liu D, Lu F, Ou D, Zhou Y, Huo J, Zhou Z. Endoscopic band liga-tion versus endoscopic hemoclip placement for bleeding due to Dieulafoy lesions in the upper gastrointestinal tract. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009;34(9):905–9.108. Kim YI, Choi IJ, Cho SJ, Lee JY, Kim CG, Kim MJ, et\\xa0al. Outcome of endoscopic therapy for cancer bleeding in patients with unresect-able gastric cancer. J Gastroenterol Hepatol. 2013;28(9):1489–95.109. Sheibani S, Kim JJ, Chen B, Park S, Saberi B, Keyashian K, et\\xa0al. Natural history of acute upper GI bleeding due to tumours: short-\\xadterm success and long-\\xadterm recurrence with or without endo-scopic therapy. Aliment Pharmacol Ther. 2013;38(2):144–50.110. Martins BC, Abnader Machado A, Scomparin RC, Paulo GA, Safatle-\\xadRibeiro A, Naschold Geiger S, et\\xa0 al. TC-\\xad325 hemostatic powder in the management of upper gastrointestinal malig-nant bleeding: a randomized controlled trial. Endosc Int Open. 2022;10(10):E1350–E1357.111. Cheng HC, Wu CT, Chang WL, Cheng WC, Chen WY, Sheu BS.\",\n",
       " 'nant bleeding: a randomized controlled trial. Endosc Int Open. 2022;10(10):E1350–E1357.111. Cheng HC, Wu CT, Chang WL, Cheng WC, Chen WY, Sheu BS. Double oral esomeprazole after a 3-\\xadday intravenous esomeprazole infusion reduces recurrent peptic ulcer bleeding in high-\\xadrisk pa-tients: a randomised controlled study. Gut. 2014;63(12):1864–72.112. Lau JY, Sung JJ, Lam YH, Chan AC, Ng EK, Lee DW, et\\xa0al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med. 1999;340(10):751–6. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " '| \\u20031081SHUNG and LAINE113. Tarasconi A, Baiocchi GL, Pattonieri V, Perrone G, Abongwa HK, Molfino S, et\\xa0 al. Transcatheter arterial embolization versus sur-gery for refractory non-\\xadvariceal upper gastrointestinal bleeding: a meta-\\xadanalysis. World J Emerg Surg. 2019;14:3.114. Sverden E, Mattsson F, Lindstrom D, Sonden A, Lu Y, Lagergren J. Transcatheter arterial embolization compared with surgery for un-controlled peptic ulcer bleeding: a population-\\xadbased cohort study. Ann Surg. 2019;269(2):304–9.115. García-\\xadPagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et\\xa0al. Early use of TIPS in patients with cirrhosis and Variceal bleeding. N Engl J Med. 2010;362(25):2370–9.116. Lv Y, Yang Z, Liu L, Li K, He C, Wang Z, et\\xa0al. Early TIPS with cov-ered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(8):587–98.117. Dunne PDJ, Sinha R, Stanley AJ, Lachlan N, Ireland H, Shams A, et\\xa0al. Randomised clinical trial: standard of care versus early-\\xadtransjugular intrahepatic porto-\\xadsystemic shunt (TIPSS) in pa-tients with cirrhosis and oesophageal variceal bleeding. Aliment Pharmacol Ther. 2020;52(1):98–106.118. Nicoară-\\xadFarcău O, Han G, Rudler M, Angrisani D, Monescillo A, Torres F, et\\xa0al. Effects of Early placement of transjugular porto-systemic shunts in patients with high-\\xadrisk acute variceal bleed-ing: a meta-\\xadanalysis of individual patient data. Gastroenterology. 2021;160(1):193–205.e110.119. Weichselbaum L, Lepida A, Marot A, Trépo E, Moreno C, Deltenre P. Salvage transjugular intrahepatic portosystemic shunt in pa-tients with cirrhosis and refractory variceal bleeding: a system-atic review with meta-\\xadanalysis. United European Gastroenterol J. 2022;10(8):874–87.120. Zhang H, Zhang H, Li H, Zhang H, Zheng D, Sun CM, et\\xa0al. TIPS versus endoscopic therapy for variceal rebleeding in cirrhosis: a',\n",
       " '2022;10(8):874–87.120. Zhang H, Zhang H, Li H, Zhang H, Zheng D, Sun CM, et\\xa0al. TIPS versus endoscopic therapy for variceal rebleeding in cirrhosis: a meta-\\xadanalysis update. J Huazhong Univ Sci Technolog Med Sci. 2017;37(4):475–85.SUPPORTING INFORMATIONAdditional supporting information will be found online in the Supporting Information section.How to cite this article: Shung DL, Laine L. Review article: Upper gastrointestinal bleeding – review of current evidence and implications for management. Aliment Pharmacol Ther. 2024;59:1062–1081. https://doi.org/10.1111/apt.17949APPENDIX APubMed Search:((gastrointestinal haemorrhage[MeSH Terms]) OR (hematemesis[MeSH Terms]) OR (melena[MeSH Terms]) OR (haemorrhage, peptic ulcer[MeSH Terms]) OR (“Gastrointestinal Hemorrhage/drug therapy”[MAJR]) OR (“Gastrointestinal Haemorrhage/mortality”[MeSH]))Medline Search:1exp gastrointestinal haemorrhage/.mp.2(gastrointestinal haemorrhage* or gastrointestinal haemorrhage*).mp.3gastrointestinal bleeding.mp.4(gi bleeding or gib).mp.5haematochezia*.mp.6(gastrointestinal adj3 bleeding).mp.7melena.mp. or exp Melena/8hematemesis.mp. or exp Hematemesis/9(peptic ulcer adj2 (haemorrhage* or haemorrhage*)).mp.10\"Esophageal and Gastric Varices\"/11variceal bleeding.mp.12gastric bleeding.mp.131 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License',\n",
       " 'REVIEWEvidence-based clinical practice guidelines for peptic ulcer disease2020Tomoari Kamada1,2 • Kiichi Satoh2 • Toshiyuki Itoh2 • Masanori Ito2 •Junichi Iwamoto2 • Tadayoshi Okimoto2 • Takeshi Kanno2 • Mitsushige Sugimoto2 •Toshimi Chiba2 • Sachiyo Nomura2 • Mitsuyo Mieda2 • Hideyuki Hiraishi2 •Junji Yoshino2 • Atsushi Takagi2 • Sumio Watanabe2 • Kazuhiko Koike2Received: 7 October 2020 / Accepted: 3 February 2021 / Published online: 23 February 2021 The Author(s) 2021Abstract TheJapaneseSocietyofGastroenterology(JSGE) revised the third edition of evidence-based clinicalpractice guidelines for peptic ulcer disease in 2020 andcreated an English version. The revised guidelines consistof nine items: epidemiology, hemorrhagic gastric andduodenal ulcers, Helicobacter pylori (H. pylori) eradica-tion therapy, non-eradication therapy, drug-induced ulcers,non-H. pylori, and nonsteroidal anti-inﬂammatory drug(NSAID) ulcers, remnant gastric ulcers, surgical treatment,and conservative therapy for perforation and stenosis.Therapeutic algorithms for the treatment of peptic ulcersdiffer based on ulcer complications. In patients withNSAID-induced ulcers, NSAIDs are discontinued and anti-ulcer therapy is administered. If NSAIDs cannot be dis-continued, the ulcer is treated with proton pump inhibitors(PPIs). Vonoprazan (VPZ) with antibiotics is recom-mended as the ﬁrst-line treatment for H. pylori eradication,and PPIs or VPZ with antibiotics is recommended as asecond-line therapy. Patients who do not use NSAIDs andare H. pylori negative are considered to have idiopathicpeptic ulcers. Algorithms for the prevention of NSAID-and low-dose aspirin (LDA)-related ulcers are presented inthis guideline. These algorithms differ based on the con-comitant use of LDA or NSAIDs and ulcer history orhemorrhagic ulcer history. In patients with a history ofulcers receiving NSAID therapy, PPIs with or withoutcelecoxib are recommended and the administration of VPZ',\n",
       " 'hemorrhagic ulcer history. In patients with a history ofulcers receiving NSAID therapy, PPIs with or withoutcelecoxib are recommended and the administration of VPZis suggested for the prevention of ulcer recurrence. Inpatients with a history of ulcers receiving LDA therapy,PPIs or VPZ are recommended and the administration of ahistamine 2-receptor antagonist is suggested for the pre-vention of ulcer recurrence.Keywords Peptic ulcer  Helicobacter pylori eradication Nonsteroidal anti-inﬂammatory drug  Low-dose aspirin Idiopathic ulcerIntroductionIn 2009, the Japanese Society of Gastroenterology (JSGE)developed evidence-based clinical practice guidelines forpeptic ulcer disease. The guidelines were revised in 2015and again in 2020. Of the 90 clinical questions (CQs)included in the previous guidelines, those with a clearconclusion were considered background questions (BQs)and those requiring future research were considered futureresearch questions (FRQs) in this revised guideline. Thus,the revised guidelines consist of nine items (28 CQs andone FRQ), including, for the ﬁrst time, epidemiology andremnant gastric ulcer. Both epidemiology and conservativetherapy for perforation and stenosis included only BQ. Theprevention of hemorrhagic peptic ulcers in patients takingThe members of the Guidelines Committee are listed in the Appendix.The original version of this article appeared in Japanese as ‘‘ShokaseiKaiyo Sinryo Guideline 2020’’ from the Japanese Society ofGastroenterology (JSGE), published by Nankodo, Tokyo, in 2020.Please see the article on the standards, methods, and process ofdeveloping the guidelines.& Tomoari Kamadatkamada@med.kawasaki-m.ac.jp1Department of Health Care Medicine, Kawasaki MedicalSchool General Medical Center, 2-6-1, Nakasange, Kita-ku,Okayama 700-8505, Japan2Guidelines Committee for Creating and Evaluating the‘‘Evidence-Based Clinical Practice Guidelines for PepticUlcer,’’ the Japanese Society of Gastroenterology (JSGE), 6F',\n",
       " 'Okayama 700-8505, Japan2Guidelines Committee for Creating and Evaluating the‘‘Evidence-Based Clinical Practice Guidelines for PepticUlcer,’’ the Japanese Society of Gastroenterology (JSGE), 6FShimbashi i-MARK Bldg., 2-6-2 Shimbashi, Minato-ku,Tokyo 105-0004, Japan123J Gastroenterol (2021) 56:303–322https://doi.org/10.1007/s00535-021-01769-0a6JSGETheJapaneseSocietyof Gastroenterology1898',\n",
       " 'antithrombotic drugs and the treatment of ischemic duo-denal ulcers have been added as a CQ and FRQ,respectively.A literature search of Medline and the Cochrane Librarywas performed for data regarding the CQs publishedbetween 1983 and October 2018, and the Igaku ChuoZasshi databases were searched for data published between1983 and December 2018. The guidelines were developedusing the Grading of Recommendations Assessment,Development and Evaluation (GRADE) system [1]. Thequality of evidence was graded as A (high), B (moderate),C (low), and D (very low). Recommendation strength wasindicated as either a ‘‘strong recommendation’’ or a ‘‘weakrecommendation’’ The systematic review (SR) team con-ducted meta-analysis (MA) and decided the total strengthof the evidence from A to D. The consensus was previouslydeﬁned as 70% or more votes in agreement.In Japan, incidence of cerebral infarction and myocar-dial infarction are increasing, and many patients undergoantithrombotic therapy including dual antiplatelet therapy(DAPT). In endoscopic clinical practice, focus has shiftedfrom the risk of gastrointestinal (GI) bleeding to throm-boembolism associated with the withdrawal of antithrom-botic therapy [2, 3]. In addition, for nearly 50 years, theonly oral anticoagulants were vitamin K antagonists(warfarin); however, four non-vitamin K antagonist directoral anticoagulants (DOACs) are currently available. Thehemorrhagic gastric and duodenal ulcer section of therevised guidelines emphasizes methods for the discontin-uation of antithrombotic therapy including DOACs and forthe prevention of hemorrhagic ulcers in patients takinganticoagulant and antiplatelet drugs, such as DAPT.Vonoprazan (VPZ) provides potent and long-lastinginhibition of gastric acid secretion, and its efﬁcacy is,therefore, expected to be superior to that of proton pumpinhibitors (PPIs). Recent reports have shown that tripletherapy including VPZ is as effective as ﬁrst-line and',\n",
       " 'therefore, expected to be superior to that of proton pumpinhibitors (PPIs). Recent reports have shown that tripletherapy including VPZ is as effective as ﬁrst-line andsecond-line therapies for the eradication of Helicobacterpylori [4]. Several reports have indicated that VPZ effec-tively heals peptic ulcers [5] and prevents the recurrence ofnonsteroidal anti-inﬂammatory drugs (NSAIDs) [6] andlow-dose aspirin (LDA)-related ulcers [7]. This revisedversion also emphasizes the clinical results of VPZ.Hemorrhagic gastric and duodenal ulcersNon-endoscopic hemostatic therapyCQ-1Treatment of with patients with hemorrhagic peptic ulcersif they prescribed anticoagulants and/or antiplatelet agents?•Recommended that aspirin be continued for conditionsat high risk for thromboembolic events.Recommendation: strong, 100% agreed, evidence levelB.•Suggested to change antiplatelet agents to aspirin inpatients with conditions with a high risk of throm-boembolic events.Recommendation: weak, 100% agreed, evidence levelD.•Suggested to suspend antiplatelet agents, except for inpatients at high risk for thromboembolic events.Recommendation: weak, 100% agreed, evidence levelD.•Recommended to suspend warfarin, if necessary, inendoscopic hemostasis patients. If warfarin is discon-tinued, we suggest heparin or resuming warfarin assoon as hemostasis is established.Recommendation: strong, 100% agreed, evidence levelC.•Suggested to resume DOACs early (within 1–2 days)after conﬁrming endoscopic hemostasis.Recommendation: weak, 100% agreed, evidence levelD.•In patients receiving both antiplatelet agents andwarfarin, suggested to change antiplatelet agents toaspirin or cilostazol. Continue warfarin under a suit-able prothrombin time-international normalized ratio(PT-INR) or to change warfarin to heparin.Recommendation: weak, 100% agreed, evidence levelD.•In patients receiving dual antiplatelet agents, recom-mended that aspirin alone should be continued.',\n",
       " '(PT-INR) or to change warfarin to heparin.Recommendation: weak, 100% agreed, evidence levelD.•In patients receiving dual antiplatelet agents, recom-mended that aspirin alone should be continued.Recommendation: strong, 100% agreed, evidence levelD.Comment: The risk of re-bleeding due to continuinganticoagulant and/or antiplatelet agents and the risk ofthromboembolism associated with their withdrawalshould be considered. One randomized controlled trial(RCT) [8] reported signiﬁcantly lower mortality in thecontinuing LDA group compared with the group thatdid not. However, clinical evidence is currently lackingto support the management of patients who receiveantiplatelet agents excluding aspirin, warfarin, andDOACs with peptic ulcer bleeding (PUB). We consid-ered that these recommendations are based on expertopinions of the guidelines of Japan GastroenterologicalEndoscopy, Asia–Paciﬁc working group and EuropeanSociety of Gastroenterological Endoscopy. It is neces-sary to collaborate closely with gastroenterologists andcardiologists as patients at high risk of thromboem-bolism with PUB could be unstable.304J Gastroenterol (2021) 56:303–322123',\n",
       " 'CQ-2Is interventional radiology (IVR) effective in patientsundergoing refractory endoscopic treatment for hemor-rhagic peptic ulcers?•In patients undergoing refractory endoscopic treatmentfor hemorrhagic peptic ulcers, interventional radiology(IVR) is suggested due to its safety and effectiveness.Recommendation: weak, 100% agreed, evidence levelC.Comment: The effectiveness of IVR with transcatheterarterial embolization was proven by two MAs [9, 10].They reported that compared to surgery, IVR exhibits ahigher re-bleeding rate, but no signiﬁcant difference inmortality, need for additional interventions, or compli-cation rates between treatments. IVR could be a viableoption for the treatment of refractory PUB; however, alimited number of institutions can perform IVR.CQ-3Is medication with antacid agents required after endoscopictreatment for hemorrhagic peptic ulcers?•PPI administration after endoscopic treatment forhemorrhagic peptic ulcers is recommended to improvetreatment outcomes.Recommendation: strong, 100% agreed, evidence levelA.Comment: Compared with placebo, intravenous PPItherapy after endoscopic treatment for hemorrhagicpeptic ulcers has been proven to reduce the rate of re-bleeding, volume of blood transfusion, period ofadmission, and rate of conversion to surgery in twoMAs [11, 12] and some randomized controlled trials.The efﬁcacy of high-dose PPI therapy is not higher thannon-high-dose PPI regarding decreasing re-bleeding,surgical intervention, or mortality after post-endoscopichemostasis [13].There was no signiﬁcant difference effect between oraland intravenous PPI therapy on mortality, re-bleeding,need for blood transfusion, length of hospital stays, orsurgery [14].Compared to intravenous histamine 2-receptor antago-nist (H2RA) therapy, PPI therapy reduces rates of ulcerre-bleeding, surgical intervention, and overall durationof hospital stay with no signiﬁcant difference inmortality [15]. Considering patient beneﬁts, we recom-',\n",
       " 're-bleeding, surgical intervention, and overall durationof hospital stay with no signiﬁcant difference inmortality [15]. Considering patient beneﬁts, we recom-mended PPI therapy after endoscopic treatment forhemorrhagic peptic ulcers.Prevention of hemorrhagic peptic ulcerCQ-4What drugs are recommended for the prevention of hem-orrhagic ulcers in antithrombotic users?•In DAPT, we recommend the combined use of PPIs toprevent upper gastrointestinal bleeding (UGIB).Recommendation: strong, 100% agreed, evidence levelA.•If taking warfarin, we suggest using PPIs to preventUGIB in patients taking antiplatelet drugs or NSAIDsin combination.Recommendation: weak, 100% agreed, evidence levelC.(PPI is not covered by Japanese insurance for primaryprevention of PUB in patients taking LDA or NSAIDs).Comment: MAs of RCTs aimed to determine whetherthe combination of PPIs is useful for the prevention ofUGIB in DAPT with clopidogrel and aspirin. Inaddition to the large randomized COGENT trial [16],an MA was conducted involving three studies (twoRCTs) [17, 18] comparing PPI usage. PPIs signiﬁcantlyprevented UGIB (risk ratio [RR] 0.26; 95% conﬁdenceinterval [CI] 0.13–0.53, P = 0.0002) (Fig. 1). Therewas no signiﬁcant difference in major adverse cardio-vascular events, with or without PPI (RR 1.01; 95% CI0.80–1.26, P = 0.96). In the 2017 focused update onDAPT in coronary artery disease of the EuropeanSociety of Cardiology, PPIs in combination with DAPTwere recommended (recommendation class I) [19].Only observational studies were available regarding theUGIB preventive effect of PPI in patients takingwarfarin. Ray et al. [20], in large retrospective cohortstudy, found that PPI administration signiﬁcantlyreduced the risk of hospitalization for UGIB in patientsreceiving warfarin with concomitant antiplatelet drugsor NSAIDs (45% reduction (hazard ratio 0.55; 95% CI0.39–0.77), P = 0.0004).H. pylori eradication therapyFirst-line eradication therapyCQ-5',\n",
       " 'receiving warfarin with concomitant antiplatelet drugsor NSAIDs (45% reduction (hazard ratio 0.55; 95% CI0.39–0.77), P = 0.0004).H. pylori eradication therapyFirst-line eradication therapyCQ-5What kind of regimen should we select for ﬁrst-line H.pylori eradication therapy?•As triple eradication therapy using VPZ with amoxi-cillin and clarithromycin has a high eradication rateJ Gastroenterol (2021) 56:303–322305123',\n",
       " 'compared with that of PPIs, VPZ is recommended as aﬁrst-line therapy.Recommendation: strong, 100% agreed, evidence levelA.•The recommended antibiotics for ﬁrst-line therapyinclude amoxicillin, clarithromycin, or metronidazole.In Japan, the combination of amoxicillin and metron-idazole is recommended due to the high incidence rateof clarithromycin-resistant strains (not covered by theJapanese insurance system).Recommendation: strong, 100% agreed, evidence levelA.•When PPIs are used, sequential therapy and concomi-tant quadruple therapy are suggested due to the higheradication rate in the ﬁrst-line therapy compared withtriple therapy (not covered by the Japanese insurancesystem).Recommendation: weak, 100% agreed, evidence levelA.Comment: In the Japanese insurance system, tripletherapy with a PPI or VPZ, amoxicillin, and clar-ithromycin is used as ﬁrst-line therapy [21]. As thedegree and duration of acid inhibition are related to thecure rate of H. pylori [22], an MA compared theefﬁcacy of VPZ-containing therapies to PPI-containingtherapies (Fig. 2) [23]. In areas with high clar-ithromycin-resistance rates ([ 15%), the MaastrichtV/Florence Consensus Report suggested that whenculture/sensitivity testing is not performed beforeeradication, ﬁrst-linetherapyusing clarithromycinshould not be used; bismuth quadruple (PPI/bismuth/tetracycline/metronidazole) or concomitant quadrupletherapy (PPI/amoxicillin/clarithromycin/nitroimidazoleor metronidazole) is recommended [24]. In addition, inareas with low metronidazole- and high clarithromycin-resistance rates, PPI/amoxicillin/metronidazole has ahighereradicationratethanPPI/amoxicillin/clar-ithromycin (Fig. 3) [25].Second-line eradication therapyCQ-6What regimen should we select for second-line H. pylorieradication therapy?•Triple therapy with PPI/VPZ, amoxicillin, and metron-idazole is recommended.Recommendation: strong, 100% agreed, evidence levelA.',\n",
       " 'eradication therapy?•Triple therapy with PPI/VPZ, amoxicillin, and metron-idazole is recommended.Recommendation: strong, 100% agreed, evidence levelA.Comment: Two MAs [26, 27] found that tetracycline/quinolone-based quintuple or quadruple therapies weremore effective than other therapies. One RCT revealedthat levoﬂoxacin sequential therapy was more effectivethan levoﬂoxacin triple therapy [28]. These drugs havenot been approved for H. pylori eradication therapy inFig. 1 Forest plots of proton pump inhibitors (PPIs) against control for upper gastrointestinal bleeding preventive effect in dual antiplatelettherapy (DAPT). In meta-analysis, PPIs signiﬁcantly have reduced bleeding risk compared to controls (RR 0.26; 95%CI 0.13–0.53, P = 0.0002)Fig. 2 Forest plots of eradication rates of ﬁrst-line therapy betweenvonoprazan-containing triple therapy and proton pump inhibitor(PPI)-containing triple therapy in the randomized control trials. Inmeta-analysis, the eradication rates of vonoprazan-containing tripletherapy are signiﬁcantly higher than that of PPI-containing tripletherapy (odds ratio 0.28; 95% CI 0.19–0.41, P \\\\ 0.00001)306J Gastroenterol (2021) 56:303–322123PPIControlRiskRatioRiskRatioStudyorSubgroupEventsTotalEventsTotalWeightM-H,Random,95%ClYearM-H,Random,95%ClBhatt8187626188582.3%0.31 [0.14, 0.68]2010Ren862865.6%0.20 [0.01, 4.11]2011Wei112388412.1%0.09[0.01,0.67]2016Total (95% CI)20852055100.0%0.26 [0.13, 0.53]Totalevents936Heter0geneity:Tau²=0.00;Chi²=1.35,df=2(P=0.51);F=0%0.010.110100Testfor overall effect:Z=3.70(P=0.0002)FavoursPPIFavourssControlVPZPPIOddsRatioOddsRatioStudyorSubgroupEventsTotalEventsTotalWeightM-H,Fixed,95%CIYearM-H,Fixed,95%CIMurakami2016303298032170.1%0.30[0.19,0.48]2016Maruyama2017372216919.6%0.10 [0.03, 0.35]2017Sue 2018755125110.3%0.47[0.17, 1.32]2018Total(95%CI)456441100.0%0.28 [0.19, 0.41]Totalevents40113',\n",
       " '3298032170.1%0.30[0.19,0.48]2016Maruyama2017372216919.6%0.10 [0.03, 0.35]2017Sue 2018755125110.3%0.47[0.17, 1.32]2018Total(95%CI)456441100.0%0.28 [0.19, 0.41]Totalevents40113Heterogeneity: Chi² = 3.70, df = 2 (P = 0.16); 1² = 46%0.010.1110100Testforoveralleffect:Z=6.42（P<0.00001)Favours[vonoprazan]Favours[PPI]',\n",
       " 'Japan. In addition, the rate of H. pylori infection withprimary resistance to levoﬂoxacin is high in Japan. Theeradication rate of triple therapy with PPI/VPZ, amox-icillin, and metronidazole is still high [4], and does notdiffer between the two regimens [29–31].Third-line eradication therapyCQ-7What regimen should we select for third-line H. pylorieradication therapy?•Triple therapy with PPI, sitaﬂoxacin, and metronida-zole or PPI, sitaﬂoxacin, and amoxicillin is suggested(not covered by the Japanese insurance system).Recommendation: weak, 100% agreed, evidence levelB.Comment: Three Japanese RCTs of third-line therapiesshowed that the eradication rates were 70.0–90.9%[32–34]. The eradication rate of triple therapy with PPI,sitaﬂoxacin,andmetronidazolewas70.0–88.9%[32–34], and that of PPI, sitaﬂoxacin, and amoxicillinwas 72.4–90.9% [33, 34]. Because these eradicationrates were not high enough, these regimens are notrecommended, but suggested.Ulcer recurrence after H. pylori eradicationCQ-8Is maintenance treatment necessary for the recurrence ofpeptic ulcer after successful H. pylori eradication?•When the cause of peptic ulcer recurrence is unclear,long-term maintenance treatment with PPIs or H2RAsis suggested.Recommendation: weak, 100% agreed, evidence levelD.Comment: There are currently no published RCTs orMAs. Causes of the recurrence of peptic ulcers aftersuccessful H. pylori eradication include using LDA andNSAIDs, reinfection with H. pylori, and smokinghabits. To prevent peptic ulcer recurrence, the exclu-sion of these factors is necessary. Idiopathic pepticulcers are thought to be one of unknown causes ofpeptic ulcers after successful H. pylori eradication;therefore, long-term maintenance treatment with PPIsor H2RAs is suggested, when the cause of peptic ulcerrecurrence is unclear.Non-eradication therapyInitial therapy.Gastric ulcerCQ-9What is the ﬁrst-line drug for the initial non-eradicationtreatment of gastric ulcers?•',\n",
       " 'recurrence is unclear.Non-eradication therapyInitial therapy.Gastric ulcerCQ-9What is the ﬁrst-line drug for the initial non-eradicationtreatment of gastric ulcers?•Either PPIs or P-CAB is recommended.Recommendation: strong, 100% agreed, evidence levelA.•If PPIs and P-CAB cannot be prescribed, H2RAs arerecommended.Recommendation: strong, 100% agreed, evidence levelB.•If PPIs and P-CAB cannot be prescribed, pirenzepine,sucralfate, and misoprostol are suggested.Recommendation: weak, 100% agreed, evidence levelB.•If the above drugs cannot be prescribed, gastricmucosa-protecting agents (excluding sucralfate andmisoprostol) are suggested.Recommendation: weak, 100% agreed, evidence levelB.Comment: We recommend either PPIs or P-CAB due totheir demonstrated ulcer healing rate of PPIs beingsigniﬁcantly higher than that of H2RAs [35–38].Fig. 3 Forest plots of eradication rates of second-line therapybetween proton pump inhibitor/amoxicillin/metronidazole (PAM)therapyandprotonpumpinhibitor/amoxicillin/clarithromycin(PAC) therapy in the randomized control trials in Japan. In meta-analysis, the eradication rates of PAM therapy are signiﬁcantly higherthan that of PAC therapy (odds ratio 0.14; 95% CI 0.08–0.24)J Gastroenterol (2021) 56:303–322307123PAMPACOddsRatioOddsRatioStudyorSubgroupEventsTotalEventsTotalWeightM-H,Fixed,95%CIYearM-H,Fixed,95%CINishizawa2015664166017.6%0.28[0.10,0.79]2015Adachi2017672206822.2%0.22[0.08,0.58]2017Mabe201861694813760.2%0.07[0.03, 0.17]2018Total (95% CI)305265100.0%0.14[0.08,0.24]Totalevents1884Heterogeneity:Chi²=5.17,df=2 (P =0.08);1²=61%0.010.1110100Testforoveralleffect:Z=7.18(P<0.00001)Favours[PAM]Favours[PAC]',\n",
       " 'P-CAB gained popularity in recent years due to theirhigh ulcer healing rate for gastric ulcers compared withlansoprazole [39]. When PPIs and P-CAB cannot beprescribed, H2RAs are recommended. There were noreported signiﬁcant differences in ulcer healing ratesbetween H2RAs. Moreover, pirenzepine, sucralfate, andmisoprostol are suggested as their ulcer healing ratesare equivalent to those of H2RAs.Duodenal ulcerCQ-10What is the ﬁrst-line drug for the initial non-eradicationtreatment of duodenal ulcer?•Either PPIs or P-CAB is recommended.Recommendation: strong, 100% agreed, evidence levelA.•If PPIs and P-CAB cannot be prescribed, H2RAs arerecommended.Recommendation: strong, 100% agreed, evidence levelB.•If PPIs and P-CAB cannot be prescribed, pirenzepine,sucralfate, and misoprostol are suggested.Recommendation: weak, 100% agreed, evidence levelB.Comment: We recommend either PPIs or P-CAB as theulcer healing rate of PPIs is signiﬁcantly higher thanthat of H2RAs [40]. P-CAB gained popularity in recentyears due to their high ulcer healing rate for duodenalulcers compared with lansoprazole [39]. When PPIscannot be prescribed, H2RAs are recommended.Drug-induced ulcerNonselective NSAID-induced ulcer.TreatmentCQ-11How should NSAID-induced ulcers be treated?•NSAIDs should be discontinued, and administration ofanti-ulcer drugs is recommended.Recommendation: strong, 100% agreed, evidence levelA.•If NSAIDs cannot be discontinued, administration ofPPIs is recommended as a ﬁrst-line therapy.Recommendation: strong, 100% agreed, evidence levelA.Comment: Gastric and duodenal ulcers in NSAID usersheal to a high rate when NSAIDs are withdrawn [41]. Incomparative studies of PPIs vs. H2RA [42] and PPIs vs.PG analogs [43], the healing rate of gastric andduodenal ulcers was highest in PPI groups. The originalMA in this guideline indicated that the healing rate ofpeptic ulcers over 8 weeks was higher in PPI groupsthan in H2RA groups; thus PPIs are recommended as',\n",
       " 'MA in this guideline indicated that the healing rate ofpeptic ulcers over 8 weeks was higher in PPI groupsthan in H2RA groups; thus PPIs are recommended asthe ﬁrst-line therapy (Fig. 4).PreventionCQ-12If a patient receiving NSAIDs tests positive for H. pyloriinfection,shouldH.pylorieradicationtherapybeadministered?•Eradication of H. pylori is recommended for preventionof ulcers in NSAID-naı¨ve patients.Recommendation: strong, 100% agreed, evidence levelA.Comment: In comparative studies of PPIs and H. pylorieradication, PPIs are superior to the eradication of H.pylori in preventing recurrent bleeding in patientstaking NSAIDs [44].Studies have [45, 46] indicated that H. pylori eradica-tion therapy reduces the incidence of ulcers in patientsreceiving NSAIDs; however, an effect of H. pylorieradication therapy on preventing peptic ulcer cannotbe expected during NSAID therapy. In an MA reportedin 2012, the efﬁcacy of H. pylori eradication therapy forpreventing peptic ulcer was observed, especially innaı¨ve users and in Asian populations [46].CQ-13Is preventive therapy for NSAID-induced ulcers necessaryin patients with no history of ulcers?•Prevention of NSAID-induced ulcers by administrationof PPIs is necessary and suggested even in patients withno history of ulcers.Recommendation: weak, 100% agreed, evidence levelA.(PPIs are not covered by Japanese insurance forprimarypreventionofulcersinpatientstakingNSAIDs).Comment: In patients receiving NSAID therapy formore than three months, the efﬁcacy of PG analogs[47], PPIs [48], or high-dose H2RAs [49] given asprimary preventions has been reported. Scally B et al.[50] showed that PPIs had larger protective effects than308J Gastroenterol (2021) 56:303–322123',\n",
       " 'H2RAs or PG analogs for peptic ulcers and furtherbleeding; therefore, PPIs are suggested as a ﬁrst-linetherapy.CQ-14How should recurrence be prevented in patients with ahistory of ulcers or bleeding ulcers who are starting NSAIDtherapy?•PPIs are recommended, and VPZ is suggested toprevent NSAID-induced ulcers in patients with ahistory of ulcers.Recommendation: weak, 100% agreed, evidence levelB.•Concomitant administration of the selective cyclooxy-genase (COX)-2 inhibitor with a PPI is recommendedfor preventing recurrence of bleeding NSAID-inducedulcers in patients with a history of bleeding ulcers.Recommendation: strong, 100% agreed, evidence levelB.Comment: Although the efﬁcacy of PG analogs [51] forsecondarypreventionwasobservedinhigh-riskpatients with a history of peptic ulcers, patient drop-out due to diarrhea is common.Studies found that PPIs were superior to placebos inreducing the risk of gastric or duodenal ulcer recurrencein patients with a history of ulcers requiring long-termNSAID therapy [52, 53]. The original MA in thisguideline indicated that the recurrence rate of pepticulcers in patients with a history of ulcers requiringlong-term NSAID therapy was lower in PPI groups thanin placebo groups. Therefore, PPIs are recommended asthe ﬁrst-line therapy (Fig. 5).Chan et al. [54] suggested that combination treatmentwith a selective COX-2 inhibitor and a PPI was moreeffective than a selective COX-2 inhibitor alone forprevention of ulcer bleeding in patients at high risk.Mizokami et al. [6] reported that VPZ was not inferiorto PPIs, indicating that VPZ can be recommended forthe second prevention of NSAID-induced peptic ulceras well as PPIs.CQ-15How should NSAID-induced ulcers be prevented inpatients receiving high-dose NSAIDs or a combination ofNSAIDs and antithrombotic drugs or glucocorticoids orbisphosphonates,whoareelderly,orhaveseverecomplications?•In patients receiving combinations of NSAIDs and',\n",
       " 'NSAIDs and antithrombotic drugs or glucocorticoids orbisphosphonates,whoareelderly,orhaveseverecomplications?•In patients receiving combinations of NSAIDs andglucocorticoids or antithrombotic drugs, administrationof a COX-2 inhibitor is recommended for ulcerprevention.Recommendation: strong, 100% agreed, evidence levelB.•In elderly or patients with severe complications,administration of PPIs is recommended for the preven-tion of NSAID-induced ulcers.Recommendation: strong, 100% agreed, evidence levelA.Comment: Concomitant use of nonselective NSAIDs orLDA, but not selective COX-2 inhibitors, with corti-costeroids, or anticoagulants, increases the risk ofUGIB, indicating that selective COX-2 inhibitors donot increase the risk of UGIB [55]. The efﬁcacy of PPIsfor prevention of complications has been demonstratedin a previous study [56].Selective NSAID (COX-2 selective inhibitor)-inducedulcers.CQ-16Is a COX-2 selective inhibitor useful for the prevention ofNSAID-induced ulcers?•COX-2 selective inhibitors are recommended for theprevention of NSAID-induced ulcers.Recommendation: strong, 100% agreed, evidence levelFig. 4 Meta-analysis of comparison of ulcer curative effect between PPI and H2RA under the NSAIDs continuation. In meta-analysis, thehealing rate of peptic ulcers for 8 weeks is higher in the PPI groups than in the H2RA groupsJ Gastroenterol (2021) 56:303–322309123PPIH2RAOddsRatioOddsRatioStudyorSubgroupEventsTotalEventsTotalWeightM-H,Fixed,95%CIM-H,Fixed,95%CIAgrawal 2000371185411523.1%0.52 [0.30, 0.88]Campbell20027522611322546.6%0.49 [0.34, 0.72]Goldstein2007211383313917.2%0.58 [0.31, 1.06]Yeomans1998967257013.0%0.28 [0.12, 0.66]Total (95% CI)549549100.0%0.48 [0.37,0.63]Total events142225Heter0geneity:Chi²=1.97,df=3(P=0.58);F=0%0.010.110100Testforoveralleffect:Z=5.42(P<0.00001)PPIH2RA',\n",
       " 'A.Comment: The incidence rate of peptic ulcers inWestern countries is signiﬁcantly lower in patientstaking COX-2 selective inhibitors than in patientstaking nonselective NSAIDs [57–59]. We conducted anMA and found that the incidence of gastric ulcers (RR0.21; 95% CI 0.18–0.25, P \\\\ 0.00001) (Fig. 6a) andduodenalulcers(RR0.38;95%CI0.29–0.51,P \\\\ 0.00001) (Fig. 6b) was lower in patients usingCOX-2 selective inhibitors than in patients usingFig. 5 Meta-analysis of preventive effect in the secondary prevention of NSAIDs ulcer. In meta-analysis, the recurrence rate of peptic ulcers inpatients with a history of gastric or duodenal ulcers who required long-term NSAID therapy is lower in the PPI groups than in the placebo groupsFig. 6 Forest plots of peptic ulcer risk between COX-2 selectiveinhibitor and NSAID therapy in the randomized control trials(a gastric ulcer, b duodenal ulcer). In meta-analysis, the incidenceof gastric (risk ratio 0.21; 95% CI 0.18–0.25) (a) and duodenal ulcers(risk ratio 0.38; 95% CI 0.29–0.51) (b) are lower in patients usingCOX-2 selective inhibitors than in patients using NSAIDs310J Gastroenterol (2021) 56:303–322123PPIPlaceboOdds RatioOddsRatioStudyorSubgroupEventsTotalEventsTotalWeightM-H,Fixed,95%CIM-H,Fixed,95%ClChan200701371213611.0%0.04 [0.00, 0.62]Sugano2012（Es0me)?1736016851.4%0.08 [0.03, 0.17]Sugano2012(Lanso)151684616237.6%0.25 [0.13, 0.46]Total (95% CI)478466100.0%0.14[0.08,0.22]Totalevents22118Heter0geneity:Chi²=6.23,df=2(P=0.04):F=68%0.010.110100Testfor0veralleffect:Z=8.16（P<0.00001)Favours[PPI]Favours[Placebo]COX2-inhibitorNSAIDsRisk RatioRisk RatioStudy or SubgroupEventsTotalEventsTotalWeightIV, Random, 95% CI YearIV, Random, 95% ClEmery1999５212242133.3%0.21 [0.08, 0.54]1999Simon 199917423291379.3%0.19 [0.11, 0.33] 1999Laine 1999173644016710.4%0.19 [0.11, 0.33] 1999Hawkey 2000303698518721.0%0.18 [0.12, 0.26]   2000Goldstein 20011326976257',\n",
       " '1999Simon 199917423291379.3%0.19 [0.11, 0.33] 1999Laine 1999173644016710.4%0.19 [0.11, 0.33] 1999Hawkey 2000303698518721.0%0.18 [0.12, 0.26]   2000Goldstein 200113269762579.4%0.16 [0.09, 0.29]  2001Sikes 200211299402947.1%0.27 [0.14, 0.52]  2002Kivitz 200216547161836.6%0.33 [0.17, 0.66]  2002Pavelka 200310483312396.2%0.16 [0.08, 0.32]  2003Hawkey 200313219482208.8%0.27 [0.15, 0.49]2003Kivitz 200414419291997.9%0.23 [0.12, 0.42]  2004Hawkey 200420763222488.6%0.30 [0.16, 0.53] 2004Cheung 20102434144351.4%0.14 [0.03, 0.63] 2010Total (95% CI)48012779100.0%0.21 [0.18, 0.25]Total events168454Heterogeneity. Tau²= 0.00; Chi²= 7.05, df= 11 (P = 0.80); F= 0%0.010.110100Test for overall effect: Z= 17.57 (P < 0.00001)Favours COX2-inhibitorFavours NSAIDs(b）COX-2 inhibitorNSAIDsRisk RatioRisk RatioStudy or SubgroupEventsTotalEventsTotalWeightIV, Fixed, 95% CIYearIV, Fixed, 95% ClLaine 1999５364101677.3%0.23 [0.08, 0.66]1999Simon 1999642381377.6%0.24 [0.09, 0.69]] 1999Emery 19994212152187.0%0.27 [0.09, 0.81] 1999Hawkey 2000153691018713.5%0.76 [0.35, 1.66]   2000Goldstein 200192691926713.7%0.47 [0.22, 1.02]  2001Kivit 2002554721833.1%0.84 [0.16, 4.27]  2002Sikes 20023299132945.3%0.23 [0.07, 0.79]  2002Hawkey 20032219112203.7%0.18 [0.04, 0.81]  2003Pavelka 2003124831423914.4%0.42 [0.20, 0.90]   2003Hawkey 200497632024813.7%0.15 [0.07, 0.32] 2004Kivit 2004463221992.9%0.63 [0.12, 3.41]   2004Cheung 2010937763607.9%1.43 [0.52, 3.98] 2010Total (95% CI)49572719100.0% 0.38 [0.29, 0.51]Total events83130Heterogeneity: Chi²= 20.47,df= 11 (P = 0.04):F= 46%0.010.110100Test for 0verall effect: Z = 6.60 (P < 0.00001)Favours COX-2inhibitorFavours NSAIDs',\n",
       " 'NSAIDs. Using COX-2 selective inhibitors had a lowerrisk of developing serious ulcer complications.A RCT including healthy Japanese volunteers showedthat the incidence of gastroduodenal ulcers was 1.4%,27.6%, and 2.7% in the celecoxib, loxoprofen, andplacebo groups, respectively (P \\\\ 0.0001 in favor ofthe celecoxib group) [60]. We conducted an MA andfound that the incidence of peptic ulcers was lower inpatients using COX-2 selective inhibitors than inpatients using NSAIDs (RR 0.13; 95% CI 0.04–0.44,P = 0.0010), similar to ﬁndings from patients inWestern countries. These results indicate that COX-2selective inhibitors are useful for the prevention ofNSAID-induced ulcers and serious ulcer complications.CQ-17Is preventive medication with anti-ulcer agents required forpatients taking a COX-2 selective inhibitor?•Prevention with anti-ulcer agents is recommended forpatients taking COX-2 selective inhibitors with ahistory of peptic ulcers or hemorrhage.Recommendation: strong, 100% agreed, evidence levelB.•No prevention with anti-ulcer agents is recommendedfor patients taking COX-2 selective inhibitors without apast history of peptic ulcer.Recommendation: strong, 100% agreed, evidence levelB.Comment: An MA revealed that the incidence of drug-induced peptic ulcer development was similar betweenpatients who received COX-2 selective inhibitors andplacebos, suggesting that COX-2 selective inhibitors donot increase the risk of drug-induced peptic ulcers[60–62]. In a network MA, concomitant dosing ofCOX-2 selective inhibitors with PPIs effectively pre-vented the development of drug-induced peptic ulcercompared with COX-2 selective inhibitors alone [63].However, patients with a history of peptic ulcers have ahigher risk of developing drug-induced peptic ulcers.LDA-induced ulcerTreatmentCQ-18How should LDA-related peptic ulcers be treated?•Concomitant use of PPIs with continuous LDA therapyis recommended for LDA-related peptic ulcers.',\n",
       " 'LDA-induced ulcerTreatmentCQ-18How should LDA-related peptic ulcers be treated?•Concomitant use of PPIs with continuous LDA therapyis recommended for LDA-related peptic ulcers.Recommendation: strong, 100% agreed, evidence levelA.Comment: For patients with a history of LDA-relatedPUB, concomitant use of PPIs with continuous LDAtherapy after endoscopic hemostasis was equivalent inthe recurrence of PUB compared to concomitant use ofplacebos and PPIs. Furthermore, continuous LDAtherapy reduces overall mortality rates related tocardiovascular (CV) events [8]. In the same study,concomitant use of PPIs with continuation of LDAtherapy did not increase the incidence of PUB recur-rence [8]. The peptic ulcer healing rate was similarbetween the PPI alone and the LDA combined with PPI[64].Prevention.CQ-19What kind of concomitant use of medicine should beeffective for reducing the incidence and prevalence ofLDA-related peptic ulcers?•PPIs or H2RAs is recommended for the reduction of theincidence and prevalence of LDA-related peptic ulcers.Recommendation: strong, 100% agreed, evidence levelA.(PPIs and H2RAs are not covered by Japanese insur-ance for primary prevention of ulcers in patients takingLDA).(H2RAs are not covered by Japanese insurance forsecondary prevention of ulcers in patients taking LDA).Comment: MA indicated that LDA treatment withconcomitant use of H2RAs or PPIs reduced the risk ofLDA-related peptic ulcers [65, 66]. PPIs were superiorto H2RAs in preventing upper GI ulcers related to LDA[67]. However, a RCT by Chan et al. [68] indicated thatthere were no signiﬁcant differences between rabepra-zole and famotidine in the incidence of recurrent ulcersin patients taking LDA. We used data from two RCTs[69, 70] in Mo et al. [67] and one RCT [68] toindependently conduct an MA. We found no signiﬁcantdifference (RR 0.26; 95% CI 0.04–1.81, P = 0.17) inthe incidence of LDA-related upper GI ulcers betweenPPIs and H2RAs (Fig. 7).CQ-20',\n",
       " 'independently conduct an MA. We found no signiﬁcantdifference (RR 0.26; 95% CI 0.04–1.81, P = 0.17) inthe incidence of LDA-related upper GI ulcers betweenPPIs and H2RAs (Fig. 7).CQ-20What kind of concomitant use of medicine should beeffective for reducing the incidence and prevalence rate ofLDA-related PUB?•PPIs or VPZ is recommended for the reduction of theincidence and prevalence of LDA-related PUB.J Gastroenterol (2021) 56:303–322311123',\n",
       " 'Recommendation: strong, 100% agreed, evidence levelA.(PPI and VPZ are not covered by Japanese insurancefor primary and secondary prevention of PUB inpatients taking LDA).Comment: MA revealed that LDA treatment withconcomitant use of H2RAs or PPIs reduced the risk ofLDA-related PUB [65, 71]. PPIs were superior toH2RAs in preventing upper GI ulcer bleeding related toLDA [66, 67]. We used data from three RCTs [68–70]in Mo et al. [67] and three RCTs [72–74], whichcompared PPIs and H2RAs to independently conduct anMA. We found that PPIs were superior to H2RAs (RR0.28; 95% CI 0.16–0.50, P \\\\ 0.0001) in the preventionof LDA-related upper GI bleeding (Fig. 8). Further-more, the incidence of bleeding in the stomach orduodenum was signiﬁcantly lower with both 10 mg and20 mg of VPZ compared to 15 mg of lansoprazole inpatients taking LDA with a history of ulcers [7].CQ-21What kind of concomitant use of medicine should beeffective for reducing the incidence and prevalence rate ofrecurrent LDA-related PUB?•PPIs in addition to the eradication of H. pylori infectionare recommended for the reduction of the incidence andprevalence rate of LDA-related PUB.Recommendation: strong, 100% agreed, evidence levelB.(PPI is not covered by Japanese insurance for secondprevention of peptic ulcer bleeding in patients takingLDA).•H2RAs in addition to the eradication of H. pyloriinfection are suggested for the reduction of theincidence and prevalence rate of LDA-related PUB.Recommendation: weak, 100% agreed, evidence levelC.(H2RAs are not covered by Japanese insurance forsecond prevention of PUB in patients taking LDA).Comment: The eradication of H. pylori is equivalent inthe probability of recurrent bleeding to treatment withomeprazole in patients receiving LDA [75]. In patientswith ulcer complications related to the long-term use ofLDA, treatment with lansoprazole in addition to theeradication of H. pylori signiﬁcantly reduced recur-',\n",
       " 'with ulcer complications related to the long-term use ofLDA, treatment with lansoprazole in addition to theeradication of H. pylori signiﬁcantly reduced recur-rence rates of ulcer bleeding compared to placebo plusH. pylori eradication [76]. In patients with LDA-relatedpeptic ulcers, high-dose famotidine therapy is inferiorto pantoprazole in preventing recurrent ulcer bleedingthat continues to receive LDA [69]. LDA treatmentFig. 7 Effects of proton pump inhibitors (PPIs) and histamine2-receptor antagonists (H2RAs) in preventing upper gastrointestinal(GI) ulcers related to low dose aspirin (LDA). An independentlymeta-analysis demonstrates that no signiﬁcant difference (RR 0.26;95% CI 0.04–1.81, P = 0.17) in the incidence of LDA-related upperGI ulcers between PPIs and H2RAsFig. 8 Effects of proton pump inhibitors (PPIs) and histamine2-receptor antagonists (H2RAs) in preventing upper gastrointestinal(GI)ulcer bleeding related to low dose aspirin(LDA). Anindependently meta-analysis demonstrated that PPIs are superior toH2Ras (RR 0.28; 95% CI 0.16–0.50, P \\\\ 0.0001) in prevention ofLDA-related upper GI bleeding312J Gastroenterol (2021) 56:303–322123PPIH2RARiskRatioRiskRatioStudyorSubgroupEventsTotalEventsTotalWeightM-H,Random,95%ClYearM-H,Random,95%ClNg 201006566525.4%0.08 [0.00, 1.34]2010Ng 20120163514825.1%0.08 [0.00, 1.48]2012Chan20178138913249.5%0.85 [0.34,2.14]2017Total (95% CI)366345100.0%0.26 [0.04, 1.81]Totalevents820Heter0geneity:Tau²=1.79;Chi²=4.91,df=2(P=0.09);F=59%0.0010.1101000Testfor0veralleffect:Z=1.36（P=0.17)FavoursPPIFavoursH2RAPPIH2RARiskRatioRiskRatioStudyorSubgroupEventsTotalEventsTotalWeightM-H,Random,95%ClYearM-H,Random,95%CINg 20100655654.2%0.09 [0.01,1.61]2010Tunggal 20110442443.8%0.20 [0.01, 4.05]2011Yano20120651653.4%0.33 [0.01, 8.03]2012Ng 201231631214822.3%0.23 [0.07,0.79]2012WangZ201310163147759.0%0.34 [0.16, 0.73]2013Chan201711384132',\n",
       " '2443.8%0.20 [0.01, 4.05]2011Yano20120651653.4%0.33 [0.01, 8.03]2012Ng 201231631214822.3%0.23 [0.07,0.79]2012WangZ201310163147759.0%0.34 [0.16, 0.73]2013Chan2017113841327.3%0.24 [0.03, 2.11]2017Total (95%CI)638531100.0%0.28 [0.16, 0.50]Totalevents1438Heter0geneity.Tau²=0.00;Chi²=1.06,df=5(P=0.96);F=0%0.0010.1101000TestforoveralleffectZ=4.25(P<0.0001)FavoursPPIFavoursH2RA',\n",
       " 'with concomitant use of rabeprazole showed no differ-ence in the incidence of recurrent upper GI ulcerbleeding rates compared to famotidine in patients witha history of LDA-related peptic ulcer bleeding [68].CQ-22How should LDA-related peptic ulcer recurrence be pre-vented in patients with a history of peptic ulcers?•PPI or VPZ is recommended to reduce the recurrencerate of LDA-related peptic ulcers.Recommendation: strong, 100% agreed, evidence levelA.•H2RAs are suggested to reduce the recurrence rate ofLDA-related peptic ulcers.Recommendation: weak, 100% agreed, evidence levelC.Comment: In patients with a history of LDA-relatedpeptic ulcers who continued to receive LDA, panto-prazole was superior to famotidine in preventingrecurrent bleeding ulcers [69]. LDA treatment withconcomitant use of 20 mg rabeprazole showed nodifference in the recurrence of upper GI ulcer bleedingcompared to 40 mg of famotidine in patients with ahistory of LDA-related PUB [68]. An independent MAof four RCT articles [77–80] demonstrated that PPIswere superior to control drugs, placebos, gefarnate, andteprenone, in preventing the recurrence of LDA-relatedupperGIulcers(RR0.09;95%CI0.06–0.15,P \\\\ 0.00001). A study found that 47–53% of patientswith gastroduodenal ulcer scars on endoscopy atbaseline, famotidine was superior to placebo in pre-vention of the incidence of gastroduodenal ulcers inpatients taking LDA [81]. An RCT by Kawai et al.indicated that 10 mg of VPZ was superior to 15 mg oflansoprazole in the prevention of peptic ulcer recur-rence in patients with a history of peptic ulcers whorequired LDA [7].CQ-23In patients without a history of peptic ulcer, is the pre-vention of LDA-related peptic ulcers necessary?•PPIs are recommended for the primary prevention ofLDA-related peptic ulcers without a history of ulcers.Recommendation: strong, 82% agreed, evidence levelA.Comment: In an RCT by Takeuchi et al., famotidine',\n",
       " 'LDA-related peptic ulcers without a history of ulcers.Recommendation: strong, 82% agreed, evidence levelA.Comment: In an RCT by Takeuchi et al., famotidinewas superior to teprenone in reducing the number oferosions during LDA use in 94% of patients without ahistory of peptic ulcers [82]. Scheiman et al. [83]indicated that esomeprazole reduced the occurrence ofpeptic ulcers in patients taking LDA in 73% of patientswithout a history of peptic ulcers. Ng et al. [70] foundthat esomeprazole was superior to famotidine inpreventing upper GI complications related to LDA,clopidogrel, and thrombolytics in 95% of patientswithout a peptic ulcer.CQ-24Can COX-2 selective inhibitors reduce the risk of pepticulcers compared to nonselective NSAIDs when adminis-tered with LDA?•COX-2 selective inhibitors reduce the risk of pepticulcers and bleeding in patients taking LDA compared tononselective NSAIDs.Recommendation: strong, 100% agreed, evidence levelA.•Concomitant use of celecoxib with PPIs is recom-mended for the prevention of gastric injury in patientswith moderate or lower risk of peptic ulcers requiringLDA and NSAIDs.Recommendation: strong, 100% agreed, evidence levelA.Comment: Concomitant use of a COX-2 selectiveinhibitor with LDA increased the incidence of pepticulcers [84], whereas COX-2 selective inhibitors low-ered the risk of peptic ulcers compared to nonselectiveNSAIDs when using LDA [85, 86]. In patients takingLDA, the use of celecoxib or naproxen with PPIsresulted in similar rates of gastroduodenal ulceration[87]. In patients at high risk of both CV and GI eventsrequiring concomitant LDA and NSAIDs, celecoxibwith PPIs was the preferred treatment to reduce the riskof recurrent upper GI bleeding compared to naproxenwith esomeprazole [88]. A study found that in 45% ofarthritis patients taking LDA, the risk of GI events waslower with celecoxib than with naproxen or ibuprofen[89]. COX-2 selective inhibitors and nonselective',\n",
       " 'arthritis patients taking LDA, the risk of GI events waslower with celecoxib than with naproxen or ibuprofen[89]. COX-2 selective inhibitors and nonselectiveNSAIDs increased the risk and incidence of CV events[90], whereas celecoxib was non-inferior to naproxenor ibuprofen with regard to CV safety [88, 89]. Inaddition, the American College of Gastroenterology(ACG) guidelines suggest that concomitant use ofCOX-2 selective inhibitors or nonselective NSAIDs inpatients taking LDA should not be prescribed inpatients at high risk of peptic ulcer [91].J Gastroenterol (2021) 56:303–322313123',\n",
       " 'CQ-25Is PPI recommended for the prevention of recurrence ofpeptic ulcers with NSAID treatment in patients takingLDA?•Celecoxib with concomitant use of PPI is recom-mended for the prevention of peptic ulcer recurrenceafter NSAID treatment in patients taking LDA.Recommendation: strong, 100% agreed, evidence levelA.(PPI is not covered by Japanese insurance for theprimary prevention of ulcers in patients taking LDA).Comment: In patients with a history of ulcer who arereceiving combinations of NSAIDs and LDA, con-comitant use of PPI lowered the risk for gastric ulcerrecurrence as misoprostol [92]. In addition, Goldsteinet al. indicated that naproxen with esomeprazolelowered the incidence of gastric ulcers compared tonaproxen in LDA users [93]. There were fewer GIevents in patients using both COX-2 inhibitors andLDA than nonselective NSAIDs and LDA [85, 86], andthere were no differences in the occurrence of CVevents between celecoxib and naproxen or ibuprofen[88, 89].Non-H. pylori, non-NSAIDs ulcerCQ-26How should non-H. pylori and non-NSAIDs ulcers betreated?•PPIs are suggested for the initial treatment of non-H.pylori and non-NSAID idiopathic ulcers with PPIs orH2RAs for the prevention of recurrence.Recommendation: weak, 100% agreed, evidence level:C.Comment: As hyperacidity and hypergastrinemia havebeen observed in patients with idiopathic ulcers [94],we suggest PPIs as the initial treatment. However,Kanno et al. [95] reported that the healing rate at12 weeks with PPIs was 77.4% for idiopathic ulcerscompared to 95.0% for H. pylori ulcers. Therefore, PPIsmay be insufﬁcient for the treatment of idiopathiculcers. Wong et al. [96] reported that the cumulativerecurrence rate of the idiopathic ulcer group for 7 yearswithout preventive treatment was 42.3%, higher thanthat of the H. pylori ulcer group (11.2%). Furthermore,in the following RCT conducted by them, theycompared the efﬁcacy of PPI and H2RA in preventing',\n",
       " 'without preventive treatment was 42.3%, higher thanthat of the H. pylori ulcer group (11.2%). Furthermore,in the following RCT conducted by them, theycompared the efﬁcacy of PPI and H2RA in preventingrecurrence of idiopathic ulcers and reported that thecumulativeincidenceofupperGIbleedingat24 months was 0.88% for PPI (lansoprazole: 30 mgonce per day) and 2.63% for H2RA (famotidine: 40 mgonce per day) The effect was not signiﬁcantly differentbetween the two groups (P = 0.336) [97]. Therefore,we suggest that both PPIs and H2RAs are candidates forthe prevention of recurrence.Remnant gastric ulcerCQ-27What is the treatment for ulcers in the gastric remnant?•PPI treatment is recommended for ulcers in the gastricremnant.Recommendation: strong, 100% agreed, evidence levelC.Comment: The ﬁrst choice for the treatment of ulcers ingastric remnant is drug therapy. In an open-label trialcomparing omeprazole, cimetidine, sucralfate, colloidalbismuth, and misoprostol for ulcers in the gastricremnant, omeprazole was the best in terms of cure rateand cure speed [98]. The cure rates of ulcer in 2 weeks’treatment were 66.7, 43.3, 22.2, 22.2, and 16.7% foromeprazole, cimetidine, sucralfate, colloidal bismuth,and misoprostol, respectively.To date, there has not been a RCT regarding the H.pylori eradication effect. However, in several cross-sectional studies comparing the H. pylori positivity ratebetween gastric remnants with and without ulcers, therewas no difference [99–102]. From these results, theeradication effect for ulcer occurrence in the gastricremnant is unknown. The preventive effect of eradica-tion for carcinogenesis in the gastric remnant is alsoundeﬁned. However, speculating from histologicalimprovement after eradication, it would be effectivefor preventing carcinogenesis. We should be cautiousabout the recovery of acid secretion after eradicationfor ulcer occurrence in the gastric remnant.Surgical treatmentCQ-28',\n",
       " 'for preventing carcinogenesis. We should be cautiousabout the recovery of acid secretion after eradicationfor ulcer occurrence in the gastric remnant.Surgical treatmentCQ-28Is eradication of H. pylori recommended after surgery forpeptic ulcers?•Eradication of H. pylori is recommended after omentalpatch or omental ﬁlling procedure for peptic ulcers if H.pylori positive.Recommendation: strong, 100% agreed, evidence levelA.Comment:Forpost-surgerytreatment,reports314J Gastroenterol (2021) 56:303–322123',\n",
       " 'regarding eradication therapy were found, but not forPPI or H2RA treatment. Several reports were inagreement with the recommendation of eradicationtherapy for prevention of peptic ulcer recurrence afterstomach preserving surgery [103–107]. El-Nakeeb et al.[107] indicated that early eradication after omentalpatch surgery for duodenal ulcer perforation is recom-mended for accelerating ulcer healing 8 weeks aftersurgery.Preventive effects for ulcer recurrence by eradicationafter gastrectomy were not consistent between reports.Further analysis is needed to determine the effect ofacid secretion recovery after eradication of pepticulcers.FRQ-1What is the treatment for an ischemic duodenal ulcer?•Suggested PPIs or misoprostol as conservative treat-ments. Background conditions such as thrombosis andarterial stenosis should be investigated. IVR or surgerymay be considered if the patient’s condition is exac-erbated following conservative treatment.Comment: Fourteen case reports regarding ischemicduodenal ulcers were identiﬁed. Symptoms includedacute onset abdominal pain, melena or hematemesis,chronic abdominal pain, and weight loss. Typicalendoscopic ﬁndings for ischemia were longitudinalulcers, and edematous and reddish changes in thesurrounding mucosa other than the ulcer. The causes ofacute ischemia include embolization for GI bleedinghemostasis or embolization therapy for hepatocellularcarcinoma, systemic thromboembolism [108, 109], andunknown cases. Chronic symptoms were reported inpatients at risk of atherosclerotic disease and severestenosis of the celiac artery/superior mesenteric artery.Fasting and acid-secreting inhibitors have been used asconservative treatments. However, the clinical effec-tiveness of acid suppression in the posterior part of thebulb, which is exposed to bile and pancreatic juice,remains unclear. From the viewpoint of mucosalprotection, misoprostol is suggested. In the case ofacute onset ischemic ulcers, careful observation is',\n",
       " 'remains unclear. From the viewpoint of mucosalprotection, misoprostol is suggested. In the case ofacute onset ischemic ulcers, careful observation isrequired,consideringthepossibilityofsystemicthrombosis.Therapeutic algorithmFigure 9 shows the algorithm for the treatment of pepticulcer disease. If complications are present, they areaddressed prior to the treatment of the ulcer. Perforation orstenosis is treated with surgery or conservative therapy.Hemorrhagic ulcers are treated via endoscopic hemostasis.When endoscopic hemostasis failed, surgery or IVR isperformed. When no complications are present, medicaltherapy is provided immediately (Fig. 9a).NSAIDs are discontinued, and anti-ulcer therapy isprovided for the treatment of NSAID-induced ulcers. IfNSAIDs cannot be discontinued, the ulcer should be trea-ted with a PPI. Patients with peptic ulcers who do not useNSAIDs should be tested for H. pylori. Eradication therapyis recommended for patients who are H. pylori positive. Ifﬁrst-line therapy fails, second-line therapy is provided. Ifthe second-line therapy fails, a specialist is consulted forthird-line therapy. For patients without an indication foreradication therapy, non-eradication therapy is providedfollowed by maintenance therapy to prevent ulcer recur-rence. A remnant gastric ulcer is treated with a PPI, and anidiopathic ulcer is treated with PPI followed by mainte-nance therapy with a PPI or H2RA (Fig. 9b).*1Contraindications.Onlywhenadministrationisunavoidable as it cannot be discontinued.*2Patients who do not use NSAIDs and are H. pylorinegative are considered to have idiopathic peptic ulcers.Figure 10 shows the algorithm for the prevention ofNSAID-induced ulcers. In patients with no ulcer historyreceiving NSAID therapy, celecoxib (CXB) is recom-mended and PPIs are suggested for ulcer prevention.However, PPIs are recommended for elderly patients andpatients with serious complications. If patients are both',\n",
       " 'mended and PPIs are suggested for ulcer prevention.However, PPIs are recommended for elderly patients andpatients with serious complications. If patients are bothNSAID-naı¨ve and H. pylori positive, eradication therapy isrecommended. For patients with a history of ulcers that donot include bleeding who are receiving NSAID therapy, aPPI with or without CXB is recommended, and theadministration of VPZ is suggested for the prevention ofulcer recurrence. For patients with a history of hemorrhagiculcers who are receiving NSAID therapy, CXB with a PPIis recommended. CXB with a PPI is recommended forpatients receiving combined NSAID therapy and LDA.Figure 11 shows the algorithm for the prevention ofLDA-related ulcers. PPIs are recommended for ulcer pre-vention in patients receiving LDA therapy with no ulcerhistory. For patients with a history of ulcers withoutbleeding who are receiving LDA therapy, PPIs or VPZ arerecommended and H2RAs are suggested. A PPI is recom-mended and H2RA is suggested for patients with a historyof hemorrhagic ulcers who are receiving LDA therapy.However, if the patients are H. pylori positive, eradicationJ Gastroenterol (2021) 56:303–322315123',\n",
       " 'therapy is recommended. Finally, for patients receivingcombinations of LDA and NSAID therapy, CXB with aPPI is recommended.Acknowledgements This article was supported by a Grant-in-Aidfrom JSGE. The authors thank the investigators and supporters forparticipating in the studies. The authors express special appreciationto Mr. Yuji Tatsugami and Miss. Ayari Sada (Nankodo) for their helpin creating these guidelines.Author contributions Writing-original draft: TKa, KS, TI, MI, JI,TO, TKan, MS, TC, SN, MM. Writing-review and editing: TKa andKS Supervision: HH, JY, AT, SW, and KK Approval of ﬁnalmanuscript: All authors.Compliance with ethical standardsConﬂict of interest Any ﬁnancial relationship with enterprises,businesses or academic institutions in the subject matter or materialsdiscussed in the manuscript are listed as follows: (1) those fromwhom the authors, the spouse, partner or immediate relatives ofauthors, who have received individually any income, honoraria or anyother types of remuneration: Astellas Pharma Inc., AstraZeneca K.K.,DaiichiSankyo Company, Limited, Eisai Co., Ltd., Otsuka Pharma-ceutical Co.,Ltd., Pﬁzer Japan Inc., Takeda Pharmaceutical CompanyLimited. and (2) those from whom the academic institutions of theFig. 9 Algorithm for the treatment of peptic ulcer disease316J Gastroenterol (2021) 56:303–322123Peptic ulcerComplicationComplication(±)(-)EndoscopicPerforationorBleedinghemostasisstenosisConservativeSuccessFailureSurgerytherapySurgeryIVRSuccessFailureSurgeryMedicaltherapy(b)MedicaltherapyNSAIDs (+)NSAIDs (-)H. pylori (+)H. pylori (-)H. pylori (+)H. pylori (-)WithindicationWithoutindicationRemnantIdiopathicfor H. pylorifor H.pylorigastric ulcerulcerNSAIDs*1DiscontinuanceEradication and anti-Non-eradicationcontinuingofNSAIDsulcertherapytherapyInitial therapy1)PPIorP-CABEradicationEradication2)HRAsuccessfailure3)Selectivemuscarinicreceptor antagonist orsome mucosal defensiveHealed',\n",
       " 'continuingofNSAIDsulcertherapytherapyInitial therapy1)PPIorP-CABEradicationEradication2)HRAsuccessfailure3)Selectivemuscarinicreceptor antagonist orsome mucosal defensiveHealedSecond-linetherapyagentsHealed*2MaintenanceEradicationEradicationHealedUnhealedfailuretherapysuccessHealedMaintenancePPI/H2RAConsult a specialist(third-line therapy)therapy',\n",
       " 'authors received support (commercial/academic cooperation): Aji-nomoto Pharmaceuticals Co., Ltd., AsTellas Pharma Inc., AstraZe-necaK. K., Bayer Yakuhin, Ltd., Chugai PharmaCeutical Co., Ltd.,DaiichiSankyo Company, Limited, Eisai Co., Ltd., KishuhosokawaCo., Ltd., Maruso Co., Ltd, Mitsubishi Tanabe Pharma Corporation,MSD K.K., Nihon Pharmaceutical Co. Ltd., Nippon Shinyaku Co.,Ltd., Okahatanoen Co., Ltd., Otsuka Pharmaceutical Co., Ltd., PﬁzerJapan Inc., SanoﬁK.K., Taiho Pharmaceutical Co., Ltd., TakedaPharmaceutical.Open Access This article is licensed under a Creative CommonsAttribution 4.0 International License, which permits use, sharing,adaptation, distribution and reproduction in any medium or format, aslong as you give appropriate credit to the original author(s) and thesource, provide a link to the Creative Commons licence, and indicateif changes were made. The images or other third party material in thisarticle are included in the article’s Creative Commons licence, unlessindicated otherwise in a credit line to the material. If material is notincluded in the article’s Creative Commons licence and your intendeduse is not permitted by statutory regulation or exceeds the permitteduse, you will need to obtain permission directly from the copyrightholder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Fig. 10 Algorithm for the prevention of NSAID-induced ulcersFig. 11 Algorithm for the prevention of LDA-related ulcersJ Gastroenterol (2021) 56:303–322317123Concomitant useConcomitantuseof LDA(-)ofLDA(+)Ulcer history (-)Ulcer history (+)EradicationofH.pylori(CQ24)inNSAID-naivecasesHemorrhagiculcerHemorrhagic ulcerhistory (-)history (+)(CQ 12) CXBOPPIOCXB+PPIO PPIOCXB+PPI(CQ14)（PPI:elderpatients/seriouscomplications)OVPZ(CQ13)(CQ14)(CQ15)(CQ 17)(CQ16):recommendation,：suggestion)ConcomitantuseConcomitantuseof NSAIDs (-)ofNSAIDs (+)Ulcer/hemorrhagiculcer historyNoYesUlcer history',\n",
       " 'OVPZ(CQ13)(CQ14)(CQ15)(CQ 17)(CQ16):recommendation,：suggestion)ConcomitantuseConcomitantuseof NSAIDs (-)ofNSAIDs (+)Ulcer/hemorrhagiculcer historyNoYesUlcer historyHemorrhagiculcerhistoryEradication in H.pylori-positive casesOPPIOPPI/VPZ,H2RAOPPI,OH2RACXB+PPI(CQ 23)(CQ 22)(CQ 21)(CQ 24)recommendation,O: suggestion)',\n",
       " 'AppendixMembers of the Guidelines Committee who created andevaluated the JSGE ‘‘Evidence-based clinical practiceguidelines for peptic ulcer disease 20200’ are listed below.Executive committeeChair: Kiichi Satoh (Department of Gastroenterology,International University of Health and Welfare Hospital).Vice-Chair: Tomoari Kamada (Department of Health CareMedicine, Kawasaki Medical School). Members: Tosh-iyuki Itoh (Education Center for Medicine and Nursing,Shiga University of Medical Science), Masanori Ito(Department of General Internal Medicine, HiroshimaUniversity Hospital), Junichi Iwamoto (Department ofGastroenterology,TokyoMedicalUniversityIbarakiMedical Center), Tadayoshi Okimoto (Department ofGastroenterology, Faculty of Medicine, Oita University),Takeshi Kanno (Division of Gastroenterology, TohokuUniversity Hospital), Mitsushige Sugimoto (Department ofGastroenterological Endoscopy, Tokyo Medical UniversityHospital), Toshimi Chiba (Division of Internal Medicine,Department of Oral Medicine, Iwate, Medical University),Sachiyo Nomura (Department of Gastrointestinal Surgery,Graduate School of Medicine, The University of Tokyo),andMitsuyoMieda(DivisionofGastroenterology,Department of Medicine, Jichi Medical University).Evaluation committeeChair: Hideyuki Hiraishi (Niigataseirou Hospital).Vice-Chair: Junji Yoshino (Fujita Medical University).Member:AtsushiTakagi(KamedaMorinosatoHospital).The Japanese Society of GastroenterologyPresident: Kazuhiko Koike (Department of Gastroenterol-ogy, Graduate School of Medicine, The University ofTokyo). Past President: Tooru Shimosegawa (South MiyagiMedical Center). Director Responsible: Hiroto Miwa(Division of Gastroenterology, Department of InternalMedicine, Hyogo College of Medicine), Nobuyuki Eno-moto (First Department of Internal Medicine, Faculty ofMedicine, University of Yamanashi).SR collaboratorRyo Ogawa (Department of Gastroenterology, Faculty of',\n",
       " 'moto (First Department of Internal Medicine, Faculty ofMedicine, University of Yamanashi).SR collaboratorRyo Ogawa (Department of Gastroenterology, Faculty ofMedicine, Oita University), Sotaro Ozaka (Department ofGastroenterology, Faculty of Medicine, Oita University),Yoshinari Kawahara (Department of Gastroenterology,Faculty of Medicine, Oita University), Xiaoyi Jin (Divisionof Gastroenterology, Tohoku University Hospital), NaokiSumi (Department of Health Care Medicine, KawasakiMedical School), Kenichiro Nakagawa (Division of Gas-troenterology,TohokuUniversityHospital),KensukeFukuda (Department of Gastroenterology, Faculty ofMedicine, Oita University).Tomoyuki Boda (Department of Gastroenterology andMetabolism, Graduate School of Biomedical and HealthSciences, Hiroshima University), Hitomi Mizuno (ToyodaAoba Clinic), Masaki Murata (Department of Gastroen-terology, National Hospital Organization, Kyoto MedicalCenter), Mohammad Yaghoobi (Division of Gastroen-terology, Health Sciences Centre, McMaster University,Canada), and Yuan Yuhong (Division of Gastroenterology,Health Sciences Centre, McMaster University, Canada).Cooperative societyThe Japanese Gastroenterological Association.Japan Gastroenterological Endoscopy Society.References1. Yoshida M, Kinoshita Y, Watanabe M, et al. JSGE clinicalpractice guideline 2014: standards, methods, and process ofdeveloping guidelines. J Gastroenterol. 2015;50:4–10.2. Fujimoto K, Fujishiro M, Kato M, et al. Guidelines for gas-troenterological endoscopy in patients undergoing antithrom-botic treatment. Dig Endosc. 2014;26:1–14.3. Kato M, Uedo N, Hokimoto S, et al. Guidelines for gastroen-terological endoscopy in patients undergoing antithrombotictreatment: 2017 appendix on anticoagulants including direct oralanticoagulants. Dig Endosc. 2018;30:433–40.4. Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novelpotassium-competitive acid blocker, as a component of ﬁrst-line',\n",
       " 'anticoagulants. Dig Endosc. 2018;30:433–40.4. Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novelpotassium-competitive acid blocker, as a component of ﬁrst-lineand second-line triple therapy for Helicobacter pylori eradica-tion:aphaseIII,randomised,double-blindstudy.Gut.2016;65:1439–46.5. Miwa H, Uedo N, Watari J, et al. Randomised clinical trial:efﬁcacy and safety of vonoprazan vs. lansoprazole in patientswith gastric or duodenal ulcers-results from two phase 3, non-inferiority randomised controlled trials. Aliment PharmacolTher. 2017;45:240–52.6. Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcerrecurrence during long-term NSAID therapy: randomised, lan-soprazole-controlled non-inferiority and single-blind extensionstudy. Gut. 2018;67:1042–51.318J Gastroenterol (2021) 56:303–322123',\n",
       " '7. Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-doseaspirin-associated ulcer recurrence: randomised phase 3 study.Gut. 2018;67:1033–41.8. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-doseaspirin therapy in peptic ulcer bleeding: a randomized trial. AnnIntern Med. 2010;152:1–9.9. Tarasconi A, Baiocchi GL, Pattonieri V, et al. Transcatheterarterial embolization versus surgery for refractory non-varicealupper gastrointestinal bleeding: a meta-analysis. World J EmergSurg. 2019;14:3.10. Kyaw M, Tse Y, Ang D, et al. Embolization versus surgery forpeptic ulcer bleeding after failed endoscopic hemostasis: a meta-analysis. Endos Int Open. 2014;2:E6-14.11. Selby NM, Kubba AK, Hawkey CJ. Acid suppression in pepticulcer haemorrhage: a ‘meta-analysis.’ Aliment Pharmacol Ther.2000;14:1119–26.12. Leontiadis GI, Sharma VK, Howden CW. Systematic reviewand meta-analysis: proton-pump inhibitor treatment for ulcerbleeding reduces transfusion requirements and hospital stay-re-sults from the Cochrane Collaboration. Aliment PharmacolTher. 2005;22:169–74.13. George S, George G, Androniki P, et al. High-dose vs. low-doseproton pump inhibitors post endoscopic hemostasis in patientswith bleeding peptic ulcer: a meta-analysis and meta-regressionanalysis. Turk J Gastroenterol. 2018;29:22–31.14. Jian Z, Li H, Race NS, et al. Is the era of intravenous protonpump inhibitors coming to an end in patients with bleedingpeptic ulcers? Meta-analysis of the published literature. Br JClin Pharmacol. 2016;82:880–9.15. Wang J, Yang K, Ma B, et al. Intravenous pantoprazole as anadjuvant therapy following successful endoscopic treatment forpeptic ulcer bleeding. Can J Gastroenterol. 2009;23:287–99.16. Bhatt DL, Cryer BL, Contant CF, COGENT Investigators, et al.Clopidogrel with or without omeprazole in coronary arterydisease. N Engl J Med. 2010;363:1909–17.17. Ren YH, Zhao M, Chen YD, et al. Omeprazole affects clopi-dogrel efﬁcacy but not ischemic events in patients with acute',\n",
       " 'disease. N Engl J Med. 2010;363:1909–17.17. Ren YH, Zhao M, Chen YD, et al. Omeprazole affects clopi-dogrel efﬁcacy but not ischemic events in patients with acutecoronary syndrome undergoing elective percutaneous coronaryintervention. Chin Med J. 2011;124:856–61.18. Wei P, Zhang YG, Ling L, et al. Effects of the short-termapplication of pantoprazole combined with aspirin and clopi-dogrel in the treatment of acute STEMI. Exp Ther Med.2016;12:2861–4.19. Valgimigli M, Bueno H, Byrne RA, ESC Scientiﬁc DocumentGroup; ESC Committee for Practice Guidelines (CPG); ESCNational Cardiac Societies, et al. 2017 ESC focused update ondual antiplatelet therapy in coronary artery disease developed incollaboration with EACTS: The Task Force for dual antiplatelettherapy in coronary artery disease of the European Society ofCardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–60.20. Ray WA, Chung CP, Murray KT, et al. Association of protonpump inhibitors with reduced risk of warfarin-related seriousuppergastrointestinalbleeding.Gastroenterology.2016;151:1105–12.21. Kato M, Ota H, Okuda M, et al. Guidelines for the managementof Helicobacter pylori infection in Japan: 2016 Revised Edition.Helicobacter. 2019;24:e12597.22. Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degreeand duration of acid suppression are related to Helicobacterpylorieradicationbytripletherapy.Helicobacter.2007;12:317–23.23. Sugimoto M, Yamaoka Y. Role of vonoprazan in HelicobacterpylorieradicationtherapyinJapan.FrontPharmacol.2018;9:1560.24. Malfertheiner P, Megraud F, O’Morain CA, et al. Managementof Helicobacter pylori infection-the Maastricht V/FlorenceConsensus Report. Gut. 2017;66:6–30.25. Murata M, Sugimoto M, Mizuno H, et al. Clarithromycin versusmetronidazole in ﬁrst-line Helicobacter pylori triple eradicationtherapy based on resistance to antimicrobial agents: meta-anal-ysis. J Clin Med. 2020;9:543.',\n",
       " 'metronidazole in ﬁrst-line Helicobacter pylori triple eradicationtherapy based on resistance to antimicrobial agents: meta-anal-ysis. J Clin Med. 2020;9:543.26. Mansour-Ghanaei F, Joukar F, Naghipour MR, et al. Seven-dayquintuple regimen as a rescue therapy for Helicobacter pylorieradication. World J Gastroenterol. 2015;21:661–6.27. Hsu PI, Tsai FW, Kao SS, et al. Ten-day quadruple therapycomprising proton pump inhibitor, bismuth, tetracycline, andlevoﬂoxacin is more effective than standard levoﬂoxacin tripletherapy in the second-line treatment of Helicobacter pyloriinfection: a randomized controlled trial. Am J Gastroenterol.2017;112:1374–81.28. Liou JM, Bair MJ, Chen CC, et al. Levoﬂoxacin sequentialtherapy vs levoﬂoxacin triple therapy in the second-line treat-ment of Helicobacter pylori: a randomized trial. Am J Gas-troenterol. 2016;111:381–7.29. Tsujimae M, Yamashita H, Hashimura H, et al. A comparativestudy of a new class of gastric acid suppressant agent namedvonoparazan versus esomeprazole for the eradication of Heli-cobacter pylori. Digestion. 2016;94:240–6.30. Sakurai K, Suda H, Ido Y, et al. Comparative study: Vonoprazanand proton pump inhibitors in Helicobacter pylori eradicationtherapy. World J Gastroenterol. 2017;23:668–75.31. Sue S, Kuwashima H, Iwata Y, et al. The superiority of vono-prazan-based ﬁrst-line triple therapy with clarithromycin: aprospective multi-center cohort study on Helicobacter pylorieradication. Intern Med. 2017;56:1277–85.32. Murakami K, Furuta T, Ando T, et al. Multi-center randomizedcontrolled study to establish the standard third-line regimen forHelicobacter pylori eradication in Japan. J Gastroenterol.2013;48:1128–35.33. Furuta T, Sugimoto M, Kodaira C, et al. Sitaﬂoxacin-basedthird-line rescue regimens for Helicobacter pylori infection inJapan. J Gastroenterol Hepatol. 2014;29:487–93.34. Mori H, Suzuki H, Matsuzaki J, et al. Efﬁcacy of 10-day sita-ﬂoxacin-containing third-line therapies for Helicobacter pylori',\n",
       " 'Japan. J Gastroenterol Hepatol. 2014;29:487–93.34. Mori H, Suzuki H, Matsuzaki J, et al. Efﬁcacy of 10-day sita-ﬂoxacin-containing third-line therapies for Helicobacter pyloristrainscontainingthegyrAmutation.Helicobacter.2015;21:286–94.35. Di Mario F, Battaglia G, Leandro G, et al. Short-term treatmentof gastric ulcer: a meta-analytical evaluation of blind trials. DigDis Sci. 1996;41:1108–31.36. Eriksson S, Langstrom G, Rikner L, et al. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer,gastric ulcer and reﬂux oesophagitis: a meta-analysis. Eur JGastroenterol Hepatol. 1995;7:467–75.37. Salas M, Ward A, Caro J. Are proton pump inhibitors the ﬁrstchoice for acute treatment of gastric ulcers? A meta-analysis ofrandomized clinical trials. BMC Gastroenterol. 2002;2:17.38. Tunis SR, Sheinhait IA, Schmid CH, et al. Lansoprazole com-pared with histamine 2-receptor antagonists in healing gastriculcers: a meta-analysis. Clin Ther. 1997;19:743–57.39. EchizenH.Theﬁrst-in-classpotassium-competitiveacidblocker, vonoprazan fumarate: pharmacokinetic and pharmaco-dynamic considerations. Clin Pharmacokinet. 2015;55:409–18([Epub ahead of print]).40. Poynard T, Lemaire M, Agostini H. Meta-analysis of random-ized clinical trials comparing lansoprazole with ranitidine orfamotidine in the treatment of acute duodenal ulcer. Eur JGastroenterol Hepatol. 1995;7:661–5.41. Tildesley G, Ehsanullah RS, Wood JR. Ranitidine in the treat-ment of gastric and duodenal ulcers associated with non-ster-oidal anti-inﬂammatory drugs. Br J Rheumatol. 1993;32:474–8.J Gastroenterol (2021) 56:303–322319123',\n",
       " '42. Agrawal NM, Campbell DR, Safdi MA, NSAID-AssociatedGastric Ulcer Study Group, et al. Superiority of lansoprazole vsranitidine in healing nonsteroidal anti-inﬂammatory drug-asso-ciated gastric ulcers: results of a double-blind, randomized,multicenter study. Arch Intern Med. 2000;160:1455–61.43. Hawkey CJ, Karrasch JA, Szczepan˜ski L, Omeprazole vs.MisoprostolforNSAID-inducedUlcerManagement(OMNIUM) Group, et al. Omeprazole compared with miso-prostol for ulcers associated with nonsteroidal antiinﬂammatorydrugs. N Engl J Med. 1998;338:727–34.44. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacterpylori and risk of peptic ulcers in patients starting long-termtreatment with non-steroidal anti-inﬂammatory drugs: a ran-domised trial. Lancet. 2002;359:9–13.45. Vergara M, Catalan M, Gisbert JP, et al. Meta-analysis: role ofHelicobacter pylori eradication in the prevention of peptic ulcerin NSAID users. Aliment Pharmacol Ther. 2005;21:1411–8.46. Tang CL, Ye F, Liu W, et al. Eradication of Helicobacter pyloriinfection reduces the incidence of peptic ulcer disease in patientsusing nonsteroidal anti-inﬂammatory drugs: a meta-analysis.Helicobacter. 2012;17:286–96.47. Koch M. Non-steroidal anti-inﬂammatory drug gastropathy:clinical results with misoprostol. Ital J Gastroenterol Hepatol.1999;31(Suppl 1):S54-62.48. Bianchi Porro G, Lazzaroni M, Petrillo M, et al. Prevention ofgastroduodenal damage with omeprazole in patients receivingcontinuous NSAIDs treatment: a double blind placebo con-trolled study. Ital J Gastroenterol Hepatol. 1998;30:43–7.49. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for theprevention of gastric and duodenal ulcers caused by nonsteroidalantiinﬂammatory drugs. N Engl J Med. 1996;334:1435–9.50. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotec-tant drugs for the prevention and treatment of peptic ulcer dis-ease and its complications: a meta-analysis of randomised trials.Lancet Gastroenterol Hepatol. 2018;3:231–41.',\n",
       " 'tant drugs for the prevention and treatment of peptic ulcer dis-ease and its complications: a meta-analysis of randomised trials.Lancet Gastroenterol Hepatol. 2018;3:231–41.51. Koch M, Deiz A, Tarquini M, et al. Prevention of non-steroidalanti-inﬂammatory drug-induced gastrointestinal mucosal injury:risk factors for serious complications. Digest Liver Dis.2000;32:138–51.52. Sugano K, Kontani T, Katsuo S, et al. Lansoprazole for sec-ondary prevention of gastric or duodenal ulcers associated withlong-term non-steroidal anti-inﬂammatory drug (NSAID) ther-apy: results of a prospective, multicenter, double-blind, ran-domized,double-dummy,active-controlledtrial.J Gastroenterol. 2012;47:540–52.53. Sugano K, Kinoshita Y, Miwa H, Esomeprazole NSAIDPreventive Study Group, et al. Randomised clinical trial:esomeprazole for the prevention of nonsteroidal anti-inﬂam-matory drug-related peptic ulcers in Japanese patients. AlimentPharmacol Ther. 2012;36:115–25.54. Chan FK, Wong VW, Suen BY, et al. Combination of acyclooxygenase-2 inhibitor and a proton-pump inhibitor forprevention of recurrent ulcer bleeding in patients at very highrisk: a double-blind, randomised trial. Lancet. 2007;369:1621–6.55. Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of uppergastrointestinal bleeding from different drug combinations.Gastroenterology. 2014;147:784–92.56. Vonkeman HE, Fernandes RW, van der Palen J, et al. Proton-pump inhibitors are associated with a reduced risk for bleedingand perforated gastroduodenal ulcers attributable to non-ster-oidal anti-inﬂammatory drugs: a nested case-control study.Arthritis Res Ther. 2007;9:R52.57. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versusdiclofenac in long-term management of rheumatoid arthritis:randomizeddouble-blindcomparison.Lancet.1999;354:2106–11.58. Laine L, Harper S, Simon T, et al. A randomized trial comparingthe effect of rofecoxib, a cyclooxygenase 2-speciﬁc inhibitor,',\n",
       " 'randomizeddouble-blindcomparison.Lancet.1999;354:2106–11.58. Laine L, Harper S, Simon T, et al. A randomized trial comparingthe effect of rofecoxib, a cyclooxygenase 2-speciﬁc inhibitor,with that of ibuprofen on the gastroduodenal mucosa of patientswith osteoarthritis: Rofecoxib Osteoarthritis Endoscopy StudyGroup. Gastroenterology. 1999;117:776–83.59. Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effectiveas diclofenac in the management of rheumatoid arthritis with alower incidence of gastroduodenal ulcers: results of a 26-weektrial. Rheumatology. 2003;42:1207–15.60. Sakamoto C, Kawai T, Nakamura S, et al. Comparison of gas-troduodenal ulcer incidence in healthy Japanese subjects takingcelecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. Aliment PharmacolTher. 2013;37:346–54.61. Goldstein JL, Kivitz AJ, Verburg KM, et al. A comparison of theupper gastrointestinal mucosal effects of valdecoxib, naproxenand placebo in healthy elderly subjects. Aliment PharmacolTher. 2003;18:125–32.62. Feng GS, Ma JL, Wong BC, et al. Celecoxib-related gastro-duodenal ulcer and cardiovascular events in a randomized trialforgastriccancerprevention.WorldJGastroenterol.2008;14:4535–9.63. Yuan JQ, Tsoi KK, Yang M, et al. Systematic review withnetwork meta-analysis: comparative effectiveness and safety ofstrategies for preventing NSAID-associated gastrointestinaltoxicity. Aliment Pharmacol Ther. 2016;43:1262–75.64. Liu CP, Chen WC, Lai KH, et al. Esomeprazole alone comparedwith esomeprazole plus aspirin for the treatment of aspirin-re-lated peptic ulcers. Am J Gastroenterol. 2012;107:1022–9.65. Tricco AC, Alateeq A, Tashkandi M, et al. Histamine H2receptor antagonists for decreasing gastrointestinal harms inadults using acetylsalicylic acid: systematic review and meta-analysis. Open Med. 2012;6:e109–17.66. Mo C, Sun G, Lu ML, et al. Proton pump inhibitors in pre-',\n",
       " 'adults using acetylsalicylic acid: systematic review and meta-analysis. Open Med. 2012;6:e109–17.66. Mo C, Sun G, Lu ML, et al. Proton pump inhibitors in pre-vention of low-dose aspirin-associated upper gastrointestinalinjuries. World J Gastroenterol. 2015;21:5382–92.67. Mo C, Sun G, Wang Y, et al. PPI versus histamine H2 receptorantagonists for prevention of upper gastrointestinal injuryassociated with low-dose aspirin: Systematic review and meta-analysis. PLoS ONE. 2015;10:e0131558.68. Chan FK, Kyaw M, Tanigawa T, et al. Similar efﬁcacy ofproton-pump inhibitors vs H2-receptor antagonists in reducingrisk of upper gastrointestinal bleeding or ulcers in high-riskusers of low-dose aspirin. Gastroenterology. 2017;152:105–10.69. Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior topantoprazole in preventing recurrence of aspirin-related pepticulcers or erosions. Gastroenterology. 2010;138:82–8.70. Ng FH, Tunggal P, Chu WM, et al. Esomeprazole comparedwith famotidine in the prevention of upper gastrointestinalbleeding in patients with acute coronary syndrome or myocar-dial infarction. Am J Gastroenterol. 2012;107:389–96.71. Lanas A, Wu P, Medin J, et al. Low doses of acetylsaiicyiic acidincrease risk of gastrointestinal bleeding in a meta-analysis. ClinGastroenterol Hepatol. 2011;9:762–8.72. Yano H, Tsukahara K, Morita S, et al. Inﬂuence of omeprazoleand famotidine on the antiplatelet effects of clopidogrel inaddition to aspirin in patients with acute coronary syndromes: aprospective,randomized,multicenterstudy.CircJ.2012;76:2673–80.73. Wang Z, Yang X, Cai J, et al. Inﬂuence of different proton pumpinhibitors on platelet function in acute myocardial infarctionpatients receiving clopidogrel treatment after percutaneouscoronary intervention. Biomed Res. 2013;24:453–7.74. Tunggal P, Ng FH, Lam KF, et al. Effect of esomeprazole versusfamotidine on platelet inhibition by clopidogrel: a double-blind,randomized trial. Am Heart J. 2011;162:870–4.320',\n",
       " '74. Tunggal P, Ng FH, Lam KF, et al. Effect of esomeprazole versusfamotidine on platelet inhibition by clopidogrel: a double-blind,randomized trial. Am Heart J. 2011;162:870–4.320J Gastroenterol (2021) 56:303–322123',\n",
       " '75. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent uppergastrointestinal bleeding in patients with Helicobacter pyloriinfection who are taking low-dose aspirin or naproxen. N Engl JMed. 2001;344:967–73.76. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the pre-vention of recurrence of ulcer complications from long-termlow-dose aspirin use. N Engl J Med. 2002;346:2033–8.77. Sugano K, Matsumoto Y, Itabashi T, et al. Lansoprazole forsecondary prevention of gastric or duodenal ulcers associatedwith long-term low-dose aspirin therapy: results of a prospec-tive, multicenter, double-blind, randomized, double-dummy,active-controlled trial. J Gastroenterol. 2011;46:724–5.78. Sanuki T, Fujita T, Kutsumi H, Case Study Group, et al.Rabeprazole reduces the recurrence risk of peptic ulcers asso-ciated with low-dose aspirin in patients with cardiovascular orcerebrovascular disease: a prospective randomized active-con-trolled trial. J Gastroenterol. 2012;47:1186–97.79. Iwakiri R, Higuchi K, Kato M, et al. Randomised clinical trial:prevention of recurrence of peptic ulcers by rabeprazole inpatients taking low-dose aspirin. Aliment Pharmacol Ther.2014;40:780–95.80. Sugano K, Choi MG, Lin JT, on behalf of the LAVENDERStudy Group, et al. Multinational, double-blind, randomised,placebo-controlled, prospective study of esomeprazole in theprevention of recurrent peptic ulcer in low-dose acetylsalicylicacid users: the LAVENDER study. Gut. 2014;63:1061–8.81. Taha AS, McCloskey C, Prasad R, et al. Famotidine for theprevention of peptic ulcers and oesophagitis in patients takinglow-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:119–25.82. Takeuchi T, Ota K, Harada S, et al. Comparison of teprenoneand famotidine against gastroduodenal mucosal damage inpatients taking low-dose aspirin. J Gastroenterol Hepatol.2014;29(Suppl. 4):11–5.83. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of',\n",
       " 'and famotidine against gastroduodenal mucosal damage inpatients taking low-dose aspirin. J Gastroenterol Hepatol.2014;29(Suppl. 4):11–5.83. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention ofpeptic ulcers with esomeprazole in patients at risk of ulcerdevelopment treated with low-dose acetylsalicylic acid: a ran-domised, controlled trial (OBERON). Heart. 2011;97:797–802.84. Laine L, Maller ES, Yu C, et al. Ulcer formation with low-doseenteric-coated aspirin and the effect of COX-2 selective inhi-bition:adouble-blindtrial.Gastroenterology.2004;127:395–402.85. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inﬂammatory drugs in patients with risk of car-diovasculareventstakinglow-doseaspirin.Lancet.2007;370:2138–51.86. Goldstein J, Lowry SC, Lanza FL, et al. The impact of low-doseaspirin on endoscopic gastric and duodenal ulcer rates in usersof a non-selective non-steroidal anti-inﬂammatory drug or acyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther.2006;23:1489–98.87. Goldstein JL, Cryer B, Amer F, et al. Celecoxib plus aspirinversus naproxen and lansoprazole plus aspirin: a randomized,double-blind, endoscopic trial. Clin Gastroenterol Hepatol.2007;5:1167–74.88. Chan FKL, Ching JYL, Tse YK, et al. Gastrointestinal safety ofcelecoxib versus naproxen in patients with cardiothromboticdiseases and arthritis after upper gastrointestinal bleeding(CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet. 2017;389:2375–82.89. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascularsafety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl JMed. 2016;375:2519–29.90. Mcgettigan P, Henry D. Cardiovascular risk and inhibition ofcyclooxygenase: a systematic review of the observationalstudies of selective and nonselective inhibitors of cyclooxyge-nase 2. JAMA. 2006;296:1633–44.91. Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention',\n",
       " 'studies of selective and nonselective inhibitors of cyclooxyge-nase 2. JAMA. 2006;296:1633–44.91. Lanza FL, Chan FKL, Quigley EMM. Guidelines for preventionof NSAID-related ulcer complications. Am J Gastroenterol.2009;104:728–38.92. Goldstein JL, Huang B, Amer F, et al. Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inﬂammatory drugs pluslow-dose aspirin: results of a post Hoc subanalysis. Clin Ther.2004;26:1637–43.93. Goldstein JL, Hochberg MC, Fort JG, et al. Clinical trial: theincidence of NSAID-associated endoscopic gastric ulcers inpatients treated with PN 400 (naproxen plus esomeprazolemagnesium) vs. enteric-coated naproxen alone. Aliment Phar-macol Ther. 2010;32:401–13.94. Mcoll KEL, LE- Nujumi AM, Chittajallu RS, et al. A study ofthe pathogenesis of Helicobacter pylori negative chronic duo-denal ulceration. Gut. 1993;34:762–8.95. Kanno T, Iijima K, Abe Y, et al. Helicobacter pylori-negativeand non-steroidal anti-inﬂammatory drugs-negative idiopathicpeptic ulcers show refractoriness and high recurrence incidence:multicenter follow-up study of peptic ulcers in Japan. DigEndosc. 2016;28:556–63.96. Wong GL, Wong VW, Chan Y, et al. High incidence of mor-tality and recurrent bleeding in patients with Helicobacterpylori-negative idiopathic bleeding ulcers. Gastroenterology.2009;137:525–31.97. Wong GLH, Lau LHS, Ching JYL, et al. Prevention of recurrentidiopathic gastroduodenal ulcer bleeding: a double-blind, ran-domised trial. Gut. 2020;69:652–7.98. Janke A, Stasiewicz J, Namiot Z, et al. Treatment of gastricstump ulcer: an open study with ﬁve drugs. Hepatogastroen-terology. 2000;47:1195–8.99. Leivonene MK, Haglund CH, Nordling SFA. Helicobacterpylori infection after partial gastrectomy for peptic ulcer and itsroleinrelapsingdisease.EurJGastroenterolHepatol.1997;9:371–4.100. Lee YT, Sung JJ, Choi CL, et al. Ulcer recurrence after gastricsurgery: is Helicobacter pylori the culprit? Am J Gastroenterol.1998;93:928–31.',\n",
       " 'disease.EurJGastroenterolHepatol.1997;9:371–4.100. Lee YT, Sung JJ, Choi CL, et al. Ulcer recurrence after gastricsurgery: is Helicobacter pylori the culprit? Am J Gastroenterol.1998;93:928–31.101. Huang WH, Wang HH, Wu WW, et al. Helicobacter pyloriinfection in patients with ulcer recurrence after partial gastrec-tomy. Hepatogastroenterology. 2004;51:1551–3.102. Schilling D, Adamek HE, Wilke J, et al. Prevalence and clinicalimportance of Helicobacter pylori infection in patients afterpartial gastric resection for peptic ulcer disease. Z Gastroenterol.1999;37:127–32.103. Rodrı´guez-Sanjua´n JC, Ferna´ndez-Santiago R, Garcı´a RA, et al.Perforated peptic ulcer treated by simple closure and Heli-cobacter pylori eradication. World J Surg. 2005;29:849–52.104. Ng EK, Lam YH, Sung JJ, et al. Eradication of Helicobacterpylori prevents recurrence of ulcer after simple closure ofduodenal ulcer perforation: randomized controlled trial. AnnSurg. 2000;231:153–8.105. Kate V, Ananthakrishnan N, Badrinath S. Effect of Helicobacterpylori eradication on the ulcer recurrence rate after simple clo-sure of perforated duodenal ulcer: retrospective and prospectiverandomized controlled studies. Br J Surg. 2001;88:1054–8.106. Tomtitchong P, Siribumrungwong B, Vilaichone RK, et al.Systematic review and meta-analysis: Helicobacter pylorieradication therapy after simple closure of perforated duodenalulcer. Helicobacter. 2012;17:148–52.107. El-Nakeeb A, Fikry A, Abd El-Hamed TM, et al. Effect ofHelicobacter pylori eradication on ulcer recurrence after simpleclosure of perforated duodenal ulcer. Int J Surg. 2009;7:126–9.108. Force T, MacDonald D, Eade OE, et al. Ischemic gastritis andduodenitis. Dig Dis Sci. 1980;25:307–10.J Gastroenterol (2021) 56:303–322321123',\n",
       " '109. Julka RN, Aduli F, Lamps LW, et al. Ischemic duodenal ulcer,an unusual presentation of sickle cell disease. J Natl Med Assoc.2008;100:339–41.Publisher’s NoteSpringer Nature remains neutral with regard tojurisdictional claims in published maps and institutional afﬁliations.322J Gastroenterol (2021) 56:303–322123',\n",
       " 'www.thelancet.com   Vol 390   August 5, 2017613SeminarPeptic ulcer diseaseAngel Lanas, Francis K L ChanThe rapidly declining prevalence of Helicobacter pylori infection and widespread use of potent anti-secretory drugs means peptic ulcer disease has become substantially less prevalent than it was two decades ago. Management has, however, become more challenging than ever because of the threat of increasing antimicrobial resistance worldwide and widespread use of complex anti-thrombotic therapy in the ageing population. Peptic ulcers not associated with H pylori infection or the use of non-steroidal anti-inflammatory drugs are now also imposing substantial diagnostic and therapeutic challenges. This Seminar aims to provide a balanced overview of the latest advances in the pathogenetic mechanisms of peptic ulcers, guidelines on therapies targeting H pylori infection, approaches to treatment of peptic ulcer complications associated with anti-inflammatory analgesics and anti-thrombotic agents, and the unmet needs in terms of our knowledge and management of this increasingly challenging condition.IntroductionThe term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel’s diverticulum. In this Seminar, the term peptic ulcer disease refers to peptic ulcers located in the stomach or duodenum.1Traditionally, a hypersecretory acidic environment together with dietary factors or stress were thought to cause most peptic ulcer diseases, but the discovery of Helicobacter pylori infection and the widespread use of non-steroidal anti-inflammatory drugs (NSAIDs) in the second half of the 20th century have changed this perception.EpidemiologyLifetime prevalence of peptic ulcer disease in the general population has been estimated to be about 5−10%, and',\n",
       " 'half of the 20th century have changed this perception.EpidemiologyLifetime prevalence of peptic ulcer disease in the general population has been estimated to be about 5−10%, and incidence 0·1–0·3% per year.1–3 However, the prevalence and incidence of peptic ulcer disease is now probably lower than these estimates worldwide, especially in high-income countries, because epidemiological studies have shown a sharp decreasing trend in the incidence, rates of hospital admissions, and mortality associated with the disease in the past 20–30 years.4−9 These decreasing numbers could be due to the introduction of new therapies, or they might be due to a cohort trend that cannot be fully explained by known causes (eg, H pylori infection and NSAID treatment). Many gastrointestinal diseases are characterised by rises and falls in prevalence,4 suggesting that an underlying birth-cohort trend might be present for peptic ulcer disease. Mortality associated with peptic ulcer disease peaked in generations born at the end of the 19th century and fell in those born in the 20th century. Although the decrease noted includes all types of ulcers (H pylori-associated, NSAID-associated, and idiopathic), the overall pattern corresponds to the decreasing prevalence of H pylori infection in the population, in which a birth-cohort effect is also seen in countries with low prevalence of the infection. These observations emphasise the key role of H pylori infection in both the cause and documented temporal variations of peptic ulcer disease.4−7In European countries with different health-care systems and socioeconomic status, between 1921 and 2004, the risk of dying from gastric ulcers preceded that of dying from duodenal ulcers by 10−30 years.5 In Central America, South America, and Asia, a decline in mortality from gastric ulcers and duodenal ulcers has also been recorded, and showed a birth-cohort effect that was similar to that in Europe, with high rates reported in',\n",
       " 'in mortality from gastric ulcers and duodenal ulcers has also been recorded, and showed a birth-cohort effect that was similar to that in Europe, with high rates reported in people born in the late 19th century and a 10−20-year delayed peak mortality for those with duodenal ulcers.6 In Asia, a steady decline in the prevalence of peptic ulcer disease has been reported in different ethnic groups, including Malay, Chinese, and Indian populations, for the past 20 years. This decline paralleled a decrease in H pylori-associated peptic ulcer disease.7Although increased use of NSAIDs or introduction of anti-secretory medications does not seem to explain trends in ulcer-related mortality reported by Sonnenberg,5 other studies8,9 have reported falling hospital admissions for complications of peptic ulcer disease in the 21st century, with an incidence of 79 cases per 100\\u2009000 people per year and less than 30 cases of peptic ulcer disease complications per 100\\u2009000 people per year.8,9 The reduction in peptic ulcer disease complications might be associated with the widespread use of anti-secretory drugs around the world and a more rational use of NSAIDs than before8–10 (appendix p 8). Lancet 2017; 390: 613–24Published OnlineFebruary 24, 2017http://dx.doi.org/10.1016/S0140-6736(16)32404-7Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, CIBEREHD, Zaragoza, Spain (Prof A Lanas MD); and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China (F K L Chan MD)Correspondence to:Prof Angel Lanas, Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, Calle San Juan Bosco 15, Zaragoza 50009, Spainalanas@unizar.es Search strategy and selection criteriaWe searched MEDLINE and Embase (from Jan 1, 2010, to March 31, 2016) using the terms “peptic ulcer” in',\n",
       " '50009, Spainalanas@unizar.es Search strategy and selection criteriaWe searched MEDLINE and Embase (from Jan 1, 2010, to March 31, 2016) using the terms “peptic ulcer” in combination with “clinical trials”, “meta-analysis”, “guideline”, “epidemiology”, “risk factors”, “physiopathology”, “genetics”, or “diagnosis”. We selected publications from the past 6 years, but did not exclude commonly cited references that we regarded as seminal work. Articles or reviews published in the past 15–20 years were also identified, and we selected those publications we judged relevant. We have also cited review articles and book chapters to provide readers with additional references and a more detailed overview than this Seminar.See Online for appendix',\n",
       " 'Seminar614www.thelancet.com   Vol 390   August 5, 2017Pathogenic mechanisms and risk factorsH pylori and the use of NSAIDs or aspirin are the main risk factors of both gastric and duodenal ulcers.1,11−13 However, only a few people with H pylori infection or taking NSAIDs or aspirin develop peptic ulcer disease, suggesting that individual susceptibility to bacterial virulence and drug toxicity is essential to the initiation of mucosal damage.The interaction between bacterial and host factors determines the outcome of H pylori infection. The ability of H pylori strains to produce different proteins has been linked to their virulence and to the host immune response.1 The organism produces urease to create an alkaline environment, which is essential for its survival in the stomach under the mucosal barrier. It also expresses adhesins such as blood group antigen adhesin (BabA) or outer inflammatory protein adhesin (OipA), which facilitate attachment of bacteria to gastric epithelium. A genome pathogenic island encodes the virulent factors CagA and PicB, which—together with other bacterial factors—are thought to interact strongly with host tissue and be linked to gastric mucosal inflammatory cell infiltration and gastric epithelial injury (appendix p 9).14–16 Almost all H pylori strains contain the vacA gene, which encodes a vacuolating cytotoxin, although half the strains do not express the protein. The role of VacA protein in disease pathogenesis is unclear.16 Variations in the vacA gene structure (ie, a combination of signal sequence allelic types [s1a, 1b, and 2] and mid-region allelic types [m1 and m2]) might have functional implications. Most cagA-positive strains carry the vacA-s1 genotypes, whereas almost all cagA-negative strains are classified as vacA s2/m2 strains with low cytokine response and host interaction, which could have clinical consequences.14–18Host interaction and the mucosal inflammatory',\n",
       " 'vacA s2/m2 strains with low cytokine response and host interaction, which could have clinical consequences.14–18Host interaction and the mucosal inflammatory response to H pylori can be determined, at least in part, genetically and define the outcome of peptic ulcer and other acid-related diseases.14 Functional polymorphisms in different cytokine genes have been related to peptic ulcer disease. Interleukin 1β, encoded by IL1B, is a cytokine associated with the inflammatory response to H pylori infection and with inhibition of gastric secretion.19 Polymorphisms of IL1B affect mucosal interleukin 1β production in diverse populations, suggesting that these polymorphisms have a role in the pathogenesis of H pylori-associated gastroduodenal diseases, including peptic ulcer disease.14,20−24 Genes encoding tumour necrosis factor and lymphotoxin-α have also proved to be associated with duodenal ulcers, gastric ulcers, and antral inflammation caused by H pylori infection.25−27 A genome-wide association study and meta-analysis28 identified an association between the locus of Toll-like receptor 1 (TLR1) and H pylori seroprevalence in a white population with European ancestry. Other cytokines have also been linked to the pathogenesis of H pylori-induced diseases, but their role is unclear.14NSAIDs and aspirin are the other major risk factors linked to peptic ulcer disease and its complications. Compared with non-users, NSAID and aspirin use increase the risk of complications of peptic ulcer disease by four times in NSAID users, and by two times in aspirin users.13,29,30 As well as NSAID and aspirin use or H pylori infection, complications are largely driven by comorbidity31 and ageing.32−34 Concomitant use of NSAIDs or aspirin with selective serotonin-reuptake inhibitors, corticosteroids, aldosterone antagonists, or anticoagulants substantially increase the risk of upper gastrointestinal bleeding.33 The role of smoking and poor socioeconomic status is unclear.34',\n",
       " 'aldosterone antagonists, or anticoagulants substantially increase the risk of upper gastrointestinal bleeding.33 The role of smoking and poor socioeconomic status is unclear.34 Studies have shown a link between aspirin use and an increased risk of peptic ulcer disease in patients carrying some specific genetic polymorphisms, but the clinical relevance of these studies also remains to be determined.35−39Many people who habitually take NSAIDs or aspirin have concurrent H pylori infection. The interaction of these two factors in peptic ulcer disease is controversial. Randomised controlled trials have shown that eradication of H pylori is beneficial in patients who start taking NSAIDs but not in those who are on long-term NSAID treatment.40 A meta-analysis13 of observational studies found that uncomplicated peptic ulcer disease was more common in H pylori-positive patients than in H pylori-negative patients (odds ratio [OR] 2·12, 95% CI 1·68−2·67). The interpretation of this meta-analysis was that both H pylori infection and the use of NSAIDs and aspirin independently increase the risk of peptic ulcer disease, and that the disease was uncommon in patients without H pylori infection who do not take NSAIDs or aspirin.13,41,42H pylori-negative, NSAID-negative, and aspirin-negative peptic ulcer disease can be diagnosed in at least a fifth of cases.43 Life-threatening conditions could also induce the disease. For example, soon after the Great East Japan Earthquake in 2011, an unusual increase in cases of H pylori-negative haemorrhagic multiple peptic ulcer disease was recorded.44 Accommodation in a refugee shelter was a strong risk factor for peptic ulcer bleeding after a large-scale disaster.45 A Danish study46 showed that psychological stress was associated with an increased incidence, in part by influencing health risk behaviours, and had similar effects on the disease related or unrelated to either H pylori or NSAIDs. The true prevalence of',\n",
       " 'incidence, in part by influencing health risk behaviours, and had similar effects on the disease related or unrelated to either H pylori or NSAIDs. The true prevalence of idiopathic peptic ulcer disease not related to NSAIDs or H pylori infection is unknown because a molecular investigation of patients with chronic gastritis but negative for H pylori showed that almost half were false negatives.47PathophysiologyHow H pylori induces the development of different types of lesions in the gastroduodenal mucosa is not completely understood. Inflammation associated with H pylori infection can result in either hypochlorhydria or hyperchlorhydria,48 and thus determine the type of peptic ulcer formed. These effects can be mediated by cytokines',\n",
       " 'Seminarwww.thelancet.com   Vol 390   August 5, 2017615that inhibit parietal cell secretion,49 or directly by H pylori products on the H+/K+ ATPase α-subunit, activation of calcitonin-gene related peptide (CGRP) sensory neurons linked to somatostatin, or inhibition of gastrin.50 Pangastritis is associated with hyposecretion and linked to the formation of gastric ulcers. However, 10–15% of patients with H pylori infection have antral predominant gastritis associated with duodenal ulcers and increased gastric secretion derived from hyper\\xadgastrinaemia and reduced antral somatostatin content.51 Inhibition of somatostatin and the subsequent stimulation of gastrin increases histamine secretion from enterochromaffin-like cells, leading to increased secretion of acid or pepsin from parietal and gastric chief cells. The importance of the interaction between somatostatin and gastrin in this process seems clear, because the number of D-cells and somatostatin levels are reduced, whereas G:D cell ratios and gastrin:somatostatin ratios are increased, in the antral tissue of patients with duodenal ulcers. Conversely, eradication of H pylori is followed by an increase in somatostatin mRNA expression and a concomitant decrease in gastrin mRNA expression in patients with duodenal ulcers.52 Gastric hypersecretion in antral-predominant gastritis and inadequate feedback inhibition might be associated with an acidic environment and the development of gastric metaplasia in the duodenal bulb, which might be colonised by and favour ulcer formation in the bulb15 (appendix p 10). NSAIDs damage the gastroduodenal mucosa through both systemic and local mechanisms, but the systemic inhibition of constitutively expressed cyclooxygenase 1 (COX-1)-derived prostaglandins is regarded as the main mechanism. Reduced mucosal prostaglandin values are associated with low mucus and bicarbonate secretion, inhibition of cell proliferation, and decreased mucosal',\n",
       " 'mechanism. Reduced mucosal prostaglandin values are associated with low mucus and bicarbonate secretion, inhibition of cell proliferation, and decreased mucosal blood flow, which are essential to maintenance of mucosal integrity. The COX hypothesis is supported by studies showing that coadministration of exogenous prostaglandins reduces mucosal damage.53 COX-2-selective NSAIDs, which spare COX-1, reduce the risk of ulcers.54 However, this hypothesis does not fully explain the spectrum of mucosal damage. People taking NSAIDs could have a profound decrease in mucosal prostaglandins without necessarily developing gastric lesions.55−58 NSAIDs have different physicochemical properties and a wide range of pKa values, which account for some differences in their toxicity and extent of topical damage.55 NSAIDs initiate mucosal damage in the cell through disruption of mucus phospholipids or the cell membrane and by uncoupling of mitochondrial oxidative phosphorylation. The loss of mucosal integrity is followed by tissue reaction amplified by luminal content such as acid, pepsin, food, bile, and H pylori.57−59 Therefore, COX-derived prostaglandin inhibition, vascular damage, and topical effects are the main players in the pathogenesis of ulcers caused by NSAIDs (appendix p 11).Low-dose aspirin can also induce mucosal damage in patients through both topical and systemic mechanisms, although direct evidence of the systemic effect is weak.60,61 Once the damage has been induced, prostaglandins derived from both constitutively expressed COX-1 and inducible COX-2 enzymes seem to have a central role in mucosal repair, since non-selective and COX-2-selective NSAIDs have been shown to delay healing of peptic ulcers.57,62The pathogenic mechanisms behind the development of idiopathic peptic ulcers are largely unknown. An imbalance between mucosal defensive mechanisms and aggressive factors, including a gastric acid hypersecretory status, is',\n",
       " 'idiopathic peptic ulcers are largely unknown. An imbalance between mucosal defensive mechanisms and aggressive factors, including a gastric acid hypersecretory status, is believed to exist. However, most gastric secretion studies were done in the pre-H pylori era, and we now know that most of the alterations were secondary to the effect of H pylori infection. Other possible pathogenetic factors include ischaemia, drugs, metabolic disturbances, viruses, histamine, radiotherapy, basophilia, and eosinophilic infiltration.63Clinical presentation and diagnosisSymptoms of peptic ulcer disease have limited predictive value because they are non-specific. Patients with duodenal ulcers typically feel hungry or have nocturnal abdominal pain. By contrast, patients with gastric ulcers have postprandial abdominal pain, nausea, vomiting, and weight loss. Patients with untreated peptic ulcer disease typically have relapsing symptoms because of spontaneous healing and relapse while the causal factor (eg, H pylori infection or NSAID use) persists. Elderly patients with peptic ulcer disease are frequently asymptomatic or have only mild symptoms.Bleeding, perforation, or gastric outlet obstruction are the main complications of peptic ulcer disease. Bleeding, which manifests as melena or haematemesis, can occur without any warning symptoms in almost half of patients.64 Hospital admissions for peptic ulcer bleeding have declined steadily worldwide, but the case fatality rate remains stable at 5−10%.8,9 Perforation typically presents with sudden onset of intense pain in the upper abdomen. Dependent on age and comorbidity, mortality can be as high as 20%.Endoscopy is the gold standard for diagnosis of peptic ulcer disease. Apart from exclusion of malignant disease, detection of H pylori infection with histology or rapid urease tests is essential to the subsequent treatment plan. Since H pylori is the cause of most types of peptic',\n",
       " 'detection of H pylori infection with histology or rapid urease tests is essential to the subsequent treatment plan. Since H pylori is the cause of most types of peptic ulcer disease, a test-and-treat strategy with a non-invasive test (eg, urea breath and stool antigen tests) to exclude infection has been advocated in patients younger than 50−55 years (dependent on geographical areas) who present with non-investigated dyspepsia and no alarming symptoms in geographical regions where gastric cancer is uncommon and the prevalence of H pylori infection is greater than 20%.65 In older patients, upper gastrointestinal endoscopy is the recommended test to exclude or confirm the disease.',\n",
       " 'Seminar616www.thelancet.com   Vol 390   August 5, 2017ManagementPrevention of ulcer recurrence is the most important long-term goal to reduce morbidity and mortality. The appendix (p 12) provides an overview of the management of peptic ulcer disease. Mounting evidence suggests that eradication of H pylori infection alone is sufficient to heal associated peptic ulcers and to prevent relapse and recurrent bleeding in the absence of maintenance acid suppressive therapy. However, successful treatment of H pylori infection is a global challenge because of the growing prevalence of antibiotic resistance. The standard first-line therapies used to be regimens, consisting of a proton-pump inhibitor (PPI) and two antibiotics, such as clarithromycin plus amoxicillin or metronidazole given for 7−14 days (termed PPI-based triple therapy).35,66−68 With increasing prevalence of antibiotic resistance, however, the effectiveness of H pylori eradication with this regimen has fallen from more than 90% two decades ago to less than 70% now in many countries.67,68 Ideally, treatment should be based on antimicrobial susceptibility tests. Since these tests are not widely available, the choice of first-line therapies should be based on local prevalence of antibiotic resistance.67−69 If susceptibility testing is not feasible, PPI-based triple therapy regimens containing clarithromycin should be abandoned in areas where the local clarithromycin resistance rate is more than 15%.67−69In areas with low resistance to clarithromycin or when individual susceptibility to clarithromycin has been confirmed, PPI-clarithromycin-amoxicillin or PPI-clarithromycin-metronidazole regimens can be used. The rate of eradication can be increased with the use of high-dose PPI (twice the conventional dose) and by extending the duration of triple therapy from 7 days to a maximum of 14 days.40,68−73 The recommended standard first-line therapy is either a bismuth-containing quadruple therapy',\n",
       " 'the duration of triple therapy from 7 days to a maximum of 14 days.40,68−73 The recommended standard first-line therapy is either a bismuth-containing quadruple therapy for 14 days (PPI, a bismuth salt, tetracycline, and metronidazole) or a non-bismuth-based quadruple concomitant therapy (PPI, clarithromycin, amoxicillin, and metronidazole) for 14 days; both regimens have an eradication rate of more than 90% (table 1).67,68,70,74,75Sequential therapy is another form of quadruple therapy, which consists of a 5-day dual therapy with a PPI and amoxicillin followed by a 5-day triple therapy with a PPI, clarithromycin, and tinidazole or metronidazole. Overall, the eradication rate of sequential therapy is better than that of 7-day and 10-day triple therapy regimens but not better than the eradication rate of 14-day triple therapy, bismuth-based therapy, and non-bismuth-based concomitant therapy,76,77 and this treatment is not recommended (figure 1).40,67,68 Hybrid quadruple therapies combine 10−14 days of dual therapy with PPI and amoxicillin with 7 days of treatment with clarithromycin and metronidazole. Hybrid quadruple therapy has shown similar effectiveness to quadruple concomitant or sequential quadruple therapy, and is more effective in non-Italian populations than in other populations studied.78,79 In a Japanese cohort,80 vonoprazan, a potent, novel, potassium-competitive acid blocker, combined with amoxicillin and clarithromycin or metronidazole as a first-line or second-line treatment, achieved an eradication rate of more than 90% in patients with a history of peptic ulcer disease.For rescue therapy, levofloxacin-containing triple therapy (PPI, levofloxacin, and amoxicillin) achieves eradication rates of 74–81% as a second-line therapy in areas with low (<10%) quinolone resistance.40,67,68,81 However, a rapid increase in primary quinolone resistance to H pylori reduces the effectiveness of levofloxacin-',\n",
       " 'areas with low (<10%) quinolone resistance.40,67,68,81 However, a rapid increase in primary quinolone resistance to H pylori reduces the effectiveness of levofloxacin-containing therapy.81–83 A bismuth-containing quadruple therapy is an effective second-line therapy after failure of standard triple therapies, with eradication rates of 77–93%. This regimen is recommended after failure of other non-bismuth-containing quadruple therapies.67,68 The addition of bismuth to a levofloxacin-containing triple regimen means that a triple-therapy regimen becomes a quadruple-therapy regimen.68,84 All these strategies are now recommended to be used for 14 days.67,68 Susceptibility testing is strongly recommended after one treatment is unsuccessful (if an endoscopy is done and a non-bismuth-based therapy is considered) or after two consecutive treatment failures.68 When culture of H pylori is not available, or when at least three recommended options have been unsuccessful, rifabutin-based triple therapy Drug combinationsRegimen Recommended durationTriple therapyPPI plus amoxicillin* plus clarithromycinDouble dose† of PPI every 12 h1000 mg amoxicillin every 12 h500 mg clarithromycin every 12 h14 daysQuadruple non-bismuth-based concomitant therapyPPI plus amoxicillin plus clarithromycin plus metronidazoleStandard dose of PPI every 12 h1000 mg amoxicillin every 12 h500 mg clarithromycin every 12 h500 mg metronidazole every 12 h14 daysBismuth-based quadruple therapyPPI plus bismuth subcitrate plus tetracycline plus metronidazoleStandard dose of PPI every 12 h120 mg bismuth subcitrate every 6 h500 mg tetracycline every 6 h500 mg metronidazole every 8 h14 daysFluoroquinolone-based triple therapy‡PPI plus amoxicillin plus levofloxacin with or without bismuthStandard dose of PPI every 12 h1000 mg amoxicillin every 12 h500 mg levofloxacin every 24 h240 mg bismuth every 12 h14 daysRifabutin-based triple therapy§PPI plus amoxicillin plus rifabutin',\n",
       " 'Standard dose of PPI every 12 h1000 mg amoxicillin every 12 h500 mg levofloxacin every 24 h240 mg bismuth every 12 h14 daysRifabutin-based triple therapy§PPI plus amoxicillin plus rifabutinStandard dose of PPI every 12 h1000 mg amoxicillin every 12 h150 mg rifabutin every 12 h10 daysOther regimens used in the treatment of Helicobacter pylori combine different antibiotics with similar results (eg, triple therapy could combine a proton pump inhibitor [PPI] plus amoxicillin plus metronidazole or PPI plus metronidazole plus clarithromycin). Sequential quadruple therapy consists of a 5-day dual therapy with a PPI and amoxicillin followed by a 5-day triple therapy with a PPI plus clarithromycin plus tinidazole or metronidazole. Hybrid quadruple therapies combine 10–14 days of dual therapy with PPI and amoxicillin with 7 days of treatment with clarithromycin and metronidazole at the end (or start, for reverse therapy). *Use metronidazole if patients have penicillin allergy. †Double doses: omeprazole 40 mg, lansoprazole 60 mg, rabeprazole 40 mg, esomeprazole 40 mg. ‡Used as rescue regimen; bismuth-based therapy can be added to these drugs (for fluoroquinolone-based quadruple therapy). §To be used when at least three recommended options have failed and if H pylori susceptibility testing is not available.Table 1: Most frequent regimens recommended for treatment of Helicobacter pylori infection in peptic ulcer disease67,68',\n",
       " 'Seminarwww.thelancet.com   Vol 390   August 5, 2017617(PPI, rifabutin, and amoxicillin) for 10 days is an effective rescue option, with eradication rates of 66–70%.85,86 In patients with penicillin allergy, a bismuth-based quadruple therapy is recommended as first-line treatment, and a fluoroquinolone-based regimen can be used as a rescue option. In areas of low (<15%) clarithromycin resistance, a PPI-clarithromycin-metronidazole combination could be prescribed as a first-line treatment (figure 1; table 1).67,68There is growing interest in the use of probiotics as an adjuvant therapy to increase H pylori eradication rates and reduce antibiotic-related adverse events, although further studies are needed.67,68 A randomised phase 3 trial87 of an oral recombinant H pylori vaccine recruited more than 4400 children in China who had no current or past H pylori infection. The investigators reported a vaccine efficacy of 71·8% in 3 years.87NSAIDs and aspirin are the most important cause of peptic ulcer disease in high-income countries where the prevalence of H pylori is declining.1 Since H pylori-associated ulcers cannot be differentiated from NSAID-associated ulcers, testing and treating of H pylori is recommended. More than 85% of NSAID-associated or aspirin-associated ulcers heal with 6−8 weeks of PPI therapy, provided that NSAIDs or aspirin are discontinued. Ulcer healing can be achieved, but it is delayed if patients continue to use NSAIDs.Co-therapy with an antisecretory agent is a recommended preventive strategy for patients at risk of NSAID-associated or aspirin-associated peptic ulcer disease. In a randomised placebo-controlled trial,88 a histamine H₂ receptor antagonist was effective in prevention of ulcers in average-risk aspirin users. Whether PPI is better than an H₂ receptor antagonist for aspirin users has yielded conflicting results. One randomised trial89 found that famotidine was inferior to',\n",
       " 'Whether PPI is better than an H₂ receptor antagonist for aspirin users has yielded conflicting results. One randomised trial89 found that famotidine was inferior to pantoprazole for prevention of upper gastrointestinal bleeding or severe dyspepsia. By contrast, a multicentre randomised trial90 found that, among high-risk aspirin users, rates of recurrent bleeding were similar between the groups receiving PPI and standard-dose H₂ receptor antagonist. PPIs are clearly effective for the prevention of ulcer bleeding with aspirin. However, famotidine might be a reasonable alternative for patients who do not comply with or want to be on PPIs in the long term.The role of H pylori infection in aspirin users with ulcer bleeding deserves further investigation. In a 7-year prospective cohort study91 of aspirin users presenting with ulcer bleeding, one cohort of H pylori-positive patients resumed aspirin without gastroprotective therapy after eradication of H pylori was confirmed. The cumulative incidence of recurrent ulcer bleeding in these patients did not differ substantially from that of average-risk aspirin users with no history of ulcers.91 This finding suggests that eradication of H pylori is associated with a low risk of recurrent ulcer bleeding with aspirin use even in the absence of gastroprotective therapy.Among NSAID users, many strategies are available for the prevention of gastroduodenal ulcers and their Peptic ulcer associated with Helicobacter pylori infectionFirst-line therapiesRescue therapiesPenicillin allergy?YesNoBismuth plus PPI plustetracycline plusmetronidazole (14 days)PPI plus clarithromycin pluslevoﬂoxacin with orwithout bismuth (14 days)Bismuth plus PPI plustetracycline plusmetronidazole (14 days)Culture susceptibility testingIf not available: rifabutin plus PPI plus amoxicillin for 10 days, after failure of three recommended optionsPPI plus amoxicillin pluslevoﬂoxacin with orwithout bismuth (14 days)PPI plus amoxicillin plus',\n",
       " 'PPI plus amoxicillin pluslevoﬂoxacin with orwithout bismuth (14 days)PPI plus amoxicillin plusclarithromycin plusmetronidazole (14 days)Double-dose PPI plusmetronidazole plusclarithromycin (14 days)Double-dose PPI plusamoxicillin plusclarithromycin (14 days)If clarithromycin resistance <15%If clarithromycin resistance <15%Bismuth plus PPI plustetracycline plusmetronidazole (14 days)*PPI plus amoxicillin plusclarithromycin plusmetronidazole (14 days)Figure 1: Algorithm for management of Helicobacter pylori in peptic ulcer diseasePPI=proton pump inhibitor. *Preferred option in areas with high resistance to clarithromycin and metronidazole.',\n",
       " 'Seminar618www.thelancet.com   Vol 390   August 5, 2017complications. These strategies include co-therapy of NSAIDs with a PPI, H₂ receptor antagonist, or misoprostol; substitution of non-selective NSAIDs with COX-2-selective NSAIDs; or combination of a COX-2-selective NSAID with a gastroprotective agent.92−94 PPIs are the most popular prophylactic agents. A systematic review and meta-analysis95 consisting of more than 125\\u2009000 participants found that combination of COX-2-selective NSAIDs and a PPI offers the best protection against peptic ulcer complications. This combination was followed in effectiveness by COX-2-selective NSAIDs alone, non-selective NSAIDs plus a PPI, and non-selective NSAIDs plus misoprostol.95 Unlike low-dose aspirin, no evidence exists that H₂ receptor antagonists can prevent ulcer bleeding associated with NSAIDs. Another meta-analysis96 found that standard doses of H₂ receptor antagonists cannot reduce the risk of gastric ulcers. Although misoprostol effectively prevents peptic ulcer complications with NSAIDs, gastrointestinal upset and abortifacient actions limit the use of misoprostol for gastric protection. The gastroprotective effect of PPIs seems a class effect97 and is not dose-dependent.Patients taking NSAIDs often use aspirin, non-aspirin antiplatelet drugs, anticoagulants, and corticosteroids. Although concomitant aspirin use reduces the gastrointestinal-sparing effect of COX-2 inhibitors,92,96 indirect evidence suggests that patients taking COX-2 inhibitors and aspirin might have fewer peptic ulcer complications than do those taking non-selective NSAIDs and aspirin. In a meta-analysis96 of 17\\u2009276 patients, the risk of clinically significant outcomes was lower in the group receiving aspirin plus a COX-2-selective NSAID than in the group receiving aspirin plus a non-selective NSAID (relative risk 0·72, 95% CI 0·62–0·95). A similar conclusion has been reached in another meta-analysis.98 These data, however, were',\n",
       " 'a non-selective NSAID (relative risk 0·72, 95% CI 0·62–0·95). A similar conclusion has been reached in another meta-analysis.98 These data, however, were derived from a post-hoc analysis.96,98 Table 2 summarises the management of peptic ulcer disease prevention with NSAIDs, which requires assessment of both gastrointestinal and cardiovascular risk factors, since NSAIDs might also increase the risk of major cardiovascular events.54,92−94Notably, NSAIDs and aspirin can cause lower gastrointestinal bleeding and acid suppression cannot prevent mucosal damage beyond the duodenum. Two large-scale randomised trials99,100 that used a combined endpoint of upper and lower gastrointestinal events showed that celecoxib was more effective than a non-selective NSAID plus a PPI. The advantage of celecoxib over non-selective NSAIDs plus a PPI is attributable to a substantial reduction in anaemia secondary to presumed small bowel bleeding. However, different non-selective NSAIDs vary in their tendency to cause lower gastrointestinal bleeding, and data suggest that PPIs could aggravate NSAID-induced small bowel injury through dysbiosis.101 Whether the superiority of celecoxib in the lower gastrointestinal tract recorded in these two large-scale trials can be extrapolated to other non-selective NSAIDs remains unclear.Most cases of peptic ulcer disease heal after 6−8 weeks of PPI therapy. If ulcers fail to heal, drug compliance should be checked. Blood tests and a carefully taken patient history can often reveal continuous or surreptitious use of NSAIDs, which is often overlooked in patients with refractory ulcers.102 Doubling of PPI dose for another 6–8 weeks is often recommended, although no reliable evidence proves that this strategy is better than standard-dose PPI in this setting. Serological tests could be useful to detect false-negative H pylori infection. After exclusion of surreptitious use of NSAIDs or aspirin, or false-negative H pylori status,',\n",
       " 'setting. Serological tests could be useful to detect false-negative H pylori infection. After exclusion of surreptitious use of NSAIDs or aspirin, or false-negative H pylori status, unusual causes of peptic ulcer should be explored, examples of which include malignancies, infections (eg, cytomegalovirus), Crohn’s disease, vasculitis, upper abdominal radiotherapy, crack cocaine use, and Zollinger-Ellison syndrome, which is associated with high acid secretion and often causes the development of multiple ulcers extending to the distal duodenum.With the declining prevalence of H pylori infection, patients with idiopathic ulcers are increasingly being recognised, and these patients could be at increased risk of recurrence, bleeding complications, and death.103,104 Although long-term PPI therapy is often recommended, no evidence is available that this approach will improve clinical outcomes.105Management of peptic ulcer bleedingBleeding peptic ulcers account for 40−60% of all causes of acute upper gastrointestinal bleeding.8 Timely endoscopic treatment and acid suppressive therapy are key for successful outcomes. Although surgery is the cornerstone for management of patients with uncontrolled or massive recurrent bleeding, radiological intervention has also gained importance in recent years.Patients presenting with upper gastrointestinal bleeding should be assessed promptly and resuscitation should begin with crystalloid solutions. Transfusion policy should be restrictive and aimed to maintain haemoglobin concentrations over 70 g/L, as this approach Low gastrointestinal risk*High gastrointestinal risk†Low cardiovascular riskNon-selective NSAIDsNon-selective NSAIDs plus PPI; celecoxib plus PPI‡; eradicate Helicobacter pylori§High cardiovascular risk¶Naproxen; add PPI if patient is taking aspirinNo NSAIDs; naproxen plus PPI; low-dose celecoxib plus aspirin plus PPI might be an alternative option',\n",
       " 'High cardiovascular risk¶Naproxen; add PPI if patient is taking aspirinNo NSAIDs; naproxen plus PPI; low-dose celecoxib plus aspirin plus PPI might be an alternative optionPrevention of peptic ulcer disease and associated complications in patients on non-steroidal anti-inflammatory drug (NSAID) treatment requires assessment of the presence of both gastrointestinal and cardiovascular risk factors.92–94 PPI=proton pump inhibitor. *No risk factors. †Presence of risk factors (patients aged 60 years or older, with a history of ulcers, or patients on concomitant medication with antiplatelet agents, anticoagulants, corticosteroids, or selective serotonin reuptake inhibitors). ‡Especially indicated in patients with a complicated ulcer history or the presence of several risk factors. §In patients with a history of ulcers, adopt a test-and-treat strategy with the use of non-invasive tests (urea breath and stool antigen tests) to exclude H pylori infection, although invasive tests with endoscopy are also possible. ¶Use risk charts (eg, Framingham risk scores or the European SCORE system) to estimate cardiovascular risk on the basis of several variables. Patients with a history of cardiovascular events or diabetes are considered at high cardiovascular risk. In most cases, aspirin co-therapy might be indicated. Cyclooxygenase 2 (COX-2)-selctive NSAIDs are contraindicated by the European Medicines Agency (EMA) in patients with a history of cardiovascular events.Table 2: Management of peptic ulcer disease prevention in patients on NSAIDs',\n",
       " 'Seminarwww.thelancet.com   Vol 390   August 5, 2017619has been associated with reduced mortality.106 Risk stratification should identify high-risk patients for early intervention and reduce the duration of hospital stay for low-risk patients. The Rockall and Glasgow-Blatchford scores have been extensively studied. A Glasgow-Blatchford score of zero accurately identifies patients not requiring treatment in hospital.107Maintenance of a neutral gastric pH seems essential to prevent platelet disaggregation and clot lysis over the eroded artery of a bleeding peptic ulcer. Peak acid suppression after intravenous administration of a PPI occurs within hours, compared with several days later after oral administration. The intravenous route of administration offers a faster onset of gastric suppression, achievement of intragastric pH closer to neutrality, and better bioavailability than the oral route.108 A meta-analysis109 of randomised controlled trials showed that pre-emptive intravenous high-dose PPIs led to a decreased proportion of patients with high-risk endoscopic stigmata and reduced the need for endoscopic haemostatic treatment, but intravenous administration of PPIs should not substitute or delay early endoscopy for high-risk patients. Tranexamic acid and antifibrinolytic agents do not seem to be effective in this setting.110 Prokinetic agents, such as intravenous erythromycin and metoclopramide, given before endoscopy have improved endoscopic view and reduce the need for a second look endoscopy111 (panel).Early endoscopy done within 24 h provides prognostic information based on endoscopic stigmata and effective therapy. In a meta-analysis112 of randomised controlled trials, endoscopic treatment was shown to reduce rebleeding, surgery, and mortality. Endoscopy also identifies low-risk patients suitable for early hospital discharge. Endoscopic treatment is indicated in ulcers showing active bleeding, a non-bleeding visible vessel, or',\n",
       " 'identifies low-risk patients suitable for early hospital discharge. Endoscopic treatment is indicated in ulcers showing active bleeding, a non-bleeding visible vessel, or an adherent clot. Two meta-analyses113,114 of randomised controlled trials have shown that addition of a second modality to epinephrine injection is better than epinephrine injection alone in reducing recurrent bleeding, surgery, and mortality.Acid suppression has a crucial role in prevention of recurrent bleeding after initial endoscopic haemostasis. In a systematic review of 24 trials,110 PPI therapy reduced recurrent bleeding and need for surgery. A substantial reduction in mortality was also noted in a subgroup of patients with active bleeding or non-bleeding visible vessels. The optimum dose of a PPI after endoscopy continues to be controversial. A meta-analysis115 of randomised controlled trials found that high-dose PPIs and low-dose PPIs were similarly effective in reducing the risk of recurrent ulcer bleeding. High-dose PPIs were defined as a dose equivalent to an 80 mg bolus of omeprazole or pantoprazole, followed by continuous intravenous infusion of the drug at 8 mg/h for 72 h. Continuous-infusion doses exceeding 192 mg per day were also considered high-dose PPIs. Other doses were considered low-dose PPIs. However, this meta-analysis included trials with suboptimum design, such as ulcers with low-risk endoscopic stigmata. Another meta-analysis,116 which was largely based on trials done in Asia, found that intermittent high-dose PPI therapy was not less effective than continuous infusion of a PPI in patients with Panel: Strategies for management of bleeding peptic ulcers Before endoscopyRisk stratiﬁcationGlasgow-Blatchford scores are superior to Rockall scores in prediction of endoscopic treatment and surgery. A Glasgow-Blatchford score of zero reliably predicts early discharge without intervention.Restrictive blood transfusion strategy',\n",
       " 'treatment and surgery. A Glasgow-Blatchford score of zero reliably predicts early discharge without intervention.Restrictive blood transfusion strategyBlood transfusion when haemoglobin values are below 70 g/L leads to less rebleeding and better survival than does liberal transfusion.Correction of anticoagulation with a target INR of about 1·5The optimum INR remains undefined, and recommendations are based on expert opinion only.Use of prokinetic drugsProkinetic drugs lead to improved endoscopic view, and reduce the need for second look endoscopy.Pre-emptive PPIsPre-emptive PPIs reduce the presence of high-risk stigmata at endoscopy, and reduce the need for endoscopic therapy. Endoscopic treatmentAddition of a second modality to epinephrine injection reduces recurrent bleeding and need for surgery.Endoscopy within 24 h There is no clear evidence that immediate endoscopy offers advantages over endoscopy done within 24 h. Combination therapyPPIs reduce rebleeding and the need for surgery.After endoscopyMantain or initiate (if not started before endoscopy) PPI therapy.Adjuvant PPI therapyTreatment with high-dose parenteral PPI indicated if high-risk peptic ulcer stigmata present. Oral PPI given if patients had no high-risk peptic ulcer stigmata.High-dose PPI infusion for 72 hIntermittent high-dose PPI therapy seems similar to continuous high-dose PPI infusion.Recurrent bleeding Further endoscopic treatment versus early surgeryOne randomised controlled trial showed a higher rate of complications in the group that underwent surgery than in the group that received repeat endoscopy. High mortality was recorded in both groups. Shock and an ulcer size with a diameter greater than 2 cm was predictive of endoscopic treatment failure.Angiographic embolisationRetrospective studies suggested a higher rebleeding rate in the angiography group than in the surgery group, but no difference in mortality.INR=international normalised ratio. PPI=proton pump inhibitor.',\n",
       " 'Seminar620www.thelancet.com   Vol 390   August 5, 2017high-risk stigmata. Unlike Asian populations, most North American and European populations carry genetic polymorphisms associated with rapid metabolism of PPIs.117 Therefore, whether intermittent high-dose PPI is as effective as continuous high-dose PPI infusion in all high-income populations remains uncertain. Continuous high-dose PPI infusion is still the preferred post-endoscopic adjuvant treatment for high-risk patients (panel).Uncontrolled or recurrent bleeding is the most important adverse prognostic factor predicting mortality. In a randomised study118 comparing endoscopic retreatment with surgery after an initial endoscopy, large ulcers and hypotension were predictive of failure to repeat endoscopic treatment. Early surgery or angiographic embolisation are potential alternative options for these high-risk patients110,118 (panel).Management of patients on antiplatelet or anti-thrombotic therapy complicated by upper gastrointestinal bleeding is difficult because the data are scanty. Decisions often need to be tailored to individual patients on the basis of the severity of bleeding and risk of thromboembolism. In aspirin users with peptic ulcers complicated by bleeding and requiring endoscopic treatment, a randomised controlled trial showed that those who continued to take aspirin had a two-times increased risk of recurrent bleeding but a ten-times reduced risk of all-cause mortality at 8 weeks compared with those who discontinued aspirin.119 Patients receiving dual antiplatelet therapy for a drug-eluting stent should avoid stopping both antiplatelet drugs even for a brief period, because of the high risk of stent thrombosis.120,121Patients receiving warfarin complicated by severe gastrointestinal bleeding resulting from coagulopathy can be treated with vitamin K, fresh frozen plasma, prothrombin complex concentrates, or recombinant',\n",
       " 'gastrointestinal bleeding resulting from coagulopathy can be treated with vitamin K, fresh frozen plasma, prothrombin complex concentrates, or recombinant factor VIIa. Fresh frozen plasma could precipitate fluid overload. High-dose vitamin K should be avoided because it will extend the time required for re-warfarinisation, thereby increasing the risk of thromboembolism. Prothrombin complex concentrates are preferred in patients with severe bleeding. Recombinant factor VIIa should be reserved for uncontrolled life-threatening bleeding because it increases the risk of thrombosis. The use of direct oral anticoagulants (DOACs) has gained popularity. A meta-analysis122 of randomised trials showed that DOACs are more effective than warfarin in reducing thromboembolic risk. However, some DOACs have been associated with a higher risk of major gastrointestinal bleeding than warfarin.122 Unlike bleeding induced by warfarin, that induced by DOACs cannot be reversed by vitamin K. Activated charcoal given within 4 h of ingestion can be used to treat toxicity resulting from DOAC overdose. The value of prothrombin complex concentrate or recombinant factor\\xa0VIIa for massive bleeding associated with DOACs remains uncertain. Haemodialysis can be used for life-threatening bleeding with dabigatran but not for other DOACs. Idarucizumab has been approved by the For more on idarucizumab see http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm467396.htmPeptic ulcer bleeding while on antiplatelet or anticoagulant agentsHigh-risk stigmata on endoscopyLow-risk stigmata on endoscopyAspirinDualantiplatelettherapyResumeby day 3Antiplatelet agent forprimary preventionAntiplatelet agent for secondary preventionAnticoagulants*Antiplatelet agent forprimary preventionAntiplatelet agent forsecondary preventionAnticoagulants*Endoscopytreatmentsuccessful• Withhold antiplatelet    agent• Reassess indication• Reintroduce after   ulcer healing or earlier',\n",
       " 'Antiplatelet agent forsecondary preventionAnticoagulants*Endoscopytreatmentsuccessful• Withhold antiplatelet    agent• Reassess indication• Reintroduce after   ulcer healing or earlier• Keep aspirin• Consult cardiologist for    resumption of second    antiplatelet agent• Withhold antiplatelet agent• Reassess indication• Reintroduce before    hospital discharge if    indicated for prevention • Reassess indication• Resume early or do    not interrupt if    anticoagulants within    therapeutic range Resume anticoagulantsonce adequate haemostasisis achievedKeep aspirin or dualantiplatelet therapyFigure 2: Management of antiplatelet or anticoagulant therapy in patients who develop peptic ulcer bleedingModified from Gralnek and colleagues,123 by permission of Thieme Medical Publishers. In patients at high risk of developing cardiovascular disease, early resumption of antiplatelet or anticoagulant therapy is recommended, because although the risk of rebleeding increases, overall mortality decreases. *Vitamin K or prothrombin complex concentrates should be considered in patients with bleeding associated with warfarin overdose.',\n",
       " 'Seminarwww.thelancet.com   Vol 390   August 5, 2017621US\\xa0Food and Drug Administration (FDA) for reversal of uncontrolled bleeding in patients receiving dabigatran.The optimum timing for resuming anticoagulant therapy is largely based on retrospective data or expert opinion.123,124 Warfarin should be resumed once adequate haemostasis has been achieved. For patients with high thromboembolic risk, such as those with a metallic mitral valve replacement, low-molecular-weight heparin should be given on the same day of resuming warfarin until a satisfactory international normalised ratio is achieved. With the rapid onset of action of DOACs and the absence of effective or approved agents for most oral anticoagulants, re-initiation of these drugs should be delayed until adequate haemostasis has been achieved. Figure 2 summarises the standard position on the optimum timing of resuming antiplatelet or anticoagulant therapy after a peptic ulcer disease bleeding event (appendix pp 1–4). Controversies and future research questionsThe global decline of peptic ulcer disease during the past century has occurred most rapidly in the past two decades. This decreasing trend could be related to a cohort effect that occurred before the introduction of potent anti-secretory agents and H pylori treatment.4−9 The parallel decline in the prevalence of H pylori infection resulting from improvements in socioeconomic status has had an important role. Widespread use of PPIs has probably also contributed to the rapid decline of peptic ulcer disease. However, an overuse of PPIs, which are estimated to be used inappropriately in almost 50% of cases, might have led to unexpected new side-effects that are now being gradually unravelled.10 The reduction of H pylori-associated, NSAID-associated, and aspirin-associated peptic ulcer disease has uncovered idiopathic disease. The occurrence of idiopathic ulcers seems to be increasing and is associated',\n",
       " 'NSAID-associated, and aspirin-associated peptic ulcer disease has uncovered idiopathic disease. The occurrence of idiopathic ulcers seems to be increasing and is associated with high mortality.103,104 The mechanisms and optimum management of idiopathic disease will need to be defined.How H pylori infection and NSAID or aspirin interact remains controversial, and the best strategy to manage patients with both risk factors to prevent the onset of peptic ulcer disease is a contested and unresolved issue. The ongoing HEAT trial125 in the UK to investigate whether H pylori eradication will reduce the incidence of hospital admissions for ulcer bleeding in aspirin users might provide some answers.The pathogenesis of a wide range of H pylori-related gastric lesions is still not fully understood. Development of these lesions is probably led by a combination of H pylori virulent factors and the host immune response, but the specific combination of H pylori factors and the host genetic profile has not yet been clarified. Technological advances in genome-wide association studies might provide some insight by identifying genetic polymorphisms associated with peptic ulcer disease in specific populations. Why some patients are more susceptible than others to the gastric toxicity of NSAIDs and aspirin also remains unclear.Antibiotic resistance continues to be a major challenge for successful treatment of H pylori infection. New therapies are in fact old therapies with different drug combinations and longer durations of treatment. Molecular targets against essential bacterial proteins could be key to resolving antibiotic resistance.126Complications of peptic ulcer disease, such as bleeding, remain life-threatening. Advances in endoscopic and pharmacological therapies have not substantially reduced the mortality associated with such bleeding, because comorbidities are now the major cause of death in these patients. Increasing use of anti-thrombotic agents in',\n",
       " 'the mortality associated with such bleeding, because comorbidities are now the major cause of death in these patients. Increasing use of anti-thrombotic agents in patients with multiple comorbidities has led to new challenges in the management of bleeding. Prospective data and randomised controlled trials are urgently needed to define the best strategy for patient care (appendix pp 1–5). ContributorsAL and FKLC contributed equally in the literature search, in designing the structure of the manuscript, and in writing the manuscript. Declaration of interestsAL has served as a consultant to Bayer Pharma AG and his institution has received a researcher-initiated grant on aspirin chemoprevention from Bayer Pharma AG. FKLC has served as a consultant to Pfizer, Eisai, Takeda, and Otsuka. FLKC has received an independent research grant from Pfizer and has been paid lecture fees (including for his service on speakers’ bureaus) by Pfizer, AstraZeneca, and Takeda.AcknowledgmentsAL’s work was partly funded by a grant (PI11/02578) from the Carlos III Health Institute.References1Del Valle J. Peptic ulcer disease and related disorders. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine (19th edn). New York, NY: McGraw Hill Education, 2015: 1911−32.2Rosenstock SJ, Jørgensen T. Prevalence and incidence of peptic ulcer disease in a Danish County—a prospective cohort study. Gut 1995; 36: 819−24.3Kurata JH, Nogawa AN, Abbey DE, Petersen F. A prospective study of risk for peptic ulcer disease in seventh-day adventists. Gastroenterology 1992; 102: 902−09.4Sonnenberg A. Review article: historic changes of Helicobacter pylori-associated diseases. Aliment Pharmacol Ther 2013; 38: 329−42.5Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 2007; 132: 2320−27.6Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol 2007; 102: 1101−07.7',\n",
       " 'Gastroenterology 2007; 132: 2320−27.6Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol 2007; 102: 1101−07.7Leow AH, Lim YY, Liew WC, Goh KL. Time trends in upper gastrointestinal diseases and Helicobacter pylori infection in a multiracial Asian population — a 20-year experience over three time periods. Aliment Pharmacol Ther 2016; 43: 831−37.8Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther 2011; 33: 585−91.9Malmi H, Kautiainen H, Virta LJ, Färkkilä N, Koskenpato J, Färkkilä MA. Incidence and complications of peptic ulcer disease requiring hospitalisation have markedly decreased in Finland. Aliment Pharmacol Ther 2014; 39: 496−506.10Lanas A. We are using too many PPIs, and we need to stop: a European perspective. Am J Gastroenterol 2016; 111: 1085–86.11Zhang BB, Li Y, Liu XQ, Wang PJ,Yang B, Bian DL. Association between vacA genotypes and the risk of duodenal ulcer: a meta-analysis. Mol Biol Rep 2014; 41: 7241−54.12Sugimoto M, Yamaoka Y. The association of vacA genotype and\\xa0Helicobacter pylori-related disease in Latin American and African populations. Clin Microbiol Infect 2009; 15: 835−42.',\n",
       " 'Seminar622www.thelancet.com   Vol 390   August 5, 201713Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14−22.14Datta D, Roychoidhury S. To be or not to be: the host genetic factor and beyond Helicobacter pylori mediated gastro-duodenal diseases. World J Gastroenterol 2015; 21: 2883−95.15Shiotani A, Graham DY. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med Clin North Am 2002; 86: 1447−66.16Yamaoka Y, Graham DY. Helicobacter pylori virulence and cancer pathogenesis. Future Oncol 2014; 10: 1487−500.17Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett 2014; 345: 196−20.18Chen MY, He CY, Meng X, Yuan Y. Association of Helicobacter pylori babA2 with peptic ulcer disease and gastric cancer. World J Gastroenterol 2013; 19: 4242−51.19Guo T, Qian JM, Zhao YQ, Li XB, Zhang JZ. Effects of IL-1β on the proliferation and apoptosis of gastric epithelial cells and acid secretion from isolated rabbit parietal cells. Mol Med Rep 2013; 7: 299−305.20 Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H. Interleukin 1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002; 123: 92−105.21El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398−402.22 Chakravorty M, Ghosh A, Choudhury A, Santra A, Hembrum J, Roychoudhury S. Interaction between IL1B gene promoter polymorphisms in determining susceptibility to Helicobacter pylori associated duodenal ulcer. Hum Mutat 2006; 27: 411−19.23 García-González MA, Lanas A, Savelkoul PH, et al. Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. Clin Exp Immunol 2003; 134: 525–31.24',\n",
       " '23 García-González MA, Lanas A, Savelkoul PH, et al. Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. Clin Exp Immunol 2003; 134: 525–31.24Robert A, Olafsson AS, Lancaster C, Zhang WR. Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying. Life Sci 1991; 48: 123−34.25 Zhang BB, Liu XZ, Sun J, Yin YW, Sun QQ. Association between TNF α gene polymorphisms and the risk of duodenal ulcer: a meta-analysis. PLoS One 2013; 8: e57167.26 Trejo-de la OA, Torres J, Sánchez-Zauco N, et al. Polymorphisms in TLR9 but not in TLR5 increase the risk for duodenal ulcer and alter cytokine expression in the gastric mucosa. Innate Immun 2015; 21: 706−13.27Lanas A, García-González MA, Santolaria S, et al. TNF and LTA gene polymorphisms reveal different risk in gastric and duodenal ulcer patients. Genes Immun 2001; 2: 415−21.28 Mayerle J, den Hoed CM, Schurmann C, et al. Identification of genetic loci associated with Helicobacter pylori serologic status. JAMA 2013; 309: 1912−20.29 Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731−38.30 Lanas Á, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015; 13: 906−12.31Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 2013; 144: 1384−93.32 Chan FK, Goto S, Wu MS, et al. Burden of nonsteroidal anti-inflammatory and antiplatelet drug use in Asia: a multidisciplinary working party report. Clin Gastroenterol Hepatol 2012; 10: 753−60.33 Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper',\n",
       " 'inflammatory and antiplatelet drug use in Asia: a multidisciplinary working party report. Clin Gastroenterol Hepatol 2012; 10: 753−60.33 Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding\\xa0from different drug combinations. Gastroenterology 2014; 147: 784−92.34González-Pérez A, Sáez ME, Johansson S, Nagy P, García Rodríguez LA. Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS One 2014; 9: e101768.35 Tanikawa C, Urabe Y, Matsuo K, et al. A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. Nat Genet 2012; 44: 430−34.36 García-González MA, Bujanda L, Quintero E, et al. Association of PSCA rs2294008 gene variants with poor prognosis and increased susceptibility to gastric cancer and decreased risk of duodenal ulcer disease. Int J Cancer 2015; 137: 1362−73.37Shiotani A, Murao T, Fujita Y, et al. Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding. J Gastroenterol Hepatol 2014; 29 (suppl 4): 47−52.38 Wang PY, Chen HP, Chen A, et al. Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin. Biomed Res Int 2014; 2014: 616018.39 Shiotani A, Fujita Y, Nishio K. Low-dose aspirin-associated upper and mid gastrointestinal tract damage and gene polymorphism. Curr Pharm Des 2015; 21: 5066−72.40Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646−64.41Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am J Gastroenterol 2015; 110: 684−89.42Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative',\n",
       " 'bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am J Gastroenterol 2015; 110: 684−89.42Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009; 30: 791−815.43Charpignon C, Lesgourgues B, Pariente A, et al. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. Aliment Pharmacol Ther 2013; 38: 946−54.44Yamanaka K, Miyatani H, Yoshida Y, et al. Hemorrhagic gastric and duodenal ulcers after the Great East Japan earthquake disaster. World J Gastroenterol 2013; 19: 7426−32.45Kanno T, Iijima K, Koike T, et al. Accommodation in a refugee shelter as a risk factor for peptic ulcer bleeding after the Great East Japan Earthquake: a case-control study of 329 patients. J Gastroenterol 2015; 50: 31−40.46Levenstein S, Rosenstock S, Jacobsen RK, Jorgensen T. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol 2015; 13: 498−506.47Kiss S, Zsikla V, Frank A, Willi N, Cathomas G. Helicobacter-negative gastritis: polymerase chain reaction for\\xa0Helicobacter\\xa0DNA is a valuable tool to elucidate the diagnosis. Aliment Pharmacol Ther 2016; 43: 924–32.48Meyer-Rosberg K, Scott DR, Rex D, Melchers K, Sachs G. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 1996; 111: 886−900.49Beales IL, Calam J. Inhibition of carbachol stimulated acid secretion by interleukin 1β in rabbit parietal cells requires protein kinase C. Gut 2001; 48: 782−89.50 Zaki M, Coudron PE, McCuen RW, Harrington L, Chu S, Schubert ML. H. pylori acutely inhibits gastric secretion by activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine secretion. Am J Physiol Gastrointest Liver Physiol 2013; 304: G715−22.51',\n",
       " 'activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine secretion. Am J Physiol Gastrointest Liver Physiol 2013; 304: G715−22.51El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15−24.52 Moss SF, Legon S, Bishop AE, Polak JM, Calam J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992; 340: 930−32.53 Silverstein FE, Graham GY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatoy drugs. Ann Int Med 1995; 123: 241−49.54Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382: 769−79.55 Bjarnason I, Scarpignato C, Takeuchi K, Rainsford KD. Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Ther 2007; 26: 95−106.56 Ligumski M, Golanska EM, Hansen DG, Kauffman GL. Aspirin can inhibit gastric mucosal cyclo-oxigenase without causing lesions in the rat. Gastroenterology 1983; 84: 756−61.',\n",
       " 'Seminarwww.thelancet.com   Vol 390   August 5, 201762357Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000−16.58 Lanas A, Panés J, Piqué JM. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des 2003; 9: 2253−66.59 Sigthorsson G, Tibble J, Hayllar J, et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998; 43: 506−51.60 Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17−25.61Sostres C, Lanas A. Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol 2011; 8: 385−94.62 Perini RF, Ma L, Wallace JL. Mucosal repair and COX-2 inhibition. Curr Pharm Des 2003; 9: 2207−11.63McColl KE. Helicobacter pylori-negative nonsteroidal anti-inflammatory drug-negative ulcer. Gastroenterol Clin North Am 2009; 38: 353−61.64Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999; 56: 18−24.65 Agréus L, Talley NJ, Jones M. Value of the “Test & Treat” strategy for uninvestigated dyspepsia at low prevalence rates of Helicobacter pylori in the population. Helicobacter 2016; 23: 186–91.66 Fock\\xa0KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter\\xa0pylori infection. J Gastroenterol Hepatol 2009; 24: 1587−600.67Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016; 151: 51−69.68 Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6–30.69 Graham DY, Laine L. The Toronto Helicobacter pylori consensus in context. Gastroenterology 2016; 151: 9−12c.70',\n",
       " 'Report. Gut 2017; 66: 6–30.69 Graham DY, Laine L. The Toronto Helicobacter pylori consensus in context. Gastroenterology 2016; 151: 9−12c.70Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 2016; 65: 870−78.71Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter\\xa0pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121−28.72Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.73Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 868−77.74Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010; 15: 233−38.75Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011; 34: 604−17.76Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.77Nyssen OP, McNicholl AG, Megraud F, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016; 6: CD009034.78Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: a systemic review and meta-analysis. World J Gastroenterol 2015; 21: 12954−62.79Hsu PI, Kao SS, Wu DC, et al. A randomized controlled study comparing reverse hybrid therapy and standard triple therapy for Helicobacter pylori infection. Medicine 2015; 94: e2104.',\n",
       " '79Hsu PI, Kao SS, Wu DC, et al. A randomized controlled study comparing reverse hybrid therapy and standard triple therapy for Helicobacter pylori infection. Medicine 2015; 94: e2104.80 Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016; 65: 1439–46.81Chen PY, Wu MS, Chen CY, et al. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther 2016; 44: 427−37.82 Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of levofloxacin resistance in Helicobacter pylori isolates in Bogotá-Colombia (2009−2014). PLoS One 2016; 11: e0160007.83 Chuah SK, Liang CM, Lee CH, et al. A randomized control trial comparing 2 levofloxacin-containing second-line therapies for Helicobacter pylori eradication. Medicine 2016; 95: e3586.84Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015; 41: 768−75.85 Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory\\xa0Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209−21.86 Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177−86.87Zeng M, Mao XH, Li JX, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386: 1457−64.',\n",
       " 'of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386: 1457−64.88 Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 119−25.89 Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010; 138: 82−88.90Chan FK, Kyaw M, Tanigawa T, et al. Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology 2017; 152: 105–10.e1.91Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144: 528−35.92 Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, Hunt RH, for the International NSAID Consensus Group. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis—an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med 2015; 13: 55.93 Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet 2007; 369: 1580−81.94Chan FK. Primer: managing NSAID-induced ulcer complications—balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 563−73.95 Yuan JQ, Tsoi KK, Yang M, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther 2016; 43: 1262−75.96 Rostom A, Muir K, Dube C, Lanas A, Jolicoeur E, Tugwell P. Prevention of NSAID-related upper gastrointestinal toxicity:',\n",
       " 'Aliment Pharmacol Ther 2016; 43: 1262−75.96 Rostom A, Muir K, Dube C, Lanas A, Jolicoeur E, Tugwell P. Prevention of NSAID-related upper gastrointestinal toxicity: a\\xa0meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Health Patient Saf 2009; 1: 47−71.97Regula J, Butruk E, Dekkers CP, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 2006; 101: 1747−55.98 Yuan JQ, Yang M, Threapleton DE, et al. Systematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin. Aliment Pharmacol Ther 2016; 44: 785–95.99 Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173−79.100 Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol 2013; 108: 392−400.101 Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314−22.',\n",
       " 'Seminar624www.thelancet.com   Vol 390   August 5, 2017102 Lanas AI, Remacha B, Esteva F, Sáinz R. Risk factors associated with refractory peptic ulcers. Gastroenterology 1995; 109: 1124−33.103 Hung LC, Ching JY, Sung JJ, et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 2005; 128: 1845−50.104 Wong GL, Wong VW, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009; 137: 525−31.105 Wong GL, Au KW, Lo AO, et al. Gastroprotective therapy does not improve outcomes of patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Clin Gastroenterol Hepatol 2012; 10: 1124−29.106 Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368: 11–21.107 Stanley AJ, Dalton HR, Blatchford O, et al. Multicenter comparison of the Glasgow Blatchford and Rockall Scores in the prediction of clinical end-points after upper gastrointestinal hemorrhage. Aliment Pharmacol Ther 2011; 34: 470–75.108 Baker DE. Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole. Rev Gastroenterol Disord 2009; 9: E111−18.109 Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010; 7: CD005415.110 Lau JY, Barkun A, Fan DM, Kuipers EJ, Yang YS, Chan FK. Challenges in the management of acute peptic ulcer bleeding. Lancet 2013; 381: 2033−43.111 Barkun A, Bardou M, Martel M, Gralnek IM, Sung JY. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc 2010; 72: 1138–45.112 Cook DJ, Guyatt GH, Salena BJ, Laine LA. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage:',\n",
       " 'Gastrointest Endosc 2010; 72: 1138–45.112 Cook DJ, Guyatt GH, Salena BJ, Laine LA. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterology 1992; 102: 139–48.113 Sung JJ, Tsoi KK, Lai LH, Wu JC, Lau JY. Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta-analysis. Gut 2007; 56: 1364–73.114 Marmo R, Rotondano G, Bianco MA, Piscopo R, Prisco A, Cipolletta L. Outcome of endoscopic treatment for peptic ulcer bleeding: is a second look necessary? A meta-analysis. Gastrointest Endosc 2003; 57: 62–67.115 Wang CH, Ma MH, Chou HC, et al. High-dose vs. non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2010; 170: 751–58.116 Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med 2014; 174: 1755−62.117 Hunfeld N, Touw D, Mathot R, Mulder P, Van Schaik R, Kuipers E. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 2010; 31: 150–59.118 Lau JY, Sung JJ, Lam YH, et al. Endoscopic re-treatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999; 340: 751–56.119 Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152: 1–9.120 Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745–54.121 Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and',\n",
       " 'drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745–54.121 Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug eluting stent implantation. JAMA 2007; 297: 159–68.122 Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955−62.123 Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 17: 1–8.124 Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: a1−46.125 Dumbleton JS, Avery AJ, Coupland C, et al. The Helicobacter Eradication Aspirin Trial (HEAT): a large simple randomised controlled trial using novel methodology in primary care. EBioMedicine 2015; 2: 1200−04.126 Cremades N, Velázquez-Campoy A, Martínez-Júlvez M, et al. Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection. ACS Chem Biol 2009; 4: 928−38.',\n",
       " 'Acute upper gastrointestinalbleeding in over 16s:managementClinical guidelinePublished: 13 June 2012www.nice.org.uk/guidance/cg141© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016',\n",
       " 'YYour responsibilityour responsibilityThe recommendations in this guideline represent the view of NICE, arrived at after carefulconsideration of the evidence available. When exercising their judgement, professionals andpractitioners are expected to take this guideline fully into account, alongside the individual needs,preferences and values of their patients or the people using their service. It is not mandatory toapply the recommendations, and the guideline does not override the responsibility to makedecisions appropriate to the circumstances of the individual, in consultation with them and theirfamilies and carers or guardian.Local commissioners and providers of healthcare have a responsibility to enable the guideline to beapplied when individual professionals and people using services wish to use it. They should do so inthe context of local and national priorities for funding and developing services, and in light of theirduties to have due regard to the need to eliminate unlawful discrimination, to advance equality ofopportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in away that would be inconsistent with complying with those duties.Commissioners and providers have a responsibility to promote an environmentally sustainablehealth and care system and should assess and reduce the environmental impact of implementingNICE recommendations wherever possible.Acute upper gastrointestinal bleeding in over 16s: management (CG141)© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016Page 2of 13',\n",
       " 'ContentsContentsIntroduction .........................................................................................................................................................................4Patient-centred care.........................................................................................................................................................5Key priorities for implementation...............................................................................................................................61 Guidance ............................................................................................................................................................................81.1 Risk assessment ........................................................................................................................................................................81.2 Resuscitation and initial management.............................................................................................................................81.3 Timing of endoscopy................................................................................................................................................................91.4 Management of non-variceal bleeding ............................................................................................................................91.5 Management of variceal bleeding...................................................................................................................................... 101.6 Control of bleeding and prevention of re-bleeding in patients on NSAIDs, aspirin or clopidogrel ......... 111.7 Primary prophylaxis for acutely ill patients in critical care...................................................................................... 11',\n",
       " '1.7 Primary prophylaxis for acutely ill patients in critical care...................................................................................... 111.8 Information and support for patients and carers ........................................................................................................ 11More information............................................................................................................................................................................. 12Update information........................................................................................................................................................... 13Acute upper gastrointestinal bleeding in over 16s: management (CG141)© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016Page 3of 13',\n",
       " \"This guideline is the basis of QS38.IntroductionIntroductionAcute upper gastrointestinal bleeding is a common medical emergency that has a 10% hospitalmortality rate. Despite changes in management, mortality has not significantly improved over thepast 50 years.Elderly patients and people with chronic medical diseases withstand acute upper gastrointestinalbleeding less well than younger, fitter patients, and have a higher risk of death. Almost all peoplewho develop acute upper gastrointestinal bleeding are treated in hospital and the guidelinetherefore focuses on hospital care. The most common causes are peptic ulcer and oesophago-gastric varices.Endoscopy is the primary diagnostic investigation in patients with acute upper gastrointestinalbleeding but it has not always been clear whether urgent endoscopy is cost effective as well asclinically valuable. Endoscopy aids diagnosis, yields information that helps predict outcome andmost importantly allows treatments to be delivered that can stop bleeding and reduce the risk ofre-bleeding.Drugs may have a complementary role in reducing gastric acid secretion and portal vein pressure.Not every patient responds to endoscopic and drug treatments; emergency surgery and a range ofradiological procedures may be needed to control bleeding.This guideline aims to identify which diagnostic and therapeutic steps are useful in managing acuteupper gastrointestinal bleeding. This should enable hospitals to develop a structure in whichclinical teams can deliver an optimum service for people who develop this condition.The guideline will assume that prescribers will use a drug's summary of product characteristics toinform decisions made with individual patients.Acute upper gastrointestinal bleeding in over 16s: management (CG141)© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016Page 4of 13\",\n",
       " \"PPatient-centred careatient-centred careThis guideline offers best practice advice on the care of adults and young people aged 16 years andolder with acute variceal and non-variceal upper gastrointestinal bleeding.Treatment and care should take into account patients' needs, preferences and religious beliefs.People with acute upper gastrointestinal bleeding should have the opportunity to make informeddecisions about their care and treatment, in partnership with their healthcare professionals. Ifpatients do not have the capacity to make decisions, healthcare professionals should follow theDepartment of Health's advice on consent and the code of practice that accompanies the MentalCapacity Act. In Wales, healthcare professionals should follow advice on consent from the WelshGovernment. In taking account of patients' religious beliefs in the context of blood transfusion,healthcare professionals should follow the advice from UK Blood Transfusion and TissueTransplantation Services.Good communication between healthcare professionals and patients is essential. It should besupported by evidence-based written information tailored to the patient's needs. Treatment andcare, and the information patients are given about it, should be culturally appropriate. It should alsobe accessible to people with additional needs such as physical, sensory or learning disabilities, andto people who do not speak or read English.If the patient agrees, families and carers should have the opportunity to be involved in decisionsabout treatment and care.Families and carers should also be given the information and support they need.Acute upper gastrointestinal bleeding in over 16s: management (CG141)© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016Page 5of 13\",\n",
       " 'KKeey priorities for implementationy priorities for implementationThe following recommendations have been identified as priorities for implementation.Risk assessmentRisk assessmentUse the following formal risk assessment scores for all patients with acute uppergastrointestinal bleeding:the Blatchford score at first assessment, andandthe full Rockall score after endoscopy.Timing of endoscopTiming of endoscopyyOffer endoscopy to unstable patients with severe acute upper gastrointestinal bleedingimmediately after resuscitation.Offer endoscopy within 24 hours of admission to all other patients with upper gastrointestinalbleeding.Units seeing more than 330 cases a year should offer daily endoscopy lists. Units seeing fewerthan 330 cases a year should arrange their service according to local circumstances.Management of non-variceal bleedingManagement of non-variceal bleedingDo not use adrenaline as monotherapy for the endoscopic treatment of non-variceal uppergastrointestinal bleeding.For the endoscopic treatment of non-variceal upper gastrointestinal bleeding, use one of thefollowing:a mechanical method (for example, clips) with or without adrenalinethermal coagulation with adrenalinefibrin or thrombin with adrenaline.Offer interventional radiology to unstable patients who re-bleed after endoscopic treatment.Refer urgently for surgery if interventional radiology is not promptly available.Acute upper gastrointestinal bleeding in over 16s: management (CG141)© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016Page 6of 13',\n",
       " 'Management of variceal bleedingManagement of variceal bleedingOffer prophylactic antibiotic therapy at presentation to patients with suspected or confirmedvariceal bleeding.Consider transjugular intrahepatic portosystemic shunts (TIPS) if bleeding from oesophagealvarices is not controlled by band ligation.Control of bleeding and preControl of bleeding and prevvention of re-bleeding in patients on NSAIDs, aspirin or clopidogrelention of re-bleeding in patients on NSAIDs, aspirin or clopidogrelContinue low-dose aspirin for secondary prevention of vascular events in patients with uppergastrointestinal bleeding in whom haemostasis has been achieved.Acute upper gastrointestinal bleeding in over 16s: management (CG141)© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016Page 7of 13',\n",
       " \"11GuidanceGuidanceThe following guidance is based on the best available evidence. The full guideline gives details ofthe methods and the evidence used to develop the guidance.1.11.1 Risk assessmentRisk assessment1.1.1Use the following formal risk assessment scores for all patients with acuteupper gastrointestinal bleeding:the Blatchford score at first assessment, andandthe full Rockall score after endoscopy.1.1.2Consider early discharge for patients with a pre-endoscopy Blatchfordscore of 0.1.21.2 Resuscitation and initial managementResuscitation and initial management1.2.1Transfuse patients with massive bleeding with blood, platelets and clottingfactors in line with local protocols for managing massive bleeding.1.2.2Base decisions on blood transfusion on the full clinical picture, recognising thatover-transfusion may be as damaging as under-transfusion.1.2.3Do not offer platelet transfusion to patients who are not actively bleeding andare haemodynamically stable.1.2.4Offer platelet transfusion to patients who are actively bleeding and have aplatelet count of less than 50 x 109/litre.Offer fresh frozen plasma to patients who are actively bleeding and have aprothrombin time (or international normalised ratio) or activated partialthromboplastin time greater than 1.5 times normal. If a patient's fibrinogen levelremains less than 1.5 g/litre despite fresh frozen plasma use, offer cryoprecipitate aswell.1.2.5Offer prothrombin complex concentrate to patients who are taking warfarinAcute upper gastrointestinal bleeding in over 16s: management (CG141)© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016Page 8of 13\",\n",
       " 'and actively bleeding.1.2.6Treat patients who are taking warfarin and whose upper gastrointestinalbleeding has stopped in line with local warfarin protocols.1.2.7Do not use recombinant factor Vlla except when all other methods have failed.1.31.3 Timing of endoscopTiming of endoscopyy1.3.1Offer endoscopy to unstable patients with severe acute upper gastrointestinalbleeding immediately after resuscitation.1.3.2Offer endoscopy within 24 hours of admission to all other patients with uppergastrointestinal bleeding.1.3.3Units seeing more than 330 cases a year should offer daily endoscopy lists. Unitsseeing fewer than 330 cases a year should arrange their service according tolocal circumstances.1.41.4 Management of non-variceal bleedingManagement of non-variceal bleedingEndoscopic treatmentEndoscopic treatment1.4.1Do not use adrenaline as monotherapy for the endoscopic treatment of non-variceal upper gastrointestinal bleeding.1.4.2For the endoscopic treatment of non-variceal upper gastrointestinal bleeding,use one of the following:a mechanical method (for example, clips) with or without adrenalinethermal coagulation with adrenalinefibrin or thrombin with adrenaline.Proton pump inhibitorsProton pump inhibitors1.4.3Do not offer acid-suppression drugs (proton pump inhibitors or H2-receptorantagonists) before endoscopy to patients with suspected non-variceal uppergastrointestinal bleeding.Acute upper gastrointestinal bleeding in over 16s: management (CG141)© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016Page 9of 13',\n",
       " '1.4.4Offer proton pump inhibitors to patients with non-variceal uppergastrointestinal bleeding and stigmata of recent haemorrhage shown atendoscopy.TTreatment after first or failed endoscopic treatmentreatment after first or failed endoscopic treatment1.4.5Consider a repeat endoscopy, with treatment as appropriate, for all patients athigh risk of re-bleeding, particularly if there is doubt about adequatehaemostasis at the first endoscopy.1.4.6Offer a repeat endoscopy to patients who re-bleed with a view to furtherendoscopic treatment or emergency surgery.1.4.7Offer interventional radiology to unstable patients who re-bleed afterendoscopic treatment. Refer urgently for surgery if interventional radiology isnot promptly available.1.51.5 Management of variceal bleedingManagement of variceal bleeding1.5.1Offer terlipressin to patients with suspected variceal bleeding at presentation.Stop treatment after definitive haemostasis has been achieved, or after 5 days,unless there is another indication for its use[1].1.5.2Offer prophylactic antibiotic therapy at presentation to patients with suspectedor confirmed variceal bleeding.Oesophageal varicesOesophageal varices1.5.3Use band ligation in patients with upper gastrointestinal bleeding fromoesophageal varices.1.5.4Consider transjugular intrahepatic portosystemic shunts (TIPS) if bleeding fromoesophageal varices is not controlled by band ligation.Gastric varicesGastric varices1.5.5Offer endoscopic injection of N-butyl-2-cyanoacrylate to patients with uppergastrointestinal bleeding from gastric varices.Acute upper gastrointestinal bleeding in over 16s: management (CG141)© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016Page 10of 13',\n",
       " '1.5.6Offer TIPS if bleeding from gastric varices is not controlled by endoscopicinjection of N-butyl-2-cyanoacrylate.1.61.6 Control of bleeding and preControl of bleeding and prevvention of re-bleeding inention of re-bleeding inpatients on NSAIDs, aspirin or clopidogrelpatients on NSAIDs, aspirin or clopidogrel1.6.1Continue low-dose aspirin for secondary prevention of vascular events inpatients with upper gastrointestinal bleeding in whom haemostasis has beenachieved.1.6.2Stop other non-steroidal anti-inflammatory drugs (including cyclooxygenase-2[COX-2] inhibitors) during the acute phase in patients presenting with uppergastrointestinal bleeding.1.6.3Discuss the risks and benefits of continuing clopidogrel (or any otherthienopyridine antiplatelet agents) in patients with upper gastrointestinalbleeding with the appropriate specialist (for example, a cardiologist or a strokespecialist) and with the patient.1.71.7 Primary prophPrimary prophylaxis for acutely ill patients in criticalylaxis for acutely ill patients in criticalcarecare1.7.1Offer acid-suppression therapy (H2-receptor antagonists or proton pumpinhibitors) for primary prevention of upper gastrointestinal bleeding in acutelyill patients admitted to critical care. If possible, use the oral form of the drug.[2]1.7.2Review the ongoing need for acid-suppression drugs for primary prevention ofupper gastrointestinal bleeding in acutely ill patients when they recover or aredischarged from critical care.1.81.8 Information and support for patients and carersInformation and support for patients and carers1.8.1Establish good communication between clinical staff and patients and theirfamily and carers at the time of presentation, throughout their time in hospitaland following discharge. This should include:giving verbal information that is recorded in medical recordsAcute upper gastrointestinal bleeding in over 16s: management (CG141)',\n",
       " 'and following discharge. This should include:giving verbal information that is recorded in medical recordsAcute upper gastrointestinal bleeding in over 16s: management (CG141)© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016Page 11of 13',\n",
       " \"different members of clinical teams providing consistent informationproviding written information where appropriateensuring patients and their families and carers receive consistent information.More informationMore informationYou can also see this guideline in the NICE pathway on Acute upper gastrointestinal bleeding.To find out what NICE has said on topics related to this guideline, see our web page on Digestivetract conditions.See also the guideline committee's discussion and the evidence reviews (in the full guideline),and information about how the guideline was developed, including details of the committee.[1]At the time of publication (June 2012), terlipressin was indicated for the treatment of bleedingfrom oesophageal varices, with a maximum duration of treatment of 72 hours (3 days). Prescribersshould consult the relevant summary of product characteristics. Informed consent for off-label useof terlipressin should be obtained and documented.[2]As of August 2016, only the H2-receptor antagonists ranitidine and cimetidine are licensed forprophylaxis of gastrointestinal bleeding in acutely ill patients. The proton pump inhibitorsomeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole are not licensed forprophylaxis of gastrointestinal bleeding in acutely ill patients. The use of proton pump inhibitors orH2-receptor antagonists other than ranitidine and cimetidine for this indication would be off label.Acute upper gastrointestinal bleeding in over 16s: management (CG141)© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016Page 12of 13\",\n",
       " 'Update informationUpdate informationAugust 2016August 2016: A footnote was added to recommendation 1.7.1 about which proton pump inhibitorsand H2-receptor antagonists are licensed for use and which are classed as off-label.April 2015April 2015: Recommendation 1.2.5 has been amended to add the use of cryoprecipitate as furthertreatment.ISBN: 978-1-4731-2041-9AccreditationAccreditationAcute upper gastrointestinal bleeding in over 16s: management (CG141)© NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated August 2016Page 13of 13',\n",
       " \"Aliment Pharmacol Ther. 2020;52:789–797.\\ufeff \\u2003|\\u2003 789wileyonlinelibrary.com/journal/apt Received: 11 March 2020\\u2003 |\\u2003 First decision: 28 March 2020\\u2003 |\\u2003 Accepted: 15 May 2020DOI: 10.1111/apt.15865  Randomised clinical trial: tegoprazan, a novel  potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcerYu Kyung\\xa0Cho1\\u2003|   Myung-Gyu\\xa0Choi1\\u2003|   Suck Chei\\xa0Choi2\\u2003|   Kee Myung\\xa0Lee3\\u2003|    Tae Oh\\xa0Kim4\\u2003|   Soo-Heon\\xa0Park1\\u2003|   Jeong Seop\\xa0Moon1\\u2003|   Yun Jeong\\xa0Lim5\\u2003|    Dae Hwan\\xa0Kang6\\u2003|   Gab Jin\\xa0Cheon7\\u2003|   Gwang Ho\\xa0Baik8\\u2003|   Kyoung Oh\\xa0Kim9\\u2003|    Kwang Bum\\xa0Cho10\\u2003|   Jin Seok\\xa0Jang4\\u2003|   Jong-Jae\\xa0Park1\\u2003|   Byoung Kwan\\xa0Son1\\u2003|    Hye-Kyung\\xa0Jung1\\u2003|   Byung-Wook\\xa0Kim9\\u2003|   Sung Kuk\\xa0Kim10\\u2003|   Soo Teik\\xa0Lee11\\u2003|    Jae Myung\\xa0Cha1\\u2003|   Ah Rong\\xa0Kim1\\u2003|   Eun Ji\\xa0Kim1\\u2003|   Hyun Wook\\xa0Park1\\u2003|   Geun Seog\\xa0Song1This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.© 2020 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons LtdThe Handling Editor for this article was Dr Colin Howden, and it was accepted for publication after full peer-review. The complete list of authors' affiliation are listed in Appendix\\xa01. 1Seoul, Korea2Iksan, Korea3Suwon, Korea4Busan, Korea5Goyang, Korea6Yangsan, Korea7Gangneung, Korea8Chuncheon, Korea9Incheon, Korea10Daegu, Korea11Jeonju, KoreaCorrespondenceProf. Myung-Gyu Choi, Division of Gastroenterology, Department of Medicine, College of Medicine, The Catholic University of Korea, Seoul St, Mary's hospital, Banpodaero 222, Seochogu, Seoul, Korea.Email: choim@catholic.ac.krFunding informationThis study was funded in full by HK inno.N Corp., Seoul, Korea.SummaryBackground: Tegoprazan is a novel potassium-competitive acid blocker for the treat-ment of acid-related disorders.\",\n",
       " 'This study was funded in full by HK inno.N Corp., Seoul, Korea.SummaryBackground: Tegoprazan is a novel potassium-competitive acid blocker for the treat-ment of acid-related disorders.Aims: To assess whether tegoprazan is non-inferior to lansoprazole in terms of ef-ficacy and safety in patients with gastric ulcers.Methods: In this phase 3, double-blind, active control, multicentre study, 306 gastric ulcer patients were randomised to one of three treatment groups: tegoprazan 50\\xa0mg, tegoprazan 100\\xa0mg and lansoprazole 30\\xa0mg once daily for 4 or 8\\xa0weeks. The primary endpoint was the cumulative proportion of patients with healed ulcers confirmed by en-doscopy up to 8\\xa0weeks from treatment initiation. Symptoms and safety were assessed.Results: In the full analysis set, the cumulative healing rates at week 8 were 94.8% (91/96) for the tegoprazan 50\\xa0mg, 95.0% (94/99) for the tegoprazan 100\\xa0mg and 95.7% (89/93) for the lansoprazole 30\\xa0mg groups. At week 4, the respective healing rates were 90.6% (87/96), 91.9% (91/99), and 89.2% (83/93). In per protocol analysis, 4-week healing rates were 95.4% (84/88), 94.6% (88/93) and 92.9% (79/85) for tego-prazan 50\\xa0mg, tegoprazan 100\\xa0mg and lansoprazole 30\\xa0mg, respectively. Both doses of tegoprazan were non-inferior to lansoprazole in ulcer healing at 4 and 8\\xa0weeks. The incidence of drug-related treatment-emergent adverse events did not differ among groups. The increase in serum gastrin concentration was not higher in tegoprazan-treated patients than in lansoprazole-treated patients.Conclusions: Tegoprazan 50 or 100\\xa0mg were not inferior to lansoprazole 30\\xa0mg once daily in the treatment of gastric ulcers.',\n",
       " '790\\u2003 |\\u2003 \\u2003\\u2002CHO et al.1\\u2003|\\u2003INTRODUCTIONProton pump inhibitors (PPIs) are used widely for the treatment of acid-related diseases, and their therapeutic effects are con-sidered to be satisfactory,1 although some inadequacies must be addressed. First, PPIs have a relatively short plasma half-life (60-90\\xa0minutes), and taking PPIs twice a day may be insufficient for inhibiting gastric acid reflux at night. Second, PPIs are prodrugs that are activated under acid-secreting conditions, and the effects of PPIs can be affected by food intake. Third, a rapid response cannot be achieved because of the slow onset of the PPI effect and the time needed to achieve maximum efficacy.2-4 Potassium-competitive acid blockers (P-CABs) comprise a new class of drugs that exhibit rapid and effective anti-secretory activity by compet-itively and reversibly binding to H+/K+-ATPase in parietal cells.5 Unlike conventional PPIs, P-CABs can immediately inhibit proton pumps without gastric acid activation, even in the absence of food intake, and therefore provide a fast onset of action and full ef-fect from the first dose.6,7 Vonoprazan, which is available P-CAB in Japan, has a more potent acid-inhibitory effect.8 It is superior to PPIs for the first-line treatment for Helicobacter pylori eradication,9 and is not inferior to PPIs for the treatment of gastroesophageal re-flux disease (GERD),10 gastric ulcers (GUs) or duodenal ulcers.11-13Tegoprazan is a novel P-CAB, originally developed by a RaQualia Pharma Inc HK inno.N Corporation which has the exclusive right, has completely developed and commercialised tegoprazan as a treat-ment for acid-related disorders. Tegoprazan was approved as a treat-ment for gastroesophageal reflux disease, gastric ulcer and H.\\xa0pylori eradication in South Korea from July 2018. Tegoprazan showed rapid response from the time of initial administration, and sustained acid suppression are demonstrated in the several experimental and',\n",
       " 'eradication in South Korea from July 2018. Tegoprazan showed rapid response from the time of initial administration, and sustained acid suppression are demonstrated in the several experimental and clinical studies.14 Tegoprazan shows dose-dependent pH >4 hold-ing time and a rapid and sustained acid suppressive effect compared with esomeprazole in healthy male volunteers.15 Its effects on intra-gastric pH >4 holding time at day 1 and day 7 are similar to vono-prazan.16 The superior ulcer healing effect of tegoprazan compared with esomeprazole was recently shown in a rat peptic ulcer model.17 Tegoprazan at doses of 50 and 100\\xa0mg is not inferior to esomepra-zole 40\\xa0mg for healing endoscopic esophagitis has been reported.18The present study was a phase 3 clinical trial that was designed to evaluate whether tegoprazan is non-inferior in efficacy and safety to lansoprazole in treating patients with GUs. Another aim of this trial was to determine whether the proper dose of tegoprazan for healing GUs and safety is 50\\xa0mg or 100\\xa0mg.2\\u2003|\\u2003MATERIALS AND METHODS2.1\\u2003|\\u2003Study designThis phase 3 study was a multicentre study involving 33 investigators in 33 centres in South Korea. The study was a randomised, double-blind, active-controlled, comparative study designed to assess the non-inferiority of tegoprazan 50 and 100\\xa0mg to lansoprazole 30\\xa0mg q.d. for 4 or 8\\xa0weeks in patients with GU. The protocol for this study was approved by the institutional review boards at each institute ac-cording to the Declaration of Helsinki and the International Congress on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use-Good Clinical Practice guidelines. The study was registered with ClinicalTrials.gov under the number NCT02761512 (Study title: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients with Gastric Ulcer).2.2\\u2003|\\u2003Study populationPatients who met all of the following criteria were eligible to enter',\n",
       " \"of CJ-12420 in Patients with Gastric Ulcer).2.2\\u2003|\\u2003Study populationPatients who met all of the following criteria were eligible to enter the study: men or women aged 20-75\\xa0years living in South Korea and being an outpatient who had been diagnosed with one or more ac-tive GUs measuring ≥3\\xa0mm to ≤30\\xa0mm of A1 or A2 stage according to the Sakita-Miwa classification obtained with open biopsy forceps during upper gastrointestinal (GI) endoscopy within 14\\xa0days before the initiation of the study treatment.Patients with any one of the following conditions were ineligible to enter the study: Zollinger-Ellison syndrome; GI bleeding; oesoph-ageal stricture; ulcer stenosis; pyloric stenosis; oesophageal gastric varices; Barrett's oesophagus measuring >3\\xa0cm; intractable ulcer; di-gestive ulcer perforation or malignancy on upper GI endoscopy; clin-ically significant hepatic, renal, cardiovascular, respiratory, endocrine or central nervous system disorder; history of malignancy or psychi-atric disorder; pregnant or nursing mother; history of allergy to any of the study drugs or their related compounds; clinically significant liver disease or renal disease; using anti-psychotics, anti-depressants, or anxiolytics; using a PPI, H2-blocker, prokinetic agent, or antacid within 14\\xa0days before screening; or persistent daily use of non-steroidal an-ti-inflammatory drugs (NSAIDs) or aspirin during the study period.2.3\\u2003|\\u2003Study protocol2.3.1\\u2003|\\u2003Randomisation, treatment and follow-upClinical Development Division, HK inno.N Corp., Seoul, Korea, car-ried out centralised randomisation and allocation to tegoprazan 50, 100\\xa0mg or lansoprazole 30\\xa0mg group at a 1:1:1 ratio. All randomi-sation information was securely stored and could be accessed by authorised personnel only. A double-dummy method, using match-ing tegoprazan 50\\xa0mg, tegoprazan 100\\xa0mg, lansoprazole 30\\xa0mg and placebo tablets, was employed to ensure that the study was double\",\n",
       " 'authorised personnel only. A double-dummy method, using match-ing tegoprazan 50\\xa0mg, tegoprazan 100\\xa0mg, lansoprazole 30\\xa0mg and placebo tablets, was employed to ensure that the study was double blinded with key codes kept off site by an external data manager. All medications were provided in sealed boxes and supplied by the med-ication supervisor to ensure blinded allocation. Study patients were instructed to take two tablets and one capsule, one of tegoprazan 50, 100\\xa0mg or lansoprazole 30\\xa0mg and two placebos once daily be-fore eating breakfast. Treatment was completed after 4\\xa0weeks or 8\\xa0weeks if not healed.',\n",
       " '| \\u2003791CHO et al.At the start of the screening period, patient demographics and other baseline characteristics were recorded, including medical history, medication history, vital signs, physical examination, clin-ical laboratory tests, pregnancy test, electrocardiogram test and Helicobacter pylori test were performed. At week 4 or 8, vital signs, physical examination, clinical laboratory tests and pregnancy test were performed. Additionally, adverse events, concomitant medica-tion and treatment compliance were checked. Endoscopy was per-formed at screening, week 4 or 8. The follow-up period began when healing of the GU was endoscopically confirmed (ie the white ulcer coating was not visible) or at week 8. Patients whose GU had healed by week 4 had a follow-up visit for safety assessment 2\\xa0weeks later (visit 3-1). Those not achieving GU healing at week 4 received an-other batch of drugs and continued the treatment for an additional 4\\xa0weeks. For these patients, endoscopic assessment was conducted at week 8, and the final follow-up visit for safety assessment was performed 2\\xa0weeks later (visit 4-1). Symptoms were assessed using the Nepean Dyspepsia Index - Korean version (NDI-K), which was completed on the first visit before the treatment period and repeated at visits 3, 3-1 or 4, 4-1. Patient diary entries were also recorded. Serum gastrin was collected at visit 2, visit 3 and visit 3-1 for 4\\xa0weeks or at visit 2, visit 4 and visit 4-1 for 8\\xa0weeks under fasting conditions.Helicobacter pylori infection status was checked using one of silver stains, CLO test and urea breath test prior to study enrol-ment. Helicobacter infection status was notified to all of subject at time of screening. All subjects who were positive for Helicobacter were treated using standard triple therapy (lansoprazole 30\\xa0 mg b.i.d\\xa0+\\xa0amoxicillin 1\\xa0g b.i.d\\xa0+\\xa0clarithromycin 500\\xa0mg b.i.d for 7\\xa0days) after last follow-up. H.\\xa0pylori eradication and follow-up urea breath',\n",
       " 'b.i.d\\xa0+\\xa0amoxicillin 1\\xa0g b.i.d\\xa0+\\xa0clarithromycin 500\\xa0mg b.i.d for 7\\xa0days) after last follow-up. H.\\xa0pylori eradication and follow-up urea breath test were done in clinical practice.2.3.2\\u2003|\\u2003Outcome parameters used to assess efficacyThe primary efficacy endpoint was set as the cumulative healing rate of GUs at week 8 as assessed by upper GI endoscopy. Following the Sakita-Miwa classification, healing was defined as the disappearance of all ulcers with a white coating or healing of the mucosal defect (S1 or S2 stage). The secondary efficacy endpoints were as follows: (a) heal-ing rate of GUs, also classified according to the Sakita-Miwa classifica-tion at week 4; (b) healing rate of GUs according to H.\\xa0pylori infections status; (c) change in ulcer size; and (d) improvement of GI symptoms.2.3.3\\u2003|\\u2003Safety assessmentSafety was evaluated through physical examination, electrocardiogra-phy, vital signs (blood pressure, heart rate and body temperature), lab-oratory test results (haematology, blood chemistry, blood coagulation and urinalysis) and incidence of treatment-emergent adverse events (TEAEs). A TEAE was defined as an adverse event (AE) occurring after the participant received a study drug. TEAEs were categorised by severity and relativity and compared between treatment groups. All TEAEs including AEs, adverse drug reactions and serious AEs were coded by system organ class and preferred term using MedDRA, and compared between treatment groups. Additional safety assessments were conducted at the discretion of the investigators.2.4\\u2003|\\u2003Statistical analysisHypothesis testing was conducted by setting the primary efficacy end-point as the cumulative GU healing rate at week 8. The union-intersec-tion test was used with the Hochberg method to adjust for multiple comparisons and to control for a family-wise type I error, which was set at 0.025 (one-sided). A power of >90% was assumed for detecting non-inferiority as shown by the difference in the percentages of patients',\n",
       " 'at 0.025 (one-sided). A power of >90% was assumed for detecting non-inferiority as shown by the difference in the percentages of patients with healed GUs between the treatment groups, with a non-inferiority margin of 8.54% at the lower limit of 95% confidence intervals (CIs).Sample size was determined according to the primary end-point. For sample size calculation, the cumulative healing rate after 8\\xa0weeks of treatment was assumed as 96.8% for both tegoprazan and lansoprazole, and a sample size of 102 patients (considering a 20% dropout rate) per treatment group was calculated, giving a total sample size of 306 patients.Efficacy assessments were performed primarily using the per-protocol set (PPS) and complementarily using the full analysis set (FAS). The safety assessments were performed on the safety set. The FAS included all patients who were randomised to the study treatment and who received ≥1 dose of a study drug and who had at least one valid efficacy assessment. The PPS included all patients in the FAS with an evaluable primary endpoint who were randomised to a study treatment, completed their study treatment and had no major protocol deviation. The safety population included all patients who received ≥1 dose of a study drug.All statistical analyses were done using SAS® (version 9.3; Windows) in accordance with the statistical analysis plan. For con-tinuous variables, the values are expressed as number of partici-pants, mean, standard deviation, median, minimum and maximum. For categorical variables, the values are presented as frequency and percentage. Demographic and other baseline characteristics, GU characteristics and serum gastrin concentrations were com-pared between treatment groups. The percentages of patients with healed GUs and GI symptoms were analysed by calculating frequencies, point estimates and two-sided 95% CIs for each treatment group.3\\u2003|\\u2003RESULTS3.1\\u2003|\\u2003Patient characteristics and demographics',\n",
       " 'with healed GUs and GI symptoms were analysed by calculating frequencies, point estimates and two-sided 95% CIs for each treatment group.3\\u2003|\\u2003RESULTS3.1\\u2003|\\u2003Patient characteristics and demographicsAmong the 376 patients with GUs who were screened, 51 were in-eligible based on the inclusion/exclusion criteria, 18 withdrew their consent and 1 was a foreigner. These patients were considered as screening failures, and the remaining 306 patients were randomised',\n",
       " \"792\\u2003 |\\u2003 \\u2003\\u2002CHO et al.in a 1:1:1 ratio to one of the three treatment arms: tegoprazan 50\\xa0mg, tegoprazan 100\\xa0mg or lansoprazole 30\\xa0mg. Among the 306 randomised patients, 28 (9.2%) were discontinued from the study because of voluntary withdrawal (n\\xa0=\\xa08, 28.6%), inclusion/exclusion criteria violation (n\\xa0 =\\xa0 6, 21.4%), the use of contraindicated drugs (n\\xa0=\\xa05, 17.9%), AEs (n\\xa0=\\xa05, 17.9%), follow-up loss (n\\xa0=\\xa02, 7.1%) or investigator discretion (n\\xa0=\\xa02, 7.1%). The patients' characteristics are summarised in Figure\\xa01 and the details of the patients' demographics and baseline characteristics are summarised in Table\\xa01. No signifi-cant differences in demographic characteristics between treatment groups were observed. Most patients were not using NSAIDs or low-dose aspirin at the time of enrolment. Most patients had a single GU and the most common size of the ulcers was <10\\xa0mm.3.2\\u2003|\\u2003Efficacy analysis3.2.1\\u2003|\\u2003The primary efficacy endpointsIn the PPS population, the percentages of patients with healed GUs over the 8-week treatment period were 100% in the tegoprazan 50\\xa0mg group, 97.85% in the tegoprazan 100\\xa0mg group and 100% in the lansoprazole 30\\xa0mg group. The percentage difference between tegoprazan 100\\xa0 mg and lansoprazole 30\\xa0 mg in PPS analysis was <8.54% (95% CI −7.66 to 2.43, P\\xa0 =\\xa0 0.0137), which confirmed the non-inferiority of tegoprazan 50\\xa0mg and 100\\xa0mg compared with lan-soprazole 30\\xa0mg. At week 4, the healing rates were 95.45% (84/88, P\\xa0=\\xa00.0038 vs lansoprazole 30\\xa0mg) for tegoprazan 50\\xa0mg, 94.62% (88/93, P\\xa0=\\xa00.0024 vs lansoprazole 30\\xa0mg) for tegoprazan 100\\xa0mg and 92.94% (79/85) for lansoprazole 30\\xa0mg, the percentage differences between each dose of tegoprazan and lansoprazole 30\\xa0mg showed both dose of tegoprazan were not inferior to lansoprazole (Table\\xa02).These findings were supported by the secondary analyses in the FAS. In the FAS analysis, the cumulative healing rates at week 8 were 94.79% (91/96), 94.95% (94/99) and 95.70% (89/93) and the respec-\",\n",
       " 'These findings were supported by the secondary analyses in the FAS. In the FAS analysis, the cumulative healing rates at week 8 were 94.79% (91/96), 94.95% (94/99) and 95.70% (89/93) and the respec-tive healing rates at week 4 were 90.63% (87/96), 91.92% (91/99) and 89.25% (83/93) in tegoprazan 50, 100\\xa0 mg and lansoprazole groups. The differences between the tegoprazan group (both doses) and the lansoprazole group were significant (P\\xa0<\\xa00.025) at both time points, for both analysis sets according to the Hochberg method, it confirmed the non-inferiority of tegoprazan to lansoprazole.Secondary endpoint analyses showed similar healing rates between pylori subgroup and both treatment of tegoprazan and lansoprazole had positive effects on gastrointestinal symptoms. Both doses of te-goprazan were non-inferior to lansoprazole 30\\xa0mg in H.\\xa0pylori-positive patients at 4- and 8-week ulcer healing. In H.\\xa0pylori-positive patients, the 4-week healing rates were 96.15% (50/52) for tegoprazan 50\\xa0mg, 98.33% (59/60) for tegoprazan 100\\xa0mg and 92.98% (53/57) for lanso-prazole 30\\xa0mg. The 8-week cumulative healing rates were 100% in all of three groups. In the H.\\xa0pylori-negative patients, the 4-week healing rates were 94.44% (34/36) for tegoprazan 50\\xa0mg, 87.88% (29/33) for tego-prazan 100\\xa0mg and 92.86% (26/28) for lansoprazole 30\\xa0mg. The 8-week healing rates were 100% (36/36) for tegoprazan 50\\xa0mg, 93.94% (31/33), for tegoprazan 100\\xa0mg, and 100%(28/28) for lansoprazole 30\\xa0mg.FI G U R E 1\\u2003Disposition of SubjectsN=376Subject screenedInclusion/ExclusionViolationn=51Withdrawalofinformedconsentn=18Foreignern=1N=306Subject randomisedN=102N=102N=102Tegoprazan 50 mgTegoprazan100mgLansoprazole 30 mgN=92N=10N=97N=5N=89N=13CompletedDrop outCompletedDrop outCompletedDrop outWithdrawal of subjectsn=3Withdrawalofsubjectsn=2Withdrawalofsubjectsn=3Inclusion/exclusion violationn=2Adverse eventn=2Inclusion/exclusionviolationn=4Contraindicated drugsn=1',\n",
       " 'Drop outWithdrawal of subjectsn=3Withdrawalofsubjectsn=2Withdrawalofsubjectsn=3Inclusion/exclusion violationn=2Adverse eventn=2Inclusion/exclusionviolationn=4Contraindicated drugsn=1Discretion by investigatorn=1Contraindicated drugsn=4Adverse eventn=2Adverse eventn=1Follow-up lossn=1Follow-up lossn=1Discretionbyinvestigatorn=1',\n",
       " '| \\u2003793CHO et al.3.3\\u2003|\\u2003Safety analysisSafety analysis was performed in 304 patients who received ≥1 dose of a study drug and had ≥1 safety assessment in this clinical trial. Among the 304 patients, 113 cases of TEAEs were reported by 66 patients (Table\\xa03). Drug-related TEAEs accounted for 9.80% (10/102, 17 events) in the tegoprazan 50\\xa0mg group, 13.73% (14/102, 18 events) in the te-goprazan 100\\xa0mg group, and 12.00% (12/100, 19 events) in the lanso-prazole 30\\xa0mg group. Four cases of serious TEAEs were reported in the tegoprazan 50\\xa0mg group, two in the tegoprazan 100\\xa0mg group and one in the lansoprazole 30\\xa0mg group; however, none of these were causally related to treatment with the study drug (Table\\xa03). The most common drug-related TEAE in all treatment groups classified by system organ class was GI disorders; the incidence rates were 4.90% (5/102) for tegoprazan 50\\xa0mg, 6.86% (7/102) for tegoprazan 100\\xa0mg, and 4.00% (4/100) for lansoprazole 30\\xa0mg. Diarrhoea (2.94%) in tegoprazan 50\\xa0mg and abdominal discomfort (2%) and blood gastrin increased (2%) in lansoprazole 30\\xa0mg were the most frequently reported drug-related TEAEs (Table\\xa04). The incidence of any TEAE did not differ between the tegoprazan 50 and 100\\xa0mg treatment groups.3.4\\u2003|\\u2003Serum gastrin concentrationThe baseline serum gastrin concentrations were 54.84\\xa0±\\xa059.26\\xa0pg/mL, 55.63\\xa0±\\xa046.40\\xa0pg/mL, and 70.92\\xa0±\\xa0107.08\\xa0pg/mL for the tegoprazan 50\\xa0mg, tegoprazan 100\\xa0mg and lansoprazole 30\\xa0mg groups respectively (Figure\\xa02). The final serum gastrin concentrations at week 4 or 8 were 85.52\\xa0±\\xa077.97\\xa0pg/mL, 119.54\\xa0±\\xa094.05\\xa0pg/mL and 121.75\\xa0±\\xa0114.84\\xa0pg/mL. The change in serum gastrin concentration did not differ signifi-cantly between the tegoprazan and lansoprazole groups. Serum gastrin concentrations increased after treatment in all three treatment groups, but these returned to their baseline levels after completion of the treat-ment period. No significant changes in serum gastrin concentration',\n",
       " 'but these returned to their baseline levels after completion of the treat-ment period. No significant changes in serum gastrin concentration were observed between groups during the study period (Figure\\xa02).4\\u2003|\\u2003DISCUSSIONThe present study was designed to evaluate whether tegoprazan is non-inferior to lansoprazole in terms of the efficacy and safety in patients with GUs. At week 8, the cumulative endoscopic healing rates of GUs were 100% in the tegoprazan 50\\xa0 mg group, 97.85% in the tegoprazan 100\\xa0 mg group and 100% in the lansoprazole 30\\xa0mg group. At week 4, the respective endoscopic healing rates were 95.45%, 94.62% and 92.94%. These results demonstrate the non-inferiority of both tegoprazan 50 and 100\\xa0mg compared with lansoprazole 30\\xa0mg in terms of endoscopic healing rates. Our study showed similar results to vonoprazan. A previous study reported that vonoprazan produced non- inferior healing rates for gastric and duodenal ulcers in H.\\xa0pylori-positive patients at 8\\xa0weeks. In the PPS analysis, the ulcer healing rates were 93.5% in the vonoprazan group and 93.8% in the lansoprazole group.11One aim of our study was to determine the proper dose of te-goprazan for GU healing. The PPS and FAS analyses showed similar healing rates for the two doses of tegoprazan (50 and 100\\xa0mg) at Tegoprazan 50\\xa0mg (N\\xa0=\\xa088)Tegoprazan 100\\xa0mg (N\\xa0=\\xa093)Lansoprazole 30\\xa0mg (N\\xa0=\\xa085)Age (y)53.3954.1154.22GenderMale58 (65.91)61(65.59)47(55.29)Female30 (34.09)32 (34.41)38 (44.71)Height (cm)166.82166.27165.22Weight (kg)66.7767.1865.80Smoking; yes36 (40.91)33 (35.48)30 (35.29)Alcohol; yes42 (47.73)39 (41.94)38 (44.71)NSAID/ASA2(2.27)4(4.30)3(3.53)Helicobacter pylori positive52 (59.09)60 (64.52)57 (67.06)Current ulcers; numberSingle74 (84.09)73 (78.49)73 (85.88)Multiple14 (15.91)20 (21.51)12 (14.12)Current ulcer; size3-5\\xa0mm23 (20.54)27 (21.95)29 (26.85)5-10\\xa0mm60 (53.57)60 (48.78)47 (43.52)10-20\\xa0mm25(22.32)28 (22.76)25(23.15)20-30\\xa0mm',\n",
       " '73 (85.88)Multiple14 (15.91)20 (21.51)12 (14.12)Current ulcer; size3-5\\xa0mm23 (20.54)27 (21.95)29 (26.85)5-10\\xa0mm60 (53.57)60 (48.78)47 (43.52)10-20\\xa0mm25(22.32)28 (22.76)25(23.15)20-30\\xa0mm4 (3.57)8 (6.5)7 (6.48)TA B LE 1\\u2003Patient demographics and baseline characteristics (per protocol set)',\n",
       " '794\\u2003 |\\u2003 \\u2003\\u2002CHO et al.4 and 8\\xa0weeks. The increase in serum gastrin concentration, and safety profiles were similar in both groups. Tegoprazan 50\\xa0 mg would be effective as 100\\xa0mg in GU healing. In a phase 3 dose-rang-ing study of erosive esophagitis to compare tegoprazan with es-omeprazole, the percentage of patients with erosive esophagitis and cumulative healing rates at week 8 did not differ between the tegoprazan 50\\xa0 mg and tegoprazan 100\\xa0 mg groups.18 It is gener-ally accepted that suppressing gastric acid secretion enhances treatment of acid-related disorders, with better efficacy achieved when intragastric pH >4 is sustained for as long of a duration as possible.19-21 There has not been the direct comparison data of in-tragastric pH >4 holding time between tegoprazan and lansopra-zole. The previous pharmacodynamic study showed pH >4 holding time over 24\\xa0hours increased in a dose-dependent manner after a single dose of 50-400\\xa0mg of tegoprazan.15 The pH 4 > holding time in multiple dosing of tegoprazan 50\\xa0mg is 54.2%-68.2%, and Tegoprazan 50\\xa0mgTegoprazan 100\\xa0mgLansoprazole 30\\xa0mgAt 8\\xa0wks;Per protocol setN\\xa0=\\xa088N\\xa0=\\xa093N\\xa0=\\xa085Number(%) of healed patients88 (100.00)91 (97.85)85 (100.00)Difference from lansoprazole with 95% CId\\u200a(−7.66, 2.43)b\\u200aP valuea\\u200a—0.0137Full analysis setN\\xa0=\\xa096N\\xa0=\\xa099N\\xa0=\\xa093Number(%) of healed patients91 (94.79)94 (94.95)89 (95.70)Difference from lansoprazole with 95% CId\\u200a(−7.98, 6.09)b\\u200a(−7.69, 6.31)b\\u200aP valuea\\u200a0.01770.0146At 4\\xa0wks;Per protocol setN\\xa0=\\xa088N\\xa0=\\xa093N\\xa0=\\xa085Number(%) of healed patients84 (95.45)88 (94.62)79 (92.94)Difference from lansoprazole with 95% CId\\u200a(−5.18, 10.77)b\\u200a(−5.44, 8.80)c\\u200aP valuea\\u200a0.00380.0024Full analysis setN\\xa0=\\xa096N\\xa0=\\xa099N\\xa0=\\xa093Number(%) of healed patients87 (90.63)91 (91.92)83 (89.25)Difference from lansoprazole with 95% CId\\u200a(−7.20, 9.96)c\\u200a(−5.60, 10.95)c\\u200aP valuea\\u200a0.01170.0040Note: Non-inferiority margin −8.54%.aNon-inferiority test.',\n",
       " \"87 (90.63)91 (91.92)83 (89.25)Difference from lansoprazole with 95% CId\\u200a(−7.20, 9.96)c\\u200a(−5.60, 10.95)c\\u200aP valuea\\u200a0.01170.0040Note: Non-inferiority margin −8.54%.aNon-inferiority test. bExact unconditional confidence interval. cWald confidence interval. dAccording to Hochberg method, significant level for the test of tegoprazon and lansoprazole is 0.025 (one sided). TA B LE 2\\u2003Endoscopic healing rate (%) of gastric ulcer up to 4 and 8\\xa0weeksTegoprazan 50\\xa0mg (N\\xa0=\\xa0102)Tegoprazan 100\\xa0mg (N\\xa0=\\xa0102)Lansoprazole 30\\xa0mg (N\\xa0=\\xa0100)N (%)N (%)N (%)TEAE18 (17.65)23 (22.55)25 (25.00)95% CI, P valuea\\u200a[0.10-0.25], 0.2018[0.14, 0.31], 0.6824[0.17, 0.33]Drug-related TEAE10 (9.80)14 (13.73)12 (12.00)95% CI, P valuea\\u200a[0.04, 0.06], 0.6164[0.07, 0.20], 0.7143[0.06, 0.18]Serious TEAE3 (2.94)2 (1.96)1 (1.00)95% CI, P valuea\\u200a[0.00, 0.06], 0.6213[0.00, 0.05], 1.0000[0.00, 0.03]aχ2 or Fisher's exact test. TA B LE 3\\u2003Summary of treatment-emergent adverse events (TEAEs)\",\n",
       " '| \\u2003795CHO et al.66.55% of tegoprazan 100\\xa0mg in healthy males. Because two doses of tegoprazan showed similar ulcer healing rates, acid suppressive effect of tegoprazan seems satisfactory even in dose of 50\\xa0mg.Tegoprazan showed better efficacy in H.\\xa0 pylori positive pa-tients. In patients with H.\\xa0pylori infection, the both doses of te-goprazan were not inferior to lansoprazole 30\\xa0 mg. The 8-week healing rates were 100% in all of three groups. Subgroup analyses of H.\\xa0 pylori-negative patients showed the healing rate of tego-prazan 100\\xa0mg was not inferior, whereas tegoprazan 50\\xa0mg was not non-inferior to the lansoprazole. A previous study reported that vonoprazan also produced non- inferior healing rates to lan-soprazole for gastric and duodenal ulcers in H.\\xa0pylori-positive pa-tients at 8\\xa0weeks.12We also analysed the incidence rates of symptoms of epigastric pain, abdominal distension, nausea, heartburn and anorexia. The symptoms had resolved by the last study visit in >90% of patients in all three treatment groups. This finding shows the additional benefit to those patients who had both peptic ulcer disease and associated symptoms.Tegoprazan was generally well tolerated. The incidence of TEAEs did not differ significantly between groups, and no serious drug-related AEs were reported throughout the study. The safety and tolerability profiles were similar to those of lansoprazole. Most TEAEs were mild in severity, and few drug-related TEAEs were re-ported. Moreover, the magnitude of the increase in serum gastrin concentration did not differ significantly between groups, and the serum gastrin concentration returned to the baseline levels after the patients completed their treatment. Additionally, vonoprazan in-creased serum gastrin levels more than lansoprazole in GU study.11 But changes of serum gastrin levels were comparable among tego-prazan and lansoprazole groups in this study.This is the study to compare tegoprazan and lansoprazole, or',\n",
       " 'But changes of serum gastrin levels were comparable among tego-prazan and lansoprazole groups in this study.This is the study to compare tegoprazan and lansoprazole, or to compare P-CABs and PPIs in the GU healing. The healing effect did not differ between the tegoprazan doses of 50 and 100\\xa0 mg. The healing rate at 8\\xa0weeks was nearly 100%. The strengths of this study include the randomised, double-blind, double-dummy, mul-tisite design, the large sample size and the focus on a Korean pop-ulation. One limitation of our study is that, given the study design, we could examine only the non-inferiority and not the superiority Tegoprazan  50\\xa0mg (N\\xa0=\\xa0102)Tegoprazan 100\\xa0mg (N\\xa0=\\xa0102)Lansoprazole 30\\xa0mg (N\\xa0=\\xa0100)N (%)N (%)N (%)Gastrointestinal disorders5 (4.90)7 (6.86)4 (4.00)Diarrhoea3 (2.94)2 (1.96)0 (0.00)Upper abdominal pain0 (0.00)1 (0.98)0 (0.00)Constipation0 (0.00)1 (0.98)0 (0.00)Dyspepsia1 (0.98)1 (0.98)0 (0.00)Abdominal discomfort0 (0.00)0 (0.00)2 (2.00)Investigations2 (1.96)2 (1.96)3 (3.00)Serum gastrin increased1 (0.98)0 (0.00)2 (2.00)Alanine aminotransferase increased1 (0.98)1 (0.98)0 (0.00)Aspartate aminotransferase increased0 (0.00)1 (0.98)1 (1.00)Blood bilirubin increased0 (0.00)1 (0.98)0 (0.00)Gamma-glutamyltransferase increased1 (0.98)0 (0.00)0 (0.00)Blood triglycerides increased1 (0.98)0 (0.00)0 (0.00)Headache1 (0.98)0 (0.00)1 (1.00)Chest discomfort or pain2 (1.96)0 (0.00)1 (1.00)TA B LE 4\\u2003Drug-related treatment-emergent adverse events (TEAEs) reported in the treatment groupFI G U R E 2\\u2003Gastrin levels from baseline (pg/mL) during treatment and follow-up periods (safety set)260240220200180/6d）160gastrin140Serum12010080604020BaselineFinal(Week 4or 8)Safety follow-upVisitGroup:Tegoprazan50mg--Tegoprazan 100 mgLansoprazole 30 mg',\n",
       " \"796\\u2003 |\\u2003 \\u2003\\u2002CHO et al.of tegoprazan compared with lansoprazole. In conclusion, we have shown that tegoprazan at doses of 50 and 100\\xa0mg was non-inferior to lansoprazole 30\\xa0mg and had a favourable safety profile in patients with GUs.ACKNOWLEDGEMENTSDeclaration of personal interests: The authors thank all the investiga-tors who contributed to this study. Statistical analysis was supported by Kyeong min Oh, Ah Rong Kim, Chung Hyun Choi, Hyun Wook, Park, Eun Ji Kim and Geun Seog Song who are employees of HK inno.N Corp., Seoul, Korea.AUTHORSHIPGuarantor of the article: Myung-Gyu Choi.Author contributions: All authors were involved in patients' enrollment, performing the study, acquisition of data and inter-pretation of study results. Prof, Myung-Gyu Choi was involved in the study design, drafting of the manuscript and critical revision of the manuscript. DrYu Kyung Cho wrote the manuscript, all au-thors approved the final version of the manuscript, including the authorship list.ORCIDMyung-Gyu Choi\\xa0 https://orcid.org/0000-0002-7297-6577 Hye-Kyung Jung\\xa0 https://orcid.org/0000-0002-6653-5214 Byung-Wook Kim\\xa0 https://orcid.org/0000-0002-2290-4954 REFERENCES 1. Hunt RH, Cederberg C, Dent J, et al. Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci. 1995;40:24S-49S. 2. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibi-tors for the practising physician. Best Pract Res Clin Gastroenterol. 2001;15:355-370. 3. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25-35. 4. Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liv. 2017;15:27-37. 5. Oshima T, Miwa H. Potent potassium-competitive acid block-ers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;30:334-344.\",\n",
       " '5. Oshima T, Miwa H. Potent potassium-competitive acid block-ers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;30:334-344. 6. Mori H, Suzuki H. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil. 2019;25:6-14. 7. Matsukawa J, Hori Y, Nishida H, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81:1145-1151. 8. Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55:409-418. 9. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter py-lori eradication. Aliment Pharmacol Ther. 2017;46:106-114.10. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vono-prazan, a novel potassium-competitive acid blocker, vs. lansopra-zole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240-251.11. Komori H, Ueyama H, Nagahara A, et al. A prospective randomized trial of a potassium competitive acid blocker vs proton pump in-hibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia. J Int Med Res. 2019;47:1441-1452.12. Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority ran-domised controlled trials. Aliment Pharmacol Ther. 2017;45:240-252.13. Liu C, Feng BC, Zhang Y, Li LX, Zuo XL, Li YQ. The efficacy of vono-prazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: a meta-analysis. J Dig Dis. 2019;20:503-511.',\n",
       " \"prazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: a meta-analysis. J Dig Dis. 2019;20:503-511.14. Takahashi N, Take Y. Tegoprazan, a novel potassium-competi-tive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther. 2018;364:275-286.15. Han S, Choi HY, Kim YH, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potas-sium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019;50:751-759.16. Scarpignato C, Hunt RH. Editorial: potassium-competitive acid blockers for acid-related diseases—tegoprazan, a new kid on the block. Aliment Pharmacol Ther. 2019;50:960-962.17. Kim DK, Lee KH, Kim SJ, et al. Effects of tegoprazan, a novel potas-sium-competitive acid blocker, on rat models of gastric acid-related disease. Pharmacol Exp Ther. 2019;369:318-327.18. Lee KJ, Son BK, Kim GH, et al. Randomised phase 3 trial: tego-prazan, a novel potassium-competitive acid blocker, vs. esomepra-zole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49:864-872.19. Gerson LB, Fass R. A systematic review of the definitions, preva-lence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009;7:372-378.20. Orr WC. Review article: sleep-related gastro-oesophageal reflux as a distinct clinical entity. Aliment Pharmacol Ther. 2010;31:47-56.21. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134:1842-1860.How to cite this article: Cho YK, Choi M-G, Choi SC, et al. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther. 2020;52:789–797. https://doi.org/10.1111/apt.15865APPENDIX 1The authors' complete affiliation list\",\n",
       " \"competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther. 2020;52:789–797. https://doi.org/10.1111/apt.15865APPENDIX 1The authors' complete affiliation listYu Kyung Cho and Myung-Gyu Choi: Catholic Photomedicine Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Suck Chei Choi: Wonkwang University Hospital, Iksan, Korea. Kee Myung Lee: Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea. Tae Oh Kim: Haeundae Paik Hospital, Inje University School of Medicine, Busan, Korea. Soo-Heon Park: Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Jeong Seop Moon: Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea. Yun Jeong Lim: Dongguk University IIsan Hospital, Dongguk University College of Medicine,\",\n",
       " \"| \\u2003797CHO et al.Goyang, Korea. Dae Hwan Kang: Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea. Gab Jin Cheon: Gangneung Asan Hospital, Ulsan University College of Medicine, Gangneung, Korea. Gwang Ho Baik: Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea. Kyoung Oh Kim: Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Korea. Kwang Bum Cho: Keimyung University School of Medicine, Daegu, Korea. Jin Seok Jang: Dong-A University College of Medicine, Busan, Korea. Jong-Jae Park: Korea University College of Medicine, Seoul, Korea. Byoung Kwan Son: Eulji University Hospital, Seoul, Korea. Hye-Kyung Jung: Ewha Woman's University Mokdong Hospital, Seoul, Korea. Byung-Wook Kim: Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea. Sung Kuk Kim: Kyungpook University School of Medicine, Daegu, Korea. Soo Teik Lee: Chonbuk National University Medical School, Jeonju, Korea. Jae Myung Cha: KyungHee University Hospital at Gangdong, KyungHee University School of Medicine, Seoul, Korea. Ah Rong Kim, Eun Ji Kim, Hyun Wook Park and Geun Seog Song: Clinical Development Division, HK inno.N Corp., Seoul, Korea. Jae Young Jang: Kyung Hee University College of Medicine, Seoul, Korea. Jeong Eun Shin: Dankook University College of Medicine, Cheonan, Korea. Dong Il Park: Kangbuk Samsung Hospital, Samsung Medical Center, Seoul, Korea. Su Jin Hong: Soonchunhyang University Buchen Hospital, Bucheon, Korea. Yong Chan Lee: Severance Hospital, Seoul, Korea. Eun Kwang Choi: Jeju National University School of Medicine, Jeju, Korea. Chan Guk Park: Chosun University Hospital, Chosun University College of Medicines, Gwangju, Korea. Jae Gyu Kim: Chung-Ang University College of Medicine, Seoul, Korea. Seong Woo Jeon: Gastric Cancer Center, Kyungpook National University\",\n",
       " 'University College of Medicines, Gwangju, Korea. Jae Gyu Kim: Chung-Ang University College of Medicine, Seoul, Korea. Seong Woo Jeon: Gastric Cancer Center, Kyungpook National University Chilgok Hospital, Daegu, Korea. Ji Won Kim: Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea. Sang Woo Lee: Korea University Ansan Hospital, Ansan, Korea. Kwang Hyun Ko: Digestive Disease Center, CHA Medical Center, CHA University, Seongnam, Korea. Hyun Soo Kim: Yonsei University Wonju College of Medicine, Wonju Christian Hospital, Wonju, Korea.',\n",
       " 'The new england  journal of medicinen engl j med 382;14\\u2003 nejm.org\\u2003 April 2, 20201299established in 1812April 2, 2020vol. 382\\u2003no. 14From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong. Address reprint re‑quests to Dr. Lau at the Department of Surgery, Rm. 64026, Lui Chee Woo Clini‑cal Science Bldg., Prince of Wales Hospi‑tal, 32 Ngan Shing St., Shatin, Hong Kong, or at \\xadlaujyw@\\u200b\\xadsurgery\\u200b.\\xadcuhk\\u200b.\\xadedu\\u200b.\\xadhk.N Engl J Med 2020;382:1299-308.DOI: 10.1056/NEJMoa1912484Copyright © 2020 Massachusetts Medical Society.BACKGROUNDIt is recommended that patients with acute upper gastrointestinal bleeding undergo endoscopy within 24 hours after gastroenterologic consultation. The role of endos-copy performed within time frames shorter than 24 hours has not been adequately defined.METHODSTo evaluate whether urgent endoscopy improves outcomes in patients predicted to be at high risk for further bleeding or death, we randomly assigned patients with overt signs of acute upper gastrointestinal bleeding and a Glasgow–Blatchford score of 12 or higher (scores range from 0 to 23, with higher scores indicating a higher risk of further bleeding or death) to undergo endoscopy within 6 hours (urgent-endoscopy group) or between 6 and 24 hours (early-endoscopy group) after gastroenterologic consultation. The primary end point was death from any cause within 30 days after randomization.RESULTSA total of 516 patients were enrolled. The 30-day mortality was 8.9% (23 of 258 patients) in the urgent-endoscopy group and 6.6% (17 of 258) in the early-endoscopy group (difference, 2.3 percentage points; 95% confidence interval [CI], −2.3 to 6.9). Further bleeding within 30 days occurred in 28 patients (10.9%) in the urgent-endoscopy group and in 20 (7.8%) in the early-endoscopy group (difference, 3.1 percentage points; 95% CI, −1.9 to 8.1). Ulcers with active bleeding or visible ves-',\n",
       " 'endoscopy group and in 20 (7.8%) in the early-endoscopy group (difference, 3.1 percentage points; 95% CI, −1.9 to 8.1). Ulcers with active bleeding or visible ves-sels were found on initial endoscopy in 105 of the 158 patients (66.4%) with peptic ulcers in the urgent-endoscopy group and in 76 of 159 (47.8%) in the early-endos-copy group. Endoscopic hemostatic treatment was administered at initial endoscopy for 155 patients (60.1%) in the urgent-endoscopy group and for 125 (48.4%) in the early-endoscopy group.CONCLUSIONSIn patients with acute upper gastrointestinal bleeding who were at high risk for further bleeding or death, endoscopy performed within 6 hours after gastroen-terologic consultation was not associated with lower 30-day mortality than endos-copy performed between 6 and 24 hours after consultation. (Funded by the Health and Medical Fund of the Food and Health Bureau, Government of Hong Kong Special Administrative Region; ClinicalTrials.gov number, NCT01675856.)abstr actTiming of Endoscopy for Acute Upper Gastrointestinal BleedingJames\\xa0Y.W. Lau, M.D., Yuanyuan Yu, Ph.D., Raymond\\xa0S.Y. Tang, M.D., Heyson\\xa0C.H. Chan, M.B., Ch.B., Hon‑Chi Yip, M.B., Ch.B., Shannon\\xa0M. Chan, M.B., Ch.B., Sally\\xa0W.Y. Luk, M.B., Ch.B., Sunny\\xa0H. Wong, Ph.D., Louis\\xa0H.S. Lau, M.B., Ch.B., Rashid\\xa0N. Lui, M.B., Ch.B., Ting\\xa0T. Chan, M.B., Ch.B., Joyce\\xa0W.Y. Mak, M.B., Ch.B., Francis\\xa0K.L. Chan, M.D., and Joseph\\xa0J.Y. Sung, M.D.\\u200bThe New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 382;14\\u2003 nejm.org\\u2003 April 2, 20201300The new engl and jour nal of medicineAcute upper gastrointestinal bleed-ing is one of the most common medical emergencies. A national audit from the United Kingdom estimated a crude overall in-hospital mortality of 10% after acute upper gas-trointestinal bleeding.1 Endoscopy allows iden\\xadtification of the source of bleeding, as well as hemostatic treatment for actively bleeding le-sions. Endoscopic hemostatic treatment of high-risk lesions stops bleeding and reduces the risk of further bleeding and the need for surgery.2 An international consensus group recommends en-doscopy within 24 hours after presentation for patients with acute upper gastrointestinal bleed-ing.3 For patients who are at high risk for further bleeding or death, the consensus group could not make a recommendation for or against per-forming endoscopy within 12 hours as opposed to performing endoscopy later. Many observa-tional studies,4-16 three randomized, controlled trials,17-19 and two systematic reviews20,21 have shown that urgent endoscopy (the definitions of which have varied among studies, ranging from within 2 hours to within 12 hours after presen-tation) in unselected patients with acute upper gastrointestinal bleeding did not decrease mor-tality. The three randomized trials were not de-signed to focus on patients at high risk for fur-ther bleeding or death and did not report an assessment of patients’ risk.The Glasgow–Blatchford score is a validated risk-assessment score for the prediction of clini-cal outcomes, including the need for interven-tions and the risk of death (scores range from 0 to 23, with higher scores indicating a higher risk of further bleeding or death). In an interna-tional multicenter prospective study involving 3012 patients, a threshold score of 7 or higher was shown to provide the most accurate predic-tion of whether a patient will be determined to need endoscopic treatment.22 In our own valida-',\n",
       " '3012 patients, a threshold score of 7 or higher was shown to provide the most accurate predic-tion of whether a patient will be determined to need endoscopic treatment.22 In our own valida-tion study, a higher score was associated with a greater likelihood of undergoing endoscopic treat-ment, as well as with a higher risk of death.23 Recently, two large cohort studies16,24 provided conflicting results regarding the association between urgent endoscopy (within 6 hours after admission) and mortality. In a prospective co-hort study involving 961 patients with Glasgow–Blatchford scores greater than 7, Cho et al.24 found that endoscopy performed within 6 hours, as compared with between 6 and 24 hours, was an independent predictor of lower mortality (odds ratio for death, 0.36; 95% confidence in-terval [CI], 0.14 to 0.95). However, in the study by Laursen et al.,16 involving 2944 patients, the time frame for endoscopy that was associated with the lowest mortality was between 6 and 24 hours after admission. Mortality was higher among patients with hemodynamic instability or severe coexisting illnesses, defined as an American Society of Anesthesiologists grade of 3 to 5. A risk-assessment score was not used in that study.In this trial, we hypothesized that for patients with acute gastrointestinal bleeding who were predicted to be at high risk for further bleeding or death, endoscopy performed within 6 hours after gastroenterologic consultation would fore-stall further bleeding and improve outcomes as compared with endoscopy performed between 6 and 24 hours after consultation.MethodsTrial Design and OversightThe Joint Chinese University of Hong Kong–New Territories East Cluster Hospital Ethics Commit-tee approved the protocol. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol, avail-able with the full text of this article at NEJM.org. We reported all serious adverse events, within 24',\n",
       " 'for the fidelity of the trial to the protocol, avail-able with the full text of this article at NEJM.org. We reported all serious adverse events, within 24 hours after their occurrence, to the Clinical Re-search and Ethics Committee at the Chinese Uni-versity of Hong Kong. Serious adverse events were defined as events that were life-threaten-ing, that led to prolongation of existing hospital-ization, or that led to persistent or substantial disability or incapacitation. The committee pro-vided ethics oversight and scientific oversight during the period of the trial. Senior physicians and biostatisticians on the committee adjudicated outcomes and monitored the progress of the trial.PatientsOur gastrointestinal bleeding team screened pa-tients for eligibility and performed randomiza-tion either in the emergency department or after admission to a medical ward. Patients who had overt signs of acute upper gastrointestinal bleed-ing (hematemesis, melena, or both) and who were predicted to be at high risk for further bleeding or death on the basis of a Glasgow–Blatchford score of 12 or higher were eligible for A Quick Take is  available at  NEJM.org The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 382;14\\u2003 nejm.org\\u2003 April 2, 20201301Endoscopy for Upper Gastrointestinal Bleedingenrollment. The Glasgow–Blatchford score is based on the systolic blood pressure, pulse rate, hemoglobin and serum urea levels at admission, whether the patient presented with melena or syncope, and the presence or absence of hepatic disease or cardiac failure. Eligible inpatients in whom gastrointestinal bleeding developed while they were hospitalized for other medical illnesses also underwent randomization at the first gastro-intestinal consultation. We calculated the Glasgow–Blatchford score on the basis of the lowest sys-tolic blood pressure and highest pulse rate recorded and the hemoglobin and urea levels on admission to the emergency department (or, for patients already hospitalized, recent values ob-tained before gastrointestinal consultation). All patients provided written informed consent.We excluded patients who were younger than 18 years of age, unable to provide written in-formed consent, pregnant, or moribund from terminal illness. We also excluded patients who were in hypotensive shock or whose condition did not stabilize after initial resuscitation, since they required urgent intervention.Randomization, Interventions, and Data CollectionWe randomly assigned patients in a 1:1 ratio us-ing a computer-generated sequence. After obtain-ing written informed consent from the patient, the admitting resident then logged on to a Web-based randomization program, which generated the randomization number and assigned treat-ment. We randomly assigned patients to under-go either urgent endoscopy within 6 hours after gastroenterologic consultation (urgent-endoscopy group) or early endoscopy the next morning and within 24 hours (early-endoscopy group). Patients in the early-endoscopy group whose gastroen-terologic consultation took place between mid-night and 8 a.m. underwent endoscopy in the morning endoscopy session of the same day of',\n",
       " 'in the early-endoscopy group whose gastroen-terologic consultation took place between mid-night and 8 a.m. underwent endoscopy in the morning endoscopy session of the same day of their admission and were scheduled for a time of endoscopy that was a minimum of 6 hours after consultation. Patients in the early-endoscopy group whose gastroenterologic consultation took place between 8 a.m. and 11:59 p.m. underwent endoscopy the next morning. We monitored these patients closely and offered emergency endoscopy if there were signs of further bleed-ing (i.e., fresh hematemesis or hematochezia, hypotensive shock, or both). The hospitals offer 24-hour endoscopy service with a fellow and a consultant on the team. All after-hours endos-copy procedures were supported by endoscopy nurses with skills in assisting with therapeutic endoscopy.Both groups of patients received an intrave-nous high-dose infusion of a proton-pump in-hibitor (80-mg bolus followed by 8 mg per hour) on admission, as well as at the first sign of bleeding during the hospital stay. Patients with suspected variceal bleeding (known liver disease, stigmata of liver cirrhosis, or a history of bleed-ing esophagogastric varices) received a vasoac-tive drug as well as intravenous antibiotic agents.At endoscopy, gastroduodenal ulcers with ac-tive bleeding or with nonbleeding visible vessels were treated with either hemoclips or contact thermocoagulation, with or without preinjection of diluted epinephrine. Bleeding esophageal and gastric varices were treated with band ligation and injection of cyanoacrylate (a tissue adhesive), respectively. After endoscopic hemostatic treat-ment of the bleeding ulcers in these patients, a high-dose intravenous infusion of a proton-pump inhibitor was continued for 72 hours. We de-fined further bleeding as a composite of persis-tent bleeding (i.e., bleeding that was not suc-cessfully controlled at the first endoscopy) or',\n",
       " 'inhibitor was continued for 72 hours. We de-fined further bleeding as a composite of persis-tent bleeding (i.e., bleeding that was not suc-cessfully controlled at the first endoscopy) or recurrent bleeding (i.e., bleeding that recurred after hemostatic treatment). We generally adopt\\xaded criteria from international guidelines on defini-tions of recurrent bleeding.25 Endoscopy togeth-er with further hemostatic treatment was per-formed for patients with overt signs of recurrent bleeding after initial endoscopic control.End PointsThe primary end point was death from any cause within 30 days after randomization. Secondary end points included receipt of endoscopic ther\\xadapy at first endoscopy, further bleeding (defined as persistent or recurrent bleeding),25 duration of stay in the hospital and intensive care unit, re-ceipt of further endoscopic treatment, emergency surgery or angiographic embolization to achieve hemostasis, blood transfusions, and adverse events within 30 days after randomization.Statistical AnalysisWe determined that a sample of 258 patients per group would provide 80% power to detect an 8-percentage-point difference (i.e., 16% vs. 8%) The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 382;14\\u2003 nejm.org\\u2003 April 2, 20201302The new engl and jour nal of medicinein 30-day mortality, with a two-sided α level of 5%. We considered a 50% relative difference in mortality to be clinically significant. In our vali-dation study of the Glasgow–Blatchford score,23 21% of patients had a score of 12 or higher, and the 30-day mortality in that group was 16.1%.Our analysis was performed on an intention-to-treat basis. We did not have any data missing from our data set. We used the log-rank test to compare the time from randomization to the end points of death and further bleeding and a Cox proportional-hazards model to estimate the hazard ratio and 95% confidence intervals. We used the Schoenfeld residual test to verify the assumption of proportional hazards in the Cox analysis, which was fulfilled for the end points of death from any cause and further bleeding. Secondary end points were compared between the groups with a chi-square test for difference in proportions and with Student’s t-test and a Mann–Whitney U test for parametric and nonparametric data, respectively. All tests of sig-nificance were two-tailed, and a P value of 0.025 or less was considered to indicate statistical sig-nificance for the primary end point, since we reported one unplanned interim analysis in 2015.26 There was no prespecified plan to adjust for multiple comparisons of the secondary end points; the results for secondary end points are reported with 95% confidence intervals and with-out P values. Confidence intervals have not been adjusted for multiple comparisons and should not be used to infer treatment effects.ResultsPatientsFrom July 2012 through October 2018, a total of 4715 patients with acute upper gastrointesti-nal bleeding underwent screening; 598 had a Glasgow–Blatchford score of 12 or higher, and 516 were enrolled in the trial and underwent randomization (258 assigned to each group) (Fig. S1 in the Supplementary Appendix, avail-',\n",
       " 'Glasgow–Blatchford score of 12 or higher, and 516 were enrolled in the trial and underwent randomization (258 assigned to each group) (Fig. S1 in the Supplementary Appendix, avail-able at NEJM.org). The baseline demographic and clinical characteristics and the endoscopic findings are shown in Table\\xa0 1. Peptic ulcers were the source of bleeding in 158 patients (61.2%) in the urgent-endoscopy group and 159 patients (61.6%) in the early-endoscopy group, and esophagogastric varices were the cause in 25 (9.7%) and 19 (7.3%), respectively.In the urgent-endoscopy group, 3 patients did not undergo endoscopy (1 had undergone recent endovascular repair for an abdominal aneurysm and had cardiac arrest before endoscopy could be performed, 1 had acute pulmonary edema, and 1 declined), and 6 had endoscopy performed more than 6 hours after gastroenterologic con-sultation. In the early-endoscopy group, 5 patients did not undergo endoscopy (4 died before endos-copy [2 from ongoing bleeding, 1 from acute coronary syndrome, and 1 from a ruptured tho-racic aortic aneurysm], and 1 declined). Emer-gency endoscopy was performed in 20 patients (7.8%) in the early-endoscopy group because of new-onset signs of bleeding: hypotension in 11 patients, fresh hematemesis in 6, fresh melena in 2, and a substantial decrease in hemoglobin level in 1. Three patients in the early-endoscopy group underwent endoscopy more than 24 hours after gastroenterologic consultation (Table\\xa02).Timing of EndoscopyThe mean (±SD) time from presentation to gas-troenterologic consultation was 7.4±6.2 hours in the urgent-endoscopy group and 8.0±7.1 hours in the early-endoscopy group (Table\\xa02), and the mean time from gastroenterologic consultation to endoscopy was 2.5±1.7 hours and 16.8±6.8 hours, respectively. Therefore, the mean time from presentation to endoscopy was 9.9±6.1 hours in the urgent-endoscopy group and 24.7±9.0 hours in the early-endoscopy group. In the urgent-',\n",
       " 'hours, respectively. Therefore, the mean time from presentation to endoscopy was 9.9±6.1 hours in the urgent-endoscopy group and 24.7±9.0 hours in the early-endoscopy group. In the urgent-endoscopy group, 72 patients (27.9%) underwent endoscopy within 6 hours after presentation, and 124 patients (48.1%) underwent endoscopy within 12 hours (Fig. S3B). The time of day that patients had their gastroenterologic consultation was similar in the two groups. Endoscopy was performed between 6 p.m. and 5:59 a.m. in 96 of 255 patients (37.6%) in the urgent-endoscopy group and 17 of 253 patients (6.7%) in the early-endoscopy group. Additional details about the timing of endoscopy in each group are provided in Table\\xa02 and Figure S3.30-Day MortalityAll-cause mortality at 30 days after randomiza-tion did not differ significantly between the two groups. A total of 23 patients (8.9%) in the urgent-endoscopy group and 17 (6.6%) in the early-endoscopy group died (hazard ratio, 1.35; 95% CI, 0.72 to 2.54; P\\u2009=\\u20090.34). (Fig.\\xa01A and Table\\xa03). The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 382;14\\u2003 nejm.org\\u2003 April 2, 20201303Endoscopy for Upper Gastrointestinal BleedingThe difference in mortality between the groups was 2.3 percentage points (95% CI, −2.3 to 6.9). Deaths from gastrointestinal bleeding accounted for 5 of the 23 deaths in the urgent-endoscopy group and 2 of the 17 deaths in the early-endos-copy group. Advanced cancer was present in 11 of 23 and 8 of 17 patients who died, respectively. The causes of deaths are listed in Table S2.Table 1. Baseline Characteristics of the Patients.*CharacteristicsUrgent-Endoscopy Group (N\\u2009=\\u2009258)Early-Endoscopy Group (N\\u2009=\\u2009258)Age — yr69.6±16.071.4±14.9Male sex — no. (%)157 (60.9)168 (65.1)Hemoglobin level on admission — g/dl7.4±1.87.2±1.6Systolic blood pressure — mm Hg109.6±22.1107.8±20.8Systolic blood pressure <90 mm Hg — no. (%)46 (17.8)37 (14.3)Heart rate >100 beats/min — no. (%)85 (32.9)92 (35.7)Glasgow–Blatchford score†13.7±1.513.7±1.6Glasgow–Blatchford score category — no. (%)12 to 14193 (74.8)183 (70.9)15 to 2365 (25.2)75 (29.1)Bleeding during hospitalization — no. (%)‡22 (8.5)20 (7.8)Coexisting diseases — no. (%)Ischemic heart disease33 (12.8)29 (11.2)Cancer31 (12.0)25 (9.7)Renal disease25 (9.7)21 (8.1)Liver cirrhosis11 (4.3)10 (3.9)History of bleeding peptic ulcers — no. (%)49 (19.0)41 (15.9)Risk factors for peptic ulcer disease — no. (%)NSAID use42 (16.3)45 (17.4)Aspirin use77 (29.8)65 (25.2)Clopidogrel use3 (1.2)4 (1.6)Warfarin or direct oral anticoagulant use7 (2.7)10 (3.9)Endoscopic findingsPeptic ulcer — no. (%)158 (61.2)159 (61.6)Gastric ulcer6977Duodenal ulcer8174Anastomotic ulcer or jejunal ulcer44Esophageal ulcer44Esophageal or gastric varices — no. (%)25 (9.7)19 (7.4)Other findings on endoscopy — no. (%)§72 (27.9)75 (29.1)No abnormality detected — no.312*Plus–minus values are means ±SD. NSAID denotes nonsteroidal antiinflammatory drug.',\n",
       " '25 (9.7)19 (7.4)Other findings on endoscopy — no. (%)§72 (27.9)75 (29.1)No abnormality detected — no.312*Plus–minus values are means ±SD. NSAID denotes nonsteroidal antiinflammatory drug.†The Glasgow–Blatchford score ranges from 0 to 23, with higher scores indicating a higher risk of further bleeding or death.‡This category includes patients who had been admitted with other medical illnesses and in whom symptoms of acute upper gastrointestinal bleeding subsequently developed during hospitalization.§Other findings included esophagitis, gastritis, duodenitis or erosions, gastrointestinal cancers and submucosal tumors, Dieulafoy’s lesions, angiodysplasia, Mallory–Weiss tears, antral vascular ectasia, gastric polyps, duodenal diverticulum, bleeding varices at anastomosis, papilloma, hiatal hernia, submucosal hematoma, post-sphincterotomy bleeding, hemo‑bilia, and diffuse gastric hemorrhage.The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 382;14\\u2003 nejm.org\\u2003 April 2, 20201304The new engl and jour nal of medicineFurther Bleeding, Endoscopic Treatment,  and Other End PointsFurther bleeding within 30 days occurred in 28 patients (10.9%) in the urgent-endoscopy group and 20 patients (7.8%) in the early-endoscopy group (hazard ratio, 1.46; 95% CI, 0.83 to 2.58). The between-group difference in the percentage of patients with further bleeding was 3.1 per-centage points (95% CI, −1.9 to 8.1) (Fig.\\xa01B and Table\\xa0 3). Persistent bleeding at endoscopy oc-curred in 2 patients in the urgent-endoscopy group (one of whom had gastric varices and bled again on day 3 but was counted only once in the analysis of the composite end point of further bleeding) and in 1 patient in the early-endoscopy group. Recurrent bleeding occurred in 27 patients (10.5%) in the urgent-endoscopy group and in 19 patients (7.4%) in the early-endoscopy group.Endoscopic hemostatic treatment was per-formed during the first endoscopy in 155 pa-tients (60.1%) in the urgent-endoscopy group and in 125 patients (48.4%) in the early-endos-copy group (difference, 11.6 percentage points; 95% CI, 0.3 to 20.0) (Table\\xa03). Endoscopic hemo-static treatment for bleeding peptic ulcers was performed in 109 of the 158 patients with ulcers (68.9%) in the urgent-endoscopy group and in 81 of the 159 patients with ulcers (50.9%) in the early-endoscopy group. (The endoscopic stigmata of bleeding observed in peptic ulcers are shown in Fig. S2.) Among the patients who had peptic ulcers, ulcers with active bleeding or visible vessels Table 2. Timing of Endoscopy.*MeasureUrgent-Endoscopy Group (N\\u2009=\\u2009258)Early-Endoscopy Group (N\\u2009=\\u2009258)Time from presentation to gastroenterologic consultation — hr†7.4±6.28.0±7.1Time from gastroenterologic consultation to endoscopy — hr2.5±1.716.8±6.8Time from presentation to endoscopy — hr‡9.9±6.124.7±9.0Distribution of time from gastroenterologic consultation to  endoscopy — no./total no. (%)‡≤6 hr',\n",
       " '2.5±1.716.8±6.8Time from presentation to endoscopy — hr‡9.9±6.124.7±9.0Distribution of time from gastroenterologic consultation to  endoscopy — no./total no. (%)‡≤6 hr249/255 (97.6)15/253 (5.9)>6–12 hr5/255 (2.0)44/253 (17.4)>12–18 hr0/25560/253 (23.7)>18–24 hr0/255131/253 (51.8)>24 hr1/255 (0.4)3/253 (1.2)Time of gastroenterologic consultation — no. (%)6 a.m. to 11:59 a.m.70 (27.1)49 (19.0)Noon to 5:59 p.m.140 (54.3)135 (52.3)6 p.m. to 11:59 p.m.35 (13.6)48 (18.6)Midnight to 5:59 a.m.13 (5.0)26 (10.1)Time of endoscopy — no. (%)‡6 a.m. to 11:59 a.m.31/255 (12.2)152/253 (60.1)Noon to 5:59 p.m.128/255 (50.2)84/253 (33.2)6 p.m. to 11:59 p.m.83/255 (32.5)13/253 (5.1)Midnight to 5:59 a.m.13/255 (5.1)4/253 (1.6)Endoscopy not performed — no. (%)3/255 (1.2)5/253 (2.0)*Plus–minus values are means ±SD. Percentages may not total 100 because of rounding.†Symptoms of acute upper gastrointestinal bleeding developed during hospitalization in 8.5% of patients in the urgent-endoscopy group and in 7.8% of patients in the early-endoscopy group.‡In the urgent-endoscopy group, 3 patients did not undergo endoscopy; the reasons were death on the day of enrollment (1), acute pulmonary edema (1), and the patient declining to undergo endoscopy (1). In the early-endoscopy group,  5 patients did not undergo endoscopy; the reasons were death on the day of or the day after enrollment (4) and the patient declining to undergo endoscopy (1).The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 382;14\\u2003 nejm.org\\u2003 April 2, 20201305Endoscopy for Upper Gastrointestinal Bleedingwere found in 105 patients (66.4%) in the urgent-endoscopy group and in 76 (47.8) in the early-endoscopy group. The two groups did not dif-fer substantially in the number of patients who underwent surgery (2 in the urgent-endoscopy group and 1 in the early-endoscopy group) or angiographic treatment (3 and 2, respectively).The duration of hospitalization did not differ between the urgent-endoscopy group and the early-endoscopy group (median of 5 days in both groups), and the two groups were similar in the number of patients who were admitted to the in-tensive care unit (4 and 3, respectively), the per-centage of patients who received a transfusion (89.5% and 90.7%), and the mean number of units of packed red cells received by transfusion (2.4 units in both groups).Timing of Endoscopy and Clinical End PointsWe performed a post hoc analysis to investigate the association between the time of day during which patients underwent endoscopy and the end points of further bleeding and death (Table S1). We analyzed end points in the urgent-endos-copy group after endoscopy performed during office hours (6 a.m. to 5:59 p.m.) and after endos-copy performed after hours (6 p.m. to 5:59 a.m.). The percentage of patients with further bleeding and the percentage of patients who died did not differ significantly according to the time of day of endoscopy (further bleeding, 10.7% [17 of 159] for endoscopy performed during office hours and 10.4% [10 of 96] for endoscopy performed after hours; death, 7.5% [12 of 159] and 10.4% [10 of 96], respectively). In the early-endoscopy group, 4 of 15 patients (26.7%) who underwent endoscopy within 6 hours after randomization and 3 of 44 (6.8%) of those who underwent en-doscopy between 6 and 12 hours after random-ization died within 30 days; among the 194 pa-tients who underwent endoscopy more than 12',\n",
       " 'and 3 of 44 (6.8%) of those who underwent en-doscopy between 6 and 12 hours after random-ization died within 30 days; among the 194 pa-tients who underwent endoscopy more than 12 hours after randomization, 6 (3.1%) died. Addi-tional details regarding nonfatal and fatal serious adverse events are provided in Table S3.DiscussionIn this randomized trial involving patients with upper gastrointestinal bleeding who were pre-dicted to be at high risk for further bleeding or\\xa0 death, we found that endoscopy performed within 6 hours after gastroenterologic consulta-tion did not lead to lower mortality or a lower incidence of further bleeding than endoscopy performed within 24 hours after consultation. In this trial, randomization was performed at the time of gastroenterologic consultation and ap-proximately 7 to 8 hours after patients presented with bleeding to the emergency department. Our trial, therefore, evaluated endoscopy performed at a mean of 9.9 hours as compared with 24.7 hours after initial presentation.In the urgent-endoscopy group, we found more Figure 1. Kaplan–Meier Estimates of the Cumulative Incidences of Death and Further Bleeding.Panel A shows the estimates of mortality during the 30 days after random‑ization, and Panel B shows the estimates of the incidence of further bleed‑ing during the 30 days after randomization. The inset in each panel shows the same data on an enlarged y axis.Cumulative Probability1.000.800.900.700.600.400.300.100.500.200.00051015202530Days since RandomizationB Cumulative Probability of Further BleedingA Cumulative Probability of DeathNo. at RiskUrgent endoscopyEarly endoscopy258258252249246245242245238243238242235241Urgent endoscopyEarly endoscopy0.250.200.100.050.150.00051015202530Cumulative Probability1.000.800.900.700.600.400.300.100.500.200.00051015202530Days since RandomizationNo. at RiskUrgent endoscopyEarly endoscopy258258243237228231220',\n",
       " '202530Cumulative Probability1.000.800.900.700.600.400.300.100.500.200.00051015202530Days since RandomizationNo. at RiskUrgent endoscopyEarly endoscopy258258243237228231220230214228213226210223Urgent endoscopyEarly endoscopy0.250.200.100.050.150.00051015202530The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 382;14\\u2003 nejm.org\\u2003 April 2, 20201306The new engl and jour nal of medicineulcers that were actively bleeding and that had major stigmata of bleeding, resulting in more frequent endoscopic treatment. The more fre-quent endoscopic treatment, however, did not translate into a lower incidence of further bleed-ing or fewer deaths. Patients in the early-endos-copy group, on the other hand, received over-night acid suppression. The longer period until endoscopy and longer duration of acid suppres-sion reduced the number of ulcers with active bleeding and major stigmata of bleeding. This observation corroborates the findings from an earlier randomized, controlled trial27 that evalu-ated the use of a high-dose proton-pump inhibi-tor before endoscopy. Acid suppression before endoscopy can reduce the need for endoscopic treatment.In our trial, the observed mortality was lower than what was assumed in the sample-size calcu-lation. There may be several explanations. First, Table 3. Primary and Secondary End Points.*OutcomeUrgent-Endoscopy  Group (N\\u2009=\\u2009258)Early-Endoscopy  Group (N\\u2009=\\u2009258)Relative Risk or Hazard Ratio  (95% CI)†P ValuePrimary end pointDeath from any cause within 30 days — no. (%)23 (8.9)17 (6.6)1.35 (0.72–2.54)0.34Secondary end pointsFurther bleeding — no. (%)‡Within 7 days15 (5.8)14 (5.4)1.07 (0.53–2.17)Within 30 days28 (10.9)20 (7.8)1.46 (0.83–2.58)Source of further bleeding — no.Bleeding peptic ulcers1912Bleeding esophagogastric varices43Other55Treatment for bleedingEndoscopic treatment administered during initial endoscopy — no. (%)155 (60.1)125 (48.4)1.24 (1.06–1.46)Endoscopic treatment for bleeding ulcers — no. of patients/total no. with ulcers109/15881/1591.35 (1.13–1.63)Endoscopic treatment for varices — no. of patients/ total no. with varices20/2517/190.89 (0.70–1.15)Endoscopic treatment for other conditions — no. of  patients/total no. of patients26/7227/751.02 (0.66–1.56)',\n",
       " 'total no. with varices20/2517/190.89 (0.70–1.15)Endoscopic treatment for other conditions — no. of  patients/total no. of patients26/7227/751.02 (0.66–1.56)Surgical treatment — no. (%)2 (0.8)1 (0.4)2.00 (0.18–21.92)Angiographic embolization — no. (%)3 (1.2)2 (0.8)1.50 (0.25–8.90)Median duration of hospitalization after randomization (range) — days§5 (4–9)5 (3–8)ICU admission — no. (%)4 (1.6)3 (1.2)1.33 (0.30–5.90)Red-cell transfusion — no. (%)231 (89.5)234 (90.7)0.99 (0.93–1.05)Units of red cells received by transfusion2.4±2.32.4±2.1*Plus–minus values are means ±SD.†The relative risk is shown for all end points with the exception of death from any cause within 30 days and further bleeding within 30 days, for which the hazard ratio is shown.‡Further bleeding was defined as a composite of persistent bleeding or recurrent bleeding. Persistent bleeding occurred in 2 patients in the urgent-endoscopy group (1 had gastric varices and bled again on day 3 but was counted only once in the analysis of the composite end point of further bleeding) and in 1 patient in the early-endoscopy group, and recurrent bleeding occurred in 27 patients and 19 patients, \\xadrespectively.§For patients in whom bleeding developed during hospitalization, the duration of the hospital stay was calculated from the day of randomi\\xadzation.The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 382;14\\u2003 nejm.org\\u2003 April 2, 20201307Endoscopy for Upper Gastrointestinal Bleedingour earlier validation study was conducted over a 12-month period in 2006. Our management of these conditions may have improved over the past decade, resulting in better outcomes. Second, in this trial, we enrolled only patients whose condi-tion could be stabilized after initial resuscitation. These patients probably belonged to a lower-risk group than we had assumed in our predictions of mortality. Third, patients are better moni-tored in the context of a clinical trial, and their outcomes are better in general than those in real-life contexts.The observed higher incidences of further bleeding and death with urgent endoscopy than with early endoscopy contrast sharply with our hypothesis that urgent endoscopy would be asso-ciated with improved outcomes. With a between-group difference in mortality of 2.3 percentage points and a 95% confidence interval of −2 to 7\\xa0percentage points in favor of early endoscopy, our trial ruled out a mortality benefit of greater than 2 percentage points in association with urgent endoscopy. A substantially larger sample would have been required to rule out smaller benefits. We observed numerically more deaths in the urgent-endoscopy group. This raises the possibility that patients may benefit from treat-ment for coexisting medical illnesses and a peri-od of acid suppression. In a post hoc analysis, outcomes after endoscopy performed during of-fice hours and endoscopy performed after hours were similar, which suggests that the quality of after-hours endoscopy was not inferior.To detect possible benefits of urgent endos-copy, we selected high-risk patients who present-ed with acute upper gastrointestinal bleeding. We used the Glasgow–Blatchford score as a measure of risk; the score has been shown to correlate with mortality.22 In an observational study from Asia,14 a delay of endoscopy in patients with a',\n",
       " 'used the Glasgow–Blatchford score as a measure of risk; the score has been shown to correlate with mortality.22 In an observational study from Asia,14 a delay of endoscopy in patients with a Glasgow–Blatchford score of 12 or higher was as-sociated with a significant increase in mortality.There were limitations of our trial. Although we enrolled patients who were predicted to be at high risk for further bleeding and death, we ex-cluded patients who had persistent hypotensive shock despite undergoing resuscitation. Thus, our results are not generalizable to patients with on-going bleeding and hypotensive shock, who re-quire urgent intervention. In addition, our hospi-tals offered around-the-clock endoscopy service with a fellow and a senior endoscopist. Our re-sults are not generalizable to hospitals that do not have such support. Finally, the proportion of patients with variceal bleeding in our cohort was small. Our trial findings may not be applicable in localities with a high prevalence of esophago-gastric varices.In this trial, endoscopy that was performed within 6 hours, rather than between 6 and 24 hours, after gastroenterologic consultation did not reduce mortality among patients in stable condition who were hospitalized with acute upper gastrointestinal bleeding and who were assessed as having a high risk of further bleeding and death.Supported by the Health and Medical Fund of the Food and Health Bureau, Government of Hong Kong Special Administra-tive Region.Dr. J. Lau reports receiving fees for serving as an investi-gator for Boston Scientific; and Dr. F. Chan, receiving grant support from Triangle Pharmaceuticals and Given Imaging, grant support, advisory fees, and lecture fees from Pfizer and AstraZeneca, advisory fees from the Rome Foundation and Antibe Therapeutics, lecture fees from Eisai, EA Pharma, Pfizer Upjohn Korea, and Fuji Film, and grant support and lecture fees from Takeda Pharmaceuticals, Takeda (China) Holdings, and',\n",
       " 'Antibe Therapeutics, lecture fees from Eisai, EA Pharma, Pfizer Upjohn Korea, and Fuji Film, and grant support and lecture fees from Takeda Pharmaceuticals, Takeda (China) Holdings, and Olympus Hong Kong and China. No other potential conflict of interest relevant to this article was reported.Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.References1. Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011;\\u200b60:\\u200b1327-35.2. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastro-enterol 2012;\\u200b107:\\u200b345-60.3. Barkun AN, Almadi M, Kuipers EJ,  et al. Management of nonvariceal upper gastrointestinal bleeding: guideline rec-ommendations from the International Consensus Group. Ann Intern Med 2019;\\u200b171:\\u200b805-22.4. Choudari CP, Palmer KR. Outcome of endoscopic injection therapy for bleeding peptic ulcer in relation to the timing of the procedure. Eur J Gastroenterol Hepa-tol 1993;\\u200b5:\\u200b951-3.5. Cooper GS, Chak A, Connors AF Jr, Harper DL, Rosenthal GE. The effective-ness of early endoscopy for upper gastro-intestinal hemorrhage: a community-based analysis. Med Care 1998;\\u200b36:\\u200b462-74.6. Cooper GS, Chak A, Way LE, Hammar PJ, Harper DL, Rosenthal GE. Early en-doscopy in upper gastrointestinal hemor-rhage: associations with recurrent bleed-ing, surgery, and length of hospital stay. Gastrointest Endosc 1999;\\u200b49:\\u200b145-52.7. Chak A, Cooper GS, Lloyd LE, Kolz CS, Barnhart BA, Wong RC. Effectiveness of endoscopy in patients admitted to the intensive care unit with upper GI hemor-rhage. Gastrointest Endosc 2001;\\u200b53:\\u200b6-13.8. Adamopoulos AB, Baibas NM, Efsta-thiou SP, et al. Differentiation between patients with acute upper gastrointestinal',\n",
       " 'rhage. Gastrointest Endosc 2001;\\u200b53:\\u200b6-13.8. Adamopoulos AB, Baibas NM, Efsta-thiou SP, et al. Differentiation between patients with acute upper gastrointestinal The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 382;14\\u2003 nejm.org\\u2003 April 2, 20201308Endoscopy for Upper Gastrointestinal Bleedingbleeding who need early urgent upper gas-trointestinal endoscopy and those who do not: a prospective study. Eur J Gastroen-terol Hepatol 2003;\\u200b15:\\u200b381-7.9. Schacher GM, Lesbros-Pantoflickova D, Ortner MA, Wasserfallen JB, Blum AL, Dorta G. Is early endoscopy in the emer-gency room beneficial in patients with bleeding peptic ulcer? A “fortuitously controlled” study. Endoscopy 2005;\\u200b37:\\u200b324-8.10. Robins GG, Sarwar MS, Armstrong MJ, et al. Evaluation of the need for en-doscopy to identify low-risk patients pre-senting with an acute upper gastrointesti-nal bleed suitable for early discharge. Postgrad Med J 2007;\\u200b83:\\u200b768-72.11. Romagnuolo J, Barkun AN, Enns R, Armstrong D, Gregor J. Simple clinical predictors may obviate urgent endoscopy in selected patients with nonvariceal up-per gastrointestinal tract bleeding. Arch Intern Med 2007;\\u200b167:\\u200b265-70.12.Tai CM, Huang SP, Wang HP, et al. High-risk ED patients with nonvariceal upper gastrointestinal hemorrhage under-going emergency or urgent endoscopy:  a retrospective analysis. Am J Emerg Med 2007;\\u200b25:\\u200b273-8.13. Targownik LE, Murthy S, Keyvani L, Leeson S. The role of rapid endoscopy for high-risk patients with acute nonvariceal upper gastrointestinal bleeding. Can J Gas-troenterol 2007;\\u200b21:\\u200b425-9.14. Lim LG, Ho KY, Chan YH, et al. Ur-gent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleed-ing. Endoscopy 2011;\\u200b43:\\u200b300-6.15. Kumar NL, Travis AC, Saltzman JR. Initial management and timing of endos-copy in nonvariceal upper\\xa0 GI bleeding. Gastrointest Endosc 2016;\\u200b84:\\u200b10-7.16. Laursen SB, Leontiadis GI, Stanley AJ, Møller MH, Hansen JM, Schaffalitzky de Muckadell OB. Relationship between tim-ing of endoscopy and mortality in\\xa0patients with peptic ulcer bleeding: a nationwide cohort\\xa0 study. Gastrointest Endosc 2017;\\u200b85(5):\\u200b936-944.e3.',\n",
       " 'Muckadell OB. Relationship between tim-ing of endoscopy and mortality in\\xa0patients with peptic ulcer bleeding: a nationwide cohort\\xa0 study. Gastrointest Endosc 2017;\\u200b85(5):\\u200b936-944.e3.17. Lin HJ, Wang K, Perng CL, et al. Early or delayed endoscopy for patients with peptic ulcer bleeding: a prospective ran-domized study. J Clin Gastroenterol 1996;\\u200b22:\\u200b267-71.18.Lee JG, Turnipseed S, Romano PS,  et al. Endoscopy-based triage significant-ly reduces hospitalization rates and costs of treating upper GI bleeding: a random-ized controlled trial. Gastrointest Endosc 1999;\\u200b50:\\u200b755-61.19. Bjorkman DJ, Zaman A, Fennerty MB, Lieberman D, Disario JA, Guest-Warnick G. Urgent vs. elective endoscopy for acute non-variceal upper-GI bleeding: an effec-tiveness study. Gastrointest Endosc 2004;\\u200b60:\\u200b1-8.20.Spiegel BMR, Vakil NB, Ofman JJ. En-doscopy for acute nonvariceal upper gas-trointestinal tract hemorrhage: is sooner better? A systematic review. Arch Intern Med 2001;\\u200b161:\\u200b1393-404.21.Tsoi KK, Ma TK, Sung JJ. Endoscopy for upper gastrointestinal bleeding: how urgent is it? Nat Rev Gastroenterol Hepa-tol 2009;\\u200b6:\\u200b463-9.22.Stanley AJ, Laine L, Dalton HR, et al. Comparison of risk scoring systems for patients presenting with upper gastroin-testinal bleeding: international multi-centre prospective study. BMJ 2017;\\u200b356:\\u200bi6432.23.Pang SH, Ching JY, Lau JY, Sung JJ, Graham DY, Chan FK. Comparing the Blatchford and pre-endoscopic Rockall score in predicting the need for endo-scopic therapy in patients with upper GI hemorrhage. Gastrointest Endosc 2010;\\u200b71:\\u200b1134-40.24.Cho SH, Lee YS, Kim YJ, et al. Out-comes and role of urgent endoscopy in high-risk patients with acute nonvariceal gastrointestinal bleeding. Clin Gastroen-terol Hepatol 2018;\\u200b16:\\u200b370-7.25.Laine L, Spiegel B, Rostom A, et al. Methodology for randomized trials of pa-tients with nonvariceal upper gastrointes-tinal bleeding: recommendations from an international consensus conference. Am J',\n",
       " 'Methodology for randomized trials of pa-tients with nonvariceal upper gastrointes-tinal bleeding: recommendations from an international consensus conference. Am J Gastroenterol 2010;\\u200b105:\\u200b540-50.26.Wong JC, Lau JY, Tang RS, Au KWL, Chan FKL, Sung JJY. Urgent versus early endoscopy for upper gastrointestinal bleed-ing with Glasgow–Blatchford score ≥12. Gastroenterology 2015;\\u200b148:\\u200bSuppl:\\u200bS-154. ab-stract.27. Lau JY, Leung WK, Wu JCY, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007;\\u200b356:\\u200b1631-40.Copyright © 2020 Massachusetts Medical Society.ARTICLE METRICS NOW AVAILABLEVisit the article page at NEJM.org and click on Metrics to view comprehensive and cumulative article metrics compiled from multiple sources, including Altmetrics. NEJM.org/about-nejm/article-metrics.The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.',\n",
       " 'Indications for the Use of Proton Pump Inhibitorsfor Stress Ulcer Prophylaxis and Peptic UlcerBleeding in Hospitalized PatientsKaren Clarke, MD, MSc, MPH,a Nicole Adler, MD,b Deepak Agrawal, MD, MPH,c Dimpal Bhakta, MD,dSuchita Shah Sata, MD,e Sarguni Singh, MD,f Arjun Gupta, MD,g Amit Pahwa, MD,h Emily Pherson, PharmD,iAlexander Sun, MD,e Frank Volpicelli, MD,b,j Hyung J. Cho, MDj,kaDivision of Hospital Medicine, Emory University School of Medicine, Atlanta, Ga; bDepartment of Medicine, New York University Gross-man School of Medicine, New York, NY; cDivision of Gastroenterology and Hepatology, Dell Seton Medical Center, Austin, Tex; dDivisionof Gastroenterology, New York University School of Medicine, New York, NY; eDepartment of Medicine, Duke University School of Medi-cine, Durham, NC; fDivision of Hospital Medicine, University of Colorado, Aurora; gSidney Kimmel Comprehensive Cancer Center, JohnsHopkins University School of Medicine, Baltimore, Md; hDivision of General Internal Medicine, Division of General Pediatrics, JohnsHopkins University School of Medicine, Baltimore, Md; iDepartment of Pharmacy, Johns Hopkins Hospital, Baltimore, Md; jDivision ofHospital Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; kNew York City Health and Hospitals, New York, NY.ABSTRACTProton pump inhibitors are widely used throughout the world for the treatment of gastrointestinal disordersthat are related to acid secretion, such as peptic ulcer disease and dyspepsia. Another common indicationfor proton pump inhibitors is stress ulcer prophylaxis. Proton pump inhibitors have proven efﬁcacy for thetreatment of acid-related gastrointestinal disorders, but there is concern that their use may be associatedwith the development of signiﬁcant complications, such as fractures, Clostridium difﬁcile infection, acutekidney injury, chronic kidney disease, and hypomagnesemia. Proton pump inhibitors are overused in the',\n",
       " 'kidney injury, chronic kidney disease, and hypomagnesemia. Proton pump inhibitors are overused in thehospital setting, both for stress ulcer prophylaxis and gastrointestinal bleeding, and then they are ofteninappropriately continued after discharge from the hospital. This narrative review article outlines the evi-dence surrounding appropriate proton pump inhibitor use for stress ulcer prophylaxis and peptic ulcerbleeding. 2021 Elsevier Inc. All rights reserved.  The American Journal of Medicine (2022) 135:313−317KEYWORDS: Gastrointestinal bleed; Indications; Peptic ulcer; Proton pump inhibitor; Stress ulcer prophylaxisINTRODUCTIONProton pump inhibitors are one of the most commonly pre-scribed medications in the world because they are effectivefor the treatment of acid-related gastrointestinal orders,including gastroesophageal disease and peptic ulcer dis-ease.1 Use of acid-suppressive therapy is common amonghospitalized patients; that is, approximately 40%-70% ofthem receive either proton pump inhibitors or histamine 2receptor antagonists during their hospitalization.2,3 Unfortu-nately, about half of the patients who are newly started onacid suppressive therapy during their hospitalization aredischarged to home on this medication, even though itsongoing use is usually not warranted.2,3Although proton pump inhibitors were previouslythought to be relatively safe medications with few sideeffects, over time their association with signiﬁcant com-plications has been demonstrated, including acute kidneyinjury,4 chronic kidney disease,4 Clostridium difﬁcileinfection,5 hypomagnesemia,⁶ and fractures.7 Becausethere is concern about the ubiquitous use of protonpump inhibitors and the complications associated withthese medications, their appropriate use in the hospitalsetting should be a priority. With the intention of pro-moting value-based quality improvement, in this narra-tive review article we discuss the evidence behind the',\n",
       " 'setting should be a priority. With the intention of pro-moting value-based quality improvement, in this narra-tive review article we discuss the evidence behind theRequests for reprints should be addressed to Karen Clarke, Division ofHospital Medicine, Emory University School of Medicine, 1364 CliftonRoad NE, Atlanta, GA, 30322.E-mail address: summarizephilosophy@yahoo.com0002-9343/© 2021 Elsevier Inc. All rights reserved.https://doi.org/10.1016/j.amjmed.2021.09.010REVIEWTHEAMERICANJOURNALofMEDICINER',\n",
       " 'use of proton pump inhibitors for stress ulcer prophy-laxis and peptic ulcer bleeding.EVIDENCE AND GUIDELINES FOR PROTON PUMPINHIBITOR USE FOR SPECIFIC INDICATIONSIn this narrative review we address 2 indications for protonpump inhibitor use, that is, stressulcer prophylaxis and peptic ulcerbleeding, and provide our evidence-based recommendations on appro-priate use.Stress Ulcer ProphylaxisStressulcersusuallystarttodevelop within hours following theonset of serious illness or majortrauma. They are most commonlynoted in the body and fundus of thestomach and are typically shallow.Stress ulcers are thought to developmost often because of deﬁcientmucosal protection (which is com-monly noted in patients with criticalillness). Hypersecretion of acid is aless common factor in the develop-ment of stress ulcers. Stress ulcersin the upper gastrointestinal tract can lead to gastrointesti-nal bleeding, the severity of which can range from beingminimal (ie, no overt bleeding) to clinically importantstress-related gastrointestinal bleeding (ie, overt gastroin-testinal bleeding: hematemesis or melena). Medicationssuch as proton pump inhibitors and histamine 2 receptorantagonists are often administered prophylactically todecrease the risk of stress ulcer development. However,recent studies have questioned the efﬁcacy of stress ulcerprophylaxis.A pilot randomized controlled trial and meta-analysis in2017 evaluating the safety of withholding pantoprazole forstress ulcer prophylaxis in critically ill patients found nosigniﬁcant increase in risk for upper gastrointestinal tractbleeding, mortality, or infections when pantoprazole washeld for stress ulcer prophylaxis.8A 2018 European study enrolled 3298 patients in 33intensive care units in Denmark, Finland, Netherlands, Nor-way, Switzerland, and the United Kingdom.9 This multicen-ter, parallel-group, blinded, randomized controlled trialevaluated patients who were admitted to an intensive care',\n",
       " 'way, Switzerland, and the United Kingdom.9 This multicen-ter, parallel-group, blinded, randomized controlled trialevaluated patients who were admitted to an intensive careunit and were at risk for clinically important stress-relatedgastrointestinal bleeding. The trial compared pantoprazolewith placebo, and it did not show a difference in 90-daymortality or composite outcome of clinically importantevent, which was a composite of clinically important stress-related gastrointestinal bleeding, pneumonia, C. difﬁcileinfection, or myocardial ischemia.9 For patients receivingpantoprazole, 2.5% had clinically important stress-relatedgastrointestinal bleeding, in comparison with 4.2% of thosewho received a placebo. Although the relative risk was0.58, no P value was presented because the study did notmake adjustments for multiple comparisons.Multiple national and international clinical guidelinesoutline the role of stress ulcer prophylaxis in intensive careunit settings, including the American Society of Health Sys-tem Pharmacists in 1999, Surviving Sepsis Campaign in2016 and the Danish Society ofIntensive Care Medicine and theDanish Society of Anesthesiologyand Intensive Care Medicine in2014.10-12 No national or societyguidelinesrecommendroutinestress ulcer prophylaxis in noncriti-cal care settings. All guidelines rec-ommend stress ulcer prophylaxis tobe administered to patients withcritical illness with additional riskfactorsforclinicallyimportantstress-related gastrointestinal bleed-ing. The most important additionalrisk factors are coagulopathy andthe need for mechanical ventilationfor more than 48 hours. Other riskfactorsforclinicallyimportantstress-related gastrointestinal bleed-ing include the requirement forrenal replacement therapy, established liver disease, andelevated scores of organ failure.Prior studies on the utility of stress ulcer prophy-laxis had been inconclusive and suggested the need for',\n",
       " 'renal replacement therapy, established liver disease, andelevated scores of organ failure.Prior studies on the utility of stress ulcer prophy-laxis had been inconclusive and suggested the need fora large randomized controlled trial. With the recentdata discussed previously it appears that stress ulcerprophylaxis is not beneﬁcial overall in hospitalizedpatients, although it may decrease the rate of clinicallyimportant stress-related gastrointestinal bleeding in thecritically ill at high risk.12 However, patients with avalid indication for proton pump inhibitors for othermedical reasons, who take these medications in the out-patient setting, should continue to take them duringtheir hospitalization.Peptic Ulcer BleedingIn vitro studies have shown that a pH > 4 (some studiessuggest pH > 6) helps in platelet aggregation and clot stabi-lization and, thus, reduces risk of rebleeding.13,14 This pro-vides the rationale for prescribing proton pump inhibitors topatients who have high-risk stigmata of bleeding on endos-copy (ie, active bleeding, overlying clot on an ulcer, or avisible vessel).Before endoscopy, it is not known which patients havehigh-risk stigmata. Hence, the conservative and practicalapproach has been to assume all patients are at high riskwhen they present with upper gastrointestinal tract bleed-ing. However, it is important to note that there is no strongevidence to support the widespread (and now consideredCLINICAL SIGNIFICANCE Proton pump inhibitors are widely usedfortreatmentofgastrointestinalbleeding related to acid secretion andalso for stress ulcer prophylaxis. Overuse of proton pump inhibitors maybe associated with complications. Proton pump inhibitors are often inap-propriately initiated in the hospitalsetting and then are often inappropri-ately continued after hospital dis-charge. Clinicians require guidance in regard toappropriate proton pump inhibitor useto improve patient outcomes.314',\n",
       " 'setting and then are often inappropri-ately continued after hospital dis-charge. Clinicians require guidance in regard toappropriate proton pump inhibitor useto improve patient outcomes.314The American Journal of Medicine, Vol 135, No 3, March 2022',\n",
       " 'standard of care) practice of administering proton pumpinhibitors to patients before endoscopy. There have been 2randomized trials of intravenous omeprazole versus placeboadministered to patients with hematemesis or melena beforeendoscopy. In both studies, omeprazole failed to reducetransfusion requirements, rebleeding, or mortality, butpatients were less likely to have high-risk stigmata of bleed-ing on endoscopy and, thus, had a reduced need for endo-scopic therapy.15,16 This, in turn, may also help to reducelength of hospital stay because patients with high-risk stig-mata on endoscopy are often monitored in the hospital for72 hours.1⁶There are 4 factors to consider when prescribing protonpump inhibitors: dose, frequency, route, and type. High-dose proton pump inhibitor (Table) is often thought to benecessary to consistently achieve pH > 4 (or pH > 6)across different populations. Given the pharmacokineticsof proton pump inhibitors and diurnal variation in acidsecretion, at least twice-a-day dosing may be necessary.Proton pump inhibitors have a half-life of about 60-90minutes, and they covalently bind to active H+-K+ pumps.Hence, their inhibitory effects last much longer (up to 48hours). However, newly activated H+-K+ pumps may con-tinue to produce some acid.17 A theoretical explanationnotwithstanding, a meta-analysis of 9 randomized con-trolled trials comparing rebleeding rates with high-doseproton pump inhibitor versus low-dose proton pumpinhibitor following endoscopic treatment showed that the2 dosages had similar efﬁcacy.18 Moreover, the initialstudies on proton pump inhibitors and upper gastrointesti-nal tract bleeding used the intravenous route and giventhe favorable clinical results, this was adopted in clinicalpractice. However, oral proton pump inhibitors haveexcellent bioavailability ranging from 70%-90% andshould be as efﬁcacious as those administered intrave-nously.18 Studies comparing oral proton pump inhibitors',\n",
       " 'excellent bioavailability ranging from 70%-90% andshould be as efﬁcacious as those administered intrave-nously.18 Studies comparing oral proton pump inhibitorsversus placebo achieved clinical outcomes similar tothose that used intravenous proton pump inhibitors.19-21Three studies directly comparing intravenous and oralproton pump inhibitors in preventing rebleeding afterendoscopic treatment found the 2 routes to have similaroutcomes.22-24 However, giving a loading dose intrave-nously may achieve higher pH up to an hour earlier.24After review of the evidence, there was no consistent clin-ical difference between different formulations of protonpump inhibitors, but it is worth noting that the dosagesvaryamongthestudies.Practicepatternsdonotconsistently follow this evidence, in turn leading to lowervalue care.25The American College of Gastroenterology Guidelinesfor Management of Patients with Ulcer Bleeding makes aconditional recommendation for pre-endoscopic medicaltherapy, such as proton pump inhibitor 80 mg bolus fol-lowed by 8 mg/h infusion, which may reduce the frequencyof higher risk stigmata of hemorrhage at the time ofendoscopy.26,27 Following endoscopy, the American Col-lege of Gastroenterology has a strong recommendation forthe administration of intravenous proton pump inhibitor80 mg bolus followed by 8 mg/h infusion for 72 hours forpatients who have any of the following: ulcer with activebleeding, adherent clot, or a nonbleeding visible vessel.27For generalizability, ease in formulating recommenda-tions, and a value-based approach, while remaining cogni-zant that it may be difﬁcult to change practices (pendingmore data), we recommend a bolus dose of intravenous pro-ton pump inhibitor when patients present with active uppergastrointestinal bleeding (hematemesis or melena) followedby oral or intravenous proton pump inhibitor twice a day(high-doseprotonpumpinhibitor).Afterendoscopy,',\n",
       " 'gastrointestinal bleeding (hematemesis or melena) followedby oral or intravenous proton pump inhibitor twice a day(high-doseprotonpumpinhibitor).Afterendoscopy,patients with high-risk stigmata (especially those with sig-niﬁcant comorbidities) remain at rebleeding risk for up to72 hours. Hence, high-dose proton pump inhibitor (twice-a-day dosing) should be continued for 72 hours. This can begiven orally if the patient is having per oral intake. It shouldbe noted that the data on high-dose proton pump inhibitor(twice-a-day dosing) is geared to lower rebleeding risk andnot for ulcer healing, so patients need not be dischargedhome on high-dose proton pump inhibitors. Further, ifpatients are given oral proton pump inhibitor, they need notstay in the hospital for 72 hours provided they are otherwisestable to be discharged and understand there may be a riskof rebleeding (due to lack of studies). Duration of treatmentwith proton pump inhibitors for gastric ulcer is generally 2months except when the risk of bleeding is not mitigated(ongoing use of nonsteroidal anti-inﬂammatory drugs, anti-coagulation, or antiplatelets, unresectable malignant ulcer).At the time of discharge, the frequency and duration of pro-ton pump inhibitors should be speciﬁed.REDUCING INAPPROPRIATE USE OF PROTONPUMP INHIBITORS AFTER HOSPITAL DISCHARGEProton pump inhibitors are often initiated in the hospitalsetting, and up to half of these new prescriptions are contin-ued at discharge.28-30The inappropriate continuation of proton pump inhibi-tors at the time of discharge exposes patients to an excessrisk of long-term adverse events.31 Therefore, it is desirableto implement interventions that lead to the discontinuationof inappropriate proton pump inhibitor use both during hos-pitalization and at the time of discharge from the hospital.Such interventions focus on appropriate indications for pro-ton pump inhibitor use and include education for providers,Table',\n",
       " 'pitalization and at the time of discharge from the hospital.Such interventions focus on appropriate indications for pro-ton pump inhibitor use and include education for providers,TablePPI Dose, Frequency, Route, and TypePPIStandard doseHigh doseEsomeprazole20 mg once a day40 mg once a dayLansoprazole30 mg once a day30 mg twice a dayOmeprazole20 mg once a day40 mg once a dayPantoprazole40 mg once a day40 mg twice a dayRabeprazole20 mg once a day20 mg twice a dayClarke et alIndications for the Use of Proton Pump Inhibitors in Hospitalized Patients315',\n",
       " 'development of clinical guidelines, and pharmacist-ledinterventions.32-37COMPLICATIONS OF LONG-TERM PROTON PUMPINHIBITOR USEComplications of proton pump inhibitor use include bonefractures, hypomagnesemia, C. difﬁcile infection, acute kid-ney injury, and chronic kidney disease. An increased risk ofbone fractures may be noted within the ﬁrst year of protonpump inhibitor use.38 In a meta-analysis that included 18observational studies (with 244,109 fracture cases), Zhouet al38 concluded that the use of proton pump inhibitorsmodestly increased the risk of fractures. The relative risk offractures occurring in the hip was 1.26 in proton pumpinhibitor users compared with nonusers. For fractures in thespine, the relative risk in proton pump inhibitor users versusnonusers was 1.58, and for fractures at any site, the relativerisk was 1.33 in proton pump inhibitor users versusnonusers.38Proton pump inhibitor use can lead to hypomagnesemia,which when severe can precipitate cardiac arrhythmias,seizures, muscle weakness, tetany, and hypotension. Also,the risk of developing acute kidney injury is increased inpatients with hypomagnesemia, and this electrolyte abnor-mality decreases the likelihood of resolution of acute kid-ney injury. For proton pump inhibitor users who develophypomagnesemia, the initiation of magnesium supplemen-tation may not be sufﬁcient to replete low magnesium lev-els, unless the proton pump inhibitor is discontinued. Thepooled risk ratio of hypomagnesemia was 1.43 in protonpump inhibitor users compared with nonusers, according toa meta-analysis of 9 observational studies (which included109,798 patients).6An increased risk of C. difﬁcile infection has been notedin proton pump inhibitor users. In their meta-analysis of 39observational studies, Kwok et al5 found that the risk ofdeveloping a C. difﬁcile infection was increased in protonpump inhibitor users, who had an odds ratio of 1.74 com-',\n",
       " 'observational studies, Kwok et al5 found that the risk ofdeveloping a C. difﬁcile infection was increased in protonpump inhibitor users, who had an odds ratio of 1.74 com-pared with nonusers. Similarly, the risk of recurrent C. difﬁ-cile infection was higher in proton pump inhibitor users,who had an odds ratio of 2.51 compared with nonusers.Adverse effects of proton pump inhibitor use on kidneyfunction have been documented; that is, this may lead tothe development of both acute kidney injury and chronickidney disease. Acute interstitial nephritis may be themechanism by which proton pump inhibitors cause acutekidney injury. In a population-based study that included290,592 patients, Antoniou et al39 found that in comparisonwith nonusers, proton pump inhibitor users had a hazardratio of 2.52 for the development of acute kidney injury.The study also showed a hazard ratio of 3.00 in protonpump inhibitor users versus nonusers for the developmentof acute interstitial nephritis. The nested case control studyinvolving 184,480 patients that was done by Klepser et al40showed that proton pump inhibitor use was associated withan increased risk of acute kidney injury in proton pumpinhibitor users, who had an odds ratio of 1.72 comparedwith nonusers.In a population-based cohort study by Lazarus et al41that involved 10,482 patients who were followed for13.9 years, the hazard ratio for incident chronic kidney dis-ease was 1.45 for proton pump inhibitor users comparedwith nonusers. A dose response was noted in this studybecause the risk of developing chronic kidney disease washigher in patients who used a proton pump inhibitor twicedaily, in comparison with those who used a proton pumpinhibitor once daily. These ﬁndings were reproduced inanother large cohort study.41 The mechanism by which pro-ton pump inhibitor use leads to chronic kidney disease maybe either hypomagnesemia or recurrent episodes of acutekidney injury.CONCLUSION',\n",
       " 'another large cohort study.41 The mechanism by which pro-ton pump inhibitor use leads to chronic kidney disease maybe either hypomagnesemia or recurrent episodes of acutekidney injury.CONCLUSIONThe use of proton pump inhibitors for stress ulcer prophy-laxis should be limited to high-risk patients in the intensivecare unit. Patients who receive proton pump inhibitor fortreatment for gastrointestinal bleeding during their hospital-ization do not need to be discharged home on high-dose(twice daily) proton pump inhibitors. Overuse of protonpump inhibitors during hospitalization is prevalent andoften leads to the inappropriate continuation of these medi-cations at the time of hospital discharge. Because the long-term use of proton pump inhibitors is often inappropriateand may be associated with signiﬁcant adverse effects, it isimportant to limit their use to only appropriate indications.References1. Safer D. Overprescribed medications for US adults: 4 major examples.J Clin Med Res 2019;11(9):617–22.2. Sattayalertyanyong O, Thitilertdecha P, Auesomwang C. The inappro-priate use of proton pump inhibitors during admission and after dis-charge: a prospective cross-sectional study. Int J Clin Pharm2020;42:174–83.3. Shin S. Evaluation of costs accrued through inadvertent continuationof hospital-initiated proton pump inhibitor therapy for stress ulcer pro-phylaxis beyond hospital discharge: a retrospective chart review. TherClin Risk Manag 2015;11:649–57.4. Moledina DG, Perazella MA. PPIs and kidney disease: from AIN toCKD. J Nephrol 2016;29(5):611–6.5. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK.Risk of Clostridium difﬁcile infection with acid suppressing drugs andantibiotics: meta-analysis. Am J Gastroenterol 2012;107(7):1011–9.6. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al.Proton pump inhibitors linked to hypomagnesemia: a systematicreview and meta-analysis of observational studies. Ren Fail 2015;37(7):1237–41.',\n",
       " 'Proton pump inhibitors linked to hypomagnesemia: a systematicreview and meta-analysis of observational studies. Ren Fail 2015;37(7):1237–41.7. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pumpinhibitor therapy and risk of hip fracture. JAMA 2006;296(24):2947–53.8. Alhazzani W, Guyatt G, Alshahrani M, et al. Withholding pantopra-zole for stress ulcer prophylaxis in critically ill patients: a pilot ran-domizedclinicaltrialandmeta-analysis.CritCareMed2017;45:1121–9.9. Krag M, Marker S, Perner A, et al. Pantoprazole in patients at risk forgastrointestinal bleeding in the ICU. N Engl J Med 2018;379:2199–208.316The American Journal of Medicine, Vol 135, No 3, March 2022',\n",
       " \"10. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHPCommission on Therapeutics and approved by the ASHP Board ofDirectors on November 14, 1998. Am J Health Syst Pharm, 56; 1999.p. 1999347–79.11. Rhodes A, Evans LE, Alhazzani W, et al. surviving sepsis campaign:international guidelines for management of sepsis and septic shock:2016. Intensive Care Med 2017;43(3):304–77.12. Madsen KR, Lorentzen K, Clausen N, et al. Guideline for stress ulcerprophylaxis in the intensive care unit. Dan Med J 2014;61(3):C4811.13. Green FW Jr, Kaplan MM, Curtis LE, Levine PH. Effect of acid andpepsin on blood coagulation and platelet aggregation. A possible con-tributor prolonged gastroduodenal mucosal hemorrhage. Gastroenter-ology 1978;74(1):38–43.14. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP. Clotlysis by gastric juice: an in vitro study. Gut 1989;30(12):1704–7.15. Daneshmend TK, Hawkey CJ, Langman MJ, Logan RF, Long RG,Walt RP. Omeprazole versus placebo for acute upper gastrointestinalbleeding: randomised double blind controlled trial. BMJ 1992;304(6820):143–7.16. Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy inpatients with gastrointestinal bleeding. N Engl J Med 2007;356(16):1631–40.17. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. CurrGastroenterol Rep 2008;10(6):528–34.18. Wu LC, Cao YF, Huang JH, Liao C, Gao F. High-dose vs low-doseproton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis. World J Gastroenterol 2010;16(20):2558–65.19. Khuroo MS, Yattoo GN, Javid G, et al. A comparison of omeprazoleand placebo for bleeding peptic ulcer. N Engl J Med 1997;336(15):1054–8.20. Javid G, Masoodi I, Zargar SA, et al. Omeprazole as adjuvant therapyto endoscopic combination injection sclerotherapy for treating bleed-ing peptic ulcer. Am J Med 2001;111(4):280–4.21. Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omep-razole in reducing re-bleeding in bleeding peptic ulcers: a prospective,\",\n",
       " 'ing peptic ulcer. Am J Med 2001;111(4):280–4.21. Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omep-razole in reducing re-bleeding in bleeding peptic ulcers: a prospective,double-blind, randomized, clinical trial. Aliment Pharmacol Ther2003;17(2):211–6.22. Bajaj JS, Dua KS, Hanson K, Presberg K. Prospective, randomizedtrial comparing effect of oral versus intravenous pantoprazole onrebleeding after nonvariceal upper gastrointestinal bleeding: a pilotstudy. Dig Dis Sci 2007;52(9):2190–4.23. Yen HH, Yang CW, Su WW, Soon MS, Wu SS, Lin HJ. Oral versusintravenous proton pump inhibitors in preventing re-bleeding forpatients with peptic ulcer bleeding after successful endoscopic ther-apy. BMC Gastroenterol 2012;12:66.24. Laine L, Shah A, Bemanian S. Intragastric pH with oral vs intravenousbolus plus infusion proton-pump inhibitor therapy in patients withbleeding ulcers. Gastroenterol 2008;134(7):1836–41.25. Rodriguez E, Donath E, Waljee A, Sussman D. Value of oral protonpump inhibitors in acute nonvariceal upper gastrointestinal bleeding: anetwork meta-analysis. J Clin Gastroenterol 2017;51(8):707–19.26. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews ofthe clinical effectiveness and cost-effectiveness of proton pumpinhibitors in acute upper gastrointestinal bleeding. Health TechnolAssess 2007;11(51) [iii-iv, 1-164.27. Laine L, Jensen D. Guidelines for the management of patients withulcer bleeding. Am J Gastroenterol 2012;107(3):345–60.28. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive ther-apy in hospitalized patients. Am J Gastroenterol 2000;95(11):3118–22. https://doi.org/10.1111/j.1572-0241.2000.03259.x.29. Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acidsuppression started inappropriately during hospitalization. AlimentPharmacol Ther 2005;21(10):1203–9. https://doi.org/10.1111/j.1365-2036.2005.02454.x.30. Pham CQ, Regal RE, Bostwick TR, Knauf KS. Acid suppressive ther-',\n",
       " 'Pharmacol Ther 2005;21(10):1203–9. https://doi.org/10.1111/j.1365-2036.2005.02454.x.30. Pham CQ, Regal RE, Bostwick TR, Knauf KS. Acid suppressive ther-apy use on an inpatient internal medicine service. Ann Pharmacother2006;40(7-8):1261–6. https://doi.org/10.1345/aph.1g703.31. Schoenfeld AJ, Grady D. Adverse effects associated with proton pumpinhibitors [editorial]. JAMA Intern Med 2016;176(2):172–4. https://doi.org/10.1001/jamainternmed.2015.7927.32. Belﬁeld KD, Kuyumjian AG, Teran R, Amadi M, Blatt M, Bicking K.Impact of a collaborative strategy to reduce the inappropriate use of acidsuppressive therapy in non-intensive care unit patients. Ann Pharmac-other 2017;51(7):577–83. https://doi.org/10.1177/1060028017698797.33. Del Giorno R, Ceschi A, Pironi M, Zasa A, Greco A, Gabutti L. Multi-faceted intervention to curb in-hospital over-prescription of protonpumpinhibitors:alongitudinalmulticenterquasi-experimentalbefore-and-after study. Eur J Intern Med 2018;50:52–9. https://doi.org/10.1016/j.ejim.2017.11.002.34. Gupta R, Marshall J, Munoz JC, Kottoor R, Jamal MM, Vega KJ.Decreased acid suppression therapy overuse after education and medi-cation reconciliation. Int J Clin Pract 2013;67(1):60–5. https://doi.org/10.1111/ijcp.12046.35. Hatch JB, Schulz L, Fish JT. Stress ulcer prophylaxis: reducing non-indicated prescribing after hospital discharge. Ann Pharmacother2010;44(10):1565–71. https://doi.org/10.1345/aph.1p167.36. McDonald EG, Jones J, Green L, Jayaraman D, Lee TC. Reduction ofinappropriate exit prescriptions for proton pump inhibitors: a before-after study using education paired with a web-based quality-improve-ment tool. J Hosp Med 2015;10(5):281–6. https://doi.org/10.1002/jhm.2330.37. Tasaka CL, Burg C, VanOsdol SJ, et al. An interprofessional approachto reducing the overutilization of stress ulcer prophylaxis in adultmedical and surgical intensive care units. Ann Pharmacother 2014;48(4):462–9. https://doi.org/10.1177/1060028013517088.',\n",
       " 'to reducing the overutilization of stress ulcer prophylaxis in adultmedical and surgical intensive care units. Ann Pharmacother 2014;48(4):462–9. https://doi.org/10.1177/1060028013517088.38. Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk offractures: an updated meta-analysis. Osteoporosis Int 2016;27:339–47.39. Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitorsand the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open 2015;3(2):E166–71.40. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors andacute kidney injury: a nested case-control study. BMC Nephrol2013;14:150.41. Lazarus B, Yuan , Wilson FP, et al. Proton pump inhibitor use and therisk of chronic kidney disease. JAMA Intern Med 2016;176(2):238–46.Clarke et alIndications for the Use of Proton Pump Inhibitors in Hospitalized Patients317',\n",
       " 'CLINICAL PRACTICE UPDATEAGA Clinical Practice Update on Endoscopic Therapies for Non-Variceal Upper Gastrointestinal Bleeding: Expert ReviewDaniel K. Mullady,1 Andrew Y. Wang,2 and Kevin A. Waschke31Division of Gastroenterology, Washington University in St Louis School of Medicine, St Louis, Missouri; 2Division ofGastroenterology and Hepatology, University of Virginia, Charlottesville, Virginia; and 3Division of Gastroenterology, McGillUniversity, Montreal, Quebec, CanadaDESCRIPTION: The purpose of this American Gastroenterolog-ical Association (AGA) Institute Clinical Practice Update is to re-view the available evidence and best practice advice statementsregarding the use of endoscopic therapies in treating patientswith non-variceal upper gastrointestinal bleeding. METHODS:This expert review was commissioned and approved by the AGAInstitute Clinical Practice Updates Committee and the AGA Gov-erning Board to provide timely guidance on a topic of high clinicalimportance to the AGA membership, and underwent internalpeer review by the Clinical Practice Updates Committee andexternal peer review through standard procedures of Gastroen-terology. This review is framed around the 10 best practice advicepoints agreed upon by the authors, which reﬂect landmark andrecent published articles in this ﬁeld. This expert review alsoreﬂects the experiences of the authors who are gastroenterolo-gists with extensive experience in managing and teaching otherstotreatpatientswithnon-varicealuppergastrointestinalbleeding (NVUGIB). BEST PRACTICE ADVICE 1: Endoscopictherapy should achieve hemostasis in the majority of patientswith NVUGIB. BEST PRACTICE ADVICE 2: Initial management ofthe patient with NVUGIB should focus on resuscitation, triage,and preparation for upper endoscopy. After stabilization, patientswith NVUGIB should undergo endoscopy with endoscopic treat-ment of sites with active bleeding or high-risk stigmata for',\n",
       " 'and preparation for upper endoscopy. After stabilization, patientswith NVUGIB should undergo endoscopy with endoscopic treat-ment of sites with active bleeding or high-risk stigmata forrebleeding. BEST PRACTICE ADVICE 3: Endoscopists should befamiliar with the indications, efﬁcacy, and limitations of currentlyavailable tools and techniques for endoscopic hemostasis, and becomfortable applying conventional thermal therapy and placinghemoclips. BEST PRACTICE ADVICE 4: Monopolar hemostaticforceps with low-voltage coagulation can be an effective alter-native to other mechanical and thermal treatments for NVUGIB,particularly for ulcers in difﬁcult locations or those with a rigidand ﬁbrotic base. BEST PRACTICE ADVICE 5: Hemostasis usingan over-the-scope clip should be considered in select patientswith NVUGIB, in whom conventional electrosurgical coagulationand hemostatic clips are unsuccessful or predicted to be inef-fective. BEST PRACTICE ADVICE 6: Hemostatic powders are anoncontact endoscopic option that may be considered in cases ofmassive bleeding with poor visualization, for salvage therapy, andfor diffuse bleeding from malignancy. BEST PRACTICE ADVICE7: Hemostatic powder should be preferentially used as a rescuetherapy and not for primary hemostasis, except in cases of ma-lignant bleeding or massive bleeding with inability to performthermal therapy or hemoclip placement. BEST PRACTICEADVICE 8: Endoscopists should understand the risk of bleedingfrom therapeutic endoscopic interventions (eg, endoluminalresection and endoscopic sphincterotomy) and be familiar withthe endoscopic tools and techniques to treat intraproceduralbleeding and minimize the risk of delayed bleeding. BESTPRACTICE ADVICE 9: In patients with endoscopically refractoryNVUGIB, the etiology of bleeding (peptic ulcer disease, unknownsource, post surgical); patient factors (hemodynamic instability,coagulopathy, multi-organ failure, surgical history); risk of',\n",
       " 'NVUGIB, the etiology of bleeding (peptic ulcer disease, unknownsource, post surgical); patient factors (hemodynamic instability,coagulopathy, multi-organ failure, surgical history); risk ofrebleeding; and potential adverse events should be taken intoconsideration when deciding on a case-by-case basis betweentranscatheter arterial embolization and surgery. BEST PRACTICEADVICE 10: Prophylactic transcatheter arterial embolization ofhigh-risk ulcers after successful endoscopic therapy is notencouraged.Keywords: Upper Gastrointestinal Tract Bleeding; Endoscopy;Hemostatic Powder; Hemospray; Hemostatic Forceps; Clips;Rebleeding.Non-varicealuppergastrointestinalbleeding(NVUGIB) is a serious clinical problem with anincidence of approximately 61–78 cases per 100,000 per-sons in the United States in 2009–2012.1 Mortality fromNVUGIB is estimated to be between 2% and 10%.1,2Endoscopic evaluation and treatment for NVUGIB remainsthe clinical mainstay of care in patients who can be hemo-dynamically stabilized to undergo upper gastrointestinalendoscopy,typicallybyesophagogastroduodenoscopy.Numerous endoscopic devices have been developed over thepast 30 years with demonstrated effectiveness in treatingNVUGIB, including the use of hemoclips,3 over-the-scopeclips,4 hemostatic forceps,5 and sprayed hemostatic pow-der.6 The purpose of this Clinical Practice Update is to reviewthe key concepts, new devices, and therapeutic strategies inendoscopically combating this age-old clinical dilemma.Initial ManagementAlthough endoscopy is a cornerstone in the management ofNVUGIB, it should come after triage, medical management, andstabilization. The treating provider should consider patient-Abbreviations used in this paper: AT, antithrombotic; EMR, endoscopicmucosalresection;ESD,endoscopicsubmucosal dissection;MHF,monopolar hemostatic forceps; NVUGIB, non-variceal upper gastroin-testinal bleeding; RCT, randomized controlled trial; TAE, transcatheterarterial embolization.',\n",
       " 'endoscopicsubmucosal dissection;MHF,monopolar hemostatic forceps; NVUGIB, non-variceal upper gastroin-testinal bleeding; RCT, randomized controlled trial; TAE, transcatheterarterial embolization.Most current article© 2020 by the AGA Institute0016-5085/$36.00https://doi.org/10.1053/j.gastro.2020.05.095Gastroenterology 2020;159:1120–1128CLINICAL PRACTICE UPDATE',\n",
       " 'related issues, including age, comorbid conditions, prior sur-gery, history of gastrointestinal bleeding, and medications (eg,antihypertensives,antithrombotics,nonsteroidalanti-inﬂammatory medications), which can contribute to the pa-tient’s clinical presentation and hemodynamic status and mightpredict bleedingthatisdifﬁcult to control. Patientswith NVUGIBmay have variable presentations ranging from harmless, minor,self-limited bleeding that can be managed with an outpatientworkup, to hypovolemic shock requiring transfer to the inten-sive care unit. The treating provider should be familiar withvarious scoring systems that have been developed to help triagepatients with NVUGIB.7–10 These scoring systems are based onclinical parameters and endoscopic ﬁndings that predict mor-tality and rebleeding risk in patients with NVUGIB (Table 1).After proper triage of the patient with suspected NVU-GIB, the focus should be on medical management, includingvolume resuscitation with intravenous ﬂuids and bloodproducts via large bore catheters. Target hemoglobin isgenerally 9 g/dL in patients with signiﬁcant cardiovasculardisease and 7 g/dL for all others.11–13 The consensusrecommendation by an international group of experts wasfor blood transfusion for hemoglobin levels <8 g/dL with ahigher threshold for those with cardiovascular disease.14The need for reversal of antithrombotic (AT) medications(which for this article includes anticoagulant and antiplateletagents) requires careful consideration of the risks of throm-boembolic events, particularly in patients who present withactive upper gastrointestinal tract bleeding.15,16 These de-cisions should be made by the gastroenterologist in consul-tationwithintensivists,cardiologists,neurologists,andhematologists when appropriate to provide advice, includinguse of reversal agents, safe length of time to hold AT medi-cations, and whether alternative shorter-acting agents (eg,',\n",
       " 'neurologists,andhematologists when appropriate to provide advice, includinguse of reversal agents, safe length of time to hold AT medi-cations, and whether alternative shorter-acting agents (eg,heparin drip) should be used as bridge therapy.17 When thereis doubt, it is usually better to err on the side of not reversingAT medication because a cardiopulmonary or neurologicthromboembolic event is usually far more devastating thanongoing NVUGIB, which can often be managed with sup-portive care in relatively stable patients.Intravenous proton pump inhibitors should be administeredto all patients with suspected NVUGIB because these have theeffect of downgrading the stigmata of recent hemorrhage onsubsequent endoscopy, but should not delay endoscopic inter-vention.14,18 High-dose intravenous proton pump inhibitorsshould be continued post endoscopy because their use is asso-ciated with decreased risk of rebleeding.14,19 A single dose ofTable 1.Three Established and Commonly Used Risk Assessment Scores That Stratify Patients Into Lower- and Higher-RiskGroups for Poor Outcomes Related to Gastrointestinal BleedingScoring systemComponentsNo. of pointsKey conceptsGlasgow-Blatchford score Systolic BP1, 2, 3Score ranges from 0–23BUN2, 3, 4, 6Calculated on admissionHemoglobin1, 3, 6 (men);1, 6 (women)Patients with a score of 0 or 1 can bemanaged as an outpatientTachycardia1Superior in predicting a combined end point ofintervention and deathPotentially leads to overadmission (ie, has low sensitivity)Melena1Syncope2Hepatic disease2Cardiac failure2Rockall scoreAge0, 1, 2Requires endoscopic evaluation to determinethe full scorePredicts risk of additional bleeding and death inhospitalized patientsSigns of hemodynamic shock0,1 , 2Major comorbidities0, 2, 3Endoscopic diagnosis0, 2Stigmata of recent hemorrhageand/or presence of blood onendoscopy0, 2AIMS-65Albumin (<3 mg/dL)0, 1Easy to calculateINR (>1.5)0, 1Can be calculated pre-endoscopy',\n",
       " 'Endoscopic diagnosis0, 2Stigmata of recent hemorrhageand/or presence of blood onendoscopy0, 2AIMS-65Albumin (<3 mg/dL)0, 1Easy to calculateINR (>1.5)0, 1Can be calculated pre-endoscopyAltered mental status0, 1Less sensitive for than Glasgow-Blatchford score and RockallSystolic BP (<100 mm Hg)0, 1AIMS-65 score (% inpatient mortality):Age (>65 years)0, 10 (0.3%), 1 (3.2%), 2 (5.3%), 3 (10.3%), 4 (16.5%), 5 (24.5%)NOTE. These risk assessment scores cannot precisely identify individual high-risk patients who will die from gastrointestinalbleeding if they do not receive an intervention, but may have a clinical role in identifying patients who are at very low risk formortality and may be amenable to outpatient medical care/endoscopy.1BP, blood pressure; BUN, blood urea nitrogen; GI, gastrointestinal; INR, international normalized ratio.September 2020Endoscopic Therapies for NVUGIB 1121CLINICAL PRACTICE UPDATE',\n",
       " 'erythromycin or metoclopramide may be given intravenously toselected patients before upper endoscopy to aid gastricemptying of clot to improve visualization, particularly of thegastric fundus, where clots tend to obscure complete visualiza-tion. Use of these prokinetics have been associated with reducedneed for repeat endoscopy, with the published data favoring theuse of erythromycin.20 Both erythromycin and metoclopramideshould be used cautiously in patients with prolonged QT in-tervals.20,21 Use of octreotide is not recommended in NVUGIB,but there should be a low threshold for its use if there is concernfor underlying portal hypertension. Prophylactic antibiotics arenot indicated in the setting of NVUGIB.The use of nasogastric tubes in the evaluation andmanagement of suspected NVUGIB is controversial, as theiruse does not impact clinical outcomes. Nasogastric lavagecan assist in the removal of blood from the stomach andsuggests the need for emergent endoscopy if there is returnof continuous and copious bright red blood; however, anegative lavage should not delay endoscopy, particularly ifother parameters are suggestive of active NVUGIB.14Endoscopy Best PracticesAfter assessment, triage, resuscitation, and medical opti-mization, endoscopy should be performed to determine thesource of bleeding, to assess rebleeding risk, and to treatlesionsat high risk for rebleeding (Figure 1). Exactly when theendoscopy should be performed is a clinical judgment made bythe gastroenterologist in consultation with the primary service.Understanding that the deﬁnitions of emergent, urgent, andelective endoscopy are somewhat variable, endoscopy shouldgenerally be performed within 12 hours for emergent cases,within 24 hours for urgent cases, and can wait more than 24hours for elective cases.22,23 A common decision is decidingwhether or not to wait until the next morning to performendoscopy on a patient presenting after hours with suspected',\n",
       " 'hours for elective cases.22,23 A common decision is decidingwhether or not to wait until the next morning to performendoscopy on a patient presenting after hours with suspectedNVUGIB. Patients with suspected NVUGIB with persistent he-modynamic compromise after initial resuscitation and thosewith moderate- to large-volume hematemesis likely havepersistent NVUGIB and should undergo emergent endoscopy. Itshould be noted, however, that patients undergoing emergentendoscopy may have worse outcomes, possibly due to inade-quate resuscitation.22,23 Patients who are hemodynamicallystable, do not have ongoing hematemesis, and have melenaonly can generally be deferred to the following morning.A recently published trial included patients who presentedwith acute upper gastrointestinal tract bleeding and were athigh risk for further bleeding or death (Glasgow-Blatchfordscore 12). Patients were randomized to urgent (within 6hours) or early (the next morning and within 24 hours)endoscopyaftergastroenterologyconsultation,whichoccurred on average 7–8 hours after presentation. This studyincluded patients with variceal hemorrhage and excluded,among others, patients in hypotensive shock or whose con-dition did not stabilize after initial resuscitation. This pivotaltrial demonstrated that urgent endoscopy was not associatedwith lower 30-day mortality than endoscopy performed thenext morning or between 6 and 24 hours after consultation.24In general, patients with suspected NVUGIB and a Glasgow-Blatchford score of 0–1 may be discharged from the emer-gency department for timely outpatient management.25,26Themethodofsedation(endoscopist-directedorrequiring anesthesia support) and whether airway protec-tion is necessary are important considerations beforeendoscopy. Patients with suspected ongoing or massiveNVUGIB, active hematemesis, or suspected retained gastriccontentsshouldundergoendotrachealintubationtodecrease the risk of aspiration.27 The choice of endoscope is',\n",
       " 'NVUGIB, active hematemesis, or suspected retained gastriccontentsshouldundergoendotrachealintubationtodecrease the risk of aspiration.27 The choice of endoscope islargely at the discretion of the endoscopist. Therapeuticupper endoscopes have a larger working channel thataccommodate 10F accessories and also enable improvedsuction of retained gastric contents and blood clots and maybe preferred in situations of severe bleeding.27Upper endoscopy in the patient with suspected NVUGIBshould be performed methodically. The esophagus should beexamined carefully for pathology such as varices and Mallory-Weiss tears. Careful examination of the esophagus should bedone on the initial scope insertion because retching during theprocedure can cause a Mallory-Weiss tear and create a diag-nostic and treatment dilemma. If there is a large clot in thestomach, it is not advised to spend time clearing the clot unlessa source is not found distally. There are various ways tomanipulate clots and improve visualization of the fundus,including repositioning the patient (eg, reverse Trendelenburgor supine/right lateral decubitus), preprocedural prokinetics,using “clot busting” tubing/6-mm channel endoscopes (thatprovide increased suction power), and extraction/foreign-bodyretrieval nets. If no bleeding source is found and retained clotprevents full examination of the stomach, endoscopy should beFigure 1. Approach to theinitial management, clinicaltriage,andendoscopicdecision making in treatingpatients with acute NVU-GIB.ETT,endotrachealtube;GBS,Glasgow-Blatchford bleeding score;IV, intravenous; PPI, pro-ton pump inhibitor.1122 Mullady et alGastroenterology Vol. 159, No. 3CLINICAL PRACTICE UPDATEInitial managementTriageEndoscopyAssess hemodynamic status·ICu levelcarePlan forsedation·Resuscitation·Unstable vital signs·Need for ETT for airwayprotectionorgeneral·IV fluids, blood products·Multiplecomorbiditiesanesthesia?Medications·Need for endotracheal tube',\n",
       " 'Plan forsedation·Resuscitation·Unstable vital signs·Need for ETT for airwayprotectionorgeneral·IV fluids, blood products·Multiplecomorbiditiesanesthesia?Medications·Need for endotracheal tubeIdentifybleeding source(ETT)·Presence/absence ofActivebleeding/stigmata ofanti-thrombotic therapy·Ongoing massive bleedingrecenthemorrhage· PPI (IV route)·Medical/surgical floor· Thermal (probe, forceps)·Prokinetictherapy·Hemodynamically stable· Clips (through-the-scope,· Octreotide (if any suspicion·No hematemesisover-the-scope)for portal hypertension,·Outpatient managementvarices)·GBS0-1',\n",
       " 'repeated after allowing time for gastric emptying to completethe examination of the stomach, with the timing dependent onpatient stability and the degree of bleeding.The etiology of bleeding frequently dictates endoscopictherapy. Broadly speaking, deﬁnitive endoscopic therapy canbe categorized as mechanical (eg, clips) or thermal (eg, heaterprobes, bipolar/multipolar catheters, hemostatic forceps).Within each group, there are multiple available endoscopictools and techniques for the management of NVUGIB.28,29Diluted epinephrine (1:10,000 dilution, which is equivalentto 100 mg/mL) can be injected at or near the bleeding site toattain initial hemostasis by inducing vasospasm, but this is onlya temporizing measure that allows for improved visualizationto target deﬁnitive therapy. Epinephrine monotherapy shouldbe avoided, given the high risk for rebleeding.30–32 Ifepinephrine injection is used, a second endoscopic-hemostasismodality should be employed;27,32 however, dual therapy withepinephrine and another endoscopic therapy has no advantageover properly applied thermal or mechanical monotherapy.30In subgroup analyses from meta-analyses, there was no dif-ference between hemoclips and thermal treatment in terms ofpeptic ulcer rebleeding rates30–32; data showing superiority ofone modality over the other are largely lacking.As there is no deﬁnitively superior modality for endo-scopic hemostasis, use of through-the-scope hemoclips vsthermal therapy for active NVUGIB or for treatment ofstigmata of recent hemorrhage is largely at the discretion ofthe endoscopist. In terms of active peptic ulcer bleeding andstigmata of recent hemorrhage (using the Forrest classiﬁ-cation), the endoscopist should consider the location of thebleeding, as certain locations (eg, posterior wall of duo-denum, lesser curvature of the stomach) and certain ulcercharacteristics (eg ﬁbrosis, large ulceration, size of visiblevessel) can make clip placement more challenging and less',\n",
       " 'denum, lesser curvature of the stomach) and certain ulcercharacteristics (eg ﬁbrosis, large ulceration, size of visiblevessel) can make clip placement more challenging and lesseffective than thermal therapy. In many situations, a low-proﬁle distal attachment cap on a forward-viewing endo-scope can facilitate visualization and therapy.33 Similarly, aduodenoscope might be required for lesions in the posteriorduodenal bulb and second portion of the duodenum.Endoscopically identiﬁed lesions at increased risk forpersistent bleeding or rebleeding, such as Forrest Ia(spurting), Ib (oozing), and IIa (nonbleeding visible vessel)ulcers should receive endoscopic-hemostasis therapy. Pepticulcers with an adherent clot should be treated by endo-scopic clot removal to evaluate for high-risk stigmata thatmight require endotherapy.27When applying contact thermal therapy, the endoscopistshould use, when possible a 10F probe. Generator settings of25–30 J per pulse, for 4–5 pulses, for a total of 100–150 J,should be used with a heater probe, and 15–20 W are rec-ommended for bipolar/multipolar probes. Forceful contactusing the probe should be applied for an extended period (atleast 8 seconds), with the tip of the scope as close as possibleto the treatment site to ensure complete obliteration of theculprit vessel.28,34–36 Failure to obliterate the culprit vesselmay cause bleeding during treatment or increase the risk forrebleeding. Excellent visualization is paramount to successfulhemostasis, and endoscopes that possess a dedicated waterjet should be used to treat NVUGIB.After achievement of hemostasis, use of a through-the-scopeDoppler probe can be considered, as data suggest presence ofDoppler signal after hemostasis is a risk factor for rebleeding. Asingle-blind randomized controlled trial (RCT) demonstrated asigniﬁcantly decreased rate of rebleeding within 30 days ofendoscopic hemostasis in patients randomized to post-treatmentDoppler assessment compared with controls.37',\n",
       " 'signiﬁcantly decreased rate of rebleeding within 30 days ofendoscopic hemostasis in patients randomized to post-treatmentDoppler assessment compared with controls.37Hemostatic Forceps and Concepts inElectrosurgical EnergyMonopolar hemostatic forceps (MHF) were initially usedfor the treatment of bleeding during endoscopic submucosaldissection (ESD) using low-voltage current.38 The MHF haverelatively small, ﬂat, rotatable jaws (Coagrasper, OlympusAmerica, Center Valley, PA) that can be used to grasp andcoagulate exposed submucosal vessels in order to treat activebleeding and prevent delayed bleeding from ESD. Using thelow-voltage, soft coagulation mode (80W, effect 4) producedby the ERBE VIO series of the electrosurgical generators limitspeak voltage thereby minimizing depth of penetration andtissue effect. A variety of studies have examined the use ofMHF soft coagulation in peptic ulcer bleeding, including arecent randomized trial of 112 patients that demonstratedtheir effectiveness compared with the use of hemostatic clipsfor Forest Ia, Ib, and IIa gastric or duodenal ulcers.5 The initialhemostasis success rate was 98% in the MHF soft coagulationgroup and 80% in the hemoclip group (P ¼ .004).5 Of note, inpeptic ulcer bleeding studies, the technique differs from ESD,as the MHF are applied to a bleeding point closed (withoutﬁrst opening the atraumatic jaws to grasp the bleedingvessel), followed by applying soft coagulation (80W, effect 4,1–2 seconds), and then retracting the forceps and retreatingas needed. A particular advantage of the MHF stems from theease and ﬂexibility of targeting with the forceps. The smaller-sized forceps can be used in difﬁcult locations, particularlywhen clip application is deemed difﬁcult due to location or arigid ﬁbrotic base. Unlike certain thermal probes units, whichapply a ﬁxed current for a deﬁned time, the application ofcurrent is also controlled by the endoscopist and the elec-',\n",
       " 'rigid ﬁbrotic base. Unlike certain thermal probes units, whichapply a ﬁxed current for a deﬁned time, the application ofcurrent is also controlled by the endoscopist and the elec-trosurgical generator, making retreatment more controlled,with less tissue injury. A potential downside to the use of MHFsoft coagulation occurs when there is limited coagulation ef-fect at the bleeding point. Treating in the presence of a largeblood clot would potentially dissipate the coagulation effect,preventing hemostasis from occurring. Another situationwhere the limited tissue effect is potentially suboptimal iswhen a large area of tissue needs to be treated and repeatedapplications could be required.As the hemostatic forceps (typically available in ESDcenters) are relatively costly, some endoscopists use a snaretip to apply soft coagulation for hemostasis, and others havetried to apply noncontact thermal methods (such as argonplasmacoagulation)toconductand/orprovideheatthrough already applied hemostatic clips. Another lesscostly alternative is to use closed, hot biopsy forceps thatusually cost a fraction of the cost of MHF. However, theseuses of thermal energy delivery to treat peptic ulcerbleedinghavenotbeenformallystudied.SwitchingSeptember 2020Endoscopic Therapies for NVUGIB 1123CLINICAL PRACTICE UPDATE',\n",
       " 'generator settings to a forced coagulation mode (availableon several commercially available electrosurgical genera-tors), for example, could be used to overcome pools of liquidor blood between the forceps and bleeding point; however,the endoscopist could potentially treat a larger area thandesired and have less ability to limit the depth of tissueinjury. Endoscopists should monitor the coagulum beingcreated and be aware of the potential for deep tissue injury,perforation, or delayed bleeding whenever electrosurgicalenergy is applied. Until their effectiveness is formallystudied, these latter techniques should be employed only byendoscopists very familiar with their use in advancedendoscopic procedures and who possess a good under-standing of electrosurgical current settings.Over-the-Scope ClipsIn selected patients with peptic ulcer bleeding or othercauses of NVUGIB, over-the-scope clips can be an effectivetreatment option. There are currently 2 clips (OTSC; OvescoEndoscopy, Cary, NC) and (Padlock clip; Steris Endoscopy,Mentor, OH) with different designs and deployment mecha-nisms. There have been no head-to-head comparisons of theseclips or head-to-head trials of over-the-scope clips to through-the-scope clips or thermal therapy. Most of the reportedexperience with over-the-scope clips in NVUGIB has been withpeptic ulcer bleeding. There are several scenarios in whichover-the-scope clips may be utilized in NVUGIB, includingrescue treatment, rebleeding, and initial treatment.In the setting of persistent bleeding despite conventionalmethods of hemostasis, data from small case series suggestthat over-the-scope clips are an effective rescue modality.39–42A recent RCT demonstrated that over-the-scope clips weremore effective than standard therapy in patients with recur-rent peptic ulcer bleeding.4 There are also nonrandomizeddata suggesting that over-the-scope clips may be superior tostandard treatment in initial treatment of peptic ulcer',\n",
       " 'rent peptic ulcer bleeding.4 There are also nonrandomizeddata suggesting that over-the-scope clips may be superior tostandard treatment in initial treatment of peptic ulcerbleeding compared with historical rebleeding rates.43–46Before suggesting a paradigm shift to over-the-scope clips,large RCTs are needed that demonstrate considerable beneﬁt.However, there may be situations in which over-the-scopeclips should be considered as ﬁrst-line treatment—namely,large, ﬁbrotic ulcer beds with a large visible vessel that maynot be amenable to through-the-scope hemoclip ﬁxation orwhen thermal therapy is predicted to be ineffective.Hemostatic PowderTopical hemostatic agents are a noncontact modalitythat can be used to treat NVUGIB. The main advantage ofthese agents is related to their mode of action and techniqueof deployment. Unlike other endoscopic hemostatic modal-ities, topical hemostatic powders can be diffusely deployedfrom a catheter without having to be positioned en face anddo not require advanced endoscopic training or skills. Muchof the initial clinical experience with these agents occurredin countries outside of the United States. Initially, hemo-static powder was used only in cases of NVUGIB due toconcern of embolization risk, but a recent study in patientswith variceal bleeding demonstrated clinical effectivenesswithout adverse events.47 Although patients in hemostaticpowder studies have experienced adverse events, they wereunlikely to be due to the sprayed powder.48Although there are a few hemostatic agents availableworldwide, the commercially available product in NorthAmerica is TC-325 (Hemospray, Cook Medical, Bloomington,IN). This agent is propelled through a delivery catheter on toa bleeding lesion using a carbon dioxide canister. Uponcontact with moisture, the endoscopic powder aggregates,creating a mechanical barrier upon the mucosa.49 Thismakes it particularly useful in situations where bleeding is',\n",
       " 'contact with moisture, the endoscopic powder aggregates,creating a mechanical barrier upon the mucosa.49 Thismakes it particularly useful in situations where bleeding isdiffuse, cannot be localized, or if visualization is poor due tobleeding (Figure 2). In most instances, hemostatic powdershould be preferentially used as a rescue therapy and notfor primary hemostasis, except in cases of malignantbleeding or massive bleeding with inability to performthermal therapy or hemoclip placement.When using this type of hemostatic powder and deliverysystem, the endoscopist should make an effort to prevent thedelivery catheter from becoming blocked. Both 7F and 10Fcatheters are available for different-sized accessory channels(such as those found in diagnostic vs therapeutic endoscopes).Care must be taken when using duodenoscope elevators orwhen in retroﬂexed positions to avoid kinking the deliverycatheter. Additional steps must also be taken to avoid moisturecoming into contact with the catheter, such as keeping thecatheter tip out of contact with pools of ﬂuid or blood, as thiswill prematurely activate the powder within the catheter andprevent deployment. Keeping the accessory channel free ofmoisture by preﬂushing with air (using a 60-mL syringe) anddetaching suction tubing temporarily before inserting the de-livery catheter to avoid inadvertent suctioning are steps thatmay minimize unintended activation of the powder within thedelivery catheter. Once in position near the bleeding site, thespray is typically deployed from a distance of 1–2 cm away inshort controlled bursts. Once delivery begins, the endoscopistshould take care to avoid accidental powder spray on the lens.Overapplication can lead to a diffuse spray effect, potentiallylimiting subsequent mucosal assessment. Subsequent washingat the lesion site is not recommended, as this can wash awaythe powder. If multiple treatment modalities are planned, it is',\n",
       " 'limiting subsequent mucosal assessment. Subsequent washingat the lesion site is not recommended, as this can wash awaythe powder. If multiple treatment modalities are planned, it isideal to plan the timing and sequence of modalities due to theeffect of powder deployment on endoscopic visibility.Retrospective studies demonstrated the powder remainspresent less than 24 hours,50 hence monotherapy with TC-325 is not recommended in ulcers with high-risk stigmatafor rebleeding. In these situations, hemostatic powdershould be used as a temporary measure to stop bleeding,followed by another treatment modality either at the indexprocedure or during a second-look endoscopy.14 However, 2pilot RCTs6,51 and a noncontrolled registry study52 havesuggested a potential role for TC-325/Hemospray as mon-otherapy in patients with upper gastrointestinal tractbleeding, raising the need for an appropriately poweredclinical trial. Hemostatic powder may be particularly usefulin centers where advanced endoscopic expertise is not al-ways available and temporizing methods are needed beforemore deﬁnitive therapy or transfer to a specialized center.1124 Mullady et alGastroenterology Vol. 159, No. 3CLINICAL PRACTICE UPDATE',\n",
       " 'Diffuse tumor bleeding is a challenging clinical problemthat is often not responsive to conventional endoscopictherapy. A pilot RCT51 did show that hemostatic powdermay be useful in such situations, optimally as a bridge toradiotherapy or surgery.According to the US Food and Drug Administration, onFebruary 4, 2020 Cook Medical recalled their HemosprayEndoscopic Hemostat (hemostatic powder) device due to“Complaints that the handle and/or activation knob on He-mostat devices have cracked or broken when the device isactivated. In some cases, this has caused the carbon dioxidecartridge to exit the handle.”53 This was in conjunction with avoluntary global recall initiated by the company in January2020 for the same reason. Cook Medical has addressed thisissue. On June 10, 2020 the US Food and Drug Administrationissued 510(k) premarket approval (K200972) for Hemospray.At the time this Clinical Practice Update went to print,Hemospray is available again in the US and Canadian marketsand in many other countries worldwide.Hemostatic Considerations inAdvanced Endoscopy SettingsThere are certain endoscopic interventions that are asso-ciated with an increased risk for inducing bleeding.15 Theseinclude endoscopic mucosal resection (EMR), ESD, andendoscopic sphincterotomy. Bleeding can be immediate/intraproceduralordelayed/postprocedural.Endoscopistswho perform these procedures should be comfortable man-aging bleeding and have tools readily available in the event ofintraproceduralbleeding.Procedure-relatedbleedingistreated in the same manner as other types of NVUGIB, butwith special considerations. For example, thermal therapy,particularly with hemostatic forceps, for bleeding during EMRor ESD may be preferable to treatment with hemoclipsbecause the latter may interfere with completing the resec-tion. For post-sphincterotomy bleeding, biliary stents may beused to tamponade a bleeding site. Clips and thermal therapy',\n",
       " 'because the latter may interfere with completing the resec-tion. For post-sphincterotomy bleeding, biliary stents may beused to tamponade a bleeding site. Clips and thermal therapycan also be used to treat post-sphincterotomy bleeding;however, the endoscopist needs to be aware of the potentialdifﬁculty in clip placement through a duodenoscope and thepossibility of pancreatitis with thermal therapy or errant clipplacement. Therefore, when clips or thermal coagulation areused in post-sphincterotomy bleeding, a low threshold forplacing a prophylactic pancreatic duct stent should exist.Endoscopists should be prepared to perform an endoscopicretrogradecholangiopancreatography,ifneeded,foralldelayedpost-sphincterotomybleeds,asbiliaryand/orpancreatic duct stenting may be required.Postprocedural bleeding prophylaxis is an important issuethat the endoscopist should address. This is particularityimportant in patients who require reinstitution of AT therapy.Although there is recent evidence that clip closure of right-sided colonic EMR sites might decrease the risk of post-polypectomy bleeding,54 there is no similar high-level evi-dence for upper gastrointestinal interventions. For bleedingprophylaxis of upper gastrointestinal EMR or ESD sites, op-tions include use of MHF to treat visible vessels or closure ofthe defect with clips or endosuturing. There are no compar-ative trials to guide practice, but consideration should beFigure2. Flowdiagramincorporatinghemostaticpowder therapy as an op-tion for the management ofacute NVUGIB.September 2020Endoscopic Therapies for NVUGIB 1125CLINICAL PRACTICE UPDATEFindings at initial endoscopyPoor visibility or suspectedInitial attempts at bleedingdiffuse bleedingcontrol with standardendoscopic therapy arenot successfulSpray hemostatic powderto improve local controlSpray hemostatic powderas a second-line modalityand retreat as neededConsider repeat endoscopy,MalignancyNon-malignancy',\n",
       " 'not successfulSpray hemostatic powderto improve local controlSpray hemostatic powderas a second-line modalityand retreat as neededConsider repeat endoscopy,MalignancyNon-malignancytransarterial embolization,or surgery, depending onclinical factorsSurgery orFurther endoscopicradiotherapytherapy',\n",
       " 'given to closing sites, when amenable, in patients who requireimmediate resumption of AT medications. There are no datawith regard to prophylaxis of post-sphincterotomy bleeding;however, in patients who require immediate resumption ofAT medication, a fully covered metallic biliary stent may beused.Interventions for Recurrent orRefractory BleedingIn patients who rebleed after endoscopic therapy, a sec-ond attempt at endoscopic hemostasis is typically advised. Inpatients treated initially with thermal therapy who rebleed,additional thermal therapy might be possible, or mechanicaltherapy with a clip could be applied. Hemospray should alsobe considered as rescue therapy. In difﬁcult situations, asecond opinion from a colleague or assistance from a moreexperienced endoscopist are important considerations.However, despite the increasing availability of differenteffective endoscopic modalities, a subset of patients withNVUGIB will still develop rebleeding despite high-qualityendoscopic interventions. The exact point at which an endo-scopist will determine that repeat endoscopic invention has alow chance of technical and clinical success is a complex de-cision that will depend on local expertise and resources; fa-miliarity with advanced endoscopic techniques; and clinicalpredictors, such as type of disease, severity, and location.Second-look endoscopy should not be performed routinely, butit does have a role in cases where rebleeding risk is high,despite initial endoscopic success or if the index proceduredoes not adequately control bleeding. Prior endoscopic therapycan be suboptimal due to ulcer characteristics, such as size,location, or presence of ﬁbrosis; the use of epinephrine-injection monotherapy or single use of a hemostatic powderfor a high-risk lesion; or if thermal or mechanical therapy aloneor in combination was performed but did not adequatelycontrol bleeding for technical reasons (eg, inadequate coagu-',\n",
       " 'for a high-risk lesion; or if thermal or mechanical therapy aloneor in combination was performed but did not adequatelycontrol bleeding for technical reasons (eg, inadequate coagu-lation or insufﬁcient tissue grasped by a hemostatic clip).The main options in cases of endoscopic failure withrebleeding or refractory bleeding are transcatheter arterialembolization (TAE) and surgery. In earlier studies, a variety ofsurgical options were used, with TAE reserved for poor sur-gical candidates. With high technical and clinical success rates,TAE has been shown to be equally effective, with trends to-ward lower 30-day mortality rates compared with surgicalintervention.55–57 TAE has become increasingly available, withthe advantage of being able to be used in patients who areunﬁt for surgery, even in the setting of coagulopathy. Studiesof TAE have shown fewer complications than surgery, albeitwith higher rebleeding rates.57 Embolization is most effectivewhen active extravasation can be demonstrated, or if a sitecan be endoscopically prelocalized (either anatomically or byusing a hemoclip) before empiric embolization. Studies ofembolization show that multiple or large duodenal ulcers,gastritis, coagulopathy, or multi-organ failure are believed tocontribute to clinical failures.58 The choice of embolic agentshould also be taken into account by the performing inter-ventional radiologist, as the multiple agents that exist havedifferent properties that inﬂuence rebleeding rate, risk ofrecanalization, and subsequent ischemic complications. Animportant point is that prophylactic TAE of high-risk ulcersafter successful endoscopic therapy is not recommended.1,59As patients with rebleeding and refractory bleeding aretypicallycomplex,withmultiplecomorbidities,oftenreceiving anticoagulants, or with severe coagulopathies(such as seen in hematologic malignancies), the choiceamong repeat endoscopy, surgery, and TAE must be decided',\n",
       " 'withmultiplecomorbidities,oftenreceiving anticoagulants, or with severe coagulopathies(such as seen in hematologic malignancies), the choiceamong repeat endoscopy, surgery, and TAE must be decidedon a case-by-case basis. Weighing the risks and beneﬁts ofeach intervention will depend on the expected rates ofclinical success, risk of rebleeding, potential adverse events,and after taking into account local expertise and resourceavailability. For optimal clinical outcomes in refractorybleeding, a multidisciplinary approach is required involvinggastrointestinal endoscopists, intensivists, surgeons, inter-ventional radiologists, and in some cases hematologistsand/or oncologists.SummaryRecent advances in endoscopic devices and techniquesnow enable endoscopists to treat NVUGIB lesions moreeffectively and with a variety of often complementarymethods. With this expanded endoscopic armamentarium,endoscopic therapy should achieve hemostasis in the majorityof patients with NVUGIB. Hemostatic forceps, over-the-scopeclips, and sprayed hemostatic powders are newer and rela-tively expensive endoscopic devices that have establishedroles in treating NVUGIB, and may be particularly useful indifﬁcult-to-treat or recurrent bleeding lesions. Despite theincreased costs of newer devices or multimodal therapy,effective hemostasis to prevent rebleeding and the need forhospital readmission is likely to be a dominant cost-savingstrategy. Practicing endoscopists should be comfortableapplying conventional thermal therapy and placing hemoclips,and they should familiarize themselves with newer tech-niques to manage NVUGIB, which can occur from a variety ofetiologies ranging from peptic ulcer disease to adverse eventsafter therapeutic endoscopy. In situations where thermal ormechanical therapies are not successful at achieving hemo-stasis, sprayed hemostatic powder is a valuable rescue ther-apy; and it might also enable endoscopists with limited',\n",
       " 'mechanical therapies are not successful at achieving hemo-stasis, sprayed hemostatic powder is a valuable rescue ther-apy; and it might also enable endoscopists with limitedtraining or backup to temporize severely bleeding lesions toallow time for transfer to a specialized referral center. Finally,multidisciplinary consultation and an assessment of endo-scopic, radiographic, and surgical expertise should inform theselection of therapy in refractory NVUGIB.References1. Stanley AJ, Laine L. Management of acute uppergastrointestinal bleeding. BMJ 2019;364:l536.2. Wang AY, Peura DA. The prevalence and incidence ofHelicobacter pylori-associated peptic ulcer disease andupper gastrointestinal bleeding throughout the world.Gastrointest Endosc Clin N Am 2011;21:613–635.3. Binmoeller KF, Thonke F, Soehendra N. Endoscopichemocliptreatmentforgastrointestinalbleeding.Endoscopy 1993;25:167–170.1126 Mullady et alGastroenterology Vol. 159, No. 3CLINICAL PRACTICE UPDATE',\n",
       " '4. Schmidt A, Golder S, Goetz M, et al. Over-the-scopeclips are more effective than standard endoscopic ther-apy for patients with recurrent bleeding of peptic ulcers.Gastroenterology 2018;155:674–686.e6.5. Toka B, Eminler AT, Karacaer C, et al. Comparison ofmonopolar hemostatic forceps with soft coagulationversus hemoclip for peptic ulcer bleeding: a random-izedtrial(withvideo).GastrointestEndosc2019;89:792–802.6. Baracat FI, de Moura DTH, Brunaldi VO, et al. Ran-domized controlled trial of hemostatic powder versusendoscopic clipping for non-variceal upper gastrointes-tinal bleeding. Surg Endosc 2020;34:317–324.7. Blatchford O, Murray WR, Blatchford M. A risk score topredict need for treatment for upper-gastrointestinalhaemorrhage. Lancet 2000;356:1318–1321.8. Rockall TA, Logan RF, Devlin HB, et al. Variation inoutcome after acute upper gastrointestinal haemorrhage.The National Audit of Acute Upper GastrointestinalHaemorrhage. Lancet 1995;346:346–350.9. Rockall TA, Logan RF, Devlin HB, et al. Incidence of andmortality from acute upper gastrointestinal haemorrhagein the United Kingdom. Steering Committee and mem-bers of the National Audit of Acute Upper Gastrointes-tinal Haemorrhage. BMJ 1995;311:222–226.10. Saltzman JR, Tabak YP, Hyett BH, et al. A simple riskscore accurately predicts in-hospital mortality, length ofstay, and cost in acute upper GI bleeding. GastrointestEndosc 2011;74:1215–1224.11. Odutayo A, Desborough MJ, Trivella M, et al. Restrictiveversusliberalbloodtransfusionforgastrointestinalbleeding: a systematic review and meta-analysis ofrandomised controlled trials. Lancet Gastroenterol Hep-atol 2017;2:354–360.12. Qaseem A, Humphrey LL, Fitterman N, et al. Treatmentof anemia in patients with heart disease: a clinicalpractice guideline from the American College of Physi-cians. Ann Intern Med 2013;159:770–779.13. Villanueva C, Colomo A, Bosch A. Transfusion for acuteupper gastrointestinal bleeding. N Engl J Med 2013;',\n",
       " 'cians. Ann Intern Med 2013;159:770–779.13. Villanueva C, Colomo A, Bosch A. Transfusion for acuteupper gastrointestinal bleeding. N Engl J Med 2013;368:1362–1363.14. Barkun AN, Almadi M, Kuipers EJ, et al. Management ofnonvariceal upper gastrointestinal bleeding: guidelinerecommendations from the International ConsensusGroup. Ann Intern Med 2019;171:805–822.15. ASGE Standards of Practice Committee, Acosta RD,Abraham NS, et al. The management of antithromboticagents for patients undergoing GI endoscopy. Gastro-intest Endosc 2016;83:3–16.16. Chan FKL, Goh KL, Reddy N, et al. Management of pa-tients on antithrombotic agents undergoing emergencyand elective endoscopy: Joint Asian Paciﬁc Associationof Gastroenterology (APAGE) and Asian Paciﬁc Societyfor Digestive Endoscopy (APSDE) practice guidelines.Gut 2018;67:405–417.17. Nagata N, Yasunaga H, Matsui H, et al. Therapeuticendoscopy-related GI bleeding and thromboembolicevents in patients using warfarin or direct oral antico-agulants: results from a large nationwide databaseanalysis. Gut 2018;67:1805–1812.18. Dorward S, Sreedharan A, Leontiadis GI, et al. Protonpump inhibitor treatment initiated prior to endoscopicdiagnosis in upper gastrointestinal bleeding. CochraneDatabase Syst Rev 2006:CD005415.19. Chan WH, Khin LW, Chung YF, et al. Randomized controlledtrial of standard versus high-dose intravenous omeprazoleafter endoscopic therapy in high-risk patients with acutepeptic ulcer bleeding. Br J Surg 2011;98:640–644.20. Barkun AN, Bardou M, Martel M, et al. Prokinetics inacute upper GI bleeding: a meta-analysis. GastrointestEndosc 2010;72:1138–1145.21. Ellidokuz E, Kaya D. The effect of metoclopramide on QTdynamicity: double-blind, placebo-controlled, cross-overstudy in healthy male volunteers. Aliment PharmacolTher 2003;18:151–155.22. Kumar NL, Cohen AJ, Nayor J, et al. Timing of upper endos-copy inﬂuences outcomes in patients with acute nonvariceal',\n",
       " 'study in healthy male volunteers. Aliment PharmacolTher 2003;18:151–155.22. Kumar NL, Cohen AJ, Nayor J, et al. Timing of upper endos-copy inﬂuences outcomes in patients with acute nonvaricealupper GI bleeding. Gastrointest Endosc 2017;85:945–952.e1.23. Laursen SB, Leontiadis GI, Stanley AJ, et al. Relationshipbetween timing of endoscopy and mortality in patientswith peptic ulcer bleeding: a nationwide cohort study.Gastrointest Endosc 2017;85:936–944.e3.24. Lau JYW, Yu Y, Tang RSY, et al. Timing of endoscopy foracute upper gastrointestinal bleeding. N Engl J Med2020;382:1299–1308.25. Stanley AJ, Ashley D, Dalton HR, et al. Outpatient man-agement of patients with low-risk upper-gastrointestinalhaemorrhage: multicentre validation and prospectiveevaluation. Lancet 2009;373:42–47.26. Laursen SB, Dalton HR, Murray IA, et al. Performance ofnew thresholds of the Glasgow Blatchford score inmanaging patients with upper gastrointestinal bleeding.Clin Gastroenterol Hepatol 2015;13:115–121 e2.27. Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosisand management of nonvariceal upper gastrointestinalhemorrhage:EuropeanSocietyofGastrointestinalEndoscopy (ESGE) Guideline. Endoscopy 2015;47:a1–46.28. ASGE Technology Committee, Parsi MA, Schulman AR,et al. Devices for endoscopic hemostasis of nonvaricealGI bleeding (with videos). VideoGIE 2019;4:285–299.29. Martinez-Alcala A, Monkemuller K. Emerging endoscopictreatments for nonvariceal upper gastrointestinal hemor-rhage. Gastrointest Endosc Clin N Am 2018;28:307–320.30. Marmo R, Rotondano G, Piscopo R, et al. Dual therapyversus monotherapy in the endoscopic treatment ofhigh-risk bleeding ulcers: a meta-analysis of controlledtrials. Am J Gastroenterol 2007;102:279–289; quiz 469.31. Vergara M, Bennett C, Calvet X, et al. Epinephrine in-jectionversusepinephrineinjectionand asecondendoscopicmethodinhigh-riskbleedingulcers.Cochrane Database Syst Rev 2014:CD005584.',\n",
       " '31. Vergara M, Bennett C, Calvet X, et al. Epinephrine in-jectionversusepinephrineinjectionand asecondendoscopicmethodinhigh-riskbleedingulcers.Cochrane Database Syst Rev 2014:CD005584.32. Sung JJ, Tsoi KK, Lai LH, et al. Endoscopic clippingversus injection and thermo-coagulation in the treatmentof non-variceal upper gastrointestinal bleeding: a meta-analysis. Gut 2007;56:1364–1373.33. Sanchez-Yague A, Kaltenbach T, Yamamoto H, et al.The endoscopic cap that can (with videos). GastrointestEndosc 2012;76:169–178; e1–e2.34. Laine L. Determination of the optimal technique for bi-polarelectrocoagulationtreatment.An experimentalSeptember 2020Endoscopic Therapies for NVUGIB 1127CLINICAL PRACTICE UPDATE',\n",
       " 'evaluation of the BICAP and Gold probes. Gastroenter-ology 1991;100:107–112.35. Laine L, Long GL, Bakos GJ, et al. Optimizing bipolarelectrocoagulation for endoscopic hemostasis: assess-ment of factors inﬂuencing energy delivery and coagu-lation. Gastrointest Endosc 2008;67:502–508.36. Laine L, Jensen DM. Management of patients with ulcerbleeding. Am J Gastroenterol 2012;107:345–360; quiz 361.37. Jensen DM, Kovacs TOG, Ohning GV, et al. DopplerEndoscopic probe monitoring of blood ﬂow improvesrisk stratiﬁcation and outcomes of patients with severenonvariceal upper gastrointestinal hemorrhage. Gastro-enterology 2017;152:1310–1318.e1.38. Sugawa C, Masuyama H. An endoscopic monopolarhemostatic electrocoagulation forceps (grasping coagu-lator). Gastrointest Endosc 1986;32:114–116.39. Chan SM, Chiu PW, Teoh AY, et al. Use of the over-the-scope clip for treatment of refractory upper gastroin-testinalbleeding: a caseseries. Endoscopy2014;46:428–431.40. El Douaihy Y, Kesavan M, Deeb L, et al. Over-the-scopeclip to the rescue of a bleeding gastroduodenal arterypseudoaneurysm. Gastrointest Endosc 2016;84:854–855.41. Manta R, Galloro G, Mangiavillano B, et al. Over-the-scope clip (OTSC) represents an effective endoscopictreatment for acute GI bleeding after failure of conven-tional techniques. Surg Endosc 2013;27:3162–3164.42. Skinner M, Gutierrez JP, Neumann H, et al. Over-the-scope clip placement is effective rescue therapy for se-vere acute upper gastrointestinal bleeding. Endosc IntOpen 2014;2:E37–E40.43. Golder S, Neuhas L, Freuer D, et al. Over-the-scope clipin peptic ulcer bleeding: clinical success in primary andsecondary treatment and factors associated with treat-ment failure. Endosc Int Open 2019;7:E846–E854.44. Manno M, Mangiaﬁco S, Caruso A, et al. First-lineendoscopic treatment with OTSC in patients with high-risk non-variceal upper gastrointestinal bleeding: pre-liminary experience in 40 cases. Surg Endosc 2016;30:2026–2029.',\n",
       " 'endoscopic treatment with OTSC in patients with high-risk non-variceal upper gastrointestinal bleeding: pre-liminary experience in 40 cases. Surg Endosc 2016;30:2026–2029.45. Richter-Schrag HJ, Glatz T, Walker C, et al. First-lineendoscopic treatment with over-the-scope clips signiﬁcantlyimproves the primary failure and rebleeding rates in high-riskgastrointestinal bleeding: a single-center experience with100 cases. World J Gastroenterol 2016;22:9162–9171.46. Wedi E, Fischer A, Hochberger J, et al. Multicenterevaluation of ﬁrst-line endoscopic treatment with theOTSCinacutenon-varicealuppergastrointestinalbleeding and comparison with the Rockall cohort: theFLETRock study. Surg Endosc 2018;32:307–314.47. Ibrahim M, El-Mikkawy A, Abdel Hamid M, et al. Earlyapplication of haemostatic powder added to standardmanagement for oesophagogastric variceal bleeding: arandomised trial. Gut 2019;68:844–853.48. Rodriguez de Santiago E, Burgos-Santamaria D, Perez-Carazo L, et al. Hemostatic spray powder TC-325 for GIbleeding in a nationwide study: survival and predictors offailure via competing risks analysis. Gastrointest Endosc2019;90:581–590.e6.49. Barkun AN, Moosavi S, Martel M. Topical hemostaticagents: a systematic review with particular emphasis onendoscopic application in GI bleeding. GastrointestEndosc 2013;77:692–700.50. Chen YI, Barkun AN. Hemostatic powders in gastroin-testinal bleeding: a systematic review. GastrointestEndosc Clin N Am 2015;25:535–552.51. Chen YI, Wyse J, Lu Y, et al. TC-325 hemostatic powderversus current standard of care in managing malignantGI bleeding: a pilot randomized clinical trial. GastrointestEndosc 2020;91:321–328.e1.52. Alzoubaidi D, Hussein M, Rusu R, et al. Outcomes froman international multicenter registry of patients withacute gastrointestinal bleeding undergoing endoscopictreatment with Hemospray. Dig Endosc 2020;32:96–105.53. US Food and Drug Administration. Class 2 Device Recall',\n",
       " 'acute gastrointestinal bleeding undergoing endoscopictreatment with Hemospray. Dig Endosc 2020;32:96–105.53. US Food and Drug Administration. Class 2 Device RecallCook Hemospray Endoscopic Hemostat (Recall Number:Z-1746-2020).Availableat:https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/res.cfm?ID¼179474.Accessed April 25, 2020.54. Pohl H, Grimm IS, Moyer MT, et al. Clip closure preventsbleeding after endoscopic resection of large colonpolyps in a randomized trial. Gastroenterology 2019;157:977–984.e3.55. Jairath V, Kahan BC, Logan RF, et al. National audit ofthe use of surgery and radiological embolization afterfailed endoscopic haemostasis for non-variceal uppergastrointestinal bleeding. Br J Surg 2012;99:1672–1680.56. Ripoll C, Banares R, Beceiro I, et al. Comparison oftranscatheter arterial embolization and surgery for treat-ment of bleeding peptic ulcer after endoscopic treatmentfailure. J Vasc Interv Radiol 2004;15:447–450.57. Tarasconi A, Baiocchi GL, Pattonieri V, et al. Trans-catheter arterial embolization versus surgery for re-fractory non-variceal upper gastrointestinal bleeding: ameta-analysis. World J Emerg Surg 2019;14:3.58. Loffroy R, Rao P, Ota S, et al. Embolization of acutenonvariceal upper gastrointestinal hemorrhage resistantto endoscopic treatment: results and predictors ofrecurrent bleeding. Cardiovasc Intervent Radiol 2010;33:1088–1100.59. Lau JYW, Pittayanon R, Wong KT, et al. Prophylacticangiographic embolisation after endoscopic control ofbleedingtohigh-riskpepticulcers:arandomisedcontrolled trial. Gut 2019;68:796–803.Received March 25, 2020. Accepted May 18, 2020.CorrespondenceAddress correspondence to: Andrew Y. Wang, MD, AGAF, FACG, FASGE,Division of Gastroenterology and Hepatology, University of Virginia, Box800708, Charlottesville, Virginia 22908. e-mail: ayw7d@virginia.edu; fax: 434-244-7590.AcknowledgmentsAuthor contributions: Each of the authors contributed to drafting of the',\n",
       " '800708, Charlottesville, Virginia 22908. e-mail: ayw7d@virginia.edu; fax: 434-244-7590.AcknowledgmentsAuthor contributions: Each of the authors contributed to drafting of themanuscript and critical revision of the manuscript for important intellectualcontent.Conﬂicts of interestDanielMulladydisclosesthefollowing:consultant,BostonScientiﬁc;consultant,ConMed;HemosprayAdvisoryBoard,CookMedical.Theremaining authors disclose no conﬂicts.1128 Mullady et alGastroenterology Vol. 159, No. 3CLINICAL PRACTICE UPDATE',\n",
       " 'For personal use only 1 of 13summarizing evidence for risk assessment, resuscitation, blood transfusion, medical and endoscopic therapy, and early post-endoscopic management. We will not review interventions for long term secondary prevention of bleeding, such as testing for and treating Helicobacter pylori infection, use of non-steroidal anti-inflammatory drugs (NSAIDs), or maintenance antisecretory therapy.Upper gastrointestinal bleeding is managed by many cli\\xadnicians across many specialties, including emergency room physicians, hospitalists, internists, gastroenterologists, surgeons, interventional radiologists, and hematologists.A variety of topics—including risk assessment, the threshold for blood transfusion, the timing of endoscopy, and medical and endoscopic therapies—have continued to evolve in recent years. In addition, it has become increas\\xadingly important and complex to determine the appropriate management of patients who need antithrombotic agents, with gastroenterological, cardiovascular, and hematologi\\xadcal aspects needing to be considered.This article provides a comprehensive and evidence based summary of the assessment and management of patients with acute upper gastrointestinal bleeding, which is relevant to clinician specialists, academics, and clinical researchers. A summary of management is provided in the box.STATE OF THE ART REVIEWIntroductionUpper gastrointestinal bleeding is a common medical emergency worldwide and refers to bleeding from the esophagus, stomach, or duodenum. Patients present with hematemesis (bloody or coffee ground emesis) or melena, although hematochezia can occur in the context of a major bleed and is typically associated with hemodynamic insta\\xadbility. Patients with melena present with lower hemo\\xadglobin values than patients with hematemesis, probably because presentation is more likely to be delayed.1 There\\xadfore, patients with melena more often require transfusion,',\n",
       " 'globin values than patients with hematemesis, probably because presentation is more likely to be delayed.1 There\\xadfore, patients with melena more often require transfusion, although mortality is lower in patients with melena than in those with hematemesis in some series.1 Numerous improvements in the management of upper gastrointesti\\xadnal bleeding have been incorporated into clinical practice in recent years. However, many patients now have risk factors for a poorer outcome, including increasing age and major medical comorbidities.2Although the cause of a bleeding episode is uncertain until endoscopy is undertaken, guidelines often separate upper gastrointestinal bleeding into variceal and non-variceal bleeding because management and outcomes differ.3‑9 This article covers the acute management of patients with overt upper gastrointestinal bleeding, ABSTRACTUpper gastrointestinal bleeding (UGIB) is a common medical emergency, with a reported mortality of 2-10%. Patients identified as being at very low risk of either needing an intervention or death can be managed as outpatients. For all other patients, intravenous fluids as needed for resuscitation and red cell transfusion at a hemoglobin threshold of 70-80 g/L are recommended. After resuscitation is initiated, proton pump inhibitors (PPIs) and the prokinetic agent erythromycin may be administered, with antibiotics and vasoactive drugs recommended in patients who have cirrhosis. Endoscopy should be undertaken within 24 hours, with earlier endoscopy considered after resuscitation in patients at high risk, such as those with hemodynamic instability. Endoscopic treatment is used for variceal bleeding (for example, ligation for esophageal varices and tissue glue for gastric varices) and for high risk non-variceal bleeding (for example, injection, thermal probes, or clips for lesions with active bleeding or non-bleeding visible vessel). Patients who require endoscopic therapy for ulcer',\n",
       " 'non-variceal bleeding (for example, injection, thermal probes, or clips for lesions with active bleeding or non-bleeding visible vessel). Patients who require endoscopic therapy for ulcer bleeding should receive high dose proton pump inhibitors after endoscopy, whereas those who have variceal bleeding should continue taking antibiotics and vasoactive drugs. Recurrent ulcer bleeding is treated with repeat endoscopic therapy, with subsequent bleeding managed by interventional radiology or surgery. Recurrent variceal bleeding is generally treated with transjugular intrahepatic portosystemic shunt. In patients who require antithrombotic agents, outcomes appear to be better when these drugs are reintroduced earlyManagement of acute upper gastrointestinal bleedingAdrian J Stanley,1 Loren Laine21Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow G4 OSF, UK2Section of Digestive Diseases, Yale School of Medicine, New Haven, and VA Connecticut Healthcare System, West Haven, Connecticut, CT 06520, USACorrespondence to: A J Stanley adrian.stanley@ggc.scot.nhs.uk and adrianstanley99@gmail.comCite this as: BMJ 2019;364:l536doi: 10.1136/bmj.l536Series explanation: State of the Art Reviews are commissioned on the basis of their relevance to academics and specialists in the US and internationally. For this reason they are written predominantly by US authors on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 2 of 13Overall quality of evidenceNumerous randomized controlled trials (RCTs) and meta-analyses have assessed the use of medical and endoscopic therapy, and the optimal blood transfusion strategy in patients with acute upper gastrointestinal bleeding, thereby providing high quality data to guide management. Although the evidence regarding resuscita\\xadtion, risk assessment, timing of endoscopy, and reintro\\xadduction of antithrombotic drugs is of lower quality, large recent studies in these areas have helped inform patient management.IncidenceThe incidence of upper gastrointestinal bleeding in the United Kingdom in the 1990s was 103-172/100\\u2009000 adults per year.10\\xa011 Recent reports from the United States using nationwide administrative databases indicate that the incidence of hospital admission for the condition was 61-78 per 100\\u2009000 persons in 2009-2012.12‑14 Peptic ulcers are the most common cause of hospital admission for upper gastrointestinal bleeding, accounting for just over half of all cases.12\\xa014 The incidence of hospital admis\\xadsion for the condition has decreased 21-23% during the past 10 years.12\\xa014 This decrease is largely accounted for by decreases in peptic ulcer bleeding (and bleeding ascribed to “gastritis”) probably because of the decreas\\xading prevalence of H pylori and increasing use of antisecre\\xadtory drugs. Case fatality rates from these database studies were low, in the range of 1.9-2.5%.12‑14 By contrast, large observational cohort studies from Europe suggest higher fatality rates of around 10%.15\\xa016 The reason for these differences is unknown but might be partly related to reliance on coding in database studies and differences in practice, such as low risk patients being more often managed in outpatient settings in Europe.Sources and selection criteriaWe searched PubMed, Medline, and Cochrane databases from 2010 to August 2018 using the search terms gastro\\xad',\n",
       " 'managed in outpatient settings in Europe.Sources and selection criteriaWe searched PubMed, Medline, and Cochrane databases from 2010 to August 2018 using the search terms gastro\\xadintestinal hemorrhage, peptic ulcer bleeding, and variceal bleeding. References were also identified from the inter\\xadnational, UK, European, American, and Asia-Pacific guidelines on upper gastrointestinal bleeding published during this period in addition to relevant review articles. We selected systematic reviews, meta-analyses, RCTs, and observational studies (excluding case reports and small (<15 cases) case series). We also excluded articles that were not peer reviewed and those not published in Eng\\xadlish. Studies were prioritized by design, as noted above, and by patient numbers, quality, and publication date.Initial resuscitationAs with any new patient with a medical emergency, the initial clinical evaluation of patients presenting with upper gastrointestinal bleeding involves assessment of the patient’s airway, breathing, and circulation. Many patients are hemodynamically stable at presentation, but for those with major bleeding, early resuscitation is essential. In general, two large bore intravenous cannu\\xadlae are inserted, although central venous access may be preferred in certain cases. Regular monitoring of pulse, blood pressure, and oxygen saturations is crucial. Hypo\\xadtension is associated with increased mortality; a multi\\xadcenter observational study of 1882 patients reported an odds ratio of 9.8 (95% confidence interval 5.1 to 19) with systolic blood pressure <90 mm Hg versus ≥90 mm Hg.11 Tracheal intubation may be used to protect the airway in patients with severe ongoing hematemesis, especially in those at increased risk of aspiration (such as those with an altered mental status or lack of gag reflex).No RCTs have assessed fluid resuscitation in upper gas\\xadtrointestinal bleeding. By contrast, a comparative study',\n",
       " 'an altered mental status or lack of gag reflex).No RCTs have assessed fluid resuscitation in upper gas\\xadtrointestinal bleeding. By contrast, a comparative study and an RCT in patients with hemorrhagic shock as a result of trauma suggest that a more restrictive fluid resuscita\\xadtion may be better (or not worse) than more intensive fluid resuscitation.17\\xa018 The choice of intravenous fluid for ini\\xadtial resuscitation is unclear, with crystalloids or colloids often being used while the need for the transfusion of blood products is assessed. A meta-analysis of 70 trials with 22\\u2009392 patients found no difference in mortality between colloid and crystalloid solutions for fluid resus\\xadcitation in critically ill patients: relative risk 1.01 (0.93 to 1.10) for albumin or plasma proteins versus crystalloid solutions, and similar negative results when other col\\xadloids were compared with crystalloids.19 An RCT of 15 802 critically ill hospital inpatients found reduced acute SUMMARY OF THE MANAGEMENT OF UPPER GASTROINTESTINAL BLEEDINGPre-endoscopic management•Hemodynamic assessment and resuscitation as needed•Blood transfusion at a hemoglobin threshold of 70-80 g/L; higher threshold if severe bleeding with hypotension•Risk assessment:-If Glasgow-Blatchford score ≤1 consider outpatient endoscopy and management•Erythromycin (as a prokinetic agent) and proton pump inhibitor may be considered•Patients with cirrhosis should receive vasoactive drugs and antibioticsEndoscopic•Endoscopy is generally recommended within 24 hours in patients admitted to hospital–– If the patient has severe bleeding with hemodynamic instability, urgent endoscopy should be performed after resuscitation•Ulcers with active bleeding and non-bleeding visible vessels should receive endoscopic therapy; endoscopic therapy may also be used for ulcers with adherent clots•Injection therapy (eg, epinephrine), thermal probes (eg, bipolar electrocoagulation, heater probe), or clips should be used',\n",
       " 'therapy; endoscopic therapy may also be used for ulcers with adherent clots•Injection therapy (eg, epinephrine), thermal probes (eg, bipolar electrocoagulation, heater probe), or clips should be used•Epinephrine injection should always be followed by a second modality•Recurrent bleeding should be treated with repeat endoscopic therapy but subsequent bleeding by transarterial embolization or surgery•Esophageal variceal bleeding should be treated with ligation and gastric varices with the injection of tissue adhesive•Refractory variceal bleeding should be treated with transjugular portosystemic shunt•For massive refractory esophageal variceal bleeding a removable covered metal stent is preferred to balloon tamponade as a temporizing measurePost-endoscopic management•Patients who have ulcers with high risk lesions (active bleeding, visible vessel, adherent clot) should receive high dose proton pump inhibitors for 72 h•Patients with cirrhosis should continue antibiotics for up to seven days regardless of the bleeding source•Variceal bleeding should be treated with vasoactive drugs for up to five days•When used for secondary prevention, aspirin should be continued or reintroduced soon after hemostasis is achieved•Early reintroduction of other antithrombotic drugs is also recommended after hemostasis is achieved to reduce thrombotic events and death on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 3 of 13kidney injury (odds ratio 0.91, 0.84 to 0.99) and a trend towards reduced mortality in hospital (10.3% v 11.1%; P=0.08) with balanced crystalloids versus saline.20 Whether these data can be fully extrapolated to upper gastrointestinal bleeding is uncertain.Red blood cell transfusionA meta-analysis of 31 RCTs comprising 12\\u2009587 patients in a variety of populations found that a more restrictive approach to red cell transfusion (variably defined at hemoglobin threshold 70-90 g/L) does not adversely affect outcomes; hospital mortality was lower with a restrictive strategy but 30 day mortality was not significantly differ\\xadent (risk ratio 0.97, 0.81 to 1.16).21 This systematic review concluded that a restrictive policy seemed to be safe in patients with underlying cardiovascular disease but no evidence was available for patients presenting with acute coronary syndrome. On that basis, current US guidelines recommend transfusion at a threshold of hemoglobin of 70 g/L for hemodynamically stable adult inpatients and 80 g/L for those undergoing orthopedic or cardiac surgery or with pre-existing cardiovascular disease.22 Others have suggested a threshold in patients with cardiovascular dis\\xadease of ≥80 g/L.23Importantly, results for the general populations described above may not be applicable to those with upper gastrointestinal bleeding. In such patients a restrictive transfusion approach appears not only to be safe but also to provide clinical benefit for rebleeding and mortality. A small study in 1986 first showed reduced rebleeding with restrictive transfusion.24 A large high quality Spanish RCT in 921 patients found significantly lower mortality at six weeks (hazard ratio 0.55, 0.33 to 0.92) and rebleeding (0.68, 0.47 to 0.98) with a transfusion hemoglobin thresh\\xadold of 70 g/L versus 90 g/L.25 A subsequent six center cluster randomized feasibility trial in the UK reported no',\n",
       " '(0.68, 0.47 to 0.98) with a transfusion hemoglobin thresh\\xadold of 70 g/L versus 90 g/L.25 A subsequent six center cluster randomized feasibility trial in the UK reported no benefit from a liberal transfusion policy when hemoglobin thresholds of 80 g/L versus 100 g/L were compared (mor\\xadtality difference −1%, −8% to 6% in 640 patients).26 A meta-analysis of five RCTs comprising 1965 patients with upper gastrointestinal bleeding reported that restrictive transfusion was associated with lower mortality (relative risk 0.65, 0.44 to 0.97) and reduced rebleeding (0.58, 0.40 to 0.84) (fig 1).27Thus, in most patients with upper gastrointestinal bleeding, red cell transfusion should be withheld until a hemoglobin threshold of 70-80 g/L is reached.5 6 28 Patients with severe bleeding and hemodynamic com\\xadpromise, who were generally excluded from the trials described above, require transfusion at higher thresholds because their hemoglobin will equilibrate to much lower levels as their intravascular volume is repleted with fluid. Transfusion thresholds in patients with cardiovascular disease, especially those with acute coronary syndrome, are less certain, but thresholds of 80 g/L or higher are vari\\xadably recommended.22\\xa023Risk assessmentMany risk assessment scores have been developed for patients with upper gastrointestinal bleeding, includ\\xading those that can be calculated early after presentation (pre-endoscopy) and those that include endoscopic find\\xadings.29‑34 They were designed to predict a variety of end\\xadpoints. We believe pre-endoscopy scores are of greater practical use because it is probably most important to predict risk soon after presentation to help direct man\\xadagement. The use of risk scores has been recommended to stratify patients into those at higher or lower risk of poor )DYRUVUHVWULFWLYH)DYRUVOLEHUDO0RUWDOLW\\\\)DYRUVUHVWULFWLYH)DYRUVOLEHUDO%ODLU-DLUDWK9LOODQXHYD7RWDOO 3 $%ODLU/HH-DLUDWK9LOODQXHYD7RWDOO 3 %',\n",
       " ')DYRUVUHVWULFWLYH)DYRUVOLEHUDO0RUWDOLW\\\\)DYRUVUHVWULFWLYH)DYRUVOLEHUDO%ODLU-DLUDWK9LOODQXHYD7RWDOO 3 $%ODLU/HH-DLUDWK9LOODQXHYD7RWDOO 3 %5HVWULFWLYHQ15HVWULFWLYHQ1/LEHUDOQ1/LEHUDOQ15HEOHHGLQJWRWRWRWR55&OWRWRWRWRWR55&O :HLJKWLQJ :HLJKWLQJFig 1\\u2009|\\u2009\\xa0Blood transfusion meta-analysis: liberal versus restrictive transfusion for (A) mortality and (B) rebleeding.27 Reproduced with permission from Elsevier. Abbreviations: CI=confidence interval; RR=relative risk. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 4 of 13outcome.3\\xa06 This enables patients predicted to be high risk to be managed in high dependency or intensive care units and receive urgent endoscopy, whereas those at very low risk can be managed as outpatients.The most well established and commonly used pre-endoscopic scores are the Glasgow Blatchford score (GBS), the pre-endoscopic or “admission” Rockall score, and the AIMS65score (Albumin <3 mg/dL, International normalized ratio >1.5, altered Mental status, Systolic blood pressure <90 mm Hg, age >65 years).29 32 34 The GBS was developed to predict a composite of clinical intervention or death, whereas the other two were designed to predict death. Many studies have compared these and other scores, and GBS seems to be superior at predicting a combined endpoint of intervention or death (fig 2).35‑37These risk assessment scores cannot precisely identify individual high risk patients who will definitely die if they do not receive the intervention. Therefore, they have limited clinical utility for predicting which patients are at higher risk. However, risk scores do seem to have a clini\\xadcal role in identifying patients who are at very low risk.38 When aiming to identify a cohort of patients who are at very low risk and could be managed as outpatients, it is important to achieve a very high sensitivity so that almost no patients who may come to harm are sent home.A systematic review of 16 studies on the use of pre-endoscopy scores in emergency departments to predict intervention, rebleeding, or death concluded that a GBS of zero provided the highest sensitivity (0.99), although specificity was very low (0.08).39 In 2012, both US and UK guidelines recommended that a GBS of zero could be used to identify very low risk patients who could avoid admis\\xadsion and be offered outpatient endoscopy.4\\xa028Subsequently two large international comparative studies of risk assessment scores, with 3012 and 2305',\n",
       " 'sion and be offered outpatient endoscopy.4\\xa028Subsequently two large international comparative studies of risk assessment scores, with 3012 and 2305 patients, were published.35\\xa040 These studies reported that GBS ≤1 was the optimum low risk threshold, with a sen\\xadsitivity of 99% and specificity of 35-40%. The authors suggested that this threshold could be used to identify patients who could be safely discharged from the emer\\xadgency department for outpatient management, thereby avoiding admission in 19-24% of patients presenting with upper gastrointestinal bleeding. This approach has been accepted by recent European and Asia-Pacific guide\\xadlines.5\\xa06 No high quality interventional trial has assessed outcomes after the introduction of a risk score, although a pre-post design study showed the safety of outpatient management in 84 patients with a GBS score of zero.38Management of patients taking antithrombotic drugsThe increasing use of antiplatelet and anticoagulant (antithrombotic) medication in the management of car\\xaddiovascular disease means that many patients now pre\\xadsenting with upper gastrointestinal bleeding are taking these drugs. A recent multicenter observational study of 619 patients requiring endoscopic therapy for upper gastrointestinal bleeding reported that 44% were taking an antithrombotic drug at presentation, with 25% taking more than one.41 Although these drugs are a recognized risk factor for upper gastrointestinal bleeding,42\\xa043 no clear evidence indicates that their use worsens outcomes after the bleed.41\\xa044The 2016 US guideline on management of antithrom\\xadbotic agents for patients undergoing endoscopy suggests that platelet transfusion is an option for life threaten\\xading or serious bleeding in patients taking antiplatelet agents.45 However, observational studies have failed to identify clinical benefit, and a cohort study with 408 patients showed significantly higher mortality with plate\\xad',\n",
       " \"agents.45 However, observational studies have failed to identify clinical benefit, and a cohort study with 408 patients showed significantly higher mortality with plate\\xadlet transfusion (odds ratio 5.6, 1.5 to 27.1).46 This find\\xading led the recent Asia-Pacific guideline panel to suggest that platelet transfusions should not be used in patients taking antiplatelet agents who present with upper gas\\xadtrointestinal bleeding.6 Platelet dysfunction may also be present in patients on hemodialysis or those who have had cardiac bypass surgery.47Less information is available regarding the manage\\xadment of anticoagulants, including warfarin and the newer direct oral anticoagulants (DOACs), in patients with upper gastrointestinal bleeding. For patients taking warfarin, recent guidelines suggested the use of prothrombin com\\xadplex concentrate (PCC) along with vitamin K to prevent rebound coagulopathy in patients with a life threatening bleed or hemodynamic instability.5\\xa06 PCC is preferable *%6$852&$56$852&)56$852&$,06$852&31('$852&5HIHUHQFH6HQVLWLYLW\\\\VSHFLƟFLW\\\\Fig 2\\u2009|\\u2009\\xa0Comparison of five upper gastrointestinal bleeding risk scores in prediction of the need for any intervention (transfusion, endoscopic therapy, interventional radiology, or surgery) or 30 day mortality (n=1704).35 Abbreviations: AIMS65=see text; ARS=admission Rockall score; AUROC=area under the receiver operating characteristic curve; FRS=full Rockall score; GBS=Glasgow Blatchford score; PNED=Progetto Nazionale Emorragia digestive score. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from\",\n",
       " 'STATE OF THE ART REVIEWFor personal use only 5 of 13to fresh frozen plasma because of the smaller volume needed, its more rapid onset, lack of the need to check the patient’s blood group, and the minimal infectious risk.5 US guidelines suggest either four factor PCC plus vitamin K or fresh frozen plasma.45Guidelines also suggest that the international normal\\xadized ratio (INR) should be corrected to <2.5 if possible before undertaking endoscopy, with the potential need for endoscopic therapy if the clinical situation allows.5\\xa045 This suggestion is based on observational studies which indicate that the outcome after endoscopic therapy is similar in patients with an INR of 1.3-2.7 to that in those not taking warfarin.48\\xa049 Other studies report that the INR value does not predict rebleeding.50Data on DOACs are limited, but because of their short half lives (5-17 h), anticoagulant activity wanes rapidly over one to two days (in the absence of renal disease). Thus, European guidelines state that “time is the most important antidote against DOACs.”5 Although PCC may be of some use in severe bleeding, particularly for Xa inhibitors, neither vitamin K nor fresh frozen plasma has been shown to be beneficial.5\\xa051 Reversal agents for dabigatran (idarucizumab)52 and the factor Xa inhibitors (andexanet alfa)53 are now approved in the US. Their role in patients with upper gastrointestinal bleeding is unclear given the uncertain risk of thrombotic events and the short half lives of DOACS. They would mainly be used in patients with a severe ongoing bleed, especially if DOAC ingestion was recent or if renal disease was present.Coagulopathy and thrombocytopenia in patients with cirrhosisInterpretation of the complex clotting abnormalities seen in cirrhosis can be difficult. Patients with cirrhosis have parallel decreases in procoagulant and anticoagulant factors.54 The prothrombin time measures procoagulant activity only; therefore, prothrombin time or INR is not a',\n",
       " 'parallel decreases in procoagulant and anticoagulant factors.54 The prothrombin time measures procoagulant activity only; therefore, prothrombin time or INR is not a reliable indicator of coagulation status in patients with cirrhosis.54 Fresh frozen plasma is often given to patients with upper gastrointestinal bleeding, cirrhosis, and raised prothrombin time, but it has not been shown to provide benefit and could have adverse effects. For these reasons, the most recent US guidelines on portal hyper\\xadtensive bleeding recommend against correcting INR with fresh frozen plasma or recombinant factor VIIa in patients with cirrhosis and acute variceal bleeding.9Platelets from patients with cirrhosis generate throm\\xadbin in a similar way to those from healthy controls, and patients with cirrhosis have pro-hemostatic fac\\xadtors (increased von-Willebrand factor and decreased ADAMTS-13, a protease that cleaves von-Willebrand factor).54\\xa055 However, patients with cirrhosis often have thrombocytopenia as a result of splenic sequestra\\xadtion. The experimental finding that a platelet count of 56×109/L leads to thrombin generation at the 10th centile of healthy control values54 provides the basis for giving platelet transfusions at around 50×109/L.4\\xa07 However, no studies have assessed platelet thresholds or results with platelet transfusions, and some current guidelines state that no recommendation can be made regarding platelet transfusions.8\\xa09Pre-endoscopic medical therapyThe use of pre-endoscopic intravenous proton pump inhibitors (PPIs) has been assessed in several studies. A meta-analysis of six RCTs comprising 2223 patients found that the use of these drugs before endoscopy is associated with both reduced high risk stigmata of bleeding and the need for endoscopic therapy (odds ratio 0.68, 0.50 to 0.93) but has no effect on patient outcomes, including rebleeding, need for surgery, or mortality (1.12, 0.72 to 1.73).56 As a result, UK National Institute for Health and',\n",
       " '0.93) but has no effect on patient outcomes, including rebleeding, need for surgery, or mortality (1.12, 0.72 to 1.73).56 As a result, UK National Institute for Health and Care Excellence (NICE) guidelines do not support the routine use of these drugs before endoscopy.4 However, several other international guidelines suggest PPIs may have a role before endoscopy, particularly for patients in whom endoscopy may be delayed. 3 5 6 28 57Prokinetic agents have been assessed for their ability to improve gastric emptying, thereby improving visu\\xadalization at endoscopy. Erythromycin, usually given as a 250 mg infusion 30-120 minutes before endoscopy, has been most widely studied. The most recent meta-analysis of 598 patients in eight RCTs showed improved visuali\\xadzation, reduced need for second look endoscopy, and reduced length of hospital stay (mean difference −1.75 days, 2.43 to −1.06) after erythromycin infusion before endoscopy.58Tranexamic acid (TXA) inhibits the fibrinolytic activity of plasmin. A meta-analysis reported reduced mortality with TXA in patients with upper gastrointestinal bleed\\xading, but many studies were of poor quality and had been undertaken before the widespread use of PPIs and endo\\xadscopic therapy.59 Furthermore, other outcomes such as bleeding episodes and transfusions were not reduced. Therefore, it is difficult to draw firm conclusions from these data. A meta-analysis of two RCTs comprising 40\\u2009138 patients with acute severe traumatic or postpar\\xadtum bleeding suggested even a short delay in the admin\\xadistration of TXA reduces benefit: immediate treatment improved survival (odds ratio 1.72, 1.42 to 2.10), but survival fell 10% with every 15 minutes delay, with no benefit beyond three hours.60 A large international study (HALT-IT) will finish recruitment shortly and the results should help clarify the role of TXA in upper gastrointes\\xadtinal bleeding.61Pre-endoscopic medical therapy in patients with cirrhosis',\n",
       " '(HALT-IT) will finish recruitment shortly and the results should help clarify the role of TXA in upper gastrointes\\xadtinal bleeding.61Pre-endoscopic medical therapy in patients with cirrhosisVasoactive drugs (terlipressin, somatostatin, or its ana\\xadlogs octreotide and vapreotide), which cause splanch\\xadnic artery vasoconstriction, are used in patients with cirrhosis and variceal bleeding. When combined with endoscopic therapy, the different vasoactive drugs seem to have similar efficacy.62 Three double blind RCTs exam\\xadined the use of vasoactive drugs (terlipressin, somatosta\\xadtin, and vapreotide) given before endoscopy in patients with cirrhosis and upper gastrointestinal bleeding.63‑65 Two studies reported less active bleeding at endoscopy in the active treatment group,64\\xa065 and the third noted significantly more control of bleeding (clear gastric lav\\xadage and stable hemoglobin) at 12 hours with vasoactive drug therapy.63Current guidelines recommend starting vasoactive drugs as soon as variceal hemorrhage is suspected.7‑9  on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 6 of 13PPIs should not be given concurrently to patients who are receiving somatostatin (or analogs) because somato\\xadstatin provides inhibition of gastric acid secretion compa\\xadrable to that provided by PPIs.66\\xa067 Recommended doses are terlipressin 2 mg every four hours, somatostatin 250 μg bolus followed by 250-500 μg/h, and octreotide and vapreotide 50 μg bolus followed by 50 μg/h.9 These drugs are generally given for up to five days.7‑9A meta-analysis of 12 RCTs compromising 1241 patients showed that antibiotics reduce infections, rebleeding, and mortality (relative risk 0.79, 0.63 to 0.98) in patients with cirrhosis and upper gastrointestinal bleeding.68 An RCT comparing intravenous ceftriaxone versus oral norfloxacin for seven days in 111 patients with advanced cirrhosis and gastrointestinal bleeding showed reduced proven infections with ceftriaxone (11% v 26%; P=0.03).69 However, the results may not be gener\\xadalizable to all patients with cirrhosis because only 9% of screened patients were enrolled. Current guidelines sug\\xadgest that antibiotics should be given from admission for up to seven days.7‑9 Intravenous ceftriaxone is preferred in patients with advanced cirrhosis or those taking qui\\xadnolone prophylaxis and those in areas of high quinolone resistance, although the choice of antibiotic is dependent on local antimicrobial sensitivity patterns.7‑9Role of non-endoscopic diagnostic modalities before endoscopyBecause upper gastrointestinal bleeding can be diag\\xadnosed and treated with endoscopy, which is available in most hospitals, the role of other diagnostic modalities in patients presenting with an acute bleed is limited. In almost all cases, the initial diagnostic test will be upper endoscopy. Rarely, angiography or computed tomogra\\xadphy is used in patients who are not candidates for endos\\xadcopy. However, these investigations are most commonly used if no source of bleeding is identified at endoscopy',\n",
       " 'phy is used in patients who are not candidates for endos\\xadcopy. However, these investigations are most commonly used if no source of bleeding is identified at endoscopy in patients with melena. A technetium-99m labelled red cell scan may also be used in this situation, but computed tomography angiography seems to be more accurate.70\\xa071 Early use of capsule endoscopy has been reported, with goals including stratifying risk and determining the timing of endoscopy,72 but more studies are needed to establish any potential role.Timing of endoscopyOn the basis of improved outcomes in observational studies,3 5 28 guidelines recommend that, after appropri\\xadate resuscitation, most patients who are admitted with upper gastrointestinal bleeding should undergo endos\\xadcopy within 24 hours. Some guidelines suggest that patients with hemodynamic compromise and those with cirrhosis, who may have varices, undergo endoscopy within 12 hours after presentation,5 6 8 9 28 because some observational studies and subgroup analysis of an RCT provided limited evidence of improved outcome in high risk patients when endoscopy is performed within six to 13 hours.73‑75 Features that have been considered high risk include GBS ≥8-12, bloody gastric lavage or persis\\xadtent bloody emesis in hospital, hypotension, tachycardia, and comorbidities such as cirrhosis. However, evidence that can precisely identify high risk patients who should undergo early endoscopy is not available. In general, patients with persistent hemodynamic instability despite aggressive resuscitation will require urgent endoscopy.Endoscopy should not be undertaken before the patient’s hemodynamic status is dealt with by initiating appropriate resuscitation and aiming to optimize comor\\xadbidities. This is illustrated by a recent observational study of 12\\u2009601 Danish patients with upper gastrointestinal bleeding secondary to peptic ulcers. This study suggested a survival benefit from delaying endoscopy for 12 hours in',\n",
       " 'of 12\\u2009601 Danish patients with upper gastrointestinal bleeding secondary to peptic ulcers. This study suggested a survival benefit from delaying endoscopy for 12 hours in hemodynamically stable patients with American Society of Anesthesiologists score 3-5 (odds ratio 0.48, 0.34 to 0.67), and for six hours in patients with hemodynamic instability (0.73, 0.54 to 0.98) (fig 3).76 Most deaths after upper gastrointestinal bleeding are caused by underlying comorbidities rather than exsanguination, so attention to other medical problems is key to patient management.77Two small RCTs compared urgent (<2-6 h) with elective (>48 h) endoscopy for patients presenting with upper gas\\xadtrointestinal bleeding who were hemodynamically stable and had no serious comorbidities.78\\xa079 As expected in these low risk patients, no difference in clinical outcomes was identified. However, ~40-45% of patients had low risk endoscopic findings that would allow for early discharge. Thus, non-emergent endoscopy, undertaken as soon as possible within routine business hours, is recommended in low risk patients to allow safe early discharge in many of these patients.80Endoscopic therapyNon-variceal bleedingRecommended modalities for ulcer bleeding include injection of epinephrine (eg, 1:10\\u2009000 dilution), injection $6$$6$)LWWHGYDOXHV7LPLQJK0RUWDOLW\\\\3 Fig 3\\u2009|\\u2009\\xa0Association between timing of endoscopy and mortality in hospital patients with hemodynamic instability after correction for confounding variables.76 Abbreviation: ASA=American Society of Anesthesiologists score. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 7 of 13of sclerosants such as absolute ethanol, thermal contact devices such as bipolar electrocoagulation probes or heater probes, and through-the-scope clips.5\\xa028 RCT data supporting efficacy in ulcer bleeding are more limited for non-contact thermal devices such as argon plasma coagulation.28 Vascular ectasias may also be treated with thermal methods, commonly argon plasma coagu\\xadlation; radiofrequency ablation is another thermal con\\xadtact modality sometimes used for gastric antral vascular ectasia.81Endoscopic injection of epinephrine should not be used as a single modality treatment. Meta-analyses have reported lower rates of further bleeding with an alterna\\xadtive modality compared with epinephrine alone (relative risk 0.58, 0.36 to 0.93) and with epinephrine combined with a second modality versus epinephrine alone (relative risk 0.34, 0.23 to 0.50).82\\xa083 Epinephrine can be used for temporary control of bleeding to aid visualization of the lesion before definitive treatment with another modal\\xadity (such as a thermal or mechanical) or to decrease the risk of inducing bleeding with the application of a second modality.Most data on non-variceal upper gastrointestinal bleed\\xading are from patients with peptic ulcer bleeding. The For\\xadrest classification of endoscopic stigmata is commonly used by endoscopists to identify higher risk lesions that require the application of endoscopic therapy.84 Endo\\xadscopic therapy significantly decreases further bleeding and the need for urgent intervention in patients with ulcers with spurting or oozing blood (Forrest 1a or 1b) or with non-bleeding visible vessels (Forrest 2a; fig 4A).28 Patients with adherent clots (Forrest 2b) were not shown to benefit from endoscopic therapy in a meta-analysis of RCTs, but results of individual trials were very heteroge\\xadneous.80 This has led to guideline recommendations that either endoscopic plus medical therapy or medical man\\xad',\n",
       " 'RCTs, but results of individual trials were very heteroge\\xadneous.80 This has led to guideline recommendations that either endoscopic plus medical therapy or medical man\\xadagement alone may be used for patients with adherent clots.5\\xa028 Around 25-50% of patients admitted to hospital with bleeding ulcers have Forrest 1a, 1b, 2a, or 2b stig\\xadmata.76\\xa085 Endoscopic treatment is not needed for ulcers with flat pigmented spots or a clean base (Forrest 2c or 3).5\\xa028Variceal bleedingVariceal bleeding accounted for 11% of patients admit\\xadted to hospital with acute upper gastrointestinal bleed\\xading in a nationwide UK audit.15 However, the proportion of patients with variceal bleeding varies widely and is related to the proportion of people with liver disease in the population served. Patients with variceal bleeding have a higher mortality than those with non-variceal bleeding, and this is largely related to the severity of underlying liver disease.14\\xa086The optimal endoscopic therapy for esophageal variceal bleeding is variceal band ligation, which is associated with less rebleeding and fewer side effects than sclero\\xadtherapy.4 7 9 87 If gastric varices are found, ligation can be used for gastroesophageal varices type-1, where esopha\\xadgeal varices extend several centimeters distally along the gastric lesser curve. Injection of tissue adhesive (eg, N-butyl-cyanoacrylate) is the recommended endoscopic approach for all other types of gastric varices, although thrombin injection can be considered.7 9 88-90  Thrombin injection has been described for gastric variceal bleeding in cohort studies, but to date no RCTs have compared it with other treatments.91‑93Post-endoscopic managementPPI therapyA meta-analysis of RCTs comparing PPIs to placebo or no therapy in high risk patients undergoing successful endo\\xadscopic therapy showed that high dose PPIs, usually given as an intravenous bolus of 80 mg followed by continu\\xadous infusion at 8 mg/h for 72 hours, reduced rebleeding',\n",
       " 'scopic therapy showed that high dose PPIs, usually given as an intravenous bolus of 80 mg followed by continu\\xadous infusion at 8 mg/h for 72 hours, reduced rebleeding (relative risk 0.40, 0.28 to 0.59) and mortality (0.41, 0.20 to 0.84). Intermittent intravenous or oral PPIs reduced rebleeding (0.53, 0.35 to 0.78) but not mortality.82 A Fig 4\\u2009|\\u2009\\xa0(A) Endoscopic view of a large posterior duodenal ulcer with intermittent bleeding from a visible vessel. The patient, a middle aged man taking anticoagulant drugs, was admitted with hematemesis, hemodynamic instability, and a hemoglobin concentration of 55 g/L. After resuscitation, transfusion to hemoglobin 70-80 g/L, and correction of coagulopathy, endoscopy was undertaken. (B) Through-the-scope clips were applied after dilute epinephrine was injected into the four quadrants of the ulcer base. The fibrotic base made application of the clips problematic. (C) There was ongoing intermittent oozing of blood. Given the high risk ulcer, hemostatic powder spray was then applied to good effect. High dose intravenous proton pump inhibitors (PPIs) were given and the patient was managed in the hospital high dependency unit. Because of the clinical situation and the difficulty in providing endoscopic therapy to this large fibrotic ulcer, the plan for urgent referral for radiological embolization—should early rebleeding occur—was clearly documented by the endoscopist as a “rebleeding plan.” (D) Fifteen hours later the patient rebled and became hemodynamically unstable. He was again resuscitated appropriately, after which an interventional radiologist performed coil embolization of the gastroduodenal artery. The patient had no further bleeding and was restarted on anticoagulants on day 3. When he was discharged from hospital a week later he was still taking oral PPIs twice daily, but when the 14 day course was finished, the dose was reduced to once daily.',\n",
       " 'on day 3. When he was discharged from hospital a week later he was still taking oral PPIs twice daily, but when the 14 day course was finished, the dose was reduced to once daily. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from ABD',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 8 of 13meta-analysis of 13 studies found that a bolus followed by intermittent doses of intravenous or oral PPIs was non-inferior to continuous infusion (further bleeding risk ratio 0.72; one sided 95% confidence interval upper boundary 0.97), although most individual studies were relatively small and not designed to answer this question.94 No conclusions could be made regarding oral versus intra\\xadvenous dosing,94 although oral administration provides an antisecretory effect comparable to equivalent doses of intravenous PPIs.95 Guidelines have recommended an intravenous bolus followed by continuous infusion PPI therapy,3 5 6 28 although recent guidelines also suggest con\\xadsidering intermittent high doses of oral or intravenous PPI (eg, 80-160 mg daily in divided doses after an initial 80 mg bolus), rather than continuous infusion.5\\xa06Patients with peptic ulcer bleeding generally receive four to eight weeks of once daily oral PPIs. Those with low risk endoscopic lesions (clean base, flat spot) should receive PPIs once a day from the time of diagnosis. Those with high risk endoscopic lesions and clinical features should receive high dose PPIs on days one to three as above, followed by twice daily oral PPI on days four to 14. This regimen is based on an RCT of 187 patients that showed significantly less rebleeding with twice daily ver\\xadsus once daily PPIs (relative risk 0.41, 0.18 to 0.93) during this period.96The benefits of PPIs outweigh potential risks when used after bleeding from a peptic ulcer. Multiple phar\\xadmacodynamics studies report that omeprazole reduces the antiplatelet effect of clopidogrel, but a double blind placebo controlled trial in 3761 clopidogrel users found no evidence that omeprazole increased cardiovascular events (hazard ratio 0.99, 0.68 to 1.44).97 The US Food and Drug Administration recommends avoiding the use of omeprazole or esomeprazole in patients who are taking clopidogrel.98',\n",
       " 'events (hazard ratio 0.99, 0.68 to 1.44).97 The US Food and Drug Administration recommends avoiding the use of omeprazole or esomeprazole in patients who are taking clopidogrel.98Patients with cirrhosis and variceal bleedingAs noted above, in patients with cirrhosis and upper gas\\xadtrointestinal bleeding, antibiotics should be continued for up to seven days,7‑9 regardless of whether varices are identified as the source of the bleeding. Patients who have documented variceal bleeding at endoscopy should also have their vasoactive drugs continued for up to five days.7‑9 Combined treatment with endoscopic ligation and vasoac\\xadtive drugs is superior to ligation alone or vasoactive drugs alone in reducing further bleeding in hospital or during the first seven days after treatment.99\\xa0100Transjugular intrahepatic portosystemic shunt (TIPS) may also be used after initial endoscopic therapy in the first three days after presentation for the treatment of acute esophageal variceal bleeding in patients with Child-Pugh class C cirrhosis (score 10-13)8\\xa09 A multicenter RCT com\\xadpared early (within 72 h) TIPS placement versus standard treatment with variceal ligation plus drug therapy in 63 patients with Child-Pugh C cirrhosis or Child-Pugh B cir\\xadrhosis with active bleeding. It reported that more patients were free from further bleeding at one year with early TIPS (97% v 50%; P<0.001).101 One year survival was also higher with early TIPS (86% v 61%; P<0.001) and encephalopathy was not increased. Subsequent reports suggest that the benefit is primarily in those with Child-Pugh C disease.102 However the evidence for early TIPS remains relatively limited and the practicalities may be challenging for many units.Reintroduction of antithrombotic drugsSeveral studies suggest a survival benefit from continuing or reintroducing antithrombotic drugs after upper gastroin\\xadtestinal bleeding.103\\xa0104 This is perhaps unsurprising given',\n",
       " 'Several studies suggest a survival benefit from continuing or reintroducing antithrombotic drugs after upper gastroin\\xadtestinal bleeding.103\\xa0104 This is perhaps unsurprising given that mortality after presentation with a bleed is more often caused by underlying comorbidities, particularly cardio\\xadvascular disease, rather than the bleed itself.77 However, balancing the risks and benefits of reintroducing these drugs after a patient presents with upper gastrointestinal bleeding can be challenging. If an antithrombotic drug is reintroduced, a PPI is usually also administered.Aspirin is the most widely studied antithrombotic drug in patients with upper gastrointestinal bleeding. Strati\\xadfication of patients must be based on whether aspirin is given for secondary or primary cardiovascular preven\\xadtion. This is because the benefit in secondary prevention is far greater than that for primary prevention, with a number needed to treat to prevent myocardial infarction, stroke, or vascular death of 67 versus 1745.80A randomized study of 156 patients with peptic ulcer bleeding who had been taking aspirin for secondary prevention reported reduced mortality at eight weeks in those who continued aspirin compared with those who discontinued the drug (1.3% v 12.9%; difference 11.6%, 3.7% to 19.5%).103 Therefore, current guidelines suggest continuing aspirin (or reintroducing the drug within three days for higher risk endoscopic lesions) once hemosta\\xadsis is achieved.4-6 105 106 It has been suggested that when aspirin has been prescribed for primary prophylaxis, it should be stopped in most patients because the bleed\\xading risk probably outweighs the cardiovascular benefit.28 If primary prevention is still clinically required after the bleed, it can be reintroduced after the ulcer has healed, or earlier depending on the clinical situation.5No randomized studies are available to guide clinicians on the reintroduction of thienopyridines (eg, clopidogrel)',\n",
       " 'or earlier depending on the clinical situation.5No randomized studies are available to guide clinicians on the reintroduction of thienopyridines (eg, clopidogrel) or anticoagulants. Recent guidelines suggest that for patients receiving dual antiplatelet therapy, at least one drug, usually aspirin, should be reintroduced early as above, with the second drug withheld for up to five days after hemostasis, or the timing discussed with a cardio\\xadvascular specialist.5 6 105Similar to the situation with antiplatelet agents, obser\\xadvational studies in patients who develop upper gastro\\xadintestinal bleeding while taking warfarin indicate that those who restart warfarin have markedly lower rates of death and thromboembolic events, without a higher rate of recurrent bleeding, when compared with those whose warfarin is not restarted.104\\xa0107 Recent guidelines suggest restarting warfarin from “as soon as hemostasis is estab\\xadlished”6 to seven to 15 days after the bleeding event.5 The indication for anticoagulation should be assessed at the time of the bleed, with early reintroduction (zero to seven days) recommended in patients with a higher thrombo\\xadembolic risk.5\\xa06 However, robust data on the optimal tim\\xading of reintroduction are not available. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 9 of 13Data on the timing of the reintroduction of DOACs after bleeding has been controlled are limited, and this clearly depends on the balance of risk between rebleeding and thromboembolic events. Use of the CHA2DS2-VASC (Congestive heart failure, Hypertension, Age-2, Diabetes, Stroke/TIA-2, Vascular disease) and HAS-BLED (Hyper\\xadtension, Abnormal renal and liver function, Stroke, prior Bleeding, Labile INRs, Elderly (>65 years), Drugs and alcohol) scores may help in this situation.108‑110 The recent Asia-Pacific guidelines suggest reintroducing DOACs in patients with a high thromboembolic risk as soon as hemostasis is achieved, although others have suggested that patients should have their anticoagulant restarted at day 7, with possible bridging therapy with low molecu\\xadlar weight heparin from days 2 to 7 in those with a low bleeding risk.6 In general, patients with an increased thromboembolic risk should have early reintroduction of antithrombotic drugs, because the risks and severity of thromboembolic events generally outweigh those of bleeding events.Management of persistent or recurrent bleeding, including role of interventional radiology and surgeryNon-variceal bleedingThe results of an RCT comparing repeat endoscopic ther\\xadapy with surgery in 92 patients with recurrent peptic ulcer bleeding indicate that endoscopic therapy should be repeated when bleeding recurs after initial endoscopic control.111 This study reported similar mortality, although more patients had complications with surgery (36.4% v 14.6%; P=0.03). For patients with persistent or refrac\\xadtory bleeding from non-variceal sources despite optimal standard endoscopic and medical therapy, the addition of hemostatic powder spray for temporary control (12-24 h) or over-the-scope clips (OTSC) as a rescue modality is suggested, in parallel with ongoing resuscitation.5 6 112 113For peptic ulcer bleeding not controlled by endoscopic',\n",
       " 'h) or over-the-scope clips (OTSC) as a rescue modality is suggested, in parallel with ongoing resuscitation.5 6 112 113For peptic ulcer bleeding not controlled by endoscopic therapy, two recent meta-analyses of observational stud\\xadies that compared surgery with radiological interven\\xadtion reported lower rebleeding with surgery, but similar mortality and need for further interventions, although patients receiving radiological intervention were older and in worse general health.114\\xa0115 Because many patients with recurrent bleeding are elderly with comorbidities, interventional radiology is generally preferred if locally available. Therefore, if bleeding continues despite opti\\xadmal endoscopic therapy, transarterial embolization is recommended, although surgery should be considered if radiological therapy is likely to be delayed.4\\xa05Prophylactic transarterial embolization of high risk ulcers after endoscopic therapy is not recommended: it did not significantly reduce rebleeding when compared with standard treatment (10.2% v 11.4%) in an RCT of 241 patients.116Variceal bleedingPatients with rebleeding after initial endoscopic and medical therapy for varices may have repeat endoscopic therapy performed.8 TIPS is recommended for those with persistent or severe recurrent bleeding.7‑9 For patients with severe bleeding refractory to endoscopic therapy, balloon tamponade has been recommended as a tempo\\xadrary bridge to definitive therapy.7\\xa08 However, balloon tam\\xadponade is associated with serious complications (such as esophageal rupture and aspiration pneumonia) in about 12% of patients and its use was lethal in 6% of patients in a case series.117 Recently, removable self expanding covered metal esophageal stents designed for the treat\\xadment of severe esophageal variceal bleeding have become available (although they are not approved in the US). An RCT of 28 patients compared these stents with balloon tamponade in patients with esophageal variceal bleed\\xad',\n",
       " 'available (although they are not approved in the US). An RCT of 28 patients compared these stents with balloon tamponade in patients with esophageal variceal bleed\\xading refractory to medical and endoscopic therapy and showed that the stents led to improved bleeding control (85% v 47%; Fisher’s exact test P=0.055), with similar mortality.118Emerging treatmentsHemostatic powder sprayHemostatic powder spray provides high rates of initial hemostasis for active non-variceal upper gastrointestinal bleeding, but with relatively high rebleeding rates, sug\\xadgesting a temporary effect.119‑123 A systematic review of 195 cases reported initial hemostasis in 92% and a seven day rebleeding rate of 21%.112 Currently, hemostatic powder is often used as a temporary rescue treatment for bleeding that cannot be controlled using established methods, and it may have a role for the initial control of diffuse bleeding from tumors.6\\xa0112 More limited data are available on hemostatic powder spray for variceal bleeding, often as a temporizing method until definitive therapy is applied.124Over-the-scope clipsTreatment with OTSC is another relatively new technique. These clips are much larger than standard through-the-scope clips so may be successful when applied to larger fibrotic lesions or larger feeding vessels. A multicenter RCT of 66 patients with recurrent ulcer bleeding after ini\\xadtial hemostasis showed that significantly fewer patients treated with OTSC had further bleeding compared with those on standard therapy (15% v 58%; difference 42%, 22% to 63%).125 Further data are awaited, but at present OTSC may be considered as a rescue therapy when stand\\xadard therapies do not achieve permanent hemostasis.Doppler probesEndoscopic Doppler probes have also been studied as a guide to endoscopic therapy. A recent dual center RCT of 148 patients with severe non-variceal upper gastro\\xadintestinal bleeding that compared endoscopic therapy',\n",
       " 'guide to endoscopic therapy. A recent dual center RCT of 148 patients with severe non-variceal upper gastro\\xadintestinal bleeding that compared endoscopic therapy guided by Doppler probe positive signals with standard endoscopic therapy guided by endoscopic stigmata found reduced 30 day rebleeding with Doppler guided therapy (11.1% v 26.3%; P=0.02).126 Further data on the clinical utility and practicalities of this approach are needed, and currently the use of these probes is not recommended by guidelines.5 6GuidelinesAs already noted, international, UK (NICE), American, European, and Asia-Pacific guidelines on upper gastro\\xad on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 10 of 13intestinal bleeding (non-variceal and variceal) have been published over the past eight years. We have therefore referenced them as appropriate throughout. The most recent ones—the European (2015) and Asia-Pacific (2018) guidelines on non-variceal bleeding, and the UK, international, and US guidelines on variceal bleed\\xading—differ slightly from earlier ones, largely because they assessed more recently published studies (table). These guidelines have generally been written by experts in this field, although methodology has varied.ConclusionsUpper gastrointestinal bleeding remains a common cause of presentation to hospitals worldwide, and many recent studies have assessed the management of patients with this condition. The evidence of improved outcomes from a relatively restrictive approach to blood transfusion and the ability to identify patients who are at very low risk and suitable for outpatient management have recently altered clinical practice, and these alterations to management are now recommended by international guidelines. RCTs and meta-analyses confirm a benefit from pre-endoscopy anti\\xadbiotics and vasoactive drugs in patients with cirrhosis, and post-endoscopy high dose PPIs for high risk peptic ulcer bleeding.Endoscopic therapy has advanced dramatically over the past decades, with recent additions to the endoscopist’s “toolkit,” including hemostatic powder spray, over-the-scope clips, and Doppler probes. These join the estab\\xadlished and widely studied injection therapies, thermal probes, and clips used for non-variceal bleeding, and endoscopic band ligation and tissue adhesive injection for variceal bleeding. However, the newer modalities require further study to clarify their exact role in endo\\xadscopic management. Technical improvements and more widely available services for interventional radiology have led to it being the most commonly used rescue therapy',\n",
       " 'scopic management. Technical improvements and more widely available services for interventional radiology have led to it being the most commonly used rescue therapy for persistent or recurrent upper gastrointestinal bleeding that is refractory to endoscopic treatment. Surgery is now typically reserved for situations in which interventional radiology is unavailable, delayed, or unsuccessful.The more widespread use of antiplatelet and anti\\xadcoagulants drugs has led to uncertainty in managing patients taking these medications who develop upper gastrointestinal bleeding. However, recent data suggest that relatively early reintroduction of these drugs once hemostasis has been achieved is the best approach in those with appropriate cardiovascular indications. New approaches under investigation for managing upper gastrointestinal bleeding include the early use of TXA and novel endoscopic techniques to reduce rebleeding. These and other developments will hopefully continue to improve management and outcomes for patients with upper gastrointestinal bleeding.Recommendations from major published guidelines on non-variceal UGIBGuidelineRisk scoringProkineticsPre-endoscopy PPIsTiming of endoscopyPost-endoscopy PPIsInternational, 20103Prognostic scales recommended to identify high and low risk groupsPromotility agents should not be used routinelyMay be considered but should not delay endoscopyWithin 24 h for most patientsIV PPI bolus then infusion if high risk stigmata and have had successful endoscopic therapyUS, ACG (ulcer bleeding only) 201228Carry out risk assessment to stratify into higher and lower risk groups. Consider discharge from ED if GBS=0Consider IV erythromycinIV PPIs may be consideredWithin 24 h after resuscitation. Consider within 12 h if high risk features (eg, hemodynamic instability, bloody emesis in hospital)After successful endoscopic hemostasis, give IV PPI bolus then infusion to those with active',\n",
       " 'Consider within 12 h if high risk features (eg, hemodynamic instability, bloody emesis in hospital)After successful endoscopic hemostasis, give IV PPI bolus then infusion to those with active bleeding, NBVV, or adherent clotUS, ASGE 201257No specific recommendation but notes that GBS=0 identifies a very low risk groupSuggest IV prokinetic if high probability of fresh blood or clot in stomachIV PPIs recommendedDepends on clinical factors but recommends within 24 h in the presence of cancer, cirrhosis, hematemesis, hypovolemia, or Hb <80 g/LIV PPI bolus then infusion after endoscopic therapy for ulcers with high risk stigmataUK, NICE 20124Use GBS before endoscopy and full Rockall score after endoscopy. Consider early discharge if GBS=0Not assessedDo not give PPIs before endoscopyWithin 24 h, but immediately after resuscitation if unstable and severe UGIBOffer PPIs if stigmata of recent bleeding seen at endoscopyEurope, ESGE 20155Patients with GBS 0-1 do not require early endoscopy or admissionRecommend IV erythromycin if clinically severe or ongoing active UGIBIV bolus then infusion but should not delay endoscopyWithin 24 h of resuscitation, but consider within 12 h if high risk features (eg, hemodynamic instability despite resuscitation, inpatient bloody emesis, contraindication to stopping anticoagulants)IV PPI bolus then 72 h infusion for patients who receive endoscopic hemostasis and those with adherent clots. Consider giving PPIs as intermittent IV bolus or high dose oralAsia-Pacific, 20186Use GBS; adopting a cut off at GBS ≤1 allows most hospitals to reduce unnecessary admissionsNot assessedIV PPIs recommended if suspected UGIB awaiting endoscopy (especially if endoscopy is not available within 24 h)Within 24 h, but urgent (within 12 h) if hemodynamic instability, after resuscitation and stabilizationAfter endoscopic hemostasis is achieved high dose oral PPIs can be used for 72 h as an alternative',\n",
       " 'h) if hemodynamic instability, after resuscitation and stabilizationAfter endoscopic hemostasis is achieved high dose oral PPIs can be used for 72 h as an alternative to high dose IV PPIsAbbreviations: ACG=American College of Gastroenterology; ASGE=American Society for Gastrointestinal Endoscopy; ED=emergency department; ESGE= European Society of Gastrointestinal Endoscopy; GBS=Glasgow Blatchford score; Hb=hemoglobin; NBVV=non-bleeding visible vessel; NICE=National Institute for Health and Care Excellence; PPIs=proton pump inhibitors; IV=intravenous; UGIB=upper gastrointestinal bleeding.QUESTIONS FOR FUTURE RESEARCH•What is the optimal approach to fluid resuscitation in patients with acute upper gastrointestinal bleeding?•Can risk assessment tools be developed to allow accurate early identification of high risk patients with upper gastrointestinal bleeding, such as those who require endoscopic therapy or those with high mortality?•What is the optimal timing of endoscopy after upper gastrointestinal bleeding?•What is the exact role of hemostatic powder spray, over-the-scope clips, and Doppler ultrasound probes in the endoscopic management of upper gastrointestinal bleeding?•When is the best time to reintroduce antithrombotic drugs after upper gastrointestinal bleeding? on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 11 of 13Thanks to Deepak Vishwanath for help with the radiological image in fig 4.Contributors: Both authors contributed equally to the planning and writing of the article and both are responsible for the overall content as guarantors.Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following interests: AJS, none; LL has had single consultancies to Takeda and to Bayer and his full competing interests are available from her on request.1Laine\\xa0L,\\xa0Laursen\\xa0SB,\\xa0Zakko\\xa0L,\\xa0et al. Severity and outcomes of upper gastrointestinal bleeding with bloody vs coffee-grounds hematemesis. Am J Gastroenterol 2018;113:358-66. 10.1038/ajg.2018.5.\\xa0\\xa0pmid:29380820.2Lanas\\xa0A. Editorial: Upper GI bleeding-associated mortality: challenges to improving a resistant outcome. Am J Gastroenterol 2010;105:90-2. 10.1038/ajg.2009.517\\xa0\\xa0pmid:20054306.3Barkun\\xa0AN,\\xa0Bardou\\xa0M,\\xa0Kuipers\\xa0EJ,\\xa0et al.\\xa0International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101-13. 10.7326/0003-4819-152-2-201001190-00009\\xa0\\xa0pmid:20083829.4National Institute for Health and Care Excellence. Acute upper gastrointestinal bleeding in over 16s: management. CG141. 2012. https://www.nice.org.uk/guidance/cg141.5Gralnek\\xa0IM,\\xa0Dumonceau\\xa0JM,\\xa0Kuipers\\xa0EJ,\\xa0et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015;47:a1-46. 10.1055/s-0034-1393172\\xa0\\xa0pmid:26417980.6Sung\\xa0JJ,\\xa0Chiu\\xa0PW,\\xa0Chan\\xa0FKL,\\xa0et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut 2018;67:1757-68. 10.1136/gutjnl-2018-316276.\\xa0\\xa0pmid:29691276.7Tripathi\\xa0D,\\xa0Stanley\\xa0AJ,\\xa0Hayes\\xa0PC,\\xa0et al.\\xa0Clinical Services and Standards',\n",
       " '2018;67:1757-68. 10.1136/gutjnl-2018-316276.\\xa0\\xa0pmid:29691276.7Tripathi\\xa0D,\\xa0Stanley\\xa0AJ,\\xa0Hayes\\xa0PC,\\xa0et al.\\xa0Clinical Services and Standards Committee of the British Society of Gastroenterology. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015;64:1680-704. 10.1136/gutjnl-2015-309262\\xa0\\xa0pmid:25887380.8de Franchis\\xa0R.\\xa0Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743-52. 10.1016/j.jhep.2015.05.022\\xa0\\xa0pmid:26047908.9Garcia-Tsao\\xa0G,\\xa0Abraldes\\xa0JG,\\xa0Berzigotti\\xa0A,\\xa0Bosch\\xa0J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65:310-35. 10.1002/hep.28906\\xa0\\xa0pmid:27786365.10Rockall\\xa0TA,\\xa0Logan\\xa0RFA,\\xa0Devlin\\xa0HB,\\xa0Northfield\\xa0TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the UK. BMJ 1995;311:222-6. 10.1136/bmj.311.6999.222\\xa0\\xa0pmid:7627034.11Blatchford\\xa0O,\\xa0Davidson\\xa0LA,\\xa0Murray\\xa0WR,\\xa0Blatchford\\xa0M,\\xa0Pell\\xa0J. Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study. BMJ 1997;315:510-4. 10.1136/bmj.315.7107.510\\xa0\\xa0pmid:9329304.12Laine\\xa0L,\\xa0Yang\\xa0H,\\xa0Chang\\xa0SC,\\xa0Datto\\xa0C. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol 2012;107:1190-5, quiz 1196. 10.1038/ajg.2012.168\\xa0\\xa0pmid:22688850.13Abougergi\\xa0MS,\\xa0Travis\\xa0AC,\\xa0Saltzman\\xa0JR. The in-hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a nationwide analysis. Gastrointest Endosc 2015;81:882-8.e1. 10.1016/j.gie.2014.09.027\\xa0\\xa0pmid:25484324.14Wuerth\\xa0BA,\\xa0Rockey\\xa0DC. Changing epidemiology of upper gastrointestinal hemorrhage in the last decade: a nationwide analysis. Dig Dis Sci 2018;63:1286-93. 10.1007/s10620-017-4882-6\\xa0\\xa0pmid:29282637.15',\n",
       " 'Wuerth\\xa0BA,\\xa0Rockey\\xa0DC. Changing epidemiology of upper gastrointestinal hemorrhage in the last decade: a nationwide analysis. Dig Dis Sci 2018;63:1286-93. 10.1007/s10620-017-4882-6\\xa0\\xa0pmid:29282637.15Hearnshaw\\xa0SA,\\xa0Logan\\xa0RFA,\\xa0Lowe\\xa0D,\\xa0Travis\\xa0SP,\\xa0Murphy\\xa0MF,\\xa0Palmer\\xa0KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011;60:1327-35. 10.1136/gut.2010.228437\\xa0\\xa0pmid:21490373.16Nahon\\xa0S,\\xa0Hagège\\xa0H,\\xa0Latrive\\xa0JP,\\xa0et al.\\xa0Groupe des Hémorragies Digestives Hautes de l’ANGH. Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study. Endoscopy 2012;44:998-1008. 10.1055/s-0032-1310006\\xa0\\xa0pmid:23108771.17Bickell\\xa0WH,\\xa0Wall\\xa0MJ\\xa0Jr,\\xa0,\\xa0Pepe\\xa0PE,\\xa0et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994;331:1105-9. 10.1056/NEJM199410273311701\\xa0\\xa0pmid:7935634.18Carrick\\xa0MM,\\xa0Morrison\\xa0CA,\\xa0Tapia\\xa0NM,\\xa0et al. Intraoperative hypotensive resuscitation for patients undergoing laparotomy or thoracotomy for trauma: Early termination of a randomized prospective clinical trial. J Trauma Acute Care Surg 2016;80:886-96. 10.1097/TA.0000000000001044\\xa0\\xa0pmid:27015578.19Perel\\xa0P,\\xa0Roberts\\xa0I,\\xa0Ker\\xa0K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013;28:CD000567.pmid:23450531.20 Semler\\xa0MW,\\xa0Self\\xa0WH,\\xa0Wanderer\\xa0JP,\\xa0et al.\\xa0SMART Investigators and the Pragmatic Critical Care Research Group. Balanced crystalloids versus saline in critically ill adults. N Engl J Med 2018;378:829-39. 10.1056/NEJMoa1711584\\xa0\\xa0pmid:29485925.21Carson\\xa0JL,\\xa0Stanworth\\xa0SJ,\\xa0Roubinian\\xa0N,\\xa0et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2016;10:CD002042.pmid:27731885.22Carson\\xa0JL,\\xa0Guyatt\\xa0G,\\xa0Heddle\\xa0NM,\\xa0et al. Clinical practice guidelines from',\n",
       " 'Cochrane Database Syst Rev 2016;10:CD002042.pmid:27731885.22Carson\\xa0JL,\\xa0Guyatt\\xa0G,\\xa0Heddle\\xa0NM,\\xa0et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 2016;316:2025-35. 10.1001/jama.2016.9185\\xa0\\xa0pmid:27732721.23Docherty\\xa0AB,\\xa0O’Donnell\\xa0R,\\xa0Brunskill\\xa0S,\\xa0et al. Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting: systematic review and meta-analysis. BMJ 2016;352:i1351. 10.1136/bmj.i1351\\xa0\\xa0pmid:27026510.24Blair\\xa0SD,\\xa0Janvrin\\xa0SB,\\xa0McCollum\\xa0CN,\\xa0Greenhalgh\\xa0RM. Effect of early blood transfusion on gastrointestinal haemorrhage. Br J Surg 1986;73:783-5. 10.1002/bjs.1800731007\\xa0\\xa0pmid:3533203.25Villanueva\\xa0C,\\xa0Colomo\\xa0A,\\xa0Bosch\\xa0A,\\xa0et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11-21. 10.1056/NEJMoa1211801\\xa0\\xa0pmid:23281973.26Jairath\\xa0V,\\xa0Kahan\\xa0BC,\\xa0Gray\\xa0A,\\xa0et al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet 2015;386:137-44. 10.1016/S0140-6736(14)61999-1\\xa0\\xa0pmid:25956718.27Odutayo\\xa0A,\\xa0Desborough\\xa0MJ,\\xa0Trivella\\xa0M,\\xa0et al. Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. Lancet Gastroenterol Hepatol 2017;2:354-60. 10.1016/S2468-1253(17)30054-7.\\xa0\\xa0pmid:28397699.28Laine\\xa0L,\\xa0Jensen\\xa0DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012;107:345-60, quiz 361. 10.1038/ajg.2011.480\\xa0\\xa0pmid:22310222.29 Rockall\\xa0TA,\\xa0Logan\\xa0RF,\\xa0Devlin\\xa0HB,\\xa0Northfield\\xa0TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:316-21. 10.1136/gut.38.3.316\\xa0\\xa0pmid:8675081.30 Saeed\\xa0ZA,\\xa0Winchester\\xa0CB,\\xa0Michaletz\\xa0PA,\\xa0Woods\\xa0KL,\\xa0Graham\\xa0DY. A scoring system to predict rebleeding after endoscopic therapy of nonvariceal',\n",
       " 'gut.38.3.316\\xa0\\xa0pmid:8675081.30 Saeed\\xa0ZA,\\xa0Winchester\\xa0CB,\\xa0Michaletz\\xa0PA,\\xa0Woods\\xa0KL,\\xa0Graham\\xa0DY. A scoring system to predict rebleeding after endoscopic therapy of nonvariceal upper gastrointestinal hemorrhage, with a comparison of heat probe and ethanol injection. Am J Gastroenterol 1993;88:1842-9.pmid:8237930.31Hay\\xa0JA,\\xa0Maldonado\\xa0L,\\xa0Weingarten\\xa0SR,\\xa0Ellrodt\\xa0AG. Prospective evaluation of a clinical guideline recommending hospital length of stay in upper gastrointestinal tract hemorrhage. JAMA 1997;278:2151-6. 10.1001/jama.1997.03550240041031\\xa0\\xa0pmid:9417008.32Blatchford\\xa0O,\\xa0Murray\\xa0WR,\\xa0Blatchford\\xa0M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000;356:1318-21. 10.1016/S0140-6736(00)02816-6\\xa0\\xa0pmid:11073021.33Marmo\\xa0R,\\xa0Koch\\xa0M,\\xa0Cipolletta\\xa0L,\\xa0et al.\\xa0Italian registry on upper gastrointestinal bleeding (Progetto Nazionale Emorragie Digestive--PNED 2). Predicting mortality in non-variceal upper gastrointestinal bleeders: validation of the Italian PNED Score and Prospective Comparison with the Rockall Score. Am J Gastroenterol 2010;105:1284-91. 10.1038/ajg.2009.687\\xa0\\xa0pmid:20051943.34 Saltzman\\xa0JR,\\xa0Tabak\\xa0YP,\\xa0Hyett\\xa0BH,\\xa0Sun\\xa0X,\\xa0Travis\\xa0AC,\\xa0Johannes\\xa0RS. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc 2011;74:1215-24. 10.1016/j.gie.2011.06.024\\xa0\\xa0pmid:21907980.35Stanley\\xa0AJ,\\xa0Laine\\xa0L,\\xa0Dalton\\xa0HR,\\xa0et al.\\xa0International Gastrointestinal Bleeding Consortium. Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study. BMJ 2017;356:i6432. 10.1136/bmj.i6432\\xa0\\xa0pmid:28053181.36 Laursen\\xa0SB,\\xa0Hansen\\xa0JM,\\xa0Schaffalitzky de Muckadell\\xa0OB. The Glasgow Blatchford score is the most accurate assessment of patients with upper gastrointestinal hemorrhage. Clin Gastroenterol Hepatol 2012;10:1130-1135.e1. 10.1016/j.cgh.2012.06.022\\xa0\\xa0pmid:22801061.37',\n",
       " 'Blatchford score is the most accurate assessment of patients with upper gastrointestinal hemorrhage. Clin Gastroenterol Hepatol 2012;10:1130-1135.e1. 10.1016/j.cgh.2012.06.022\\xa0\\xa0pmid:22801061.37Yang\\xa0HM,\\xa0Jeon\\xa0SW,\\xa0Jung\\xa0JT,\\xa0et al.\\xa0Daegu-Gyeongbuk Gastrointestinal Study Group (DGSG). Comparison of scoring systems for nonvariceal upper gastrointestinal bleeding: a multicenter prospective cohort study. J Gastroenterol Hepatol 2016;31:119-25. 10.1111/jgh.13057\\xa0\\xa0pmid:26211939.38 Stanley\\xa0AJ,\\xa0Ashley\\xa0D,\\xa0Dalton\\xa0HR,\\xa0et al. Outpatient management of patients with low-risk upper-gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet 2009;373:42-7. 10.1016/S0140-6736(08)61769-9\\xa0\\xa0pmid:19091393.39Ramaekers\\xa0R,\\xa0Mukarram\\xa0M,\\xa0Smith\\xa0CA,\\xa0Thiruganasambandamoorthy\\xa0V. The predictive value of preendoscopic risk scores to predict adverse outcomes in emergency department patients with upper gastrointestinal bleeding: a systematic review. Acad Emerg Med 2016;23:1218-27. 10.1111/acem.13101\\xa0\\xa0pmid:27640399.40 Laursen\\xa0SB,\\xa0Dalton\\xa0HR,\\xa0Murray\\xa0IA,\\xa0et al.\\xa0Upper Gastrointestinal Hemorrhage International Consortium\\xa0Upper Gastrointestinal Hemorrhage International Consortium. Performance of new thresholds of the Glasgow Blatchford score in managing patients with upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2015;13:115-21.e2. 10.1016/j.cgh.2014.07.023\\xa0\\xa0pmid:25058843.HOW PATIENTS WERE INVOLVED IN THE CREATION OF THIS ARTICLEAfter email communication from the UK Gastroenterology Charity “Guts-UK” (previously CORE) to their members and related charities, three patients kindly volunteered to review the manuscript. In response to their comments, the sections on blood transfusion and timing of endoscopy were revised. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 12 of 1341Dunne\\xa0PDJ,\\xa0Laursen\\xa0SB,\\xa0Laine\\xa0L,\\xa0et al. Previous use of antithrombotic agents reduces mortality and length of hospital stay in patients with high-risk upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2019;17:440-447.e2. 10.1016/j.cgh.2018.04.046.\\xa0\\xa0pmid:29705263.42Chang\\xa0HY,\\xa0Zhou\\xa0M,\\xa0Tang\\xa0W,\\xa0Alexander\\xa0GC,\\xa0Singh\\xa0S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015;350:h1585. 10.1136/bmj.h1585\\xa0\\xa0pmid:25911526.43Huang\\xa0ES,\\xa0Strate\\xa0LL,\\xa0Ho\\xa0WW,\\xa0Lee\\xa0SS,\\xa0Chan\\xa0AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011;124:426-33. 10.1016/j.amjmed.2010.12.022\\xa0\\xa0pmid:21531232.44 Ahsberg\\xa0K,\\xa0Höglund\\xa0P,\\xa0Kim\\xa0WH,\\xa0von Holstein\\xa0CS. Impact of aspirin, NSAIDs, warfarin, corticosteroids and SSRIs on the site and outcome of non-variceal upper and lower gastrointestinal bleeding. Scand J Gastroenterol 2010;45:1404-15. 10.3109/00365521.2010.510567\\xa0\\xa0pmid:20695720.45Acosta\\xa0RD,\\xa0Abraham\\xa0NS,\\xa0Chandrasekhara\\xa0V,\\xa0et al.\\xa0ASGE Standards of Practice Committee. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016;83:3-16. 10.1016/j.gie.2015.09.035\\xa0\\xa0pmid:26621548.46 Zakko\\xa0L,\\xa0Rustagi\\xa0T,\\xa0Douglas\\xa0M,\\xa0Laine\\xa0L. No benefit from platelet transfusion for gastrointestinal bleeding in patients taking antiplatelet agents. Clin Gastroenterol Hepatol 2017;15:46-52. 10.1016/j.cgh.2016.07.017\\xa0\\xa0pmid:27464591.47Razzaghi\\xa0A,\\xa0Barkun\\xa0AN. Platelet transfusion threshold in patients with upper gastrointestinal bleeding: a systematic review. J Clin Gastroenterol 2012;46:482-6. 10.1097/MCG.0b013e31823d33e3\\xa0\\xa0pmid:22688143.48 Choudari\\xa0CP,\\xa0Rajgopal\\xa0C,\\xa0Palmer\\xa0KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut 1994;35:464-6. 10.1136/gut.35.4.464\\xa0\\xa0pmid:8174982.49Wolf\\xa0AT,\\xa0Wasan\\xa0SK,\\xa0Saltzman\\xa0JR. Impact of anticoagulation on rebleeding',\n",
       " 'treatment. Gut 1994;35:464-6. 10.1136/gut.35.4.464\\xa0\\xa0pmid:8174982.49Wolf\\xa0AT,\\xa0Wasan\\xa0SK,\\xa0Saltzman\\xa0JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol 2007;102:290-6. 10.1111/j.1572-0241.2006.00969.x\\xa0\\xa0pmid:17100959.50 Shingina\\xa0A,\\xa0Barkun\\xa0AN,\\xa0Razzaghi\\xa0A,\\xa0Martel\\xa0M,\\xa0Bardou\\xa0M,\\xa0Gralnek\\xa0I.\\xa0RUGBE Investigators. Systematic review: the presenting international normalised ratio (INR) as a predictor of outcome in patients with upper nonvariceal gastrointestinal bleeding. Aliment Pharmacol Ther 2011;33:1010-8. 10.1111/j.1365-2036.2011.04618.x\\xa0\\xa0pmid:21385193.51Veitch\\xa0AM,\\xa0Vanbiervliet\\xa0G,\\xa0Gershlick\\xa0AH,\\xa0et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Gut 2016;65:374-89. 10.1136/gutjnl-2015-311110\\xa0\\xa0pmid:26873868.52Pollack\\xa0CV\\xa0Jr,\\xa0,\\xa0Reilly\\xa0PA,\\xa0van Ryn\\xa0J,\\xa0et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med 2017;377:431-41. 10.1056/NEJMoa1707278\\xa0\\xa0pmid:28693366.53Connolly\\xa0SJ,\\xa0Milling\\xa0TJ\\xa0Jr,\\xa0,\\xa0Eikelboom\\xa0JW,\\xa0et al.\\xa0ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016;375:1131-41. 10.1056/NEJMoa1607887\\xa0\\xa0pmid:27573206.54 Tripodi\\xa0A,\\xa0Mannucci\\xa0PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365:147-56. 10.1056/NEJMra1011170\\xa0\\xa0pmid:21751907.55Tripodi\\xa0A,\\xa0Primignani\\xa0M,\\xa0Chantarangkul\\xa0V,\\xa0et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006;44:440-5. 10.1002/hep.21266\\xa0\\xa0pmid:16871542.56 Sreedharan\\xa0A,\\xa0Martin\\xa0J,\\xa0Leontiadis\\xa0GI,\\xa0et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010;7:CD005415.pmid:20614440.57Hwang\\xa0JH,\\xa0Fisher\\xa0DA,\\xa0Ben-Menachem\\xa0T,\\xa0et al.\\xa0Standards of Practice',\n",
       " 'bleeding. Cochrane Database Syst Rev 2010;7:CD005415.pmid:20614440.57Hwang\\xa0JH,\\xa0Fisher\\xa0DA,\\xa0Ben-Menachem\\xa0T,\\xa0et al.\\xa0Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy. The role of endoscopy in the management of acute non-variceal upper GI bleeding. Gastrointest Endosc 2012;75:1132-8. 10.1016/j.gie.2012.02.033\\xa0\\xa0pmid:22624808.58 Rahman\\xa0R,\\xa0Nguyen\\xa0DL,\\xa0Sohail\\xa0U,\\xa0et al. Pre-endoscopic erythromycin administration in upper gastrointestinal bleeding: an updated meta-analysis and systematic review. Ann Gastroenterol 2016;29:312-7.pmid:27366031.59Gluud\\xa0LL,\\xa0Klingenberg\\xa0SL,\\xa0Langholz\\xa0E. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2012;1:CD006640.pmid:22258969.60 Gayet-Ageron\\xa0A,\\xa0Prieto-Merino\\xa0D,\\xa0Ker\\xa0K,\\xa0Shakur\\xa0H,\\xa0Ageron\\xa0FX,\\xa0Roberts\\xa0I.\\xa0Antifibrinolytic Trials Collaboration. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40\\u2008138 bleeding patients. Lancet 2018;391:125-32. 10.1016/S0140-6736(17)32455-8.\\xa0\\xa0pmid:29126600.61Roberts\\xa0I,\\xa0Coats\\xa0T,\\xa0Edwards\\xa0P,\\xa0et al. HALT-IT--tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial. Trials 2014;15:450. 10.1186/1745-6215-15-450.\\xa0\\xa0pmid:25409738.62Seo\\xa0YS,\\xa0Park\\xa0SY,\\xa0Kim\\xa0MY,\\xa0et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology 2014;60:954-63. 10.1002/hep.27006\\xa0\\xa0pmid:24415445.63Levacher\\xa0S,\\xa0Letoumelin\\xa0P,\\xa0Pateron\\xa0D,\\xa0Blaise\\xa0M,\\xa0Lapandry\\xa0C,\\xa0Pourriat\\xa0JL. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995;346:865-8. 10.1016/S0140-6736(95)92708-5\\xa0\\xa0pmid:7564670.64 Avgerinos\\xa0A,\\xa0Nevens\\xa0F,\\xa0Raptis\\xa0S,\\xa0Fevery\\xa0J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal',\n",
       " '5\\xa0\\xa0pmid:7564670.64 Avgerinos\\xa0A,\\xa0Nevens\\xa0F,\\xa0Raptis\\xa0S,\\xa0Fevery\\xa0J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997;350:1495-9. 10.1016/S0140-6736(97)05099-X\\xa0\\xa0pmid:9388396.65Calès\\xa0P,\\xa0Masliah\\xa0C,\\xa0Bernard\\xa0B,\\xa0et al.\\xa0French Club for the Study of Portal Hypertension. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med 2001;344:23-8. 10.1056/NEJM200101043440104\\xa0\\xa0pmid:11136956.66 Avgerinos\\xa0A,\\xa0Sgouros\\xa0S,\\xa0Viazis\\xa0N,\\xa0et al. Somatostatin inhibits gastric acid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: a prospective, randomized, placebo-controlled trial. Scand J Gastroenterol 2005;40:515-22. 10.1080/00365520510015458\\xa0\\xa0pmid:16036503.67Whitehouse\\xa0I,\\xa0Beglinger\\xa0C,\\xa0Fried\\xa0M,\\xa0Gyr\\xa0K. The effect of an octapeptide somatostatin analogue (SMS 201-995) and somatostatin-14 (SST-14) on pentagastrin-stimulated gastric acid secretion: a comparative study in man. Hepatogastroenterology 1984;31:227-9.pmid:6150888.68 Chavez-Tapia\\xa0NC,\\xa0Barrientos-Gutierrez\\xa0T,\\xa0Tellez-Avila\\xa0F,\\xa0et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding—an updated Cochrane review. Aliment Pharmacol Ther 2011;34:509-18. 10.1111/j.1365-2036.2011.04746.x\\xa0\\xa0pmid:21707680.69Fernández\\xa0J,\\xa0Ruiz del Arbol\\xa0L,\\xa0Gómez\\xa0C,\\xa0et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006;131:1049-56, quiz 1285. 10.1053/j.gastro.2006.07.010\\xa0\\xa0pmid:17030175.70Strate\\xa0LL,\\xa0Gralnek\\xa0IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol 2016;111:459-74. 10.1038/ajg.2016.41.\\xa0\\xa0pmid:26925883.71Pasha\\xa0SF,\\xa0Shergill\\xa0A,\\xa0Acosta\\xa0RD,\\xa0et al.\\xa0ASGE Standards of Practice',\n",
       " 'acute lower gastrointestinal bleeding. Am J Gastroenterol 2016;111:459-74. 10.1038/ajg.2016.41.\\xa0\\xa0pmid:26925883.71Pasha\\xa0SF,\\xa0Shergill\\xa0A,\\xa0Acosta\\xa0RD,\\xa0et al.\\xa0ASGE Standards of Practice Committee. The role of endoscopy in the patient with lower GI bleeding. Gastrointest Endosc 2014;79:875-85. 10.1016/j.gie.2013.10.039\\xa0\\xa0pmid:24703084.72Nadler\\xa0M,\\xa0Eliakim\\xa0R. The role of capsule endoscopy in acute gastrointestinal bleeding. Therap Adv Gastroenterol 2014;7:87-92. 10.1177/1756283X13504727\\xa0\\xa0pmid:24587821.73 Lim\\xa0LG,\\xa0Ho\\xa0KY,\\xa0Chan\\xa0YH,\\xa0et al. Urgent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleeding. Endoscopy 2011;43:300-6. 10.1055/s-0030-1256110\\xa0\\xa0pmid:21360421.74Cho\\xa0SH,\\xa0Lee\\xa0YS,\\xa0Kim\\xa0YJ,\\xa0et al. Outcomes and role of urgent endoscopy in high-risk patients with acute nonvariceal gastrointestinal bleeding. Clin Gastroenterol Hepatol 2018;16:370-7. 10.1016/j.cgh.2017.06.029\\xa0\\xa0pmid:28634135.75Lin\\xa0HJ,\\xa0Wang\\xa0K,\\xa0Perng\\xa0CL,\\xa0et al. Early or delayed endoscopy for patients with peptic ulcer bleeding. A prospective randomized study. J Clin Gastroenterol 1996;22:267-71. 10.1097/00004836-199606000-00005\\xa0\\xa0pmid:8771420.76Laursen\\xa0SB,\\xa0Leontiadis\\xa0GI,\\xa0Stanley\\xa0AJ,\\xa0Møller\\xa0MH,\\xa0Hansen\\xa0JM,\\xa0Schaffalitzky de Muckadell\\xa0OB. Relationship between timing of endoscopy and mortality in\\xa0patients with peptic ulcer bleeding: a nationwide cohort\\xa0study. Gastrointest Endosc 2017;85:936-944.e3. 10.1016/j.gie.2016.08.049\\xa0\\xa0pmid:27623102.77 Sung\\xa0JJ,\\xa0Tsoi\\xa0KK,\\xa0Ma\\xa0TK,\\xa0Yung\\xa0MY,\\xa0Lau\\xa0JY,\\xa0Chiu\\xa0PW. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am J Gastroenterol 2010;105:84-9. 10.1038/ajg.2009.507\\xa0\\xa0pmid:19755976.78Lee\\xa0JG,\\xa0Turnipseed\\xa0S,\\xa0Romano\\xa0PS,\\xa0et al. Endoscopy-based triage significantly reduces hospitalization rates and costs of treating upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 1999;50:755-61. 10.1016/S0016-5107(99)70154-9\\xa0\\xa0pmid:10570332.79',\n",
       " 'upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 1999;50:755-61. 10.1016/S0016-5107(99)70154-9\\xa0\\xa0pmid:10570332.79Bjorkman\\xa0DJ,\\xa0Zaman\\xa0A,\\xa0Fennerty\\xa0MB,\\xa0Lieberman\\xa0D,\\xa0Disario\\xa0JA,\\xa0Guest-Warnick\\xa0G. Urgent vs. elective endoscopy for acute non-variceal upper-GI bleeding: an effectiveness study. Gastrointest Endosc 2004;60:1-8. 10.1016/S0016-5107(04)01287-8\\xa0\\xa0pmid:15229417.80 Laine\\xa0L. Upper gastrointestinal bleeding due to a peptic ulcer. N Engl J Med 2016;374:2367-76. 10.1056/NEJMcp1514257\\xa0\\xa0pmid:27305194.81Maida\\xa0M,\\xa0Camilleri\\xa0S,\\xa0Manganaro\\xa0M,\\xa0Garufi\\xa0S,\\xa0Scarpulla\\xa0G. Radiofrequency ablation for treatment of refractory gastric antral vascular ectasia: a systematic review of the literature. Gastroenterol Res Pract 2017;2017:5609647. 10.1155/2017/5609647\\xa0\\xa0pmid:28835751.82Laine\\xa0L,\\xa0McQuaid\\xa0KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol 2009;7:33-47, quiz 1-2. 10.1016/j.cgh.2008.08.016\\xa0\\xa0pmid:18986845.83Vergara\\xa0M,\\xa0Bennett\\xa0C,\\xa0Calvet\\xa0X,\\xa0Gisbert\\xa0JP. Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers. Cochrane Database Syst Rev 2014;10:CD005584.pmid:25308912.84 Forrest\\xa0JA,\\xa0Finlayson\\xa0ND,\\xa0Shearman\\xa0DJ. Endoscopy in gastrointestinal bleeding. Lancet 1974;2:394-7. 10.1016/S0140-6736(74)91770-X\\xa0\\xa0pmid:4136718. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 13 of 1385Enestvedt\\xa0BK,\\xa0Gralnek\\xa0IM,\\xa0Mattek\\xa0N,\\xa0Lieberman\\xa0DA,\\xa0Eisen\\xa0G. An evaluation of endoscopic indications and findings related to nonvariceal upper-GI hemorrhage in a large multicenter consortium. Gastrointest Endosc 2008;67:422-9. 10.1016/j.gie.2007.09.024\\xa0\\xa0pmid:18206878.86 Jairath\\xa0V,\\xa0Rehal\\xa0S,\\xa0Logan\\xa0R,\\xa0et al. Acute variceal haemorrhage in the United Kingdom: patient characteristics, management and outcomes in a nationwide audit. Dig Liver Dis 2014;46:419-26. 10.1016/j.dld.2013.12.010\\xa0\\xa0pmid:24433997.87Laine\\xa0L,\\xa0Cook\\xa0D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995;123:280-7. 10.7326/0003-4819-123-4-199508150-00007\\xa0\\xa0pmid:7611595.88 Lo\\xa0GH,\\xa0Lai\\xa0KH,\\xa0Cheng\\xa0JS,\\xa0Chen\\xa0MH,\\xa0Chiang\\xa0HT. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001;33:1060-4. 10.1053/jhep.2001.24116\\xa0\\xa0pmid:11343232.89 Tan\\xa0PC,\\xa0Hou\\xa0MC,\\xa0Lin\\xa0HC,\\xa0et al. A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology 2006;43:690-7. 10.1002/hep.21145\\xa0\\xa0pmid:16557539.90 Cheng\\xa0LF,\\xa0Wang\\xa0ZQ,\\xa0Li\\xa0CZ,\\xa0Lin\\xa0W,\\xa0Yeo\\xa0AE,\\xa0Jin\\xa0B. Low incidence of complications from endoscopic gastric variceal obturation with butyl cyanoacrylate. Clin Gastroenterol Hepatol 2010;8:760-6. 10.1016/j.cgh.2010.05.019\\xa0\\xa0pmid:20621678.91Ramesh\\xa0J,\\xa0Limdi\\xa0JK,\\xa0Sharma\\xa0V,\\xa0Makin\\xa0AJ. The use of thrombin injections in the management of bleeding gastric varices: a single-center experience. Gastrointest Endosc 2008;68:877-82. 10.1016/j.gie.2008.02.065\\xa0\\xa0pmid:18534583.92McAvoy\\xa0NC,\\xa0Plevris\\xa0JN,\\xa0Hayes\\xa0PC. Human thrombin for the treatment of gastric and ectopic varices. World J Gastroenterol 2012;18:5912-7. 10.3748/wjg.v18.i41.5912\\xa0\\xa0pmid:23139607.93Smith\\xa0MR,\\xa0Tidswell\\xa0R,\\xa0Tripathi\\xa0D. Outcomes of endoscopic human thrombin',\n",
       " 'and ectopic varices. World J Gastroenterol 2012;18:5912-7. 10.3748/wjg.v18.i41.5912\\xa0\\xa0pmid:23139607.93Smith\\xa0MR,\\xa0Tidswell\\xa0R,\\xa0Tripathi\\xa0D. Outcomes of endoscopic human thrombin injection in the management of gastric varices. Eur J Gastroenterol Hepatol 2014;26:846-52. 10.1097/MEG.0000000000000119\\xa0\\xa0pmid:24892515.94Sachar\\xa0H,\\xa0Vaidya\\xa0K,\\xa0Laine\\xa0L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med 2014;174:1755-62. 10.1001/jamainternmed.2014.4056\\xa0\\xa0pmid:25201154.95Freston\\xa0JW,\\xa0Pilmer\\xa0BL,\\xa0Chiu\\xa0YL,\\xa0et al. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole. Aliment Pharmacol Ther 2004;19:1111-22. 10.1111/j.1365-2036.2004.01942.x\\xa0\\xa0pmid:15142201.96 Cheng\\xa0HC,\\xa0Wu\\xa0CT,\\xa0Chang\\xa0WL,\\xa0Cheng\\xa0WC,\\xa0Chen\\xa0WY,\\xa0Sheu\\xa0BS. Double oral esomeprazole after a 3-day intravenous esomeprazole infusion reduces recurrent peptic ulcer bleeding in high-risk patients: a randomised controlled study. Gut 2014;63:1864-72. 10.1136/gutjnl-2013-306531\\xa0\\xa0pmid:24658598.97Bhatt\\xa0DL,\\xa0Cryer\\xa0BL,\\xa0Contant\\xa0CF,\\xa0et al.\\xa0COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17. 10.1056/NEJMoa1007964\\xa0\\xa0pmid:20925534.98 Sanofi; Bristol-Myers Squibb. Plavix. Highlights of prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020839s069lbl.pdf.99 Lo\\xa0GH,\\xa0Chen\\xa0WC,\\xa0Wang\\xa0HM,\\xa0et al. Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices. Gut 2009;58:1275-80. 10.1136/gut.2008.165910\\xa0\\xa0pmid:19386609.100 Sung\\xa0JJ,\\xa0Chung\\xa0SC,\\xa0Yung\\xa0MY,\\xa0et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995;346:1666-9. 10.1016/S0140-6736(95)92840-5\\xa0\\xa0pmid:8551824.101 García-Pagán\\xa0JC,\\xa0Caca\\xa0K,\\xa0Bureau\\xa0C,\\xa0et al.\\xa0Early TIPS (Transjugular Intrahepatic',\n",
       " 'ligation. Lancet 1995;346:1666-9. 10.1016/S0140-6736(95)92840-5\\xa0\\xa0pmid:8551824.101 García-Pagán\\xa0JC,\\xa0Caca\\xa0K,\\xa0Bureau\\xa0C,\\xa0et al.\\xa0Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362:2370-9. 10.1056/NEJMoa0910102\\xa0\\xa0pmid:20573925.102 Conejo\\xa0I,\\xa0Guardascione\\xa0MA,\\xa0Tandon\\xa0P,\\xa0et al. Multicenter external validation of risk stratification criteria for patients with variceal bleeding. Clin Gastroenterol Hepatol 2018;16:132-139.e8. 10.1016/j.cgh.2017.04.042\\xa0\\xa0pmid:28501536.103 Sung\\xa0JJ,\\xa0Lau\\xa0JY,\\xa0Ching\\xa0JY,\\xa0et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010;152:1-9. 10.7326/0003-4819-152-1-201001050-00179\\xa0\\xa0pmid:19949136.104 Qureshi\\xa0W,\\xa0Mittal\\xa0C,\\xa0Patsias\\xa0I,\\xa0et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014;113:662-8. 10.1016/j.amjcard.2013.10.044\\xa0\\xa0pmid:24355310.105 Chan\\xa0FKL,\\xa0Goh\\xa0KL,\\xa0Reddy\\xa0N,\\xa0et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. Gut 2018;67:405-17. 10.1136/gutjnl-2017-315131\\xa0\\xa0pmid:29331946.106 Scott\\xa0MJ,\\xa0Veitch\\xa0A,\\xa0Thachil\\xa0J. Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when?Br J Haematol 2017;177:185-97. 10.1111/bjh.14599.\\xa0\\xa0pmid:28272736.107 Witt\\xa0DM,\\xa0Delate\\xa0T,\\xa0Garcia\\xa0DA,\\xa0et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012;172:1484-91. 10.1001/archinternmed.2012.4261\\xa0\\xa0pmid:22987143.108 Gage\\xa0BF,\\xa0Waterman\\xa0AD,\\xa0Shannon\\xa0W,\\xa0Boechler\\xa0M,\\xa0Rich\\xa0MW,\\xa0Radford\\xa0MJ. Validation of clinical classification schemes for predicting stroke: results',\n",
       " '10.1001/archinternmed.2012.4261\\xa0\\xa0pmid:22987143.108 Gage\\xa0BF,\\xa0Waterman\\xa0AD,\\xa0Shannon\\xa0W,\\xa0Boechler\\xa0M,\\xa0Rich\\xa0MW,\\xa0Radford\\xa0MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70. 10.1001/jama.285.22.2864\\xa0\\xa0pmid:11401607.109 Lip\\xa0GY,\\xa0Frison\\xa0L,\\xa0Halperin\\xa0JL,\\xa0Lane\\xa0DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011;57:173-80. 10.1016/j.jacc.2010.09.024\\xa0\\xa0pmid:21111555.110 Zulkifly\\xa0H,\\xa0Lip\\xa0GYH,\\xa0Lane\\xa0DA. Bleeding risk scores in atrial fibrillation and venous thromboembolism. Am J Cardiol 2017;120:1139-45. 10.1016/j.amjcard.2017.06.058\\xa0\\xa0pmid:28800833.111 Lau\\xa0JYW,\\xa0Sung\\xa0JJY,\\xa0Lam\\xa0YH,\\xa0et al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999;340:751-6. 10.1056/NEJM199903113401002\\xa0\\xa0pmid:10072409.112 Chen\\xa0Y-I,\\xa0Barkun\\xa0AN. Hemostatic powders in gastrointestinal bleeding: a systematic review. Gastrointest Endosc Clin N Am 2015;25:535-52. 10.1016/j.giec.2015.02.008\\xa0\\xa0pmid:26142037.113 Troland\\xa0D,\\xa0Stanley\\xa0A. Endotherapy for peptic ulcer bleeding. Gastrointest Endosc Clin N Am 2018;28:277-89. 10.1016/j.giec.2018.02.002\\xa0\\xa0pmid:29933775.114 Kyaw\\xa0M,\\xa0Tse\\xa0Y,\\xa0Ang\\xa0D,\\xa0Ang\\xa0TL,\\xa0Lau\\xa0J. Embolization versus surgery for peptic ulcer bleeding after failed endoscopic hemostasis: a meta-analysis. Endosc Int Open 2014;2:E6-14. 10.1055/s-0034-1365235\\xa0\\xa0pmid:26134614.115 Beggs\\xa0AD,\\xa0Dilworth\\xa0MP,\\xa0Powell\\xa0SL,\\xa0Atherton\\xa0H,\\xa0Griffiths\\xa0EA. A systematic review of transarterial embolization versus emergency surgery in treatment of major nonvariceal upper gastrointestinal bleeding. Clin Exp Gastroenterol 2014;7:93-104. 10.2147/CEG.S56725\\xa0\\xa0pmid:24790465.',\n",
       " 'surgery in treatment of major nonvariceal upper gastrointestinal bleeding. Clin Exp Gastroenterol 2014;7:93-104. 10.2147/CEG.S56725\\xa0\\xa0pmid:24790465.116 Lau\\xa0JYW,\\xa0Pittayanon\\xa0R,\\xa0Wong\\xa0KT,\\xa0et al. Prophylactic angiographic embolisation after endoscopic control of bleeding to high-risk peptic ulcers: a randomised controlled trial. Gut 2018;gutjnl-2018-316074. 10.1136/gutjnl-2018-316074.\\xa0\\xa0pmid:29802172.117 Cook\\xa0D,\\xa0Laine\\xa0L. Indications, technique, and complications of balloon tamponade for variceal gastrointestinal bleeding. J Intensive Care Med 1992;7:212-8. 10.1177/088506669200700408\\xa0\\xa0pmid:10147943.118 Escorsell\\xa0À,\\xa0Pavel\\xa0O,\\xa0Cárdenas\\xa0A,\\xa0et al.\\xa0Variceal Bleeding Study Group. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology 2016;63:1957-67. 10.1002/hep.28360\\xa0\\xa0pmid:26600191.119 Sung\\xa0JJ,\\xa0Luo\\xa0D,\\xa0Wu\\xa0JC,\\xa0et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011;43:291-5. 10.1055/s-0030-1256311\\xa0\\xa0pmid:21455870.120 Smith\\xa0LA,\\xa0Stanley\\xa0AJ,\\xa0Bergman\\xa0JJ,\\xa0et al. Hemospray application in nonvariceal upper gastrointestinal bleeding: results of the Survey to Evaluate the Application of Hemospray in the Luminal Tract. J Clin Gastroenterol 2014;48:e89-92. 10.1097/MCG.054.\\xa0\\xa0pmid:24326829.121 Sulz\\xa0MC,\\xa0Frei\\xa0R,\\xa0Meyenberger\\xa0C,\\xa0Bauerfeind\\xa0P,\\xa0Semadeni\\xa0GM,\\xa0Gubler\\xa0C. Routine use of Hemospray for gastrointestinal bleeding: prospective two-center experience in Switzerland. Endoscopy 2014;46:619-24. 10.1055/s-0034-1365505\\xa0\\xa0pmid:24770964.122 Changela\\xa0K,\\xa0Papafragkakis\\xa0H,\\xa0Ofori\\xa0E,\\xa0et al. Hemostatic powder spray: a new method for managing gastrointestinal bleeding. Therap Adv Gastroenterol 2015;8:125-35. 10.1177/1756283X15572587\\xa0\\xa0pmid:26082803.123 Kwek\\xa0BEA,\\xa0Ang\\xa0TL,\\xa0Ong\\xa0PLJ,\\xa0et al. TC-325 versus the conventional combined technique for endoscopic treatment of peptic ulcers with high-',\n",
       " '10.1177/1756283X15572587\\xa0\\xa0pmid:26082803.123 Kwek\\xa0BEA,\\xa0Ang\\xa0TL,\\xa0Ong\\xa0PLJ,\\xa0et al. TC-325 versus the conventional combined technique for endoscopic treatment of peptic ulcers with high-risk bleeding stigmata: A randomized pilot study. J Dig Dis 2017;18:323-9. 10.1111/1751-2980.12481.\\xa0\\xa0pmid:28485544.124 Ibrahim\\xa0M,\\xa0El-Mikkawy\\xa0A,\\xa0Abdel Hamid\\xa0M,\\xa0et al. Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial. Gut 2018;gutjnl-2017-314653. 10.1136/gutjnl-2017-314653.\\xa0\\xa0pmid:29730601.125 Schmidt\\xa0A,\\xa0Gölder\\xa0S,\\xa0Goetz\\xa0M,\\xa0et al. Over the scope clips are more effective than standard endoscopic therapy for patients with recurrent bleeding of peptic ulcers. Gastroenterology 2018;155:674-686.e6. 10.1053/j.gastro.2018.05.037.\\xa0\\xa0pmid:29803838.126 Jensen\\xa0DM,\\xa0Kovacs\\xa0TOG,\\xa0Ohning\\xa0GV,\\xa0et al. Doppler endoscopic probe monitoring of blood flow improves risk stratification and outcomes of patients with severe nonvariceal upper gastrointestinal hemorrhage. Gastroenterology 2017;152:1310-1318.e1. 10.1053/j.gastro.2017.01.042\\xa0\\xa0pmid:28167214. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 14 of 13 on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'STATE OF THE ART REVIEWFor personal use only 15 of 13 on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from',\n",
       " 'The new engl and jour nal of medicinen engl j med 374;24\\u2003 nejm.org\\u2003 June 16, 20162367Clinical PracticeA 55-year-old woman presents to the emergency department at 11:30 p.m. with hematemesis. She is otherwise healthy and has no risk factors for liver disease. Her only medication is aspirin (at a dose of 81 mg daily), which she started to take 6\\xa0months ago after reading that it reduces the risk of heart disease. The blood pres-sure is 94/60 mm Hg, and the heart rate is 108 beats per minute; the physical exami-nation is otherwise normal. The hemoglobin level is 11.0 g per deciliter, platelet count 220,000 per cubic millimeter, international normalized ratio 1.0, and blood urea nitrogen level 20 mg per deciliter (7.1 mmol per liter). How should this case be further evaluated and managed?The Clinical ProblemGastrointestinal bleeding, the most common cause of hospital-ization due to gastrointestinal disease in the United States, accounts for more than 507,000 hospitalizations and $4.85 billion in costs annually.1 Upper gastrointestinal bleeding, defined as bleeding from the esophagus, stomach, or duodenum, is responsible for 50% or more of these hospitalizations.2 The case fatality rate among hospitalized patients with upper gastrointestinal bleeding has decreased over the past 20 years and ranges from 2.1 to 2.5% in U.S. nationwide database studies3,4 to 10% in large, prospective European observational studies.5,6 The rate of death among patients who are already hospitalized for another condi-tion when upper gastrointestinal bleeding develops is approximately 3 to 4 times as high as the rate among patients who are admitted to the hospital for upper gastrointestinal bleeding.5Peptic ulcers, which are primarily due to Helicobacter pylori infection or the use of nonsteroidal antiinflammatory drugs (NSAIDs), occur in the stomach or duo-denum and are the most frequent cause of upper gastrointestinal bleeding.4 Ero-',\n",
       " 'of nonsteroidal antiinflammatory drugs (NSAIDs), occur in the stomach or duo-denum and are the most frequent cause of upper gastrointestinal bleeding.4 Ero-sions in the esophagus (which are caused by gastroesophageal reflux disease) or in the stomach or duodenum (which are frequently due to NSAIDs) are also common sources of upper gastrointestinal bleeding. Erosions are breaks confined to the mucosa (the most superficial layer of the gastrointestinal tract) and should not cause severe bleeding because veins and arteries are not normally present in the mucosa. Mallory–Weiss tears, linear tears that usually occur on the gastric side of the gastroesophageal junction, may cause severe bleeding and usually occur after retching or vomiting. Less common causes of nonvariceal upper gastrointestinal An audio version of this article is available at NEJM.orgFrom the Yale School of Medicine, New Haven, and VA Connecticut Healthcare System, West Haven — both in Connecti-cut. Address reprint requests to Dr. Laine at the Section of Digestive Diseases, Yale School of Medicine, P.O. Box 208019, New Haven, CT 06520-8019, or at \\xadloren\\u200b.\\xadlaine@\\u200b\\xadyale\\u200b.\\xadedu.N Engl J Med 2016;374:2367-76.DOI: 10.1056/NEJMcp1514257Copyright © 2016 Massachusetts Medical Society.Caren\\xa0G. Solomon, M.D., M.P.H., EditorUpper Gastrointestinal Bleeding Due  to a Peptic UlcerLoren Laine, M.D.\\u200bThis Journal feature begins with a case vignette highlighting a common clinical problem. Evidence \\xadsupporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author’s clinical recommendations.The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 374;24\\u2003 nejm.org\\u2003 June 16, 20162368The new engl and jour nal of medicine2368bleeding include neoplasms, vascular ectasias (in-cluding gastric antral vascular ectasias), Dieulafoy’s lesions (aberrant vessels in the mucosa), bleed-ing from the bile duct or pancreatic duct, and aortoenteric fistulas. The proportion of upper gastrointestinal bleeding that is attributable to varices varies widely, from 1.9% to more than 30%,4,6 depending on the characteristics of the patient population (e.g., the prevalence of injec-tion-drug or alcohol use and the country of origin). This article, which considers only nonvariceal upper gastrointestinal bleeding, focuses on ulcer bleeding.Str ategies and EvidenceInitial AssessmentAt the initial encounter with a patient, risk as-sessment is performed to determine the severity of upper gastrointestinal bleeding according to vital signs and patient factors. Tachycardia (heart rate ≥100 beats per minute), hypotension (systolic blood pressure ≤100 mm Hg), age older than 60 years, and major coexisting conditions are associated with an increased risk of further bleeding and death.7Risk-assessment tools are available and are use-ful in identifying patients at very low risk. For example, discharge from the emergency depart-ment followed by outpatient care has been sug-gested for patients with a Glasgow–Blatchford score of 0, 0 to 1, or, in patients who are younger than 70 years of age, 0 to 2 (on a scale of 0 to 23, with higher scores indicating higher risk) (Table\\xa0 1).8-11 A prospective study showed that when hospitalized, less than 1% of such patients require intervention and less than 0.5% die.10Hemoglobin levels should be monitored; how-ever, unlike blood pressure and heart rate, they are a poor initial indicator of the severity of up-per gastrointestinal bleeding. Because patients bleed whole blood, the hemoglobin level does not drop immediately but takes hours to equili-',\n",
       " 'are a poor initial indicator of the severity of up-per gastrointestinal bleeding. Because patients bleed whole blood, the hemoglobin level does not drop immediately but takes hours to equili-brate as the intravascular volume is replenished with intravenous and interstitial fluid.Initial Therapy before EndoscopyTransfusion of red cells is generally recommend-ed when the hemoglobin level decreases below 7 g per deciliter. A randomized trial showed lower rates of death (the primary outcome), rebleeding, and adverse events with a transfusion threshold of 7 g per deciliter than with a transfusion threshold of 9 g per deciliter.12 For patients in hemodynamically stable condition who have pre-existing cardiovascular disease, guidelines recom-mend transfusion at a hemoglobin level of less than 8 g per deciliter or in patients with symp-toms. These guidelines are based on random-ized trials that primarily involved patients with-out gastrointestinal bleeding who had undergone surgery.13 In patients with hypotension due to severe upper gastrointestinal bleeding, transfu-sion before the hemoglobin level decreases be-low 7 g per deciliter is reasonable to prevent the decreases to levels well below 7 g per deciliter that will occur with fluid resuscitation alone.A meta-analysis of six randomized trials showed that a proton-pump inhibitor adminis-tered to patients with upper gastrointestinal Key Clinical PointsUpper Gastrointestinal Bleeding•Gastrointestinal bleeding is the most common cause of hospitalization due to gastrointestinal disease in the United States.•Peptic ulcers, primarily due to Helicobacter pylori infection and the use of nonsteroidal antiinflammatory drugs (NSAIDs), are the most common cause of upper gastrointestinal bleeding.•In patients with upper gastrointestinal bleeding, tachycardia (heart rate, ≥100 beats per minute), hypotension (systolic blood pressure, ≤100 mm Hg), age older than 60 years, and major coexisting',\n",
       " '•In patients with upper gastrointestinal bleeding, tachycardia (heart rate, ≥100 beats per minute), hypotension (systolic blood pressure, ≤100 mm Hg), age older than 60 years, and major coexisting conditions are associated with increased risks of further bleeding and death.•Patients with bleeding ulcers due to H. pylori infection should receive treatment for this infection and, after eradication is confirmed, discontinue antisecretory medications.•Patients with bleeding ulcers due to NSAIDs other than low-dose aspirin should discontinue NSAIDs; if NSAIDs must be resumed, a cyclooxygenase-2 (COX-2)–selective NSAID plus a proton-pump inhibitor should be used.•Patients with bleeding ulcers due to low-dose aspirin taken for secondary cardiovascular prevention should resume the use of aspirin within 1 to 7 days after bleeding stops.The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 374;24\\u2003 nejm.org\\u2003 June 16, 20162369Clinical Practicebleeding soon after presentation did not signifi-cantly reduce the risks of further bleeding, sur-gery, or death. The use of this therapy was associ-ated with a decrease in the frequency of high-risk endoscopic findings (active bleeding, a nonbleed-ing visible vessel, or an adherent clot) and the need for endoscopic therapy.14 Although they are based on the same data, guidelines vary sub-stantively regarding the use of proton-pump in-hibitors before endoscopy. Some recommend high-dose intravenous proton-pump inhibitors,11,15 others indicate that proton-pump inhibitors “may be considered,”8,16 and still others recommend that clinicians not administer proton-pump in-hibitors.17Erythromycin (at a dose of 250 mg intrave-nously 30 minutes before endoscopy) increases gastric motility and improves visualization of the gastric mucosa at endoscopy. A meta-analysis of four randomized trials showed that the use of erythromycin decreased the need for blood trans-fusion and repeat endoscopy.18Use of a Nasogastric TubeA nasogastric tube is not required in patients with upper gastrointestinal bleeding.8 Observa-tional evidence does not suggest a clinical bene-fit. Standard-bore nasogastric tubes probably do not allow sufficient clearance of clots to sub-stantially improve visualization of the gastric mucosa at endoscopy.EndoscopyMost patients who are hospitalized with upper gastrointestinal bleeding should undergo endos-copy within 24 hours, after appropriate resusci-tation and transfusion, as needed, to a hemoglo-bin level greater than 7 g per deciliter. In some observational studies, prompt endoscopy, as compared with endoscopy after 24 hours, has been associated with reductions in the need for surgery, length of hospitalization, and mortal-ity.8,11,16,17,19,20Most patients with a low clinical risk (normal blood pressure and heart rate and no major co-',\n",
       " 'surgery, length of hospitalization, and mortal-ity.8,11,16,17,19,20Most patients with a low clinical risk (normal blood pressure and heart rate and no major co-existing conditions) should undergo endoscopy as soon as possible during routine clinical hours. Approximately 40 to 45% of patients who undergo endoscopy within 2 to 6 hours have low-risk endoscopic findings that allow dis-charge, thereby reducing costs.21,22 An observa-tional study and a subgroup analysis of a ran-domized trial suggest that endoscopy within 12 to 13 hours in patients with high clinical risk (Glasgow–Blatchford score ≥12, bloody nasogas-tric aspirate, hypotension, and tachycardia) may be associated with improved outcomes.8,23,24Endoscopic features of ulcers are key in pre-dicting risk and determining management strat-egies (Fig.\\xa01). Rates of further bleeding are high-est among patients with active bleeding and nonbleeding visible vessels. If endoscopic treat-ment is not provided, serious further bleeding Values at AdmissionPointsBlood urea nitrogen — mg/dl<18.2018.2 to <22.4222.4 to <28.0328.0 to <70.04≥70.06Hemoglobin — g/dl≥13.0 (men); ≥12.0 (women)012.0 to <13.0 (men); 10.0 to <12.0 (women)110.0 to <12.0 (men)3<10.0 (men and women)6Systolic blood pressure — mm Hg≥1100100–109190–992<903Heart rate — beats/min<1000≥1001Other variablesMelena1Syncope2Hepatic disease according to history or clinical and laboratory evidence2Cardiac failure according to history or clinical and echocardio-graphic evidence2*Glasgow–Blatchford scores range from 0 to 23, with higher scores indicating higher risk. Positive predictive values were calculated in a study by Laursen et al.10 Among 2305 patients presenting to a hospital with upper gastrointestinal bleeding, 313 (14%) had a score of 0 (positive predictive value, 99.0%), 562 (24%) had a score of 0 or 1 (positive predictive value, 98.8%), and 588 (26%)',\n",
       " 'bleeding, 313 (14%) had a score of 0 (positive predictive value, 99.0%), 562 (24%) had a score of 0 or 1 (positive predictive value, 98.8%), and 588 (26%) had a score of 0 to 2 and were younger than 70 years of age (positive predic-tive value, 99.0%). To convert the values for blood urea nitrogen to millimoles per liter, multiply by 0.357.Table 1. Glasgow–Blatchford Score.*The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 374;24\\u2003 nejm.org\\u2003 June 16, 20162370The new engl and jour nal of medicineoccurs in approximately 25% of patients with actively oozing hemorrhage, approximately 35% with nonbleeding visible vessels, and more than 60% with actively spurting hemorrhage.8,25 An adherent clot is also a high-risk endoscopic find-ing, although randomized trials show that rates of rebleeding without endoscopic therapy vary widely, from 0 to 35%.26 Flat, pigmented spots and clean-base ulcers, which are detected at en-doscopy in approximately 70% of patients with ulcer bleeding,27 are associated with low rates of serious rebleeding (5.6% and 0.5%, respectively, in a pooled analysis).25Endoscopic therapy with injection (e.g., of epinephrine or alcohol), thermal devices (such as bipolar electrocoagulation probes or heater probes), or clips (Fig.\\xa02) is performed in patients who have ulcers with active bleeding or a non-bleeding visible vessel. A meta-analysis of ran-domized trials revealed absolute risk reductions in further bleeding of 58 percentage points among patients with active bleeding and 20 per-centage points among patients with nonbleeding visible vessels.26 Endoscopic therapy may be con-sidered for ulcers with adherent clots, for which randomized trials show heterogeneous results.26If bleeding recurs, endoscopic therapy should be repeated. A randomized trial involving pa-tients with rebleeding after endoscopic therapy showed that surgery was avoided in 73% of cases and adverse events were significantly less common with endoscopic therapy than with surgical therapy.28 Transcatheter arterial emboli-zation or surgery is performed if repeat endo-scopic therapy fails. Complications of bleeding or perforation occur in approximately 0.5% of patients who undergo endoscopic therapy.26 En-doscopic therapy also may be used for vascular ectasias, Dieulafoy’s lesions, neoplasms, and actively bleeding Mallory–Weiss tears.11In patients with ulcers or erosions, biopsy',\n",
       " 'doscopic therapy also may be used for vascular ectasias, Dieulafoy’s lesions, neoplasms, and actively bleeding Mallory–Weiss tears.11In patients with ulcers or erosions, biopsy specimens should be obtained from lesion-free areas of the gastric body and antral mucosa for assessment of H. pylori infection.8,11 A pooled analysis indicated that such testing has 83% sensitivity and 100% specificity for H. pylori.29 If this testing is negative for H. pylori, subsequent retesting (e.g., with a stool test or breath test) Figure 1. Initial Treatment of Patients with Ulcer Bleeding, According to the Endoscopic Features of the Ulcer.Intensive proton-pump inhibitor (PPI) therapy is an intravenous bolus (80 mg) followed by an infusion (8 mg per hour) for 72 hours or an oral or intravenous bolus (e.g., 80 mg) followed by intermittent high-dose PPI therapy (e.g., 40 to 80 mg twice daily) for 3 days.11 The diets shown are diets after endoscopy in patients who do not have nausea or vomiting. The duration of hospital stay after endoscopy is shown in patients who are in stable condition and do not have further bleeding or concurrent medical conditions requiring hospitalization.EndoscopictherapyActive bleedingor visible vesselMay considerendoscopic therapyAdherent clotNo endoscopictherapyFlat pigmentedspotNo endoscopictherapyClean baseIntensive PPItherapyIntensive PPItherapyOnce-daily PPItherapyOnce-daily PPItherapyClear liquids forapproximately2 daysClear liquids forapproximately2 daysClear liquids forapproximately1 dayRegular dietHospitalizefor 3 daysHospitalizefor 3 daysHospitalize for1 or 2 daysDischarge afterendoscopyEndoscopic FeaturesEndoscopic TherapyMedical TherapyDietHospital StayThe New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 374;24 nejm.org June 16, 20162371Clinical Practicehas been recommended because some observa-tional studies suggest decreased sensitivity of testing during acute upper gastrointestinal bleeding.11,16,29 Care after EndoscopyGuidelines recommend that patients with ulcers and high-risk endoscopic findings receive an intravenous proton-pump inhibitor bolus (at a dose of 80 mg) followed by a continuous infu-sion (8 mg per hour) for 72 hours.8,11,16 A meta-analysis of randomized trials showed that this strategy, as compared with endoscopic therapy alone, significantly reduced risks of further bleeding, the need for surgery, and mortality.26However, a recent meta-analysis showed that intermittent oral or intravenous proton-pump inhibitor therapy resulted in outcomes that were noninferior to those after continuous infusion30; this suggests that intermittent proton-pump in-hibitor may be used in place of continuous infu-sion.11 The most appropriate intermittent dosing is not known, but an initial oral or intravenous bolus of 80 mg followed by 40 to 80 mg twice daily for 72 hours has been suggested.11Early studies suggested that rebleeding was uncommon more than 3 days after endoscopy, so patients who present with ulcers and high-risk endoscopic findings typically are hospitalized for 3 days after endoscopy if they have no fur-ther bleeding and no other reasons for hospital-ization. However, in a systematic review of five randomized trials in which patients received endoscopic therapy and infusion of high-dose proton-pump inhibitors, among patients who had rebleeding (overall rate, 11% over 30 days), rebleeding occurred after 3 days in 44% of pa-tients and after 7 days in 24%.31 Nevertheless, anticipation that a small number of patients may have rebleeding in the coming weeks does not justify hospitalization for more than 3 days in patients who are in stable condition and do not have other medical problems. Patients should be',\n",
       " 'have rebleeding in the coming weeks does not justify hospitalization for more than 3 days in patients who are in stable condition and do not have other medical problems. Patients should be informed about symptoms of recurrent upper gastrointestinal bleeding and the need to return to the emergency department if any occur.After discharge, patients who presented with high-risk endoscopic findings and clinical fac-tors (hemodynamic instability, older age, or a major coexisting condition) should receive twice-daily proton-pump inhibitor therapy for 2 weeks, followed by a proton-pump inhibitor once daily. Figure 2. Endoscopic Hemostatic Therapies.Panel A shows an injection catheter with the retractable needle extruded and the needle placed into the base of the ulcer next to the visible vessel. The visible vessel marks the site from which the ulcer bled and is asso-ciated with a high risk of recurrent bleeding. Panel B shows a thermal probe being applied to the visible vessel in the ulcer base. Panel C shows closed clips on either side of the visible vessel in the ulcer base and an open clip over the visible vessel. The open clip is about to be closed on the visible vessel.InjectioncatheterUlcerbaseVisiblevesselB  Thermal TherapyC  ClippingbaseThermalprobeOpenclipClosedclipClosedclipclipClosedClosedA  InjectioncatheterThe New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.BThenelThepFEnnietion',\n",
       " 'n engl j med 374;24\\u2003 nejm.org\\u2003 June 16, 20162372The new engl and jour nal of medicineA trial compared once-daily with twice-daily proton-pump inhibitor dosing for 11 days (fol-lowed in both groups by 2 weeks of treatment with a proton-pump inhibitor once daily) in high-risk patients who had undergone infusion of a proton-pump inhibitor for 3 days.32 This trial showed a significantly lower rate of ulcer rebleed-ing with twice-daily therapy than with once-daily therapy (11% vs. 29%).Patients with low-risk clinical features (a nor-mal heart rate and blood pressure and no major coexisting conditions), low-risk endoscopic find-ings (clean-base ulcers, erosions, or nonbleeding Mallory–Weiss tears), and outpatient support can be discharged home after endoscopy, and a regu-lar diet can be resumed33 (Fig.\\xa0 1). Once-daily proton-pump inhibitor therapy is recommended in patients with erosions or ulcers without high-risk endoscopic features.16Prevention of Recurrent Ulcer BleedingRebleeding is common after ulcer healing if strategies to prevent recurrence are not used. For example, a systematic review of studies with a 12-month follow-up showed a 26% rebleeding rate among patients with H. pylori–associated bleeding ulcers who did not receive treatment for H. pylori infection.34Strategies to prevent recurrent ulcer bleeding depend on the cause of the ulcer. The three major causes are H. pylori infection, the use of NSAIDs (including aspirin), and an idiopathic cause (Fig.\\xa03).H. pylori InfectionPatients with H. pylori infection should receive therapy to eradicate the bacteria. A meta-analy-sis of randomized trials of such therapy showed significantly less rebleeding in patients who re-ceived this therapy than in patients who did not receive treatment for H. pylori infection and in those who received maintenance antisecretory therapy.34Eradication of H. pylori should be confirmed after therapy with a breath test, a stool test, or,',\n",
       " 'those who received maintenance antisecretory therapy.34Eradication of H. pylori should be confirmed after therapy with a breath test, a stool test, or, if repeat endoscopy is performed for another reason, gastric biopsy. Patients must not receive bismuth or antibiotics for at least 4 weeks and should not receive proton-pump inhibitors for at least 2 weeks before testing to avoid false nega-tive results; histamine H2-receptor antagonists are permissible. In a systematic review of studies with a mean follow-up of 11 to 53 months,34 the incidence of rebleeding was only 1.3% among patients with confirmed eradication of H. pylori.NSAIDs Other Than Low-Dose AspirinPatients who have bleeding ulcers while taking NSAIDs should discontinue NSAIDs permanently if possible. If NSAIDs must be resumed, a com-bination of a cyclooxygenase-2 (COX-2)–selective NSAID and a proton-pump inhibitor is recom-mended. Studies have shown rates of rebleeding of 4 to 6% within 6 months among patients who had a bleeding ulcer and were subsequently treated with COX-2–selective NSAIDs alone or traditional NSAIDs plus a proton-pump inhibi-tor.36-38 A 12-month double-blind trial showed significantly less ulcer rebleeding with a COX-2–selective NSAID plus a proton-pump inhibitor than with a COX-2–selective NSAID alone (0 vs. 9%).39Low-Dose AspirinDecisions regarding continuation of low-dose aspirin (50 to 325 mg daily) for prevention of cardiovascular events should be based on wheth-er the therapy is for primary or secondary preven-tion. When used for primary prevention, aspirin has been shown to result in significant but small reductions in the absolute risk of cardiovascular events; the estimated number needed to treat to prevent one myocardial infarction, stroke, or vascular death is 1745.40 The risk of recurrent upper gastrointestinal bleeding probably out-weighs the potential benefit of resuming pri-mary prevention in most patients.',\n",
       " 'vascular death is 1745.40 The risk of recurrent upper gastrointestinal bleeding probably out-weighs the potential benefit of resuming pri-mary prevention in most patients.In contrast, the absolute reduction in cardio-vascular events is much greater when aspirin is used for secondary prevention (estimated num-ber needed to treat, 67).41 A randomized trial involving patients with bleeding ulcers and high-risk endoscopic features who were taking low-dose aspirin for secondary prevention compared resumption of aspirin use within 24 hours ver-sus withholding aspirin for 8 weeks.42 Patients assigned to prompt resumption of aspirin, as compared with those in whom aspirin was with-held, had no significant increase in the risk of rebleeding and had significantly lower mortality at 30 days (1% vs. 9%) and 8 weeks (1% vs. 13%). The risk of cardiovascular events may increase within 1 to 2 weeks after discontinuing aspirin The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 374;24\\u2003 nejm.org\\u2003 June 16, 20162373Clinical Practiceused for secondary prevention43,44; thus, aspirin should be resumed 1 to 7 days after bleeding stops.8,11,45 Cotherapy with a proton-pump in-hibitor also should be administered to reduce rebleeding.8,45,46Combined H. pylori Infection and NSAID UseIn patients who have received NSAIDs and who are found to have H. pylori infection, both eradi-cation of H. pylori infection and discontinuation of NSAIDs are recommended. Randomized trials have compared outcomes of treatment for H. py-lori infection with the use of a proton-pump in-hibitor (omeprazole at a dose of 20 mg daily) in H. pylori–positive patients who had upper gastro-intestinal bleeding while taking low-dose aspi-rin or an NSAID other than aspirin. Among pa-tients who had bleeding while taking an NSAID and received naproxen after ulcer healing, re-bleeding occurred by 6 months in 19% after treatment for H. pylori infection and in 4% of patients who received maintenance therapy with a proton-pump inhibitor.36 In contrast, among patients who had bleeding while taking low-dose aspirin and resumed low-dose aspirin after ulcer healing, rebleeding occurred by 6 months in 2% and 1%, respectively; this suggests that eradication of H. pylori infection may reduce risk among patients who receive low-dose aspirin (although no placebo group was included).36Figure 3. Long-Term Treatment of Patients with Bleeding Ulcers, According to the Cause of the Ulcer.Patients with Helicobacter pylori infection who receive low-dose aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) require interventions for both causes. Two first-line therapies (both administered for 14 days) are recom-mended for H. pylori infection if local patterns of clarithromycin resistance or eradication rates with triple therapy are not known: bismuth-containing quadruple therapy and concomitant (non–bismuth-containing quadruple) ther\\xad',\n",
       " 'are not known: bismuth-containing quadruple therapy and concomitant (non–bismuth-containing quadruple) ther\\xadapy.35 Bismuth-containing quadruple therapy is a PPI at a dose of 20 to 40 mg twice daily, bismuth (bismuth sub-salicylate at a dose of 262 mg, 2 tablets four times a day; colloidal bismuth subcitrate at a dose of 120 mg, 2 tablets twice daily or 1 tablet four times a day; bismuth biskalcitrate at a dose of 140 mg, 3 tablets four times a day; or bis-muth subcitrate potassium at a dose of 140 mg as part of combination tablets, 3 tablets four times a day), metroni-dazole at a dose of 500 mg three times a day or 400 mg four times a day, and tetracycline 500 mg four times a day. Concomitant (non–bismuth-containing quadruple) therapy is a PPI at a dose of 20 to 40 mg twice daily, amoxicillin at a dose of 1 g twice daily, clarithromycin at a dose of 500 mg twice daily, and metronidazole at a dose of 500 mg twice daily. Triple therapy (e.g., a PPI at a dose of 20 to 40 mg twice daily, amoxicillin 1 g twice daily, and clarithro-mycin at a dose of 500 mg twice daily, all administered for 14 days) should only be used in geographic areas where the prevalence of clarithromycin-resistant H. pylori is known to be less than 15% or the eradication rate is known to be greater than 85%.Continue PPI therapyin the long termIdiopathic causeTherapy for H. pyloriinfectionH. pylori infectionDiscontinue NSAIDsDocument cure ofH. pylori infectionand discontinueantisecretory therapyIf NSAIDs are resumed,use COX-2–selectiveNSAID+PPINSAIDs (other thanlow-dose aspirin)Low-dose aspirin forprevention of cardio-vascular eventsSecondary preventionPrimary preventionResume aspirin 1–7days after bleedingstops in most patientsand continue PPItherapy in thelong termDiscontinue aspirinpermanently inmost patientsThe New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.',\n",
       " 'long termDiscontinue aspirinpermanently inmost patientsThe New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 374;24\\u2003 nejm.org\\u2003 June 16, 20162374The new engl and jour nal of medicineHowever, treatment with a proton-pump inhibi-tor is still recommended if aspirin is continued. A 12-month randomized trial involving H. pylori–positive patients with ulcer complications who were receiving low-dose aspirin showed that even after eradication of H. pylori infection, ulcer rebleeding was significantly less frequent with a proton-pump inhibitor than with a placebo (2% vs. 15%).46Idiopathic UlcerAn observational study47 showed a 42% incidence of rebleeding at 7 years among patients who did not have H. pylori infection, use NSAIDs, or have another uncommon identified cause of an ulcer (e.g., the Zollinger–Ellison syndrome or neo-plasm) and who did not receive gastroprotective therapy. Thus, these patients should continue to receive once-daily maintenance therapy with a proton-pump inhibitor.8,16Areas of UncertaintyData from studies of new endoscopic tools such as Doppler ultrasonography (to assess bleeding risk and the adequacy of endoscopic therapy) and application of powders or cryotherapy (for hemostasis) are insufficient to establish the role of these tools in clinical practice. The appropri-ate dosing of proton-pump inhibitors to treat ul-cers in patients with high-risk findings requires further study. In addition, more data are needed to guide the choice between interventional radio-logic and surgical treatment in patients in whom endoscopic therapy has failed. Observational studies show associations between proton-pump inhibitors and adverse outcomes (e.g., dementia, chronic kidney disease, cardiovascular events, fractures, pneumonia, and enteric infections).48-50 The strengths of these associations are generally modest (odds ratios or hazard ratios <2 except for enteric infections), and it is not known whether they are causal.48-50 In patients with a prior bleeding ulcer, the documented benefit of proton-pump inhibitors outweighs the small and',\n",
       " 'for enteric infections), and it is not known whether they are causal.48-50 In patients with a prior bleeding ulcer, the documented benefit of proton-pump inhibitors outweighs the small and uncertain risks.GuidelinesGuidelines for the management of upper gastro-intestinal bleeding have been published by U.S. and international professional societies.8,11,15,17 The recommendations in this article are gener-ally concordant with these guidelines. Only the European Society of Gastrointestinal Endoscopy guideline,11 which was published after the meta-analysis comparing intermittent with continuous proton-pump inhibitors30 became available, sug-gests consideration of intermittent rather than continuous proton-pump inhibitors for bleeding ulcers in patients with high-risk endoscopic findings.Conclusions and RecommendationsUlcer bleeding is the most likely cause of upper gastrointestinal bleeding in the patient described in the vignette. Her aspirin use may have caused a new ulcer or may have induced bleeding from a preexisting lesion (e.g., an H. pylori–related ulcer).I would initiate an intravenous normal saline infusion and recheck the patient’s hemoglobin level after volume resuscitation. I would perform endoscopy the next morning, within 12 hours after presentation because of the patient’s initial hypotension. If an ulcer is detected, I would perform endoscopic therapy for active bleeding or a nonbleeding visible vessel, perform biopsies of the gastric mucosa to detect H. pylori, initiate treatment with a proton-pump inhibitor, and discontinue aspirin given the patient’s low car-diovascular risk. If H. pylori was not present, I would prescribe a proton-pump inhibitor for 6 to 8 weeks. If H. pylori was detected, I would pre-scribe therapy for H. pylori infection for 2 weeks, followed by 2 to 4 weeks of a proton-pump in-hibitor. I would confirm eradication of the infec-tion by retesting for H. pylori after switching the',\n",
       " 'scribe therapy for H. pylori infection for 2 weeks, followed by 2 to 4 weeks of a proton-pump in-hibitor. I would confirm eradication of the infec-tion by retesting for H. pylori after switching the patient’s treatment to a histamine H2-receptor antagonist for 2 weeks. If H. pylori infection was eradicated (or was never present) and the patient agreed not to use aspirin and other NSAIDs, I would discontinue antisecretory medications.Dr. Laine reports receiving fees for serving on data and safety monitoring boards from Bayer and Pharmaceutical Product De-velopment (a contract research organization that oversaw trials sponsored by Eisai), and providing a review for a law firm repre-senting Mylan in a patent-litigation case regarding formulation of a pill combining an NSAID and a proton-pump inhibitor. No other potential conflict of interest relevant to this article was reported.Disclosure forms provided by the author are available with the full text of this article at NEJM.org.The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 374;24\\u2003 nejm.org\\u2003 June 16, 20162375Clinical PracticeReferences1. Peery AF, Crockett SD, Barritt AS, et al. Burden of gastrointestinal, liver, and pan-creatic diseases in the United States. Gas-troenterology 2015;\\u200b149(7):\\u200b1731-1741.e3.2. Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009;\\u200b104:\\u200b1633-41.3. Abougergi MS, Travis AC, Saltzman JR. The in-hospital mortality rate for up-per GI hemorrhage has decreased over  2 decades in the United States: a nation-wide analysis. Gastrointest Endosc 2015;\\u200b81(4):\\u200b882-888.e1.4. Laine L, Yang H, Chang SC, Datto C. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol 2012;\\u200b107:\\u200b1190-5.5. Hearnshaw SA, Logan RFA, Lowe D, Travis SPL, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and out-comes in the 2007 UK audit. Gut 2011;\\u200b60:\\u200b1327-35.6. Nahon S, Hagège H, Latrive JP, et al. Epidemiological and prognostic factors involved in upper gastrointestinal bleed-ing: results of a French prospective multi-center study. Endoscopy 2012;\\u200b44:\\u200b998-1008.7. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;\\u200b38:\\u200b316-21.8. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastro-enterol 2012;\\u200b107:\\u200b345-60.9. Stanley AJ, Ashley D, Dalton HR, et al. Outpatient management of patients with low-risk upper-gastrointestinal haemor-rhage: multicentre validation and pro-spective evaluation. Lancet 2009;\\u200b373:\\u200b 42-7.10. Laursen SB, Dalton HR, Murray IA, et al. Performance of new thresholds of the Glasgow Blatchford score in managing patients with upper gastrointestinal bleed-ing. Clin Gastroenterol Hepatol 2015;\\u200b13(1):\\u200b115-121.e2.',\n",
       " 'al. Performance of new thresholds of the Glasgow Blatchford score in managing patients with upper gastrointestinal bleed-ing. Clin Gastroenterol Hepatol 2015;\\u200b13(1):\\u200b115-121.e2.11. Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemor-rhage: European Society of Gastrointesti-nal Endoscopy (ESGE) Guideline. Endos-copy 2015;\\u200b47(10):\\u200ba1-46.12.Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;\\u200b368:\\u200b11-21.13. Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2012;\\u200b157:\\u200b49-58.14. Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010;\\u200b7:\\u200bCD005415.15. Hwang JH, Fisher DA, Ben-Menachem T, et al. The role of endoscopy in the man-agement of acute non-variceal upper GI bleeding. Gastrointest Endosc 2012;\\u200b75:\\u200b1132-8.16. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommenda-tions on the management of patients with nonvariceal upper gastrointestinal bleed-ing. Ann Intern Med 2010;\\u200b152:\\u200b101-13.17. National Institute for Health and Clin-ical Excellence. Acute upper gastrointesti-nal bleeding: management. London:\\u200b Na-tional Clinical Guideline Centre at the Royal College of Physicians, 2012.18.Bai Y, Guo JF, Li ZS. Meta-analysis: erythromycin before endoscopy for acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 2011;\\u200b34:\\u200b166-71.19. Cooper GS, Chak A, Connors AF Jr, Harper DL, Rosenthal GE. The effective-ness of early endoscopy for upper gastro-intestinal hemorrhage: a community-based analysis. Med Care 1998;\\u200b36:\\u200b462-74.20.Wysocki JD, Srivastav S, Winstead NS. A nationwide analysis of risk factors for mortality and time to endoscopy in upper',\n",
       " 'analysis. Med Care 1998;\\u200b36:\\u200b462-74.20.Wysocki JD, Srivastav S, Winstead NS. A nationwide analysis of risk factors for mortality and time to endoscopy in upper gastrointestinal haemorrhage. Aliment Pharmacol Ther 2012;\\u200b36:\\u200b30-6.21.Lee JG, Turnipseed S, Romano PS, et al. Endoscopy-based triage significantly reduces hospitalization rates and costs of treating upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 1999;\\u200b50:\\u200b755-61.22.Bjorkman DJ, Zaman A, Fennerty MB, Lieberman D, Disario JA, Guest-Warnick G. Urgent vs. elective endoscopy for acute non-variceal upper-GI bleeding: an effec-tiveness study. Gastrointest Endosc 2004;\\u200b60:\\u200b1-8.23.Lim LG, Ho KY, Chan YH, et al. Ur-gent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleed-ing. Endoscopy 2011;\\u200b43:\\u200b300-6.24.Lin HJ, Wang K, Perng CL, et al. Early or delayed endoscopy for patients with peptic ulcer bleeding: a prospective ran-domized study. J Clin Gastroenterol 1996;\\u200b22:\\u200b267-71.25.Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994;\\u200b331:\\u200b717-27.26.Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gas-troenterol Hepatol 2009;\\u200b7:\\u200b33-47.27. Enestvedt BK, Gralnek IM, Mattek N, Lieberman DA, Eisen G. An evaluation of endoscopic indications and findings re-lated to nonvariceal upper-GI hemorrhage in a large multicenter consortium. Gas-trointest Endosc 2008;\\u200b67:\\u200b422-9.28.Lau JYW, Sung JJY, Lam Y, et al. Endo-scopic retreatment compared with sur-gery in patients with recurrent bleeding after initial endoscopic control of bleed-ing ulcers. N Engl J Med 1999;\\u200b340:\\u200b751-6.29. Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a sys-tematic review and meta-analysis. Am J Gastroenterol 2006;\\u200b101:\\u200b848-63.30.Sachar H, Vaidya K, Laine L. Intermit-',\n",
       " 'Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a sys-tematic review and meta-analysis. Am J Gastroenterol 2006;\\u200b101:\\u200b848-63.30.Sachar H, Vaidya K, Laine L. Intermit-tent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers:  a systematic review and meta-analysis. JAMA Intern Med 2014;\\u200b174:\\u200b1755-62.31. El Ouali S, Barkun A, Martel M, Mag-gio D. Timing of rebleeding in high-risk peptic ulcer bleeding after successful hemo-stasis: a systematic review. Can J Gastro-enterol Hepatol 2014;\\u200b28:\\u200b543-8.32.Cheng HC, Wu CT, Chang WL, Cheng WC, Chen WY, Sheu BS. Double oral esomeprazole after a 3-day intravenous esomeprazole infusion reduces recurrent peptic ulcer bleeding in high-risk pa-tients: a randomised controlled study. Gut 2014;\\u200b63:\\u200b1864-72.33. Laine L, Cohen H, Brodhead J, Cantor D, Garcia F, Mosquera M. Prospective eval-uation of immediate versus delayed refeed-ing and prognostic value of endoscopy in patients with upper gastrointestinal hem-orrhage. Gastroenterology 1992;\\u200b102:\\u200b314-6.34.Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Muñoz E. Meta-analysis: Helicobacter pylori eradi-cation therapy vs. antisecretory non-eradi-cation therapy for the prevention of recur-rent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004;\\u200b19:\\u200b617-29.35. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treat-ment of Helicobacter pylori infection in adults. Gastroenterology 2016 April 18 (Epub ahead of print).36.Chan FKL, Chung SCS, Suen BY, et al. Preventing recurrent upper gastrointesti-nal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;\\u200b344:\\u200b967-73.37. Chan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac and omepra-zole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;\\u200b347:\\u200b2104-10.38.Lai KC, Chu KM, Hui WM, et al. Cele-',\n",
       " 'Celecoxib versus diclofenac and omepra-zole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;\\u200b347:\\u200b2104-10.38.Lai KC, Chu KM, Hui WM, et al. Cele-coxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005;\\u200b118:\\u200b1271-8.39. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 in-hibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007;\\u200b369:\\u200b1621-6.40.Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.',\n",
       " 'n engl j med 374;24\\u2003 nejm.org\\u2003 June 16, 20162376Clinical Practicenejm clinical practice centerExplore a new page designed specifically for practicing clinicians,  the NEJM Clinical Practice Center, at NEJM.org/clinical-practice-center.  Find practice-changing research, reviews from our Clinical Practice series,  a curated collection of clinical cases, and interactive features  designed to hone your diagnostic skills.of cardiovascular events in patients with-out clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J 2011;\\u200b162(1):\\u200b115-124.e2.41. Antithrombotic Trialists’ (ATT) Col-laboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;\\u200b373:\\u200b1849-60.42.Sung JJ, Lau JY, Ching JY, et al. Con-tinuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010;\\u200b152:\\u200b1-9.43. Biondi-Zoccai GG, Lotrionte M, Agos-toni P, et al. A systematic review and meta-analysis on the hazards of discon-tinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006;\\u200b27:\\u200b2667-74.44.Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for sec-ondary cardiovascular prevention — car-diovascular risks after its perioperative withdrawal versus bleeding risks with its continuation — review and meta-analy-sis. J Intern Med 2005;\\u200b257:\\u200b399-414.45. Bhatt DL, Scheiman J, Abraham NS,  et al. ACCF/ACG/AHA 2008 expert con-sensus document on reducing the gastro-intestinal risks of antiplatelet therapy and NSAID use: a report of the American Col-lege of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;\\u200b118:\\u200b1894-909.46.Lai KC, Lam SK, Chu KM, et al. Lanso-prazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;\\u200b346:\\u200b2033-8.',\n",
       " '46.Lai KC, Lam SK, Chu KM, et al. Lanso-prazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;\\u200b346:\\u200b2033-8.47. Wong GL, Wong VW, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009;\\u200b137:\\u200b525-31.48.Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gas-troenterol 2012;\\u200b28:\\u200b615-20.49. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016;\\u200b176:\\u200b238-46.50.Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepide-miological claims data analysis. JAMA Neurol 2016;\\u200b73:\\u200b410-6.Copyright © 2016 Massachusetts Medical Society.The New England Journal of MedicineDownloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only.  No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.',\n",
       " 'Management of Nonvariceal Upper Gastrointestinal Bleeding:Guideline Recommendations From the International Consensus GroupAlan N. Barkun, MD; Majid Almadi, MD; Ernst J. Kuipers, MD; Loren Laine, MD; Joseph Sung, MD; Frances Tse, MD;Grigorios I. Leontiadis, MD; Neena S. Abraham, MD; Xavier Calvet, MD; Francis K.L. Chan, MD; James Douketis, MD;Robert Enns, MD; Ian M. Gralnek, MD; Vipul Jairath, MD; Dennis Jensen, MD; James Lau, MD; Gregory Y.H. Lip, MD;Romaric Loffroy, MD; Fauze Maluf-Filho, MD; Andrew C. Meltzer, MD; Nageshwar Reddy, MD; John R. Saltzman, MD;John K. Marshall, MD; and Marc Bardou, MDDescription: This update of the 2010 International ConsensusRecommendations on the Management of Patients With Non-variceal Upper Gastrointestinal Bleeding (UGIB) reﬁnes previousimportant statements and presents new clinically relevantrecommendations.Methods: An international multidisciplinary group of expertsdeveloped the recommendations. Data sources included evi-dence summarized in previous recommendations, as well as sys-tematic reviews and trials identiﬁed from a series of literaturesearches of several electronic bibliographic databases from in-ception to April 2018. Using an iterative process, group mem-bers formulated key questions. Two methodologists preparedevidence proﬁles and assessed quality (certainty) of evidence rel-evant to the key questions according to the GRADE (Grading ofRecommendations Assessment, Development and Evaluation)approach. Group members reviewed the evidence proﬁles and,using a consensus process, voted on recommendationsanddeterminedthestrengthofrecommendationsasstrong or conditional.Recommendations: Preendoscopic management: The groupsuggests using a Glasgow Blatchford score of 1 or less to identifypatients at very low risk for rebleeding, who may not requirehospitalization. In patients without cardiovascular disease, thesuggested hemoglobin threshold for blood transfusion is less',\n",
       " 'patients at very low risk for rebleeding, who may not requirehospitalization. In patients without cardiovascular disease, thesuggested hemoglobin threshold for blood transfusion is lessthan 80 g/L, with a higher threshold for those with cardiovasculardisease. Endoscopic management: The group suggests that pa-tients with acute UGIB undergo endoscopy within 24 hours ofpresentation. Thermocoagulation and sclerosant injection arerecommended, and clips are suggested, for endoscopic therapyin patients with high-risk stigmata. Use of TC-325 (hemostaticpowder) was suggested as temporizing therapy, but not as soletreatment, in patients with actively bleeding ulcers. Pharmaco-logic management: The group recommends that patients withbleeding ulcers with high-risk stigmata who have had successfulendoscopic therapy receive high-dose proton-pump inhibitor(PPI) therapy (intravenous loading dose followed by continuousinfusion) for 3 days. For these high-risk patients, continued oralPPI therapy is suggested twice daily through 14 days, then oncedaily for a total duration that depends on the nature of thebleeding lesion. Secondary prophylaxis: The group suggests PPItherapy for patients with previous ulcer bleeding who re-quire antiplatelet or anticoagulant therapy for cardiovascu-lar prophylaxis.Ann Intern Med. 2019;171:805-822. doi:10.7326/M19-1795Annals.orgFor author afﬁliations, see end of text.This article was published at Annals.org on 22 October 2019.Acute upper gastrointestinal bleeding (UGIB) iscommon, but the annual incidence has been de-creasing: from 78 to 61 cases in 100 000 persons from2001 to 2009 in one survey (1). Nonetheless, 30-daymortality remains high, at up to 11% (2).The most recent guidelines for managing UGIBwere published primarily between 2010 and 2015,including those from our group (in 2003, with an up-date in 2010) (3, 4), the American College of Gastro-enterology (in 2012) (5), the American Society for',\n",
       " 'including those from our group (in 2003, with an up-date in 2010) (3, 4), the American College of Gastro-enterology (in 2012) (5), the American Society forGastrointestinal Endoscopy (in 2012) (6), the NationalInstitute for Health and Care Excellence (NICE) (in2012) (7), and the European Society of Gastrointesti-nal Endoscopy (in 2015) (8). More recently, guide-lines from the Asia-Paciﬁc Working Group were up-dated in 2018 (9).The management of UGIB has advanced withnew endoscopic techniques, and the pharmacologiclandscape has changed. Anticoagulant or antiplatelettherapy, including combination therapy, is becomingmore common, substantially increasing the risk forUGIB (10). Thus, the International Consensus Groupagreed that an update to the 2010 recommendationsfor the management of UGIB (4) was warranted.METHODSScope and PurposeSimilar to the 2003 (3) and 2010 (4) guidelines, thisupdate focuses on resuscitation and risk assessment;preendoscopic, endoscopic, and pharmacologic man-agement; and secondary prophylaxis for recurrentUGIB. Speciﬁc PICO (patient population, intervention,comparator, and outcome) questions were developedby the cochairs (A.N.B. and M.B.), steering committee(L.L., M.A., J.S., and E.J.K.), and GRADE (Grading ofRecommendationsAssessment,DevelopmentandEvaluation) methodologists (F.T. and G.I.L.) and ﬁnal-ized through a consensus process of iterative discus-sions with all other voting participants.See also:Editorial comment . . . . . . . . . . . . . . . . . . . . . . . . . 853Web-OnlySupplementCME/MOC activityAnnals of Internal MedicineCLINICAL GUIDELINE© 2019 American College of Physicians 805Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " 'Sources, Literature Searches, and SystematicReviewsSources included the evidentiary base of previousguidelines (3, 4) and English-language literaturesearches of MEDLINE, EMBASE (Elsevier), the Co-chrane Database of Systematic Reviews (Wiley), andthe Cochrane Central Register of Controlled Trials (Wi-ley) done by the editorial ofﬁce of the Cochrane UpperGastrointestinal and Pancreatic Diseases Group at Mc-Master University. Initial searches were conducted fromdatabase inception to 2 April 2018, with supplemental,focused searches to mid-May 2018. Key search termsand details of search strategies are shown in Supple-ment Appendix 1 (available at Annals.org). Conferenceabstracts, case reports, and studies in animals wereexcluded.Teams of reviewers (A.B., M.B., X.C., L.L., G.I.L., andF.T.) screened titles and abstracts in duplicate and in-dependently, and obtained full texts of potentially rel-evant studies. Reviewers also scanned bibliographiesof retrieved systematic reviews. The cochairs, steeringcommittee, and methodologists then selected the stud-ies relevant for each PICO question. Discrepancies re-garding inclusion were resolved by consensus.A modiﬁed version of AMSTAR-2 (A MeasurementTool to Assess Systematic Reviews) (11) was used as adecision tool to assess the methodological quality ofexisting systematic reviews. We selected the most re-cent of the well-conducted, relevant systematic reviewsas our baseline source. Selected reviews were usedwholly or partially (with only some of the following com-ponents: included studies, study characteristics, numer-ical data extractions, forest plots, or risk-of-bias tables)and were updated or improved as needed by addingnew studies, removing inappropriate studies, or furtherassessing the quality of the included studies (Supple-ment Appendix 2, available at Annals.org).Assessment of the Quality of EvidenceThe methodologists (F.T. and G.I.L.) assessed riskof bias, indirectness, inconsistency, imprecision, and',\n",
       " 'ment Appendix 2, available at Annals.org).Assessment of the Quality of EvidenceThe methodologists (F.T. and G.I.L.) assessed riskof bias, indirectness, inconsistency, imprecision, andother limitations (including publication bias) of the evi-dence by using the GRADE approach (12). Overallquality of evidence (QoE) was graded as very low, low,moderate, or high for each recommendation.Evidence proﬁles (GRADE tables) were preparedfor each PICO question and contained clear descrip-tions of beneﬁts and harms as well as a QoE rating forindividual outcomes. The proﬁles, systematic reviews,and meta-analyses were made available to voting par-ticipants 1 week before the consensus meeting (Sup-plement Appendix 2).One statement (A1) met the criteria for “good prac-tice” (13). The consensus group agreed that this recom-mendation was clinically obvious and that collectionand analysis of evidence were unnecessary.Consensus ProcessParticipantsinthemultidisciplinaryconsensusgroup were from 11 countries and included gastroen-terologists, a cardiologist, a hematologist, a radiologist,a surgeon, and an emergency medicine specialist. Themeeting included up to 20 voting participants for eachstatement (numbers varied, mainly because of traveldifﬁculties), 2 nonvoting GRADE methodologists, and anonvoting moderator (J.K.M).The cochairs, other steering committee members,and methodologists generated a list of new and oldstatements that were presented to the group throughan anonymous, Web-based consensus platform (ECDSolutions). Via teleconference, the steering committeemembers reached consensus on which statements war-ranted inclusion in the guideline by focusing on priorityareas. Using a modiﬁed Delphi process (14), all votingparticipants modiﬁed and ﬁnalized the new statements.After reviewing the evidence proﬁles, the participantsanonymously voted on their degree of agreement ordisagreement with each statement and submitted com-',\n",
       " \"After reviewing the evidence proﬁles, the participantsanonymously voted on their degree of agreement ordisagreement with each statement and submitted com-ments. Votes were nonbinding and designed to gaugethe extent of agreement and the pattern of evidenceuncertainty to guide the allotment of time for discus-sion during the meeting. The Canadian Association ofGastroenterology (CAG) ofﬁce tabulated the votes andcomments and presented the results to the group. Al-though initially discussed in the form of declarativestatements, these were edited into speciﬁc PICO ques-tions by the methodologists before the consensusmeeting.At a 2-day consensus meeting in May 2018, thegroup applied the GRADE Evidence to Decision frame-work to move from evidence to recommendations byassessing 7 key criteria: the balance between desirableand undesirable effects, quality (certainty) of the evi-dence, variability in patients' values and preferences,resource requirements, cost-effectiveness, acceptabil-ity, and feasibility (Supplement Appendix 2) (15–17).Participants voted on the direction of the PICO ques-tion (for or against) as yes, uncertain, or no. Consensusfor or against a speciﬁc strategy was reached if at least75% of the participants voted yes or no, respectively.For PICO questions on which agreement was reached,the group then discussed the strength of the recom-mendation (strong vs. conditional) by considering thefactors in the Evidence to Decision framework (18). Incases of low or very low QoE, unless at least 1 of theother 3 factors was overwhelmingly strong, the strengthof the recommendation would default (without a vote)to “conditional” by using the phrase “we suggest.” If thestatement warranted a vote and at least 75% of the par-ticipants voted “strong,” then the recommendationwould be designated as strong with the phrase “werecommend.”Consensus was not reached on 4 PICO questions(no recommendation A to D), because fewer than 75%\",\n",
       " 'would be designated as strong with the phrase “werecommend.”Consensus was not reached on 4 PICO questions(no recommendation A to D), because fewer than 75%of the participants voted either yes or no. No corre-sponding statements were developed for these ques-tions, but the pertinent evidence and discussions aresummarized brieﬂy in the text.Oversight and ReviewThe guideline process was overseen by the CAGclinical affairs committee to ensure methodologicalquality and a transparent, nonbiased, evidence-basedCLINICAL GUIDELINEManagement of Upper Gastrointestinal Bleeding806 Annals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019Annals.orgDownloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " 'decision-making process. Recommendations are basedon evidence from the literature and consensus discus-sion and may not fully reﬂect the product labeling for agiven country.The manuscript was initially drafted by the cochairs(A.N.B. and M.B.) and the GRADE experts (F.T. andG.I.L.). It was reviewed and revised by the steering com-mittee members (E.J.K., J.S., L.L., and M.A.) before dis-semination to the full consensus group for feedback.Finally, the manuscript was posted on the CAG Website, and members were invited via e-mail to submitcomments over a 2-week period.In accordance with CAG policy, written conﬂict-of-interest disclosures for the 24 months preceding theconsensus meeting were provided by all participantsand made available to the group.Role of the Funding SourceFunding for the consensus meeting was providedby unrestricted, arms-length grants to the CAG fromthe Institute of Nutrition, Metabolism and Diabetes ofthe Canadian Institutes of Health Research and theSaudi Gastroenterology Association. The CAG adminis-tered all aspects of the meeting; the funding sourceshad no involvement in, nor were they made aware of,any part of the process, from the development ofsearch strings and statements to drafting and approv-ing these guidelines.RECOMMENDATION STATEMENTS FOR UGIBEach statement is followed by the strength of evi-dence based on GRADE analyses and a discussion ofthe evidence. The voting results are shown in Table 1,along with summaries of the new recommendations es-tablished from this consensus, recommendations thatwere revised from the 2003 and 2010 guidelines (3, 4),and recommendations that were unchanged becausemost of the group believed that they currently did notrequire revision (3, 4).Section A: Resuscitation, Risk Assessment, andPreendoscopy ManagementStatement A1For patients with acute UGIB and hemodynamic in-stability, resuscitation should be initiated.(Designated a good practice statement.)',\n",
       " 'Preendoscopy ManagementStatement A1For patients with acute UGIB and hemodynamic in-stability, resuscitation should be initiated.(Designated a good practice statement.)Discussion. Fluid resuscitation should be initiatedin patients with UGIB and hemodynamic instability, be-cause hemorrhagic shock may lead to multiorgan fail-ure and death. The goals of ﬂuid resuscitation are torestore end-organ perfusion and tissue oxygenationwhile steps are taken to control bleeding.Uncertainty remains regarding the type of ﬂuid(colloid vs. crystalloid) and the rate and timing of resus-citation (aggressive vs. restrictive). A Cochrane system-atic review including 70 randomized controlled trialsfound no difference in mortality between critically illpatients who received colloids (albumin or plasma pro-tein fraction, hydroxyethyl starch, modiﬁed gelatin,dextran, colloids in hypertonic crystalloid, or colloids inisotonic crystalloid) and those who received crystalloids(normal saline, Ringer lactate, or hypertonic saline) forﬂuid resuscitation (19). One small randomized trial con-ducted in patients with UGIB who had hemorrhagicshock found no statistically signiﬁcant difference inmortality between hypertonic saline dextran and Ringerlactate (relative risk [RR], 0.18 [95% CI, 0.02 to 1.41])(20). A large trial, published after the systematic review,that included 2857 critically ill patients showed no dif-ference in 28-day mortality between those given col-loids and those who received crystalloids (21). The trialfound an unexpected borderline reduction in 90-daymortality among patients receiving colloids (RR, 0.92[CI, 0.86 to 0.99])—a ﬁnding that was considered hy-pothesis generating (21). Because current evidencedoes not show that colloids increase survival rates com-pared with crystalloids and because colloids are moreexpensive, the consensus group agreed that routineuse in clinical practice is not justiﬁed (19).Uncertainty also exists regarding the type of crys-',\n",
       " 'pared with crystalloids and because colloids are moreexpensive, the consensus group agreed that routineuse in clinical practice is not justiﬁed (19).Uncertainty also exists regarding the type of crys-talloid for use in ﬂuid resuscitation. A recent random-ized trial in 15 802 critically ill patients found a smallreduction in acute kidney injury (odds ratio [OR], 0.91[CI, 0.84 to 0.99]) and a possible small reduction in in-hospital mortality (10.3% vs. 11.1%; P = 0.08) with bal-anced crystalloids (such as Ringer lactate) vs. saline(22).Animal models have shown that early aggressiveﬂuid resuscitation to increase blood pressure to normalvalues may exacerbate blood loss, disrupt coagulation,and increase mortality (23, 24). The alternative is restric-tive or hypotensive resuscitation, in which ﬂuid is givenbut the target end point is less than normotension. ACochrane systematic review included 6 randomized tri-als that examined timing and volume of ﬂuid adminis-tration in 2128 patients with bleeding. Trials were het-erogeneous regarding patient types, clinical settings,types of ﬂuids, and resuscitation protocols (25). Nonefound restrictive ﬂuid resuscitation (with a delayed orsmaller volume of ﬂuid) to be inferior to more aggres-sive ﬂuid resuscitation (with an early or a larger volumeof ﬂuid) with regard to mortality (25). Two randomizedtrials published since the review also found no differ-ences in mortality between restrictive and aggressiveresuscitation in patients with trauma and hemorrhagicshock (26, 27). The consensus group agreed that theevidence was insufﬁcient to make a recommendationregarding restrictive ﬂuid resuscitation. The importantissue in patients with hemorrhagic shock due to traumaor UGIB is to stop the bleeding while minimizing hemo-dynamic compromise.Statement A2aFor patients with acute UGIB, we suggest using aGlasgow Blatchford score of 1 or less to identify pa-tients who are at very low risk for rebleeding or mor-',\n",
       " 'dynamic compromise.Statement A2aFor patients with acute UGIB, we suggest using aGlasgow Blatchford score of 1 or less to identify pa-tients who are at very low risk for rebleeding or mor-tality and thus may not require hospitalization or in-patient endoscopy.(GRADE: conditional recommendation, low-qualityevidence)Management of Upper Gastrointestinal BleedingCLINICAL GUIDELINEAnnals.orgAnnals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019 807Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " 'Table 1. Summary of Consensus Recommendations for the Management of UGIB*A. Resuscitation, risk assessment, and preendoscopy managementA1. For patients with acute UGIB and hemodynamic instability, resuscitation should be initiated.Designated a good practice statement (see PICO question 1 in Supplement Appendix 2, available at Annals.org)A2a. For patients with acute UGIB, we suggest using a Glasgow Blatchford score of ≤1 to identify patients who are at very low risk for rebleeding ormortality and thus may not require hospitalization or inpatient endoscopy.GRADE: conditional recommendation, low-quality evidence. Vote on PICO question: yes, 76%; uncertain/neutral, 18%; no, 6% (see PICO question 2 inSupplement Appendix 2)A2b. For patients with acute UGIB, we suggest against using the AIMS65 prognostic score to identify patients who are at very low risk for rebleeding ormortality and thus may not require hospitalization or inpatient endoscopy.GRADE: conditional recommendation, low-quality evidence. Vote on PICO question: no, 100% (see PICO question 2 in Supplement Appendix 2)A3. Consider placement of a nasogastric tube in selected patients because the ﬁndings may have prognostic value.†A4. In patients with acute UGIB without underlying cardiovascular disease, we suggest giving blood transfusions for those with a hemoglobin level<80 g/L.GRADE: conditional recommendation, low-quality evidence. Vote on PICO question: yes, 75%; uncertain/neutral, 15%; no, 10% (see PICO question3a in Supplement Appendix 2)A5. In patients with acute UGIB with underlying cardiovascular disease, we suggest giving blood transfusions at a higher hemoglobin threshold than forthose without cardiovascular disease.GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 80%; uncertain/neutral, 5%; no, 15% (see PICO question3b in Supplement Appendix 2)',\n",
       " 'GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 80%; uncertain/neutral, 5%; no, 15% (see PICO question3b in Supplement Appendix 2)A6. In patients with acute UGIB receiving anticoagulants (vitamin K antagonists, DOACs), we suggest not delaying endoscopy (with or without endoscopichemostatic therapy).GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 100% (see PICO question 4 in Supplement Appendix 2)A7. Promotility agents should not be used routinely before endoscopy to increase the diagnostic yield.‡A8. Selected patients with acute ulcer bleeding who are at low risk for rebleeding on the basis of clinical and endoscopic criteria may be dischargedpromptly after endoscopy.‡A9. Pre-endoscopic PPI therapy may be considered to downstage the endoscopic lesion and decrease the need for endoscopic intervention but shouldnot delay endoscopy.‡B. Endoscopic managementB1. Develop institution-speciﬁc protocols for multidisciplinary management. Include access to an endoscopist trained in endoscopic hemostasis.†B2. Have support staff trained to assist in endoscopy available on an urgent basis.†B3: For patients admitted with acute UGIB, we suggest performing early endoscopy (within 24 hours of presentation).GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 100% (see PICO question 5a in Appendix 2)B4. Endoscopic hemostatic therapy is not indicated for patients with low-risk stigmata (a clean-based ulcer or a nonprotuberant pigmented dot in an ulcerbed).†B5. A ﬁnding of a clot in an ulcer bed warrants targeted irrigation in an attempt at dislodgement, with appropriate treatment of the underlying lesion.‡B6. The role of endoscopic therapy for ulcers with adherent clots is controversial. Endoscopic therapy may be considered, although intensive PPI therapyalone may be sufﬁcient.‡',\n",
       " 'B6. The role of endoscopic therapy for ulcers with adherent clots is controversial. Endoscopic therapy may be considered, although intensive PPI therapyalone may be sufﬁcient.‡B7. Endoscopic hemostatic therapy is indicated for patients with high-risk stigmata (active bleeding or a visible vessel in an ulcer bed).†B8. Epinephrine injection alone provides suboptimal efﬁcacy and should be used in combination with another method.‡B9. No single method of endoscopic thermal coaptive therapy is superior to another.†B10a. For patients with acutely bleeding ulcers with high-risk stigmata, we recommend endoscopic therapy with thermocoagulation or sclerosantinjection.GRADE: strong recommendation, low-quality evidence. Vote on PICO question: yes, 94%; uncertain/neutral, 6% (see PICO question 6a1 in SupplementAppendix 2)B10b. For patients with acutely bleeding ulcers with high-risk stigmata, we suggest endoscopic therapy with (through-the-scope) clips.GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 94%; uncertain/neutral, 6% (see PICO question 6a2 inSupplement Appendix 2)B11a. In patients with actively bleeding ulcers, we suggest using TC-325 as a temporizing therapy to stop bleeding when conventional endoscopictherapies are not available or fail.GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 82%; uncertain/neutral, 18% (see PICO question 6b2 inSupplement Appendix 2)B11b. In patients with actively bleeding ulcers, we suggest against using TC-325 as a single therapeutic strategy vs. conventional endoscopic therapy(clips alone, thermocoagulation alone, or combination therapy).GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 12%; uncertain/neutral, 12%; no, 76% (see PICO question6b1 in Supplement Appendix 2)B12. Routine second-look endoscopy is not recommended.‡B13. A second attempt at endoscopic therapy is generally recommended in cases of rebleeding.†',\n",
       " '6b1 in Supplement Appendix 2)B12. Routine second-look endoscopy is not recommended.‡B13. A second attempt at endoscopic therapy is generally recommended in cases of rebleeding.†C. Pharmacologic managementC1. H2RAs are not recommended for patients with acute ulcer bleeding.†C2. Somatostatin and octreotide are not routinely recommended for patients with acute ulcer bleeding.†C3. For patients with bleeding ulcers with high-risk stigmata who have undergone successful endoscopic therapy, we recommend using PPI therapy viaintravenous loading dose followed by continuous intravenous infusion (as opposed to no treatment or H2RAs).GRADE: strong recommendation, moderate-quality evidence. Vote on PICO question: yes, 100% (see PICO question 8a in Supplement Appendix 2)C4. For patients who present with ulcer bleeding at high risk for rebleeding (that is, an ulcer requiring endoscopic therapy followed by 3 days ofhigh-dose PPI therapy), we suggest using twice-daily oral PPIs (vs. once-daily) through 14 days, followed by once daily.GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 95%; uncertain/neutral, 5% (see PICO question 10 inSupplement Appendix 2)C5. Patients should be discharged with a prescription for a single daily-dose oral PPI for a duration as dictated by the underlying cause.‡Continued on following pageCLINICAL GUIDELINEManagement of Upper Gastrointestinal Bleeding808 Annals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019Annals.orgDownloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " 'No Recommendation AFor patients with acute UGIB, the consensus groupcould not make a recommendation for or against usingthe preendoscopic Rockall prognostic scale to identifypatients who are at very low risk for rebleeding or mor-tality and thus may not require hospitalization or inpa-tient endoscopy.(GRADE for PICO: very low-quality evidence)Statement A2bFor patients with acute UGIB, we suggest againstusing the AIMS65 prognostic score to identify patientswho are at very low risk for rebleeding or mortalityand thus may not require hospitalization or inpatientendoscopy.(GRADE: conditional recommendation, low-qualityevidence)Key Evidence.Evidence proﬁles for the 3 best-studied prognostic scores (Glasgow Blatchford [GBS],preendoscopic Rockall, and AIMS65) were consideredseparately. The QoE review focused on studies that as-sessed the use of preendoscopic scoring systems toidentify patients at very low risk for undesirable out-comes. No randomized trials that directly assessed theclinical impact of using versus not using prognosticscales were identiﬁed. Therefore, the evidence was de-rived from “before–after” studies (28) and studies of di-agnostic test accuracy that assessed the surrogate out-come of diagnostic (prognostic) accuracy of the scales.A beforeafter study by Stanley and colleagues(28) assessed a strategy of not admitting emergencyTable 1—ContinuedD. Nonendoscopic and nonpharmacologic in-hospital managementD1. Patients at low risk after endoscopy can be fed within 24 hours.†D2. Most patients who have undergone endoscopic hemostasis for high-risk stigmata should be hospitalized for at least 72 hours thereafter.‡D3. Seek surgical consultation for patients for whom endoscopic therapy has failed.†D4. Where available, percutaneous embolization can be considered as an alternative to surgery for patients for whom endoscopic therapy has failed.‡',\n",
       " 'D4. Where available, percutaneous embolization can be considered as an alternative to surgery for patients for whom endoscopic therapy has failed.‡D5. Patients with bleeding peptic ulcers should be tested for Helicobacter pylori and receive eradication therapy if it is present, with conﬁrmation oferadication.‡D6. Negative H pylori diagnostic tests obtained in the acute setting should be repeated.‡E. Secondary prophylaxis§E1. In patients with previous ulcer bleeding who require an NSAID, it should be recognized that treatment with a traditional NSAID plus a PPI or COX-2inhibitor alone is still associated with a clinically important risk for recurrent ulcer bleeding.‡E2. In patients with previous ulcer bleeding who require an NSAID, the combination of a PPI and a COX-2 inhibitor is recommended to reduce the risk forrecurrent bleeding from that of COX-2 inhibitors alone.‡E3. In patients who receive low-dose ASA and develop acute ulcer bleeding, ASA therapy should be restarted as soon as the risk for cardiovascularcomplication is thought to outweigh the risk for bleeding.‡E4. In patients with previous ulcer bleeding receiving cardiovascular prophylaxis with single- or dual-antiplatelet therapy, we suggest using PPI therapy vs.no PPI therapy.GRADE: conditional recommendation, low-quality evidence. Vote on PICO question (single): yes, 95%; uncertain/neutral: 5%. Vote on PICO question(double): yes, 100% (see PICO questions 9a and 9c in Supplement Appendix 2)E5. In patients with previous ulcer bleeding requiring continued cardiovascular prophylaxis with anticoagulant therapy (vitamin K antagonists, DOACs), wesuggest using PPI therapy vs. no PPI therapy.GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 85%; uncertain/neutral, 15% (see PICO question 9b inSupplement Appendix 2)No recommendation statements',\n",
       " 'GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 85%; uncertain/neutral, 15% (see PICO question 9b inSupplement Appendix 2)No recommendation statementsNo recommendation A: For patients with acute UGIB, the consensus group could not make a recommendation for or against using the preendoscopicRockall prognostic scale to identify patients who are at very low risk for rebleeding or mortality and thus may not require hospitalization or inpatientendoscopy.GRADE: no recommendation, very low-quality evidence. Vote on PICO question: yes, 12%; uncertain/neutral, 18%; no, 71% (see PICO question 2 inSupplement Appendix 2)No recommendation B: For patients with acute UGIB at high risk for rebleeding or mortality, the consensus group could not make a recommendation foror against performing endoscopy within 12 hours vs. performing endoscopy later.GRADE: no recommendation, very low-quality evidence. Vote on PICO question: yes, 41%; uncertain/neutral, 47%; no, 12% (see PICO question 5b inSupplement Appendix 2)No recommendation C: In patients with acutely bleeding ulcers who have undergone endoscopic therapy, the consensus group could not make arecommendation for or against using DEP vs. no DEP to assess the need for further endoscopic therapy.GRADE: no recommendation, very low-quality evidence. Vote on PICO question: yes, 47%; uncertain/neutral, 41%; no, 12% (see PICO question 7 inSupplement Appendix 2)No recommendation D: For patients with bleeding ulcers with high-risk stigmata who have undergone successful endoscopic therapy, the consensusgroup could not make a recommendation for or against using non–high-dose PPI therapy (as opposed to no treatment or H2RAs).GRADE: no recommendation, very low-quality evidence. Vote on PICO question: yes, 24%; uncertain/neutral, 47%; no, 29% (see PICO question 8b inSupplement Appendix 2)',\n",
       " \"GRADE: no recommendation, very low-quality evidence. Vote on PICO question: yes, 24%; uncertain/neutral, 47%; no, 29% (see PICO question 8b inSupplement Appendix 2)ASA = acetylsalicylic acid; COX-2 = cyclooxygenase-2; DEP = Doppler endoscopic probe; DOAC = direct oral anticoagulant; GRADE = Grading ofRecommendations Assessment, Development and Evaluation; H2RA = H2-receptor antagonist; NSAID = nonsteroidal anti-inﬂammatory drug; PICO =patient population, intervention, comparator, and outcome; PPI = proton-pump inhibitor; UGIB = upper gastrointestinal bleeding.* The strength of each recommendation was assigned by the consensus group, according to the GRADE system, as strong (“we recommend...”) orconditional (“we suggest...”) on the basis of 4 components: QoE, beneﬁt–harm balance, patients' values and preferences, and resource require-ments (18). However, when quality of evidence was low or very low, the strength of the recommendation would typically default (without a vote) toconditional, unless at least 1 of the other 3 factors was overwhelmingly strong.† Recommendation unchanged from the 2003 guidelines. See reference 3 for supporting evidence and discussions.‡ Recommendation unchanged from the 2010 guidelines. See reference 4 for supporting evidence and discussions.§ Section was titled “Postdischarge, ASA, and NSAIDs” in the 2010 consensus recommendations (4). Voting threshold of ≥75 for either yes or no was not reached.Management of Upper Gastrointestinal BleedingCLINICAL GUIDELINEAnnals.orgAnnals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019 809Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.\",\n",
       " 'department patients with UGIB who were predicted tobe at very low risk for undesirable outcomes (GBS of 0).This reduced the number of hospitalization, and no dif-ference was demonstrated in safety outcomes, al-though the study was not powered for safety outcomes.The relevant evidence included 2 high-quality sys-tematic reviews and meta-analyses of studies of diag-nostic test accuracy (7, 29) as well as 2 additional stud-ies notable for their quality and sample sizes (30, 31).The sensitivity of low cutoff values for detecting pa-tients at high risk for undesirable clinical outcomes wasvery good for the GBS (0.99) and preendoscopic Rock-all score (range, 0.93 to 0.96, but with more heteroge-neity), and lower for AIMS65 (range, 0.78 to 0.82) (Ap-pendix Table 1, available at Annals.org) (7, 29–31).For the GBS and AIMS65, the QoE was low, withthe evidence being downgraded for indirectness, im-precision, and inconsistency. For the preendoscopicRockall score, QoE was very low, with the evidence be-ing downgraded for the same reasons plus risk of bias.Discussion. Use of prognostic scales and early dis-charge of patients at low risk have the potential to re-duce the need for endoscopy, hospital stays, and asso-ciated costs without increasing harms. Sensitivity fordetecting high-risk patients is a critical outcome, be-cause it is important to avoid incorrectly classifying highrisk as low risk when making decisions about early dis-charge. Speciﬁcity is less crucial, because low speciﬁc-ity results in more low-risk patients being hospitalizedbut not in high-risk patients being discharged. Patientpreferences also should be considered; some patientsmay prefer diagnostic certainty, whereas others mayprefer not to be hospitalized. Other factors when con-sidering early discharge include urban versus rural en-vironment, access to hospital or ambulance services,access to out-of-hours endoscopy, and reimbursementissues.Whether using a prognostic scale results in better',\n",
       " 'vironment, access to hospital or ambulance services,access to out-of-hours endoscopy, and reimbursementissues.Whether using a prognostic scale results in betterpatient outcomes than using clinical judgment alone isnot known. Because clinical judgment cannot be stan-dardized, the consensus group agreed that use of aprognostic scoring system would help ensure consis-tent risk assessment and communication. Education isnow needed to embed a scoring tool into clinical prac-tice (such as in electronic medical records).The consensus group suggests the GBS as the pre-ferred prognostic tool because of its high sensitivity(misclassifying ≤1% of high-risk patients as low risk).The preendoscopic Rockall scale has good sensitivity,but it may misclassify 4% to 7% of high-risk patients.Given differing views regarding the threshold sensitiv-ity for discharge, the consensus group could not makea recommendation for or against use of the pre-endoscopic Rockall score.The AIMS65 was designed to be used with highcutoff values to identify patients at high risk for death(32) rather than those at low risk for safe discharge. Theconsensus group suggested not using AIMS65 in thissetting, because even at low cutoff values approxi-mately 20% of high-risk patients may be misclassiﬁedas low risk.Statement A4In patients with acute UGIB without underlying car-diovascular disease, we suggest giving blood transfu-sions for those with a hemoglobin level less than 80 g/L.(GRADE: conditional recommendation, low-qualityevidence)Key Evidence. Evidence for a hemoglobin thresh-old for the effectiveness and safety of red blood celltransfusions was available from a summary of studiescomparing restrictive (70 to 80 g/L) versus liberal (90 to100 g/L) transfusion thresholds for patients with acuteUGIB (33).In the systematic review of 5 randomized con-trolled trials in patients with UGIB (n = 1965), restrictivetransfusion was associated with a lower risk for all-',\n",
       " 'UGIB (33).In the systematic review of 5 randomized con-trolled trials in patients with UGIB (n = 1965), restrictivetransfusion was associated with a lower risk for all-cause mortality (RR, 0.65 [CI, 0.45 to 0.97]) and furtherbleeding (RR, 0.58 [CI, 0.40 to 0.84]) (33) (AppendixTable 2, available at Annals.org). No subgroup differ-ences were found with regard to risks for myocardialinfarction, stroke or transient ischemic attack, or acutekidney injury (33), or to the rate of surgical or radiologicintervention between the 2 strategies (34, 35). Thesedata were downgraded for serious risk of bias and se-rious indirectness. However, the QoE for the superiorityof the restrictive transfusion strategy is higher (less in-directness) than the QoE for speciﬁc thresholds oftransfusion.Two other systematic reviews and meta-analysesthat provided supportive data on patients in variousclinical settings (cardiac surgery, orthopedic surgery,vascular surgery, acute blood loss or trauma, criticalcare, acute myocardial infarction, and hematologic can-cer) including UGIB, found no difference in 30-day mor-tality, rebleeding, cardiac events, myocardial infarction,or stroke between the 2 strategies in the combined pa-tient groups (36, 37).Discussion.The data suggest that a restrictivetransfusion strategy is beneﬁcial in patients with UGIB(33) and is not associated with adverse events (36, 37).The restrictive threshold led to a decrease in the pro-portion of patients exposed to transfusions (36, 37) andin the mean number of units transfused (33). A studyassessing direct and indirect costs reported that the to-tal cost per red blood cell unit in 2008 was approxi-mately $760 (38). Although cost per unit may varygreatly across institutions, a restrictive strategy is prob-ably the least expensive.Only 3 randomized trials provided mortality data inthe UGIB-speciﬁc review, with 2 high-quality trials pro-viding 98.2% of the weight in the meta-analysis (33). A',\n",
       " 'ably the least expensive.Only 3 randomized trials provided mortality data inthe UGIB-speciﬁc review, with 2 high-quality trials pro-viding 98.2% of the weight in the meta-analysis (33). Asingle-center study found reductions in mortality andrebleeding with a hemoglobin threshold of 70 g/L ver-sus 90 g/L (35), whereas a cluster randomized trialfound no reduction in mortality or rebleeding with athreshold of 80 g/L versus 100 g/L (34). Although it didnot look at hemoglobin thresholds, 1 trial in UGIB pa-tients with hemodynamic instability found no differencein mortality between early versus delayed blood trans-fusion; however, the study was underpowered (RR, 5.4[CI, 0.3 to 107.1]) (39).Factors that may affect the timing of transfusionsinclude the availability of venipuncture staff, capacityfor frequent assessments, timing of blood typing, avail-CLINICAL GUIDELINEManagement of Upper Gastrointestinal Bleeding810 Annals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019Annals.orgDownloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " \"ability of units, hemodilution factors, and degree of he-modynamic stability. In addition, some patients mayhave underlying, undiagnosed cardiovascular disease,potentially placing them at higher risk for negative out-comes. Therefore, the consensus group suggested thata more conservative hemoglobin threshold of 80 g/L isprudent, with a target of greater than 80 g/L. Thethreshold recommendation does not apply to patientswith exsanguinating bleeding. In the setting of acuteblood loss, hemoglobin values may initially remain un-changed from baseline because of plasma equilibriumtimes. In such situations, transfusion should not be dic-tated by current hemoglobin level alone but shouldtake into account the predicted drop in hemoglobinand the patient's clinical status.Statement A5In patients with acute UGIB and underlying cardio-vascular disease, we suggest giving blood transfusionsat a higher hemoglobin threshold than for those withoutcardiovascular disease.(GRADE: conditional recommendation, very low-quality evidence)Key Evidence.Two meta-analyses, 1 in patientswith UGIB (33) and 1 in patients with cardiovasculardisease in various clinical settings (40), included ananalysis of 1 randomized trial (34) that provided sub-group data on patients with and without cardiovasculardisease. This small, underpowered trial (34) found nosigniﬁcantdifferencebetweenliberal(hemoglobinthreshold, 100 g/L) and restrictive (hemoglobin thresh-old, 80 g/L) transfusion with regard to mortality (RR,4.10 [CI, 0.86 to 19.47]) (40) or further bleeding inadults with or without ischemic heart disease (RR, 0.50[CI, 0.23 to 1.12], and RR, 0.69 [CI, 0.13 to 3.77]) (33).This study was downgraded for serious risk of bias (lackof blinding, possible selection bias) and very seriousimprecision (very small sample size).Reanalysis of the overall data from the meta-analysis of 11 trials in patients with cardiovascular dis-ease (40) found no signiﬁcant differences between the\",\n",
       " \"imprecision (very small sample size).Reanalysis of the overall data from the meta-analysis of 11 trials in patients with cardiovascular dis-ease (40) found no signiﬁcant differences between theliberal (90 to 113 g/L) and restrictive (70 to 97 g/L)strategies with regard to 30-day mortality (RR, 0.87 [CI,0.67 to 1.13]) or acute pulmonary edema (RR, 1.58 [CI,0.55 to 4.53]) but did ﬁnd a reduced risk for cardiovas-cular events with the liberal transfusion strategy (RR,0.56 [CI, 0.37 to 0.85]). This analysis was downgradedfor serious risk of bias, very serious indirectness, andserious imprecision. Because of the variation in out-comes included in the trials as well as in the meta-analyses, several sensitivity analyses were conducted.Although the results became more imprecise, the di-rection of effect did not change.Discussion.The data suggest that a more liberalhemoglobin threshold for transfusion may be associ-ated with a lower risk for cardiovascular events in pa-tients with cardiovascular disease. This is based on datafrom studies in various clinical settings with heteroge-neous patient subgroups (such as those with coronarysyndromes, ischemic heart disease, congestive heartfailure, peripheral vascular disease, or stroke or thosewith only cardiovascular risk factors, such as hyperten-sion and diabetes). The effects of liberal versus restric-tive transfusion strategies may differ among varioussubgroups. In addition, various deﬁnitions were usedfor the restrictive and liberal groups, including hemo-globin levels and the presence of anemia, and hemo-globin cutoff values varied.On the basis of these limited data, the consensusgroup suggested that a higher hemoglobin thresholdbe considered in patients with cardiovascular diseasethan in those without it (<80 g/L; statement A4). Thegroup did not recommend a speciﬁc cutoff, stating thata cutoff would depend on other factors, including thepatient's clinical status, the type and severity of cardio-\",\n",
       " \"group did not recommend a speciﬁc cutoff, stating thata cutoff would depend on other factors, including thepatient's clinical status, the type and severity of cardio-vascular disease, and the severity of bleeding. Guide-lines from NICE recommend a higher transfusion levelfor patients with cardiovascular disease than for thosewithout it, whereas the AABB (formerly known as theAmerican Association of Blood Banks) (41) recom-mends a hemoglobin threshold of 80 g/L for patientswith cardiovascular disease, compared with 70 g/L forthose without it. Again, this statement does not apply topatients with exsanguinating bleeding, who may re-quire more liberal transfusion.Statement A6In patients with acute UGIB receiving anticoagu-lants (vitamin K antagonists, direct oral anticoagulants),we suggest not delaying endoscopy (with or without en-doscopic hemostatic therapy).(GRADE: conditional recommendation, very low-quality evidence)Key Evidence. No systematic reviews, randomizedtrials, or observational studies that speciﬁcally ad-dressed the timing of endoscopy as a primary outcomein patients receiving anticoagulants were found. A ret-rospective cohort study in patients with acute UGIB(47%) or lower gastrointestinal bleeding compared 157patients using anticoagulants with 157 matched controlparticipants (42). An international normalized ratio (INR)greater than 2.5 was seen in 22.9% of the patients re-ceiving anticoagulants versus 6.4% of the control par-ticipants. No statistically signiﬁcant differences wereobserved in rates of rebleeding (13.4% vs. 15.9%; P =0.52) or thromboembolism (5.7% vs. 3.2%; P = 0.68)between the anticoagulant and control groups. Amongthe patients receiving anticoagulants, early endoscopy(<24 hours after onset) was not associated with re-bleeding (OR, 0.7 [CI, 0.3 to 1.8]), thromboembolicevents (OR, 0.5 [CI, 0.1 to 2.1]), or endoscopy-relatedadverse events (0%). Rebleeding also was not associ-\",\n",
       " 'bleeding (OR, 0.7 [CI, 0.3 to 1.8]), thromboembolicevents (OR, 0.5 [CI, 0.1 to 2.1]), or endoscopy-relatedadverse events (0%). Rebleeding also was not associ-ated with an INR of 2.5 or greater (OR, 0.7 [CI, 0.2 to2.3]). In contrast, probably because of rapid correctionof INR periendoscopically (43, 44), thromboembolismwas associated with an INR of 2.5 or greater (OR, 7.3[CI, 1.5 to 35.3]) and the use of a reversal agent (OR,4.1 [CI, 1.0 to 16.5]) (42).No differences were found in rebleeding or throm-boembolism risks between patients receiving directoral anticoagulants (DOACs) and those receiving war-farin. However, patients using warfarin had a greaterneed for transfusion (4.3 ± 5.9 units vs. 2.2 ± 3.1 units;P = 0.046). Periendoscopic use of a reversal agent (vi-tamin K) was associated with a higher risk for thrombo-Management of Upper Gastrointestinal BleedingCLINICAL GUIDELINEAnnals.orgAnnals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019 811Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " 'embolism but not rebleeding, whereas anticoagulantinterruption did not affect the risk for either outcome.The results of anticoagulant use in patients with UGIBwere not reported separately, but UGIB was associatedwith a higher rate of endoscopic therapy and transfu-sions compared with lower gastrointestinal bleeding,suggesting that the combined results may not be en-tirely generalizable to patients with UGIB (42). Thisstudy was downgraded for serious indirectness andimprecision.Discussion. For patients receiving anticoagulants,the 2010 UGIB guidelines suggested that coagulopathybe corrected but that endoscopy not be delayed (4).This recommendation was made on the basis of cohortstudies suggesting that early endoscopy (≤24 hours)may be performed safely in patients using anticoagu-lants after partial correction of the INR, without an in-crease in rebleeding rates versus persons not usinganticoagulants (45, 46). In the study by Nagata and col-leagues (42), anticoagulant interruption did not affectrisks and no increased risk was found in patients withan INR of 2.5 or greater. The consensus group cannotspecify an INR cutoff level that should prompt correc-tion of the INR.Although available new data were limited, the in-troduction of DOACs prompted the update to this rec-ommendation. Nagata and colleagues (42) found thatpatients receiving DOACs had less need for transfusionthan those receiving warfarin. The DOACs have a shorthalf-life—8 to 12 hours—and their anticoagulant effectresolves more rapidly than that of warfarin. Reversalagents are now available, although criteria for their usein patients with UGIB are not yet deﬁned and availabil-ity may be limited in some areas. Whether the type orextent of anticoagulation would affect the type of en-doscopic hemostatic therapy was not addressed.Other guidelines recommend administration of vi-tamin K supplemented with intravenous prothrombincomplex concentrate (PCC), with use of fresh frozen',\n",
       " 'doscopic hemostatic therapy was not addressed.Other guidelines recommend administration of vi-tamin K supplemented with intravenous prothrombincomplex concentrate (PCC), with use of fresh frozenplasma only if PCC is unavailable (8, 9, 47). Four-factorPCC has demonstrated efﬁcacy in correcting INR (43,44), as have speciﬁcally targeted anticoagulant reversalagents (48, 49). Some data suggest a higher risk forthrombosis with rapid reversal of anticoagulation (42,48), but this is beyond the scope of these guidelines.The consensus group agreed that the degree ofcoagulopathy should be assessed objectively beforetherapeutic decisions are made. The anticoagulantagent, patient physiology, and patient compliance withtherapy may affect anticoagulation. Because of the rec-ognized beneﬁts of early endoscopy (statement B3),coagulopathy should be treated as necessary but en-doscopy should not be delayed.Section B: Endoscopic ManagementStatement B3For patients admitted with acute UGIB, we sug-gest performing early endoscopy (within 24 hours ofpresentation).(GRADE: conditional recommendation, very low-quality evidence)Key Evidence.Evidence for early endoscopy wasassessed separately for patients at low and high risk forunfavorable outcomes (death, rebleeding) (Supple-ment Appendix 2).Low-risk patients: Two systematic reviews (4, 50) in-cluding 3 randomized trials (51–53) assessed the timingof endoscopy in patients with UGIB. Two of the trialsincluded low-risk patients randomly assigned to earlyversus later endoscopy (within 1 to 2 hours vs. 1 to 2days [52], or within 6 hours vs. 48 hours [53]). No dif-ferences in mortality or rebleeding were found be-tween groups in either trial (52, 53), but 1 study foundthat early endoscopy reduced length of stay and cost ofcare (52). The QoE was downgraded for serious risk ofbias, indirectness, and very serious imprecision.Observational studies were seriously confoundedby severity of bleeding and comorbidity, which may',\n",
       " 'care (52). The QoE was downgraded for serious risk ofbias, indirectness, and very serious imprecision.Observational studies were seriously confoundedby severity of bleeding and comorbidity, which maybias the results in favor or against early endoscopy.Three retrospective cohort studies included exclusivelyor separately reported data on low-risk patients andadjusted for confounders (54–56). In 1 study, urgentendoscopy was a predictor of negative outcomes (com-posite of death; rebleeding; and surgical, radiologic, orendoscopic intervention) among low-risk patients withUGIB (adjusted OR, 0.71 per 6 hours [CI, 0.55 to 0.91])(54). The deﬁnition of low risk in this study was a GBSless than 12, instead of the more common GBS of 2 orless. In another study using the same criterion, time toendoscopy was not associated with in-hospital mortal-ity (55). In the largest study, among low-risk patientsendoscopy within 24 hours was associated with lowerin-hospital mortality (OR, 0.48 [CI, 0.24 to 0.97]), butnot rebleeding, compared with later endoscopy (56).The QoE was downgraded for serious risk of bias andindirectness.High-risk patients: See text under “No Recommen-dation B.”Discussion.Safety concerns regarding early en-doscopy, including the potential for inadequate resus-citation before the procedure and the need to performendoscopy during off-hours when fewer endoscopy re-sources are available, must be weighed against the po-tential for worse outcomes due to ongoing bleeding.Because such concerns are less of an issue in low-riskpatients than in high-risk ones, the decision to performearly endoscopy in those at low risk is driven mainly bycost and length of stay.The 2010 UGIB guidelines recommended early en-doscopy (within 24 hours of presentation) for most pa-tients with acute UGIB (4). This recommendation wasbased on data suggesting that early endoscopy al-lowed for safe discharge of low-risk patients, improved',\n",
       " \"tients with acute UGIB (4). This recommendation wasbased on data suggesting that early endoscopy al-lowed for safe discharge of low-risk patients, improvedoutcomes for high-risk patients, and reduced resourceuse (4).Although the data were very low quality, they sup-port the conclusion that for low-risk patients, early en-doscopy may be performed safely and can reduce re-source use. To reduce hospitalization and costs, theendoscopist's recommendations for early discharge oflow-risk patients must be embraced by the attendingphysician. In the trial in which early endoscopy did notreduce resource use, only 21% of eligible patients weredischarged early (53). Early endoscopy may also yieldCLINICAL GUIDELINEManagement of Upper Gastrointestinal Bleeding812 Annals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019Annals.orgDownloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.\",\n",
       " 'more high-risk endoscopic stigmata that would haveresolved spontaneously (52, 53), which may offset ben-eﬁts in terms of hospitalization.Availability of endoscopy resources is an importantconsideration. A meta-analysis of 20 cohort studiesfound that patients with UGIB hospitalized during off-hours were less likely to undergo endoscopy within 24hours and had higher mortality rates (57). This was notthe case in hospitals with formal out-of-hours endos-copy services.On the basis of the available data, the consensusgroup suggested that endoscopy be performed within24 hours of presentation, both for low- and high-riskpatients.For high-risk patients, see the discussion under “NoRecommendation B.”No Recommendation BFor patients with acute UGIB at high risk for re-bleeding or mortality, the consensus group could notmake a recommendation for or against performing en-doscopy within 12 hours versus performing endoscopylater.(GRADE for PICO: very low-quality evidence)Key Evidence.No randomized trial assessed thetiming of endoscopy speciﬁcally in high-risk patientswith UGIB. One trial in patients with peptic ulcer bleed-ing, including a high proportion of high-risk patients(44% with shock), found no difference in mortality withendoscopy before or after 12 hours (Appendix Table 3,available at Annals.org) (51). The QoE was down-graded for serious risk of bias and indirectness, andvery serious imprecision.Seven observational studies in high-risk patientswith UGIB were assessed (54–56, 58–61); however,only 2 provided adjusted results for mortality (Appen-dix Table 3) (56, 58). One study found a reduction inmortality with very early endoscopy (<6 hours) com-pared with later endoscopy (>6 to ≤48 hours) (58). Alarge cohort study suggested that among hemodynam-ically unstable patients, very early endoscopy (≤6hours) may increase mortality risk, whereas early en-doscopy between 6 and 24 hours may reduce mortalityrisk compared with endoscopy outside that time frame',\n",
       " 'hours) may increase mortality risk, whereas early en-doscopy between 6 and 24 hours may reduce mortalityrisk compared with endoscopy outside that time frame(56). These data were downgraded for serious risk ofbias, inconsistency, and imprecision.Unadjusted results from observational studies werenot considered for this guideline. Such results conﬂictand are difﬁcult to interpret, because the effects of theconfounders are bidirectional. More severe bleeding orcomorbid conditions are associated with worse out-comes and present a clear bias toward more rapid en-doscopy; however, if the severity is too great, then en-doscopy might be delayed.Discussion. Statement B3 recommends endoscopywithin 24 hours for patients with UGIB. Whether high-risk patients would beneﬁt from very early endoscopy(within 12 hours) remains unanswered. Although activebleeding is associated with a poor prognosis, patientswho are hemodynamically unstable may have more ad-verse outcomes during endoscopy. Therefore, veryearly endoscopy may be associated with a paradoxicalnegative effect in high-risk patients (56).Because of conﬂicting data, widely variable patientpopulations (such as those differing in age, bleedingseverity, comorbid conditions, or hemodynamic insta-bility), and the potential for harm, the consensus groupconcluded that insufﬁcient data exist to recommend foror against endoscopy more urgently than the 24-hourwindow in high-risk patients. Practitioners are re-minded that for patients with suspected variceal bleed-ing, existing recommendations suggest endoscopywithin 12 hours of presentation (62, 63).Statement B10aFor patients with acutely bleeding ulcers with high-risk stigmata, we recommend endoscopic therapy withthermocoagulation or sclerosant injection.(GRADE:strongrecommendation,low-qualityevidence)Statement B10bFor patients with acutely bleeding ulcers with high-risk stigmata, we suggest endoscopic therapy with(through-the-scope) clips.',\n",
       " '(GRADE:strongrecommendation,low-qualityevidence)Statement B10bFor patients with acutely bleeding ulcers with high-risk stigmata, we suggest endoscopic therapy with(through-the-scope) clips.(GRADE: conditional recommendation, very low-quality evidence)Key Evidence. Systematic reviews and meta-analyseshave assessed the role of endoscopic therapy in pa-tients with UGIB (64–67). One review looked only atepinephrine injection alone and in combination (66),whereas another was suboptimally reported (67). Forthis guideline, the evidence was derived mainly fromthe 2009 reviews by Laine and McQuaid (64) andBarkun and colleagues (65), which were updated vianew literature searches from 2006 to 2018. For thecomparison of endoscopic treatment with no endo-scopic treatment, no new randomized trials werefound; therefore, these analyses remain unchanged(64, 65).Compared with pharmacotherapy or no treatment,thermocoagulation (heater probe or bipolar electroco-agulation) or sclerosant injection reduced mortality andrebleeding (64, 65). No randomized trials were foundcomparing hemoclips with no treatment.The QoE was downgraded for risk of bias (mainlylack of blinding). The QoE for efﬁcacy was moderate forall therapies combined and for sclerosant injection;QoE was low for thermocoagulation and was down-graded further for imprecision.For comparisons of various active treatments, themeta-analysis by Barkun and colleagues (65) was up-dated with 3 new trials (68–70) (Supplement Appendix2). No differences were found for mortality or rebleed-ing in comparisons of thermocoagulation, sclerosant in-jection, hemoclips, and combination therapies (64, 65).Meta-analysis of data from 2 trials showed that hemo-clips were superior to epinephrine injection alone withregard to rebleeding (RR, 0.17 [CI, 0.05 to 0.55]) butnot mortality (RR, 2.15 [CI, 0.59 to 7.78]) (68, 71).Discussion.Endoscopic hemostatic therapy hasbeen well documented to improve outcomes. The con-',\n",
       " 'not mortality (RR, 2.15 [CI, 0.59 to 7.78]) (68, 71).Discussion.Endoscopic hemostatic therapy hasbeen well documented to improve outcomes. The con-Management of Upper Gastrointestinal BleedingCLINICAL GUIDELINEAnnals.orgAnnals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019 813Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " 'sensus group agreed with the prior statements that en-doscopic therapy is indicated in patients with high-riskstigmata (active bleeding, visible vessel) and may beconsidered in patients with an adherent clot (state-ments B6 and B7). Debate continues with regard to theoptimal method. Sclerosant therapy is used less com-monly in clinical practice but remains a viable option.Lack of routine PPI therapy and the constantly changingprevalence of Helicobacter pylori may affect the resultsof older studies. The group chose not to address otherendoscopic mechanical techniques, such as over-the-scope clips.On the basis of the available data, a strong recom-mendation was made for thermocoagulation or sclero-sant injections, whereas hemoclips were suggested(conditional recommendation). However, the data gen-erally have failed to show superiority of any onemethod, and each may be useful depending on loca-tion of the bleeding source and patient characteristics.Statement B11aIn patients with actively bleeding ulcers, we suggestusing TC-325 as a temporizing therapy to stop bleedingwhen conventional endoscopic therapies are not avail-able or fail.(GRADE: conditional recommendation, very low-quality evidence)Statement B11bIn patients with actively bleeding ulcers, we suggestagainst using TC-325 as a single therapeutic strategyversus conventional endoscopic therapy (clips alone,thermocoagulation alone, or combination therapy).(GRADE: conditional recommendation, very low-quality evidence)Key Evidence. Evidence for the efﬁcacy of TC-325(hemostatic powder spray) was available from 1 smallunderpowered trial (72) and from observational studies(73, 74). The trial randomly assigned 20 patients andfound no statistically signiﬁcant differences in initial he-mostasis (90% vs. 100%) or rebleeding (33% vs. 10%)with TC-325 monotherapy versus a conventional com-bination endoscopic technique (epinephrine injectionwith either hemoclip or heater probe application) (72).',\n",
       " 'with TC-325 monotherapy versus a conventional com-bination endoscopic technique (epinephrine injectionwith either hemoclip or heater probe application) (72).Among 8 patients with actively bleeding (spurting oroozing) ulcers, 4 of 5 in the TC-325 group had success-ful initial hemostasis, but 3 had rebleeding. In contrast,all 3 in the conventional treatment group achieved ini-tial hemostasis and none had rebleeding.A systematic review of observational data found animmediate hemostasis rate of 90% but very high re-bleeding rates (72-hour, 19%; 7-day, 22%) among 86patients with ulcer bleeds treated with TC-325 (73). Re-bleeding rates (72-hour and 7-day) were highestamong patients with active bleeding (spurting, 40%and 60%; oozing, 13% and 16%). Another large pro-spective cohort study included 202 patients with bleed-ing treated with TC-325; the rate of initial hemostasiswas 97%, with day 8 and day 30 rebleeding rates of27% and 34%, respectively (74).Evidence was downgraded for serious risk of bias(lack of blinding) and very serious imprecision (smallsample sizes and low total number of events).Discussion.The success of TC-325 hemostaticpowder spray seems to depend on the cause of bleed-ing and whether the powder is used alone or in com-bination with other hemostatic therapy. The powderadheres only to actively bleeding lesions (73), its resi-dency time is 24 hours or less (75), and it does notinduce tissue healing (73).TC-325 use in UGIB is associated with a low com-plication rate, although rare cases of perforation andtransient biliary obstruction have been reported (73,76). Additional experience is needed to deﬁne thesafety proﬁle more clearly.Decision modeling suggests that a strategy of con-ventional therapy followed by TC-325 improved the ef-fectiveness and was less costly compared with conven-tional therapy alone or TC-325 alone in most patientpopulations with nonvariceal UGIB (77). TC-325 fol-lowed by conventional therapy was the most effective',\n",
       " \"tional therapy alone or TC-325 alone in most patientpopulations with nonvariceal UGIB (77). TC-325 fol-lowed by conventional therapy was the most effectivestrategy for nonulcer high-risk bleeding lesions at lowrisk for delayed rebleeding.On the basis of TC-325's mechanism of action andthe clinical evidence, the consensus group concludedthat TC-325 monotherapy may not adequately treat ul-cers with high-risk stigmata, but may be useful as a tem-porary measure to stop bleeding, and that second-lookendoscopy or a second hemostatic technique shouldbe used.No Recommendation CIn patients with acutely bleeding ulcers who haveundergone endoscopic therapy, the consensus groupcould not make a recommendation for or againstDoppler endoscopic probe (DEP) versus no DEP to as-sess the need for further endoscopic therapy.(GRADE for PICO: very low-quality evidence)Key Evidence.Two randomized trials comparedDEP-guided versus conventional endoscopic treatmentin patients with acute UGIB (78, 79). In a 1997 study byKohler and colleagues (78), all patients had peptic ulcerbleeding, but actively bleeding lesions were excluded.Endoscopic treatment was directed by Doppler ﬁnd-ings, injection therapy alone was used, and second-look endoscopy was performed for all patients. In a2017 study by Jensen and colleagues (79), most of the148 patients with severe nonvariceal UGIB (85%) hadpeptic ulcer bleeding (active bleeding, visible vessel,adherent clot, or ﬂat spot). A meta-analysis of these 2studies (78, 79) was performed for this guideline (Sup-plement Appendix 2). However, at the face-to-facemeeting, it was decided to focus the evidence proﬁleson the trial by Jensen and colleagues, which reporteddata for patients with high-risk lesions (active bleeding,visible vessel) or adherent clot. Data for patients withlow-risk lesions (ﬂat spot) were considered indirect, be-cause these lesions are not routinely subjected to en-doscopic therapy. In Jensen and colleagues' study (79),\",\n",
       " \"low-risk lesions (ﬂat spot) were considered indirect, be-cause these lesions are not routinely subjected to en-doscopic therapy. In Jensen and colleagues' study (79),DEP reduced rebleeding for all lesions (RR, 0.42 [CI,0.20 to 0.90]) but not for high-risk lesions (RR, 0.50 [CI,0.24 to 1.08]).Overall, the QoE was downgraded for risk of bias,indirectness (population and intervention), and impre-cision (moderate sample size).CLINICAL GUIDELINEManagement of Upper Gastrointestinal Bleeding814 Annals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019Annals.orgDownloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.\",\n",
       " 'Discussion. More studies are needed to determinewhether DEP would be useful to guide endoscopictreatment decisions before or after initial therapy or inboth settings. One study found only 58% agreementbetween DEP and ﬁndings at index endoscopy (78).Used to determine the need for additional therapy,DEP would be an add-on test with conventional endo-scopic treatment for high-risk lesions, which would addcost related to the DEP technology. A cost-minimizationanalysis found that DEP-directed combination endo-scopic therapy was cost-effective compared with com-bination therapy only for the management of high-riskpatients (80).The consensus group concluded that data suggest-ing efﬁcacy for DEP is very limited and that lack of avail-ability and expertise in many centers affects feasibility.The group generally agreed that although making arecommendation for or against DEP to manage UGIB ispremature, it has the potential to alter the usual ap-proach to visually assessing bleeding lesion risk whenevaluating the need for, and adequacy of, endoscopichemostasis.Section C: Pharmacologic ManagementStatement C3For patients with bleeding ulcers with high-riskstigmata who have undergone successful endoscopictherapy, we recommend using PPI therapy via intra-venous loading dose followed by continuous intrave-nous infusion (as opposed to no treatment or H2-receptor antagonists).(GRADE: strong recommendation, moderate-quality ev-idence)No Recommendation DFor patients with bleeding ulcers with high-riskstigmata who have undergone successful endoscopictherapy, the consensus group could not make a rec-ommendation for or against non–high-dose PPI ther-apy (as opposed to no treatment or H2-receptorantagonists).(GRADE for PICO: very low-quality evidence)Key Evidence.Two Cochrane reviews on PPIs inUGIB were updated for this guideline (81, 82). The ﬁrst(81), which included 24 trials comparing PPIs with pla-cebo or H2-receptor antagonists (H2RAs), was updated',\n",
       " 'Two Cochrane reviews on PPIs inUGIB were updated for this guideline (81, 82). The ﬁrst(81), which included 24 trials comparing PPIs with pla-cebo or H2-receptor antagonists (H2RAs), was updatedwith an additional 14 randomized trials. Of these, 12included data on patients with high-risk stigmata (activebleeding, visible vessel) or adherent clot who had un-dergone appropriate endoscopic therapy. There wasmoderate QoE that PPI therapy versus no PPIs or H2RAsreduced mortality risk (OR, 0.56 [CI, 0.34 to 0.94]) andhigh QoE that it reduced rebleeding risk (OR, 0.43 [CI,0.29 to 0.63]) (Table 2). The evidence for mortality wasdowngraded because of serious risk of bias (mainlylack of blinding in some trials).The second meta-analysis (82), which included 22trials comparing various PPI regimens, was updatedwith an additional 18 trials. Of these, 25 comparedhigh-dose PPIs (deﬁned as an 80-mg intravenous bolusfollowed by 72 hours of an 8-mg/h continuous intrave-nous infusion) with non–high-dose PPIs, and 17 in-cluded data on patients with high-risk stigmata oradherentclotswhohadundergoneendoscopictreatment. No differences were found in the risk formortality or rebleeding between high-dose and non–high-dose PPIs (low and moderate QoE) or betweenhigh-dose and oral PPIs (very low and low QoE) (Table2). Indirect comparisons between high-dose PPIs andno treatment or H2RAs and between non–high-dosePPIs and no treatment or H2RAs yielded very low QoEfor the superiority of high-dose PPI therapy (update of[81]). Moderate QoE supported the superiority ofnon–high-dose PPIs versus no PPIs for the outcomeof rebleeding, but the QoE for mortality was low. Theevidence was downgraded, mainly because of impreci-sion and risk of bias for some comparisons.Adverse effects were poorly reported in most ofthe studies. Overall, no consistent signal of a differencewas found between PPI therapy and placebo or H2RAs,between high-dose and non–high-dose PPIs, or be-',\n",
       " 'the studies. Overall, no consistent signal of a differencewas found between PPI therapy and placebo or H2RAs,between high-dose and non–high-dose PPIs, or be-tween intravenous and oral PPI therapy. The exceptionwas an increased risk for thrombophlebitis with PPIsadministered intravenously versus orally.Discussion.High-dose PPI therapy (that is, an80-mg intravenous bolus followed by 72 hours of8-mg/h continuous intravenous infusion) reduces re-bleeding and mortality. Because non–high-dose ther-apy has been associated with a reduction in rebleedingTable 2. Pooled ORs and Absolute Risks of Unfavorable Outcomes, According to PPI Regimen, in Patients with High-RiskStigmata Who Had Endoscopic TherapyStudiesActiveTreatment, n/N (%)Control,n/N (%)OR (95% CI)*Absolute Effect,per 1000 Persons (95% CI)PPIs vs. placebo or H2RAsDeaths: 1 SR and MA (update of reference 81); 10 RCTs24/1202 (2.0)43/1220 (3.5)0.56 (0.34 to 0.94)−15 (−23 to −2)Rebleeds: 1 SR and MA (update of reference 81); 12 RCTs88/1269 (6.9)169/1277 (13.2)0.43 (0.29 to 0.63)−71 (−90 to −45)High-dose vs. non–high-dose PPIsDeaths: 1 SR and MA (update of reference 82); 15 RCTs28/1042 (2.7)27/1027 (2.6)1.02 (0.59 to 1.76)1 (−11 to +20)Rebleeds: 1 SR and MA (update of reference 82); 17 RCTs126/1175 (10.7)107/1191 (9.0)1.25 (0.93 to 1.66)20 (−6 to +51)High-dose vs. oral PPIsDeaths: 1 SR and MA (update of reference 81); 3 RCTs0/117 (0)2/116 (1.7)0.31 (0.04 to 2.93)−12 (−17 to +33)Rebleeds: 1 SR and MA (update of reference 81); 4 RCTs16/235 (6.8)15/242 (6.2)1.09 (0.54 to 2.17)6 (−29 to +72)OR = odds ratio; H2RA = H2-receptor antagonist; MA = meta-analysis; PPI = proton-pump inhibitor; RCT = randomized controlled trial; SR =systematic review.* Boldface signiﬁes statistically signiﬁcant results.Management of Upper Gastrointestinal BleedingCLINICAL GUIDELINEAnnals.orgAnnals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019 815',\n",
       " '* Boldface signiﬁes statistically signiﬁcant results.Management of Upper Gastrointestinal BleedingCLINICAL GUIDELINEAnnals.orgAnnals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019 815Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " 'but not mortality compared with no PPI therapy, a ma-jority of the consensus group did not vote to recom-mendnon–high-dosePPItherapy.Theconsensusgroup is not conﬁdent that the precision of the esti-mates of absolute differences between high- and non–high-dose PPI therapy regarding mortality and rebleed-ing is sufﬁcient to consider the 2 therapies equivalent.Studies of non–high-dose PPI therapy are complicatedby different dosing regimens and methods of adminis-tration, including continuous intravenous infusion, in-travenous bolus, and oral regimens.Cost-effectiveness studies have suggested thathigh-dose intravenous PPIs after successful endoscopichemostasis improve outcomes at a modest cost in-crease relative to non–high-dose intravenous or oralPPI strategies (83–86). In addition, the incrementalcosts of different PPI regimens (continuous or intermit-tent, before or after endoscopic therapy) are modestcompared with total per-patient costs.The consensus group concluded that the evidencesupports a strong recommendation for high-dose PPIsfor patients with bleeding ulcers with high-risk stigmata(active bleeding or visible vessel) who have had suc-cessful endoscopic therapy. The recommendation forpatients with adherent clots remains unchanged (state-ment B6) and includes endoscopic therapy or consid-eration of PPI therapy alone (Table 1). Given the dem-onstrated beneﬁts on rebleeding outcomes and thatthe costs and availability of intravenous formulationsmay be issues in some areas, the consensus group alsodid not make a recommendation against using lowerPPI doses.Statement C4For patients who present with ulcer bleeding athigh risk for rebleeding (that is, an ulcer requiring en-doscopic therapy followed by 3 days of high-dose PPItherapy), we suggest using twice-daily oral PPIs (vs.once daily) through 14 days, followed by once daily.(GRADE: conditional recommendation, very low-quality evidence)Key Evidence. One trial enrolled patients at high-',\n",
       " 'once daily) through 14 days, followed by once daily.(GRADE: conditional recommendation, very low-quality evidence)Key Evidence. One trial enrolled patients at high-risk for rebleeding (Rockall scores ≥6) who had under-gone successful endoscopic therapy and received 3days of high-dose PPI therapy (intravenous esomepra-zole, 80-mg loading dose followed by 8-mg/h continu-ous infusion) (87). Patients were randomly assigned toreceive oral esomeprazole, 40 mg, either once or twicedaily for 11 days (days 3 to 14). All patients received anadditional 2 weeks of once-daily PPI therapy. A reduc-tion was found in rebleeding (RR, 0.37 [CI, 0.19 to0.73]) but not mortality rates (RR, 0.38 [CI, 0.10 to 1.38])with twice- versus once-daily PPIs. The QoE was down-graded for risk of bias and imprecision.Discussion. Based on the data suggesting superi-ority over the standard dosage for rebleeding, the con-sensus group suggested the use of twice-daily PPIs tocomplete 2 weeks of PPI therapy, after 3 days of high-dose therapy.Section D: Nonendoscopic andNonpharmacologic In-Hospital ManagementNo updates to the 2010 international UGIB guide-lines (4).Section E: Secondary ProphylaxisStatement E4In patients with previous ulcer bleeding receivingcardiovascularprophylaxiswithsingle-ordual-antiplatelet therapy, we suggest using PPI therapy ver-sus no PPI therapy.(GRADE: conditional recommendation, low-qualityevidence)Key Evidence. Single-antiplatelet therapy: Evidencefor the role of PPI therapy in patients receiving single-agent antiplatelet therapy was available from 5 ran-domized trials (88–92) comparing PPIs versus no PPIs inpatients requiring continued antiplatelet therapy. Be-cause of heterogeneity in study designs and compari-son groups, a meta-analysis of all 5 studies was notdone. All 5 trials were conducted in Hong Kong. A his-tory of H pylori infection and eradication treatment wascommon.One trial found PPIs to be more effective than pla-',\n",
       " 'done. All 5 trials were conducted in Hong Kong. A his-tory of H pylori infection and eradication treatment wascommon.One trial found PPIs to be more effective than pla-cebo in reducing recurrent complications (bleeding,perforation, and obstruction) (RR, 0.11 [CI, 0.01 to0.84]) in patients with previous ulcer complications whohad successful H pylori eradication and required con-tinued antiplatelet therapy (acetylsalicylic acid [ASA])(88). A meta-analysis of 2 trials showed that PPIs plusASA reduced rebleeding rates versus clopidogrelalone (RR, 0.07 [CI, 0.01 to 0.34]) in patients with pre-vious ASA-associated ulcer bleeding who did not haveH pylori infection or who had it successfully eradicated(90, 91). In patients with previous ASA-associated ulcerbleeding, trials found no difference between PPIs anderadication treatment in those with H pylori infection(89), or between PPIs and H2RAs in patients without Hpylori infection or those in whom H pylori infection waseradicated (92). Two trials found no differences in mor-tality rates between PPI and placebo groups (88) or be-tween PPIs plus ASA versus clopidogrel (89).The evidence was downgraded, primarily for veryserious imprecision (small studies, very low number ofevents).Dual-antiplatelet therapy (DAPT): No randomizedtrials were found assessing the use of PPIs in patientsreceiving DAPT who had a history of ulcer bleeding.Two systematic reviews were found in patients receiv-ing DAPT after percutaneous coronary intervention orin the presence of coronary artery disease (93, 94). Thereporting and methodological quality of both reviewswere suboptimal, with inclusion of studies that were noteligible (for example, because of patients not receivingDAPT, incorrect comparisons, or double counting). Ameta-analysis conducted for this guideline included 4randomized trials (n = 4805) comparing PPI versus noPPI therapy in patients receiving prophylactic DAPT(ASA and clopidogrel). The largest study was interna-',\n",
       " 'randomized trials (n = 4805) comparing PPI versus noPPI therapy in patients receiving prophylactic DAPT(ASA and clopidogrel). The largest study was interna-tional (95), whereas the other 3 were conducted inChina (96–98). The meta-analysis showed a reductionin gastrointestinal bleeding risk with PPI therapy versusplacebo (n = 4 studies; RR, 0.25 [CI, 0.14 to 0.45]) andCLINICAL GUIDELINEManagement of Upper Gastrointestinal Bleeding816 Annals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019Annals.orgDownloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " 'no effects on mortality (n = 3 studies; RR, 1.02 [CI, 0.68to 1.54]) or myocardial infarction risk (n = 2 studies; RR,0.96 [CI, 0.51 to 1.81]).No studies were found that assessed ASA in com-bination with other antiplatelet drugs, such as prasug-rel or ticagrelor. The evidence was downgraded forhigh or unclear risk of bias in the Chinese studies andfor serious indirectness in all 4 trials (most patients didnot have a history of ulcer bleeding).Discussion.The evidence consistently supports abeneﬁt with PPI therapy in patients with previous ulcerbleeding who continue single- or dual-antiplatelet ther-apy and suggest that PPI therapy is superior to clopi-dogrel alone in patients receiving ASA.Most patients in these studies had H pylori infectionbefore PPI therapy, and in 1 study eradication treat-ment alone was as effective as PPI therapy (89). Obser-vational data suggest that ulcer rebleeding risk in pa-tients receiving low-dose ASA may be reduced amongthose who had H pylori infection eradicated comparedwith those who were never infected (99). It is antici-pated that PPI therapy should be beneﬁcial in popula-tions with lower rates of H pylori infection, although themagnitude of effect may be decreased. The consensusgroup suggested that eradication therapy alone maybe sufﬁcient to reduce bleeding risk for some patientswith H pylori infection, with only incremental beneﬁtsassociated with additional PPI therapy.Although various adverse events have been re-ported with PPI therapy (statement E5), the systematicreview and meta-analysis conducted for this guidelinefound no increased risk for myocardial infarction in pa-tients receiving DAPT.On the basis of the evidence, the consensus groupsuggests PPI therapy to prevent rebleeding in most pa-tients who require single- or dual-antiplatelet therapyfor a duration consistent with the ongoing need for an-tiplatelet therapy.Statement E5In patients with previous ulcer bleeding requiring',\n",
       " 'tients who require single- or dual-antiplatelet therapyfor a duration consistent with the ongoing need for an-tiplatelet therapy.Statement E5In patients with previous ulcer bleeding requiringcontinued cardiovascular prophylaxis with anticoagu-lant therapy (vitamin K antagonists, DOACs), we sug-gest using PPI therapy versus no PPI therapy.(GRADE: conditional recommendation, very low-quality evidence)Key Evidence. Compared with no PPI therapy, theuse of PPIs in patients receiving anticoagulant therapywas associated with a reduced risk for rebleeding in 2large cohort studies (100, 101) but not in 3 case–control studies (102–104). Most patients included inthese studies did not have a history of ulcer bleeding.In 1 small case–control study in patients with a historyof UGIB, rebleeding risk was not signiﬁcantly reducedin patients receiving warfarin plus PPIs (RR, 1.93 [CI,0.23 to 16.28]) compared with those not receiving war-farin (103). In contrast, in 1 of the cohort studies thegreatest risk reduction with PPI therapy versus no PPItherapy was seen in patients with a history of pepticulcers or gastrointestinal bleeding (adjusted incidencerate ratio, 0.14 [CI, 0.06 to 0.30]) (101). None of theincluded studies assessed mortality.The evidence was downgraded for indirectness(most patients did not have previous ulcer bleeding).Discussion.A history of ulcer bleeding is associ-ated with an increased risk for bleeding, and althoughanticoagulants do not cause ulcer bleeding, they in-crease the risk for bleeding from sites that have muco-sal breaks.Meta-analyses of primarily observational studieshave suggested potential associations between PPItherapy and adverse effects, including community-acquired pneumonia, hip fracture, colorectal cancer,chronic kidney disease, community-acquired enteric in-fection, and Clostridium difﬁcile infection (105–109). Ananalysis of factors, such as consistency, speciﬁcity, tem-porality, and biological plausibility, as well as con-',\n",
       " 'fection, and Clostridium difﬁcile infection (105–109). Ananalysis of factors, such as consistency, speciﬁcity, tem-porality, and biological plausibility, as well as con-founding factors, showed that the evidence for causal-ity is very weak (110). The consensus group concludedthat for high-risk patients with an ongoing need for an-ticoagulants, the evidence suggests that the beneﬁts ofsecondary prophylaxis outweigh the risks. The un-proven potential and rare safety concerns should notprevent treatment for patients at risk for life-threateningconsequences.ONGOING AND RESEARCH RECOMMENDATIONSAlthough UGIB management has improved sub-stantially during the past 2 decades, areas remain inwhich more data are needed (Appendix Table 4, avail-able at Annals.org). In particular, more studies areneeded to deﬁne the beneﬁts of speciﬁc prognosticscales, the role of a restrictive versus liberal transfusionpractice in patients with UGIB and cardiovascular dis-ease, optimal PPI regimens, optimal endoscopic hemo-static therapies, and the role of PPIs in patients receiv-ing antithrombotic therapy. Planned analyses from theCOMPASS (Cardiovascular Outcomes for People UsingAnticoagulation Strategies) trial may clarify the efﬁcacyand safety of PPIs versus no PPIs in patients receivinganticoagulant therapy (111).Several pertinent articles that were not available atthe time of this consensus have been published sincethe literature searches were completed (as of May2018). These include a large randomized trial in pa-tients with cardiovascular disease that compared theefﬁcacy and safety of DOACs or ASA with or without PPItherapy (112, 113). Randomized trials have assessedPPIs versus H2RAs for recurrent UGIB (114), as well asendoscopic therapy with hemostatic powder and he-moclips (115, 116). In addition, the use of DEP to guidehemostasis has been studied further (117). Although adiscussion of over-the-scope clips for recurrent peptic',\n",
       " 'moclips (115, 116). In addition, the use of DEP to guidehemostasis has been studied further (117). Although adiscussion of over-the-scope clips for recurrent pepticulcer bleeding is beyond the scope of the statementsaddressed in this guideline, data are emerging (118).These are just some examples of new or ongoing stud-ies that have the potential to affect clinical practice, butthey may not do so. The consensus group cannot com-ment on the results of these trials, because a systematicManagement of Upper Gastrointestinal BleedingCLINICAL GUIDELINEAnnals.orgAnnals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019 817Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " \"literature search was not performed and the GRADEapproach was not applied.APPLICABILITY AND IMPLEMENTATION ISSUESPlans are under way to develop a user-friendly clin-ical algorithm for UGIB management, slide presenta-tions, short videos, and CAG podcasts. The guidelinesand supporting materials will be disseminated to allparticipating societies and regions through such ven-ues as symposia sessions or workshops at society meet-ings. Major recommendations will be posted on societyand government health Web sites. Finally, we antici-pate that these guidelines will continue to be updatedas new data become available.From McGill University, Montreal, Quebec, Canada (A.N.B.);McGill University, Montreal, Quebec, Canada, and King SaudUniversity, Riyadh, Saudi Arabia (M.A.); Erasmus UniversityMedical Center, Rotterdam, the Netherlands (E.J.K.); YaleSchool of Medicine, New Haven, Connecticut, and VA Con-necticut Healthcare System, West Haven, Connecticut (L.L.);Chinese University of Hong Kong, Hong Kong SAR (J.S.,F.K.C., J.L.); McMaster University, Hamilton, Ontario, Canada(F.T., G.I.L., J.D., J.K.M.); Mayo Clinic, Scottsdale, Arizona(N.S.A.); Hospital Parc Taulı´ de Sabadell, University of Barce-lona, Sabadell, Spain, and CiberEHD (Instituto de Salud Car-los III), Madrid, Spain (X.C.); St. Paul's Hospital, University ofBritish Columbia, Vancouver, British Columbia, Canada (R.E.);Technion-Israel Institute of Technology, Emek Medical Center,Afula, Israel (I.M.G.); Western University, London, Ontario,Canada (V.J.); University of California, Los Angeles, Los Angeles,California (D.J.); University of Liverpool and Liverpool Heart andChest Hospital, Liverpool, United Kingdom, and Aalborg Univer-sity, Aalborg, Denmark (G.Y.L.); Dijon-Bourgogne UniversityHospital, Dijon, France (R.L., M.B.); University of Sa˜o Paulo, Sa˜oPaulo, Brazil (F.M.); George Washington University, Washington,DC (A.C.M.); Asian Institute of Gastroenterology, Hyderabad, In-\",\n",
       " \"Hospital, Dijon, France (R.L., M.B.); University of Sa˜o Paulo, Sa˜oPaulo, Brazil (F.M.); George Washington University, Washington,DC (A.C.M.); Asian Institute of Gastroenterology, Hyderabad, In-dia (N.R.); and Brigham and Women's Hospital, Harvard MedicalSchool, Boston, Massachusetts (J.R.S.).Note: This clinical practice guideline (CPG) on UGIB was de-veloped under the direction of Drs. Alan N. Barkun and MarcBardou, in accordance with the policies and procedures of theCAG and under the direction of CAG Clinical Affairs. It hasbeen reviewed by the CAG Clinical Affairs Committee and theCAG Board of Directors. The CPG was developed after a thor-ough consideration of the medical literature and the bestavailable evidence and clinical experience. It represents theconsensus of a Canadian and international panel comprisingexperts on this topic. The CPG aims to provide a reasonableand practical approach to care for specialists and allied healthprofessionals who are charged with providing optimal care topatients and their families, and it may be subject to change asscientiﬁc knowledge and technology advance and as practicepatterns evolve.Disclaimer: The CPG is not intended as a substitute for physi-cians using their individual judgment in managing clinicalcare in consultation with the patient, with appropriate regardto all the individual circumstances of the patient, the diagnos-tic and treatment options available, and the available re-sources. Adherence to these recommendations will not nec-essarily produce successful outcomes in every case.Acknowledgment: The CAG thanks the Canadian Institutes ofHealth Research (CIHR) Institute of Nutrition, Metabolism andDiabetes and the Saudi Gastroenterology Association for theirgenerous support of the guideline process. The consensusgroup thanks Dr. Waleed Alhazzani (McMaster University) forparticipation in the development of PICO questions and inpreliminary discussions and voting; Paul Sinclair, Cindy Roll,\",\n",
       " 'group thanks Dr. Waleed Alhazzani (McMaster University) forparticipation in the development of PICO questions and inpreliminary discussions and voting; Paul Sinclair, Cindy Roll,and Lesley Marshall (CAG representatives) for administrativeand technical support and logistical assistance; and PaulineLavigne and Steven Portelance for editorial assistance andmedical writing services (supported by funds from the CAG).Financial Support: By an unrestricted grant to the CAG by theCIHR Institute of Nutrition, Metabolism and Diabetes and theSaudi Gastroenterology Association.Disclosures: Dr. Barkun reports grants and consulting feesfrom and advisory board membership at Pendopharm and At-Gen, and advisory membership at Olympus and Cook, outsidethe submitted work. Dr. Chan reports grants from the ResearchGrant Council of Hong Kong during the conduct of the studyand advisory board membership at Pﬁzer, AstraZeneca, theRome Foundation, Antibe Therapeutics, and the AGA Council;personal fees and honoraria from Pﬁzer, AstraZeneca, Eisai,Takeda Pharmaceuticals, EA Pharma, Japan GastroenterologicalEndoscopy Society, Takeda (China) Holdings, Ministry of Healthof Singapore, Olympus Hong Kong and China, Medical Associ-ation of Guangdong Province, and Associacao Dos MedicosHospitalares Da Funcao Publica De Macau; personal fees androyalties from Wiley; grants from Pﬁzer, AstraZeneca, TrianglePharmaceuticals, Given Imaging, Osaka City University, andOlympus Hong Kong and China; and commentary for AmericanCollege of Physicians Journal Club, Nature Review: Gastroenter-ology and Hepatology, Evidence-based Medicine and Ministryof Health P.R. China, and Ministry of Health of Singapore, outsidethe submitted work. Dr. Douketis reports personal fees fromBoehringer Ingelheim, Janssen, Pﬁzer, Bayer, Bristol-MyersSquibb, Sanoﬁ, and Daiichi Sankyo outside the submitted work.Dr. Gralnek reports personal fees from Boston Scientiﬁc and',\n",
       " 'Boehringer Ingelheim, Janssen, Pﬁzer, Bayer, Bristol-MyersSquibb, Sanoﬁ, and Daiichi Sankyo outside the submitted work.Dr. Gralnek reports personal fees from Boston Scientiﬁc andTaro Pharmaceuticals outside the submitted work. Dr. Jairath re-ports personal fees from AbbVie, Takeda, Pﬁzer, Sandoz, Jans-sen, Arena Pharma, GSK, Eli Lilly, Ferring, Shire, Robarts ClinicalTrials, Genentech, Merck, Topivert, Celltrion, Sublimity Thera-peutics, F. Hoffman-La Roche, and Sigmatic Limited outside thesubmitted work. Dr. Jensen reports grants from the National In-stitute of Diabetes and Digestive and Kidney Diseases; U.S. Vet-erans Affairs Clinical Merit Review, and American Society forGastrointestinal Endoscopy Research Foundation; grants andpersonal fees from Vascular Technology; and personal fees fromBoston Scientiﬁc outside the submitted work. Dr. Lip reportsconsulting and speakers fees from Bayer, Bayer/Janssen, BMS/Pﬁzer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife,Roche, and Daiichi Sankyo outside the submitted work. Dr. Melt-zer reports an active research grant from Medtronic to study gas-trointestinal bleeding and serves on an advisory board for AnXRobotics. Dr. Saltzman reports personal fees from Cook Endos-copy outside the submitted work. Authors not named here havedisclosed no conﬂicts of interest. Disclosures can also be viewedat www.acponline.org/authors/icmje/ConﬂictOfInterestForms.do?msNum=M19-1795.CLINICAL GUIDELINEManagement of Upper Gastrointestinal Bleeding818 Annals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019Annals.orgDownloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " 'Corresponding Author: Alan N. Barkun, MD, Division of Gas-troenterology, McGill University and the McGill University HealthCentre, 1650 Cedar Avenue, Room D7.346, Montreal, QuebecH3G 1A4, Canada; e-mail, alan.barkun@muhc.mcgill.ca.Current author addresses and author contributions are avail-able at Annals.org.References1. Laine L, Yang H, Chang SC, et al. Trends for incidence of hospi-talization and death due to GI complications in the United Statesfrom 2001 to 2009. Am J Gastroenterol. 2012;107:1190-5; quiz1196. [PMID: 22688850] doi:10.1038/ajg.2012.1682. Rosenstock SJ, Møller MH, Larsson H, et al. Improving quality ofcare in peptic ulcer bleeding: nationwide cohort study of 13,498consecutive patients in the Danish Clinical Register of EmergencySurgery. Am J Gastroenterol. 2013;108:1449-57. [PMID: 23732464]doi:10.1038/ajg.2013.1623. Barkun A, Bardou M, Marshall JK; Nonvariceal Upper GI BleedingConsensus Conference Group. Consensus recommendations formanaging patients with nonvariceal upper gastrointestinal bleeding.Ann Intern Med. 2003;139:843-57. [PMID: 14623622]4. Barkun AN, Bardou M, Kuipers EJ, et al; International ConsensusUpper Gastrointestinal Bleeding Conference Group. Internationalconsensus recommendations on the management of patients withnonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101-13.[PMID:20083829]doi:10.7326/0003-4819-152-2-201001190-000095. Laine L, Jensen DM. Management of patients with ulcer bleeding.Am J Gastroenterol. 2012;107:345-60; quiz 361. [PMID: 22310222]doi:10.1038/ajg.2011.4806. Hwang JH, Fisher DA, Ben-Menachem T, et al; Standards of Prac-tice Committee of the American Society for Gastrointestinal Endos-copy. The role of endoscopy in the management of acute non-variceal upper GI bleeding. Gastrointest Endosc. 2012;75:1132-8.[PMID: 22624808] doi:10.1016/j.gie.2012.02.0337. National Institute for Health and Care Excellence. Acute uppergastrointestinal bleeding: management (NICE clinical guideline',\n",
       " '[PMID: 22624808] doi:10.1016/j.gie.2012.02.0337. National Institute for Health and Care Excellence. Acute uppergastrointestinal bleeding: management (NICE clinical guideline141), 2012. Last update: November 2018. Accessed at www.nice.org.uk/guidance/cg141 on 12 August 2019.8. Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis andmanagement of nonvariceal upper gastrointestinal hemorrhage: eu-ropean society of gastrointestinal endoscopy (ESGE) guideline. En-doscopy. 2015;47:a1-46. [PMID: 26417980] doi:10.1055/s-0034-13931729. Sung JJ, Chiu PW, Chan FKL, et al. Asia-Paciﬁc working groupconsensus on non-variceal upper gastrointestinal bleeding: anupdate 2018. Gut. 2018;67:1757-1768. [PMID: 29691276] doi:10.1136/gutjnl-2018-31627610. Abraham NS, Hartman C, Richardson P, et al. Risk of lowerand upper gastrointestinal bleeding, transfusions, and hospi-talizations with complex antithrombotic therapy in elderly pa-tients. Circulation. 2013;128:1869-77. [PMID: 24025594] doi:10.1161/CIRCULATIONAHA.113.00474711. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisaltool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. [PMID: 28935701] doi:10.1136/bmj.j400812. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group.GRADE: an emerging consensus on rating quality of evidenceand strength of recommendations. BMJ. 2008;336:924-6. [PMID:18436948] doi:10.1136/bmj.39489.470347.AD13. Guyatt GH, Schu¨nemann HJ, Djulbegovic B, et al. Guideline pan-els should not GRADE good practice statements. J Clin Epidemiol.2015;68:597-600.[PMID:25660962]doi:10.1016/j.jclinepi.2014.12.01114. Dalkey N. An experimental study of group opinion: the Delphimethod. Futures. 1969;1:408-26.15. Schu¨nemann HJ, Mustafa R, Brozek J, et al; GRADE WorkingGroup. GRADE Guidelines: 16. GRADE evidence to decision frame-works for tests in clinical practice and public health. J Clin Epidemiol.',\n",
       " '15. Schu¨nemann HJ, Mustafa R, Brozek J, et al; GRADE WorkingGroup. GRADE Guidelines: 16. GRADE evidence to decision frame-works for tests in clinical practice and public health. J Clin Epidemiol.2016;76:89-98. [PMID: 26931285] doi:10.1016/j.jclinepi.2016.01.03216. Alonso-Coello P, Oxman AD, Moberg J, et al; GRADE WorkingGroup. GRADE Evidence to Decision (EtD) frameworks: a systematicand transparent approach to making well informed healthcarechoices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089. [PMID:27365494] doi:10.1136/bmj.i208917. Alonso-Coello P, Schu¨nemann HJ, Moberg J, et al; GRADEWorking Group. GRADE Evidence to Decision (EtD) frameworks: asystematic and transparent approach to making well informedhealthcare choices. 1: Introduction. BMJ. 2016;353:i2016. [PMID:27353417] doi:10.1136/bmj.i201618. Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group.Going from evidence to recommendations. BMJ. 2008;336:1049-51.[PMID: 18467413] doi:10.1136/bmj.39493.646875.AE19. Perel P, Roberts I, Ker K. Colloids versus crystalloids forﬂuid resuscitation in critically ill patients. Cochrane Database SystRev. 2013:CD000567. [PMID: 23450531] doi:10.1002/14651858.CD000567.pub620. Cha´vez-Negrete A, Majluf Cruz S, Frati Munari A, et al. Treatmentof hemorrhagic shock with intraosseous or intravenous infusion ofhypertonic saline dextran solution. Eur Surg Res. 1991;23:123-9.[PMID: 1718756]21. Annane D, Siami S, Jaber S, et al; CRISTAL Investigators. Effectsof ﬂuid resuscitation with colloids vs crystalloids on mortality in criti-cally ill patients presenting with hypovolemic shock: the CRISTALrandomized trial. JAMA. 2013;310:1809-17. [PMID: 24108515]doi:10.1001/jama.2013.28050222. Semler MW, Self WH, Wanderer JP, et al; SMART Investigatorsand the Pragmatic Critical Care Research Group. Balanced crystal-loids versus saline in critically ill adults. N Engl J Med. 2018;378:829-839. [PMID: 29485925] doi:10.1056/NEJMoa1711584',\n",
       " 'and the Pragmatic Critical Care Research Group. Balanced crystal-loids versus saline in critically ill adults. N Engl J Med. 2018;378:829-839. [PMID: 29485925] doi:10.1056/NEJMoa171158423. Kowalenko T, Stern S, Dronen S, et al. Improved outcome withhypotensive resuscitation of uncontrolled hemorrhagic shock in aswine model. J Trauma. 1992;33:349-53; discussion 361-2. [PMID:1404501]24. Stern SA, Dronen SC, Birrer P, et al. Effect of blood pressure onhemorrhage volume and survival in a near-fatal hemorrhage modelincorporating a vascular injury. Ann Emerg Med. 1993;22:155-63.[PMID: 8427424]25. Kwan I, Bunn F, Chinnock P, et al. Timing and volume of ﬂuidadministration for patients with bleeding. Cochrane Database SystRev. 2014:CD002245. [PMID: 24599652] doi:10.1002/14651858.CD002245.pub226. Schreiber MA, Meier EN, Tisherman SA, et al; ROC Investigators.A controlled resuscitation strategy is feasible and safe in hypotensivetrauma patients: results of a prospective randomized pilot trial.J Trauma Acute Care Surg. 2015;78:687-95; discussion 695-7.[PMID: 25807399] doi:10.1097/TA.000000000000060027. Carrick MM, Morrison CA, Tapia NM, et al. Intraoperative hypo-tensive resuscitation for patients undergoing laparotomy or thora-cotomy for trauma: early termination of a randomized prospectiveclinical trial. J Trauma Acute Care Surg. 2016;80:886-96. [PMID:27015578] doi:10.1097/TA.000000000000104428. Stanley AJ, Ashley D, Dalton HR, et al. Outpatient managementof patients with low-risk upper-gastrointestinal haemorrhage: multi-centre validation and prospective evaluation. Lancet. 2009;373:42-7.[PMID: 19091393] doi:10.1016/S0140-6736(08)61769-929. Ramaekers R, Mukarram M, Smith CA, et al. The predictive valueof preendoscopic risk scores to predict adverse outcomes in emer-gency department patients with upper gastrointestinal bleeding: asystematic review. Acad Emerg Med. 2016;23:1218-1227. [PMID:27640399] doi:10.1111/acem.13101',\n",
       " 'gency department patients with upper gastrointestinal bleeding: asystematic review. Acad Emerg Med. 2016;23:1218-1227. [PMID:27640399] doi:10.1111/acem.1310130. Laursen SB, Dalton HR, Murray IA, et al; Upper GastrointestinalHemorrhage International Consortium. Performance of new thresh-olds of the Glasgow Blatchford score in managing patients with up-Management of Upper Gastrointestinal BleedingCLINICAL GUIDELINEAnnals.orgAnnals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019 819Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " 'per gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2015;13:115-21.e2. [PMID: 25058843] doi:10.1016/j.cgh.2014.07.02331. Stanley AJ, Laine L, Dalton HR, et al; International Gastrointesti-nal Bleeding Consortium. Comparison of risk scoring systems forpatients presenting with upper gastrointestinal bleeding: interna-tional multicentre prospective study. BMJ. 2017;356:i6432. [PMID:28053181] doi:10.1136/bmj.i643232. Saltzman JR, Tabak YP, Hyett BH, et al. A simple risk score accu-rately predicts in-hospital mortality, length of stay, and cost in acuteupper GI bleeding. Gastrointest Endosc. 2011;74:1215-24. [PMID:21907980] doi:10.1016/j.gie.2011.06.02433. Odutayo A, Desborough MJ, Trivella M, et al. Restrictive versusliberal blood transfusion for gastrointestinal bleeding: a systematicreview and meta-analysis of randomised controlled trials. LancetGastroenterol Hepatol. 2017;2:354-360. [PMID: 28397699] doi:10.1016/S2468-1253(17)30054-734. Jairath V, Kahan BC, Gray A, et al. Restrictive versus liberal bloodtransfusion for acute upper gastrointestinal bleeding (TRIGGER): apragmatic, open-label, cluster randomised feasibility trial. Lancet.2015;386:137-44. [PMID: 25956718] doi:10.1016/S0140-6736(14)61999-135. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies foracute upper gastrointestinal bleeding. N Engl J Med. 2013;368:11-21. [PMID: 23281973] doi:10.1056/NEJMoa121180136. Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresh-olds and other strategies for guiding allogeneic red blood cell trans-fusion. Cochrane Database Syst Rev. 2016;10:CD002042. [PMID:27731885]37. Holst LB, Petersen MW, Haase N, et al. Restrictive versus liberaltransfusion strategy for red blood cell transfusion: systematic reviewof randomised trials with meta-analysis and trial sequential analysis.BMJ. 2015;350:h1354. [PMID: 25805204] doi:10.1136/bmj.h135438. Shander A, Hofmann A, Ozawa S, et al. Activity-based costs of',\n",
       " 'of randomised trials with meta-analysis and trial sequential analysis.BMJ. 2015;350:h1354. [PMID: 25805204] doi:10.1136/bmj.h135438. Shander A, Hofmann A, Ozawa S, et al. Activity-based costs ofblood transfusions in surgical patients at four hospitals. Transfusion.2010;50:753-65. [PMID: 20003061] doi:10.1111/j.1537-2995.2009.02518.x39. Blair SD, Janvrin SB, McCollum CN, et al. Effect of early bloodtransfusion on gastrointestinal haemorrhage. Br J Surg. 1986;73:783-5. [PMID: 3533203]40. Docherty AB, O’Donnell R, Brunskill S, et al. Effect of restrictiveversus liberal transfusion strategies on outcomes in patients with car-diovascular disease in a non-cardiac surgery setting: systematic re-view and meta-analysis. BMJ. 2016;352:i1351. [PMID: 27026510]doi:10.1136/bmj.i135141. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guide-lines from the AABB: red blood cell transfusion thresholds and stor-age. JAMA. 2016;316:2025-2035. [PMID: 27732721] doi:10.1001/jama.2016.918542. Nagata N, Sakurai T, Moriyasu S, et al. Impact of INR monitoring,reversal agent use, heparin bridging, and anticoagulant interruptionon rebleeding and thromboembolism in acute gastrointestinalbleeding. PLoS One. 2017;12:e0183423. [PMID: 28863196] doi:10.1371/journal.pone.018342343. Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor pro-thrombin complex concentrate versus plasma for rapid vitamin K an-tagonist reversal in patients needing urgent surgical or invasive in-terventions: a phase 3b, open-label, non-inferiority, randomised trial.Lancet. 2015;385:2077-87. [PMID: 25728933] doi:10.1016/S0140-6736(14)61685-844. Sarode R, Milling TJ Jr, Refaai MA, et al. Efﬁcacy and safety of a4-factor prothrombin complex concentrate in patients on vitamin Kantagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234-43. [PMID:23935011] doi:10.1161/CIRCULATIONAHA.113.002283',\n",
       " 'antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234-43. [PMID:23935011] doi:10.1161/CIRCULATIONAHA.113.00228345. Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinalhaemorrhage in anticoagulated patients: diagnoses and response toendoscopic treatment. Gut. 1994;35:464-6. [PMID: 8174982]46. Thomopoulos KC, Mimidis KP, Theocharis GJ, et al. Acute uppergastrointestinal bleeding in patients on long-term oral anticoagula-tion therapy: endoscopic ﬁndings, clinical management and out-come. World J Gastroenterol. 2005;11:1365-8. [PMID: 15761977]47. National Institute for Health and Care Excellence. Blood transfu-sion (NICE clinical guideline 24), 2015. Last update: November 2015.Accessed at www.nice.org.uk/guidance/ng24 on 12 August 2019.48. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al; ANNEXA-4 In-vestigators. Andexanet alfa for acute major bleeding associated withfactor Xa inhibitors. N Engl J Med. 2016;375:1131-41. [PMID:27573206] doi:10.1056/NEJMoa160788749. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dab-igatran reversal - full cohort analysis. N Engl J Med. 2017;377:431-441. [PMID: 28693366] doi:10.1056/NEJMoa170727850. Spiegel BM, Vakil NB, Ofman JJ. Endoscopy for acute non-variceal upper gastrointestinal tract hemorrhage: is sooner better? Asystematic review. Arch Intern Med. 2001;161:1393-404. [PMID:11386888]51. Lin HJ, Wang K, Perng CL, et al. Early or delayed endoscopy forpatients with peptic ulcer bleeding. A prospective randomizedstudy. J Clin Gastroenterol. 1996;22:267-71. [PMID: 8771420]52. Lee JG, Turnipseed S, Romano PS, et al. Endoscopy-based triagesigniﬁcantly reduces hospitalization rates and costs of treating upperGI bleeding: a randomized controlled trial. Gastrointest Endosc.1999;50:755-61. [PMID: 10570332]53. Bjorkman DJ, Zaman A, Fennerty MB, et al. Urgent vs. electiveendoscopy for acute non-variceal upper-GI bleeding: an effective-',\n",
       " '1999;50:755-61. [PMID: 10570332]53. Bjorkman DJ, Zaman A, Fennerty MB, et al. Urgent vs. electiveendoscopy for acute non-variceal upper-GI bleeding: an effective-ness study. Gastrointest Endosc. 2004;60:1-8. [PMID: 15229417]54. Kumar NL, Cohen AJ, Nayor J, et al. Timing of upper endo-scopy inﬂuences outcomes in patients with acute nonvariceal upperGI bleeding. Gastrointest Endosc. 2017;85:945-952.e1. [PMID:27693643] doi:10.1016/j.gie.2016.09.02955. Lim LG, Ho KY, Chan YH, et al. Urgent endoscopy is asso-ciated with lower mortality in high-risk but not low-risk non-variceal upper gastrointestinal bleeding. Endoscopy. 2011;43:300-6. [PMID: 21360421] doi:10.1055/s-0030-125611056. Laursen SB, Leontiadis GI, Stanley AJ, et al. Relationship be-tween timing of endoscopy and mortality in patients with peptic ul-cer bleeding: a nationwide cohort study. Gastrointest Endosc. 2017;85:936-944.e3. [PMID: 27623102] doi:10.1016/j.gie.2016.08.04957. Xia XF, Chiu PWY, Tsoi KKF, et al. The effect of off-hours hospitaladmission on mortality and clinical outcomes for patients with uppergastrointestinal hemorrhage: a systematic review and meta-analysisof 20 cohorts. United European Gastroenterol J. 2018;6:367-381.[PMID: 29774150] doi:10.1177/205064061773265158. Cho SH, Lee YS, Kim YJ, et al. Outcomes and role of urgentendoscopy in high-risk patients with acute nonvariceal gastrointesti-nal bleeding. Clin Gastroenterol Hepatol. 2018;16:370-377. [PMID:28634135] doi:10.1016/j.cgh.2017.06.02959. Ahn DW, Park YS, Lee SH, et al. Clinical outcome of acute non-variceal upper gastrointestinal bleeding after hours: the role of ur-gent endoscopy. Korean J Intern Med. 2016;31:470-8. [PMID:27048253] doi:10.3904/kjim.2014.09960. Targownik LE, Murthy S, Keyvani L, et al. The role of rapid en-doscopy for high-risk patients with acute nonvariceal upper gastro-intestinal bleeding. Can J Gastroenterol. 2007;21:425-9. [PMID:17637943]61. Tai CM, Huang SP, Wang HP, et al. High-risk ED patients with',\n",
       " 'intestinal bleeding. Can J Gastroenterol. 2007;21:425-9. [PMID:17637943]61. Tai CM, Huang SP, Wang HP, et al. High-risk ED patients withnonvariceal upper gastrointestinal hemorrhage undergoing emer-gency or urgent endoscopy: a retrospective analysis. Am J EmergMed. 2007;25:273-8. [PMID: 17349900]62. Garcia-Tsao G, Sanyal AJ, Grace ND, et al; Practice GuidelinesCommittee of American Association for Study of Liver Diseases. Pre-vention and management of gastroesophageal varices and varicealhemorrhage in cirrhosis. Am J Gastroenterol. 2007;102:2086-102.[PMID: 17727436]63. de Franchis R; Baveno V Faculty. Revising consensus in portalhypertension: report of the Baveno V consensus workshop on meth-odology of diagnosis and therapy in portal hypertension. J Hepatol.2010;53:762-8. [PMID: 20638742] doi:10.1016/j.jhep.2010.06.00464. Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: anevidence-based approach based on meta-analyses of randomizedCLINICAL GUIDELINEManagement of Upper Gastrointestinal Bleeding820 Annals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019Annals.orgDownloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " \"controlled trials. Clin Gastroenterol Hepatol. 2009;7:33-47; quiz 1-2.[PMID: 18986845] doi:10.1016/j.cgh.2008.08.01665. Barkun AN, Martel M, Toubouti Y, et al. Endoscopic hemostasisin peptic ulcer bleeding for patients with high-risk lesions: a seriesof meta-analyses. Gastrointest Endosc. 2009;69:786-99. [PMID:19152905] doi:10.1016/j.gie.2008.05.03166. Vergara M, Bennett C, Calvet X, et al. Epinephrine injection ver-sus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers. Cochrane Database Syst Rev. 2014:CD005584.[PMID: 25308912] doi:10.1002/14651858.CD005584.pub367. Baracat F, Moura E, Bernardo W, et al. Endoscopic hemostasisfor peptic ulcer bleeding: systematic review and meta-analyses ofrandomized controlled trials. Surg Endosc. 2016;30:2155-68. [PMID:26487199] doi:10.1007/s00464-015-4542-x68. Ljubicic N, Budimir I, Biscanin A, et al. Endoclips vs large orsmall-volume epinephrine in peptic ulcer recurrent bleeding. WorldJ Gastroenterol. 2012;18:2219-24. [PMID: 22611315] doi:10.3748/wjg.v18.i18.221969. Cui J, Huang LY, Liu YX, et al. Efﬁcacy of endoscopic therapy forgastrointestinal bleeding from Dieulafoy's lesion. World J Gastroen-terol. 2011;17:1368-72. [PMID: 21455339] doi:10.3748/wjg.v17.i10.136870. Grgov S, Radovanovic-Dinic B, Tasic T. Could application of epi-nephrine improve hemostatic efﬁcacy of hemoclips for bleedingpeptic ulcers? A prospective randomized study. Vojnosanit Pregl.2013;70:824-9. [PMID: 24266309]71. Chung IK, Ham JS, Kim HS, et al. Comparison of the hemostaticefﬁcacy of the endoscopic hemoclip method with hypertonic saline-epinephrine injection and a combination of the two for the manage-ment of bleeding peptic ulcers. Gastrointest Endosc. 1999;49:13-8.[PMID: 9869717]72. Kwek BEA, Ang TL, Ong PLJ, et al. TC-325 versus the conven-tional combined technique for endoscopic treatment of peptic ul-cers with high-risk bleeding stigmata: A randomized pilot study.\",\n",
       " '72. Kwek BEA, Ang TL, Ong PLJ, et al. TC-325 versus the conven-tional combined technique for endoscopic treatment of peptic ul-cers with high-risk bleeding stigmata: A randomized pilot study.J Dig Dis. 2017;18:323-329. [PMID: 28485544] doi:10.1111/1751-2980.1248173. Chen YI, Barkun AN. Hemostatic powders in gastrointestinalbleeding: a systematic review. Gastrointest Endosc Clin N Am. 2015;25:535-52. [PMID: 26142037] doi:10.1016/j.giec.2015.02.00874. Haddara S, Jacques J, Lecleire S, et al. A novel hemostaticpowder for upper gastrointestinal bleeding: a multicenter study(the “GRAPHE” registry). Endoscopy. 2016;48:1084-1095. [PMID:27760437]75. Chen YI, Barkun A, Nolan S. Hemostatic powder TC-325 in themanagement of upper and lower gastrointestinal bleeding: a two-year experience at a single institution. Endoscopy. 2015;47:167-71.[PMID: 25264762] doi:10.1055/s-0034-137809876. Hagel AF, Albrecht H, Na¨gel A, et al. The application of hemos-pray in gastrointestinal bleeding during emergency endoscopy.Gastroenterol Res Pract. 2017;2017:3083481. [PMID: 28232848]doi:10.1155/2017/308348177. Barkun AN, Adam V, Lu Y, et al. Using hemospray improves thecost-effectiveness ratio in the management of upper gastrointestinalnonvariceal bleeding. J Clin Gastroenterol. 2018;52:36-44. [PMID:27749635] doi:10.1097/MCG.000000000000070978. Kohler B, Maier M, Benz C, et al. Acute ulcer bleeding. A pro-spective randomized trial to compare Doppler and Forrest classiﬁca-tions in endoscopic diagnosis and therapy. Dig Dis Sci. 1997;42:1370-4. [PMID: 9246030]79. Jensen DM, Kovacs TOG, Ohning GV, et al. Doppler endo-scopic probe monitoring of blood ﬂow improves risk stratiﬁcationand outcomes of patients with severe nonvariceal upper gastro-intestinal hemorrhage. Gastroenterology. 2017;152:1310-1318.e1.[PMID: 28167214] doi:10.1053/j.gastro.2017.01.04280. Chen VK, Wong RC. Endoscopic Doppler ultrasound versus en-doscopic stigmata-directed management of acute peptic ulcer hem-',\n",
       " '[PMID: 28167214] doi:10.1053/j.gastro.2017.01.04280. Chen VK, Wong RC. Endoscopic Doppler ultrasound versus en-doscopic stigmata-directed management of acute peptic ulcer hem-orrhage: a multimodel cost analysis. Dig Dis Sci. 2007;52:149-60.[PMID: 17109216]81. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitortreatment for acute peptic ulcer bleeding. Cochrane Database SystRev. 2006:CD002094. [PMID: 16437441]82. Neumann I, Letelier LM, Rada G, et al. Comparison of differentregimens of proton pump inhibitors for acute peptic ulcer bleeding.Cochrane Database Syst Rev. 2013:CD007999. [PMID: 23760821]doi:10.1002/14651858.CD007999.pub283. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviewsof the clinical effectiveness and cost-effectiveness of proton pumpinhibitors in acute upper gastrointestinal bleeding. Health TechnolAssess. 2007;11:iii-iv, 1-164. [PMID: 18021578]84. Barkun AN, Adam V, Sung JJ, et al. Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding. Phar-macoeconomics. 2010;28:217-30. [PMID: 20151726] doi:10.2165/11531480-000000000-0000085. Al-Sabah S, Barkun AN, Herba K, et al. Cost-effectiveness ofproton-pumpinhibitionbeforeendoscopyinuppergastro-intestinal bleeding. Clin Gastroenterol Hepatol. 2008;6:418-25.[PMID: 18304891] doi:10.1016/j.cgh.2007.12.03786. Lu Y, Adam V, Teich V, et al. Timing or dosing of intravenousproton pump inhibitors in acute upper gastrointestinal bleeding haslow impact on costs. Am J Gastroenterol. 2016;111:1389-1398.[PMID: 27140030] doi:10.1038/ajg.2016.15787. Cheng HC, Wu CT, Chang WL, et al. Double oral esomeprazoleafter a 3-day intravenous esomeprazole infusion reduces recurrentpeptic ulcer bleeding in high-risk patients: a randomised controlledstudy. Gut. 2014;63:1864-72. [PMID: 24658598] doi:10.1136/gutjnl-2013-30653188. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention ofrecurrences of ulcer complications from long-term low-dose aspirin',\n",
       " '-2013-30653188. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention ofrecurrences of ulcer complications from long-term low-dose aspirinuse. N Engl J Med. 2002;346:2033-8. [PMID: 12087138]89. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent uppergastrointestinal bleeding in patients with Helicobacter pylori infec-tion who are taking low-dose aspirin or naproxen. N Engl J Med.2001;344:967-73. [PMID: 11274623]90. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirinand esomeprazole to prevent recurrent ulcer bleeding. N Engl JMed. 2005;352:238-44. [PMID: 15659723]91. Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirinversus clopidogrel for prevention of recurrent gastrointestinal ulcercomplications. Clin Gastroenterol Hepatol. 2006;4:860-5. [PMID:16797240]92. Chan FK, Kyaw M, Tanigawa T, et al. Similar efﬁcacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of uppergastrointestinal bleeding or ulcers in high-risk users of low-dose as-pirin. Gastroenterology. 2017;152:105-110.e1. [PMID: 27641510]doi:10.1053/j.gastro.2016.09.00693. Khan MY, Siddiqui WJ, Alvarez C, et al. Reduction in postpercu-taneous coronary intervention angina in addition to gastrointestinalevents in patients on combined proton pump inhibitors and dualantiplatelet therapy: a systematic review and meta-analysis. Eur JGastroenterol Hepatol. 2018;30:847-853. [PMID: 29596078] doi:10.1097/MEG.000000000000112594. Hu W, Tong J, Kuang X, et al. Inﬂuence of proton pump inhibi-tors on clinical outcomes in coronary heart disease patients receivingaspirin and clopidogrel: a meta-analysis. Medicine (Baltimore). 2018;97:e9638. [PMID: 29504996] doi:10.1097/MD.000000000000963895. Bhatt DL, Cryer BL, Contant CF, et al; COGENT Investigators.Clopidogrel with or without omeprazole in coronary artery disease.N Engl J Med. 2010;363:1909-17. [PMID: 20925534] doi:10.1056/NEJMoa100796496. Wei P, Zhang YG, Ling L, et al. Effects of the short-term applica-',\n",
       " 'N Engl J Med. 2010;363:1909-17. [PMID: 20925534] doi:10.1056/NEJMoa100796496. Wei P, Zhang YG, Ling L, et al. Effects of the short-term applica-tion of pantoprazole combined with aspirin and clopidogrel in thetreatment of acute STEMI. Exp Ther Med. 2016;12:2861-2864.[PMID: 27882086]97. Ren YH, Zhao M, Chen YD, et al. Omeprazole affects clopidogrelefﬁcacy but not ischemic events in patients with acute coronary syn-drome undergoing elective percutaneous coronary intervention.Chin Med J (Engl). 2011;124:856-61. [PMID: 21518592]Management of Upper Gastrointestinal BleedingCLINICAL GUIDELINEAnnals.orgAnnals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019 821Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " '98. Wu H, Jing Q, Wang J, et al. Pantoprazole for the prevention ofgastrointestinal bleeding in high-risk patients with acute coronarysyndromes. J Crit Care. 2011;26:434.e1-6. [PMID: 21273036] doi:10.1016/j.jcrc.2010.12.00799. Chan FK, Ching JY, Suen BY, et al. Effects of Helicobacter pyloriinfection on long-term risk of peptic ulcer bleeding in low-dose as-pirin users. Gastroenterology. 2013;144:528-35. [PMID: 23333655]doi:10.1053/j.gastro.2012.12.038100. Ray WA, Chung CP, Murray KT, et al. Association of protonpump inhibitors with reduced risk of warfarin-related serious uppergastrointestinal bleeding. Gastroenterology. 2016;151:1105-1112.e10.[PMID: 27639805] doi:10.1053/j.gastro.2016.08.054101. Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: apopulation-based study. Gastroenterology. 2015;149:586-95.e3.[PMID: 25960019] doi:10.1053/j.gastro.2015.05.002102. Lin KJ, Herna´ndez-Dı´az S, Garcı´a Rodrı´guez LA. Acid suppres-sants reduce risk of gastrointestinal bleeding in patients on anti-thrombotic or anti-inﬂammatory therapy. Gastroenterology. 2011;141:71-9. [PMID: 21458456] doi:10.1053/j.gastro.2011.03.049103. Masso´ Gonza´lez EL, Garcı´a Rodrı´guez LA. Proton pump inhibi-tors reduce the long-term risk of recurrent upper gastrointestinalbleeding: an observational study. Aliment Pharmacol Ther. 2008;28:629-37. [PMID: 18616644] doi:10.1111/j.1365-2036.2008.03780.x104. Lanas A, Garcı´a-Rodrı´guez LA, Arroyo MT, et al; Investigatorsof the Asociacio´ n Espan˜ola de Gastroenterologı´a (AEG). Effect ofantisecretory drugs and nitrates on the risk of ulcer bleeding associ-ated with nonsteroidal anti-inﬂammatory drugs, antiplatelet agents,and anticoagulants. Am J Gastroenterol. 2007;102:507-15. [PMID:17338735]105. Islam MM, Poly TN, Walther BA, et al. Adverse outcomes oflong-term use of proton pump inhibitors: a systematic review and',\n",
       " \"and anticoagulants. Am J Gastroenterol. 2007;102:507-15. [PMID:17338735]105. Islam MM, Poly TN, Walther BA, et al. Adverse outcomes oflong-term use of proton pump inhibitors: a systematic review andmeta-analysis. Eur J Gastroenterol Hepatol. 2018;30:1395-1405.[PMID: 30028775] doi:10.1097/MEG.0000000000001198106. Hussain S, Siddiqui AN, Habib A, et al. Proton pump inhibitors'use and risk of hip fracture: a systematic review and meta-analysis.Rheumatol Int. 2018;38:1999-2014. [PMID: 30159775] doi:10.1007/s00296-018-4142-x107. Nochaiwong S, Ruengorn C, Awiphan R, et al. The associationbetween proton pump inhibitor use and the risk of adverse kidneyoutcomes: a systematic review and meta-analysis. Nephrol DialTransplant. 2018;33:331-342. [PMID: 28339835] doi:10.1093/ndt/gfw470108. Haﬁz RA, Wong C, Paynter S, et al. The risk of community-acquired enteric infection in proton pump inhibitor therapy: system-atic review and meta-analysis. Ann Pharmacother. 2018;52:613-622.[PMID: 29457492] doi:10.1177/1060028018760569109. Cao F, Chen CX, Wang M, et al. Updated meta-analysis of con-trolled observational studies: proton-pump inhibitors and risk ofClostridium difﬁcile infection. J Hosp Infect. 2018;98:4-13. [PMID:28842261] doi:10.1016/j.jhin.2017.08.017110. Vaezi MF, Yang YX, Howden CW. Complications of protonpump inhibitor therapy. Gastroenterology. 2017;153:35-48. [PMID:28528705] doi:10.1053/j.gastro.2017.04.047111. Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, designand baseline characteristics of participants in the cardiovascular out-comes for people using anticoagulation strategies (COMPASS) trial.Can J Cardiol. 2017;33:1027-1035. [PMID: 28754388] doi:10.1016/j.cjca.2017.06.001112. Moayyedi P, Eikelboom JW, Bosch J, et al; COMPASS Investi-gators. Pantoprazole to prevent gastroduodenal events in patientsreceiving rivaroxaban and/or aspirin in a randomized, double-blind,placebo-controlled trial. Gastroenterology. 2019;157:403-412.e5.\",\n",
       " 'gators. Pantoprazole to prevent gastroduodenal events in patientsreceiving rivaroxaban and/or aspirin in a randomized, double-blind,placebo-controlled trial. Gastroenterology. 2019;157:403-412.e5.[PMID: 31054846] doi:10.1053/j.gastro.2019.04.041113. Moayyedi P, Eikelboom JW, Bosch J, et al; COMPASS Investi-gators. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin.Gastroenterology. 2019;157:682-691.e2. [PMID: 31152740] doi:10.1053/j.gastro.2019.05.056114. Wong GLH, Lau LHS, Ching JYL, et al. Prevention of recurrentidiopathic gastroduodenal ulcer bleeding: a double-blind, ran-domised trial. Gut. 2019. [PMID: 31229990] doi:10.1136/gutjnl-2019-318715115. Baracat FI, de Moura DTH, Brunaldi VO, et al. Randomized con-trolled trial of hemostatic powder versus endoscopic clipping fornon-variceal upper gastrointestinal bleeding. Surg Endosc. 2019.[PMID: 30927124] doi:10.1007/s00464-019-06769-z116. Toka B, Eminler AT, Karacaer C, et al. Comparison of monopo-lar hemostatic forceps with soft coagulation versus hemoclip for pep-tic ulcer bleeding: a randomized trial (with video). Gastrointest En-dosc. 2019;89:792-802. [PMID: 30342026] doi:10.1016/j.gie.2018.10.011117. Kantowski M, Schoepfer AM, Settmacher U, et al. Assessmentof endoscopic Doppler to guide hemostasis in high risk pepticulcer bleeding. Scand J Gastroenterol. 2018;53:1311-1318. [PMID:30394134] doi:10.1080/00365521.2018.1509121118. Schmidt A, Go¨ lder S, Goetz M, et al. Over-the-scope clips aremore effective than standard endoscopic therapy for patients withrecurrent bleeding of peptic ulcers. Gastroenterology. 2018;155:674-686.e6. [PMID: 29803838] doi:10.1053/j.gastro.2018.05.037CLINICAL GUIDELINEManagement of Upper Gastrointestinal Bleeding822 Annals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019Annals.orgDownloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " \"Current Author Addresses: Dr. Barkun: Division of Gastroen-terology, McGill University and the McGill University HealthCentre, 1650 Cedar Avenue, Room D7.346, Montreal, Que-bec H3G 1A4, Canada.Dr. Almadi: Division of Gastroenterology, Department ofMedicine, College of Medicine, King Khalid University Hospi-tal, King Saud University 12372, Riyadh, Saudi Arabia.Dr. Kuipers: Erasmus MC University Medical Center, P.O. Box2040, 3000CA Rotterdam, the Netherlands.Dr. Laine: Section of Digestive Diseases, Yale School of Med-icine, P.O. Box 208019, New Haven, CT 06520.Dr. Sung: Department of Medicine and Therapeutics, Instituteof Digestive Disease, The Chinese University of Hong Kong,Shatin, Hong Kong.Dr. Tse: Division of Gastroenterology, Department of Medi-cine, McMaster University, Room 2F53, 1200 Main StreetWest, Hamilton, Ontario L8N 3Z5, Canada.Dr. Leontiadis: Division of Gastroenterology, Department ofMedicine, McMaster University, 1280 Main Street West, Health Sci-ences Centre, Suite 3V3, Hamilton, Ontario L8S 4K1, Canada.Dr. Abraham: Mayo Clinic, 13400 East Shea Boulevard, Scotts-dale, AZ 85259.Dr. Calvet: Servei d’Aparell Digestiu, Coproracio´ Sanita´riaUniversita´ria Parc Taulı´, Parc Taulı´ 1, 08208 Sabadell, Barce-lona, Catalunya, Spain.Dr. Chan: Institute of Digestive Disease, Chinese University ofHong Kong, Hong Kong SAR.Dr. Douketis: Department of Medicine, McMaster Universityand St. Joseph's Healthcare, 50 Charlton Avenue East, Hamil-ton, Ontario L8N 4A6, Canada.Dr. Enns: Division of Gastroenterology, University of BritishColumbia, Vancouver, British Columbia V6Z 2K5, Canada.Dr. Gralnek: Rappaport Faculty of Medicine, Technion-IsraelInstitute of Technology, Haifa, Israel.Dr. Jairath: London Health Sciences Centre, Room A10-228,University Hospital, London, Ontario N6A 4V2, Canada.Dr. Jensen: Ronald Reagan UCLA Medical Center, DigestiveDiseases–Westwood, 200 MP, 200 UCLA Medical Plaza, Suite365C, Los Angeles, CA 90024.\",\n",
       " \"University Hospital, London, Ontario N6A 4V2, Canada.Dr. Jensen: Ronald Reagan UCLA Medical Center, DigestiveDiseases–Westwood, 200 MP, 200 UCLA Medical Plaza, Suite365C, Los Angeles, CA 90024.Dr. Lau: Department of Surgery, Prince of Wales Hospital, TheChinese University of Hong Kong, Shatin, Hong Kong SAR.Dr. Lip: Liverpool Centre for Cardiovascular Science, Univer-sity of Liverpool, William Henry Duncan Building, 6 WestDerby Street, Liverpool L7 8TX, United Kingdom.Dr. Loffroy: Department of Interventional Radiology, Image-Guided Therapy Centre, Dijon-Bourgogne University Hospi-tal, 14 rue Gaffarel, 21000 Dijon, France.Dr. Maluf-Filho: Cancer Institute of Sa˜o Paulo–ICESP–USP, Av.Dr. Arnaldo, 251, CEP 01246-000, Sa˜o Paulo–SP, Brazil.Dr. Meltzer: Department of Emergency Medicine, GW Medi-cal Faculty Associates, 2120 L Street Northwest, Washington,DC 20037.Dr. Reddy: Asian Institute of Gastroenterology, 6-3-661,Somajiguda, Hyderabad–500 082, India.Dr. Saltzman: Division of Gastroenterology, Hepatology andEndoscopy, Brigham and Women's Hospital, 75 FrancisStreet, Boston, MA 02115.Dr. Marshall: Division of Gastroenterology, McMaster Univer-sity, 1280 Main Street West, Room 2F59, Hamilton, OntarioL8S 4K1, Canada.Dr. Bardou: Clinical Investigation Centre INSERM 1432, Hos-pitalisation Unit and Gastroenterology and Liver Department,CHU Dijon-Bourgogne, Hopital Francois Mitterrand, 14 rueGaffarel, BP77908, 21079 Dijon Cedex, France.Author Contributions: Conception and design: A.N. Barkun,M. Almadi, E.J. Kuipers, L. Laine, F. Tse, G.I. Leontiadis, I.M.Gralnek, A.C. Meltzer, J.K. Marshall, M. Bardou.Analysis and interpretation of the data: A.N. Barkun, M.Almadi, E.J. Kuipers, L. Laine, J. Sung, F. Tse, G.I. Leontiadis,N.S. Abraham, X. Calvet, J. Douketis, R. Enns, I.M. Gralnek, V.Jairath, J. Lau, G.Y.H. Lip, R. Loffroy, F. Maluf-Filho, A.C.Meltzer, J.R. Saltzman, M. Bardou.Drafting of the article: A.N. Barkun, M. Almadi, J. Sung, F. Tse,\",\n",
       " 'Jairath, J. Lau, G.Y.H. Lip, R. Loffroy, F. Maluf-Filho, A.C.Meltzer, J.R. Saltzman, M. Bardou.Drafting of the article: A.N. Barkun, M. Almadi, J. Sung, F. Tse,G.I. Leontiadis, N.S. Abraham, F.K.L. Chan, R. Enns, I.M.Gralnek, M. Bardou.Criticalrevisionforimportantintellectualcontent:A.N.Barkun, M. Almadi, E.J. Kuipers, L. Laine, J. Sung, F. Tse, G.I.Leontiadis, N.S. Abraham, X. Calvet, F.K.L. Chan, J. Douketis,I.M. Gralnek, V. Jairath, D. Jensen, G.Y.H. Lip, R. Loffroy, F.Maluf-Filho, A.C. Meltzer, N. Reddy, J.R. Saltzman, J.K.Marshall.Final approval of the article: A.N. Barkun, M. Almadi, E.J.Kuipers, L. Laine, J. Sung, F. Tse, G.I. Leontiadis, N.S.Abraham, X. Calvet, F.K.L. Chan, J. Douketis, R. Enns, I.M.Gralnek, V. Jairath, D. Jensen, J. Lau, G.Y.H. Lip, R. Loffroy, F.Maluf-Filho, A.C. Meltzer, N. Reddy, J.R. Saltzman, J.K.Marshall, M. Bardou.Statistical expertise: A.N. Barkun, M. Almadi, L. Laine, G.I.Leontiadis.Obtaining of funding: A.N. Barkun, M. Almadi.Administrative, technical, or logistic support: A.N. Barkun, G.I.Leontiadis, M. Bardou.Collection and assembly of data: A.N. Barkun, F. Tse, G.I.Leontiadis, X. Calvet, R. Enns, I.M. Gralnek, F. Maluf-Filho, A.C.Meltzer, J.K. Marshall, M. Bardou.Annals.orgAnnals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " 'Appendix Table 1. Pooled Sensitivity and Speciﬁcity of Pre-endoscopic Scoring Systems to Identify Patients at High Risk forUndesirable Clinical OutcomesStudy, Year (Reference)Study TypeCutoffValuePooled Sensitivity(95% CI)*Pooled Speciﬁcity(95% CI)*Glasgow Blatchford scoreNICE CPG, 2012 (7)1 SR and MA of 7 DTA studies00.99 (0.98–1.00)0.20 (0.06–0.34)Ramaekers et al, 2016 (29)1 SR and MA of 6 DTA studies00.99 (0.98–1.00)0.08 (0.07–0.09)Laursen et al, 2015 (30)1 DTA study010.997 (NR)0.992 (NR)0.222 (NR)0.398 (NR)Stanley et al, 2017 (31)1 DTA study10.986 (NR)0.346 (NR)Pre-endoscopic Rockall scoreNICE CPG, 2012 (7)1 SR and MA of 7 DTA studiesNot speciﬁed0.96 (0.84–1.00)0.29 (0.17–0.41)Ramaekers et al, 2016 (29)1 SR and MA of 8 DTA studies0 (6 studies)2 (2 studies)0.93 (0.91–0.94)0.95 (0.91–0.97)0.19 (0.18–0.20)0.38 (0.35–0.40)Stanley et al, 2017 (31)1 DTA study00.956 (NR)0.234 (NR)AIMS65 scoreRamaekers et al, 2016 (29)1 SR and MA of 3 DTA studies0 (2 studies)2 (1 study)0.78 (0.73–0.83)0.79 (0.76–0.82)0.49 (0.45–0.53)0.61 (0.61–0.61)Stanley et al, 2017 (31)1 DTA study00.815 (NR)0.499 (NR)CPG = clinical practice guideline; DTA = diagnostic test accuracy; MA = meta-analysis; NICE = National Institute for Health and Care Excellence;NR = not reported; SR = systematic review.* Boldface signiﬁes statistically signiﬁcant results.Appendix Table 2. Pooled Relative and Absolute Risks for Adverse Outcomes, According to Restrictive or Liberal RBCTransfusion Thresholds in Patients With UGIBOutcomeStudies(Reference)TransfusionStrategy, n/N (%)RR (95% CI)*Absolute Risk,per 1000 (95% CI)Restrictive†Liberal‡Death1 SR and MA, 3 RCTs (33)§37/727 (5.1)68/851 (8.0)0.65 (0.44 to 0.97)−28 (−45 to −2)Further bleeding (persistent or recurrent)1 SR and MA, 5 RCTs (33)64/765 (8.5)117/877 (13.5)0.58 (0.40 to 0.84)−56 (−80 to −21)Surgical or radiologic intervention2 RCTs (34, 35)14/485 (2.9)23/592 (3.9)0.73 (0.38 to 1.42)',\n",
       " '1 SR and MA, 5 RCTs (33)64/765 (8.5)117/877 (13.5)0.58 (0.40 to 0.84)−56 (−80 to −21)Surgical or radiologic intervention2 RCTs (34, 35)14/485 (2.9)23/592 (3.9)0.73 (0.38 to 1.42)−10 (−24 to +16)Myocardial infarction1 SR and MA, 2 RCTs (33)10/684 (1.5)15/787 (1.9)0.79 (0.33 to 1.89)−4 (−13 to +17)Stroke or transient ischemic attack1 SR and MA, 1 RCT (33)3/444 (0.7)6/445 (1.3)0.49 (0.12 to 2.01)−7 (−12 to +14)Acute kidney injury1 SR and MA, 2 RCTs (33)83/685 (12.1)110/792 (13.9)0.77 (0.56 to 1.05)−32 (−61 to +6)MA = meta-analysis; RBC = red blood cell; RCT = randomized controlled trial; RR = relative risk; SR = systematic review; UGIB = upper gastroin-testinal bleeding.* Boldface signiﬁes statistically signiﬁcant results.† Hemoglobin threshold, 70–80 g/L.‡ Hemoglobin threshold, 90–100 g/L.§ 2 RCTs provided 97% of all patients. 2 RCTs provided 91% of all patients.Annals of Internal Medicine • Vol. 171 No. 11 • 3 December 2019Annals.orgDownloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.',\n",
       " ...]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "page_contents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "65ab697c-3b29-420b-963c-acc8c61fba15",
   "metadata": {},
   "outputs": [],
   "source": [
    "# data[5].metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "af09a001-f1ed-4eb9-a7a5-c59804bf052a",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "acm",
   "language": "python",
   "name": "acm"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
